<?xml version='1.0' encoding='utf-8' standalone='yes'?>
<collection>
  <source></source>
  <date>2021-07-14</date>
  <key></key>
  <document>
    <id>15917650</id>
    <passage>
      <offset>0</offset>
      <text>Inhibition of c-fms by imatinib: expanding the spectrum of treatment.	Imatinib is a selective protein tyrosine kinase inhibitor currently used in the treatment of chronic myeloid leukaemia (CML). It specifically suppresses the growth of bcr-abl expressing CML progenitor cells by blocking the ATP-binding site of the kinase domain of bcr-abl. Imatinib also inhibits the c-abl, platelet derived growth factor receptor (PDGFR), abl-related gene and stem cell factor receptor, c-kit, protein tyrosine kinases. It is through inhibition of c-kit that imatinib is also used clinically in the treatment of gastrointestinal stromal tumours. We have recently demonstrated that imatinib also specifically targets the macrophage colony stimulating factor receptor, c-fms, at therapeutic concentrations. Although this finding has important implications with regard to potential side effects in patients currently receiving imatinib therapy, these results suggest that imatinib may also be useful in the treatment of diseases where c-fms is implicated. This includes breast and ovarian cancer and inflammatory conditions such as rheumatoid arthritis. We also speculate that imatinib may be used in diseases where bone destruction occurs due to excessive osteoclast activity, such as in the haematologic malignancy, multiple myeloma.</text>
      <sentence>
        <offset>0</offset>
        <text>Inhibition of c-fms by imatinib: expanding the spectrum of treatment.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="23" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-fms</infon>
          <location offset="14" length="5"/>
          <text>c-fms</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>70</offset>
        <text>Imatinib is a selective protein tyrosine kinase inhibitor currently used in the treatment of chronic myeloid leukaemia (CML).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="70" length="8"/>
          <text>Imatinib</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="102" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein tyrosine kinase</infon>
          <location offset="94" length="23"/>
          <text>protein tyrosine kinase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>196</offset>
        <text>It specifically suppresses the growth of bcr-abl expressing CML progenitor cells by blocking the ATP-binding site of the kinase domain of bcr-abl.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="293" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr</infon>
          <location offset="237" length="3"/>
          <text>bcr</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abl</infon>
          <location offset="241" length="3"/>
          <text>abl</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase domain</infon>
          <location offset="317" length="13"/>
          <text>kinase domain</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr</infon>
          <location offset="334" length="3"/>
          <text>bcr</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abl</infon>
          <location offset="338" length="3"/>
          <text>abl</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>343</offset>
        <text>Imatinib also inhibits the c-abl, platelet derived growth factor receptor (PDGFR), abl-related gene and stem cell factor receptor, c-kit, protein tyrosine kinases.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="489" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-abl</infon>
          <location offset="370" length="5"/>
          <text>c-abl</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">platelet derived growth factor receptor</infon>
          <location offset="377" length="39"/>
          <text>platelet derived growth factor receptor</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgfr</infon>
          <location offset="418" length="5"/>
          <text>PDGFR</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abl</infon>
          <location offset="426" length="3"/>
          <text>abl</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">stem cell factor receptor</infon>
          <location offset="447" length="25"/>
          <text>stem cell factor receptor</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-kit</infon>
          <location offset="474" length="5"/>
          <text>c-kit</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein tyrosine kinases</infon>
          <location offset="481" length="24"/>
          <text>protein tyrosine kinases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>507</offset>
        <text>It is through inhibition of c-kit that imatinib is also used clinically in the treatment of gastrointestinal stromal tumours.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="546" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-kit</infon>
          <location offset="535" length="5"/>
          <text>c-kit</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>633</offset>
        <text>We have recently demonstrated that imatinib also specifically targets the macrophage colony stimulating factor receptor, c-fms, at therapeutic concentrations.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="668" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">macrophage colony stimulating factor receptor</infon>
          <location offset="707" length="45"/>
          <text>macrophage colony stimulating factor receptor</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-fms</infon>
          <location offset="754" length="5"/>
          <text>c-fms</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>792</offset>
        <text>Although this finding has important implications with regard to potential side effects in patients currently receiving imatinib therapy, these results suggest that imatinib may also be useful in the treatment of diseases where c-fms is implicated.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="911" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="956" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-fms</infon>
          <location offset="1019" length="5"/>
          <text>c-fms</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1040</offset>
        <text>This includes breast and ovarian cancer and inflammatory conditions such as rheumatoid arthritis.</text>
      </sentence>
      <sentence>
        <offset>1138</offset>
        <text>We also speculate that imatinib may be used in diseases where bone destruction occurs due to excessive osteoclast activity, such as in the haematologic malignancy, multiple myeloma.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1161" length="8"/>
          <text>imatinib</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23583009</id>
    <passage>
      <offset>0</offset>
      <text>Quercetin suppressed CYP2E1-dependent ethanol hepatotoxicity via depleting heme pool and releasing CO.	Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (HO-1) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect. However, the precise mechanism by which quercetin counteracts CYP2E1-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear. To explore the potential mechanism, herein, ethanol (4.0g/kg.bw.) was administrated to rats for 90 days. Our data showed that chronic ethanol over-activated CYP2E1 but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.). Quercetin (100μM) induced HO-1 and depleted heme pool when incubated to human hepatocytes. Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation. CO scavenging blocked the suppression of quercetin only on CYP2E1 activity. CO donor dose-dependently inactivated CYP2E1 of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger. Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by quercetin through HO-1 induction. Depleted heme pool and CO releasing limited protein synthesis and inhibited enzymatic activity of CYP2E1, respectively.</text>
      <sentence>
        <offset>0</offset>
        <text>Quercetin suppressed CYP2E1-dependent ethanol hepatotoxicity via depleting heme pool and releasing CO.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="0" length="9"/>
          <text>Quercetin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="38" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">co</infon>
          <location offset="99" length="2"/>
          <text>CO</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="21" length="6"/>
          <text>CYP2E1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>103</offset>
        <text>Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (HO-1) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbon monoxide</infon>
          <location offset="234" length="15"/>
          <text>carbon monoxide</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">co</infon>
          <location offset="251" length="2"/>
          <text>CO</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="122" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="158" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">heme</infon>
          <location offset="196" length="4"/>
          <text>heme</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="214" length="4"/>
          <text>HO-1</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">heme oxygenase-1</infon>
          <location offset="196" length="16"/>
          <text>heme oxygenase-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>310</offset>
        <text>However, the precise mechanism by which quercetin counteracts CYP2E1-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="350" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="388" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="372" length="6"/>
          <text>CYP2E1</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="419" length="4"/>
          <text>HO-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>458</offset>
        <text>To explore the potential mechanism, herein, ethanol (4.0g/kg.bw.) was administrated to rats for 90 days.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="502" length="7"/>
          <text>ethanol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>563</offset>
        <text>Our data showed that chronic ethanol over-activated CYP2E1 but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="592" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="718" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="615" length="6"/>
          <text>CYP2E1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="637" length="4"/>
          <text>HO-1</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>744</offset>
        <text>Quercetin (100μM) induced HO-1 and depleted heme pool when incubated to human hepatocytes.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="744" length="9"/>
          <text>Quercetin</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="770" length="4"/>
          <text>HO-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>835</offset>
        <text>Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="835" length="7"/>
          <text>Ethanol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="900" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">heme</infon>
          <location offset="965" length="4"/>
          <text>heme</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="862" length="6"/>
          <text>CYP2E1</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="934" length="4"/>
          <text>HO-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T18" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>984</offset>
        <text>CO scavenging blocked the suppression of quercetin only on CYP2E1 activity.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">co</infon>
          <location offset="984" length="2"/>
          <text>CO</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="1025" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="1043" length="6"/>
          <text>CYP2E1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1060</offset>
        <text>CO donor dose-dependently inactivated CYP2E1 of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1108" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">co</infon>
          <location offset="1191" length="2"/>
          <text>CO</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">co</infon>
          <location offset="1060" length="2"/>
          <text>CO</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="1159" length="4"/>
          <text>HO-1</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="1098" length="6"/>
          <text>CYP2E1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1205</offset>
        <text>Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by quercetin through HO-1 induction.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1227" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="1268" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="1211" length="6"/>
          <text>CYP2E1</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="1286" length="4"/>
          <text>HO-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1302</offset>
        <text>Depleted heme pool and CO releasing limited protein synthesis and inhibited enzymatic activity of CYP2E1, respectively.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">co</infon>
          <location offset="1325" length="2"/>
          <text>CO</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="1400" length="6"/>
          <text>CYP2E1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12398910</id>
    <passage>
      <offset>0</offset>
      <text>MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities.	Low levels of serotonin may reduce the density of the serotonin transporter (SERT) by either increasing trafficking or reducing synthesis; a "neuroadaptive response". To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured. As expected, both treatments led to serotonin depletion 1, 7 and 14 days later. However, only MDMA reduced SERT density. This observation suggests that MDMA-induced reductions in SERT density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA.</text>
      <sentence>
        <offset>0</offset>
        <text>MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="0" length="4"/>
          <text>MDMA</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-chlorophenylalanine</infon>
          <location offset="10" length="21"/>
          <text>p-chlorophenylalanine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="53" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="85" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serotonin transporter</infon>
          <location offset="85" length="21"/>
          <text>serotonin transporter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>118</offset>
        <text>Low levels of serotonin may reduce the density of the serotonin transporter (SERT) by either increasing trafficking or reducing synthesis; a "neuroadaptive response".</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="132" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="172" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serotonin transporter</infon>
          <location offset="172" length="21"/>
          <text>serotonin transporter</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="195" length="4"/>
          <text>SERT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>285</offset>
        <text>To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3,4-methylenedioxymethamphetamine</infon>
          <location offset="306" length="33"/>
          <text>3,4-methylenedioxymethamphetamine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="341" length="4"/>
          <text>MDMA</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-chlorophenylalanine</infon>
          <location offset="420" length="21"/>
          <text>p-chlorophenylalanine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="445" length="4"/>
          <text>MDMA</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="486" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="369" length="4"/>
          <text>SERT</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="500" length="4"/>
          <text>SERT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>528</offset>
        <text>As expected, both treatments led to serotonin depletion 1, 7 and 14 days later.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="564" length="9"/>
          <text>serotonin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>608</offset>
        <text>However, only MDMA reduced SERT density.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="622" length="4"/>
          <text>MDMA</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="635" length="4"/>
          <text>SERT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>649</offset>
        <text>This observation suggests that MDMA-induced reductions in SERT density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="680" length="4"/>
          <text>MDMA</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="790" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="882" length="4"/>
          <text>MDMA</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="707" length="4"/>
          <text>SERT</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23189968</id>
    <passage>
      <offset>0</offset>
      <text>Impact of thyroid dysfunction on erythropoietin dosage in hemodialysis patients.	Background: Although thyroid diseases exist in patients with renal failure, thyroid function tests are not routine tests in patients on chronic hemodialysis (HD). Therefore, the impact of thyroid diseases on erythropoietin (EPO) dosage in HD patients is not well defined. This study evaluated the relationship between the dose of EPO and the presence or absence of thyroid dysfunction in HD patients. Methods: This study included 1013 adult patients on HD who did not have a malignancy, liver cirrhosis, thalassemia, iron deficiency, gastrointestinal bleeding, or a major operation within 6 months. Patients were characterized as being euthyroid, or having the sick euthyroid syndrome, primary hypothyroidism, subclinical hypothyroidism, hyperthyroidism, or subclinical hyperthyroidism based on thyroid function tests. Routine biochemistry profiles including an index of the efficiency of HD, along with clinical data over the previous 6-month period, were collected and analyzed. Multiple regression models were employed to assess the relationship between the dose of EPO and the presence or absence of thyroid status. Results: The mean monthly EPO dosages were 77.7±37.0, 70.2±40.6, 90.8±68.4, 78.5±46.7, and 82.3±41.2 μg, respectively, in the sick euthyroid syndrome, euthyroid patients, hypothyroidism, subclinical hypothyroidism, and subclinical hyperthyroidism groups (p&lt;0.05). After adjustment of all other variables in multiple regression, the mean monthly EPO dosage was 19.00±8.59 μg more in hypothyroid patients compared with euthyroid patients (p=0.027). Further, considering an interaction with the presence of diabetes, the mean monthly EPO dosage in patients with either hypothyroidism or subclinical hypothyroidism and diabetes was 54.66±17.12 μg (p=0.001) and 31.51±10.38 μg more than that of euthyroid patients, respectively (p=0.002). Conclusions: In HD patients, the EPO dosage required to maintain the target hemoglobin level is significantly higher in patients having both hypothyroidism or subclinical hypothyroidism and diabetes than in euthyroid patients.</text>
      <sentence>
        <offset>0</offset>
        <text>Impact of thyroid dysfunction on erythropoietin dosage in hemodialysis patients.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erythropoietin</infon>
          <location offset="33" length="14"/>
          <text>erythropoietin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>81</offset>
        <text>Background: Although thyroid diseases exist in patients with renal failure, thyroid function tests are not routine tests in patients on chronic hemodialysis (HD).</text>
      </sentence>
      <sentence>
        <offset>244</offset>
        <text>Therefore, the impact of thyroid diseases on erythropoietin (EPO) dosage in HD patients is not well defined.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erythropoietin</infon>
          <location offset="289" length="14"/>
          <text>erythropoietin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epo</infon>
          <location offset="305" length="3"/>
          <text>EPO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>353</offset>
        <text>This study evaluated the relationship between the dose of EPO and the presence or absence of thyroid dysfunction in HD patients.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epo</infon>
          <location offset="411" length="3"/>
          <text>EPO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>482</offset>
        <text>Methods: This study included 1013 adult patients on HD who did not have a malignancy, liver cirrhosis, thalassemia, iron deficiency, gastrointestinal bleeding, or a major operation within 6 months.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="598" length="4"/>
          <text>iron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>680</offset>
        <text>Patients were characterized as being euthyroid, or having the sick euthyroid syndrome, primary hypothyroidism, subclinical hypothyroidism, hyperthyroidism, or subclinical hyperthyroidism based on thyroid function tests.</text>
      </sentence>
      <sentence>
        <offset>900</offset>
        <text>Routine biochemistry profiles including an index of the efficiency of HD, along with clinical data over the previous 6-month period, were collected and analyzed.</text>
      </sentence>
      <sentence>
        <offset>1062</offset>
        <text>Multiple regression models were employed to assess the relationship between the dose of EPO and the presence or absence of thyroid status.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epo</infon>
          <location offset="1150" length="3"/>
          <text>EPO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1201</offset>
        <text>Results: The mean monthly EPO dosages were 77.7±37.0, 70.2±40.6, 90.8±68.4, 78.5±46.7, and 82.3±41.2 μg, respectively, in the sick euthyroid syndrome, euthyroid patients, hypothyroidism, subclinical hypothyroidism, and subclinical hyperthyroidism groups (p&lt;0.05).</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epo</infon>
          <location offset="1227" length="3"/>
          <text>EPO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1465</offset>
        <text>After adjustment of all other variables in multiple regression, the mean monthly EPO dosage was 19.00±8.59 μg more in hypothyroid patients compared with euthyroid patients (p=0.027).</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epo</infon>
          <location offset="1546" length="3"/>
          <text>EPO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1648</offset>
        <text>Further, considering an interaction with the presence of diabetes, the mean monthly EPO dosage in patients with either hypothyroidism or subclinical hypothyroidism and diabetes was 54.66±17.12 μg (p=0.001) and 31.51±10.38 μg more than that of euthyroid patients, respectively (p=0.002).</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epo</infon>
          <location offset="1732" length="3"/>
          <text>EPO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1935</offset>
        <text>Conclusions: In HD patients, the EPO dosage required to maintain the target hemoglobin level is significantly higher in patients having both hypothyroidism or subclinical hypothyroidism and diabetes than in euthyroid patients.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epo</infon>
          <location offset="1968" length="3"/>
          <text>EPO</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemoglobin</infon>
          <location offset="2011" length="10"/>
          <text>hemoglobin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23469927</id>
    <passage>
      <offset>0</offset>
      <text>Polyclonal Antibody to Soman-Tyrosine.	Soman forms a stable, covalent bond with tyrosine 411 of human albumin, with tyrosines 257 and 593 in human transferrin, and with tyrosine in many other proteins. The pinacolyl group of soman is retained, suggesting that pinacolyl methylphosphonate bound to tyrosine could generate specific antibodies. Tyrosine in the pentapeptide RYGRK was covalently modified with soman simply by adding soman to the peptide. The phosphonylated-peptide was linked to keyhole limpet hemocyanin, and the conjugate was injected into rabbits. The polyclonal antiserum recognized soman-labeled human albumin, soman-mouse albumin, and soman human transferrin but not nonphosphonylated control proteins. The soman-labeled tyrosines in these proteins are surrounded by different amino acid sequences, suggesting that the polyclonal recognizes soman-tyrosine independent of the amino acid sequence. Antiserum obtained after 4 antigen injections over a period of 18 weeks was tested in a competition ELISA where it had an IC50 of 10(-11) M. The limit of detection on Western blots was 0.01 μg (15 picomoles) of soman-labeled albumin. In conclusion, a high-affinity, polyclonal antibody that specifically recognizes soman adducts on tyrosine in a variety of proteins has been produced. Such an antibody could be useful for identifying secondary targets of soman toxicity.</text>
      <sentence>
        <offset>0</offset>
        <text>Polyclonal Antibody to Soman-Tyrosine.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="23" length="5"/>
          <text>Soman</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="29" length="8"/>
          <text>Tyrosine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>39</offset>
        <text>Soman forms a stable, covalent bond with tyrosine 411 of human albumin, with tyrosines 257 and 593 in human transferrin, and with tyrosine in many other proteins.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="39" length="5"/>
          <text>Soman</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="169" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="80" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosines</infon>
          <location offset="116" length="9"/>
          <text>tyrosines</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human transferrin</infon>
          <location offset="141" length="17"/>
          <text>human transferrin</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human albumin</infon>
          <location offset="96" length="13"/>
          <text>human albumin</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T22" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>202</offset>
        <text>The pinacolyl group of soman is retained, suggesting that pinacolyl methylphosphonate bound to tyrosine could generate specific antibodies.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pinacolyl</infon>
          <location offset="206" length="9"/>
          <text>pinacolyl</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="225" length="5"/>
          <text>soman</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pinacolyl methylphosphonate</infon>
          <location offset="260" length="27"/>
          <text>pinacolyl methylphosphonate</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="297" length="8"/>
          <text>tyrosine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>342</offset>
        <text>Tyrosine in the pentapeptide RYGRK was covalently modified with soman simply by adding soman to the peptide.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="342" length="8"/>
          <text>Tyrosine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pentapeptide</infon>
          <location offset="358" length="12"/>
          <text>pentapeptide</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="406" length="5"/>
          <text>soman</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="429" length="5"/>
          <text>soman</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rygrk</infon>
          <location offset="371" length="5"/>
          <text>RYGRK</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T11" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>451</offset>
        <text>The phosphonylated-peptide was linked to keyhole limpet hemocyanin, and the conjugate was injected into rabbits.</text>
      </sentence>
      <sentence>
        <offset>564</offset>
        <text>The polyclonal antiserum recognized soman-labeled human albumin, soman-mouse albumin, and soman human transferrin but not nonphosphonylated control proteins.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="600" length="5"/>
          <text>soman</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="629" length="5"/>
          <text>soman</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="654" length="5"/>
          <text>soman</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human albumin</infon>
          <location offset="614" length="13"/>
          <text>human albumin</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mouse albumin</infon>
          <location offset="635" length="13"/>
          <text>mouse albumin</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human transferrin</infon>
          <location offset="660" length="17"/>
          <text>human transferrin</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>722</offset>
        <text>The soman-labeled tyrosines in these proteins are surrounded by different amino acid sequences, suggesting that the polyclonal recognizes soman-tyrosine independent of the amino acid sequence.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="726" length="5"/>
          <text>soman</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosines</infon>
          <location offset="740" length="9"/>
          <text>tyrosines</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="796" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="860" length="5"/>
          <text>soman</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="866" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="894" length="10"/>
          <text>amino acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>915</offset>
        <text>Antiserum obtained after 4 antigen injections over a period of 18 weeks was tested in a competition ELISA where it had an IC50 of 10(-11) M.</text>
      </sentence>
      <sentence>
        <offset>1056</offset>
        <text>The limit of detection on Western blots was 0.01 μg (15 picomoles) of soman-labeled albumin.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="1126" length="5"/>
          <text>soman</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">albumin</infon>
          <location offset="1140" length="7"/>
          <text>albumin</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1149</offset>
        <text>In conclusion, a high-affinity, polyclonal antibody that specifically recognizes soman adducts on tyrosine in a variety of proteins has been produced.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="1230" length="5"/>
          <text>soman</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="1247" length="8"/>
          <text>tyrosine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1300</offset>
        <text>Such an antibody could be useful for identifying secondary targets of soman toxicity.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="1370" length="5"/>
          <text>soman</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23631440</id>
    <passage>
      <offset>0</offset>
      <text>Matrix Metalloproteinase Inhibitors Based on the 3-Mercaptopyrrolidine Core.	New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated. Exhibiting unique properties over other MMPIs (e.g., hydroxamates), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM). Additionally these compounds are selective to intermediate- and deep-pocket MMPs but not shallow-pocketed MMPs (e.g., MMP-1, ~850 to &gt;50,000 nM; MMP-7, ~4,000 to &gt;25,000 nM). Our previous work with the mercaptosulfide functionality attached to both cyclopentane and pyrrolidine frameworks demonstrated that the cis-(3S,4R)- stereochemistry was optimal for all of the MMPs tested. However, in our newest compounds an interesting shift of preference to the trans- form of the mercaptosulfonamides was observed with increased oxidative stability and biological compatibility. We also report several kinetic and biological characteristics showing that these compounds may be used to probe the mechanistic activities of MMPs in disease.</text>
      <sentence>
        <offset>0</offset>
        <text>Matrix Metalloproteinase Inhibitors Based on the 3-Mercaptopyrrolidine Core.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-mercaptopyrrolidine</infon>
          <location offset="49" length="21"/>
          <text>3-Mercaptopyrrolidine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">matrix metalloproteinase</infon>
          <location offset="0" length="24"/>
          <text>Matrix Metalloproteinase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>77</offset>
        <text>New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrrolidine mercaptosulfide</infon>
          <location offset="91" length="27"/>
          <text>pyrrolidine mercaptosulfide</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-mercaptocyclopentane arylsulfonamide</infon>
          <location offset="120" length="38"/>
          <text>2-mercaptocyclopentane arylsulfonamide</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-mercapto-4-arylsulfonamido pyrrolidine</infon>
          <location offset="164" length="40"/>
          <text>3-mercapto-4-arylsulfonamido pyrrolidine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">matrix metalloproteinase</infon>
          <location offset="205" length="24"/>
          <text>matrix metalloproteinase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>292</offset>
        <text>Exhibiting unique properties over other MMPIs (e.g., hydroxamates), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydroxamates</infon>
          <location offset="345" length="12"/>
          <text>hydroxamates</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mmps</infon>
          <location offset="439" length="4"/>
          <text>MMPs</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mmp-2</infon>
          <location offset="482" length="5"/>
          <text>MMP-2</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mmp-13</infon>
          <location offset="503" length="6"/>
          <text>MMP-13</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mmp-14</infon>
          <location offset="529" length="6"/>
          <text>MMP-14</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>551</offset>
        <text>Additionally these compounds are selective to intermediate- and deep-pocket MMPs but not shallow-pocketed MMPs (e.g., MMP-1, ~850 to &gt;50,000 nM; MMP-7, ~4,000 to &gt;25,000 nM).</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mmps</infon>
          <location offset="627" length="4"/>
          <text>MMPs</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mmps</infon>
          <location offset="657" length="4"/>
          <text>MMPs</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mmp-1</infon>
          <location offset="669" length="5"/>
          <text>MMP-1</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mmp-7</infon>
          <location offset="696" length="5"/>
          <text>MMP-7</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>726</offset>
        <text>Our previous work with the mercaptosulfide functionality attached to both cyclopentane and pyrrolidine frameworks demonstrated that the cis-(3S,4R)- stereochemistry was optimal for all of the MMPs tested.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mercaptosulfide</infon>
          <location offset="753" length="15"/>
          <text>mercaptosulfide</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclopentane</infon>
          <location offset="800" length="12"/>
          <text>cyclopentane</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrrolidine</infon>
          <location offset="817" length="11"/>
          <text>pyrrolidine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mmps</infon>
          <location offset="918" length="4"/>
          <text>MMPs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>931</offset>
        <text>However, in our newest compounds an interesting shift of preference to the trans- form of the mercaptosulfonamides was observed with increased oxidative stability and biological compatibility.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mercaptosulfonamides</infon>
          <location offset="1025" length="20"/>
          <text>mercaptosulfonamides</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1124</offset>
        <text>We also report several kinetic and biological characteristics showing that these compounds may be used to probe the mechanistic activities of MMPs in disease.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mmps</infon>
          <location offset="1266" length="4"/>
          <text>MMPs</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>20360896</id>
    <passage>
      <offset>0</offset>
      <text>Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials.	The clinical benefits of endocrine therapy for patients with hormonosensitive breast cancer are well established. For many years, 5 years of tamoxifen was the gold standard of adjuvant treatment. The recent development of new endocrine agents provides physicians with a more effective therapeutic approach. Nevertheless, the success of neoadjuvant endocrine therapy is much more recent and less reported in the literature. This article reviews the studies published about neoadjuvant endocrine treatment (tamoxifen and aromatase inhibitors). According to the literature, neoadjuvant endocrine therapy seems to be effective. In contrast to neoadjuvant chemotherapy, neoadjuvant endocrine therapy is well tolerated, with very few patients having to discontinue the treatment because of side effects. It does not constitute a standard treatment but could have potential for elderly women with operable, hormonosensitive, well differentiated and slowly progressing (SBR I) tumor or for patients with lobular MSBR 1 carcinoma (low chemosensitivity). The newer generation of aromatase inhibitors (letrozole, anastrozole, exemestane) appears to be more active (in terms of overall response rates and conservative surgery rate) than tamoxifen. Patients with an estrogen receptor Allred score of 6 and over are more likely to respond and gain a clinical benefit. The optimal duration of neoadjuvant therapy has not yet been investigated in detail. These preliminary results should be confirmed by further studies.</text>
      <sentence>
        <offset>0</offset>
        <text>Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials.</text>
      </sentence>
      <sentence>
        <offset>102</offset>
        <text>The clinical benefits of endocrine therapy for patients with hormonosensitive breast cancer are well established.</text>
      </sentence>
      <sentence>
        <offset>216</offset>
        <text>For many years, 5 years of tamoxifen was the gold standard of adjuvant treatment.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="243" length="9"/>
          <text>tamoxifen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>298</offset>
        <text>The recent development of new endocrine agents provides physicians with a more effective therapeutic approach.</text>
      </sentence>
      <sentence>
        <offset>409</offset>
        <text>Nevertheless, the success of neoadjuvant endocrine therapy is much more recent and less reported in the literature.</text>
      </sentence>
      <sentence>
        <offset>525</offset>
        <text>This article reviews the studies published about neoadjuvant endocrine treatment (tamoxifen and aromatase inhibitors).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="607" length="9"/>
          <text>tamoxifen</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="621" length="9"/>
          <text>aromatase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>644</offset>
        <text>According to the literature, neoadjuvant endocrine therapy seems to be effective.</text>
      </sentence>
      <sentence>
        <offset>726</offset>
        <text>In contrast to neoadjuvant chemotherapy, neoadjuvant endocrine therapy is well tolerated, with very few patients having to discontinue the treatment because of side effects.</text>
      </sentence>
      <sentence>
        <offset>900</offset>
        <text>It does not constitute a standard treatment but could have potential for elderly women with operable, hormonosensitive, well differentiated and slowly progressing (SBR I) tumor or for patients with lobular MSBR 1 carcinoma (low chemosensitivity).</text>
      </sentence>
      <sentence>
        <offset>1147</offset>
        <text>The newer generation of aromatase inhibitors (letrozole, anastrozole, exemestane) appears to be more active (in terms of overall response rates and conservative surgery rate) than tamoxifen.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">letrozole</infon>
          <location offset="1193" length="9"/>
          <text>letrozole</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anastrozole</infon>
          <location offset="1204" length="11"/>
          <text>anastrozole</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">exemestane</infon>
          <location offset="1217" length="10"/>
          <text>exemestane</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="1327" length="9"/>
          <text>tamoxifen</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="1171" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1338</offset>
        <text>Patients with an estrogen receptor Allred score of 6 and over are more likely to respond and gain a clinical benefit.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">estrogen receptor</infon>
          <location offset="1355" length="17"/>
          <text>estrogen receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1456</offset>
        <text>The optimal duration of neoadjuvant therapy has not yet been investigated in detail.</text>
      </sentence>
      <sentence>
        <offset>1541</offset>
        <text>These preliminary results should be confirmed by further studies.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23567314</id>
    <passage>
      <offset>0</offset>
      <text>Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes.	While perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) have been studied at length, less is known about the biological activity of other perfluoroalkyl acids (PFAAs) detected in the environment. Using a transient transfection assay developed in COS-1 cells, our group has previously evaluated a variety of PFAAs for activity associated with activation of peroxisome proliferator-activated receptor alpha (PPARα). Here we use primary heptatocytes to further assess the biological activity of a similar group of PFAAs using custom designed Taqman Low Density Arrays. Primary mouse and human hepatoyctes were cultured for 48h in the presence of varying concentrations of 12 different PFAAs or Wy14,643, a known activator of PPARα. Total RNA was collected and the expression of 48 mouse or human genes evaluated. Gene selection was based on either in-house liver microarray data (mouse) or published data using primary hepatocytes (human). Gene expression in primary mouse hepatocytes was more restricted than expected. Genes typically regulated in whole tissue by PPARα agonists were not altered in mouse cells including Acox1, Me1, Acaa1a, Hmgcs1, and Slc27a1. Cyp2b10, a gene regulated by the constitutive androstane receptor and a transcript normally up-regulated by in vivo exposure to PFAAs, was also unchanged in cultured mouse hepatocytes. Cyp4a14, Ehhadh, Pdk4, Cpt1b, and Fabp1 were regulated as expected in mouse cells. A larger group of genes were differentially expressed in human primary hepatocytes, however, little consistency was observed across compounds with respect to which genes produced a significant dose response making the determination of relative biological activity difficult. This likely reflects weaker activation of PPARα in human versus rodent cells as well as variation among individual cell donors. Unlike mouse cells, CYP2B6 was up-regulated in human hepatocytes by a number of PFAAs as was PPARδ. Rankings were conducted on the limited dataset. In mouse hepatocytes, the pattern was similar to that previously observed in the COS-1 reporter cell assay. With the exception of PFHxA, longer chain PFAA carboxylates were the most active. The pattern was similar in human hepatocytes, although PFDA and PFOS showed higher activity than previously observed while PFOA showed somewhat less activity. These data reflect inherent challenges in using primary hepatocytes to predict toxicological response.</text>
      <sentence>
        <offset>0</offset>
        <text>Evaluation of perfluoroalkyl acid activity using primary mouse and human hepatocytes.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">perfluoroalkyl acid</infon>
          <location offset="14" length="19"/>
          <text>perfluoroalkyl acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>86</offset>
        <text>While perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) have been studied at length, less is known about the biological activity of other perfluoroalkyl acids (PFAAs) detected in the environment.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">perfluoroalkyl acids</infon>
          <location offset="241" length="20"/>
          <text>perfluoroalkyl acids</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfaas</infon>
          <location offset="263" length="5"/>
          <text>PFAAs</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfoa</infon>
          <location offset="116" length="4"/>
          <text>PFOA</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">perfluorooctane sulfonate</infon>
          <location offset="126" length="25"/>
          <text>perfluorooctane sulfonate</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">perfluorooctanoic acid</infon>
          <location offset="92" length="22"/>
          <text>perfluorooctanoic acid</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfos</infon>
          <location offset="153" length="4"/>
          <text>PFOS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>299</offset>
        <text>Using a transient transfection assay developed in COS-1 cells, our group has previously evaluated a variety of PFAAs for activity associated with activation of peroxisome proliferator-activated receptor alpha (PPARα).</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfaas</infon>
          <location offset="410" length="5"/>
          <text>PFAAs</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor alpha</infon>
          <location offset="459" length="48"/>
          <text>peroxisome proliferator-activated receptor alpha</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparα</infon>
          <location offset="509" length="5"/>
          <text>PPARα</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>517</offset>
        <text>Here we use primary heptatocytes to further assess the biological activity of a similar group of PFAAs using custom designed Taqman Low Density Arrays.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfaas</infon>
          <location offset="614" length="5"/>
          <text>PFAAs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>669</offset>
        <text>Primary mouse and human hepatoyctes were cultured for 48h in the presence of varying concentrations of 12 different PFAAs or Wy14,643, a known activator of PPARα.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfaas</infon>
          <location offset="785" length="5"/>
          <text>PFAAs</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wy14,643</infon>
          <location offset="794" length="8"/>
          <text>Wy14,643</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparα</infon>
          <location offset="825" length="5"/>
          <text>PPARα</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T18" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>832</offset>
        <text>Total RNA was collected and the expression of 48 mouse or human genes evaluated.</text>
      </sentence>
      <sentence>
        <offset>913</offset>
        <text>Gene selection was based on either in-house liver microarray data (mouse) or published data using primary hepatocytes (human).</text>
      </sentence>
      <sentence>
        <offset>1040</offset>
        <text>Gene expression in primary mouse hepatocytes was more restricted than expected.</text>
      </sentence>
      <sentence>
        <offset>1120</offset>
        <text>Genes typically regulated in whole tissue by PPARα agonists were not altered in mouse cells including Acox1, Me1, Acaa1a, Hmgcs1, and Slc27a1.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparα</infon>
          <location offset="1165" length="5"/>
          <text>PPARα</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acox1</infon>
          <location offset="1222" length="5"/>
          <text>Acox1</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">me1</infon>
          <location offset="1229" length="3"/>
          <text>Me1</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acaa1a</infon>
          <location offset="1234" length="6"/>
          <text>Acaa1a</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hmgcs1</infon>
          <location offset="1242" length="6"/>
          <text>Hmgcs1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">slc27a1</infon>
          <location offset="1254" length="7"/>
          <text>Slc27a1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1263</offset>
        <text>Cyp2b10, a gene regulated by the constitutive androstane receptor and a transcript normally up-regulated by in vivo exposure to PFAAs, was also unchanged in cultured mouse hepatocytes.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androstane</infon>
          <location offset="1309" length="10"/>
          <text>androstane</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfaas</infon>
          <location offset="1391" length="5"/>
          <text>PFAAs</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2b10</infon>
          <location offset="1263" length="7"/>
          <text>Cyp2b10</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">constitutive androstane receptor</infon>
          <location offset="1296" length="32"/>
          <text>constitutive androstane receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1448</offset>
        <text>Cyp4a14, Ehhadh, Pdk4, Cpt1b, and Fabp1 were regulated as expected in mouse cells.</text>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp4a14</infon>
          <location offset="1448" length="7"/>
          <text>Cyp4a14</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ehhadh</infon>
          <location offset="1457" length="6"/>
          <text>Ehhadh</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdk4</infon>
          <location offset="1465" length="4"/>
          <text>Pdk4</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cpt1b</infon>
          <location offset="1471" length="5"/>
          <text>Cpt1b</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fabp1</infon>
          <location offset="1482" length="5"/>
          <text>Fabp1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1531</offset>
        <text>A larger group of genes were differentially expressed in human primary hepatocytes, however, little consistency was observed across compounds with respect to which genes produced a significant dose response making the determination of relative biological activity difficult.</text>
      </sentence>
      <sentence>
        <offset>1806</offset>
        <text>This likely reflects weaker activation of PPARα in human versus rodent cells as well as variation among individual cell donors.</text>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparα</infon>
          <location offset="1848" length="5"/>
          <text>PPARα</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1934</offset>
        <text>Unlike mouse cells, CYP2B6 was up-regulated in human hepatocytes by a number of PFAAs as was PPARδ.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfaas</infon>
          <location offset="2014" length="5"/>
          <text>PFAAs</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2b6</infon>
          <location offset="1954" length="6"/>
          <text>CYP2B6</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparδ</infon>
          <location offset="2027" length="5"/>
          <text>PPARδ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2034</offset>
        <text>Rankings were conducted on the limited dataset.</text>
      </sentence>
      <sentence>
        <offset>2082</offset>
        <text>In mouse hepatocytes, the pattern was similar to that previously observed in the COS-1 reporter cell assay.</text>
      </sentence>
      <sentence>
        <offset>2190</offset>
        <text>With the exception of PFHxA, longer chain PFAA carboxylates were the most active.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfaa</infon>
          <location offset="2232" length="4"/>
          <text>PFAA</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carboxylates</infon>
          <location offset="2237" length="12"/>
          <text>carboxylates</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2272</offset>
        <text>The pattern was similar in human hepatocytes, although PFDA and PFOS showed higher activity than previously observed while PFOA showed somewhat less activity.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfda</infon>
          <location offset="2327" length="4"/>
          <text>PFDA</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfos</infon>
          <location offset="2336" length="4"/>
          <text>PFOS</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pfoa</infon>
          <location offset="2395" length="4"/>
          <text>PFOA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2431</offset>
        <text>These data reflect inherent challenges in using primary hepatocytes to predict toxicological response.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23150493</id>
    <passage>
      <offset>0</offset>
      <text>Susceptibility to fatty acid-induced β-cell dysfunction is enhanced in prediabetic diabetes-prone biobreeding rats: a potential link between β-cell lipotoxicity and islet inflammation.	β-Cell lipotoxicity is thought to play an important role in the development of type 2 diabetes. However, no study has examined its role in type 1 diabetes, which could be clinically relevant for slow-onset type 1 diabetes. Reports of enhanced cytokine toxicity in fat-laden islets are consistent with the hypothesis that lipid and cytokine toxicity may be synergistic. Thus, β-cell lipotoxicity could be enhanced in models of autoimmune diabetes. To determine this, we examined the effects of prolonged free fatty acids elevation on β-cell secretory function in the prediabetic diabetes-prone BioBreeding (dp-BB) rat, its diabetes-resistant BioBreeding (dr-BB) control, and normal Wistar-Furth (WF) rats. Rats received a 48-h iv infusion of saline or Intralipid plus heparin (IH) (to elevate free fatty acid levels ~2-fold) followed by hyperglycemic clamp or islet secretion studies ex vivo. IH significantly decreased β-cell function, assessed both by the disposition index (insulin secretion corrected for IH-induced insulin resistance) and in isolated islets, in dp-BB, but not in dr-BB or WF, rats, and the effect of IH was inhibited by the antioxidant N-acetylcysteine. Furthermore, IH significantly increased islet cytokine mRNA and plasma cytokine levels (monocyte chemoattractant protein-1 and IL-10) in dp-BB, but not in dr-BB or WF, rats. All dp-BB rats had mononuclear infiltration of islets, which was absent in dr-BB and WF rats. In conclusion, the presence of insulitis was permissive for IH-induced β-cell dysfunction in the BB rat, which suggests a link between β-cell lipotoxicity and islet inflammation.</text>
      <sentence>
        <offset>0</offset>
        <text>Susceptibility to fatty acid-induced β-cell dysfunction is enhanced in prediabetic diabetes-prone biobreeding rats: a potential link between β-cell lipotoxicity and islet inflammation.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="18" length="10"/>
          <text>fatty acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>185</offset>
        <text>β-Cell lipotoxicity is thought to play an important role in the development of type 2 diabetes.</text>
      </sentence>
      <sentence>
        <offset>281</offset>
        <text>However, no study has examined its role in type 1 diabetes, which could be clinically relevant for slow-onset type 1 diabetes.</text>
      </sentence>
      <sentence>
        <offset>408</offset>
        <text>Reports of enhanced cytokine toxicity in fat-laden islets are consistent with the hypothesis that lipid and cytokine toxicity may be synergistic.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine</infon>
          <location offset="428" length="8"/>
          <text>cytokine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine</infon>
          <location offset="516" length="8"/>
          <text>cytokine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>554</offset>
        <text>Thus, β-cell lipotoxicity could be enhanced in models of autoimmune diabetes.</text>
      </sentence>
      <sentence>
        <offset>632</offset>
        <text>To determine this, we examined the effects of prolonged free fatty acids elevation on β-cell secretory function in the prediabetic diabetes-prone BioBreeding (dp-BB) rat, its diabetes-resistant BioBreeding (dr-BB) control, and normal Wistar-Furth (WF) rats.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acids</infon>
          <location offset="693" length="11"/>
          <text>fatty acids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>890</offset>
        <text>Rats received a 48-h iv infusion of saline or Intralipid plus heparin (IH) (to elevate free fatty acid levels ~2-fold) followed by hyperglycemic clamp or islet secretion studies ex vivo.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="982" length="10"/>
          <text>fatty acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1077</offset>
        <text>IH significantly decreased β-cell function, assessed both by the disposition index (insulin secretion corrected for IH-induced insulin resistance) and in isolated islets, in dp-BB, but not in dr-BB or WF, rats, and the effect of IH was inhibited by the antioxidant N-acetylcysteine.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-acetylcysteine</infon>
          <location offset="1342" length="16"/>
          <text>N-acetylcysteine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1204" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1161" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1360</offset>
        <text>Furthermore, IH significantly increased islet cytokine mRNA and plasma cytokine levels (monocyte chemoattractant protein-1 and IL-10) in dp-BB, but not in dr-BB or WF, rats.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine</infon>
          <location offset="1406" length="8"/>
          <text>cytokine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine</infon>
          <location offset="1431" length="8"/>
          <text>cytokine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monocyte chemoattractant protein-1</infon>
          <location offset="1448" length="34"/>
          <text>monocyte chemoattractant protein-1</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-10</infon>
          <location offset="1487" length="5"/>
          <text>IL-10</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1534</offset>
        <text>All dp-BB rats had mononuclear infiltration of islets, which was absent in dr-BB and WF rats.</text>
      </sentence>
      <sentence>
        <offset>1628</offset>
        <text>In conclusion, the presence of insulitis was permissive for IH-induced β-cell dysfunction in the BB rat, which suggests a link between β-cell lipotoxicity and islet inflammation.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17109615</id>
    <passage>
      <offset>0</offset>
      <text>Trilostane in advanced breast cancer.	Antiestrogens, principally tamoxifen, and aromatase inhibitors have been used as the first- and second-line therapy in patients with advanced postmenopausal breast cancer for many years. However, some patients acquire resistance to these treatments and, at present, further endocrine treatment is achieved by merely substituting the current medication with a different antiestrogen or aromatase inhibitor. Trilostane offers an alternative endocrine treatment due to its unique mode of action. It is an allosteric modulator of the estrogen receptor and targets both the estrogen- and growth factor-dependent pathways through which estradiol stimulates cell proliferation. In clinical trials, trilostane has been shown to be an effective treatment for breast cancer in patients who have relapsed after receiving treatment with one or more forms of endocrine therapy. Ongoing and future clinical trials are examining the potential for the use of trilostane in premenopausal breast cancer, as well as in other malignancies such as prostate cancer.</text>
      <sentence>
        <offset>0</offset>
        <text>Trilostane in advanced breast cancer.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trilostane</infon>
          <location offset="0" length="10"/>
          <text>Trilostane</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>38</offset>
        <text>Antiestrogens, principally tamoxifen, and aromatase inhibitors have been used as the first- and second-line therapy in patients with advanced postmenopausal breast cancer for many years.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="65" length="9"/>
          <text>tamoxifen</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="80" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>225</offset>
        <text>However, some patients acquire resistance to these treatments and, at present, further endocrine treatment is achieved by merely substituting the current medication with a different antiestrogen or aromatase inhibitor.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="423" length="9"/>
          <text>aromatase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>444</offset>
        <text>Trilostane offers an alternative endocrine treatment due to its unique mode of action.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trilostane</infon>
          <location offset="444" length="10"/>
          <text>Trilostane</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>531</offset>
        <text>It is an allosteric modulator of the estrogen receptor and targets both the estrogen- and growth factor-dependent pathways through which estradiol stimulates cell proliferation.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="568" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="607" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estradiol</infon>
          <location offset="668" length="9"/>
          <text>estradiol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">estrogen receptor</infon>
          <location offset="568" length="17"/>
          <text>estrogen receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>709</offset>
        <text>In clinical trials, trilostane has been shown to be an effective treatment for breast cancer in patients who have relapsed after receiving treatment with one or more forms of endocrine therapy.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trilostane</infon>
          <location offset="729" length="10"/>
          <text>trilostane</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>903</offset>
        <text>Ongoing and future clinical trials are examining the potential for the use of trilostane in premenopausal breast cancer, as well as in other malignancies such as prostate cancer.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trilostane</infon>
          <location offset="981" length="10"/>
          <text>trilostane</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23266732</id>
    <passage>
      <offset>0</offset>
      <text>Effects of Yerba Mate tea (Ilex paraguariensis) on vascular endothelial function and liver lipoprotein receptor gene expression in hyperlipidemic rats.	Yerba Mate tea (Mate), an infusion made from the leaves of the tree Ilex paraguariensis, is a widely consumed beverage in South America. This study was performed to investigate the effect of Mate tea on vascular endothelial dysfunction and liver lipoprotein receptor gene expression in hyperlipidemic rats, with the aim of gaining insight into its known lipid-lowering protective mechanisms. Sixty male Sprague-Dawley rats were randomly divided into five groups: a normal control group (NC), a high-fat diet group (HC), and three Mate tea-treated groups. In the NC group, rats were fed with standard diet while in the other groups the rats were fed a high-fat diet for 8weeks. In the Mate tea-treated groups, the rats were fed a high-fat diet supplemented with low, moderate or high concentrations of aqueous Mate tea extract for the final 4weeks. Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1). These findings indicate that Mate tea administration might have a regulatory effect on blood fat and endothelial function in hyperlipidemia rats. The mechanism may involve protecting vascular endothelial cell function and upregulating the expression of LDLR and SR-B1 genes, thereby inhibiting the occurrence of atherosclerosis.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of Yerba Mate tea (Ilex paraguariensis) on vascular endothelial function and liver lipoprotein receptor gene expression in hyperlipidemic rats.</text>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lipoprotein receptor</infon>
          <location offset="91" length="20"/>
          <text>lipoprotein receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>152</offset>
        <text>Yerba Mate tea (Mate), an infusion made from the leaves of the tree Ilex paraguariensis, is a widely consumed beverage in South America.</text>
      </sentence>
      <sentence>
        <offset>289</offset>
        <text>This study was performed to investigate the effect of Mate tea on vascular endothelial dysfunction and liver lipoprotein receptor gene expression in hyperlipidemic rats, with the aim of gaining insight into its known lipid-lowering protective mechanisms.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lipoprotein receptor</infon>
          <location offset="398" length="20"/>
          <text>lipoprotein receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>544</offset>
        <text>Sixty male Sprague-Dawley rats were randomly divided into five groups: a normal control group (NC), a high-fat diet group (HC), and three Mate tea-treated groups.</text>
      </sentence>
      <sentence>
        <offset>707</offset>
        <text>In the NC group, rats were fed with standard diet while in the other groups the rats were fed a high-fat diet for 8weeks.</text>
      </sentence>
      <sentence>
        <offset>829</offset>
        <text>In the Mate tea-treated groups, the rats were fed a high-fat diet supplemented with low, moderate or high concentrations of aqueous Mate tea extract for the final 4weeks.</text>
      </sentence>
      <sentence>
        <offset>1000</offset>
        <text>Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">no</infon>
          <location offset="1154" length="2"/>
          <text>NO</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-keto prostaglandin f(1α)</infon>
          <location offset="1162" length="26"/>
          <text>6-keto prostaglandin F(1α)</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-keto-pgf(1α)</infon>
          <location offset="1190" length="14"/>
          <text>6-keto-PGF(1α)</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thromboxane b(2)</infon>
          <location offset="1093" length="16"/>
          <text>thromboxane B(2)</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">txb(2)</infon>
          <location offset="1111" length="6"/>
          <text>TXB(2)</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="1140" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">intercellular adhesion molecule-1</infon>
          <location offset="1300" length="33"/>
          <text>intercellular adhesion molecule-1</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">icam-1</infon>
          <location offset="1335" length="6"/>
          <text>ICAM-1</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">low density lipoprotein receptor</infon>
          <location offset="1428" length="32"/>
          <text>low density lipoprotein receptor</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldlr</infon>
          <location offset="1462" length="4"/>
          <text>LDLR</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">scavenger receptor b1</infon>
          <location offset="1472" length="21"/>
          <text>scavenger receptor B1</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sr-b1</infon>
          <location offset="1495" length="5"/>
          <text>SR-B1</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">endothelin</infon>
          <location offset="1073" length="10"/>
          <text>endothelin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">et</infon>
          <location offset="1085" length="2"/>
          <text>ET</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1503</offset>
        <text>These findings indicate that Mate tea administration might have a regulatory effect on blood fat and endothelial function in hyperlipidemia rats.</text>
      </sentence>
      <sentence>
        <offset>1649</offset>
        <text>The mechanism may involve protecting vascular endothelial cell function and upregulating the expression of LDLR and SR-B1 genes, thereby inhibiting the occurrence of atherosclerosis.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldlr</infon>
          <location offset="1756" length="4"/>
          <text>LDLR</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sr-b1</infon>
          <location offset="1765" length="5"/>
          <text>SR-B1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11350861</id>
    <passage>
      <offset>0</offset>
      <text>The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.	The anti-emetic and pharmacological profile of AS-8112 ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent dopamine D2, D3 and 5-hydroxytryptamine-3 (5-HT3) receptors ligand, was investigated in the present study. In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a 5-HT3 receptor agonist (pA2 value of 7.04). Other 5-HT3 receptor antagonists also produced such a shift in the following antagonistic-potency order: granisetron&gt; ondansetron=AS-8112&gt;&gt;metoclopramide. In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.). Domperidone and haloperidol, which have affinity for dopamine D3 receptor, also inhibited R(+)-7-OH-DPAT-induced hypothermia. In ferrets or dogs, AS-8112 dose-dependently inhibited emesis induced by R(+)-7-OH-DPAT, apomorphine, morphine or cisplatin with ID50 values of 2.22 microg kg(-1) s.c., 10.5 microg kg(-1) s.c., 14.2 microg kg(-1) i.v. and 17.6 microg kg(-1) i.v., respectively. Moreover, oral administration of AS-8112 significantly inhibited emesis induced by these emetogens. AS-8112 (0.3 mg kg(-1) i.v.) significantly inhibited emesis induced by cyclophosphamide and doxorubicin. In conclusion, AS-8112 is a potent dopamine D2, D3 and 5-HT3 receptors antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity. These results suggest that this compound is worthy of clinical investigation.</text>
      <sentence>
        <offset>0</offset>
        <text>The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.</text>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">as-8112</infon>
          <location offset="43" length="7"/>
          <text>AS-8112</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="60" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine d2, d3</infon>
          <location offset="60" length="15"/>
          <text>dopamine D2, D3</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht3 receptors</infon>
          <location offset="80" length="15"/>
          <text>5-HT3 receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T30" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>108</offset>
        <text>The anti-emetic and pharmacological profile of AS-8112 ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent dopamine D2, D3 and 5-hydroxytryptamine-3 (5-HT3) receptors ligand, was investigated in the present study.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="306" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-hydroxytryptamine</infon>
          <location offset="326" length="19"/>
          <text>5-hydroxytryptamine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">as-8112</infon>
          <location offset="155" length="7"/>
          <text>AS-8112</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate</infon>
          <location offset="164" length="120"/>
          <text>(R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine d2, d3</infon>
          <location offset="306" length="15"/>
          <text>dopamine D2, D3</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-hydroxytryptamine-3 (5-ht3) receptors</infon>
          <location offset="326" length="39"/>
          <text>5-hydroxytryptamine-3 (5-HT3) receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>413</offset>
        <text>In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a 5-HT3 receptor agonist (pA2 value of 7.04).</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">as-8112</infon>
          <location offset="443" length="7"/>
          <text>AS-8112</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-methyl-5ht</infon>
          <location offset="518" length="12"/>
          <text>2-methyl-5HT</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht3 receptor</infon>
          <location offset="534" length="14"/>
          <text>5-HT3 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T14" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T13" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>578</offset>
        <text>Other 5-HT3 receptor antagonists also produced such a shift in the following antagonistic-potency order: granisetron&gt; ondansetron=AS-8112&gt;&gt;metoclopramide.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">granisetron</infon>
          <location offset="683" length="11"/>
          <text>granisetron</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ondansetron</infon>
          <location offset="696" length="11"/>
          <text>ondansetron</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">as-8112</infon>
          <location offset="708" length="7"/>
          <text>AS-8112</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metoclopramide</infon>
          <location offset="717" length="14"/>
          <text>metoclopramide</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht3 receptor</infon>
          <location offset="584" length="14"/>
          <text>5-HT3 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T20" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T17" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T19" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T18" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>733</offset>
        <text>In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">as-8112</infon>
          <location offset="742" length="7"/>
          <text>AS-8112</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="823" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">r(+)-7-oh-dpat</infon>
          <location offset="853" length="14"/>
          <text>R(+)-7-OH-DPAT</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">r(+)-7-hydroxy-2-(n,n-di-n-propylamino)tetraline</infon>
          <location offset="869" length="48"/>
          <text>R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d3 receptor</infon>
          <location offset="823" length="20"/>
          <text>dopamine D3 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T23" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T24" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>941</offset>
        <text>Domperidone and haloperidol, which have affinity for dopamine D3 receptor, also inhibited R(+)-7-OH-DPAT-induced hypothermia.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">domperidone</infon>
          <location offset="941" length="11"/>
          <text>Domperidone</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">haloperidol</infon>
          <location offset="957" length="11"/>
          <text>haloperidol</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="994" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">r(+)-7-oh-dpat</infon>
          <location offset="1031" length="14"/>
          <text>R(+)-7-OH-DPAT</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d3 receptor</infon>
          <location offset="994" length="20"/>
          <text>dopamine D3 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T26" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T25" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1067</offset>
        <text>In ferrets or dogs, AS-8112 dose-dependently inhibited emesis induced by R(+)-7-OH-DPAT, apomorphine, morphine or cisplatin with ID50 values of 2.22 microg kg(-1) s.c., 10.5 microg kg(-1) s.c., 14.2 microg kg(-1) i.v. and 17.6 microg kg(-1) i.v., respectively.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">r(+)-7-oh-dpat</infon>
          <location offset="1140" length="14"/>
          <text>R(+)-7-OH-DPAT</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">apomorphine</infon>
          <location offset="1156" length="11"/>
          <text>apomorphine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="1169" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="1181" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">as-8112</infon>
          <location offset="1087" length="7"/>
          <text>AS-8112</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1328</offset>
        <text>Moreover, oral administration of AS-8112 significantly inhibited emesis induced by these emetogens.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">as-8112</infon>
          <location offset="1361" length="7"/>
          <text>AS-8112</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1428</offset>
        <text>AS-8112 (0.3 mg kg(-1) i.v.) significantly inhibited emesis induced by cyclophosphamide and doxorubicin.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">as-8112</infon>
          <location offset="1428" length="7"/>
          <text>AS-8112</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclophosphamide</infon>
          <location offset="1499" length="16"/>
          <text>cyclophosphamide</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1520" length="11"/>
          <text>doxorubicin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1533</offset>
        <text>In conclusion, AS-8112 is a potent dopamine D2, D3 and 5-HT3 receptors antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">as-8112</infon>
          <location offset="1548" length="7"/>
          <text>AS-8112</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1568" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine d2, d3</infon>
          <location offset="1568" length="15"/>
          <text>dopamine D2, D3</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht3 receptors</infon>
          <location offset="1588" length="15"/>
          <text>5-HT3 receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1693</offset>
        <text>These results suggest that this compound is worthy of clinical investigation.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15481543</id>
    <passage>
      <offset>0</offset>
      <text>[Heteologous expression of Mortierella isabellina delta6 -fatty acid desaturase gene in soybean].	Gamma-linolenic acid (GLA, C18:3delta(6, 9, 12) is one of nutritionally important polyunsaturated fatty acids in human and animal diets. Vast majority oilseeds crops do not produce GLA. Delta6-fatty acid desaturase (D6D) is the rate-limiting enzyme, which catalyzes the conversion of linoleic acid (LA) and alpha-linolenic acid (ALA) to GLA and octadecatetraenoic acid (OTA). In this study, a delta6-fatty acid desaturase gene isolated from Mortierella isabellina was transformed into some soybean cultivars Jilin 35, Jilin 47, Suinong 10, Suinong 14 and Heinong 37 successfully by agrobacterium-mediated cotylendon node transformation system. The results of PCR analysis, Southern blotting and Northern blotting with transgenic plants indicated that target gene was integrated into transgenic soybean genome and expressed at the level of RNA. Meanwhile, total fatty acids were extracted from transgenic seeds and methyl-esterified. Analysis of gas chromatograph (GC) showed that a novel peak corresponding to the standard of GLA methyl ester was detected, the highest percentage of gamma-lenolenic acid to total fatty acids in transgenic seeds was 27. 067%, which indicated that Mortierella isabellina delta6-fatty acid desaturase gene was expressed in transgenic soybean. It is so far the first report on the expression of delta6-fatty acid desaturase gene in transgenic soybean in the world.</text>
      <sentence>
        <offset>0</offset>
        <text>[Heteologous expression of Mortierella isabellina delta6 -fatty acid desaturase gene in soybean].</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="58" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mortierella isabellina delta6 -fatty acid desaturase</infon>
          <location offset="27" length="52"/>
          <text>Mortierella isabellina delta6 -fatty acid desaturase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>98</offset>
        <text>Gamma-linolenic acid (GLA, C18:3delta(6, 9, 12) is one of nutritionally important polyunsaturated fatty acids in human and animal diets.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gamma-linolenic acid</infon>
          <location offset="98" length="20"/>
          <text>Gamma-linolenic acid</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gla</infon>
          <location offset="120" length="3"/>
          <text>GLA</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acids</infon>
          <location offset="196" length="11"/>
          <text>fatty acids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>235</offset>
        <text>Vast majority oilseeds crops do not produce GLA.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gla</infon>
          <location offset="279" length="3"/>
          <text>GLA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>284</offset>
        <text>Delta6-fatty acid desaturase (D6D) is the rate-limiting enzyme, which catalyzes the conversion of linoleic acid (LA) and alpha-linolenic acid (ALA) to GLA and octadecatetraenoic acid (OTA).</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="291" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">linoleic acid</infon>
          <location offset="382" length="13"/>
          <text>linoleic acid</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">la</infon>
          <location offset="397" length="2"/>
          <text>LA</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alpha-linolenic acid</infon>
          <location offset="405" length="20"/>
          <text>alpha-linolenic acid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="427" length="3"/>
          <text>ALA</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gla</infon>
          <location offset="435" length="3"/>
          <text>GLA</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">octadecatetraenoic acid</infon>
          <location offset="443" length="23"/>
          <text>octadecatetraenoic acid</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ota</infon>
          <location offset="468" length="3"/>
          <text>OTA</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">delta6-fatty acid desaturase</infon>
          <location offset="284" length="28"/>
          <text>Delta6-fatty acid desaturase</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d6d</infon>
          <location offset="314" length="3"/>
          <text>D6D</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T14" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T14" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T16" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T16" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>474</offset>
        <text>In this study, a delta6-fatty acid desaturase gene isolated from Mortierella isabellina was transformed into some soybean cultivars Jilin 35, Jilin 47, Suinong 10, Suinong 14 and Heinong 37 successfully by agrobacterium-mediated cotylendon node transformation system.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="498" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">delta6-fatty acid desaturase</infon>
          <location offset="491" length="28"/>
          <text>delta6-fatty acid desaturase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>742</offset>
        <text>The results of PCR analysis, Southern blotting and Northern blotting with transgenic plants indicated that target gene was integrated into transgenic soybean genome and expressed at the level of RNA.</text>
      </sentence>
      <sentence>
        <offset>942</offset>
        <text>Meanwhile, total fatty acids were extracted from transgenic seeds and methyl-esterified.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acids</infon>
          <location offset="959" length="11"/>
          <text>fatty acids</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methyl</infon>
          <location offset="1012" length="6"/>
          <text>methyl</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1031</offset>
        <text>Analysis of gas chromatograph (GC) showed that a novel peak corresponding to the standard of GLA methyl ester was detected, the highest percentage of gamma-lenolenic acid to total fatty acids in transgenic seeds was 27. 067%, which indicated that Mortierella isabellina delta6-fatty acid desaturase gene was expressed in transgenic soybean.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gla methyl ester</infon>
          <location offset="1124" length="16"/>
          <text>GLA methyl ester</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gamma-lenolenic acid</infon>
          <location offset="1181" length="20"/>
          <text>gamma-lenolenic acid</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acids</infon>
          <location offset="1211" length="11"/>
          <text>fatty acids</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="1308" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mortierella isabellina delta6-fatty acid desaturase</infon>
          <location offset="1278" length="51"/>
          <text>Mortierella isabellina delta6-fatty acid desaturase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1372</offset>
        <text>It is so far the first report on the expression of delta6-fatty acid desaturase gene in transgenic soybean in the world.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="1430" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">delta6-fatty acid desaturase</infon>
          <location offset="1423" length="28"/>
          <text>delta6-fatty acid desaturase</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23510370</id>
    <passage>
      <offset>0</offset>
      <text>Ectopic Thyroid Tissue in the Adrenal Gland: Report of 2 Cases with Pathogenetic Implications.	Background: Ectopic thyroid tissue is usually found anywhere along the embryonic descent pathway of the medial thyroid anlage from the tongue to the trachea (Wölfler area). However, ectopic thyroid tissue in the adrenal gland (ETTAG) is not easy to understand on the basis of thyroid embryology; because it is so rare, the possibility of metastasis should first be considered. Here, we describe 2 cases of ETTAG with pathogenetic implications and review the literature. Patient findings: Two cases of ETTAG presented as incidental cystic adrenal masses in adult females, one having a congenital hernia of Morgagni. The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human sodium iodide symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis. No C cells (negativity for calcitonin, cromogranin and synaptophysin) were present. Neither BRAF nor KRAS mutations were detected with real-time polymerase chain reaction analysis. Further work-up did not show evidence of thyroid malignancy. Summary: ETTAG is a rare finding, with only 7 cases reported; women are much more frequently affected than men (8:1) and it usually clinically presents in the fifth decade (mean age: 54, range: 38-67) as a cystic adrenal mass incidentally discovered on abdominal ultrasonography and/or in computed tomography images. ETTAG is composed of normal follicular cells without C cells. The expression of some transcription factors (TTF-1, PAX8 and FOXE1) involved in development and/or migration of the medial thyroid anlage is preserved. Coexistence of a congenital hernia of Morgagni in one patient suggests an over-descent of medial thyroid anlage derived cells in its pathogenesis. Conclusion: Although ETTAG pathogenesis remains unknown, the lack of C cells together with the coexistence of a congenital defect of the anterior diaphragm (hernia of Morgagni) in one of our patients could suggest an over-descent of medial thyroid anlagen derived cells in the origin of this heterotopia.</text>
      <sentence>
        <offset>0</offset>
        <text>Ectopic Thyroid Tissue in the Adrenal Gland: Report of 2 Cases with Pathogenetic Implications.</text>
      </sentence>
      <sentence>
        <offset>95</offset>
        <text>Background: Ectopic thyroid tissue is usually found anywhere along the embryonic descent pathway of the medial thyroid anlage from the tongue to the trachea (Wölfler area).</text>
      </sentence>
      <sentence>
        <offset>268</offset>
        <text>However, ectopic thyroid tissue in the adrenal gland (ETTAG) is not easy to understand on the basis of thyroid embryology; because it is so rare, the possibility of metastasis should first be considered.</text>
      </sentence>
      <sentence>
        <offset>472</offset>
        <text>Here, we describe 2 cases of ETTAG with pathogenetic implications and review the literature.</text>
      </sentence>
      <sentence>
        <offset>565</offset>
        <text>Patient findings: Two cases of ETTAG presented as incidental cystic adrenal masses in adult females, one having a congenital hernia of Morgagni.</text>
      </sentence>
      <sentence>
        <offset>710</offset>
        <text>The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human sodium iodide symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium iodide</infon>
          <location offset="1007" length="13"/>
          <text>sodium iodide</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thyroglobulin</infon>
          <location offset="1134" length="13"/>
          <text>thyroglobulin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thyroglobulin</infon>
          <location offset="874" length="13"/>
          <text>thyroglobulin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thyroperoxidase</infon>
          <location offset="889" length="15"/>
          <text>thyroperoxidase</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thyroid transcription factor-1</infon>
          <location offset="906" length="30"/>
          <text>thyroid transcription factor-1</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ttf-1</infon>
          <location offset="938" length="5"/>
          <text>TTF-1</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">titf-1</infon>
          <location offset="944" length="6"/>
          <text>Titf-1</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nkx2.1</infon>
          <location offset="951" length="6"/>
          <text>Nkx2.1</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokeratin</infon>
          <location offset="960" length="11"/>
          <text>cytokeratin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ck</infon>
          <location offset="973" length="2"/>
          <text>CK</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ck 7</infon>
          <location offset="986" length="4"/>
          <text>CK 7</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pendrin</infon>
          <location offset="992" length="7"/>
          <text>pendrin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human sodium iodide symporter</infon>
          <location offset="1001" length="29"/>
          <text>human sodium iodide symporter</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hnis</infon>
          <location offset="1032" length="4"/>
          <text>hNIS</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">paired box gene 8</infon>
          <location offset="1039" length="17"/>
          <text>paired box gene 8</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pax8</infon>
          <location offset="1058" length="4"/>
          <text>PAX8</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">foxe1</infon>
          <location offset="1068" length="5"/>
          <text>FOXE1</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ttf-2</infon>
          <location offset="1075" length="5"/>
          <text>TTF-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1188</offset>
        <text>No C cells (negativity for calcitonin, cromogranin and synaptophysin) were present.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">calcitonin</infon>
          <location offset="1215" length="10"/>
          <text>calcitonin</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cromogranin</infon>
          <location offset="1227" length="11"/>
          <text>cromogranin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">synaptophysin</infon>
          <location offset="1243" length="13"/>
          <text>synaptophysin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1272</offset>
        <text>Neither BRAF nor KRAS mutations were detected with real-time polymerase chain reaction analysis.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">braf</infon>
          <location offset="1280" length="4"/>
          <text>BRAF</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kras</infon>
          <location offset="1289" length="4"/>
          <text>KRAS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1369</offset>
        <text>Further work-up did not show evidence of thyroid malignancy.</text>
      </sentence>
      <sentence>
        <offset>1430</offset>
        <text>Summary: ETTAG is a rare finding, with only 7 cases reported; women are much more frequently affected than men (8:1) and it usually clinically presents in the fifth decade (mean age: 54, range: 38-67) as a cystic adrenal mass incidentally discovered on abdominal ultrasonography and/or in computed tomography images.</text>
      </sentence>
      <sentence>
        <offset>1747</offset>
        <text>ETTAG is composed of normal follicular cells without C cells.</text>
      </sentence>
      <sentence>
        <offset>1809</offset>
        <text>The expression of some transcription factors (TTF-1, PAX8 and FOXE1) involved in development and/or migration of the medial thyroid anlage is preserved.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ttf-1</infon>
          <location offset="1855" length="5"/>
          <text>TTF-1</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pax8</infon>
          <location offset="1862" length="4"/>
          <text>PAX8</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">foxe1</infon>
          <location offset="1871" length="5"/>
          <text>FOXE1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1962</offset>
        <text>Coexistence of a congenital hernia of Morgagni in one patient suggests an over-descent of medial thyroid anlage derived cells in its pathogenesis.</text>
      </sentence>
      <sentence>
        <offset>2109</offset>
        <text>Conclusion: Although ETTAG pathogenesis remains unknown, the lack of C cells together with the coexistence of a congenital defect of the anterior diaphragm (hernia of Morgagni) in one of our patients could suggest an over-descent of medial thyroid anlagen derived cells in the origin of this heterotopia.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23313794</id>
    <passage>
      <offset>0</offset>
      <text>Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs.	2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures. To understand the possible mechanism of PhIP-associated stomach cancer, the effects of PhIP on morphology, oxidative stress, gene expression of c-fos, c-jun and p16 in rat stomachs were investigated. The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control. With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control. The data indicated that PhIP could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and p16 in rat stomachs.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine</infon>
          <location offset="11" length="50"/>
          <text>2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phip</infon>
          <location offset="63" length="4"/>
          <text>PhIP</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-fos</infon>
          <location offset="124" length="5"/>
          <text>c-fos</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-jun</infon>
          <location offset="131" length="5"/>
          <text>c-jun</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p16</infon>
          <location offset="141" length="3"/>
          <text>p16</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>162</offset>
        <text>2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) is one of the most abundant heterocyclic amines (HCAs) generated from overcooking meat at high temperatures.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine</infon>
          <location offset="162" length="50"/>
          <text>2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hcas</infon>
          <location offset="269" length="4"/>
          <text>HCAs</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phip</infon>
          <location offset="214" length="4"/>
          <text>PhIP</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">heterocyclic amines</infon>
          <location offset="248" length="19"/>
          <text>heterocyclic amines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>329</offset>
        <text>To understand the possible mechanism of PhIP-associated stomach cancer, the effects of PhIP on morphology, oxidative stress, gene expression of c-fos, c-jun and p16 in rat stomachs were investigated.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phip</infon>
          <location offset="369" length="4"/>
          <text>PhIP</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phip</infon>
          <location offset="416" length="4"/>
          <text>PhIP</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-fos</infon>
          <location offset="473" length="5"/>
          <text>c-fos</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-jun</infon>
          <location offset="480" length="5"/>
          <text>c-jun</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p16</infon>
          <location offset="490" length="3"/>
          <text>p16</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>529</offset>
        <text>The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phip</infon>
          <location offset="577" length="4"/>
          <text>PhIP</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phip</infon>
          <location offset="647" length="4"/>
          <text>PhIP</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="696" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">superoxide dismutase</infon>
          <location offset="696" length="20"/>
          <text>superoxide dismutase</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sod</infon>
          <location offset="718" length="3"/>
          <text>SOD</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathioneperoxidase</infon>
          <location offset="727" length="21"/>
          <text>glutathioneperoxidase</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gpx</infon>
          <location offset="750" length="3"/>
          <text>GPx</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catalase</infon>
          <location offset="783" length="8"/>
          <text>catalase</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cat</infon>
          <location offset="793" length="3"/>
          <text>CAT</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>834</offset>
        <text>With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phip</infon>
          <location offset="861" length="4"/>
          <text>PhIP</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malondialdehyde</infon>
          <location offset="867" length="15"/>
          <text>malondialdehyde</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mda</infon>
          <location offset="884" length="3"/>
          <text>MDA</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbonyl</infon>
          <location offset="907" length="8"/>
          <text>carbonyl</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phip</infon>
          <location offset="1035" length="4"/>
          <text>PhIP</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-jun</infon>
          <location offset="1163" length="5"/>
          <text>c-jun</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p16</infon>
          <location offset="1103" length="3"/>
          <text>p16</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-fos</infon>
          <location offset="1153" length="5"/>
          <text>c-fos</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1201</offset>
        <text>The data indicated that PhIP could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phip</infon>
          <location offset="1225" length="4"/>
          <text>PhIP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phip</infon>
          <location offset="1406" length="4"/>
          <text>PhIP</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-fos</infon>
          <location offset="1320" length="5"/>
          <text>c-fos</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-jun</infon>
          <location offset="1330" length="5"/>
          <text>c-jun</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p16</infon>
          <location offset="1356" length="3"/>
          <text>p16</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16278927</id>
    <passage>
      <offset>0</offset>
      <text>In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid.	The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation. 4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM. The inhibitory effects of the following seven NSAIDs were investigated: acetaminophen, diclofenac, diflunisal, indomethacin, ketoprofen, naproxen and niflumic acid. Niflumic acid had the most potent inhibitory effect on 4-MUG with an IC50 value of 0.0341 microM. The IC50 values of diflunisal, diclofenac and indomethacin were 1.31, 24.2, and 34.1 microM, respectively, while acetaminophen, ketoprofen and naproxen showed less potent inhibition. Niflumic acid, diflunisal, diclofenac and indomethacin inhibited 4-MUG competitively with Ki values of 0.0275, 0.710, 53.3 and 69.9 microM, respectively, being similar to each IC50 value. In conclusion, of the seven NSAIDs investigated, niflumic acid was the most potent inhibitor of recombinant UGT1A9 via 4-MUG in a competitive manner.</text>
      <sentence>
        <offset>0</offset>
        <text>In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="131" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">niflumic acid</infon>
          <location offset="185" length="13"/>
          <text>niflumic acid</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroidal</infon>
          <location offset="35" length="9"/>
          <text>steroidal</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-methylumbelliferone</infon>
          <location offset="72" length="21"/>
          <text>4-methylumbelliferone</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human udp-glucuronosyltransferase 1a9</infon>
          <location offset="125" length="37"/>
          <text>human UDP-glucuronosyltransferase 1A9</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T26" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>200</offset>
        <text>The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-methylumbelliferone</infon>
          <location offset="377" length="21"/>
          <text>4-methylumbelliferone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-mu</infon>
          <location offset="400" length="4"/>
          <text>4-MU</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroidal</infon>
          <location offset="232" length="9"/>
          <text>steroidal</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="278" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human ugt1a9</infon>
          <location offset="358" length="12"/>
          <text>human UGT1A9</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">udp-glucuronosyltransferase (ugt) 1a9</infon>
          <location offset="278" length="37"/>
          <text>UDP-glucuronosyltransferase (UGT) 1A9</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>442</offset>
        <text>4-MU glucuronidation (4-MUG) showed Michaelis-Menten kinetics with a Km value of 6.7 microM.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-mu</infon>
          <location offset="442" length="4"/>
          <text>4-MU</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>535</offset>
        <text>The inhibitory effects of the following seven NSAIDs were investigated: acetaminophen, diclofenac, diflunisal, indomethacin, ketoprofen, naproxen and niflumic acid.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetaminophen</infon>
          <location offset="607" length="13"/>
          <text>acetaminophen</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diclofenac</infon>
          <location offset="622" length="10"/>
          <text>diclofenac</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diflunisal</infon>
          <location offset="634" length="10"/>
          <text>diflunisal</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="646" length="12"/>
          <text>indomethacin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketoprofen</infon>
          <location offset="660" length="10"/>
          <text>ketoprofen</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">naproxen</infon>
          <location offset="672" length="8"/>
          <text>naproxen</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">niflumic acid</infon>
          <location offset="685" length="13"/>
          <text>niflumic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>700</offset>
        <text>Niflumic acid had the most potent inhibitory effect on 4-MUG with an IC50 value of 0.0341 microM.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">niflumic acid</infon>
          <location offset="700" length="13"/>
          <text>Niflumic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>798</offset>
        <text>The IC50 values of diflunisal, diclofenac and indomethacin were 1.31, 24.2, and 34.1 microM, respectively, while acetaminophen, ketoprofen and naproxen showed less potent inhibition.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diflunisal</infon>
          <location offset="817" length="10"/>
          <text>diflunisal</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diclofenac</infon>
          <location offset="829" length="10"/>
          <text>diclofenac</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="844" length="12"/>
          <text>indomethacin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetaminophen</infon>
          <location offset="911" length="13"/>
          <text>acetaminophen</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketoprofen</infon>
          <location offset="926" length="10"/>
          <text>ketoprofen</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">naproxen</infon>
          <location offset="941" length="8"/>
          <text>naproxen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>981</offset>
        <text>Niflumic acid, diflunisal, diclofenac and indomethacin inhibited 4-MUG competitively with Ki values of 0.0275, 0.710, 53.3 and 69.9 microM, respectively, being similar to each IC50 value.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">niflumic acid</infon>
          <location offset="981" length="13"/>
          <text>Niflumic acid</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diflunisal</infon>
          <location offset="996" length="10"/>
          <text>diflunisal</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diclofenac</infon>
          <location offset="1008" length="10"/>
          <text>diclofenac</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="1023" length="12"/>
          <text>indomethacin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1169</offset>
        <text>In conclusion, of the seven NSAIDs investigated, niflumic acid was the most potent inhibitor of recombinant UGT1A9 via 4-MUG in a competitive manner.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">niflumic acid</infon>
          <location offset="1218" length="13"/>
          <text>niflumic acid</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ugt1a9</infon>
          <location offset="1277" length="6"/>
          <text>UGT1A9</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22841397</id>
    <passage>
      <offset>0</offset>
      <text>Effects of biotin supplementation in the diet on insulin secretion, islet gene expression, glucose homeostasis and beta-cell proportion.	Besides its role as a carboxylase cofactor, biotin has a wide repertoire of effects on gene expression, development and metabolism. Pharmacological concentrations of biotin enhance insulin secretion and the expression of genes and signaling pathways that favor islet function in vitro. However, the in vivo effects of biotin supplementation on pancreatic islet function are largely unknown. In the present study, we investigated whether in vivo biotin supplementation in the diet has positive effects in rodent pancreatic islets. Male BALB/cAnN Hsd mice were fed a control or a biotin-supplemented diet over 8 weeks postweaning and tested for glucose homeostasis, insulin secretion, islet gene expression and pancreatic morphometry. Insulin secretion increased from the islets of biotin-supplemented mice, together with the messenger RNA (mRNA) expression of several transcription factors regulating insulin expression and secretion, including forkhead box A2, pancreatic and duodenal homeobox 1 and hepatocyte nuclear factor 4α. The mRNA abundance of glucokinase, Cacna1d, acetyl-CoA carboxylase, and insulin also increased. Consistent with these effects, glucose tolerance improved, and glucose-stimulated serum insulin levels increased in biotin-supplemented mice, without changes in fasting glucose levels or insulin tolerance. Biotin supplementation augmented the proportion of beta cells by enlarging islet size and, unexpectedly, also increased the percentage of islets with alpha cells at the islet core. mRNA expression of neural cell adhesion molecule 1, an adhesion protein participating in the maintenance of islet architecture, decreased in biotin-supplemented islets. These findings provide, for the first time, insight into how biotin supplementation exerts its effects on function and proportion of beta cells, suggesting a role for biotin in the prevention and treatment of diabetes.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of biotin supplementation in the diet on insulin secretion, islet gene expression, glucose homeostasis and beta-cell proportion.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="11" length="6"/>
          <text>biotin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="91" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="49" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">islet</infon>
          <location offset="68" length="5"/>
          <text>islet</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>137</offset>
        <text>Besides its role as a carboxylase cofactor, biotin has a wide repertoire of effects on gene expression, development and metabolism.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="181" length="6"/>
          <text>biotin</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">carboxylase</infon>
          <location offset="159" length="11"/>
          <text>carboxylase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>269</offset>
        <text>Pharmacological concentrations of biotin enhance insulin secretion and the expression of genes and signaling pathways that favor islet function in vitro.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="303" length="6"/>
          <text>biotin</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="318" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>423</offset>
        <text>However, the in vivo effects of biotin supplementation on pancreatic islet function are largely unknown.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="455" length="6"/>
          <text>biotin</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">islet</infon>
          <location offset="492" length="5"/>
          <text>islet</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>528</offset>
        <text>In the present study, we investigated whether in vivo biotin supplementation in the diet has positive effects in rodent pancreatic islets.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="582" length="6"/>
          <text>biotin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>667</offset>
        <text>Male BALB/cAnN Hsd mice were fed a control or a biotin-supplemented diet over 8 weeks postweaning and tested for glucose homeostasis, insulin secretion, islet gene expression and pancreatic morphometry.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="715" length="6"/>
          <text>biotin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="780" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="801" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">islet</infon>
          <location offset="820" length="5"/>
          <text>islet</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>870</offset>
        <text>Insulin secretion increased from the islets of biotin-supplemented mice, together with the messenger RNA (mRNA) expression of several transcription factors regulating insulin expression and secretion, including forkhead box A2, pancreatic and duodenal homeobox 1 and hepatocyte nuclear factor 4α.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="917" length="6"/>
          <text>biotin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hepatocyte nuclear factor 4α</infon>
          <location offset="1137" length="28"/>
          <text>hepatocyte nuclear factor 4α</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="870" length="7"/>
          <text>Insulin</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1037" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">forkhead box a2</infon>
          <location offset="1081" length="15"/>
          <text>forkhead box A2</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pancreatic and duodenal homeobox 1</infon>
          <location offset="1098" length="34"/>
          <text>pancreatic and duodenal homeobox 1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1167</offset>
        <text>The mRNA abundance of glucokinase, Cacna1d, acetyl-CoA carboxylase, and insulin also increased.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetyl-coa</infon>
          <location offset="1211" length="10"/>
          <text>acetyl-CoA</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucokinase</infon>
          <location offset="1189" length="11"/>
          <text>glucokinase</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cacna1d</infon>
          <location offset="1202" length="7"/>
          <text>Cacna1d</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetyl-coa carboxylase</infon>
          <location offset="1211" length="22"/>
          <text>acetyl-CoA carboxylase</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1239" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1263</offset>
        <text>Consistent with these effects, glucose tolerance improved, and glucose-stimulated serum insulin levels increased in biotin-supplemented mice, without changes in fasting glucose levels or insulin tolerance.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1294" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1326" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="1379" length="6"/>
          <text>biotin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1432" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1351" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1450" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1469</offset>
        <text>Biotin supplementation augmented the proportion of beta cells by enlarging islet size and, unexpectedly, also increased the percentage of islets with alpha cells at the islet core.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="1469" length="6"/>
          <text>Biotin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1650</offset>
        <text>mRNA expression of neural cell adhesion molecule 1, an adhesion protein participating in the maintenance of islet architecture, decreased in biotin-supplemented islets.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="1791" length="6"/>
          <text>biotin</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neural cell adhesion molecule 1</infon>
          <location offset="1669" length="31"/>
          <text>neural cell adhesion molecule 1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1819</offset>
        <text>These findings provide, for the first time, insight into how biotin supplementation exerts its effects on function and proportion of beta cells, suggesting a role for biotin in the prevention and treatment of diabetes.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="1880" length="6"/>
          <text>biotin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="1986" length="6"/>
          <text>biotin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11006272</id>
    <passage>
      <offset>0</offset>
      <text>A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization.	Leukotriene B(4) (LTB(4)) is a product of eicosanoid metabolism and acts as an extremely potent chemotactic mediator for inflammation. LTB(4) exerts positive effects on the immigration and activation of leukocytes. These effects suggest an involvement of LTB(4) in several diseases: inflammatory bowel disease, psoriasis, arthritis, and asthma. LTB(4) elicits actions through interaction with one or more cell surface receptors that lead to chemotaxis and inflammation. One leukotriene B(4) receptor has been recently identified (LTB(4)-R1). In this report we describe cloning of a cDNA encoding a novel 358-amino acid receptor (LTB(4)-R2) that possesses seven membrane-spanning domains and is homologous (42%) and genetically linked to LTB(4)-R1. Expression of LTB(4)-R2 is broad but highest in liver, intestine, spleen, and kidney. In radioligand binding assays, membranes prepared from COS-7 cells transfected with LTB(4)-R2 cDNA displayed high affinity (K(d) = 0.17 nm) for [(3)H]LTB(4). Radioligand competition assays revealed high affinities of the receptor for LTB(4) and LTB(5), and 20-hydroxy-LTB(4), and intermediate affinities for 15(S)-HETE and 12-oxo-ETE. Three LTB(4) receptor antagonists, 14,15-dehydro-LTB(4), LTB(4)-3-aminopropylamide, and U-75302, had high affinity for LTB(4)-R1 but not for LTB(4)-R2. No apparent affinity binding for the receptors was detected for the CysLT1-selective antagonists montelukast and zafirlukast. LTB(4) functionally mobilized intracellular calcium and inhibited forskolin-stimulated cAMP production in 293 cells. The discovery of this new receptor should aid in further understanding the roles of LTB(4) in pathologies in these tissues and may provide a tool in identification of specific antagonists/agonists for potential therapeutic treatments.</text>
      <sentence>
        <offset>0</offset>
        <text>A novel hepatointestinal leukotriene B4 receptor.</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">leukotriene b4</infon>
          <location offset="25" length="14"/>
          <text>leukotriene B4</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">leukotriene b4 receptor</infon>
          <location offset="25" length="23"/>
          <text>leukotriene B4 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>50</offset>
        <text>Cloning and functional characterization.</text>
      </sentence>
      <sentence>
        <offset>91</offset>
        <text>Leukotriene B(4) (LTB(4)) is a product of eicosanoid metabolism and acts as an extremely potent chemotactic mediator for inflammation.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">leukotriene b(4)</infon>
          <location offset="91" length="16"/>
          <text>Leukotriene B(4)</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="109" length="6"/>
          <text>LTB(4)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>226</offset>
        <text>LTB(4) exerts positive effects on the immigration and activation of leukocytes.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="226" length="6"/>
          <text>LTB(4)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>306</offset>
        <text>These effects suggest an involvement of LTB(4) in several diseases: inflammatory bowel disease, psoriasis, arthritis, and asthma.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="346" length="6"/>
          <text>LTB(4)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>436</offset>
        <text>LTB(4) elicits actions through interaction with one or more cell surface receptors that lead to chemotaxis and inflammation.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="436" length="6"/>
          <text>LTB(4)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>561</offset>
        <text>One leukotriene B(4) receptor has been recently identified (LTB(4)-R1).</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">leukotriene b(4)</infon>
          <location offset="565" length="16"/>
          <text>leukotriene B(4)</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="621" length="6"/>
          <text>LTB(4)</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">leukotriene b(4) receptor</infon>
          <location offset="565" length="25"/>
          <text>leukotriene B(4) receptor</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ltb(4)-r1</infon>
          <location offset="621" length="9"/>
          <text>LTB(4)-R1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>633</offset>
        <text>In this report we describe cloning of a cDNA encoding a novel 358-amino acid receptor (LTB(4)-R2) that possesses seven membrane-spanning domains and is homologous (42%) and genetically linked to LTB(4)-R1.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="699" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="720" length="6"/>
          <text>LTB(4)</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="828" length="6"/>
          <text>LTB(4)</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ltb(4)-r2</infon>
          <location offset="720" length="9"/>
          <text>LTB(4)-R2</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">membrane-spanning domains</infon>
          <location offset="752" length="25"/>
          <text>membrane-spanning domains</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ltb(4)-r1</infon>
          <location offset="828" length="9"/>
          <text>LTB(4)-R1</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T22" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T22" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>839</offset>
        <text>Expression of LTB(4)-R2 is broad but highest in liver, intestine, spleen, and kidney.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="853" length="6"/>
          <text>LTB(4)</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ltb(4)-r2</infon>
          <location offset="853" length="9"/>
          <text>LTB(4)-R2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>925</offset>
        <text>In radioligand binding assays, membranes prepared from COS-7 cells transfected with LTB(4)-R2 cDNA displayed high affinity (K(d) = 0.17 nm) for [(3)H]LTB(4).</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="1009" length="6"/>
          <text>LTB(4)</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(3)h]ltb(4)</infon>
          <location offset="1069" length="12"/>
          <text>[(3)H]LTB(4)</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ltb(4)-r2</infon>
          <location offset="1009" length="9"/>
          <text>LTB(4)-R2</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T27" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1083</offset>
        <text>Radioligand competition assays revealed high affinities of the receptor for LTB(4) and LTB(5), and 20-hydroxy-LTB(4), and intermediate affinities for 15(S)-HETE and 12-oxo-ETE.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="1159" length="6"/>
          <text>LTB(4)</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(5)</infon>
          <location offset="1170" length="6"/>
          <text>LTB(5)</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">20-hydroxy-ltb(4)</infon>
          <location offset="1182" length="17"/>
          <text>20-hydroxy-LTB(4)</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">15(s)-hete</infon>
          <location offset="1233" length="10"/>
          <text>15(S)-HETE</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">12-oxo-ete</infon>
          <location offset="1248" length="10"/>
          <text>12-oxo-ETE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1260</offset>
        <text>Three LTB(4) receptor antagonists, 14,15-dehydro-LTB(4), LTB(4)-3-aminopropylamide, and U-75302, had high affinity for LTB(4)-R1 but not for LTB(4)-R2.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="1266" length="6"/>
          <text>LTB(4)</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">14,15-dehydro-ltb(4)</infon>
          <location offset="1295" length="20"/>
          <text>14,15-dehydro-LTB(4)</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)-3-aminopropylamide</infon>
          <location offset="1317" length="25"/>
          <text>LTB(4)-3-aminopropylamide</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">u-75302</infon>
          <location offset="1348" length="7"/>
          <text>U-75302</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="1379" length="6"/>
          <text>LTB(4)</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="1401" length="6"/>
          <text>LTB(4)</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ltb(4) receptor</infon>
          <location offset="1266" length="15"/>
          <text>LTB(4) receptor</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ltb(4)-r1</infon>
          <location offset="1379" length="9"/>
          <text>LTB(4)-R1</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ltb(4)-r2</infon>
          <location offset="1401" length="9"/>
          <text>LTB(4)-R2</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T10" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T8" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1412</offset>
        <text>No apparent affinity binding for the receptors was detected for the CysLT1-selective antagonists montelukast and zafirlukast.</text>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyslt1</infon>
          <location offset="1480" length="6"/>
          <text>CysLT1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1538</offset>
        <text>LTB(4) functionally mobilized intracellular calcium and inhibited forskolin-stimulated cAMP production in 293 cells.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="1538" length="6"/>
          <text>LTB(4)</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="1625" length="4"/>
          <text>cAMP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1655</offset>
        <text>The discovery of this new receptor should aid in further understanding the roles of LTB(4) in pathologies in these tissues and may provide a tool in identification of specific antagonists/agonists for potential therapeutic treatments.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb(4)</infon>
          <location offset="1739" length="6"/>
          <text>LTB(4)</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12172398</id>
    <passage>
      <offset>0</offset>
      <text>Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil.	PURPOSE: The effect of gemfibrozil is mediated by the activation of peroxisome proliferator-activated receptor alpha (PPAR alpha). The objective of this study was to determine whether the lipid response to gemfibrozil therapy is influenced by the PPAR alpha-L162V polymorphism. METHODS: Sixty-three abdominally obese men were randomly assigned to a 6-month-intervention program with either receiving a placebo (N = 31) or gemfibrozil (N = 32). RESULTS: In response to gemfibrozil therapy, L162-homozygotes exhibited a 5.5% increase in high-density lipoprotein 2 cholesterol (HDL(2)-C) levels compared with a 50.0% increase among carriers of the V162 allele (P = 0.03). CONCLUSION: These results suggest that the HDL(2)-C response to gemfibrozil is modulated by the PPAR alpha-L162V polymorphism.</text>
      <sentence>
        <offset>0</offset>
        <text>Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gemfibrozil</infon>
          <location offset="124" length="11"/>
          <text>gemfibrozil</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="65" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar alpha</infon>
          <location offset="18" length="10"/>
          <text>PPAR alpha</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">l162v</infon>
          <location offset="29" length="5"/>
          <text>L162V</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hdl</infon>
          <location offset="58" length="3"/>
          <text>HDL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>137</offset>
        <text>PURPOSE: The effect of gemfibrozil is mediated by the activation of peroxisome proliferator-activated receptor alpha (PPAR alpha).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gemfibrozil</infon>
          <location offset="160" length="11"/>
          <text>gemfibrozil</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar alpha</infon>
          <location offset="255" length="10"/>
          <text>PPAR alpha</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor alpha</infon>
          <location offset="205" length="48"/>
          <text>peroxisome proliferator-activated receptor alpha</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>268</offset>
        <text>The objective of this study was to determine whether the lipid response to gemfibrozil therapy is influenced by the PPAR alpha-L162V polymorphism.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gemfibrozil</infon>
          <location offset="343" length="11"/>
          <text>gemfibrozil</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar alpha</infon>
          <location offset="384" length="10"/>
          <text>PPAR alpha</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">l162v</infon>
          <location offset="395" length="5"/>
          <text>L162V</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>415</offset>
        <text>METHODS: Sixty-three abdominally obese men were randomly assigned to a 6-month-intervention program with either receiving a placebo (N = 31) or gemfibrozil (N = 32).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gemfibrozil</infon>
          <location offset="559" length="11"/>
          <text>gemfibrozil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>581</offset>
        <text>RESULTS: In response to gemfibrozil therapy, L162-homozygotes exhibited a 5.5% increase in high-density lipoprotein 2 cholesterol (HDL(2)-C) levels compared with a 50.0% increase among carriers of the V162 allele (P = 0.03).</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gemfibrozil</infon>
          <location offset="605" length="11"/>
          <text>gemfibrozil</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="699" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">high-density lipoprotein</infon>
          <location offset="672" length="24"/>
          <text>high-density lipoprotein</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hdl</infon>
          <location offset="712" length="3"/>
          <text>HDL</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>806</offset>
        <text>CONCLUSION: These results suggest that the HDL(2)-C response to gemfibrozil is modulated by the PPAR alpha-L162V polymorphism.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gemfibrozil</infon>
          <location offset="870" length="11"/>
          <text>gemfibrozil</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hdl</infon>
          <location offset="849" length="3"/>
          <text>HDL</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar alpha</infon>
          <location offset="902" length="10"/>
          <text>PPAR alpha</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">l162v</infon>
          <location offset="913" length="5"/>
          <text>L162V</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>14505791</id>
    <passage>
      <offset>0</offset>
      <text>Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists.	The potent histamine H(1)-receptor antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine. In this Commentary, we examine some biological properties of cetirizine and levocetirizine, namely enantioselectivity in pharmacological activity and pharmacokinetic properties, with emphasis on the possibility of racemization, the compared behavior of the two enantiomers, and the potential for interactions with other drugs. Recent data demonstrate that the antihistaminergic activity of the racemate is primarily due to levocetirizine. Levocetirizine is rapidly and extensively absorbed, poorly metabolized, and not subject to racemization. Its pharmacokinetic characteristics are comparable after administration alone or in the racemate. Its apparent volume of distribution is smaller than that of dextrocetirizine (0.41 L kg(-1) vs. 0.60 L kg(-1)). Moreover, the non-renal (mostly hepatic) clearance of levocetirizine is also significantly lower than that of dextrocetirizine (11.8 mL min(-1) vs. 29.2 mL min(-1)). Our conclusion is that levocetirizine is indeed the eutomer of cetirizine. The evidence reviewed here confirms preclinical findings and offers a rationale for the chiral switch from the racemate to levocetirizine.</text>
      <sentence>
        <offset>0</offset>
        <text>Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cetirizine</infon>
          <location offset="62" length="10"/>
          <text>cetirizine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levocetirizine</infon>
          <location offset="77" length="14"/>
          <text>levocetirizine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="97" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h1-receptor</infon>
          <location offset="97" length="21"/>
          <text>histamine H1-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T17" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T18" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>132</offset>
        <text>The potent histamine H(1)-receptor antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="143" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">xyzal</infon>
          <location offset="272" length="5"/>
          <text>Xyzal</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dextrocetirizine</infon>
          <location offset="282" length="16"/>
          <text>dextrocetirizine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cetirizine</infon>
          <location offset="178" length="10"/>
          <text>cetirizine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zyrtec</infon>
          <location offset="190" length="6"/>
          <text>Zyrtec</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levocetirizine</infon>
          <location offset="222" length="14"/>
          <text>levocetirizine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h(1)-receptor</infon>
          <location offset="143" length="23"/>
          <text>histamine H(1)-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T6" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T15" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T11" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T10" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>300</offset>
        <text>In this Commentary, we examine some biological properties of cetirizine and levocetirizine, namely enantioselectivity in pharmacological activity and pharmacokinetic properties, with emphasis on the possibility of racemization, the compared behavior of the two enantiomers, and the potential for interactions with other drugs.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cetirizine</infon>
          <location offset="361" length="10"/>
          <text>cetirizine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levocetirizine</infon>
          <location offset="376" length="14"/>
          <text>levocetirizine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>627</offset>
        <text>Recent data demonstrate that the antihistaminergic activity of the racemate is primarily due to levocetirizine.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levocetirizine</infon>
          <location offset="723" length="14"/>
          <text>levocetirizine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>739</offset>
        <text>Levocetirizine is rapidly and extensively absorbed, poorly metabolized, and not subject to racemization.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levocetirizine</infon>
          <location offset="739" length="14"/>
          <text>Levocetirizine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>844</offset>
        <text>Its pharmacokinetic characteristics are comparable after administration alone or in the racemate.</text>
      </sentence>
      <sentence>
        <offset>942</offset>
        <text>Its apparent volume of distribution is smaller than that of dextrocetirizine (0.41 L kg(-1) vs. 0.60 L kg(-1)).</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dextrocetirizine</infon>
          <location offset="1002" length="16"/>
          <text>dextrocetirizine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1054</offset>
        <text>Moreover, the non-renal (mostly hepatic) clearance of levocetirizine is also significantly lower than that of dextrocetirizine (11.8 mL min(-1) vs. 29.2 mL min(-1)).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dextrocetirizine</infon>
          <location offset="1164" length="16"/>
          <text>dextrocetirizine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levocetirizine</infon>
          <location offset="1108" length="14"/>
          <text>levocetirizine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1220</offset>
        <text>Our conclusion is that levocetirizine is indeed the eutomer of cetirizine.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levocetirizine</infon>
          <location offset="1243" length="14"/>
          <text>levocetirizine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cetirizine</infon>
          <location offset="1283" length="10"/>
          <text>cetirizine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1295</offset>
        <text>The evidence reviewed here confirms preclinical findings and offers a rationale for the chiral switch from the racemate to levocetirizine.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levocetirizine</infon>
          <location offset="1418" length="14"/>
          <text>levocetirizine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23220616</id>
    <passage>
      <offset>0</offset>
      <text>Hepatic metabolism of sulfur amino acids in db/db mice.	To determine the effect of type-2 diabetes and obesity on the hepatic metabolism of sulfur amino acids, hepatic sulfur amino acid metabolism was determined in db/db mice. Hepatic methionine was markedly decreased in db/db mice, although the hepatic activity of betaine homocysteine methyltransferase was increased. The decrease in hepatic methionine was reflected by decreased sulfur-containing methionine metabolites, including S-adenosylmethionine, homocysteine, cysteine, and hypotaurine in liver and plasma. In contrast, S-adenosylhomocysteine, putrescine, and spermidine were increased in db/db mice. The hepatic level and activity of methionine adenosyltransferase I/III, an S-adenosylmethionine synthesizing enzyme, were significantly increased. These results suggest that increased polyamine synthesis, in conjunction with decreased hepatic methionine levels, is partly responsible for the reduction in hepatic S-adenosylmethionine. Decreased homocysteine in liver and plasma may be attributable to the decrease in hepatic methionine and upregulation of hepatic betaine homocysteine methyltransferase. Glutathione in liver and plasma did not change despite decreased γ-glutamylcysteine ligase activity. The decreased hepatic hypotaurine may be attributable to the downregulation of cysteine dioxygenase. The major finding of this study is that db/db mice exhibited decreases in hepatic methionine and its sulfurcontaining metabolites.</text>
      <sentence>
        <offset>0</offset>
        <text>Hepatic metabolism of sulfur amino acids in db/db mice.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfur amino acids</infon>
          <location offset="22" length="18"/>
          <text>sulfur amino acids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>56</offset>
        <text>To determine the effect of type-2 diabetes and obesity on the hepatic metabolism of sulfur amino acids, hepatic sulfur amino acid metabolism was determined in db/db mice.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfur amino acid</infon>
          <location offset="168" length="17"/>
          <text>sulfur amino acid</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfur amino acids</infon>
          <location offset="140" length="18"/>
          <text>sulfur amino acids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>227</offset>
        <text>Hepatic methionine was markedly decreased in db/db mice, although the hepatic activity of betaine homocysteine methyltransferase was increased.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methionine</infon>
          <location offset="235" length="10"/>
          <text>methionine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="325" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">betaine homocysteine methyltransferase</infon>
          <location offset="317" length="38"/>
          <text>betaine homocysteine methyltransferase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>371</offset>
        <text>The decrease in hepatic methionine was reflected by decreased sulfur-containing methionine metabolites, including S-adenosylmethionine, homocysteine, cysteine, and hypotaurine in liver and plasma.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methionine</infon>
          <location offset="395" length="10"/>
          <text>methionine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfur</infon>
          <location offset="433" length="6"/>
          <text>sulfur</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methionine</infon>
          <location offset="451" length="10"/>
          <text>methionine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s-adenosylmethionine</infon>
          <location offset="485" length="20"/>
          <text>S-adenosylmethionine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="507" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteine</infon>
          <location offset="521" length="8"/>
          <text>cysteine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hypotaurine</infon>
          <location offset="535" length="11"/>
          <text>hypotaurine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>568</offset>
        <text>In contrast, S-adenosylhomocysteine, putrescine, and spermidine were increased in db/db mice.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s-adenosylhomocysteine</infon>
          <location offset="581" length="22"/>
          <text>S-adenosylhomocysteine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">putrescine</infon>
          <location offset="605" length="10"/>
          <text>putrescine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spermidine</infon>
          <location offset="621" length="10"/>
          <text>spermidine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>662</offset>
        <text>The hepatic level and activity of methionine adenosyltransferase I/III, an S-adenosylmethionine synthesizing enzyme, were significantly increased.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methionine</infon>
          <location offset="696" length="10"/>
          <text>methionine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s-adenosylmethionine</infon>
          <location offset="737" length="20"/>
          <text>S-adenosylmethionine</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">methionine adenosyltransferase i/iii</infon>
          <location offset="696" length="36"/>
          <text>methionine adenosyltransferase I/III</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>809</offset>
        <text>These results suggest that increased polyamine synthesis, in conjunction with decreased hepatic methionine levels, is partly responsible for the reduction in hepatic S-adenosylmethionine.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyamine</infon>
          <location offset="846" length="9"/>
          <text>polyamine</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methionine</infon>
          <location offset="905" length="10"/>
          <text>methionine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s-adenosylmethionine</infon>
          <location offset="975" length="20"/>
          <text>S-adenosylmethionine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>997</offset>
        <text>Decreased homocysteine in liver and plasma may be attributable to the decrease in hepatic methionine and upregulation of hepatic betaine homocysteine methyltransferase.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methionine</infon>
          <location offset="1087" length="10"/>
          <text>methionine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="1134" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="1007" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">betaine homocysteine methyltransferase</infon>
          <location offset="1126" length="38"/>
          <text>betaine homocysteine methyltransferase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T26" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1166</offset>
        <text>Glutathione in liver and plasma did not change despite decreased γ-glutamylcysteine ligase activity.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="1166" length="11"/>
          <text>Glutathione</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">γ-glutamylcysteine</infon>
          <location offset="1231" length="18"/>
          <text>γ-glutamylcysteine</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">γ-glutamylcysteine ligase</infon>
          <location offset="1231" length="25"/>
          <text>γ-glutamylcysteine ligase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1267</offset>
        <text>The decreased hepatic hypotaurine may be attributable to the downregulation of cysteine dioxygenase.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hypotaurine</infon>
          <location offset="1289" length="11"/>
          <text>hypotaurine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteine</infon>
          <location offset="1346" length="8"/>
          <text>cysteine</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cysteine dioxygenase</infon>
          <location offset="1346" length="20"/>
          <text>cysteine dioxygenase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1368</offset>
        <text>The major finding of this study is that db/db mice exhibited decreases in hepatic methionine and its sulfurcontaining metabolites.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17289086</id>
    <passage>
      <offset>0</offset>
      <text>Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells.	Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) broadly used in the treatment of human mood disorders and gastrointestinal diseases involving the serotoninergic system. The effectiveness of this therapy depends on repeated long-term treatment. Most of the long-term studies in vivo of SSRI effects on serotoninergic activity have focused on their effects on autoreceptors or postsynaptic receptors. The chronic effect of SSRIs on the activity of the serotonin transporter (SERT) has been less studied and the results have been contradictory. The aim of this study was to determine the specific effect of long-term fluoxetine treatment on human serotonin transporter (hSERT) in vitro, by using the human enterocyte-like cell line Caco-2. Results show that fluoxetine diminished the 5-HT uptake in a concentration-dependent way and that this effect was reversible. Fluoxetine affected mainly the hSERT transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the hSERT mRNA level. These results suggest that the effect of fluoxetine on the expression of hSERT is post-translational and has shown itself to be independent of PKC and PKA activity. This study may be useful to clarify the effect of the long-term fluoxetine therapy in both gastrointestinal and central nervous system disorders.</text>
      <sentence>
        <offset>0</offset>
        <text>Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="20" length="10"/>
          <text>fluoxetine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="54" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human serotonin transporter</infon>
          <location offset="48" length="27"/>
          <text>human serotonin transporter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>93</offset>
        <text>Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) broadly used in the treatment of human mood disorders and gastrointestinal diseases involving the serotoninergic system.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="93" length="10"/>
          <text>Fluoxetine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="119" length="9"/>
          <text>serotonin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>276</offset>
        <text>The effectiveness of this therapy depends on repeated long-term treatment.</text>
      </sentence>
      <sentence>
        <offset>351</offset>
        <text>Most of the long-term studies in vivo of SSRI effects on serotoninergic activity have focused on their effects on autoreceptors or postsynaptic receptors.</text>
      </sentence>
      <sentence>
        <offset>506</offset>
        <text>The chronic effect of SSRIs on the activity of the serotonin transporter (SERT) has been less studied and the results have been contradictory.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="557" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serotonin transporter</infon>
          <location offset="557" length="21"/>
          <text>serotonin transporter</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="580" length="4"/>
          <text>SERT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>649</offset>
        <text>The aim of this study was to determine the specific effect of long-term fluoxetine treatment on human serotonin transporter (hSERT) in vitro, by using the human enterocyte-like cell line Caco-2.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="721" length="10"/>
          <text>fluoxetine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="751" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human serotonin transporter</infon>
          <location offset="745" length="27"/>
          <text>human serotonin transporter</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsert</infon>
          <location offset="774" length="5"/>
          <text>hSERT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>844</offset>
        <text>Results show that fluoxetine diminished the 5-HT uptake in a concentration-dependent way and that this effect was reversible.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="862" length="10"/>
          <text>fluoxetine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="888" length="4"/>
          <text>5-HT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>970</offset>
        <text>Fluoxetine affected mainly the hSERT transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the hSERT mRNA level.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="970" length="10"/>
          <text>Fluoxetine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsert</infon>
          <location offset="1137" length="5"/>
          <text>hSERT</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsert</infon>
          <location offset="1166" length="5"/>
          <text>hSERT</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsert</infon>
          <location offset="1001" length="5"/>
          <text>hSERT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1184</offset>
        <text>These results suggest that the effect of fluoxetine on the expression of hSERT is post-translational and has shown itself to be independent of PKC and PKA activity.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="1225" length="10"/>
          <text>fluoxetine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsert</infon>
          <location offset="1257" length="5"/>
          <text>hSERT</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pkc</infon>
          <location offset="1327" length="3"/>
          <text>PKC</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pka</infon>
          <location offset="1335" length="3"/>
          <text>PKA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1349</offset>
        <text>This study may be useful to clarify the effect of the long-term fluoxetine therapy in both gastrointestinal and central nervous system disorders.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="1413" length="10"/>
          <text>fluoxetine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23274771</id>
    <passage>
      <offset>0</offset>
      <text>NF-κB-associated mechanisms underlying the response of embryonic cells to Doxorubicin.	The involvement of NF-κB in the regulation of teratogen-induced apoptosis has not been established yet. Therefore, we tried to assess the involvement of the p65 subunit of NF-κB in the embryonic response to the anti-cancer drug Doxorubicin (DOX). Thus, exposure of p65 knockout (p65(-/-)) or wild type (WT) mouse embryonic fibroblasts (MEFs) to DOX resulted in a decrease in cell survival, culture density and cell proliferation, which was found to be more prominent in p65(-/-) MEFs. Those phenomena were accompanied by a DOX-induced increase in the proportion of apoptotic cells, which was demonstrated only in p65(-/-) cells and a G2/M arrest, which was found to be more prominent in WT cells. Furthermore, DOX-treated WT and p65(-/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of p65-positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of IκBα-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter. The fact that the response of the cells to the teratogen was clearly p65-dependent implicates this molecule to be involved in the response of the embryonic cells to DOX.</text>
      <sentence>
        <offset>0</offset>
        <text>NF-κB-associated mechanisms underlying the response of embryonic cells to Doxorubicin.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="74" length="11"/>
          <text>Doxorubicin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="0" length="5"/>
          <text>NF-κB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>87</offset>
        <text>The involvement of NF-κB in the regulation of teratogen-induced apoptosis has not been established yet.</text>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="106" length="5"/>
          <text>NF-κB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>191</offset>
        <text>Therefore, we tried to assess the involvement of the p65 subunit of NF-κB in the embryonic response to the anti-cancer drug Doxorubicin (DOX).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="315" length="11"/>
          <text>Doxorubicin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dox</infon>
          <location offset="328" length="3"/>
          <text>DOX</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="244" length="3"/>
          <text>p65</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="259" length="5"/>
          <text>NF-κB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>334</offset>
        <text>Thus, exposure of p65 knockout (p65(-/-)) or wild type (WT) mouse embryonic fibroblasts (MEFs) to DOX resulted in a decrease in cell survival, culture density and cell proliferation, which was found to be more prominent in p65(-/-) MEFs.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dox</infon>
          <location offset="432" length="3"/>
          <text>DOX</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="352" length="3"/>
          <text>p65</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="366" length="3"/>
          <text>p65</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="557" length="3"/>
          <text>p65</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>572</offset>
        <text>Those phenomena were accompanied by a DOX-induced increase in the proportion of apoptotic cells, which was demonstrated only in p65(-/-) cells and a G2/M arrest, which was found to be more prominent in WT cells.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dox</infon>
          <location offset="610" length="3"/>
          <text>DOX</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="700" length="3"/>
          <text>p65</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>784</offset>
        <text>Furthermore, DOX-treated WT and p65(-/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of p65-positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of IκBα-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dox</infon>
          <location offset="797" length="3"/>
          <text>DOX</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="1144" length="5"/>
          <text>bcl-2</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="816" length="3"/>
          <text>p65</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="963" length="3"/>
          <text>p65</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="1027" length="3"/>
          <text>p53</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">iκbα</infon>
          <location offset="1079" length="4"/>
          <text>IκBα</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1196</offset>
        <text>The fact that the response of the cells to the teratogen was clearly p65-dependent implicates this molecule to be involved in the response of the embryonic cells to DOX.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dox</infon>
          <location offset="1361" length="3"/>
          <text>DOX</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="1265" length="3"/>
          <text>p65</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11447307</id>
    <passage>
      <offset>0</offset>
      <text>Hemodynamic effects of bosentan in patients with chronic heart failure.	A role of the potent and long-acting vasoconstrictor peptide endothelin-1 and the pathophysiology of chronic human heart failure has been postulated based upon indirect evidence such as elevated plasma endothelin-1 levels and their with the degree of hemodynamic impairment. The advent of specific of endothelin-1 receptor antagonists has provided the opportunity not only to directly evaluate its pathophysiological role but also to assess its potential role as a new approach to heart failure therapy. This brief review summarizes the evidence linking endothelin-1 to the pathophysiology of chronic heart failure and the clinical results obtained in patients during acute, intravenous and more prolonged, oral administration with bosentan, a mixed ET(A)/ET(B)-receptor antagonist. Bosentan acutely and during short-term oral therapy markedly improved hemodynamics in patients in addition to standard heart failure therapy, including an ACE-inhibitor. These effects were associated with a reduced responsiveness of the renin-angiotensin system to diuretic therapy and reduced basal plasma aldosterone levels. Although the hemodynamic and neurohumoral profile of short-term bosentan therapy looks promising for the treatment of patients with chronic heart failure appropriate trials will have to be performed to document clinical benefit during long-term therapy. Finally, the question remains open whether mixed endothelin-1 receptor antagonists like bosentan will have similar effects as compared to antagonists which block the ET(A) receptor only.</text>
      <sentence>
        <offset>0</offset>
        <text>Hemodynamic effects of bosentan in patients with chronic heart failure.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="23" length="8"/>
          <text>bosentan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>72</offset>
        <text>A role of the potent and long-acting vasoconstrictor peptide endothelin-1 and the pathophysiology of chronic human heart failure has been postulated based upon indirect evidence such as elevated plasma endothelin-1 levels and their with the degree of hemodynamic impairment.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">endothelin-1</infon>
          <location offset="274" length="12"/>
          <text>endothelin-1</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">endothelin-1</infon>
          <location offset="133" length="12"/>
          <text>endothelin-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>347</offset>
        <text>The advent of specific of endothelin-1 receptor antagonists has provided the opportunity not only to directly evaluate its pathophysiological role but also to assess its potential role as a new approach to heart failure therapy.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">endothelin-1 receptor</infon>
          <location offset="373" length="21"/>
          <text>endothelin-1 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>576</offset>
        <text>This brief review summarizes the evidence linking endothelin-1 to the pathophysiology of chronic heart failure and the clinical results obtained in patients during acute, intravenous and more prolonged, oral administration with bosentan, a mixed ET(A)/ET(B)-receptor antagonist.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="804" length="8"/>
          <text>bosentan</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">endothelin-1</infon>
          <location offset="626" length="12"/>
          <text>endothelin-1</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">et(a)</infon>
          <location offset="822" length="5"/>
          <text>ET(A)</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">et(b)-receptor</infon>
          <location offset="828" length="14"/>
          <text>ET(B)-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>855</offset>
        <text>Bosentan acutely and during short-term oral therapy markedly improved hemodynamics in patients in addition to standard heart failure therapy, including an ACE-inhibitor.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="855" length="8"/>
          <text>Bosentan</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ace</infon>
          <location offset="1010" length="3"/>
          <text>ACE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1025</offset>
        <text>These effects were associated with a reduced responsiveness of the renin-angiotensin system to diuretic therapy and reduced basal plasma aldosterone levels.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin</infon>
          <location offset="1098" length="11"/>
          <text>angiotensin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="1162" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="1092" length="5"/>
          <text>renin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin</infon>
          <location offset="1098" length="11"/>
          <text>angiotensin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1182</offset>
        <text>Although the hemodynamic and neurohumoral profile of short-term bosentan therapy looks promising for the treatment of patients with chronic heart failure appropriate trials will have to be performed to document clinical benefit during long-term therapy.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="1246" length="8"/>
          <text>bosentan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1436</offset>
        <text>Finally, the question remains open whether mixed endothelin-1 receptor antagonists like bosentan will have similar effects as compared to antagonists which block the ET(A) receptor only.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="1524" length="8"/>
          <text>bosentan</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">endothelin-1 receptor</infon>
          <location offset="1485" length="21"/>
          <text>endothelin-1 receptor</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">et(a) receptor</infon>
          <location offset="1602" length="14"/>
          <text>ET(A) receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11885959</id>
    <passage>
      <offset>0</offset>
      <text>Differential binding mode of diverse cyclooxygenase inhibitors.	Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid. There are at least two different isoforms of the enzyme known as COX-1 and -2. Site directed mutagenesis studies suggest that non-selective COX inhibitors of diverse chemical families exhibit differential binding modes to the two isozymes. These results cannot clearly be explained from the sole analysis of the crystal structures of COX available from X-ray diffraction studies. With the aim to elucidate the structural features governing the differential inhibitory binding behavior of these inhibitors, molecular modeling studies were undertaken to generate atomic models compatible with the experimental data available. Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program. The results of the present study provide new insights into a better understanding of the differential binding mode of diverse families of COX inhibitors, and are expected to contribute to the design of new selective compounds.</text>
      <sentence>
        <offset>0</offset>
        <text>Differential binding mode of diverse cyclooxygenase inhibitors.</text>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyclooxygenase</infon>
          <location offset="37" length="14"/>
          <text>cyclooxygenase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>64</offset>
        <text>Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prostaglandins</infon>
          <location offset="204" length="14"/>
          <text>prostaglandins</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thromboxanes</infon>
          <location offset="223" length="12"/>
          <text>thromboxanes</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arachidonic acid</infon>
          <location offset="241" length="16"/>
          <text>arachidonic acid</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroidal</infon>
          <location offset="68" length="9"/>
          <text>steroidal</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyclooxygenase</infon>
          <location offset="141" length="14"/>
          <text>cyclooxygenase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="157" length="3"/>
          <text>COX</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>259</offset>
        <text>There are at least two different isoforms of the enzyme known as COX-1 and -2.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox-1 and -2</infon>
          <location offset="324" length="12"/>
          <text>COX-1 and -2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>338</offset>
        <text>Site directed mutagenesis studies suggest that non-selective COX inhibitors of diverse chemical families exhibit differential binding modes to the two isozymes.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="399" length="3"/>
          <text>COX</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>499</offset>
        <text>These results cannot clearly be explained from the sole analysis of the crystal structures of COX available from X-ray diffraction studies.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="593" length="3"/>
          <text>COX</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>639</offset>
        <text>With the aim to elucidate the structural features governing the differential inhibitory binding behavior of these inhibitors, molecular modeling studies were undertaken to generate atomic models compatible with the experimental data available.</text>
      </sentence>
      <sentence>
        <offset>883</offset>
        <text>Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meclofenamic acid</infon>
          <location offset="1064" length="17"/>
          <text>meclofenamic acid</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rofecoxib</infon>
          <location offset="980" length="9"/>
          <text>rofecoxib</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketoprofen</infon>
          <location offset="991" length="10"/>
          <text>ketoprofen</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">suprofen</infon>
          <location offset="1003" length="8"/>
          <text>suprofen</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carprofen</infon>
          <location offset="1013" length="9"/>
          <text>carprofen</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zomepirac</infon>
          <location offset="1024" length="9"/>
          <text>zomepirac</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="1035" length="12"/>
          <text>indomethacin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diclofenac</infon>
          <location offset="1049" length="10"/>
          <text>diclofenac</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="917" length="3"/>
          <text>COX</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1123</offset>
        <text>The results of the present study provide new insights into a better understanding of the differential binding mode of diverse families of COX inhibitors, and are expected to contribute to the design of new selective compounds.</text>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="1261" length="3"/>
          <text>COX</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15598972</id>
    <passage>
      <offset>0</offset>
      <text>Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.	The voltage-dependent M-type potassium current (M-current) plays a major role in controlling brain excitability by stabilizing the membrane potential and acting as a brake for neuronal firing. The KCNQ2/Q3 heteromeric channel complex was identified as the molecular correlate of the M-current. Furthermore, the KCNQ2 and KCNQ3 channel alpha subunits are mutated in families with benign familial neonatal convulsions, a neonatal form of epilepsy. Enhancement of KCNQ2/Q3 potassium currents may provide an important target for antiepileptic drug development. Here, we show that meclofenamic acid (meclofenamate) and diclofenac, two related molecules previously used as anti-inflammatory drugs, act as novel KCNQ2/Q3 channel openers. Extracellular application of meclofenamate (EC(50) = 25 microM) and diclofenac (EC(50) = 2.6 microM) resulted in the activation of KCNQ2/Q3 K(+) currents, heterologously expressed in Chinese hamster ovary cells. Both openers activated KCNQ2/Q3 channels by causing a hyperpolarizing shift of the voltage activation curve (-23 and -15 mV, respectively) and by markedly slowing the deactivation kinetics. The effects of the drugs were stronger on KCNQ2 than on KCNQ3 channel alpha subunits. In contrast, they did not enhance KCNQ1 K(+) currents. Both openers increased KCNQ2/Q3 current amplitude at physiologically relevant potentials and led to hyperpolarization of the resting membrane potential. In cultured cortical neurons, meclofenamate and diclofenac enhanced the M-current and reduced evoked and spontaneous action potentials, whereas in vivo diclofenac exhibited an anticonvulsant activity (ED(50) = 43 mg/kg). These compounds potentially constitute novel drug templates for the treatment of neuronal hyperexcitability including epilepsy, migraine, or neuropathic pain.</text>
      <sentence>
        <offset>0</offset>
        <text>Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meclofenamic acid</infon>
          <location offset="0" length="17"/>
          <text>Meclofenamic acid</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diclofenac</infon>
          <location offset="22" length="10"/>
          <text>diclofenac</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">potassium</infon>
          <location offset="62" length="9"/>
          <text>potassium</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kcnq2/q3</infon>
          <location offset="53" length="8"/>
          <text>KCNQ2/Q3</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">potassium channel</infon>
          <location offset="62" length="17"/>
          <text>potassium channel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>161</offset>
        <text>The voltage-dependent M-type potassium current (M-current) plays a major role in controlling brain excitability by stabilizing the membrane potential and acting as a brake for neuronal firing.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">potassium</infon>
          <location offset="190" length="9"/>
          <text>potassium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>354</offset>
        <text>The KCNQ2/Q3 heteromeric channel complex was identified as the molecular correlate of the M-current.</text>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kcnq2/q3</infon>
          <location offset="358" length="8"/>
          <text>KCNQ2/Q3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>455</offset>
        <text>Furthermore, the KCNQ2 and KCNQ3 channel alpha subunits are mutated in families with benign familial neonatal convulsions, a neonatal form of epilepsy.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kcnq2</infon>
          <location offset="472" length="5"/>
          <text>KCNQ2</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kcnq3 channel alpha subunits</infon>
          <location offset="482" length="28"/>
          <text>KCNQ3 channel alpha subunits</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>607</offset>
        <text>Enhancement of KCNQ2/Q3 potassium currents may provide an important target for antiepileptic drug development.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">potassium</infon>
          <location offset="631" length="9"/>
          <text>potassium</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kcnq2/q3</infon>
          <location offset="622" length="8"/>
          <text>KCNQ2/Q3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>718</offset>
        <text>Here, we show that meclofenamic acid (meclofenamate) and diclofenac, two related molecules previously used as anti-inflammatory drugs, act as novel KCNQ2/Q3 channel openers.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meclofenamic acid</infon>
          <location offset="737" length="17"/>
          <text>meclofenamic acid</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meclofenamate</infon>
          <location offset="756" length="13"/>
          <text>meclofenamate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diclofenac</infon>
          <location offset="775" length="10"/>
          <text>diclofenac</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kcnq2/q3</infon>
          <location offset="866" length="8"/>
          <text>KCNQ2/Q3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>892</offset>
        <text>Extracellular application of meclofenamate (EC(50) = 25 microM) and diclofenac (EC(50) = 2.6 microM) resulted in the activation of KCNQ2/Q3 K(+) currents, heterologously expressed in Chinese hamster ovary cells.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meclofenamate</infon>
          <location offset="921" length="13"/>
          <text>meclofenamate</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diclofenac</infon>
          <location offset="960" length="10"/>
          <text>diclofenac</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kcnq2/q3</infon>
          <location offset="1023" length="8"/>
          <text>KCNQ2/Q3</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1104</offset>
        <text>Both openers activated KCNQ2/Q3 channels by causing a hyperpolarizing shift of the voltage activation curve (-23 and -15 mV, respectively) and by markedly slowing the deactivation kinetics.</text>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kcnq2/q3</infon>
          <location offset="1127" length="8"/>
          <text>KCNQ2/Q3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1294</offset>
        <text>The effects of the drugs were stronger on KCNQ2 than on KCNQ3 channel alpha subunits.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kcnq2</infon>
          <location offset="1336" length="5"/>
          <text>KCNQ2</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kcnq3 channel alpha subunits</infon>
          <location offset="1350" length="28"/>
          <text>KCNQ3 channel alpha subunits</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1380</offset>
        <text>In contrast, they did not enhance KCNQ1 K(+) currents.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kcnq1</infon>
          <location offset="1414" length="5"/>
          <text>KCNQ1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1435</offset>
        <text>Both openers increased KCNQ2/Q3 current amplitude at physiologically relevant potentials and led to hyperpolarization of the resting membrane potential.</text>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kcnq2/q3</infon>
          <location offset="1458" length="8"/>
          <text>KCNQ2/Q3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1588</offset>
        <text>In cultured cortical neurons, meclofenamate and diclofenac enhanced the M-current and reduced evoked and spontaneous action potentials, whereas in vivo diclofenac exhibited an anticonvulsant activity (ED(50) = 43 mg/kg).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meclofenamate</infon>
          <location offset="1618" length="13"/>
          <text>meclofenamate</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diclofenac</infon>
          <location offset="1636" length="10"/>
          <text>diclofenac</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diclofenac</infon>
          <location offset="1740" length="10"/>
          <text>diclofenac</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1809</offset>
        <text>These compounds potentially constitute novel drug templates for the treatment of neuronal hyperexcitability including epilepsy, migraine, or neuropathic pain.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11056242</id>
    <passage>
      <offset>0</offset>
      <text>Effect of hormonal agents on monocyte chemotactic protein-1 expression by endometrial epithelial cells of women with endometriosis.	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as danazol and GnRH agonist, exert direct regulatory action on monocyte chemotactic protein-1 (MCP-1) expression by endometrial epithelial cells. DESIGN: Primary cultures of epithelial cells isolated from human endometrium were exposed to different concentrations of cytokines and steroid hormone analogs. Expression of MCP-1 was analyzed at the levels of protein and messenger RNA. SETTING: Gynecology clinic and laboratory of endocrinology of reproduction. PATIENT(S): Women presenting for infertility or pelvic pain in whom endometriosis was diagnosed by using laparoscopy. INTERVENTION(S): Endometrial tissue biopsy performed at laparoscopy. MAIN OUTCOME MEASURE(S): Secretion of MCP-1 protein was measured by using enzyme-linked immunosorbent assay, and mRNA steady-state levels were measured by performing Northern blot analysis. RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression. This effect occurred at the level of protein and mRNA. CONCLUSION(S): The findings of the study may affect understanding of the mechanisms by which hormonal treatments act on endometriosis and influence its clinical manifestations.</text>
      <sentence>
        <offset>0</offset>
        <text>Effect of hormonal agents on monocyte chemotactic protein-1 expression by endometrial epithelial cells of women with endometriosis.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monocyte chemotactic protein-1</infon>
          <location offset="29" length="30"/>
          <text>monocyte chemotactic protein-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>132</offset>
        <text>OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as danazol and GnRH agonist, exert direct regulatory action on monocyte chemotactic protein-1 (MCP-1) expression by endometrial epithelial cells.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">danazol</infon>
          <location offset="233" length="7"/>
          <text>danazol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh</infon>
          <location offset="245" length="4"/>
          <text>GnRH</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monocyte chemotactic protein-1</infon>
          <location offset="293" length="30"/>
          <text>monocyte chemotactic protein-1</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="325" length="5"/>
          <text>MCP-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>376</offset>
        <text>DESIGN: Primary cultures of epithelial cells isolated from human endometrium were exposed to different concentrations of cytokines and steroid hormone analogs.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="511" length="7"/>
          <text>steroid</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="497" length="9"/>
          <text>cytokines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>536</offset>
        <text>Expression of MCP-1 was analyzed at the levels of protein and messenger RNA.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="550" length="5"/>
          <text>MCP-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>613</offset>
        <text>SETTING: Gynecology clinic and laboratory of endocrinology of reproduction.</text>
      </sentence>
      <sentence>
        <offset>689</offset>
        <text>PATIENT(S): Women presenting for infertility or pelvic pain in whom endometriosis was diagnosed by using laparoscopy.</text>
      </sentence>
      <sentence>
        <offset>807</offset>
        <text>INTERVENTION(S): Endometrial tissue biopsy performed at laparoscopy.</text>
      </sentence>
      <sentence>
        <offset>876</offset>
        <text>MAIN OUTCOME MEASURE(S): Secretion of MCP-1 protein was measured by using enzyme-linked immunosorbent assay, and mRNA steady-state levels were measured by performing Northern blot analysis.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="914" length="5"/>
          <text>MCP-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1066</offset>
        <text>RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">danazol</infon>
          <location offset="1182" length="7"/>
          <text>danazol</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">testosterone</infon>
          <location offset="1211" length="12"/>
          <text>testosterone</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexamethasone</infon>
          <location offset="1236" length="13"/>
          <text>dexamethasone</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">buserelin acetate</infon>
          <location offset="1077" length="17"/>
          <text>Buserelin acetate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="1156" length="5"/>
          <text>MCP-1</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="1372" length="5"/>
          <text>MCP-1</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh</infon>
          <location offset="1098" length="4"/>
          <text>GnRH</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T6" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1390</offset>
        <text>This effect occurred at the level of protein and mRNA.</text>
      </sentence>
      <sentence>
        <offset>1445</offset>
        <text>CONCLUSION(S): The findings of the study may affect understanding of the mechanisms by which hormonal treatments act on endometriosis and influence its clinical manifestations.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23535363</id>
    <passage>
      <offset>0</offset>
      <text>Interferon-γ Promoter Is Hypermethylated in Blood DNA from Workers with Confirmed Diisocyanate Asthma.	Risk factors have not been identified that determine susceptibility for development of diisocyanate-induced occupational asthma (DA). We hypothesized that diisocyanate (DI) exposure could modify gene promoter regions regulating transcription of cytokine mediators and thereby influence expression of DA. A cross-sectional study was designed to investigate the promoter methylation status of candidate genes in DI-exposed workers. Subjects consisted of 131 workers in three groups: 40 cases with DA confirmed by a positive specific inhalation challenge (SIC) (DA+), 41 exposed workers with lower respiratory symptoms and negative SIC (DA-), and 50 asymptomatic exposed workers (AWs). We studied four candidate genes (GSTM1, DUSP22, IFN-γ, and IL-4) for which altered promoter methylation has been previously investigated for relationships with a variety of other environmental exposures. Methylation status was determined using methylation-specific quantitative PCR performed on genomic DNA extracted from whole blood. Results showed that relative methylation of IFN-γ promoter was significantly increased in DA+ in comparison with both comparator groups (DA- and AW), and it exhibited good sensitivity (77.5%) and specificity (80%) for identifying DA workers in a multivariate predictive model after adjusting for type of DI exposure, smoking status, methacholine PC20, and gender. IL-4 promoter was slightly less methylated only in DA+ compared with AW among nonsmoking workers. Both GSTM1 and DUSP22 promoter methylations were found not associated with DA. Our finding suggests that exposure to occupational chemicals could play a heretofore undefined mechanistic role via epigenetic modification of specific genes in the promoter region.</text>
      <sentence>
        <offset>0</offset>
        <text>Interferon-γ Promoter Is Hypermethylated in Blood DNA from Workers with Confirmed Diisocyanate Asthma.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diisocyanate</infon>
          <location offset="82" length="12"/>
          <text>Diisocyanate</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">interferon-γ promoter</infon>
          <location offset="0" length="21"/>
          <text>Interferon-γ Promoter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>103</offset>
        <text>Risk factors have not been identified that determine susceptibility for development of diisocyanate-induced occupational asthma (DA).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diisocyanate</infon>
          <location offset="190" length="12"/>
          <text>diisocyanate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>237</offset>
        <text>We hypothesized that diisocyanate (DI) exposure could modify gene promoter regions regulating transcription of cytokine mediators and thereby influence expression of DA.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diisocyanate</infon>
          <location offset="258" length="12"/>
          <text>diisocyanate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine</infon>
          <location offset="348" length="8"/>
          <text>cytokine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>407</offset>
        <text>A cross-sectional study was designed to investigate the promoter methylation status of candidate genes in DI-exposed workers.</text>
      </sentence>
      <sentence>
        <offset>533</offset>
        <text>Subjects consisted of 131 workers in three groups: 40 cases with DA confirmed by a positive specific inhalation challenge (SIC) (DA+), 41 exposed workers with lower respiratory symptoms and negative SIC (DA-), and 50 asymptomatic exposed workers (AWs).</text>
      </sentence>
      <sentence>
        <offset>786</offset>
        <text>We studied four candidate genes (GSTM1, DUSP22, IFN-γ, and IL-4) for which altered promoter methylation has been previously investigated for relationships with a variety of other environmental exposures.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gstm1</infon>
          <location offset="819" length="5"/>
          <text>GSTM1</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dusp22</infon>
          <location offset="826" length="6"/>
          <text>DUSP22</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ifn-γ</infon>
          <location offset="834" length="5"/>
          <text>IFN-γ</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-4</infon>
          <location offset="845" length="4"/>
          <text>IL-4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>990</offset>
        <text>Methylation status was determined using methylation-specific quantitative PCR performed on genomic DNA extracted from whole blood.</text>
      </sentence>
      <sentence>
        <offset>1121</offset>
        <text>Results showed that relative methylation of IFN-γ promoter was significantly increased in DA+ in comparison with both comparator groups (DA- and AW), and it exhibited good sensitivity (77.5%) and specificity (80%) for identifying DA workers in a multivariate predictive model after adjusting for type of DI exposure, smoking status, methacholine PC20, and gender.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methacholine</infon>
          <location offset="1454" length="12"/>
          <text>methacholine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ifn-γ promoter</infon>
          <location offset="1165" length="14"/>
          <text>IFN-γ promoter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1485</offset>
        <text>IL-4 promoter was slightly less methylated only in DA+ compared with AW among nonsmoking workers.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">il-4 promoter</infon>
          <location offset="1485" length="13"/>
          <text>IL-4 promoter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1583</offset>
        <text>Both GSTM1 and DUSP22 promoter methylations were found not associated with DA.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gstm1 and dusp22 promoter</infon>
          <location offset="1588" length="25"/>
          <text>GSTM1 and DUSP22 promoter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1662</offset>
        <text>Our finding suggests that exposure to occupational chemicals could play a heretofore undefined mechanistic role via epigenetic modification of specific genes in the promoter region.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16253547</id>
    <passage>
      <offset>0</offset>
      <text>Rat hepatic stellate cells become retinoid unresponsive during activation.	Hepatic stellate cells (HSC) play an essential role in fibrogenesis. Many stimuli cause HSC to activate, lose their Vitamin A and produce collagen. It is unclear whether Vitamin A loss causes activation, potentiates it or is simply an event in the cascade of activation changes. We determine if exogenous retinoids prevent the activation of freshly isolated rat HSC activated by plating on plastic. We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC nuclear receptors for retinoic acid (RAR) in HSC that are becoming activated or are chronically activated. Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation. RAR-alpha, RAR-beta and RAR-gamma mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after retinoic acid supplementation. Activation markers in chronically activated HSC were only slightly decreased after retinoid exposure. We conclude that exposure of HSC to extracellular retinoids diminishes some markers of activation but does not prevent HSC activation.</text>
      <sentence>
        <offset>0</offset>
        <text>Rat hepatic stellate cells become retinoid unresponsive during activation.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoid</infon>
          <location offset="34" length="8"/>
          <text>retinoid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>75</offset>
        <text>Hepatic stellate cells (HSC) play an essential role in fibrogenesis.</text>
      </sentence>
      <sentence>
        <offset>144</offset>
        <text>Many stimuli cause HSC to activate, lose their Vitamin A and produce collagen.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin a</infon>
          <location offset="191" length="9"/>
          <text>Vitamin A</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">collagen</infon>
          <location offset="213" length="8"/>
          <text>collagen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>223</offset>
        <text>It is unclear whether Vitamin A loss causes activation, potentiates it or is simply an event in the cascade of activation changes.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin a</infon>
          <location offset="245" length="9"/>
          <text>Vitamin A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>354</offset>
        <text>We determine if exogenous retinoids prevent the activation of freshly isolated rat HSC activated by plating on plastic.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoids</infon>
          <location offset="380" length="9"/>
          <text>retinoids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>474</offset>
        <text>We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC nuclear receptors for retinoic acid (RAR) in HSC that are becoming activated or are chronically activated.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoids</infon>
          <location offset="495" length="9"/>
          <text>retinoids</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoid</infon>
          <location offset="573" length="8"/>
          <text>retinoid</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="643" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nuclear receptors for retinoic acid</infon>
          <location offset="621" length="35"/>
          <text>nuclear receptors for retinoic acid</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rar</infon>
          <location offset="658" length="3"/>
          <text>RAR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>728</offset>
        <text>Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinol</infon>
          <location offset="799" length="7"/>
          <text>retinol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="810" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoid</infon>
          <location offset="849" length="8"/>
          <text>retinoid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>873</offset>
        <text>mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="950" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoid</infon>
          <location offset="1027" length="8"/>
          <text>retinoid</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rar-alpha</infon>
          <location offset="889" length="9"/>
          <text>RAR-alpha</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rar-beta</infon>
          <location offset="900" length="8"/>
          <text>RAR-beta</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rar-gamma</infon>
          <location offset="913" length="9"/>
          <text>RAR-gamma</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nuclear receptors</infon>
          <location offset="928" length="17"/>
          <text>nuclear receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1053</offset>
        <text>RAR-alpha, RAR-beta and RAR-gamma mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after retinoic acid supplementation.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="1185" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rar-gamma</infon>
          <location offset="1077" length="9"/>
          <text>RAR-gamma</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rar-beta</infon>
          <location offset="1096" length="8"/>
          <text>RAR-beta</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rar-alpha</infon>
          <location offset="1053" length="9"/>
          <text>RAR-alpha</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rar-beta</infon>
          <location offset="1064" length="8"/>
          <text>RAR-beta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1216</offset>
        <text>Activation markers in chronically activated HSC were only slightly decreased after retinoid exposure.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoid</infon>
          <location offset="1299" length="8"/>
          <text>retinoid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1318</offset>
        <text>We conclude that exposure of HSC to extracellular retinoids diminishes some markers of activation but does not prevent HSC activation.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoids</infon>
          <location offset="1368" length="9"/>
          <text>retinoids</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>20427668</id>
    <passage>
      <offset>0</offset>
      <text>Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males.	A complex dynamic ultradian rhythm underlies the hypothalamic-pituitary-adrenal (HPA) circadian rhythm. We have investigated in normal human male subjects the importance, site of action, and receptor-mediated processes involved in rapid basal corticosteroid feedback and its interaction with corticotrophin releasing hormone (CRH) drive. Pro-opiomelanocortin (POMC), ACTH, and cortisol were measured every 10 min from healthy males during the awakening period or late afternoon using an automated blood sampling system. Mathematical modeling into discrete pulses of activity revealed that intravenous infusion of the synthetic mixed glucocorticoid/mineralocorticoid agonist prednisolone produced rapid inhibition of ACTH and cortisol pulsatility within 30 min in the morning and afternoon. Any pulse that had commenced at the time of injection was unaffected, and subsequent pulsatility was inhibited. Prednisolone also inhibited ACTH and cortisol secretion in response to exogenous CRH stimulation, inferring rapid feedback inhibition at the anterior pituitary. Circulating POMC peptide concentrations were unaffected, suggesting that the rapid corticosteroid inhibitory effect specifically targeted ACTH secretion from pituitary corticotrophs. Prednisolone fast feedback was only reduced by glucocorticoid receptor antagonist pretreatment and not by mineralocorticoid receptor antagonism, suggesting a glucocorticoid receptor-mediated pathway. The intravenous prednisolone suppression test provides a powerful new tool to investigate HPA abnormalities underlying metabolic and psychiatric disease states.</text>
      <sentence>
        <offset>0</offset>
        <text>Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="6" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>121</offset>
        <text>A complex dynamic ultradian rhythm underlies the hypothalamic-pituitary-adrenal (HPA) circadian rhythm.</text>
      </sentence>
      <sentence>
        <offset>225</offset>
        <text>We have investigated in normal human male subjects the importance, site of action, and receptor-mediated processes involved in rapid basal corticosteroid feedback and its interaction with corticotrophin releasing hormone (CRH) drive.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosteroid</infon>
          <location offset="364" length="14"/>
          <text>corticosteroid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">corticotrophin releasing hormone</infon>
          <location offset="413" length="32"/>
          <text>corticotrophin releasing hormone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crh</infon>
          <location offset="447" length="3"/>
          <text>CRH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>459</offset>
        <text>Pro-opiomelanocortin (POMC), ACTH, and cortisol were measured every 10 min from healthy males during the awakening period or late afternoon using an automated blood sampling system.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pro-opiomelanocortin</infon>
          <location offset="459" length="20"/>
          <text>Pro-opiomelanocortin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pomc</infon>
          <location offset="481" length="4"/>
          <text>POMC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>641</offset>
        <text>Mathematical modeling into discrete pulses of activity revealed that intravenous infusion of the synthetic mixed glucocorticoid/mineralocorticoid agonist prednisolone produced rapid inhibition of ACTH and cortisol pulsatility within 30 min in the morning and afternoon.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="795" length="12"/>
          <text>prednisolone</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cortisol</infon>
          <location offset="846" length="8"/>
          <text>cortisol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>911</offset>
        <text>Any pulse that had commenced at the time of injection was unaffected, and subsequent pulsatility was inhibited.</text>
      </sentence>
      <sentence>
        <offset>1023</offset>
        <text>Prednisolone also inhibited ACTH and cortisol secretion in response to exogenous CRH stimulation, inferring rapid feedback inhibition at the anterior pituitary.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="1023" length="12"/>
          <text>Prednisolone</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cortisol</infon>
          <location offset="1060" length="8"/>
          <text>cortisol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crh</infon>
          <location offset="1104" length="3"/>
          <text>CRH</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1184</offset>
        <text>Circulating POMC peptide concentrations were unaffected, suggesting that the rapid corticosteroid inhibitory effect specifically targeted ACTH secretion from pituitary corticotrophs.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosteroid</infon>
          <location offset="1267" length="14"/>
          <text>corticosteroid</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pomc</infon>
          <location offset="1196" length="4"/>
          <text>POMC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1367</offset>
        <text>Prednisolone fast feedback was only reduced by glucocorticoid receptor antagonist pretreatment and not by mineralocorticoid receptor antagonism, suggesting a glucocorticoid receptor-mediated pathway.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="1367" length="12"/>
          <text>Prednisolone</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="1414" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mineralocorticoid receptor</infon>
          <location offset="1473" length="26"/>
          <text>mineralocorticoid receptor</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="1525" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1567</offset>
        <text>The intravenous prednisolone suppression test provides a powerful new tool to investigate HPA abnormalities underlying metabolic and psychiatric disease states.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="1583" length="12"/>
          <text>prednisolone</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23383423</id>
    <passage>
      <offset>0</offset>
      <text>International Union of Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors.	The activation of the complement cascade, a cornerstone of the innate immune response, produces a number of small (74-77 amino acid) fragments, originally termed anaphylatoxins, that are potent chemoattractants and secretagogues that act on a wide variety of cell types. These fragments, C5a, C4a, and C3a, participate at all levels of the immune response and are also involved in other processes such as neural development and organ regeneration. Their primary function, however, is in inflammation, so they are important targets for the development of antiinflammatory therapies. Only three receptors for complement peptides have been found, but there are no satisfactory antagonists as yet, despite intensive investigation. In humans, there is a single receptor for C3a (C3a receptor), no known receptor for C4a, and two receptors for C5a (C5a₁ receptor and C5a₂ receptor). The most recently characterized receptor, the C5a₂ receptor (previously known as C5L2 or GPR77), has been regarded as a passive binding protein, but signaling activities are now ascribed to it, so we propose that it be formally identified as a receptor and be given a name to reflect this. Here, we describe the complex biology of the complement peptides, introduce a new suggested nomenclature, and review our current knowledge of receptor pharmacology.</text>
      <sentence>
        <offset>0</offset>
        <text>International Union of Pharmacology.</text>
      </sentence>
      <sentence>
        <offset>37</offset>
        <text>LXXXVII.</text>
      </sentence>
      <sentence>
        <offset>46</offset>
        <text>Complement peptide C5a, C4a, and C3a receptors.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">complement peptide c5a, c4a, and c3a receptors</infon>
          <location offset="46" length="46"/>
          <text>Complement peptide C5a, C4a, and C3a receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>94</offset>
        <text>The activation of the complement cascade, a cornerstone of the innate immune response, produces a number of small (74-77 amino acid) fragments, originally termed anaphylatoxins, that are potent chemoattractants and secretagogues that act on a wide variety of cell types.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="215" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">anaphylatoxins</infon>
          <location offset="256" length="14"/>
          <text>anaphylatoxins</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">complement</infon>
          <location offset="116" length="10"/>
          <text>complement</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T2" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>365</offset>
        <text>These fragments, C5a, C4a, and C3a, participate at all levels of the immune response and are also involved in other processes such as neural development and organ regeneration.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c5a</infon>
          <location offset="382" length="3"/>
          <text>C5a</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c4a</infon>
          <location offset="387" length="3"/>
          <text>C4a</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c3a</infon>
          <location offset="396" length="3"/>
          <text>C3a</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>542</offset>
        <text>Their primary function, however, is in inflammation, so they are important targets for the development of antiinflammatory therapies.</text>
      </sentence>
      <sentence>
        <offset>676</offset>
        <text>Only three receptors for complement peptides have been found, but there are no satisfactory antagonists as yet, despite intensive investigation.</text>
      </sentence>
      <sentence>
        <offset>821</offset>
        <text>In humans, there is a single receptor for C3a (C3a receptor), no known receptor for C4a, and two receptors for C5a (C5a₁ receptor and C5a₂ receptor).</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c3a</infon>
          <location offset="863" length="3"/>
          <text>C3a</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c3a receptor</infon>
          <location offset="868" length="12"/>
          <text>C3a receptor</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c4a</infon>
          <location offset="905" length="3"/>
          <text>C4a</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c5a</infon>
          <location offset="932" length="3"/>
          <text>C5a</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c5a₁ receptor</infon>
          <location offset="937" length="13"/>
          <text>C5a₁ receptor</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c5a₂ receptor</infon>
          <location offset="955" length="13"/>
          <text>C5a₂ receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>971</offset>
        <text>The most recently characterized receptor, the C5a₂ receptor (previously known as C5L2 or GPR77), has been regarded as a passive binding protein, but signaling activities are now ascribed to it, so we propose that it be formally identified as a receptor and be given a name to reflect this.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c5a₂</infon>
          <location offset="1017" length="4"/>
          <text>C5a₂</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c5l2</infon>
          <location offset="1052" length="4"/>
          <text>C5L2</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr77</infon>
          <location offset="1060" length="5"/>
          <text>GPR77</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1261</offset>
        <text>Here, we describe the complex biology of the complement peptides, introduce a new suggested nomenclature, and review our current knowledge of receptor pharmacology.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23411241</id>
    <passage>
      <offset>0</offset>
      <text>Compositional characterisation of soluble apple polysaccharides, and their antioxidant and hepatoprotective effects on acute CCl4-caused liver damage in mice.	Water-soluble apple peel polysaccharides (APP) and apple flesh polysaccharides (AFP) were isolated from Pink Lady fruits, and their in vitro antioxidant capacities were characterised by DPPH(), HO(), and O(2)(-) systems, and ferric-reducing antioxidant power assay. Oral administration of APP at 250 and 500 mg/kg bw in mice was shown to be as effective as AFP in lowering the CCl(4)-caused increases of serum alanine aminotransferase, aspartate aminotransferase and lactic dehydrogenase activities, and hepatic malondialdehyde level, and antagonising the decreases in antioxidant superoxide dismutase and glutathione peroxidase activities caused by CCl(4) (p&lt;0.05). Histopathological examinations further confirmed that both APP and AFP could protect the liver from CCl(4)-induced histological alteration. HPLC analysis also showed similar profiles of monosaccharide composition for APP and AFP with arabinose, galactose and galacturonic acid being main component monosaccharides. All of these findings demonstrate that the extracts of both APP and AFP possess antioxidant and hepatoprotective potential.</text>
      <sentence>
        <offset>0</offset>
        <text>Compositional characterisation of soluble apple polysaccharides, and their antioxidant and hepatoprotective effects on acute CCl4-caused liver damage in mice.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl4</infon>
          <location offset="125" length="4"/>
          <text>CCl4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>159</offset>
        <text>Water-soluble apple peel polysaccharides (APP) and apple flesh polysaccharides (AFP) were isolated from Pink Lady fruits, and their in vitro antioxidant capacities were characterised by DPPH(), HO(), and O(2)(-) systems, and ferric-reducing antioxidant power assay.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dpph</infon>
          <location offset="345" length="4"/>
          <text>DPPH</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ho</infon>
          <location offset="353" length="2"/>
          <text>HO</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o(2)(-)</infon>
          <location offset="363" length="7"/>
          <text>O(2)(-)</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ferric</infon>
          <location offset="384" length="6"/>
          <text>ferric</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>425</offset>
        <text>Oral administration of APP at 250 and 500 mg/kg bw in mice was shown to be as effective as AFP in lowering the CCl(4)-caused increases of serum alanine aminotransferase, aspartate aminotransferase and lactic dehydrogenase activities, and hepatic malondialdehyde level, and antagonising the decreases in antioxidant superoxide dismutase and glutathione peroxidase activities caused by CCl(4) (p&lt;0.05).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl(4)</infon>
          <location offset="536" length="6"/>
          <text>CCl(4)</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alanine</infon>
          <location offset="569" length="7"/>
          <text>alanine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspartate</infon>
          <location offset="595" length="9"/>
          <text>aspartate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malondialdehyde</infon>
          <location offset="671" length="15"/>
          <text>malondialdehyde</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="740" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="765" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl(4)</infon>
          <location offset="809" length="6"/>
          <text>CCl(4)</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serum alanine aminotransferase</infon>
          <location offset="563" length="30"/>
          <text>serum alanine aminotransferase</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aspartate aminotransferase</infon>
          <location offset="595" length="26"/>
          <text>aspartate aminotransferase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lactic dehydrogenase</infon>
          <location offset="626" length="20"/>
          <text>lactic dehydrogenase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">superoxide dismutase</infon>
          <location offset="740" length="20"/>
          <text>superoxide dismutase</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathione peroxidase</infon>
          <location offset="765" length="22"/>
          <text>glutathione peroxidase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>826</offset>
        <text>Histopathological examinations further confirmed that both APP and AFP could protect the liver from CCl(4)-induced histological alteration.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl(4)</infon>
          <location offset="926" length="6"/>
          <text>CCl(4)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>966</offset>
        <text>HPLC analysis also showed similar profiles of monosaccharide composition for APP and AFP with arabinose, galactose and galacturonic acid being main component monosaccharides.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arabinose</infon>
          <location offset="1060" length="9"/>
          <text>arabinose</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">galactose</infon>
          <location offset="1071" length="9"/>
          <text>galactose</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">galacturonic acid</infon>
          <location offset="1085" length="17"/>
          <text>galacturonic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1141</offset>
        <text>All of these findings demonstrate that the extracts of both APP and AFP possess antioxidant and hepatoprotective potential.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10579749</id>
    <passage>
      <offset>0</offset>
      <text>Pharmacological properties of angiotensin II receptor antagonists.	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors. Losartan was the first, but by no means remained the only, AT1 receptor antagonist. Numerous other 'sartans' have emerged in the past several years and successfully completed clinical development. With the exception of eprosartan, all others, ie, candesartan, irbesartan, saprisartan, tasosartan, telmisartan, valsartan and zolasartan, are based on medications of losartan's prototypical chemical structure. Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280. The mode of (functional) AT1 receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174). It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism. However, competitive or noncompetitive antagonism does not determine the antihypertensive efficacy, but the slow off-rate may extend the occupancy of the AT1 receptor and thereby lengthen the duration of the antihypertensive effect.</text>
      <sentence>
        <offset>0</offset>
        <text>Pharmacological properties of angiotensin II receptor antagonists.</text>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="30" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">angiotensin ii receptor</infon>
          <location offset="30" length="23"/>
          <text>angiotensin II receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>67</offset>
        <text>The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin</infon>
          <location offset="282" length="11"/>
          <text>angiotensin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="294" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="406" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin i</infon>
          <location offset="458" length="13"/>
          <text>angiotensin I</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="147" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="276" length="5"/>
          <text>renin</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin</infon>
          <location offset="282" length="11"/>
          <text>angiotensin</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at1</infon>
          <location offset="333" length="3"/>
          <text>AT1</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="406" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin i converting enzyme</infon>
          <location offset="458" length="31"/>
          <text>angiotensin I converting enzyme</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin ii type 1 (at1) receptor</infon>
          <location offset="147" length="36"/>
          <text>angiotensin II type 1 (AT1) receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>502</offset>
        <text>Losartan was the first, but by no means remained the only, AT1 receptor antagonist.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">losartan</infon>
          <location offset="502" length="8"/>
          <text>Losartan</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at1</infon>
          <location offset="561" length="3"/>
          <text>AT1</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T20" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>586</offset>
        <text>Numerous other 'sartans' have emerged in the past several years and successfully completed clinical development.</text>
      </sentence>
      <sentence>
        <offset>699</offset>
        <text>With the exception of eprosartan, all others, ie, candesartan, irbesartan, saprisartan, tasosartan, telmisartan, valsartan and zolasartan, are based on medications of losartan's prototypical chemical structure.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eprosartan</infon>
          <location offset="721" length="10"/>
          <text>eprosartan</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="749" length="11"/>
          <text>candesartan</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">irbesartan</infon>
          <location offset="762" length="10"/>
          <text>irbesartan</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">saprisartan</infon>
          <location offset="774" length="11"/>
          <text>saprisartan</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tasosartan</infon>
          <location offset="787" length="10"/>
          <text>tasosartan</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">telmisartan</infon>
          <location offset="799" length="11"/>
          <text>telmisartan</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">valsartan</infon>
          <location offset="812" length="9"/>
          <text>valsartan</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zolasartan</infon>
          <location offset="826" length="10"/>
          <text>zolasartan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>910</offset>
        <text>Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">losartan</infon>
          <location offset="1094" length="8"/>
          <text>losartan</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tasosartan</infon>
          <location offset="1108" length="10"/>
          <text>tasosartan</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">losartan</infon>
          <location offset="1123" length="8"/>
          <text>losartan</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eprosartan</infon>
          <location offset="1136" length="10"/>
          <text>eprosartan</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan cilexetil</infon>
          <location offset="1167" length="21"/>
          <text>candesartan cilexetil</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="1031" length="11"/>
          <text>candesartan</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">telmisartan</infon>
          <location offset="1046" length="11"/>
          <text>telmisartan</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">e3174</infon>
          <location offset="1062" length="5"/>
          <text>E3174</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at1</infon>
          <location offset="928" length="3"/>
          <text>AT1</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T31" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T30" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T31" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T32" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T32" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T30" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1194</offset>
        <text>The mode of (functional) AT1 receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">losartan</infon>
          <location offset="1298" length="8"/>
          <text>losartan</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tasosartan</infon>
          <location offset="1308" length="10"/>
          <text>tasosartan</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eprosartan</infon>
          <location offset="1320" length="10"/>
          <text>eprosartan</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="1366" length="11"/>
          <text>candesartan</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">saprisartan</infon>
          <location offset="1379" length="11"/>
          <text>saprisartan</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zolasartan</infon>
          <location offset="1392" length="10"/>
          <text>zolasartan</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">irbesartan</infon>
          <location offset="1404" length="10"/>
          <text>irbesartan</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">valsartan</infon>
          <location offset="1416" length="9"/>
          <text>valsartan</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">telmisartan</infon>
          <location offset="1427" length="11"/>
          <text>telmisartan</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">e3174</infon>
          <location offset="1440" length="5"/>
          <text>E3174</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at1</infon>
          <location offset="1219" length="3"/>
          <text>AT1</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T13" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T8" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T12" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T6" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T15" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T14" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T10" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T11" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1448</offset>
        <text>It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism.</text>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at1</infon>
          <location offset="1507" length="3"/>
          <text>AT1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1556</offset>
        <text>However, competitive or noncompetitive antagonism does not determine the antihypertensive efficacy, but the slow off-rate may extend the occupancy of the AT1 receptor and thereby lengthen the duration of the antihypertensive effect.</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at1</infon>
          <location offset="1710" length="3"/>
          <text>AT1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22933107</id>
    <passage>
      <offset>0</offset>
      <text>Manganese-enhanced magnetic resonance imaging detects declining pancreatic β-cell mass in a cyclophosphamide-accelerated mouse model of type 1 diabetes.	Currently, there is no ideal noninvasive method to quantify the progressive loss of pancreatic β-cell mass (BCM) that occurs in type 1 diabetes. Magnetic resonance imaging has detected gross differences in BCM between healthy and diabetic mice using the contrast agent manganese, which labels functional β-cells and increases the water proton relaxation rate (R1), but its ability to measure gradations in BCM during disease progression is unknown. Our objective was to test the hypothesis that measurements of the manganese-enhanced pancreatic R1 could detect decreasing BCM in a mouse model of type 1 diabetes. We used cyclophosphamide-accelerated BDC2.5 T-cell receptor transgenic nonobese diabetic mice, which experience development of type 1 diabetes during a 7-day time period after cyclophosphamide injection, whereas transgene-negative mice do not. We measured the manganese-enhanced pancreatic R1 before cyclophosphamide injection (day 0) and on days 3, 4, 5, and 7 afterward. Pancreatic R1 remained constant in transgene-negative mice and decreased stepwise day-to-day in transgene-positive mice, mirroring their loss of BCM, confirmed by pancreatic insulin measurements and histology. Changes in R1 in transgene-positive mice occurred before elevations in blood glucose, a clinical indicator of diabetes, suggesting potential for early noninvasive detection of changes in functional BCM.</text>
      <sentence>
        <offset>0</offset>
        <text>Manganese-enhanced magnetic resonance imaging detects declining pancreatic β-cell mass in a cyclophosphamide-accelerated mouse model of type 1 diabetes.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="0" length="9"/>
          <text>Manganese</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclophosphamide</infon>
          <location offset="92" length="16"/>
          <text>cyclophosphamide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>153</offset>
        <text>Currently, there is no ideal noninvasive method to quantify the progressive loss of pancreatic β-cell mass (BCM) that occurs in type 1 diabetes.</text>
      </sentence>
      <sentence>
        <offset>298</offset>
        <text>Magnetic resonance imaging has detected gross differences in BCM between healthy and diabetic mice using the contrast agent manganese, which labels functional β-cells and increases the water proton relaxation rate (R1), but its ability to measure gradations in BCM during disease progression is unknown.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="422" length="9"/>
          <text>manganese</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>602</offset>
        <text>Our objective was to test the hypothesis that measurements of the manganese-enhanced pancreatic R1 could detect decreasing BCM in a mouse model of type 1 diabetes.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="668" length="9"/>
          <text>manganese</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>766</offset>
        <text>We used cyclophosphamide-accelerated BDC2.5 T-cell receptor transgenic nonobese diabetic mice, which experience development of type 1 diabetes during a 7-day time period after cyclophosphamide injection, whereas transgene-negative mice do not.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclophosphamide</infon>
          <location offset="774" length="16"/>
          <text>cyclophosphamide</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclophosphamide</infon>
          <location offset="942" length="16"/>
          <text>cyclophosphamide</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">t-cell receptor</infon>
          <location offset="810" length="15"/>
          <text>T-cell receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1010</offset>
        <text>We measured the manganese-enhanced pancreatic R1 before cyclophosphamide injection (day 0) and on days 3, 4, 5, and 7 afterward.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="1026" length="9"/>
          <text>manganese</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclophosphamide</infon>
          <location offset="1066" length="16"/>
          <text>cyclophosphamide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1139</offset>
        <text>Pancreatic R1 remained constant in transgene-negative mice and decreased stepwise day-to-day in transgene-positive mice, mirroring their loss of BCM, confirmed by pancreatic insulin measurements and histology.</text>
      </sentence>
      <sentence>
        <offset>1349</offset>
        <text>Changes in R1 in transgene-positive mice occurred before elevations in blood glucose, a clinical indicator of diabetes, suggesting potential for early noninvasive detection of changes in functional BCM.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1426" length="7"/>
          <text>glucose</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15299009</id>
    <passage>
      <offset>0</offset>
      <text>A disorder to order transition accompanies catalysis in retinaldehyde dehydrogenase type II.	Retinaldehyde dehydrogenase II (RalDH2) converts retinal to the transcriptional regulator retinoic acid in the developing embryo. The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel. We asked whether this disordered loop might order during the course of catalysis and provide a means for an enzyme that requires a large substrate access channel to restrict access to the catalytic machinery by smaller compounds that might potentially enter the active site and be metabolized. Our experiments, a combination of kinetic, spectroscopic, and crystallographic techniques, suggest that a disorder to order transition is linked to catalytic activity.</text>
      <sentence>
        <offset>0</offset>
        <text>A disorder to order transition accompanies catalysis in retinaldehyde dehydrogenase type II.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinaldehyde</infon>
          <location offset="56" length="13"/>
          <text>retinaldehyde</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">retinaldehyde dehydrogenase type ii</infon>
          <location offset="56" length="35"/>
          <text>retinaldehyde dehydrogenase type II</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>93</offset>
        <text>Retinaldehyde dehydrogenase II (RalDH2) converts retinal to the transcriptional regulator retinoic acid in the developing embryo.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinaldehyde</infon>
          <location offset="93" length="13"/>
          <text>Retinaldehyde</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">retinaldehyde dehydrogenase ii</infon>
          <location offset="93" length="30"/>
          <text>Retinaldehyde dehydrogenase II</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">raldh2</infon>
          <location offset="125" length="6"/>
          <text>RalDH2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>223</offset>
        <text>The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldehyde</infon>
          <location offset="332" length="8"/>
          <text>aldehyde</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="393" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinaldehyde</infon>
          <location offset="444" length="13"/>
          <text>retinaldehyde</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldehyde</infon>
          <location offset="507" length="8"/>
          <text>aldehyde</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldehyde dehydrogenases</infon>
          <location offset="332" length="23"/>
          <text>aldehyde dehydrogenases</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">retinaldehyde dehydrogenase ii</infon>
          <location offset="444" length="30"/>
          <text>retinaldehyde dehydrogenase II</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldehyde dehydrogenases</infon>
          <location offset="507" length="23"/>
          <text>aldehyde dehydrogenases</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>602</offset>
        <text>We asked whether this disordered loop might order during the course of catalysis and provide a means for an enzyme that requires a large substrate access channel to restrict access to the catalytic machinery by smaller compounds that might potentially enter the active site and be metabolized.</text>
      </sentence>
      <sentence>
        <offset>896</offset>
        <text>Our experiments, a combination of kinetic, spectroscopic, and crystallographic techniques, suggest that a disorder to order transition is linked to catalytic activity.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12969258</id>
    <passage>
      <offset>0</offset>
      <text>Dopamine-dependent increases in phosphorylation of cAMP response element binding protein (CREB) during precipitated morphine withdrawal in primary cultures of rat striatum.	Chronic morphine leads to compensatory up-regulation of cAMP signaling pathways in numerous brain regions. One potential consequence of up-regulated cAMP signaling is increased phosphorylation of cAMP response element binding protein (CREB), a transcription factor that may regulate neuroadaptations related to morphine dependence. Altered gene expression within the nucleus accumbens (NAc), a ventral component of the striatum that receives substantial dopaminergic input, may play a role in some of the motivational aspects of opiate withdrawal. To determine if morphine withdrawal leads to increased CREB phosphorylation in striatal tissues, we examined the effects of naloxone-precipitated morphine withdrawal on CREB phosphorylation in primary cultures of rat striatal neurons. Precipitated morphine withdrawal was associated with enhanced dopamine-, SKF 82958 (D1 receptor agonist)-, and forskolin-induced CREB phosphorylation. During precipitated withdrawal, D1 receptor-mediated CREB phosphorylation was dependent on cAMP-dependent protein kinase (PKA). Precipitated withdrawal also led to up-regulation of c-fos mRNA in response to SKF 82958. CREB protein levels were not altered by acute or chronic morphine. These results suggest that D1 receptor-mediated signal transduction is enhanced during morphine withdrawal. Furthermore, they are consistent with in vivo evidence suggesting that increased CREB activation in portions of the striatum (e.g. the NAc) is related to dysphoric states associated with drug withdrawal.</text>
      <sentence>
        <offset>0</offset>
        <text>Dopamine-dependent increases in phosphorylation of cAMP response element binding protein (CREB) during precipitated morphine withdrawal in primary cultures of rat striatum.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="0" length="8"/>
          <text>Dopamine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="116" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="51" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">camp response element binding protein</infon>
          <location offset="51" length="37"/>
          <text>cAMP response element binding protein</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="90" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>173</offset>
        <text>Chronic morphine leads to compensatory up-regulation of cAMP signaling pathways in numerous brain regions.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="229" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="181" length="8"/>
          <text>morphine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>280</offset>
        <text>One potential consequence of up-regulated cAMP signaling is increased phosphorylation of cAMP response element binding protein (CREB), a transcription factor that may regulate neuroadaptations related to morphine dependence.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="322" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="369" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="484" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">camp response element binding protein</infon>
          <location offset="369" length="37"/>
          <text>cAMP response element binding protein</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="408" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>505</offset>
        <text>Altered gene expression within the nucleus accumbens (NAc), a ventral component of the striatum that receives substantial dopaminergic input, may play a role in some of the motivational aspects of opiate withdrawal.</text>
      </sentence>
      <sentence>
        <offset>721</offset>
        <text>To determine if morphine withdrawal leads to increased CREB phosphorylation in striatal tissues, we examined the effects of naloxone-precipitated morphine withdrawal on CREB phosphorylation in primary cultures of rat striatal neurons.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="737" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">naloxone</infon>
          <location offset="845" length="8"/>
          <text>naloxone</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="867" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="776" length="4"/>
          <text>CREB</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="890" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>956</offset>
        <text>Precipitated morphine withdrawal was associated with enhanced dopamine-, SKF 82958 (D1 receptor agonist)-, and forskolin-induced CREB phosphorylation.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="969" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1018" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">skf 82958</infon>
          <location offset="1029" length="9"/>
          <text>SKF 82958</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">forskolin</infon>
          <location offset="1067" length="9"/>
          <text>forskolin</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d1 receptor</infon>
          <location offset="1040" length="11"/>
          <text>D1 receptor</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="1085" length="4"/>
          <text>CREB</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T15" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1107</offset>
        <text>During precipitated withdrawal, D1 receptor-mediated CREB phosphorylation was dependent on cAMP-dependent protein kinase (PKA).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="1198" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">camp-dependent protein kinase</infon>
          <location offset="1198" length="29"/>
          <text>cAMP-dependent protein kinase</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pka</infon>
          <location offset="1229" length="3"/>
          <text>PKA</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d1 receptor</infon>
          <location offset="1139" length="11"/>
          <text>D1 receptor</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="1160" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1235</offset>
        <text>Precipitated withdrawal also led to up-regulation of c-fos mRNA in response to SKF 82958.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">skf 82958</infon>
          <location offset="1314" length="9"/>
          <text>SKF 82958</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-fos</infon>
          <location offset="1288" length="5"/>
          <text>c-fos</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1325</offset>
        <text>CREB protein levels were not altered by acute or chronic morphine.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="1382" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="1325" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1392</offset>
        <text>These results suggest that D1 receptor-mediated signal transduction is enhanced during morphine withdrawal.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="1479" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d1 receptor</infon>
          <location offset="1419" length="11"/>
          <text>D1 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1500</offset>
        <text>Furthermore, they are consistent with in vivo evidence suggesting that increased CREB activation in portions of the striatum (e.g. the NAc) is related to dysphoric states associated with drug withdrawal.</text>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="1581" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15871445</id>
    <passage>
      <offset>0</offset>
      <text>Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance.	Intolerance reactions to acetyl salicylic acid (ASA) and nonsteroidal anti-inflammatory drugs (NSAIDs) are common and caused by inhibition of COX-1 enzyme. Therefore, drugs that selectively inhibit COX-2 enzyme may be safe in these subjects. In this study, we evaluated the tolerability of celecoxib, a selective COX-2 inhibitor, in patients with analgesic intolerance. The eligible study population consisted of patients with a history of urticaria/angioedema, naso-ocular symptoms, bronchospasm, and/or anaphylactoid reaction induced by ASA and/or NSAIDs. A single-blind, placebo-controlled oral challenge test was performed in the hospital setting. On 2 separate days, 1/4 and 3/4 divided doses of placebo and celecoxib (Celebrex 200 mg, Pfizer, Turkey) were given with 2-hour intervals. Seventy-five subjects (mean age: 38.2 +/- 1.4 years; F:M: 55:20) were included in the study. Twenty-one subjects had asthma. No reaction was observed with placebo or celecoxib provocation. Although celecoxib seems to be a safe alternative drug in our study group, considering its serious adverse events reported in the literature, the drug should be recommended for patients with analgesic intolerance only after being tested by an experienced allergist.</text>
      <sentence>
        <offset>0</offset>
        <text>Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celecoxib</infon>
          <location offset="52" length="9"/>
          <text>celecoxib</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyclooxygenase</infon>
          <location offset="26" length="14"/>
          <text>cyclooxygenase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>103</offset>
        <text>Intolerance reactions to acetyl salicylic acid (ASA) and nonsteroidal anti-inflammatory drugs (NSAIDs) are common and caused by inhibition of COX-1 enzyme.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetyl salicylic acid</infon>
          <location offset="128" length="21"/>
          <text>acetyl salicylic acid</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asa</infon>
          <location offset="151" length="3"/>
          <text>ASA</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-1</infon>
          <location offset="245" length="5"/>
          <text>COX-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>259</offset>
        <text>Therefore, drugs that selectively inhibit COX-2 enzyme may be safe in these subjects.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="301" length="5"/>
          <text>COX-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>345</offset>
        <text>In this study, we evaluated the tolerability of celecoxib, a selective COX-2 inhibitor, in patients with analgesic intolerance.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celecoxib</infon>
          <location offset="393" length="9"/>
          <text>celecoxib</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="416" length="5"/>
          <text>COX-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>473</offset>
        <text>The eligible study population consisted of patients with a history of urticaria/angioedema, naso-ocular symptoms, bronchospasm, and/or anaphylactoid reaction induced by ASA and/or NSAIDs.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asa</infon>
          <location offset="642" length="3"/>
          <text>ASA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>661</offset>
        <text>A single-blind, placebo-controlled oral challenge test was performed in the hospital setting.</text>
      </sentence>
      <sentence>
        <offset>755</offset>
        <text>On 2 separate days, 1/4 and 3/4 divided doses of placebo and celecoxib (Celebrex 200 mg, Pfizer, Turkey) were given with 2-hour intervals.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celecoxib</infon>
          <location offset="816" length="9"/>
          <text>celecoxib</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celebrex</infon>
          <location offset="827" length="8"/>
          <text>Celebrex</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>894</offset>
        <text>Seventy-five subjects (mean age: 38.2 +/- 1.4 years; F:M: 55:20) were included in the study.</text>
      </sentence>
      <sentence>
        <offset>987</offset>
        <text>Twenty-one subjects had asthma.</text>
      </sentence>
      <sentence>
        <offset>1019</offset>
        <text>No reaction was observed with placebo or celecoxib provocation.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celecoxib</infon>
          <location offset="1060" length="9"/>
          <text>celecoxib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1083</offset>
        <text>Although celecoxib seems to be a safe alternative drug in our study group, considering its serious adverse events reported in the literature, the drug should be recommended for patients with analgesic intolerance only after being tested by an experienced allergist.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celecoxib</infon>
          <location offset="1092" length="9"/>
          <text>celecoxib</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>6222739</id>
    <passage>
      <offset>0</offset>
      <text>Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes.	A number of physiological and synthetic progestins were tested for their ability to compete with [3H]dexamethasone for the binding to the glucocorticoid receptor of human mononuclear leukocytes and their ability to elicit glucocorticoid-like effects on the same cells. As compared to the reference compound dexamethasone (relative receptor binding affinity defined as 100%), two potent synthetic progestins with a pregnane-type structure, megestrol acetate and medroxyprogesterone acetate, were found to display a considerable binding affinity towards the receptor (46 and 42%, respectively). The relative binding affinity of the naturally occurring ligand, cortisol, to the receptor was clearly lower (25%). The effective binding of medroxyprogesterone acetate to the glucocorticoid receptor was confirmed by direct binding studies utilizing a tritiated derivative of this steroid. No evidence for the existence of a specific progesterone receptor in human mononuclear leukocytes was obtained as judged by the results of competition experiments where a progesterone receptor-specific ligand [3H]Org 2058 was used. Medroxyprogesterone acetate and megestrol acetate also induced glucocorticoid-like effects on the lymphocyte functions. These included inhibition of the proliferative responses to the T-cell mitogens concanavalin A and phytohaemagglutinin and an enhanced accumulation of immunoglobulin secreting cells in pokeweed mitogen-stimulated cultures. The progestin effect appears to be mediated through a radiosensitive (suppressor) subpopulation of T lymphocytes. In contrast, the synthetic progestins related structurally to 19-nortestosterone, norethisterone and d-norgestrel, were virtually devoid of binding affinity towards the glucocorticoid receptor nor did they measurably influence the in vitro lymphocyte functions. These studies demonstrate that certain progestins in common clinical use probably possess inherent glucocorticoid activity and suggest that side effects attributable to this character (e.g. suppression of the pituitary-adrenal axis) might be expected when these compounds are used in pharmacological doses.</text>
      <sentence>
        <offset>0</offset>
        <text>Binding of progestins to the glucocorticoid receptor.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestins</infon>
          <location offset="11" length="10"/>
          <text>progestins</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="29" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T22" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>54</offset>
        <text>Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes.</text>
      </sentence>
      <sentence>
        <offset>158</offset>
        <text>A number of physiological and synthetic progestins were tested for their ability to compete with [3H]dexamethasone for the binding to the glucocorticoid receptor of human mononuclear leukocytes and their ability to elicit glucocorticoid-like effects on the same cells.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestins</infon>
          <location offset="198" length="10"/>
          <text>progestins</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]dexamethasone</infon>
          <location offset="255" length="17"/>
          <text>[3H]dexamethasone</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="296" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>427</offset>
        <text>As compared to the reference compound dexamethasone (relative receptor binding affinity defined as 100%), two potent synthetic progestins with a pregnane-type structure, megestrol acetate and medroxyprogesterone acetate, were found to display a considerable binding affinity towards the receptor (46 and 42%, respectively).</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexamethasone</infon>
          <location offset="465" length="13"/>
          <text>dexamethasone</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestins</infon>
          <location offset="554" length="10"/>
          <text>progestins</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pregnane</infon>
          <location offset="572" length="8"/>
          <text>pregnane</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">megestrol acetate</infon>
          <location offset="597" length="17"/>
          <text>megestrol acetate</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">medroxyprogesterone acetate</infon>
          <location offset="619" length="27"/>
          <text>medroxyprogesterone acetate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>751</offset>
        <text>The relative binding affinity of the naturally occurring ligand, cortisol, to the receptor was clearly lower (25%).</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cortisol</infon>
          <location offset="816" length="8"/>
          <text>cortisol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>867</offset>
        <text>The effective binding of medroxyprogesterone acetate to the glucocorticoid receptor was confirmed by direct binding studies utilizing a tritiated derivative of this steroid.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">medroxyprogesterone acetate</infon>
          <location offset="892" length="27"/>
          <text>medroxyprogesterone acetate</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="1032" length="7"/>
          <text>steroid</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="927" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1041</offset>
        <text>No evidence for the existence of a specific progesterone receptor in human mononuclear leukocytes was obtained as judged by the results of competition experiments where a progesterone receptor-specific ligand [3H]Org 2058 was used.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="1212" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]org 2058</infon>
          <location offset="1250" length="12"/>
          <text>[3H]Org 2058</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="1085" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">progesterone receptor</infon>
          <location offset="1212" length="21"/>
          <text>progesterone receptor</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">progesterone receptor</infon>
          <location offset="1085" length="21"/>
          <text>progesterone receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1273</offset>
        <text>Medroxyprogesterone acetate and megestrol acetate also induced glucocorticoid-like effects on the lymphocyte functions.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">medroxyprogesterone acetate</infon>
          <location offset="1273" length="27"/>
          <text>Medroxyprogesterone acetate</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">megestrol acetate</infon>
          <location offset="1305" length="17"/>
          <text>megestrol acetate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1393</offset>
        <text>These included inhibition of the proliferative responses to the T-cell mitogens concanavalin A and phytohaemagglutinin and an enhanced accumulation of immunoglobulin secreting cells in pokeweed mitogen-stimulated cultures.</text>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">concanavalin a</infon>
          <location offset="1473" length="14"/>
          <text>concanavalin A</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phytohaemagglutinin</infon>
          <location offset="1492" length="19"/>
          <text>phytohaemagglutinin</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">immunoglobulin</infon>
          <location offset="1544" length="14"/>
          <text>immunoglobulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1616</offset>
        <text>The progestin effect appears to be mediated through a radiosensitive (suppressor) subpopulation of T lymphocytes.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestin</infon>
          <location offset="1620" length="9"/>
          <text>progestin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1730</offset>
        <text>In contrast, the synthetic progestins related structurally to 19-nortestosterone, norethisterone and d-norgestrel, were virtually devoid of binding affinity towards the glucocorticoid receptor nor did they measurably influence the in vitro lymphocyte functions.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestins</infon>
          <location offset="1757" length="10"/>
          <text>progestins</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">19-nortestosterone</infon>
          <location offset="1792" length="18"/>
          <text>19-nortestosterone</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">norethisterone</infon>
          <location offset="1812" length="14"/>
          <text>norethisterone</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-norgestrel</infon>
          <location offset="1831" length="12"/>
          <text>d-norgestrel</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="1899" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1992</offset>
        <text>These studies demonstrate that certain progestins in common clinical use probably possess inherent glucocorticoid activity and suggest that side effects attributable to this character (e.g. suppression of the pituitary-adrenal axis) might be expected when these compounds are used in pharmacological doses.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestins</infon>
          <location offset="2031" length="10"/>
          <text>progestins</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>9138687</id>
    <passage>
      <offset>0</offset>
      <text>Pharmacological characterization of an alpha 1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat.	1. The alpha 1-adrenoceptor population mediating contraction of caudal artery of rat has been characterized by using quantitative receptor pharmacology. 2. Cumulative concentration-effect (E/[A]) curves to noradrenaline (NA) yielded a p[A]50 of 5.56 +/- 0.05 (n = 16). Prazosin caused concentration-dependent, parallel, dextral shifts of E/[A] curves to NA yielding a pKb of 8.9 (Schild regression slope = 1.0). RS-17053 (N-[2-(2-cyclopropyl methoxy phenoxy) ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole- 3-ethanamine hydrochloride; 10-100 nM), a selective alpha 1 A-adrenoceptor antagonist, produced non-parallel, biphasic, dextral shifts of E/[A] curves to NA, suggesting the involvement of more than one alpha 1-adrenoceptor subtype. Analysis of the high affinity component yielded an apparent pA2 value of 9.2 +/- 0.3. 3. A-61603, a selective agonist at alpha 1A adrenoceptors behaved as a full agonist relative to NA and yielded monophasic E/[A] curves with a p[A50] of 7.59 +/- 0.04 (n = 15). Pretreatment of tissues with chloroethylclonidine (CEC; 100 microM for 20 min, followed by 40 min washout), which preferentially alkylates alpha 1B- and alpha 1D-adrenoceptors, did not alter E/[A] curves to A-61603. Prazosin (3-300 nM) caused concentration-dependent, parallel, dextral shifts of E/[A] curves to A-61603 yielding a pA2 estimate of 9.2 +/- 0.2. 4. Experiments with alpha 1-adrenoceptor antagonists of varying subtype selectivities (RS-17053, SNAP 5089, tamsulosin, 5-methylurapidil, BMY 7378, HV 723 and REC 15/2739) revealed parallel dextral shifts of E/[A] curves to A-61603. Schild regression analyses yielded pA2 estimates of 9.2, 9.3, 11.2, 9.0, 6.3, 8.7 and 10.0 for RS-17053, SNAP 5089, tamsulosin, 5-methylurapidil, BMY 7378, HV 723 and REC 15/2739, respectively, although deviations from unit slope (possibly reflecting a secondary involvement of another alpha 1-adrenoceptor) hindered estimations of pKb for some antagonists. The antagonist affinity profile obtained reflects best that described for the alpha 1A-adrenoceptor. 5. In conclusion, caudal artery of rat contracts in response to NA via activation of at least two alpha 1-adrenoceptor subtypes. One of these subtypes displays the pharmacology of the alpha 1A-adrenoceptor, while the other remains to be defined. Use of the novel selective agonist, A-61603, allows for limited pharmacological isolation of the alpha 1A-adrenoceptor permitting characterization of the properties of selective antagonists.</text>
      <sentence>
        <offset>0</offset>
        <text>Pharmacological characterization of an alpha 1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat.</text>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">noradrenaline</infon>
          <location offset="96" length="13"/>
          <text>noradrenaline</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha 1a-adrenoceptor</infon>
          <location offset="39" length="21"/>
          <text>alpha 1A-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>144</offset>
        <text>1. The alpha 1-adrenoceptor population mediating contraction of caudal artery of rat has been characterized by using quantitative receptor pharmacology.</text>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha 1-adrenoceptor</infon>
          <location offset="151" length="20"/>
          <text>alpha 1-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>297</offset>
        <text>2. Cumulative concentration-effect (E/[A]) curves to noradrenaline (NA) yielded a p[A]50 of 5.56 +/- 0.05 (n = 16).</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">noradrenaline</infon>
          <location offset="350" length="13"/>
          <text>noradrenaline</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="365" length="2"/>
          <text>NA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>413</offset>
        <text>Prazosin caused concentration-dependent, parallel, dextral shifts of E/[A] curves to NA yielding a pKb of 8.9 (Schild regression slope = 1.0).</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prazosin</infon>
          <location offset="413" length="8"/>
          <text>Prazosin</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="498" length="2"/>
          <text>NA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>556</offset>
        <text>RS-17053 (N-[2-(2-cyclopropyl methoxy phenoxy) ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole- 3-ethanamine hydrochloride; 10-100 nM), a selective alpha 1 A-adrenoceptor antagonist, produced non-parallel, biphasic, dextral shifts of E/[A] curves to NA, suggesting the involvement of more than one alpha 1-adrenoceptor subtype.</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rs-17053</infon>
          <location offset="556" length="8"/>
          <text>RS-17053</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-[2-(2-cyclopropyl methoxy phenoxy) ethyl]-5-chloro-alpha, alpha-dimethyl-1h-indole- 3-ethanamine hydrochloride</infon>
          <location offset="566" length="112"/>
          <text>N-[2-(2-cyclopropyl methoxy phenoxy) ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole- 3-ethanamine hydrochloride</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="806" length="2"/>
          <text>NA</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha 1 a-adrenoceptor</infon>
          <location offset="704" length="22"/>
          <text>alpha 1 A-adrenoceptor</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 1-adrenoceptor</infon>
          <location offset="854" length="20"/>
          <text>alpha 1-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T30" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T28" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T29" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>884</offset>
        <text>Analysis of the high affinity component yielded an apparent pA2 value of 9.2 +/- 0.3. 3. A-61603, a selective agonist at alpha 1A adrenoceptors behaved as a full agonist relative to NA and yielded monophasic E/[A] curves with a p[A50] of 7.59 +/- 0.04 (n = 15).</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-61603</infon>
          <location offset="973" length="7"/>
          <text>A-61603</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="1066" length="2"/>
          <text>NA</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha 1a adrenoceptors</infon>
          <location offset="1005" length="22"/>
          <text>alpha 1A adrenoceptors</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST-ACTIVATOR</infon>
          <node refid="T31" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T32" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1146</offset>
        <text>Pretreatment of tissues with chloroethylclonidine (CEC; 100 microM for 20 min, followed by 40 min washout), which preferentially alkylates alpha 1B- and alpha 1D-adrenoceptors, did not alter E/[A] curves to A-61603.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloroethylclonidine</infon>
          <location offset="1175" length="20"/>
          <text>chloroethylclonidine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cec</infon>
          <location offset="1197" length="3"/>
          <text>CEC</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alkylates</infon>
          <location offset="1275" length="9"/>
          <text>alkylates</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-61603</infon>
          <location offset="1353" length="7"/>
          <text>A-61603</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 1b- and alpha 1d-adrenoceptors</infon>
          <location offset="1285" length="36"/>
          <text>alpha 1B- and alpha 1D-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1362</offset>
        <text>Prazosin (3-300 nM) caused concentration-dependent, parallel, dextral shifts of E/[A] curves to A-61603 yielding a pA2 estimate of 9.2 +/- 0.2. 4. Experiments with alpha 1-adrenoceptor antagonists of varying subtype selectivities (RS-17053, SNAP 5089, tamsulosin, 5-methylurapidil, BMY 7378, HV 723 and REC 15/2739) revealed parallel dextral shifts of E/[A] curves to A-61603.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prazosin</infon>
          <location offset="1362" length="8"/>
          <text>Prazosin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-61603</infon>
          <location offset="1458" length="7"/>
          <text>A-61603</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rs-17053</infon>
          <location offset="1593" length="8"/>
          <text>RS-17053</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">snap 5089</infon>
          <location offset="1603" length="9"/>
          <text>SNAP 5089</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamsulosin</infon>
          <location offset="1614" length="10"/>
          <text>tamsulosin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-methylurapidil</infon>
          <location offset="1626" length="16"/>
          <text>5-methylurapidil</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bmy 7378</infon>
          <location offset="1644" length="8"/>
          <text>BMY 7378</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hv 723</infon>
          <location offset="1654" length="6"/>
          <text>HV 723</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rec 15/2739</infon>
          <location offset="1665" length="11"/>
          <text>REC 15/2739</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-61603</infon>
          <location offset="1730" length="7"/>
          <text>A-61603</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha 1-adrenoceptor</infon>
          <location offset="1526" length="20"/>
          <text>alpha 1-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T13" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T10" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T14" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T8" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T12" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T11" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1739</offset>
        <text>Schild regression analyses yielded pA2 estimates of 9.2, 9.3, 11.2, 9.0, 6.3, 8.7 and 10.0 for RS-17053, SNAP 5089, tamsulosin, 5-methylurapidil, BMY 7378, HV 723 and REC 15/2739, respectively, although deviations from unit slope (possibly reflecting a secondary involvement of another alpha 1-adrenoceptor) hindered estimations of pKb for some antagonists.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rs-17053</infon>
          <location offset="1834" length="8"/>
          <text>RS-17053</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">snap 5089</infon>
          <location offset="1844" length="9"/>
          <text>SNAP 5089</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamsulosin</infon>
          <location offset="1855" length="10"/>
          <text>tamsulosin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-methylurapidil</infon>
          <location offset="1867" length="16"/>
          <text>5-methylurapidil</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bmy 7378</infon>
          <location offset="1885" length="8"/>
          <text>BMY 7378</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hv 723</infon>
          <location offset="1895" length="6"/>
          <text>HV 723</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rec 15/2739</infon>
          <location offset="1906" length="11"/>
          <text>REC 15/2739</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2097</offset>
        <text>The antagonist affinity profile obtained reflects best that described for the alpha 1A-adrenoceptor.</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha 1a-adrenoceptor</infon>
          <location offset="2175" length="21"/>
          <text>alpha 1A-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2198</offset>
        <text>5. In conclusion, caudal artery of rat contracts in response to NA via activation of at least two alpha 1-adrenoceptor subtypes.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="2262" length="2"/>
          <text>NA</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 1-adrenoceptor</infon>
          <location offset="2296" length="20"/>
          <text>alpha 1-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2327</offset>
        <text>One of these subtypes displays the pharmacology of the alpha 1A-adrenoceptor, while the other remains to be defined.</text>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha 1a-adrenoceptor</infon>
          <location offset="2382" length="21"/>
          <text>alpha 1A-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2444</offset>
        <text>Use of the novel selective agonist, A-61603, allows for limited pharmacological isolation of the alpha 1A-adrenoceptor permitting characterization of the properties of selective antagonists.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-61603</infon>
          <location offset="2480" length="7"/>
          <text>A-61603</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha 1a-adrenoceptor</infon>
          <location offset="2541" length="21"/>
          <text>alpha 1A-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T25" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17065073</id>
    <passage>
      <offset>0</offset>
      <text>Adenosine kinase from rat liver: new biochemical properties.	Adenosine kinase is a well-known enzyme which catalyzes the phosphorylation of adenosine to AMP: Its metabolic and kinetic properties are well studied. Here, we report new properties of rat liver enzyme, demonstrating a new reaction: ADP can be a phosphate donor instead ATP, according to the reaction: adenosine + ADP --&gt; 2AMP) demonstrating the efficiency of AdK to phosphorylate adenosine, also starting from ADP. Cells could exploited this property in situations in which ATP levels are strongly decreased and ADP decreases slowly.</text>
      <sentence>
        <offset>0</offset>
        <text>Adenosine kinase from rat liver: new biochemical properties.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine</infon>
          <location offset="0" length="9"/>
          <text>Adenosine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adenosine kinase</infon>
          <location offset="0" length="16"/>
          <text>Adenosine kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>61</offset>
        <text>Adenosine kinase is a well-known enzyme which catalyzes the phosphorylation of adenosine to AMP: Its metabolic and kinetic properties are well studied.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine</infon>
          <location offset="61" length="9"/>
          <text>Adenosine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine</infon>
          <location offset="140" length="9"/>
          <text>adenosine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="153" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adenosine kinase</infon>
          <location offset="61" length="16"/>
          <text>Adenosine kinase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T12" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>213</offset>
        <text>Here, we report new properties of rat liver enzyme, demonstrating a new reaction: ADP can be a phosphate donor instead ATP, according to the reaction: adenosine + ADP --&gt; 2AMP) demonstrating the efficiency of AdK to phosphorylate adenosine, also starting from ADP.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adp</infon>
          <location offset="295" length="3"/>
          <text>ADP</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="332" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine</infon>
          <location offset="364" length="9"/>
          <text>adenosine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adp</infon>
          <location offset="376" length="3"/>
          <text>ADP</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2amp</infon>
          <location offset="384" length="4"/>
          <text>2AMP</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine</infon>
          <location offset="443" length="9"/>
          <text>adenosine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adp</infon>
          <location offset="473" length="3"/>
          <text>ADP</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adk</infon>
          <location offset="422" length="3"/>
          <text>AdK</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>478</offset>
        <text>Cells could exploited this property in situations in which ATP levels are strongly decreased and ADP decreases slowly.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="537" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adp</infon>
          <location offset="575" length="3"/>
          <text>ADP</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23408858</id>
    <passage>
      <offset>0</offset>
      <text>Novel inhibition of archaeal family-D DNA polymerase by uracil.	Archaeal family-D DNA polymerase is inhibited by the presence of uracil in DNA template strands. When the enzyme encounters uracil, following three parameters change: DNA binding increases roughly 2-fold, the rate of polymerization slows by a factor of ∼5 and 3'-5' proof-reading exonuclease activity is stimulated by a factor of ∼2. Together these changes result in a significant decrease in polymerization activity and a reduction in net DNA synthesis. Pol D appears to interact with template strand uracil irrespective of its distance ahead of the replication fork. Polymerization does not stop at a defined location relative to uracil, rather a general decrease in DNA synthesis is observed. 'Trans' inhibition, the slowing of Pol D by uracil on a DNA strand not being replicated is also observed. It is proposed that Pol D is able to interact with uracil by looping out the single-stranded template, allowing simultaneous contact of both the base and the primer-template junction to give a polymerase-DNA complex with diminished extension ability.</text>
      <sentence>
        <offset>0</offset>
        <text>Novel inhibition of archaeal family-D DNA polymerase by uracil.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">uracil</infon>
          <location offset="56" length="6"/>
          <text>uracil</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">archaeal family-d dna polymerase</infon>
          <location offset="20" length="32"/>
          <text>archaeal family-D DNA polymerase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>64</offset>
        <text>Archaeal family-D DNA polymerase is inhibited by the presence of uracil in DNA template strands.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">uracil</infon>
          <location offset="129" length="6"/>
          <text>uracil</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">archaeal family-d dna polymerase</infon>
          <location offset="64" length="32"/>
          <text>Archaeal family-D DNA polymerase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>161</offset>
        <text>When the enzyme encounters uracil, following three parameters change: DNA binding increases roughly 2-fold, the rate of polymerization slows by a factor of ∼5 and 3'-5' proof-reading exonuclease activity is stimulated by a factor of ∼2.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">uracil</infon>
          <location offset="188" length="6"/>
          <text>uracil</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">exonuclease</infon>
          <location offset="344" length="11"/>
          <text>exonuclease</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>398</offset>
        <text>Together these changes result in a significant decrease in polymerization activity and a reduction in net DNA synthesis.</text>
      </sentence>
      <sentence>
        <offset>519</offset>
        <text>Pol D appears to interact with template strand uracil irrespective of its distance ahead of the replication fork.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">uracil</infon>
          <location offset="566" length="6"/>
          <text>uracil</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pol d</infon>
          <location offset="519" length="5"/>
          <text>Pol D</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>633</offset>
        <text>Polymerization does not stop at a defined location relative to uracil, rather a general decrease in DNA synthesis is observed.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">uracil</infon>
          <location offset="696" length="6"/>
          <text>uracil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>760</offset>
        <text>'Trans' inhibition, the slowing of Pol D by uracil on a DNA strand not being replicated is also observed.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">uracil</infon>
          <location offset="804" length="6"/>
          <text>uracil</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pol d</infon>
          <location offset="795" length="5"/>
          <text>Pol D</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>866</offset>
        <text>It is proposed that Pol D is able to interact with uracil by looping out the single-stranded template, allowing simultaneous contact of both the base and the primer-template junction to give a polymerase-DNA complex with diminished extension ability.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">uracil</infon>
          <location offset="917" length="6"/>
          <text>uracil</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pol d</infon>
          <location offset="886" length="5"/>
          <text>Pol D</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">polymerase-dna</infon>
          <location offset="1059" length="14"/>
          <text>polymerase-DNA</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23545568</id>
    <passage>
      <offset>0</offset>
      <text>Stable and high-rate overcharge protection for rechargeable lithium batteries.	Rechargeable lithium or lithium-ion cells can be overcharge-protected by an electroactive polymer composite separator. The use of non-woven fibrous membranes instead of conventional microporous membranes as the composite substrates allowed better distribution of the electroactive polymer, which led to improved utilization and a 40-fold increase in sustainable current density. For the first time, stable overcharge protection for hundreds of cycles was demonstrated in several cell chemistries, including LiNi1/3Co1/3Mn1/3O2, LiFePO4, and spinel Li1.05Mn1.95O4 half-cells. Protection at a charging rate as high as 5 C was achieved at a steady state cell potential below 4.85 V.</text>
      <sentence>
        <offset>0</offset>
        <text>Stable and high-rate overcharge protection for rechargeable lithium batteries.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lithium</infon>
          <location offset="60" length="7"/>
          <text>lithium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>79</offset>
        <text>Rechargeable lithium or lithium-ion cells can be overcharge-protected by an electroactive polymer composite separator.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lithium</infon>
          <location offset="92" length="7"/>
          <text>lithium</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lithium</infon>
          <location offset="103" length="7"/>
          <text>lithium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>198</offset>
        <text>The use of non-woven fibrous membranes instead of conventional microporous membranes as the composite substrates allowed better distribution of the electroactive polymer, which led to improved utilization and a 40-fold increase in sustainable current density.</text>
      </sentence>
      <sentence>
        <offset>458</offset>
        <text>For the first time, stable overcharge protection for hundreds of cycles was demonstrated in several cell chemistries, including LiNi1/3Co1/3Mn1/3O2, LiFePO4, and spinel Li1.05Mn1.95O4 half-cells.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lini1</infon>
          <location offset="586" length="5"/>
          <text>LiNi1</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3co1</infon>
          <location offset="592" length="4"/>
          <text>3Co1</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3mn1</infon>
          <location offset="597" length="4"/>
          <text>3Mn1</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3o2</infon>
          <location offset="602" length="3"/>
          <text>3O2</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lifepo4</infon>
          <location offset="607" length="7"/>
          <text>LiFePO4</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">li1.05mn1.95o4</infon>
          <location offset="627" length="14"/>
          <text>Li1.05Mn1.95O4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>654</offset>
        <text>Protection at a charging rate as high as 5 C was achieved at a steady state cell potential below 4.85 V.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23443628</id>
    <passage>
      <offset>0</offset>
      <text>A population-based study of dosing and persistence with anti-dementia medications.	PURPOSE: Cholinesterase inhibitors and memantine are the mainstay of pharmacological intervention for the cognitive symptoms of Alzheimer's disease (AD). This study assessed the adequacy of dosing and persistence with AD medications and the predictors of these variables in the 'real world' (outside the clinical trial setting). METHODS: The Health Service Executive-Primary Care Reimbursement Services prescription claims database in the Republic of Ireland contains prescription information for 1.6 million people. Patients aged &gt;70 years who received at least two prescriptions for donepezil, rivastigmine, galantamine and memantine between January 2006 and December 2010 were included in the study. Rates of dose-maximisation were recorded by examining the initiation dose of each AD drug commenced during the study period and any subsequent dose titrations. Non-persistence was defined by a gap in prescribing of more than 63 consecutive days. Predictors of dose-maximisation and non-persistence were also analysed. RESULTS: Between January 2006 and December 2010, 20,729 patients aged &gt;70 years received a prescription for an AD medication. Despite most patients on donepezil and memantine receiving a prescription for the maximum drug dose, this dose was maintained for 2 consecutive months in only two-thirds of patients. Patients were significantly more likely to have their doses of donepezil and memantine maximised if prescribed in more recent years (2010 vs. 2007). Rates of non-persistence were 30.1 % at 6 months and 43.8 % at 12 months. Older age [75+ vs. &lt;75 years; hazards ratio (HR) 1.16, 95 % confidence interval (CI) 1.06-1.27] and drug type (rivastigmine vs. donepezil; HR 1.15, 95 % CI 1.03-1.27) increased the risk of non-persistence. Non-persistence was lower for those commencing therapy in more recent years (2010 vs. 2007; HR 0.81, 95 % CI 0.73-0.89, p &lt; 0.001) and for those on multiple anti-dementia medications (HR 0.59, 95 % CI 0.54-0.65, p &lt; 0.001). Persistence was significantly higher when memantine was co-prescribed with donepezil (p &lt; 0.0001). CONCLUSION: Future studies should explore the reasons underlying non-persistence and failure to maintain dose-maximisation in patients on AD medications. There may be scope to improve the dosing and persistence with these medications in the community.</text>
      <sentence>
        <offset>0</offset>
        <text>A population-based study of dosing and persistence with anti-dementia medications.</text>
      </sentence>
      <sentence>
        <offset>83</offset>
        <text>PURPOSE: Cholinesterase inhibitors and memantine are the mainstay of pharmacological intervention for the cognitive symptoms of Alzheimer's disease (AD).</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">memantine</infon>
          <location offset="122" length="9"/>
          <text>memantine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cholinesterase</infon>
          <location offset="92" length="14"/>
          <text>Cholinesterase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>237</offset>
        <text>This study assessed the adequacy of dosing and persistence with AD medications and the predictors of these variables in the 'real world' (outside the clinical trial setting).</text>
      </sentence>
      <sentence>
        <offset>412</offset>
        <text>METHODS: The Health Service Executive-Primary Care Reimbursement Services prescription claims database in the Republic of Ireland contains prescription information for 1.6 million people.</text>
      </sentence>
      <sentence>
        <offset>600</offset>
        <text>Patients aged &gt;70 years who received at least two prescriptions for donepezil, rivastigmine, galantamine and memantine between January 2006 and December 2010 were included in the study.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">donepezil</infon>
          <location offset="668" length="9"/>
          <text>donepezil</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rivastigmine</infon>
          <location offset="679" length="12"/>
          <text>rivastigmine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">galantamine</infon>
          <location offset="693" length="11"/>
          <text>galantamine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">memantine</infon>
          <location offset="709" length="9"/>
          <text>memantine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>786</offset>
        <text>Rates of dose-maximisation were recorded by examining the initiation dose of each AD drug commenced during the study period and any subsequent dose titrations.</text>
      </sentence>
      <sentence>
        <offset>946</offset>
        <text>Non-persistence was defined by a gap in prescribing of more than 63 consecutive days.</text>
      </sentence>
      <sentence>
        <offset>1032</offset>
        <text>Predictors of dose-maximisation and non-persistence were also analysed.</text>
      </sentence>
      <sentence>
        <offset>1104</offset>
        <text>RESULTS: Between January 2006 and December 2010, 20,729 patients aged &gt;70 years received a prescription for an AD medication.</text>
      </sentence>
      <sentence>
        <offset>1230</offset>
        <text>Despite most patients on donepezil and memantine receiving a prescription for the maximum drug dose, this dose was maintained for 2 consecutive months in only two-thirds of patients.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">donepezil</infon>
          <location offset="1255" length="9"/>
          <text>donepezil</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">memantine</infon>
          <location offset="1269" length="9"/>
          <text>memantine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1413</offset>
        <text>Patients were significantly more likely to have their doses of donepezil and memantine maximised if prescribed in more recent years (2010 vs. 2007).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">donepezil</infon>
          <location offset="1476" length="9"/>
          <text>donepezil</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">memantine</infon>
          <location offset="1490" length="9"/>
          <text>memantine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1562</offset>
        <text>Rates of non-persistence were 30.1 % at 6 months and 43.8 % at 12 months.</text>
      </sentence>
      <sentence>
        <offset>1636</offset>
        <text>Older age [75+ vs. &lt;75 years; hazards ratio (HR) 1.16, 95 % confidence interval (CI) 1.06-1.27] and drug type (rivastigmine vs. donepezil; HR 1.15, 95 % CI 1.03-1.27) increased the risk of non-persistence.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rivastigmine</infon>
          <location offset="1747" length="12"/>
          <text>rivastigmine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">donepezil</infon>
          <location offset="1764" length="9"/>
          <text>donepezil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1842</offset>
        <text>Non-persistence was lower for those commencing therapy in more recent years (2010 vs. 2007; HR 0.81, 95 % CI 0.73-0.89, p &lt; 0.001) and for those on multiple anti-dementia medications (HR 0.59, 95 % CI 0.54-0.65, p &lt; 0.001).</text>
      </sentence>
      <sentence>
        <offset>2066</offset>
        <text>Persistence was significantly higher when memantine was co-prescribed with donepezil (p &lt; 0.0001).</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">memantine</infon>
          <location offset="2108" length="9"/>
          <text>memantine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">donepezil</infon>
          <location offset="2141" length="9"/>
          <text>donepezil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2165</offset>
        <text>CONCLUSION: Future studies should explore the reasons underlying non-persistence and failure to maintain dose-maximisation in patients on AD medications.</text>
      </sentence>
      <sentence>
        <offset>2319</offset>
        <text>There may be scope to improve the dosing and persistence with these medications in the community.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1328609</id>
    <passage>
      <offset>0</offset>
      <text>Involvement of supraspinal epsilon and mu opioid receptors in inhibition of the tail-flick response induced by etorphine in the mouse.	Etorphine, a potent opioid agonist, has been reported to bind to both mu and epsilon opioid receptors. The present studies were designed to determine what types of opioid receptors and neurotransmitters for descending pain control systems were involved in antinociception induced by etorphine in mice. Morphine, a typical mu opioid receptor agonist, and beta-endorphin, an epsilon opioid receptor agonist, were used for comparison. Antinociceptive response induced by etorphine (20 ng) given i.c.v was blocked by i.c.v administration of D-Phe-Cys-Tyr-D-Tyr-Orn-Thr-Pen-Thr-NH2 (CTOP, 25 ng) and beta-endorphin-(1-27) [beta-EP-(1-27)] (6 micrograms), but not ICI 174,864 (ICI, 5 micrograms) or norbinaltorphimine (N-BNI, 5 micrograms). The antinociception induced by i.c.v. etorphine was also antagonized by the i.c.v. pretreatment of beta-funaltrexamine (beta-FNA, 50 ng, 24 hr). Intracerebroventricular administration of beta-EP-(1-27) (3 micrograms) caused a further attenuation of the i.c.v. etorphine-induced antinociception in mice pretreated with beta-FNA. The antinociceptive response induced by morphine (2 micrograms) given i.c.v. was blocked by i.c.v. administration of CTOP (25 ng) or beta-FNA (50 ng), but not beta-EP-(1-27) (6 micrograms), ICI (5 micrograms) or N-BNI (5 micrograms). These results indicate that the antinociception induced by etorphine given i.c.v. is mediated by the stimulation of both mu and epsilon opioid receptors whereas the antinociception induced by morphine given i.c.v. is mediated by the stimulation of mu, but not epsilon opioid receptors at supraspinal sites.(ABSTRACT TRUNCATED AT 250 WORDS)</text>
      <sentence>
        <offset>0</offset>
        <text>Involvement of supraspinal epsilon and mu opioid receptors in inhibition of the tail-flick response induced by etorphine in the mouse.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etorphine</infon>
          <location offset="111" length="9"/>
          <text>etorphine</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epsilon</infon>
          <location offset="27" length="7"/>
          <text>epsilon</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mu opioid receptors</infon>
          <location offset="39" length="19"/>
          <text>mu opioid receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>135</offset>
        <text>Etorphine, a potent opioid agonist, has been reported to bind to both mu and epsilon opioid receptors.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etorphine</infon>
          <location offset="135" length="9"/>
          <text>Etorphine</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">opioid</infon>
          <location offset="155" length="6"/>
          <text>opioid</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mu</infon>
          <location offset="205" length="2"/>
          <text>mu</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epsilon opioid receptors</infon>
          <location offset="212" length="24"/>
          <text>epsilon opioid receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>238</offset>
        <text>The present studies were designed to determine what types of opioid receptors and neurotransmitters for descending pain control systems were involved in antinociception induced by etorphine in mice.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etorphine</infon>
          <location offset="418" length="9"/>
          <text>etorphine</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">opioid receptors</infon>
          <location offset="299" length="16"/>
          <text>opioid receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>437</offset>
        <text>Morphine, a typical mu opioid receptor agonist, and beta-endorphin, an epsilon opioid receptor agonist, were used for comparison.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="437" length="8"/>
          <text>Morphine</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mu opioid receptor</infon>
          <location offset="457" length="18"/>
          <text>mu opioid receptor</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta-endorphin</infon>
          <location offset="489" length="14"/>
          <text>beta-endorphin</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epsilon opioid receptor</infon>
          <location offset="508" length="23"/>
          <text>epsilon opioid receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T11" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>567</offset>
        <text>Antinociceptive response induced by etorphine (20 ng) given i.c.v was blocked by i.c.v administration of D-Phe-Cys-Tyr-D-Tyr-Orn-Thr-Pen-Thr-NH2 (CTOP, 25 ng) and beta-endorphin-(1-27) [beta-EP-(1-27)] (6 micrograms), but not ICI 174,864 (ICI, 5 micrograms) or norbinaltorphimine (N-BNI, 5 micrograms).</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etorphine</infon>
          <location offset="603" length="9"/>
          <text>etorphine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-phe-cys-tyr-d-tyr-orn-thr-pen-thr-nh2</infon>
          <location offset="672" length="39"/>
          <text>D-Phe-Cys-Tyr-D-Tyr-Orn-Thr-Pen-Thr-NH2</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ctop</infon>
          <location offset="713" length="4"/>
          <text>CTOP</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici 174,864</infon>
          <location offset="793" length="11"/>
          <text>ICI 174,864</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici</infon>
          <location offset="806" length="3"/>
          <text>ICI</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">norbinaltorphimine</infon>
          <location offset="828" length="18"/>
          <text>norbinaltorphimine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-bni</infon>
          <location offset="848" length="5"/>
          <text>N-BNI</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta-endorphin</infon>
          <location offset="730" length="14"/>
          <text>beta-endorphin</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta-ep</infon>
          <location offset="753" length="7"/>
          <text>beta-EP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>870</offset>
        <text>The antinociception induced by i.c.v. etorphine was also antagonized by the i.c.v. pretreatment of beta-funaltrexamine (beta-FNA, 50 ng, 24 hr).</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etorphine</infon>
          <location offset="908" length="9"/>
          <text>etorphine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">beta-funaltrexamine</infon>
          <location offset="969" length="19"/>
          <text>beta-funaltrexamine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">beta-fna</infon>
          <location offset="990" length="8"/>
          <text>beta-FNA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1015</offset>
        <text>Intracerebroventricular administration of beta-EP-(1-27) (3 micrograms) caused a further attenuation of the i.c.v. etorphine-induced antinociception in mice pretreated with beta-FNA.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">beta-fna</infon>
          <location offset="1188" length="8"/>
          <text>beta-FNA</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etorphine</infon>
          <location offset="1130" length="9"/>
          <text>etorphine</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta-ep</infon>
          <location offset="1057" length="7"/>
          <text>beta-EP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1198</offset>
        <text>The antinociceptive response induced by morphine (2 micrograms) given i.c.v. was blocked by i.c.v. administration of CTOP (25 ng) or beta-FNA (50 ng), but not beta-EP-(1-27) (6 micrograms), ICI (5 micrograms) or N-BNI (5 micrograms).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="1238" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ctop</infon>
          <location offset="1315" length="4"/>
          <text>CTOP</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">beta-fna</infon>
          <location offset="1331" length="8"/>
          <text>beta-FNA</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici</infon>
          <location offset="1388" length="3"/>
          <text>ICI</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-bni</infon>
          <location offset="1410" length="5"/>
          <text>N-BNI</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta-ep</infon>
          <location offset="1357" length="7"/>
          <text>beta-EP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1432</offset>
        <text>These results indicate that the antinociception induced by etorphine given i.c.v. is mediated by the stimulation of both mu and epsilon opioid receptors whereas the antinociception induced by morphine given i.c.v. is mediated by the stimulation of mu, but not epsilon opioid receptors at supraspinal sites.(ABSTRACT TRUNCATED AT 250 WORDS)</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etorphine</infon>
          <location offset="1491" length="9"/>
          <text>etorphine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="1624" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mu</infon>
          <location offset="1553" length="2"/>
          <text>mu</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epsilon opioid receptors</infon>
          <location offset="1560" length="24"/>
          <text>epsilon opioid receptors</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mu</infon>
          <location offset="1680" length="2"/>
          <text>mu</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epsilon opioid receptors</infon>
          <location offset="1692" length="24"/>
          <text>epsilon opioid receptors</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23161868</id>
    <passage>
      <offset>0</offset>
      <text>Ras-dva is a novel Pit-1- and glucocorticoid-regulated gene in the embryonic anterior pituitary gland.	Glucocorticoids play a role in functional differentiation of pituitary somatotrophs and lactotrophs during embryogenesis. Ras-dva was identified as a gene regulated by anterior neural fold protein-1/homeobox expressed in embryonic stem cells-1, a transcription factor known to be critical in pituitary development, and has an expression profile in the chicken embryonic pituitary gland that is consistent with in vivo regulation by glucocorticoids. The objective of this study was to characterize expression and regulation of ras-dva mRNA in the developing chicken anterior pituitary. Pituitary ras-dva mRNA levels increased during embryogenesis to a maximum on embryonic day (e) 18 and then decreased and remained low or undetectable after hatch. Ras-dva expression was highly enriched in the pituitary gland on e18 relative to other tissues examined. Glucocorticoid treatment of pituitary cells from mid- and late-stage embryos rapidly increased ras-dva mRNA, suggesting it may be a direct transcriptional target of glucocorticoids. A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by corticosterone. Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1. However, mutating putative GR binding sites did not substantially reduce induction of ras-dva promoter activity by corticosterone, suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation. We have identified ras-dva as a glucocorticoid-regulated gene that is likely expressed in cells of the Pit-1 lineage within the developing anterior pituitary gland.</text>
      <sentence>
        <offset>0</offset>
        <text>Ras-dva is a novel Pit-1- and glucocorticoid-regulated gene in the embryonic anterior pituitary gland.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ras-dva</infon>
          <location offset="0" length="7"/>
          <text>Ras-dva</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pit-1</infon>
          <location offset="19" length="5"/>
          <text>Pit-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>103</offset>
        <text>Glucocorticoids play a role in functional differentiation of pituitary somatotrophs and lactotrophs during embryogenesis.</text>
      </sentence>
      <sentence>
        <offset>225</offset>
        <text>Ras-dva was identified as a gene regulated by anterior neural fold protein-1/homeobox expressed in embryonic stem cells-1, a transcription factor known to be critical in pituitary development, and has an expression profile in the chicken embryonic pituitary gland that is consistent with in vivo regulation by glucocorticoids.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ras-dva</infon>
          <location offset="225" length="7"/>
          <text>Ras-dva</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">anterior neural fold protein-1/homeobox</infon>
          <location offset="271" length="39"/>
          <text>anterior neural fold protein-1/homeobox</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>552</offset>
        <text>The objective of this study was to characterize expression and regulation of ras-dva mRNA in the developing chicken anterior pituitary.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ras-dva</infon>
          <location offset="629" length="7"/>
          <text>ras-dva</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>688</offset>
        <text>Pituitary ras-dva mRNA levels increased during embryogenesis to a maximum on embryonic day (e) 18 and then decreased and remained low or undetectable after hatch.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ras-dva</infon>
          <location offset="698" length="7"/>
          <text>ras-dva</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>851</offset>
        <text>Ras-dva expression was highly enriched in the pituitary gland on e18 relative to other tissues examined.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ras-dva</infon>
          <location offset="851" length="7"/>
          <text>Ras-dva</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>956</offset>
        <text>Glucocorticoid treatment of pituitary cells from mid- and late-stage embryos rapidly increased ras-dva mRNA, suggesting it may be a direct transcriptional target of glucocorticoids.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ras-dva</infon>
          <location offset="1051" length="7"/>
          <text>ras-dva</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1138</offset>
        <text>A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by corticosterone.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosterone</infon>
          <location offset="1437" length="14"/>
          <text>corticosterone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">chicken ras-dva</infon>
          <location offset="1181" length="15"/>
          <text>chicken ras-dva</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pituitary-specific transcription factor-1 (pit-1) binding sites</infon>
          <location offset="1241" length="63"/>
          <text>pituitary-specific transcription factor-1 (Pit-1) binding sites</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glucocorticoid receptor (gr) binding sites</infon>
          <location offset="1323" length="42"/>
          <text>glucocorticoid receptor (GR) binding sites</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T4" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T3" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T5" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1453</offset>
        <text>Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pit-1 site</infon>
          <location offset="1486" length="10"/>
          <text>Pit-1 site</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ras-dva</infon>
          <location offset="1582" length="7"/>
          <text>ras-dva</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pit-1</infon>
          <location offset="1593" length="5"/>
          <text>Pit-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1600</offset>
        <text>However, mutating putative GR binding sites did not substantially reduce induction of ras-dva promoter activity by corticosterone, suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosterone</infon>
          <location offset="1715" length="14"/>
          <text>corticosterone</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gr binding sites</infon>
          <location offset="1627" length="16"/>
          <text>GR binding sites</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ras-dva promoter</infon>
          <location offset="1686" length="16"/>
          <text>ras-dva promoter</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dna elements</infon>
          <location offset="1753" length="12"/>
          <text>DNA elements</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1843</offset>
        <text>We have identified ras-dva as a glucocorticoid-regulated gene that is likely expressed in cells of the Pit-1 lineage within the developing anterior pituitary gland.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ras-dva</infon>
          <location offset="1862" length="7"/>
          <text>ras-dva</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pit-1</infon>
          <location offset="1946" length="5"/>
          <text>Pit-1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23612487</id>
    <passage>
      <offset>0</offset>
      <text>Sphingosine-1-phosphate promotes the nuclear translocation of β-catenin and thereby induces osteoprotegerin gene expression in osteoblast-like cell lines.	Sphingosine-1-phosphate (S1P) is a well-known signaling sphingolipid and bioactive lipid mediator. Recently, it was reported that S1P inhibits osteoclast differentiation and bone resorption. On the other hand, S1P effects on osteoblasts and bone formation are little known. In this study, we investigated the effects of S1P on osteoblasts, using two osteoblast-like cell lines, SaOS-2 and MC3T3-E1. S1P activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells. The inhibitors of PI3K and Akt suppressed S1P-induced nuclear localization of β-catenin. We further investigated the effects of PI3K/Akt signaling on the Wnt/β-catenin signaling pathway, since β-catenin takes a central role in this signaling pathway. Both inhibitors for PI3K and Akt suppressed the nuclear localization of β-catenin and T-cell factor transcriptional activity induced by Wnt-3a. S1P increased the amount of osteoprotegerin at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization. These findings suggest that S1P activates the PI3K/Akt signaling pathway leading to the promotion of nuclear translocation of β-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.</text>
      <sentence>
        <offset>0</offset>
        <text>Sphingosine-1-phosphate promotes the nuclear translocation of β-catenin and thereby induces osteoprotegerin gene expression in osteoblast-like cell lines.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sphingosine-1-phosphate</infon>
          <location offset="0" length="23"/>
          <text>Sphingosine-1-phosphate</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="62" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">osteoprotegerin</infon>
          <location offset="92" length="15"/>
          <text>osteoprotegerin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>155</offset>
        <text>Sphingosine-1-phosphate (S1P) is a well-known signaling sphingolipid and bioactive lipid mediator.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sphingosine-1-phosphate</infon>
          <location offset="155" length="23"/>
          <text>Sphingosine-1-phosphate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s1p</infon>
          <location offset="180" length="3"/>
          <text>S1P</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sphingolipid</infon>
          <location offset="211" length="12"/>
          <text>sphingolipid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>254</offset>
        <text>Recently, it was reported that S1P inhibits osteoclast differentiation and bone resorption.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s1p</infon>
          <location offset="285" length="3"/>
          <text>S1P</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>346</offset>
        <text>On the other hand, S1P effects on osteoblasts and bone formation are little known.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s1p</infon>
          <location offset="365" length="3"/>
          <text>S1P</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>429</offset>
        <text>In this study, we investigated the effects of S1P on osteoblasts, using two osteoblast-like cell lines, SaOS-2 and MC3T3-E1.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s1p</infon>
          <location offset="475" length="3"/>
          <text>S1P</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>554</offset>
        <text>S1P activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s1p</infon>
          <location offset="554" length="3"/>
          <text>S1P</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phosphatidylinositol</infon>
          <location offset="568" length="20"/>
          <text>phosphatidylinositol</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphatidylinositol 3-kinase</infon>
          <location offset="568" length="29"/>
          <text>phosphatidylinositol 3-kinase</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="599" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="605" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glycogen synthase kinase-3β</infon>
          <location offset="649" length="27"/>
          <text>glycogen synthase kinase-3β</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="710" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="781" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">t-cell factor</infon>
          <location offset="791" length="13"/>
          <text>T-cell factor</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>864</offset>
        <text>The inhibitors of PI3K and Akt suppressed S1P-induced nuclear localization of β-catenin.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s1p</infon>
          <location offset="906" length="3"/>
          <text>S1P</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="882" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="891" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="942" length="9"/>
          <text>β-catenin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>953</offset>
        <text>We further investigated the effects of PI3K/Akt signaling on the Wnt/β-catenin signaling pathway, since β-catenin takes a central role in this signaling pathway.</text>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="992" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="997" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">wnt</infon>
          <location offset="1018" length="3"/>
          <text>Wnt</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="1022" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="1057" length="9"/>
          <text>β-catenin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1115</offset>
        <text>Both inhibitors for PI3K and Akt suppressed the nuclear localization of β-catenin and T-cell factor transcriptional activity induced by Wnt-3a.</text>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="1187" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">t-cell factor</infon>
          <location offset="1201" length="13"/>
          <text>T-cell factor</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">wnt-3a</infon>
          <location offset="1251" length="6"/>
          <text>Wnt-3a</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="1135" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="1144" length="3"/>
          <text>Akt</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1259</offset>
        <text>S1P increased the amount of osteoprotegerin at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s1p</infon>
          <location offset="1259" length="3"/>
          <text>S1P</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">osteoprotegerin</infon>
          <location offset="1287" length="15"/>
          <text>osteoprotegerin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alkaline phosphatase</infon>
          <location offset="1366" length="20"/>
          <text>alkaline phosphatase</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1419</offset>
        <text>These findings suggest that S1P activates the PI3K/Akt signaling pathway leading to the promotion of nuclear translocation of β-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s1p</infon>
          <location offset="1447" length="3"/>
          <text>S1P</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="1465" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="1470" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="1545" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">osteoptotegerin</infon>
          <location offset="1614" length="15"/>
          <text>osteoptotegerin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alkaline phosphatase</infon>
          <location offset="1679" length="20"/>
          <text>alkaline phosphatase</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17369473</id>
    <passage>
      <offset>0</offset>
      <text>Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration.	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP). Metformin and phenformin, which are biguanides, have been reported to increase AMPK activity without increasing AMP/ATP. This study tests the hypothesis that these biguanides increase AMPK activity in the heart by increasing cytosolic [AMP]. Groups of isolated rat hearts (n = 5-7 each) were perfused with Krebs-Henseleit buffer with or without 0.2 mM phenformin or 10 mM metformin, and (31)P-NMR-measured phosphocreatine, ATP, and intracellular pH were used to calculate cytosolic [AMP]. At various times, hearts were freeze-clamped and assayed for AMPK activity, phosphorylation of Thr(172) on AMPK-alpha, and phosphorylation of Ser(79) on acetyl-CoA carboxylase, an AMPK target. In hearts treated with phenformin for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and AMPK activity was elevated at 36 min. In hearts treated with metformin, [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min. In metformin-treated hearts, HPLC-measured total AMP content and total AMP/ATP did not increase. In summary, phenformin and metformin increase AMPK activity and phosphorylation in the isolated heart. The increase in AMPK activity was always preceded by and correlated with increased cytosolic [AMP]. Total AMP content and total AMP/ATP did not change. Cytosolic [AMP] reported metabolically active AMP, which triggered increased AMPK activity, but measures of total AMP did not.</text>
      <sentence>
        <offset>0</offset>
        <text>Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration.</text>
        <annotation id="T40">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="0" length="9"/>
          <text>Metformin</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="100" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenformin</infon>
          <location offset="14" length="10"/>
          <text>phenformin</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="34" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T59">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">amp-activated protein kinase</infon>
          <location offset="34" length="28"/>
          <text>AMP-activated protein kinase</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T40" role="head"/>
          <node refid="T59" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T42" role="head"/>
          <node refid="T59" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>119</offset>
        <text>AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="119" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="219" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="239" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="252" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="259" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="270" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="274" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">amp-activated protein kinase</infon>
          <location offset="119" length="28"/>
          <text>AMP-activated protein kinase</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="149" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>280</offset>
        <text>Metformin and phenformin, which are biguanides, have been reported to increase AMPK activity without increasing AMP/ATP.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="280" length="9"/>
          <text>Metformin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenformin</infon>
          <location offset="294" length="10"/>
          <text>phenformin</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biguanides</infon>
          <location offset="316" length="10"/>
          <text>biguanides</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="392" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="396" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="359" length="4"/>
          <text>AMPK</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T26" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T25" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>401</offset>
        <text>This study tests the hypothesis that these biguanides increase AMPK activity in the heart by increasing cytosolic [AMP].</text>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biguanides</infon>
          <location offset="444" length="10"/>
          <text>biguanides</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="516" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="464" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>522</offset>
        <text>Groups of isolated rat hearts (n = 5-7 each) were perfused with Krebs-Henseleit buffer with or without 0.2 mM phenformin or 10 mM metformin, and (31)P-NMR-measured phosphocreatine, ATP, and intracellular pH were used to calculate cytosolic [AMP].</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenformin</infon>
          <location offset="632" length="10"/>
          <text>phenformin</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="652" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(31)p</infon>
          <location offset="667" length="5"/>
          <text>(31)P</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phosphocreatine</infon>
          <location offset="686" length="15"/>
          <text>phosphocreatine</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="703" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="763" length="3"/>
          <text>AMP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>769</offset>
        <text>At various times, hearts were freeze-clamped and assayed for AMPK activity, phosphorylation of Thr(172) on AMPK-alpha, and phosphorylation of Ser(79) on acetyl-CoA carboxylase, an AMPK target.</text>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetyl-coa</infon>
          <location offset="922" length="10"/>
          <text>acetyl-CoA</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="830" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk-alpha</infon>
          <location offset="876" length="10"/>
          <text>AMPK-alpha</text>
        </annotation>
        <annotation id="T56">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">acetyl-coa carboxylase</infon>
          <location offset="922" length="22"/>
          <text>acetyl-CoA carboxylase</text>
        </annotation>
        <annotation id="T57">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="949" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>962</offset>
        <text>In hearts treated with phenformin for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and AMPK activity was elevated at 36 min.</text>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenformin</infon>
          <location offset="985" length="10"/>
          <text>phenformin</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="1066" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T58">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="1103" length="4"/>
          <text>AMPK</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T38" role="head"/>
          <node refid="T58" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1141</offset>
        <text>In hearts treated with metformin, [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="1164" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="1176" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetyl-coa</infon>
          <location offset="1264" length="10"/>
          <text>acetyl-CoA</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="1209" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="1239" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphorylated acetyl-coa carboxylase</infon>
          <location offset="1249" length="37"/>
          <text>phosphorylated acetyl-CoA carboxylase</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1312</offset>
        <text>In metformin-treated hearts, HPLC-measured total AMP content and total AMP/ATP did not increase.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="1315" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="1361" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="1383" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="1387" length="3"/>
          <text>ATP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1409</offset>
        <text>In summary, phenformin and metformin increase AMPK activity and phosphorylation in the isolated heart.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenformin</infon>
          <location offset="1421" length="10"/>
          <text>phenformin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="1436" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="1455" length="4"/>
          <text>AMPK</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1512</offset>
        <text>The increase in AMPK activity was always preceded by and correlated with increased cytosolic [AMP].</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="1606" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="1528" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1612</offset>
        <text>Total AMP content and total AMP/ATP did not change.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="1618" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="1640" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="1644" length="3"/>
          <text>ATP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1664</offset>
        <text>Cytosolic [AMP] reported metabolically active AMP, which triggered increased AMPK activity, but measures of total AMP did not.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="1675" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="1710" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="1778" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="1741" length="4"/>
          <text>AMPK</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T22" role="head"/>
          <node refid="T50" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18056711</id>
    <passage>
      <offset>0</offset>
      <text>Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.	DNA topoisomerase I (Top1p) catalyzes the relaxation of supercoiled DNA via a concerted mechanism of DNA strand cleavage and religation. Top1p is the cellular target of the anti-cancer drug camptothecin (CPT), which reversibly stabilizes a covalent enzyme-DNA intermediate. Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site Tyr of the C-terminal domain within the catalytic pocket. The physical connection of the linker with the Top1p clamp as well as linker flexibility affect enzyme sensitivity to CPT. Crystallographic data reveal that a conserved Gly residue (located at the juncture between the linker and C-terminal domains) is at one end of a short alpha-helix, which extends to the active site Tyr covalently linked to the DNA. In the presence of drug, the linker is rigid and this alpha-helix extends to include Gly and the preceding Leu. We report that mutation of this conserved Gly in yeast Top1p alters enzyme sensitivity to CPT. Mutating Gly to Asp, Glu, Asn, Gln, Leu, or Ala enhanced enzyme CPT sensitivity, with the acidic residues inducing the greatest increase in drug sensitivity in vivo and in vitro. By contrast, Val or Phe substituents rendered the enzyme CPT-resistant. Mutation-induced alterations in enzyme architecture preceding the active site Tyr suggest these structural transitions modulate enzyme sensitivity to CPT, while enhancing the rate of DNA cleavage. We postulate that this conserved Gly residue provides a flexible hinge within the Top1p catalytic pocket to facilitate linker dynamics and the structural alterations that accompany drug binding of the covalent enzyme-DNA intermediate.</text>
      <sentence>
        <offset>0</offset>
        <text>Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camptothecin</infon>
          <location offset="90" length="12"/>
          <text>camptothecin</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dna topoisomerase i</infon>
          <location offset="26" length="19"/>
          <text>DNA topoisomerase I</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>104</offset>
        <text>DNA topoisomerase I (Top1p) catalyzes the relaxation of supercoiled DNA via a concerted mechanism of DNA strand cleavage and religation.</text>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dna topoisomerase i</infon>
          <location offset="104" length="19"/>
          <text>DNA topoisomerase I</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">top1p</infon>
          <location offset="125" length="5"/>
          <text>Top1p</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>241</offset>
        <text>Top1p is the cellular target of the anti-cancer drug camptothecin (CPT), which reversibly stabilizes a covalent enzyme-DNA intermediate.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camptothecin</infon>
          <location offset="294" length="12"/>
          <text>camptothecin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cpt</infon>
          <location offset="308" length="3"/>
          <text>CPT</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">top1p</infon>
          <location offset="241" length="5"/>
          <text>Top1p</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>378</offset>
        <text>Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site Tyr of the C-terminal domain within the catalytic pocket.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c</infon>
          <location offset="431" length="1"/>
          <text>C</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyr</infon>
          <location offset="538" length="3"/>
          <text>Tyr</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c</infon>
          <location offset="549" length="1"/>
          <text>C</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">top1p</infon>
          <location offset="378" length="5"/>
          <text>Top1p</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha-helices</infon>
          <location offset="476" length="13"/>
          <text>alpha-helices</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">linker domain</infon>
          <location offset="491" length="13"/>
          <text>linker domain</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T20" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T19" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T20" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T19" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T21" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T21" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T19" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>596</offset>
        <text>The physical connection of the linker with the Top1p clamp as well as linker flexibility affect enzyme sensitivity to CPT.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cpt</infon>
          <location offset="714" length="3"/>
          <text>CPT</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">top1p</infon>
          <location offset="643" length="5"/>
          <text>Top1p</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>719</offset>
        <text>Crystallographic data reveal that a conserved Gly residue (located at the juncture between the linker and C-terminal domains) is at one end of a short alpha-helix, which extends to the active site Tyr covalently linked to the DNA.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gly</infon>
          <location offset="765" length="3"/>
          <text>Gly</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c</infon>
          <location offset="825" length="1"/>
          <text>C</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyr</infon>
          <location offset="916" length="3"/>
          <text>Tyr</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha-helix</infon>
          <location offset="870" length="11"/>
          <text>alpha-helix</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T24" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T25" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T23" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>950</offset>
        <text>In the presence of drug, the linker is rigid and this alpha-helix extends to include Gly and the preceding Leu.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gly</infon>
          <location offset="1035" length="3"/>
          <text>Gly</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">leu</infon>
          <location offset="1057" length="3"/>
          <text>Leu</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha-helix</infon>
          <location offset="1004" length="11"/>
          <text>alpha-helix</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T27" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T26" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1062</offset>
        <text>We report that mutation of this conserved Gly in yeast Top1p alters enzyme sensitivity to CPT.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gly</infon>
          <location offset="1104" length="3"/>
          <text>Gly</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cpt</infon>
          <location offset="1152" length="3"/>
          <text>CPT</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">yeast top1p</infon>
          <location offset="1111" length="11"/>
          <text>yeast Top1p</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1157</offset>
        <text>Mutating Gly to Asp, Glu, Asn, Gln, Leu, or Ala enhanced enzyme CPT sensitivity, with the acidic residues inducing the greatest increase in drug sensitivity in vivo and in vitro.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gly</infon>
          <location offset="1166" length="3"/>
          <text>Gly</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asp</infon>
          <location offset="1173" length="3"/>
          <text>Asp</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glu</infon>
          <location offset="1178" length="3"/>
          <text>Glu</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asn</infon>
          <location offset="1183" length="3"/>
          <text>Asn</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gln</infon>
          <location offset="1188" length="3"/>
          <text>Gln</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">leu</infon>
          <location offset="1193" length="3"/>
          <text>Leu</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="1201" length="3"/>
          <text>Ala</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cpt</infon>
          <location offset="1221" length="3"/>
          <text>CPT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1336</offset>
        <text>By contrast, Val or Phe substituents rendered the enzyme CPT-resistant.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">val</infon>
          <location offset="1349" length="3"/>
          <text>Val</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phe</infon>
          <location offset="1356" length="3"/>
          <text>Phe</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cpt</infon>
          <location offset="1393" length="3"/>
          <text>CPT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1408</offset>
        <text>Mutation-induced alterations in enzyme architecture preceding the active site Tyr suggest these structural transitions modulate enzyme sensitivity to CPT, while enhancing the rate of DNA cleavage.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyr</infon>
          <location offset="1486" length="3"/>
          <text>Tyr</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cpt</infon>
          <location offset="1558" length="3"/>
          <text>CPT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1605</offset>
        <text>We postulate that this conserved Gly residue provides a flexible hinge within the Top1p catalytic pocket to facilitate linker dynamics and the structural alterations that accompany drug binding of the covalent enzyme-DNA intermediate.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gly</infon>
          <location offset="1638" length="3"/>
          <text>Gly</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">top1p</infon>
          <location offset="1687" length="5"/>
          <text>Top1p</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T16" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15943176</id>
    <passage>
      <offset>0</offset>
      <text>In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis.	The aim of this study was to compare the in vivo effects on free radical metabolism of 2 non-steroidal anti-inflammatory drugs (NSAIDs): tenoxicam, an oxicam preferentially cyclooxygenase-1 (COX-1) inhibitor, and celecoxib, a sulfonamide selective COX-2 inhibitor. The serum levels of oxidative stress-related enzymes (ie, xanthine oxidase (XO), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px)), of a lipid peroxidation marker (malondialdehyde (MDA)), and of nitric oxide (NO) in patients with knee osteoarthritis were studied at baseline and after a 4-wk course of treatment with celecoxib (n = 11) and tenoxicam (n = 12). Celecoxib-treated patients had significant decrease in nitrite levels (p = 0.043), whereas SOD, XO, GSH-Px enzyme activities, and MDA levels did not change significantly compared to baseline. Tenoxicam-treated patients had significant decrease in nitrite levels (p = 0.036) and XO activity (p = 0.01), but their SOD, GSH-Px enzyme activities, and MDA levels were unchanged from baseline. There was significant correlation between the patients' (n = 23) Western Ontario and McMaster Universities (WOMAC) LK3.0 Osteoarthritis Index, WOMAC-pain scores, and MDA levels (r = 0.50, p = 0.014) and the patients' WOMAC-stiffness scores and XO enzyme activity (r = 0.46, p = 0.027) at baseline. Significant improvement was found in pain-VAS, patients' global assessment, and WOMAC pain, stiffness, and physical function scores in celecoxib and tenoxicam-treated groups. In summary, our study revealed that tenoxicam may have antioxidant effects, and that celecoxib and tenoxicam may reduce nitrite levels, indicating an alteration of NO pathways.</text>
      <sentence>
        <offset>0</offset>
        <text>In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis.</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celecoxib</infon>
          <location offset="18" length="9"/>
          <text>celecoxib</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tenoxicam</infon>
          <location offset="32" length="9"/>
          <text>tenoxicam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>112</offset>
        <text>The aim of this study was to compare the in vivo effects on free radical metabolism of 2 non-steroidal anti-inflammatory drugs (NSAIDs): tenoxicam, an oxicam preferentially cyclooxygenase-1 (COX-1) inhibitor, and celecoxib, a sulfonamide selective COX-2 inhibitor.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tenoxicam</infon>
          <location offset="249" length="9"/>
          <text>tenoxicam</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celecoxib</infon>
          <location offset="325" length="9"/>
          <text>celecoxib</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfonamide</infon>
          <location offset="338" length="11"/>
          <text>sulfonamide</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroidal</infon>
          <location offset="205" length="9"/>
          <text>steroidal</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclooxygenase-1</infon>
          <location offset="285" length="16"/>
          <text>cyclooxygenase-1</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-1</infon>
          <location offset="303" length="5"/>
          <text>COX-1</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="360" length="5"/>
          <text>COX-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>377</offset>
        <text>The serum levels of oxidative stress-related enzymes (ie, xanthine oxidase (XO), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px)), of a lipid peroxidation marker (malondialdehyde (MDA)), and of nitric oxide (NO) in patients with knee osteoarthritis were studied at baseline and after a 4-wk course of treatment with celecoxib (n = 11) and tenoxicam (n = 12).</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">xanthine</infon>
          <location offset="435" length="8"/>
          <text>xanthine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="458" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="486" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="510" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malondialdehyde</infon>
          <location offset="552" length="15"/>
          <text>malondialdehyde</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mda</infon>
          <location offset="569" length="3"/>
          <text>MDA</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="583" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">no</infon>
          <location offset="597" length="2"/>
          <text>NO</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celecoxib</infon>
          <location offset="705" length="9"/>
          <text>celecoxib</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tenoxicam</infon>
          <location offset="728" length="9"/>
          <text>tenoxicam</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">xanthine oxidase</infon>
          <location offset="435" length="16"/>
          <text>xanthine oxidase</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">xo</infon>
          <location offset="453" length="2"/>
          <text>XO</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">superoxide dismutase</infon>
          <location offset="458" length="20"/>
          <text>superoxide dismutase</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sod</infon>
          <location offset="480" length="3"/>
          <text>SOD</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathione peroxidase</infon>
          <location offset="486" length="22"/>
          <text>glutathione peroxidase</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gsh-px</infon>
          <location offset="510" length="6"/>
          <text>GSH-Px</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>748</offset>
        <text>Celecoxib-treated patients had significant decrease in nitrite levels (p = 0.043), whereas SOD, XO, GSH-Px enzyme activities, and MDA levels did not change significantly compared to baseline.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celecoxib</infon>
          <location offset="748" length="9"/>
          <text>Celecoxib</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitrite</infon>
          <location offset="803" length="7"/>
          <text>nitrite</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="848" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mda</infon>
          <location offset="878" length="3"/>
          <text>MDA</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sod</infon>
          <location offset="839" length="3"/>
          <text>SOD</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">xo</infon>
          <location offset="844" length="2"/>
          <text>XO</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gsh-px</infon>
          <location offset="848" length="6"/>
          <text>GSH-Px</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>940</offset>
        <text>Tenoxicam-treated patients had significant decrease in nitrite levels (p = 0.036) and XO activity (p = 0.01), but their SOD, GSH-Px enzyme activities, and MDA levels were unchanged from baseline.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tenoxicam</infon>
          <location offset="940" length="9"/>
          <text>Tenoxicam</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitrite</infon>
          <location offset="995" length="7"/>
          <text>nitrite</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="1065" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mda</infon>
          <location offset="1095" length="3"/>
          <text>MDA</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">xo</infon>
          <location offset="1026" length="2"/>
          <text>XO</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sod</infon>
          <location offset="1060" length="3"/>
          <text>SOD</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gsh-px</infon>
          <location offset="1065" length="6"/>
          <text>GSH-Px</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T26" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1136</offset>
        <text>There was significant correlation between the patients' (n = 23) Western Ontario and McMaster Universities (WOMAC) LK3.0 Osteoarthritis Index, WOMAC-pain scores, and MDA levels (r = 0.50, p = 0.014) and the patients' WOMAC-stiffness scores and XO enzyme activity (r = 0.46, p = 0.027) at baseline.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mda</infon>
          <location offset="1302" length="3"/>
          <text>MDA</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">xo</infon>
          <location offset="1380" length="2"/>
          <text>XO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1434</offset>
        <text>Significant improvement was found in pain-VAS, patients' global assessment, and WOMAC pain, stiffness, and physical function scores in celecoxib and tenoxicam-treated groups.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celecoxib</infon>
          <location offset="1569" length="9"/>
          <text>celecoxib</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tenoxicam</infon>
          <location offset="1583" length="9"/>
          <text>tenoxicam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1609</offset>
        <text>In summary, our study revealed that tenoxicam may have antioxidant effects, and that celecoxib and tenoxicam may reduce nitrite levels, indicating an alteration of NO pathways.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tenoxicam</infon>
          <location offset="1645" length="9"/>
          <text>tenoxicam</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">celecoxib</infon>
          <location offset="1694" length="9"/>
          <text>celecoxib</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tenoxicam</infon>
          <location offset="1708" length="9"/>
          <text>tenoxicam</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitrite</infon>
          <location offset="1729" length="7"/>
          <text>nitrite</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">no</infon>
          <location offset="1773" length="2"/>
          <text>NO</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23629861</id>
    <passage>
      <offset>0</offset>
      <text>Basic evidence for epidermal H2O2/ONOO--mediated oxidation/nitration in segmental vitiligo is supported by repigmentation of skin and eyelashes after reduction of epidermal H2O2 with topical NB-UVB-activated pseudocatalase PC-KUS.	Nonsegmental vitiligo (NSV) is characterized by loss of inherited skin color. The cause of the disease is still unknown despite accumulating in vivo and in vitro evidence of massive epidermal oxidative stress via H2O2 and peroxynitrite (ONOO(-)) in affected individuals. The most favored hypothesis is based on autoimmune mechanisms. Strictly segmental vitiligo (SSV) with dermatomal distribution is a rare entity, often associated with stable outcome. Recently, it was documented that this form can be associated with NSV (mixed vitiligo). We here asked the question whether ROS and possibly ONOO(-) could be players in the pathogenesis of SSV. Our in situ results demonstrate for the first time epidermal biopterin accumulation together with significantly decreased epidermal catalase, thioredoxin/thioreoxin reductase, and MSRA/MSRB expression. Moreover, we show epidermal ONOO(-) accumulation. In vivo FT-Raman spectroscopy reveals the presence of H2O2, methionine sulfoxide, and tryptophan metabolites; i.e., N-formylkynurenine and kynurenine, implying Fenton chemistry in the cascade (n=10). Validation of the basic data stems from successful repigmentation of skin and eyelashes in affected individuals, regardless of SSV or segmental vitiligo in association with NSV after reduction of epidermal H2O2 (n=5). Taken together, our contribution strongly supports H2O2/ONOO-mediated stress in the pathogenesis of SSV. Our findings offer new treatment intervention for lost skin and hair color.-Schallreuter, K. U., Salem, M. A. E. L., Holtz, S., Panske, A. Basic evidence for epidermal H2O2/ONOO(-)-mediated oxidation/nitration in segmental vitiligo is supported by repigmentation of skin and eyelashes after reduction of epidermal H2O2 with topical NB-UVB-activated pseudocatalase PC-KUS.</text>
      <sentence>
        <offset>0</offset>
        <text>Basic evidence for epidermal H2O2/ONOO--mediated oxidation/nitration in segmental vitiligo is supported by repigmentation of skin and eyelashes after reduction of epidermal H2O2 with topical NB-UVB-activated pseudocatalase PC-KUS.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="173" length="4"/>
          <text>H2O2</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="29" length="4"/>
          <text>H2O2</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">onoo</infon>
          <location offset="34" length="4"/>
          <text>ONOO</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pseudocatalase</infon>
          <location offset="208" length="14"/>
          <text>pseudocatalase</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pc</infon>
          <location offset="223" length="2"/>
          <text>PC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>231</offset>
        <text>Nonsegmental vitiligo (NSV) is characterized by loss of inherited skin color.</text>
      </sentence>
      <sentence>
        <offset>309</offset>
        <text>The cause of the disease is still unknown despite accumulating in vivo and in vitro evidence of massive epidermal oxidative stress via H2O2 and peroxynitrite (ONOO(-)) in affected individuals.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="444" length="4"/>
          <text>H2O2</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peroxynitrite</infon>
          <location offset="453" length="13"/>
          <text>peroxynitrite</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">onoo(-)</infon>
          <location offset="468" length="7"/>
          <text>ONOO(-)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>502</offset>
        <text>The most favored hypothesis is based on autoimmune mechanisms.</text>
      </sentence>
      <sentence>
        <offset>565</offset>
        <text>Strictly segmental vitiligo (SSV) with dermatomal distribution is a rare entity, often associated with stable outcome.</text>
      </sentence>
      <sentence>
        <offset>684</offset>
        <text>Recently, it was documented that this form can be associated with NSV (mixed vitiligo).</text>
      </sentence>
      <sentence>
        <offset>772</offset>
        <text>We here asked the question whether ROS and possibly ONOO(-) could be players in the pathogenesis of SSV.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">onoo(-)</infon>
          <location offset="824" length="7"/>
          <text>ONOO(-)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>877</offset>
        <text>Our in situ results demonstrate for the first time epidermal biopterin accumulation together with significantly decreased epidermal catalase, thioredoxin/thioreoxin reductase, and MSRA/MSRB expression.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catalase</infon>
          <location offset="1009" length="8"/>
          <text>catalase</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">thioredoxin/thioreoxin reductase</infon>
          <location offset="1019" length="32"/>
          <text>thioredoxin/thioreoxin reductase</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">msra</infon>
          <location offset="1057" length="4"/>
          <text>MSRA</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">msrb</infon>
          <location offset="1062" length="4"/>
          <text>MSRB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1079</offset>
        <text>Moreover, we show epidermal ONOO(-) accumulation.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">onoo(-)</infon>
          <location offset="1107" length="7"/>
          <text>ONOO(-)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1129</offset>
        <text>In vivo FT-Raman spectroscopy reveals the presence of H2O2, methionine sulfoxide, and tryptophan metabolites; i.e., N-formylkynurenine and kynurenine, implying Fenton chemistry in the cascade (n=10).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-formylkynurenine</infon>
          <location offset="1245" length="18"/>
          <text>N-formylkynurenine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">kynurenine</infon>
          <location offset="1268" length="10"/>
          <text>kynurenine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="1183" length="4"/>
          <text>H2O2</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methionine sulfoxide</infon>
          <location offset="1189" length="20"/>
          <text>methionine sulfoxide</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptophan</infon>
          <location offset="1215" length="10"/>
          <text>tryptophan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1329</offset>
        <text>Validation of the basic data stems from successful repigmentation of skin and eyelashes in affected individuals, regardless of SSV or segmental vitiligo in association with NSV after reduction of epidermal H2O2 (n=5).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="1535" length="4"/>
          <text>H2O2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1547</offset>
        <text>Taken together, our contribution strongly supports H2O2/ONOO-mediated stress in the pathogenesis of SSV.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="1598" length="4"/>
          <text>H2O2</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">onoo-</infon>
          <location offset="1603" length="5"/>
          <text>ONOO-</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1652</offset>
        <text>Our findings offer new treatment intervention for lost skin and hair color.-Schallreuter, K. U., Salem, M. A. E. L., Holtz, S., Panske, A. Basic evidence for epidermal H2O2/ONOO(-)-mediated oxidation/nitration in segmental vitiligo is supported by repigmentation of skin and eyelashes after reduction of epidermal H2O2 with topical NB-UVB-activated pseudocatalase PC-KUS.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="1820" length="4"/>
          <text>H2O2</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">onoo(-)</infon>
          <location offset="1825" length="7"/>
          <text>ONOO(-)</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="1966" length="4"/>
          <text>H2O2</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pseudocatalase</infon>
          <location offset="2001" length="14"/>
          <text>pseudocatalase</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pc</infon>
          <location offset="2016" length="2"/>
          <text>PC</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12181427</id>
    <passage>
      <offset>0</offset>
      <text>Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.	To identify amino acid residues involved in PDE3-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of PDE3A using a model created on basis of homology to the PDE4B crystal structure. We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol, specific inhibitors of PDE3. The mutants displayed differential sensitivity to the inhibitors. Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A). In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A. Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site. Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the cilostazol selectivity of PDE3A. Detailed knowledge of the structure of inhibitory sites should contribute to development of more potent and specific inhibitory drugs.</text>
      <sentence>
        <offset>0</offset>
        <text>Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cilostazol</infon>
          <location offset="102" length="10"/>
          <text>cilostazol</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleotide</infon>
          <location offset="46" length="10"/>
          <text>nucleotide</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">milrinone</infon>
          <location offset="88" length="9"/>
          <text>milrinone</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phosphodiesterase type 3a</infon>
          <location offset="57" length="25"/>
          <text>phosphodiesterase type 3A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>169</offset>
        <text>To identify amino acid residues involved in PDE3-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of PDE3A using a model created on basis of homology to the PDE4B crystal structure.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="181" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde3a</infon>
          <location offset="330" length="5"/>
          <text>PDE3A</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde4b</infon>
          <location offset="386" length="5"/>
          <text>PDE4B</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde3</infon>
          <location offset="213" length="4"/>
          <text>PDE3</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>411</offset>
        <text>We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol, specific inhibitors of PDE3.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alanine</infon>
          <location offset="438" length="7"/>
          <text>alanine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">milrinone</infon>
          <location offset="625" length="9"/>
          <text>milrinone</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cilostazol</infon>
          <location offset="639" length="10"/>
          <text>cilostazol</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde3</infon>
          <location offset="674" length="4"/>
          <text>PDE3</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>680</offset>
        <text>The mutants displayed differential sensitivity to the inhibitors.</text>
      </sentence>
      <sentence>
        <offset>746</offset>
        <text>Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">milrinone</infon>
          <location offset="806" length="9"/>
          <text>milrinone</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cilostazol</infon>
          <location offset="942" length="10"/>
          <text>cilostazol</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">y751a</infon>
          <location offset="754" length="5"/>
          <text>Y751A</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d950a</infon>
          <location offset="761" length="5"/>
          <text>D950A</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">f1004a</infon>
          <location offset="772" length="6"/>
          <text>F1004A</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde3a</infon>
          <location offset="867" length="5"/>
          <text>PDE3A</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde3a</infon>
          <location offset="1031" length="5"/>
          <text>PDE3A</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1039</offset>
        <text>In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cilostazol</infon>
          <location offset="1113" length="10"/>
          <text>cilostazol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">milrinone</infon>
          <location offset="1146" length="9"/>
          <text>milrinone</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde3a</infon>
          <location offset="1177" length="5"/>
          <text>PDE3A</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">t844a</infon>
          <location offset="1064" length="5"/>
          <text>T844A</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">f972a</infon>
          <location offset="1071" length="5"/>
          <text>F972A</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">q975a</infon>
          <location offset="1081" length="5"/>
          <text>Q975A</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1184</offset>
        <text>Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cilostazol</infon>
          <location offset="1231" length="10"/>
          <text>cilostazol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">milrinone</infon>
          <location offset="1246" length="9"/>
          <text>milrinone</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde3</infon>
          <location offset="1215" length="4"/>
          <text>PDE3</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde3</infon>
          <location offset="1422" length="4"/>
          <text>PDE3</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1440</offset>
        <text>Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the cilostazol selectivity of PDE3A.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cilostazol</infon>
          <location offset="1643" length="10"/>
          <text>cilostazol</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde</infon>
          <location offset="1518" length="3"/>
          <text>PDE</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde3a</infon>
          <location offset="1669" length="5"/>
          <text>PDE3A</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1676</offset>
        <text>Detailed knowledge of the structure of inhibitory sites should contribute to development of more potent and specific inhibitory drugs.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23481676</id>
    <passage>
      <offset>0</offset>
      <text>Cytotoxic and Anti-Inflammatory Eunicellin-Based Diterpenoids from the Soft Coral Cladiella krempfi.	Five new eunicellin-based diterpenoids, krempfielins E-I (1-5) and seven known compounds (6-12) were isolated from the organic extract of a Taiwanese soft coral Cladiella krempfi. The structures of the new metabolites were elucidated on the basis of extensive spectroscopic analysis. Metabolites 5, 6, 10 and 12 were shown to exhibit cytotoxicity against a limited panel of cancer cell lines. Furthermore, compounds 6 and 10 could potently inhibit the accumulation of the pro-inflammatory iNOS protein, and 6 and 12 could significantly reduce the expression of COX-2 protein in LPS-stimulated RAW264.7 macrophage cells.</text>
      <sentence>
        <offset>0</offset>
        <text>Cytotoxic and Anti-Inflammatory Eunicellin-Based Diterpenoids from the Soft Coral Cladiella krempfi.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eunicellin</infon>
          <location offset="32" length="10"/>
          <text>Eunicellin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diterpenoids</infon>
          <location offset="49" length="12"/>
          <text>Diterpenoids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>101</offset>
        <text>Five new eunicellin-based diterpenoids, krempfielins E-I (1-5) and seven known compounds (6-12) were isolated from the organic extract of a Taiwanese soft coral Cladiella krempfi.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diterpenoids</infon>
          <location offset="127" length="12"/>
          <text>diterpenoids</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">krempfielins e-i</infon>
          <location offset="141" length="16"/>
          <text>krempfielins E-I</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eunicellin</infon>
          <location offset="110" length="10"/>
          <text>eunicellin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>281</offset>
        <text>The structures of the new metabolites were elucidated on the basis of extensive spectroscopic analysis.</text>
      </sentence>
      <sentence>
        <offset>385</offset>
        <text>Metabolites 5, 6, 10 and 12 were shown to exhibit cytotoxicity against a limited panel of cancer cell lines.</text>
      </sentence>
      <sentence>
        <offset>494</offset>
        <text>Furthermore, compounds 6 and 10 could potently inhibit the accumulation of the pro-inflammatory iNOS protein, and 6 and 12 could significantly reduce the expression of COX-2 protein in LPS-stimulated RAW264.7 macrophage cells.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inos</infon>
          <location offset="590" length="4"/>
          <text>iNOS</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="662" length="5"/>
          <text>COX-2</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22940283</id>
    <passage>
      <offset>0</offset>
      <text>Relation between dynamics, activity and thermal stability within the cholinesterase family.	Incoherent neutron scattering is one of the most powerful tools for studying dynamics in biological matter. Using the cold neutron backscattering spectrometer IN16 at the Institut Laue Langevin (ILL, Grenoble, France), temperature dependence of cholinesterases' dynamics (human butyrylcholinesterase from plasma: hBChE; recombinant human acetylcholinesterase: hAChE and recombinant mouse acetylcholinesterase: mAChE) was examined using elastic incoherent neutron scattering (EINS). The dynamics was characterized by the averaged atomic mean square displacement (MSD), associated with the sample flexibility at a given temperature. We found MSD values of hAChE above the dynamical transition temperature (around 200K) larger than for mAChE and hBChE, implying that hAChE is more flexible than the other ChEs. Activation energies for thermodynamical transition were extracted through the frequency window model (FWM) (Becker et al. 2004) [1] and turned out to increase from hBChE to mAChE and finally to hAChE, inversely to the MSDs relations. Between 280 and 316K, catalytic studies of these enzymes were carried out using thiocholine esters: at the same temperature, the hAChE activity was systematically higher than the mAChE or hBChE ones. Our results thus suggest a strong correlation between dynamics and activity within the ChE family. We also studied and compared the ChEs thermal inactivation kinetics. Here, no direct correlation with the dynamics was observed, thus suggesting that relations between enzyme dynamics and catalytic stability are more complex. Finally, the possible relation between flexibility and protein ability to grow in crystals is discussed.</text>
      <sentence>
        <offset>0</offset>
        <text>Relation between dynamics, activity and thermal stability within the cholinesterase family.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cholinesterase</infon>
          <location offset="69" length="14"/>
          <text>cholinesterase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>92</offset>
        <text>Incoherent neutron scattering is one of the most powerful tools for studying dynamics in biological matter.</text>
      </sentence>
      <sentence>
        <offset>200</offset>
        <text>Using the cold neutron backscattering spectrometer IN16 at the Institut Laue Langevin (ILL, Grenoble, France), temperature dependence of cholinesterases' dynamics (human butyrylcholinesterase from plasma: hBChE; recombinant human acetylcholinesterase: hAChE and recombinant mouse acetylcholinesterase: mAChE) was examined using elastic incoherent neutron scattering (EINS).</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human butyrylcholinesterase</infon>
          <location offset="364" length="27"/>
          <text>human butyrylcholinesterase</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hbche</infon>
          <location offset="405" length="5"/>
          <text>hBChE</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human acetylcholinesterase</infon>
          <location offset="424" length="26"/>
          <text>human acetylcholinesterase</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hache</infon>
          <location offset="452" length="5"/>
          <text>hAChE</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mouse acetylcholinesterase</infon>
          <location offset="474" length="26"/>
          <text>mouse acetylcholinesterase</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mache</infon>
          <location offset="502" length="5"/>
          <text>mAChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>574</offset>
        <text>The dynamics was characterized by the averaged atomic mean square displacement (MSD), associated with the sample flexibility at a given temperature.</text>
      </sentence>
      <sentence>
        <offset>723</offset>
        <text>We found MSD values of hAChE above the dynamical transition temperature (around 200K) larger than for mAChE and hBChE, implying that hAChE is more flexible than the other ChEs.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hache</infon>
          <location offset="746" length="5"/>
          <text>hAChE</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mache</infon>
          <location offset="825" length="5"/>
          <text>mAChE</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hbche</infon>
          <location offset="835" length="5"/>
          <text>hBChE</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hache</infon>
          <location offset="856" length="5"/>
          <text>hAChE</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ches</infon>
          <location offset="894" length="4"/>
          <text>ChEs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>900</offset>
        <text>Activation energies for thermodynamical transition were extracted through the frequency window model (FWM) (Becker et al.</text>
      </sentence>
      <sentence>
        <offset>1022</offset>
        <text>2004) [1] and turned out to increase from hBChE to mAChE and finally to hAChE, inversely to the MSDs relations.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hache</infon>
          <location offset="1094" length="5"/>
          <text>hAChE</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hbche</infon>
          <location offset="1064" length="5"/>
          <text>hBChE</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mache</infon>
          <location offset="1073" length="5"/>
          <text>mAChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1134</offset>
        <text>Between 280 and 316K, catalytic studies of these enzymes were carried out using thiocholine esters: at the same temperature, the hAChE activity was systematically higher than the mAChE or hBChE ones.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiocholine esters</infon>
          <location offset="1214" length="18"/>
          <text>thiocholine esters</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hache</infon>
          <location offset="1263" length="5"/>
          <text>hAChE</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mache</infon>
          <location offset="1313" length="5"/>
          <text>mAChE</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hbche</infon>
          <location offset="1322" length="5"/>
          <text>hBChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1334</offset>
        <text>Our results thus suggest a strong correlation between dynamics and activity within the ChE family.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">che</infon>
          <location offset="1421" length="3"/>
          <text>ChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1433</offset>
        <text>We also studied and compared the ChEs thermal inactivation kinetics.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ches</infon>
          <location offset="1466" length="4"/>
          <text>ChEs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1502</offset>
        <text>Here, no direct correlation with the dynamics was observed, thus suggesting that relations between enzyme dynamics and catalytic stability are more complex.</text>
      </sentence>
      <sentence>
        <offset>1659</offset>
        <text>Finally, the possible relation between flexibility and protein ability to grow in crystals is discussed.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17251323</id>
    <passage>
      <offset>0</offset>
      <text>Glucocorticoids stimulate ENaC upregulation in bovine mammary epithelium.	Mammary epithelia produce an isotonic, low-Na(+) fluid that is rich in nutrients. Mechanisms that account for the low electrolyte concentration have not been elucidated, although amiloride-sensitive ion transport has been reported in some situations. We hypothesized that corticosteroid exposure modulates epithelial Na(+) channel (ENaC) expression and/or activity in bovine mammary epithelial cells. BME-UV cells were grown to confluent monolayers on permeable supports with a standard basolateral medium and apical medium of low-electrolyte, high-lactose composition that resembles the ionic composition of milk. Ion transport was assessed in modified Ussing flux chambers. Exposure to glucocorticoids (dexamethasone, cortisol, or prednisolone), but not aldosterone, increased short-circuit current (I(sc)), a sensitive measure of net ion transport, whereas apical exposure to amiloride or benzamil reduced corticosteroid-induced I(sc) close to basal levels. Quantitative RT-PCR indicated a glucocorticoid-induced increase in mRNA for beta- and gamma-ENaC, whereas alpha-ENaC mRNA expression was only mildly affected. Exposure to mifepristone (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA. We conclude that Na(+) movement across mammary epithelia is modulated by corticosteroids via a glucocorticoid receptor-mediated mechanism that regulates the expression of the beta- and gamma-subunits of ENaC. ENaC expression and activity could account for the low Na(+) concentration that is typical of milk.</text>
      <sentence>
        <offset>0</offset>
        <text>Glucocorticoids stimulate ENaC upregulation in bovine mammary epithelium.</text>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">enac</infon>
          <location offset="26" length="4"/>
          <text>ENaC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>74</offset>
        <text>Mammary epithelia produce an isotonic, low-Na(+) fluid that is rich in nutrients.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="117" length="5"/>
          <text>Na(+)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>156</offset>
        <text>Mechanisms that account for the low electrolyte concentration have not been elucidated, although amiloride-sensitive ion transport has been reported in some situations.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amiloride</infon>
          <location offset="253" length="9"/>
          <text>amiloride</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>325</offset>
        <text>We hypothesized that corticosteroid exposure modulates epithelial Na(+) channel (ENaC) expression and/or activity in bovine mammary epithelial cells.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="391" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epithelial na(+) channel</infon>
          <location offset="380" length="24"/>
          <text>epithelial Na(+) channel</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">enac</infon>
          <location offset="406" length="4"/>
          <text>ENaC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>475</offset>
        <text>BME-UV cells were grown to confluent monolayers on permeable supports with a standard basolateral medium and apical medium of low-electrolyte, high-lactose composition that resembles the ionic composition of milk.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactose</infon>
          <location offset="623" length="7"/>
          <text>lactose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>689</offset>
        <text>Ion transport was assessed in modified Ussing flux chambers.</text>
      </sentence>
      <sentence>
        <offset>750</offset>
        <text>Exposure to glucocorticoids (dexamethasone, cortisol, or prednisolone), but not aldosterone, increased short-circuit current (I(sc)), a sensitive measure of net ion transport, whereas apical exposure to amiloride or benzamil reduced corticosteroid-induced I(sc) close to basal levels.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexamethasone</infon>
          <location offset="779" length="13"/>
          <text>dexamethasone</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cortisol</infon>
          <location offset="794" length="8"/>
          <text>cortisol</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="807" length="12"/>
          <text>prednisolone</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="830" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amiloride</infon>
          <location offset="953" length="9"/>
          <text>amiloride</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzamil</infon>
          <location offset="966" length="8"/>
          <text>benzamil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1035</offset>
        <text>Quantitative RT-PCR indicated a glucocorticoid-induced increase in mRNA for beta- and gamma-ENaC, whereas alpha-ENaC mRNA expression was only mildly affected.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta- and gamma-enac</infon>
          <location offset="1111" length="20"/>
          <text>beta- and gamma-ENaC</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha-enac</infon>
          <location offset="1141" length="10"/>
          <text>alpha-ENaC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1194</offset>
        <text>Exposure to mifepristone (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="1206" length="12"/>
          <text>mifepristone</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spironolactone</infon>
          <location offset="1267" length="14"/>
          <text>spironolactone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amiloride</infon>
          <location offset="1380" length="9"/>
          <text>amiloride</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="1222" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mineralocorticoid receptor</infon>
          <location offset="1285" length="26"/>
          <text>mineralocorticoid receptor</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta- and gamma-enac</infon>
          <location offset="1433" length="20"/>
          <text>beta- and gamma-ENaC</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1460</offset>
        <text>We conclude that Na(+) movement across mammary epithelia is modulated by corticosteroids via a glucocorticoid receptor-mediated mechanism that regulates the expression of the beta- and gamma-subunits of ENaC.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1477" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="1555" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta- and gamma-subunits of enac</infon>
          <location offset="1635" length="32"/>
          <text>beta- and gamma-subunits of ENaC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1669</offset>
        <text>ENaC expression and activity could account for the low Na(+) concentration that is typical of milk.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1724" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">enac</infon>
          <location offset="1669" length="4"/>
          <text>ENaC</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23055538</id>
    <passage>
      <offset>0</offset>
      <text>Regulation of hepatic phase II metabolism in pregnant mice.	Phase II enzymes, including Ugts, Sults, and Gsts, are critical for the disposition and detoxification of endo- and xenobiotics. In this study, the mRNA and protein expression of major phase II enzymes, as well as key regulatory transcription factors, were quantified in livers of time-matched pregnant and virgin control C57BL/6 mice on gestation days (GD) 7, 11, 14, 17, and postnatal days (PND) 1, 15, and 30. Compared with virgin controls, the mRNA expression of Ugt1a1, 1a6, 1a9, 2a3, 2b1, 2b34, and 2b35 decreased 40 to 80% in pregnant dams. Protein expression of Ugt1a6 also decreased and corresponded with reduced in vitro glucuronidation of bisphenol A in S9 fractions from livers of pregnant mice. Similar to Ugts levels, Gsta1 and a4 mRNAs were reduced in pregnant dams in mid to late gestation; however no change in protein expression was observed. Conversely, Sult1a1, 2a1/2, and 3a1 mRNAs increased 100 to 500% at various time points in pregnant and lactating mice and corresponded with enhanced in vitro sulfation of acetaminophen in liver S9 fractions. Coinciding with maximal decreases in Ugts as well as increases in Sults, the expression of transcription factors CAR, PPARα, and PXR and their target genes were downregulated, whereas ERα mRNA was upregulated. Collectively, these data demonstrate altered regulation of hepatic phase II metabolism in mice during pregnancy and suggest that CAR, PPARα, PXR, and ERα signaling pathways may be candidate signaling pathways responsible for these changes.</text>
      <sentence>
        <offset>0</offset>
        <text>Regulation of hepatic phase II metabolism in pregnant mice.</text>
      </sentence>
      <sentence>
        <offset>60</offset>
        <text>Phase II enzymes, including Ugts, Sults, and Gsts, are critical for the disposition and detoxification of endo- and xenobiotics.</text>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ugts</infon>
          <location offset="88" length="4"/>
          <text>Ugts</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sults</infon>
          <location offset="94" length="5"/>
          <text>Sults</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gsts</infon>
          <location offset="105" length="4"/>
          <text>Gsts</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>189</offset>
        <text>In this study, the mRNA and protein expression of major phase II enzymes, as well as key regulatory transcription factors, were quantified in livers of time-matched pregnant and virgin control C57BL/6 mice on gestation days (GD) 7, 11, 14, 17, and postnatal days (PND) 1, 15, and 30.</text>
      </sentence>
      <sentence>
        <offset>473</offset>
        <text>Compared with virgin controls, the mRNA expression of Ugt1a1, 1a6, 1a9, 2a3, 2b1, 2b34, and 2b35 decreased 40 to 80% in pregnant dams.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ugt1a1, 1a6, 1a9, 2a3, 2b1, 2b34, and 2b35</infon>
          <location offset="527" length="42"/>
          <text>Ugt1a1, 1a6, 1a9, 2a3, 2b1, 2b34, and 2b35</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>608</offset>
        <text>Protein expression of Ugt1a6 also decreased and corresponded with reduced in vitro glucuronidation of bisphenol A in S9 fractions from livers of pregnant mice.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bisphenol a</infon>
          <location offset="710" length="11"/>
          <text>bisphenol A</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ugt1a6</infon>
          <location offset="630" length="6"/>
          <text>Ugt1a6</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>768</offset>
        <text>Similar to Ugts levels, Gsta1 and a4 mRNAs were reduced in pregnant dams in mid to late gestation; however no change in protein expression was observed.</text>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ugts</infon>
          <location offset="779" length="4"/>
          <text>Ugts</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gsta1 and a4</infon>
          <location offset="792" length="12"/>
          <text>Gsta1 and a4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>921</offset>
        <text>Conversely, Sult1a1, 2a1/2, and 3a1 mRNAs increased 100 to 500% at various time points in pregnant and lactating mice and corresponded with enhanced in vitro sulfation of acetaminophen in liver S9 fractions.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetaminophen</infon>
          <location offset="1092" length="13"/>
          <text>acetaminophen</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sult1a1, 2a1/2, and 3a1</infon>
          <location offset="933" length="23"/>
          <text>Sult1a1, 2a1/2, and 3a1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1129</offset>
        <text>Coinciding with maximal decreases in Ugts as well as increases in Sults, the expression of transcription factors CAR, PPARα, and PXR and their target genes were downregulated, whereas ERα mRNA was upregulated.</text>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ugts</infon>
          <location offset="1166" length="4"/>
          <text>Ugts</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sults</infon>
          <location offset="1195" length="5"/>
          <text>Sults</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">car</infon>
          <location offset="1242" length="3"/>
          <text>CAR</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparα</infon>
          <location offset="1247" length="5"/>
          <text>PPARα</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pxr</infon>
          <location offset="1258" length="3"/>
          <text>PXR</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erα</infon>
          <location offset="1313" length="3"/>
          <text>ERα</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1339</offset>
        <text>Collectively, these data demonstrate altered regulation of hepatic phase II metabolism in mice during pregnancy and suggest that CAR, PPARα, PXR, and ERα signaling pathways may be candidate signaling pathways responsible for these changes.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">car</infon>
          <location offset="1468" length="3"/>
          <text>CAR</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparα</infon>
          <location offset="1473" length="5"/>
          <text>PPARα</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pxr</infon>
          <location offset="1480" length="3"/>
          <text>PXR</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erα</infon>
          <location offset="1489" length="3"/>
          <text>ERα</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23361305</id>
    <passage>
      <offset>0</offset>
      <text>Left ventricular noncompaction (LVNC) and low mitochondrial membrane potential are specific for Barth syndrome.	Barth syndrome (BTHS) is an X-linked mitochondrial defect characterised by dilated cardiomyopathy, neutropaenia and 3-methylglutaconic aciduria (3-MGCA). We report on two affected brothers with c.646G &gt; A (p.G216R) TAZ gene mutations. The pathogenicity of the mutation, as indicated by the structure-based functional analyses, was further confirmed by abnormal monolysocardiolipin/cardiolipin ratio in dry blood spots of the patients as well as the occurrence of this mutation in another reported BTHS proband. In both brothers, 2D-echocardiography revealed some features of left ventricular noncompaction (LVNC) despite marked differences in the course of the disease; the eldest child presented with isolated cardiomyopathy from late infancy, whereas the youngest showed severe lactic acidosis without 3-MGCA during the neonatal period. An examination of the patients' fibroblast cultures revealed that extremely low mitochondrial membrane potentials (mtΔΨ about 50 % of the control value) dominated other unspecific mitochondrial changes detected (respiratory chain dysfunction, abnormal ROS production and depressed antioxidant defense). 1) Our studies confirm generalised mitochondrial dysfunction in the skeletal muscle and the fibroblasts of BTHS patients, especially a severe impairment in the mtΔΨ and the inhibition of complex V activity. It can be hypothesised that impaired mtΔΨ and mitochondrial ATP synthase activity may contribute to episodes of cardiac arrhythmia that occurred unexpectedly in BTHS patients. 2) Severe lactic acidosis without 3-methylglutaconic aciduria in male neonates as well as an asymptomatic mild left ventricular noncompaction may characterise the ranges of natural history of Barth syndrome.</text>
      <sentence>
        <offset>0</offset>
        <text>Left ventricular noncompaction (LVNC) and low mitochondrial membrane potential are specific for Barth syndrome.</text>
      </sentence>
      <sentence>
        <offset>112</offset>
        <text>Barth syndrome (BTHS) is an X-linked mitochondrial defect characterised by dilated cardiomyopathy, neutropaenia and 3-methylglutaconic aciduria (3-MGCA).</text>
      </sentence>
      <sentence>
        <offset>266</offset>
        <text>We report on two affected brothers with c.646G &gt; A (p.G216R) TAZ gene mutations.</text>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">646g &gt; a</infon>
          <location offset="308" length="8"/>
          <text>646G &gt; A</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g216r</infon>
          <location offset="320" length="5"/>
          <text>G216R</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">taz</infon>
          <location offset="327" length="3"/>
          <text>TAZ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>347</offset>
        <text>The pathogenicity of the mutation, as indicated by the structure-based functional analyses, was further confirmed by abnormal monolysocardiolipin/cardiolipin ratio in dry blood spots of the patients as well as the occurrence of this mutation in another reported BTHS proband.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monolysocardiolipin</infon>
          <location offset="473" length="19"/>
          <text>monolysocardiolipin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cardiolipin</infon>
          <location offset="493" length="11"/>
          <text>cardiolipin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>623</offset>
        <text>In both brothers, 2D-echocardiography revealed some features of left ventricular noncompaction (LVNC) despite marked differences in the course of the disease; the eldest child presented with isolated cardiomyopathy from late infancy, whereas the youngest showed severe lactic acidosis without 3-MGCA during the neonatal period.</text>
      </sentence>
      <sentence>
        <offset>951</offset>
        <text>An examination of the patients' fibroblast cultures revealed that extremely low mitochondrial membrane potentials (mtΔΨ about 50 % of the control value) dominated other unspecific mitochondrial changes detected (respiratory chain dysfunction, abnormal ROS production and depressed antioxidant defense).</text>
      </sentence>
      <sentence>
        <offset>1254</offset>
        <text>1) Our studies confirm generalised mitochondrial dysfunction in the skeletal muscle and the fibroblasts of BTHS patients, especially a severe impairment in the mtΔΨ and the inhibition of complex V activity.</text>
      </sentence>
      <sentence>
        <offset>1461</offset>
        <text>It can be hypothesised that impaired mtΔΨ and mitochondrial ATP synthase activity may contribute to episodes of cardiac arrhythmia that occurred unexpectedly in BTHS patients.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="1521" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mitochondrial atp synthase</infon>
          <location offset="1507" length="26"/>
          <text>mitochondrial ATP synthase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1637</offset>
        <text>2) Severe lactic acidosis without 3-methylglutaconic aciduria in male neonates as well as an asymptomatic mild left ventricular noncompaction may characterise the ranges of natural history of Barth syndrome.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23480174</id>
    <passage>
      <offset>0</offset>
      <text>MD simulations of the formation of stable clusters in mixtures of alkaline salts and imidazolium-based ionic liquids.	Structural and dynamical properties of room-temperature ionic liquids containing the cation 1-butyl-3-methylimidazolium ([BMIM](+)) and three different anions (hexafluorophosphate, [PF6](-), tetrafluoroborate, [BF4](-), and bis(trifluoromethylsulfonyl)imide, [NTf2](-)) doped with several molar fractions of lithium salts with a common anion at 298.15 K and 1 atm were investigated by means of molecular dynamics simulations. The effect of the size of the salt cation was also analyzed by comparing these results with those for mixtures of [BMIM][PF6] with NaPF6. Lithium/sodium solvation and ionic mobilities were analyzed via the study of radial distribution functions, coordination numbers, cage autocorrelation functions, mean-square displacements (including the analysis of both ballistic and diffusive regimes), self-diffusion coefficients of all the ionic species, velocity and current autocorrelation functions, and ionic conductivity in all the ionic liquid/salt systems. We found that lithium and sodium cations are strongly coordinated in two different positions with the anion present in the mixture. Moreover, [Li](+) and [Na](+) cations were found to form bonded-like, long-lived aggregates with the anions in their first solvation shell, which act as very stable kinetic entities within which a marked rattling motion of salt ions takes place. With very long MD simulation runs, this phenomenon is proved to be on the basis of the decrease of self-diffusion coefficients and ionic conductivities previously reported in experimental and computational results.</text>
      <sentence>
        <offset>0</offset>
        <text>MD simulations of the formation of stable clusters in mixtures of alkaline salts and imidazolium-based ionic liquids.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alkaline salts</infon>
          <location offset="66" length="14"/>
          <text>alkaline salts</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imidazolium</infon>
          <location offset="85" length="11"/>
          <text>imidazolium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>118</offset>
        <text>Structural and dynamical properties of room-temperature ionic liquids containing the cation 1-butyl-3-methylimidazolium ([BMIM](+)) and three different anions (hexafluorophosphate, [PF6](-), tetrafluoroborate, [BF4](-), and bis(trifluoromethylsulfonyl)imide, [NTf2](-)) doped with several molar fractions of lithium salts with a common anion at 298.15 K and 1 atm were investigated by means of molecular dynamics simulations.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[bmim](+)</infon>
          <location offset="239" length="9"/>
          <text>[BMIM](+)</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hexafluorophosphate</infon>
          <location offset="278" length="19"/>
          <text>hexafluorophosphate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[pf6](-)</infon>
          <location offset="299" length="8"/>
          <text>[PF6](-)</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetrafluoroborate</infon>
          <location offset="309" length="17"/>
          <text>tetrafluoroborate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[bf4](-)</infon>
          <location offset="328" length="8"/>
          <text>[BF4](-)</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bis(trifluoromethylsulfonyl)imide</infon>
          <location offset="342" length="33"/>
          <text>bis(trifluoromethylsulfonyl)imide</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[ntf2](-)</infon>
          <location offset="377" length="9"/>
          <text>[NTf2](-)</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lithium</infon>
          <location offset="426" length="7"/>
          <text>lithium</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1-butyl-3-methylimidazolium</infon>
          <location offset="210" length="27"/>
          <text>1-butyl-3-methylimidazolium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>544</offset>
        <text>The effect of the size of the salt cation was also analyzed by comparing these results with those for mixtures of [BMIM][PF6] with NaPF6.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[bmim][pf6]</infon>
          <location offset="658" length="11"/>
          <text>[BMIM][PF6]</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">napf6</infon>
          <location offset="675" length="5"/>
          <text>NaPF6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>682</offset>
        <text>Lithium/sodium solvation and ionic mobilities were analyzed via the study of radial distribution functions, coordination numbers, cage autocorrelation functions, mean-square displacements (including the analysis of both ballistic and diffusive regimes), self-diffusion coefficients of all the ionic species, velocity and current autocorrelation functions, and ionic conductivity in all the ionic liquid/salt systems.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lithium</infon>
          <location offset="682" length="7"/>
          <text>Lithium</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="690" length="6"/>
          <text>sodium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1099</offset>
        <text>We found that lithium and sodium cations are strongly coordinated in two different positions with the anion present in the mixture.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="1125" length="6"/>
          <text>sodium</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lithium</infon>
          <location offset="1113" length="7"/>
          <text>lithium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1231</offset>
        <text>Moreover, [Li](+) and [Na](+) cations were found to form bonded-like, long-lived aggregates with the anions in their first solvation shell, which act as very stable kinetic entities within which a marked rattling motion of salt ions takes place.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[li](+)</infon>
          <location offset="1241" length="7"/>
          <text>[Li](+)</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[na](+)</infon>
          <location offset="1253" length="7"/>
          <text>[Na](+)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1477</offset>
        <text>With very long MD simulation runs, this phenomenon is proved to be on the basis of the decrease of self-diffusion coefficients and ionic conductivities previously reported in experimental and computational results.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>19663609</id>
    <passage>
      <offset>0</offset>
      <text>Conivaptan: promise of treatment in heart failure.	Conivaptan, the first vasopressin receptor antagonist approved by the FDA, is available for the treatment of hyponatremia in euvolemic and hypervolemic patients. The renin-angiotensin-aldosterone system is activated in heart failure (HF) causing clinical worsening. Arginine vasopressin levels are also elevated in HF. Conivaptan is an effective and FDA approved for the treatment of euvolemic and hypervolemic hyponatremia and may offer an extra treatment option in HF by targeting V(1a) and V(2) receptors. In this article we review the physiology, preclinical studies as well as the human clinical studies on the use of conivaptan and its potential and promise in the treatment of HF.</text>
      <sentence>
        <offset>0</offset>
        <text>Conivaptan: promise of treatment in heart failure.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">conivaptan</infon>
          <location offset="0" length="10"/>
          <text>Conivaptan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>51</offset>
        <text>Conivaptan, the first vasopressin receptor antagonist approved by the FDA, is available for the treatment of hyponatremia in euvolemic and hypervolemic patients.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">conivaptan</infon>
          <location offset="51" length="10"/>
          <text>Conivaptan</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vasopressin</infon>
          <location offset="73" length="11"/>
          <text>vasopressin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vasopressin receptor</infon>
          <location offset="73" length="20"/>
          <text>vasopressin receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>213</offset>
        <text>The renin-angiotensin-aldosterone system is activated in heart failure (HF) causing clinical worsening.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin</infon>
          <location offset="223" length="11"/>
          <text>angiotensin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="235" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="217" length="5"/>
          <text>renin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin</infon>
          <location offset="223" length="11"/>
          <text>angiotensin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>317</offset>
        <text>Arginine vasopressin levels are also elevated in HF.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arginine vasopressin</infon>
          <location offset="317" length="20"/>
          <text>Arginine vasopressin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">arginine vasopressin</infon>
          <location offset="317" length="20"/>
          <text>Arginine vasopressin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>370</offset>
        <text>Conivaptan is an effective and FDA approved for the treatment of euvolemic and hypervolemic hyponatremia and may offer an extra treatment option in HF by targeting V(1a) and V(2) receptors.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">conivaptan</infon>
          <location offset="370" length="10"/>
          <text>Conivaptan</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">v(1a)</infon>
          <location offset="534" length="5"/>
          <text>V(1a)</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">v(2) receptors</infon>
          <location offset="544" length="14"/>
          <text>V(2) receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>560</offset>
        <text>In this article we review the physiology, preclinical studies as well as the human clinical studies on the use of conivaptan and its potential and promise in the treatment of HF.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">conivaptan</infon>
          <location offset="674" length="10"/>
          <text>conivaptan</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>20590599</id>
    <passage>
      <offset>0</offset>
      <text>The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.	BACKGROUND AND PURPOSE: There are two important properties of receptor-ligand interactions: affinity (the ability of the ligand to bind to the receptor) and efficacy (the ability of the receptor-ligand complex to induce a response). Ligands are classified as agonists or antagonists depending on whether or not they have efficacy. In theory, it is possible to develop selective agonists based on selective affinity, selective intrinsic efficacy or both. This study examined the affinity and intrinsic efficacy of 31 beta-adrenoceptor agonists at the three human beta-adrenoceptors to determine whether the current agonists are subtype selective because of affinity or intrinsic efficacy. EXPERIMENTAL APPROACH: Stable clonal CHO-K1 cell lines, transfected with either the human beta(1), beta(2) or beta(3)-adrenoceptor, were used, and whole-cell [(3)H]-CGP 12177 radioligand binding and [(3)H]-cAMP accumulation were measured. KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity. However, the intrinsic efficacy of salmeterol, formoterol and isoprenaline was similar across all three receptor subtypes. Other ligands (e.g. denopamine for beta(1); clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy. Several ligands appeared to activate two agonist conformations of the beta(1)- and beta(3)-adrenoceptors. CONCLUSIONS AND IMPLICATIONS: There are agonists with subtype selectivity based upon both selective affinity and selective intrinsic efficacy. Therefore, there is scope to develop better selective agonists based upon both selective affinity and selective intrinsic efficacy.</text>
      <sentence>
        <offset>0</offset>
        <text>The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.</text>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenoceptor</infon>
          <location offset="19" length="17"/>
          <text>beta-adrenoceptor</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human beta1-, beta2- and beta3-adrenoceptors</infon>
          <location offset="49" length="44"/>
          <text>human beta1-, beta2- and beta3-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>95</offset>
        <text>BACKGROUND AND PURPOSE: There are two important properties of receptor-ligand interactions: affinity (the ability of the ligand to bind to the receptor) and efficacy (the ability of the receptor-ligand complex to induce a response).</text>
      </sentence>
      <sentence>
        <offset>328</offset>
        <text>Ligands are classified as agonists or antagonists depending on whether or not they have efficacy.</text>
      </sentence>
      <sentence>
        <offset>426</offset>
        <text>In theory, it is possible to develop selective agonists based on selective affinity, selective intrinsic efficacy or both.</text>
      </sentence>
      <sentence>
        <offset>549</offset>
        <text>This study examined the affinity and intrinsic efficacy of 31 beta-adrenoceptor agonists at the three human beta-adrenoceptors to determine whether the current agonists are subtype selective because of affinity or intrinsic efficacy.</text>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenoceptor</infon>
          <location offset="611" length="17"/>
          <text>beta-adrenoceptor</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human beta-adrenoceptors</infon>
          <location offset="651" length="24"/>
          <text>human beta-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>783</offset>
        <text>EXPERIMENTAL APPROACH: Stable clonal CHO-K1 cell lines, transfected with either the human beta(1), beta(2) or beta(3)-adrenoceptor, were used, and whole-cell [(3)H]-CGP 12177 radioligand binding and [(3)H]-cAMP accumulation were measured.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(3)h]-cgp 12177</infon>
          <location offset="941" length="16"/>
          <text>[(3)H]-CGP 12177</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(3)h]-camp</infon>
          <location offset="982" length="11"/>
          <text>[(3)H]-cAMP</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human beta(1), beta(2) or beta(3)-adrenoceptor</infon>
          <location offset="867" length="46"/>
          <text>human beta(1), beta(2) or beta(3)-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1022</offset>
        <text>KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salmeterol</infon>
          <location offset="1130" length="10"/>
          <text>salmeterol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">formoterol</infon>
          <location offset="1145" length="10"/>
          <text>formoterol</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoprenaline</infon>
          <location offset="1235" length="12"/>
          <text>isoprenaline</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(2)-adrenoceptor</infon>
          <location offset="1165" length="20"/>
          <text>beta(2)-adrenoceptor</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(1)</infon>
          <location offset="1195" length="7"/>
          <text>beta(1)</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(3)</infon>
          <location offset="1206" length="7"/>
          <text>beta(3)</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1282</offset>
        <text>However, the intrinsic efficacy of salmeterol, formoterol and isoprenaline was similar across all three receptor subtypes.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salmeterol</infon>
          <location offset="1317" length="10"/>
          <text>salmeterol</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">formoterol</infon>
          <location offset="1329" length="10"/>
          <text>formoterol</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoprenaline</infon>
          <location offset="1344" length="12"/>
          <text>isoprenaline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1405</offset>
        <text>Other ligands (e.g. denopamine for beta(1); clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">denopamine</infon>
          <location offset="1425" length="10"/>
          <text>denopamine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clenbuterol</infon>
          <location offset="1449" length="11"/>
          <text>clenbuterol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">az 40140d</infon>
          <location offset="1462" length="9"/>
          <text>AZ 40140d</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salbutamol</infon>
          <location offset="1473" length="10"/>
          <text>salbutamol</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(1)</infon>
          <location offset="1440" length="7"/>
          <text>beta(1)</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(2)</infon>
          <location offset="1488" length="7"/>
          <text>beta(2)</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1554</offset>
        <text>Several ligands appeared to activate two agonist conformations of the beta(1)- and beta(3)-adrenoceptors.</text>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta(1)- and beta(3)-adrenoceptors</infon>
          <location offset="1624" length="34"/>
          <text>beta(1)- and beta(3)-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1660</offset>
        <text>CONCLUSIONS AND IMPLICATIONS: There are agonists with subtype selectivity based upon both selective affinity and selective intrinsic efficacy.</text>
      </sentence>
      <sentence>
        <offset>1803</offset>
        <text>Therefore, there is scope to develop better selective agonists based upon both selective affinity and selective intrinsic efficacy.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23239555</id>
    <passage>
      <offset>0</offset>
      <text>Boron-based inhibitors of acyl protein thioesterases 1 and 2.	Ras proteins are of importance in cell proliferation, and hence their mutated forms play causative roles in many kinds of cancer in different tissues. Inhibition of the Ras-depalmitoylating enzyme acyl protein thioesterases APT1 and -2 is a new approach to modulating the Ras cycle. Here we present boronic and borinic acid derivatives as a new class of potent and nontoxic APT inhibitors. These compounds were detected by extensive library screening using chemical arrays and turned out to inhibit human APT1 and -2 in a competitive mode. Furthermore, one of the molecules was demonstrated to inhibit Erk1/2 phosphorylation significantly.</text>
      <sentence>
        <offset>0</offset>
        <text>Boron-based inhibitors of acyl protein thioesterases 1 and 2.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">boron</infon>
          <location offset="0" length="5"/>
          <text>Boron</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acyl</infon>
          <location offset="26" length="4"/>
          <text>acyl</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">acyl protein thioesterases 1 and 2</infon>
          <location offset="26" length="34"/>
          <text>acyl protein thioesterases 1 and 2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>62</offset>
        <text>Ras proteins are of importance in cell proliferation, and hence their mutated forms play causative roles in many kinds of cancer in different tissues.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ras</infon>
          <location offset="62" length="3"/>
          <text>Ras</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>213</offset>
        <text>Inhibition of the Ras-depalmitoylating enzyme acyl protein thioesterases APT1 and -2 is a new approach to modulating the Ras cycle.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acyl</infon>
          <location offset="259" length="4"/>
          <text>acyl</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ras</infon>
          <location offset="231" length="3"/>
          <text>Ras</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">acyl protein thioesterases apt1 and -2</infon>
          <location offset="259" length="38"/>
          <text>acyl protein thioesterases APT1 and -2</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ras</infon>
          <location offset="334" length="3"/>
          <text>Ras</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>345</offset>
        <text>Here we present boronic and borinic acid derivatives as a new class of potent and nontoxic APT inhibitors.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">boronic</infon>
          <location offset="361" length="7"/>
          <text>boronic</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">borinic acid</infon>
          <location offset="373" length="12"/>
          <text>borinic acid</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">apt</infon>
          <location offset="436" length="3"/>
          <text>APT</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>452</offset>
        <text>These compounds were detected by extensive library screening using chemical arrays and turned out to inhibit human APT1 and -2 in a competitive mode.</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human apt1 and -2</infon>
          <location offset="561" length="17"/>
          <text>human APT1 and -2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>602</offset>
        <text>Furthermore, one of the molecules was demonstrated to inhibit Erk1/2 phosphorylation significantly.</text>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="664" length="6"/>
          <text>Erk1/2</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23566515</id>
    <passage>
      <offset>0</offset>
      <text>Synthesis and structure-activity relationships of 2-amino-3-carboxy-4-phenylthiophenes as novel atypical protein kinase C inhibitors.	Recent evidence suggests atypical protein kinase C (aPKC) isoforms are required for both TNF- and VEGF-induced breakdown of the blood-retinal barrier (BRB) and endothelial permeability to 70kDa dextran or albumin. A chemical library screen revealed a series of novel small molecule phenylthiophene based inhibitors of aPKC isoforms that effectively block permeability in cell culture and in vivo. In an effort to further elucidate the structural requirements of this series of inhibitors, we detail in this study a structure-activity relationship (SAR) built on screening hit 1, which expands on our initial pharmacophore model. The biological activity of our analogues was evaluated in models of bona fide aPKC-dependent signaling including NFκB driven-gene transcription as a marker for an inflammatory response and VEGF/TNF-induced vascular endothelial permeability. The EC50 for the most efficacious inhibitors (6, 32) was in the low nanomolar range in these two cellular assays. Our study demonstrates the key structural elements that confer inhibitory activity and highlights the requirement for electron-donating moieties off the C-4 aryl moiety of the 2-amino-3-carboxy-4-phenylthiophene backbone. These studies suggest that this class has potential for further development into small molecule aPKC inhibitors with therapeutic efficacy in a host of diseases involving increased vascular permeability and inflammation.</text>
      <sentence>
        <offset>0</offset>
        <text>Synthesis and structure-activity relationships of 2-amino-3-carboxy-4-phenylthiophenes as novel atypical protein kinase C inhibitors.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-amino-3-carboxy-4-phenylthiophenes</infon>
          <location offset="50" length="36"/>
          <text>2-amino-3-carboxy-4-phenylthiophenes</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atypical protein kinase c</infon>
          <location offset="96" length="25"/>
          <text>atypical protein kinase C</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>134</offset>
        <text>Recent evidence suggests atypical protein kinase C (aPKC) isoforms are required for both TNF- and VEGF-induced breakdown of the blood-retinal barrier (BRB) and endothelial permeability to 70kDa dextran or albumin.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinal</infon>
          <location offset="268" length="7"/>
          <text>retinal</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">albumin</infon>
          <location offset="339" length="7"/>
          <text>albumin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atypical protein kinase c</infon>
          <location offset="159" length="25"/>
          <text>atypical protein kinase C</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">apkc</infon>
          <location offset="186" length="4"/>
          <text>aPKC</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf</infon>
          <location offset="223" length="3"/>
          <text>TNF</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="232" length="4"/>
          <text>VEGF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>348</offset>
        <text>A chemical library screen revealed a series of novel small molecule phenylthiophene based inhibitors of aPKC isoforms that effectively block permeability in cell culture and in vivo.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenylthiophene</infon>
          <location offset="416" length="15"/>
          <text>phenylthiophene</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">apkc</infon>
          <location offset="452" length="4"/>
          <text>aPKC</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>531</offset>
        <text>In an effort to further elucidate the structural requirements of this series of inhibitors, we detail in this study a structure-activity relationship (SAR) built on screening hit 1, which expands on our initial pharmacophore model.</text>
      </sentence>
      <sentence>
        <offset>763</offset>
        <text>The biological activity of our analogues was evaluated in models of bona fide aPKC-dependent signaling including NFκB driven-gene transcription as a marker for an inflammatory response and VEGF/TNF-induced vascular endothelial permeability.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">apkc</infon>
          <location offset="841" length="4"/>
          <text>aPKC</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nfκb</infon>
          <location offset="876" length="4"/>
          <text>NFκB</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="952" length="4"/>
          <text>VEGF</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf</infon>
          <location offset="957" length="3"/>
          <text>TNF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1004</offset>
        <text>The EC50 for the most efficacious inhibitors (6, 32) was in the low nanomolar range in these two cellular assays.</text>
      </sentence>
      <sentence>
        <offset>1118</offset>
        <text>Our study demonstrates the key structural elements that confer inhibitory activity and highlights the requirement for electron-donating moieties off the C-4 aryl moiety of the 2-amino-3-carboxy-4-phenylthiophene backbone.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-amino-3-carboxy-4-phenylthiophene</infon>
          <location offset="1294" length="35"/>
          <text>2-amino-3-carboxy-4-phenylthiophene</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1340</offset>
        <text>These studies suggest that this class has potential for further development into small molecule aPKC inhibitors with therapeutic efficacy in a host of diseases involving increased vascular permeability and inflammation.</text>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">apkc</infon>
          <location offset="1436" length="4"/>
          <text>aPKC</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11799102</id>
    <passage>
      <offset>0</offset>
      <text>Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.	Renin is the main determinant of angiotensin (Ang) II levels. It, therefore, always appeared desirable to reduce Ang II levels by direct inhibition of renin. So far, specific renin inhibitors lacked potency and/or oral availability. We tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol. In 3 periods of 8 days, separated by wash-outs of 6 days, each volunteer received 2 dosage levels of Aliskiren (low before high; 40 and 80 or 160 and 640 mg/d) and randomized placebo or 20 mg enalapril. Aliskiren was well tolerated. Not surprisingly, blood pressure and heart rate remained unchanged in these normotensive subjects. There was a dose-dependent decrease in plasma renin activity, Ang I, and Ang II following single doses of Aliskiren starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo. At the same time, mean plasma active renin was increased 16- and 34-fold at the highest dose of Aliskiren. Plasma drug levels of Aliskiren were dose-dependent with maximal concentrations reached between 3 to 6 hours after administration; steady state was reached between 5 and 8 days after multiple dosing. Less than 1% of dose was excreted in the urine. Plasma and urinary aldosterone levels were decreased after doses of Aliskiren &gt; or =80 mg and after enalapril. Aliskiren at 160 and 640 mg enhanced natriuresis on Day 1 by +45% and +62%, respectively, compared with placebo (100%, ie, 87+/-11 mmol/24h) and enalapril (+54%); kaliuresis remained unchanged. In conclusion, the renin inhibitor Aliskiren dose-dependently decreases Ang II levels in humans following oral administration. The effect is long-lasting and, at a dose of 160 mg, is equivalent to that of 20 mg enalapril. Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.</text>
      <sentence>
        <offset>0</offset>
        <text>Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="0" length="14"/>
          <text>Angiotensin II</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">enalapril</infon>
          <location offset="110" length="9"/>
          <text>enalapril</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="74" length="9"/>
          <text>Aliskiren</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spp100</infon>
          <location offset="85" length="6"/>
          <text>SPP100</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="0" length="14"/>
          <text>Angiotensin II</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="58" length="5"/>
          <text>renin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T29" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T29" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T30" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T30" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>121</offset>
        <text>Renin is the main determinant of angiotensin (Ang) II levels.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin (ang) ii</infon>
          <location offset="154" length="20"/>
          <text>angiotensin (Ang) II</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="121" length="5"/>
          <text>Renin</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin (ang) ii</infon>
          <location offset="154" length="20"/>
          <text>angiotensin (Ang) II</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>183</offset>
        <text>It, therefore, always appeared desirable to reduce Ang II levels by direct inhibition of renin.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="234" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="234" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="272" length="5"/>
          <text>renin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>279</offset>
        <text>So far, specific renin inhibitors lacked potency and/or oral availability.</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="296" length="5"/>
          <text>renin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>354</offset>
        <text>We tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spp100</infon>
          <location offset="414" length="6"/>
          <text>SPP100</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="422" length="9"/>
          <text>Aliskiren</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">octanamide</infon>
          <location offset="436" length="10"/>
          <text>octanamide</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="568" length="6"/>
          <text>sodium</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="398" length="5"/>
          <text>renin</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>628</offset>
        <text>In 3 periods of 8 days, separated by wash-outs of 6 days, each volunteer received 2 dosage levels of Aliskiren (low before high; 40 and 80 or 160 and 640 mg/d) and randomized placebo or 20 mg enalapril.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="729" length="9"/>
          <text>Aliskiren</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">enalapril</infon>
          <location offset="820" length="9"/>
          <text>enalapril</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>831</offset>
        <text>Aliskiren was well tolerated.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="831" length="9"/>
          <text>Aliskiren</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>861</offset>
        <text>Not surprisingly, blood pressure and heart rate remained unchanged in these normotensive subjects.</text>
      </sentence>
      <sentence>
        <offset>960</offset>
        <text>There was a dose-dependent decrease in plasma renin activity, Ang I, and Ang II following single doses of Aliskiren starting with 40 mg.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ang i</infon>
          <location offset="1022" length="5"/>
          <text>Ang I</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="1033" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="1066" length="9"/>
          <text>Aliskiren</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="1006" length="5"/>
          <text>renin</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ang i</infon>
          <location offset="1022" length="5"/>
          <text>Ang I</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="1033" length="6"/>
          <text>Ang II</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T26" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T26" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T26" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1097</offset>
        <text>Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="1189" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="1274" length="9"/>
          <text>Aliskiren</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="1189" length="6"/>
          <text>Ang II</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1311</offset>
        <text>At the same time, mean plasma active renin was increased 16- and 34-fold at the highest dose of Aliskiren.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="1407" length="9"/>
          <text>Aliskiren</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="1348" length="5"/>
          <text>renin</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1418</offset>
        <text>Plasma drug levels of Aliskiren were dose-dependent with maximal concentrations reached between 3 to 6 hours after administration; steady state was reached between 5 and 8 days after multiple dosing.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="1440" length="9"/>
          <text>Aliskiren</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1618</offset>
        <text>Less than 1% of dose was excreted in the urine.</text>
      </sentence>
      <sentence>
        <offset>1666</offset>
        <text>Plasma and urinary aldosterone levels were decreased after doses of Aliskiren &gt; or =80 mg and after enalapril.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="1685" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="1734" length="9"/>
          <text>Aliskiren</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">enalapril</infon>
          <location offset="1766" length="9"/>
          <text>enalapril</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1777</offset>
        <text>Aliskiren at 160 and 640 mg enhanced natriuresis on Day 1 by +45% and +62%, respectively, compared with placebo (100%, ie, 87+/-11 mmol/24h) and enalapril (+54%); kaliuresis remained unchanged.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="1777" length="9"/>
          <text>Aliskiren</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">enalapril</infon>
          <location offset="1922" length="9"/>
          <text>enalapril</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1971</offset>
        <text>In conclusion, the renin inhibitor Aliskiren dose-dependently decreases Ang II levels in humans following oral administration.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="2006" length="9"/>
          <text>Aliskiren</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="2043" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="1990" length="5"/>
          <text>renin</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="2043" length="6"/>
          <text>Ang II</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2098</offset>
        <text>The effect is long-lasting and, at a dose of 160 mg, is equivalent to that of 20 mg enalapril.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">enalapril</infon>
          <location offset="2182" length="9"/>
          <text>enalapril</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2193</offset>
        <text>Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aliskiren</infon>
          <location offset="2193" length="9"/>
          <text>Aliskiren</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="2326" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="2255" length="5"/>
          <text>renin</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ace</infon>
          <location offset="2307" length="3"/>
          <text>ACE</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ang ii receptor</infon>
          <location offset="2326" length="15"/>
          <text>Ang II receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T14" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23369343</id>
    <passage>
      <offset>0</offset>
      <text>Evaluation of in vivo anti-hyperglycemic and antioxidant potentials of α-santalol and sandalwood oil.	Sandalwood finds numerous mentions across diverse traditional medicinal systems in use worldwide. The objective of this study was to evaluate the in vivo anti-hyperglycemic and antioxidant potential of sandalwood oil and its major constituent α-santalol. The in vivo anti-hyperglycemic experiment was conducted in alloxan-induced diabetic male Swiss albino mice models. The in vivo antioxidant experiment was performed in d-galactose mediated oxidative stress induced male Swiss albino mice models. Intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for an week modulated parameters such as body weight, blood glucose, serum bilirubin, liver glycogen, and lipid peroxides contents to normoglycemic levels in the alloxan-induced diabetic mice. Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice. Besides, it was observed that the beneficial effects of α-santalol were well complimented, differentially by other constituents present in sandalwood oil, thus indicating synergism in biological activity of this traditionally used bioresource.</text>
      <sentence>
        <offset>0</offset>
        <text>Evaluation of in vivo anti-hyperglycemic and antioxidant potentials of α-santalol and sandalwood oil.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">α-santalol</infon>
          <location offset="71" length="10"/>
          <text>α-santalol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>102</offset>
        <text>Sandalwood finds numerous mentions across diverse traditional medicinal systems in use worldwide.</text>
      </sentence>
      <sentence>
        <offset>200</offset>
        <text>The objective of this study was to evaluate the in vivo anti-hyperglycemic and antioxidant potential of sandalwood oil and its major constituent α-santalol.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">α-santalol</infon>
          <location offset="345" length="10"/>
          <text>α-santalol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>357</offset>
        <text>The in vivo anti-hyperglycemic experiment was conducted in alloxan-induced diabetic male Swiss albino mice models.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alloxan</infon>
          <location offset="416" length="7"/>
          <text>alloxan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>472</offset>
        <text>The in vivo antioxidant experiment was performed in d-galactose mediated oxidative stress induced male Swiss albino mice models.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-galactose</infon>
          <location offset="524" length="11"/>
          <text>d-galactose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>601</offset>
        <text>Intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for an week modulated parameters such as body weight, blood glucose, serum bilirubin, liver glycogen, and lipid peroxides contents to normoglycemic levels in the alloxan-induced diabetic mice.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">α-santalol</infon>
          <location offset="635" length="10"/>
          <text>α-santalol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="750" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bilirubin</infon>
          <location offset="765" length="9"/>
          <text>bilirubin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peroxides</infon>
          <location offset="802" length="9"/>
          <text>peroxides</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alloxan</infon>
          <location offset="852" length="7"/>
          <text>alloxan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>883</offset>
        <text>Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfhydryl</infon>
          <location offset="1121" length="10"/>
          <text>sulfhydryl</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbonyl</infon>
          <location offset="1141" length="8"/>
          <text>carbonyl</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="1151" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peroxide</infon>
          <location offset="1177" length="8"/>
          <text>peroxide</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-galactose</infon>
          <location offset="1224" length="11"/>
          <text>d-galactose</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">α-santalol</infon>
          <location offset="928" length="10"/>
          <text>α-santalol</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bilirubin</infon>
          <location offset="1073" length="9"/>
          <text>bilirubin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="1084" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catalase</infon>
          <location offset="1106" length="8"/>
          <text>catalase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aminotransferases</infon>
          <location offset="1032" length="17"/>
          <text>aminotransferases</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alkaline phosphatase</infon>
          <location offset="1051" length="20"/>
          <text>alkaline phosphatase</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">superoxide dismutase</infon>
          <location offset="1084" length="20"/>
          <text>superoxide dismutase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1276</offset>
        <text>Besides, it was observed that the beneficial effects of α-santalol were well complimented, differentially by other constituents present in sandalwood oil, thus indicating synergism in biological activity of this traditionally used bioresource.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">α-santalol</infon>
          <location offset="1332" length="10"/>
          <text>α-santalol</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23249624</id>
    <passage>
      <offset>0</offset>
      <text>Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.	Brain metastases are a common cause of death in stage IV metastatic melanoma. Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma. Clinical trials with dabrafenib have shown encouraging results; however, the central nervous system distribution of dabrafenib remains unknown. Thus, the objective of the current study was to evaluate the brain distribution of dabrafenib in mice, and to see whether active efflux by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) restricts its delivery across the blood-brain barrier (BBB). In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that dabrafenib is an avid substrate for both P-gp and BCRP. Directional flux studies revealed greater transport in the basolateral to apical direction with corrected efflux ratios greater than 2 for both P-gp and Bcrp1 transfected cell lines. In vivo, the ratio of area under the concentration-time curve (AUC)(brain) to AUC(plasma) (K(p)) of dabrafenib after an i.v. dose (2.5 mg/kg) was 0.023, which increased by 18-fold in Mdr1 a/b(-/-)Bcrp1(-/-) mice to 0.42. Dabrafenib plasma exposure was ∼2-fold greater in Mdr1 a/b(-/-)Bcrp1(-/-) mice as compared with wild-type with an oral dose (25 mg/kg); however, the brain distribution was increased by ~10-fold with a resulting K(p) of 0.25. Further, compared with vemurafenib, another BRAF(V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose. In conclusion, the dabrafenib brain distribution is limited in an intact BBB model, and the data presented herein may have clinical implications in the prevention and treatment of melanoma brain metastases.</text>
      <sentence>
        <offset>0</offset>
        <text>Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">threonine</infon>
          <location offset="40" length="9"/>
          <text>threonine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dabrafenib</infon>
          <location offset="88" length="10"/>
          <text>dabrafenib</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">threonine-protein kinase b-raf</infon>
          <location offset="40" length="30"/>
          <text>threonine-protein kinase B-RaF</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">v600e</infon>
          <location offset="71" length="5"/>
          <text>V600E</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>174</offset>
        <text>Brain metastases are a common cause of death in stage IV metastatic melanoma.</text>
      </sentence>
      <sentence>
        <offset>252</offset>
        <text>Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="288" length="6"/>
          <text>serine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">threonine</infon>
          <location offset="295" length="9"/>
          <text>threonine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">valine</infon>
          <location offset="387" length="6"/>
          <text>valine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamic acid</infon>
          <location offset="401" length="13"/>
          <text>glutamic acid</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serine/threonine-protein kinase b-raf</infon>
          <location offset="288" length="37"/>
          <text>serine/threonine-protein kinase B-Raf</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">valine 600 to glutamic acid</infon>
          <location offset="387" length="27"/>
          <text>valine 600 to glutamic acid</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">braf</infon>
          <location offset="429" length="4"/>
          <text>BRAF</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">v600e</infon>
          <location offset="434" length="5"/>
          <text>V600E</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">braf</infon>
          <location offset="268" length="4"/>
          <text>BRAF</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T9" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>491</offset>
        <text>Clinical trials with dabrafenib have shown encouraging results; however, the central nervous system distribution of dabrafenib remains unknown.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dabrafenib</infon>
          <location offset="512" length="10"/>
          <text>dabrafenib</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dabrafenib</infon>
          <location offset="607" length="10"/>
          <text>dabrafenib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>635</offset>
        <text>Thus, the objective of the current study was to evaluate the brain distribution of dabrafenib in mice, and to see whether active efflux by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) restricts its delivery across the blood-brain barrier (BBB).</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dabrafenib</infon>
          <location offset="718" length="10"/>
          <text>dabrafenib</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="774" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="790" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">breast cancer resistance protein</infon>
          <location offset="800" length="32"/>
          <text>breast cancer resistance protein</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="834" length="4"/>
          <text>BCRP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>901</offset>
        <text>In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that dabrafenib is an avid substrate for both P-gp and BCRP.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dabrafenib</infon>
          <location offset="993" length="10"/>
          <text>dabrafenib</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="1034" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="1043" length="4"/>
          <text>BCRP</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1049</offset>
        <text>Directional flux studies revealed greater transport in the basolateral to apical direction with corrected efflux ratios greater than 2 for both P-gp and Bcrp1 transfected cell lines.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="1193" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp1</infon>
          <location offset="1202" length="5"/>
          <text>Bcrp1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1232</offset>
        <text>In vivo, the ratio of area under the concentration-time curve (AUC)(brain) to AUC(plasma) (K(p)) of dabrafenib after an i.v. dose (2.5 mg/kg) was 0.023, which increased by 18-fold in Mdr1 a/b(-/-)Bcrp1(-/-) mice to 0.42.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dabrafenib</infon>
          <location offset="1332" length="10"/>
          <text>dabrafenib</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mdr1 a/b</infon>
          <location offset="1415" length="8"/>
          <text>Mdr1 a/b</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp1</infon>
          <location offset="1428" length="5"/>
          <text>Bcrp1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1453</offset>
        <text>Dabrafenib plasma exposure was ∼2-fold greater in Mdr1 a/b(-/-)Bcrp1(-/-) mice as compared with wild-type with an oral dose (25 mg/kg); however, the brain distribution was increased by ~10-fold with a resulting K(p) of 0.25.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dabrafenib</infon>
          <location offset="1453" length="10"/>
          <text>Dabrafenib</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mdr1 a/b</infon>
          <location offset="1503" length="8"/>
          <text>Mdr1 a/b</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp1</infon>
          <location offset="1516" length="5"/>
          <text>Bcrp1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1678</offset>
        <text>Further, compared with vemurafenib, another BRAF(V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vemurafenib</infon>
          <location offset="1701" length="11"/>
          <text>vemurafenib</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dabrafenib</infon>
          <location offset="1745" length="10"/>
          <text>dabrafenib</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">braf</infon>
          <location offset="1722" length="4"/>
          <text>BRAF</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">v600e</infon>
          <location offset="1727" length="5"/>
          <text>V600E</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1810</offset>
        <text>In conclusion, the dabrafenib brain distribution is limited in an intact BBB model, and the data presented herein may have clinical implications in the prevention and treatment of melanoma brain metastases.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dabrafenib</infon>
          <location offset="1829" length="10"/>
          <text>dabrafenib</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22982248</id>
    <passage>
      <offset>0</offset>
      <text>NMDA receptor signaling mediates the expression of protein inhibitor of activated STAT1 (PIAS1) in rat hippocampus.	Protein inhibitor of activated STAT1 (PIAS1) was shown to play an important role in inflammation and innate immune response, but how PIAS1 is regulated is not known. We have recently demonstrated that PIAS1 enhances spatial learning and memory performance in rats. In this study, we examined the signaling pathway and neural mechanism that regulate PIAS1 expression in the brain by using pharmacological and molecular approaches. Our results revealed that pias1 gene expression is rapidly induced upon NMDA receptor activation in rat hippocampus, but this effect is blocked by transfection of sub-threshold concentrations of ERK1 siRNA/ERK2 siRNA or CREB siRNA. Pias1 gene expression is similarly induced by overexpression of the ERK1/ERK2 plasmids in rat hippocampus, and this effect is also blocked by sub-threshold concentration of CREB siRNA transfection. On the other hand, transfection of ERK1 siRNA/ERK2 siRNA or CREB siRNA at a higher concentration is sufficient to down-regulate PIAS1 expression. Inhibition of PI-3 kinase signaling and CaMKII signaling, which both result in CREB inactivation, similarly decreases PIAS1 expression. But NMDA and MK-801 do not affect the expression of IL-6 and TNFα. NMDA also did not affect the expression of PIAS2, PIAS3 and PIAS4. Further, pias1 mRNA has a similar degradation rate to that of the zif268 gene. These results together suggest that pias1 may function as an immediate early gene in an activity-dependent manner and PIAS1 expression is regulated by the NMDA-MAPK/ERK-CREB signaling pathway implicated in neuronal plasticity.</text>
      <sentence>
        <offset>0</offset>
        <text>NMDA receptor signaling mediates the expression of protein inhibitor of activated STAT1 (PIAS1) in rat hippocampus.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="0" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptor</infon>
          <location offset="0" length="13"/>
          <text>NMDA receptor</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">stat1</infon>
          <location offset="82" length="5"/>
          <text>STAT1</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="89" length="5"/>
          <text>PIAS1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>116</offset>
        <text>Protein inhibitor of activated STAT1 (PIAS1) was shown to play an important role in inflammation and innate immune response, but how PIAS1 is regulated is not known.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="249" length="5"/>
          <text>PIAS1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">stat1</infon>
          <location offset="147" length="5"/>
          <text>STAT1</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="154" length="5"/>
          <text>PIAS1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>282</offset>
        <text>We have recently demonstrated that PIAS1 enhances spatial learning and memory performance in rats.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="317" length="5"/>
          <text>PIAS1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>381</offset>
        <text>In this study, we examined the signaling pathway and neural mechanism that regulate PIAS1 expression in the brain by using pharmacological and molecular approaches.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="465" length="5"/>
          <text>PIAS1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>546</offset>
        <text>Our results revealed that pias1 gene expression is rapidly induced upon NMDA receptor activation in rat hippocampus, but this effect is blocked by transfection of sub-threshold concentrations of ERK1 siRNA/ERK2 siRNA or CREB siRNA.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="618" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="572" length="5"/>
          <text>pias1</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptor</infon>
          <location offset="618" length="13"/>
          <text>NMDA receptor</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk1</infon>
          <location offset="741" length="4"/>
          <text>ERK1</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk2</infon>
          <location offset="752" length="4"/>
          <text>ERK2</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="766" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>778</offset>
        <text>Pias1 gene expression is similarly induced by overexpression of the ERK1/ERK2 plasmids in rat hippocampus, and this effect is also blocked by sub-threshold concentration of CREB siRNA transfection.</text>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="778" length="5"/>
          <text>Pias1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk1</infon>
          <location offset="846" length="4"/>
          <text>ERK1</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk2</infon>
          <location offset="851" length="4"/>
          <text>ERK2</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="951" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>976</offset>
        <text>On the other hand, transfection of ERK1 siRNA/ERK2 siRNA or CREB siRNA at a higher concentration is sufficient to down-regulate PIAS1 expression.</text>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk1</infon>
          <location offset="1011" length="4"/>
          <text>ERK1</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk2</infon>
          <location offset="1022" length="4"/>
          <text>ERK2</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="1036" length="4"/>
          <text>CREB</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="1104" length="5"/>
          <text>PIAS1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1122</offset>
        <text>Inhibition of PI-3 kinase signaling and CaMKII signaling, which both result in CREB inactivation, similarly decreases PIAS1 expression.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi-3 kinase</infon>
          <location offset="1136" length="11"/>
          <text>PI-3 kinase</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">camkii</infon>
          <location offset="1162" length="6"/>
          <text>CaMKII</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="1201" length="4"/>
          <text>CREB</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="1240" length="5"/>
          <text>PIAS1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1258</offset>
        <text>But NMDA and MK-801 do not affect the expression of IL-6 and TNFα.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="1262" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mk-801</infon>
          <location offset="1271" length="6"/>
          <text>MK-801</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-6</infon>
          <location offset="1310" length="4"/>
          <text>IL-6</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnfα</infon>
          <location offset="1319" length="4"/>
          <text>TNFα</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1325</offset>
        <text>NMDA also did not affect the expression of PIAS2, PIAS3 and PIAS4.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="1325" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias2</infon>
          <location offset="1368" length="5"/>
          <text>PIAS2</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias3</infon>
          <location offset="1375" length="5"/>
          <text>PIAS3</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias4</infon>
          <location offset="1385" length="5"/>
          <text>PIAS4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1392</offset>
        <text>Further, pias1 mRNA has a similar degradation rate to that of the zif268 gene.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="1401" length="5"/>
          <text>pias1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zif268</infon>
          <location offset="1458" length="6"/>
          <text>zif268</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1471</offset>
        <text>These results together suggest that pias1 may function as an immediate early gene in an activity-dependent manner and PIAS1 expression is regulated by the NMDA-MAPK/ERK-CREB signaling pathway implicated in neuronal plasticity.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="1626" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="1507" length="5"/>
          <text>pias1</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pias1</infon>
          <location offset="1589" length="5"/>
          <text>PIAS1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="1631" length="4"/>
          <text>MAPK</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="1636" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="1640" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16997906</id>
    <passage>
      <offset>0</offset>
      <text>Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies.	Arginine decarboxylase (ADC) and ornithine decarboxylase (ODC) are involved in the biosynthesis of putrescine, which is the precursor of other polyamines in animals, plants, and bacteria. These pyridoxal-5'-phosphate-dependent decarboxylases belong to the alanine racemase (AR) structural family together with diaminopimelate decarboxylase (DapDC), which catalyzes the final step of lysine biosynthesis in bacteria. We have constructed a multiple-sequence alignment of decarboxylases in the AR structural family and, based on the alignment, inferred phylogenetic trees. The phylogenetic tree consists of 3 distinct clades formed by ADC, DapDC, and ODC that diverged from an ancestral decarboxylase. The ancestral decarboxylase probably was able to recognize several substrates, and in archaea and bacteria, ODC may have retained the ability to bind other amino acids. Previously, a paralogue of ODC has been proposed to account for ADC activity detected in mammalian cells. According to our results, this appears unlikely, emphasizing the need for more caution in functional assignment made using sequence data and illustrating the continuing value of phylogenetic analysis in clarifying relationships and putative functions.</text>
      <sentence>
        <offset>0</offset>
        <text>Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="29" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alanine</infon>
          <location offset="64" length="7"/>
          <text>alanine</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">amino acid decarboxylases</infon>
          <location offset="29" length="25"/>
          <text>amino acid decarboxylases</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alanine racemase</infon>
          <location offset="64" length="16"/>
          <text>alanine racemase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>124</offset>
        <text>Arginine decarboxylase (ADC) and ornithine decarboxylase (ODC) are involved in the biosynthesis of putrescine, which is the precursor of other polyamines in animals, plants, and bacteria.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arginine</infon>
          <location offset="124" length="8"/>
          <text>Arginine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ornithine</infon>
          <location offset="157" length="9"/>
          <text>ornithine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">putrescine</infon>
          <location offset="223" length="10"/>
          <text>putrescine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">arginine decarboxylase</infon>
          <location offset="124" length="22"/>
          <text>Arginine decarboxylase</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adc</infon>
          <location offset="148" length="3"/>
          <text>ADC</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ornithine decarboxylase</infon>
          <location offset="157" length="23"/>
          <text>ornithine decarboxylase</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">odc</infon>
          <location offset="182" length="3"/>
          <text>ODC</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>312</offset>
        <text>These pyridoxal-5'-phosphate-dependent decarboxylases belong to the alanine racemase (AR) structural family together with diaminopimelate decarboxylase (DapDC), which catalyzes the final step of lysine biosynthesis in bacteria.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyridoxal-5'-phosphate</infon>
          <location offset="318" length="22"/>
          <text>pyridoxal-5'-phosphate</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alanine</infon>
          <location offset="380" length="7"/>
          <text>alanine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diaminopimelate</infon>
          <location offset="434" length="15"/>
          <text>diaminopimelate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lysine</infon>
          <location offset="507" length="6"/>
          <text>lysine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">decarboxylases</infon>
          <location offset="351" length="14"/>
          <text>decarboxylases</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alanine racemase</infon>
          <location offset="380" length="16"/>
          <text>alanine racemase</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ar</infon>
          <location offset="398" length="2"/>
          <text>AR</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">diaminopimelate decarboxylase</infon>
          <location offset="434" length="29"/>
          <text>diaminopimelate decarboxylase</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dapdc</infon>
          <location offset="465" length="5"/>
          <text>DapDC</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>540</offset>
        <text>We have constructed a multiple-sequence alignment of decarboxylases in the AR structural family and, based on the alignment, inferred phylogenetic trees.</text>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">decarboxylases</infon>
          <location offset="593" length="14"/>
          <text>decarboxylases</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ar</infon>
          <location offset="615" length="2"/>
          <text>AR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>694</offset>
        <text>The phylogenetic tree consists of 3 distinct clades formed by ADC, DapDC, and ODC that diverged from an ancestral decarboxylase.</text>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adc</infon>
          <location offset="756" length="3"/>
          <text>ADC</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dapdc</infon>
          <location offset="761" length="5"/>
          <text>DapDC</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">odc</infon>
          <location offset="772" length="3"/>
          <text>ODC</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">decarboxylase</infon>
          <location offset="808" length="13"/>
          <text>decarboxylase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>823</offset>
        <text>The ancestral decarboxylase probably was able to recognize several substrates, and in archaea and bacteria, ODC may have retained the ability to bind other amino acids.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="979" length="11"/>
          <text>amino acids</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">decarboxylase</infon>
          <location offset="837" length="13"/>
          <text>decarboxylase</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">odc</infon>
          <location offset="931" length="3"/>
          <text>ODC</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>992</offset>
        <text>Previously, a paralogue of ODC has been proposed to account for ADC activity detected in mammalian cells.</text>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">odc</infon>
          <location offset="1019" length="3"/>
          <text>ODC</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adc</infon>
          <location offset="1056" length="3"/>
          <text>ADC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1098</offset>
        <text>According to our results, this appears unlikely, emphasizing the need for more caution in functional assignment made using sequence data and illustrating the continuing value of phylogenetic analysis in clarifying relationships and putative functions.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23247010</id>
    <passage>
      <offset>0</offset>
      <text>Regulation of human carbonyl reductase 1 (CBR1, SDR21C1) gene by transcription factor Nrf2.	Monomeric carbonyl reductase 1 (CBR1, SDR21C1) is a member of the short-chain dehydrogenase/reductase superfamily and is involved in the metabolism of anthracycline anti-cancer drugs, prostaglandins, and isatin, which is an endogenous inhibitor of monoamine oxidases. Additionally, cancer progression may be partly regulated by CBR1. In the present study, we screened more than 10 drugs for the induction of the human CBR1 gene to investigate its regulation. Of the drugs, butylated hydroxyanisole (BHA) was found to be an inducer. BHA induced the mRNA and protein expression of CBR1 in hepatoma HepG2 cells. In a luciferase reporter gene assay, the promoter region between -2062 bp and the transcription start site of CBR1 was also activated by BHA. The transcription factor Nrf2 is known to be activated by BHA. There are 2 anti-oxidant responsive elements (ARE) that are bound by Nrf2 in this region. Mutation analyses revealed that one of the AREs participates in the gene regulation of CBR1 by Nrf2. Electrophoretic mobility shift assay revealed that Nrf2 binds the site. Moreover, to determine whether the functional ARE of CBR1 is conserved with the promoter region of homologues in other species, the nucleotide sequences of the functional AREs of the Chcr1 and Chcr2 genes, which are the Chinese hamster homologues of CBR1, were determined. The region has 2 AREs, and these genes were also induced by the forced expression of Nrf2 (cotransfection of pNrf2) in the luciferase reporter gene assay. In conclusion, Nrf2 is a novel transcriptional regulator of CBR1 genes in humans and the Chinese hamster. Because the regulation of CBR1 appears to be important for diseases, the induction of CBR1 by Nrf2 may be a therapeutic target.</text>
      <sentence>
        <offset>0</offset>
        <text>Regulation of human carbonyl reductase 1 (CBR1, SDR21C1) gene by transcription factor Nrf2.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbonyl</infon>
          <location offset="20" length="8"/>
          <text>carbonyl</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human carbonyl reductase 1</infon>
          <location offset="14" length="26"/>
          <text>human carbonyl reductase 1</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cbr1</infon>
          <location offset="42" length="4"/>
          <text>CBR1</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sdr21c1</infon>
          <location offset="48" length="7"/>
          <text>SDR21C1</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="86" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>92</offset>
        <text>Monomeric carbonyl reductase 1 (CBR1, SDR21C1) is a member of the short-chain dehydrogenase/reductase superfamily and is involved in the metabolism of anthracycline anti-cancer drugs, prostaglandins, and isatin, which is an endogenous inhibitor of monoamine oxidases.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbonyl</infon>
          <location offset="102" length="8"/>
          <text>carbonyl</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anthracycline</infon>
          <location offset="243" length="13"/>
          <text>anthracycline</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prostaglandins</infon>
          <location offset="276" length="14"/>
          <text>prostaglandins</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isatin</infon>
          <location offset="296" length="6"/>
          <text>isatin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoamine</infon>
          <location offset="340" length="9"/>
          <text>monoamine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monomeric carbonyl reductase 1</infon>
          <location offset="92" length="30"/>
          <text>Monomeric carbonyl reductase 1</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">monoamine oxidases</infon>
          <location offset="340" length="18"/>
          <text>monoamine oxidases</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cbr1</infon>
          <location offset="124" length="4"/>
          <text>CBR1</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sdr21c1</infon>
          <location offset="130" length="7"/>
          <text>SDR21C1</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dehydrogenase</infon>
          <location offset="170" length="13"/>
          <text>dehydrogenase</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">reductase</infon>
          <location offset="184" length="9"/>
          <text>reductase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>360</offset>
        <text>Additionally, cancer progression may be partly regulated by CBR1.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cbr1</infon>
          <location offset="420" length="4"/>
          <text>CBR1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>426</offset>
        <text>In the present study, we screened more than 10 drugs for the induction of the human CBR1 gene to investigate its regulation.</text>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human cbr1</infon>
          <location offset="504" length="10"/>
          <text>human CBR1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>551</offset>
        <text>Of the drugs, butylated hydroxyanisole (BHA) was found to be an inducer.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">butylated hydroxyanisole</infon>
          <location offset="565" length="24"/>
          <text>butylated hydroxyanisole</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bha</infon>
          <location offset="591" length="3"/>
          <text>BHA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>624</offset>
        <text>BHA induced the mRNA and protein expression of CBR1 in hepatoma HepG2 cells.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bha</infon>
          <location offset="624" length="3"/>
          <text>BHA</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cbr1</infon>
          <location offset="671" length="4"/>
          <text>CBR1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>701</offset>
        <text>In a luciferase reporter gene assay, the promoter region between -2062 bp and the transcription start site of CBR1 was also activated by BHA.</text>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cbr1</infon>
          <location offset="811" length="4"/>
          <text>CBR1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>843</offset>
        <text>The transcription factor Nrf2 is known to be activated by BHA.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bha</infon>
          <location offset="901" length="3"/>
          <text>BHA</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="868" length="4"/>
          <text>Nrf2</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>906</offset>
        <text>There are 2 anti-oxidant responsive elements (ARE) that are bound by Nrf2 in this region.</text>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">anti-oxidant responsive elements</infon>
          <location offset="918" length="32"/>
          <text>anti-oxidant responsive elements</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">are</infon>
          <location offset="952" length="3"/>
          <text>ARE</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="975" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>996</offset>
        <text>Mutation analyses revealed that one of the AREs participates in the gene regulation of CBR1 by Nrf2.</text>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ares</infon>
          <location offset="1039" length="4"/>
          <text>AREs</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cbr1</infon>
          <location offset="1083" length="4"/>
          <text>CBR1</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1091" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1097</offset>
        <text>Electrophoretic mobility shift assay revealed that Nrf2 binds the site.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1148" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1169</offset>
        <text>Moreover, to determine whether the functional ARE of CBR1 is conserved with the promoter region of homologues in other species, the nucleotide sequences of the functional AREs of the Chcr1 and Chcr2 genes, which are the Chinese hamster homologues of CBR1, were determined.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleotide</infon>
          <location offset="1301" length="10"/>
          <text>nucleotide</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">are</infon>
          <location offset="1215" length="3"/>
          <text>ARE</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cbr1</infon>
          <location offset="1222" length="4"/>
          <text>CBR1</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ares</infon>
          <location offset="1340" length="4"/>
          <text>AREs</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">chcr1</infon>
          <location offset="1352" length="5"/>
          <text>Chcr1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">chcr2</infon>
          <location offset="1362" length="5"/>
          <text>Chcr2</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cbr1</infon>
          <location offset="1419" length="4"/>
          <text>CBR1</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1442</offset>
        <text>The region has 2 AREs, and these genes were also induced by the forced expression of Nrf2 (cotransfection of pNrf2) in the luciferase reporter gene assay.</text>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ares</infon>
          <location offset="1459" length="4"/>
          <text>AREs</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1527" length="4"/>
          <text>Nrf2</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pnrf2</infon>
          <location offset="1551" length="5"/>
          <text>pNrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1597</offset>
        <text>In conclusion, Nrf2 is a novel transcriptional regulator of CBR1 genes in humans and the Chinese hamster.</text>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1612" length="4"/>
          <text>Nrf2</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cbr1</infon>
          <location offset="1657" length="4"/>
          <text>CBR1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1703</offset>
        <text>Because the regulation of CBR1 appears to be important for diseases, the induction of CBR1 by Nrf2 may be a therapeutic target.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cbr1</infon>
          <location offset="1729" length="4"/>
          <text>CBR1</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cbr1</infon>
          <location offset="1789" length="4"/>
          <text>CBR1</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1797" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18423812</id>
    <passage>
      <offset>0</offset>
      <text>Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.	BACKGROUND: Agents inhibiting the renin-angiotensin-aldosterone (RAAS) system have an important role in slowing the progression of chronic kidney disease. We evaluated the hypothesis that the addition of an aldosterone receptor antagonist to an angiotensin-converting enzyme (ACE) inhibitor and angiotensin II type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade). DESIGN: Randomized open controlled crossover study. SETTING &amp; PARTICIPANTS: 18 whites (7 women, 11 men) from the Outpatient Department of Nephrology with chronic nondiabetic proteinuric kidney diseases, mean age 42.4 +/- 1.9 years (SEM). INTERVENTIONS: In the 8-week run-in period, all participants received the ACE inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg. Participants were then randomly assigned to 2 treatment sequences, either the addition of spironolactone (25 mg) (triple RAAS blockade) through 8 weeks followed by double RAAS blockade through 8 weeks (sequence 1) or double RAAS blockade followed by triple RAAS blockade (sequence 2). MAIN OUTCOME MEASURES: 24-hour urine protein excretion (primary end point) and markers of tubular injury and fibrosis (secondary end points). Analysis was performed using analysis of variance for repeated measurements. RESULTS: At baseline, mean serum creatinine level was 1.16 +/- 0.09 mg/dL (103 +/- 8 micromol/L), estimated glomerular filtration rate was 107.8 mL/min (95% confidence interval, 93 to 140.9 [1.8 mL/s; 95% confidence interval, 1.55 to 2.35; Cockcroft-Gault formula), and 24-hour mean proteinuria was 0.97 +/- 0.18 g. Mean urine protein excretion was 0.7 g/24 h (95% confidence interval, 0.48 to 0.92) less after triple RAAS blockade than after double RAAS blockade (P = 0.01), without change in blood pressure. Urine excretion of N-acetyl-beta-d-glucosaminidase (P = 0.02) and amino-terminal propeptide of type III procollagen (P = 0.05) also significantly decreased. Potassium levels increased significantly after triple therapy (P = 0.02). However, no patient was withdrawn because of adverse effects. LIMITATIONS: Absence of blinding, small sample size, short treatment period, absence of histological assessment. CONCLUSIONS: Administration of an aldosterone receptor antagonist in addition to double RAAS blockade with an ACE inhibitor and ARB may slow the progression of chronic kidney disease. Additional studies are necessary to confirm this result.</text>
      <sentence>
        <offset>0</offset>
        <text>Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="57" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="39" length="5"/>
          <text>renin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin</infon>
          <location offset="45" length="11"/>
          <text>angiotensin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>149</offset>
        <text>BACKGROUND: Agents inhibiting the renin-angiotensin-aldosterone (RAAS) system have an important role in slowing the progression of chronic kidney disease.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="201" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">renin</infon>
          <location offset="183" length="5"/>
          <text>renin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin</infon>
          <location offset="189" length="11"/>
          <text>angiotensin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>304</offset>
        <text>We evaluated the hypothesis that the addition of an aldosterone receptor antagonist to an angiotensin-converting enzyme (ACE) inhibitor and angiotensin II type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="356" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="444" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aldosterone receptor</infon>
          <location offset="356" length="20"/>
          <text>aldosterone receptor</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin-converting enzyme</infon>
          <location offset="394" length="29"/>
          <text>angiotensin-converting enzyme</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ace</infon>
          <location offset="425" length="3"/>
          <text>ACE</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin ii type 1 (at-1) receptor</infon>
          <location offset="444" length="37"/>
          <text>angiotensin II type 1 (AT-1) receptor</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ace</infon>
          <location offset="570" length="3"/>
          <text>ACE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>616</offset>
        <text>DESIGN: Randomized open controlled crossover study.</text>
      </sentence>
      <sentence>
        <offset>668</offset>
        <text>SETTING &amp; PARTICIPANTS: 18 whites (7 women, 11 men) from the Outpatient Department of Nephrology with chronic nondiabetic proteinuric kidney diseases, mean age 42.4 +/- 1.9 years (SEM).</text>
      </sentence>
      <sentence>
        <offset>854</offset>
        <text>INTERVENTIONS: In the 8-week run-in period, all participants received the ACE inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cilazapril</infon>
          <location offset="942" length="10"/>
          <text>cilazapril</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">telmisarta</infon>
          <location offset="969" length="10"/>
          <text>telmisarta</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrochlorothiazide</infon>
          <location offset="1007" length="19"/>
          <text>hydrochlorothiazide</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ace</infon>
          <location offset="928" length="3"/>
          <text>ACE</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1125</offset>
        <text>Participants were then randomly assigned to 2 treatment sequences, either the addition of spironolactone (25 mg) (triple RAAS blockade) through 8 weeks followed by double RAAS blockade through 8 weeks (sequence 1) or double RAAS blockade followed by triple RAAS blockade (sequence 2).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spironolactone</infon>
          <location offset="1215" length="14"/>
          <text>spironolactone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1410</offset>
        <text>MAIN OUTCOME MEASURES: 24-hour urine protein excretion (primary end point) and markers of tubular injury and fibrosis (secondary end points).</text>
      </sentence>
      <sentence>
        <offset>1552</offset>
        <text>Analysis was performed using analysis of variance for repeated measurements.</text>
      </sentence>
      <sentence>
        <offset>1629</offset>
        <text>RESULTS: At baseline, mean serum creatinine level was 1.16 +/- 0.09 mg/dL (103 +/- 8 micromol/L), estimated glomerular filtration rate was 107.8 mL/min (95% confidence interval, 93 to 140.9 [1.8 mL/s; 95% confidence interval, 1.55 to 2.35; Cockcroft-Gault formula), and 24-hour mean proteinuria was 0.97 +/- 0.18 g.</text>
      </sentence>
      <sentence>
        <offset>1945</offset>
        <text>Mean urine protein excretion was 0.7 g/24 h (95% confidence interval, 0.48 to 0.92) less after triple RAAS blockade than after double RAAS blockade (P = 0.01), without change in blood pressure.</text>
      </sentence>
      <sentence>
        <offset>2139</offset>
        <text>Urine excretion of N-acetyl-beta-d-glucosaminidase (P = 0.02) and amino-terminal propeptide of type III procollagen (P = 0.05) also significantly decreased.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">n-acetyl-beta-d-glucosaminidase</infon>
          <location offset="2158" length="31"/>
          <text>N-acetyl-beta-d-glucosaminidase</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">type iii procollagen</infon>
          <location offset="2234" length="20"/>
          <text>type III procollagen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2296</offset>
        <text>Potassium levels increased significantly after triple therapy (P = 0.02).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">potassium</infon>
          <location offset="2296" length="9"/>
          <text>Potassium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2370</offset>
        <text>However, no patient was withdrawn because of adverse effects.</text>
      </sentence>
      <sentence>
        <offset>2432</offset>
        <text>LIMITATIONS: Absence of blinding, small sample size, short treatment period, absence of histological assessment.</text>
      </sentence>
      <sentence>
        <offset>2545</offset>
        <text>CONCLUSIONS: Administration of an aldosterone receptor antagonist in addition to double RAAS blockade with an ACE inhibitor and ARB may slow the progression of chronic kidney disease.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="2579" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aldosterone receptor</infon>
          <location offset="2579" length="20"/>
          <text>aldosterone receptor</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ace</infon>
          <location offset="2655" length="3"/>
          <text>ACE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2729</offset>
        <text>Additional studies are necessary to confirm this result.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23505146</id>
    <passage>
      <offset>0</offset>
      <text>Diverse effects of macromolecular crowding on the sequential glycan-processing pathway involved in glycoprotein quality control.	Compared with in vitro conditions, the intracellular environment is highly crowded with biomolecules; this has numerous effects on protein functions, including enzymatic activity. We examined the effects of macromolecular crowding on glycan processing of N-glycoprotein in the endoplasmic reticulum as a model sequential metabolic pathway. Experiments with synthetic substrates of physiological glycan structure clearly showed that the first half of the pathway (glucose trimming) was accelerated, whereas the second (mannose trimming) was decelerated under molecular crowding conditions. Furthermore, calreticulin, a lectin-like molecular chaperone, bound more strongly to a glycan-processing intermediate under these conditions. This study demonstrates the diverse effects of molecular crowding on sequential enzymatic processing, and the importance of the effects of macromolecular crowding on in vitro assays for understanding sequential metabolic pathways.</text>
      <sentence>
        <offset>0</offset>
        <text>Diverse effects of macromolecular crowding on the sequential glycan-processing pathway involved in glycoprotein quality control.</text>
      </sentence>
      <sentence>
        <offset>129</offset>
        <text>Compared with in vitro conditions, the intracellular environment is highly crowded with biomolecules; this has numerous effects on protein functions, including enzymatic activity.</text>
      </sentence>
      <sentence>
        <offset>309</offset>
        <text>We examined the effects of macromolecular crowding on glycan processing of N-glycoprotein in the endoplasmic reticulum as a model sequential metabolic pathway.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="384" length="1"/>
          <text>N</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>469</offset>
        <text>Experiments with synthetic substrates of physiological glycan structure clearly showed that the first half of the pathway (glucose trimming) was accelerated, whereas the second (mannose trimming) was decelerated under molecular crowding conditions.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="592" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mannose</infon>
          <location offset="647" length="7"/>
          <text>mannose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>718</offset>
        <text>Furthermore, calreticulin, a lectin-like molecular chaperone, bound more strongly to a glycan-processing intermediate under these conditions.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">calreticulin</infon>
          <location offset="731" length="12"/>
          <text>calreticulin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lectin</infon>
          <location offset="747" length="6"/>
          <text>lectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>860</offset>
        <text>This study demonstrates the diverse effects of molecular crowding on sequential enzymatic processing, and the importance of the effects of macromolecular crowding on in vitro assays for understanding sequential metabolic pathways.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23288051</id>
    <passage>
      <offset>0</offset>
      <text>Influence of DNA repair on nonlinear dose-responses for mutation.	Recent evidence has challenged the default assumption that all DNA-reactive alkylating agents exhibit a linear dose-response. Emerging evidence suggests that the model alkylating agents methyl- and ethylmethanesulfonate and methylnitrosourea (MNU) and ethylnitrosourea observe a nonlinear dose-response with a no observed genotoxic effect level (NOGEL). Follow-up mechanistic studies are essential to understand the mechanism of cellular tolerance and biological relevance of such NOGELs. MNU is one of the most mutagenic simple alkylators. Therefore, understanding the mechanism of mutation induction, following low-dose MNU treatment, sets precedence for weaker mutagenic alkylating agents. Here, we tested MNU at 10-fold lower concentrations than a previous study and report a NOGEL of 0.0075 µg/ml (72.8nM) in human lymphoblastoid cells, quantified through the hypoxanthine (guanine) phosphoribosyltransferase assay (OECD 476). Mechanistic studies reveal that the NOGEL is dependent upon repair of O(6)-methylguanine (O(6)MeG) by the suicide enzyme O(6)MeG-DNA methyltransferase (MGMT). Inactivation of MGMT sensitizes cells to MNU-induced mutagenesis and shifts the NOGEL to the left on the dose axis.</text>
      <sentence>
        <offset>0</offset>
        <text>Influence of DNA repair on nonlinear dose-responses for mutation.</text>
      </sentence>
      <sentence>
        <offset>66</offset>
        <text>Recent evidence has challenged the default assumption that all DNA-reactive alkylating agents exhibit a linear dose-response.</text>
      </sentence>
      <sentence>
        <offset>192</offset>
        <text>Emerging evidence suggests that the model alkylating agents methyl- and ethylmethanesulfonate and methylnitrosourea (MNU) and ethylnitrosourea observe a nonlinear dose-response with a no observed genotoxic effect level (NOGEL).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methyl</infon>
          <location offset="252" length="6"/>
          <text>methyl</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethylmethanesulfonate</infon>
          <location offset="264" length="21"/>
          <text>ethylmethanesulfonate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methylnitrosourea</infon>
          <location offset="290" length="17"/>
          <text>methylnitrosourea</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mnu</infon>
          <location offset="309" length="3"/>
          <text>MNU</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethylnitrosourea</infon>
          <location offset="318" length="16"/>
          <text>ethylnitrosourea</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>420</offset>
        <text>Follow-up mechanistic studies are essential to understand the mechanism of cellular tolerance and biological relevance of such NOGELs.</text>
      </sentence>
      <sentence>
        <offset>555</offset>
        <text>MNU is one of the most mutagenic simple alkylators.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mnu</infon>
          <location offset="555" length="3"/>
          <text>MNU</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>607</offset>
        <text>Therefore, understanding the mechanism of mutation induction, following low-dose MNU treatment, sets precedence for weaker mutagenic alkylating agents.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mnu</infon>
          <location offset="688" length="3"/>
          <text>MNU</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>759</offset>
        <text>Here, we tested MNU at 10-fold lower concentrations than a previous study and report a NOGEL of 0.0075 µg/ml (72.8nM) in human lymphoblastoid cells, quantified through the hypoxanthine (guanine) phosphoribosyltransferase assay (OECD 476).</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mnu</infon>
          <location offset="775" length="3"/>
          <text>MNU</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hypoxanthine</infon>
          <location offset="931" length="12"/>
          <text>hypoxanthine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">guanine</infon>
          <location offset="945" length="7"/>
          <text>guanine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hypoxanthine (guanine) phosphoribosyltransferase</infon>
          <location offset="931" length="48"/>
          <text>hypoxanthine (guanine) phosphoribosyltransferase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>998</offset>
        <text>Mechanistic studies reveal that the NOGEL is dependent upon repair of O(6)-methylguanine (O(6)MeG) by the suicide enzyme O(6)MeG-DNA methyltransferase (MGMT).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o(6)-methylguanine</infon>
          <location offset="1068" length="18"/>
          <text>O(6)-methylguanine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o(6)meg</infon>
          <location offset="1088" length="7"/>
          <text>O(6)MeG</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o(6)meg</infon>
          <location offset="1119" length="7"/>
          <text>O(6)MeG</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">o(6)meg-dna methyltransferase</infon>
          <location offset="1119" length="29"/>
          <text>O(6)MeG-DNA methyltransferase</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mgmt</infon>
          <location offset="1150" length="4"/>
          <text>MGMT</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1157</offset>
        <text>Inactivation of MGMT sensitizes cells to MNU-induced mutagenesis and shifts the NOGEL to the left on the dose axis.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mnu</infon>
          <location offset="1198" length="3"/>
          <text>MNU</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mgmt</infon>
          <location offset="1173" length="4"/>
          <text>MGMT</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>7994588</id>
    <passage>
      <offset>0</offset>
      <text>[Potentiation of the photocytotoxic effect of photofrin II: synergistic action of verapamil and lovastatin].	Photofrin II (P2) is at the present time the most used drug in the photochemotherapy of tumors. As previous studies from our group have demonstrated that P2 is taken up by cells mainly via the low density lipoprotein (LDL) receptor pathway, we tried to increase the amount of drug delivered to cells by enhancing the LDL receptor expression. For this purpose, we used hydroxy methyl glutaryl Coenzyme A (HMG-CoA) reductase inhibitors such as lovastatin. In the present work, we show that the calcium antagonist verapamil, which is currently used in human chemotherapy to overcome multidrug resistance, enhances in a synergistic manner the potentiating action of lovastatin on the photocytotoxic effect of P2.</text>
      <sentence>
        <offset>0</offset>
        <text>[Potentiation of the photocytotoxic effect of photofrin II: synergistic action of verapamil and lovastatin].</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">verapamil</infon>
          <location offset="82" length="9"/>
          <text>verapamil</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lovastatin</infon>
          <location offset="96" length="10"/>
          <text>lovastatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>109</offset>
        <text>Photofrin II (P2) is at the present time the most used drug in the photochemotherapy of tumors.</text>
      </sentence>
      <sentence>
        <offset>205</offset>
        <text>As previous studies from our group have demonstrated that P2 is taken up by cells mainly via the low density lipoprotein (LDL) receptor pathway, we tried to increase the amount of drug delivered to cells by enhancing the LDL receptor expression.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">low density lipoprotein (ldl) receptor</infon>
          <location offset="302" length="38"/>
          <text>low density lipoprotein (LDL) receptor</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldl receptor</infon>
          <location offset="426" length="12"/>
          <text>LDL receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>451</offset>
        <text>For this purpose, we used hydroxy methyl glutaryl Coenzyme A (HMG-CoA) reductase inhibitors such as lovastatin.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydroxy methyl glutaryl coenzyme a</infon>
          <location offset="477" length="34"/>
          <text>hydroxy methyl glutaryl Coenzyme A</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hmg-coa</infon>
          <location offset="513" length="7"/>
          <text>HMG-CoA</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lovastatin</infon>
          <location offset="551" length="10"/>
          <text>lovastatin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hydroxy methyl glutaryl coenzyme a (hmg-coa) reductase</infon>
          <location offset="477" length="54"/>
          <text>hydroxy methyl glutaryl Coenzyme A (HMG-CoA) reductase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>563</offset>
        <text>In the present work, we show that the calcium antagonist verapamil, which is currently used in human chemotherapy to overcome multidrug resistance, enhances in a synergistic manner the potentiating action of lovastatin on the photocytotoxic effect of P2.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="601" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">verapamil</infon>
          <location offset="620" length="9"/>
          <text>verapamil</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lovastatin</infon>
          <location offset="771" length="10"/>
          <text>lovastatin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23605691</id>
    <passage>
      <offset>0</offset>
      <text>Cytochrome p450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.	In recent years the use of the opioid oxycodone has increased markedly and replacing morphine as the first-line choice of opioid in several countries. There are formulations for oral immediate, oral extended release and intravenous use. The bioavailability is higher than for morphine and less variable. Oxycodone is primarily metabolized in the liver by the cytochrome P450 (CYP) enzymes with CYP3A as the major metabolic pathway and CYP2D6 as the minor metabolic pathway to noroxycodone, oxymorphone and noroxymorphone. Oxycodone exerts its analgesic effect via the µ-opioid receptor. The metabolism of CYP2D6 substrates varies to a large degree between individuals as a result of allele functionality. Poor metabolizers (PM) have two non-functional alleles, extensive metabolizers (EM) are homozygous with two functional alleles or heterozygous with one functional allele and ultrarapid metabolizers (UM) have more than two functional alleles. There are pronounced interethnic differences in the allele distribution. On the basis of studies performed thus far, oxycodone concentrations in comparison with EM are similar in PM and reduced in UM. The pharmacokinetics in UM are insufficiently investigated. Simultaneous inhibition of both CYP3A and CYP2D6 results in increased oxycodone concentrations and such a combination should be avoided. A similar effect is to be expected with use of a CYP3A inhibitor in CYP2D6 PM. Concomitant use of enzyme inducers such as rifampicin, St John's wort and carbamazepine should be avoided because of the risk of subtherapeutic concentrations of oxycodone. When the dosage of morphine may result in unpredictable bioavailability, like in patients with severe hepatic cirrhosis, oxycodone might be beneficial because it has higher and less variability in bioavailability between patients than morphine.</text>
      <sentence>
        <offset>0</offset>
        <text>Cytochrome p450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxycodone</infon>
          <location offset="36" length="9"/>
          <text>oxycodone</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450</infon>
          <location offset="0" length="15"/>
          <text>Cytochrome p450</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>113</offset>
        <text>In recent years the use of the opioid oxycodone has increased markedly and replacing morphine as the first-line choice of opioid in several countries.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxycodone</infon>
          <location offset="151" length="9"/>
          <text>oxycodone</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="198" length="8"/>
          <text>morphine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>264</offset>
        <text>There are formulations for oral immediate, oral extended release and intravenous use.</text>
      </sentence>
      <sentence>
        <offset>350</offset>
        <text>The bioavailability is higher than for morphine and less variable.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="389" length="8"/>
          <text>morphine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>417</offset>
        <text>Oxycodone is primarily metabolized in the liver by the cytochrome P450 (CYP) enzymes with CYP3A as the major metabolic pathway and CYP2D6 as the minor metabolic pathway to noroxycodone, oxymorphone and noroxymorphone.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxycodone</infon>
          <location offset="417" length="9"/>
          <text>Oxycodone</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">noroxycodone</infon>
          <location offset="589" length="12"/>
          <text>noroxycodone</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymorphone</infon>
          <location offset="603" length="11"/>
          <text>oxymorphone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">noroxymorphone</infon>
          <location offset="619" length="14"/>
          <text>noroxymorphone</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450</infon>
          <location offset="472" length="15"/>
          <text>cytochrome P450</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp</infon>
          <location offset="489" length="3"/>
          <text>CYP</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="507" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="548" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T14" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T14" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>635</offset>
        <text>Oxycodone exerts its analgesic effect via the µ-opioid receptor.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxycodone</infon>
          <location offset="635" length="9"/>
          <text>Oxycodone</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">µ-opioid receptor</infon>
          <location offset="681" length="17"/>
          <text>µ-opioid receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>700</offset>
        <text>The metabolism of CYP2D6 substrates varies to a large degree between individuals as a result of allele functionality.</text>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="718" length="6"/>
          <text>CYP2D6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>818</offset>
        <text>Poor metabolizers (PM) have two non-functional alleles, extensive metabolizers (EM) are homozygous with two functional alleles or heterozygous with one functional allele and ultrarapid metabolizers (UM) have more than two functional alleles.</text>
      </sentence>
      <sentence>
        <offset>1060</offset>
        <text>There are pronounced interethnic differences in the allele distribution.</text>
      </sentence>
      <sentence>
        <offset>1133</offset>
        <text>On the basis of studies performed thus far, oxycodone concentrations in comparison with EM are similar in PM and reduced in UM.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxycodone</infon>
          <location offset="1177" length="9"/>
          <text>oxycodone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1261</offset>
        <text>The pharmacokinetics in UM are insufficiently investigated.</text>
      </sentence>
      <sentence>
        <offset>1321</offset>
        <text>Simultaneous inhibition of both CYP3A and CYP2D6 results in increased oxycodone concentrations and such a combination should be avoided.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxycodone</infon>
          <location offset="1391" length="9"/>
          <text>oxycodone</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="1353" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="1363" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1458</offset>
        <text>A similar effect is to be expected with use of a CYP3A inhibitor in CYP2D6 PM.</text>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="1507" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="1526" length="6"/>
          <text>CYP2D6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1537</offset>
        <text>Concomitant use of enzyme inducers such as rifampicin, St John's wort and carbamazepine should be avoided because of the risk of subtherapeutic concentrations of oxycodone.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="1580" length="10"/>
          <text>rifampicin</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbamazepine</infon>
          <location offset="1611" length="13"/>
          <text>carbamazepine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxycodone</infon>
          <location offset="1699" length="9"/>
          <text>oxycodone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1710</offset>
        <text>When the dosage of morphine may result in unpredictable bioavailability, like in patients with severe hepatic cirrhosis, oxycodone might be beneficial because it has higher and less variability in bioavailability between patients than morphine.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="1729" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxycodone</infon>
          <location offset="1831" length="9"/>
          <text>oxycodone</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="1945" length="8"/>
          <text>morphine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16513877</id>
    <passage>
      <offset>0</offset>
      <text>DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.	OBJECTIVE: All antipsychotics act on the dopamine D(2) receptor. The present study extends prior pharmacogenetic investigations of the D(2) receptor gene (DRD2) by examining, in first-episode schizophrenia patients, promoter region variation as a predictor of response time to two first-line atypical antipsychotics. METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (A-241G and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or olanzapine. Time until sustained response (two consecutive ratings without significant positive symptoms) for rare allele carriers versus wild types was examined by using Kaplan-Meier curves. RESULTS: Relative to wild type homozygotes, G carriers (A-241G) exhibited a significantly faster time until response, whereas -141C Del carriers took a significantly longer time to respond. Diplotype analysis revealed similar results. CONCLUSIONS: These findings suggest that variation in the D(2) receptor gene can, in part, explain variation in the timing of clinical response to antipsychotics in patients with first-episode schizophrenia.</text>
      <sentence>
        <offset>0</offset>
        <text>DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">drd2 promoter</infon>
          <location offset="0" length="13"/>
          <text>DRD2 promoter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>137</offset>
        <text>OBJECTIVE: All antipsychotics act on the dopamine D(2) receptor.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="178" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d(2) receptor</infon>
          <location offset="178" length="22"/>
          <text>dopamine D(2) receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>202</offset>
        <text>The present study extends prior pharmacogenetic investigations of the D(2) receptor gene (DRD2) by examining, in first-episode schizophrenia patients, promoter region variation as a predictor of response time to two first-line atypical antipsychotics.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d(2) receptor</infon>
          <location offset="272" length="13"/>
          <text>D(2) receptor</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">drd2</infon>
          <location offset="292" length="4"/>
          <text>DRD2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>454</offset>
        <text>METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (A-241G and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or olanzapine.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="685" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">olanzapine</infon>
          <location offset="700" length="10"/>
          <text>olanzapine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">drd2 promoter</infon>
          <location offset="551" length="13"/>
          <text>DRD2 promoter</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">a-241g</infon>
          <location offset="587" length="6"/>
          <text>A-241G</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>712</offset>
        <text>Time until sustained response (two consecutive ratings without significant positive symptoms) for rare allele carriers versus wild types was examined by using Kaplan-Meier curves.</text>
      </sentence>
      <sentence>
        <offset>892</offset>
        <text>RESULTS: Relative to wild type homozygotes, G carriers (A-241G) exhibited a significantly faster time until response, whereas -141C Del carriers took a significantly longer time to respond.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">a-241g</infon>
          <location offset="948" length="6"/>
          <text>A-241G</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1082</offset>
        <text>Diplotype analysis revealed similar results.</text>
      </sentence>
      <sentence>
        <offset>1127</offset>
        <text>CONCLUSIONS: These findings suggest that variation in the D(2) receptor gene can, in part, explain variation in the timing of clinical response to antipsychotics in patients with first-episode schizophrenia.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d(2) receptor</infon>
          <location offset="1185" length="13"/>
          <text>D(2) receptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23229509</id>
    <passage>
      <offset>0</offset>
      <text>Regions on adenylyl cyclase VII required for selective regulation by the G13 pathway.	Regulation of multiple adenylyl cyclases (AC) provides unique inputs to mediate the synthesis of cAMP, a ubiquitous second messenger that controls many aspects of cellular function. On stimulation by G(s), the activities of ACs can be further selectively modulated by other pathways to ensure precise control of intracellular cAMP responses to specific stimuli. Recently, we reported that one of the AC isoforms, AC7, is uniquely regulated by the G(13) pathway. To understand more fully the molecular mechanism of this regulation, we compared the regulation of AC7 with that of AC2 in bone marrow-derived macrophages devoid of AC7. Although both enzymes could fully restore regulation of cAMP by Gβγ, activation of the G(13) pathway preferentially synergized with AC7. Exchange of domains between the two isoforms indicates that the C1b domain and the N-terminus of the C1a domain are important for directing selective regulation of AC7 by the G(13) pathway. A mutagenesis screen identified more specific regions of AC7 that differentially mediate its regulation by distinct pathways.</text>
      <sentence>
        <offset>0</offset>
        <text>Regions on adenylyl cyclase VII required for selective regulation by the G13 pathway.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenylyl</infon>
          <location offset="11" length="8"/>
          <text>adenylyl</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adenylyl cyclase vii</infon>
          <location offset="11" length="20"/>
          <text>adenylyl cyclase VII</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">g13</infon>
          <location offset="73" length="3"/>
          <text>G13</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>86</offset>
        <text>Regulation of multiple adenylyl cyclases (AC) provides unique inputs to mediate the synthesis of cAMP, a ubiquitous second messenger that controls many aspects of cellular function.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenylyl</infon>
          <location offset="109" length="8"/>
          <text>adenylyl</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="183" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adenylyl cyclases</infon>
          <location offset="109" length="17"/>
          <text>adenylyl cyclases</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ac</infon>
          <location offset="128" length="2"/>
          <text>AC</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>268</offset>
        <text>On stimulation by G(s), the activities of ACs can be further selectively modulated by other pathways to ensure precise control of intracellular cAMP responses to specific stimuli.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="412" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g(s)</infon>
          <location offset="286" length="4"/>
          <text>G(s)</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">acs</infon>
          <location offset="310" length="3"/>
          <text>ACs</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>448</offset>
        <text>Recently, we reported that one of the AC isoforms, AC7, is uniquely regulated by the G(13) pathway.</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ac</infon>
          <location offset="486" length="2"/>
          <text>AC</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ac7</infon>
          <location offset="499" length="3"/>
          <text>AC7</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">g(13)</infon>
          <location offset="533" length="5"/>
          <text>G(13)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>548</offset>
        <text>To understand more fully the molecular mechanism of this regulation, we compared the regulation of AC7 with that of AC2 in bone marrow-derived macrophages devoid of AC7.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ac7</infon>
          <location offset="647" length="3"/>
          <text>AC7</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ac2</infon>
          <location offset="664" length="3"/>
          <text>AC2</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ac7</infon>
          <location offset="713" length="3"/>
          <text>AC7</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>718</offset>
        <text>Although both enzymes could fully restore regulation of cAMP by Gβγ, activation of the G(13) pathway preferentially synergized with AC7.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="774" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gβγ</infon>
          <location offset="782" length="3"/>
          <text>Gβγ</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">g(13)</infon>
          <location offset="805" length="5"/>
          <text>G(13)</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ac7</infon>
          <location offset="850" length="3"/>
          <text>AC7</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>855</offset>
        <text>Exchange of domains between the two isoforms indicates that the C1b domain and the N-terminus of the C1a domain are important for directing selective regulation of AC7 by the G(13) pathway.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="938" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c1b domain</infon>
          <location offset="919" length="10"/>
          <text>C1b domain</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c1a domain</infon>
          <location offset="956" length="10"/>
          <text>C1a domain</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ac7</infon>
          <location offset="1019" length="3"/>
          <text>AC7</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">g(13)</infon>
          <location offset="1030" length="5"/>
          <text>G(13)</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1045</offset>
        <text>A mutagenesis screen identified more specific regions of AC7 that differentially mediate its regulation by distinct pathways.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ac7</infon>
          <location offset="1102" length="3"/>
          <text>AC7</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>14629008</id>
    <passage>
      <offset>0</offset>
      <text>Trimethoprim induces heat shock proteins and protein aggregation in E. coli cells.	Trimethoprim (TMP), an inhibitor of dihydrofolate reductase, decreases the level of tetrahydrofolate supplying one-carbon units for biosynthesis of nucleotides, proteins, and panthotenate. We have demonstrated for the first time that one of the effects of the TMP action in E. coli cells is protein aggregation and induction of heat shock proteins (Hsps). TMP caused induction of DnaK, DnaJ, GroEL, ClpB, and IbpA/B Hsps. Among these Hsps, IbpA/B were most efficiently induced by TMP and coaggregated with the insoluble proteins. Upon folate stress, deletion of the delta ibpA/B operon resulted in increased protein aggregation but did not influence cell viability.</text>
      <sentence>
        <offset>0</offset>
        <text>Trimethoprim induces heat shock proteins and protein aggregation in E. coli cells.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trimethoprim</infon>
          <location offset="0" length="12"/>
          <text>Trimethoprim</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">heat shock proteins</infon>
          <location offset="21" length="19"/>
          <text>heat shock proteins</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>83</offset>
        <text>Trimethoprim (TMP), an inhibitor of dihydrofolate reductase, decreases the level of tetrahydrofolate supplying one-carbon units for biosynthesis of nucleotides, proteins, and panthotenate.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trimethoprim</infon>
          <location offset="83" length="12"/>
          <text>Trimethoprim</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbon</infon>
          <location offset="198" length="6"/>
          <text>carbon</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tmp</infon>
          <location offset="97" length="3"/>
          <text>TMP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleotides</infon>
          <location offset="231" length="11"/>
          <text>nucleotides</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">panthotenate</infon>
          <location offset="258" length="12"/>
          <text>panthotenate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydrofolate</infon>
          <location offset="119" length="13"/>
          <text>dihydrofolate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetrahydrofolate</infon>
          <location offset="167" length="16"/>
          <text>tetrahydrofolate</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dihydrofolate reductase</infon>
          <location offset="119" length="23"/>
          <text>dihydrofolate reductase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>272</offset>
        <text>We have demonstrated for the first time that one of the effects of the TMP action in E. coli cells is protein aggregation and induction of heat shock proteins (Hsps).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tmp</infon>
          <location offset="343" length="3"/>
          <text>TMP</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">heat shock proteins</infon>
          <location offset="411" length="19"/>
          <text>heat shock proteins</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hsps</infon>
          <location offset="432" length="4"/>
          <text>Hsps</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>439</offset>
        <text>TMP caused induction of DnaK, DnaJ, GroEL, ClpB, and IbpA/B Hsps.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tmp</infon>
          <location offset="439" length="3"/>
          <text>TMP</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dnak</infon>
          <location offset="463" length="4"/>
          <text>DnaK</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dnaj</infon>
          <location offset="469" length="4"/>
          <text>DnaJ</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">groel</infon>
          <location offset="475" length="5"/>
          <text>GroEL</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">clpb</infon>
          <location offset="482" length="4"/>
          <text>ClpB</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ibpa/b</infon>
          <location offset="492" length="6"/>
          <text>IbpA/B</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hsps</infon>
          <location offset="499" length="4"/>
          <text>Hsps</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>505</offset>
        <text>Among these Hsps, IbpA/B were most efficiently induced by TMP and coaggregated with the insoluble proteins.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tmp</infon>
          <location offset="563" length="3"/>
          <text>TMP</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hsps</infon>
          <location offset="517" length="4"/>
          <text>Hsps</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ibpa/b</infon>
          <location offset="523" length="6"/>
          <text>IbpA/B</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>613</offset>
        <text>Upon folate stress, deletion of the delta ibpA/B operon resulted in increased protein aggregation but did not influence cell viability.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">folate</infon>
          <location offset="618" length="6"/>
          <text>folate</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ibpa/b</infon>
          <location offset="655" length="6"/>
          <text>ibpA/B</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23169608</id>
    <passage>
      <offset>0</offset>
      <text>Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation.	3-n-Butylphthalide (NBP) is a cardiovascular drug currently used for the treatment of cerebral ischemia. The present study aims to investigate the metabolism, pharmacokinetics, and excretion of NBP in humans and identify the enzymes responsible for the formation of major metabolites. NBP underwent extensive metabolism after an oral administration of 200 mg NBP and 23 metabolites were identified in human plasma and urine. Principal metabolic pathways included hydroxylation on alkyl side chain, particularly at 3-, ω-1-, and ω-carbons, and further oxidation and conjugation. Approximately 81.6% of the dose was recovered in urine, mainly as NBP-11-oic acid (M5-2) and glucuronide conjugates of M5-2 and mono-hydroxylated products. 10-Keto-NBP (M2), 3-hydroxy-NBP (M3-1), 10-hydroxy-NBP (M3-2), and M5-2 were the major circulating metabolites, wherein the areas under the curve values were 1.6-, 2.9-, 10.3-, and 4.1-fold higher than that of NBP. Reference standards of these four metabolites were obtained through microbial biotransformation by Cunninghamella blakesleana. In vitro phenotyping studies demonstrated that multiple cytochrome P450 (P450) isoforms, especially CYP3A4, 2E1, and 1A2, were involved in the formation of M3-1, M3-2, and 11-hydroxy-NBP. Using M3-2 and 11-hydroxy-NBP as substrates, human subcellular fractions experiments revealed that P450, alcohol dehydrogenase, and aldehyde dehydrogenase catalyzed the generation of M2 and M5-2. Formation of M5-2 was much faster than that of M2, and M5-2 can undergo β-oxidation to yield phthalide-3-acetic acid in rat liver homogenate. Overall, our study demonstrated that NBP was well absorbed and extensively metabolized by multiple enzymes to various metabolites prior to urinary excretion.</text>
      <sentence>
        <offset>0</offset>
        <text>Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcohol</infon>
          <location offset="104" length="7"/>
          <text>alcohol</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-n-butylphthalide</infon>
          <location offset="35" length="18"/>
          <text>3-n-butylphthalide</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nbp</infon>
          <location offset="55" length="3"/>
          <text>NBP</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alcohol dehydrogenase</infon>
          <location offset="104" length="21"/>
          <text>alcohol dehydrogenase</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450s</infon>
          <location offset="83" length="16"/>
          <text>cytochrome P450s</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>148</offset>
        <text>3-n-Butylphthalide (NBP) is a cardiovascular drug currently used for the treatment of cerebral ischemia.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-n-butylphthalide</infon>
          <location offset="148" length="18"/>
          <text>3-n-Butylphthalide</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nbp</infon>
          <location offset="168" length="3"/>
          <text>NBP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>253</offset>
        <text>The present study aims to investigate the metabolism, pharmacokinetics, and excretion of NBP in humans and identify the enzymes responsible for the formation of major metabolites.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nbp</infon>
          <location offset="342" length="3"/>
          <text>NBP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>433</offset>
        <text>NBP underwent extensive metabolism after an oral administration of 200 mg NBP and 23 metabolites were identified in human plasma and urine.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nbp</infon>
          <location offset="433" length="3"/>
          <text>NBP</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nbp</infon>
          <location offset="507" length="3"/>
          <text>NBP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>573</offset>
        <text>Principal metabolic pathways included hydroxylation on alkyl side chain, particularly at 3-, ω-1-, and ω-carbons, and further oxidation and conjugation.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alkyl</infon>
          <location offset="628" length="5"/>
          <text>alkyl</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-, ω-1-, and ω-carbons</infon>
          <location offset="662" length="23"/>
          <text>3-, ω-1-, and ω-carbons</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>726</offset>
        <text>Approximately 81.6% of the dose was recovered in urine, mainly as NBP-11-oic acid (M5-2) and glucuronide conjugates of M5-2 and mono-hydroxylated products.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nbp-11-oic acid</infon>
          <location offset="792" length="15"/>
          <text>NBP-11-oic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>882</offset>
        <text>10-Keto-NBP (M2), 3-hydroxy-NBP (M3-1), 10-hydroxy-NBP (M3-2), and M5-2 were the major circulating metabolites, wherein the areas under the curve values were 1.6-, 2.9-, 10.3-, and 4.1-fold higher than that of NBP.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">10-keto-nbp</infon>
          <location offset="882" length="11"/>
          <text>10-Keto-NBP</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-hydroxy-nbp</infon>
          <location offset="900" length="13"/>
          <text>3-hydroxy-NBP</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">10-hydroxy-nbp</infon>
          <location offset="922" length="14"/>
          <text>10-hydroxy-NBP</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nbp</infon>
          <location offset="1092" length="3"/>
          <text>NBP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1097</offset>
        <text>Reference standards of these four metabolites were obtained through microbial biotransformation by Cunninghamella blakesleana.</text>
      </sentence>
      <sentence>
        <offset>1224</offset>
        <text>In vitro phenotyping studies demonstrated that multiple cytochrome P450 (P450) isoforms, especially CYP3A4, 2E1, and 1A2, were involved in the formation of M3-1, M3-2, and 11-hydroxy-NBP.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">11-hydroxy-nbp</infon>
          <location offset="1396" length="14"/>
          <text>11-hydroxy-NBP</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450</infon>
          <location offset="1280" length="15"/>
          <text>cytochrome P450</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p450</infon>
          <location offset="1297" length="4"/>
          <text>P450</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp3a4, 2e1, and 1a2</infon>
          <location offset="1324" length="20"/>
          <text>CYP3A4, 2E1, and 1A2</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1412</offset>
        <text>Using M3-2 and 11-hydroxy-NBP as substrates, human subcellular fractions experiments revealed that P450, alcohol dehydrogenase, and aldehyde dehydrogenase catalyzed the generation of M2 and M5-2.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">11-hydroxy-nbp</infon>
          <location offset="1427" length="14"/>
          <text>11-hydroxy-NBP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcohol</infon>
          <location offset="1517" length="7"/>
          <text>alcohol</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldehyde</infon>
          <location offset="1544" length="8"/>
          <text>aldehyde</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p450</infon>
          <location offset="1511" length="4"/>
          <text>P450</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alcohol dehydrogenase</infon>
          <location offset="1517" length="21"/>
          <text>alcohol dehydrogenase</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldehyde dehydrogenase</infon>
          <location offset="1544" length="22"/>
          <text>aldehyde dehydrogenase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1608</offset>
        <text>Formation of M5-2 was much faster than that of M2, and M5-2 can undergo β-oxidation to yield phthalide-3-acetic acid in rat liver homogenate.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phthalide-3-acetic acid</infon>
          <location offset="1701" length="23"/>
          <text>phthalide-3-acetic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1750</offset>
        <text>Overall, our study demonstrated that NBP was well absorbed and extensively metabolized by multiple enzymes to various metabolites prior to urinary excretion.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nbp</infon>
          <location offset="1787" length="3"/>
          <text>NBP</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23219339</id>
    <passage>
      <offset>0</offset>
      <text>Neuroprotective effects of oxymatrine against excitotoxicity partially through down-regulation of NR2B-containing NMDA receptors.	Oxymatrine (OMT) is a major bioactive component derived from Sophora flavescens Ait (kushen), which is widely used in Chinese medicine. Recent studies have shown that it has neuroprotective effects; however, its underlying mechanisms remain unclear. We focus on the mechanisms of pharmacologic action in OMT by detecting its pharmacological properties against focal cerebral ischemia in vivo and NMDA-induced neurotoxicity in vitro. OMT prevented cerebral ischemic injury in mice induced via a 2 h middle cerebral artery occlusion and a 24 h reperfusion, in vivo. In vitro cultured neurons challenged with N-methyl-D-aspartate (NMDA, 200 μM) for 30 min showed significant decrease in the viability of neurons; however, OMT was able to protect neurons against induced neurotoxicity via NMDA exposure. Western blot analysis revealed that OMT decreased the expression of Bax and repaired the balance of pro- and anti-apoptotic proteins. Furthermore, OMT significantly reversed the up-regulation of NR2B and inhibited the calcium overload in the cultured neurons after challenging the NMDA. OMT showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of Bcl-2 family. Our results provide new insights into the development of natural therapeutic anti-oxidants against ischemia.</text>
      <sentence>
        <offset>0</offset>
        <text>Neuroprotective effects of oxymatrine against excitotoxicity partially through down-regulation of NR2B-containing NMDA receptors.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="114" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymatrine</infon>
          <location offset="27" length="10"/>
          <text>oxymatrine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptors</infon>
          <location offset="114" length="14"/>
          <text>NMDA receptors</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr2b</infon>
          <location offset="98" length="4"/>
          <text>NR2B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>130</offset>
        <text>Oxymatrine (OMT) is a major bioactive component derived from Sophora flavescens Ait (kushen), which is widely used in Chinese medicine.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymatrine</infon>
          <location offset="130" length="10"/>
          <text>Oxymatrine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omt</infon>
          <location offset="142" length="3"/>
          <text>OMT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>266</offset>
        <text>Recent studies have shown that it has neuroprotective effects; however, its underlying mechanisms remain unclear.</text>
      </sentence>
      <sentence>
        <offset>380</offset>
        <text>We focus on the mechanisms of pharmacologic action in OMT by detecting its pharmacological properties against focal cerebral ischemia in vivo and NMDA-induced neurotoxicity in vitro.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omt</infon>
          <location offset="434" length="3"/>
          <text>OMT</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="526" length="4"/>
          <text>NMDA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>563</offset>
        <text>OMT prevented cerebral ischemic injury in mice induced via a 2 h middle cerebral artery occlusion and a 24 h reperfusion, in vivo.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omt</infon>
          <location offset="563" length="3"/>
          <text>OMT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>694</offset>
        <text>In vitro cultured neurons challenged with N-methyl-D-aspartate (NMDA, 200 μM) for 30 min showed significant decrease in the viability of neurons; however, OMT was able to protect neurons against induced neurotoxicity via NMDA exposure.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-methyl-d-aspartate</infon>
          <location offset="736" length="20"/>
          <text>N-methyl-D-aspartate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="758" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omt</infon>
          <location offset="849" length="3"/>
          <text>OMT</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="915" length="4"/>
          <text>NMDA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>930</offset>
        <text>Western blot analysis revealed that OMT decreased the expression of Bax and repaired the balance of pro- and anti-apoptotic proteins.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omt</infon>
          <location offset="966" length="3"/>
          <text>OMT</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="998" length="3"/>
          <text>Bax</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1064</offset>
        <text>Furthermore, OMT significantly reversed the up-regulation of NR2B and inhibited the calcium overload in the cultured neurons after challenging the NMDA.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="1148" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="1211" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omt</infon>
          <location offset="1077" length="3"/>
          <text>OMT</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr2b</infon>
          <location offset="1125" length="4"/>
          <text>NR2B</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1217</offset>
        <text>OMT showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of Bcl-2 family.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omt</infon>
          <location offset="1217" length="3"/>
          <text>OMT</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="1310" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr2b</infon>
          <location offset="1294" length="4"/>
          <text>NR2B</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptors</infon>
          <location offset="1310" length="14"/>
          <text>NMDA receptors</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="1346" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1360</offset>
        <text>Our results provide new insights into the development of natural therapeutic anti-oxidants against ischemia.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17494951</id>
    <passage>
      <offset>0</offset>
      <text>IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells.	Little is known concerning the possible contribution of T helper 2 (Th2)-type cytokines to the recruitment of neutrophils into the lung tissue. In the present study, endothelial cells from equine pulmonary arteries were cultured in the presence of recombinant equine (re) IL-4 and reIL-5, and the cytokine mRNA expression of molecules implicated in the chemotaxis and migration of neutrophils was studied using real-time RT-PCR. The functional response of reIL-4-induced endothelial cell stimulation on neutrophil migration was also studied using a chemotaxis chamber. ReIL-4 either increased the expression of CXCL-8, E-selectin, vascular endothelial growth factor (VEGF), and inducible nitric oxide synthase (iNOS), or potentiated the coeffects of lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha) on CXCL-8. Supernatants collected from cultured endothelial cells stimulated with reIL-4 significantly promoted neutrophil migration in a dose-dependent manner. Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS. DXM and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS. Neither equine nor human recombinant IL-5 influenced the mRNA expression of CXCL-8, E-selectin, or VEGF. These findings suggest that Th2-type cytokines may contribute to pulmonary neutrophilia during allergic inflammation by the increased expression of neutrophil chemokines and adhesion molecules by endothelial cells. DXM and the iNOS inhibitors may decrease pulmonary neutrophilia due, in part, to a direct inhibition of some of these factors.</text>
      <sentence>
        <offset>0</offset>
        <text>IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="74" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-4</infon>
          <location offset="0" length="4"/>
          <text>IL-4</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cxcl-8</infon>
          <location offset="34" length="6"/>
          <text>CXCL-8</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">e-selectin</infon>
          <location offset="42" length="10"/>
          <text>E-selectin</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="54" length="4"/>
          <text>VEGF</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inducible nitric oxide synthase</infon>
          <location offset="64" length="31"/>
          <text>inducible nitric oxide synthase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>147</offset>
        <text>Little is known concerning the possible contribution of T helper 2 (Th2)-type cytokines to the recruitment of neutrophils into the lung tissue.</text>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="225" length="9"/>
          <text>cytokines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>291</offset>
        <text>In the present study, endothelial cells from equine pulmonary arteries were cultured in the presence of recombinant equine (re) IL-4 and reIL-5, and the cytokine mRNA expression of molecules implicated in the chemotaxis and migration of neutrophils was studied using real-time RT-PCR.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">equine (re) il-4</infon>
          <location offset="407" length="16"/>
          <text>equine (re) IL-4</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">reil-5</infon>
          <location offset="428" length="6"/>
          <text>reIL-5</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine</infon>
          <location offset="444" length="8"/>
          <text>cytokine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>576</offset>
        <text>The functional response of reIL-4-induced endothelial cell stimulation on neutrophil migration was also studied using a chemotaxis chamber.</text>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">reil-4</infon>
          <location offset="603" length="6"/>
          <text>reIL-4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>716</offset>
        <text>ReIL-4 either increased the expression of CXCL-8, E-selectin, vascular endothelial growth factor (VEGF), and inducible nitric oxide synthase (iNOS), or potentiated the coeffects of lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha) on CXCL-8.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="835" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">reil-4</infon>
          <location offset="716" length="6"/>
          <text>ReIL-4</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cxcl-8</infon>
          <location offset="758" length="6"/>
          <text>CXCL-8</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">e-selectin</infon>
          <location offset="766" length="10"/>
          <text>E-selectin</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vascular endothelial growth factor</infon>
          <location offset="778" length="34"/>
          <text>vascular endothelial growth factor</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="814" length="4"/>
          <text>VEGF</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inducible nitric oxide synthase</infon>
          <location offset="825" length="31"/>
          <text>inducible nitric oxide synthase</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inos</infon>
          <location offset="858" length="4"/>
          <text>iNOS</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor-alpha</infon>
          <location offset="926" length="27"/>
          <text>tumor necrosis factor-alpha</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="955" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cxcl-8</infon>
          <location offset="969" length="6"/>
          <text>CXCL-8</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>977</offset>
        <text>Supernatants collected from cultured endothelial cells stimulated with reIL-4 significantly promoted neutrophil migration in a dose-dependent manner.</text>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">reil-4</infon>
          <location offset="1048" length="6"/>
          <text>reIL-4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1127</offset>
        <text>Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1400w dihydrochloride</infon>
          <location offset="1223" length="21"/>
          <text>1400W dihydrochloride</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1400w</infon>
          <location offset="1246" length="5"/>
          <text>1400W</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexamethasone</infon>
          <location offset="1127" length="13"/>
          <text>Dexamethasone</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dxm</infon>
          <location offset="1142" length="3"/>
          <text>DXM</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cxcl-8</infon>
          <location offset="1175" length="6"/>
          <text>CXCL-8</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="1183" length="4"/>
          <text>VEGF</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inos</infon>
          <location offset="1193" length="4"/>
          <text>iNOS</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">reil-4</infon>
          <location offset="1209" length="6"/>
          <text>reIL-4</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inos</infon>
          <location offset="1279" length="4"/>
          <text>iNOS</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">e-selectin</infon>
          <location offset="1313" length="10"/>
          <text>E-selectin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="1325" length="4"/>
          <text>VEGF</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inos</infon>
          <location offset="1335" length="4"/>
          <text>iNOS</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1341</offset>
        <text>DXM and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dxm</infon>
          <location offset="1341" length="3"/>
          <text>DXM</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1400w</infon>
          <location offset="1349" length="5"/>
          <text>1400W</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">e-selectin</infon>
          <location offset="1389" length="10"/>
          <text>E-selectin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inos</infon>
          <location offset="1404" length="4"/>
          <text>iNOS</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">reil-4</infon>
          <location offset="1441" length="6"/>
          <text>reIL-4</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">retnf-alpha</infon>
          <location offset="1449" length="11"/>
          <text>reTNF-alpha</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1471</offset>
        <text>Neither equine nor human recombinant IL-5 influenced the mRNA expression of CXCL-8, E-selectin, or VEGF.</text>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">equine nor human recombinant il-5</infon>
          <location offset="1479" length="33"/>
          <text>equine nor human recombinant IL-5</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cxcl-8</infon>
          <location offset="1547" length="6"/>
          <text>CXCL-8</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">e-selectin</infon>
          <location offset="1555" length="10"/>
          <text>E-selectin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="1570" length="4"/>
          <text>VEGF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1576</offset>
        <text>These findings suggest that Th2-type cytokines may contribute to pulmonary neutrophilia during allergic inflammation by the increased expression of neutrophil chemokines and adhesion molecules by endothelial cells.</text>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="1613" length="9"/>
          <text>cytokines</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">chemokines</infon>
          <location offset="1735" length="10"/>
          <text>chemokines</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adhesion molecules</infon>
          <location offset="1750" length="18"/>
          <text>adhesion molecules</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1791</offset>
        <text>DXM and the iNOS inhibitors may decrease pulmonary neutrophilia due, in part, to a direct inhibition of some of these factors.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dxm</infon>
          <location offset="1791" length="3"/>
          <text>DXM</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inos</infon>
          <location offset="1803" length="4"/>
          <text>iNOS</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23523101</id>
    <passage>
      <offset>0</offset>
      <text>Activation of PPARγ is required for hydroxysafflor yellow A of Carthamus tinctorius to attenuate hepatic fibrosis induced by oxidative stress.	Oxidative stress caused hepatic fibrosis by activating hepatic stellate cells (HSCs), which were implemented by depressing PPARγ activation. Hydroxysafflor yellow A (HSYA) as a nature active ingredient with antioxidant capacity was able to effectively attenuate oxidative stress mediated injury. So it will be very interesting to study effect of HSYA on HSCs activation and liver fibrosis, and reveal the role of PPARγ·CCl4 and H2O2 were used to mimic oxidative stress mediated hepatic injury in vitro and in vivo respectively. The anti-fibrosis effects of HSYA were evaluated and its mechanisms were disclosed by applying western blot, histopathological analysis, flow cytometry, RT-PCR and ELISA. Our results showed that HSCs activation and proliferation could be induced by oxidative stress, and the expressive levels of TGF-β1 and TIMP-1, the serum levels of ALT, AST, HA, LN, III-C and IV-C were also enhanced by oxidative stress, which is correlated with liver fibrosis (p&lt;0.05 or p&lt;0.01). HSYA was able to effectively inhibit oxidative stress mediated hepatic injury by increasing the activities of antioxidant enzymes, up regulating the expression of PPARγ and MMP-2, and down regulating the expression of TGF-β1 and TIMP-1, and reducing α-SMA level. The protective effect of HSYA can be significantly attenuated by GW9662 via blocking PPARγ (p&lt;0.05 or p&lt;0.01). Taken together, these results demonstrate that HSYA is able to significantly protect the liver from oxidative stress, which requires for HSYA to stimulate PPARγ activity, reduce cell proliferation and suppress ECM synthesis.</text>
      <sentence>
        <offset>0</offset>
        <text>Activation of PPARγ is required for hydroxysafflor yellow A of Carthamus tinctorius to attenuate hepatic fibrosis induced by oxidative stress.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydroxysafflor yellow a</infon>
          <location offset="36" length="23"/>
          <text>hydroxysafflor yellow A</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparγ</infon>
          <location offset="14" length="5"/>
          <text>PPARγ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>143</offset>
        <text>Oxidative stress caused hepatic fibrosis by activating hepatic stellate cells (HSCs), which were implemented by depressing PPARγ activation.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparγ</infon>
          <location offset="266" length="5"/>
          <text>PPARγ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>284</offset>
        <text>Hydroxysafflor yellow A (HSYA) as a nature active ingredient with antioxidant capacity was able to effectively attenuate oxidative stress mediated injury.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydroxysafflor yellow a</infon>
          <location offset="284" length="23"/>
          <text>Hydroxysafflor yellow A</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hsya</infon>
          <location offset="309" length="4"/>
          <text>HSYA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>439</offset>
        <text>So it will be very interesting to study effect of HSYA on HSCs activation and liver fibrosis, and reveal the role of PPARγ·CCl4 and H2O2 were used to mimic oxidative stress mediated hepatic injury in vitro and in vivo respectively.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hsya</infon>
          <location offset="489" length="4"/>
          <text>HSYA</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl4</infon>
          <location offset="562" length="4"/>
          <text>CCl4</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="571" length="4"/>
          <text>H2O2</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparγ</infon>
          <location offset="556" length="5"/>
          <text>PPARγ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>671</offset>
        <text>The anti-fibrosis effects of HSYA were evaluated and its mechanisms were disclosed by applying western blot, histopathological analysis, flow cytometry, RT-PCR and ELISA.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hsya</infon>
          <location offset="700" length="4"/>
          <text>HSYA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>842</offset>
        <text>Our results showed that HSCs activation and proliferation could be induced by oxidative stress, and the expressive levels of TGF-β1 and TIMP-1, the serum levels of ALT, AST, HA, LN, III-C and IV-C were also enhanced by oxidative stress, which is correlated with liver fibrosis (p&lt;0.05 or p&lt;0.01).</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β1</infon>
          <location offset="967" length="6"/>
          <text>TGF-β1</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">timp-1</infon>
          <location offset="978" length="6"/>
          <text>TIMP-1</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alt</infon>
          <location offset="1006" length="3"/>
          <text>ALT</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ast</infon>
          <location offset="1011" length="3"/>
          <text>AST</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ln</infon>
          <location offset="1020" length="2"/>
          <text>LN</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">iii-c</infon>
          <location offset="1024" length="5"/>
          <text>III-C</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">iv-c</infon>
          <location offset="1034" length="4"/>
          <text>IV-C</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1139</offset>
        <text>HSYA was able to effectively inhibit oxidative stress mediated hepatic injury by increasing the activities of antioxidant enzymes, up regulating the expression of PPARγ and MMP-2, and down regulating the expression of TGF-β1 and TIMP-1, and reducing α-SMA level.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hsya</infon>
          <location offset="1139" length="4"/>
          <text>HSYA</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparγ</infon>
          <location offset="1302" length="5"/>
          <text>PPARγ</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mmp-2</infon>
          <location offset="1312" length="5"/>
          <text>MMP-2</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β1</infon>
          <location offset="1357" length="6"/>
          <text>TGF-β1</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">timp-1</infon>
          <location offset="1368" length="6"/>
          <text>TIMP-1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">α-sma</infon>
          <location offset="1389" length="5"/>
          <text>α-SMA</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1402</offset>
        <text>The protective effect of HSYA can be significantly attenuated by GW9662 via blocking PPARγ (p&lt;0.05 or p&lt;0.01).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hsya</infon>
          <location offset="1427" length="4"/>
          <text>HSYA</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gw9662</infon>
          <location offset="1467" length="6"/>
          <text>GW9662</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparγ</infon>
          <location offset="1487" length="5"/>
          <text>PPARγ</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1513</offset>
        <text>Taken together, these results demonstrate that HSYA is able to significantly protect the liver from oxidative stress, which requires for HSYA to stimulate PPARγ activity, reduce cell proliferation and suppress ECM synthesis.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hsya</infon>
          <location offset="1560" length="4"/>
          <text>HSYA</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hsya</infon>
          <location offset="1650" length="4"/>
          <text>HSYA</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparγ</infon>
          <location offset="1668" length="5"/>
          <text>PPARγ</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23318431</id>
    <passage>
      <offset>0</offset>
      <text>ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.	ErbB2 is frequently highly expressed in premalignant breast cancers, including ductal carcinoma in situ (DCIS); however, little is known about the signals or pathways it contributes to progression into the invasive/malignant state. Radiotherapy is often used to treat early premalignant lesions regardless of ErbB2 status. Here, we show that clinically relevant doses of ionizing radiation (IR)-induce cellular invasion of ErbB2-expressing breast cancer cells, as well as MCF10A cells overexpressing ErbB2. ErbB2-negative breast cancer cells, such as MCF7 and T47D, do not invade following treatment with IR nor do MCF10A cells overexpressing epidermal growth factor receptor. ErbB2 becomes phosphorylated at tyrosine 877 in a dose- and time- dependent manner following exposure to X-rays, and activates downstream signaling cascades including PI3K/Akt. Inhibition of these pathways, as well as inhibition of reactive oxygen species (ROS) with antioxidants, prevents IR-induced invasion. Activation of ErbB2-dependent signaling results in upregulation of the forkhead family transcription factor, FoxM1, and its transcriptional targets, including matrix metalloproteinase 2 (MMP2). Inhibition of FoxM1 by RNA interference prevented induction of invasion by IR, and overexpression of FoxM1 in MCF10A cells was sufficient to promote IR-induced invasion. Moreover, we found that 14-3-3ζ is also upregulated by IR in cancer cells in a ROS-dependent manner, is required for IR-induced invasion in ErbB2-positive breast cancer cells and together with FoxM1 is sufficient for invasion in ErbB2-negative breast cancer cells. Thus, our data show that IR-mediated activation of ErbB2 and induction of 14-3-3ζ collaborate to regulate FoxM1 and promote invasion of breast cancer cells and furthermore, may serve as therapeutic targets to enhance radiosensitivity of breast cancers.Oncogene advance online publication, 14 January 2013; doi:10.1038/onc.2012.629.</text>
      <sentence>
        <offset>0</offset>
        <text>ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb2</infon>
          <location offset="0" length="5"/>
          <text>ErbB2</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">14-3-3ζ</infon>
          <location offset="17" length="7"/>
          <text>14-3-3ζ</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">foxm1</infon>
          <location offset="7" length="5"/>
          <text>FoxM1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>99</offset>
        <text>ErbB2 is frequently highly expressed in premalignant breast cancers, including ductal carcinoma in situ (DCIS); however, little is known about the signals or pathways it contributes to progression into the invasive/malignant state.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb2</infon>
          <location offset="99" length="5"/>
          <text>ErbB2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>331</offset>
        <text>Radiotherapy is often used to treat early premalignant lesions regardless of ErbB2 status.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb2</infon>
          <location offset="408" length="5"/>
          <text>ErbB2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>422</offset>
        <text>Here, we show that clinically relevant doses of ionizing radiation (IR)-induce cellular invasion of ErbB2-expressing breast cancer cells, as well as MCF10A cells overexpressing ErbB2.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb2</infon>
          <location offset="522" length="5"/>
          <text>ErbB2</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb2</infon>
          <location offset="599" length="5"/>
          <text>ErbB2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>606</offset>
        <text>ErbB2-negative breast cancer cells, such as MCF7 and T47D, do not invade following treatment with IR nor do MCF10A cells overexpressing epidermal growth factor receptor.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb2</infon>
          <location offset="606" length="5"/>
          <text>ErbB2</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epidermal growth factor receptor</infon>
          <location offset="742" length="32"/>
          <text>epidermal growth factor receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>776</offset>
        <text>ErbB2 becomes phosphorylated at tyrosine 877 in a dose- and time- dependent manner following exposure to X-rays, and activates downstream signaling cascades including PI3K/Akt.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="808" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb2</infon>
          <location offset="776" length="5"/>
          <text>ErbB2</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="943" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="948" length="3"/>
          <text>Akt</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>953</offset>
        <text>Inhibition of these pathways, as well as inhibition of reactive oxygen species (ROS) with antioxidants, prevents IR-induced invasion.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="1017" length="6"/>
          <text>oxygen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1087</offset>
        <text>Activation of ErbB2-dependent signaling results in upregulation of the forkhead family transcription factor, FoxM1, and its transcriptional targets, including matrix metalloproteinase 2 (MMP2).</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb2</infon>
          <location offset="1101" length="5"/>
          <text>ErbB2</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">forkhead family transcription factor</infon>
          <location offset="1158" length="36"/>
          <text>forkhead family transcription factor</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">foxm1</infon>
          <location offset="1196" length="5"/>
          <text>FoxM1</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">matrix metalloproteinase 2</infon>
          <location offset="1246" length="26"/>
          <text>matrix metalloproteinase 2</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mmp2</infon>
          <location offset="1274" length="4"/>
          <text>MMP2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1281</offset>
        <text>Inhibition of FoxM1 by RNA interference prevented induction of invasion by IR, and overexpression of FoxM1 in MCF10A cells was sufficient to promote IR-induced invasion.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">foxm1</infon>
          <location offset="1295" length="5"/>
          <text>FoxM1</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">foxm1</infon>
          <location offset="1382" length="5"/>
          <text>FoxM1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1451</offset>
        <text>Moreover, we found that 14-3-3ζ is also upregulated by IR in cancer cells in a ROS-dependent manner, is required for IR-induced invasion in ErbB2-positive breast cancer cells and together with FoxM1 is sufficient for invasion in ErbB2-negative breast cancer cells.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">14-3-3ζ</infon>
          <location offset="1475" length="7"/>
          <text>14-3-3ζ</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb2</infon>
          <location offset="1591" length="5"/>
          <text>ErbB2</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">foxm1</infon>
          <location offset="1644" length="5"/>
          <text>FoxM1</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb2</infon>
          <location offset="1680" length="5"/>
          <text>ErbB2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1716</offset>
        <text>Thus, our data show that IR-mediated activation of ErbB2 and induction of 14-3-3ζ collaborate to regulate FoxM1 and promote invasion of breast cancer cells and furthermore, may serve as therapeutic targets to enhance radiosensitivity of breast cancers.Oncogene advance online publication, 14 January 2013; doi:10.1038/onc.2012.629.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb2</infon>
          <location offset="1767" length="5"/>
          <text>ErbB2</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">14-3-3ζ</infon>
          <location offset="1790" length="7"/>
          <text>14-3-3ζ</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">foxm1</infon>
          <location offset="1822" length="5"/>
          <text>FoxM1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22951949</id>
    <passage>
      <offset>0</offset>
      <text>Diethyldithiocarbamate induces apoptosis in neuroblastoma cells by raising the intracellular copper level, triggering cytochrome c release and caspase activation.	Dithiocarbamates are nitrogen- and sulfur-containing compounds commonly used in pharmacology, medicine and agriculture. The molecular effects of dithiocarbamates on neuronal cell systems are not fully understood, especially in terms of their ability to accumulate copper ions inside the cell. In this work, the molecular effects of N,N-diethyldithiocarbamate (DEDTC) were studied in human SH-SY5Y neuroblastoma cells to determine the role of copper in the DEDTC toxicity and the pathway trigged in cell by the complex Cu-DEDTC. From concentration-dependent studies, we found that 5 μM of this compound induced a drastic decrease in viable cells with a concomitant accumulation in intracellular copper resulted from complexation with DEDTC, measured by atomic absorption spectroscopy. The mechanism of DEDTC-induced apoptosis in neuronal model cells is thought to occur through the death receptor signaling triggered by DEDTC-copper complex in low concentration that is associated with the activation of caspase 8. Our results indicated that the mechanism of cell death involves cytochrome c release forming the apoptosome together with Apaf-1 and caspase 9, converting the caspase 9 into its active form, allowing it to activate caspase 3 as observed by immunofluorescence. This pathway is induced by the cytotoxic effects that occur when DEDTC forms a complex with the copper ions present in the culture medium and transports them into the cell, suggesting that the DEDTC by itself was not able to cause cell death and the major effect is from its copper-complex in neuroblastoma cells. The present study suggests a role for the influence of copper by low concentrations of DEDTC in the extracellular media, the absorption and accumulation of copper in the cell and apoptotic events, induced by the cytotoxic effects that occur when DEDTC forms a complex with the copper ions.</text>
      <sentence>
        <offset>0</offset>
        <text>Diethyldithiocarbamate induces apoptosis in neuroblastoma cells by raising the intracellular copper level, triggering cytochrome c release and caspase activation.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diethyldithiocarbamate</infon>
          <location offset="0" length="22"/>
          <text>Diethyldithiocarbamate</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="93" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome c</infon>
          <location offset="118" length="12"/>
          <text>cytochrome c</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">caspase</infon>
          <location offset="143" length="7"/>
          <text>caspase</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T24" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T24" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>163</offset>
        <text>Dithiocarbamates are nitrogen- and sulfur-containing compounds commonly used in pharmacology, medicine and agriculture.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dithiocarbamates</infon>
          <location offset="163" length="16"/>
          <text>Dithiocarbamates</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitrogen</infon>
          <location offset="184" length="8"/>
          <text>nitrogen</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfur</infon>
          <location offset="198" length="6"/>
          <text>sulfur</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>283</offset>
        <text>The molecular effects of dithiocarbamates on neuronal cell systems are not fully understood, especially in terms of their ability to accumulate copper ions inside the cell.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dithiocarbamates</infon>
          <location offset="308" length="16"/>
          <text>dithiocarbamates</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="427" length="6"/>
          <text>copper</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>456</offset>
        <text>In this work, the molecular effects of N,N-diethyldithiocarbamate (DEDTC) were studied in human SH-SY5Y neuroblastoma cells to determine the role of copper in the DEDTC toxicity and the pathway trigged in cell by the complex Cu-DEDTC.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n,n-diethyldithiocarbamate</infon>
          <location offset="495" length="26"/>
          <text>N,N-diethyldithiocarbamate</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dedtc</infon>
          <location offset="523" length="5"/>
          <text>DEDTC</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="605" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dedtc</infon>
          <location offset="619" length="5"/>
          <text>DEDTC</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu-dedtc</infon>
          <location offset="681" length="8"/>
          <text>Cu-DEDTC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>691</offset>
        <text>From concentration-dependent studies, we found that 5 μM of this compound induced a drastic decrease in viable cells with a concomitant accumulation in intracellular copper resulted from complexation with DEDTC, measured by atomic absorption spectroscopy.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="857" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dedtc</infon>
          <location offset="896" length="5"/>
          <text>DEDTC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>947</offset>
        <text>The mechanism of DEDTC-induced apoptosis in neuronal model cells is thought to occur through the death receptor signaling triggered by DEDTC-copper complex in low concentration that is associated with the activation of caspase 8.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dedtc</infon>
          <location offset="964" length="5"/>
          <text>DEDTC</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dedtc-copper</infon>
          <location offset="1082" length="12"/>
          <text>DEDTC-copper</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase 8</infon>
          <location offset="1166" length="9"/>
          <text>caspase 8</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">death receptor</infon>
          <location offset="1044" length="14"/>
          <text>death receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1177</offset>
        <text>Our results indicated that the mechanism of cell death involves cytochrome c release forming the apoptosome together with Apaf-1 and caspase 9, converting the caspase 9 into its active form, allowing it to activate caspase 3 as observed by immunofluorescence.</text>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome c</infon>
          <location offset="1241" length="12"/>
          <text>cytochrome c</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apaf-1</infon>
          <location offset="1299" length="6"/>
          <text>Apaf-1</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase 9</infon>
          <location offset="1310" length="9"/>
          <text>caspase 9</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase 9</infon>
          <location offset="1336" length="9"/>
          <text>caspase 9</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase 3</infon>
          <location offset="1392" length="9"/>
          <text>caspase 3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1437</offset>
        <text>This pathway is induced by the cytotoxic effects that occur when DEDTC forms a complex with the copper ions present in the culture medium and transports them into the cell, suggesting that the DEDTC by itself was not able to cause cell death and the major effect is from its copper-complex in neuroblastoma cells.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dedtc</infon>
          <location offset="1502" length="5"/>
          <text>DEDTC</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="1533" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dedtc</infon>
          <location offset="1630" length="5"/>
          <text>DEDTC</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="1712" length="6"/>
          <text>copper</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1751</offset>
        <text>The present study suggests a role for the influence of copper by low concentrations of DEDTC in the extracellular media, the absorption and accumulation of copper in the cell and apoptotic events, induced by the cytotoxic effects that occur when DEDTC forms a complex with the copper ions.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="1806" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dedtc</infon>
          <location offset="1838" length="5"/>
          <text>DEDTC</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="1907" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dedtc</infon>
          <location offset="1997" length="5"/>
          <text>DEDTC</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="2028" length="6"/>
          <text>copper</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22981737</id>
    <passage>
      <offset>0</offset>
      <text>Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.	Acetylcholinesterase (AChE) at the neuromuscular junction (NMJ) is anchored to the synaptic basal lamina via a triple helical collagen Q (ColQ) in the form of asymmetric AChE (AChE/ColQ). The C-terminal domain of ColQ binds to MuSK, the muscle-specific receptor tyrosine kinase, that mediates a signal for acetylcholine receptor (AChR) clustering at the NMJ. ColQ also binds to heparan sulfate proteoglycans including perlecan. Congenital defects of ColQ cause endplate AChE deficiency. A single intravenous administration of adeno-associated virus serotype 8 (AAV8)-COLQ to Colq-/- mice rescued motor functions, synaptic transmission, and the ultrastructure of NMJ. We also injected AAV1-COLQ-IRES-EGFP to the left tibialis anterior and observed colocalization of AChE/ColQ at all the examined NMJs of the non-injected limbs. Additionally, injection of purified recombinant AChE/ColQ protein complex into gluteus maximus accumulated AChE in non-injected forelimbs. These observations suggest that the tissue-targeting signal of ColQ can be exploited to specifically deliver the transgene product to the target tissue. MuSK antibody-positive myasthenia gravis (MG) accounts for 5-15% of autoimmune MG. As AChR deficiency is typically mild and as cholinesterase inhibitors are generally ineffective or worsen myasthenic symptoms, we asked if the patient's MuSK-IgG interferes with binding of ColQ to MuSK. In vitro overlay of AChE/ColQ to muscle sections of Colq-/- mice revealed that MuSK-IgG blocks binding of ColQ to the NMJ. In vitro plate-binding of MuSK to ColQ disclosed that MuSK-IgG exerts a dose-dependent block of MuSK-ColQ interaction. In addition, passive transfer of MuSK-IgG to mice reduced the size and density of ColQ to ∼10% of controls and had a lesser effect on the sizes and densities of AChR and MuSK. Elucidation of molecular mechanisms of specific binding of ColQ to the NMJ enabled us to ameliorate devastating myasthenic symptoms of Colq-/- mice and to reveal bases of anti-MuSK MG.</text>
      <sentence>
        <offset>0</offset>
        <text>Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.</text>
        <annotation id="T53">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">collagen q</infon>
          <location offset="20" length="10"/>
          <text>collagen Q</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>147</offset>
        <text>Acetylcholinesterase (AChE) at the neuromuscular junction (NMJ) is anchored to the synaptic basal lamina via a triple helical collagen Q (ColQ) in the form of asymmetric AChE (AChE/ColQ).</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="147" length="20"/>
          <text>Acetylcholinesterase</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">collagen q</infon>
          <location offset="273" length="10"/>
          <text>collagen Q</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="285" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="317" length="4"/>
          <text>AChE</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="323" length="4"/>
          <text>AChE</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="328" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="169" length="4"/>
          <text>AChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>335</offset>
        <text>The C-terminal domain of ColQ binds to MuSK, the muscle-specific receptor tyrosine kinase, that mediates a signal for acetylcholine receptor (AChR) clustering at the NMJ.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c</infon>
          <location offset="339" length="1"/>
          <text>C</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="409" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="453" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="360" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">musk</infon>
          <location offset="374" length="4"/>
          <text>MuSK</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">receptor tyrosine kinase</infon>
          <location offset="400" length="24"/>
          <text>receptor tyrosine kinase</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">acetylcholine receptor</infon>
          <location offset="453" length="22"/>
          <text>acetylcholine receptor</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">achr</infon>
          <location offset="477" length="4"/>
          <text>AChR</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>506</offset>
        <text>ColQ also binds to heparan sulfate proteoglycans including perlecan.</text>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="506" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">heparan sulfate proteoglycans</infon>
          <location offset="525" length="29"/>
          <text>heparan sulfate proteoglycans</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">perlecan</infon>
          <location offset="565" length="8"/>
          <text>perlecan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>575</offset>
        <text>Congenital defects of ColQ cause endplate AChE deficiency.</text>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="597" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="617" length="4"/>
          <text>AChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>634</offset>
        <text>A single intravenous administration of adeno-associated virus serotype 8 (AAV8)-COLQ to Colq-/- mice rescued motor functions, synaptic transmission, and the ultrastructure of NMJ.</text>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="714" length="4"/>
          <text>COLQ</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="722" length="4"/>
          <text>Colq</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>814</offset>
        <text>We also injected AAV1-COLQ-IRES-EGFP to the left tibialis anterior and observed colocalization of AChE/ColQ at all the examined NMJs of the non-injected limbs.</text>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="836" length="4"/>
          <text>COLQ</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ires</infon>
          <location offset="841" length="4"/>
          <text>IRES</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="912" length="4"/>
          <text>AChE</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="917" length="4"/>
          <text>ColQ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>974</offset>
        <text>Additionally, injection of purified recombinant AChE/ColQ protein complex into gluteus maximus accumulated AChE in non-injected forelimbs.</text>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="1022" length="4"/>
          <text>AChE</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="1027" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="1081" length="4"/>
          <text>AChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1113</offset>
        <text>These observations suggest that the tissue-targeting signal of ColQ can be exploited to specifically deliver the transgene product to the target tissue.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="1176" length="4"/>
          <text>ColQ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1266</offset>
        <text>MuSK antibody-positive myasthenia gravis (MG) accounts for 5-15% of autoimmune MG.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">musk</infon>
          <location offset="1266" length="4"/>
          <text>MuSK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1349</offset>
        <text>As AChR deficiency is typically mild and as cholinesterase inhibitors are generally ineffective or worsen myasthenic symptoms, we asked if the patient's MuSK-IgG interferes with binding of ColQ to MuSK.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">achr</infon>
          <location offset="1352" length="4"/>
          <text>AChR</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cholinesterase</infon>
          <location offset="1393" length="14"/>
          <text>cholinesterase</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">musk</infon>
          <location offset="1502" length="4"/>
          <text>MuSK</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="1538" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">musk</infon>
          <location offset="1546" length="4"/>
          <text>MuSK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1552</offset>
        <text>In vitro overlay of AChE/ColQ to muscle sections of Colq-/- mice revealed that MuSK-IgG blocks binding of ColQ to the NMJ.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="1577" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="1604" length="4"/>
          <text>Colq</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="1658" length="4"/>
          <text>ColQ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1675</offset>
        <text>In vitro plate-binding of MuSK to ColQ disclosed that MuSK-IgG exerts a dose-dependent block of MuSK-ColQ interaction.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="1709" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">musk</infon>
          <location offset="1729" length="4"/>
          <text>MuSK</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">igg</infon>
          <location offset="1734" length="3"/>
          <text>IgG</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">musk</infon>
          <location offset="1771" length="4"/>
          <text>MuSK</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="1776" length="4"/>
          <text>ColQ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1794</offset>
        <text>In addition, passive transfer of MuSK-IgG to mice reduced the size and density of ColQ to ∼10% of controls and had a lesser effect on the sizes and densities of AChR and MuSK.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">musk</infon>
          <location offset="1827" length="4"/>
          <text>MuSK</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">igg</infon>
          <location offset="1832" length="3"/>
          <text>IgG</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="1876" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">achr</infon>
          <location offset="1955" length="4"/>
          <text>AChR</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">musk</infon>
          <location offset="1964" length="4"/>
          <text>MuSK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1970</offset>
        <text>Elucidation of molecular mechanisms of specific binding of ColQ to the NMJ enabled us to ameliorate devastating myasthenic symptoms of Colq-/- mice and to reveal bases of anti-MuSK MG.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="2029" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="2105" length="4"/>
          <text>Colq</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">musk</infon>
          <location offset="2146" length="4"/>
          <text>MuSK</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23454202</id>
    <passage>
      <offset>0</offset>
      <text>Curcumin loaded solid lipid nanoparticles: An efficient formulation approach for cerebral ischemic reperfusion injury in rats.	SCOPE: To evaluate curcumin loaded solid lipid nanoparticles (C-SLNs) in the experimental paradigm of cerebral ischemia (BCCAO model) in rats. METHODS AND RESULTS: Oral administration of free curcumin and C-SLNs (25 and 50mg/kg) was started 5days prior and continued for 3days after BCCAO. Alleviation in behavioral, oxidative and nitrosative stress, acetylcholinesterase, mitochondrial enzyme complexes, and physiological parameters were assessed. Confirmation of effective brain delivery of C-SLNs (p.o) was done using biodistribution studies in mice and confocal microscopy of rat brain section. There was an improvement of 90% in cognition and 52% inhibition of acetylcholinesterase versus cerebral ischemic group (I/R). Neurological scoring improved by 79%. Levels of superoxide dismutase, catalase, glutathione, and mitochondrial complex enzyme activities were significantly increased, while lipid peroxidation, nitrite, and acetylcholinesterase levels decreased (p&lt;0.05) after C-SLNs administration. It is noteworthy to report the restoration of SOD, GSH, catalase, and mitochondrial complex enzyme levels equivalent to sham control values. Gamma-scintigraphic studies show 16.4 and 30 times improvement in brain bioavailability (AUC) upon oral and i.v administration of C-SLNs versus solubilized curcumin (C-S). CONCLUSIONS: Study indicates protective role of curcumin against cerebral ischemic insult; provided it is packaged suitably for improved brain delivery.</text>
      <sentence>
        <offset>0</offset>
        <text>Curcumin loaded solid lipid nanoparticles: An efficient formulation approach for cerebral ischemic reperfusion injury in rats.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">curcumin</infon>
          <location offset="0" length="8"/>
          <text>Curcumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>127</offset>
        <text>SCOPE: To evaluate curcumin loaded solid lipid nanoparticles (C-SLNs) in the experimental paradigm of cerebral ischemia (BCCAO model) in rats.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">curcumin</infon>
          <location offset="146" length="8"/>
          <text>curcumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>270</offset>
        <text>METHODS AND RESULTS: Oral administration of free curcumin and C-SLNs (25 and 50mg/kg) was started 5days prior and continued for 3days after BCCAO.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">curcumin</infon>
          <location offset="319" length="8"/>
          <text>curcumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>417</offset>
        <text>Alleviation in behavioral, oxidative and nitrosative stress, acetylcholinesterase, mitochondrial enzyme complexes, and physiological parameters were assessed.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="478" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>576</offset>
        <text>Confirmation of effective brain delivery of C-SLNs (p.o) was done using biodistribution studies in mice and confocal microscopy of rat brain section.</text>
      </sentence>
      <sentence>
        <offset>726</offset>
        <text>There was an improvement of 90% in cognition and 52% inhibition of acetylcholinesterase versus cerebral ischemic group (I/R).</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="793" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>852</offset>
        <text>Neurological scoring improved by 79%.</text>
      </sentence>
      <sentence>
        <offset>890</offset>
        <text>Levels of superoxide dismutase, catalase, glutathione, and mitochondrial complex enzyme activities were significantly increased, while lipid peroxidation, nitrite, and acetylcholinesterase levels decreased (p&lt;0.05) after C-SLNs administration.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="900" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="932" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitrite</infon>
          <location offset="1045" length="7"/>
          <text>nitrite</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">superoxide dismutase</infon>
          <location offset="900" length="20"/>
          <text>superoxide dismutase</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catalase</infon>
          <location offset="922" length="8"/>
          <text>catalase</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mitochondrial complex</infon>
          <location offset="949" length="21"/>
          <text>mitochondrial complex</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="1058" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1134</offset>
        <text>It is noteworthy to report the restoration of SOD, GSH, catalase, and mitochondrial complex enzyme levels equivalent to sham control values.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="1185" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sod</infon>
          <location offset="1180" length="3"/>
          <text>SOD</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catalase</infon>
          <location offset="1190" length="8"/>
          <text>catalase</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mitochondrial complex</infon>
          <location offset="1204" length="21"/>
          <text>mitochondrial complex</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1275</offset>
        <text>Gamma-scintigraphic studies show 16.4 and 30 times improvement in brain bioavailability (AUC) upon oral and i.v administration of C-SLNs versus solubilized curcumin (C-S).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">curcumin</infon>
          <location offset="1431" length="8"/>
          <text>curcumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1447</offset>
        <text>CONCLUSIONS: Study indicates protective role of curcumin against cerebral ischemic insult; provided it is packaged suitably for improved brain delivery.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">curcumin</infon>
          <location offset="1495" length="8"/>
          <text>curcumin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1983158</id>
    <passage>
      <offset>0</offset>
      <text>H1- and H2-histamine receptor blockers and opiate analgesia in mice.	In this paper, the interactions between opiates and antihistaminic compounds, both H1- and H2-blockers, were studied. CD1 mice were used, treated with saline, morphine CHl (5 mg/kg), and 1 or 10 mg/kg of the H1-antihistaminics tripelennamine, chlorpheniramine, diphenhydramine and cyclizine and the H2-antihistaminics ranitidine and cimetidine, all compounds by s.c. route. Using the hot-plate test, it was observed that the two doses of tripelennamine and the higher doses of chlorpheniramine and cimetidine had antinociceptive activity. This increase on analgesia was also observed after chronic treatment with all H1-antihistaminics (10 mg/kg, 3 times daily for 4 days). When antihistaminics were administered with morphine, it was observed that only ranitidine (10 mg/kg) blocked opiate analgesia. On the other hand, previous administration of the opiate antagonist naloxone (1 mg/kg) blocked the antinociceptive action of tripelennamine and chlorpheniramine (10 mg/kg) in control mice. In morphine-dependent mice (by s.c. implantation of a 75-mg morphine pellet), a single injection of diphenhydramine or ranitidine blocked the analgesic action of morphine. Chronic administration of all antihistaminics did not modify morphine analgesia. These data are discussed in relation to the possible binding to the opioid receptors by antihistaminics and their facility in crossing the blood-brain barrier.</text>
      <sentence>
        <offset>0</offset>
        <text>H1- and H2-histamine receptor blockers and opiate analgesia in mice.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="11" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">h1- and h2-histamine receptor</infon>
          <location offset="0" length="29"/>
          <text>H1- and H2-histamine receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>69</offset>
        <text>In this paper, the interactions between opiates and antihistaminic compounds, both H1- and H2-blockers, were studied.</text>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">h1- and h2</infon>
          <location offset="152" length="10"/>
          <text>H1- and H2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>187</offset>
        <text>CD1 mice were used, treated with saline, morphine CHl (5 mg/kg), and 1 or 10 mg/kg of the H1-antihistaminics tripelennamine, chlorpheniramine, diphenhydramine and cyclizine and the H2-antihistaminics ranitidine and cimetidine, all compounds by s.c. route.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="228" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tripelennamine</infon>
          <location offset="296" length="14"/>
          <text>tripelennamine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpheniramine</infon>
          <location offset="312" length="16"/>
          <text>chlorpheniramine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diphenhydramine</infon>
          <location offset="330" length="15"/>
          <text>diphenhydramine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclizine</infon>
          <location offset="350" length="9"/>
          <text>cyclizine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ranitidine</infon>
          <location offset="387" length="10"/>
          <text>ranitidine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cimetidine</infon>
          <location offset="402" length="10"/>
          <text>cimetidine</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h1</infon>
          <location offset="277" length="2"/>
          <text>H1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h2</infon>
          <location offset="368" length="2"/>
          <text>H2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>443</offset>
        <text>Using the hot-plate test, it was observed that the two doses of tripelennamine and the higher doses of chlorpheniramine and cimetidine had antinociceptive activity.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tripelennamine</infon>
          <location offset="507" length="14"/>
          <text>tripelennamine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpheniramine</infon>
          <location offset="546" length="16"/>
          <text>chlorpheniramine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cimetidine</infon>
          <location offset="567" length="10"/>
          <text>cimetidine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>608</offset>
        <text>This increase on analgesia was also observed after chronic treatment with all H1-antihistaminics (10 mg/kg, 3 times daily for 4 days).</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h1</infon>
          <location offset="686" length="2"/>
          <text>H1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>743</offset>
        <text>When antihistaminics were administered with morphine, it was observed that only ranitidine (10 mg/kg) blocked opiate analgesia.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="787" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ranitidine</infon>
          <location offset="823" length="10"/>
          <text>ranitidine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>871</offset>
        <text>On the other hand, previous administration of the opiate antagonist naloxone (1 mg/kg) blocked the antinociceptive action of tripelennamine and chlorpheniramine (10 mg/kg) in control mice.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">naloxone</infon>
          <location offset="939" length="8"/>
          <text>naloxone</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tripelennamine</infon>
          <location offset="996" length="14"/>
          <text>tripelennamine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpheniramine</infon>
          <location offset="1015" length="16"/>
          <text>chlorpheniramine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1060</offset>
        <text>In morphine-dependent mice (by s.c. implantation of a 75-mg morphine pellet), a single injection of diphenhydramine or ranitidine blocked the analgesic action of morphine.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="1120" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diphenhydramine</infon>
          <location offset="1160" length="15"/>
          <text>diphenhydramine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ranitidine</infon>
          <location offset="1179" length="10"/>
          <text>ranitidine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="1222" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="1063" length="8"/>
          <text>morphine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1232</offset>
        <text>Chronic administration of all antihistaminics did not modify morphine analgesia.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="1293" length="8"/>
          <text>morphine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1313</offset>
        <text>These data are discussed in relation to the possible binding to the opioid receptors by antihistaminics and their facility in crossing the blood-brain barrier.</text>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">opioid receptors</infon>
          <location offset="1381" length="16"/>
          <text>opioid receptors</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23229512</id>
    <passage>
      <offset>0</offset>
      <text>Vitamin K2 covalently binds to Bak and induces Bak-mediated apoptosis.	Vitamin K2 (VK2, menaquinone) is known to have anticancer activity in vitro and in vivo. Although its effect is thought to be mediated, at least in part, by the induction of apoptosis, the underlying molecular mechanism remains elusive. Here, we identified Bcl-2 antagonist killer 1 (Bak) as a molecular target of VK2-induced apoptosis. VK2 directly interacts with Bak and induces mitochondrial-mediated apoptosis. Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2-induced cytochrome c (cyt c) release and cell death. Moreover, VK2-2,3 epoxide, an intracellular metabolite of VK2, was shown to covalently bind to the cysteine-166 residue of Bak. Several lines of evidence suggested that the covalent attachment of VK2 is critical for apoptosis induction. Thus this study reveals a specific role for Bak in mitochondria-mediated apoptosis. This study also provides insight into the anticancer effects of VK2 and suggests that Bak may be a potential target of cancer therapy.</text>
      <sentence>
        <offset>0</offset>
        <text>Vitamin K2 covalently binds to Bak and induces Bak-mediated apoptosis.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin k2</infon>
          <location offset="0" length="10"/>
          <text>Vitamin K2</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bak</infon>
          <location offset="31" length="3"/>
          <text>Bak</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bak</infon>
          <location offset="47" length="3"/>
          <text>Bak</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>71</offset>
        <text>Vitamin K2 (VK2, menaquinone) is known to have anticancer activity in vitro and in vivo.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin k2</infon>
          <location offset="71" length="10"/>
          <text>Vitamin K2</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vk2</infon>
          <location offset="83" length="3"/>
          <text>VK2</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">menaquinone</infon>
          <location offset="88" length="11"/>
          <text>menaquinone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>160</offset>
        <text>Although its effect is thought to be mediated, at least in part, by the induction of apoptosis, the underlying molecular mechanism remains elusive.</text>
      </sentence>
      <sentence>
        <offset>308</offset>
        <text>Here, we identified Bcl-2 antagonist killer 1 (Bak) as a molecular target of VK2-induced apoptosis.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vk2</infon>
          <location offset="385" length="3"/>
          <text>VK2</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="328" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bak</infon>
          <location offset="355" length="3"/>
          <text>Bak</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>408</offset>
        <text>VK2 directly interacts with Bak and induces mitochondrial-mediated apoptosis.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vk2</infon>
          <location offset="408" length="3"/>
          <text>VK2</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bak</infon>
          <location offset="436" length="3"/>
          <text>Bak</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>486</offset>
        <text>Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2-induced cytochrome c (cyt c) release and cell death.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vk2</infon>
          <location offset="666" length="3"/>
          <text>VK2</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bak</infon>
          <location offset="495" length="3"/>
          <text>Bak</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2-associated x protein</infon>
          <location offset="503" length="26"/>
          <text>Bcl-2-associated X protein</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="531" length="3"/>
          <text>Bax</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="559" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bak</infon>
          <location offset="630" length="3"/>
          <text>Bak</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome c</infon>
          <location offset="678" length="12"/>
          <text>cytochrome c</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyt c</infon>
          <location offset="692" length="5"/>
          <text>cyt c</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>723</offset>
        <text>Moreover, VK2-2,3 epoxide, an intracellular metabolite of VK2, was shown to covalently bind to the cysteine-166 residue of Bak.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vk2-2,3 epoxide</infon>
          <location offset="733" length="15"/>
          <text>VK2-2,3 epoxide</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vk2</infon>
          <location offset="781" length="3"/>
          <text>VK2</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteine</infon>
          <location offset="822" length="8"/>
          <text>cysteine</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bak</infon>
          <location offset="846" length="3"/>
          <text>Bak</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>851</offset>
        <text>Several lines of evidence suggested that the covalent attachment of VK2 is critical for apoptosis induction.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vk2</infon>
          <location offset="919" length="3"/>
          <text>VK2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>960</offset>
        <text>Thus this study reveals a specific role for Bak in mitochondria-mediated apoptosis.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bak</infon>
          <location offset="1004" length="3"/>
          <text>Bak</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1044</offset>
        <text>This study also provides insight into the anticancer effects of VK2 and suggests that Bak may be a potential target of cancer therapy.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vk2</infon>
          <location offset="1108" length="3"/>
          <text>VK2</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bak</infon>
          <location offset="1130" length="3"/>
          <text>Bak</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23052195</id>
    <passage>
      <offset>0</offset>
      <text>Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and c-AMP response element-binding protein in phenylpropanolamine-treated rats.	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression. Here, we investigated whether Y1 receptor (Y1R) might be involved in this regulation. Rats were daily treated with PPA for 4 days. Changes in the contents of NPY, Y1R, glutathione peroxidase (GP), and CREB were assessed and compared. Results showed that Y1R, GP, and CREB increased, with a maximal increase about 100, 200, and 150 %, respectively, on Day 2. By contrast, NPY decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during PPA treatment was opposite to those of Y1R, GP, and CREB. Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of PPA and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of Y1R in regulating NPY, GP, and CREB. These results suggest that Y1R participates in the reciprocal regulation of NPY, GP, and CREB in the hypothalamus during PPA treatment in conscious rats. The present results may aid the therapeutic research of PPA and related antiobesity drugs.</text>
      <sentence>
        <offset>0</offset>
        <text>Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and c-AMP response element-binding protein in phenylpropanolamine-treated rats.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenylpropanolamine</infon>
          <location offset="117" length="19"/>
          <text>phenylpropanolamine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="48" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c-amp</infon>
          <location offset="75" length="5"/>
          <text>c-AMP</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuropeptide y y1 receptor</infon>
          <location offset="0" length="26"/>
          <text>Neuropeptide Y Y1 receptor</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathione peroxidase</infon>
          <location offset="48" length="22"/>
          <text>glutathione peroxidase</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c-amp response element-binding protein</infon>
          <location offset="75" length="38"/>
          <text>c-AMP response element-binding protein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>151</offset>
        <text>It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenylpropanolamine</infon>
          <location offset="299" length="19"/>
          <text>phenylpropanolamine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ppa</infon>
          <location offset="320" length="3"/>
          <text>PPA</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c-amp</infon>
          <location offset="226" length="5"/>
          <text>c-AMP</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="266" length="4"/>
          <text>CREB</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuropeptide y</infon>
          <location offset="200" length="14"/>
          <text>neuropeptide Y</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">npy</infon>
          <location offset="216" length="3"/>
          <text>NPY</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c-amp response element-binding protein</infon>
          <location offset="226" length="38"/>
          <text>c-AMP response element-binding protein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>356</offset>
        <text>Here, we investigated whether Y1 receptor (Y1R) might be involved in this regulation.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">y1 receptor</infon>
          <location offset="386" length="11"/>
          <text>Y1 receptor</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">y1r</infon>
          <location offset="399" length="3"/>
          <text>Y1R</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>442</offset>
        <text>Rats were daily treated with PPA for 4 days.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ppa</infon>
          <location offset="471" length="3"/>
          <text>PPA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>487</offset>
        <text>Changes in the contents of NPY, Y1R, glutathione peroxidase (GP), and CREB were assessed and compared.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="524" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">npy</infon>
          <location offset="514" length="3"/>
          <text>NPY</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">y1r</infon>
          <location offset="519" length="3"/>
          <text>Y1R</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathione peroxidase</infon>
          <location offset="524" length="22"/>
          <text>glutathione peroxidase</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gp</infon>
          <location offset="548" length="2"/>
          <text>GP</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="557" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>590</offset>
        <text>Results showed that Y1R, GP, and CREB increased, with a maximal increase about 100, 200, and 150 %, respectively, on Day 2.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">y1r</infon>
          <location offset="610" length="3"/>
          <text>Y1R</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gp</infon>
          <location offset="615" length="2"/>
          <text>GP</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="623" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>714</offset>
        <text>By contrast, NPY decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during PPA treatment was opposite to those of Y1R, GP, and CREB.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ppa</infon>
          <location offset="823" length="3"/>
          <text>PPA</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">npy</infon>
          <location offset="727" length="3"/>
          <text>NPY</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">y1r</infon>
          <location offset="862" length="3"/>
          <text>Y1R</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gp</infon>
          <location offset="867" length="2"/>
          <text>GP</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="875" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>881</offset>
        <text>Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of PPA and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of Y1R in regulating NPY, GP, and CREB.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ppa</infon>
          <location offset="1004" length="3"/>
          <text>PPA</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">y1r</infon>
          <location offset="953" length="3"/>
          <text>Y1R</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">npy</infon>
          <location offset="1046" length="3"/>
          <text>NPY</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gp</infon>
          <location offset="1054" length="2"/>
          <text>GP</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="1061" length="4"/>
          <text>CREB</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">y1r</infon>
          <location offset="1099" length="3"/>
          <text>Y1R</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">npy</infon>
          <location offset="1117" length="3"/>
          <text>NPY</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gp</infon>
          <location offset="1122" length="2"/>
          <text>GP</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="1130" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1136</offset>
        <text>These results suggest that Y1R participates in the reciprocal regulation of NPY, GP, and CREB in the hypothalamus during PPA treatment in conscious rats.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ppa</infon>
          <location offset="1257" length="3"/>
          <text>PPA</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">y1r</infon>
          <location offset="1163" length="3"/>
          <text>Y1R</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">npy</infon>
          <location offset="1212" length="3"/>
          <text>NPY</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gp</infon>
          <location offset="1217" length="2"/>
          <text>GP</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="1225" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1290</offset>
        <text>The present results may aid the therapeutic research of PPA and related antiobesity drugs.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ppa</infon>
          <location offset="1346" length="3"/>
          <text>PPA</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>8827452</id>
    <passage>
      <offset>0</offset>
      <text>Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator.	A novel hyaluronan-binding protein (PHBP) was purified from human plasma by affinity chromatography on hyaluronan-conjugated Sepharose. The contaminating IgM and albumin in the partially purified preparation were removed with anti-IgG antibody-conjugated Sepharose and anti-albumin antibody-conjugated Sepharose, respectively, and no other contaminant was observed. Finally, 800 micrograms of PHBP was isolated from 500 ml of human plasma. PHBP gave a single 70-kDa band on SDS-PAGE under non-reducing conditions, and 50-kDa and 17-kDa bands under reducing conditions. Thus, PHBP was a heterodimer composed of 50-kDa and 17-kDa subunits, bridged by a disulfide linkage. Both subunits had novel N-terminal amino acid sequences, indicating that PHBP was a novel hyaluronan-binding protein in human plasma. The amino acid sequence deduced from the nucleotide sequence of the cloned PHBP cDNA exhibited significant homology to that of hepatocyte growth factor activator (HGFA). The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA. The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.</text>
      <sentence>
        <offset>0</offset>
        <text>Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="132" length="6"/>
          <text>serine</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serine protease domain</infon>
          <location offset="132" length="22"/>
          <text>serine protease domain</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hyaluronan-binding protein</infon>
          <location offset="45" length="26"/>
          <text>hyaluronan-binding protein</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phbp</infon>
          <location offset="73" length="4"/>
          <text>PHBP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>203</offset>
        <text>A novel hyaluronan-binding protein (PHBP) was purified from human plasma by affinity chromatography on hyaluronan-conjugated Sepharose.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phbp</infon>
          <location offset="239" length="4"/>
          <text>PHBP</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hyaluronan-binding protein</infon>
          <location offset="211" length="26"/>
          <text>hyaluronan-binding protein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>339</offset>
        <text>The contaminating IgM and albumin in the partially purified preparation were removed with anti-IgG antibody-conjugated Sepharose and anti-albumin antibody-conjugated Sepharose, respectively, and no other contaminant was observed.</text>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">igm</infon>
          <location offset="357" length="3"/>
          <text>IgM</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">albumin</infon>
          <location offset="365" length="7"/>
          <text>albumin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">igg</infon>
          <location offset="434" length="3"/>
          <text>IgG</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">albumin</infon>
          <location offset="477" length="7"/>
          <text>albumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>569</offset>
        <text>Finally, 800 micrograms of PHBP was isolated from 500 ml of human plasma.</text>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phbp</infon>
          <location offset="596" length="4"/>
          <text>PHBP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>643</offset>
        <text>PHBP gave a single 70-kDa band on SDS-PAGE under non-reducing conditions, and 50-kDa and 17-kDa bands under reducing conditions.</text>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phbp</infon>
          <location offset="643" length="4"/>
          <text>PHBP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>772</offset>
        <text>Thus, PHBP was a heterodimer composed of 50-kDa and 17-kDa subunits, bridged by a disulfide linkage.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">disulfide</infon>
          <location offset="854" length="9"/>
          <text>disulfide</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phbp</infon>
          <location offset="778" length="4"/>
          <text>PHBP</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>873</offset>
        <text>Both subunits had novel N-terminal amino acid sequences, indicating that PHBP was a novel hyaluronan-binding protein in human plasma.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-terminal amino acid</infon>
          <location offset="897" length="21"/>
          <text>N-terminal amino acid</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phbp</infon>
          <location offset="946" length="4"/>
          <text>PHBP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1007</offset>
        <text>The amino acid sequence deduced from the nucleotide sequence of the cloned PHBP cDNA exhibited significant homology to that of hepatocyte growth factor activator (HGFA).</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="1011" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleotide</infon>
          <location offset="1048" length="10"/>
          <text>nucleotide</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phbp</infon>
          <location offset="1082" length="4"/>
          <text>PHBP</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hepatocyte growth factor activator</infon>
          <location offset="1134" length="34"/>
          <text>hepatocyte growth factor activator</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hgfa</infon>
          <location offset="1170" length="4"/>
          <text>HGFA</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T7" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1177</offset>
        <text>The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phbp</infon>
          <location offset="1268" length="4"/>
          <text>PHBP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1279</offset>
        <text>The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="1386" length="6"/>
          <text>serine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="1419" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="1562" length="6"/>
          <text>serine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="1595" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phbp</infon>
          <location offset="1306" length="4"/>
          <text>PHBP</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epidermal growth factor (egf) domains</infon>
          <location offset="1324" length="37"/>
          <text>epidermal growth factor (EGF) domains</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kringle domain</infon>
          <location offset="1365" length="14"/>
          <text>kringle domain</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serine protease domain</infon>
          <location offset="1386" length="22"/>
          <text>serine protease domain</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hgfa</infon>
          <location offset="1440" length="4"/>
          <text>HGFA</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fibronectin type ii domain</infon>
          <location offset="1451" length="26"/>
          <text>fibronectin type II domain</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">egf domain</infon>
          <location offset="1482" length="10"/>
          <text>EGF domain</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fibronectin type i domain</infon>
          <location offset="1496" length="25"/>
          <text>fibronectin type I domain</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">egf domain</infon>
          <location offset="1526" length="10"/>
          <text>EGF domain</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kringle domain</infon>
          <location offset="1540" length="14"/>
          <text>kringle domain</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serine protease domain</infon>
          <location offset="1562" length="22"/>
          <text>serine protease domain</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23507868</id>
    <passage>
      <offset>0</offset>
      <text>Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: evidence from patients with abetalipoproteinemia.	There is evidence that high-density lipoproteins (HDLs) may regulate platelet function, but disparate results exist regarding the effects of oxidized HDLs on platelets. The objective of our study was to determine the role of in vivo oxidized HDLs on platelet aggregation. Platelet aggregation and redox status were investigated in 5 patients with abetalipoproteinemia (ABLP) or homozygous hypobetalipoproteinemia, two rare metabolic diseases characterized by the absence of apolipoprotein B-containing lipoproteins, compared to 5 control subjects. Platelets isolated from plasma of patients with ABLP aggregated 4 to 10 times more than control platelets, depending on the agonist. By contrast, no differences in the extent of platelet aggregation were observed between ABLP platelet-rich plasma (PRP) and control PRP, suggesting the presence of a protective factor in ABLP plasma. ABLP HDLs inhibited agonist-induced platelet aggregation by binding to SR-BI, while control HDLs had no effect. On the other hand, lipoprotein-deficient plasma from patients with ABLP did not inhibit platelet aggregation. Severe oxidative stress was evidenced in patients with ABLP. Compared to control HDLs, ABLP HDLs showed a 40% decrease of α-tocopherol and an 11-fold increased malondialdehyde concentration. These results demonstrate that in vivo oxidized HDLs do not lose their antiaggregatory properties despite oxidation.-Calzada, C., Véricel, E., Colas, R., Guillot, N., El Khoury, G., Drai, J., Sassolas, A., Peretti, N., Ponsin, G., Lagarde, M., Moulin, P. Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: evidence from patients with abetalipoproteinemia.</text>
      <sentence>
        <offset>0</offset>
        <text>Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: evidence from patients with abetalipoproteinemia.</text>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">oxidized high-density lipoproteins</infon>
          <location offset="30" length="34"/>
          <text>oxidized high-density lipoproteins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>140</offset>
        <text>There is evidence that high-density lipoproteins (HDLs) may regulate platelet function, but disparate results exist regarding the effects of oxidized HDLs on platelets.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hdls</infon>
          <location offset="290" length="4"/>
          <text>HDLs</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">high-density lipoproteins</infon>
          <location offset="163" length="25"/>
          <text>high-density lipoproteins</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hdls</infon>
          <location offset="190" length="4"/>
          <text>HDLs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>309</offset>
        <text>The objective of our study was to determine the role of in vivo oxidized HDLs on platelet aggregation.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">oxidized hdls</infon>
          <location offset="373" length="13"/>
          <text>oxidized HDLs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>412</offset>
        <text>Platelet aggregation and redox status were investigated in 5 patients with abetalipoproteinemia (ABLP) or homozygous hypobetalipoproteinemia, two rare metabolic diseases characterized by the absence of apolipoprotein B-containing lipoproteins, compared to 5 control subjects.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apolipoprotein b</infon>
          <location offset="614" length="16"/>
          <text>apolipoprotein B</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lipoproteins</infon>
          <location offset="642" length="12"/>
          <text>lipoproteins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>688</offset>
        <text>Platelets isolated from plasma of patients with ABLP aggregated 4 to 10 times more than control platelets, depending on the agonist.</text>
      </sentence>
      <sentence>
        <offset>821</offset>
        <text>By contrast, no differences in the extent of platelet aggregation were observed between ABLP platelet-rich plasma (PRP) and control PRP, suggesting the presence of a protective factor in ABLP plasma.</text>
      </sentence>
      <sentence>
        <offset>1021</offset>
        <text>ABLP HDLs inhibited agonist-induced platelet aggregation by binding to SR-BI, while control HDLs had no effect.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hdls</infon>
          <location offset="1026" length="4"/>
          <text>HDLs</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sr-bi</infon>
          <location offset="1092" length="5"/>
          <text>SR-BI</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hdls</infon>
          <location offset="1113" length="4"/>
          <text>HDLs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1133</offset>
        <text>On the other hand, lipoprotein-deficient plasma from patients with ABLP did not inhibit platelet aggregation.</text>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lipoprotein</infon>
          <location offset="1152" length="11"/>
          <text>lipoprotein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1243</offset>
        <text>Severe oxidative stress was evidenced in patients with ABLP.</text>
      </sentence>
      <sentence>
        <offset>1304</offset>
        <text>Compared to control HDLs, ABLP HDLs showed a 40% decrease of α-tocopherol and an 11-fold increased malondialdehyde concentration.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">α-tocopherol</infon>
          <location offset="1365" length="12"/>
          <text>α-tocopherol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malondialdehyde</infon>
          <location offset="1403" length="15"/>
          <text>malondialdehyde</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hdls</infon>
          <location offset="1324" length="4"/>
          <text>HDLs</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hdls</infon>
          <location offset="1335" length="4"/>
          <text>HDLs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1434</offset>
        <text>These results demonstrate that in vivo oxidized HDLs do not lose their antiaggregatory properties despite oxidation.-Calzada, C., Véricel, E., Colas, R., Guillot, N., El Khoury, G., Drai, J., Sassolas, A., Peretti, N., Ponsin, G., Lagarde, M., Moulin, P. Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: evidence from patients with abetalipoproteinemia.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">oxidized hdls</infon>
          <location offset="1473" length="13"/>
          <text>oxidized HDLs</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">oxidized high-density lipoproteins</infon>
          <location offset="1719" length="34"/>
          <text>oxidized high-density lipoproteins</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17253779</id>
    <passage>
      <offset>0</offset>
      <text>Specificity of zebrafish retinol saturase: formation of all-trans-13,14-dihydroretinol and all-trans-7,8- dihydroretinol.	Metabolism of vitamin A, all-trans-retinol, leads to the formation of 11-cis-retinaldehyde, the visual chromophore, and all-trans-retinoic acid, which is involved in the regulation of gene expression through the retinoic acid receptor. Enzymes and binding proteins involved in retinoid metabolism are highly conserved across species. We previously described a novel mammalian enzyme that saturates the 13-14 double bond of all-trans-retinol to produce all-trans-13,14-dihydroretinol, which then follows the same metabolic fate as that of all-trans-retinol. Specifically, all-trans-13,14-dihydroretinol is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by Cyp26 enzymes. Here, we report the identification of two putative RetSat homologues in zebrafish, one of which, zebrafish RetSat A (zRetSat A), also had retinol saturase activity, whereas zebrafish RetSat B (zRetSat B) was inactive under similar conditions. Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish. The dual enzymatic activity of zRetSat A displays a newly acquired specificity for the 13-14 double bond retained in higher vertebrates and also the evolutionarily preserved activity of bacterial phytoene desaturases and plant carotenoid isomerases. Expression of zRetSat A was restricted to the liver and intestine of hatchlings and adult zebrafish, whereas zRetSat B was expressed in the same tissues but at earlier developmental stages. Exogenous all-trans-retinol, all-trans-13,14-dihydroretinol, or all-trans-7,8-dihydroretinol led to the strong induction of the expression of the retinoic acid-metabolizing enzyme, Cyp26A1, arguing for an active signaling function of dihydroretinoid metabolites in zebrafish. These findings point to a conserved function but altered specificity of RetSat in vertebrates, leading to the generation of various dihydroretinoid compounds, some of which could have signaling functions.</text>
      <sentence>
        <offset>0</offset>
        <text>Specificity of zebrafish retinol saturase: formation of all-trans-13,14-dihydroretinol and all-trans-7,8- dihydroretinol.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinol</infon>
          <location offset="25" length="7"/>
          <text>retinol</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-13,14-dihydroretinol</infon>
          <location offset="56" length="30"/>
          <text>all-trans-13,14-dihydroretinol</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-7,8- dihydroretinol</infon>
          <location offset="91" length="29"/>
          <text>all-trans-7,8- dihydroretinol</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zebrafish retinol saturase</infon>
          <location offset="15" length="26"/>
          <text>zebrafish retinol saturase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T28" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T27" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>122</offset>
        <text>Metabolism of vitamin A, all-trans-retinol, leads to the formation of 11-cis-retinaldehyde, the visual chromophore, and all-trans-retinoic acid, which is involved in the regulation of gene expression through the retinoic acid receptor.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-retinoic acid</infon>
          <location offset="242" length="23"/>
          <text>all-trans-retinoic acid</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin a</infon>
          <location offset="136" length="9"/>
          <text>vitamin A</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="334" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-retinol</infon>
          <location offset="147" length="17"/>
          <text>all-trans-retinol</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">11-cis-retinaldehyde</infon>
          <location offset="192" length="20"/>
          <text>11-cis-retinaldehyde</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">retinoic acid receptor</infon>
          <location offset="334" length="22"/>
          <text>retinoic acid receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>358</offset>
        <text>Enzymes and binding proteins involved in retinoid metabolism are highly conserved across species.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoid</infon>
          <location offset="399" length="8"/>
          <text>retinoid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>456</offset>
        <text>We previously described a novel mammalian enzyme that saturates the 13-14 double bond of all-trans-retinol to produce all-trans-13,14-dihydroretinol, which then follows the same metabolic fate as that of all-trans-retinol.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-retinol</infon>
          <location offset="545" length="17"/>
          <text>all-trans-retinol</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-13,14-dihydroretinol</infon>
          <location offset="574" length="30"/>
          <text>all-trans-13,14-dihydroretinol</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-retinol</infon>
          <location offset="660" length="17"/>
          <text>all-trans-retinol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>679</offset>
        <text>Specifically, all-trans-13,14-dihydroretinol is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by Cyp26 enzymes.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-13,14-dihydroretinol</infon>
          <location offset="693" length="30"/>
          <text>all-trans-13,14-dihydroretinol</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-13,14-dihydroretinoic acid</infon>
          <location offset="751" length="36"/>
          <text>all-trans-13,14-dihydroretinoic acid</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp26</infon>
          <location offset="821" length="5"/>
          <text>Cyp26</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T22" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>836</offset>
        <text>Here, we report the identification of two putative RetSat homologues in zebrafish, one of which, zebrafish RetSat A (zRetSat A), also had retinol saturase activity, whereas zebrafish RetSat B (zRetSat B) was inactive under similar conditions.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinol</infon>
          <location offset="974" length="7"/>
          <text>retinol</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">retsat</infon>
          <location offset="887" length="6"/>
          <text>RetSat</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zebrafish retsat a</infon>
          <location offset="933" length="18"/>
          <text>zebrafish RetSat A</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zretsat a</infon>
          <location offset="953" length="9"/>
          <text>zRetSat A</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">retinol saturase</infon>
          <location offset="974" length="16"/>
          <text>retinol saturase</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zebrafish retsat b</infon>
          <location offset="1009" length="18"/>
          <text>zebrafish RetSat B</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zretsat b</infon>
          <location offset="1029" length="9"/>
          <text>zRetSat B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1079</offset>
        <text>Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-retinol</infon>
          <location offset="1203" length="17"/>
          <text>all-trans-retinol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-13,14-dihydroretinol</infon>
          <location offset="1239" length="30"/>
          <text>all-trans-13,14-dihydroretinol</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-7,8-dihydroretinol</infon>
          <location offset="1273" length="28"/>
          <text>all-trans-7,8-dihydroretinol</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mouse retsat</infon>
          <location offset="1086" length="12"/>
          <text>mouse RetSat</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mretsat</infon>
          <location offset="1100" length="7"/>
          <text>mRetSat</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zretsat a</infon>
          <location offset="1110" length="9"/>
          <text>zRetSat A</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1317</offset>
        <text>zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-3,4-didehydroretinol</infon>
          <location offset="1375" length="30"/>
          <text>all-trans-3,4-didehydroretinol</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin a2</infon>
          <location offset="1407" length="10"/>
          <text>vitamin A2</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin a</infon>
          <location offset="1448" length="9"/>
          <text>vitamin A</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zretsat a</infon>
          <location offset="1317" length="9"/>
          <text>zRetSat A</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1472</offset>
        <text>The dual enzymatic activity of zRetSat A displays a newly acquired specificity for the 13-14 double bond retained in higher vertebrates and also the evolutionarily preserved activity of bacterial phytoene desaturases and plant carotenoid isomerases.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phytoene</infon>
          <location offset="1668" length="8"/>
          <text>phytoene</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zretsat a</infon>
          <location offset="1503" length="9"/>
          <text>zRetSat A</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">bacterial phytoene desaturases</infon>
          <location offset="1658" length="30"/>
          <text>bacterial phytoene desaturases</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">plant carotenoid isomerases</infon>
          <location offset="1693" length="27"/>
          <text>plant carotenoid isomerases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1722</offset>
        <text>Expression of zRetSat A was restricted to the liver and intestine of hatchlings and adult zebrafish, whereas zRetSat B was expressed in the same tissues but at earlier developmental stages.</text>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zretsat a</infon>
          <location offset="1736" length="9"/>
          <text>zRetSat A</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zretsat b</infon>
          <location offset="1831" length="9"/>
          <text>zRetSat B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1912</offset>
        <text>Exogenous all-trans-retinol, all-trans-13,14-dihydroretinol, or all-trans-7,8-dihydroretinol led to the strong induction of the expression of the retinoic acid-metabolizing enzyme, Cyp26A1, arguing for an active signaling function of dihydroretinoid metabolites in zebrafish.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-retinol</infon>
          <location offset="1922" length="17"/>
          <text>all-trans-retinol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-13,14-dihydroretinol</infon>
          <location offset="1941" length="30"/>
          <text>all-trans-13,14-dihydroretinol</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">all-trans-7,8-dihydroretinol</infon>
          <location offset="1976" length="28"/>
          <text>all-trans-7,8-dihydroretinol</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="2058" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydroretinoid</infon>
          <location offset="2146" length="15"/>
          <text>dihydroretinoid</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp26a1</infon>
          <location offset="2093" length="7"/>
          <text>Cyp26A1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2188</offset>
        <text>These findings point to a conserved function but altered specificity of RetSat in vertebrates, leading to the generation of various dihydroretinoid compounds, some of which could have signaling functions.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydroretinoid</infon>
          <location offset="2320" length="15"/>
          <text>dihydroretinoid</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">retsat</infon>
          <location offset="2260" length="6"/>
          <text>RetSat</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10531013</id>
    <passage>
      <offset>0</offset>
      <text>Caffeine inhibits the checkpoint kinase ATM.	The basis of many anti-cancer therapies is the use of genotoxic agents that damage DNA and thus kill dividing cells. Agents that cause cells to override the DNA-damage checkpoint are predicted to sensitize cells to killing by genotoxic agents. They have therefore been sought as adjuncts in radiation therapy and chemotherapy. One such compound, caffeine, uncouples cell-cycle progression from the replication and repair of DNA [1] [2]. Caffeine therefore servers as a model compound in establishing the principle that agents that override DNA-damage checkpoints can be used to sensitize cells to the killing effects of genotoxic drugs [3]. But despite more than 20 years of use, the molecular mechanisms by which caffeine affects the cell cycle and checkpoint responses have not been identified. We investigated the effects of caffeine on the G2/M DNA-damage checkpoint in human cells. We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro. Inhibition of ATM provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of caffeine-treated cells [6] [7] [8].</text>
      <sentence>
        <offset>0</offset>
        <text>Caffeine inhibits the checkpoint kinase ATM.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="0" length="8"/>
          <text>Caffeine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="33" length="6"/>
          <text>kinase</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atm</infon>
          <location offset="40" length="3"/>
          <text>ATM</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>45</offset>
        <text>The basis of many anti-cancer therapies is the use of genotoxic agents that damage DNA and thus kill dividing cells.</text>
      </sentence>
      <sentence>
        <offset>162</offset>
        <text>Agents that cause cells to override the DNA-damage checkpoint are predicted to sensitize cells to killing by genotoxic agents.</text>
      </sentence>
      <sentence>
        <offset>289</offset>
        <text>They have therefore been sought as adjuncts in radiation therapy and chemotherapy.</text>
      </sentence>
      <sentence>
        <offset>372</offset>
        <text>One such compound, caffeine, uncouples cell-cycle progression from the replication and repair of DNA [1] [2].</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="391" length="8"/>
          <text>caffeine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>482</offset>
        <text>Caffeine therefore servers as a model compound in establishing the principle that agents that override DNA-damage checkpoints can be used to sensitize cells to the killing effects of genotoxic drugs [3].</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="482" length="8"/>
          <text>Caffeine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>686</offset>
        <text>But despite more than 20 years of use, the molecular mechanisms by which caffeine affects the cell cycle and checkpoint responses have not been identified.</text>
      </sentence>
      <sentence>
        <offset>842</offset>
        <text>We investigated the effects of caffeine on the G2/M DNA-damage checkpoint in human cells.</text>
      </sentence>
      <sentence>
        <offset>932</offset>
        <text>We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="1115" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="1044" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atm</infon>
          <location offset="1070" length="3"/>
          <text>ATM</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="1074" length="6"/>
          <text>kinase</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="987" length="6"/>
          <text>kinase</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cds1</infon>
          <location offset="994" length="4"/>
          <text>Cds1</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">chk2</infon>
          <location offset="1018" length="4"/>
          <text>Chk2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1134</offset>
        <text>Inhibition of ATM provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of caffeine-treated cells [6] [7] [8].</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="1281" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atm</infon>
          <location offset="1148" length="3"/>
          <text>ATM</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11444497</id>
    <passage>
      <offset>0</offset>
      <text>Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.	SUMMARY: The effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II (Ang II)-induced facilitation of noradrenergic neurotransmission was investigated in the isolated rat mesenteric artery under isometric conditions. Electrical field stimulation (2, 4, and 8 Hz) caused a frequency-dependent increase of contractile force. At stimulation frequencies of 2, 4, and 8 Hz, Ang 11 (10 nM) increased the stimulation-induced vasoconstrictor responses by a factor 4.8 +/- 0.9, 2.9 +/- 0.7, and 1.3 +/- 0.1, respectively (p &lt; 0.05 compared with control for all frequencies). The enhancement could be concentration-dependently antagonized by losartan (1 nM-1 microM), irbesartan (0.1 nM-0.1 microM), and telmisartan (0.01 nM-0.01 microM). At a stimulation frequency of 2 Hz, the relation between stimulation-induced vasoconstrictor responses (in presence of Ang II 10 nM) and the concentration of the AT1-antagonists used could be described by linear regression. The order of potency concerning sympathoinhibition was telmisartan &gt; irbesartan &gt; losartan (p &lt; 0.05 between linear regression lines). Contractile responses to exogenous noradrenaline were unaltered in the presence of Ang II 10 nM. We conclude that the facilitating effect of Ang II on noradrenergic neurotransmission is mediated by presynaptically located AT1-receptors. Conversely, this facilitating effect can be dose-dependently counteracted by blockade of these receptors. Sympathoinhibitory properties are likely to contribute to the therapeutic effect of AT1-blockers, in particular in conditions in which the sympathetic nervous system is activated, such as congestive heart failure and hypertension.</text>
      <sentence>
        <offset>0</offset>
        <text>Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">losartan</infon>
          <location offset="39" length="8"/>
          <text>losartan</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">irbesartan</infon>
          <location offset="49" length="10"/>
          <text>irbesartan</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">telmisartan</infon>
          <location offset="65" length="11"/>
          <text>telmisartan</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="80" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">at1-receptor</infon>
          <location offset="14" length="12"/>
          <text>AT1-receptor</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="80" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T17" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T16" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T15" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>179</offset>
        <text>SUMMARY: The effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II (Ang II)-induced facilitation of noradrenergic neurotransmission was investigated in the isolated rat mesenteric artery under isometric conditions.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="288" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">losartan</infon>
          <location offset="231" length="8"/>
          <text>losartan</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">irbesartan</infon>
          <location offset="241" length="10"/>
          <text>irbesartan</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">telmisartan</infon>
          <location offset="257" length="11"/>
          <text>telmisartan</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="272" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="288" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">at1-receptor</infon>
          <location offset="206" length="12"/>
          <text>AT1-receptor</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="272" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T13" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>435</offset>
        <text>Electrical field stimulation (2, 4, and 8 Hz) caused a frequency-dependent increase of contractile force.</text>
      </sentence>
      <sentence>
        <offset>541</offset>
        <text>At stimulation frequencies of 2, 4, and 8 Hz, Ang 11 (10 nM) increased the stimulation-induced vasoconstrictor responses by a factor 4.8 +/- 0.9, 2.9 +/- 0.7, and 1.3 +/- 0.1, respectively (p &lt; 0.05 compared with control for all frequencies).</text>
      </sentence>
      <sentence>
        <offset>784</offset>
        <text>The enhancement could be concentration-dependently antagonized by losartan (1 nM-1 microM), irbesartan (0.1 nM-0.1 microM), and telmisartan (0.01 nM-0.01 microM).</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">losartan</infon>
          <location offset="850" length="8"/>
          <text>losartan</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">irbesartan</infon>
          <location offset="876" length="10"/>
          <text>irbesartan</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">telmisartan</infon>
          <location offset="912" length="11"/>
          <text>telmisartan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>947</offset>
        <text>At a stimulation frequency of 2 Hz, the relation between stimulation-induced vasoconstrictor responses (in presence of Ang II 10 nM) and the concentration of the AT1-antagonists used could be described by linear regression.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="1066" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">at1</infon>
          <location offset="1109" length="3"/>
          <text>AT1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1171</offset>
        <text>The order of potency concerning sympathoinhibition was telmisartan &gt; irbesartan &gt; losartan (p &lt; 0.05 between linear regression lines).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">telmisartan</infon>
          <location offset="1226" length="11"/>
          <text>telmisartan</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">irbesartan</infon>
          <location offset="1240" length="10"/>
          <text>irbesartan</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">losartan</infon>
          <location offset="1253" length="8"/>
          <text>losartan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1306</offset>
        <text>Contractile responses to exogenous noradrenaline were unaltered in the presence of Ang II 10 nM.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">noradrenaline</infon>
          <location offset="1341" length="13"/>
          <text>noradrenaline</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="1389" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="1389" length="6"/>
          <text>Ang II</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1403</offset>
        <text>We conclude that the facilitating effect of Ang II on noradrenergic neurotransmission is mediated by presynaptically located AT1-receptors.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="1447" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ang ii</infon>
          <location offset="1447" length="6"/>
          <text>Ang II</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">at1-receptors</infon>
          <location offset="1528" length="13"/>
          <text>AT1-receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1543</offset>
        <text>Conversely, this facilitating effect can be dose-dependently counteracted by blockade of these receptors.</text>
      </sentence>
      <sentence>
        <offset>1649</offset>
        <text>Sympathoinhibitory properties are likely to contribute to the therapeutic effect of AT1-blockers, in particular in conditions in which the sympathetic nervous system is activated, such as congestive heart failure and hypertension.</text>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">at1</infon>
          <location offset="1733" length="3"/>
          <text>AT1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17645691</id>
    <passage>
      <offset>0</offset>
      <text>Multiple protective effects of melatonin against maternal cholestasis-induced oxidative stress and apoptosis in the rat fetal liver-placenta-maternal liver trio.	Maternal cholestasis is usually a benign condition for the mother but induces profound placental damage and may be lethal for the fetus. The aim of this study was to investigate the protective effects in rat maternal and fetal livers as also the placenta of melatonin or silymarin against the oxidative stress and apoptosis induced by maternal obstructive cholestasis during the last third of pregnancy (OCP). Melatonin or silymarin administration (i.e. 5 mg/100 g bw/day after ligation of the maternal common bile duct on day 14 of pregnancy) reduced OCP-induced lipid peroxidation, and prevented decreases in total glutathione levels. However, the protective effect on OCP-induced impairment in the GSH/GSSG ratio was mild in the placenta and fetal liver, while absent in maternal liver. Melatonin or silymarin also reduced OCP-induced signs of apoptosis (increased caspase-3 activity and Bax-alpha upregulation) in all the organs assayed. Moreover, melatonin (but not silymarin) upregulated several proteins involved in the cellular protection against the oxidative stress in rats with OCP. These included, biliverdin-IX alpha reductase and the sodium-dependent vitamin C transport proteins SVCT1 and SVCT2, whose expression levels were enhanced in maternal and fetal liver by melatonin treatment. In contrast, in placenta only biliverdin-IX alpha reductase and SVCT2 were upregulated. These results indicate that whereas the treatment of cholestatic pregnant rats with melatonin or silymarin affords a direct protective antioxidant activity, only melatonin has dual beneficial effects against OCP-induced oxidative challenge in that it stimulates the expression of some components of the endogenous cellular antioxidant defense.</text>
      <sentence>
        <offset>0</offset>
        <text>Multiple protective effects of melatonin against maternal cholestasis-induced oxidative stress and apoptosis in the rat fetal liver-placenta-maternal liver trio.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melatonin</infon>
          <location offset="31" length="9"/>
          <text>melatonin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>162</offset>
        <text>Maternal cholestasis is usually a benign condition for the mother but induces profound placental damage and may be lethal for the fetus.</text>
      </sentence>
      <sentence>
        <offset>299</offset>
        <text>The aim of this study was to investigate the protective effects in rat maternal and fetal livers as also the placenta of melatonin or silymarin against the oxidative stress and apoptosis induced by maternal obstructive cholestasis during the last third of pregnancy (OCP).</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melatonin</infon>
          <location offset="420" length="9"/>
          <text>melatonin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">silymarin</infon>
          <location offset="433" length="9"/>
          <text>silymarin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>572</offset>
        <text>Melatonin or silymarin administration (i.e. 5 mg/100 g bw/day after ligation of the maternal common bile duct on day 14 of pregnancy) reduced OCP-induced lipid peroxidation, and prevented decreases in total glutathione levels.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melatonin</infon>
          <location offset="572" length="9"/>
          <text>Melatonin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">silymarin</infon>
          <location offset="585" length="9"/>
          <text>silymarin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="779" length="11"/>
          <text>glutathione</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>799</offset>
        <text>However, the protective effect on OCP-induced impairment in the GSH/GSSG ratio was mild in the placenta and fetal liver, while absent in maternal liver.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="863" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gssg</infon>
          <location offset="867" length="4"/>
          <text>GSSG</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>952</offset>
        <text>Melatonin or silymarin also reduced OCP-induced signs of apoptosis (increased caspase-3 activity and Bax-alpha upregulation) in all the organs assayed.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melatonin</infon>
          <location offset="952" length="9"/>
          <text>Melatonin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">silymarin</infon>
          <location offset="965" length="9"/>
          <text>silymarin</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="1030" length="9"/>
          <text>caspase-3</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax-alpha</infon>
          <location offset="1053" length="9"/>
          <text>Bax-alpha</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1104</offset>
        <text>Moreover, melatonin (but not silymarin) upregulated several proteins involved in the cellular protection against the oxidative stress in rats with OCP.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melatonin</infon>
          <location offset="1114" length="9"/>
          <text>melatonin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">silymarin</infon>
          <location offset="1133" length="9"/>
          <text>silymarin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1256</offset>
        <text>These included, biliverdin-IX alpha reductase and the sodium-dependent vitamin C transport proteins SVCT1 and SVCT2, whose expression levels were enhanced in maternal and fetal liver by melatonin treatment.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biliverdin</infon>
          <location offset="1272" length="10"/>
          <text>biliverdin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="1310" length="6"/>
          <text>sodium</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin c</infon>
          <location offset="1327" length="9"/>
          <text>vitamin C</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melatonin</infon>
          <location offset="1442" length="9"/>
          <text>melatonin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">biliverdin-ix alpha reductase</infon>
          <location offset="1272" length="29"/>
          <text>biliverdin-IX alpha reductase</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">svct1</infon>
          <location offset="1356" length="5"/>
          <text>SVCT1</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">svct2</infon>
          <location offset="1366" length="5"/>
          <text>SVCT2</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1463</offset>
        <text>In contrast, in placenta only biliverdin-IX alpha reductase and SVCT2 were upregulated.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biliverdin</infon>
          <location offset="1493" length="10"/>
          <text>biliverdin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">biliverdin-ix alpha reductase</infon>
          <location offset="1493" length="29"/>
          <text>biliverdin-IX alpha reductase</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">svct2</infon>
          <location offset="1527" length="5"/>
          <text>SVCT2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1551</offset>
        <text>These results indicate that whereas the treatment of cholestatic pregnant rats with melatonin or silymarin affords a direct protective antioxidant activity, only melatonin has dual beneficial effects against OCP-induced oxidative challenge in that it stimulates the expression of some components of the endogenous cellular antioxidant defense.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melatonin</infon>
          <location offset="1635" length="9"/>
          <text>melatonin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">silymarin</infon>
          <location offset="1648" length="9"/>
          <text>silymarin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melatonin</infon>
          <location offset="1713" length="9"/>
          <text>melatonin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23541982</id>
    <passage>
      <offset>0</offset>
      <text>Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid.	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover. It is reduced in neurodegenerative disease states proportionally to the severity of disease and the degree of brain atrophy. In the early phases of active disease, a higher rate of turnover may result in transitory increases in plasma 24OHC. Less than 1% of the total brain excretion of 24OHC occurs via the cerebrospinal fluid (CSF) whereas almost all 27-hydroxycholesterol (27OHC) excretion is dependent on the function of the blood-cerebrospinal fluid barrier. Iincreased CSF oxysterols were found in patients with neurodegenerative and neuroinflammatory diseases in the presence of barrier dysfunction. In neurodegeneration, free cholesterol released from dying cells may engulf neurons. Cholesterol also increases Amyloid β (Aβ) deposition and tau pathology. ApoE, 24OHC, tau and soluble APP were correlated in Alzheimer disease (AD) samples. Excess of cholesterol converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for Aβ and Tau. In AD this protective mechanism seems to be inefficient, probably due to the presence of high concentrations of 27OHC, microvascular dysfunction and the decreased efficiency of ApoE4 as lipid transporter and Aβ scavenger. 24OHC itself was cytotoxic. Analysis of side chain oxysterols in the CSF is likely to provided useful information about cholesterol metabolism and ApoE function in the pathogenesis of AD.</text>
      <sentence>
        <offset>0</offset>
        <text>Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterols</infon>
          <location offset="48" length="10"/>
          <text>oxysterols</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>103</offset>
        <text>The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte ApoE.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">24ohc</infon>
          <location offset="211" length="5"/>
          <text>24OHC</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="121" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="170" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">24s-hydroxycholesterol</infon>
          <location offset="187" length="22"/>
          <text>24S-hydroxycholesterol</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">liver x receptor</infon>
          <location offset="233" length="16"/>
          <text>liver X receptor</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lxr</infon>
          <location offset="251" length="3"/>
          <text>LXR</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apoe</infon>
          <location offset="312" length="4"/>
          <text>ApoE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>318</offset>
        <text>24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">24ohc</infon>
          <location offset="318" length="5"/>
          <text>24OHC</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="410" length="11"/>
          <text>cholesterol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>432</offset>
        <text>It is reduced in neurodegenerative disease states proportionally to the severity of disease and the degree of brain atrophy.</text>
      </sentence>
      <sentence>
        <offset>557</offset>
        <text>In the early phases of active disease, a higher rate of turnover may result in transitory increases in plasma 24OHC.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">24ohc</infon>
          <location offset="667" length="5"/>
          <text>24OHC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>674</offset>
        <text>Less than 1% of the total brain excretion of 24OHC occurs via the cerebrospinal fluid (CSF) whereas almost all 27-hydroxycholesterol (27OHC) excretion is dependent on the function of the blood-cerebrospinal fluid barrier.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">24ohc</infon>
          <location offset="719" length="5"/>
          <text>24OHC</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">27-hydroxycholesterol</infon>
          <location offset="785" length="21"/>
          <text>27-hydroxycholesterol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">27ohc</infon>
          <location offset="808" length="5"/>
          <text>27OHC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>896</offset>
        <text>Iincreased CSF oxysterols were found in patients with neurodegenerative and neuroinflammatory diseases in the presence of barrier dysfunction.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterols</infon>
          <location offset="911" length="10"/>
          <text>oxysterols</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1039</offset>
        <text>In neurodegeneration, free cholesterol released from dying cells may engulf neurons.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="1066" length="11"/>
          <text>cholesterol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1124</offset>
        <text>Cholesterol also increases Amyloid β (Aβ) deposition and tau pathology.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="1124" length="11"/>
          <text>Cholesterol</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">amyloid β</infon>
          <location offset="1151" length="9"/>
          <text>Amyloid β</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aβ</infon>
          <location offset="1162" length="2"/>
          <text>Aβ</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tau</infon>
          <location offset="1181" length="3"/>
          <text>tau</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1196</offset>
        <text>ApoE, 24OHC, tau and soluble APP were correlated in Alzheimer disease (AD) samples.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">24ohc</infon>
          <location offset="1202" length="5"/>
          <text>24OHC</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apoe</infon>
          <location offset="1196" length="4"/>
          <text>ApoE</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tau</infon>
          <location offset="1209" length="3"/>
          <text>tau</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">soluble app</infon>
          <location offset="1217" length="11"/>
          <text>soluble APP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1280</offset>
        <text>Excess of cholesterol converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for Aβ and Tau.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="1290" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">24ohc</infon>
          <location offset="1317" length="5"/>
          <text>24OHC</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apoe</infon>
          <location offset="1339" length="4"/>
          <text>ApoE</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aβ</infon>
          <location offset="1379" length="2"/>
          <text>Aβ</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tau</infon>
          <location offset="1386" length="3"/>
          <text>Tau</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1391</offset>
        <text>In AD this protective mechanism seems to be inefficient, probably due to the presence of high concentrations of 27OHC, microvascular dysfunction and the decreased efficiency of ApoE4 as lipid transporter and Aβ scavenger.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">27ohc</infon>
          <location offset="1503" length="5"/>
          <text>27OHC</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apoe4</infon>
          <location offset="1568" length="5"/>
          <text>ApoE4</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aβ</infon>
          <location offset="1599" length="2"/>
          <text>Aβ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1613</offset>
        <text>24OHC itself was cytotoxic.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">24ohc</infon>
          <location offset="1613" length="5"/>
          <text>24OHC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1641</offset>
        <text>Analysis of side chain oxysterols in the CSF is likely to provided useful information about cholesterol metabolism and ApoE function in the pathogenesis of AD.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterols</infon>
          <location offset="1664" length="10"/>
          <text>oxysterols</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="1733" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apoe</infon>
          <location offset="1760" length="4"/>
          <text>ApoE</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23512787</id>
    <passage>
      <offset>0</offset>
      <text>Neuroprotective Effects of Puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's Disease Model in Mice.	Puerarin, an active component of Pueraria montana var. lobata (Willd.) Sanjappa &amp; Pradeep is well-known for its anti-oxidative and neuroprotective activities. Although anti-Parkinson's disease activity of puerarin was reported in both of in vivo and in vitro model, detailed mechanisms are not clarified. In this study, we addressed that puerarin attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced behavioral deficits, dopaminergic neuronal degeneration and dopamine depletion. Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice. In addition to the effect on ROS, puerarin ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (Lamp 2A) expression. Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression. Copyright © 2013 John Wiley &amp; Sons, Ltd.</text>
      <sentence>
        <offset>0</offset>
        <text>Neuroprotective Effects of Puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's Disease Model in Mice.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">puerarin</infon>
          <location offset="27" length="8"/>
          <text>Puerarin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</infon>
          <location offset="39" length="44"/>
          <text>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>127</offset>
        <text>Puerarin, an active component of Pueraria montana var.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">puerarin</infon>
          <location offset="127" length="8"/>
          <text>Puerarin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>182</offset>
        <text>lobata (Willd.)</text>
      </sentence>
      <sentence>
        <offset>198</offset>
        <text>Sanjappa &amp; Pradeep is well-known for its anti-oxidative and neuroprotective activities.</text>
      </sentence>
      <sentence>
        <offset>286</offset>
        <text>Although anti-Parkinson's disease activity of puerarin was reported in both of in vivo and in vitro model, detailed mechanisms are not clarified.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">puerarin</infon>
          <location offset="332" length="8"/>
          <text>puerarin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>432</offset>
        <text>In this study, we addressed that puerarin attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced behavioral deficits, dopaminergic neuronal degeneration and dopamine depletion.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">puerarin</infon>
          <location offset="465" length="8"/>
          <text>puerarin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</infon>
          <location offset="485" length="44"/>
          <text>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mptp</infon>
          <location offset="531" length="4"/>
          <text>MPTP</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="605" length="8"/>
          <text>dopamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>625</offset>
        <text>Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">puerarin</infon>
          <location offset="625" length="8"/>
          <text>Puerarin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="658" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="671" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mptp</infon>
          <location offset="804" length="4"/>
          <text>MPTP</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="861" length="6"/>
          <text>oxygen</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glial cell line-derived neurotrophic factor</infon>
          <location offset="686" length="43"/>
          <text>glial cell line-derived neurotrophic factor</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gdnf</infon>
          <location offset="731" length="4"/>
          <text>GDNF</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="752" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="757" length="3"/>
          <text>Akt</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>901</offset>
        <text>In addition to the effect on ROS, puerarin ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (Lamp 2A) expression.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">puerarin</infon>
          <location offset="935" length="8"/>
          <text>puerarin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mptp</infon>
          <location offset="956" length="4"/>
          <text>MPTP</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lysosome-associated membrane protein type 2a</infon>
          <location offset="969" length="44"/>
          <text>lysosome-associated membrane protein type 2A</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lamp 2a</infon>
          <location offset="1015" length="7"/>
          <text>Lamp 2A</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1036</offset>
        <text>Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="1199" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mptp</infon>
          <location offset="1245" length="4"/>
          <text>MPTP</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">puerarin</infon>
          <location offset="1078" length="8"/>
          <text>puerarin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mptp</infon>
          <location offset="1098" length="4"/>
          <text>MPTP</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gdnf</infon>
          <location offset="1161" length="4"/>
          <text>GDNF</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="1178" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="1183" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lamp 2a</infon>
          <location offset="1288" length="7"/>
          <text>Lamp 2A</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1308</offset>
        <text>Copyright © 2013 John Wiley &amp; Sons, Ltd.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10871202</id>
    <passage>
      <offset>0</offset>
      <text>Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.	Low plasma fibrinolytic activity in association with increased plasma plasminogen activator inhibitor 1 (PAI-1) levels has been linked to an increased risk of atherosclerosis in obesity and type 2 diabetes. We tested the hypothesis that troglitazone, which improves insulin sensitivity and lowers plasma insulin levels in insulin-resistant obese subjects and patients with type 2 diabetes, would also lower circulating PAI-1 antigen concentrations and activity. We assessed insulin sensitivity (5-h, 80 mU x m(-2) x min(-1) hyperinsulinemic-euglycemic clamp) and measured plasma PAI-1 antigen and activities and tissue plasminogen activator (tPA) in 14 patients with type 2 diabetes and 20 normal control subjects (10 lean, 10 obese) before and after 3 months of treatment with troglitazone (600 mg/day). At baseline, plasma PAI-1 antigen levels after an overnight fast were significantly higher in the obese (33.5 +/- 4.7 microg/l) and type 2 diabetic subjects (54.9 +/- 6.3 microg/l) than in the lean control subjects (16.3 +/- 3.2 microg/l; P &lt; 0.01 and P &lt; 0.001, respectively). Troglitazone decreased plasma PAI-1 antigen concentrations in the diabetic patients (36.8 +/- 5.0 microg/l; P &lt; 0.001 vs. baseline), but the reduction in the obese subjects did not reach statistical significance (baseline, 33.5 +/- 4.7; after troglitazone, 25.6 +/- 5.2 microg/l). Changes in plasma PAI-1 activity paralleled those of PAI-1 antigen. The extent of the reduction in plasma PAI-1 antigen concentrations in the diabetic patients after troglitazone correlated with the reductions in fasting plasma insulin (r = 0.60, P &lt; 0.05), nonesterified fatty acid (r = 0.63, P &lt; 0.02), and glucose concentrations (r = 0.64, P &lt; 0.02) but not with the improvement in glucose disposal rates during the glucose clamps. Three nonresponders to troglitazone with respect to effects on insulin sensitivity and fasting glucose and insulin levels also had no reduction in circulating PAI-1. In conclusion, troglitazone enhances fibrinolytic system activity in insulin-resistant type 2 diabetic patients. This effect appears to be intimately linked to its potential to lower plasma insulin levels and improve glycemic control through its peripheral tissue insulin-sensitizing effects.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="11" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasminogen activator inhibitor 1</infon>
          <location offset="51" length="33"/>
          <text>plasminogen activator inhibitor 1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>157</offset>
        <text>Low plasma fibrinolytic activity in association with increased plasma plasminogen activator inhibitor 1 (PAI-1) levels has been linked to an increased risk of atherosclerosis in obesity and type 2 diabetes.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pai-1</infon>
          <location offset="262" length="5"/>
          <text>PAI-1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasminogen activator inhibitor 1</infon>
          <location offset="227" length="33"/>
          <text>plasminogen activator inhibitor 1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>364</offset>
        <text>We tested the hypothesis that troglitazone, which improves insulin sensitivity and lowers plasma insulin levels in insulin-resistant obese subjects and patients with type 2 diabetes, would also lower circulating PAI-1 antigen concentrations and activity.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="394" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="423" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="461" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="479" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pai-1</infon>
          <location offset="576" length="5"/>
          <text>PAI-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>619</offset>
        <text>We assessed insulin sensitivity (5-h, 80 mU x m(-2) x min(-1) hyperinsulinemic-euglycemic clamp) and measured plasma PAI-1 antigen and activities and tissue plasminogen activator (tPA) in 14 patients with type 2 diabetes and 20 normal control subjects (10 lean, 10 obese) before and after 3 months of treatment with troglitazone (600 mg/day).</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="935" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="631" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pai-1</infon>
          <location offset="736" length="5"/>
          <text>PAI-1</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tissue plasminogen activator</infon>
          <location offset="769" length="28"/>
          <text>tissue plasminogen activator</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tpa</infon>
          <location offset="799" length="3"/>
          <text>tPA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>962</offset>
        <text>At baseline, plasma PAI-1 antigen levels after an overnight fast were significantly higher in the obese (33.5 +/- 4.7 microg/l) and type 2 diabetic subjects (54.9 +/- 6.3 microg/l) than in the lean control subjects (16.3 +/- 3.2 microg/l; P &lt; 0.01 and P &lt; 0.001, respectively).</text>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pai-1</infon>
          <location offset="982" length="5"/>
          <text>PAI-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1240</offset>
        <text>Troglitazone decreased plasma PAI-1 antigen concentrations in the diabetic patients (36.8 +/- 5.0 microg/l; P &lt; 0.001 vs. baseline), but the reduction in the obese subjects did not reach statistical significance (baseline, 33.5 +/- 4.7; after troglitazone, 25.6 +/- 5.2 microg/l).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1240" length="12"/>
          <text>Troglitazone</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1483" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pai-1</infon>
          <location offset="1270" length="5"/>
          <text>PAI-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1521</offset>
        <text>Changes in plasma PAI-1 activity paralleled those of PAI-1 antigen.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pai-1</infon>
          <location offset="1539" length="5"/>
          <text>PAI-1</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pai-1</infon>
          <location offset="1574" length="5"/>
          <text>PAI-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1589</offset>
        <text>The extent of the reduction in plasma PAI-1 antigen concentrations in the diabetic patients after troglitazone correlated with the reductions in fasting plasma insulin (r = 0.60, P &lt; 0.05), nonesterified fatty acid (r = 0.63, P &lt; 0.02), and glucose concentrations (r = 0.64, P &lt; 0.02) but not with the improvement in glucose disposal rates during the glucose clamps.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1687" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nonesterified fatty acid</infon>
          <location offset="1779" length="24"/>
          <text>nonesterified fatty acid</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1830" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1906" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1940" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pai-1</infon>
          <location offset="1627" length="5"/>
          <text>PAI-1</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1749" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1956</offset>
        <text>Three nonresponders to troglitazone with respect to effects on insulin sensitivity and fasting glucose and insulin levels also had no reduction in circulating PAI-1.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1979" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="2051" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="2019" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="2063" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pai-1</infon>
          <location offset="2115" length="5"/>
          <text>PAI-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2122</offset>
        <text>In conclusion, troglitazone enhances fibrinolytic system activity in insulin-resistant type 2 diabetic patients.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="2137" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="2191" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2235</offset>
        <text>This effect appears to be intimately linked to its potential to lower plasma insulin levels and improve glycemic control through its peripheral tissue insulin-sensitizing effects.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="2312" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="2386" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16232421</id>
    <passage>
      <offset>0</offset>
      <text>Effect of gene disruptions of the TCA cycle on production of succinic acid in Saccharomyces cerevisiae.	Succinate is the main taste component produced by yeasts during sake (Japanese rice wine) fermentation. The pathway leading to accumulation of succinate was examined in liquid culture in the presence of a high concentration (15%) of glucose under aerobic and anaerobic conditions using a series of Saccharomyces cerevisiae strains in which various genes that encode the expression of enzymes required in TCA cycle were disrupted. When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate. On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all. These results indicate that succinate, fumarate and malate are mainly synthesized through the TCA cycle (oxidative direction) even in the presence of glucose at a concentration as high as 15%. When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in SDH1 disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed. A double mutant of the two fumarate reductase isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution. These results indicate that succinate could be synthesized through two pathways, namely, alpha-ketoglutarate oxidation via the TCA cycle and fumarate reduction under anaerobic conditions.</text>
      <sentence>
        <offset>0</offset>
        <text>Effect of gene disruptions of the TCA cycle on production of succinic acid in Saccharomyces cerevisiae.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tca</infon>
          <location offset="34" length="3"/>
          <text>TCA</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">succinic acid</infon>
          <location offset="61" length="13"/>
          <text>succinic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>104</offset>
        <text>Succinate is the main taste component produced by yeasts during sake (Japanese rice wine) fermentation.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">succinate</infon>
          <location offset="104" length="9"/>
          <text>Succinate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>208</offset>
        <text>The pathway leading to accumulation of succinate was examined in liquid culture in the presence of a high concentration (15%) of glucose under aerobic and anaerobic conditions using a series of Saccharomyces cerevisiae strains in which various genes that encode the expression of enzymes required in TCA cycle were disrupted.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">succinate</infon>
          <location offset="247" length="9"/>
          <text>succinate</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="337" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tca</infon>
          <location offset="508" length="3"/>
          <text>TCA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>534</offset>
        <text>When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="577" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alpha-ketoglutarate</infon>
          <location offset="621" length="19"/>
          <text>alpha-ketoglutarate</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">succinate</infon>
          <location offset="704" length="9"/>
          <text>succinate</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">succinate</infon>
          <location offset="757" length="9"/>
          <text>succinate</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">succinate</infon>
          <location offset="835" length="9"/>
          <text>succinate</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kgd1</infon>
          <location offset="615" length="4"/>
          <text>KGD1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha-ketoglutarate dehydrogenase</infon>
          <location offset="621" length="33"/>
          <text>alpha-ketoglutarate dehydrogenase</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sdh1</infon>
          <location offset="751" length="4"/>
          <text>SDH1</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">succinate dehydrogenase</infon>
          <location offset="757" length="23"/>
          <text>succinate dehydrogenase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T19" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T17" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T19" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T17" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>846</offset>
        <text>On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fumarate</infon>
          <location offset="947" length="8"/>
          <text>fumarate</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malate</infon>
          <location offset="973" length="6"/>
          <text>malate</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fum1</infon>
          <location offset="869" length="4"/>
          <text>FUM1</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fumarase</infon>
          <location offset="875" length="8"/>
          <text>fumarase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T20" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T20" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>988</offset>
        <text>These results indicate that succinate, fumarate and malate are mainly synthesized through the TCA cycle (oxidative direction) even in the presence of glucose at a concentration as high as 15%.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1138" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">succinate</infon>
          <location offset="1016" length="9"/>
          <text>succinate</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fumarate</infon>
          <location offset="1027" length="8"/>
          <text>fumarate</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malate</infon>
          <location offset="1040" length="6"/>
          <text>malate</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tca</infon>
          <location offset="1082" length="3"/>
          <text>TCA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1181</offset>
        <text>When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in SDH1 disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">succinate</infon>
          <location offset="1269" length="9"/>
          <text>succinate</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">succinate</infon>
          <location offset="1354" length="9"/>
          <text>succinate</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sdh1</infon>
          <location offset="1282" length="4"/>
          <text>SDH1</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kgd1</infon>
          <location offset="1371" length="4"/>
          <text>KGD1</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1406</offset>
        <text>A double mutant of the two fumarate reductase isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fumarate</infon>
          <location offset="1433" length="8"/>
          <text>fumarate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">succinate</infon>
          <location offset="1491" length="9"/>
          <text>succinate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1576" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fumarate reductase</infon>
          <location offset="1433" length="18"/>
          <text>fumarate reductase</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">osm1</infon>
          <location offset="1467" length="4"/>
          <text>OSM1</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">frds</infon>
          <location offset="1476" length="4"/>
          <text>FRDS</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1603</offset>
        <text>These results indicate that succinate could be synthesized through two pathways, namely, alpha-ketoglutarate oxidation via the TCA cycle and fumarate reduction under anaerobic conditions.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">succinate</infon>
          <location offset="1631" length="9"/>
          <text>succinate</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alpha-ketoglutarate</infon>
          <location offset="1692" length="19"/>
          <text>alpha-ketoglutarate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tca</infon>
          <location offset="1730" length="3"/>
          <text>TCA</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fumarate</infon>
          <location offset="1744" length="8"/>
          <text>fumarate</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12184062</id>
    <passage>
      <offset>0</offset>
      <text>The clinical profile of the angiotensin II receptor blocker eprosartan.	Angiotensin II receptor antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of angiotensin in the vasculature. By this mechanism, they induce similar pharmacological effects to angiotensin-converting enzyme (ACE) inhibitors, resulting in a lowering of blood pressure (BP). However, AT1 antagonists differ from ACE inhibitors with respect to side effects, and induce less cough, which is related to bradykinin activation. Within the class of angiotensin II antagonists, eprosartan differs from other currently clinically available agents in terms of its chemical structure and its dual pharmacological mode of action. Eprosartan acts not only at vascular AT1 receptors but also at presynaptic AT1 receptors, causing inhibition of sympathetically stimulated noradrenaline release. Eprosartan is not metabolized by cytochrome P450 enzymes and therefore has a low potential for metabolic drug interactions, which may be of importance when treating the elderly and patients on multiple drugs. In clinical trials eprosartan has proven to be at least as effective as the ACE inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects. Eprosartan is safe, effective and well tolerated in long-term treatment, either as monotherapy or in combination with other antihypertensive drugs such as hydrochlorothiazide.</text>
      <sentence>
        <offset>0</offset>
        <text>The clinical profile of the angiotensin II receptor blocker eprosartan.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="28" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eprosartan</infon>
          <location offset="60" length="10"/>
          <text>eprosartan</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">angiotensin ii receptor</infon>
          <location offset="28" length="23"/>
          <text>angiotensin II receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>72</offset>
        <text>Angiotensin II receptor antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of angiotensin in the vasculature.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="72" length="14"/>
          <text>Angiotensin II</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin</infon>
          <location offset="186" length="11"/>
          <text>angiotensin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="114" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">angiotensin ii receptor</infon>
          <location offset="72" length="23"/>
          <text>Angiotensin II receptor</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin</infon>
          <location offset="186" length="11"/>
          <text>angiotensin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin ii type 1 (at1) receptors</infon>
          <location offset="114" length="37"/>
          <text>angiotensin II type 1 (AT1) receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>218</offset>
        <text>By this mechanism, they induce similar pharmacological effects to angiotensin-converting enzyme (ACE) inhibitors, resulting in a lowering of blood pressure (BP).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin</infon>
          <location offset="284" length="11"/>
          <text>angiotensin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin-converting enzyme</infon>
          <location offset="284" length="29"/>
          <text>angiotensin-converting enzyme</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ace</infon>
          <location offset="315" length="3"/>
          <text>ACE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>380</offset>
        <text>However, AT1 antagonists differ from ACE inhibitors with respect to side effects, and induce less cough, which is related to bradykinin activation.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at1</infon>
          <location offset="389" length="3"/>
          <text>AT1</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ace</infon>
          <location offset="417" length="3"/>
          <text>ACE</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bradykinin</infon>
          <location offset="505" length="10"/>
          <text>bradykinin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>528</offset>
        <text>Within the class of angiotensin II antagonists, eprosartan differs from other currently clinically available agents in terms of its chemical structure and its dual pharmacological mode of action.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="548" length="14"/>
          <text>angiotensin II</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="548" length="14"/>
          <text>angiotensin II</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>724</offset>
        <text>Eprosartan acts not only at vascular AT1 receptors but also at presynaptic AT1 receptors, causing inhibition of sympathetically stimulated noradrenaline release.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eprosartan</infon>
          <location offset="724" length="10"/>
          <text>Eprosartan</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">noradrenaline</infon>
          <location offset="863" length="13"/>
          <text>noradrenaline</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at1</infon>
          <location offset="761" length="3"/>
          <text>AT1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at1</infon>
          <location offset="799" length="3"/>
          <text>AT1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>886</offset>
        <text>Eprosartan is not metabolized by cytochrome P450 enzymes and therefore has a low potential for metabolic drug interactions, which may be of importance when treating the elderly and patients on multiple drugs.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eprosartan</infon>
          <location offset="886" length="10"/>
          <text>Eprosartan</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450</infon>
          <location offset="919" length="15"/>
          <text>cytochrome P450</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1095</offset>
        <text>In clinical trials eprosartan has proven to be at least as effective as the ACE inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eprosartan</infon>
          <location offset="1114" length="10"/>
          <text>eprosartan</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ace</infon>
          <location offset="1171" length="3"/>
          <text>ACE</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1269</offset>
        <text>Eprosartan is safe, effective and well tolerated in long-term treatment, either as monotherapy or in combination with other antihypertensive drugs such as hydrochlorothiazide.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eprosartan</infon>
          <location offset="1269" length="10"/>
          <text>Eprosartan</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrochlorothiazide</infon>
          <location offset="1424" length="19"/>
          <text>hydrochlorothiazide</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1284246</id>
    <passage>
      <offset>0</offset>
      <text>The primary structure of porcine aminoacylase 1 deduced from cDNA sequence.	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced. From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that porcine kidney ACY-1 consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus. A cDNA encoding porcine liver ACY-1 was also cloned. The amino acid sequence deduced from the nucleotide sequence of the cDNA from porcine liver was identical to that deduced for porcine kidney ACY-1. Northern blot analysis suggested that ACY-1 is more highly expressed in kidney than in liver. Comparison of the amino acid sequence of porcine ACY-1 with those of other Zn2+-binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites. This indicates that ACY-1 is a new type of metalloprotein.</text>
      <sentence>
        <offset>0</offset>
        <text>The primary structure of porcine aminoacylase 1 deduced from cDNA sequence.</text>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">porcine aminoacylase 1</infon>
          <location offset="25" length="22"/>
          <text>porcine aminoacylase 1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>76</offset>
        <text>A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zn2+</infon>
          <location offset="235" length="4"/>
          <text>Zn2+</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-acylated l-amino acids</infon>
          <location offset="292" length="24"/>
          <text>N-acylated L-amino acids</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-aspartic acid</infon>
          <location offset="324" length="15"/>
          <text>L-aspartic acid</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="105" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-acylamino acid</infon>
          <location offset="144" length="16"/>
          <text>N-acylamino acid</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acy-1</infon>
          <location offset="177" length="5"/>
          <text>ACY-1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ec 3.5.1.14</infon>
          <location offset="185" length="11"/>
          <text>EC 3.5.1.14</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">metalloprotein</infon>
          <location offset="209" length="14"/>
          <text>metalloprotein</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aminoacylase 1</infon>
          <location offset="128" length="14"/>
          <text>aminoacylase 1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">n-acylamino acid aminohydrolase</infon>
          <location offset="144" length="31"/>
          <text>N-acylamino acid aminohydrolase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>419</offset>
        <text>From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that porcine kidney ACY-1 consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="462" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c</infon>
          <location offset="469" length="1"/>
          <text>C</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="480" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="663" length="11"/>
          <text>amino acids</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylalanine</infon>
          <location offset="680" length="13"/>
          <text>acetylalanine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="701" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">porcine kidney acy-1</infon>
          <location offset="544" length="20"/>
          <text>porcine kidney ACY-1</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T9" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T11" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T7" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>713</offset>
        <text>A cDNA encoding porcine liver ACY-1 was also cloned.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">porcine liver acy-1</infon>
          <location offset="729" length="19"/>
          <text>porcine liver ACY-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>766</offset>
        <text>The amino acid sequence deduced from the nucleotide sequence of the cDNA from porcine liver was identical to that deduced for porcine kidney ACY-1.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="770" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleotide</infon>
          <location offset="807" length="10"/>
          <text>nucleotide</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">porcine kidney acy-1</infon>
          <location offset="892" length="20"/>
          <text>porcine kidney ACY-1</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T14" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T13" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>914</offset>
        <text>Northern blot analysis suggested that ACY-1 is more highly expressed in kidney than in liver.</text>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acy-1</infon>
          <location offset="952" length="5"/>
          <text>ACY-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1008</offset>
        <text>Comparison of the amino acid sequence of porcine ACY-1 with those of other Zn2+-binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zn2+</infon>
          <location offset="1083" length="4"/>
          <text>Zn2+</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="1026" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">zn2+-binding metalloenzymes</infon>
          <location offset="1083" length="27"/>
          <text>Zn2+-binding metalloenzymes</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">porcine acy-1</infon>
          <location offset="1049" length="13"/>
          <text>porcine ACY-1</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1231</offset>
        <text>This indicates that ACY-1 is a new type of metalloprotein.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acy-1</infon>
          <location offset="1251" length="5"/>
          <text>ACY-1</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">metalloprotein</infon>
          <location offset="1274" length="14"/>
          <text>metalloprotein</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17486539</id>
    <passage>
      <offset>0</offset>
      <text>Retinoic acid is required for specification of the ventral eye field and for Rathke's pouch in the avian embryo.	We have investigated the role of retinoic acid (RA) in eye development using the vitamin A deficient quail model system, which overcomes problems of retinoic acid synthesising enzyme redundancy in the embryo. In the absence of retinoic acid, the ventral optic stalk and ventral retina are missing, whereas the dorsal optic stalk and dorsal retina develop appropriately. Other ocular abnormalities observed were a thinner retina and the lack of differentiation of the lens. In an attempt to explain this, we studied the expression of various dorsally and ventrally expressed genes such as Pax2, Pax6, Tbx6, Vax2, Raldh1 and Raldh3 and noted that they were unchanged in their expression patterns. In contrast, the RA catabolising enzymes Cyp26A1 and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye. At much earlier stages, the expression domain of Shh in the prechordal plate was reduced, as was Nkx2.1 and we suggest a model whereby the eye field is specified according to the concentration of SHH protein that is present. We also describe another organ, Rathke's pouch which fails to develop in the absence of retinoic acid. We attribute this to the down-regulation of Bmp2, Shh and Fgf8 which are known to be involved in the induction of this structure.</text>
      <sentence>
        <offset>0</offset>
        <text>Retinoic acid is required for specification of the ventral eye field and for Rathke's pouch in the avian embryo.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="0" length="13"/>
          <text>Retinoic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>113</offset>
        <text>We have investigated the role of retinoic acid (RA) in eye development using the vitamin A deficient quail model system, which overcomes problems of retinoic acid synthesising enzyme redundancy in the embryo.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="262" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="146" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ra</infon>
          <location offset="161" length="2"/>
          <text>RA</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin a</infon>
          <location offset="194" length="9"/>
          <text>vitamin A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>322</offset>
        <text>In the absence of retinoic acid, the ventral optic stalk and ventral retina are missing, whereas the dorsal optic stalk and dorsal retina develop appropriately.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="340" length="13"/>
          <text>retinoic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>483</offset>
        <text>Other ocular abnormalities observed were a thinner retina and the lack of differentiation of the lens.</text>
      </sentence>
      <sentence>
        <offset>586</offset>
        <text>In an attempt to explain this, we studied the expression of various dorsally and ventrally expressed genes such as Pax2, Pax6, Tbx6, Vax2, Raldh1 and Raldh3 and noted that they were unchanged in their expression patterns.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pax2</infon>
          <location offset="701" length="4"/>
          <text>Pax2</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pax6</infon>
          <location offset="707" length="4"/>
          <text>Pax6</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tbx6</infon>
          <location offset="713" length="4"/>
          <text>Tbx6</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vax2</infon>
          <location offset="719" length="4"/>
          <text>Vax2</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">raldh1</infon>
          <location offset="725" length="6"/>
          <text>Raldh1</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">raldh3</infon>
          <location offset="736" length="6"/>
          <text>Raldh3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>808</offset>
        <text>In contrast, the RA catabolising enzymes Cyp26A1 and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ra</infon>
          <location offset="825" length="2"/>
          <text>RA</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ra</infon>
          <location offset="891" length="2"/>
          <text>RA</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp26a1</infon>
          <location offset="849" length="7"/>
          <text>Cyp26A1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp26b1</infon>
          <location offset="861" length="7"/>
          <text>Cyp26B1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>954</offset>
        <text>At much earlier stages, the expression domain of Shh in the prechordal plate was reduced, as was Nkx2.1 and we suggest a model whereby the eye field is specified according to the concentration of SHH protein that is present.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">shh</infon>
          <location offset="1150" length="3"/>
          <text>SHH</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">shh</infon>
          <location offset="1003" length="3"/>
          <text>Shh</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nkx2.1</infon>
          <location offset="1051" length="6"/>
          <text>Nkx2.1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1179</offset>
        <text>We also describe another organ, Rathke's pouch which fails to develop in the absence of retinoic acid.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="1267" length="13"/>
          <text>retinoic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1282</offset>
        <text>We attribute this to the down-regulation of Bmp2, Shh and Fgf8 which are known to be involved in the induction of this structure.</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">bmp2</infon>
          <location offset="1326" length="4"/>
          <text>Bmp2</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">shh</infon>
          <location offset="1332" length="3"/>
          <text>Shh</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fgf8</infon>
          <location offset="1340" length="4"/>
          <text>Fgf8</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>9643444</id>
    <passage>
      <offset>0</offset>
      <text>Investigation into the presence of insulin-degrading enzyme in cultured type II alveolar cells and the effects of enzyme inhibitors on pulmonary bioavailability of insulin in rats.	The purpose of this study was to investigate the role of insulin-degrading enzyme (IDE, EC 3.4.22.11) in insulin degradation in alveolar epithelium. The primary culture of isolated rat type-II pneumocytes was used for the in-vitro characterization of IDE. Insulin was then administered intratracheally with various inhibitors to assess the improvement in its pulmonary bioavailability. In cultured type-II pneumocytes, the cytosolic insulin-degrading activity contributed 81% of total insulin degradation, reached a maximum at pH 7.5 and had an apparent Michaelis-Menten constant (Km) of 135 nM. N-Ethylmaleimide, p-chloromercuribenzoic acid and 1,10-phenanthroline inhibited insulin-degrading activity almost completely in both crude homogenate and cytosol. An immunoprecipitation study showed that IDE contributed 74% of cytosolic insulin-degrading activity. Western blot analysis showing a single band of 110 kDa on reduced SDS (sodium dodecylsulphate) gels confirmed the presence of IDE in cultured type-II cells. When given intratracheally with insulin, inhibitors including N-ethylmaleimide, p-chloromercuribenzoic acid, and 1,10-phenanthroline significantly enhanced the absolute bioavailability of insulin and the compound's hypoglycaemic effects. These results suggest that IDE is present in alveolar epithelium and might be involved in limiting insulin absorption in the lung.</text>
      <sentence>
        <offset>0</offset>
        <text>Investigation into the presence of insulin-degrading enzyme in cultured type II alveolar cells and the effects of enzyme inhibitors on pulmonary bioavailability of insulin in rats.</text>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="164" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin-degrading enzyme</infon>
          <location offset="35" length="24"/>
          <text>insulin-degrading enzyme</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>181</offset>
        <text>The purpose of this study was to investigate the role of insulin-degrading enzyme (IDE, EC 3.4.22.11) in insulin degradation in alveolar epithelium.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="286" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin-degrading enzyme</infon>
          <location offset="238" length="24"/>
          <text>insulin-degrading enzyme</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ide</infon>
          <location offset="264" length="3"/>
          <text>IDE</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ec 3.4.22.11</infon>
          <location offset="269" length="12"/>
          <text>EC 3.4.22.11</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>330</offset>
        <text>The primary culture of isolated rat type-II pneumocytes was used for the in-vitro characterization of IDE.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ide</infon>
          <location offset="432" length="3"/>
          <text>IDE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>437</offset>
        <text>Insulin was then administered intratracheally with various inhibitors to assess the improvement in its pulmonary bioavailability.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="437" length="7"/>
          <text>Insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>567</offset>
        <text>In cultured type-II pneumocytes, the cytosolic insulin-degrading activity contributed 81% of total insulin degradation, reached a maximum at pH 7.5 and had an apparent Michaelis-Menten constant (Km) of 135 nM.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="614" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="666" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>777</offset>
        <text>N-Ethylmaleimide, p-chloromercuribenzoic acid and 1,10-phenanthroline inhibited insulin-degrading activity almost completely in both crude homogenate and cytosol.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-ethylmaleimide</infon>
          <location offset="777" length="16"/>
          <text>N-Ethylmaleimide</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-chloromercuribenzoic acid</infon>
          <location offset="795" length="27"/>
          <text>p-chloromercuribenzoic acid</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1,10-phenanthroline</infon>
          <location offset="827" length="19"/>
          <text>1,10-phenanthroline</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="857" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>940</offset>
        <text>An immunoprecipitation study showed that IDE contributed 74% of cytosolic insulin-degrading activity.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ide</infon>
          <location offset="981" length="3"/>
          <text>IDE</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1014" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1042</offset>
        <text>Western blot analysis showing a single band of 110 kDa on reduced SDS (sodium dodecylsulphate) gels confirmed the presence of IDE in cultured type-II cells.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium dodecylsulphate</infon>
          <location offset="1113" length="22"/>
          <text>sodium dodecylsulphate</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ide</infon>
          <location offset="1168" length="3"/>
          <text>IDE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1199</offset>
        <text>When given intratracheally with insulin, inhibitors including N-ethylmaleimide, p-chloromercuribenzoic acid, and 1,10-phenanthroline significantly enhanced the absolute bioavailability of insulin and the compound's hypoglycaemic effects.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-ethylmaleimide</infon>
          <location offset="1261" length="16"/>
          <text>N-ethylmaleimide</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-chloromercuribenzoic acid</infon>
          <location offset="1279" length="27"/>
          <text>p-chloromercuribenzoic acid</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1,10-phenanthroline</infon>
          <location offset="1312" length="19"/>
          <text>1,10-phenanthroline</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1231" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1387" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1437</offset>
        <text>These results suggest that IDE is present in alveolar epithelium and might be involved in limiting insulin absorption in the lung.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ide</infon>
          <location offset="1464" length="3"/>
          <text>IDE</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1536" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17355872</id>
    <passage>
      <offset>0</offset>
      <text>Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin.	Sirtuins are NAD(+)-dependent protein deacetylases and are emerging as molecular targets for the development of pharmaceuticals to treat human metabolic and neurological diseases and cancer. To date, several sirtuin inhibitors and activators have been identified, but the structural mechanisms of how these compounds modulate sirtuin activity have not yet been determined. We identified suramin as a compound that binds to human SIRT5 and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM. To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of SIRT5, one in complex with ADP-ribose, the other bound to suramin. Our structural studies provide a view of a synthetic inhibitory compound in a sirtuin active site revealing that suramin binds into the NAD(+), the product, and the substrate-binding site. Finally, our structures may enable the rational design of more potent inhibitors.</text>
      <sentence>
        <offset>0</offset>
        <text>Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nad+</infon>
          <location offset="44" length="4"/>
          <text>NAD+</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">suramin</infon>
          <location offset="80" length="7"/>
          <text>suramin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human nad+-dependent deacetylase sirt5</infon>
          <location offset="38" length="38"/>
          <text>human NAD+-dependent deacetylase SIRT5</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>89</offset>
        <text>Sirtuins are NAD(+)-dependent protein deacetylases and are emerging as molecular targets for the development of pharmaceuticals to treat human metabolic and neurological diseases and cancer.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nad(+)</infon>
          <location offset="102" length="6"/>
          <text>NAD(+)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>280</offset>
        <text>To date, several sirtuin inhibitors and activators have been identified, but the structural mechanisms of how these compounds modulate sirtuin activity have not yet been determined.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sirtuin</infon>
          <location offset="297" length="7"/>
          <text>sirtuin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sirtuin</infon>
          <location offset="415" length="7"/>
          <text>sirtuin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>462</offset>
        <text>We identified suramin as a compound that binds to human SIRT5 and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">suramin</infon>
          <location offset="476" length="7"/>
          <text>suramin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nad(+)</infon>
          <location offset="558" length="6"/>
          <text>NAD(+)</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human sirt5</infon>
          <location offset="512" length="11"/>
          <text>human SIRT5</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sirt5 nad(+)-dependent deacetylase</infon>
          <location offset="552" length="34"/>
          <text>SIRT5 NAD(+)-dependent deacetylase</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>631</offset>
        <text>To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of SIRT5, one in complex with ADP-ribose, the other bound to suramin.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adp</infon>
          <location offset="770" length="3"/>
          <text>ADP</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">suramin</infon>
          <location offset="801" length="7"/>
          <text>suramin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sirt5</infon>
          <location offset="743" length="5"/>
          <text>SIRT5</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>810</offset>
        <text>Our structural studies provide a view of a synthetic inhibitory compound in a sirtuin active site revealing that suramin binds into the NAD(+), the product, and the substrate-binding site.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">suramin</infon>
          <location offset="923" length="7"/>
          <text>suramin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nad(+)</infon>
          <location offset="946" length="6"/>
          <text>NAD(+)</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sirtuin</infon>
          <location offset="888" length="7"/>
          <text>sirtuin</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T7" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>999</offset>
        <text>Finally, our structures may enable the rational design of more potent inhibitors.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23391443</id>
    <passage>
      <offset>0</offset>
      <text>An intra-articular salmon calcitonin-based nanocomplex reduces experimental inflammatory arthritis.	Prolonged inappropriate inflammatory responses contribute to the pathogenesis of rheumatoid arthritis (RA) and to aspects of osteoarthritis (OA). The orphan nuclear receptor, NR4A2, is a key regulator and potential biomarker for inflammation and represents a potentially valuable therapeutic target. Both salmon calcitonin (sCT) and hyaluronic acid (HA) attenuated activated mRNA expression of NR4A1, NR4A2, NR4A3, and matrix metalloproteinases (MMPs) 1, 3 and 13 in three human cell lines: SW1353 chondrocytes, U937 and THP-1 monocytes. Ad-mixtures of sCT and HA further down-regulated expression of NR4A2 compared to either agent alone at specific concentrations, hence the rationale for their formulation in nanocomplexes (NPs) using chitosan. The sCT released from NP stimulated cAMP production in human T47D breast cancer cells expressing sCT receptors. When NP were injected by the intra-articular (I.A.) route to the mouse knee during on-going inflammatory arthritis of the K/BxN serum transfer model, joint inflammation was reduced together with NR4A2 expression, and local bone architecture was preserved. These data highlight remarkable anti-inflammatory effects of sCT and HA at the level of reducing NR4A2 mRNA expression in vitro. Combining them in NP elicits anti-arthritic effects in vivo following I.A. delivery.</text>
      <sentence>
        <offset>0</offset>
        <text>An intra-articular salmon calcitonin-based nanocomplex reduces experimental inflammatory arthritis.</text>
      </sentence>
      <sentence>
        <offset>100</offset>
        <text>Prolonged inappropriate inflammatory responses contribute to the pathogenesis of rheumatoid arthritis (RA) and to aspects of osteoarthritis (OA).</text>
      </sentence>
      <sentence>
        <offset>246</offset>
        <text>The orphan nuclear receptor, NR4A2, is a key regulator and potential biomarker for inflammation and represents a potentially valuable therapeutic target.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">orphan nuclear receptor, nr4a2</infon>
          <location offset="250" length="30"/>
          <text>orphan nuclear receptor, NR4A2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>400</offset>
        <text>Both salmon calcitonin (sCT) and hyaluronic acid (HA) attenuated activated mRNA expression of NR4A1, NR4A2, NR4A3, and matrix metalloproteinases (MMPs) 1, 3 and 13 in three human cell lines: SW1353 chondrocytes, U937 and THP-1 monocytes.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr4a1</infon>
          <location offset="494" length="5"/>
          <text>NR4A1</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr4a2</infon>
          <location offset="501" length="5"/>
          <text>NR4A2</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr4a3</infon>
          <location offset="508" length="5"/>
          <text>NR4A3</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">matrix metalloproteinases (mmps) 1, 3 and 13</infon>
          <location offset="519" length="44"/>
          <text>matrix metalloproteinases (MMPs) 1, 3 and 13</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>638</offset>
        <text>Ad-mixtures of sCT and HA further down-regulated expression of NR4A2 compared to either agent alone at specific concentrations, hence the rationale for their formulation in nanocomplexes (NPs) using chitosan.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr4a2</infon>
          <location offset="701" length="5"/>
          <text>NR4A2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>847</offset>
        <text>The sCT released from NP stimulated cAMP production in human T47D breast cancer cells expressing sCT receptors.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="883" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sct receptors</infon>
          <location offset="944" length="13"/>
          <text>sCT receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>959</offset>
        <text>When NP were injected by the intra-articular (I.A.) route to the mouse knee during on-going inflammatory arthritis of the K/BxN serum transfer model, joint inflammation was reduced together with NR4A2 expression, and local bone architecture was preserved.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr4a2</infon>
          <location offset="1154" length="5"/>
          <text>NR4A2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1215</offset>
        <text>These data highlight remarkable anti-inflammatory effects of sCT and HA at the level of reducing NR4A2 mRNA expression in vitro.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr4a2</infon>
          <location offset="1312" length="5"/>
          <text>NR4A2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1344</offset>
        <text>Combining them in NP elicits anti-arthritic effects in vivo following I.A. delivery.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23328126</id>
    <passage>
      <offset>0</offset>
      <text>Omega-3 Fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance.	Fish oils (FOs) have anti-inflammatory effects and lower serum triglycerides. This study examined adipose and muscle inflammatory markers after treatment of humans with FOs and measured the effects of ω-3 fatty acids on adipocytes and macrophages in vitro. Insulin-resistant, nondiabetic subjects were treated with Omega-3-Acid Ethyl Esters (4 g/day) or placebo for 12 weeks. Plasma macrophage chemoattractant protein 1 (MCP-1) levels were reduced by FO, but the levels of other cytokines were unchanged. The adipose (but not muscle) of FO-treated subjects demonstrated a decrease in macrophages, a decrease in MCP-1, and an increase in capillaries, and subjects with the most macrophages demonstrated the greatest response to treatment. Adipose and muscle ω-3 fatty acid content increased after treatment; however, there was no change in insulin sensitivity or adiponectin. In vitro, M1-polarized macrophages expressed high levels of MCP-1. The addition of ω-3 fatty acids reduced MCP-1 expression with no effect on TNF-α. In addition, ω-3 fatty acids suppressed the upregulation of adipocyte MCP-1 that occurred when adipocytes were cocultured with macrophages. Thus, FO reduced adipose macrophages, increased capillaries, and reduced MCP-1 expression in insulin-resistant humans and in macrophages and adipocytes in vitro; however, there was no measureable effect on insulin sensitivity.</text>
      <sentence>
        <offset>0</offset>
        <text>Omega-3 Fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omega-3 fatty acids</infon>
          <location offset="0" length="19"/>
          <text>Omega-3 Fatty acids</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="77" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>97</offset>
        <text>Fish oils (FOs) have anti-inflammatory effects and lower serum triglycerides.</text>
      </sentence>
      <sentence>
        <offset>175</offset>
        <text>This study examined adipose and muscle inflammatory markers after treatment of humans with FOs and measured the effects of ω-3 fatty acids on adipocytes and macrophages in vitro.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ω-3 fatty acids</infon>
          <location offset="298" length="15"/>
          <text>ω-3 fatty acids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>354</offset>
        <text>Insulin-resistant, nondiabetic subjects were treated with Omega-3-Acid Ethyl Esters (4 g/day) or placebo for 12 weeks.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omega-3-acid ethyl esters</infon>
          <location offset="412" length="25"/>
          <text>Omega-3-Acid Ethyl Esters</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="354" length="7"/>
          <text>Insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>473</offset>
        <text>Plasma macrophage chemoattractant protein 1 (MCP-1) levels were reduced by FO, but the levels of other cytokines were unchanged.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasma macrophage chemoattractant protein 1</infon>
          <location offset="473" length="43"/>
          <text>Plasma macrophage chemoattractant protein 1</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="518" length="5"/>
          <text>MCP-1</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="576" length="9"/>
          <text>cytokines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>602</offset>
        <text>The adipose (but not muscle) of FO-treated subjects demonstrated a decrease in macrophages, a decrease in MCP-1, and an increase in capillaries, and subjects with the most macrophages demonstrated the greatest response to treatment.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="708" length="5"/>
          <text>MCP-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>835</offset>
        <text>Adipose and muscle ω-3 fatty acid content increased after treatment; however, there was no change in insulin sensitivity or adiponectin.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ω-3 fatty acid</infon>
          <location offset="854" length="14"/>
          <text>ω-3 fatty acid</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="936" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adiponectin</infon>
          <location offset="959" length="11"/>
          <text>adiponectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>972</offset>
        <text>In vitro, M1-polarized macrophages expressed high levels of MCP-1.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="1032" length="5"/>
          <text>MCP-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1039</offset>
        <text>The addition of ω-3 fatty acids reduced MCP-1 expression with no effect on TNF-α.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ω-3 fatty acids</infon>
          <location offset="1055" length="15"/>
          <text>ω-3 fatty acids</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="1114" length="5"/>
          <text>TNF-α</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="1079" length="5"/>
          <text>MCP-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1121</offset>
        <text>In addition, ω-3 fatty acids suppressed the upregulation of adipocyte MCP-1 that occurred when adipocytes were cocultured with macrophages.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ω-3 fatty acids</infon>
          <location offset="1134" length="15"/>
          <text>ω-3 fatty acids</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="1191" length="5"/>
          <text>MCP-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1261</offset>
        <text>Thus, FO reduced adipose macrophages, increased capillaries, and reduced MCP-1 expression in insulin-resistant humans and in macrophages and adipocytes in vitro; however, there was no measureable effect on insulin sensitivity.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="1334" length="5"/>
          <text>MCP-1</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1354" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1467" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23314331</id>
    <passage>
      <offset>0</offset>
      <text>Copper induced upregulation of apoptosis related genes in zebrafish (Danio rerio) gill.	Copper (Cu) is an essential micronutrient that, when present in high concentrations, becomes toxic to aquatic organisms. It is known that Cu toxicity may induce apoptotic cell death. However, the precise mechanism and the pathways that are activated, in fish, are still unclear. Thus, this study aimed to assess which apoptotic pathways are triggered by Cu, in zebrafish (Danio rerio) gill, the main target of waterborne pollutants. Fish where exposed to 12.5 and 100 μg/L of Cu during 6, 12, 24 and 48 h. Fish gills were collected to TUNEL assay and mRNA expression analysis of selected genes by real time PCR. An approach to different apoptosis pathways was done selecting p53, caspase-8, caspase-9 and apoptosis inducing factor (AIF) genes. The higher incidence of TUNEL-positive cells, in gill epithelia of the exposed fish, proved that Cu induced apoptosis. The results suggest that different apoptosis pathways are triggered by Cu at different time points of the exposure period, as the increase in transcripts was sequential, instead of simultaneous. Apoptosis seems to be initiated via intrinsic pathway (caspase-9), through p53 activation; then followed by the extrinsic pathway (caspase-8) and finally by the caspase-independent pathway (AIF). A possible model for Cu-induce apoptosis pathways is proposed.</text>
      <sentence>
        <offset>0</offset>
        <text>Copper induced upregulation of apoptosis related genes in zebrafish (Danio rerio) gill.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="0" length="6"/>
          <text>Copper</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>88</offset>
        <text>Copper (Cu) is an essential micronutrient that, when present in high concentrations, becomes toxic to aquatic organisms.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="88" length="6"/>
          <text>Copper</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="96" length="2"/>
          <text>Cu</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>209</offset>
        <text>It is known that Cu toxicity may induce apoptotic cell death.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="226" length="2"/>
          <text>Cu</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>271</offset>
        <text>However, the precise mechanism and the pathways that are activated, in fish, are still unclear.</text>
      </sentence>
      <sentence>
        <offset>367</offset>
        <text>Thus, this study aimed to assess which apoptotic pathways are triggered by Cu, in zebrafish (Danio rerio) gill, the main target of waterborne pollutants.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="442" length="2"/>
          <text>Cu</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>521</offset>
        <text>Fish where exposed to 12.5 and 100 μg/L of Cu during 6, 12, 24 and 48 h.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="564" length="2"/>
          <text>Cu</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>594</offset>
        <text>Fish gills were collected to TUNEL assay and mRNA expression analysis of selected genes by real time PCR.</text>
      </sentence>
      <sentence>
        <offset>700</offset>
        <text>An approach to different apoptosis pathways was done selecting p53, caspase-8, caspase-9 and apoptosis inducing factor (AIF) genes.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="763" length="3"/>
          <text>p53</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-8</infon>
          <location offset="768" length="9"/>
          <text>caspase-8</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-9</infon>
          <location offset="779" length="9"/>
          <text>caspase-9</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apoptosis inducing factor</infon>
          <location offset="793" length="25"/>
          <text>apoptosis inducing factor</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aif</infon>
          <location offset="820" length="3"/>
          <text>AIF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>832</offset>
        <text>The higher incidence of TUNEL-positive cells, in gill epithelia of the exposed fish, proved that Cu induced apoptosis.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="929" length="2"/>
          <text>Cu</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>951</offset>
        <text>The results suggest that different apoptosis pathways are triggered by Cu at different time points of the exposure period, as the increase in transcripts was sequential, instead of simultaneous.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="1022" length="2"/>
          <text>Cu</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1146</offset>
        <text>Apoptosis seems to be initiated via intrinsic pathway (caspase-9), through p53 activation; then followed by the extrinsic pathway (caspase-8) and finally by the caspase-independent pathway (AIF).</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-9</infon>
          <location offset="1201" length="9"/>
          <text>caspase-9</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="1221" length="3"/>
          <text>p53</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-8</infon>
          <location offset="1277" length="9"/>
          <text>caspase-8</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">caspase</infon>
          <location offset="1307" length="7"/>
          <text>caspase</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aif</infon>
          <location offset="1336" length="3"/>
          <text>AIF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1342</offset>
        <text>A possible model for Cu-induce apoptosis pathways is proposed.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="1363" length="2"/>
          <text>Cu</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23371303</id>
    <passage>
      <offset>0</offset>
      <text>Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.	Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. This review summarizes the existing data published for ceftazidime-avibactam, including relevant chemistry, mechanisms of action and resistance, microbiology, pharmacokinetics, pharmacodynamics, and efficacy and safety data from animal and human trials. Although not a β-lactam, the chemical structure of avibactam closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to β-lactamases. Very little is known about the potential for avibactam to select for resistance. The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of β-lactamase enzyme(s). Against Pseudomonas aeruginosa, the addition of avibactam also improves the activity of ceftazidime (~fourfold MIC reduction). Limited data suggest that the addition of avibactam does not improve the activity of ceftazidime versus Acinetobacter species or most anaerobic bacteria (exceptions: Bacteroides fragilis, Clostridium perfringens, Prevotella spp. and Porphyromonas spp.). The pharmacokinetics of avibactam follow a two-compartment model and do not appear to be altered by the co-administration of ceftazidime. The maximum plasma drug concentration (C(max)) and area under the plasma concentration-time curve (AUC) of avibactam increase linearly with doses ranging from 50 mg to 2,000 mg. The mean volume of distribution and half-life of 22 L (~0.3 L/kg) and ~2 hours, respectively, are similar to ceftazidime. Like ceftazidime, avibactam is primarily renally excreted, and clearance correlates with creatinine clearance. Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates. The safety and tolerability of ceftazidime-avibactam has been reported in three phase I pharmacokinetic studies and two phase II clinical studies. Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus ß-lactamase-producing Gram-negative bacilli. The exact roles for ceftazidime-avibactam will be defined by efficacy and safety data from further clinical trials. Potential future roles for ceftazidime-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases. In addition, ceftazidime-avibactam may be used in combination (with metronidazole) for suspected polymicrobial infections. Finally, the increased activity of ceftazidime-avibactam versus P. aeruginosa may be of clinical benefit in patients with suspected or documented P. aeruginosa infections.</text>
      <sentence>
        <offset>0</offset>
        <text>Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.</text>
        <annotation id="T47">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="0" length="11"/>
          <text>Ceftazidime</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="12" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cephalosporin</infon>
          <location offset="31" length="13"/>
          <text>cephalosporin</text>
        </annotation>
        <annotation id="T62">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-lactamase</infon>
          <location offset="45" length="11"/>
          <text>β-lactamase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T48" role="head"/>
          <node refid="T62" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T47" role="head"/>
          <node refid="T62" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>80</offset>
        <text>Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="80" length="9"/>
          <text>Avibactam</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nxl104</infon>
          <location offset="100" length="6"/>
          <text>NXL104</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ave1330a</infon>
          <location offset="108" length="8"/>
          <text>AVE1330A</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">β-lactam</infon>
          <location offset="137" length="8"/>
          <text>β-lactam</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ambler class a and c β-lactamases</infon>
          <location offset="201" length="33"/>
          <text>Ambler class A and C β-lactamases</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ambler class d</infon>
          <location offset="244" length="14"/>
          <text>Ambler class D</text>
        </annotation>
        <annotation id="T60">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-lactamase</infon>
          <location offset="147" length="11"/>
          <text>β-lactamase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T60" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T30" role="head"/>
          <node refid="T60" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T30" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T60" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>268</offset>
        <text>This review summarizes the existing data published for ceftazidime-avibactam, including relevant chemistry, mechanisms of action and resistance, microbiology, pharmacokinetics, pharmacodynamics, and efficacy and safety data from animal and human trials.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="323" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="335" length="9"/>
          <text>avibactam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>522</offset>
        <text>Although not a β-lactam, the chemical structure of avibactam closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to β-lactamases.</text>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">β-lactam</infon>
          <location offset="537" length="8"/>
          <text>β-lactam</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="573" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cephem</infon>
          <location offset="617" length="6"/>
          <text>cephem</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="650" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T59">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-lactamases</infon>
          <location offset="697" length="12"/>
          <text>β-lactamases</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T40" role="head"/>
          <node refid="T59" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T41" role="head"/>
          <node refid="T59" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>711</offset>
        <text>Very little is known about the potential for avibactam to select for resistance.</text>
        <annotation id="T43">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="756" length="9"/>
          <text>avibactam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>792</offset>
        <text>The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of β-lactamase enzyme(s).</text>
        <annotation id="T44">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="808" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="914" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T61">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-lactamase</infon>
          <location offset="1008" length="11"/>
          <text>β-lactamase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T44" role="head"/>
          <node refid="T61" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T45" role="head"/>
          <node refid="T61" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1031</offset>
        <text>Against Pseudomonas aeruginosa, the addition of avibactam also improves the activity of ceftazidime (~fourfold MIC reduction).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="1119" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="1079" length="9"/>
          <text>avibactam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1158</offset>
        <text>Limited data suggest that the addition of avibactam does not improve the activity of ceftazidime versus Acinetobacter species or most anaerobic bacteria (exceptions: Bacteroides fragilis, Clostridium perfringens, Prevotella spp. and Porphyromonas spp.).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="1200" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="1243" length="11"/>
          <text>ceftazidime</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1412</offset>
        <text>The pharmacokinetics of avibactam follow a two-compartment model and do not appear to be altered by the co-administration of ceftazidime.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="1436" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="1537" length="11"/>
          <text>ceftazidime</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1550</offset>
        <text>The maximum plasma drug concentration (C(max)) and area under the plasma concentration-time curve (AUC) of avibactam increase linearly with doses ranging from 50 mg to 2,000 mg.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="1657" length="9"/>
          <text>avibactam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1728</offset>
        <text>The mean volume of distribution and half-life of 22 L (~0.3 L/kg) and ~2 hours, respectively, are similar to ceftazidime.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="1837" length="11"/>
          <text>ceftazidime</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1850</offset>
        <text>Like ceftazidime, avibactam is primarily renally excreted, and clearance correlates with creatinine clearance.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="1855" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="1868" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">creatinine</infon>
          <location offset="1939" length="10"/>
          <text>creatinine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1961</offset>
        <text>Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="1995" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="2007" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="2118" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="2179" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="2191" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbapenem</infon>
          <location offset="2229" length="10"/>
          <text>carbapenem</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cephalosporin</infon>
          <location offset="2360" length="13"/>
          <text>cephalosporin</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">β-lactamase</infon>
          <location offset="2048" length="11"/>
          <text>β-lactamase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T52" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T52" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2408</offset>
        <text>The safety and tolerability of ceftazidime-avibactam has been reported in three phase I pharmacokinetic studies and two phase II clinical studies.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="2439" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="2451" length="9"/>
          <text>avibactam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2555</offset>
        <text>Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus ß-lactamase-producing Gram-negative bacilli.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="2555" length="11"/>
          <text>Ceftazidime</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="2567" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="2749" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="2793" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ß-lactamase</infon>
          <location offset="2812" length="11"/>
          <text>ß-lactamase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T26" role="head"/>
          <node refid="T53" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T27" role="head"/>
          <node refid="T53" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2857</offset>
        <text>The exact roles for ceftazidime-avibactam will be defined by efficacy and safety data from further clinical trials.</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="2877" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="2889" length="9"/>
          <text>avibactam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2973</offset>
        <text>Potential future roles for ceftazidime-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases.</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="3000" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="3012" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">extended-spectrum ß-lactamase</infon>
          <location offset="3134" length="29"/>
          <text>extended-spectrum ß-lactamase</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">esbl</infon>
          <location offset="3165" length="4"/>
          <text>ESBL</text>
        </annotation>
        <annotation id="T56">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">klebsiella pneumoniae carbapenemases</infon>
          <location offset="3172" length="36"/>
          <text>Klebsiella pneumoniae carbapenemases</text>
        </annotation>
        <annotation id="T57">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kpcs</infon>
          <location offset="3210" length="4"/>
          <text>KPCs</text>
        </annotation>
        <annotation id="T58">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampc ß-lactamases</infon>
          <location offset="3223" length="17"/>
          <text>AmpC ß-lactamases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>3242</offset>
        <text>In addition, ceftazidime-avibactam may be used in combination (with metronidazole) for suspected polymicrobial infections.</text>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="3255" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="3267" length="9"/>
          <text>avibactam</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metronidazole</infon>
          <location offset="3310" length="13"/>
          <text>metronidazole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>3365</offset>
        <text>Finally, the increased activity of ceftazidime-avibactam versus P. aeruginosa may be of clinical benefit in patients with suspected or documented P. aeruginosa infections.</text>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceftazidime</infon>
          <location offset="3400" length="11"/>
          <text>ceftazidime</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avibactam</infon>
          <location offset="3412" length="9"/>
          <text>avibactam</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17334413</id>
    <passage>
      <offset>0</offset>
      <text>H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway.	Histamine regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, H3R and H4R). As H3R exerts their effects by coupling to Galpha(i/o) proteins reducing adenosine 3', 5'-monophosphate (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth. We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats. BDL rats (immediately after BDL) were treated daily with RAMH, thioperamide maleate or histamine in the absence/presence of thioperamide maleate for 1 week. Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, cAMP levels and PKA, ERK1/2 and Elk-1 phosphorylation. Cholangiocytes from normal and BDL rats express H3R. The expression of H3R mRNA increased in BDL compared to normal cholangiocytes. Histamine decreased cholangiocyte growth of BDL rats to a lower extent than that observed in BDL RAMH-treated rats; histamine-induced inhibition of cholangiocyte growth was partly blocked by thioperamide maleate. In BDL rats treated with thioperamide maleate, cholangiocyte hyperplasia was slightly higher than that of BDL rats. In vitro, RAMH inhibited the proliferation of BDL cholangiocytes. RAMH inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/ERK1/2/Elk-1 phosphorylation. Downregulation of cAMP-dependent PKA/ERK1/2/Elk-1 phosphorylation (by activation of H3R) is important in the inhibition of cholangiocyte growth in liver diseases.</text>
      <sentence>
        <offset>0</offset>
        <text>H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway.</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="3" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="91" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T60">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h3 histamine receptor</infon>
          <location offset="0" length="21"/>
          <text>H3 histamine receptor</text>
        </annotation>
        <annotation id="T61">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="110" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T62">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">elk-1</infon>
          <location offset="117" length="5"/>
          <text>ELK-1</text>
        </annotation>
        <annotation id="T63">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">camp-dependent pka</infon>
          <location offset="91" length="18"/>
          <text>cAMP-dependent PKA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>132</offset>
        <text>Histamine regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, H3R and H4R).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="132" length="9"/>
          <text>Histamine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="186" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h3r</infon>
          <location offset="235" length="3"/>
          <text>H3R</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h4r</infon>
          <location offset="243" length="3"/>
          <text>H4R</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">histamine g-coupled receptor proteins</infon>
          <location offset="186" length="37"/>
          <text>histamine G-coupled receptor proteins</text>
        </annotation>
        <annotation id="T57">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h1r</infon>
          <location offset="225" length="3"/>
          <text>H1R</text>
        </annotation>
        <annotation id="T59">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h2r</infon>
          <location offset="230" length="3"/>
          <text>H2R</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T49" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T59" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>249</offset>
        <text>As H3R exerts their effects by coupling to Galpha(i/o) proteins reducing adenosine 3', 5'-monophosphate (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine 3', 5'-monophosphate</infon>
          <location offset="322" length="30"/>
          <text>adenosine 3', 5'-monophosphate</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="354" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">h3r</infon>
          <location offset="252" length="3"/>
          <text>H3R</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">galpha(i/o)</infon>
          <location offset="292" length="11"/>
          <text>Galpha(i/o)</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h3r</infon>
          <location offset="462" length="3"/>
          <text>H3R</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>503</offset>
        <text>We posed the following questions: (1) Do cholangiocytes express H3R?</text>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">h3r</infon>
          <location offset="567" length="3"/>
          <text>H3R</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>572</offset>
        <text>(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(r)-(alpha)-(-)-methylhistamine dihydrobromide</infon>
          <location offset="607" length="46"/>
          <text>(R)-(alpha)-(-)-methylhistamine dihydrobromide</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ramh</infon>
          <location offset="655" length="4"/>
          <text>RAMH</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thioperamide maleate</infon>
          <location offset="676" length="20"/>
          <text>thioperamide maleate</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="717" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thioperamide maleate</infon>
          <location offset="755" length="20"/>
          <text>thioperamide maleate</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ramh</infon>
          <location offset="860" length="4"/>
          <text>RAMH</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="922" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h3r</infon>
          <location offset="662" length="3"/>
          <text>H3R</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h3r</infon>
          <location offset="698" length="3"/>
          <text>H3R</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein kinase a</infon>
          <location offset="956" length="16"/>
          <text>protein kinase A</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pka</infon>
          <location offset="974" length="3"/>
          <text>PKA</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">extracellular signal-regulated kinase 1/2</infon>
          <location offset="979" length="41"/>
          <text>extracellular signal-regulated kinase 1/2</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="1022" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ets-like gene-1</infon>
          <location offset="1030" length="15"/>
          <text>ets-like gene-1</text>
        </annotation>
        <annotation id="T56">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">elk-1</infon>
          <location offset="1047" length="5"/>
          <text>Elk-1</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T21" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T20" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T22" role="head"/>
          <node refid="T50" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1055</offset>
        <text>The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats.</text>
        <annotation id="T58">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h3r</infon>
          <location offset="1073" length="3"/>
          <text>H3R</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1225</offset>
        <text>BDL rats (immediately after BDL) were treated daily with RAMH, thioperamide maleate or histamine in the absence/presence of thioperamide maleate for 1 week.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ramh</infon>
          <location offset="1282" length="4"/>
          <text>RAMH</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thioperamide maleate</infon>
          <location offset="1288" length="20"/>
          <text>thioperamide maleate</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="1312" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thioperamide maleate</infon>
          <location offset="1349" length="20"/>
          <text>thioperamide maleate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1382</offset>
        <text>Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, cAMP levels and PKA, ERK1/2 and Elk-1 phosphorylation.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ramh</infon>
          <location offset="1427" length="4"/>
          <text>RAMH</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ramh</infon>
          <location offset="1496" length="4"/>
          <text>RAMH</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="1544" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pka</infon>
          <location offset="1560" length="3"/>
          <text>PKA</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="1565" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">elk-1</infon>
          <location offset="1576" length="5"/>
          <text>Elk-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1599</offset>
        <text>Cholangiocytes from normal and BDL rats express H3R.</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h3r</infon>
          <location offset="1647" length="3"/>
          <text>H3R</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1652</offset>
        <text>The expression of H3R mRNA increased in BDL compared to normal cholangiocytes.</text>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h3r</infon>
          <location offset="1670" length="3"/>
          <text>H3R</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1731</offset>
        <text>Histamine decreased cholangiocyte growth of BDL rats to a lower extent than that observed in BDL RAMH-treated rats; histamine-induced inhibition of cholangiocyte growth was partly blocked by thioperamide maleate.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="1731" length="9"/>
          <text>Histamine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ramh</infon>
          <location offset="1828" length="4"/>
          <text>RAMH</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="1847" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thioperamide maleate</infon>
          <location offset="1922" length="20"/>
          <text>thioperamide maleate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1944</offset>
        <text>In BDL rats treated with thioperamide maleate, cholangiocyte hyperplasia was slightly higher than that of BDL rats.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thioperamide maleate</infon>
          <location offset="1969" length="20"/>
          <text>thioperamide maleate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2060</offset>
        <text>In vitro, RAMH inhibited the proliferation of BDL cholangiocytes.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ramh</infon>
          <location offset="2070" length="4"/>
          <text>RAMH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2126</offset>
        <text>RAMH inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/ERK1/2/Elk-1 phosphorylation.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ramh</infon>
          <location offset="2126" length="4"/>
          <text>RAMH</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="2196" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pka</infon>
          <location offset="2212" length="3"/>
          <text>PKA</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="2216" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">elk-1</infon>
          <location offset="2223" length="5"/>
          <text>Elk-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2246</offset>
        <text>Downregulation of cAMP-dependent PKA/ERK1/2/Elk-1 phosphorylation (by activation of H3R) is important in the inhibition of cholangiocyte growth in liver diseases.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="2264" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pka</infon>
          <location offset="2279" length="3"/>
          <text>PKA</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="2283" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">elk-1</infon>
          <location offset="2290" length="5"/>
          <text>Elk-1</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h3r</infon>
          <location offset="2330" length="3"/>
          <text>H3R</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23265901</id>
    <passage>
      <offset>0</offset>
      <text>Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.	We report the discovery of novel series of highly potent TLR7 agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety. The introduction of the amino group resulted in not only improved water solubility but also enhanced TLR7 agonistic activity. In particular compound 20 (DSR-6434) indicated an optimal balance between the agonistic potency and high water solubility. It also demonstrated a strong antitumor effect in vivo by intravenous administration in a tumor bearing mice model.</text>
      <sentence>
        <offset>0</offset>
        <text>Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8-oxoadenine</infon>
          <location offset="28" length="12"/>
          <text>8-oxoadenine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">toll-like receptor 7</infon>
          <location offset="63" length="20"/>
          <text>Toll-like receptor 7</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>121</offset>
        <text>We report the discovery of novel series of highly potent TLR7 agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tertiary amines</infon>
          <location offset="262" length="15"/>
          <text>tertiary amines</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="287" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenine</infon>
          <location offset="308" length="7"/>
          <text>adenine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8-oxoadenines</infon>
          <location offset="201" length="13"/>
          <text>8-oxoadenines</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tlr7</infon>
          <location offset="178" length="4"/>
          <text>TLR7</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T6" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>324</offset>
        <text>The introduction of the amino group resulted in not only improved water solubility but also enhanced TLR7 agonistic activity.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino</infon>
          <location offset="348" length="5"/>
          <text>amino</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tlr7</infon>
          <location offset="425" length="4"/>
          <text>TLR7</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>450</offset>
        <text>In particular compound 20 (DSR-6434) indicated an optimal balance between the agonistic potency and high water solubility.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dsr-6434</infon>
          <location offset="477" length="8"/>
          <text>DSR-6434</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>573</offset>
        <text>It also demonstrated a strong antitumor effect in vivo by intravenous administration in a tumor bearing mice model.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23578392</id>
    <passage>
      <offset>0</offset>
      <text>The time point of β-catenin knockout in hepatocytes determines their response to xenobiotic activation of the constitutive androstane receptor.	The constitutive androstane receptor (CAR) controls the expression of drug-metabolizing enzymes and regulates hepatocyte proliferation. Studies with transgenic mice with an early postnatal conditional hepatocyte-specific knockout of the β-catenin gene Ctnnb1 revealed that β-catenin deficiency decreases the magnitude of induction of drug-metabolizing enzymes by CAR activators, abrogates zonal differences in the hepatocytes' susceptibility to these compounds, and impacts on hepatocyte proliferation. These data, however, do not allow distinguishing between effects caused by β-catenin deficiency during postnatal liver development and acute effects of β-catenin deficiency in the adult animal at the time point of CAR activation. Therefore, CAR activation was now studied in a different mouse model allowing for the hepatocyte-specific knockout of β-catenin in adult mice. Treatment of these mice with 3mg/kg body weight of the model CAR activator 1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) confirmed previous findings related to the coordinate regulation of drug metabolism by β-catenin and CAR. More importantly, the present study clarified that the impact of β-catenin signaling on CAR-mediated enzyme induction in the liver is not merely due to developmental defects caused by a postnatal lack of β-catenin, but depends on the presence of β-catenin at the time point of xenobiotic treatment. The study also revealed interesting differences between the two mouse models: hepatic zonation of TCPOBOP-dependent induction of drug-metabolizing enzymes was restored in mice with late knockout of β-catenin, and the strong proliferative response of female mice was exclusively abolished when using animals with a late β-catenin knockout. This suggests a β-catenin-dependent postnatal priming of hepatocytes during postnatal liver development, later affecting the proliferative response of adult animals to CAR-activating xenobiotics.</text>
      <sentence>
        <offset>0</offset>
        <text>The time point of β-catenin knockout in hepatocytes determines their response to xenobiotic activation of the constitutive androstane receptor.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androstane</infon>
          <location offset="123" length="10"/>
          <text>androstane</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">constitutive androstane receptor</infon>
          <location offset="110" length="32"/>
          <text>constitutive androstane receptor</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="18" length="9"/>
          <text>β-catenin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>144</offset>
        <text>The constitutive androstane receptor (CAR) controls the expression of drug-metabolizing enzymes and regulates hepatocyte proliferation.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androstane</infon>
          <location offset="161" length="10"/>
          <text>androstane</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">car</infon>
          <location offset="182" length="3"/>
          <text>CAR</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">constitutive androstane receptor</infon>
          <location offset="148" length="32"/>
          <text>constitutive androstane receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>280</offset>
        <text>Studies with transgenic mice with an early postnatal conditional hepatocyte-specific knockout of the β-catenin gene Ctnnb1 revealed that β-catenin deficiency decreases the magnitude of induction of drug-metabolizing enzymes by CAR activators, abrogates zonal differences in the hepatocytes' susceptibility to these compounds, and impacts on hepatocyte proliferation.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="381" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ctnnb1</infon>
          <location offset="396" length="6"/>
          <text>Ctnnb1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="417" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">car</infon>
          <location offset="507" length="3"/>
          <text>CAR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>647</offset>
        <text>These data, however, do not allow distinguishing between effects caused by β-catenin deficiency during postnatal liver development and acute effects of β-catenin deficiency in the adult animal at the time point of CAR activation.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="722" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="799" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">car</infon>
          <location offset="861" length="3"/>
          <text>CAR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>877</offset>
        <text>Therefore, CAR activation was now studied in a different mouse model allowing for the hepatocyte-specific knockout of β-catenin in adult mice.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">car</infon>
          <location offset="888" length="3"/>
          <text>CAR</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="995" length="9"/>
          <text>β-catenin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1020</offset>
        <text>Treatment of these mice with 3mg/kg body weight of the model CAR activator 1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) confirmed previous findings related to the coordinate regulation of drug metabolism by β-catenin and CAR.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene</infon>
          <location offset="1095" length="43"/>
          <text>1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcpobop</infon>
          <location offset="1140" length="7"/>
          <text>TCPOBOP</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="1236" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">car</infon>
          <location offset="1250" length="3"/>
          <text>CAR</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">car</infon>
          <location offset="1081" length="3"/>
          <text>CAR</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1255</offset>
        <text>More importantly, the present study clarified that the impact of β-catenin signaling on CAR-mediated enzyme induction in the liver is not merely due to developmental defects caused by a postnatal lack of β-catenin, but depends on the presence of β-catenin at the time point of xenobiotic treatment.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="1320" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">car</infon>
          <location offset="1343" length="3"/>
          <text>CAR</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="1459" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="1501" length="9"/>
          <text>β-catenin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1554</offset>
        <text>The study also revealed interesting differences between the two mouse models: hepatic zonation of TCPOBOP-dependent induction of drug-metabolizing enzymes was restored in mice with late knockout of β-catenin, and the strong proliferative response of female mice was exclusively abolished when using animals with a late β-catenin knockout.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcpobop</infon>
          <location offset="1652" length="7"/>
          <text>TCPOBOP</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="1752" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="1873" length="9"/>
          <text>β-catenin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1893</offset>
        <text>This suggests a β-catenin-dependent postnatal priming of hepatocytes during postnatal liver development, later affecting the proliferative response of adult animals to CAR-activating xenobiotics.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">β-catenin</infon>
          <location offset="1909" length="9"/>
          <text>β-catenin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">car</infon>
          <location offset="2061" length="3"/>
          <text>CAR</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23044094</id>
    <passage>
      <offset>0</offset>
      <text>Establishment of an in vitro photoallergy test using NCTC2544 cells and IL-18 production.	Differentiation between photoallergenic and phototoxic reactions induced by low molecular weight compounds represents a current problem. The use of keratinocytes as a potential tool for the detection of photoallergens as opposed to photoirritants is considered an interesting strategy for developing in vitro methods. We have previously demonstrated the possibility to use the human keratinocyte cell line NCTC2455 and the production of interleukin-18 (IL-18) to screen low molecular weight sensitizers. The purpose of this work was to explore the possibility to use the NCTC2544 assay to identify photoallergens and discriminate from phototoxic chemicals. First, we identified suitable condition of UV-irradiation (3.5 J/cm(2)) by investigating the effect of UVA irradiation on intracellular IL-18 on untreated or chloropromazine (a representative phototoxic compound)-treated NCTC2544 cells. Then, the effect of UVA-irradiation over NCTC2544 cells treated with increasing concentrations of 15 compounds including photoallergens (benzophenone, 4-ter-butyl-4-methoxy-dibenzoylmethane, 2-ethylexyl-p-methoxycinnamate, ketoprofen, 6-methylcumarin); photoirritant and photoallergen (4-aminobenzoic acid, chlorpromazine, promethazine); photoirritants (acridine, ibuprofen, 8-methoxypsoralen, retinoic acid); and negative compounds (lactic acid, SDS and p-phenilendiamine) was investigated. Twenty-four hours after exposure, cytotoxicity was evaluated by the MTT assay or LDH leakage, while ELISA was used to measure the production of IL-18. At the maximal concentration assayed with non-cytotoxic effects (CV80 under irradiated condition), all tested photoallergens induced a significant and a dose-dependent increase of intracellular IL-18 following UVA irratiation, whereas photoirritants failed. We suggest that this system may be useful for the in vitro evaluation of the photoallergic potential of chemicals.</text>
      <sentence>
        <offset>0</offset>
        <text>Establishment of an in vitro photoallergy test using NCTC2544 cells and IL-18 production.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-18</infon>
          <location offset="72" length="5"/>
          <text>IL-18</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>90</offset>
        <text>Differentiation between photoallergenic and phototoxic reactions induced by low molecular weight compounds represents a current problem.</text>
      </sentence>
      <sentence>
        <offset>227</offset>
        <text>The use of keratinocytes as a potential tool for the detection of photoallergens as opposed to photoirritants is considered an interesting strategy for developing in vitro methods.</text>
      </sentence>
      <sentence>
        <offset>408</offset>
        <text>We have previously demonstrated the possibility to use the human keratinocyte cell line NCTC2455 and the production of interleukin-18 (IL-18) to screen low molecular weight sensitizers.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin-18</infon>
          <location offset="527" length="14"/>
          <text>interleukin-18</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-18</infon>
          <location offset="543" length="5"/>
          <text>IL-18</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>594</offset>
        <text>The purpose of this work was to explore the possibility to use the NCTC2544 assay to identify photoallergens and discriminate from phototoxic chemicals.</text>
      </sentence>
      <sentence>
        <offset>747</offset>
        <text>First, we identified suitable condition of UV-irradiation (3.5 J/cm(2)) by investigating the effect of UVA irradiation on intracellular IL-18 on untreated or chloropromazine (a representative phototoxic compound)-treated NCTC2544 cells.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloropromazine</infon>
          <location offset="905" length="15"/>
          <text>chloropromazine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-18</infon>
          <location offset="883" length="5"/>
          <text>IL-18</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>984</offset>
        <text>Then, the effect of UVA-irradiation over NCTC2544 cells treated with increasing concentrations of 15 compounds including photoallergens (benzophenone, 4-ter-butyl-4-methoxy-dibenzoylmethane, 2-ethylexyl-p-methoxycinnamate, ketoprofen, 6-methylcumarin); photoirritant and photoallergen (4-aminobenzoic acid, chlorpromazine, promethazine); photoirritants (acridine, ibuprofen, 8-methoxypsoralen, retinoic acid); and negative compounds (lactic acid, SDS and p-phenilendiamine) was investigated.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzophenone</infon>
          <location offset="1121" length="12"/>
          <text>benzophenone</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-ter-butyl-4-methoxy-dibenzoylmethane, 2-ethylexyl-p-methoxycinnamate</infon>
          <location offset="1135" length="70"/>
          <text>4-ter-butyl-4-methoxy-dibenzoylmethane, 2-ethylexyl-p-methoxycinnamate</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketoprofen</infon>
          <location offset="1207" length="10"/>
          <text>ketoprofen</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-methylcumarin</infon>
          <location offset="1219" length="15"/>
          <text>6-methylcumarin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-aminobenzoic acid</infon>
          <location offset="1270" length="19"/>
          <text>4-aminobenzoic acid</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpromazine</infon>
          <location offset="1291" length="14"/>
          <text>chlorpromazine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">promethazine</infon>
          <location offset="1307" length="12"/>
          <text>promethazine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acridine</infon>
          <location offset="1338" length="8"/>
          <text>acridine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="1348" length="9"/>
          <text>ibuprofen</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8-methoxypsoralen</infon>
          <location offset="1359" length="17"/>
          <text>8-methoxypsoralen</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="1378" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactic acid</infon>
          <location offset="1418" length="11"/>
          <text>lactic acid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sds</infon>
          <location offset="1431" length="3"/>
          <text>SDS</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-phenilendiamine</infon>
          <location offset="1439" length="17"/>
          <text>p-phenilendiamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1476</offset>
        <text>Twenty-four hours after exposure, cytotoxicity was evaluated by the MTT assay or LDH leakage, while ELISA was used to measure the production of IL-18.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mtt</infon>
          <location offset="1544" length="3"/>
          <text>MTT</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldh</infon>
          <location offset="1557" length="3"/>
          <text>LDH</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-18</infon>
          <location offset="1620" length="5"/>
          <text>IL-18</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1627</offset>
        <text>At the maximal concentration assayed with non-cytotoxic effects (CV80 under irradiated condition), all tested photoallergens induced a significant and a dose-dependent increase of intracellular IL-18 following UVA irratiation, whereas photoirritants failed.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-18</infon>
          <location offset="1821" length="5"/>
          <text>IL-18</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1885</offset>
        <text>We suggest that this system may be useful for the in vitro evaluation of the photoallergic potential of chemicals.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15963471</id>
    <passage>
      <offset>0</offset>
      <text>Effect of thiazolidinediones on equilibrative nucleoside transporter-1 in human aortic smooth muscle cells.	Thiazolidinediones are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism. These drugs also have vasodilatory and anti-proliferative effects on vascular smooth muscle cells. However the mechanisms for these actions are not fully understood. Adenosine is a vasodilator and a substrate of equilibrative nucleoside transporters (ENT). The present study studied the effects of three thiazolidinediones, troglitazone, pioglitazone and ciglitazone, on ENT1 in the human aortic smooth muscle cells (HASMCs). Although incubating HASMCs for 48h with thiazolidinediones had no effect on ENT1 mRNA and protein levels, troglitazone acutely inhibited [3H]adenosine uptake and [3H]NBMPR binding of HASMCs with IC50 values of 2.35+/-0.35 and 3.99+/-0.57microM, respectively. The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1. In contrast, pioglitazone and ciglitazone had minimal effects on [3H]adenosine uptake by HASMCs. Troglitazone differs from pioglitazone and ciglitazone in that its side-chain contains a Vitamin E moiety. The difference in structure of troglitazone did not account for its inhibitory effect on ENT1 because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs. Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that troglitazone inhibited ENT1 but had no effect on ENT2. From these results, it is suggested that troglitazone may enhance the vasodilatory effect of adenosine by inhibiting ENT1. Pharmacologically, troglitazone is a novel inhibitor of ENT1.</text>
      <sentence>
        <offset>0</offset>
        <text>Effect of thiazolidinediones on equilibrative nucleoside transporter-1 in human aortic smooth muscle cells.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiazolidinediones</infon>
          <location offset="10" length="18"/>
          <text>thiazolidinediones</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">equilibrative nucleoside transporter-1</infon>
          <location offset="32" length="38"/>
          <text>equilibrative nucleoside transporter-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>108</offset>
        <text>Thiazolidinediones are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiazolidinediones</infon>
          <location offset="108" length="18"/>
          <text>Thiazolidinediones</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="354" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor gamma</infon>
          <location offset="220" length="48"/>
          <text>peroxisome proliferator-activated receptor gamma</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar(gamma)</infon>
          <location offset="270" length="11"/>
          <text>PPAR(gamma)</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="317" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="182" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>384</offset>
        <text>These drugs also have vasodilatory and anti-proliferative effects on vascular smooth muscle cells.</text>
      </sentence>
      <sentence>
        <offset>483</offset>
        <text>However the mechanisms for these actions are not fully understood.</text>
      </sentence>
      <sentence>
        <offset>550</offset>
        <text>Adenosine is a vasodilator and a substrate of equilibrative nucleoside transporters (ENT).</text>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">equilibrative nucleoside transporters</infon>
          <location offset="596" length="37"/>
          <text>equilibrative nucleoside transporters</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ent</infon>
          <location offset="635" length="3"/>
          <text>ENT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>641</offset>
        <text>The present study studied the effects of three thiazolidinediones, troglitazone, pioglitazone and ciglitazone, on ENT1 in the human aortic smooth muscle cells (HASMCs).</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiazolidinediones</infon>
          <location offset="688" length="18"/>
          <text>thiazolidinediones</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="708" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pioglitazone</infon>
          <location offset="722" length="12"/>
          <text>pioglitazone</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ciglitazone</infon>
          <location offset="739" length="11"/>
          <text>ciglitazone</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ent1</infon>
          <location offset="755" length="4"/>
          <text>ENT1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>810</offset>
        <text>Although incubating HASMCs for 48h with thiazolidinediones had no effect on ENT1 mRNA and protein levels, troglitazone acutely inhibited [3H]adenosine uptake and [3H]NBMPR binding of HASMCs with IC50 values of 2.35+/-0.35 and 3.99+/-0.57microM, respectively.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiazolidinediones</infon>
          <location offset="850" length="18"/>
          <text>thiazolidinediones</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="916" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]adenosine</infon>
          <location offset="947" length="13"/>
          <text>[3H]adenosine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]nbmpr</infon>
          <location offset="972" length="9"/>
          <text>[3H]NBMPR</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ent1</infon>
          <location offset="886" length="4"/>
          <text>ENT1</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T25" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1069</offset>
        <text>The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1166" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1083" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar(gamma)</infon>
          <location offset="1108" length="11"/>
          <text>PPAR(gamma)</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ent1</infon>
          <location offset="1210" length="4"/>
          <text>ENT1</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ent1</infon>
          <location offset="1099" length="4"/>
          <text>ENT1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1216</offset>
        <text>In contrast, pioglitazone and ciglitazone had minimal effects on [3H]adenosine uptake by HASMCs.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pioglitazone</infon>
          <location offset="1229" length="12"/>
          <text>pioglitazone</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ciglitazone</infon>
          <location offset="1246" length="11"/>
          <text>ciglitazone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]adenosine</infon>
          <location offset="1281" length="13"/>
          <text>[3H]adenosine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1313</offset>
        <text>Troglitazone differs from pioglitazone and ciglitazone in that its side-chain contains a Vitamin E moiety.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1313" length="12"/>
          <text>Troglitazone</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pioglitazone</infon>
          <location offset="1339" length="12"/>
          <text>pioglitazone</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ciglitazone</infon>
          <location offset="1356" length="11"/>
          <text>ciglitazone</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin e</infon>
          <location offset="1402" length="9"/>
          <text>Vitamin E</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1420</offset>
        <text>The difference in structure of troglitazone did not account for its inhibitory effect on ENT1 because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1451" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin e</infon>
          <location offset="1522" length="9"/>
          <text>Vitamin E</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]adenosine</infon>
          <location offset="1548" length="13"/>
          <text>[3H]adenosine</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ent1</infon>
          <location offset="1509" length="4"/>
          <text>ENT1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1580</offset>
        <text>Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that troglitazone inhibited ENT1 but had no effect on ENT2.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1688" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nucleoside transporter</infon>
          <location offset="1590" length="22"/>
          <text>nucleoside transporter</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ent1</infon>
          <location offset="1655" length="4"/>
          <text>ENT1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ent2</infon>
          <location offset="1664" length="4"/>
          <text>ENT2</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ent1</infon>
          <location offset="1711" length="4"/>
          <text>ENT1</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ent2</infon>
          <location offset="1737" length="4"/>
          <text>ENT2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1743</offset>
        <text>From these results, it is suggested that troglitazone may enhance the vasodilatory effect of adenosine by inhibiting ENT1.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1784" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine</infon>
          <location offset="1836" length="9"/>
          <text>adenosine</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ent1</infon>
          <location offset="1860" length="4"/>
          <text>ENT1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1866</offset>
        <text>Pharmacologically, troglitazone is a novel inhibitor of ENT1.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1885" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ent1</infon>
          <location offset="1922" length="4"/>
          <text>ENT1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23265880</id>
    <passage>
      <offset>0</offset>
      <text>A new single-photon emission computed tomography (SPECT) imaging agent for serotonin transporters: [(125)I]Flip-IDAM, (2-((2-((dimethylamino)methyl)-4-iodophenyl)thio)phenyl)methanol.	New ligands for in vivo brain imaging of serotonin transporter (SERT) with single photon emission tomography (SPECT) were prepared and evaluated. An efficient synthesis and radiolabeling of a biphenylthiol, FLIP-IDAM, 4, was accomplished. The affinity of FLIP-IDAM was evaluated by an in vitro inhibitory binding assay using [(125)I]-IDAM as radioligand in rat brain tissue homogenates (K(i) = 0.03 nM). New [(125)I]Flip-IDAM exhibited excellent binding affinity to SERT binding sites with a high hypothalamus to cerebellum ratio of 4 at 30 min post iv injection. The faster in vivo kinetics for brain uptake and a rapid washout from non-specific regions provide excellent signal to noise ratio. This new agent, when labeled with (123)I, may be a useful imaging agent for mapping SERT binding sites in the human brain.</text>
      <sentence>
        <offset>0</offset>
        <text>A new single-photon emission computed tomography (SPECT) imaging agent for serotonin transporters: [(125)I]Flip-IDAM, (2-((2-((dimethylamino)methyl)-4-iodophenyl)thio)phenyl)methanol.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(2-((2-((dimethylamino)methyl)-4-iodophenyl)thio)phenyl)methanol</infon>
          <location offset="118" length="64"/>
          <text>(2-((2-((dimethylamino)methyl)-4-iodophenyl)thio)phenyl)methanol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="75" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(125)i]flip-idam</infon>
          <location offset="99" length="17"/>
          <text>[(125)I]Flip-IDAM</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serotonin transporters</infon>
          <location offset="75" length="22"/>
          <text>serotonin transporters</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>184</offset>
        <text>New ligands for in vivo brain imaging of serotonin transporter (SERT) with single photon emission tomography (SPECT) were prepared and evaluated.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="225" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serotonin transporter</infon>
          <location offset="225" length="21"/>
          <text>serotonin transporter</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="248" length="4"/>
          <text>SERT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>330</offset>
        <text>An efficient synthesis and radiolabeling of a biphenylthiol, FLIP-IDAM, 4, was accomplished.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biphenylthiol</infon>
          <location offset="376" length="13"/>
          <text>biphenylthiol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flip-idam</infon>
          <location offset="391" length="9"/>
          <text>FLIP-IDAM</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>423</offset>
        <text>The affinity of FLIP-IDAM was evaluated by an in vitro inhibitory binding assay using [(125)I]-IDAM as radioligand in rat brain tissue homogenates (K(i) = 0.03 nM).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flip-idam</infon>
          <location offset="439" length="9"/>
          <text>FLIP-IDAM</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(125)i]-idam</infon>
          <location offset="509" length="13"/>
          <text>[(125)I]-IDAM</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>588</offset>
        <text>New [(125)I]Flip-IDAM exhibited excellent binding affinity to SERT binding sites with a high hypothalamus to cerebellum ratio of 4 at 30 min post iv injection.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(125)i]flip-idam</infon>
          <location offset="592" length="17"/>
          <text>[(125)I]Flip-IDAM</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="650" length="4"/>
          <text>SERT</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>748</offset>
        <text>The faster in vivo kinetics for brain uptake and a rapid washout from non-specific regions provide excellent signal to noise ratio.</text>
      </sentence>
      <sentence>
        <offset>880</offset>
        <text>This new agent, when labeled with (123)I, may be a useful imaging agent for mapping SERT binding sites in the human brain.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(123)i</infon>
          <location offset="914" length="6"/>
          <text>(123)I</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="964" length="4"/>
          <text>SERT</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23178164</id>
    <passage>
      <offset>0</offset>
      <text>Constant light disrupts the circadian rhythm of steroidogenic proteins in the rat adrenal gland.	The circadian rhythm of corticosterone (CORT) secretion from the adrenal cortex is regulated by the suprachiasmatic nucleus (SCN), which is entrained to the light-dark cycle. Since the circadian CORT rhythm is associated with circadian expression of the steroidogenic acute regulatory (StAR) protein, we investigated the 24h pattern of hormonal secretion (ACTH and CORT), steroidogenic gene expression (StAR, SF-1, DAX1 and Nurr77) and the expression of genes involved in ACTH signalling (MC2R and MRAP) in rats entrained to a normal light-dark cycle. We found that circadian changes in ACTH and CORT were associated with the circadian expression of all gene targets; with SF-1, Nurr77 and MRAP peaking in the evening, and DAX1 and MC2R peaking in the morning. Since disruption of normal SCN activity by exposure to constant light abolishes the circadian rhythm of CORT in the rat, we also investigated whether the AM-PM variation of our target genes was also disrupted in rats exposed to constant light conditions for 5weeks. We found that the disruption of the AM-PM variation of ACTH and CORT secretion in rats exposed to constant light was accompanied by a loss of AM-PM variation in StAR, SF-1 and DAX1, and a reversed AM-PM variation in Nurr77, MC2R and MRAP. Our data suggest that circadian expression of StAR is regulated by the circadian expression of nuclear receptors and proteins involved in both ACTH signalling and StAR transcription. We propose that ACTH regulates the secretion of CORT via the circadian control of steroidogenic gene pathways that become dysregulated under the influence of constant light.</text>
      <sentence>
        <offset>0</offset>
        <text>Constant light disrupts the circadian rhythm of steroidogenic proteins in the rat adrenal gland.</text>
      </sentence>
      <sentence>
        <offset>97</offset>
        <text>The circadian rhythm of corticosterone (CORT) secretion from the adrenal cortex is regulated by the suprachiasmatic nucleus (SCN), which is entrained to the light-dark cycle.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosterone</infon>
          <location offset="121" length="14"/>
          <text>corticosterone</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cort</infon>
          <location offset="137" length="4"/>
          <text>CORT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>272</offset>
        <text>Since the circadian CORT rhythm is associated with circadian expression of the steroidogenic acute regulatory (StAR) protein, we investigated the 24h pattern of hormonal secretion (ACTH and CORT), steroidogenic gene expression (StAR, SF-1, DAX1 and Nurr77) and the expression of genes involved in ACTH signalling (MC2R and MRAP) in rats entrained to a normal light-dark cycle.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cort</infon>
          <location offset="292" length="4"/>
          <text>CORT</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cort</infon>
          <location offset="462" length="4"/>
          <text>CORT</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">steroidogenic acute regulatory (star) protein</infon>
          <location offset="351" length="45"/>
          <text>steroidogenic acute regulatory (StAR) protein</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acth</infon>
          <location offset="453" length="4"/>
          <text>ACTH</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">star</infon>
          <location offset="500" length="4"/>
          <text>StAR</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sf-1</infon>
          <location offset="506" length="4"/>
          <text>SF-1</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dax1</infon>
          <location offset="512" length="4"/>
          <text>DAX1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nurr77</infon>
          <location offset="521" length="6"/>
          <text>Nurr77</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acth</infon>
          <location offset="569" length="4"/>
          <text>ACTH</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mc2r</infon>
          <location offset="586" length="4"/>
          <text>MC2R</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrap</infon>
          <location offset="595" length="4"/>
          <text>MRAP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>649</offset>
        <text>We found that circadian changes in ACTH and CORT were associated with the circadian expression of all gene targets; with SF-1, Nurr77 and MRAP peaking in the evening, and DAX1 and MC2R peaking in the morning.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cort</infon>
          <location offset="693" length="4"/>
          <text>CORT</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acth</infon>
          <location offset="684" length="4"/>
          <text>ACTH</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sf-1</infon>
          <location offset="770" length="4"/>
          <text>SF-1</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nurr77</infon>
          <location offset="776" length="6"/>
          <text>Nurr77</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrap</infon>
          <location offset="787" length="4"/>
          <text>MRAP</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dax1</infon>
          <location offset="820" length="4"/>
          <text>DAX1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mc2r</infon>
          <location offset="829" length="4"/>
          <text>MC2R</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>858</offset>
        <text>Since disruption of normal SCN activity by exposure to constant light abolishes the circadian rhythm of CORT in the rat, we also investigated whether the AM-PM variation of our target genes was also disrupted in rats exposed to constant light conditions for 5weeks.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cort</infon>
          <location offset="962" length="4"/>
          <text>CORT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1124</offset>
        <text>We found that the disruption of the AM-PM variation of ACTH and CORT secretion in rats exposed to constant light was accompanied by a loss of AM-PM variation in StAR, SF-1 and DAX1, and a reversed AM-PM variation in Nurr77, MC2R and MRAP.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cort</infon>
          <location offset="1188" length="4"/>
          <text>CORT</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acth</infon>
          <location offset="1179" length="4"/>
          <text>ACTH</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">star</infon>
          <location offset="1285" length="4"/>
          <text>StAR</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sf-1</infon>
          <location offset="1291" length="4"/>
          <text>SF-1</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dax1</infon>
          <location offset="1300" length="4"/>
          <text>DAX1</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nurr77</infon>
          <location offset="1340" length="6"/>
          <text>Nurr77</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mc2r</infon>
          <location offset="1348" length="4"/>
          <text>MC2R</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mrap</infon>
          <location offset="1357" length="4"/>
          <text>MRAP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1363</offset>
        <text>Our data suggest that circadian expression of StAR is regulated by the circadian expression of nuclear receptors and proteins involved in both ACTH signalling and StAR transcription.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">star</infon>
          <location offset="1409" length="4"/>
          <text>StAR</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acth</infon>
          <location offset="1506" length="4"/>
          <text>ACTH</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">star</infon>
          <location offset="1526" length="4"/>
          <text>StAR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1546</offset>
        <text>We propose that ACTH regulates the secretion of CORT via the circadian control of steroidogenic gene pathways that become dysregulated under the influence of constant light.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cort</infon>
          <location offset="1594" length="4"/>
          <text>CORT</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acth</infon>
          <location offset="1562" length="4"/>
          <text>ACTH</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>25802231</id>
    <passage>
      <offset>0</offset>
      <text>Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.	Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK. Oral ibrutinib is indicated for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or TP53 mutation. This article summarizes pharmacological, efficacy and tolerability data relevant to the use of ibrutinib in these indications. In clinical studies, ibrutinib induced a high overall response rate in patients with relapsed/refractory MCL (phase II study). In addition, ibrutinib significantly prolonged progression-free survival and significantly improved the partial response rate and overall survival in patients with relapsed/refractory CLL (RESONATE study), including in those with del 17p, a subgroup with a poor prognosis. Ibrutinib had an acceptable tolerability profile in these studies with &lt;10% of patients discontinuing treatment because of adverse events. Given its efficacy and tolerability, once-daily, oral ibrutinib is an emerging treatment option for patients with relapsed/refractory MCL or CLL and CLL patients with del 17p or TP53 mutation.</text>
      <sentence>
        <offset>0</offset>
        <text>Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibrutinib</infon>
          <location offset="0" length="9"/>
          <text>Ibrutinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>103</offset>
        <text>Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibrutinib</infon>
          <location offset="103" length="9"/>
          <text>Ibrutinib</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="209" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imbruvica(r)</infon>
          <location offset="114" length="12"/>
          <text>Imbruvica(R)</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">btk</infon>
          <location offset="226" length="3"/>
          <text>BTK</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">b-cell antigen receptor</infon>
          <location offset="245" length="23"/>
          <text>B-cell antigen receptor</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">btk</infon>
          <location offset="294" length="3"/>
          <text>BTK</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bruton's tyrosine kinase</infon>
          <location offset="200" length="24"/>
          <text>Bruton's tyrosine kinase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>299</offset>
        <text>Oral ibrutinib is indicated for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or TP53 mutation.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibrutinib</infon>
          <location offset="304" length="9"/>
          <text>ibrutinib</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tp53</infon>
          <location offset="533" length="4"/>
          <text>TP53</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>548</offset>
        <text>This article summarizes pharmacological, efficacy and tolerability data relevant to the use of ibrutinib in these indications.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibrutinib</infon>
          <location offset="643" length="9"/>
          <text>ibrutinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>675</offset>
        <text>In clinical studies, ibrutinib induced a high overall response rate in patients with relapsed/refractory MCL (phase II study).</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibrutinib</infon>
          <location offset="696" length="9"/>
          <text>ibrutinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>802</offset>
        <text>In addition, ibrutinib significantly prolonged progression-free survival and significantly improved the partial response rate and overall survival in patients with relapsed/refractory CLL (RESONATE study), including in those with del 17p, a subgroup with a poor prognosis.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibrutinib</infon>
          <location offset="815" length="9"/>
          <text>ibrutinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1075</offset>
        <text>Ibrutinib had an acceptable tolerability profile in these studies with &lt;10% of patients discontinuing treatment because of adverse events.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibrutinib</infon>
          <location offset="1075" length="9"/>
          <text>Ibrutinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1214</offset>
        <text>Given its efficacy and tolerability, once-daily, oral ibrutinib is an emerging treatment option for patients with relapsed/refractory MCL or CLL and CLL patients with del 17p or TP53 mutation.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibrutinib</infon>
          <location offset="1268" length="9"/>
          <text>ibrutinib</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tp53</infon>
          <location offset="1392" length="4"/>
          <text>TP53</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23522834</id>
    <passage>
      <offset>0</offset>
      <text>Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.	Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of dihydropteridinone based Plk-2 inhibitors. By optimizing both the N-8 substituent and the biaryl region of the inhibitors we obtained single digit nanomolar compounds such as 37 with excellent selectivity for Plk-2 over Plk-1. When dosed orally in rats, compound 37 demonstrated a 41-45% reduction of pS129-α-synuclein levels in the cerebral cortex.</text>
      <sentence>
        <offset>0</offset>
        <text>Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">polo-like kinase-2</infon>
          <location offset="56" length="18"/>
          <text>Polo-like kinase-2</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plk-2</infon>
          <location offset="76" length="5"/>
          <text>Plk-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>95</offset>
        <text>Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of dihydropteridinone based Plk-2 inhibitors.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydropteridinone</infon>
          <location offset="229" length="18"/>
          <text>dihydropteridinone</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">polo-like kinase-2</infon>
          <location offset="95" length="18"/>
          <text>Polo-like kinase-2</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plk-2</infon>
          <location offset="254" length="5"/>
          <text>Plk-2</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plk-2</infon>
          <location offset="115" length="5"/>
          <text>Plk-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T3" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>272</offset>
        <text>By optimizing both the N-8 substituent and the biaryl region of the inhibitors we obtained single digit nanomolar compounds such as 37 with excellent selectivity for Plk-2 over Plk-1.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plk-2</infon>
          <location offset="438" length="5"/>
          <text>Plk-2</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plk-1</infon>
          <location offset="449" length="5"/>
          <text>Plk-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>456</offset>
        <text>When dosed orally in rats, compound 37 demonstrated a 41-45% reduction of pS129-α-synuclein levels in the cerebral cortex.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ps129-α-synuclein</infon>
          <location offset="530" length="17"/>
          <text>pS129-α-synuclein</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23040268</id>
    <passage>
      <offset>0</offset>
      <text>Lipoprotein(a) metabolism: potential sites for therapeutic targets.	Lipoprotein(a) [Lp(a)] resembles low-density lipoprotein (LDL), with an LDL lipid core and apolipoprotein B (apoB), but contains a unique apolipoprotein, apo(a). Elevated Lp(a) is an independent risk factor for coronary and peripheral vascular diseases. The size and concentration of plasma Lp(a) are related to the synthetic rate, not the catabolic rate, and are highly variable with small isoforms associated with high concentrations and pathogenic risk. Apo(a) is synthesized in the liver, although assembly of apo(a) and LDL may occur in the hepatocytes or plasma. While the uptake and clearance site of Lp(a) is poorly delineated, the kidney is the site of apo(a) fragment excretion. The structure of apo(a) has high homology to plasminogen, the zymogen for plasmin and the primary clot lysis enzyme. Apo(a) interferes with plasminogen binding to C-terminal lysines of cell surface and extracellular matrix proteins. Lp(a) and apo(a) inhibit fibrinolysis and accumulate in the vascular wall in atherosclerotic lesions. The pathogenic role of Lp(a) is not known. Small isoforms and high concentrations of Lp(a) are found in healthy octogenarians that suggest Lp(a) may also have a physiological role. Studies of Lp(a) function have been limited since it is not found in commonly studied small mammals. An important aspect of Lp(a) metabolism is the modification of circulating Lp(a), which has the potential to alter the functions of Lp(a). There are no therapeutic drugs that selectively target elevated Lp(a), but a number of possible agents are being considered. Recently, new modifiers of apo(a) synthesis have been identified. This review reports the regulation of Lp(a) metabolism and potential sites for therapeutic targets.</text>
      <sentence>
        <offset>0</offset>
        <text>Lipoprotein(a) metabolism: potential sites for therapeutic targets.</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lipoprotein(a)</infon>
          <location offset="0" length="14"/>
          <text>Lipoprotein(a)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>68</offset>
        <text>Lipoprotein(a) [Lp(a)] resembles low-density lipoprotein (LDL), with an LDL lipid core and apolipoprotein B (apoB), but contains a unique apolipoprotein, apo(a).</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lipoprotein(a)</infon>
          <location offset="68" length="14"/>
          <text>Lipoprotein(a)</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apob</infon>
          <location offset="177" length="4"/>
          <text>apoB</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">apolipoprotein</infon>
          <location offset="206" length="14"/>
          <text>apolipoprotein</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apo(a)</infon>
          <location offset="222" length="6"/>
          <text>apo(a)</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="84" length="5"/>
          <text>Lp(a)</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">low-density lipoprotein</infon>
          <location offset="101" length="23"/>
          <text>low-density lipoprotein</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldl</infon>
          <location offset="126" length="3"/>
          <text>LDL</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldl</infon>
          <location offset="140" length="3"/>
          <text>LDL</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apolipoprotein b</infon>
          <location offset="159" length="16"/>
          <text>apolipoprotein B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>230</offset>
        <text>Elevated Lp(a) is an independent risk factor for coronary and peripheral vascular diseases.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="239" length="5"/>
          <text>Lp(a)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>322</offset>
        <text>The size and concentration of plasma Lp(a) are related to the synthetic rate, not the catabolic rate, and are highly variable with small isoforms associated with high concentrations and pathogenic risk.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="359" length="5"/>
          <text>Lp(a)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>525</offset>
        <text>Apo(a) is synthesized in the liver, although assembly of apo(a) and LDL may occur in the hepatocytes or plasma.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apo(a)</infon>
          <location offset="525" length="6"/>
          <text>Apo(a)</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apo(a)</infon>
          <location offset="582" length="6"/>
          <text>apo(a)</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldl</infon>
          <location offset="593" length="3"/>
          <text>LDL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>637</offset>
        <text>While the uptake and clearance site of Lp(a) is poorly delineated, the kidney is the site of apo(a) fragment excretion.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="676" length="5"/>
          <text>Lp(a)</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apo(a)</infon>
          <location offset="730" length="6"/>
          <text>apo(a)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>757</offset>
        <text>The structure of apo(a) has high homology to plasminogen, the zymogen for plasmin and the primary clot lysis enzyme.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apo(a)</infon>
          <location offset="774" length="6"/>
          <text>apo(a)</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasminogen</infon>
          <location offset="802" length="11"/>
          <text>plasminogen</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasmin</infon>
          <location offset="831" length="7"/>
          <text>plasmin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>874</offset>
        <text>Apo(a) interferes with plasminogen binding to C-terminal lysines of cell surface and extracellular matrix proteins.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c</infon>
          <location offset="920" length="1"/>
          <text>C</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apo(a)</infon>
          <location offset="874" length="6"/>
          <text>Apo(a)</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasminogen</infon>
          <location offset="897" length="11"/>
          <text>plasminogen</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cell surface and extracellular matrix proteins</infon>
          <location offset="942" length="46"/>
          <text>cell surface and extracellular matrix proteins</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>990</offset>
        <text>Lp(a) and apo(a) inhibit fibrinolysis and accumulate in the vascular wall in atherosclerotic lesions.</text>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="990" length="5"/>
          <text>Lp(a)</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apo(a)</infon>
          <location offset="1000" length="6"/>
          <text>apo(a)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1092</offset>
        <text>The pathogenic role of Lp(a) is not known.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="1115" length="5"/>
          <text>Lp(a)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1135</offset>
        <text>Small isoforms and high concentrations of Lp(a) are found in healthy octogenarians that suggest Lp(a) may also have a physiological role.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="1177" length="5"/>
          <text>Lp(a)</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="1231" length="5"/>
          <text>Lp(a)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1273</offset>
        <text>Studies of Lp(a) function have been limited since it is not found in commonly studied small mammals.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="1284" length="5"/>
          <text>Lp(a)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1374</offset>
        <text>An important aspect of Lp(a) metabolism is the modification of circulating Lp(a), which has the potential to alter the functions of Lp(a).</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="1397" length="5"/>
          <text>Lp(a)</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="1449" length="5"/>
          <text>Lp(a)</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="1506" length="5"/>
          <text>Lp(a)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1513</offset>
        <text>There are no therapeutic drugs that selectively target elevated Lp(a), but a number of possible agents are being considered.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="1577" length="5"/>
          <text>Lp(a)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1638</offset>
        <text>Recently, new modifiers of apo(a) synthesis have been identified.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apo(a)</infon>
          <location offset="1665" length="6"/>
          <text>apo(a)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1704</offset>
        <text>This review reports the regulation of Lp(a) metabolism and potential sites for therapeutic targets.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lp(a)</infon>
          <location offset="1742" length="5"/>
          <text>Lp(a)</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23466229</id>
    <passage>
      <offset>0</offset>
      <text>PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.	The structure-based design, synthesis, and biological evaluation of a new pyrazole series of irreversible KAT II inhibitors are described herein. The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent KAT II inhibitors with excellent physicochemical properties. Compound 20 is the most potent and lipophilically efficient of these new pyrazole analogs, with a k(inact)/K(i) value of 112,000 M(-1)s(-1) and lipophilic efficiency (LipE) of 8.53. The X-ray crystal structure of 20 with KAT II demonstrates key features that contribute to this remarkable potency and binding efficiency.</text>
      <sentence>
        <offset>0</offset>
        <text>PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pf-04859989</infon>
          <location offset="0" length="11"/>
          <text>PF-04859989</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrazole</infon>
          <location offset="81" length="8"/>
          <text>pyrazole</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kat ii</infon>
          <location offset="113" length="6"/>
          <text>KAT II</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>168</offset>
        <text>The structure-based design, synthesis, and biological evaluation of a new pyrazole series of irreversible KAT II inhibitors are described herein.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrazole</infon>
          <location offset="242" length="8"/>
          <text>pyrazole</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kat ii</infon>
          <location offset="274" length="6"/>
          <text>KAT II</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>314</offset>
        <text>The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent KAT II inhibitors with excellent physicochemical properties.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydroquinolinone</infon>
          <location offset="375" length="18"/>
          <text>dihydroquinolinone</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetrahydropyrazolopyridinone</infon>
          <location offset="404" length="28"/>
          <text>tetrahydropyrazolopyridinone</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kat ii</infon>
          <location offset="481" length="6"/>
          <text>KAT II</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>542</offset>
        <text>Compound 20 is the most potent and lipophilically efficient of these new pyrazole analogs, with a k(inact)/K(i) value of 112,000 M(-1)s(-1) and lipophilic efficiency (LipE) of 8.53.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrazole</infon>
          <location offset="615" length="8"/>
          <text>pyrazole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>724</offset>
        <text>The X-ray crystal structure of 20 with KAT II demonstrates key features that contribute to this remarkable potency and binding efficiency.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kat ii</infon>
          <location offset="763" length="6"/>
          <text>KAT II</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23564646</id>
    <passage>
      <offset>0</offset>
      <text>ALLERGIC SKIN INFLAMMATION INDUCED BY CHEMICAL SENSITIZERS IS CONTROLLED BY THE TRANSCRIPTION FACTOR NRF2.	Allergic contact dermatitis (ACD) is induced by low molecular weight electrophilic chemicals and metal ions. Chemical contact sensitizers trigger reactive oxygen species (ROS) production and provoke electrophilic stress leading to the accumulation of the transcription factor nuclear related factor 2 (Nrf2) in innate immune cell types. The objective of this work was to identify the role of Nrf2 in the regulation of ACD. We used the Local Lymph Node Assay (LLNA) and the Mouse Ear Swelling Test (MEST) to study the role of Nrf2 in both the sensitization and elicitation phase in nrf2 knock out (nrf2(-/-)) and wild type (nrf2(+/+)) mice. Five chemicals were used: two compounds known to react with cysteine residues, 2,4-dinitrochlorobenzene (DNCB) and cinnamaldehyde (CinA); one sensitizer known to exhibit mixed reactivity to cysteine and lysine residues, isophorone diisocyanate (IPDI); and one reacting specifically with lysine residues, trimellitic anhydride (TMA) and croton oil a well-known irritant. In the MEST assay, DNCB (1% and 2%) induced a significant increase in ear thickness in nrf2(-/-) as compared to nrf2(+/+) mice suggesting a role for Nrf2 in the control of the inflammatory process. When DNCB was used at 0.25% and 0.5% or when mice were treated with CinA, inflammation was found only in nrf2(-/-) mice. In the LLNA all chemical sensitizers induced an increase of lymphocyte proliferation in nrf2(-/-) compared to nrf2(+/+) mice for the same chemical concentration.These results reveal an important role for Nrf2 in controlling ACD and lymphocyte proliferation in response to sensitizers.</text>
      <sentence>
        <offset>0</offset>
        <text>ALLERGIC SKIN INFLAMMATION INDUCED BY CHEMICAL SENSITIZERS IS CONTROLLED BY THE TRANSCRIPTION FACTOR NRF2.</text>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="101" length="4"/>
          <text>NRF2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>107</offset>
        <text>Allergic contact dermatitis (ACD) is induced by low molecular weight electrophilic chemicals and metal ions.</text>
      </sentence>
      <sentence>
        <offset>216</offset>
        <text>Chemical contact sensitizers trigger reactive oxygen species (ROS) production and provoke electrophilic stress leading to the accumulation of the transcription factor nuclear related factor 2 (Nrf2) in innate immune cell types.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="262" length="6"/>
          <text>oxygen</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nuclear related factor 2</infon>
          <location offset="383" length="24"/>
          <text>nuclear related factor 2</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="409" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>444</offset>
        <text>The objective of this work was to identify the role of Nrf2 in the regulation of ACD.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="499" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>530</offset>
        <text>We used the Local Lymph Node Assay (LLNA) and the Mouse Ear Swelling Test (MEST) to study the role of Nrf2 in both the sensitization and elicitation phase in nrf2 knock out (nrf2(-/-)) and wild type (nrf2(+/+)) mice.</text>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="632" length="4"/>
          <text>Nrf2</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="688" length="4"/>
          <text>nrf2</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="704" length="4"/>
          <text>nrf2</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="730" length="4"/>
          <text>nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>747</offset>
        <text>Five chemicals were used: two compounds known to react with cysteine residues, 2,4-dinitrochlorobenzene (DNCB) and cinnamaldehyde (CinA); one sensitizer known to exhibit mixed reactivity to cysteine and lysine residues, isophorone diisocyanate (IPDI); and one reacting specifically with lysine residues, trimellitic anhydride (TMA) and croton oil a well-known irritant.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteine</infon>
          <location offset="807" length="8"/>
          <text>cysteine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2,4-dinitrochlorobenzene</infon>
          <location offset="826" length="24"/>
          <text>2,4-dinitrochlorobenzene</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dncb</infon>
          <location offset="852" length="4"/>
          <text>DNCB</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cinnamaldehyde</infon>
          <location offset="862" length="14"/>
          <text>cinnamaldehyde</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cina</infon>
          <location offset="878" length="4"/>
          <text>CinA</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteine</infon>
          <location offset="937" length="8"/>
          <text>cysteine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lysine</infon>
          <location offset="950" length="6"/>
          <text>lysine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isophorone diisocyanate</infon>
          <location offset="967" length="23"/>
          <text>isophorone diisocyanate</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ipdi</infon>
          <location offset="992" length="4"/>
          <text>IPDI</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lysine</infon>
          <location offset="1034" length="6"/>
          <text>lysine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trimellitic anhydride</infon>
          <location offset="1051" length="21"/>
          <text>trimellitic anhydride</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tma</infon>
          <location offset="1074" length="3"/>
          <text>TMA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1117</offset>
        <text>In the MEST assay, DNCB (1% and 2%) induced a significant increase in ear thickness in nrf2(-/-) as compared to nrf2(+/+) mice suggesting a role for Nrf2 in the control of the inflammatory process.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dncb</infon>
          <location offset="1136" length="4"/>
          <text>DNCB</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1204" length="4"/>
          <text>nrf2</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1229" length="4"/>
          <text>nrf2</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1266" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1315</offset>
        <text>When DNCB was used at 0.25% and 0.5% or when mice were treated with CinA, inflammation was found only in nrf2(-/-) mice.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dncb</infon>
          <location offset="1320" length="4"/>
          <text>DNCB</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cina</infon>
          <location offset="1383" length="4"/>
          <text>CinA</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1420" length="4"/>
          <text>nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1436</offset>
        <text>In the LLNA all chemical sensitizers induced an increase of lymphocyte proliferation in nrf2(-/-) compared to nrf2(+/+) mice for the same chemical concentration.These results reveal an important role for Nrf2 in controlling ACD and lymphocyte proliferation in response to sensitizers.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1524" length="4"/>
          <text>nrf2</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1546" length="4"/>
          <text>nrf2</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1640" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10196703</id>
    <passage>
      <offset>0</offset>
      <text>Mortality risk in men is associated with a common mutation in the methylene-tetrahydrofolate reductase gene (MTHFR).	An elevated level of homocysteine in plasma is associated with the occurrence of cardiovascular disease. A common ala-to-val mutation in the methylenetetrahydrofolate reductase gene (MTHFR) is associated with an elevated level of plasma homocysteine. We studied the possible detrimental effects of the MTHFR mutation on mortality. Within a population-based study in the city of Leiden, the Netherlands, we first compared the MTHFR genotype distribution among 365 elderly subjects aged 85 years and over born in Leiden, and 250 young subjects aged 18 to 40 years whose families originated from the same geographical region. Second, the complete cohort of 666 subjects aged 85 years and over was followed over a period of 10 years for all-cause and cause-specific mortality and stratified according to MTHFR genotype. The frequency of the MTHFR mutation was significantly lower in the elderly than in the young (0.30 and 0.36, respectively; P = 0.03). The difference in genotype distribution was only present in men. The estimated mortality risk up to 85 years in men carrying the vallval genotype was 3.7 (95% confidence interval (CI), 1.3-10.9). Over the age of 85, mortality in men with the vallval genotype was increased 2.0-fold (95% CI, 1.1-3.9) and appeared to be attributable to cancer rather than cardiovascular causes of death. Among women aged 85 years and over, no deleterious effect of the MTHFR mutation was observed. In conclusion, the MTHFR mutation is associated with increased mortality in men in middle and old age, but not in women.</text>
      <sentence>
        <offset>0</offset>
        <text>Mortality risk in men is associated with a common mutation in the methylene-tetrahydrofolate reductase gene (MTHFR).</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methylene-tetrahydrofolate</infon>
          <location offset="66" length="26"/>
          <text>methylene-tetrahydrofolate</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mthfr</infon>
          <location offset="109" length="5"/>
          <text>MTHFR</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">methylene-tetrahydrofolate reductase</infon>
          <location offset="66" length="36"/>
          <text>methylene-tetrahydrofolate reductase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>117</offset>
        <text>An elevated level of homocysteine in plasma is associated with the occurrence of cardiovascular disease.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="138" length="12"/>
          <text>homocysteine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>222</offset>
        <text>A common ala-to-val mutation in the methylenetetrahydrofolate reductase gene (MTHFR) is associated with an elevated level of plasma homocysteine.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methylenetetrahydrofolate</infon>
          <location offset="258" length="25"/>
          <text>methylenetetrahydrofolate</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="354" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">methylenetetrahydrofolate reductase gene</infon>
          <location offset="258" length="40"/>
          <text>methylenetetrahydrofolate reductase gene</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mthfr</infon>
          <location offset="300" length="5"/>
          <text>MTHFR</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T6" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>368</offset>
        <text>We studied the possible detrimental effects of the MTHFR mutation on mortality.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mthfr</infon>
          <location offset="419" length="5"/>
          <text>MTHFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>448</offset>
        <text>Within a population-based study in the city of Leiden, the Netherlands, we first compared the MTHFR genotype distribution among 365 elderly subjects aged 85 years and over born in Leiden, and 250 young subjects aged 18 to 40 years whose families originated from the same geographical region.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mthfr</infon>
          <location offset="542" length="5"/>
          <text>MTHFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>740</offset>
        <text>Second, the complete cohort of 666 subjects aged 85 years and over was followed over a period of 10 years for all-cause and cause-specific mortality and stratified according to MTHFR genotype.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mthfr</infon>
          <location offset="917" length="5"/>
          <text>MTHFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>933</offset>
        <text>The frequency of the MTHFR mutation was significantly lower in the elderly than in the young (0.30 and 0.36, respectively; P = 0.03).</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mthfr</infon>
          <location offset="954" length="5"/>
          <text>MTHFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1067</offset>
        <text>The difference in genotype distribution was only present in men.</text>
      </sentence>
      <sentence>
        <offset>1132</offset>
        <text>The estimated mortality risk up to 85 years in men carrying the vallval genotype was 3.7 (95% confidence interval (CI), 1.3-10.9).</text>
      </sentence>
      <sentence>
        <offset>1263</offset>
        <text>Over the age of 85, mortality in men with the vallval genotype was increased 2.0-fold (95% CI, 1.1-3.9) and appeared to be attributable to cancer rather than cardiovascular causes of death.</text>
      </sentence>
      <sentence>
        <offset>1453</offset>
        <text>Among women aged 85 years and over, no deleterious effect of the MTHFR mutation was observed.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mthfr</infon>
          <location offset="1518" length="5"/>
          <text>MTHFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1547</offset>
        <text>In conclusion, the MTHFR mutation is associated with increased mortality in men in middle and old age, but not in women.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mthfr</infon>
          <location offset="1566" length="5"/>
          <text>MTHFR</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23614367</id>
    <passage>
      <offset>0</offset>
      <text>Grb10-mediated Negative Regulation of IGF1R-Activated Signalling Pathway Results in Cognitive Disorder in Diabetic Rats.	Growth factor receptor-bound protein 10(Grb10)is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane tyrosine-kinase receptors, including insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1-R). The hippocampus, which is critical for cognitive functions, is one of the main distribution areas of Grb10 in the central nervous system. In recent years, diabetic encephalopathy has been defined as a third type of diabetes and the IGF1-IR pathway has been shown to be critical for the neuropathogenic process of cognitive disorder in diabetes. However, the role of endogenous Grb10 in regulating the IGF1-IR pathway and neurobehavioral changes is not explicit. The objective of this study was to determine the in vivo function of endogenous Grb10 in diabetic encephalopathy and the underlying mechanisms. Using stereotaxic surgical techniques and lentiviral vectors expressing specific short hairpin RNA (shRNA), we could steadily knock down Grb10 expression in the hippocampus. More importantly, we demonstrated that hippocampus-specific modulation of Grb10 protein levels led to a prominent remission of cognitive disorder, including improvements in both ultrastructural pathology and abnormal neurobehavioural changes. Our findings indicate that endogenous overexpression of Grb10 functions as a suppressor of the IGF1-IR pathway, which may represent an important mechanism that regulates cognitive disorder in diabetes. This article is protected by copyright. All rights reserved.</text>
      <sentence>
        <offset>0</offset>
        <text>Grb10-mediated Negative Regulation of IGF1R-Activated Signalling Pathway Results in Cognitive Disorder in Diabetic Rats.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">grb10</infon>
          <location offset="0" length="5"/>
          <text>Grb10</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf1r</infon>
          <location offset="38" length="5"/>
          <text>IGF1R</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>121</offset>
        <text>Growth factor receptor-bound protein 10(Grb10)is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane tyrosine-kinase receptors, including insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1-R).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="278" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">growth factor receptor-bound protein 10</infon>
          <location offset="121" length="39"/>
          <text>Growth factor receptor-bound protein 10</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tyrosine-kinase receptors</infon>
          <location offset="278" length="25"/>
          <text>tyrosine-kinase receptors</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin receptor</infon>
          <location offset="315" length="16"/>
          <text>insulin receptor</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ir</infon>
          <location offset="333" length="2"/>
          <text>IR</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin-like growth factor-1 receptor</infon>
          <location offset="341" length="37"/>
          <text>insulin-like growth factor-1 receptor</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf1-r</infon>
          <location offset="380" length="6"/>
          <text>IGF1-R</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">grb10</infon>
          <location offset="161" length="5"/>
          <text>Grb10</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">src homology 2 (sh2) domain</infon>
          <location offset="172" length="27"/>
          <text>Src homology 2 (SH2) domain</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>389</offset>
        <text>The hippocampus, which is critical for cognitive functions, is one of the main distribution areas of Grb10 in the central nervous system.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">grb10</infon>
          <location offset="490" length="5"/>
          <text>Grb10</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>527</offset>
        <text>In recent years, diabetic encephalopathy has been defined as a third type of diabetes and the IGF1-IR pathway has been shown to be critical for the neuropathogenic process of cognitive disorder in diabetes.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf1-ir</infon>
          <location offset="621" length="7"/>
          <text>IGF1-IR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>734</offset>
        <text>However, the role of endogenous Grb10 in regulating the IGF1-IR pathway and neurobehavioral changes is not explicit.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">grb10</infon>
          <location offset="766" length="5"/>
          <text>Grb10</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf1-ir</infon>
          <location offset="790" length="7"/>
          <text>IGF1-IR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>851</offset>
        <text>The objective of this study was to determine the in vivo function of endogenous Grb10 in diabetic encephalopathy and the underlying mechanisms.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">grb10</infon>
          <location offset="931" length="5"/>
          <text>Grb10</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>995</offset>
        <text>Using stereotaxic surgical techniques and lentiviral vectors expressing specific short hairpin RNA (shRNA), we could steadily knock down Grb10 expression in the hippocampus.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">grb10</infon>
          <location offset="1132" length="5"/>
          <text>Grb10</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1169</offset>
        <text>More importantly, we demonstrated that hippocampus-specific modulation of Grb10 protein levels led to a prominent remission of cognitive disorder, including improvements in both ultrastructural pathology and abnormal neurobehavioural changes.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">grb10</infon>
          <location offset="1243" length="5"/>
          <text>Grb10</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1412</offset>
        <text>Our findings indicate that endogenous overexpression of Grb10 functions as a suppressor of the IGF1-IR pathway, which may represent an important mechanism that regulates cognitive disorder in diabetes.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">grb10</infon>
          <location offset="1468" length="5"/>
          <text>Grb10</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf1-ir</infon>
          <location offset="1507" length="7"/>
          <text>IGF1-IR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1614</offset>
        <text>This article is protected by copyright.</text>
      </sentence>
      <sentence>
        <offset>1654</offset>
        <text>All rights reserved.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>2087492</id>
    <passage>
      <offset>0</offset>
      <text>Barrel rotation in rats induced by SMS 201-995: suppression by ceruletide.	Intracerebroventricular administration of SMS 201-995 (5 micrograms/rat), a somatostatin analogue, induced barrel rotation in rats. Pretreatment with ceruletide (40 micrograms/100 g b. wt., IP) 3 days or 7 days prior to the injection of SMS 201-995 significantly inhibited the response rate of barrel rotation induced by SMS 201-995, but not that induced by arginine-vasopressin (1 microgram/rat, ICV). The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329, a selective peripheral CCK (CCK-A) receptor antagonist. Desulfated cerulein did not affect the barrel rotation induced by SMS 201-995. These findings suggest that ceruletide specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through CCK-A receptor.</text>
      <sentence>
        <offset>0</offset>
        <text>Barrel rotation in rats induced by SMS 201-995: suppression by ceruletide.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sms 201-995</infon>
          <location offset="35" length="11"/>
          <text>SMS 201-995</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceruletide</infon>
          <location offset="63" length="10"/>
          <text>ceruletide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>75</offset>
        <text>Intracerebroventricular administration of SMS 201-995 (5 micrograms/rat), a somatostatin analogue, induced barrel rotation in rats.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sms 201-995</infon>
          <location offset="117" length="11"/>
          <text>SMS 201-995</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">somatostatin</infon>
          <location offset="151" length="12"/>
          <text>somatostatin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">somatostatin</infon>
          <location offset="151" length="12"/>
          <text>somatostatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>207</offset>
        <text>Pretreatment with ceruletide (40 micrograms/100 g b. wt., IP) 3 days or 7 days prior to the injection of SMS 201-995 significantly inhibited the response rate of barrel rotation induced by SMS 201-995, but not that induced by arginine-vasopressin (1 microgram/rat, ICV).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceruletide</infon>
          <location offset="225" length="10"/>
          <text>ceruletide</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sms 201-995</infon>
          <location offset="312" length="11"/>
          <text>SMS 201-995</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sms 201-995</infon>
          <location offset="396" length="11"/>
          <text>SMS 201-995</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arginine-vasopressin</infon>
          <location offset="433" length="20"/>
          <text>arginine-vasopressin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">arginine-vasopressin</infon>
          <location offset="433" length="20"/>
          <text>arginine-vasopressin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>478</offset>
        <text>The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329, a selective peripheral CCK (CCK-A) receptor antagonist.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceruletide</infon>
          <location offset="504" length="10"/>
          <text>ceruletide</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mk-329</infon>
          <location offset="566" length="6"/>
          <text>MK-329</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cck</infon>
          <location offset="597" length="3"/>
          <text>CCK</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">(cck-a) receptor</infon>
          <location offset="601" length="16"/>
          <text>(CCK-A) receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>630</offset>
        <text>Desulfated cerulein did not affect the barrel rotation induced by SMS 201-995.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sms 201-995</infon>
          <location offset="696" length="11"/>
          <text>SMS 201-995</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>709</offset>
        <text>These findings suggest that ceruletide specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through CCK-A receptor.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ceruletide</infon>
          <location offset="737" length="10"/>
          <text>ceruletide</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sms 201-995</infon>
          <location offset="802" length="11"/>
          <text>SMS 201-995</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cck-a receptor</infon>
          <location offset="863" length="14"/>
          <text>CCK-A receptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23354536</id>
    <passage>
      <offset>0</offset>
      <text>Effects of repeated exposure to MDMA on 5HT1a autoreceptor function: behavioral and neurochemical responses to 8-OHDPAT.	A consistent effect of repeated exposure to 3,4 methylenedioxymethamphetamine (MDMA) is a decrease in the tissue levels of serotonin (5-HT). A variety of behavioural and neurochemical tests were conducted to determine whether the tissue deficits were accompanied by an increased sensitivity of the 5-HT1a autoreceptor. Tests were conducted 2 weeks following MDMA exposure (four injections of 10.0 mg/kg, IP, administered at 2-h intervals in a single day). The response to the 5-HT1a agonist, 8-OHDPAT (0.003-0.5 mg/kg, SC), was assessed using lower lip retraction (LLR), hypoactivity, and 5-hydroxytryptophan (5-HTP) accumulation following decarboxylase inhibition. The 8-OHDPAT produced a dose-dependent increase in LLR and hypoactivity, but these effects were comparable for MDMA and saline pretreated groups. MDMA decreased tissue levels of 5-HT and the accumulation of 5-HTP, but these effects were not reflected in the changes in autoreceptor sensitivity. The data suggest that the decrease in tissue levels of 5-HT produced by MDMA is accompanied by a decrease in tryptophan hydroxylase activity but cannot be explained by supersensitivity of the 5-HT1a autoreceptor.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of repeated exposure to MDMA on 5HT1a autoreceptor function: behavioral and neurochemical responses to 8-OHDPAT.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8-ohdpat</infon>
          <location offset="111" length="8"/>
          <text>8-OHDPAT</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="32" length="4"/>
          <text>MDMA</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5ht1a</infon>
          <location offset="40" length="5"/>
          <text>5HT1a</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>121</offset>
        <text>A consistent effect of repeated exposure to 3,4 methylenedioxymethamphetamine (MDMA) is a decrease in the tissue levels of serotonin (5-HT).</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="244" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="255" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3,4 methylenedioxymethamphetamine</infon>
          <location offset="165" length="33"/>
          <text>3,4 methylenedioxymethamphetamine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="200" length="4"/>
          <text>MDMA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>262</offset>
        <text>A variety of behavioural and neurochemical tests were conducted to determine whether the tissue deficits were accompanied by an increased sensitivity of the 5-HT1a autoreceptor.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="419" length="6"/>
          <text>5-HT1a</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>440</offset>
        <text>Tests were conducted 2 weeks following MDMA exposure (four injections of 10.0 mg/kg, IP, administered at 2-h intervals in a single day).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="479" length="4"/>
          <text>MDMA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>577</offset>
        <text>The response to the 5-HT1a agonist, 8-OHDPAT (0.003-0.5 mg/kg, SC), was assessed using lower lip retraction (LLR), hypoactivity, and 5-hydroxytryptophan (5-HTP) accumulation following decarboxylase inhibition.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8-ohdpat</infon>
          <location offset="613" length="8"/>
          <text>8-OHDPAT</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-hydroxytryptophan</infon>
          <location offset="710" length="19"/>
          <text>5-hydroxytryptophan</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-htp</infon>
          <location offset="731" length="5"/>
          <text>5-HTP</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="597" length="6"/>
          <text>5-HT1a</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">decarboxylase</infon>
          <location offset="761" length="13"/>
          <text>decarboxylase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T9" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T8" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>787</offset>
        <text>The 8-OHDPAT produced a dose-dependent increase in LLR and hypoactivity, but these effects were comparable for MDMA and saline pretreated groups.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8-ohdpat</infon>
          <location offset="791" length="8"/>
          <text>8-OHDPAT</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="898" length="4"/>
          <text>MDMA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>933</offset>
        <text>MDMA decreased tissue levels of 5-HT and the accumulation of 5-HTP, but these effects were not reflected in the changes in autoreceptor sensitivity.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="933" length="4"/>
          <text>MDMA</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="965" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-htp</infon>
          <location offset="994" length="5"/>
          <text>5-HTP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1082</offset>
        <text>The data suggest that the decrease in tissue levels of 5-HT produced by MDMA is accompanied by a decrease in tryptophan hydroxylase activity but cannot be explained by supersensitivity of the 5-HT1a autoreceptor.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="1137" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdma</infon>
          <location offset="1154" length="4"/>
          <text>MDMA</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptophan</infon>
          <location offset="1191" length="10"/>
          <text>tryptophan</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tryptophan hydroxylase</infon>
          <location offset="1191" length="22"/>
          <text>tryptophan hydroxylase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="1274" length="6"/>
          <text>5-HT1a</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23092877</id>
    <passage>
      <offset>0</offset>
      <text>GH improves spatial memory and reverses certain anabolic androgenic steroid-induced effects in intact rats.	GH has previously been shown to promote cognitive functions in GH-deficient rodents. In this study we report the effects of GH on learning and memory in intact rats pretreated with the anabolic androgenic steroid nandrolone. Male Wistar rats received nandrolone decanoate (15 mg/kg) or peanut oil every third day for 3 weeks and were subsequently treated with recombinant human GH (1.0 IU/kg) or saline for 10 consecutive days. During the GH/saline treatment spatial learning and memory were tested in the Morris water maze (MWM). Also, plasma levels of IGF1 were assessed and the gene expression of the GH receptors (Ghr), Igf1 and Igf2, in hippocampus and frontal cortex was analyzed. The results demonstrated a significant positive effect of GH on memory functions and increased gene expression of Igf1 in the hippocampus was found in the animals treated with GH. In addition, GH was demonstrated to increase the body weight gain and was able to attenuate the reduced body weight seen in nandrolone-treated animals. In general, the rats treated with nandrolone alone did not exhibit any pronounced alteration in memory compared with controls in the MWM, and in many cases GH did not induce any alteration. Regarding target zone crossings, considered to be associated with spatial memory, the difference between GH- and steroid-treated animals was significant and administration of GH improved this parameter in the latter group. In conclusion, GH improves spatial memory in intact rats and can reverse certain effects induced by anabolic androgenic steroid.</text>
      <sentence>
        <offset>0</offset>
        <text>GH improves spatial memory and reverses certain anabolic androgenic steroid-induced effects in intact rats.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="0" length="2"/>
          <text>GH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>108</offset>
        <text>GH has previously been shown to promote cognitive functions in GH-deficient rodents.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="108" length="2"/>
          <text>GH</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="171" length="2"/>
          <text>GH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>193</offset>
        <text>In this study we report the effects of GH on learning and memory in intact rats pretreated with the anabolic androgenic steroid nandrolone.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="313" length="7"/>
          <text>steroid</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nandrolone</infon>
          <location offset="321" length="10"/>
          <text>nandrolone</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="232" length="2"/>
          <text>GH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>333</offset>
        <text>Male Wistar rats received nandrolone decanoate (15 mg/kg) or peanut oil every third day for 3 weeks and were subsequently treated with recombinant human GH (1.0 IU/kg) or saline for 10 consecutive days.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nandrolone decanoate</infon>
          <location offset="359" length="20"/>
          <text>nandrolone decanoate</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human gh</infon>
          <location offset="480" length="8"/>
          <text>human GH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>536</offset>
        <text>During the GH/saline treatment spatial learning and memory were tested in the Morris water maze (MWM).</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="547" length="2"/>
          <text>GH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>639</offset>
        <text>Also, plasma levels of IGF1 were assessed and the gene expression of the GH receptors (Ghr), Igf1 and Igf2, in hippocampus and frontal cortex was analyzed.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf1</infon>
          <location offset="662" length="4"/>
          <text>IGF1</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh receptors</infon>
          <location offset="712" length="12"/>
          <text>GH receptors</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ghr</infon>
          <location offset="726" length="3"/>
          <text>Ghr</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf1</infon>
          <location offset="732" length="4"/>
          <text>Igf1</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf2</infon>
          <location offset="741" length="4"/>
          <text>Igf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>795</offset>
        <text>The results demonstrated a significant positive effect of GH on memory functions and increased gene expression of Igf1 in the hippocampus was found in the animals treated with GH.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="853" length="2"/>
          <text>GH</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf1</infon>
          <location offset="909" length="4"/>
          <text>Igf1</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="971" length="2"/>
          <text>GH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>975</offset>
        <text>In addition, GH was demonstrated to increase the body weight gain and was able to attenuate the reduced body weight seen in nandrolone-treated animals.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nandrolone</infon>
          <location offset="1099" length="10"/>
          <text>nandrolone</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="988" length="2"/>
          <text>GH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1127</offset>
        <text>In general, the rats treated with nandrolone alone did not exhibit any pronounced alteration in memory compared with controls in the MWM, and in many cases GH did not induce any alteration.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nandrolone</infon>
          <location offset="1161" length="10"/>
          <text>nandrolone</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="1283" length="2"/>
          <text>GH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1317</offset>
        <text>Regarding target zone crossings, considered to be associated with spatial memory, the difference between GH- and steroid-treated animals was significant and administration of GH improved this parameter in the latter group.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="1422" length="2"/>
          <text>GH</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="1492" length="2"/>
          <text>GH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1540</offset>
        <text>In conclusion, GH improves spatial memory in intact rats and can reverse certain effects induced by anabolic androgenic steroid.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="1660" length="7"/>
          <text>steroid</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gh</infon>
          <location offset="1555" length="2"/>
          <text>GH</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23159887</id>
    <passage>
      <offset>0</offset>
      <text>Expression of cAMP-responsive element binding proteins (CREBs) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of collagen-tailed subunit (ColQ) of acetylcholinesterase at the rat neuromuscular junction.	The gene encoding the collagen-tailed subunit (ColQ) of acetylcholinesterase (AChE) contains two distinct promoters that drive the production of two ColQ mRNAs, ColQ-1 and ColQ-1a, in slow- and fast-twitch muscles, respectively. ColQ-1a is expressed at the neuromuscular junction (NMJ) in fast-twitch muscle, and this expression depends on trophic factors supplied by motor neurons signaling via a cAMP-dependent pathway in muscle. To further elucidate the molecular basis of ColQ-1a's synaptic expression, here we investigated the expression and localization of cAMP-responsive element binding protein (CREB) at the synaptic and extra-synaptic regions of fast- and slow-twitch muscles from adult rats. The total amount of active, phosphorylated CREB (P-CREB) present in slow-twitch soleus muscle was higher than that in fast-twitch tibialis muscle, but P-CREB was predominantly expressed in the fast-twitch muscle at NMJs. In contrast, P-CREB was detected in both synaptic and extra-synaptic regions of slow-twitch muscle. These results reveal, for the first time, the differential distribution of P-CREB in fast- and slow-twitch muscles, which might support the crucial role of cAMP-dependent signaling in controlling the synapse-specific expression of ColQ-1a in fast-twitch muscles.</text>
      <sentence>
        <offset>0</offset>
        <text>Expression of cAMP-responsive element binding proteins (CREBs) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of collagen-tailed subunit (ColQ) of acetylcholinesterase at the rat neuromuscular junction.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="14" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">camp-responsive element binding proteins</infon>
          <location offset="14" length="40"/>
          <text>cAMP-responsive element binding proteins</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">collagen-tailed subunit</infon>
          <location offset="159" length="23"/>
          <text>collagen-tailed subunit</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="184" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="193" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">crebs</infon>
          <location offset="56" length="5"/>
          <text>CREBs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>249</offset>
        <text>The gene encoding the collagen-tailed subunit (ColQ) of acetylcholinesterase (AChE) contains two distinct promoters that drive the production of two ColQ mRNAs, ColQ-1 and ColQ-1a, in slow- and fast-twitch muscles, respectively.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="398" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq-1</infon>
          <location offset="410" length="6"/>
          <text>ColQ-1</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq-1a</infon>
          <location offset="421" length="7"/>
          <text>ColQ-1a</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">collagen-tailed subunit</infon>
          <location offset="271" length="23"/>
          <text>collagen-tailed subunit</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq</infon>
          <location offset="296" length="4"/>
          <text>ColQ</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="305" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="327" length="4"/>
          <text>AChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>478</offset>
        <text>ColQ-1a is expressed at the neuromuscular junction (NMJ) in fast-twitch muscle, and this expression depends on trophic factors supplied by motor neurons signaling via a cAMP-dependent pathway in muscle.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="647" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq-1a</infon>
          <location offset="478" length="7"/>
          <text>ColQ-1a</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>681</offset>
        <text>To further elucidate the molecular basis of ColQ-1a's synaptic expression, here we investigated the expression and localization of cAMP-responsive element binding protein (CREB) at the synaptic and extra-synaptic regions of fast- and slow-twitch muscles from adult rats.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="812" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq-1a's</infon>
          <location offset="725" length="9"/>
          <text>ColQ-1a's</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">camp-responsive element binding protein</infon>
          <location offset="812" length="39"/>
          <text>cAMP-responsive element binding protein</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="853" length="4"/>
          <text>CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>952</offset>
        <text>The total amount of active, phosphorylated CREB (P-CREB) present in slow-twitch soleus muscle was higher than that in fast-twitch tibialis muscle, but P-CREB was predominantly expressed in the fast-twitch muscle at NMJs.</text>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphorylated creb</infon>
          <location offset="980" length="19"/>
          <text>phosphorylated CREB</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-creb</infon>
          <location offset="1001" length="6"/>
          <text>P-CREB</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-creb</infon>
          <location offset="1103" length="6"/>
          <text>P-CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1173</offset>
        <text>In contrast, P-CREB was detected in both synaptic and extra-synaptic regions of slow-twitch muscle.</text>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-creb</infon>
          <location offset="1186" length="6"/>
          <text>P-CREB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1273</offset>
        <text>These results reveal, for the first time, the differential distribution of P-CREB in fast- and slow-twitch muscles, which might support the crucial role of cAMP-dependent signaling in controlling the synapse-specific expression of ColQ-1a in fast-twitch muscles.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="1429" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-creb</infon>
          <location offset="1348" length="6"/>
          <text>P-CREB</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">colq-1a</infon>
          <location offset="1504" length="7"/>
          <text>ColQ-1a</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23468082</id>
    <passage>
      <offset>0</offset>
      <text>Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.	PURPOSE: Activating mutations in FGFR2 have been identified as potential therapeutic targets in endometrial cancer, typically occurring alongside genetic alterations that disrupt the mTOR pathway, such as PTEN loss. These observations suggest that the mTOR pathway may act in concert with oncogenic FGFR2 to drive endometrial cancer growth in a subset of patients. The aim of this study was to examine the therapeutic potential of a rational drug combination based on the simultaneous targeting of mutant-FGFR2 and mTOR-driven signaling pathways in endometrial cancer cells. METHODS: Ponatinib is an oral multitargeted kinase inhibitor that potently inhibits all 4 members of the FGFR family. Ridaforolimus is a selective inhibitor of mTOR that has demonstrated positive clinical activity in endometrial cancer. The combinatorial effects of ponatinib and ridaforolimus on growth of endometrial cancer models, and their modes of action, were evaluated in vitro and in vivo. RESULTS: The combination of ponatinib and ridaforolimus had a synergistic effect on the in vitro growth of endometrial lines bearing an activating FGFR2 mutation, irrespective of PTEN status. Concomitant inhibition of both FGFR2 and mTOR signaling pathways was observed, with simultaneous blockade resulting in enhanced cell cycle arrest. Ponatinib and ridaforolimus each demonstrated inhibition of tumor growth in vivo, but dual inhibition by the combination of agents resulted in superior efficacy and induced tumor regression in an endometrial xenograft. CONCLUSIONS: These encouraging preclinical findings suggest the inhibition of both FGFR2 and mTOR by the ponatinib-ridaforolimus combination may provide a new therapeutic strategy to treat advanced endometrial cancers with dual pathway dysregulation.</text>
      <sentence>
        <offset>0</offset>
        <text>Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ponatinib</infon>
          <location offset="40" length="9"/>
          <text>ponatinib</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ridaforolimus</infon>
          <location offset="54" length="13"/>
          <text>ridaforolimus</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fgfr2</infon>
          <location offset="113" length="5"/>
          <text>FGFR2</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fgfr2</infon>
          <location offset="22" length="5"/>
          <text>FGFR2</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="32" length="4"/>
          <text>mTOR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>153</offset>
        <text>PURPOSE: Activating mutations in FGFR2 have been identified as potential therapeutic targets in endometrial cancer, typically occurring alongside genetic alterations that disrupt the mTOR pathway, such as PTEN loss.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="336" length="4"/>
          <text>mTOR</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pten</infon>
          <location offset="358" length="4"/>
          <text>PTEN</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fgfr2</infon>
          <location offset="186" length="5"/>
          <text>FGFR2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>369</offset>
        <text>These observations suggest that the mTOR pathway may act in concert with oncogenic FGFR2 to drive endometrial cancer growth in a subset of patients.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="405" length="4"/>
          <text>mTOR</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fgfr2</infon>
          <location offset="452" length="5"/>
          <text>FGFR2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>518</offset>
        <text>The aim of this study was to examine the therapeutic potential of a rational drug combination based on the simultaneous targeting of mutant-FGFR2 and mTOR-driven signaling pathways in endometrial cancer cells.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fgfr2</infon>
          <location offset="658" length="5"/>
          <text>FGFR2</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor-</infon>
          <location offset="668" length="5"/>
          <text>mTOR-</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>728</offset>
        <text>METHODS: Ponatinib is an oral multitargeted kinase inhibitor that potently inhibits all 4 members of the FGFR family.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ponatinib</infon>
          <location offset="737" length="9"/>
          <text>Ponatinib</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="772" length="6"/>
          <text>kinase</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fgfr</infon>
          <location offset="833" length="4"/>
          <text>FGFR</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>846</offset>
        <text>Ridaforolimus is a selective inhibitor of mTOR that has demonstrated positive clinical activity in endometrial cancer.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ridaforolimus</infon>
          <location offset="846" length="13"/>
          <text>Ridaforolimus</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="888" length="4"/>
          <text>mTOR</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>965</offset>
        <text>The combinatorial effects of ponatinib and ridaforolimus on growth of endometrial cancer models, and their modes of action, were evaluated in vitro and in vivo.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ponatinib</infon>
          <location offset="994" length="9"/>
          <text>ponatinib</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ridaforolimus</infon>
          <location offset="1008" length="13"/>
          <text>ridaforolimus</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1126</offset>
        <text>RESULTS: The combination of ponatinib and ridaforolimus had a synergistic effect on the in vitro growth of endometrial lines bearing an activating FGFR2 mutation, irrespective of PTEN status.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ponatinib</infon>
          <location offset="1154" length="9"/>
          <text>ponatinib</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ridaforolimus</infon>
          <location offset="1168" length="13"/>
          <text>ridaforolimus</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fgfr2</infon>
          <location offset="1273" length="5"/>
          <text>FGFR2</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pten</infon>
          <location offset="1305" length="4"/>
          <text>PTEN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1318</offset>
        <text>Concomitant inhibition of both FGFR2 and mTOR signaling pathways was observed, with simultaneous blockade resulting in enhanced cell cycle arrest.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fgfr2</infon>
          <location offset="1349" length="5"/>
          <text>FGFR2</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="1359" length="4"/>
          <text>mTOR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1465</offset>
        <text>Ponatinib and ridaforolimus each demonstrated inhibition of tumor growth in vivo, but dual inhibition by the combination of agents resulted in superior efficacy and induced tumor regression in an endometrial xenograft.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ponatinib</infon>
          <location offset="1465" length="9"/>
          <text>Ponatinib</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ridaforolimus</infon>
          <location offset="1479" length="13"/>
          <text>ridaforolimus</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1684</offset>
        <text>CONCLUSIONS: These encouraging preclinical findings suggest the inhibition of both FGFR2 and mTOR by the ponatinib-ridaforolimus combination may provide a new therapeutic strategy to treat advanced endometrial cancers with dual pathway dysregulation.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ponatinib</infon>
          <location offset="1789" length="9"/>
          <text>ponatinib</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ridaforolimus</infon>
          <location offset="1799" length="13"/>
          <text>ridaforolimus</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fgfr2</infon>
          <location offset="1767" length="5"/>
          <text>FGFR2</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="1777" length="4"/>
          <text>mTOR</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16277658</id>
    <passage>
      <offset>0</offset>
      <text>Role of retinoic acid receptors in squamous-cell carcinoma in human esophagus.	BACKGROUND: Worldwide, cancer in the esophagus ranks among the 10 most common cancers. Alterations of retinoic acid receptors (e.g. RARalpha, beta, gamma, and RXRalpha, beta, gamma) expression is considered to play an important role in development of squamous-cell carcinoma (SCC), which is the most common esophageal cancer. Alcohol consumption and smoking, which can alter retinoic acid receptor levels, have been identified as key risk factors in the development of carcinoma in the aero-digestive tract. Therefore, the aim of the present study was to evaluate protein levels of retinoic acid receptors (i.e. RARalpha, beta, gamma, and RXRbeta) in esophageal SCC and surrounding normal tissue of patients with untreated SCC and controls. METHODS: All study participants completed a questionnaire concerning smoking and alcohol drinking habits as well as anthropometrical parameters. Protein levels of RARalpha, beta, gamma, and RXRbeta were determined by Western Blot in normal esophageal tissue and tissue obtained from SCC of 21 patients with newly diagnosed esophageal SCC and normal esophageal tissue of 10 controls. RESULTS: Protein levels of RARgamma were significantly lower by approximately 68% in SCC compared to normal surrounding tissue in patients with SCC that smoked and/or consumed elevated amounts of alcohol. Furthermore, RARalpha protein levels were significantly lower (approximately- 45%) in SCC in comparison to normal esophageal mucosa in patients with elevated alcohol intake. When comparing protein levels of retinoic acid receptors between normal tissue of patients with SCC and controls, RARgamma protein levels were found to be significantly higher (approximately 2.7-fold) in normal esophageal tissue of SCC patients than in esophageal tissue obtained from controls. No differences were found for RARalpha, beta, and RXRbeta protein levels between normal esophageal tissue of patients and that of controls. CONCLUSION: In conclusion, results of the present study suggest that alterations of retinoic acid receptors protein may contribute in the development of SCC in esophagus and that in some patients life style (e.g. smoking and alcohol consumption) may be a critical component in the alteration of retinoic acid receptor levels in esophagus.</text>
      <sentence>
        <offset>0</offset>
        <text>Role of retinoic acid receptors in squamous-cell carcinoma in human esophagus.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="8" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">retinoic acid receptors</infon>
          <location offset="8" length="23"/>
          <text>retinoic acid receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>79</offset>
        <text>BACKGROUND: Worldwide, cancer in the esophagus ranks among the 10 most common cancers.</text>
      </sentence>
      <sentence>
        <offset>166</offset>
        <text>Alterations of retinoic acid receptors (e.g. RARalpha, beta, gamma, and RXRalpha, beta, gamma) expression is considered to play an important role in development of squamous-cell carcinoma (SCC), which is the most common esophageal cancer.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="181" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">retinoic acid receptors</infon>
          <location offset="181" length="23"/>
          <text>retinoic acid receptors</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">raralpha, beta, gamma</infon>
          <location offset="211" length="21"/>
          <text>RARalpha, beta, gamma</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rxralpha, beta, gamma</infon>
          <location offset="238" length="21"/>
          <text>RXRalpha, beta, gamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>405</offset>
        <text>Alcohol consumption and smoking, which can alter retinoic acid receptor levels, have been identified as key risk factors in the development of carcinoma in the aero-digestive tract.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcohol</infon>
          <location offset="405" length="7"/>
          <text>Alcohol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="454" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">retinoic acid receptor</infon>
          <location offset="454" length="22"/>
          <text>retinoic acid receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>587</offset>
        <text>Therefore, the aim of the present study was to evaluate protein levels of retinoic acid receptors (i.e. RARalpha, beta, gamma, and RXRbeta) in esophageal SCC and surrounding normal tissue of patients with untreated SCC and controls.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="661" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">retinoic acid receptors</infon>
          <location offset="661" length="23"/>
          <text>retinoic acid receptors</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">raralpha, beta, gamma</infon>
          <location offset="691" length="21"/>
          <text>RARalpha, beta, gamma</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rxrbeta</infon>
          <location offset="718" length="7"/>
          <text>RXRbeta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>820</offset>
        <text>METHODS: All study participants completed a questionnaire concerning smoking and alcohol drinking habits as well as anthropometrical parameters.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcohol</infon>
          <location offset="901" length="7"/>
          <text>alcohol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>965</offset>
        <text>Protein levels of RARalpha, beta, gamma, and RXRbeta were determined by Western Blot in normal esophageal tissue and tissue obtained from SCC of 21 patients with newly diagnosed esophageal SCC and normal esophageal tissue of 10 controls.</text>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">raralpha, beta, gamma</infon>
          <location offset="983" length="21"/>
          <text>RARalpha, beta, gamma</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rxrbeta</infon>
          <location offset="1010" length="7"/>
          <text>RXRbeta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1203</offset>
        <text>RESULTS: Protein levels of RARgamma were significantly lower by approximately 68% in SCC compared to normal surrounding tissue in patients with SCC that smoked and/or consumed elevated amounts of alcohol.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcohol</infon>
          <location offset="1399" length="7"/>
          <text>alcohol</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rargamma</infon>
          <location offset="1230" length="8"/>
          <text>RARgamma</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1408</offset>
        <text>Furthermore, RARalpha protein levels were significantly lower (approximately- 45%) in SCC in comparison to normal esophageal mucosa in patients with elevated alcohol intake.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcohol</infon>
          <location offset="1566" length="7"/>
          <text>alcohol</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">raralpha</infon>
          <location offset="1421" length="8"/>
          <text>RARalpha</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1582</offset>
        <text>When comparing protein levels of retinoic acid receptors between normal tissue of patients with SCC and controls, RARgamma protein levels were found to be significantly higher (approximately 2.7-fold) in normal esophageal tissue of SCC patients than in esophageal tissue obtained from controls.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="1615" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">retinoic acid receptors</infon>
          <location offset="1615" length="23"/>
          <text>retinoic acid receptors</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rargamma</infon>
          <location offset="1696" length="8"/>
          <text>RARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1877</offset>
        <text>No differences were found for RARalpha, beta, and RXRbeta protein levels between normal esophageal tissue of patients and that of controls.</text>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">raralpha, beta</infon>
          <location offset="1907" length="14"/>
          <text>RARalpha, beta</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rxrbeta</infon>
          <location offset="1927" length="7"/>
          <text>RXRbeta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2017</offset>
        <text>CONCLUSION: In conclusion, results of the present study suggest that alterations of retinoic acid receptors protein may contribute in the development of SCC in esophagus and that in some patients life style (e.g. smoking and alcohol consumption) may be a critical component in the alteration of retinoic acid receptor levels in esophagus.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="2101" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcohol</infon>
          <location offset="2242" length="7"/>
          <text>alcohol</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="2312" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">retinoic acid receptors</infon>
          <location offset="2101" length="23"/>
          <text>retinoic acid receptors</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">retinoic acid receptor</infon>
          <location offset="2312" length="22"/>
          <text>retinoic acid receptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23558297</id>
    <passage>
      <offset>0</offset>
      <text>Vinclozolin: A case study on the identification of endocrine active substances in the past and a future perspective.	In the late 1980s vinclozolin was tested for prenatal developmental toxicity in rats for registration purposes in USA. At 1000mg/kgbw, 95% of all fetuses were female upon visual inspection (ano-genital distance determination). Anti-androgenic effects (AA) were also noted in a subsequent 2-generation study. These findings triggered mechanistic investigations at BASF and at US-EPA. Results published by the latter were the starting point of the endocrine disruption (ED) discussion in the 1990s. AA effects of vinclozolin are mediated by two metabolites, which have an antagonistic effect on the androgen receptor. Currently, determination of ED has become a major end-point in toxicology testing and the US-EPA has set up an elaborated testing paradigm to fulfill this requirement. Future screening for ED can be improved making use of new technologies. ED modes of action can be determined by three alternative (3R) methods. Steroid synthesis in H295R cells (1), androgen-receptor binding in modified yeast (2) and metabolomics (3). Using vinclozolin as a case study, results indicate: (1) an effect on steroid synthesis in vitro, (2) an antagonistic effect on the androgen receptor and (3) that the metabolome profile of vinclozolin is similar to that of other receptor mediated anti-androgens (e.g. flutamide).</text>
      <sentence>
        <offset>0</offset>
        <text>Vinclozolin: A case study on the identification of endocrine active substances in the past and a future perspective.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vinclozolin</infon>
          <location offset="0" length="11"/>
          <text>Vinclozolin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>117</offset>
        <text>In the late 1980s vinclozolin was tested for prenatal developmental toxicity in rats for registration purposes in USA.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vinclozolin</infon>
          <location offset="135" length="11"/>
          <text>vinclozolin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>236</offset>
        <text>At 1000mg/kgbw, 95% of all fetuses were female upon visual inspection (ano-genital distance determination).</text>
      </sentence>
      <sentence>
        <offset>344</offset>
        <text>Anti-androgenic effects (AA) were also noted in a subsequent 2-generation study.</text>
      </sentence>
      <sentence>
        <offset>425</offset>
        <text>These findings triggered mechanistic investigations at BASF and at US-EPA.</text>
      </sentence>
      <sentence>
        <offset>500</offset>
        <text>Results published by the latter were the starting point of the endocrine disruption (ED) discussion in the 1990s.</text>
      </sentence>
      <sentence>
        <offset>614</offset>
        <text>AA effects of vinclozolin are mediated by two metabolites, which have an antagonistic effect on the androgen receptor.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vinclozolin</infon>
          <location offset="628" length="11"/>
          <text>vinclozolin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="714" length="17"/>
          <text>androgen receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T8" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>733</offset>
        <text>Currently, determination of ED has become a major end-point in toxicology testing and the US-EPA has set up an elaborated testing paradigm to fulfill this requirement.</text>
      </sentence>
      <sentence>
        <offset>901</offset>
        <text>Future screening for ED can be improved making use of new technologies.</text>
      </sentence>
      <sentence>
        <offset>973</offset>
        <text>ED modes of action can be determined by three alternative (3R) methods.</text>
      </sentence>
      <sentence>
        <offset>1045</offset>
        <text>Steroid synthesis in H295R cells (1), androgen-receptor binding in modified yeast (2) and metabolomics (3).</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="1083" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen-receptor</infon>
          <location offset="1083" length="17"/>
          <text>androgen-receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1153</offset>
        <text>Using vinclozolin as a case study, results indicate: (1) an effect on steroid synthesis in vitro, (2) an antagonistic effect on the androgen receptor and (3) that the metabolome profile of vinclozolin is similar to that of other receptor mediated anti-androgens (e.g. flutamide).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vinclozolin</infon>
          <location offset="1159" length="11"/>
          <text>vinclozolin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="1223" length="7"/>
          <text>steroid</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="1285" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vinclozolin</infon>
          <location offset="1342" length="11"/>
          <text>vinclozolin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgens</infon>
          <location offset="1405" length="9"/>
          <text>androgens</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flutamide</infon>
          <location offset="1421" length="9"/>
          <text>flutamide</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="1285" length="17"/>
          <text>androgen receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23583485</id>
    <passage>
      <offset>0</offset>
      <text>Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.	Among the various possible causes for drug interactions, pharmacokinetic factors such as inhibition of drug-metabolizing enzymes, especially cytochrome P450 (CYP) enzymes, are regarded as the most frequent and clinically important. Gypenosides is widely used as functional food and over-the-counter drug in East Asia. In this study, the in vitro inhibitory effects of gypenosides on the major human CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) activities in human liver microsomes were examined using liquid chromatography-tandem mass spectrometry. Gypenosides showed the strongest inhibition of CYP2D6, followed by CYP2C8, CYP3A4 and CYP2C9. The IC50 values were 1.61μg/mL, 20.06μg/mL, 34.76μg/mL (CYP3A4/midazolam), 46.73μg/mL (CYP3A4/testosterone), and 54.52μg/mL, respectively. Gypenosides exhibited competitive inhibition of CYP2D6 (Ki=1.18). In conclusion, Gypenosides might cause herb-drug interactions via inhibition of CYP2D6. An in vivo study is needed to examine this further.</text>
      <sentence>
        <offset>0</offset>
        <text>Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gypenosides</infon>
          <location offset="22" length="11"/>
          <text>gypenosides</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human cytochrome p450</infon>
          <location offset="43" length="21"/>
          <text>human cytochrome P450</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>83</offset>
        <text>Among the various possible causes for drug interactions, pharmacokinetic factors such as inhibition of drug-metabolizing enzymes, especially cytochrome P450 (CYP) enzymes, are regarded as the most frequent and clinically important.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450</infon>
          <location offset="224" length="15"/>
          <text>cytochrome P450</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp</infon>
          <location offset="241" length="3"/>
          <text>CYP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>315</offset>
        <text>Gypenosides is widely used as functional food and over-the-counter drug in East Asia.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gypenosides</infon>
          <location offset="315" length="11"/>
          <text>Gypenosides</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>401</offset>
        <text>In this study, the in vitro inhibitory effects of gypenosides on the major human CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) activities in human liver microsomes were examined using liquid chromatography-tandem mass spectrometry.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gypenosides</infon>
          <location offset="451" length="11"/>
          <text>gypenosides</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human cyp</infon>
          <location offset="476" length="9"/>
          <text>human CYP</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp1a2</infon>
          <location offset="495" length="6"/>
          <text>CYP1A2</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2b6</infon>
          <location offset="503" length="6"/>
          <text>CYP2B6</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2c8</infon>
          <location offset="511" length="6"/>
          <text>CYP2C8</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2c9</infon>
          <location offset="519" length="6"/>
          <text>CYP2C9</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2c19</infon>
          <location offset="527" length="7"/>
          <text>CYP2C19</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="536" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="548" length="6"/>
          <text>CYP3A4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>661</offset>
        <text>Gypenosides showed the strongest inhibition of CYP2D6, followed by CYP2C8, CYP3A4 and CYP2C9.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gypenosides</infon>
          <location offset="661" length="11"/>
          <text>Gypenosides</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="708" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2c8</infon>
          <location offset="728" length="6"/>
          <text>CYP2C8</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="736" length="6"/>
          <text>CYP3A4</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2c9</infon>
          <location offset="747" length="6"/>
          <text>CYP2C9</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>755</offset>
        <text>The IC50 values were 1.61μg/mL, 20.06μg/mL, 34.76μg/mL (CYP3A4/midazolam), 46.73μg/mL (CYP3A4/testosterone), and 54.52μg/mL, respectively.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="818" length="9"/>
          <text>midazolam</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">testosterone</infon>
          <location offset="849" length="12"/>
          <text>testosterone</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="811" length="6"/>
          <text>CYP3A4</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="842" length="6"/>
          <text>CYP3A4</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>894</offset>
        <text>Gypenosides exhibited competitive inhibition of CYP2D6 (Ki=1.18).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gypenosides</infon>
          <location offset="894" length="11"/>
          <text>Gypenosides</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="942" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>960</offset>
        <text>In conclusion, Gypenosides might cause herb-drug interactions via inhibition of CYP2D6.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gypenosides</infon>
          <location offset="975" length="11"/>
          <text>Gypenosides</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="1040" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1048</offset>
        <text>An in vivo study is needed to examine this further.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23419593</id>
    <passage>
      <offset>0</offset>
      <text>Temporal relationship between aquaporin-4 and glial fibrillary acidic protein in cerebellum of neonate and adult rats administered a BBB disrupting spider venom.	Two astrocyte markers, the glial water channel aquaporin-4 (AQP4) and the glial fibrillary acidic protein (GFAP), have been implicated in several physiological and pathological conditions in the central nervous system (CNS) as well as in blood-brain barrier breakdown (BBBb). By color segmentation the immunoreactivity of both proteins, we demonstrate that the expression of AQP4 and GFAP was increased in the cerebellum of neonate (14-day-old, P14) and adult (8-week-old) rats administered Phoneutria nigriventer spider venom (PNV) known to cause perivascular edema, BBBb and convulsion. In the cerebellum's gray matter, PNV produced a major response, especially in the granular layer. Parallel increases in AQP4 and GFAP expression occurred 24 h after envenomation in the white matter of P14 and in the molecular layer of adults, as well as in the granular layer 2 h after envenomation. In the Purkinje layer there was a tendency of increased AQP4, for both, neonates (5 h), and adults (2 and 24 h). Moreover, PNV also provoked nonparallel upregulation of both markers with prevalence of upregulation of AQP 4 for P14 rats, and GFAP for adults. The major expression of both proteins was in the gray matter. The data indicates a venom effect in water/electrolyte balance in the cerebellum and the participation of AQP4 in these effects. Age-related and time-related regional differences probably reflect specificity in AQP4 distribution in different astrocytic membrane domains as well as its participation in K(+) buffering and neural activity. This study is the first to associate astrocytic AQP4 expression and reactive gliosis in a model of BBB permeability promoted by P. nigriventer venom. Our data provide compelling evidence that AQP4 expression was increased in the cerebellum of rats administered PNV.</text>
      <sentence>
        <offset>0</offset>
        <text>Temporal relationship between aquaporin-4 and glial fibrillary acidic protein in cerebellum of neonate and adult rats administered a BBB disrupting spider venom.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aquaporin-4</infon>
          <location offset="30" length="11"/>
          <text>aquaporin-4</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glial fibrillary acidic protein</infon>
          <location offset="46" length="31"/>
          <text>glial fibrillary acidic protein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>162</offset>
        <text>Two astrocyte markers, the glial water channel aquaporin-4 (AQP4) and the glial fibrillary acidic protein (GFAP), have been implicated in several physiological and pathological conditions in the central nervous system (CNS) as well as in blood-brain barrier breakdown (BBBb).</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gfap</infon>
          <location offset="269" length="4"/>
          <text>GFAP</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glial water channel</infon>
          <location offset="189" length="19"/>
          <text>glial water channel</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aquaporin-4</infon>
          <location offset="209" length="11"/>
          <text>aquaporin-4</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aqp4</infon>
          <location offset="222" length="4"/>
          <text>AQP4</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glial fibrillary acidic protein</infon>
          <location offset="236" length="31"/>
          <text>glial fibrillary acidic protein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>438</offset>
        <text>By color segmentation the immunoreactivity of both proteins, we demonstrate that the expression of AQP4 and GFAP was increased in the cerebellum of neonate (14-day-old, P14) and adult (8-week-old) rats administered Phoneutria nigriventer spider venom (PNV) known to cause perivascular edema, BBBb and convulsion.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aqp4</infon>
          <location offset="537" length="4"/>
          <text>AQP4</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gfap</infon>
          <location offset="546" length="4"/>
          <text>GFAP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>751</offset>
        <text>In the cerebellum's gray matter, PNV produced a major response, especially in the granular layer.</text>
      </sentence>
      <sentence>
        <offset>849</offset>
        <text>Parallel increases in AQP4 and GFAP expression occurred 24 h after envenomation in the white matter of P14 and in the molecular layer of adults, as well as in the granular layer 2 h after envenomation.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aqp4</infon>
          <location offset="871" length="4"/>
          <text>AQP4</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gfap</infon>
          <location offset="880" length="4"/>
          <text>GFAP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1051</offset>
        <text>In the Purkinje layer there was a tendency of increased AQP4, for both, neonates (5 h), and adults (2 and 24 h).</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aqp4</infon>
          <location offset="1107" length="4"/>
          <text>AQP4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1164</offset>
        <text>Moreover, PNV also provoked nonparallel upregulation of both markers with prevalence of upregulation of AQP 4 for P14 rats, and GFAP for adults.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aqp 4</infon>
          <location offset="1268" length="5"/>
          <text>AQP 4</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gfap</infon>
          <location offset="1292" length="4"/>
          <text>GFAP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1309</offset>
        <text>The major expression of both proteins was in the gray matter.</text>
      </sentence>
      <sentence>
        <offset>1371</offset>
        <text>The data indicates a venom effect in water/electrolyte balance in the cerebellum and the participation of AQP4 in these effects.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aqp4</infon>
          <location offset="1477" length="4"/>
          <text>AQP4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1500</offset>
        <text>Age-related and time-related regional differences probably reflect specificity in AQP4 distribution in different astrocytic membrane domains as well as its participation in K(+) buffering and neural activity.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k(+)</infon>
          <location offset="1673" length="4"/>
          <text>K(+)</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aqp4</infon>
          <location offset="1582" length="4"/>
          <text>AQP4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1709</offset>
        <text>This study is the first to associate astrocytic AQP4 expression and reactive gliosis in a model of BBB permeability promoted by P. nigriventer venom.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aqp4</infon>
          <location offset="1757" length="4"/>
          <text>AQP4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1859</offset>
        <text>Our data provide compelling evidence that AQP4 expression was increased in the cerebellum of rats administered PNV.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aqp4</infon>
          <location offset="1901" length="4"/>
          <text>AQP4</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17114825</id>
    <passage>
      <offset>0</offset>
      <text>Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models.	The neuropathological hallmarks of Alzheimer's disease (AD) and other taupathies include neurofibrillary tangles and plaques. Despite the fact that only 2-10% of AD cases are associated with genetic mutations, no nontransgenic or metabolic models have been generated to date. The findings of tryptophanyl-tRNA synthetase (TrpRS) in plaques of the AD brain were reported recently by the authors. Here it is shown that expression of cytoplasmic-TrpRS is inversely correlated with neurofibrillary degeneration, whereas a nonionic detergent-insoluble presumably aggregated TrpRS is simultaneously accumulated in human cells treated by tryptamine, a metabolic tryptophan analog that acts as a competitive inhibitor of TrpRS. TrpRSN- terminal peptide self-assembles in double-helical fibrils in vitro. Herein, tryptamine causes neuropathy characterized by motor and behavioral deficits, hippocampal neuronal loss, neurofibrillary tangles, amyloidosis, and glucose decrease in mice. Tryptamine induced the formation of helical fibrillary tangles in both hippocampal neurons and glia. Taken together with the authors' previous findings of tryptamine-induced nephrotoxicity and filamentous tangle formation in kidney cells, the authors' data indicates a general role of tryptamine in cell degeneration and loss. It is concluded that tryptamine as a component of a normal diet can induce neurodegeneration at the concentrations, which might be consumed along with food. Tryptophan-dependent tRNAtrp aminoacylation catalyzed by TrpRS can be inhibited by its substrate tryptophan at physiological concentrations was demonstrated. These findings indicate that the dietary supplementation with tryptophan as a tryptamine competitor may not counteract the deleterious influence of tryptamine. The pivotal role of TrpRS in protecting against neurodegeneration is suggested, providing an insight into the pathogenesis and a possible treatment of neurodegenerative diseases.</text>
      <sentence>
        <offset>0</offset>
        <text>Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptamine</infon>
          <location offset="0" length="10"/>
          <text>Tryptamine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptophanyl</infon>
          <location offset="19" length="12"/>
          <text>tryptophanyl</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tryptophanyl-trna synthetase</infon>
          <location offset="19" length="28"/>
          <text>tryptophanyl-tRNA synthetase</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>136</offset>
        <text>The neuropathological hallmarks of Alzheimer's disease (AD) and other taupathies include neurofibrillary tangles and plaques.</text>
      </sentence>
      <sentence>
        <offset>262</offset>
        <text>Despite the fact that only 2-10% of AD cases are associated with genetic mutations, no nontransgenic or metabolic models have been generated to date.</text>
      </sentence>
      <sentence>
        <offset>412</offset>
        <text>The findings of tryptophanyl-tRNA synthetase (TrpRS) in plaques of the AD brain were reported recently by the authors.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptophanyl</infon>
          <location offset="428" length="12"/>
          <text>tryptophanyl</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tryptophanyl-trna synthetase</infon>
          <location offset="428" length="28"/>
          <text>tryptophanyl-tRNA synthetase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">trprs</infon>
          <location offset="458" length="5"/>
          <text>TrpRS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>531</offset>
        <text>Here it is shown that expression of cytoplasmic-TrpRS is inversely correlated with neurofibrillary degeneration, whereas a nonionic detergent-insoluble presumably aggregated TrpRS is simultaneously accumulated in human cells treated by tryptamine, a metabolic tryptophan analog that acts as a competitive inhibitor of TrpRS.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptamine</infon>
          <location offset="767" length="10"/>
          <text>tryptamine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptophan</infon>
          <location offset="791" length="10"/>
          <text>tryptophan</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytoplasmic-trprs</infon>
          <location offset="567" length="17"/>
          <text>cytoplasmic-TrpRS</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">trprs</infon>
          <location offset="705" length="5"/>
          <text>TrpRS</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">trprs</infon>
          <location offset="849" length="5"/>
          <text>TrpRS</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>856</offset>
        <text>TrpRSN- terminal peptide self-assembles in double-helical fibrils in vitro.</text>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">trprs</infon>
          <location offset="856" length="5"/>
          <text>TrpRS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>932</offset>
        <text>Herein, tryptamine causes neuropathy characterized by motor and behavioral deficits, hippocampal neuronal loss, neurofibrillary tangles, amyloidosis, and glucose decrease in mice.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptamine</infon>
          <location offset="940" length="10"/>
          <text>tryptamine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1086" length="7"/>
          <text>glucose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1112</offset>
        <text>Tryptamine induced the formation of helical fibrillary tangles in both hippocampal neurons and glia.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptamine</infon>
          <location offset="1112" length="10"/>
          <text>Tryptamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1213</offset>
        <text>Taken together with the authors' previous findings of tryptamine-induced nephrotoxicity and filamentous tangle formation in kidney cells, the authors' data indicates a general role of tryptamine in cell degeneration and loss.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptamine</infon>
          <location offset="1267" length="10"/>
          <text>tryptamine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptamine</infon>
          <location offset="1397" length="10"/>
          <text>tryptamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1439</offset>
        <text>It is concluded that tryptamine as a component of a normal diet can induce neurodegeneration at the concentrations, which might be consumed along with food.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptamine</infon>
          <location offset="1460" length="10"/>
          <text>tryptamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1596</offset>
        <text>Tryptophan-dependent tRNAtrp aminoacylation catalyzed by TrpRS can be inhibited by its substrate tryptophan at physiological concentrations was demonstrated.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptophan</infon>
          <location offset="1596" length="10"/>
          <text>Tryptophan</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptophan</infon>
          <location offset="1693" length="10"/>
          <text>tryptophan</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">trprs</infon>
          <location offset="1653" length="5"/>
          <text>TrpRS</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1754</offset>
        <text>These findings indicate that the dietary supplementation with tryptophan as a tryptamine competitor may not counteract the deleterious influence of tryptamine.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptophan</infon>
          <location offset="1816" length="10"/>
          <text>tryptophan</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptamine</infon>
          <location offset="1832" length="10"/>
          <text>tryptamine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptamine</infon>
          <location offset="1902" length="10"/>
          <text>tryptamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1914</offset>
        <text>The pivotal role of TrpRS in protecting against neurodegeneration is suggested, providing an insight into the pathogenesis and a possible treatment of neurodegenerative diseases.</text>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">trprs</infon>
          <location offset="1934" length="5"/>
          <text>TrpRS</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1687367</id>
    <passage>
      <offset>0</offset>
      <text>The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers.	1. We compared the alpha 1-, alpha 2- and beta 1-adrenoceptor blocking potencies of labetalol with those of its two stereoisomers (RR and SR) in pithed rats and in homogenized rat cerebral cortex and heart. 2. In pithed rats, labetalol and the RR-SR combination were given orally either at doses of 25 and 50 mg kg-1 body wt. or intravenously at doses of 1 and 5 mg kg-1 body wt. Prazosin 4 and 20 micrograms kg-1 body wt. and propranolol 1 and 5 mg kg-1 body wt., were given intravenously for comparison studies of potency at alpha 1- and beta 1-adrenoceptors, respectively. Effects were studied before and after i.v. administration of either phenylephrine (at doses which increased the mean arterial pressure by approximately 80 mmHg) or isoprenaline (at doses that increased heart rate by approximately 100 beats min-1). 3. In pithed rats, labetalol and the RR-SR combination antagonized, in a dose-dependent manner, the pressor effect of phenylephrine (P less than 0.05) and the chronotropic effect of isoprenaline (P less than 0.05). Following both oral and intravenous dosing, the RR-SR combination was twice potent as labetalol in terms of alpha 1- and beta 1-adrenoceptor antagonism at equivalent doses. 4. Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at alpha 1-adrenoceptors the order of potency was prazosin much greater than RR-SR greater than labetalol. At beta 1-adrenoceptors, the affinity of the compound RR-SR was about 3 times that of labetalol.5. As labetalol is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of alpha and beta receptor actions), the combination of RR and SR may be a valuable substitute for labetalol in the treatment of systemic hypertension. Although the potential for non-specific side effects (common to all four enantiomers) could be expected to be diminished, recent reports by postmarketing surveillance indicate that the RR isomer (dilevalol) can induce liver toxicity. Interestingly, labetalol is devoid of this effect; whether the combination of RR and SR enantiomers could be of clinical importance warrants further investigation.</text>
      <sentence>
        <offset>0</offset>
        <text>The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">labetalol</infon>
          <location offset="56" length="9"/>
          <text>labetalol</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha- and beta-adrenoceptor</infon>
          <location offset="4" length="28"/>
          <text>alpha- and beta-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>103</offset>
        <text>1. We compared the alpha 1-, alpha 2- and beta 1-adrenoceptor blocking potencies of labetalol with those of its two stereoisomers (RR and SR) in pithed rats and in homogenized rat cerebral cortex and heart.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">labetalol</infon>
          <location offset="187" length="9"/>
          <text>labetalol</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 1-, alpha 2- and beta 1-adrenoceptor</infon>
          <location offset="122" length="42"/>
          <text>alpha 1-, alpha 2- and beta 1-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>310</offset>
        <text>2. In pithed rats, labetalol and the RR-SR combination were given orally either at doses of 25 and 50 mg kg-1 body wt. or intravenously at doses of 1 and 5 mg kg-1 body wt.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">labetalol</infon>
          <location offset="329" length="9"/>
          <text>labetalol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>483</offset>
        <text>Prazosin 4 and 20 micrograms kg-1 body wt. and propranolol 1 and 5 mg kg-1 body wt., were given intravenously for comparison studies of potency at alpha 1- and beta 1-adrenoceptors, respectively.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prazosin</infon>
          <location offset="483" length="8"/>
          <text>Prazosin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">propranolol</infon>
          <location offset="530" length="11"/>
          <text>propranolol</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 1- and beta 1-adrenoceptors</infon>
          <location offset="630" length="33"/>
          <text>alpha 1- and beta 1-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>679</offset>
        <text>Effects were studied before and after i.v. administration of either phenylephrine (at doses which increased the mean arterial pressure by approximately 80 mmHg) or isoprenaline (at doses that increased heart rate by approximately 100 beats min-1).</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenylephrine</infon>
          <location offset="747" length="13"/>
          <text>phenylephrine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoprenaline</infon>
          <location offset="843" length="12"/>
          <text>isoprenaline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>927</offset>
        <text>3. In pithed rats, labetalol and the RR-SR combination antagonized, in a dose-dependent manner, the pressor effect of phenylephrine (P less than 0.05) and the chronotropic effect of isoprenaline (P less than 0.05).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoprenaline</infon>
          <location offset="1109" length="12"/>
          <text>isoprenaline</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">labetalol</infon>
          <location offset="946" length="9"/>
          <text>labetalol</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenylephrine</infon>
          <location offset="1045" length="13"/>
          <text>phenylephrine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1142</offset>
        <text>Following both oral and intravenous dosing, the RR-SR combination was twice potent as labetalol in terms of alpha 1- and beta 1-adrenoceptor antagonism at equivalent doses.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">labetalol</infon>
          <location offset="1228" length="9"/>
          <text>labetalol</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 1- and beta 1-adrenoceptor</infon>
          <location offset="1250" length="32"/>
          <text>alpha 1- and beta 1-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1315</offset>
        <text>4. Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at alpha 1-adrenoceptors the order of potency was prazosin much greater than RR-SR greater than labetalol.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">labetalol</infon>
          <location offset="1318" length="9"/>
          <text>Labetalol</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prazosin</infon>
          <location offset="1445" length="8"/>
          <text>prazosin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">labetalol</infon>
          <location offset="1491" length="9"/>
          <text>labetalol</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 2-adrenoceptors</infon>
          <location offset="1367" length="21"/>
          <text>alpha 2-adrenoceptors</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 1-adrenoceptors</infon>
          <location offset="1398" length="21"/>
          <text>alpha 1-adrenoceptors</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1502</offset>
        <text>At beta 1-adrenoceptors, the affinity of the compound RR-SR was about 3 times that of labetalol.5.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">labetalol</infon>
          <location offset="1588" length="9"/>
          <text>labetalol</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 1-adrenoceptors</infon>
          <location offset="1505" length="20"/>
          <text>beta 1-adrenoceptors</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1601</offset>
        <text>As labetalol is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of alpha and beta receptor actions), the combination of RR and SR may be a valuable substitute for labetalol in the treatment of systemic hypertension.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">labetalol</infon>
          <location offset="1604" length="9"/>
          <text>labetalol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">labetalol</infon>
          <location offset="1795" length="9"/>
          <text>labetalol</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha and beta receptor</infon>
          <location offset="1699" length="23"/>
          <text>alpha and beta receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1848</offset>
        <text>Although the potential for non-specific side effects (common to all four enantiomers) could be expected to be diminished, recent reports by postmarketing surveillance indicate that the RR isomer (dilevalol) can induce liver toxicity.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dilevalol</infon>
          <location offset="2044" length="9"/>
          <text>dilevalol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2082</offset>
        <text>Interestingly, labetalol is devoid of this effect; whether the combination of RR and SR enantiomers could be of clinical importance warrants further investigation.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">labetalol</infon>
          <location offset="2097" length="9"/>
          <text>labetalol</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23421517</id>
    <passage>
      <offset>0</offset>
      <text>Reversal effect of rosmarinic acid on multidrug resistance in SGC7901/Adr cell.	Multidrug resistance (MDR) has been a major problem in cancer chemotherapy. In this study, the aim was to explore the reversal effect and its potential mechanism of rosmarinic acid (RA) on SGC7901/Adr cells. 3-(4,5-Dimethylthiazol)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to investigate the reversal index of RA in SGC7901/Adr cell line. The intracellular accumulation of adriamycin, rhodamine123 (Rh123), and the expression of P-glycoprotein (P-gp) were assayed by flow cytometry. The influence of RA on the transcription of MDR1 gene was determined by reverse transcription-polymerase chain reaction. The results showed that RA could reverse the MDR of SGC7901/Adr cells, increase the intracellular accumulation of Adr and Rh123, and decrease the transcription of MDR1 gene and the expression of P-gp in SGC7901/Adr cells. These results indicated that RA was a potential multidrug resistance-reversing agent and warranted further investigations.</text>
      <sentence>
        <offset>0</offset>
        <text>Reversal effect of rosmarinic acid on multidrug resistance in SGC7901/Adr cell.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosmarinic acid</infon>
          <location offset="19" length="15"/>
          <text>rosmarinic acid</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adr</infon>
          <location offset="70" length="3"/>
          <text>Adr</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>80</offset>
        <text>Multidrug resistance (MDR) has been a major problem in cancer chemotherapy.</text>
      </sentence>
      <sentence>
        <offset>156</offset>
        <text>In this study, the aim was to explore the reversal effect and its potential mechanism of rosmarinic acid (RA) on SGC7901/Adr cells.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosmarinic acid</infon>
          <location offset="245" length="15"/>
          <text>rosmarinic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>288</offset>
        <text>3-(4,5-Dimethylthiazol)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to investigate the reversal index of RA in SGC7901/Adr cell line.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium bromide</infon>
          <location offset="288" length="56"/>
          <text>3-(4,5-Dimethylthiazol)-2,5-diphenyl tetrazolium bromide</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mtt</infon>
          <location offset="346" length="3"/>
          <text>MTT</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adr</infon>
          <location offset="417" length="3"/>
          <text>Adr</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>432</offset>
        <text>The intracellular accumulation of adriamycin, rhodamine123 (Rh123), and the expression of P-glycoprotein (P-gp) were assayed by flow cytometry.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adriamycin</infon>
          <location offset="466" length="10"/>
          <text>adriamycin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rhodamine123</infon>
          <location offset="478" length="12"/>
          <text>rhodamine123</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rh123</infon>
          <location offset="492" length="5"/>
          <text>Rh123</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="522" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="538" length="4"/>
          <text>P-gp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>576</offset>
        <text>The influence of RA on the transcription of MDR1 gene was determined by reverse transcription-polymerase chain reaction.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr1</infon>
          <location offset="620" length="4"/>
          <text>MDR1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>697</offset>
        <text>The results showed that RA could reverse the MDR of SGC7901/Adr cells, increase the intracellular accumulation of Adr and Rh123, and decrease the transcription of MDR1 gene and the expression of P-gp in SGC7901/Adr cells.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adr</infon>
          <location offset="757" length="3"/>
          <text>Adr</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adr</infon>
          <location offset="811" length="3"/>
          <text>Adr</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rh123</infon>
          <location offset="819" length="5"/>
          <text>Rh123</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr1</infon>
          <location offset="860" length="4"/>
          <text>MDR1</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="892" length="4"/>
          <text>P-gp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>919</offset>
        <text>These results indicated that RA was a potential multidrug resistance-reversing agent and warranted further investigations.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>14500570</id>
    <passage>
      <offset>0</offset>
      <text>Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity.	An increasing body of evidence has linked AMP-activated protein kinase (AMPK) and malonyl coenzyme A (CoA) to the regulation of energy balance. Thus, factors that activate AMPK and decrease the concentration of malonyl CoA in peripheral tissues, such as exercise, decrease triglyceride accumulation in the adipocyte and other cells. The data reviewed here suggest that this is related to the fact that these factors concurrently increase fatty acid oxidation, decrease the esterification of fatty acids to form glycerolipids, and, by mechanisms still unknown, increase energy expenditure. Malonyl CoA contributes to these events because it is an allosteric inhibitor of carnitine palmitoyltransferase, the enzyme that controls the transfer of long-chain fatty acyl CoA from the cytosol to the mitochondria, where they are oxidized. AMPK activation in turn increases fatty acid oxidation (by effects on enzymes that govern malonyl CoA synthesis and possibly its degradation) and inhibits triglyceride synthesis. It also increases the expression of uncoupling proteins and the transcriptional regulator peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC1alpha), which could possibly increase energy expenditure. Recent studies suggest that the ability of leptin, adiponectin, 5'-aminoimidazole 4-carboxamide riboside (AICAR), adrenergic agonists, and metformin to diminish adiposity may be mediated, at least in part, by AMPK activation in peripheral tissues. In addition, preliminary studies suggest that malonyl CoA and AMPK take part in fuel-sensing and signaling mechanisms in the hypothalamus that could regulate food intake and energy expenditure.</text>
      <sentence>
        <offset>0</offset>
        <text>Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malonyl coa</infon>
          <location offset="12" length="11"/>
          <text>malonyl CoA</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="25" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">amp-activated protein kinase</infon>
          <location offset="25" length="28"/>
          <text>AMP-activated protein kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>70</offset>
        <text>An increasing body of evidence has linked AMP-activated protein kinase (AMPK) and malonyl coenzyme A (CoA) to the regulation of energy balance.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">coa</infon>
          <location offset="172" length="3"/>
          <text>CoA</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="112" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malonyl coenzyme a</infon>
          <location offset="152" length="18"/>
          <text>malonyl coenzyme A</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">amp-activated protein kinase</infon>
          <location offset="112" length="28"/>
          <text>AMP-activated protein kinase</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="142" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>214</offset>
        <text>Thus, factors that activate AMPK and decrease the concentration of malonyl CoA in peripheral tissues, such as exercise, decrease triglyceride accumulation in the adipocyte and other cells.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malonyl coa</infon>
          <location offset="281" length="11"/>
          <text>malonyl CoA</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triglyceride</infon>
          <location offset="343" length="12"/>
          <text>triglyceride</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="242" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>403</offset>
        <text>The data reviewed here suggest that this is related to the fact that these factors concurrently increase fatty acid oxidation, decrease the esterification of fatty acids to form glycerolipids, and, by mechanisms still unknown, increase energy expenditure.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="508" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acids</infon>
          <location offset="561" length="11"/>
          <text>fatty acids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>659</offset>
        <text>Malonyl CoA contributes to these events because it is an allosteric inhibitor of carnitine palmitoyltransferase, the enzyme that controls the transfer of long-chain fatty acyl CoA from the cytosol to the mitochondria, where they are oxidized.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malonyl coa</infon>
          <location offset="659" length="11"/>
          <text>Malonyl CoA</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carnitine</infon>
          <location offset="740" length="9"/>
          <text>carnitine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">long-chain fatty acyl coa</infon>
          <location offset="813" length="25"/>
          <text>long-chain fatty acyl CoA</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">carnitine palmitoyltransferase</infon>
          <location offset="740" length="30"/>
          <text>carnitine palmitoyltransferase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>902</offset>
        <text>AMPK activation in turn increases fatty acid oxidation (by effects on enzymes that govern malonyl CoA synthesis and possibly its degradation) and inhibits triglyceride synthesis.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="936" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malonyl coa</infon>
          <location offset="992" length="11"/>
          <text>malonyl CoA</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triglyceride</infon>
          <location offset="1057" length="12"/>
          <text>triglyceride</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="902" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1081</offset>
        <text>It also increases the expression of uncoupling proteins and the transcriptional regulator peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC1alpha), which could possibly increase energy expenditure.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor gamma coactivator-1alpha</infon>
          <location offset="1171" length="67"/>
          <text>peroxisome proliferator-activated receptor gamma coactivator-1alpha</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgc1alpha</infon>
          <location offset="1240" length="9"/>
          <text>PGC1alpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1302</offset>
        <text>Recent studies suggest that the ability of leptin, adiponectin, 5'-aminoimidazole 4-carboxamide riboside (AICAR), adrenergic agonists, and metformin to diminish adiposity may be mediated, at least in part, by AMPK activation in peripheral tissues.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5'-aminoimidazole 4-carboxamide riboside</infon>
          <location offset="1366" length="40"/>
          <text>5'-aminoimidazole 4-carboxamide riboside</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aicar</infon>
          <location offset="1408" length="5"/>
          <text>AICAR</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="1441" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">leptin</infon>
          <location offset="1345" length="6"/>
          <text>leptin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="1511" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1550</offset>
        <text>In addition, preliminary studies suggest that malonyl CoA and AMPK take part in fuel-sensing and signaling mechanisms in the hypothalamus that could regulate food intake and energy expenditure.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malonyl coa</infon>
          <location offset="1596" length="11"/>
          <text>malonyl CoA</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="1612" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23147414</id>
    <passage>
      <offset>0</offset>
      <text>Linking GABA(A) receptor subunits to alcohol-induced conditioned taste aversion and recovery from acute alcohol intoxication.	GABA type A receptors (GABA(A)-R) are important for ethanol actions and it is of interest to link individual subunits with specific ethanol behaviors. We studied null mutant mice for six different GABA(A)-R subunits (α1, α2, α3, α4, α5 and δ). Only mice lacking the α2 subunit showed reduction of conditioned taste aversion (CTA) to ethanol. These results are in agreement with data from knock-in mice with mutation of the ethanol-sensitive site in the α2-subunit (Blednov et al., 2011). All together, they indicate that aversive property of ethanol is dependent on ethanol action on α2-containing GABA(A)-R. Deletion of the α2-subunit led to faster recovery whereas absence of the α3-subunit slowed recovery from ethanol-induced incoordination (rotarod). Deletion of the other four subunits did not affect this behavior. Similar changes in this behavior for the α2 and α3 null mutants were found for flurazepam motor incoordination. However, no differences in recovery were found in motor-incoordinating effects of an α1-selective modulator (zolpidem) or an α4-selective agonist (gaboxadol). Therefore, recovery of rotarod incoordination is under control of two GABA(A)-R subunits: α2 and α3. For motor activity, α3 null mice demonstrated higher activation by ethanol (1 g/kg) whereas both α2 (-/-) and α3 (-/Y) knockout mice were less sensitive to ethanol-induced reduction of motor activity (1.5 g/kg). These studies demonstrate that the effects of ethanol at GABAergic synapses containing α2 subunit are important for specific behavioral effects of ethanol which may be relevant to the genetic linkage of the α2 subunit with human alcoholism.</text>
      <sentence>
        <offset>0</offset>
        <text>Linking GABA(A) receptor subunits to alcohol-induced conditioned taste aversion and recovery from acute alcohol intoxication.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcohol</infon>
          <location offset="104" length="7"/>
          <text>alcohol</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcohol</infon>
          <location offset="37" length="7"/>
          <text>alcohol</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaba</infon>
          <location offset="8" length="4"/>
          <text>GABA</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gaba(a) receptor</infon>
          <location offset="8" length="16"/>
          <text>GABA(A) receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>126</offset>
        <text>GABA type A receptors (GABA(A)-R) are important for ethanol actions and it is of interest to link individual subunits with specific ethanol behaviors.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaba</infon>
          <location offset="126" length="4"/>
          <text>GABA</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="258" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaba</infon>
          <location offset="149" length="4"/>
          <text>GABA</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="178" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gaba type a receptors</infon>
          <location offset="126" length="21"/>
          <text>GABA type A receptors</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gaba(a)-r</infon>
          <location offset="149" length="9"/>
          <text>GABA(A)-R</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>277</offset>
        <text>We studied null mutant mice for six different GABA(A)-R subunits (α1, α2, α3, α4, α5 and δ).</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaba</infon>
          <location offset="323" length="4"/>
          <text>GABA</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gaba(a)-r subunits (α1, α2, α3, α4, α5 and δ</infon>
          <location offset="323" length="44"/>
          <text>GABA(A)-R subunits (α1, α2, α3, α4, α5 and δ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>370</offset>
        <text>Only mice lacking the α2 subunit showed reduction of conditioned taste aversion (CTA) to ethanol.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="459" length="7"/>
          <text>ethanol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>468</offset>
        <text>These results are in agreement with data from knock-in mice with mutation of the ethanol-sensitive site in the α2-subunit (Blednov et al., 2011).</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="549" length="7"/>
          <text>ethanol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>614</offset>
        <text>All together, they indicate that aversive property of ethanol is dependent on ethanol action on α2-containing GABA(A)-R.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="668" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="692" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaba</infon>
          <location offset="724" length="4"/>
          <text>GABA</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">α2-containing gaba(a)-r</infon>
          <location offset="710" length="23"/>
          <text>α2-containing GABA(A)-R</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>735</offset>
        <text>Deletion of the α2-subunit led to faster recovery whereas absence of the α3-subunit slowed recovery from ethanol-induced incoordination (rotarod).</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="840" length="7"/>
          <text>ethanol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>882</offset>
        <text>Deletion of the other four subunits did not affect this behavior.</text>
      </sentence>
      <sentence>
        <offset>948</offset>
        <text>Similar changes in this behavior for the α2 and α3 null mutants were found for flurazepam motor incoordination.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flurazepam</infon>
          <location offset="1027" length="10"/>
          <text>flurazepam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1060</offset>
        <text>However, no differences in recovery were found in motor-incoordinating effects of an α1-selective modulator (zolpidem) or an α4-selective agonist (gaboxadol).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zolpidem</infon>
          <location offset="1169" length="8"/>
          <text>zolpidem</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaboxadol</infon>
          <location offset="1207" length="9"/>
          <text>gaboxadol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1219</offset>
        <text>Therefore, recovery of rotarod incoordination is under control of two GABA(A)-R subunits: α2 and α3.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaba</infon>
          <location offset="1289" length="4"/>
          <text>GABA</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gaba(a)-r subunits: α2 and α3</infon>
          <location offset="1289" length="29"/>
          <text>GABA(A)-R subunits: α2 and α3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1320</offset>
        <text>For motor activity, α3 null mice demonstrated higher activation by ethanol (1 g/kg) whereas both α2 (-/-) and α3 (-/Y) knockout mice were less sensitive to ethanol-induced reduction of motor activity (1.5 g/kg).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1387" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1476" length="7"/>
          <text>ethanol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1532</offset>
        <text>These studies demonstrate that the effects of ethanol at GABAergic synapses containing α2 subunit are important for specific behavioral effects of ethanol which may be relevant to the genetic linkage of the α2 subunit with human alcoholism.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1578" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1679" length="7"/>
          <text>ethanol</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12213059</id>
    <passage>
      <offset>0</offset>
      <text>6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.	6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives were synthesized and characterized as activators of adenosine 5'-triphosphate (ATP) sensitive potassium (K(ATP)) channels in the beta-cells by measuring effects on membrane potential and insulin release in vitro. The effects on vascular tissue in vitro were measured on rat aorta and small mesenteric vessels. Selected compounds were characterized as competitive inhibitors of [(3)H]glibenclamide binding to membranes of HEK293 cells expressing human SUR1/Kir6.2 and as potent inhibitors of insulin release in isolated rat islets. 6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (54) was found to bind and activate the SUR1/Kir6.2 K(ATP) channels in the low nanomolar range and to be at least 1000 times more potent than the reference compound diazoxide with respect to inhibition of insulin release from rat islets. Several compounds, e.g., 3-propylamino- (30), 3-isopropylamino- (34), 3-(S)-sec-butylamino- (37), and 3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (53), which were found to be potent and beta-cell selective activators of K(ATP) channels in vitro, were found to inhibit insulin secretion in rats with minimal effects on blood pressure and to exhibit good oral pharmacokinetic properties.</text>
      <sentence>
        <offset>0</offset>
        <text>6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-chloro-3-alkylamino-4h-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide</infon>
          <location offset="0" length="68"/>
          <text>6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="115" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">potassium</infon>
          <location offset="129" length="9"/>
          <text>potassium</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atp sensitive potassium channels</infon>
          <location offset="115" length="32"/>
          <text>ATP sensitive potassium channels</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>174</offset>
        <text>6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives were synthesized and characterized as activators of adenosine 5'-triphosphate (ATP) sensitive potassium (K(ATP)) channels in the beta-cells by measuring effects on membrane potential and insulin release in vitro.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-chloro-3-alkylamino-4h-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide</infon>
          <location offset="174" length="68"/>
          <text>6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine 5'-triphosphate</infon>
          <location offset="307" length="25"/>
          <text>adenosine 5'-triphosphate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="334" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k</infon>
          <location offset="360" length="1"/>
          <text>K</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="362" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adenosine 5'-triphosphate (atp) sensitive potassium (k(atp)) channels</infon>
          <location offset="307" length="69"/>
          <text>adenosine 5'-triphosphate (ATP) sensitive potassium (K(ATP)) channels</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="442" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>468</offset>
        <text>The effects on vascular tissue in vitro were measured on rat aorta and small mesenteric vessels.</text>
      </sentence>
      <sentence>
        <offset>565</offset>
        <text>Selected compounds were characterized as competitive inhibitors of [(3)H]glibenclamide binding to membranes of HEK293 cells expressing human SUR1/Kir6.2 and as potent inhibitors of insulin release in isolated rat islets.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(3)h]glibenclamide</infon>
          <location offset="632" length="19"/>
          <text>[(3)H]glibenclamide</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human sur1</infon>
          <location offset="700" length="10"/>
          <text>human SUR1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kir6.2</infon>
          <location offset="711" length="6"/>
          <text>Kir6.2</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="746" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>786</offset>
        <text>6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (54) was found to bind and activate the SUR1/Kir6.2 K(ATP) channels in the low nanomolar range and to be at least 1000 times more potent than the reference compound diazoxide with respect to inhibition of insulin release from rat islets.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-chloro-3-(1-methylcyclobutyl)amino-4h-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide</infon>
          <location offset="786" length="83"/>
          <text>6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k</infon>
          <location offset="922" length="1"/>
          <text>K</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="924" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diazoxide</infon>
          <location offset="1035" length="9"/>
          <text>diazoxide</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sur1</infon>
          <location offset="910" length="4"/>
          <text>SUR1</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kir6.2</infon>
          <location offset="915" length="6"/>
          <text>Kir6.2</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">k(atp) channels</infon>
          <location offset="922" length="15"/>
          <text>K(ATP) channels</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1075" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1108</offset>
        <text>Several compounds, e.g., 3-propylamino- (30), 3-isopropylamino- (34), 3-(S)-sec-butylamino- (37), and 3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (53), which were found to be potent and beta-cell selective activators of K(ATP) channels in vitro, were found to inhibit insulin secretion in rats with minimal effects on blood pressure and to exhibit good oral pharmacokinetic properties.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-(s)-sec-butylamino</infon>
          <location offset="1178" length="20"/>
          <text>3-(S)-sec-butylamino</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-(1-methylcyclopropyl)amino-4h-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide</infon>
          <location offset="1210" length="75"/>
          <text>3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k</infon>
          <location offset="1360" length="1"/>
          <text>K</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="1362" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-propylamino</infon>
          <location offset="1133" length="13"/>
          <text>3-propylamino</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-isopropylamino</infon>
          <location offset="1154" length="16"/>
          <text>3-isopropylamino</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">k(atp) channels</infon>
          <location offset="1360" length="15"/>
          <text>K(ATP) channels</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1408" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23584857</id>
    <passage>
      <offset>0</offset>
      <text>Induction of the metabolic regulator Txnip in fasting-induced and natural torpor.	Torpor is a physiological state characterised by controlled lowering of metabolic rate and core body temperature, allowing substantial energy savings during periods of reduced food availability or harsh environmental conditions. The hypothalamus coordinates energy homeostasis and thermoregulation, and plays a key role in directing torpor. We recently showed that mice lacking the orphan G protein coupled receptor Gpr50 readily enter torpor in response to fasting, and have now used these mice to conduct a microarray analysis of hypothalamic gene expression changes related to the torpor state. This revealed a strong induction of thioredoxin interacting protein (Txnip) in the hypothalamus of torpid mice, which was confirmed by quantitative RT-PCR and Western blot analyses. In situ hybridisation identified the ependyma lining the third ventricle as the principal site of torpor-related expression of Txnip. To characterise further the relationship between Txnip and torpor, we profiled Txnip expression in mice during prolonged fasting, cold exposure, and 2-deoxyglucose-induced hypometabolism, as well as in naturally occurring torpor bouts in the Siberian hamster. Strikingly, pronounced upregulation of Txnip expression was only observed in WT mice when driven into torpor, and during torpor in the Siberian hamster. Increase of Txnip was not limited to the hypothalamus, with exaggerated expression in white adipose tissue, brown adipose tissue, and liver also demonstrated in torpid mice. Given the recent identification of Txnip as a molecular nutrient sensor important in the regulation of energy metabolism, our data suggest that elevated Txnip expression is critical to regulating energy expenditure and fuel utilisation during the extreme hypometabolic state of torpor.</text>
      <sentence>
        <offset>0</offset>
        <text>Induction of the metabolic regulator Txnip in fasting-induced and natural torpor.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">txnip</infon>
          <location offset="37" length="5"/>
          <text>Txnip</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>82</offset>
        <text>Torpor is a physiological state characterised by controlled lowering of metabolic rate and core body temperature, allowing substantial energy savings during periods of reduced food availability or harsh environmental conditions.</text>
      </sentence>
      <sentence>
        <offset>311</offset>
        <text>The hypothalamus coordinates energy homeostasis and thermoregulation, and plays a key role in directing torpor.</text>
      </sentence>
      <sentence>
        <offset>423</offset>
        <text>We recently showed that mice lacking the orphan G protein coupled receptor Gpr50 readily enter torpor in response to fasting, and have now used these mice to conduct a microarray analysis of hypothalamic gene expression changes related to the torpor state.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">orphan g protein coupled receptor</infon>
          <location offset="464" length="33"/>
          <text>orphan G protein coupled receptor</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr50</infon>
          <location offset="498" length="5"/>
          <text>Gpr50</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>680</offset>
        <text>This revealed a strong induction of thioredoxin interacting protein (Txnip) in the hypothalamus of torpid mice, which was confirmed by quantitative RT-PCR and Western blot analyses.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thioredoxin interacting protein</infon>
          <location offset="716" length="31"/>
          <text>thioredoxin interacting protein</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">txnip</infon>
          <location offset="749" length="5"/>
          <text>Txnip</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>862</offset>
        <text>In situ hybridisation identified the ependyma lining the third ventricle as the principal site of torpor-related expression of Txnip.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">txnip</infon>
          <location offset="989" length="5"/>
          <text>Txnip</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>996</offset>
        <text>To characterise further the relationship between Txnip and torpor, we profiled Txnip expression in mice during prolonged fasting, cold exposure, and 2-deoxyglucose-induced hypometabolism, as well as in naturally occurring torpor bouts in the Siberian hamster.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-deoxyglucose</infon>
          <location offset="1145" length="14"/>
          <text>2-deoxyglucose</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">txnip</infon>
          <location offset="1045" length="5"/>
          <text>Txnip</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">txnip</infon>
          <location offset="1075" length="5"/>
          <text>Txnip</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1256</offset>
        <text>Strikingly, pronounced upregulation of Txnip expression was only observed in WT mice when driven into torpor, and during torpor in the Siberian hamster.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">txnip</infon>
          <location offset="1295" length="5"/>
          <text>Txnip</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1409</offset>
        <text>Increase of Txnip was not limited to the hypothalamus, with exaggerated expression in white adipose tissue, brown adipose tissue, and liver also demonstrated in torpid mice.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">txnip</infon>
          <location offset="1421" length="5"/>
          <text>Txnip</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1583</offset>
        <text>Given the recent identification of Txnip as a molecular nutrient sensor important in the regulation of energy metabolism, our data suggest that elevated Txnip expression is critical to regulating energy expenditure and fuel utilisation during the extreme hypometabolic state of torpor.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">txnip</infon>
          <location offset="1618" length="5"/>
          <text>Txnip</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">txnip</infon>
          <location offset="1736" length="5"/>
          <text>Txnip</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23159790</id>
    <passage>
      <offset>0</offset>
      <text>Purification and structural characterisation of phospholipase A1 (Vespapase, Ves a 1) from Thai banded tiger wasp (Vespa affinis) venom.	The Thai banded tiger wasp (Vespa affinis) is one of the most dangerous vespid species in Southeast Asia, and stinging accidents involving this species still cause fatalities. In the present study, four forms of V. affinis phospholipase A(1) were identified through a proteomics approach. Two of these enzymes were purified by reverse-phase chromatography, and their biochemical properties were characterised. These enzymes, designated Ves a 1s, are not glycoproteins and exist as 33441.5 and 33474.4 Da proteins, which corresponded with the 34-kDa band observed via SDS-PAGE. The thermal stabilities of these enzymes were stronger than snake venom. Using an in vivo assay, no difference was found in the toxicities of the different isoforms. Furthermore, the toxicity of these enzymes does not appear to be correlated with their PLA(1) activity. The cDNAs of the full-length version of Ves a 1s revealed that the Ves a 1 gene consists of a 1005-bp ORF, which encodes 334 amino acid residues, and 67- and 227-bp 5' and 3' UTRs, respectively. The two isoforms are different by three nucleotide substitutions, resulting in the replacement of two amino acids. Through sequence alignment, these enzymes were classified as members of the pancreatic lipase family. The structural modelling of Ves a 1 used the rat pancreatic lipase-related protein 2 (1bu8A) as a template because it has PLA(1) activity, which demonstrated that this enzyme belongs to the α/β hydrolase fold family. The Ves a 1 structure, which is composed of seven α-helixes and eleven β-strands, contains the β-strand/ɛSer/α-helix structural motif, which contains the Gly-X-Ser-X-Gly consensus sequence. The typical surface structures that play important roles in substrate selectivity (the lid domain and the β9 loop) were shortened in the Ves a 1 structure, which suggests that this enzyme may only exhibit phospholipase activity. Moreover, the observed insertion of proline into the lid domain of the Ves a 1 structure is rare. We therefore propose that this proline residue might be involved in the stability and activity of Ves a 1s.</text>
      <sentence>
        <offset>0</offset>
        <text>Purification and structural characterisation of phospholipase A1 (Vespapase, Ves a 1) from Thai banded tiger wasp (Vespa affinis) venom.</text>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phospholipase a1</infon>
          <location offset="48" length="16"/>
          <text>phospholipase A1</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vespapase</infon>
          <location offset="66" length="9"/>
          <text>Vespapase</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ves a 1</infon>
          <location offset="77" length="7"/>
          <text>Ves a 1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>137</offset>
        <text>The Thai banded tiger wasp (Vespa affinis) is one of the most dangerous vespid species in Southeast Asia, and stinging accidents involving this species still cause fatalities.</text>
      </sentence>
      <sentence>
        <offset>313</offset>
        <text>In the present study, four forms of V. affinis phospholipase A(1) were identified through a proteomics approach.</text>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">v. affinis phospholipase a(1)</infon>
          <location offset="349" length="29"/>
          <text>V. affinis phospholipase A(1)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>426</offset>
        <text>Two of these enzymes were purified by reverse-phase chromatography, and their biochemical properties were characterised.</text>
      </sentence>
      <sentence>
        <offset>547</offset>
        <text>These enzymes, designated Ves a 1s, are not glycoproteins and exist as 33441.5 and 33474.4 Da proteins, which corresponded with the 34-kDa band observed via SDS-PAGE.</text>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ves a 1s</infon>
          <location offset="573" length="8"/>
          <text>Ves a 1s</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>714</offset>
        <text>The thermal stabilities of these enzymes were stronger than snake venom.</text>
      </sentence>
      <sentence>
        <offset>787</offset>
        <text>Using an in vivo assay, no difference was found in the toxicities of the different isoforms.</text>
      </sentence>
      <sentence>
        <offset>880</offset>
        <text>Furthermore, the toxicity of these enzymes does not appear to be correlated with their PLA(1) activity.</text>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pla(1)</infon>
          <location offset="967" length="6"/>
          <text>PLA(1)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>984</offset>
        <text>The cDNAs of the full-length version of Ves a 1s revealed that the Ves a 1 gene consists of a 1005-bp ORF, which encodes 334 amino acid residues, and 67- and 227-bp 5' and 3' UTRs, respectively.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="1109" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ves a 1s</infon>
          <location offset="1024" length="8"/>
          <text>Ves a 1s</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ves a 1</infon>
          <location offset="1051" length="7"/>
          <text>Ves a 1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1179</offset>
        <text>The two isoforms are different by three nucleotide substitutions, resulting in the replacement of two amino acids.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleotide</infon>
          <location offset="1219" length="10"/>
          <text>nucleotide</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="1281" length="11"/>
          <text>amino acids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1294</offset>
        <text>Through sequence alignment, these enzymes were classified as members of the pancreatic lipase family.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pancreatic lipase</infon>
          <location offset="1370" length="17"/>
          <text>pancreatic lipase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1396</offset>
        <text>The structural modelling of Ves a 1 used the rat pancreatic lipase-related protein 2 (1bu8A) as a template because it has PLA(1) activity, which demonstrated that this enzyme belongs to the α/β hydrolase fold family.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ves a 1</infon>
          <location offset="1424" length="7"/>
          <text>Ves a 1</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rat pancreatic lipase-related protein 2</infon>
          <location offset="1441" length="39"/>
          <text>rat pancreatic lipase-related protein 2</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">1bu8a</infon>
          <location offset="1482" length="5"/>
          <text>1bu8A</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pla(1)</infon>
          <location offset="1518" length="6"/>
          <text>PLA(1)</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">α/β hydrolase</infon>
          <location offset="1586" length="13"/>
          <text>α/β hydrolase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1613</offset>
        <text>The Ves a 1 structure, which is composed of seven α-helixes and eleven β-strands, contains the β-strand/ɛSer/α-helix structural motif, which contains the Gly-X-Ser-X-Gly consensus sequence.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gly</infon>
          <location offset="1767" length="3"/>
          <text>Gly</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="1773" length="3"/>
          <text>Ser</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gly</infon>
          <location offset="1779" length="3"/>
          <text>Gly</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ves a 1</infon>
          <location offset="1617" length="7"/>
          <text>Ves a 1</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gly-x-ser-x-gly</infon>
          <location offset="1767" length="15"/>
          <text>Gly-X-Ser-X-Gly</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1803</offset>
        <text>The typical surface structures that play important roles in substrate selectivity (the lid domain and the β9 loop) were shortened in the Ves a 1 structure, which suggests that this enzyme may only exhibit phospholipase activity.</text>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ves a 1</infon>
          <location offset="1940" length="7"/>
          <text>Ves a 1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phospholipase</infon>
          <location offset="2008" length="13"/>
          <text>phospholipase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2032</offset>
        <text>Moreover, the observed insertion of proline into the lid domain of the Ves a 1 structure is rare.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">proline</infon>
          <location offset="2068" length="7"/>
          <text>proline</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ves a 1</infon>
          <location offset="2103" length="7"/>
          <text>Ves a 1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2130</offset>
        <text>We therefore propose that this proline residue might be involved in the stability and activity of Ves a 1s.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">proline</infon>
          <location offset="2161" length="7"/>
          <text>proline</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ves a 1s</infon>
          <location offset="2228" length="8"/>
          <text>Ves a 1s</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T7" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23246471</id>
    <passage>
      <offset>0</offset>
      <text>Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.	Ovarian cancer is the most lethal gynecological malignancy, characterized by a high rate of chemoresistance. Current treatment strategies for ovarian cancer focus on novel drug combinations of cytotoxic agents and molecular targeted agents or novel drug delivery strategies that often involve intraperitoneal (IP) injection. Poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) micelles were loaded with paclitaxel (cytotoxic agent), cyclopamine (hedgehog inhibitor), and gossypol (Bcl-2 inhibitor). After physicochemical studies focusing on combination drug solubilization, 3-drug PEG-b-PCL micelles were evaluated in vitro in 2-D and 3-D cell culture and in vivo in xenograft models of ovarian cancer, tracking bioluminescence signals from ES-2 and SKOV3 human ovarian cancer cell lines after IP injection. 3-Drug PEG-b-PCL micelles were not significantly more potent in 2-D cell culture in comparison to paclitaxel; however, they disaggregated ES-2 tumor spheroids, whereas single drugs or 2-drug combinations only slowed growth of ES-2 tumor spheroids or had no noticeable effects. In ES-2 and SKOV3 xenograft models, 3-drug PEG-b-PCL micelles had significantly less tumor burden than paclitaxel based on bioluminescence imaging, 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET imaging, and overall survival. (18)F-FLT-PET images clearly showed that 3-drug PEG-b-PCL micelles dramatically reduce tumor volumes over paclitaxel and vehicle controls. In summary, PEG-b-PCL micelles enable the IP combination drug delivery of paclitaxel, cyclopamine and gossypol, resulting in tumor growth inhibition and prolonged survival over paclitaxel alone. These results validate a novel treatment strategy for ovarian cancer based on drug combinations of cytotoxic agents and molecular targeted agents, delivered concurrently by a nanoscale drug delivery system, e.g. PEG-b-PCL micelles.</text>
      <sentence>
        <offset>0</offset>
        <text>Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">poly(ethylene glycol)-block-poly(ε-caprolactone)</infon>
          <location offset="0" length="48"/>
          <text>Poly(ethylene glycol)-block-poly(ε-caprolactone)</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paclitaxel</infon>
          <location offset="103" length="10"/>
          <text>paclitaxel</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclopamine</infon>
          <location offset="115" length="11"/>
          <text>cyclopamine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gossypol</infon>
          <location offset="131" length="8"/>
          <text>gossypol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>195</offset>
        <text>Ovarian cancer is the most lethal gynecological malignancy, characterized by a high rate of chemoresistance.</text>
      </sentence>
      <sentence>
        <offset>304</offset>
        <text>Current treatment strategies for ovarian cancer focus on novel drug combinations of cytotoxic agents and molecular targeted agents or novel drug delivery strategies that often involve intraperitoneal (IP) injection.</text>
      </sentence>
      <sentence>
        <offset>520</offset>
        <text>Poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) micelles were loaded with paclitaxel (cytotoxic agent), cyclopamine (hedgehog inhibitor), and gossypol (Bcl-2 inhibitor).</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">poly(ethylene glycol)-block-poly(ε-caprolactone)</infon>
          <location offset="520" length="48"/>
          <text>Poly(ethylene glycol)-block-poly(ε-caprolactone)</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg-b-pcl</infon>
          <location offset="570" length="9"/>
          <text>PEG-b-PCL</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paclitaxel</infon>
          <location offset="607" length="10"/>
          <text>paclitaxel</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclopamine</infon>
          <location offset="637" length="11"/>
          <text>cyclopamine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gossypol</infon>
          <location offset="675" length="8"/>
          <text>gossypol</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="685" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>703</offset>
        <text>After physicochemical studies focusing on combination drug solubilization, 3-drug PEG-b-PCL micelles were evaluated in vitro in 2-D and 3-D cell culture and in vivo in xenograft models of ovarian cancer, tracking bioluminescence signals from ES-2 and SKOV3 human ovarian cancer cell lines after IP injection.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg-b-pcl</infon>
          <location offset="785" length="9"/>
          <text>PEG-b-PCL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1012</offset>
        <text>3-Drug PEG-b-PCL micelles were not significantly more potent in 2-D cell culture in comparison to paclitaxel; however, they disaggregated ES-2 tumor spheroids, whereas single drugs or 2-drug combinations only slowed growth of ES-2 tumor spheroids or had no noticeable effects.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg-b-pcl</infon>
          <location offset="1019" length="9"/>
          <text>PEG-b-PCL</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paclitaxel</infon>
          <location offset="1110" length="10"/>
          <text>paclitaxel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1289</offset>
        <text>In ES-2 and SKOV3 xenograft models, 3-drug PEG-b-PCL micelles had significantly less tumor burden than paclitaxel based on bioluminescence imaging, 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET imaging, and overall survival.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg-b-pcl</infon>
          <location offset="1332" length="9"/>
          <text>PEG-b-PCL</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paclitaxel</infon>
          <location offset="1392" length="10"/>
          <text>paclitaxel</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3'-deoxy-3'-(18)f-fluorothymidine</infon>
          <location offset="1437" length="33"/>
          <text>3'-deoxy-3'-(18)F-fluorothymidine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(18)f-flt</infon>
          <location offset="1472" length="9"/>
          <text>(18)F-FLT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1518</offset>
        <text>(18)F-FLT-PET images clearly showed that 3-drug PEG-b-PCL micelles dramatically reduce tumor volumes over paclitaxel and vehicle controls.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(18)f-flt</infon>
          <location offset="1518" length="9"/>
          <text>(18)F-FLT</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg-b-pcl</infon>
          <location offset="1566" length="9"/>
          <text>PEG-b-PCL</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paclitaxel</infon>
          <location offset="1624" length="10"/>
          <text>paclitaxel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1657</offset>
        <text>In summary, PEG-b-PCL micelles enable the IP combination drug delivery of paclitaxel, cyclopamine and gossypol, resulting in tumor growth inhibition and prolonged survival over paclitaxel alone.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg-b-pcl</infon>
          <location offset="1669" length="9"/>
          <text>PEG-b-PCL</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paclitaxel</infon>
          <location offset="1731" length="10"/>
          <text>paclitaxel</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclopamine</infon>
          <location offset="1743" length="11"/>
          <text>cyclopamine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gossypol</infon>
          <location offset="1759" length="8"/>
          <text>gossypol</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paclitaxel</infon>
          <location offset="1834" length="10"/>
          <text>paclitaxel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1852</offset>
        <text>These results validate a novel treatment strategy for ovarian cancer based on drug combinations of cytotoxic agents and molecular targeted agents, delivered concurrently by a nanoscale drug delivery system, e.g. PEG-b-PCL micelles.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg-b-pcl</infon>
          <location offset="2064" length="9"/>
          <text>PEG-b-PCL</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>20089905</id>
    <passage>
      <offset>0</offset>
      <text>A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons.	Ibuprofen is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of cyclooxygenases. Recently, we have demonstrated that ibuprofen inhibits intracellular signaling of RhoA and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents. In addition, another study suggests that ibuprofen reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex. The molecular mechanisms by which ibuprofen inhibits the RhoA signal in neurons, however, remain unclear. Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling ibuprofen to RhoA inhibition and subsequent neurite growth promotion in neurons. Ibuprofen activates PPARgamma in neuron-like PC12 and B104 cells. Activation of PPARgamma with traditional agonists mimics the RhoA-inhibiting properties of ibuprofen in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors. Protein knockdown with small interfering RNA specific for PPARgamma blocks RhoA suppression of PPARgamma agonists in PC12 cells. Moreover, the effect of ibuprofen on RhoA activity and neurite growth in neuronal cultures is prevented by selective PPARgamma inhibition. These findings support that PPARgamma plays an essential role in mediating the RhoA-inhibiting effect of ibuprofen. Elucidation of the novel molecular mechanisms linking ibuprofen to RhoA inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease.</text>
      <sentence>
        <offset>0</offset>
        <text>A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="26" length="9"/>
          <text>ibuprofen</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="45" length="4"/>
          <text>RhoA</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>73</offset>
        <text>Ibuprofen is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of cyclooxygenases.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="73" length="9"/>
          <text>Ibuprofen</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyclooxygenases</infon>
          <location offset="205" length="15"/>
          <text>cyclooxygenases</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>222</offset>
        <text>Recently, we have demonstrated that ibuprofen inhibits intracellular signaling of RhoA and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="258" length="9"/>
          <text>ibuprofen</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="304" length="4"/>
          <text>RhoA</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>414</offset>
        <text>In addition, another study suggests that ibuprofen reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="455" length="9"/>
          <text>ibuprofen</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">amyloid-beta42</infon>
          <location offset="487" length="14"/>
          <text>amyloid-beta42</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="530" length="4"/>
          <text>RhoA</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">amyloid-beta42</infon>
          <location offset="576" length="14"/>
          <text>amyloid-beta42</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gamma-secretase complex</infon>
          <location offset="629" length="23"/>
          <text>gamma-secretase complex</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>654</offset>
        <text>The molecular mechanisms by which ibuprofen inhibits the RhoA signal in neurons, however, remain unclear.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="688" length="9"/>
          <text>ibuprofen</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="711" length="4"/>
          <text>RhoA</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>760</offset>
        <text>Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling ibuprofen to RhoA inhibition and subsequent neurite growth promotion in neurons.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="893" length="9"/>
          <text>ibuprofen</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor gamma</infon>
          <location offset="806" length="48"/>
          <text>peroxisome proliferator-activated receptor gamma</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="856" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="906" length="4"/>
          <text>RhoA</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>974</offset>
        <text>Ibuprofen activates PPARgamma in neuron-like PC12 and B104 cells.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="974" length="9"/>
          <text>Ibuprofen</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="994" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1040</offset>
        <text>Activation of PPARgamma with traditional agonists mimics the RhoA-inhibiting properties of ibuprofen in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="1131" length="9"/>
          <text>ibuprofen</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="1165" length="9"/>
          <text>ibuprofen</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="1101" length="4"/>
          <text>RhoA</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1054" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1269</offset>
        <text>Protein knockdown with small interfering RNA specific for PPARgamma blocks RhoA suppression of PPARgamma agonists in PC12 cells.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1327" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="1344" length="4"/>
          <text>RhoA</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1364" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1398</offset>
        <text>Moreover, the effect of ibuprofen on RhoA activity and neurite growth in neuronal cultures is prevented by selective PPARgamma inhibition.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="1422" length="9"/>
          <text>ibuprofen</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="1435" length="4"/>
          <text>RhoA</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1515" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1537</offset>
        <text>These findings support that PPARgamma plays an essential role in mediating the RhoA-inhibiting effect of ibuprofen.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="1642" length="9"/>
          <text>ibuprofen</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1565" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="1616" length="4"/>
          <text>RhoA</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1653</offset>
        <text>Elucidation of the novel molecular mechanisms linking ibuprofen to RhoA inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ibuprofen</infon>
          <location offset="1707" length="9"/>
          <text>ibuprofen</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="1720" length="4"/>
          <text>RhoA</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="1813" length="4"/>
          <text>RhoA</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23349485</id>
    <passage>
      <offset>0</offset>
      <text>Disruption of the cereblon gene enhances hepatic AMPK activity and prevents high fat diet-induced obesity and insulin resistance in mice.	A nonsense mutation in cereblon (CRBN) causes a mild type of mental retardation in humans. An earlier study showed that CRBN negatively regulates the functional activity of AMP-activated protein kinase (AMPK) in vitro by binding directly to the α1 subunit of the AMPK complex. However, the in vivo role of CRBN was not studied. To elucidate the physiological functions of Crbn, a mouse strain was generated in which the Crbn gene was deleted throughout the whole body. In Crbn-deficient mice fed a normal diet, AMPK in the liver showed hyper-phosphorylation, which indicated the constitutive activation of AMPK. Since Crbn-deficient mice showed significantly less weight gain when fed a high fat diet and their insulin sensitivity was considerably improved, the functions of Crbn in the liver were primarily investigated. These results provide the first in vivo evidence that Crbn is a negative modulator of AMPK, which suggests that Crbn may be a potential target for metabolic disorders of the liver.</text>
      <sentence>
        <offset>0</offset>
        <text>Disruption of the cereblon gene enhances hepatic AMPK activity and prevents high fat diet-induced obesity and insulin resistance in mice.</text>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="110" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cereblon</infon>
          <location offset="18" length="8"/>
          <text>cereblon</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="49" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>138</offset>
        <text>A nonsense mutation in cereblon (CRBN) causes a mild type of mental retardation in humans.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cereblon</infon>
          <location offset="161" length="8"/>
          <text>cereblon</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crbn</infon>
          <location offset="171" length="4"/>
          <text>CRBN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>229</offset>
        <text>An earlier study showed that CRBN negatively regulates the functional activity of AMP-activated protein kinase (AMPK) in vitro by binding directly to the α1 subunit of the AMPK complex.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="311" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crbn</infon>
          <location offset="258" length="4"/>
          <text>CRBN</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">amp-activated protein kinase</infon>
          <location offset="311" length="28"/>
          <text>AMP-activated protein kinase</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="341" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">α1 subunit of the ampk</infon>
          <location offset="383" length="22"/>
          <text>α1 subunit of the AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>415</offset>
        <text>However, the in vivo role of CRBN was not studied.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crbn</infon>
          <location offset="444" length="4"/>
          <text>CRBN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>466</offset>
        <text>To elucidate the physiological functions of Crbn, a mouse strain was generated in which the Crbn gene was deleted throughout the whole body.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crbn</infon>
          <location offset="510" length="4"/>
          <text>Crbn</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crbn</infon>
          <location offset="558" length="4"/>
          <text>Crbn</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>607</offset>
        <text>In Crbn-deficient mice fed a normal diet, AMPK in the liver showed hyper-phosphorylation, which indicated the constitutive activation of AMPK.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crbn</infon>
          <location offset="610" length="4"/>
          <text>Crbn</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="649" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="744" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>750</offset>
        <text>Since Crbn-deficient mice showed significantly less weight gain when fed a high fat diet and their insulin sensitivity was considerably improved, the functions of Crbn in the liver were primarily investigated.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crbn</infon>
          <location offset="756" length="4"/>
          <text>Crbn</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crbn</infon>
          <location offset="913" length="4"/>
          <text>Crbn</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>960</offset>
        <text>These results provide the first in vivo evidence that Crbn is a negative modulator of AMPK, which suggests that Crbn may be a potential target for metabolic disorders of the liver.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crbn</infon>
          <location offset="1014" length="4"/>
          <text>Crbn</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="1046" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">crbn</infon>
          <location offset="1072" length="4"/>
          <text>Crbn</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23240866</id>
    <passage>
      <offset>0</offset>
      <text>Optimization of brush-like cationic copolymers for nonviral gene delivery.	Polyethylenimine (PEI) is one of the most broadly used polycations for gene delivery due to its high transfection efficiency and commercial availability but materials are cytotoxic and often polydisperse. The goal of current work is to develop an alternative family of polycations based on controlled living radical polymerization (CLRP) and to optimize the polymer structure for efficient gene delivery. In this study, well-defined poly(glycidyl methacrylate)(P(GMA)) homopolymers were synthesized using reversible addition-fragmentation chain transfer (RAFT) polymerization followed by decoration using three different types of oligoamines, i.e., tetraethylenepentamine (TEPA), pentaethylenehexamine (PEHA), and tris(2-aminoethyl)amine (TREN), respectively, to generate various P(GMA-oligoamine) homopolycations. The effect of P(GMA) backbone length and structure of oligoamine on gene transfer efficiency was then determined. The optimal polymer, P(GMA-TEPA)(50), provided comparable transfection efficiency but lower cytotoxicity than PEI. P(GMA-TEPA)(50) was then used as the cationic block in diblock copolymers containing hydrophilic N-(2-hydroxypropyl) methacrylamide (HPMA) and oligo(ethylene glycol) monomethyl ether methacrylate (OEGMA). Polyplexes of block copolymers were stable against aggregation in physiological salt condition and in Opti-MEM due to the shielding effect of P(HPMA) and P(OEGMA). However, the presence of the HPMA/OEGMA block significantly decreased the transfection efficacy of P(GMA-TEPA)(50) homopolycation. To compensate for reduced cell uptake caused by the hydrophilic shell of polyplex, the integrin-binding peptide, RGD, was conjugated to the hydrophilic chain end of P(OEGMA)(15)-b-P(GMA-TEPA)(50) copolymer by Michael-type addition reaction. At low polymer to DNA ratios, the RGD-functionalized polymer showed increased gene delivery efficiency to HeLa cells compared to analogous polymers lacking RGD.</text>
      <sentence>
        <offset>0</offset>
        <text>Optimization of brush-like cationic copolymers for nonviral gene delivery.</text>
      </sentence>
      <sentence>
        <offset>75</offset>
        <text>Polyethylenimine (PEI) is one of the most broadly used polycations for gene delivery due to its high transfection efficiency and commercial availability but materials are cytotoxic and often polydisperse.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyethylenimine</infon>
          <location offset="75" length="16"/>
          <text>Polyethylenimine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pei</infon>
          <location offset="93" length="3"/>
          <text>PEI</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>280</offset>
        <text>The goal of current work is to develop an alternative family of polycations based on controlled living radical polymerization (CLRP) and to optimize the polymer structure for efficient gene delivery.</text>
      </sentence>
      <sentence>
        <offset>480</offset>
        <text>In this study, well-defined poly(glycidyl methacrylate)(P(GMA)) homopolymers were synthesized using reversible addition-fragmentation chain transfer (RAFT) polymerization followed by decoration using three different types of oligoamines, i.e., tetraethylenepentamine (TEPA), pentaethylenehexamine (PEHA), and tris(2-aminoethyl)amine (TREN), respectively, to generate various P(GMA-oligoamine) homopolycations.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">poly(glycidyl methacrylate)</infon>
          <location offset="508" length="27"/>
          <text>poly(glycidyl methacrylate)</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p(gma)</infon>
          <location offset="536" length="6"/>
          <text>P(GMA)</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oligoamines</infon>
          <location offset="705" length="11"/>
          <text>oligoamines</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetraethylenepentamine</infon>
          <location offset="724" length="22"/>
          <text>tetraethylenepentamine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tepa</infon>
          <location offset="748" length="4"/>
          <text>TEPA</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pentaethylenehexamine</infon>
          <location offset="755" length="21"/>
          <text>pentaethylenehexamine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peha</infon>
          <location offset="778" length="4"/>
          <text>PEHA</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tris(2-aminoethyl)amine</infon>
          <location offset="789" length="23"/>
          <text>tris(2-aminoethyl)amine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tren</infon>
          <location offset="814" length="4"/>
          <text>TREN</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p(gma-oligoamine)</infon>
          <location offset="855" length="17"/>
          <text>P(GMA-oligoamine)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>890</offset>
        <text>The effect of P(GMA) backbone length and structure of oligoamine on gene transfer efficiency was then determined.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p(gma)</infon>
          <location offset="904" length="6"/>
          <text>P(GMA)</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oligoamine</infon>
          <location offset="944" length="10"/>
          <text>oligoamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1004</offset>
        <text>The optimal polymer, P(GMA-TEPA)(50), provided comparable transfection efficiency but lower cytotoxicity than PEI.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pei</infon>
          <location offset="1114" length="3"/>
          <text>PEI</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p(gma-tepa)(50)</infon>
          <location offset="1025" length="15"/>
          <text>P(GMA-TEPA)(50)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1119</offset>
        <text>P(GMA-TEPA)(50) was then used as the cationic block in diblock copolymers containing hydrophilic N-(2-hydroxypropyl) methacrylamide (HPMA) and oligo(ethylene glycol) monomethyl ether methacrylate (OEGMA).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p(gma-tepa)(50)</infon>
          <location offset="1119" length="15"/>
          <text>P(GMA-TEPA)(50)</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-(2-hydroxypropyl) methacrylamide</infon>
          <location offset="1216" length="34"/>
          <text>N-(2-hydroxypropyl) methacrylamide</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hpma</infon>
          <location offset="1252" length="4"/>
          <text>HPMA</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oligo(ethylene glycol) monomethyl ether methacrylate</infon>
          <location offset="1262" length="52"/>
          <text>oligo(ethylene glycol) monomethyl ether methacrylate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oegma</infon>
          <location offset="1316" length="5"/>
          <text>OEGMA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1324</offset>
        <text>Polyplexes of block copolymers were stable against aggregation in physiological salt condition and in Opti-MEM due to the shielding effect of P(HPMA) and P(OEGMA).</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p(hpma)</infon>
          <location offset="1466" length="7"/>
          <text>P(HPMA)</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p(oegma)</infon>
          <location offset="1478" length="8"/>
          <text>P(OEGMA)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1488</offset>
        <text>However, the presence of the HPMA/OEGMA block significantly decreased the transfection efficacy of P(GMA-TEPA)(50) homopolycation.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hpma</infon>
          <location offset="1517" length="4"/>
          <text>HPMA</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oegma</infon>
          <location offset="1522" length="5"/>
          <text>OEGMA</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p(gma-tepa)(50)</infon>
          <location offset="1587" length="15"/>
          <text>P(GMA-TEPA)(50)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1619</offset>
        <text>To compensate for reduced cell uptake caused by the hydrophilic shell of polyplex, the integrin-binding peptide, RGD, was conjugated to the hydrophilic chain end of P(OEGMA)(15)-b-P(GMA-TEPA)(50) copolymer by Michael-type addition reaction.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p(oegma)(15)-b-p(gma-tepa)(50)</infon>
          <location offset="1784" length="30"/>
          <text>P(OEGMA)(15)-b-P(GMA-TEPA)(50)</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">integrin</infon>
          <location offset="1706" length="8"/>
          <text>integrin</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1860</offset>
        <text>At low polymer to DNA ratios, the RGD-functionalized polymer showed increased gene delivery efficiency to HeLa cells compared to analogous polymers lacking RGD.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10933803</id>
    <passage>
      <offset>0</offset>
      <text>Zymogen factor IX potentiates factor IXa-catalyzed factor X activation.	Intrinsic factor X activation is accelerated &gt;10(7)-fold by assembly of the entire complex on the activated platelet surface. We have now observed that increasing the concentration of zymogen factor IX to physiologic levels ( approximately 100 nM) potentiates factor IXa-catalyzed activation of factor X on both activated platelets and on negatively charged phospholipid vesicles. In the presence and absence of factor VIIIa, factor IX (100 nM) lowered the K(d,appFIXa) approximately 4-fold on platelets and 2-10-fold on lipid vesicles. Treatment of two factor IX preparations with active-site inhibitors did not affect these observations. Autoradiographs of PAGE-separated reactions containing either (125)I-labeled factor IX or (125)I-labeled factor X showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface. Since plasma concentrations of prothrombin, factor VII, protein C, or protein S did not by themselves potentiate factor Xa generation and did not interfere with the potentiation of the reaction of factor IX, the effect is specific for factor IX and is not attributable to the Gla domain of all vitamin K-dependent proteins. These observations indicate that under physiologic conditions, plasma levels of the zymogen factor IX specifically increase the affinity of factor IXa for the intrinsic factor X activation complex.</text>
      <sentence>
        <offset>0</offset>
        <text>Zymogen factor IX potentiates factor IXa-catalyzed factor X activation.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ixa</infon>
          <location offset="30" length="10"/>
          <text>factor IXa</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="51" length="8"/>
          <text>factor X</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="8" length="9"/>
          <text>factor IX</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>72</offset>
        <text>Intrinsic factor X activation is accelerated &gt;10(7)-fold by assembly of the entire complex on the activated platelet surface.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="82" length="8"/>
          <text>factor X</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>198</offset>
        <text>We have now observed that increasing the concentration of zymogen factor IX to physiologic levels ( approximately 100 nM) potentiates factor IXa-catalyzed activation of factor X on both activated platelets and on negatively charged phospholipid vesicles.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="264" length="9"/>
          <text>factor IX</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ixa</infon>
          <location offset="332" length="10"/>
          <text>factor IXa</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="367" length="8"/>
          <text>factor X</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>453</offset>
        <text>In the presence and absence of factor VIIIa, factor IX (100 nM) lowered the K(d,appFIXa) approximately 4-fold on platelets and 2-10-fold on lipid vesicles.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor viiia</infon>
          <location offset="484" length="12"/>
          <text>factor VIIIa</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="498" length="9"/>
          <text>factor IX</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fixa</infon>
          <location offset="536" length="4"/>
          <text>FIXa</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>609</offset>
        <text>Treatment of two factor IX preparations with active-site inhibitors did not affect these observations.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="626" length="9"/>
          <text>factor IX</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>712</offset>
        <text>Autoradiographs of PAGE-separated reactions containing either (125)I-labeled factor IX or (125)I-labeled factor X showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(125)i</infon>
          <location offset="774" length="6"/>
          <text>(125)I</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(125)i</infon>
          <location offset="802" length="6"/>
          <text>(125)I</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="789" length="9"/>
          <text>factor IX</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="817" length="8"/>
          <text>factor X</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="852" length="8"/>
          <text>factor X</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor xa</infon>
          <location offset="887" length="9"/>
          <text>factor Xa</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="929" length="9"/>
          <text>factor IX</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x heavy chain</infon>
          <location offset="980" length="20"/>
          <text>factor X heavy chain</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="1020" length="9"/>
          <text>factor IX</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1128</offset>
        <text>Since plasma concentrations of prothrombin, factor VII, protein C, or protein S did not by themselves potentiate factor Xa generation and did not interfere with the potentiation of the reaction of factor IX, the effect is specific for factor IX and is not attributable to the Gla domain of all vitamin K-dependent proteins.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin k</infon>
          <location offset="1422" length="9"/>
          <text>vitamin K</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">prothrombin</infon>
          <location offset="1159" length="11"/>
          <text>prothrombin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor vii</infon>
          <location offset="1172" length="10"/>
          <text>factor VII</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">protein c</infon>
          <location offset="1184" length="9"/>
          <text>protein C</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">protein s</infon>
          <location offset="1198" length="9"/>
          <text>protein S</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">factor xa</infon>
          <location offset="1241" length="9"/>
          <text>factor Xa</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="1325" length="9"/>
          <text>factor IX</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="1363" length="9"/>
          <text>factor IX</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gla domain</infon>
          <location offset="1404" length="10"/>
          <text>Gla domain</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1452</offset>
        <text>These observations indicate that under physiologic conditions, plasma levels of the zymogen factor IX specifically increase the affinity of factor IXa for the intrinsic factor X activation complex.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="1544" length="9"/>
          <text>factor IX</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ixa</infon>
          <location offset="1592" length="10"/>
          <text>factor IXa</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="1621" length="8"/>
          <text>factor X</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23643747</id>
    <passage>
      <offset>0</offset>
      <text>Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.	The ribosomal protein S6 (rpS6) is a component of the small 40S ribosomal subunit, involved in multiple physiological functions. Here, we examined the effects produced by haloperidol, a typical antipsychotic drug, on the phosphorylation of rpS6 at Ser240/244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders. Administration of haloperidol increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express dopamine D2 receptors (D2Rs). This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1). We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (PP-1). In line with this observation, incubation of striatal slices with okadaic acid and calyculin A, two inhibitors of PP-1, increased Ser240/244 phosphorylation. These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs. They also indicate that this effect is exerted by suppressing dephosphorylation at Ser240/244, through PKA-dependent activation of DARPP-32 and inhibition of PP-1.</text>
      <sentence>
        <offset>0</offset>
        <text>Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">haloperidol</infon>
          <location offset="0" length="11"/>
          <text>Haloperidol</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="82" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="96" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein phosphatase-1</infon>
          <location offset="154" length="21"/>
          <text>protein phosphatase-1</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mtorc1</infon>
          <location offset="21" length="6"/>
          <text>mTORC1</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ribosomal protein s6</infon>
          <location offset="57" length="20"/>
          <text>ribosomal protein S6</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine- and camp-regulated phosphoprotein of 32 kda</infon>
          <location offset="82" length="53"/>
          <text>dopamine- and cAMP-regulated phosphoprotein of 32 kDa</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>177</offset>
        <text>The ribosomal protein S6 (rpS6) is a component of the small 40S ribosomal subunit, involved in multiple physiological functions.</text>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rps6</infon>
          <location offset="203" length="4"/>
          <text>rpS6</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ribosomal protein s6</infon>
          <location offset="181" length="20"/>
          <text>ribosomal protein S6</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">40s ribosomal subunit</infon>
          <location offset="237" length="21"/>
          <text>40S ribosomal subunit</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>306</offset>
        <text>Here, we examined the effects produced by haloperidol, a typical antipsychotic drug, on the phosphorylation of rpS6 at Ser240/244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">haloperidol</infon>
          <location offset="348" length="11"/>
          <text>haloperidol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="425" length="3"/>
          <text>Ser</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rps6</infon>
          <location offset="417" length="4"/>
          <text>rpS6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>530</offset>
        <text>Administration of haloperidol increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express dopamine D2 receptors (D2Rs).</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">haloperidol</infon>
          <location offset="548" length="11"/>
          <text>haloperidol</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="570" length="3"/>
          <text>Ser</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaba</infon>
          <location offset="619" length="4"/>
          <text>GABA</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="673" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2 receptors</infon>
          <location offset="673" length="21"/>
          <text>dopamine D2 receptors</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d2rs</infon>
          <location offset="696" length="4"/>
          <text>D2Rs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>703</offset>
        <text>This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="732" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="783" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pf470867</infon>
          <location offset="819" length="8"/>
          <text>PF470867</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mammalian target of rapamycin complex 1</infon>
          <location offset="763" length="39"/>
          <text>mammalian target of rapamycin complex 1</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mtorc1</infon>
          <location offset="804" length="6"/>
          <text>mTORC1</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p70 ribosomal s6 kinase 1</infon>
          <location offset="858" length="25"/>
          <text>p70 ribosomal S6 kinase 1</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">s6k1</infon>
          <location offset="885" length="4"/>
          <text>S6K1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>892</offset>
        <text>We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (PP-1).</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">haloperidol</infon>
          <location offset="925" length="11"/>
          <text>haloperidol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="940" length="3"/>
          <text>Ser</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1011" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="1025" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine- and camp-regulated phosphoprotein of 32 kda</infon>
          <location offset="1011" length="53"/>
          <text>dopamine- and cAMP-regulated phosphoprotein of 32 kDa</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">darpp-32</infon>
          <location offset="1066" length="8"/>
          <text>DARPP-32</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein phosphatase-1</infon>
          <location offset="1104" length="21"/>
          <text>protein phosphatase-1</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pp-1</infon>
          <location offset="1127" length="4"/>
          <text>PP-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1134</offset>
        <text>In line with this observation, incubation of striatal slices with okadaic acid and calyculin A, two inhibitors of PP-1, increased Ser240/244 phosphorylation.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">okadaic acid</infon>
          <location offset="1200" length="12"/>
          <text>okadaic acid</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calyculin a</infon>
          <location offset="1217" length="11"/>
          <text>calyculin A</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="1264" length="3"/>
          <text>Ser</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pp-1</infon>
          <location offset="1248" length="4"/>
          <text>PP-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1292</offset>
        <text>These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">haloperidol</infon>
          <location offset="1316" length="11"/>
          <text>haloperidol</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="1391" length="3"/>
          <text>Ser</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mtorc1</infon>
          <location offset="1337" length="6"/>
          <text>mTORC1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">s6k1</infon>
          <location offset="1349" length="4"/>
          <text>S6K1</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rps6</infon>
          <location offset="1383" length="4"/>
          <text>rpS6</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d2rs</infon>
          <location offset="1450" length="4"/>
          <text>D2Rs</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1456</offset>
        <text>They also indicate that this effect is exerted by suppressing dephosphorylation at Ser240/244, through PKA-dependent activation of DARPP-32 and inhibition of PP-1.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="1539" length="3"/>
          <text>Ser</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pka</infon>
          <location offset="1559" length="3"/>
          <text>PKA</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">darpp-32</infon>
          <location offset="1587" length="8"/>
          <text>DARPP-32</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pp-1</infon>
          <location offset="1614" length="4"/>
          <text>PP-1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23539641</id>
    <passage>
      <offset>0</offset>
      <text>Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies.	Full, persistent blockade of central neurokinin-1 (NK1) receptors may be a potential antidepressant mechanism. The selective NK1 antagonist orvepitant (GW823296) was used to test this hypothesis. A preliminary positron emission tomography study in eight male volunteers drove dose selection for two randomized six week studies in patients with major depressive disorder (MDD). Displacement of central [(11)C]GR205171 binding indicated that oral orvepitant doses of 30-60 mg/day provided &gt;99% receptor occupancy for ≥24 h. Studies 733 and 833 randomized patients with MDD and 17-item Hamilton Depression Rating Scale (HAM-D)≥22 to double-blind treatment with orvepitant 30 mg/day, orvepitant 60 mg/day or placebo (1:1:1). Primary outcome measure was change from baseline in 17-item HAM-D total score at Week 6 analyzed using mixed models repeated measures. Study 733 (n=328) demonstrated efficacy on the primary endpoint (estimated drug-placebo differences of 30 mg: -2.41, 95% confidence interval (CI) (-4.50 to -0.31) p=0.0245; 60 mg: -2.86, 95% CI (-4.97 to -0.75) p=0.0082). Study 833 (n=345) did not show significance (estimated drug-placebo differences of 30 mg: -1.67, 95% CI (-3.73 to 0.39) p=0.1122; 60 mg: -0.76, 95% CI (-2.85 to 1.32) p=0.4713). The results support the hypothesis that full, long lasting blockade of central NK1 receptors may be an efficacious mechanism for the treatment of MDD.</text>
      <sentence>
        <offset>0</offset>
        <text>Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orvepitant</infon>
          <location offset="98" length="10"/>
          <text>orvepitant</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neurokinin-1 receptor</infon>
          <location offset="13" length="21"/>
          <text>neurokinin-1 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>127</offset>
        <text>Full, persistent blockade of central neurokinin-1 (NK1) receptors may be a potential antidepressant mechanism.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neurokinin-1 (nk1) receptors</infon>
          <location offset="164" length="28"/>
          <text>neurokinin-1 (NK1) receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>238</offset>
        <text>The selective NK1 antagonist orvepitant (GW823296) was used to test this hypothesis.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orvepitant</infon>
          <location offset="267" length="10"/>
          <text>orvepitant</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gw823296</infon>
          <location offset="279" length="8"/>
          <text>GW823296</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nk1</infon>
          <location offset="252" length="3"/>
          <text>NK1</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>323</offset>
        <text>A preliminary positron emission tomography study in eight male volunteers drove dose selection for two randomized six week studies in patients with major depressive disorder (MDD).</text>
      </sentence>
      <sentence>
        <offset>504</offset>
        <text>Displacement of central [(11)C]GR205171 binding indicated that oral orvepitant doses of 30-60 mg/day provided &gt;99% receptor occupancy for ≥24 h.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(11)c]gr205171</infon>
          <location offset="528" length="15"/>
          <text>[(11)C]GR205171</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orvepitant</infon>
          <location offset="572" length="10"/>
          <text>orvepitant</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>649</offset>
        <text>Studies 733 and 833 randomized patients with MDD and 17-item Hamilton Depression Rating Scale (HAM-D)≥22 to double-blind treatment with orvepitant 30 mg/day, orvepitant 60 mg/day or placebo (1:1:1).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orvepitant</infon>
          <location offset="785" length="10"/>
          <text>orvepitant</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orvepitant</infon>
          <location offset="807" length="10"/>
          <text>orvepitant</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>848</offset>
        <text>Primary outcome measure was change from baseline in 17-item HAM-D total score at Week 6 analyzed using mixed models repeated measures.</text>
      </sentence>
      <sentence>
        <offset>983</offset>
        <text>Study 733 (n=328) demonstrated efficacy on the primary endpoint (estimated drug-placebo differences of 30 mg: -2.41, 95% confidence interval (CI) (-4.50 to -0.31) p=0.0245; 60 mg: -2.86, 95% CI (-4.97 to -0.75) p=0.0082).</text>
      </sentence>
      <sentence>
        <offset>1205</offset>
        <text>Study 833 (n=345) did not show significance (estimated drug-placebo differences of 30 mg: -1.67, 95% CI (-3.73 to 0.39) p=0.1122; 60 mg: -0.76, 95% CI (-2.85 to 1.32) p=0.4713).</text>
      </sentence>
      <sentence>
        <offset>1383</offset>
        <text>The results support the hypothesis that full, long lasting blockade of central NK1 receptors may be an efficacious mechanism for the treatment of MDD.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nk1 receptors</infon>
          <location offset="1462" length="13"/>
          <text>NK1 receptors</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12970106</id>
    <passage>
      <offset>0</offset>
      <text>Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.	1. The pharmaceutical compound, dihydroergotamine (DHE) is dispensed to prevent and reduce the occurrence of migraine attacks. Although still controversial, the prophylactic effect of this drug is believed to be caused through blockade and/or activation of numerous receptors including serotonin (5-HT) receptors of the 5-HT2 subtype. 2. To elucidate if 5-HT2 receptors (5-HT2Rs) may be involved in DHE prophylactic effect, we performed investigations aimed to determine the respective pharmacological profile of DHE and of its major metabolite 8'-hydroxy-DHE (8'-OH-DHE) at the 5-HT2B and 5-HT2CRs by binding, inositol triphosphate (IP3) or cyclic GMP (cGMP) coupling studies in transfected fibroblasts. 3. DHE and 8'-OH-DHE are competitive compounds at 5-HT2B and 5-HT2CRs. 8'-OH-DHE interaction at (5-HT2BRs) was best fitted by a biphasic competition curve and displayed the highest affinity with a Ki of 5 nm. These two compounds acted as agonists for both receptors in respect to cGMP production with pEC50 of 8.32+/-0.09 for 8'-OH-DHE at 5-HT2B and 7.83+/-0.06 at 5-HT2CRs. 4. Knowing that the antimigraine prophylactic effect of DHE is only observed after long-term treatment, we chronically exposed the recombinant cells to DHE and 8'-OH-DHE. The number of 5-HT2BR-binding sites was always more affected than 5-HT2CRs. At 5-HT2BRs, 8'-OH-DHE was more effective than DHE, with an uncoupling that persisted for more than 40 h for IP3 or cGMP. By contrast, the 5-HT2CR coupling was reversible after either treatment. 5. Chronic exposure to 8'-OH-DHE caused a persistent agonist-mediated desensitisation of 5-HT2B, but not 5-HT2CRs. This may be of relevance to therapeutic actions of the compound.</text>
      <sentence>
        <offset>0</offset>
        <text>Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydroergotamine</infon>
          <location offset="19" length="17"/>
          <text>dihydroergotamine</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2b</infon>
          <location offset="40" length="6"/>
          <text>5-HT2B</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="51" length="6"/>
          <text>5-HT2C</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T26" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T26" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>123</offset>
        <text>1. The pharmaceutical compound, dihydroergotamine (DHE) is dispensed to prevent and reduce the occurrence of migraine attacks.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydroergotamine</infon>
          <location offset="155" length="17"/>
          <text>dihydroergotamine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhe</infon>
          <location offset="174" length="3"/>
          <text>DHE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>250</offset>
        <text>Although still controversial, the prophylactic effect of this drug is believed to be caused through blockade and/or activation of numerous receptors including serotonin (5-HT) receptors of the 5-HT2 subtype.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="409" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="420" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">(5-ht) receptors</infon>
          <location offset="419" length="16"/>
          <text>(5-HT) receptors</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht2</infon>
          <location offset="443" length="5"/>
          <text>5-HT2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>458</offset>
        <text>2. To elucidate if 5-HT2 receptors (5-HT2Rs) may be involved in DHE prophylactic effect, we performed investigations aimed to determine the respective pharmacological profile of DHE and of its major metabolite 8'-hydroxy-DHE (8'-OH-DHE) at the 5-HT2B and 5-HT2CRs by binding, inositol triphosphate (IP3) or cyclic GMP (cGMP) coupling studies in transfected fibroblasts.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhe</infon>
          <location offset="522" length="3"/>
          <text>DHE</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhe</infon>
          <location offset="636" length="3"/>
          <text>DHE</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8'-hydroxy-dhe</infon>
          <location offset="668" length="14"/>
          <text>8'-hydroxy-DHE</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8'-oh-dhe</infon>
          <location offset="684" length="9"/>
          <text>8'-OH-DHE</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">inositol triphosphate</infon>
          <location offset="734" length="21"/>
          <text>inositol triphosphate</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ip3</infon>
          <location offset="757" length="3"/>
          <text>IP3</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclic gmp</infon>
          <location offset="765" length="10"/>
          <text>cyclic GMP</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cgmp</infon>
          <location offset="777" length="4"/>
          <text>cGMP</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht2 receptors</infon>
          <location offset="477" length="15"/>
          <text>5-HT2 receptors</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht2rs</infon>
          <location offset="494" length="7"/>
          <text>5-HT2Rs</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2b</infon>
          <location offset="702" length="6"/>
          <text>5-HT2B</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2crs</infon>
          <location offset="713" length="8"/>
          <text>5-HT2CRs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>828</offset>
        <text>3. DHE and 8'-OH-DHE are competitive compounds at 5-HT2B and 5-HT2CRs.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhe</infon>
          <location offset="831" length="3"/>
          <text>DHE</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8'-oh-dhe</infon>
          <location offset="839" length="9"/>
          <text>8'-OH-DHE</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2b</infon>
          <location offset="878" length="6"/>
          <text>5-HT2B</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2crs</infon>
          <location offset="889" length="8"/>
          <text>5-HT2CRs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>899</offset>
        <text>8'-OH-DHE interaction at (5-HT2BRs) was best fitted by a biphasic competition curve and displayed the highest affinity with a Ki of 5 nm.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8'-oh-dhe</infon>
          <location offset="899" length="9"/>
          <text>8'-OH-DHE</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2brs</infon>
          <location offset="925" length="8"/>
          <text>5-HT2BRs</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T24" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1037</offset>
        <text>These two compounds acted as agonists for both receptors in respect to cGMP production with pEC50 of 8.32+/-0.09 for 8'-OH-DHE at 5-HT2B and 7.83+/-0.06 at 5-HT2CRs.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8'-oh-dhe</infon>
          <location offset="1154" length="9"/>
          <text>8'-OH-DHE</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cgmp</infon>
          <location offset="1108" length="4"/>
          <text>cGMP</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2b</infon>
          <location offset="1167" length="6"/>
          <text>5-HT2B</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2crs</infon>
          <location offset="1193" length="8"/>
          <text>5-HT2CRs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1203</offset>
        <text>4. Knowing that the antimigraine prophylactic effect of DHE is only observed after long-term treatment, we chronically exposed the recombinant cells to DHE and 8'-OH-DHE.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhe</infon>
          <location offset="1259" length="3"/>
          <text>DHE</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhe</infon>
          <location offset="1355" length="3"/>
          <text>DHE</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8'-oh-dhe</infon>
          <location offset="1363" length="9"/>
          <text>8'-OH-DHE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1374</offset>
        <text>The number of 5-HT2BR-binding sites was always more affected than 5-HT2CRs.</text>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2br</infon>
          <location offset="1388" length="7"/>
          <text>5-HT2BR</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2crs</infon>
          <location offset="1440" length="8"/>
          <text>5-HT2CRs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1450</offset>
        <text>At 5-HT2BRs, 8'-OH-DHE was more effective than DHE, with an uncoupling that persisted for more than 40 h for IP3 or cGMP.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8'-oh-dhe</infon>
          <location offset="1463" length="9"/>
          <text>8'-OH-DHE</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhe</infon>
          <location offset="1497" length="3"/>
          <text>DHE</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ip3</infon>
          <location offset="1559" length="3"/>
          <text>IP3</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cgmp</infon>
          <location offset="1566" length="4"/>
          <text>cGMP</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2brs</infon>
          <location offset="1453" length="8"/>
          <text>5-HT2BRs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1572</offset>
        <text>By contrast, the 5-HT2CR coupling was reversible after either treatment.</text>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2cr</infon>
          <location offset="1589" length="7"/>
          <text>5-HT2CR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1645</offset>
        <text>5. Chronic exposure to 8'-OH-DHE caused a persistent agonist-mediated desensitisation of 5-HT2B, but not 5-HT2CRs.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8'-oh-dhe</infon>
          <location offset="1668" length="9"/>
          <text>8'-OH-DHE</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2b</infon>
          <location offset="1734" length="6"/>
          <text>5-HT2B</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2crs</infon>
          <location offset="1750" length="8"/>
          <text>5-HT2CRs</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1760</offset>
        <text>This may be of relevance to therapeutic actions of the compound.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23131798</id>
    <passage>
      <offset>0</offset>
      <text>Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists.	3D ligand-based virtual screening was employed to identify novel scaffolds for cannabinoid receptor ligand development. A total of 112 compounds with diverse structures were purchased from commercial vendors. 12 CB1 receptor antagonists/inverse agonists and 10 CB2 receptor agonists were identified in vitro. One of the CB2 agonists, N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine (19, -logEC(50)=7.5, E(max)=255%) was selected for further development. As far as we are aware, the compound's 1,3,5-triazine scaffold represents a new core structure for CB2 agonists. A library of fifty-seven 2,4,6-trisubstituted-1,3,5-triazines was created to clarify the structure-activity relationship study of the analogs.</text>
      <sentence>
        <offset>0</offset>
        <text>Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2,4,6-trisubstituted 1,3,5-triazines</infon>
          <location offset="104" length="36"/>
          <text>2,4,6-trisubstituted 1,3,5-triazines</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cb2</infon>
          <location offset="144" length="3"/>
          <text>CB2</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cannabinoid receptor</infon>
          <location offset="19" length="20"/>
          <text>cannabinoid receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>158</offset>
        <text>3D ligand-based virtual screening was employed to identify novel scaffolds for cannabinoid receptor ligand development.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cannabinoid receptor</infon>
          <location offset="237" length="20"/>
          <text>cannabinoid receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>278</offset>
        <text>A total of 112 compounds with diverse structures were purchased from commercial vendors.</text>
      </sentence>
      <sentence>
        <offset>367</offset>
        <text>12 CB1 receptor antagonists/inverse agonists and 10 CB2 receptor agonists were identified in vitro.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cb1</infon>
          <location offset="370" length="3"/>
          <text>CB1</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cb2</infon>
          <location offset="419" length="3"/>
          <text>CB2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>467</offset>
        <text>One of the CB2 agonists, N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine (19, -logEC(50)=7.5, E(max)=255%) was selected for further development.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine</infon>
          <location offset="492" length="71"/>
          <text>N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cb2</infon>
          <location offset="478" length="3"/>
          <text>CB2</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>636</offset>
        <text>As far as we are aware, the compound's 1,3,5-triazine scaffold represents a new core structure for CB2 agonists.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1,3,5-triazine</infon>
          <location offset="675" length="14"/>
          <text>1,3,5-triazine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cb2</infon>
          <location offset="735" length="3"/>
          <text>CB2</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>749</offset>
        <text>A library of fifty-seven 2,4,6-trisubstituted-1,3,5-triazines was created to clarify the structure-activity relationship study of the analogs.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2,4,6-trisubstituted-1,3,5-triazines</infon>
          <location offset="774" length="36"/>
          <text>2,4,6-trisubstituted-1,3,5-triazines</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23486447</id>
    <passage>
      <offset>0</offset>
      <text>Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants.	Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.</text>
      <sentence>
        <offset>0</offset>
        <text>Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="66" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2c19</infon>
          <location offset="77" length="7"/>
          <text>CYP2C19</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>136</offset>
        <text>Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="252" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="153" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2c19</infon>
          <location offset="164" length="7"/>
          <text>CYP2C19</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>305</offset>
        <text>Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amitriptyline</infon>
          <location offset="305" length="13"/>
          <text>Amitriptyline</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clomipramine</infon>
          <location offset="320" length="12"/>
          <text>clomipramine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxepin</infon>
          <location offset="334" length="7"/>
          <text>doxepin</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imipramine</infon>
          <location offset="343" length="10"/>
          <text>imipramine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trimipramine</infon>
          <location offset="359" length="12"/>
          <text>trimipramine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2c19</infon>
          <location offset="392" length="7"/>
          <text>CYP2C19</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>441</offset>
        <text>These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">desipramine</infon>
          <location offset="487" length="11"/>
          <text>desipramine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nortriptyline</infon>
          <location offset="503" length="13"/>
          <text>nortriptyline</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="543" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>578</offset>
        <text>Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="630" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2c19</infon>
          <location offset="641" length="7"/>
          <text>CYP2C19</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23585555</id>
    <passage>
      <offset>0</offset>
      <text>Relationship between serum thyrotropin levels and intrarenal hemodynamic parameters in euthyroid subjects.	OBJECTIVE: Low thyroid function may be associated with a reduced glomerular filtration rate (GFR) calculated on the basis of creatinine metabolism. Thyroid hormone directly affects serum creatinine in muscle and low thyroid function might exert a similar direct effect in the kidney. The goal of the study was to evaluate this possibility by assessment of the inulin-based GFR and to examine the mechanism underlying the reduction of GFR. PATIENTS AND METHODS: Renal and glomerular hemodynamics were assessed by simultaneous measurements of plasma clearance of para-aminohippurate (CPAH) and inulin (Cin) in 26 patients with serum creatinine &lt;1.00 mg/dl and without thyroid disease. All subjects were normotensive with or without antihypertensive treatment and were kept in a sodium-replete state. Renal and glomerular hemodynamics were calculated using Gomez`s formulae. RESULTS: Serum thyroid stimulating hormone (TSH), including within the normal range (0.69-4.30 μIU/ml), was positively correlated with vascular resistance at the afferent arteriole (Ra) (r = 0.609, p = 0.0010), but not at the efferent arteriole (Re). Serum TSH was significantly and negatively correlated with renal plasma flow (RPF), renal blood flow (RBF), and glomerular filtration rate (GFR) (r = -0.456, p = 0.0192; r = -0.438, p = 0.0252; r = -0.505, p = 0.0086, respectively). In multiple regression analysis, serum TSH was significantly positively associated with Ra after adjustment for age and mean blood pressure. CONCLUSIONS: These findings suggest that low thyroid function, even within the normal range, is associated with reduced RPF, RBF and GFR, which might be caused by a preferential increase of Ra.</text>
      <sentence>
        <offset>0</offset>
        <text>Relationship between serum thyrotropin levels and intrarenal hemodynamic parameters in euthyroid subjects.</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serum thyrotropin</infon>
          <location offset="21" length="17"/>
          <text>serum thyrotropin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>107</offset>
        <text>OBJECTIVE: Low thyroid function may be associated with a reduced glomerular filtration rate (GFR) calculated on the basis of creatinine metabolism.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">creatinine</infon>
          <location offset="232" length="10"/>
          <text>creatinine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>255</offset>
        <text>Thyroid hormone directly affects serum creatinine in muscle and low thyroid function might exert a similar direct effect in the kidney.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thyroid hormone</infon>
          <location offset="255" length="15"/>
          <text>Thyroid hormone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">creatinine</infon>
          <location offset="294" length="10"/>
          <text>creatinine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>391</offset>
        <text>The goal of the study was to evaluate this possibility by assessment of the inulin-based GFR and to examine the mechanism underlying the reduction of GFR.</text>
      </sentence>
      <sentence>
        <offset>546</offset>
        <text>PATIENTS AND METHODS: Renal and glomerular hemodynamics were assessed by simultaneous measurements of plasma clearance of para-aminohippurate (CPAH) and inulin (Cin) in 26 patients with serum creatinine &lt;1.00 mg/dl and without thyroid disease.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">para-aminohippurate</infon>
          <location offset="668" length="19"/>
          <text>para-aminohippurate</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">creatinine</infon>
          <location offset="738" length="10"/>
          <text>creatinine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>790</offset>
        <text>All subjects were normotensive with or without antihypertensive treatment and were kept in a sodium-replete state.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="883" length="6"/>
          <text>sodium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>905</offset>
        <text>Renal and glomerular hemodynamics were calculated using Gomez`s formulae.</text>
      </sentence>
      <sentence>
        <offset>979</offset>
        <text>RESULTS: Serum thyroid stimulating hormone (TSH), including within the normal range (0.69-4.30 μIU/ml), was positively correlated with vascular resistance at the afferent arteriole (Ra) (r = 0.609, p = 0.0010), but not at the efferent arteriole (Re).</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serum thyroid stimulating hormone</infon>
          <location offset="988" length="33"/>
          <text>Serum thyroid stimulating hormone</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tsh</infon>
          <location offset="1023" length="3"/>
          <text>TSH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1230</offset>
        <text>Serum TSH was significantly and negatively correlated with renal plasma flow (RPF), renal blood flow (RBF), and glomerular filtration rate (GFR) (r = -0.456, p = 0.0192; r = -0.438, p = 0.0252; r = -0.505, p = 0.0086, respectively).</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serum tsh</infon>
          <location offset="1230" length="9"/>
          <text>Serum TSH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1463</offset>
        <text>In multiple regression analysis, serum TSH was significantly positively associated with Ra after adjustment for age and mean blood pressure.</text>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serum tsh</infon>
          <location offset="1496" length="9"/>
          <text>serum TSH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1604</offset>
        <text>CONCLUSIONS: These findings suggest that low thyroid function, even within the normal range, is associated with reduced RPF, RBF and GFR, which might be caused by a preferential increase of Ra.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23220586</id>
    <passage>
      <offset>0</offset>
      <text>Effect of polyethylene glycol conjugation on the circulatory stability of plasma-derived human butyrylcholinesterase in mice.	Exogenously administered human serum butyrylcholinesterase (Hu BChE) was demonstrated to function as a bioscavenger of highly toxic organophosphorus (OP) compounds in several animal species. Since the enzyme is isolated from human serum, it is currently the most suitable pretreatment for human use. A dose of 200-300mg/70kg human adult is projected to provide protection from 2 X LD50 of soman. Due to the limited supply of Hu BChE, strategies aimed at reducing the dose of enzyme are being explored. In this study, we investigated the effect of modification with polyethylene glycol (PEG) on the in vivo stability of Hu BChE. Mice were given two injections of either Hu BChE or Hu BChE modified with PEG-5K or PEG-20K, six weeks apart. Pharmacokinetic parameters, such as mean residence time (MRT), maximal concentration (Cmax), elimination half-life (T1/2), and area under the plasma concentration time curve extrapolated to infinity (AUC), were determined. For the first injection, values for MRT, T1/2, Cmax, and AUC for PEG-5K-Hu BChE and PEG-20K-Hu BChE were similar to those for Hu BChE. These values for the second injection of Hu BChE as well as PEG-Hu BChEs were lower as compared to those for the first injections, likely due to antibody-mediated clearance.</text>
      <sentence>
        <offset>0</offset>
        <text>Effect of polyethylene glycol conjugation on the circulatory stability of plasma-derived human butyrylcholinesterase in mice.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyethylene glycol</infon>
          <location offset="10" length="19"/>
          <text>polyethylene glycol</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human butyrylcholinesterase</infon>
          <location offset="89" length="27"/>
          <text>human butyrylcholinesterase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>126</offset>
        <text>Exogenously administered human serum butyrylcholinesterase (Hu BChE) was demonstrated to function as a bioscavenger of highly toxic organophosphorus (OP) compounds in several animal species.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">organophosphorus</infon>
          <location offset="258" length="16"/>
          <text>organophosphorus</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human serum butyrylcholinesterase</infon>
          <location offset="151" length="33"/>
          <text>human serum butyrylcholinesterase</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hu bche</infon>
          <location offset="186" length="7"/>
          <text>Hu BChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>317</offset>
        <text>Since the enzyme is isolated from human serum, it is currently the most suitable pretreatment for human use.</text>
      </sentence>
      <sentence>
        <offset>426</offset>
        <text>A dose of 200-300mg/70kg human adult is projected to provide protection from 2 X LD50 of soman.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">soman</infon>
          <location offset="515" length="5"/>
          <text>soman</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>522</offset>
        <text>Due to the limited supply of Hu BChE, strategies aimed at reducing the dose of enzyme are being explored.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hu bche</infon>
          <location offset="551" length="7"/>
          <text>Hu BChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>628</offset>
        <text>In this study, we investigated the effect of modification with polyethylene glycol (PEG) on the in vivo stability of Hu BChE.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyethylene glycol</infon>
          <location offset="691" length="19"/>
          <text>polyethylene glycol</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg</infon>
          <location offset="712" length="3"/>
          <text>PEG</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hu bche</infon>
          <location offset="745" length="7"/>
          <text>Hu BChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>754</offset>
        <text>Mice were given two injections of either Hu BChE or Hu BChE modified with PEG-5K or PEG-20K, six weeks apart.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg</infon>
          <location offset="828" length="3"/>
          <text>PEG</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg</infon>
          <location offset="838" length="3"/>
          <text>PEG</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hu bche</infon>
          <location offset="795" length="7"/>
          <text>Hu BChE</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hu bche</infon>
          <location offset="806" length="7"/>
          <text>Hu BChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>864</offset>
        <text>Pharmacokinetic parameters, such as mean residence time (MRT), maximal concentration (Cmax), elimination half-life (T1/2), and area under the plasma concentration time curve extrapolated to infinity (AUC), were determined.</text>
      </sentence>
      <sentence>
        <offset>1087</offset>
        <text>For the first injection, values for MRT, T1/2, Cmax, and AUC for PEG-5K-Hu BChE and PEG-20K-Hu BChE were similar to those for Hu BChE.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg</infon>
          <location offset="1152" length="3"/>
          <text>PEG</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg</infon>
          <location offset="1171" length="3"/>
          <text>PEG</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hu bche</infon>
          <location offset="1159" length="7"/>
          <text>Hu BChE</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hu bche</infon>
          <location offset="1179" length="7"/>
          <text>Hu BChE</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hu bche</infon>
          <location offset="1213" length="7"/>
          <text>Hu BChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1222</offset>
        <text>These values for the second injection of Hu BChE as well as PEG-Hu BChEs were lower as compared to those for the first injections, likely due to antibody-mediated clearance.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg</infon>
          <location offset="1282" length="3"/>
          <text>PEG</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hu bche</infon>
          <location offset="1263" length="7"/>
          <text>Hu BChE</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hu bches</infon>
          <location offset="1286" length="8"/>
          <text>Hu BChEs</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11103883</id>
    <passage>
      <offset>0</offset>
      <text>In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics.	The effects of serotonin (5-HT) receptor ligands on the MK 212 (6-chloro-2[1-piperazinyl]pyrazine) discriminative stimulus and quipazine-induced head twitches were studied in rats. 5-HT1A (8-OH-DPAT) and preferential 5-HT2A (DOI) receptor agonists did not generalize to the discriminative stimulus. The 5-HT2B/2C-receptor antagonist, SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2 ,3-f]indole), and the 5-HT2A/2C-receptor antagonist, ritanserin, acted as potent antagonists, whereas the 5-HT2A-receptor antagonist, MDL 100.151 ([(+/-)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4- piperidine-methanol), produced minor and inconsistent inhibition. SB 206553 was a weak antagonist against quipazine-induced head twitches, whereas MDL 100.151 and ritanserin were potent antagonists. This suggests that the MK 212 discriminative stimulus is mediated by 5-HT2C receptors, while quipazine-induced head twitches are mediated primarily by 5-HT2A receptors. The effects on quipazine-induced head twitches were comparable to previously published effects on the DOI discriminative stimulus. 5-HT2A- and 5-HT2C-receptor antagonistic potencies of clozapine, olanzapine, risperidone, sertindole and ziprasidone were compared in the same models. Clozapine showed similar potencies in both models, while sertindole, olanzapine and risperidone inhibited quipazine-induced effects more potently than the MK 212 discriminative stimulus. Ziprasidone exerted a minor preference for 5-HT2A- compared to 5-HT2C-receptor-mediated effects. The ratio between in vivo inhibitory potencies at 5-HT2A and 5-HT2C receptors did not correlate with corresponding ratios from in-vitro affinity and ex-vivo occupancy studies in the literature.</text>
      <sentence>
        <offset>0</offset>
        <text>In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics.</text>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2a</infon>
          <location offset="22" length="6"/>
          <text>5-HT2A</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="33" length="6"/>
          <text>5-HT2C</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>89</offset>
        <text>The effects of serotonin (5-HT) receptor ligands on the MK 212 (6-chloro-2[1-piperazinyl]pyrazine) discriminative stimulus and quipazine-induced head twitches were studied in rats.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quipazine</infon>
          <location offset="216" length="9"/>
          <text>quipazine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="104" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="115" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mk 212</infon>
          <location offset="145" length="6"/>
          <text>MK 212</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-chloro-2[1-piperazinyl]pyrazine</infon>
          <location offset="153" length="33"/>
          <text>6-chloro-2[1-piperazinyl]pyrazine</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serotonin (5-ht) receptor</infon>
          <location offset="104" length="25"/>
          <text>serotonin (5-HT) receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>270</offset>
        <text>5-HT1A (8-OH-DPAT) and preferential 5-HT2A (DOI) receptor agonists did not generalize to the discriminative stimulus.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8-oh-dpat</infon>
          <location offset="278" length="9"/>
          <text>8-OH-DPAT</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="270" length="6"/>
          <text>5-HT1A</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2a</infon>
          <location offset="306" length="6"/>
          <text>5-HT2A</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T16" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>388</offset>
        <text>The 5-HT2B/2C-receptor antagonist, SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2 ,3-f]indole), and the 5-HT2A/2C-receptor antagonist, ritanserin, acted as potent antagonists, whereas the 5-HT2A-receptor antagonist, MDL 100.151 ([(+/-)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4- piperidine-methanol), produced minor and inconsistent inhibition.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sb 206553</infon>
          <location offset="423" length="9"/>
          <text>SB 206553</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2 ,3-f]indole</infon>
          <location offset="434" length="71"/>
          <text>5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2 ,3-f]indole</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ritanserin</infon>
          <location offset="547" length="10"/>
          <text>ritanserin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdl 100.151</infon>
          <location offset="628" length="11"/>
          <text>MDL 100.151</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(+/-)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4- piperidine-methanol</infon>
          <location offset="641" length="85"/>
          <text>[(+/-)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4- piperidine-methanol</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht2b/2c-receptor</infon>
          <location offset="392" length="18"/>
          <text>5-HT2B/2C-receptor</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht2a/2c-receptor</infon>
          <location offset="516" length="18"/>
          <text>5-HT2A/2C-receptor</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2a</infon>
          <location offset="600" length="6"/>
          <text>5-HT2A</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T22" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T21" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>773</offset>
        <text>SB 206553 was a weak antagonist against quipazine-induced head twitches, whereas MDL 100.151 and ritanserin were potent antagonists.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sb 206553</infon>
          <location offset="773" length="9"/>
          <text>SB 206553</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quipazine</infon>
          <location offset="813" length="9"/>
          <text>quipazine</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mdl 100.151</infon>
          <location offset="854" length="11"/>
          <text>MDL 100.151</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ritanserin</infon>
          <location offset="870" length="10"/>
          <text>ritanserin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>906</offset>
        <text>This suggests that the MK 212 discriminative stimulus is mediated by 5-HT2C receptors, while quipazine-induced head twitches are mediated primarily by 5-HT2A receptors.</text>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mk 212</infon>
          <location offset="929" length="6"/>
          <text>MK 212</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quipazine</infon>
          <location offset="999" length="9"/>
          <text>quipazine</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="975" length="6"/>
          <text>5-HT2C</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2a</infon>
          <location offset="1057" length="6"/>
          <text>5-HT2A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1075</offset>
        <text>The effects on quipazine-induced head twitches were comparable to previously published effects on the DOI discriminative stimulus.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quipazine</infon>
          <location offset="1090" length="9"/>
          <text>quipazine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1206</offset>
        <text>5-HT2A- and 5-HT2C-receptor antagonistic potencies of clozapine, olanzapine, risperidone, sertindole and ziprasidone were compared in the same models.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="1260" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">olanzapine</infon>
          <location offset="1271" length="10"/>
          <text>olanzapine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="1283" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sertindole</infon>
          <location offset="1296" length="10"/>
          <text>sertindole</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ziprasidone</infon>
          <location offset="1311" length="11"/>
          <text>ziprasidone</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2a</infon>
          <location offset="1206" length="6"/>
          <text>5-HT2A</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="1218" length="6"/>
          <text>5-HT2C</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T6" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T6" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1357</offset>
        <text>Clozapine showed similar potencies in both models, while sertindole, olanzapine and risperidone inhibited quipazine-induced effects more potently than the MK 212 discriminative stimulus.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="1357" length="9"/>
          <text>Clozapine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sertindole</infon>
          <location offset="1414" length="10"/>
          <text>sertindole</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">olanzapine</infon>
          <location offset="1426" length="10"/>
          <text>olanzapine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="1441" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quipazine</infon>
          <location offset="1463" length="9"/>
          <text>quipazine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mk 212</infon>
          <location offset="1512" length="6"/>
          <text>MK 212</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1544</offset>
        <text>Ziprasidone exerted a minor preference for 5-HT2A- compared to 5-HT2C-receptor-mediated effects.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ziprasidone</infon>
          <location offset="1544" length="11"/>
          <text>Ziprasidone</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2a</infon>
          <location offset="1587" length="6"/>
          <text>5-HT2A</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="1607" length="6"/>
          <text>5-HT2C</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T14" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1641</offset>
        <text>The ratio between in vivo inhibitory potencies at 5-HT2A and 5-HT2C receptors did not correlate with corresponding ratios from in-vitro affinity and ex-vivo occupancy studies in the literature.</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2a</infon>
          <location offset="1691" length="6"/>
          <text>5-HT2A</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="1702" length="6"/>
          <text>5-HT2C</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23397359</id>
    <passage>
      <offset>0</offset>
      <text>Temperature Effects of Sputtering of Langmuir-Blodgett Multilayers.	Time-of-flight secondary ion mass spectrometry (TOF-SIMS) and atomic force microscopy (AFM) are employed to characterize a wedge-shaped crater eroded by a 40 keV C(60) (+) cluster ion beam on an organic thin film of 402 nm of barium arachidate (AA) multilayers prepared by the Langmuir-Blodgett (LB) technique. Sample cooling to 90 K was used to help reduce chemical damage, improve depth resolution and maintain constant erosion rate during depth profiling. The film was characterized at 90 K, 135 K, 165 K, 205 K, 265 K and 300 K. It is shown that sample cooling to 205 K or lower helps to inhibit erosion rate decay, whereas at 300 K and 265 K the erosion rate continues to drop after 250 nm of erosion, reaching about half of the initial value after removal of the entire film. Depth profiles are acquired from the SIMS images of the eroded wedge crater. The results suggest that sample cooling only slightly improves the altered layer thickness, but eliminates the decrease in erosion rate observed above 265 K.</text>
      <sentence>
        <offset>0</offset>
        <text>Temperature Effects of Sputtering of Langmuir-Blodgett Multilayers.</text>
      </sentence>
      <sentence>
        <offset>68</offset>
        <text>Time-of-flight secondary ion mass spectrometry (TOF-SIMS) and atomic force microscopy (AFM) are employed to characterize a wedge-shaped crater eroded by a 40 keV C(60) (+) cluster ion beam on an organic thin film of 402 nm of barium arachidate (AA) multilayers prepared by the Langmuir-Blodgett (LB) technique.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c(60) (+)</infon>
          <location offset="230" length="9"/>
          <text>C(60) (+)</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">barium arachidate</infon>
          <location offset="294" length="17"/>
          <text>barium arachidate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>379</offset>
        <text>Sample cooling to 90 K was used to help reduce chemical damage, improve depth resolution and maintain constant erosion rate during depth profiling.</text>
      </sentence>
      <sentence>
        <offset>527</offset>
        <text>The film was characterized at 90 K, 135 K, 165 K, 205 K, 265 K and 300 K.</text>
      </sentence>
      <sentence>
        <offset>601</offset>
        <text>It is shown that sample cooling to 205 K or lower helps to inhibit erosion rate decay, whereas at 300 K and 265 K the erosion rate continues to drop after 250 nm of erosion, reaching about half of the initial value after removal of the entire film.</text>
      </sentence>
      <sentence>
        <offset>850</offset>
        <text>Depth profiles are acquired from the SIMS images of the eroded wedge crater.</text>
      </sentence>
      <sentence>
        <offset>927</offset>
        <text>The results suggest that sample cooling only slightly improves the altered layer thickness, but eliminates the decrease in erosion rate observed above 265 K.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23303191</id>
    <passage>
      <offset>0</offset>
      <text>Hyaluronan synthase 1 (HAS1) requires higher cellular UDP-GlcNAc concentration than HAS2 and HAS3.	Mammals have three homologous genes encoding proteins with hyaluronan synthase activity (Has1-3), all producing an identical polymer from UDP-N-acetylglucosamine and UDP-glucuronic acid. To compare the properties of these isoenzymes, COS-1 cells, with minor endogenous hyaluronan synthesis, were transfected with human Has1-3 isoenzymes. HAS1 was almost unable to secrete hyaluronan or form a hyaluronan coat, in contrast to HAS2 and HAS3. This failure of HAS1 to synthesize hyaluronan was compensated by increasing the cellular content of UDP-N-acetyl glucosamine by ∼10-fold with 1 mm glucosamine in the growth medium. Hyaluronan synthesis driven by HAS2 was less affected by glucosamine addition, and HAS3 was not affected at all. Glucose-free medium, leading to depletion of the UDP-sugars, markedly reduced hyaluronan synthesis by all HAS isoenzymes while raising its concentration from 5 to 25 mm had a moderate stimulatory effect. The results indicate that HAS1 is almost inactive in cells with low UDP-sugar supply, HAS2 activity increases with UDP-sugars, and HAS3 produces hyaluronan at high speed even with minimum substrate content. Transfected Has2 and particularly Has3 consumed enough UDP-sugars to reduce their content in COS-1 cells. Comparison of different human cell types revealed ∼50-fold differences in the content of UDP-N-acetylhexosamines and UDP-glucuronic acid, correlating with the expression level of Has1, suggesting cellular coordination between Has1 expression and the content of UDP-sugars.</text>
      <sentence>
        <offset>0</offset>
        <text>Hyaluronan synthase 1 (HAS1) requires higher cellular UDP-GlcNAc concentration than HAS2 and HAS3.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="54" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glcnac</infon>
          <location offset="58" length="6"/>
          <text>GlcNAc</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hyaluronan synthase 1</infon>
          <location offset="0" length="21"/>
          <text>Hyaluronan synthase 1</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has1</infon>
          <location offset="23" length="4"/>
          <text>HAS1</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has2</infon>
          <location offset="84" length="4"/>
          <text>HAS2</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has3</infon>
          <location offset="93" length="4"/>
          <text>HAS3</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T25" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T24" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T25" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T24" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>99</offset>
        <text>Mammals have three homologous genes encoding proteins with hyaluronan synthase activity (Has1-3), all producing an identical polymer from UDP-N-acetylglucosamine and UDP-glucuronic acid.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="237" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-acetylglucosamine</infon>
          <location offset="241" length="19"/>
          <text>N-acetylglucosamine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="265" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucuronic acid</infon>
          <location offset="269" length="15"/>
          <text>glucuronic acid</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hyaluronan synthase</infon>
          <location offset="158" length="19"/>
          <text>hyaluronan synthase</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">has1-3</infon>
          <location offset="188" length="6"/>
          <text>Has1-3</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T16" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T15" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T16" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T15" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>286</offset>
        <text>To compare the properties of these isoenzymes, COS-1 cells, with minor endogenous hyaluronan synthesis, were transfected with human Has1-3 isoenzymes.</text>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human has1-3</infon>
          <location offset="412" length="12"/>
          <text>human Has1-3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>437</offset>
        <text>HAS1 was almost unable to secrete hyaluronan or form a hyaluronan coat, in contrast to HAS2 and HAS3.</text>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has1</infon>
          <location offset="437" length="4"/>
          <text>HAS1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has2</infon>
          <location offset="524" length="4"/>
          <text>HAS2</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has3</infon>
          <location offset="533" length="4"/>
          <text>HAS3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>539</offset>
        <text>This failure of HAS1 to synthesize hyaluronan was compensated by increasing the cellular content of UDP-N-acetyl glucosamine by ∼10-fold with 1 mm glucosamine in the growth medium.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="639" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-acetyl glucosamine</infon>
          <location offset="643" length="20"/>
          <text>N-acetyl glucosamine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucosamine</infon>
          <location offset="686" length="11"/>
          <text>glucosamine</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has1</infon>
          <location offset="555" length="4"/>
          <text>HAS1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T19" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T17" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T18" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>720</offset>
        <text>Hyaluronan synthesis driven by HAS2 was less affected by glucosamine addition, and HAS3 was not affected at all.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucosamine</infon>
          <location offset="777" length="11"/>
          <text>glucosamine</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has2</infon>
          <location offset="751" length="4"/>
          <text>HAS2</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has3</infon>
          <location offset="803" length="4"/>
          <text>HAS3</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T20" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>833</offset>
        <text>Glucose-free medium, leading to depletion of the UDP-sugars, markedly reduced hyaluronan synthesis by all HAS isoenzymes while raising its concentration from 5 to 25 mm had a moderate stimulatory effect.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="833" length="7"/>
          <text>Glucose</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="882" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sugars</infon>
          <location offset="886" length="6"/>
          <text>sugars</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">has</infon>
          <location offset="939" length="3"/>
          <text>HAS</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T23" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T22" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1037</offset>
        <text>The results indicate that HAS1 is almost inactive in cells with low UDP-sugar supply, HAS2 activity increases with UDP-sugars, and HAS3 produces hyaluronan at high speed even with minimum substrate content.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="1105" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sugar</infon>
          <location offset="1109" length="5"/>
          <text>sugar</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="1152" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sugars</infon>
          <location offset="1156" length="6"/>
          <text>sugars</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has2</infon>
          <location offset="1123" length="4"/>
          <text>HAS2</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has3</infon>
          <location offset="1168" length="4"/>
          <text>HAS3</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has1</infon>
          <location offset="1063" length="4"/>
          <text>HAS1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1244</offset>
        <text>Transfected Has2 and particularly Has3 consumed enough UDP-sugars to reduce their content in COS-1 cells.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="1299" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sugars</infon>
          <location offset="1303" length="6"/>
          <text>sugars</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has2</infon>
          <location offset="1256" length="4"/>
          <text>Has2</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has3</infon>
          <location offset="1278" length="4"/>
          <text>Has3</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1350</offset>
        <text>Comparison of different human cell types revealed ∼50-fold differences in the content of UDP-N-acetylhexosamines and UDP-glucuronic acid, correlating with the expression level of Has1, suggesting cellular coordination between Has1 expression and the content of UDP-sugars.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="1439" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-acetylhexosamines</infon>
          <location offset="1443" length="19"/>
          <text>N-acetylhexosamines</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="1467" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucuronic acid</infon>
          <location offset="1471" length="15"/>
          <text>glucuronic acid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="1611" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sugars</infon>
          <location offset="1615" length="6"/>
          <text>sugars</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has1</infon>
          <location offset="1529" length="4"/>
          <text>Has1</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">has1</infon>
          <location offset="1576" length="4"/>
          <text>Has1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T9" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T8" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T14" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23411185</id>
    <passage>
      <offset>0</offset>
      <text>Comparative analysis of nutritional compositions of transgenic high iron rice with its non-transgenic counterpart.	Iron is an essential micronutrient for human nutrition and polished rice contains very low amount of iron. Rice with high iron content in seed endosperm has been developed by insertion of soybean ferritin gene under the control of the endosperm specific glutelin promoter into the genome of indica rice line IR68144. The nutritional composition of the brown and milled rice grain has been compared with that of the non-transgenic rice of the same variety. In this study, the nutritional components, as well as the anti-nutrient levels, were measured. Our studies established that apart from the increased level of iron and zinc in transgenic seeds, the nutritional quality of both the brown and milled rice grains from the transgenic line was substantially equivalent to that of the non-transgenic rice plants. The result clearly shows that the measured amounts of the nutritional components are well within the range of values reported for other commercial lines.</text>
      <sentence>
        <offset>0</offset>
        <text>Comparative analysis of nutritional compositions of transgenic high iron rice with its non-transgenic counterpart.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="68" length="4"/>
          <text>iron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>115</offset>
        <text>Iron is an essential micronutrient for human nutrition and polished rice contains very low amount of iron.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="115" length="4"/>
          <text>Iron</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="216" length="4"/>
          <text>iron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>222</offset>
        <text>Rice with high iron content in seed endosperm has been developed by insertion of soybean ferritin gene under the control of the endosperm specific glutelin promoter into the genome of indica rice line IR68144.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="237" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">soybean ferritin</infon>
          <location offset="303" length="16"/>
          <text>soybean ferritin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutelin promoter</infon>
          <location offset="369" length="17"/>
          <text>glutelin promoter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>432</offset>
        <text>The nutritional composition of the brown and milled rice grain has been compared with that of the non-transgenic rice of the same variety.</text>
      </sentence>
      <sentence>
        <offset>571</offset>
        <text>In this study, the nutritional components, as well as the anti-nutrient levels, were measured.</text>
      </sentence>
      <sentence>
        <offset>666</offset>
        <text>Our studies established that apart from the increased level of iron and zinc in transgenic seeds, the nutritional quality of both the brown and milled rice grains from the transgenic line was substantially equivalent to that of the non-transgenic rice plants.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="729" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc</infon>
          <location offset="738" length="4"/>
          <text>zinc</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>926</offset>
        <text>The result clearly shows that the measured amounts of the nutritional components are well within the range of values reported for other commercial lines.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11383749</id>
    <passage>
      <offset>0</offset>
      <text>Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction.	OBJECTIVE: Caspase-1 plays an important functional role mediating neuronal cell death and dysfunction after experimental traumatic brain injury (TBI) in mice. Minocycline, a derivative of the antibiotic tetracycline, inhibits caspase-1 expression. This study investigates whether minocycline can ameliorate TBI-mediated injury in mice. METHODS: Brains from mice subjected to traumatic brain injury underwent immunohistochemical analyses for caspase-1, caspase-3, and a neuronal specific marker (NeuN). Minocycline- and saline-treated mice subjected to traumatic brain injury were compared with respect to neurological function, lesion volume, and interleukin-1beta production. RESULTS: Immunohistochemical analysis revealed that activated caspase-1 and caspase-3 are present in neurons 24 hours after TBI. Intraperitoneal administration of minocycline 12 hours before or 30 minutes after TBI in mice resulted in improved neurological function when compared with mice given saline control, as assessed by Rotarod performance 1 to 4 days after TBI. The lesion volume, assessed 4 days after trauma, was significantly decreased in mice treated with minocycline before or after trauma when compared with saline-treated mice. Caspase-1 activity, quantified by measuring mature interleukin-1beta production by enzyme-linked immunosorbent assay, was considerably increased in mice that underwent TBI, and this increase was significantly diminished in minocycline-treated mice. CONCLUSION: We show for the first time that caspase-1 and caspase-3 activities localize specifically within neurons after experimental brain trauma. Further, these results indicate that minocycline is an effective pharmacological agent for reducing tissue injury and neurological deficits that result from experimental TBI, likely through a caspase-1-dependent mechanism. These results provide an experimental rationale for the evaluation of minocycline in human trauma patients.</text>
      <sentence>
        <offset>0</offset>
        <text>Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">minocycline</infon>
          <location offset="0" length="11"/>
          <text>Minocycline</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-1</infon>
          <location offset="52" length="9"/>
          <text>caspase-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>119</offset>
        <text>OBJECTIVE: Caspase-1 plays an important functional role mediating neuronal cell death and dysfunction after experimental traumatic brain injury (TBI) in mice.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-1</infon>
          <location offset="130" length="9"/>
          <text>Caspase-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>278</offset>
        <text>Minocycline, a derivative of the antibiotic tetracycline, inhibits caspase-1 expression.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">minocycline</infon>
          <location offset="278" length="11"/>
          <text>Minocycline</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetracycline</infon>
          <location offset="322" length="12"/>
          <text>tetracycline</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-1</infon>
          <location offset="345" length="9"/>
          <text>caspase-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>367</offset>
        <text>This study investigates whether minocycline can ameliorate TBI-mediated injury in mice.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">minocycline</infon>
          <location offset="399" length="11"/>
          <text>minocycline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>455</offset>
        <text>METHODS: Brains from mice subjected to traumatic brain injury underwent immunohistochemical analyses for caspase-1, caspase-3, and a neuronal specific marker (NeuN).</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-1</infon>
          <location offset="560" length="9"/>
          <text>caspase-1</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="571" length="9"/>
          <text>caspase-3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>621</offset>
        <text>Minocycline- and saline-treated mice subjected to traumatic brain injury were compared with respect to neurological function, lesion volume, and interleukin-1beta production.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">minocycline</infon>
          <location offset="621" length="11"/>
          <text>Minocycline</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin-1beta</infon>
          <location offset="766" length="17"/>
          <text>interleukin-1beta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>796</offset>
        <text>RESULTS: Immunohistochemical analysis revealed that activated caspase-1 and caspase-3 are present in neurons 24 hours after TBI.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-1</infon>
          <location offset="858" length="9"/>
          <text>caspase-1</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="872" length="9"/>
          <text>caspase-3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>925</offset>
        <text>Intraperitoneal administration of minocycline 12 hours before or 30 minutes after TBI in mice resulted in improved neurological function when compared with mice given saline control, as assessed by Rotarod performance 1 to 4 days after TBI.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">minocycline</infon>
          <location offset="959" length="11"/>
          <text>minocycline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1166</offset>
        <text>The lesion volume, assessed 4 days after trauma, was significantly decreased in mice treated with minocycline before or after trauma when compared with saline-treated mice.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">minocycline</infon>
          <location offset="1264" length="11"/>
          <text>minocycline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1339</offset>
        <text>Caspase-1 activity, quantified by measuring mature interleukin-1beta production by enzyme-linked immunosorbent assay, was considerably increased in mice that underwent TBI, and this increase was significantly diminished in minocycline-treated mice.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">minocycline</infon>
          <location offset="1562" length="11"/>
          <text>minocycline</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-1</infon>
          <location offset="1339" length="9"/>
          <text>Caspase-1</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin-1beta</infon>
          <location offset="1390" length="17"/>
          <text>interleukin-1beta</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1588</offset>
        <text>CONCLUSION: We show for the first time that caspase-1 and caspase-3 activities localize specifically within neurons after experimental brain trauma.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-1</infon>
          <location offset="1632" length="9"/>
          <text>caspase-1</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="1646" length="9"/>
          <text>caspase-3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1737</offset>
        <text>Further, these results indicate that minocycline is an effective pharmacological agent for reducing tissue injury and neurological deficits that result from experimental TBI, likely through a caspase-1-dependent mechanism.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">minocycline</infon>
          <location offset="1774" length="11"/>
          <text>minocycline</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-1</infon>
          <location offset="1929" length="9"/>
          <text>caspase-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1960</offset>
        <text>These results provide an experimental rationale for the evaluation of minocycline in human trauma patients.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">minocycline</infon>
          <location offset="2030" length="11"/>
          <text>minocycline</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23339682</id>
    <passage>
      <offset>0</offset>
      <text>Assessment of effects of IR and IPC on activities of cytochrome P450 isozymes in rats by a five-drug cocktail approach.	Abstract Background and objective: To evaluate the effects of ischemia and reperfusion (IR) and ischemic preconditioning (IPC) on the metabolic activities of cytochrome P450 (CYP) isozymes in rats by a five-drug cocktail approach. Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively. Rats were randomly divided into IR, IPC and sham groups, and then injected the mixture of five probe drugs. Blood samples were collected at a series of time-points and the concentrations of probe drugs in plasma were determined by a HPLC method with UV detection. The pharmacokinetic parameters were calculated by the software of DAS 2.0. Results: The parameters including t(1/2β), CLs, AUC, MRT and K(10) exhibited a similar tendency for both IR and IPC groups. Compared with sham group, CLs and K(10) of five probe drugs were significantly lower (p &lt; 0.05), AUC and t(1/2β) of five or some probe drugs were significantly increased in IR and IPC groups (p &lt; 0.05). Compared with IPC group, CLs of five probe drugs were decreased and AUC were significantly increased in the IR group (p &lt; 0.05). Conclusion: IR can variably decrease the activities of CYP isozymes in rats and this decrease can be attenuated by IPC.</text>
      <sentence>
        <offset>0</offset>
        <text>Assessment of effects of IR and IPC on activities of cytochrome P450 isozymes in rats by a five-drug cocktail approach.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450</infon>
          <location offset="53" length="15"/>
          <text>cytochrome P450</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>120</offset>
        <text>Abstract Background and objective: To evaluate the effects of ischemia and reperfusion (IR) and ischemic preconditioning (IPC) on the metabolic activities of cytochrome P450 (CYP) isozymes in rats by a five-drug cocktail approach.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450</infon>
          <location offset="278" length="15"/>
          <text>cytochrome P450</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp</infon>
          <location offset="295" length="3"/>
          <text>CYP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>351</offset>
        <text>Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="587" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorzoxazone</infon>
          <location offset="597" length="13"/>
          <text>chlorzoxazone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolbutamide</infon>
          <location offset="612" length="11"/>
          <text>tolbutamide</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metoprolol</infon>
          <location offset="625" length="10"/>
          <text>metoprolol</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="640" length="9"/>
          <text>midazolam</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp1a2</infon>
          <location offset="448" length="6"/>
          <text>CYP1A2</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2c9</infon>
          <location offset="456" length="6"/>
          <text>CYP2C9</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="464" length="6"/>
          <text>CYP2E1</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="472" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="483" length="6"/>
          <text>CYP3A4</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>665</offset>
        <text>Rats were randomly divided into IR, IPC and sham groups, and then injected the mixture of five probe drugs.</text>
      </sentence>
      <sentence>
        <offset>773</offset>
        <text>Blood samples were collected at a series of time-points and the concentrations of probe drugs in plasma were determined by a HPLC method with UV detection.</text>
      </sentence>
      <sentence>
        <offset>929</offset>
        <text>The pharmacokinetic parameters were calculated by the software of DAS 2.0.</text>
      </sentence>
      <sentence>
        <offset>1004</offset>
        <text>Results: The parameters including t(1/2β), CLs, AUC, MRT and K(10) exhibited a similar tendency for both IR and IPC groups.</text>
      </sentence>
      <sentence>
        <offset>1128</offset>
        <text>Compared with sham group, CLs and K(10) of five probe drugs were significantly lower (p &lt; 0.05), AUC and t(1/2β) of five or some probe drugs were significantly increased in IR and IPC groups (p &lt; 0.05).</text>
      </sentence>
      <sentence>
        <offset>1331</offset>
        <text>Compared with IPC group, CLs of five probe drugs were decreased and AUC were significantly increased in the IR group (p &lt; 0.05).</text>
      </sentence>
      <sentence>
        <offset>1460</offset>
        <text>Conclusion: IR can variably decrease the activities of CYP isozymes in rats and this decrease can be attenuated by IPC.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp isozymes</infon>
          <location offset="1515" length="12"/>
          <text>CYP isozymes</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23493372</id>
    <passage>
      <offset>0</offset>
      <text>Dexamethasone-mediated changes in adipose triacylglycerol metabolism are exaggerated, not diminished, in the absence of a functional GR dimerization domain.	The glucocorticoid (GC) receptor (GR) has multiple effector mechanisms, including dimerization-mediated transactivation of target genes via DNA binding and transcriptional repression mediated by protein-protein interactions. Much attention has been focused on developing selective GR modulators that would dissociate adverse effects from therapeutic anti-inflammatory effects. The GR(dim/dim) mouse has a mutation in the dimerization domain of GR and has been shown to have attenuated transactivation with intact repression. To understand the role of GR dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and GR(dim/dim) mice administered the potent GC dexamethasone (DEX). Absolute triglyceride synthesis was increased in both wild-type and GR(dim/dim) mice by DEX in the inguinal and epididymal fat depots. GR(dim/dim) mice showed an exaggerated response to DEX in both depots. De novo lipogenesis was also greatly increased in both depots in response to DEX in GR(dim/dim), but not wild-type mice. In contrast, the inhibitory effect of DEX on bone and skin collagen synthesis rates was greater in wild-type compared with GR(dim/dim) mice. Wild-type mice were more sensitive to DEX-dependent decreases in insulin sensitivity than GR(dim/dim) mice. Wild-type and GR(dim/dim) mice were equally sensitive to DEX-dependent decreases in muscle protein synthesis. Chronic elevation of GCs in GR(dim/dim) mice results in severe runting and lethality. In conclusion, some metabolic effects of GC treatment are exaggerated in adipose tissue of GR(dim/dim) mice, suggesting that selective GR modulators based on dissociating GR transactivation from repression should be evaluated carefully.</text>
      <sentence>
        <offset>0</offset>
        <text>Dexamethasone-mediated changes in adipose triacylglycerol metabolism are exaggerated, not diminished, in the absence of a functional GR dimerization domain.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexamethasone</infon>
          <location offset="0" length="13"/>
          <text>Dexamethasone</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triacylglycerol</infon>
          <location offset="42" length="15"/>
          <text>triacylglycerol</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gr dimerization domain</infon>
          <location offset="133" length="22"/>
          <text>GR dimerization domain</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>157</offset>
        <text>The glucocorticoid (GC) receptor (GR) has multiple effector mechanisms, including dimerization-mediated transactivation of target genes via DNA binding and transcriptional repression mediated by protein-protein interactions.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="191" length="2"/>
          <text>GR</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid (gc) receptor</infon>
          <location offset="161" length="28"/>
          <text>glucocorticoid (GC) receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>382</offset>
        <text>Much attention has been focused on developing selective GR modulators that would dissociate adverse effects from therapeutic anti-inflammatory effects.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="438" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>534</offset>
        <text>The GR(dim/dim) mouse has a mutation in the dimerization domain of GR and has been shown to have attenuated transactivation with intact repression.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="538" length="2"/>
          <text>GR</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="601" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>682</offset>
        <text>To understand the role of GR dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and GR(dim/dim) mice administered the potent GC dexamethasone (DEX).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexamethasone</infon>
          <location offset="954" length="13"/>
          <text>dexamethasone</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="969" length="3"/>
          <text>DEX</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="708" length="2"/>
          <text>GR</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="910" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>975</offset>
        <text>Absolute triglyceride synthesis was increased in both wild-type and GR(dim/dim) mice by DEX in the inguinal and epididymal fat depots.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triglyceride</infon>
          <location offset="984" length="12"/>
          <text>triglyceride</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="1063" length="3"/>
          <text>DEX</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="1043" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1110</offset>
        <text>GR(dim/dim) mice showed an exaggerated response to DEX in both depots.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="1161" length="3"/>
          <text>DEX</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="1110" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1181</offset>
        <text>De novo lipogenesis was also greatly increased in both depots in response to DEX in GR(dim/dim), but not wild-type mice.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="1258" length="3"/>
          <text>DEX</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="1265" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1302</offset>
        <text>In contrast, the inhibitory effect of DEX on bone and skin collagen synthesis rates was greater in wild-type compared with GR(dim/dim) mice.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="1340" length="3"/>
          <text>DEX</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="1425" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1443</offset>
        <text>Wild-type mice were more sensitive to DEX-dependent decreases in insulin sensitivity than GR(dim/dim) mice.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="1481" length="3"/>
          <text>DEX</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1508" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="1533" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1551</offset>
        <text>Wild-type and GR(dim/dim) mice were equally sensitive to DEX-dependent decreases in muscle protein synthesis.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="1608" length="3"/>
          <text>DEX</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="1565" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1661</offset>
        <text>Chronic elevation of GCs in GR(dim/dim) mice results in severe runting and lethality.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="1689" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1747</offset>
        <text>In conclusion, some metabolic effects of GC treatment are exaggerated in adipose tissue of GR(dim/dim) mice, suggesting that selective GR modulators based on dissociating GR transactivation from repression should be evaluated carefully.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="1838" length="2"/>
          <text>GR</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="1882" length="2"/>
          <text>GR</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="1918" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23219525</id>
    <passage>
      <offset>0</offset>
      <text>Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.	The combinations of the endothelin-1 receptor antagonists bosentan or ambrisentan with the phosphodiesterase 5 inhibitors sildenafil or tadalafil are current standard therapies of advanced pulmonary arterial hypertension. However, these drugs have a number of drug interactions. Changes of bosentan pharmacokinetics by sildenafil are attributed to reduced hepatic uptake as a consequence of inhibition of organic anion transporting polypeptides. We therefore tested in vitro the hypothesis that sildenafil and tadalafil reduce the enzyme- and transporter-inducing effects of bosentan or ambrisentan by preventing cellular access. Although intracellular concentrations of bosentan and ambrisentan (measured by high pressure liquid chromatography coupled with tandem mass-spectrometry) after four days of incubation of LS180 cells were lower when sildenafil or tadalafil were present, quantification of mRNA expression in these cells by real-time reverse transcription polymerase chain reaction revealed that bosentan and ambrisentan-mediated induction was stable or even increased in combination with sildenafil or tadalafil. For the drug transporter P-glycoprotein this was confirmed at the protein and functional level with highly significant correlations between P-gp mRNA, protein, and function. Moreover, using a reporter gene assay in LS180 cells, our study demonstrates for the first time that tadalafil is a potent, ambrisentan a weak, and sildenafil no activator of pregnane X receptor. In conclusion, our study demonstrates that although sildenafil and tadalafil indeed reduce intracellular concentrations of bosentan and ambrisentan in LS180 cells, they do not mitigate the inducing effects of these endothelin-1 receptor antagonists.</text>
      <sentence>
        <offset>0</offset>
        <text>Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ambrisentan</infon>
          <location offset="102" length="11"/>
          <text>ambrisentan</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sildenafil</infon>
          <location offset="13" length="10"/>
          <text>sildenafil</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="89" length="8"/>
          <text>bosentan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>130</offset>
        <text>The combinations of the endothelin-1 receptor antagonists bosentan or ambrisentan with the phosphodiesterase 5 inhibitors sildenafil or tadalafil are current standard therapies of advanced pulmonary arterial hypertension.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sildenafil</infon>
          <location offset="252" length="10"/>
          <text>sildenafil</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tadalafil</infon>
          <location offset="266" length="9"/>
          <text>tadalafil</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="188" length="8"/>
          <text>bosentan</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ambrisentan</infon>
          <location offset="200" length="11"/>
          <text>ambrisentan</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">endothelin-1 receptor</infon>
          <location offset="154" length="21"/>
          <text>endothelin-1 receptor</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phosphodiesterase 5</infon>
          <location offset="221" length="19"/>
          <text>phosphodiesterase 5</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T24" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T20" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>352</offset>
        <text>However, these drugs have a number of drug interactions.</text>
      </sentence>
      <sentence>
        <offset>409</offset>
        <text>Changes of bosentan pharmacokinetics by sildenafil are attributed to reduced hepatic uptake as a consequence of inhibition of organic anion transporting polypeptides.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="420" length="8"/>
          <text>bosentan</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sildenafil</infon>
          <location offset="449" length="10"/>
          <text>sildenafil</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">organic anion transporting polypeptides</infon>
          <location offset="535" length="39"/>
          <text>organic anion transporting polypeptides</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>576</offset>
        <text>We therefore tested in vitro the hypothesis that sildenafil and tadalafil reduce the enzyme- and transporter-inducing effects of bosentan or ambrisentan by preventing cellular access.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sildenafil</infon>
          <location offset="625" length="10"/>
          <text>sildenafil</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tadalafil</infon>
          <location offset="640" length="9"/>
          <text>tadalafil</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="705" length="8"/>
          <text>bosentan</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ambrisentan</infon>
          <location offset="717" length="11"/>
          <text>ambrisentan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>760</offset>
        <text>Although intracellular concentrations of bosentan and ambrisentan (measured by high pressure liquid chromatography coupled with tandem mass-spectrometry) after four days of incubation of LS180 cells were lower when sildenafil or tadalafil were present, quantification of mRNA expression in these cells by real-time reverse transcription polymerase chain reaction revealed that bosentan and ambrisentan-mediated induction was stable or even increased in combination with sildenafil or tadalafil.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="1137" length="8"/>
          <text>bosentan</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ambrisentan</infon>
          <location offset="1150" length="11"/>
          <text>ambrisentan</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sildenafil</infon>
          <location offset="1230" length="10"/>
          <text>sildenafil</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tadalafil</infon>
          <location offset="1244" length="9"/>
          <text>tadalafil</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="801" length="8"/>
          <text>bosentan</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ambrisentan</infon>
          <location offset="814" length="11"/>
          <text>ambrisentan</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sildenafil</infon>
          <location offset="975" length="10"/>
          <text>sildenafil</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tadalafil</infon>
          <location offset="989" length="9"/>
          <text>tadalafil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1255</offset>
        <text>For the drug transporter P-glycoprotein this was confirmed at the protein and functional level with highly significant correlations between P-gp mRNA, protein, and function.</text>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="1280" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="1395" length="4"/>
          <text>P-gp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1429</offset>
        <text>Moreover, using a reporter gene assay in LS180 cells, our study demonstrates for the first time that tadalafil is a potent, ambrisentan a weak, and sildenafil no activator of pregnane X receptor.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tadalafil</infon>
          <location offset="1530" length="9"/>
          <text>tadalafil</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ambrisentan</infon>
          <location offset="1553" length="11"/>
          <text>ambrisentan</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sildenafil</infon>
          <location offset="1577" length="10"/>
          <text>sildenafil</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pregnane</infon>
          <location offset="1604" length="8"/>
          <text>pregnane</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pregnane x receptor</infon>
          <location offset="1604" length="19"/>
          <text>pregnane X receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1625</offset>
        <text>In conclusion, our study demonstrates that although sildenafil and tadalafil indeed reduce intracellular concentrations of bosentan and ambrisentan in LS180 cells, they do not mitigate the inducing effects of these endothelin-1 receptor antagonists.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sildenafil</infon>
          <location offset="1677" length="10"/>
          <text>sildenafil</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tadalafil</infon>
          <location offset="1692" length="9"/>
          <text>tadalafil</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="1748" length="8"/>
          <text>bosentan</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ambrisentan</infon>
          <location offset="1761" length="11"/>
          <text>ambrisentan</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">endothelin-1 receptor</infon>
          <location offset="1840" length="21"/>
          <text>endothelin-1 receptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15133083</id>
    <passage>
      <offset>0</offset>
      <text>Polyamine metabolism in a member of the phylum Microspora (Encephalitozoon cuniculi): effects of polyamine analogues.	The uptake, biosynthesis and catabolism of polyamines in the microsporidian parasite Encephalitozoon cuniculi are detailed with reference to the effects of oligoamine and arylamine analogues of polyamines. Enc. cuniculi, an intracellular parasite of mammalian cells, has both biosynthetic and catabolic enzymes of polyamine metabolism, as demonstrated in cell-free extracts of mature spores. The uptake of polyamines was measured in immature, pre-emergent spores isolated from host cells by Percoll gradient. Spermine was rapidly taken up and metabolized to spermidine and an unknown, possibly acetamidopropanal, by spermidine/spermine N(1)-acetyltransferase (SSAT) and polyamine oxidase (PAO). Most of the spermidine and the unknown product were found in the cell incubation medium, indicating they were released from the cell. bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for PAO. The Enc. cuniculi PAO activity differed from that found in mammalian cells with respect to pH optimum, substrate specificity and sensitivity to known PAO inhibitors. SL-11158 inhibited SSAT activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine. The interest in Enc. cuniculi polyamine metabolism and the biochemical effects of these polyamine analogues is warranted since they cure model infections of Enc. cuniculi in mice and are potential candidates for human clinical trials.</text>
      <sentence>
        <offset>0</offset>
        <text>Polyamine metabolism in a member of the phylum Microspora (Encephalitozoon cuniculi): effects of polyamine analogues.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyamine</infon>
          <location offset="0" length="9"/>
          <text>Polyamine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyamine</infon>
          <location offset="97" length="9"/>
          <text>polyamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>118</offset>
        <text>The uptake, biosynthesis and catabolism of polyamines in the microsporidian parasite Encephalitozoon cuniculi are detailed with reference to the effects of oligoamine and arylamine analogues of polyamines.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oligoamine</infon>
          <location offset="274" length="10"/>
          <text>oligoamine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arylamine</infon>
          <location offset="289" length="9"/>
          <text>arylamine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyamines</infon>
          <location offset="312" length="10"/>
          <text>polyamines</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyamines</infon>
          <location offset="161" length="10"/>
          <text>polyamines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>324</offset>
        <text>Enc.</text>
      </sentence>
      <sentence>
        <offset>329</offset>
        <text>cuniculi, an intracellular parasite of mammalian cells, has both biosynthetic and catabolic enzymes of polyamine metabolism, as demonstrated in cell-free extracts of mature spores.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyamine</infon>
          <location offset="432" length="9"/>
          <text>polyamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>510</offset>
        <text>The uptake of polyamines was measured in immature, pre-emergent spores isolated from host cells by Percoll gradient.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyamines</infon>
          <location offset="524" length="10"/>
          <text>polyamines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>627</offset>
        <text>Spermine was rapidly taken up and metabolized to spermidine and an unknown, possibly acetamidopropanal, by spermidine/spermine N(1)-acetyltransferase (SSAT) and polyamine oxidase (PAO).</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n(1)</infon>
          <location offset="754" length="4"/>
          <text>N(1)</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyamine</infon>
          <location offset="788" length="9"/>
          <text>polyamine</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">spermidine/spermine n(1)-acetyltransferase</infon>
          <location offset="734" length="42"/>
          <text>spermidine/spermine N(1)-acetyltransferase</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ssat</infon>
          <location offset="778" length="4"/>
          <text>SSAT</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">polyamine oxidase</infon>
          <location offset="788" length="17"/>
          <text>polyamine oxidase</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pao</infon>
          <location offset="807" length="3"/>
          <text>PAO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>813</offset>
        <text>Most of the spermidine and the unknown product were found in the cell incubation medium, indicating they were released from the cell.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spermidine</infon>
          <location offset="825" length="10"/>
          <text>spermidine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>947</offset>
        <text>bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for PAO.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spermine</infon>
          <location offset="1137" length="8"/>
          <text>spermine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bw-1</infon>
          <location offset="1187" length="4"/>
          <text>BW-1</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bis(ethyl) oligoamine</infon>
          <location offset="947" length="21"/>
          <text>bis(Ethyl) oligoamine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyamines</infon>
          <location offset="982" length="10"/>
          <text>polyamines</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sl-11144</infon>
          <location offset="1002" length="8"/>
          <text>SL-11144</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sl-11158</infon>
          <location offset="1015" length="8"/>
          <text>SL-11158</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arylamine</infon>
          <location offset="1036" length="9"/>
          <text>arylamine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bw-1</infon>
          <location offset="1057" length="4"/>
          <text>BW-1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bis(phenylbenzyl)</infon>
          <location offset="1065" length="17"/>
          <text>bis(phenylbenzyl)</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pao</infon>
          <location offset="1216" length="3"/>
          <text>PAO</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1221</offset>
        <text>The Enc.</text>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">enc. cuniculi pao</infon>
          <location offset="1225" length="17"/>
          <text>Enc. cuniculi PAO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1230</offset>
        <text>cuniculi PAO activity differed from that found in mammalian cells with respect to pH optimum, substrate specificity and sensitivity to known PAO inhibitors.</text>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pao</infon>
          <location offset="1371" length="3"/>
          <text>PAO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1387</offset>
        <text>SL-11158 inhibited SSAT activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sl-11158</infon>
          <location offset="1387" length="8"/>
          <text>SL-11158</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spermine</infon>
          <location offset="1547" length="8"/>
          <text>spermine</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ssat</infon>
          <location offset="1406" length="4"/>
          <text>SSAT</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1557</offset>
        <text>The interest in Enc.</text>
      </sentence>
      <sentence>
        <offset>1578</offset>
        <text>cuniculi polyamine metabolism and the biochemical effects of these polyamine analogues is warranted since they cure model infections of Enc.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyamine</infon>
          <location offset="1645" length="9"/>
          <text>polyamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1719</offset>
        <text>cuniculi in mice and are potential candidates for human clinical trials.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23386417</id>
    <passage>
      <offset>0</offset>
      <text>Androgen Receptor mRNA Measured by Quantitative Real Time PCR is Decreased in the Urethral Mucosa of Patients with Middle Idiopathic Hypospadias.	Androgen action is exerted through the androgen receptor. The normal 46,XY genital virilization depends on androgen receptor gene expression, which is tissue specific, and requires normal androgen receptor mRNA levels in androgen sensitive tissues. Hypospadias is a frequent male genital abnormality, potentially related to reduced androgen sensitivity in genital tissues. The aim of this study was to compare, by quantitative real time PCR, the amount of androgen receptor mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the androgen receptor mRNA levels observed in control phimosis subjects with eutopic urethral opening. Prepubertal individuals were studied, including 41 controls and 17 hypospadias patients with mean (SD) ages of 4.7 (2.1) years and 4.0 (3.0) years, respectively. We observed significantly less androgen receptor mRNA in the urethral mucosa of patients with hypospadias than in the controls (p=0.002). The correlation between the level of androgen receptor mRNA expression and the penile size was almost statistically significant only in hypospadias patients (r=0.47; p=0.053). We also established the number of CAG repeats in exon 1 of the androgen receptor gene by GeneScan analysis. No significant difference was observed in the number of CAG repeats when patients and controls were compared. A negative correlation between the CAG repeats and penile size was detected in patients with hypospadias, but not in controls. Our data suggest that a critical lower level of androgen receptor mRNA expression could be a determining factor in the development of middle hypospadias.</text>
      <sentence>
        <offset>0</offset>
        <text>Androgen Receptor mRNA Measured by Quantitative Real Time PCR is Decreased in the Urethral Mucosa of Patients with Middle Idiopathic Hypospadias.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="0" length="8"/>
          <text>Androgen</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="0" length="17"/>
          <text>Androgen Receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>146</offset>
        <text>Androgen action is exerted through the androgen receptor.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="146" length="8"/>
          <text>Androgen</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="185" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="185" length="17"/>
          <text>androgen receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>204</offset>
        <text>The normal 46,XY genital virilization depends on androgen receptor gene expression, which is tissue specific, and requires normal androgen receptor mRNA levels in androgen sensitive tissues.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="253" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="334" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="367" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="253" length="17"/>
          <text>androgen receptor</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="334" length="17"/>
          <text>androgen receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>395</offset>
        <text>Hypospadias is a frequent male genital abnormality, potentially related to reduced androgen sensitivity in genital tissues.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="478" length="8"/>
          <text>androgen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>519</offset>
        <text>The aim of this study was to compare, by quantitative real time PCR, the amount of androgen receptor mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the androgen receptor mRNA levels observed in control phimosis subjects with eutopic urethral opening.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="602" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="724" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="602" length="17"/>
          <text>androgen receptor</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="724" length="17"/>
          <text>androgen receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>823</offset>
        <text>Prepubertal individuals were studied, including 41 controls and 17 hypospadias patients with mean (SD) ages of 4.7 (2.1) years and 4.0 (3.0) years, respectively.</text>
      </sentence>
      <sentence>
        <offset>985</offset>
        <text>We observed significantly less androgen receptor mRNA in the urethral mucosa of patients with hypospadias than in the controls (p=0.002).</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="1016" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="1016" length="17"/>
          <text>androgen receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1123</offset>
        <text>The correlation between the level of androgen receptor mRNA expression and the penile size was almost statistically significant only in hypospadias patients (r=0.47; p=0.053).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="1160" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="1160" length="17"/>
          <text>androgen receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1299</offset>
        <text>We also established the number of CAG repeats in exon 1 of the androgen receptor gene by GeneScan analysis.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="1362" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cag repeats</infon>
          <location offset="1333" length="11"/>
          <text>CAG repeats</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="1362" length="17"/>
          <text>androgen receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1407</offset>
        <text>No significant difference was observed in the number of CAG repeats when patients and controls were compared.</text>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cag repeats</infon>
          <location offset="1463" length="11"/>
          <text>CAG repeats</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1517</offset>
        <text>A negative correlation between the CAG repeats and penile size was detected in patients with hypospadias, but not in controls.</text>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cag repeats</infon>
          <location offset="1552" length="11"/>
          <text>CAG repeats</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1644</offset>
        <text>Our data suggest that a critical lower level of androgen receptor mRNA expression could be a determining factor in the development of middle hypospadias.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="1692" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">androgen receptor</infon>
          <location offset="1692" length="17"/>
          <text>androgen receptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17301410</id>
    <passage>
      <offset>0</offset>
      <text>The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR.	There is interrelationship between the immune and nervous systems that is accomplished by the molecular mediators. Dopamine is one of the most important neurotransmitters. Five different dopamine receptor genes (DRD1, DRD2, DRD3, DRD4, and DRD5) have been recognized and cloned. The expression of the dopamine receptors is well characterized in the brain but little work has been done to examine their expression in other organ tissues. In certain diseases of the immune and nervous systems, alterations in dopamine receptors gene expression in different cells have been reported. This suggests that dopamine and its receptors have important role in pathophysiology of above-mentioned diseases.In the present study, using Real Time Polymerase Chain Reaction (PCR) technique, we investigated dopamine receptors genes expression in PBMC of normal individuals. The PBMC was separated from normal whole blood by Ficoll-hypaque; the total cellular RNA was then extracted and the cDNA was synthesized. This process followed by real time-PCR using primer pairs specific for five dopamine receptors mRNAs and beta-actin as internal control. The results showed the presence of all types of dopamine receptors in lymphocytes of normal individuals. The specificities of the obtained PCR products for the respective dopamine receptors fragments were confirmed by sequenced analysis capillary system. In conclusion, the present study has shown that human lymphocytes express five dopamine receptors DR1-DR5. However, the conclusive evidence on the possible function of these receptors in lymphocytes remains unknown. Because lymphocytes express all of the five neuronal dopamine receptors, it is quite reasonable to consider them as a model of dopaminergic neuron.</text>
      <sentence>
        <offset>0</offset>
        <text>The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="17" length="8"/>
          <text>Dopamine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine gene receptors</infon>
          <location offset="17" length="23"/>
          <text>Dopamine Gene Receptors</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">drd1-drd5</infon>
          <location offset="42" length="9"/>
          <text>DRD1-DRD5</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>120</offset>
        <text>There is interrelationship between the immune and nervous systems that is accomplished by the molecular mediators.</text>
      </sentence>
      <sentence>
        <offset>235</offset>
        <text>Dopamine is one of the most important neurotransmitters.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="235" length="8"/>
          <text>Dopamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>292</offset>
        <text>Five different dopamine receptor genes (DRD1, DRD2, DRD3, DRD4, and DRD5) have been recognized and cloned.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="307" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine receptor genes (drd1, drd2, drd3, drd4, and drd5</infon>
          <location offset="307" length="57"/>
          <text>dopamine receptor genes (DRD1, DRD2, DRD3, DRD4, and DRD5</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>399</offset>
        <text>The expression of the dopamine receptors is well characterized in the brain but little work has been done to examine their expression in other organ tissues.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="421" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine receptors</infon>
          <location offset="421" length="18"/>
          <text>dopamine receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>557</offset>
        <text>In certain diseases of the immune and nervous systems, alterations in dopamine receptors gene expression in different cells have been reported.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="627" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine receptors</infon>
          <location offset="627" length="18"/>
          <text>dopamine receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>701</offset>
        <text>This suggests that dopamine and its receptors have important role in pathophysiology of above-mentioned diseases.In the present study, using Real Time Polymerase Chain Reaction (PCR) technique, we investigated dopamine receptors genes expression in PBMC of normal individuals.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="720" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="911" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine receptors</infon>
          <location offset="911" length="18"/>
          <text>dopamine receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>978</offset>
        <text>The PBMC was separated from normal whole blood by Ficoll-hypaque; the total cellular RNA was then extracted and the cDNA was synthesized.</text>
      </sentence>
      <sentence>
        <offset>1116</offset>
        <text>This process followed by real time-PCR using primer pairs specific for five dopamine receptors mRNAs and beta-actin as internal control.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1192" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine receptors</infon>
          <location offset="1192" length="18"/>
          <text>dopamine receptors</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta-actin</infon>
          <location offset="1221" length="10"/>
          <text>beta-actin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1253</offset>
        <text>The results showed the presence of all types of dopamine receptors in lymphocytes of normal individuals.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1301" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine receptors</infon>
          <location offset="1301" length="18"/>
          <text>dopamine receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1358</offset>
        <text>The specificities of the obtained PCR products for the respective dopamine receptors fragments were confirmed by sequenced analysis capillary system.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1424" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine receptors</infon>
          <location offset="1424" length="18"/>
          <text>dopamine receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1508</offset>
        <text>In conclusion, the present study has shown that human lymphocytes express five dopamine receptors DR1-DR5.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1587" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine receptors dr1-dr5</infon>
          <location offset="1587" length="26"/>
          <text>dopamine receptors DR1-DR5</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1615</offset>
        <text>However, the conclusive evidence on the possible function of these receptors in lymphocytes remains unknown.</text>
      </sentence>
      <sentence>
        <offset>1724</offset>
        <text>Because lymphocytes express all of the five neuronal dopamine receptors, it is quite reasonable to consider them as a model of dopaminergic neuron.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1777" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine receptors</infon>
          <location offset="1777" length="18"/>
          <text>dopamine receptors</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23499823</id>
    <passage>
      <offset>0</offset>
      <text>Synthesis and molecular modeling of (4'R)- and (4'S)- 4'-substituted 2'-{[(E)-androst-5-en-17-ylidene]-methyl}oxazolines.	Synthesis of four novel (4'R)- and (4'S)- 2'-{[(E)-3β-hydroxyandrost-5-en-17-ylidene]-methyl} oxazolines, comprising 4'-hydroxymethyl (1 and 2) and 4'-methoxycarbonyl (3 and 4) substituents is presented. Reaction of 17α-bromo-21-iodo-3β-acetoxypregn-5-en-20-one with either (L)-serine methyl ester, or (D)-serine methyl ester resulted in methyl N-[3β-acetoxy-21-oxopregna-5,17(20)-dien-21-yl]-(L)-serinate and methyl N-[3β-acetoxy-21-oxopregna-5,17(20)-dien-21-yl]-(D)-serinate (as mixtures of related [17(20)E]- and [17(20)Z]-isomers). Cyclization of obtained amides led to methyl 2'-{[(E)-3β-acetoxyandrost-5-en-17-ylidene]methyl}-(4'S)-4',5'-dihydro-1',3'-oxazole-4'-carboxylate and methyl 2'-{[(E)-3β-acetoxyandrost-5-en-17-ylidene]methyl}-(4'R)-4',5'-dihydro-1',3'-oxazole-4'-carboxylate which were transformed to titled compounds 1-4. The molecular docking of compounds 1-4 to ligand binding site of nuclear receptor LXRβ revealed significant differences due to stereochemical configuration of 4' atom and structure of 4'-substituent.</text>
      <sentence>
        <offset>0</offset>
        <text>Synthesis and molecular modeling of (4'R)- and (4'S)- 4'-substituted 2'-{[(E)-androst-5-en-17-ylidene]-methyl}oxazolines.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(4'r)- and (4's)- 4'-substituted 2'-{[(e)-androst-5-en-17-ylidene]-methyl}oxazolines</infon>
          <location offset="36" length="84"/>
          <text>(4'R)- and (4'S)- 4'-substituted 2'-{[(E)-androst-5-en-17-ylidene]-methyl}oxazolines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>122</offset>
        <text>Synthesis of four novel (4'R)- and (4'S)- 2'-{[(E)-3β-hydroxyandrost-5-en-17-ylidene]-methyl} oxazolines, comprising 4'-hydroxymethyl (1 and 2) and 4'-methoxycarbonyl (3 and 4) substituents is presented.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4'-hydroxymethyl</infon>
          <location offset="239" length="16"/>
          <text>4'-hydroxymethyl</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4'-methoxycarbonyl</infon>
          <location offset="270" length="18"/>
          <text>4'-methoxycarbonyl</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(4'r)- and (4's)- 2'-{[(e)-3β-hydroxyandrost-5-en-17-ylidene]-methyl} oxazolines</infon>
          <location offset="146" length="80"/>
          <text>(4'R)- and (4'S)- 2'-{[(E)-3β-hydroxyandrost-5-en-17-ylidene]-methyl} oxazolines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>326</offset>
        <text>Reaction of 17α-bromo-21-iodo-3β-acetoxypregn-5-en-20-one with either (L)-serine methyl ester, or (D)-serine methyl ester resulted in methyl N-[3β-acetoxy-21-oxopregna-5,17(20)-dien-21-yl]-(L)-serinate and methyl N-[3β-acetoxy-21-oxopregna-5,17(20)-dien-21-yl]-(D)-serinate (as mixtures of related [17(20)E]- and [17(20)Z]-isomers).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">17α-bromo-21-iodo-3β-acetoxypregn-5-en-20-one</infon>
          <location offset="338" length="45"/>
          <text>17α-bromo-21-iodo-3β-acetoxypregn-5-en-20-one</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(l)-serine methyl ester</infon>
          <location offset="396" length="23"/>
          <text>(L)-serine methyl ester</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(d)-serine methyl ester</infon>
          <location offset="424" length="23"/>
          <text>(D)-serine methyl ester</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methyl n-[3β-acetoxy-21-oxopregna-5,17(20)-dien-21-yl]-(l)-serinate</infon>
          <location offset="460" length="67"/>
          <text>methyl N-[3β-acetoxy-21-oxopregna-5,17(20)-dien-21-yl]-(L)-serinate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methyl n-[3β-acetoxy-21-oxopregna-5,17(20)-dien-21-yl]-(d)-serinate</infon>
          <location offset="532" length="67"/>
          <text>methyl N-[3β-acetoxy-21-oxopregna-5,17(20)-dien-21-yl]-(D)-serinate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>659</offset>
        <text>Cyclization of obtained amides led to methyl 2'-{[(E)-3β-acetoxyandrost-5-en-17-ylidene]methyl}-(4'S)-4',5'-dihydro-1',3'-oxazole-4'-carboxylate and methyl 2'-{[(E)-3β-acetoxyandrost-5-en-17-ylidene]methyl}-(4'R)-4',5'-dihydro-1',3'-oxazole-4'-carboxylate which were transformed to titled compounds 1-4.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amides</infon>
          <location offset="683" length="6"/>
          <text>amides</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methyl 2'-{[(e)-3β-acetoxyandrost-5-en-17-ylidene]methyl}-(4's)-4',5'-dihydro-1',3'-oxazole-4'-carboxylate</infon>
          <location offset="697" length="106"/>
          <text>methyl 2'-{[(E)-3β-acetoxyandrost-5-en-17-ylidene]methyl}-(4'S)-4',5'-dihydro-1',3'-oxazole-4'-carboxylate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methyl 2'-{[(e)-3β-acetoxyandrost-5-en-17-ylidene]methyl}-(4'r)-4',5'-dihydro-1',3'-oxazole-4'-carboxylate</infon>
          <location offset="808" length="106"/>
          <text>methyl 2'-{[(E)-3β-acetoxyandrost-5-en-17-ylidene]methyl}-(4'R)-4',5'-dihydro-1',3'-oxazole-4'-carboxylate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>963</offset>
        <text>The molecular docking of compounds 1-4 to ligand binding site of nuclear receptor LXRβ revealed significant differences due to stereochemical configuration of 4' atom and structure of 4'-substituent.</text>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nuclear receptor</infon>
          <location offset="1028" length="16"/>
          <text>nuclear receptor</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lxrβ</infon>
          <location offset="1045" length="4"/>
          <text>LXRβ</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11316248</id>
    <passage>
      <offset>0</offset>
      <text>Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid.	Mefenamic acid ingestion, usually in excess and over prolonged period is known to produce interstitial nephritis, or less commonly papillary necrosis, with acute renal failure. However, it is not dose-dependent for the induction of tubulointerstitial damage. Excess iodine ingestion is known to produce toxicity and possible death, but acute renal failure is rare. There is evidence from clinical and experimental data that iodine has toxic effect on tubular epithelial cells. Iodine has not been documented to produce red cell hemolysis and hemoglobinuria. We present a unique case of acute renal failure from hemoglobinuric and acute interstitial nephritis secondary to suicidal ingestion of potassium iodide solution and also ingestion of a few mefenamic acid tablets. These agents led to potentiation of the renal injury from hemoglobinuric tubulopathy, probably from the iodine, and renal dysfunction from alteration of renal perfusion by selective COX-1 inhibition of prostaglandin production, and induction of acute interstitial nephritis from mefenamic acid, leading to acute renal failure which was reversible by hemodialysis and supportive therapy.</text>
      <sentence>
        <offset>0</offset>
        <text>Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iodine</infon>
          <location offset="80" length="6"/>
          <text>iodine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mefenamic acid</infon>
          <location offset="91" length="14"/>
          <text>mefenamic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>107</offset>
        <text>Mefenamic acid ingestion, usually in excess and over prolonged period is known to produce interstitial nephritis, or less commonly papillary necrosis, with acute renal failure.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mefenamic acid</infon>
          <location offset="107" length="14"/>
          <text>Mefenamic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>284</offset>
        <text>However, it is not dose-dependent for the induction of tubulointerstitial damage.</text>
      </sentence>
      <sentence>
        <offset>366</offset>
        <text>Excess iodine ingestion is known to produce toxicity and possible death, but acute renal failure is rare.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iodine</infon>
          <location offset="373" length="6"/>
          <text>iodine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>472</offset>
        <text>There is evidence from clinical and experimental data that iodine has toxic effect on tubular epithelial cells.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iodine</infon>
          <location offset="531" length="6"/>
          <text>iodine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>584</offset>
        <text>Iodine has not been documented to produce red cell hemolysis and hemoglobinuria.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iodine</infon>
          <location offset="584" length="6"/>
          <text>Iodine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>665</offset>
        <text>We present a unique case of acute renal failure from hemoglobinuric and acute interstitial nephritis secondary to suicidal ingestion of potassium iodide solution and also ingestion of a few mefenamic acid tablets.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">potassium iodide</infon>
          <location offset="801" length="16"/>
          <text>potassium iodide</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mefenamic acid</infon>
          <location offset="855" length="14"/>
          <text>mefenamic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>879</offset>
        <text>These agents led to potentiation of the renal injury from hemoglobinuric tubulopathy, probably from the iodine, and renal dysfunction from alteration of renal perfusion by selective COX-1 inhibition of prostaglandin production, and induction of acute interstitial nephritis from mefenamic acid, leading to acute renal failure which was reversible by hemodialysis and supportive therapy.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mefenamic acid</infon>
          <location offset="1158" length="14"/>
          <text>mefenamic acid</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iodine</infon>
          <location offset="983" length="6"/>
          <text>iodine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prostaglandin</infon>
          <location offset="1081" length="13"/>
          <text>prostaglandin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-1</infon>
          <location offset="1061" length="5"/>
          <text>COX-1</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T9" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23454207</id>
    <passage>
      <offset>0</offset>
      <text>Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats.	Continuous dopaminergic stimulation (CDS) has been an important strategy of drug development for the treatment of Parkinson's disease (PD). Rotigotine is a non-ergoline D3/D2/D1 dopamine agonist for treating PD. As a new treatment option for CDS, rotigotine-loaded microspheres (RoMS), a long-acting sustained-release microspheres for injection with poly(lactide-co-glycolide) as drug carrier, are now being evaluated in clinical trial. In this study, subchronic toxicity of RoMS in SD rats has been characterized via intramuscular administration with RoMS (0-240mg/kg/week) on a consecutive weekly dosing schedule for 3months followed by 1-month recovery period. The No Observed Adverse Effect Level (NOAEL) was 45mg/kg/week. One male at 240mg/kg died from an extensive pulmonary embolism. The major toxicological effects were associated with the dopamine agonist-related pharmacodynamic properties of rotigotine (e.g. hyperactivity and stereotype, enlarged ovary, sporadic gastric mucous membrane lesions, decreased body weight, food consumption and prolactin, and increased mononuclear cell, neutrophil granulocyte, aspartate aminotransferase and alanine aminotransferase) and foreign body removal reaction induced by poly(lactide-co-glycolide) and carboxymethycellulose sodium. At the end of recovery period, all findings had recovered to a normal level or to a certain degree except foreign body reaction at injection sites. RoMS has exhibited high safety on SD rats.</text>
      <sentence>
        <offset>0</offset>
        <text>Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rotigotine</infon>
          <location offset="55" length="10"/>
          <text>rotigotine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>98</offset>
        <text>Continuous dopaminergic stimulation (CDS) has been an important strategy of drug development for the treatment of Parkinson's disease (PD).</text>
      </sentence>
      <sentence>
        <offset>238</offset>
        <text>Rotigotine is a non-ergoline D3/D2/D1 dopamine agonist for treating PD.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rotigotine</infon>
          <location offset="238" length="10"/>
          <text>Rotigotine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ergoline</infon>
          <location offset="258" length="8"/>
          <text>ergoline</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="276" length="8"/>
          <text>dopamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>310</offset>
        <text>As a new treatment option for CDS, rotigotine-loaded microspheres (RoMS), a long-acting sustained-release microspheres for injection with poly(lactide-co-glycolide) as drug carrier, are now being evaluated in clinical trial.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rotigotine</infon>
          <location offset="345" length="10"/>
          <text>rotigotine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">poly(lactide-co-glycolide)</infon>
          <location offset="448" length="26"/>
          <text>poly(lactide-co-glycolide)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>535</offset>
        <text>In this study, subchronic toxicity of RoMS in SD rats has been characterized via intramuscular administration with RoMS (0-240mg/kg/week) on a consecutive weekly dosing schedule for 3months followed by 1-month recovery period.</text>
      </sentence>
      <sentence>
        <offset>762</offset>
        <text>The No Observed Adverse Effect Level (NOAEL) was 45mg/kg/week.</text>
      </sentence>
      <sentence>
        <offset>825</offset>
        <text>One male at 240mg/kg died from an extensive pulmonary embolism.</text>
      </sentence>
      <sentence>
        <offset>889</offset>
        <text>The major toxicological effects were associated with the dopamine agonist-related pharmacodynamic properties of rotigotine (e.g. hyperactivity and stereotype, enlarged ovary, sporadic gastric mucous membrane lesions, decreased body weight, food consumption and prolactin, and increased mononuclear cell, neutrophil granulocyte, aspartate aminotransferase and alanine aminotransferase) and foreign body removal reaction induced by poly(lactide-co-glycolide) and carboxymethycellulose sodium.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspartate</infon>
          <location offset="1217" length="9"/>
          <text>aspartate</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alanine</infon>
          <location offset="1248" length="7"/>
          <text>alanine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">poly(lactide-co-glycolide)</infon>
          <location offset="1319" length="26"/>
          <text>poly(lactide-co-glycolide)</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="1372" length="6"/>
          <text>sodium</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="946" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rotigotine</infon>
          <location offset="1001" length="10"/>
          <text>rotigotine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">prolactin</infon>
          <location offset="1150" length="9"/>
          <text>prolactin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aspartate aminotransferase</infon>
          <location offset="1217" length="26"/>
          <text>aspartate aminotransferase</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alanine aminotransferase</infon>
          <location offset="1248" length="24"/>
          <text>alanine aminotransferase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1380</offset>
        <text>At the end of recovery period, all findings had recovered to a normal level or to a certain degree except foreign body reaction at injection sites.</text>
      </sentence>
      <sentence>
        <offset>1528</offset>
        <text>RoMS has exhibited high safety on SD rats.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17501690</id>
    <passage>
      <offset>0</offset>
      <text>Aripiprazole acts as a selective dopamine D2 receptor partial agonist.	Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser. However, recent studies have questioned the role of the 5-HT-mediated systems in the mechanism of action of aripiprazole. This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the dopamine D(2) receptor and does not affect 5-HT receptors at therapeutic doses.</text>
      <sentence>
        <offset>0</offset>
        <text>Aripiprazole acts as a selective dopamine D2 receptor partial agonist.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="33" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2 receptor</infon>
          <location offset="33" length="20"/>
          <text>dopamine D2 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>71</offset>
        <text>Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aripiprazole</infon>
          <location offset="71" length="12"/>
          <text>Aripiprazole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>291</offset>
        <text>It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="339" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aripiprazole</infon>
          <location offset="453" length="12"/>
          <text>aripiprazole</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="479" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="493" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine d(2) and 5-ht(1a) receptors</infon>
          <location offset="339" length="36"/>
          <text>dopamine D(2) and 5-HT(1A) receptors</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht(2)</infon>
          <location offset="398" length="7"/>
          <text>5-HT(2)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>510</offset>
        <text>However, recent studies have questioned the role of the 5-HT-mediated systems in the mechanism of action of aripiprazole.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="566" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aripiprazole</infon>
          <location offset="618" length="12"/>
          <text>aripiprazole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>632</offset>
        <text>This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the dopamine D(2) receptor and does not affect 5-HT receptors at therapeutic doses.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aripiprazole</infon>
          <location offset="701" length="12"/>
          <text>aripiprazole</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="757" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="800" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d(2) receptor</infon>
          <location offset="757" length="22"/>
          <text>dopamine D(2) receptor</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht receptors</infon>
          <location offset="800" length="14"/>
          <text>5-HT receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T8" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23287708</id>
    <passage>
      <offset>0</offset>
      <text>Sunset yellow FCF, a permitted food dye, alters functional responses of splenocytes at non-cytotoxic dose.	Sunset yellow FCF (SY), a permitted food color, is extensively used in various food preparations and quite often exceeds the permissible levels (100-200 mg/kg). Several toxicity studies on SY are reported, however immunomodulatory properties have not been explored yet. To investigate the immunotoxic properties of SY, splenocytes were isolated, cultured and subjected to mitogen stimulated proliferation assay (lipopolysaccharide, LPS or concanavalin A, Con A), mixed lymphocyte reaction (MLR) assay, immunophenotypic analysis of cell surface receptor expression and assay for cytokines release in the culture supernatants were performed in the presence of SY. Since SY did not exhibit any cytotoxicity up to 250 μg/ml, this dose was used for further studies. It was observed that SY (250 μg/ml) significantly (p&lt;0.05) suppressed the mitogen induced proliferation of splenocytes and MLR response. Further, immunophenotypic analysis revealed that SY alters the relative expression of CD3e/CD4/CD8 in T cells and CD19 in B-cells. Consistent with the suppression of T-cell and B-cell responses and altered surface receptor expression, SY also lowered the expression of IL2, IL4, IL6, IL-17, IFN-γ and TNF-α cytokines. These results suggest that non-cytotoxic dose of SY may have immunomodulatory effects.</text>
      <sentence>
        <offset>0</offset>
        <text>Sunset yellow FCF, a permitted food dye, alters functional responses of splenocytes at non-cytotoxic dose.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sunset yellow fcf</infon>
          <location offset="0" length="17"/>
          <text>Sunset yellow FCF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>107</offset>
        <text>Sunset yellow FCF (SY), a permitted food color, is extensively used in various food preparations and quite often exceeds the permissible levels (100-200 mg/kg).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sunset yellow fcf</infon>
          <location offset="107" length="17"/>
          <text>Sunset yellow FCF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>268</offset>
        <text>Several toxicity studies on SY are reported, however immunomodulatory properties have not been explored yet.</text>
      </sentence>
      <sentence>
        <offset>377</offset>
        <text>To investigate the immunotoxic properties of SY, splenocytes were isolated, cultured and subjected to mitogen stimulated proliferation assay (lipopolysaccharide, LPS or concanavalin A, Con A), mixed lymphocyte reaction (MLR) assay, immunophenotypic analysis of cell surface receptor expression and assay for cytokines release in the culture supernatants were performed in the presence of SY.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">concanavalin a</infon>
          <location offset="546" length="14"/>
          <text>concanavalin A</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">con a</infon>
          <location offset="562" length="5"/>
          <text>Con A</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cell surface receptor</infon>
          <location offset="638" length="21"/>
          <text>cell surface receptor</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="685" length="9"/>
          <text>cytokines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>769</offset>
        <text>Since SY did not exhibit any cytotoxicity up to 250 μg/ml, this dose was used for further studies.</text>
      </sentence>
      <sentence>
        <offset>868</offset>
        <text>It was observed that SY (250 μg/ml) significantly (p&lt;0.05) suppressed the mitogen induced proliferation of splenocytes and MLR response.</text>
      </sentence>
      <sentence>
        <offset>1005</offset>
        <text>Further, immunophenotypic analysis revealed that SY alters the relative expression of CD3e/CD4/CD8 in T cells and CD19 in B-cells.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cd19</infon>
          <location offset="1119" length="4"/>
          <text>CD19</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cd3e</infon>
          <location offset="1091" length="4"/>
          <text>CD3e</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cd4</infon>
          <location offset="1096" length="3"/>
          <text>CD4</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cd8</infon>
          <location offset="1100" length="3"/>
          <text>CD8</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1136</offset>
        <text>Consistent with the suppression of T-cell and B-cell responses and altered surface receptor expression, SY also lowered the expression of IL2, IL4, IL6, IL-17, IFN-γ and TNF-α cytokines.</text>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">surface receptor</infon>
          <location offset="1211" length="16"/>
          <text>surface receptor</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il2</infon>
          <location offset="1274" length="3"/>
          <text>IL2</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il4</infon>
          <location offset="1279" length="3"/>
          <text>IL4</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il6</infon>
          <location offset="1284" length="3"/>
          <text>IL6</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-17</infon>
          <location offset="1289" length="5"/>
          <text>IL-17</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ifn-γ</infon>
          <location offset="1296" length="5"/>
          <text>IFN-γ</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="1306" length="5"/>
          <text>TNF-α</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="1312" length="9"/>
          <text>cytokines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1323</offset>
        <text>These results suggest that non-cytotoxic dose of SY may have immunomodulatory effects.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23494944</id>
    <passage>
      <offset>0</offset>
      <text>Influence of the Green Tea Leaf Extract on Neurotoxicity of Aluminium Chloride in Rats.	Aluminium may have an important role in the aetiology/pathogenesis/precipitation of Alzheimer's disease. Because green tea (Camellia sinensis L.) reportedly has health-promoting effects in the central nervous system, we evaluated the effects of green tea leaf extract (GTLE) on aluminium chloride (AlCl3 ) neurotoxicity in rats. All solutions were injected into the cornu ammonis region 1 hippocampal region. We measured the performance of active avoidance (AA) tasks, various enzyme activities and total glutathione content (TGC) in the forebrain cortex (FbC), striatum, basal forebrain (BFb), hippocampus, brain stem and cerebellum. AlCl3 markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (AChE) in all regions. It decreased TGC in the FbC, striatum, BFb, hippocampus, brain stem and cerebellum, and increased superoxide dismutase activity in the FbC, cerebellum and BFb. GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and superoxide dismutase activity, markedly corrected COX and AChE activities, and moderately improved TGC. GTLE alone increased COX and AChE activities in almost all regions. GTLE reduces AlCl3 neurotoxicity probably via antioxidative effects and improves mitochondrial and cholinergic synaptic functions through the actions of (-)-epigallocatechin gallate and (-)-epicatechin, compounds most abundantly found in GTLE. Our results suggest that green tea might be beneficial in Alzheimer's disease. Copyright © 2013 John Wiley &amp; Sons, Ltd.</text>
      <sentence>
        <offset>0</offset>
        <text>Influence of the Green Tea Leaf Extract on Neurotoxicity of Aluminium Chloride in Rats.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium chloride</infon>
          <location offset="60" length="18"/>
          <text>Aluminium Chloride</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>88</offset>
        <text>Aluminium may have an important role in the aetiology/pathogenesis/precipitation of Alzheimer's disease.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium</infon>
          <location offset="88" length="9"/>
          <text>Aluminium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>193</offset>
        <text>Because green tea (Camellia sinensis L.) reportedly has health-promoting effects in the central nervous system, we evaluated the effects of green tea leaf extract (GTLE) on aluminium chloride (AlCl3 ) neurotoxicity in rats.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium chloride</infon>
          <location offset="366" length="18"/>
          <text>aluminium chloride</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcl3</infon>
          <location offset="386" length="5"/>
          <text>AlCl3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>417</offset>
        <text>All solutions were injected into the cornu ammonis region 1 hippocampal region.</text>
      </sentence>
      <sentence>
        <offset>497</offset>
        <text>We measured the performance of active avoidance (AA) tasks, various enzyme activities and total glutathione content (TGC) in the forebrain cortex (FbC), striatum, basal forebrain (BFb), hippocampus, brain stem and cerebellum.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="593" length="11"/>
          <text>glutathione</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>723</offset>
        <text>AlCl3 markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (AChE) in all regions.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcl3</infon>
          <location offset="723" length="5"/>
          <text>AlCl3</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome c oxidase</infon>
          <location offset="779" length="20"/>
          <text>cytochrome c oxidase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="801" length="3"/>
          <text>COX</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="810" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="832" length="4"/>
          <text>AChE</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>854</offset>
        <text>It decreased TGC in the FbC, striatum, BFb, hippocampus, brain stem and cerebellum, and increased superoxide dismutase activity in the FbC, cerebellum and BFb.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="952" length="10"/>
          <text>superoxide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1014</offset>
        <text>GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and superoxide dismutase activity, markedly corrected COX and AChE activities, and moderately improved TGC.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="1092" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcl3</infon>
          <location offset="1076" length="5"/>
          <text>AlCl3</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">superoxide dismutase</infon>
          <location offset="1092" length="20"/>
          <text>superoxide dismutase</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="1142" length="3"/>
          <text>COX</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="1150" length="4"/>
          <text>AChE</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1196</offset>
        <text>GTLE alone increased COX and AChE activities in almost all regions.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="1217" length="3"/>
          <text>COX</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="1225" length="4"/>
          <text>AChE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1264</offset>
        <text>GTLE reduces AlCl3 neurotoxicity probably via antioxidative effects and improves mitochondrial and cholinergic synaptic functions through the actions of (-)-epigallocatechin gallate and (-)-epicatechin, compounds most abundantly found in GTLE.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcl3</infon>
          <location offset="1277" length="5"/>
          <text>AlCl3</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(-)-epigallocatechin gallate</infon>
          <location offset="1417" length="28"/>
          <text>(-)-epigallocatechin gallate</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(-)-epicatechin</infon>
          <location offset="1450" length="15"/>
          <text>(-)-epicatechin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1508</offset>
        <text>Our results suggest that green tea might be beneficial in Alzheimer's disease.</text>
      </sentence>
      <sentence>
        <offset>1587</offset>
        <text>Copyright © 2013 John Wiley &amp; Sons, Ltd.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23466526</id>
    <passage>
      <offset>0</offset>
      <text>ZEB2 zinc-finger missense mutations lead to hypomorphic alleles and a mild Mowat-Wilson syndrome.	Mowat-Wilson syndrome (MWS) is a severe intellectual disability (ID)-distinctive facial gestalt-multiple congenital anomaly syndrome, commonly associating microcephaly, epilepsy, corpus callosum agenesis, conotruncal heart defects, urogenital malformations and Hirschsprung disease (HSCR). MWS is caused by de novo heterozygous mutations in the ZEB2 gene. The majority of mutations lead to haplo-insufficiency through premature stop codons or large gene deletions. Only three missense mutations have been reported so far; none of which resides in a known functional domain of ZEB2. In this study, we report and analyze the functional consequences of three novel missense mutations, p.Tyr1055Cys, p.Ser1071Pro and p.His1045Arg, identified in the highly conserved C-zinc-finger (C-ZF) domain of ZEB2. Patients' phenotype included the facial gestalt of MWS and moderate ID, but no microcephaly, heart defects or HSCR. In vitro studies showed that all the three mutations prevented binding and repression of the E-cadherin promoter, a characterized ZEB2 target gene. Taking advantage of the zebrafish morphant technology, we performed rescue experiments using wild-type (WT) and mutant human ZEB2 mRNAs. Variable, mutation-dependent, embryo rescue, correlating with the severity of patients' phenotype, was observed. Our data provide evidence that these missense mutations cause a partial loss of function of ZEB2, suggesting that its role is not restricted to repression of E-cadherin. Functional domains other than C-ZF may play a role in early embryonic development. Finally, these findings broaden the clinical spectrum of ZEB2 mutations, indicating that MWS ought to be considered in patients with lesser degrees of ID and a suggestive facial gestalt, even in the absence of congenital malformation.</text>
      <sentence>
        <offset>0</offset>
        <text>ZEB2 zinc-finger missense mutations lead to hypomorphic alleles and a mild Mowat-Wilson syndrome.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc</infon>
          <location offset="5" length="4"/>
          <text>zinc</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zeb2</infon>
          <location offset="0" length="4"/>
          <text>ZEB2</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">zinc-finger</infon>
          <location offset="5" length="11"/>
          <text>zinc-finger</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>98</offset>
        <text>Mowat-Wilson syndrome (MWS) is a severe intellectual disability (ID)-distinctive facial gestalt-multiple congenital anomaly syndrome, commonly associating microcephaly, epilepsy, corpus callosum agenesis, conotruncal heart defects, urogenital malformations and Hirschsprung disease (HSCR).</text>
      </sentence>
      <sentence>
        <offset>388</offset>
        <text>MWS is caused by de novo heterozygous mutations in the ZEB2 gene.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zeb2</infon>
          <location offset="443" length="4"/>
          <text>ZEB2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>454</offset>
        <text>The majority of mutations lead to haplo-insufficiency through premature stop codons or large gene deletions.</text>
      </sentence>
      <sentence>
        <offset>563</offset>
        <text>Only three missense mutations have been reported so far; none of which resides in a known functional domain of ZEB2.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zeb2</infon>
          <location offset="674" length="4"/>
          <text>ZEB2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>680</offset>
        <text>In this study, we report and analyze the functional consequences of three novel missense mutations, p.Tyr1055Cys, p.Ser1071Pro and p.His1045Arg, identified in the highly conserved C-zinc-finger (C-ZF) domain of ZEB2.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc</infon>
          <location offset="862" length="4"/>
          <text>zinc</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p.tyr1055cys</infon>
          <location offset="780" length="12"/>
          <text>p.Tyr1055Cys</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p.ser1071pro</infon>
          <location offset="794" length="12"/>
          <text>p.Ser1071Pro</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p.his1045arg</infon>
          <location offset="811" length="12"/>
          <text>p.His1045Arg</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c-zinc-finger (c-zf) domain</infon>
          <location offset="860" length="27"/>
          <text>C-zinc-finger (C-ZF) domain</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zeb2</infon>
          <location offset="891" length="4"/>
          <text>ZEB2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>897</offset>
        <text>Patients' phenotype included the facial gestalt of MWS and moderate ID, but no microcephaly, heart defects or HSCR.</text>
      </sentence>
      <sentence>
        <offset>1013</offset>
        <text>In vitro studies showed that all the three mutations prevented binding and repression of the E-cadherin promoter, a characterized ZEB2 target gene.</text>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">e-cadherin promoter</infon>
          <location offset="1106" length="19"/>
          <text>E-cadherin promoter</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zeb2</infon>
          <location offset="1143" length="4"/>
          <text>ZEB2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1161</offset>
        <text>Taking advantage of the zebrafish morphant technology, we performed rescue experiments using wild-type (WT) and mutant human ZEB2 mRNAs.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human zeb2</infon>
          <location offset="1280" length="10"/>
          <text>human ZEB2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1298</offset>
        <text>Variable, mutation-dependent, embryo rescue, correlating with the severity of patients' phenotype, was observed.</text>
      </sentence>
      <sentence>
        <offset>1411</offset>
        <text>Our data provide evidence that these missense mutations cause a partial loss of function of ZEB2, suggesting that its role is not restricted to repression of E-cadherin.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zeb2</infon>
          <location offset="1503" length="4"/>
          <text>ZEB2</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">e-cadherin</infon>
          <location offset="1569" length="10"/>
          <text>E-cadherin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1581</offset>
        <text>Functional domains other than C-ZF may play a role in early embryonic development.</text>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c-zf</infon>
          <location offset="1611" length="4"/>
          <text>C-ZF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1664</offset>
        <text>Finally, these findings broaden the clinical spectrum of ZEB2 mutations, indicating that MWS ought to be considered in patients with lesser degrees of ID and a suggestive facial gestalt, even in the absence of congenital malformation.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">zeb2</infon>
          <location offset="1721" length="4"/>
          <text>ZEB2</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>3320565</id>
    <passage>
      <offset>0</offset>
      <text>Pharmacological and clinical studies of the antiandrogen Anandron.	This paper summarizes the animal and human studies with Anandron available at the time of the meeting. The following was demonstrated in the rat and confirmed in man: interaction of Anandron with the prostatic androgen receptor, antiandrogen activity against testosterone (in particular against the early transient rise induced by LHRH analogs) and adrenal androgens. Thus, as shown in 4 different double blind studies performed in stage D2 prostrate cancer patients, the combination of Anandron with surgical or chemical castration enhanced the beneficial effects of castration alone and thus seems a step forward in the hormonal treatment of prostatic carcinoma.</text>
      <sentence>
        <offset>0</offset>
        <text>Pharmacological and clinical studies of the antiandrogen Anandron.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anandron</infon>
          <location offset="57" length="8"/>
          <text>Anandron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>67</offset>
        <text>This paper summarizes the animal and human studies with Anandron available at the time of the meeting.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anandron</infon>
          <location offset="123" length="8"/>
          <text>Anandron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>170</offset>
        <text>The following was demonstrated in the rat and confirmed in man: interaction of Anandron with the prostatic androgen receptor, antiandrogen activity against testosterone (in particular against the early transient rise induced by LHRH analogs) and adrenal androgens.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anandron</infon>
          <location offset="249" length="8"/>
          <text>Anandron</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="277" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">testosterone</infon>
          <location offset="326" length="12"/>
          <text>testosterone</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgens</infon>
          <location offset="424" length="9"/>
          <text>androgens</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">prostatic androgen receptor</infon>
          <location offset="267" length="27"/>
          <text>prostatic androgen receptor</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lhrh</infon>
          <location offset="398" length="4"/>
          <text>LHRH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>435</offset>
        <text>Thus, as shown in 4 different double blind studies performed in stage D2 prostrate cancer patients, the combination of Anandron with surgical or chemical castration enhanced the beneficial effects of castration alone and thus seems a step forward in the hormonal treatment of prostatic carcinoma.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anandron</infon>
          <location offset="554" length="8"/>
          <text>Anandron</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22658648</id>
    <passage>
      <offset>0</offset>
      <text>Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice.	Type 2 diabetes is a complex disease characterized by a state of insulin resistance in peripheral tissues such as skeletal muscle, adipose tissue or liver. Some inositol isomers have been reported to possess insulin-mimetic activity and to be efficient in lowering blood glucose level. The aim of the present study was to assess in mice the metabolic effects of a chronic treatment with myo-inositol, the most common stereoisomer of inositol. Mice given myo-inositol treatment (0.9 or 1.2 mg g(-1) day(-1), 15 days, orally or intraperitoneally) exhibited an improved glucose tolerance due to a greater insulin sensitivity. Mice treated with myo-inositol exhibited a decreased white adipose tissue accretion (-33%, P&lt;.005) compared with controls. The decrease in white adipose tissue deposition was due to a decrease in adipose cell volume (-33%, P&lt;.05), while no change was noticed in total adipocyte number. In skeletal muscle, in vivo as well as ex vivo myo-inositol treatment increased protein kinase B/Akt phosphorylation under baseline and insulin-stimulated conditions, suggesting a synergistic action of myo-inositol treatment and insulin on proteins of the insulin signalling pathway. Myo-inositol could therefore constitute a viable nutritional strategy for the prevention and/or treatment of insulin resistance and type 2 diabetes.</text>
      <sentence>
        <offset>0</offset>
        <text>Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">myo-inositol</infon>
          <location offset="23" length="12"/>
          <text>myo-inositol</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="88" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>124</offset>
        <text>Type 2 diabetes is a complex disease characterized by a state of insulin resistance in peripheral tissues such as skeletal muscle, adipose tissue or liver.</text>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="189" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>280</offset>
        <text>Some inositol isomers have been reported to possess insulin-mimetic activity and to be efficient in lowering blood glucose level.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">inositol</infon>
          <location offset="285" length="8"/>
          <text>inositol</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="332" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>410</offset>
        <text>The aim of the present study was to assess in mice the metabolic effects of a chronic treatment with myo-inositol, the most common stereoisomer of inositol.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">myo-inositol</infon>
          <location offset="511" length="12"/>
          <text>myo-inositol</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">inositol</infon>
          <location offset="557" length="8"/>
          <text>inositol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>567</offset>
        <text>Mice given myo-inositol treatment (0.9 or 1.2 mg g(-1) day(-1), 15 days, orally or intraperitoneally) exhibited an improved glucose tolerance due to a greater insulin sensitivity.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">myo-inositol</infon>
          <location offset="578" length="12"/>
          <text>myo-inositol</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="691" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="726" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>747</offset>
        <text>Mice treated with myo-inositol exhibited a decreased white adipose tissue accretion (-33%, P&lt;.005) compared with controls.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">myo-inositol</infon>
          <location offset="765" length="12"/>
          <text>myo-inositol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>870</offset>
        <text>The decrease in white adipose tissue deposition was due to a decrease in adipose cell volume (-33%, P&lt;.05), while no change was noticed in total adipocyte number.</text>
      </sentence>
      <sentence>
        <offset>1033</offset>
        <text>In skeletal muscle, in vivo as well as ex vivo myo-inositol treatment increased protein kinase B/Akt phosphorylation under baseline and insulin-stimulated conditions, suggesting a synergistic action of myo-inositol treatment and insulin on proteins of the insulin signalling pathway.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">myo-inositol</infon>
          <location offset="1235" length="12"/>
          <text>myo-inositol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">myo-inositol</infon>
          <location offset="1080" length="12"/>
          <text>myo-inositol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="1130" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1169" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1262" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1289" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein kinase b</infon>
          <location offset="1113" length="16"/>
          <text>protein kinase B</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1317</offset>
        <text>Myo-inositol could therefore constitute a viable nutritional strategy for the prevention and/or treatment of insulin resistance and type 2 diabetes.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">myo-inositol</infon>
          <location offset="1317" length="12"/>
          <text>Myo-inositol</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1426" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23412992</id>
    <passage>
      <offset>0</offset>
      <text>Cardiotonic steroids-mediated Na+/K+-ATPase targeting could circumvent various chemoresistance pathways.	Many cancer patients fail to respond to chemotherapy because of the intrinsic resistance of their cancer to pro-apoptotic stimuli or the acquisition of the multidrug resistant phenotype during chronic treatment. Previous data from our groups and from others point to the sodium/potassium pump (the Na+/K+-ATPase, i.e., NaK) with its highly specific ligands (i.e., cardiotonic steroids) as a new target for combating cancers associated with dismal prognoses, including gliomas, melanomas, non-small cell lung cancers, renal cell carcinomas, and colon cancers. Cardiotonic steroid-mediated Na+/K+-ATPase targeting could circumvent various resistance pathways. The most probable pathways include the involvement of Na+/K+-ATPase β subunits in invasion features and Na+/K+-ATPase α subunits in chemosensitisation by specific cardiotonic steroid-mediated apoptosis and anoïkis-sensitisation; the regulation of the expression of multidrug resistant-related genes; post-translational regulation, including glycosylation and ubiquitinylation of multidrug resistant-related proteins; c-Myc downregulation; hypoxia-inducible factor downregulation; NF-κB downregulation and deactivation; the inhibition of the glycolytic pathway with a reduction of intra-cellular ATP levels and an induction of non-apoptotic cell death. The aims of this review are to examine the various molecular pathways by which the NaK targeting can be more deleterious to biologically aggressive cancer cells than to normal cells.</text>
      <sentence>
        <offset>0</offset>
        <text>Cardiotonic steroids-mediated Na+/K+-ATPase targeting could circumvent various chemoresistance pathways.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na+</infon>
          <location offset="30" length="3"/>
          <text>Na+</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k+</infon>
          <location offset="34" length="2"/>
          <text>K+</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na+/k+-atpase</infon>
          <location offset="30" length="13"/>
          <text>Na+/K+-ATPase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>105</offset>
        <text>Many cancer patients fail to respond to chemotherapy because of the intrinsic resistance of their cancer to pro-apoptotic stimuli or the acquisition of the multidrug resistant phenotype during chronic treatment.</text>
      </sentence>
      <sentence>
        <offset>317</offset>
        <text>Previous data from our groups and from others point to the sodium/potassium pump (the Na+/K+-ATPase, i.e., NaK) with its highly specific ligands (i.e., cardiotonic steroids) as a new target for combating cancers associated with dismal prognoses, including gliomas, melanomas, non-small cell lung cancers, renal cell carcinomas, and colon cancers.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="376" length="6"/>
          <text>sodium</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">potassium</infon>
          <location offset="383" length="9"/>
          <text>potassium</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na+</infon>
          <location offset="403" length="3"/>
          <text>Na+</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k+</infon>
          <location offset="407" length="2"/>
          <text>K+</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nak</infon>
          <location offset="424" length="3"/>
          <text>NaK</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroids</infon>
          <location offset="481" length="8"/>
          <text>steroids</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sodium/potassium pump</infon>
          <location offset="376" length="21"/>
          <text>sodium/potassium pump</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na+/k+-atpase</infon>
          <location offset="403" length="13"/>
          <text>Na+/K+-ATPase</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nak</infon>
          <location offset="424" length="3"/>
          <text>NaK</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>664</offset>
        <text>Cardiotonic steroid-mediated Na+/K+-ATPase targeting could circumvent various resistance pathways.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na+</infon>
          <location offset="693" length="3"/>
          <text>Na+</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k+</infon>
          <location offset="697" length="2"/>
          <text>K+</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na+/k+-atpase</infon>
          <location offset="693" length="13"/>
          <text>Na+/K+-ATPase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>763</offset>
        <text>The most probable pathways include the involvement of Na+/K+-ATPase β subunits in invasion features and Na+/K+-ATPase α subunits in chemosensitisation by specific cardiotonic steroid-mediated apoptosis and anoïkis-sensitisation; the regulation of the expression of multidrug resistant-related genes; post-translational regulation, including glycosylation and ubiquitinylation of multidrug resistant-related proteins; c-Myc downregulation; hypoxia-inducible factor downregulation; NF-κB downregulation and deactivation; the inhibition of the glycolytic pathway with a reduction of intra-cellular ATP levels and an induction of non-apoptotic cell death.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="1358" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na+</infon>
          <location offset="817" length="3"/>
          <text>Na+</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k+</infon>
          <location offset="821" length="2"/>
          <text>K+</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na+</infon>
          <location offset="867" length="3"/>
          <text>Na+</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k+</infon>
          <location offset="871" length="2"/>
          <text>K+</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="938" length="7"/>
          <text>steroid</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-myc</infon>
          <location offset="1180" length="5"/>
          <text>c-Myc</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hypoxia-inducible factor</infon>
          <location offset="1202" length="24"/>
          <text>hypoxia-inducible factor</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="1243" length="5"/>
          <text>NF-κB</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na+/k+-atpase β</infon>
          <location offset="817" length="15"/>
          <text>Na+/K+-ATPase β</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na+/k+-atpase α</infon>
          <location offset="867" length="15"/>
          <text>Na+/K+-ATPase α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1415</offset>
        <text>The aims of this review are to examine the various molecular pathways by which the NaK targeting can be more deleterious to biologically aggressive cancer cells than to normal cells.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nak</infon>
          <location offset="1498" length="3"/>
          <text>NaK</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nak</infon>
          <location offset="1498" length="3"/>
          <text>NaK</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>2865685</id>
    <passage>
      <offset>0</offset>
      <text>Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart.	The properties of beta 1- and beta 2-adrenoceptors in right and left atria of rat heart, and their roles in mediating chronotropic and inotropic responses to beta-adrenoceptor agonists were examined. [125I](-)pindolol (125IPIN) bound saturably and specifically to a single class of high affinity sites in homogenates of both right and left atria. The k1's for association in right and left atria were 6.5 X 10(9) l/mol-min and 2.3 X 10(9) l/mol-min respectively, while the k-1's for dissociation were 0.20 min-1 and 0.17 min-1. The kinetically determined KD's were 75 pmol/l in right and 30 pmol/l in left atria and were similar to the equilibrium KD's determined from Scatchard analysis of saturation isotherms of specific 125IPIN binding. Inhibition of 125IPIN binding by beta-adrenoceptor antagonists was stereoselective and the order of potency was timolol greater than l-propranolol greater than d-propranolol greater than sotalol. Inhibition by beta 1- and beta 2-adrenoceptor subtype selective antagonists yielded flat displacement curves with low Hill coefficients. Nonlinear regression analysis of displacement by beta 1-selective (practolol, atenolol and metoprolol) and beta 2-selective (ICI 118,551) antagonists gave estimates of the proportion of beta 1- and beta 2-adrenoceptors present in rat atria. Right atria contained 67 +/- 4.2% beta 1- and 33 +/- 4.2% beta 2-adrenoceptors, while left atria contained 67 +/- 2.8% beta 1- and 33 +/- 2.8% beta 2-adrenoceptors. Increases in the rate of spontaneously beating right atria and the force of electrically driven left atria caused by beta-adrenoceptor agonists were also measured. pA2 values for non-subtype selective beta-adrenoceptor antagonists in inhibiting isoprenaline-induced increases in rate and force were highly correlated with KD values determined for specific 125IPIN binding. pA2 values for beta 1- and beta 2-selective antagonists in inhibiting isoprenaline-induced increases in rate and force correlated well with the pKD values of these drugs in binding to beta 1-adrenoceptors, but not with the pKD values in binding to beta 2-adrenoceptors. Dose-response curves for stimulation of both rate and force by the beta 2-selective agonists procaterol and zinterol were shifted to a much greater extent by selective blockade of beta 1-adrenoceptors with metoprolol than by selective blockade of beta 2-adrenoceptors with ICI 118,551, suggesting that these compounds caused their effects by activating beta 1-adrenoceptors.(ABSTRACT TRUNCATED AT 400 WORDS)</text>
      <sentence>
        <offset>0</offset>
        <text>Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart.</text>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta 1- and beta 2-adrenoceptor</infon>
          <location offset="0" length="31"/>
          <text>Beta 1- and beta 2-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>102</offset>
        <text>The properties of beta 1- and beta 2-adrenoceptors in right and left atria of rat heart, and their roles in mediating chronotropic and inotropic responses to beta-adrenoceptor agonists were examined.</text>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenoceptor</infon>
          <location offset="260" length="17"/>
          <text>beta-adrenoceptor</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta 1- and beta 2-adrenoceptors</infon>
          <location offset="120" length="32"/>
          <text>beta 1- and beta 2-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>302</offset>
        <text>[125I](-)pindolol (125IPIN) bound saturably and specifically to a single class of high affinity sites in homogenates of both right and left atria.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[125i](-)pindolol</infon>
          <location offset="302" length="17"/>
          <text>[125I](-)pindolol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">125ipin</infon>
          <location offset="321" length="7"/>
          <text>125IPIN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>449</offset>
        <text>The k1's for association in right and left atria were 6.5 X 10(9) l/mol-min and 2.3 X 10(9) l/mol-min respectively, while the k-1's for dissociation were 0.20 min-1 and 0.17 min-1.</text>
      </sentence>
      <sentence>
        <offset>630</offset>
        <text>The kinetically determined KD's were 75 pmol/l in right and 30 pmol/l in left atria and were similar to the equilibrium KD's determined from Scatchard analysis of saturation isotherms of specific 125IPIN binding.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">125ipin</infon>
          <location offset="826" length="7"/>
          <text>125IPIN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>843</offset>
        <text>Inhibition of 125IPIN binding by beta-adrenoceptor antagonists was stereoselective and the order of potency was timolol greater than l-propranolol greater than d-propranolol greater than sotalol.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">125ipin</infon>
          <location offset="857" length="7"/>
          <text>125IPIN</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-propranolol</infon>
          <location offset="976" length="13"/>
          <text>l-propranolol</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-propranolol</infon>
          <location offset="1003" length="13"/>
          <text>d-propranolol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1039</offset>
        <text>Inhibition by beta 1- and beta 2-adrenoceptor subtype selective antagonists yielded flat displacement curves with low Hill coefficients.</text>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta 1- and beta 2-adrenoceptor</infon>
          <location offset="1053" length="31"/>
          <text>beta 1- and beta 2-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1176</offset>
        <text>Nonlinear regression analysis of displacement by beta 1-selective (practolol, atenolol and metoprolol) and beta 2-selective (ICI 118,551) antagonists gave estimates of the proportion of beta 1- and beta 2-adrenoceptors present in rat atria.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">practolol</infon>
          <location offset="1243" length="9"/>
          <text>practolol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atenolol</infon>
          <location offset="1254" length="8"/>
          <text>atenolol</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metoprolol</infon>
          <location offset="1267" length="10"/>
          <text>metoprolol</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici 118,551</infon>
          <location offset="1301" length="11"/>
          <text>ICI 118,551</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta 1- and beta 2-adrenoceptors</infon>
          <location offset="1362" length="32"/>
          <text>beta 1- and beta 2-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1417</offset>
        <text>Right atria contained 67 +/- 4.2% beta 1- and 33 +/- 4.2% beta 2-adrenoceptors, while left atria contained 67 +/- 2.8% beta 1- and 33 +/- 2.8% beta 2-adrenoceptors.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptors</infon>
          <location offset="1475" length="20"/>
          <text>beta 2-adrenoceptors</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptors</infon>
          <location offset="1560" length="20"/>
          <text>beta 2-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1582</offset>
        <text>Increases in the rate of spontaneously beating right atria and the force of electrically driven left atria caused by beta-adrenoceptor agonists were also measured.</text>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenoceptor</infon>
          <location offset="1699" length="17"/>
          <text>beta-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1746</offset>
        <text>pA2 values for non-subtype selective beta-adrenoceptor antagonists in inhibiting isoprenaline-induced increases in rate and force were highly correlated with KD values determined for specific 125IPIN binding.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoprenaline</infon>
          <location offset="1827" length="12"/>
          <text>isoprenaline</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">125ipin</infon>
          <location offset="1938" length="7"/>
          <text>125IPIN</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenoceptor</infon>
          <location offset="1783" length="17"/>
          <text>beta-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1955</offset>
        <text>pA2 values for beta 1- and beta 2-selective antagonists in inhibiting isoprenaline-induced increases in rate and force correlated well with the pKD values of these drugs in binding to beta 1-adrenoceptors, but not with the pKD values in binding to beta 2-adrenoceptors.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoprenaline</infon>
          <location offset="2025" length="12"/>
          <text>isoprenaline</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 1-adrenoceptors</infon>
          <location offset="2139" length="20"/>
          <text>beta 1-adrenoceptors</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptors</infon>
          <location offset="2203" length="20"/>
          <text>beta 2-adrenoceptors</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2225</offset>
        <text>Dose-response curves for stimulation of both rate and force by the beta 2-selective agonists procaterol and zinterol were shifted to a much greater extent by selective blockade of beta 1-adrenoceptors with metoprolol than by selective blockade of beta 2-adrenoceptors with ICI 118,551, suggesting that these compounds caused their effects by activating beta 1-adrenoceptors.(ABSTRACT TRUNCATED AT 400 WORDS)</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">procaterol</infon>
          <location offset="2318" length="10"/>
          <text>procaterol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinterol</infon>
          <location offset="2333" length="8"/>
          <text>zinterol</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici 118,551</infon>
          <location offset="2498" length="11"/>
          <text>ICI 118,551</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 1-adrenoceptors</infon>
          <location offset="2405" length="20"/>
          <text>beta 1-adrenoceptors</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptors</infon>
          <location offset="2472" length="20"/>
          <text>beta 2-adrenoceptors</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 1-adrenoceptors</infon>
          <location offset="2578" length="20"/>
          <text>beta 1-adrenoceptors</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23277230</id>
    <passage>
      <offset>0</offset>
      <text>Fisetin averts oxidative stress in pancreatic tissues of streptozotocin-induced diabetic rats.	Persistent hyperglycemia is associated with chronic oxidative stress which contributes to the development and progression of diabetes-associated complications. The sensitivity of pancreatic β-cells to oxidative stress has been attributed to their low content of antioxidants compared with other tissues. Bioactive compounds with potent antidiabetic properties have been shown to ameliorate hyperglycemia mediated oxidative stress. Recently, we have reported that oral administration of fisetin (10 mg/Kg b.w.), a bioflavonoid found to be present in strawberries, persimmon, to STZ-induced experimental diabetic rats significantly improved normoglycemia. The present study was aimed to evaluate the antioxidant potential of fisetin in both in vitro and in vivo. Diabetes was induced by single intraperitoneal injection of streptozotocin (50 mg/kg body weight). Fisetin was administered orally for 30 days. At the end of the study, all animals were killed. Blood samples were collected for the biochemical estimations. The antioxidant status was evaluated. Histological examinations were performed on pancreatic tissues. Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin. The treatment also improved the antioxidant status in pancreas as well as plasma of diabetic rats indicating the antioxidant potential of fisetin. In addition, the results of DPPH and ABTS assays substantiate the free radical scavenging activity of fisetin. Histological studies of the pancreas also evidenced the tissue protective nature of fisetin. It is concluded that, fisetin possesses antioxidant and anti-inflammatory property and may be considered as an adjunct for the treatment of diabetes.</text>
      <sentence>
        <offset>0</offset>
        <text>Fisetin averts oxidative stress in pancreatic tissues of streptozotocin-induced diabetic rats.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="0" length="7"/>
          <text>Fisetin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">streptozotocin</infon>
          <location offset="57" length="14"/>
          <text>streptozotocin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>95</offset>
        <text>Persistent hyperglycemia is associated with chronic oxidative stress which contributes to the development and progression of diabetes-associated complications.</text>
      </sentence>
      <sentence>
        <offset>255</offset>
        <text>The sensitivity of pancreatic β-cells to oxidative stress has been attributed to their low content of antioxidants compared with other tissues.</text>
      </sentence>
      <sentence>
        <offset>399</offset>
        <text>Bioactive compounds with potent antidiabetic properties have been shown to ameliorate hyperglycemia mediated oxidative stress.</text>
      </sentence>
      <sentence>
        <offset>526</offset>
        <text>Recently, we have reported that oral administration of fisetin (10 mg/Kg b.w.), a bioflavonoid found to be present in strawberries, persimmon, to STZ-induced experimental diabetic rats significantly improved normoglycemia.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="581" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bioflavonoid</infon>
          <location offset="608" length="12"/>
          <text>bioflavonoid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">stz</infon>
          <location offset="672" length="3"/>
          <text>STZ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>749</offset>
        <text>The present study was aimed to evaluate the antioxidant potential of fisetin in both in vitro and in vivo.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="818" length="7"/>
          <text>fisetin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>856</offset>
        <text>Diabetes was induced by single intraperitoneal injection of streptozotocin (50 mg/kg body weight).</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">streptozotocin</infon>
          <location offset="916" length="14"/>
          <text>streptozotocin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>955</offset>
        <text>Fisetin was administered orally for 30 days.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="955" length="7"/>
          <text>Fisetin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1000</offset>
        <text>At the end of the study, all animals were killed.</text>
      </sentence>
      <sentence>
        <offset>1050</offset>
        <text>Blood samples were collected for the biochemical estimations.</text>
      </sentence>
      <sentence>
        <offset>1112</offset>
        <text>The antioxidant status was evaluated.</text>
      </sentence>
      <sentence>
        <offset>1150</offset>
        <text>Histological examinations were performed on pancreatic tissues.</text>
      </sentence>
      <sentence>
        <offset>1214</offset>
        <text>Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="1214" length="7"/>
          <text>Fisetin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1284" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="1381" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">no</infon>
          <location offset="1395" length="2"/>
          <text>NO</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glycosylated hemoglobin</infon>
          <location offset="1293" length="23"/>
          <text>glycosylated hemoglobin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hba1c</infon>
          <location offset="1318" length="5"/>
          <text>HbA1c</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kb</infon>
          <location offset="1326" length="5"/>
          <text>NF-kB</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="1332" length="3"/>
          <text>p65</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-1β</infon>
          <location offset="1359" length="5"/>
          <text>IL-1β</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1427" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1436</offset>
        <text>The treatment also improved the antioxidant status in pancreas as well as plasma of diabetic rats indicating the antioxidant potential of fisetin.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="1574" length="7"/>
          <text>fisetin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1583</offset>
        <text>In addition, the results of DPPH and ABTS assays substantiate the free radical scavenging activity of fisetin.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dpph</infon>
          <location offset="1611" length="4"/>
          <text>DPPH</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">abts</infon>
          <location offset="1620" length="4"/>
          <text>ABTS</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="1685" length="7"/>
          <text>fisetin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1694</offset>
        <text>Histological studies of the pancreas also evidenced the tissue protective nature of fisetin.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="1778" length="7"/>
          <text>fisetin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1787</offset>
        <text>It is concluded that, fisetin possesses antioxidant and anti-inflammatory property and may be considered as an adjunct for the treatment of diabetes.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="1809" length="7"/>
          <text>fisetin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23628333</id>
    <passage>
      <offset>0</offset>
      <text>Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase.	A novel 2-thio-6-oxo-1,6-dihydropyrimidine-containing inhibitor of human lactate dehydrogenase (LDH) was identified by high-throughput screening (IC50=8.1μM). Biochemical, surface plasmon resonance, and saturation transfer difference NMR experiments indicated that the compound specifically associated with human LDHA in a manner that required simultaneous binding of the NADH co-factor. Structural variation of the screening hit resulted in significant improvements in LDHA biochemical inhibition activity (best IC50=0.48μM). A crystal structure of an optimized compound bound to human LDHA was obtained and explained many of the observed structure-activity relationships.</text>
      <sentence>
        <offset>0</offset>
        <text>Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-thio-6-oxo-1,6-dihydropyrimidines</infon>
          <location offset="30" length="35"/>
          <text>2-thio-6-oxo-1,6-dihydropyrimidines</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="89" length="7"/>
          <text>lactate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human lactate dehydrogenase</infon>
          <location offset="83" length="27"/>
          <text>human lactate dehydrogenase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>112</offset>
        <text>A novel 2-thio-6-oxo-1,6-dihydropyrimidine-containing inhibitor of human lactate dehydrogenase (LDH) was identified by high-throughput screening (IC50=8.1μM).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="185" length="7"/>
          <text>lactate</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-thio-6-oxo-1,6-dihydropyrimidine</infon>
          <location offset="120" length="34"/>
          <text>2-thio-6-oxo-1,6-dihydropyrimidine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human lactate dehydrogenase</infon>
          <location offset="179" length="27"/>
          <text>human lactate dehydrogenase</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldh</infon>
          <location offset="208" length="3"/>
          <text>LDH</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>271</offset>
        <text>Biochemical, surface plasmon resonance, and saturation transfer difference NMR experiments indicated that the compound specifically associated with human LDHA in a manner that required simultaneous binding of the NADH co-factor.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadh</infon>
          <location offset="484" length="4"/>
          <text>NADH</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human ldha</infon>
          <location offset="419" length="10"/>
          <text>human LDHA</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T6" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>500</offset>
        <text>Structural variation of the screening hit resulted in significant improvements in LDHA biochemical inhibition activity (best IC50=0.48μM).</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldha</infon>
          <location offset="582" length="4"/>
          <text>LDHA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>639</offset>
        <text>A crystal structure of an optimized compound bound to human LDHA was obtained and explained many of the observed structure-activity relationships.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human ldha</infon>
          <location offset="693" length="10"/>
          <text>human LDHA</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15814851</id>
    <passage>
      <offset>0</offset>
      <text>Aromatase inhibitors in the treatment of breast cancer.	Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P450 enzyme complex called aromatase. Aromatase is present in breast tissue, and intratumoral aromatase is the source of local estrogen production in breast cancer tissues. Inhibition of aromatase is an important approach for reducing growth-stimulatory effects of estrogens in estrogen-dependent breast cancer. Steroidal inhibitors that have been developed to date build upon the basic androstenedione nucleus and incorporate chemical substituents at varying positions on the steroid. Nonsteroidal aromatase inhibitors can be divided into three classes: aminoglutethimide-like molecules, imidazole/triazole derivatives, and flavonoid analogs. Mechanism-based aromatase inhibitors are steroidal inhibitors that mimic the substrate, are converted by the enzyme to a reactive intermediate, and result in the inactivation of aromatase. Both steroidal and nonsteroidal aromatase inhibitors have shown clinical efficacy in the treatment of breast cancer. The potent and selective third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, were introduced into the market as endocrine therapy in postmenopausal patients failing antiestrogen therapy alone or multiple hormonal therapies. These agents are currently approved as first-line therapy for the treatment of postmenopausal women with metastatic estrogen-dependent breast cancer. Several clinical studies of aromatase inhibitors are currently focusing on the use of these agents in the adjuvant setting for the treatment of early breast cancer. Use of an aromatase inhibitor as initial therapy or after treatment with tamoxifen is now recommended as adjuvant hormonal therapy for a postmenopausal woman with hormone-dependent breast cancer.</text>
      <sentence>
        <offset>0</offset>
        <text>Aromatase inhibitors in the treatment of breast cancer.</text>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="0" length="9"/>
          <text>Aromatase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>56</offset>
        <text>Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P450 enzyme complex called aromatase.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estradiol</infon>
          <location offset="56" length="9"/>
          <text>Estradiol</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="94" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgens</infon>
          <location offset="127" length="9"/>
          <text>androgens</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="182" length="9"/>
          <text>aromatase</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450</infon>
          <location offset="144" length="15"/>
          <text>cytochrome P450</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T17" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T17" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>193</offset>
        <text>Aromatase is present in breast tissue, and intratumoral aromatase is the source of local estrogen production in breast cancer tissues.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="282" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="193" length="9"/>
          <text>Aromatase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="249" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T7" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>328</offset>
        <text>Inhibition of aromatase is an important approach for reducing growth-stimulatory effects of estrogens in estrogen-dependent breast cancer.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogens</infon>
          <location offset="420" length="9"/>
          <text>estrogens</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="433" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="342" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T9" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>467</offset>
        <text>Steroidal inhibitors that have been developed to date build upon the basic androstenedione nucleus and incorporate chemical substituents at varying positions on the steroid.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroidal</infon>
          <location offset="467" length="9"/>
          <text>Steroidal</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androstenedione</infon>
          <location offset="542" length="15"/>
          <text>androstenedione</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="632" length="7"/>
          <text>steroid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>641</offset>
        <text>Nonsteroidal aromatase inhibitors can be divided into three classes: aminoglutethimide-like molecules, imidazole/triazole derivatives, and flavonoid analogs.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aminoglutethimide</infon>
          <location offset="710" length="17"/>
          <text>aminoglutethimide</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imidazole</infon>
          <location offset="744" length="9"/>
          <text>imidazole</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triazole</infon>
          <location offset="754" length="8"/>
          <text>triazole</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flavonoid</infon>
          <location offset="780" length="9"/>
          <text>flavonoid</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="654" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>799</offset>
        <text>Mechanism-based aromatase inhibitors are steroidal inhibitors that mimic the substrate, are converted by the enzyme to a reactive intermediate, and result in the inactivation of aromatase.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroidal</infon>
          <location offset="840" length="9"/>
          <text>steroidal</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="977" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>988</offset>
        <text>Both steroidal and nonsteroidal aromatase inhibitors have shown clinical efficacy in the treatment of breast cancer.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroidal</infon>
          <location offset="993" length="9"/>
          <text>steroidal</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="1020" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1105</offset>
        <text>The potent and selective third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, were introduced into the market as endocrine therapy in postmenopausal patients failing antiestrogen therapy alone or multiple hormonal therapies.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anastrozole</infon>
          <location offset="1169" length="11"/>
          <text>anastrozole</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">letrozole</infon>
          <location offset="1182" length="9"/>
          <text>letrozole</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">exemestane</infon>
          <location offset="1197" length="10"/>
          <text>exemestane</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="1147" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1356</offset>
        <text>These agents are currently approved as first-line therapy for the treatment of postmenopausal women with metastatic estrogen-dependent breast cancer.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="1472" length="8"/>
          <text>estrogen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1506</offset>
        <text>Several clinical studies of aromatase inhibitors are currently focusing on the use of these agents in the adjuvant setting for the treatment of early breast cancer.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="1534" length="9"/>
          <text>aromatase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1671</offset>
        <text>Use of an aromatase inhibitor as initial therapy or after treatment with tamoxifen is now recommended as adjuvant hormonal therapy for a postmenopausal woman with hormone-dependent breast cancer.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="1744" length="9"/>
          <text>tamoxifen</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="1681" length="9"/>
          <text>aromatase</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23223177</id>
    <passage>
      <offset>0</offset>
      <text>Dissociation of Bcl-2-Beclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes.	Diabetic cardiomyopathy is associated with suppression of cardiac autophagy, and activation of AMP-activated protein kinase (AMPK) restores cardiac autophagy and prevents cardiomyopathy in diabetic mice, albeit by an unknown mechanism. We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high glucose-treated H9c2 cardiac myoblast cells. Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2. Conversely, activation of AMPK by metformin stimulated JNK1-Bcl-2 signaling and disrupted the Beclin1-Bcl-2 complex. Activation of AMPK, which normalized cardiac autophagy, attenuated high glucose-induced apoptosis in cultured H9c2 cells. This effect was attenuated by inhibition of autophagy. Finally, chronic administration of metformin in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating Beclin1 and Bcl-2. The induction of autophagy protected against cardiac apoptosis and improved cardiac structure and function in diabetic mice. We concluded that dissociation of Bcl-2 from Beclin1 may be an important mechanism for preventing diabetic cardiomyopathy via AMPK activation that restores autophagy and protects against cardiac apoptosis.</text>
      <sentence>
        <offset>0</offset>
        <text>Dissociation of Bcl-2-Beclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes.</text>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="16" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beclin1</infon>
          <location offset="22" length="7"/>
          <text>Beclin1</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ampk</infon>
          <location offset="51" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>141</offset>
        <text>Diabetic cardiomyopathy is associated with suppression of cardiac autophagy, and activation of AMP-activated protein kinase (AMPK) restores cardiac autophagy and prevents cardiomyopathy in diabetic mice, albeit by an unknown mechanism.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="236" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ampk</infon>
          <location offset="266" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">amp-activated protein kinase</infon>
          <location offset="236" length="28"/>
          <text>AMP-activated protein kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>377</offset>
        <text>We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high glucose-treated H9c2 cardiac myoblast cells.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="642" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="398" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="523" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beclin1</infon>
          <location offset="555" length="7"/>
          <text>Beclin1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="567" length="5"/>
          <text>Bcl-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>687</offset>
        <text>Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="718" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nh2</infon>
          <location offset="763" length="3"/>
          <text>NH2</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ampk</infon>
          <location offset="734" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">jun nh2-terminal kinase 1</infon>
          <location offset="759" length="25"/>
          <text>Jun NH2-terminal kinase 1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">jnk1</infon>
          <location offset="786" length="4"/>
          <text>JNK1</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">b-cell lymphoma 2</infon>
          <location offset="792" length="17"/>
          <text>B-cell lymphoma 2</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="811" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beclin1</infon>
          <location offset="842" length="7"/>
          <text>Beclin1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="861" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>868</offset>
        <text>Conversely, activation of AMPK by metformin stimulated JNK1-Bcl-2 signaling and disrupted the Beclin1-Bcl-2 complex.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ampk</infon>
          <location offset="894" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">jnk1</infon>
          <location offset="923" length="4"/>
          <text>JNK1</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="928" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beclin1</infon>
          <location offset="962" length="7"/>
          <text>Beclin1</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="970" length="5"/>
          <text>Bcl-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>985</offset>
        <text>Activation of AMPK, which normalized cardiac autophagy, attenuated high glucose-induced apoptosis in cultured H9c2 cells.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1057" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ampk</infon>
          <location offset="999" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1107</offset>
        <text>This effect was attenuated by inhibition of autophagy.</text>
      </sentence>
      <sentence>
        <offset>1162</offset>
        <text>Finally, chronic administration of metformin in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating Beclin1 and Bcl-2.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="1197" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">jnk1</infon>
          <location offset="1265" length="4"/>
          <text>JNK1</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="1270" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beclin1</infon>
          <location offset="1302" length="7"/>
          <text>Beclin1</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="1314" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1321</offset>
        <text>The induction of autophagy protected against cardiac apoptosis and improved cardiac structure and function in diabetic mice.</text>
      </sentence>
      <sentence>
        <offset>1446</offset>
        <text>We concluded that dissociation of Bcl-2 from Beclin1 may be an important mechanism for preventing diabetic cardiomyopathy via AMPK activation that restores autophagy and protects against cardiac apoptosis.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="1480" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beclin1</infon>
          <location offset="1491" length="7"/>
          <text>Beclin1</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="1572" length="4"/>
          <text>AMPK</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23629517</id>
    <passage>
      <offset>0</offset>
      <text>COMPLETE ARTIFICIAL SALIVA ALTERS EXPRESSION OF PROINFLAMMATORY CYTOKINES IN HUMAN DERMAL FIBROBLASTS.	Complete artificial saliva (CAS) is a saliva substitute often used as a vehicle for test articles, including smokeless tobacco products. In the course of a study employing normal adult human dermal fibroblasts (HDFa) as a model in vitro, we discovered that CAS as a vehicle introduced a significant change in the expression of proinflammatory cytokines. To determine the effects of CAS on gene expression, real-time quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) gene array analysis was used. Results indicate that robust changes in the expression of the proinflammatory cytokine interleukin 8 (IL8) and the vascular cell adhesion molecule 1 (VCAM1) occur within 5 hours of exposure to CAS. To determine whether CAS also alters cytokine release into the culture media, cytometric bead array (CBA) assays for human inflammatory cytokines were performed. Analysis shows that CAS induced the release of IL8 and interleukin 6 (IL6). This study focused on determining which components in CAS were responsible for the proinflammatory response in HDFa. The following components were investigated: α-amylase, lysozyme, acid phosphatase, and urea. Results demonstrated that enzymatically active α-amylase induced gene expression for proinflammatory cytokines IL8, IL6, tumor necrosis factor-α (TNFα), and interleukin 1α (IL1α), and for VCAM1. Therefore, it is important to carefully evaluate the "vehicle effects" of CAS and its components in in vitro toxicology research.</text>
      <sentence>
        <offset>0</offset>
        <text>COMPLETE ARTIFICIAL SALIVA ALTERS EXPRESSION OF PROINFLAMMATORY CYTOKINES IN HUMAN DERMAL FIBROBLASTS.</text>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="64" length="9"/>
          <text>CYTOKINES</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>103</offset>
        <text>Complete artificial saliva (CAS) is a saliva substitute often used as a vehicle for test articles, including smokeless tobacco products.</text>
      </sentence>
      <sentence>
        <offset>240</offset>
        <text>In the course of a study employing normal adult human dermal fibroblasts (HDFa) as a model in vitro, we discovered that CAS as a vehicle introduced a significant change in the expression of proinflammatory cytokines.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="446" length="9"/>
          <text>cytokines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>457</offset>
        <text>To determine the effects of CAS on gene expression, real-time quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) gene array analysis was used.</text>
      </sentence>
      <sentence>
        <offset>620</offset>
        <text>Results indicate that robust changes in the expression of the proinflammatory cytokine interleukin 8 (IL8) and the vascular cell adhesion molecule 1 (VCAM1) occur within 5 hours of exposure to CAS.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine</infon>
          <location offset="698" length="8"/>
          <text>cytokine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin 8</infon>
          <location offset="707" length="13"/>
          <text>interleukin 8</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il8</infon>
          <location offset="722" length="3"/>
          <text>IL8</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vascular cell adhesion molecule 1</infon>
          <location offset="735" length="33"/>
          <text>vascular cell adhesion molecule 1</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vcam1</infon>
          <location offset="770" length="5"/>
          <text>VCAM1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>818</offset>
        <text>To determine whether CAS also alters cytokine release into the culture media, cytometric bead array (CBA) assays for human inflammatory cytokines were performed.</text>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human inflammatory cytokines</infon>
          <location offset="935" length="28"/>
          <text>human inflammatory cytokines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>980</offset>
        <text>Analysis shows that CAS induced the release of IL8 and interleukin 6 (IL6).</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il8</infon>
          <location offset="1027" length="3"/>
          <text>IL8</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin 6</infon>
          <location offset="1035" length="13"/>
          <text>interleukin 6</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il6</infon>
          <location offset="1050" length="3"/>
          <text>IL6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1056</offset>
        <text>This study focused on determining which components in CAS were responsible for the proinflammatory response in HDFa.</text>
      </sentence>
      <sentence>
        <offset>1173</offset>
        <text>The following components were investigated: α-amylase, lysozyme, acid phosphatase, and urea.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">urea</infon>
          <location offset="1260" length="4"/>
          <text>urea</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">α-amylase</infon>
          <location offset="1217" length="9"/>
          <text>α-amylase</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lysozyme</infon>
          <location offset="1228" length="8"/>
          <text>lysozyme</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">acid phosphatase</infon>
          <location offset="1238" length="16"/>
          <text>acid phosphatase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1266</offset>
        <text>Results demonstrated that enzymatically active α-amylase induced gene expression for proinflammatory cytokines IL8, IL6, tumor necrosis factor-α (TNFα), and interleukin 1α (IL1α), and for VCAM1.</text>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">α-amylase</infon>
          <location offset="1313" length="9"/>
          <text>α-amylase</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="1367" length="9"/>
          <text>cytokines</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il8</infon>
          <location offset="1377" length="3"/>
          <text>IL8</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il6</infon>
          <location offset="1382" length="3"/>
          <text>IL6</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor-α</infon>
          <location offset="1387" length="23"/>
          <text>tumor necrosis factor-α</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnfα</infon>
          <location offset="1412" length="4"/>
          <text>TNFα</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin 1α</infon>
          <location offset="1423" length="14"/>
          <text>interleukin 1α</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il1α</infon>
          <location offset="1439" length="4"/>
          <text>IL1α</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vcam1</infon>
          <location offset="1454" length="5"/>
          <text>VCAM1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1461</offset>
        <text>Therefore, it is important to carefully evaluate the "vehicle effects" of CAS and its components in in vitro toxicology research.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23301860</id>
    <passage>
      <offset>0</offset>
      <text>Single-walled carbon nanotube surface control of complement recognition and activation.	Carbon nanotubes (CNTs) are receiving considerable attention in site-specific drug and nucleic acid delivery, photodynamic therapy, and photoacoustic molecular imaging. Despite these advances, nanotubes may activate the complement system (an integral part of innate immunity), which can induce clinically significant anaphylaxis. We demonstrate that single-walled CNTs coated with human serum albumin activate the complement system through C1q-mediated classical and the alternative pathways. Surface coating with methoxypoly(ethylene glycol)-based amphiphiles, which confers solubility and prolongs circulation profiles of CNTs, activates the complement system differently, depending on the amphiphile structure. CNTs with linear poly(ethylene glycol) amphiphiles trigger the lectin pathway of the complement through both L-ficolin and mannan-binding lectin recognition. The lectin pathway activation, however, did not trigger the amplification loop of the alternative pathway. An amphiphile with branched poly(ethylene glycol) architecture also activated the lectin pathway but only through L-ficolin recognition. Importantly, this mode of activation neither generated anaphylatoxins nor induced triggering of the effector arm of the complement system. These observations provide a major step toward nanomaterial surface modification with polymers that have the properties to significantly improve innate immunocompatibility by limiting the formation of complement C3 and C5 convertases.</text>
      <sentence>
        <offset>0</offset>
        <text>Single-walled carbon nanotube surface control of complement recognition and activation.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbon</infon>
          <location offset="14" length="6"/>
          <text>carbon</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>88</offset>
        <text>Carbon nanotubes (CNTs) are receiving considerable attention in site-specific drug and nucleic acid delivery, photodynamic therapy, and photoacoustic molecular imaging.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbon</infon>
          <location offset="88" length="6"/>
          <text>Carbon</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>257</offset>
        <text>Despite these advances, nanotubes may activate the complement system (an integral part of innate immunity), which can induce clinically significant anaphylaxis.</text>
      </sentence>
      <sentence>
        <offset>418</offset>
        <text>We demonstrate that single-walled CNTs coated with human serum albumin activate the complement system through C1q-mediated classical and the alternative pathways.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human serum albumin</infon>
          <location offset="469" length="19"/>
          <text>human serum albumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>581</offset>
        <text>Surface coating with methoxypoly(ethylene glycol)-based amphiphiles, which confers solubility and prolongs circulation profiles of CNTs, activates the complement system differently, depending on the amphiphile structure.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methoxypoly(ethylene glycol)</infon>
          <location offset="602" length="28"/>
          <text>methoxypoly(ethylene glycol)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>802</offset>
        <text>CNTs with linear poly(ethylene glycol) amphiphiles trigger the lectin pathway of the complement through both L-ficolin and mannan-binding lectin recognition.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">poly(ethylene glycol)</infon>
          <location offset="819" length="21"/>
          <text>poly(ethylene glycol)</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lectin</infon>
          <location offset="865" length="6"/>
          <text>lectin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lectin</infon>
          <location offset="940" length="6"/>
          <text>lectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>960</offset>
        <text>The lectin pathway activation, however, did not trigger the amplification loop of the alternative pathway.</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lectin</infon>
          <location offset="964" length="6"/>
          <text>lectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1067</offset>
        <text>An amphiphile with branched poly(ethylene glycol) architecture also activated the lectin pathway but only through L-ficolin recognition.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">poly(ethylene glycol)</infon>
          <location offset="1095" length="21"/>
          <text>poly(ethylene glycol)</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lectin</infon>
          <location offset="1149" length="6"/>
          <text>lectin</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T6" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1204</offset>
        <text>Importantly, this mode of activation neither generated anaphylatoxins nor induced triggering of the effector arm of the complement system.</text>
      </sentence>
      <sentence>
        <offset>1343</offset>
        <text>These observations provide a major step toward nanomaterial surface modification with polymers that have the properties to significantly improve innate immunocompatibility by limiting the formation of complement C3 and C5 convertases.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c3 and c5 convertases</infon>
          <location offset="1555" length="21"/>
          <text>C3 and C5 convertases</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23557993</id>
    <passage>
      <offset>0</offset>
      <text>A diarylheptanoid phytoestrogen from Curcuma comosa, 1,7-diphenyl-4,6-heptadien-3-ol, accelerates human osteoblast proliferation and differentiation.	Curcuma comosa Roxb. is ginger-family plant used to relieve menopausal symptoms. Previous work showed that C. comosa extracts protect mice from ovariectomy-induced osteopenia with minimal effects on reproductive organs, and identified the diarylheptanoid (3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-ol (DPHD) as the major active component of C. comosa rhizomes. At 1-10μM, DPHD increased differentiation in transformed mouse osteoblasts, but the effect of DPHD on normal bone cells was unknown. We examined the concentration dependency and mechanism of action of DPHD relative to 17β-estradiol in nontransformed human osteoblasts (h-OB). The h-OB were 10-100 fold more sensitive to DPHD than transformed osteoblasts: DPHD increased h-OB proliferation at 10nM and, at 100nM, activated MAP kinase signaling within 30min. In long-term differentiation assays, responses of h-OB to DPHD were significant at 10nM, and optimal response in most cases was at 100nM. At 7-21 days, DPHD accelerated osteoblast differentiation, indicated by alkaline phosphatase activity and osteoblast-specific mRNA production. Effects of DPHD were eliminated by the estrogen receptor antagonist ICI182780. During differentiation, DPHD promoted early expression of osteoblast transcription factors, RUNX2 and osterix. Subsequently, DPHD accelerated production of bone structural genes, including COL1A1 and osteocalcin comparably to 17β-estradiol. In h-OB, DPHD increased the osteoprotegerin to RANKL ratio and supported mineralization more efficiently than 10nM 17β-estradiol. We conclude that DPHD promotes human osteoblast function in vitro effectively at nanomolar concentrations, making it a promising compound to protect bone in menopausal women.</text>
      <sentence>
        <offset>0</offset>
        <text>A diarylheptanoid phytoestrogen from Curcuma comosa, 1,7-diphenyl-4,6-heptadien-3-ol, accelerates human osteoblast proliferation and differentiation.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diarylheptanoid</infon>
          <location offset="2" length="15"/>
          <text>diarylheptanoid</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1,7-diphenyl-4,6-heptadien-3-ol</infon>
          <location offset="53" length="31"/>
          <text>1,7-diphenyl-4,6-heptadien-3-ol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>150</offset>
        <text>Curcuma comosa Roxb. is ginger-family plant used to relieve menopausal symptoms.</text>
      </sentence>
      <sentence>
        <offset>231</offset>
        <text>Previous work showed that C. comosa extracts protect mice from ovariectomy-induced osteopenia with minimal effects on reproductive organs, and identified the diarylheptanoid (3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-ol (DPHD) as the major active component of C. comosa rhizomes.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diarylheptanoid</infon>
          <location offset="389" length="15"/>
          <text>diarylheptanoid</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(3r)-1,7-diphenyl-(4e,6e)-4,6-heptadien-3-ol</infon>
          <location offset="405" length="44"/>
          <text>(3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-ol</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="451" length="4"/>
          <text>DPHD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>510</offset>
        <text>At 1-10μM, DPHD increased differentiation in transformed mouse osteoblasts, but the effect of DPHD on normal bone cells was unknown.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="521" length="4"/>
          <text>DPHD</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="604" length="4"/>
          <text>DPHD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>643</offset>
        <text>We examined the concentration dependency and mechanism of action of DPHD relative to 17β-estradiol in nontransformed human osteoblasts (h-OB).</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="711" length="4"/>
          <text>DPHD</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">17β-estradiol</infon>
          <location offset="728" length="13"/>
          <text>17β-estradiol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>786</offset>
        <text>The h-OB were 10-100 fold more sensitive to DPHD than transformed osteoblasts: DPHD increased h-OB proliferation at 10nM and, at 100nM, activated MAP kinase signaling within 30min.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="830" length="4"/>
          <text>DPHD</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="865" length="4"/>
          <text>DPHD</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">map kinase</infon>
          <location offset="932" length="10"/>
          <text>MAP kinase</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>967</offset>
        <text>In long-term differentiation assays, responses of h-OB to DPHD were significant at 10nM, and optimal response in most cases was at 100nM.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="1025" length="4"/>
          <text>DPHD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1105</offset>
        <text>At 7-21 days, DPHD accelerated osteoblast differentiation, indicated by alkaline phosphatase activity and osteoblast-specific mRNA production.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="1119" length="4"/>
          <text>DPHD</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alkaline phosphatase</infon>
          <location offset="1177" length="20"/>
          <text>alkaline phosphatase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1248</offset>
        <text>Effects of DPHD were eliminated by the estrogen receptor antagonist ICI182780.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="1259" length="4"/>
          <text>DPHD</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="1287" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici182780</infon>
          <location offset="1316" length="9"/>
          <text>ICI182780</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">estrogen receptor</infon>
          <location offset="1287" length="17"/>
          <text>estrogen receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1327</offset>
        <text>During differentiation, DPHD promoted early expression of osteoblast transcription factors, RUNX2 and osterix.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="1351" length="4"/>
          <text>DPHD</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">runx2</infon>
          <location offset="1419" length="5"/>
          <text>RUNX2</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">osterix</infon>
          <location offset="1429" length="7"/>
          <text>osterix</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1438</offset>
        <text>Subsequently, DPHD accelerated production of bone structural genes, including COL1A1 and osteocalcin comparably to 17β-estradiol.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="1452" length="4"/>
          <text>DPHD</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">17β-estradiol</infon>
          <location offset="1553" length="13"/>
          <text>17β-estradiol</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">col1a1</infon>
          <location offset="1516" length="6"/>
          <text>COL1A1</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">osteocalcin</infon>
          <location offset="1527" length="11"/>
          <text>osteocalcin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1568</offset>
        <text>In h-OB, DPHD increased the osteoprotegerin to RANKL ratio and supported mineralization more efficiently than 10nM 17β-estradiol.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="1577" length="4"/>
          <text>DPHD</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">17β-estradiol</infon>
          <location offset="1683" length="13"/>
          <text>17β-estradiol</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">osteoprotegerin</infon>
          <location offset="1596" length="15"/>
          <text>osteoprotegerin</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rankl</infon>
          <location offset="1615" length="5"/>
          <text>RANKL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1698</offset>
        <text>We conclude that DPHD promotes human osteoblast function in vitro effectively at nanomolar concentrations, making it a promising compound to protect bone in menopausal women.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dphd</infon>
          <location offset="1715" length="4"/>
          <text>DPHD</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12057823</id>
    <passage>
      <offset>0</offset>
      <text>Serotonin transporter polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American cocaine-dependent individuals.	Considerable evidence indicates that serotonergic mechanisms, particularly the serotonin transporter (5HTT), may mediate central effects of cocaine and may also be involved in impulsive and aggressive behavior. We investigated whether polymorphisms in the 5HTT gene were related to traits of impulsivity, sensation seeking, and aggression among cocaine abusers. Standardized measures of these personality traits were obtained in a sample of 105 severely affected cocaine-dependent African-American subjects and 44 African-American controls. Two polymorphisms of the 5HTT gene were examined involving the 5' promoter (5HTTLPR) region and a 17 base pair variable-number-tandem-repeat (VNTR) marker among cocaine patients. No significant relationships were observed between polymorphic variants of the 5HTTLPR and VNTR regions and scores on any of the trait measures. Similarly, demographic variables and measures of severity of substance use and depression were unrelated to allele frequencies or genotype distributions of the variants among cocaine patients. As expected, cocaine patients scored significantly higher on total scores of impulsivity, aggression, and sensation seeking compared to controls. The findings do not seem to support an association between these polymorphisms in the 5HTT gene and impulsive-aggressive traits among cocaine-dependent African-American individuals.</text>
      <sentence>
        <offset>0</offset>
        <text>Serotonin transporter polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American cocaine-dependent individuals.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="0" length="9"/>
          <text>Serotonin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cocaine</infon>
          <location offset="122" length="7"/>
          <text>cocaine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serotonin transporter</infon>
          <location offset="0" length="21"/>
          <text>Serotonin transporter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>153</offset>
        <text>Considerable evidence indicates that serotonergic mechanisms, particularly the serotonin transporter (5HTT), may mediate central effects of cocaine and may also be involved in impulsive and aggressive behavior.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cocaine</infon>
          <location offset="293" length="7"/>
          <text>cocaine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="232" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5htt</infon>
          <location offset="255" length="4"/>
          <text>5HTT</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serotonin transporter</infon>
          <location offset="232" length="21"/>
          <text>serotonin transporter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>364</offset>
        <text>We investigated whether polymorphisms in the 5HTT gene were related to traits of impulsivity, sensation seeking, and aggression among cocaine abusers.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cocaine</infon>
          <location offset="498" length="7"/>
          <text>cocaine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5htt</infon>
          <location offset="409" length="4"/>
          <text>5HTT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>515</offset>
        <text>Standardized measures of these personality traits were obtained in a sample of 105 severely affected cocaine-dependent African-American subjects and 44 African-American controls.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cocaine</infon>
          <location offset="616" length="7"/>
          <text>cocaine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>694</offset>
        <text>Two polymorphisms of the 5HTT gene were examined involving the 5' promoter (5HTTLPR) region and a 17 base pair variable-number-tandem-repeat (VNTR) marker among cocaine patients.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cocaine</infon>
          <location offset="855" length="7"/>
          <text>cocaine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5htt</infon>
          <location offset="719" length="4"/>
          <text>5HTT</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5httlpr</infon>
          <location offset="770" length="7"/>
          <text>5HTTLPR</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">variable-number-tandem-repeat</infon>
          <location offset="805" length="29"/>
          <text>variable-number-tandem-repeat</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vntr</infon>
          <location offset="836" length="4"/>
          <text>VNTR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>873</offset>
        <text>No significant relationships were observed between polymorphic variants of the 5HTTLPR and VNTR regions and scores on any of the trait measures.</text>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5httlpr</infon>
          <location offset="952" length="7"/>
          <text>5HTTLPR</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vntr</infon>
          <location offset="964" length="4"/>
          <text>VNTR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1018</offset>
        <text>Similarly, demographic variables and measures of severity of substance use and depression were unrelated to allele frequencies or genotype distributions of the variants among cocaine patients.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cocaine</infon>
          <location offset="1193" length="7"/>
          <text>cocaine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1211</offset>
        <text>As expected, cocaine patients scored significantly higher on total scores of impulsivity, aggression, and sensation seeking compared to controls.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cocaine</infon>
          <location offset="1224" length="7"/>
          <text>cocaine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1357</offset>
        <text>The findings do not seem to support an association between these polymorphisms in the 5HTT gene and impulsive-aggressive traits among cocaine-dependent African-American individuals.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cocaine</infon>
          <location offset="1491" length="7"/>
          <text>cocaine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5htt</infon>
          <location offset="1443" length="4"/>
          <text>5HTT</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23576111</id>
    <passage>
      <offset>0</offset>
      <text>Protective effects of green tea on antioxidative biomarkers in chemical laboratory workers.	Chemical materials are environmental contaminants, are extensively used in laboratories, and may cause various forms of health hazards in laboratory workers. Therefore, this toxicity most likely is a result of the oxidative metabolism of chemical to reactive products. As green tea (GT) possesses antioxidant effects, the objective of this study was to examine any amelioration oxidative stress in chemical laboratory workers drinking one cup (3 g/300 ml water) of freshly prepared tea once daily. Baseline characteristics including age, sex, smoking, fruit consumption, and duration of exposure were recorded via questionnaire to the subjects. Saliva level oxidative stress parameters such as total antioxidant capacity (TAC), glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD) were estimated before and after consumption of GT in these workers. Treatment of subjects with GT induced a significant reduction in saliva GPx activity (406.61 ± 22.07 vs. 238.96 ± 16.26 U/l p = 0.001) and induction in TAC (0.46 ± 0.029 μmol/ml vs. 0.56 ± 0.031, p = 0.016). No statistically significant alteration was found for saliva SOD (0.080 ± 0.0019 vs. 0.079 ± 0.0014, p &gt; 0.05) and CAT (20.36 ± 0.69 vs. 19.78 ± 0.71, p &gt; 0.05) after 28 days treatment by GT. These results demonstrate that drinking GT during chemical exposure can reduce several parameters indicative of oxidative stress. In conclusion, using GT as a dietary supplement can be a rational protocol to control source of hazards in chemical laboratory workers.</text>
      <sentence>
        <offset>0</offset>
        <text>Protective effects of green tea on antioxidative biomarkers in chemical laboratory workers.</text>
      </sentence>
      <sentence>
        <offset>92</offset>
        <text>Chemical materials are environmental contaminants, are extensively used in laboratories, and may cause various forms of health hazards in laboratory workers.</text>
      </sentence>
      <sentence>
        <offset>250</offset>
        <text>Therefore, this toxicity most likely is a result of the oxidative metabolism of chemical to reactive products.</text>
      </sentence>
      <sentence>
        <offset>361</offset>
        <text>As green tea (GT) possesses antioxidant effects, the objective of this study was to examine any amelioration oxidative stress in chemical laboratory workers drinking one cup (3 g/300 ml water) of freshly prepared tea once daily.</text>
      </sentence>
      <sentence>
        <offset>590</offset>
        <text>Baseline characteristics including age, sex, smoking, fruit consumption, and duration of exposure were recorded via questionnaire to the subjects.</text>
      </sentence>
      <sentence>
        <offset>737</offset>
        <text>Saliva level oxidative stress parameters such as total antioxidant capacity (TAC), glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD) were estimated before and after consumption of GT in these workers.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="820" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="870" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathione peroxidase</infon>
          <location offset="820" length="22"/>
          <text>glutathione peroxidase</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gpx</infon>
          <location offset="844" length="3"/>
          <text>GPx</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catalase</infon>
          <location offset="850" length="8"/>
          <text>catalase</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cat</infon>
          <location offset="860" length="3"/>
          <text>CAT</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">superoxide dismutase</infon>
          <location offset="870" length="20"/>
          <text>superoxide dismutase</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sod</infon>
          <location offset="892" length="3"/>
          <text>SOD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>965</offset>
        <text>Treatment of subjects with GT induced a significant reduction in saliva GPx activity (406.61 ± 22.07 vs. 238.96 ± 16.26 U/l p = 0.001) and induction in TAC (0.46 ± 0.029 μmol/ml vs. 0.56 ± 0.031, p = 0.016).</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gpx</infon>
          <location offset="1037" length="3"/>
          <text>GPx</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1173</offset>
        <text>No statistically significant alteration was found for saliva SOD (0.080 ± 0.0019 vs. 0.079 ± 0.0014, p &gt; 0.05) and CAT (20.36 ± 0.69 vs. 19.78 ± 0.71, p &gt; 0.05) after 28 days treatment by GT.</text>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sod</infon>
          <location offset="1234" length="3"/>
          <text>SOD</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cat</infon>
          <location offset="1288" length="3"/>
          <text>CAT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1365</offset>
        <text>These results demonstrate that drinking GT during chemical exposure can reduce several parameters indicative of oxidative stress.</text>
      </sentence>
      <sentence>
        <offset>1495</offset>
        <text>In conclusion, using GT as a dietary supplement can be a rational protocol to control source of hazards in chemical laboratory workers.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23478800</id>
    <passage>
      <offset>0</offset>
      <text>Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1.	The small GTPase Rac1 has been widely implicated in mammary tumorigenesis and metastasis. Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-guanine nucleotide exchange factor P-Rex1. As the Janus tyrosine kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands. Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells. However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism. Cucurbitacin I also failed to affect the activation of P-Rex1 by heregulin. Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers. Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin. Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS). The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation. In conclusion, these results indicate that ErbB-driven Rac1 activation in breast cancer cells proceeds independently of the Jak2 pathway. Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac.</text>
      <sentence>
        <offset>0</offset>
        <text>Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cucurbitacin i</infon>
          <location offset="0" length="14"/>
          <text>Cucurbitacin I</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="138" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="77" length="6"/>
          <text>oxygen</text>
        </annotation>
        <annotation id="T56">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">janus tyrosine kinase 2</infon>
          <location offset="132" length="23"/>
          <text>janus tyrosine kinase 2</text>
        </annotation>
        <annotation id="T57">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-rex1</infon>
          <location offset="160" length="6"/>
          <text>p-rex1</text>
        </annotation>
        <annotation id="T58">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rac1</infon>
          <location offset="24" length="4"/>
          <text>rac1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T58" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>168</offset>
        <text>The small GTPase Rac1 has been widely implicated in mammary tumorigenesis and metastasis.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gtpase</infon>
          <location offset="178" length="6"/>
          <text>GTPase</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rac1</infon>
          <location offset="185" length="4"/>
          <text>Rac1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>258</offset>
        <text>Previous studies established that stimulation of ErbB receptors in breast cancer cells activates Rac1 and enhances motility via the Rac-guanine nucleotide exchange factor P-Rex1.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">guanine nucleotide</infon>
          <location offset="394" length="18"/>
          <text>guanine nucleotide</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb</infon>
          <location offset="307" length="4"/>
          <text>ErbB</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rac1</infon>
          <location offset="355" length="4"/>
          <text>Rac1</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rac-guanine nucleotide exchange factor</infon>
          <location offset="390" length="38"/>
          <text>Rac-guanine nucleotide exchange factor</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-rex1</infon>
          <location offset="429" length="6"/>
          <text>P-Rex1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>437</offset>
        <text>As the Janus tyrosine kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) pathway has been shown to be functionally associated with ErbB receptors, we asked if this pathway could mediate P-Rex1/Rac1 activation in response to ErbB ligands.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="450" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">janus tyrosine kinase 2</infon>
          <location offset="444" length="23"/>
          <text>Janus tyrosine kinase 2</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">jak2</infon>
          <location offset="469" length="4"/>
          <text>Jak2</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">signal transducer and activator of transcription 3</infon>
          <location offset="475" length="50"/>
          <text>signal transducer and activator of transcription 3</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">stat3</infon>
          <location offset="527" length="5"/>
          <text>Stat3</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb</infon>
          <location offset="592" length="4"/>
          <text>ErbB</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-rex1</infon>
          <location offset="647" length="6"/>
          <text>P-Rex1</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rac1</infon>
          <location offset="654" length="4"/>
          <text>Rac1</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb</infon>
          <location offset="685" length="4"/>
          <text>ErbB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>699</offset>
        <text>Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cucurbitacin i</infon>
          <location offset="739" length="14"/>
          <text>cucurbitacin I</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">jak2</infon>
          <location offset="757" length="4"/>
          <text>Jak2</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rac1</infon>
          <location offset="799" length="4"/>
          <text>Rac1</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb3</infon>
          <location offset="836" length="5"/>
          <text>ErbB3</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">heregulin</infon>
          <location offset="849" length="9"/>
          <text>heregulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>883</offset>
        <text>However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of cucurbitacin I occurs through a Jak2-independent mechanism.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cucurbitacin i</infon>
          <location offset="990" length="14"/>
          <text>cucurbitacin I</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rac1</infon>
          <location offset="892" length="4"/>
          <text>Rac1</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">jak2</infon>
          <location offset="928" length="4"/>
          <text>Jak2</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">stat3</infon>
          <location offset="936" length="5"/>
          <text>Stat3</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">jak2</infon>
          <location offset="1022" length="4"/>
          <text>Jak2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1050</offset>
        <text>Cucurbitacin I also failed to affect the activation of P-Rex1 by heregulin.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cucurbitacin i</infon>
          <location offset="1050" length="14"/>
          <text>Cucurbitacin I</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-rex1</infon>
          <location offset="1105" length="6"/>
          <text>P-Rex1</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">heregulin</infon>
          <location offset="1115" length="9"/>
          <text>heregulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1126</offset>
        <text>Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cucurbitacin i</infon>
          <location offset="1160" length="14"/>
          <text>cucurbitacin I</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="1194" length="4"/>
          <text>RhoA</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rho</infon>
          <location offset="1207" length="3"/>
          <text>Rho</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rho kinase</infon>
          <location offset="1220" length="10"/>
          <text>Rho kinase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rock</infon>
          <location offset="1232" length="4"/>
          <text>ROCK</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1305</offset>
        <text>Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cucurbitacin i</infon>
          <location offset="1391" length="14"/>
          <text>cucurbitacin I</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="1338" length="4"/>
          <text>RhoA</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rock</infon>
          <location offset="1343" length="4"/>
          <text>ROCK</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rac1</infon>
          <location offset="1409" length="4"/>
          <text>Rac1</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">heregulin</infon>
          <location offset="1428" length="9"/>
          <text>heregulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1439</offset>
        <text>Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cucurbitacin i</infon>
          <location offset="1480" length="14"/>
          <text>cucurbitacin I</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="1519" length="6"/>
          <text>oxygen</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="1461" length="4"/>
          <text>RhoA</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1541</offset>
        <text>The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-acetyl l-cysteine</infon>
          <location offset="1559" length="19"/>
          <text>N-acetyl l-cysteine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cucurbitacin i</infon>
          <location offset="1657" length="14"/>
          <text>cucurbitacin I</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rac1</infon>
          <location offset="1675" length="4"/>
          <text>Rac1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1692</offset>
        <text>In conclusion, these results indicate that ErbB-driven Rac1 activation in breast cancer cells proceeds independently of the Jak2 pathway.</text>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb</infon>
          <location offset="1735" length="4"/>
          <text>ErbB</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rac1</infon>
          <location offset="1747" length="4"/>
          <text>Rac1</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">jak2</infon>
          <location offset="1816" length="4"/>
          <text>Jak2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1830</offset>
        <text>Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cucurbitacin i</infon>
          <location offset="1887" length="14"/>
          <text>cucurbitacin I</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rac1</infon>
          <location offset="1905" length="4"/>
          <text>Rac1</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rho</infon>
          <location offset="1966" length="3"/>
          <text>Rho</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rac</infon>
          <location offset="1974" length="3"/>
          <text>Rac</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23530959</id>
    <passage>
      <offset>0</offset>
      <text>Multipart Copolyelectrolyte Adhesive of the Sandcastle Worm, Phragmatopoma californica (Fewkes): Catechol Oxidase Catalyzed Curing through Peptidyl-DOPA.	Tube-building sabellariid polychaetes have major impacts on the geology and ecology of shorelines worldwide. Sandcastle worms, Phragmatopoma californica (Fewkes), live along the western coast of North America. Individual sabellariid worms build tubular shells by gluing together mineral particles with a multipart polyelectrolytic adhesive. Distinct sets of oppositely charged components are packaged and stored in concentrated granules in separate cell types. Homogeneous granules contain sulfated macromolecules as counter-polyanion to polycationic Pc2 and Pc5 proteins, which become major components of the fully cured glue. Heterogeneous granules contain polyphosphoproteins, Pc3A/B, paired with divalent cations and polycationic Pc1 and Pc4 proteins. Both types of granules contain catechol oxidase that catalyzes oxidative cross-linking of L-DOPA. Co-secretion of catechol oxidase guarantees rapid and spatially homogeneous curing with limited mixing of the preassembled adhesive packets. Catechol oxidase remains active long after the glue is fully cured, perhaps providing an active cue for conspecific larval settlement.</text>
      <sentence>
        <offset>0</offset>
        <text>Multipart Copolyelectrolyte Adhesive of the Sandcastle Worm, Phragmatopoma californica (Fewkes): Catechol Oxidase Catalyzed Curing through Peptidyl-DOPA.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopa</infon>
          <location offset="148" length="4"/>
          <text>DOPA</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">catechol</infon>
          <location offset="97" length="8"/>
          <text>Catechol</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">catechol oxidase</infon>
          <location offset="97" length="16"/>
          <text>Catechol Oxidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>154</offset>
        <text>Tube-building sabellariid polychaetes have major impacts on the geology and ecology of shorelines worldwide.</text>
      </sentence>
      <sentence>
        <offset>263</offset>
        <text>Sandcastle worms, Phragmatopoma californica (Fewkes), live along the western coast of North America.</text>
      </sentence>
      <sentence>
        <offset>364</offset>
        <text>Individual sabellariid worms build tubular shells by gluing together mineral particles with a multipart polyelectrolytic adhesive.</text>
      </sentence>
      <sentence>
        <offset>495</offset>
        <text>Distinct sets of oppositely charged components are packaged and stored in concentrated granules in separate cell types.</text>
      </sentence>
      <sentence>
        <offset>615</offset>
        <text>Homogeneous granules contain sulfated macromolecules as counter-polyanion to polycationic Pc2 and Pc5 proteins, which become major components of the fully cured glue.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pc2</infon>
          <location offset="705" length="3"/>
          <text>Pc2</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pc5</infon>
          <location offset="713" length="3"/>
          <text>Pc5</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>782</offset>
        <text>Heterogeneous granules contain polyphosphoproteins, Pc3A/B, paired with divalent cations and polycationic Pc1 and Pc4 proteins.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pc3a/b</infon>
          <location offset="834" length="6"/>
          <text>Pc3A/B</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pc1</infon>
          <location offset="888" length="3"/>
          <text>Pc1</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pc4</infon>
          <location offset="896" length="3"/>
          <text>Pc4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>910</offset>
        <text>Both types of granules contain catechol oxidase that catalyzes oxidative cross-linking of L-DOPA.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">catechol</infon>
          <location offset="941" length="8"/>
          <text>catechol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-dopa</infon>
          <location offset="1000" length="6"/>
          <text>L-DOPA</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">catechol oxidase</infon>
          <location offset="941" length="16"/>
          <text>catechol oxidase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1008</offset>
        <text>Co-secretion of catechol oxidase guarantees rapid and spatially homogeneous curing with limited mixing of the preassembled adhesive packets.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">catechol</infon>
          <location offset="1024" length="8"/>
          <text>catechol</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">catechol oxidase</infon>
          <location offset="1024" length="16"/>
          <text>catechol oxidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1149</offset>
        <text>Catechol oxidase remains active long after the glue is fully cured, perhaps providing an active cue for conspecific larval settlement.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">catechol</infon>
          <location offset="1149" length="8"/>
          <text>Catechol</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">catechol oxidase</infon>
          <location offset="1149" length="16"/>
          <text>Catechol oxidase</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16964330</id>
    <passage>
      <offset>0</offset>
      <text>Antifungal agents: mode of action in yeast cells.	Different kinds of mycoses, especially invasive, have become an important public health problem as their incidence has increased dramatically in the last decades in relation to AIDS, hematological malignancies, transplant recipients and other immunosuppressed individuals. Management of fungal infections is markedly limited by problems of drug safety, resistance and effectiveness profile. Current therapy for invasive mycoses uses a relatively reduced number of antifungal drugs, such as amphotericin B, fluconazole and itraconazole. Other new antifungal agents from old and new chemical families, like voriconazole, posaconazole, ravuconazole, caspofungin and micafungin, have been introduced into the armamentarium for fungal infections management. This review is focused on the mode of action of those antifungal drugs used against pathogenic yeasts. The interaction of amphotericin B with ergosterol and other membrane sterols results in the production of aqueous pores of drug and the ergosterol biosynthetic pathway is the target of the allylamines, phenylmorpholines and azole antifungal agents. The main molecular target of azole antifungals is the cytochrome P-450 protein Erg11p/Cyp51p. Echinocandins, a new class of antifungal drugs, are fungal secondary metabolites that act against beta-1-3-D-glucan synthesis. The phenylmorpholines, of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and Erg2p (delta 8-delta 7 isomerase). The sordarins group are protein synthesis inhibitors that work by blocking the function of fungal translation elongation factor 2. Other protein inhibitors are zofimarin, BE31045, SCH57504, xylarin, hypoxysordarin and GR135402. In order to overcome the problems derived from the exploitation of azole drugs, macrolides and echinocandins, novel targets were explored. Proposed antifungal drugs have been developed against potential targets like the N-myristylation of fungal proteins, with inhibitors like myristate and histidine analogues or myristoylpeptide derivatives, aminobenzothiazoles, quinolines and benzofurans. Polymerization of cell wall carbohydrates from uridine di-phospho sugars is another potential target.</text>
      <sentence>
        <offset>0</offset>
        <text>Antifungal agents: mode of action in yeast cells.</text>
      </sentence>
      <sentence>
        <offset>50</offset>
        <text>Different kinds of mycoses, especially invasive, have become an important public health problem as their incidence has increased dramatically in the last decades in relation to AIDS, hematological malignancies, transplant recipients and other immunosuppressed individuals.</text>
      </sentence>
      <sentence>
        <offset>323</offset>
        <text>Management of fungal infections is markedly limited by problems of drug safety, resistance and effectiveness profile.</text>
      </sentence>
      <sentence>
        <offset>441</offset>
        <text>Current therapy for invasive mycoses uses a relatively reduced number of antifungal drugs, such as amphotericin B, fluconazole and itraconazole.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amphotericin b</infon>
          <location offset="540" length="14"/>
          <text>amphotericin B</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluconazole</infon>
          <location offset="556" length="11"/>
          <text>fluconazole</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">itraconazole</infon>
          <location offset="572" length="12"/>
          <text>itraconazole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>586</offset>
        <text>Other new antifungal agents from old and new chemical families, like voriconazole, posaconazole, ravuconazole, caspofungin and micafungin, have been introduced into the armamentarium for fungal infections management.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">voriconazole</infon>
          <location offset="655" length="12"/>
          <text>voriconazole</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">posaconazole</infon>
          <location offset="669" length="12"/>
          <text>posaconazole</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ravuconazole</infon>
          <location offset="683" length="12"/>
          <text>ravuconazole</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caspofungin</infon>
          <location offset="697" length="11"/>
          <text>caspofungin</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">micafungin</infon>
          <location offset="713" length="10"/>
          <text>micafungin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>803</offset>
        <text>This review is focused on the mode of action of those antifungal drugs used against pathogenic yeasts.</text>
      </sentence>
      <sentence>
        <offset>906</offset>
        <text>The interaction of amphotericin B with ergosterol and other membrane sterols results in the production of aqueous pores of drug and the ergosterol biosynthetic pathway is the target of the allylamines, phenylmorpholines and azole antifungal agents.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allylamines</infon>
          <location offset="1095" length="11"/>
          <text>allylamines</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenylmorpholines</infon>
          <location offset="1108" length="17"/>
          <text>phenylmorpholines</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">azole</infon>
          <location offset="1130" length="5"/>
          <text>azole</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amphotericin b</infon>
          <location offset="925" length="14"/>
          <text>amphotericin B</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ergosterol</infon>
          <location offset="945" length="10"/>
          <text>ergosterol</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sterols</infon>
          <location offset="975" length="7"/>
          <text>sterols</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ergosterol</infon>
          <location offset="1042" length="10"/>
          <text>ergosterol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1155</offset>
        <text>The main molecular target of azole antifungals is the cytochrome P-450 protein Erg11p/Cyp51p.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">azole</infon>
          <location offset="1184" length="5"/>
          <text>azole</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p-450</infon>
          <location offset="1209" length="16"/>
          <text>cytochrome P-450</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erg11p</infon>
          <location offset="1234" length="6"/>
          <text>Erg11p</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp51p</infon>
          <location offset="1241" length="6"/>
          <text>Cyp51p</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1249</offset>
        <text>Echinocandins, a new class of antifungal drugs, are fungal secondary metabolites that act against beta-1-3-D-glucan synthesis.</text>
      </sentence>
      <sentence>
        <offset>1376</offset>
        <text>The phenylmorpholines, of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and Erg2p (delta 8-delta 7 isomerase).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenylmorpholines</infon>
          <location offset="1380" length="17"/>
          <text>phenylmorpholines</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amorolfine</infon>
          <location offset="1408" length="10"/>
          <text>amorolfine</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erg24p</infon>
          <location offset="1510" length="6"/>
          <text>Erg24p</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">delta 14 reductase</infon>
          <location offset="1518" length="18"/>
          <text>delta 14 reductase</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erg2p</infon>
          <location offset="1542" length="5"/>
          <text>Erg2p</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">delta 8-delta 7 isomerase</infon>
          <location offset="1549" length="25"/>
          <text>delta 8-delta 7 isomerase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1577</offset>
        <text>The sordarins group are protein synthesis inhibitors that work by blocking the function of fungal translation elongation factor 2.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sordarins</infon>
          <location offset="1581" length="9"/>
          <text>sordarins</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fungal translation elongation factor 2</infon>
          <location offset="1668" length="38"/>
          <text>fungal translation elongation factor 2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1708</offset>
        <text>Other protein inhibitors are zofimarin, BE31045, SCH57504, xylarin, hypoxysordarin and GR135402.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zofimarin</infon>
          <location offset="1737" length="9"/>
          <text>zofimarin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">be31045</infon>
          <location offset="1748" length="7"/>
          <text>BE31045</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sch57504</infon>
          <location offset="1757" length="8"/>
          <text>SCH57504</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">xylarin</infon>
          <location offset="1767" length="7"/>
          <text>xylarin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hypoxysordarin</infon>
          <location offset="1776" length="14"/>
          <text>hypoxysordarin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gr135402</infon>
          <location offset="1795" length="8"/>
          <text>GR135402</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1805</offset>
        <text>In order to overcome the problems derived from the exploitation of azole drugs, macrolides and echinocandins, novel targets were explored.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">azole</infon>
          <location offset="1872" length="5"/>
          <text>azole</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">echinocandins</infon>
          <location offset="1900" length="13"/>
          <text>echinocandins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1944</offset>
        <text>Proposed antifungal drugs have been developed against potential targets like the N-myristylation of fungal proteins, with inhibitors like myristate and histidine analogues or myristoylpeptide derivatives, aminobenzothiazoles, quinolines and benzofurans.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="2025" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">myristate</infon>
          <location offset="2082" length="9"/>
          <text>myristate</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histidine</infon>
          <location offset="2096" length="9"/>
          <text>histidine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aminobenzothiazoles</infon>
          <location offset="2149" length="19"/>
          <text>aminobenzothiazoles</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quinolines</infon>
          <location offset="2170" length="10"/>
          <text>quinolines</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzofurans</infon>
          <location offset="2185" length="11"/>
          <text>benzofurans</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2198</offset>
        <text>Polymerization of cell wall carbohydrates from uridine di-phospho sugars is another potential target.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">uridine di-phospho sugars</infon>
          <location offset="2245" length="25"/>
          <text>uridine di-phospho sugars</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23335106</id>
    <passage>
      <offset>0</offset>
      <text>Fast, reversible, and general photomechanical motion in single crystals of various azo compounds using visible light.	Pseudostilbene-type single crystals exhibit ubiquitous, fast, and reversible photomechanical motion under visible-light irradiation. Push-pull substituents impart extremely rapid switching using just one wavelength of light by shortening the lifetime of the cis-form. This results in a bending motion in the microsecond regime. The influence of crystal density, thickness, and molecular orientation on optimization of the photomechanical effect is investigated.</text>
      <sentence>
        <offset>0</offset>
        <text>Fast, reversible, and general photomechanical motion in single crystals of various azo compounds using visible light.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">azo</infon>
          <location offset="83" length="3"/>
          <text>azo</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>118</offset>
        <text>Pseudostilbene-type single crystals exhibit ubiquitous, fast, and reversible photomechanical motion under visible-light irradiation.</text>
      </sentence>
      <sentence>
        <offset>251</offset>
        <text>Push-pull substituents impart extremely rapid switching using just one wavelength of light by shortening the lifetime of the cis-form.</text>
      </sentence>
      <sentence>
        <offset>386</offset>
        <text>This results in a bending motion in the microsecond regime.</text>
      </sentence>
      <sentence>
        <offset>446</offset>
        <text>The influence of crystal density, thickness, and molecular orientation on optimization of the photomechanical effect is investigated.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23160530</id>
    <passage>
      <offset>0</offset>
      <text>Gliotransmission and brain glucose sensing: critical role of endozepines.	Hypothalamic glucose sensing is involved in the control of feeding behavior and peripheral glucose homeostasis, and glial cells are suggested to play an important role in this process. Diazepam-binding inhibitor (DBI) and its processing product the octadecaneuropeptide (ODN), collectively named endozepines, are secreted by astroglia, and ODN is a potent anorexigenic factor. Therefore, we investigated the involvement of endozepines in brain glucose sensing. First, we showed that intracerebroventricular administration of glucose in rats increases DBI expression in hypothalamic glial-like tanycytes. We then demonstrated that glucose stimulates endozepine secretion from hypothalamic explants. Feeding experiments indicate that the anorexigenic effect of central administration of glucose was blunted by coinjection of an ODN antagonist. Conversely, the hyperphagic response elicited by central glucoprivation was suppressed by an ODN agonist. The anorexigenic effects of centrally injected glucose or ODN agonist were suppressed by blockade of the melanocortin-3/4 receptors, suggesting that glucose sensing involves endozepinergic control of the melanocortin pathway. Finally, we found that brain endozepines modulate blood glucose levels, suggesting their involvement in a feedback loop controlling whole-body glucose homeostasis. Collectively, these data indicate that endozepines are a critical relay in brain glucose sensing and potentially new targets in treatment of metabolic disorders.</text>
      <sentence>
        <offset>0</offset>
        <text>Gliotransmission and brain glucose sensing: critical role of endozepines.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="27" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">endozepines</infon>
          <location offset="61" length="11"/>
          <text>endozepines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>74</offset>
        <text>Hypothalamic glucose sensing is involved in the control of feeding behavior and peripheral glucose homeostasis, and glial cells are suggested to play an important role in this process.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="87" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="165" length="7"/>
          <text>glucose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>259</offset>
        <text>Diazepam-binding inhibitor (DBI) and its processing product the octadecaneuropeptide (ODN), collectively named endozepines, are secreted by astroglia, and ODN is a potent anorexigenic factor.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diazepam</infon>
          <location offset="259" length="8"/>
          <text>Diazepam</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">diazepam-binding inhibitor</infon>
          <location offset="259" length="26"/>
          <text>Diazepam-binding inhibitor</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dbi</infon>
          <location offset="287" length="3"/>
          <text>DBI</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">octadecaneuropeptide</infon>
          <location offset="323" length="20"/>
          <text>octadecaneuropeptide</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">odn</infon>
          <location offset="345" length="3"/>
          <text>ODN</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">endozepines</infon>
          <location offset="370" length="11"/>
          <text>endozepines</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">odn</infon>
          <location offset="414" length="3"/>
          <text>ODN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>451</offset>
        <text>Therefore, we investigated the involvement of endozepines in brain glucose sensing.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="518" length="7"/>
          <text>glucose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>535</offset>
        <text>First, we showed that intracerebroventricular administration of glucose in rats increases DBI expression in hypothalamic glial-like tanycytes.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="599" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dbi</infon>
          <location offset="625" length="3"/>
          <text>DBI</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>678</offset>
        <text>We then demonstrated that glucose stimulates endozepine secretion from hypothalamic explants.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="704" length="7"/>
          <text>glucose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>772</offset>
        <text>Feeding experiments indicate that the anorexigenic effect of central administration of glucose was blunted by coinjection of an ODN antagonist.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="859" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">odn</infon>
          <location offset="900" length="3"/>
          <text>ODN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>916</offset>
        <text>Conversely, the hyperphagic response elicited by central glucoprivation was suppressed by an ODN agonist.</text>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">odn</infon>
          <location offset="1009" length="3"/>
          <text>ODN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1022</offset>
        <text>The anorexigenic effects of centrally injected glucose or ODN agonist were suppressed by blockade of the melanocortin-3/4 receptors, suggesting that glucose sensing involves endozepinergic control of the melanocortin pathway.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1171" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1069" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">odn</infon>
          <location offset="1080" length="3"/>
          <text>ODN</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">melanocortin-3/4 receptors</infon>
          <location offset="1127" length="26"/>
          <text>melanocortin-3/4 receptors</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">melanocortin</infon>
          <location offset="1226" length="12"/>
          <text>melanocortin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1248</offset>
        <text>Finally, we found that brain endozepines modulate blood glucose levels, suggesting their involvement in a feedback loop controlling whole-body glucose homeostasis.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1304" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1391" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">endozepines</infon>
          <location offset="1277" length="11"/>
          <text>endozepines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1412</offset>
        <text>Collectively, these data indicate that endozepines are a critical relay in brain glucose sensing and potentially new targets in treatment of metabolic disorders.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1493" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">endozepines</infon>
          <location offset="1451" length="11"/>
          <text>endozepines</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15509185</id>
    <passage>
      <offset>0</offset>
      <text>Clinical pharmacology of tramadol.	Tramadol, a centrally acting analgesic structurally related to codeine and morphine, consists of two enantiomers, both of which contribute to analgesic activity via different mechanisms. (+)-Tramadol and the metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the mu opioid receptor. (+)-Tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake, enhancing inhibitory effects on pain transmission in the spinal cord. The complementary and synergistic actions of the two enantiomers improve the analgesic efficacy and tolerability profile of the racemate. Tramadol is available as drops, capsules and sustained-release formulations for oral use, suppositories for rectal use and solution for intramuscular, intravenous and subcutaneous injection. After oral administration, tramadol is rapidly and almost completely absorbed. Sustained-release tablets release the active ingredient over a period of 12 hours, reach peak concentrations after 4.9 hours and have a bioavailability of 87-95% compared with capsules. Tramadol is rapidly distributed in the body; plasma protein binding is about 20%. Tramadol is mainly metabolised by O- and N-demethylation and by conjugation reactions forming glucuronides and sulfates. Tramadol and its metabolites are mainly excreted via the kidneys. The mean elimination half-life is about 6 hours. The O-demethylation of tramadol to M1, the main analgesic effective metabolite, is catalysed by cytochrome P450 (CYP) 2D6, whereas N-demethylation to M2 is catalysed by CYP2B6 and CYP3A4. The wide variability in the pharmacokinetic properties of tramadol can partly be ascribed to CYP polymorphism. O- and N-demethylation of tramadol as well as renal elimination are stereoselective. Pharmacokinetic-pharmacodynamic characterisation of tramadol is difficult because of differences between tramadol concentrations in plasma and at the site of action, and because of pharmacodynamic interactions between the two enantiomers of tramadol and its active metabolites. The analgesic potency of tramadol is about 10% of that of morphine following parenteral administration. Tramadol provides postoperative pain relief comparable with that of pethidine, and the analgesic efficacy of tramadol can further be improved by combination with a non-opioid analgesic. Tramadol may prove particularly useful in patients with a risk of poor cardiopulmonary function, after surgery of the thorax or upper abdomen and when non-opioid analgesics are contraindicated. Tramadol is an effective and well tolerated agent to reduce pain resulting from trauma, renal or biliary colic and labour, and also for the management of chronic pain of malignant or nonmalignant origin, particularly neuropathic pain. Tramadol appears to produce less constipation and dependence than equianalgesic doses of strong opioids.</text>
      <sentence>
        <offset>0</offset>
        <text>Clinical pharmacology of tramadol.</text>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="25" length="8"/>
          <text>tramadol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>35</offset>
        <text>Tramadol, a centrally acting analgesic structurally related to codeine and morphine, consists of two enantiomers, both of which contribute to analgesic activity via different mechanisms.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="35" length="8"/>
          <text>Tramadol</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">codeine</infon>
          <location offset="98" length="7"/>
          <text>codeine</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="110" length="8"/>
          <text>morphine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>222</offset>
        <text>(+)-Tramadol and the metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the mu opioid receptor.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(+)-tramadol</infon>
          <location offset="222" length="12"/>
          <text>(+)-Tramadol</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(+)-o-desmethyl-tramadol</infon>
          <location offset="254" length="24"/>
          <text>(+)-O-desmethyl-tramadol</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mu opioid receptor</infon>
          <location offset="304" length="18"/>
          <text>mu opioid receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T18" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T23" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>324</offset>
        <text>(+)-Tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake, enhancing inhibitory effects on pain transmission in the spinal cord.</text>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(+)-tramadol</infon>
          <location offset="324" length="12"/>
          <text>(+)-Tramadol</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="346" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(-)-tramadol</infon>
          <location offset="369" length="12"/>
          <text>(-)-tramadol</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">norepinephrine</infon>
          <location offset="391" length="14"/>
          <text>norepinephrine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>486</offset>
        <text>The complementary and synergistic actions of the two enantiomers improve the analgesic efficacy and tolerability profile of the racemate.</text>
      </sentence>
      <sentence>
        <offset>624</offset>
        <text>Tramadol is available as drops, capsules and sustained-release formulations for oral use, suppositories for rectal use and solution for intramuscular, intravenous and subcutaneous injection.</text>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="624" length="8"/>
          <text>Tramadol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>815</offset>
        <text>After oral administration, tramadol is rapidly and almost completely absorbed.</text>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="842" length="8"/>
          <text>tramadol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>894</offset>
        <text>Sustained-release tablets release the active ingredient over a period of 12 hours, reach peak concentrations after 4.9 hours and have a bioavailability of 87-95% compared with capsules.</text>
      </sentence>
      <sentence>
        <offset>1080</offset>
        <text>Tramadol is rapidly distributed in the body; plasma protein binding is about 20%.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="1080" length="8"/>
          <text>Tramadol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1162</offset>
        <text>Tramadol is mainly metabolised by O- and N-demethylation and by conjugation reactions forming glucuronides and sulfates.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="1162" length="8"/>
          <text>Tramadol</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="1196" length="1"/>
          <text>O</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="1203" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucuronides</infon>
          <location offset="1256" length="12"/>
          <text>glucuronides</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfates</infon>
          <location offset="1273" length="8"/>
          <text>sulfates</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1283</offset>
        <text>Tramadol and its metabolites are mainly excreted via the kidneys.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="1283" length="8"/>
          <text>Tramadol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1349</offset>
        <text>The mean elimination half-life is about 6 hours.</text>
      </sentence>
      <sentence>
        <offset>1398</offset>
        <text>The O-demethylation of tramadol to M1, the main analgesic effective metabolite, is catalysed by cytochrome P450 (CYP) 2D6, whereas N-demethylation to M2 is catalysed by CYP2B6 and CYP3A4.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="1402" length="1"/>
          <text>O</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="1421" length="8"/>
          <text>tramadol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="1529" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome p450 (cyp) 2d6</infon>
          <location offset="1494" length="25"/>
          <text>cytochrome P450 (CYP) 2D6</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2b6</infon>
          <location offset="1567" length="6"/>
          <text>CYP2B6</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="1578" length="6"/>
          <text>CYP3A4</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T9" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1586</offset>
        <text>The wide variability in the pharmacokinetic properties of tramadol can partly be ascribed to CYP polymorphism.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="1644" length="8"/>
          <text>tramadol</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp</infon>
          <location offset="1679" length="3"/>
          <text>CYP</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1697</offset>
        <text>O- and N-demethylation of tramadol as well as renal elimination are stereoselective.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="1697" length="1"/>
          <text>O</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="1704" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="1723" length="8"/>
          <text>tramadol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1782</offset>
        <text>Pharmacokinetic-pharmacodynamic characterisation of tramadol is difficult because of differences between tramadol concentrations in plasma and at the site of action, and because of pharmacodynamic interactions between the two enantiomers of tramadol and its active metabolites.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="1834" length="8"/>
          <text>tramadol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="1887" length="8"/>
          <text>tramadol</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="2023" length="8"/>
          <text>tramadol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2060</offset>
        <text>The analgesic potency of tramadol is about 10% of that of morphine following parenteral administration.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="2085" length="8"/>
          <text>tramadol</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="2118" length="8"/>
          <text>morphine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2164</offset>
        <text>Tramadol provides postoperative pain relief comparable with that of pethidine, and the analgesic efficacy of tramadol can further be improved by combination with a non-opioid analgesic.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="2164" length="8"/>
          <text>Tramadol</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pethidine</infon>
          <location offset="2232" length="9"/>
          <text>pethidine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="2273" length="8"/>
          <text>tramadol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2350</offset>
        <text>Tramadol may prove particularly useful in patients with a risk of poor cardiopulmonary function, after surgery of the thorax or upper abdomen and when non-opioid analgesics are contraindicated.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="2350" length="8"/>
          <text>Tramadol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2544</offset>
        <text>Tramadol is an effective and well tolerated agent to reduce pain resulting from trauma, renal or biliary colic and labour, and also for the management of chronic pain of malignant or nonmalignant origin, particularly neuropathic pain.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="2544" length="8"/>
          <text>Tramadol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2779</offset>
        <text>Tramadol appears to produce less constipation and dependence than equianalgesic doses of strong opioids.</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tramadol</infon>
          <location offset="2779" length="8"/>
          <text>Tramadol</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23557706</id>
    <passage>
      <offset>0</offset>
      <text>mTOR Regulates Nox4-Mediated Podocyte Depletion in Diabetic Renal Injury.	Podocyte apoptosis is a critical mechanism for excessive loss of urinary albumin that eventuates in kidney fibrosis. Pharmacological doses of the mTOR inhibitor rapamycin reduce albuminura in diabetes. We explored the hypothesis that mTOR mediates podocyte injury in diabetes. High glucose (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates mTOR. HG also increases the levels of Nox4 and Nox1 and NADPH oxidase activity. Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis. Inhibition of mTOR had no effect on AMPK or tuberin phosphorylation indicating that mTOR is downstream of these signaling molecules. In isolated glomeruli of OVE26 mice, there is similar decrease in the activation of AMPK and tuberin and activation of mTOR with increase in Nox4 and NADPH oxidase activity. Inhibition of mTOR by small dose of rapamycin reduces podocyte apoptosis, attenuates glomerular injury and albuminuria. Our data provide evidence for a novel function of mTOR in Nox4-derived ROS generation and podocyte apoptosis that contributes to urinary albumin excretion in type 1 diabetes. Thus mTOR and or NADPH oxidase inhibition may represent a therapeutic modality of diabetic kidney disease.</text>
      <sentence>
        <offset>0</offset>
        <text>mTOR Regulates Nox4-Mediated Podocyte Depletion in Diabetic Renal Injury.</text>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="0" length="4"/>
          <text>mTOR</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox4</infon>
          <location offset="15" length="4"/>
          <text>Nox4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>74</offset>
        <text>Podocyte apoptosis is a critical mechanism for excessive loss of urinary albumin that eventuates in kidney fibrosis.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">albumin</infon>
          <location offset="147" length="7"/>
          <text>albumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>191</offset>
        <text>Pharmacological doses of the mTOR inhibitor rapamycin reduce albuminura in diabetes.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="235" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="220" length="4"/>
          <text>mTOR</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>276</offset>
        <text>We explored the hypothesis that mTOR mediates podocyte injury in diabetes.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="308" length="4"/>
          <text>mTOR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>351</offset>
        <text>High glucose (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates mTOR.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="356" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="410" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tuberin</infon>
          <location offset="439" length="7"/>
          <text>tuberin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="461" length="4"/>
          <text>mTOR</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>467</offset>
        <text>HG also increases the levels of Nox4 and Nox1 and NADPH oxidase activity.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadph</infon>
          <location offset="517" length="5"/>
          <text>NADPH</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox4</infon>
          <location offset="499" length="4"/>
          <text>Nox4</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox1</infon>
          <location offset="508" length="4"/>
          <text>Nox1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nadph oxidase</infon>
          <location offset="517" length="13"/>
          <text>NADPH oxidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>541</offset>
        <text>Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="572" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadph</infon>
          <location offset="618" length="5"/>
          <text>NADPH</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="555" length="4"/>
          <text>mTOR</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox4</infon>
          <location offset="603" length="4"/>
          <text>Nox4</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox1</infon>
          <location offset="612" length="4"/>
          <text>Nox1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nadph oxidase</infon>
          <location offset="618" length="13"/>
          <text>NADPH oxidase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>665</offset>
        <text>Inhibition of mTOR had no effect on AMPK or tuberin phosphorylation indicating that mTOR is downstream of these signaling molecules.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="679" length="4"/>
          <text>mTOR</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="701" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tuberin</infon>
          <location offset="709" length="7"/>
          <text>tuberin</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="749" length="4"/>
          <text>mTOR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>798</offset>
        <text>In isolated glomeruli of OVE26 mice, there is similar decrease in the activation of AMPK and tuberin and activation of mTOR with increase in Nox4 and NADPH oxidase activity.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadph</infon>
          <location offset="948" length="5"/>
          <text>NADPH</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="882" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tuberin</infon>
          <location offset="891" length="7"/>
          <text>tuberin</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="917" length="4"/>
          <text>mTOR</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox4</infon>
          <location offset="939" length="4"/>
          <text>Nox4</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nadph oxidase</infon>
          <location offset="948" length="13"/>
          <text>NADPH oxidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>972</offset>
        <text>Inhibition of mTOR by small dose of rapamycin reduces podocyte apoptosis, attenuates glomerular injury and albuminuria.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="1008" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="986" length="4"/>
          <text>mTOR</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1092</offset>
        <text>Our data provide evidence for a novel function of mTOR in Nox4-derived ROS generation and podocyte apoptosis that contributes to urinary albumin excretion in type 1 diabetes.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="1142" length="4"/>
          <text>mTOR</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox4</infon>
          <location offset="1150" length="4"/>
          <text>Nox4</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">albumin</infon>
          <location offset="1229" length="7"/>
          <text>albumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1267</offset>
        <text>Thus mTOR and or NADPH oxidase inhibition may represent a therapeutic modality of diabetic kidney disease.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadph</infon>
          <location offset="1284" length="5"/>
          <text>NADPH</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="1272" length="4"/>
          <text>mTOR</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nadph oxidase</infon>
          <location offset="1284" length="13"/>
          <text>NADPH oxidase</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22430206</id>
    <passage>
      <offset>0</offset>
      <text>Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.	The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR antibody that has been approved for use in oncology. Previously we investigated mechanisms of resistance to cetuximab using a model derived from the non-small cell lung cancer line NCI-H226. We demonstrated that cetuximab-resistant clones (Ctx(R)) had increased nuclear localization of the EGFR. This process was mediated by Src family kinases (SFKs), and nuclear EGFR had a role in resistance to cetuximab. To better understand SFK-mediated nuclear translocation of EGFR, we investigated which SFK member(s) controlled this process as well as the EGFR tyrosine residues that are involved. Analyses of mRNA and protein expression indicated upregulation of the SFK members Yes (v-Yes-1 yamaguchi sarcoma viral oncogene) and Lyn (v-yes-1 Yamaguchi sarcoma viral-related oncogene homolog) in all Ctx(R) clones. Further, immunoprecipitation analysis revealed that EGFR interacts with Yes and Lyn in Ctx(R) clones, but not in cetuximab-sensitive (Ctx(S)) parental cells. Using RNAi interference, we found that knockdown of either Yes or Lyn led to loss of EGFR translocation to the nucleus. Conversely, overexpression of Yes or Lyn in low nuclear EGFR-expressing Ctx(S) parental cells led to increased nuclear EGFR. Chromatin immunoprecipitation (ChIP) assays confirmed nuclear EGFR complexes associated with the promoter of the known EGFR target genes B-Myb and iNOS. Further, all Ctx(R) clones exhibited upregulation of B-Myb and iNOS at the mRNA and protein levels. siRNAs directed at Yes or Lyn led to decreased binding of EGFR complexes to the B-Myb and iNOS promoters based on ChIP analyses. SFKs have been shown to phosphorylate EGFR on tyrosines 845 and 1101 (Y845 and Y1101), and mutation of Y1101, but not Y845, impaired nuclear entry of the EGFR. Taken together, our findings demonstrate that Yes and Lyn phosphorylate EGFR at Y1101, which influences EGFR nuclear translocation in this model of cetuximab resistance.</text>
      <sentence>
        <offset>0</offset>
        <text>Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.</text>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">yes</infon>
          <location offset="0" length="3"/>
          <text>Yes</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epidermal growth factor receptor</infon>
          <location offset="56" length="32"/>
          <text>epidermal growth factor receptor</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lyn</infon>
          <location offset="8" length="3"/>
          <text>Lyn</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>90</offset>
        <text>The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers.</text>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="128" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epidermal growth factor receptor</infon>
          <location offset="94" length="32"/>
          <text>epidermal growth factor receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>196</offset>
        <text>Cetuximab is an anti-EGFR antibody that has been approved for use in oncology.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="217" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>275</offset>
        <text>Previously we investigated mechanisms of resistance to cetuximab using a model derived from the non-small cell lung cancer line NCI-H226.</text>
      </sentence>
      <sentence>
        <offset>413</offset>
        <text>We demonstrated that cetuximab-resistant clones (Ctx(R)) had increased nuclear localization of the EGFR.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="512" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>518</offset>
        <text>This process was mediated by Src family kinases (SFKs), and nuclear EGFR had a role in resistance to cetuximab.</text>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">src family kinases</infon>
          <location offset="547" length="18"/>
          <text>Src family kinases</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sfks</infon>
          <location offset="567" length="4"/>
          <text>SFKs</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="586" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>630</offset>
        <text>To better understand SFK-mediated nuclear translocation of EGFR, we investigated which SFK member(s) controlled this process as well as the EGFR tyrosine residues that are involved.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="775" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sfk</infon>
          <location offset="651" length="3"/>
          <text>SFK</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="689" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sfk</infon>
          <location offset="717" length="3"/>
          <text>SFK</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="770" length="4"/>
          <text>EGFR</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>812</offset>
        <text>Analyses of mRNA and protein expression indicated upregulation of the SFK members Yes (v-Yes-1 yamaguchi sarcoma viral oncogene) and Lyn (v-yes-1 Yamaguchi sarcoma viral-related oncogene homolog) in all Ctx(R) clones.</text>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sfk</infon>
          <location offset="882" length="3"/>
          <text>SFK</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">yes</infon>
          <location offset="894" length="3"/>
          <text>Yes</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">v-yes-1 yamaguchi sarcoma viral oncogene</infon>
          <location offset="899" length="40"/>
          <text>v-Yes-1 yamaguchi sarcoma viral oncogene</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lyn</infon>
          <location offset="945" length="3"/>
          <text>Lyn</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">v-yes-1 yamaguchi sarcoma viral-related oncogene homolog</infon>
          <location offset="950" length="56"/>
          <text>v-yes-1 Yamaguchi sarcoma viral-related oncogene homolog</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1030</offset>
        <text>Further, immunoprecipitation analysis revealed that EGFR interacts with Yes and Lyn in Ctx(R) clones, but not in cetuximab-sensitive (Ctx(S)) parental cells.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">yes</infon>
          <location offset="1102" length="3"/>
          <text>Yes</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lyn</infon>
          <location offset="1110" length="3"/>
          <text>Lyn</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1082" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1188</offset>
        <text>Using RNAi interference, we found that knockdown of either Yes or Lyn led to loss of EGFR translocation to the nucleus.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">yes</infon>
          <location offset="1247" length="3"/>
          <text>Yes</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lyn</infon>
          <location offset="1254" length="3"/>
          <text>Lyn</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1273" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1308</offset>
        <text>Conversely, overexpression of Yes or Lyn in low nuclear EGFR-expressing Ctx(S) parental cells led to increased nuclear EGFR.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">yes</infon>
          <location offset="1338" length="3"/>
          <text>Yes</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lyn</infon>
          <location offset="1345" length="3"/>
          <text>Lyn</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1364" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1427" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1433</offset>
        <text>Chromatin immunoprecipitation (ChIP) assays confirmed nuclear EGFR complexes associated with the promoter of the known EGFR target genes B-Myb and iNOS.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1495" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1552" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">b-myb</infon>
          <location offset="1570" length="5"/>
          <text>B-Myb</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inos</infon>
          <location offset="1580" length="4"/>
          <text>iNOS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1586</offset>
        <text>Further, all Ctx(R) clones exhibited upregulation of B-Myb and iNOS at the mRNA and protein levels.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">b-myb</infon>
          <location offset="1639" length="5"/>
          <text>B-Myb</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">inos</infon>
          <location offset="1649" length="4"/>
          <text>iNOS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1686</offset>
        <text>siRNAs directed at Yes or Lyn led to decreased binding of EGFR complexes to the B-Myb and iNOS promoters based on ChIP analyses.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">yes</infon>
          <location offset="1705" length="3"/>
          <text>Yes</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lyn</infon>
          <location offset="1712" length="3"/>
          <text>Lyn</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1744" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">b-myb and inos promoters</infon>
          <location offset="1766" length="24"/>
          <text>B-Myb and iNOS promoters</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1815</offset>
        <text>SFKs have been shown to phosphorylate EGFR on tyrosines 845 and 1101 (Y845 and Y1101), and mutation of Y1101, but not Y845, impaired nuclear entry of the EGFR.</text>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sfks</infon>
          <location offset="1815" length="4"/>
          <text>SFKs</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1853" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1969" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1975</offset>
        <text>Taken together, our findings demonstrate that Yes and Lyn phosphorylate EGFR at Y1101, which influences EGFR nuclear translocation in this model of cetuximab resistance.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">yes</infon>
          <location offset="2021" length="3"/>
          <text>Yes</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lyn</infon>
          <location offset="2029" length="3"/>
          <text>Lyn</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="2047" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="2079" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23583603</id>
    <passage>
      <offset>0</offset>
      <text>Agonistic activity of ICI 182 780 on activation of GSK 3β/AKT pathway in the rat uterus during the estrous cycle.	We examined the ability of ICI 182,780 (ICI) to block uterine cell proliferation via protein kinase b/AKT pathway in the uterus of the rat during the estrous cycle. Intact rats, with regular estrous cycles, received a subcutaneous (s.c.) injection of either vehicle or ICI at 08:00h on the day of proestrus or at 00:00h on the day of estrus and sacrificed at 13:00h of metaestrus. Estradiol (E2) and progesterone (P4) plasma levels were measured by radioimmunoassay. Both ICI treatments, induced a significant decrease (p&lt;0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals. Furthermore, we detected that ICI treatment induced glycogen synthase kinase (Gsk3-β) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization. However, some differences were observed between the two different time schedules of administration. We observed that the administration of ICI at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of Akt phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters. The overall results indicate that ICI may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the Akt pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.</text>
      <sentence>
        <offset>0</offset>
        <text>Agonistic activity of ICI 182 780 on activation of GSK 3β/AKT pathway in the rat uterus during the estrous cycle.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici 182 780</infon>
          <location offset="22" length="11"/>
          <text>ICI 182 780</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gsk 3β</infon>
          <location offset="51" length="6"/>
          <text>GSK 3β</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="58" length="3"/>
          <text>AKT</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T14" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>114</offset>
        <text>We examined the ability of ICI 182,780 (ICI) to block uterine cell proliferation via protein kinase b/AKT pathway in the uterus of the rat during the estrous cycle.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici 182,780</infon>
          <location offset="141" length="11"/>
          <text>ICI 182,780</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici</infon>
          <location offset="154" length="3"/>
          <text>ICI</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="216" length="3"/>
          <text>AKT</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein kinase b</infon>
          <location offset="199" length="16"/>
          <text>protein kinase b</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>279</offset>
        <text>Intact rats, with regular estrous cycles, received a subcutaneous (s.c.) injection of either vehicle or ICI at 08:00h on the day of proestrus or at 00:00h on the day of estrus and sacrificed at 13:00h of metaestrus.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici</infon>
          <location offset="383" length="3"/>
          <text>ICI</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>495</offset>
        <text>Estradiol (E2) and progesterone (P4) plasma levels were measured by radioimmunoassay.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estradiol</infon>
          <location offset="495" length="9"/>
          <text>Estradiol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="514" length="12"/>
          <text>progesterone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>581</offset>
        <text>Both ICI treatments, induced a significant decrease (p&lt;0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici</infon>
          <location offset="586" length="3"/>
          <text>ICI</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="653" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="717" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">estrogen receptor alpha</infon>
          <location offset="653" length="23"/>
          <text>estrogen receptor alpha</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erα</infon>
          <location offset="678" length="3"/>
          <text>ERα</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">progesterone receptor</infon>
          <location offset="717" length="21"/>
          <text>progesterone receptor</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="740" length="2"/>
          <text>PR</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin d1</infon>
          <location offset="805" length="9"/>
          <text>cyclin D1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>906</offset>
        <text>Furthermore, we detected that ICI treatment induced glycogen synthase kinase (Gsk3-β) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici</infon>
          <location offset="936" length="3"/>
          <text>ICI</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glycogen synthase kinase</infon>
          <location offset="958" length="24"/>
          <text>glycogen synthase kinase</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gsk3-β</infon>
          <location offset="984" length="6"/>
          <text>Gsk3-β</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin d1</infon>
          <location offset="1037" length="9"/>
          <text>cyclin D1</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1069</offset>
        <text>However, some differences were observed between the two different time schedules of administration.</text>
      </sentence>
      <sentence>
        <offset>1169</offset>
        <text>We observed that the administration of ICI at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of Akt phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici</infon>
          <location offset="1208" length="3"/>
          <text>ICI</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="1388" length="3"/>
          <text>Ser</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici</infon>
          <location offset="1444" length="3"/>
          <text>ICI</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="1365" length="3"/>
          <text>Akt</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1517</offset>
        <text>The overall results indicate that ICI may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the Akt pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici</infon>
          <location offset="1551" length="3"/>
          <text>ICI</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="1669" length="3"/>
          <text>Akt</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23007559</id>
    <passage>
      <offset>0</offset>
      <text>Developmental immunotoxicity of ethanol in an extended one-generation reproductive toxicity study.	The susceptibility of developing immune system to chemical disruption warrants the assessment of immune parameters in reproductive and developmental testing protocols. In this study, a wide range of immune endpoints was included in an extended one-generation reproduction toxicity study (EOGRTS) design to determine the relative sensitivity of immune and developmental parameters to ethanol (EtOH), a well-known developmental toxicant with immunomodulatory properties. Adult Wistar rats were exposed to EtOH via drinking water (0, 1.5, 4, 6.5, 9, 11.5 and 14 % (w/v EtOH)) during premating, mating, gestation and lactation and continuation of exposure of the F(1) from weaning until killed. Immune assessments were performed at postnatal days (PNDs) 21, 42 and 70. Keyhole limpet hemocyanin (KLH)-specific immune responses were evaluated following subcutaneous immunizations on PNDs 21 and 35. EtOH exposure affected innate as well as adaptive immune responses. The most sensitive immune parameters included white blood cell subpopulations, ConA-stimulated splenocyte proliferation, LPS-induced NO and TNF-α production by adherent splenocytes and KLH-specific immune responses. Most parameters showed recovery after cessation of EtOH exposure after weaning in the 14 % exposure group. However, effects on LPS-induced NO and TNF-α production by adherent splenocytes and KLH-specific parameters persisted until PND 70. The results demonstrate the relative sensitivity to EtOH of especially functional immune parameters and confirm the added value of immune parameters in the EOGRTS. Furthermore, this study identified an expanded KLH-specific parameter set and LPS-induced NO and TNF-α production by adherent splenocytes as valuable parameters that can provide additional information on functional immune effects.</text>
      <sentence>
        <offset>0</offset>
        <text>Developmental immunotoxicity of ethanol in an extended one-generation reproductive toxicity study.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="32" length="7"/>
          <text>ethanol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>99</offset>
        <text>The susceptibility of developing immune system to chemical disruption warrants the assessment of immune parameters in reproductive and developmental testing protocols.</text>
      </sentence>
      <sentence>
        <offset>267</offset>
        <text>In this study, a wide range of immune endpoints was included in an extended one-generation reproduction toxicity study (EOGRTS) design to determine the relative sensitivity of immune and developmental parameters to ethanol (EtOH), a well-known developmental toxicant with immunomodulatory properties.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="482" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etoh</infon>
          <location offset="491" length="4"/>
          <text>EtOH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>568</offset>
        <text>Adult Wistar rats were exposed to EtOH via drinking water (0, 1.5, 4, 6.5, 9, 11.5 and 14 % (w/v EtOH)) during premating, mating, gestation and lactation and continuation of exposure of the F(1) from weaning until killed.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etoh</infon>
          <location offset="602" length="4"/>
          <text>EtOH</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etoh</infon>
          <location offset="665" length="4"/>
          <text>EtOH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>790</offset>
        <text>Immune assessments were performed at postnatal days (PNDs) 21, 42 and 70.</text>
      </sentence>
      <sentence>
        <offset>864</offset>
        <text>Keyhole limpet hemocyanin (KLH)-specific immune responses were evaluated following subcutaneous immunizations on PNDs 21 and 35.</text>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">keyhole limpet hemocyanin</infon>
          <location offset="864" length="25"/>
          <text>Keyhole limpet hemocyanin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">klh</infon>
          <location offset="891" length="3"/>
          <text>KLH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>993</offset>
        <text>EtOH exposure affected innate as well as adaptive immune responses.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etoh</infon>
          <location offset="993" length="4"/>
          <text>EtOH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1061</offset>
        <text>The most sensitive immune parameters included white blood cell subpopulations, ConA-stimulated splenocyte proliferation, LPS-induced NO and TNF-α production by adherent splenocytes and KLH-specific immune responses.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">no</infon>
          <location offset="1194" length="2"/>
          <text>NO</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cona</infon>
          <location offset="1140" length="4"/>
          <text>ConA</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="1201" length="5"/>
          <text>TNF-α</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">klh</infon>
          <location offset="1246" length="3"/>
          <text>KLH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1277</offset>
        <text>Most parameters showed recovery after cessation of EtOH exposure after weaning in the 14 % exposure group.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etoh</infon>
          <location offset="1328" length="4"/>
          <text>EtOH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1384</offset>
        <text>However, effects on LPS-induced NO and TNF-α production by adherent splenocytes and KLH-specific parameters persisted until PND 70.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">no</infon>
          <location offset="1416" length="2"/>
          <text>NO</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="1423" length="5"/>
          <text>TNF-α</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">klh</infon>
          <location offset="1468" length="3"/>
          <text>KLH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1516</offset>
        <text>The results demonstrate the relative sensitivity to EtOH of especially functional immune parameters and confirm the added value of immune parameters in the EOGRTS.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etoh</infon>
          <location offset="1568" length="4"/>
          <text>EtOH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1680</offset>
        <text>Furthermore, this study identified an expanded KLH-specific parameter set and LPS-induced NO and TNF-α production by adherent splenocytes as valuable parameters that can provide additional information on functional immune effects.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">no</infon>
          <location offset="1770" length="2"/>
          <text>NO</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">klh</infon>
          <location offset="1727" length="3"/>
          <text>KLH</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="1777" length="5"/>
          <text>TNF-α</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>6150080</id>
    <passage>
      <offset>0</offset>
      <text>Amine oxidase activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (clorgyline-resistant) activity at the fat cell membrane.	Amine oxidase activity, previously described in homogenates of brown adipose tissue of the rat, has now been investigated in preparations of isolated fat cells. It was found that the specific activities of both monoamine oxidase A (MAO) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue. Brown adipocytes therefore represent a major source of both these enzymes. In plasma membranes prepared from these isolated brown fat cells by borate extraction there was a similar enrichment of activity of SSAO and of the plasma membrane marker enzyme, phosphodiesterase I. However in preparations of cell membranes made by binding the cells to polycation-coated beads, enrichment of phosphodiesterase I activity was much greater than that of SSAO. It is suggested that the disposition of the enzyme within the cell membrane may account for the discrepancy in these results, i.e. the sidedness of the membrane may be important. Histochemical visualization of enzyme activity in whole tissue at the ultrastructural level was undertaken. Positive staining of mitochondria was achieved in the presence of the MAO substrate, tryptamine. Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine. Staining was largely absent when substrate was omitted or after pretreatment with the irreversible SSAO inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide. It is not definitely proven that this staining represents sites of enzyme activity but the results are consistent with evidence from other studies indicating that SSAO in brown adipose tissue of the rat may be found predominantly at the fat cell surface.(ABSTRACT TRUNCATED AT 250 WORDS)</text>
      <sentence>
        <offset>0</offset>
        <text>Amine oxidase activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (clorgyline-resistant) activity at the fat cell membrane.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amine</infon>
          <location offset="0" length="5"/>
          <text>Amine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clorgyline</infon>
          <location offset="104" length="10"/>
          <text>clorgyline</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">semicarbazide</infon>
          <location offset="79" length="13"/>
          <text>semicarbazide</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">amine oxidase</infon>
          <location offset="0" length="13"/>
          <text>Amine oxidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>161</offset>
        <text>Amine oxidase activity, previously described in homogenates of brown adipose tissue of the rat, has now been investigated in preparations of isolated fat cells.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amine</infon>
          <location offset="161" length="5"/>
          <text>Amine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">amine oxidase</infon>
          <location offset="161" length="13"/>
          <text>Amine oxidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>322</offset>
        <text>It was found that the specific activities of both monoamine oxidase A (MAO) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoamine</infon>
          <location offset="372" length="9"/>
          <text>monoamine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">semicarbazide</infon>
          <location offset="409" length="13"/>
          <text>semicarbazide</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clorgyline</infon>
          <location offset="433" length="10"/>
          <text>clorgyline</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monoamine oxidase a</infon>
          <location offset="372" length="19"/>
          <text>monoamine oxidase A</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mao</infon>
          <location offset="393" length="3"/>
          <text>MAO</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">semicarbazide-sensitive clorgyline-resistant amine oxidase</infon>
          <location offset="409" length="58"/>
          <text>semicarbazide-sensitive clorgyline-resistant amine oxidase</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ssao</infon>
          <location offset="469" length="4"/>
          <text>SSAO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>544</offset>
        <text>Brown adipocytes therefore represent a major source of both these enzymes.</text>
      </sentence>
      <sentence>
        <offset>619</offset>
        <text>In plasma membranes prepared from these isolated brown fat cells by borate extraction there was a similar enrichment of activity of SSAO and of the plasma membrane marker enzyme, phosphodiesterase I.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">borate</infon>
          <location offset="687" length="6"/>
          <text>borate</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ssao</infon>
          <location offset="751" length="4"/>
          <text>SSAO</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphodiesterase i</infon>
          <location offset="798" length="19"/>
          <text>phosphodiesterase I</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>819</offset>
        <text>However in preparations of cell membranes made by binding the cells to polycation-coated beads, enrichment of phosphodiesterase I activity was much greater than that of SSAO.</text>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphodiesterase i</infon>
          <location offset="929" length="19"/>
          <text>phosphodiesterase I</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ssao</infon>
          <location offset="988" length="4"/>
          <text>SSAO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>994</offset>
        <text>It is suggested that the disposition of the enzyme within the cell membrane may account for the discrepancy in these results, i.e. the sidedness of the membrane may be important.</text>
      </sentence>
      <sentence>
        <offset>1173</offset>
        <text>Histochemical visualization of enzyme activity in whole tissue at the ultrastructural level was undertaken.</text>
      </sentence>
      <sentence>
        <offset>1281</offset>
        <text>Positive staining of mitochondria was achieved in the presence of the MAO substrate, tryptamine.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptamine</infon>
          <location offset="1366" length="10"/>
          <text>tryptamine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mao</infon>
          <location offset="1351" length="3"/>
          <text>MAO</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1378</offset>
        <text>Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyramine</infon>
          <location offset="1466" length="8"/>
          <text>tyramine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzylamine</infon>
          <location offset="1479" length="11"/>
          <text>benzylamine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ssao</infon>
          <location offset="1449" length="4"/>
          <text>SSAO</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1492</offset>
        <text>Staining was largely absent when substrate was omitted or after pretreatment with the irreversible SSAO inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydralazine</infon>
          <location offset="1607" length="11"/>
          <text>hydralazine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">semicarbazide</infon>
          <location offset="1656" length="13"/>
          <text>semicarbazide</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ssao</infon>
          <location offset="1591" length="4"/>
          <text>SSAO</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1671</offset>
        <text>It is not definitely proven that this staining represents sites of enzyme activity but the results are consistent with evidence from other studies indicating that SSAO in brown adipose tissue of the rat may be found predominantly at the fat cell surface.(ABSTRACT TRUNCATED AT 250 WORDS)</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ssao</infon>
          <location offset="1834" length="4"/>
          <text>SSAO</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>8922768</id>
    <passage>
      <offset>0</offset>
      <text>The reversal of profound mivacurium-induced neuromuscular blockade.	PURPOSE: Mivacurium is metabolized by plasma cholinesterase catalyzed ester hydrolysis. Acetylcholinesterase antagonists used in the reversal of muscle relaxation may also inhibit plasma cholinesterase and, therefore, delay the hydrolysis of mivacurium. The clinical interaction between acetylcholinesterase antagonists and mivacurium induced neuromuscular blockade was studied. METHOD: Intraoperative muscle relaxation was maintained with a mivacurium infusion to achieve a constant intense block (first twitch, T1, 2-3% of control). Patients were randomly divided into three groups. Patients in Group 1 received no anticholinesterase, in Group 2 neostigmine 0.07 mg.kg-1, and in Group 3 edrophonium 1 mg.kg-1. The times between termination of the mivacurium infusion (Group 1) or the administration of the anticholinesterase (Groups 2 and 3) to 25%, 50%, 75% and 95% T1 recovery, and to 50%, 70% and 90% recovery in the ratio, T4/T1 (TR) were recorded. RESULT: In the neostigmine Group, T1 recovery to 25%, 50% and 75% (2.32 +/- 1.41, 3.90 +/- 1.85 and 6.88 +/- 2.66 min) was accelerated compared with control (3.36 +/- 1.34, 5.78 +/- 2.22, and 8.58 +/- 3.60, and), but recovery to 95% (18.53 +/- 9.09 vs 13.29 +/- 5.24 min) was delayed. Also, TR recovery to 50%, 70%, and 90% was slower (14.47 +/- 8.73, 21.25 +/- 11.06 and 31.37 +/- 12.11 min vs 11.75 +/- 3.74, 13.78 +/- 4.39 and 17.86 +/- 6.44 min). However, all T1 and TR recovery times were decreased in the edrophonium group (0.88 +/- 0.51, 2.00 +/- 1.50, 4.97 +/- 2.96, and 9.35 +/- 5.24 min for T1 and 6.86 +/- 3.93, 9.05 +/- 4.51 and 12.24 +/- 6.66 min for TR). CONCLUSION: Neostigmine reversal of intense mivacurium neuromuscular block should be avoided, as this may result in prolongation of the block.</text>
      <sentence>
        <offset>0</offset>
        <text>The reversal of profound mivacurium-induced neuromuscular blockade.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mivacurium</infon>
          <location offset="25" length="10"/>
          <text>mivacurium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>68</offset>
        <text>PURPOSE: Mivacurium is metabolized by plasma cholinesterase catalyzed ester hydrolysis.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mivacurium</infon>
          <location offset="77" length="10"/>
          <text>Mivacurium</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cholinesterase</infon>
          <location offset="113" length="14"/>
          <text>cholinesterase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>156</offset>
        <text>Acetylcholinesterase antagonists used in the reversal of muscle relaxation may also inhibit plasma cholinesterase and, therefore, delay the hydrolysis of mivacurium.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mivacurium</infon>
          <location offset="310" length="10"/>
          <text>mivacurium</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cholinesterase</infon>
          <location offset="255" length="14"/>
          <text>cholinesterase</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="156" length="20"/>
          <text>Acetylcholinesterase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>322</offset>
        <text>The clinical interaction between acetylcholinesterase antagonists and mivacurium induced neuromuscular blockade was studied.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mivacurium</infon>
          <location offset="392" length="10"/>
          <text>mivacurium</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="355" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>447</offset>
        <text>METHOD: Intraoperative muscle relaxation was maintained with a mivacurium infusion to achieve a constant intense block (first twitch, T1, 2-3% of control).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mivacurium</infon>
          <location offset="510" length="10"/>
          <text>mivacurium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>603</offset>
        <text>Patients were randomly divided into three groups.</text>
      </sentence>
      <sentence>
        <offset>653</offset>
        <text>Patients in Group 1 received no anticholinesterase, in Group 2 neostigmine 0.07 mg.kg-1, and in Group 3 edrophonium 1 mg.kg-1.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">neostigmine</infon>
          <location offset="716" length="11"/>
          <text>neostigmine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">edrophonium</infon>
          <location offset="757" length="11"/>
          <text>edrophonium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>780</offset>
        <text>The times between termination of the mivacurium infusion (Group 1) or the administration of the anticholinesterase (Groups 2 and 3) to 25%, 50%, 75% and 95% T1 recovery, and to 50%, 70% and 90% recovery in the ratio, T4/T1 (TR) were recorded.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mivacurium</infon>
          <location offset="817" length="10"/>
          <text>mivacurium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1023</offset>
        <text>RESULT: In the neostigmine Group, T1 recovery to 25%, 50% and 75% (2.32 +/- 1.41, 3.90 +/- 1.85 and 6.88 +/- 2.66 min) was accelerated compared with control (3.36 +/- 1.34, 5.78 +/- 2.22, and 8.58 +/- 3.60, and), but recovery to 95% (18.53 +/- 9.09 vs 13.29 +/- 5.24 min) was delayed.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">neostigmine</infon>
          <location offset="1038" length="11"/>
          <text>neostigmine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1308</offset>
        <text>Also, TR recovery to 50%, 70%, and 90% was slower (14.47 +/- 8.73, 21.25 +/- 11.06 and 31.37 +/- 12.11 min vs 11.75 +/- 3.74, 13.78 +/- 4.39 and 17.86 +/- 6.44 min).</text>
      </sentence>
      <sentence>
        <offset>1474</offset>
        <text>However, all T1 and TR recovery times were decreased in the edrophonium group (0.88 +/- 0.51, 2.00 +/- 1.50, 4.97 +/- 2.96, and 9.35 +/- 5.24 min for T1 and 6.86 +/- 3.93, 9.05 +/- 4.51 and 12.24 +/- 6.66 min for TR).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">edrophonium</infon>
          <location offset="1534" length="11"/>
          <text>edrophonium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1692</offset>
        <text>CONCLUSION: Neostigmine reversal of intense mivacurium neuromuscular block should be avoided, as this may result in prolongation of the block.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">neostigmine</infon>
          <location offset="1704" length="11"/>
          <text>Neostigmine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mivacurium</infon>
          <location offset="1736" length="10"/>
          <text>mivacurium</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15992586</id>
    <passage>
      <offset>0</offset>
      <text>2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.	2-[4-(3,4-Dimethylphenlyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393) was identified as a potent dopamine D4 receptor antagonist with excellent receptor selectivity. [3H]-spiperone competition binding assays showed that A-381393 potently bound to membrane from cells expressing recombinant human dopamine D4.4 receptor (Ki=1.5 nM), which was 20-fold higher than that of clozapine (Ki=30.4 nM). A-381393 exhibited highly selective binding for the dopamine D4.4 receptor (&gt;2700-fold) when compared to D1, D2, D3 and D5 dopamine receptors. Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM). A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells. In contrast to L-745870, A-381393 did not exhibit any significant intrinsic activity in a D4.4 receptor. In vivo, A-381393 has good brain penetration after subcutaneous administration. A-381393 inhibited penile erection induced by the selective D4 agonist PD168077 in conscious rats. Thus, A-381393 is a novel selective D4 antagonist that will enhance the ability to study dopamine D4 receptors both in vitro and in vivo.</text>
      <sentence>
        <offset>0</offset>
        <text>2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-[4-(3,4-dimethylphenyl)piperazin-1-ylmethyl]-1h benzoimidazole</infon>
          <location offset="0" length="64"/>
          <text>2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-381393</infon>
          <location offset="66" length="8"/>
          <text>A-381393</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="89" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d4 receptor</infon>
          <location offset="89" length="20"/>
          <text>dopamine D4 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>122</offset>
        <text>2-[4-(3,4-Dimethylphenlyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393) was identified as a potent dopamine D4 receptor antagonist with excellent receptor selectivity.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-[4-(3,4-dimethylphenlyl)piperazin-1-ylmethyl]-1h benzoimidazole</infon>
          <location offset="122" length="65"/>
          <text>2-[4-(3,4-Dimethylphenlyl)piperazin-1-ylmethyl]-1H benzoimidazole</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="226" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-381393</infon>
          <location offset="189" length="8"/>
          <text>A-381393</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d4 receptor</infon>
          <location offset="226" length="20"/>
          <text>dopamine D4 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>295</offset>
        <text>[3H]-spiperone competition binding assays showed that A-381393 potently bound to membrane from cells expressing recombinant human dopamine D4.4 receptor (Ki=1.5 nM), which was 20-fold higher than that of clozapine (Ki=30.4 nM).</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]-spiperone</infon>
          <location offset="295" length="14"/>
          <text>[3H]-spiperone</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-381393</infon>
          <location offset="349" length="8"/>
          <text>A-381393</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="425" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="499" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human dopamine d4.4 receptor</infon>
          <location offset="419" length="28"/>
          <text>human dopamine D4.4 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>523</offset>
        <text>A-381393 exhibited highly selective binding for the dopamine D4.4 receptor (&gt;2700-fold) when compared to D1, D2, D3 and D5 dopamine receptors.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-381393</infon>
          <location offset="523" length="8"/>
          <text>A-381393</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="575" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="646" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine d4.4 receptor</infon>
          <location offset="575" length="22"/>
          <text>dopamine D4.4 receptor</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d1, d2, d3 and d5 dopamine receptors</infon>
          <location offset="628" length="36"/>
          <text>D1, D2, D3 and D5 dopamine receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>666</offset>
        <text>Furthermore, in comparison to clozapine and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for 5-HT2A (Ki=370 nM).</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="696" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-745870</infon>
          <location offset="710" length="8"/>
          <text>L-745870</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-381393</infon>
          <location offset="720" length="8"/>
          <text>A-381393</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2a</infon>
          <location offset="899" length="6"/>
          <text>5-HT2A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>919</offset>
        <text>A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in human dopamine D2L or D3 receptor cells.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1123" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-381393</infon>
          <location offset="919" length="8"/>
          <text>A-381393</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gtp</infon>
          <location offset="990" length="3"/>
          <text>GTP</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1029" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca2+</infon>
          <location offset="1046" length="4"/>
          <text>Ca2+</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1065" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human dopamine d4.4 receptor</infon>
          <location offset="1059" length="28"/>
          <text>human dopamine D4.4 receptor</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human dopamine d2l or d3 receptor</infon>
          <location offset="1117" length="33"/>
          <text>human dopamine D2L or D3 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1158</offset>
        <text>In contrast to L-745870, A-381393 did not exhibit any significant intrinsic activity in a D4.4 receptor.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-745870</infon>
          <location offset="1173" length="8"/>
          <text>L-745870</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-381393</infon>
          <location offset="1183" length="8"/>
          <text>A-381393</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d4.4 receptor</infon>
          <location offset="1248" length="13"/>
          <text>D4.4 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1263</offset>
        <text>In vivo, A-381393 has good brain penetration after subcutaneous administration.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-381393</infon>
          <location offset="1272" length="8"/>
          <text>A-381393</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1343</offset>
        <text>A-381393 inhibited penile erection induced by the selective D4 agonist PD168077 in conscious rats.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-381393</infon>
          <location offset="1343" length="8"/>
          <text>A-381393</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pd168077</infon>
          <location offset="1414" length="8"/>
          <text>PD168077</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1442</offset>
        <text>Thus, A-381393 is a novel selective D4 antagonist that will enhance the ability to study dopamine D4 receptors both in vitro and in vivo.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">a-381393</infon>
          <location offset="1448" length="8"/>
          <text>A-381393</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1531" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine d4 receptors</infon>
          <location offset="1531" length="21"/>
          <text>dopamine D4 receptors</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23535287</id>
    <passage>
      <offset>0</offset>
      <text>Cajaninstilbene acid (CSA) exerts cytoprotective effects against oxidative stress through the Nrf2-dependent antioxidant pathway.	Cajaninstilbene acid (CSA), an active compound separated from pigeon pea leaves, possesses the highly efficient antioxidant activities. Transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2) is an important regulator of cellular oxidative stress. This study examined the role of Nrf2 in CSA-mediated antioxidant effects on human hepatocarcinoma (HepG2) cell line. The generation of reactive oxygen species (ROS) upon H2O2 and CSA treatment was lower than that of H2O2 alone. CSA activated Nrf2 as evaluated by Western blotting. A luciferase reporter assay also demonstrated that CSA-activated signaling resulted in the increased transcriptional activity of Nrf2 through binding to the antioxidant response element (ARE) enhancer sequence. Our study indicated that treatment of HepG2 cells with CSA induces Nrf2-dependent ARE activity and gene expression of heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutamate-cysteine ligase modifier subunits by activation of PI3K/AKT, ERK and JNK signaling pathways. Inhibition of Nrf2 by siRNA reduced CSA-induced upregulation of these Nrf2-related enzymes. These results suggest that the Nrf2/ARE pathway plays an important role in the regulation of CSA-mediated antioxidant effects in HepG2 cells.</text>
      <sentence>
        <offset>0</offset>
        <text>Cajaninstilbene acid (CSA) exerts cytoprotective effects against oxidative stress through the Nrf2-dependent antioxidant pathway.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cajaninstilbene acid</infon>
          <location offset="0" length="20"/>
          <text>Cajaninstilbene acid</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">csa</infon>
          <location offset="22" length="3"/>
          <text>CSA</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="94" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>130</offset>
        <text>Cajaninstilbene acid (CSA), an active compound separated from pigeon pea leaves, possesses the highly efficient antioxidant activities.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cajaninstilbene acid</infon>
          <location offset="130" length="20"/>
          <text>Cajaninstilbene acid</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">csa</infon>
          <location offset="152" length="3"/>
          <text>CSA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>266</offset>
        <text>Transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2) is an important regulator of cellular oxidative stress.</text>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nuclear factor-erythroid 2-related factor 2</infon>
          <location offset="287" length="43"/>
          <text>nuclear factor-erythroid 2-related factor 2</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="332" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>394</offset>
        <text>This study examined the role of Nrf2 in CSA-mediated antioxidant effects on human hepatocarcinoma (HepG2) cell line.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">csa</infon>
          <location offset="434" length="3"/>
          <text>CSA</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="426" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>511</offset>
        <text>The generation of reactive oxygen species (ROS) upon H2O2 and CSA treatment was lower than that of H2O2 alone.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="538" length="6"/>
          <text>oxygen</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="564" length="4"/>
          <text>H2O2</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">csa</infon>
          <location offset="573" length="3"/>
          <text>CSA</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="610" length="4"/>
          <text>H2O2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>622</offset>
        <text>CSA activated Nrf2 as evaluated by Western blotting.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">csa</infon>
          <location offset="622" length="3"/>
          <text>CSA</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="636" length="4"/>
          <text>Nrf2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>675</offset>
        <text>A luciferase reporter assay also demonstrated that CSA-activated signaling resulted in the increased transcriptional activity of Nrf2 through binding to the antioxidant response element (ARE) enhancer sequence.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">csa</infon>
          <location offset="726" length="3"/>
          <text>CSA</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="804" length="4"/>
          <text>Nrf2</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">antioxidant response element</infon>
          <location offset="832" length="28"/>
          <text>antioxidant response element</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">are</infon>
          <location offset="862" length="3"/>
          <text>ARE</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>886</offset>
        <text>Our study indicated that treatment of HepG2 cells with CSA induces Nrf2-dependent ARE activity and gene expression of heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutamate-cysteine ligase modifier subunits by activation of PI3K/AKT, ERK and JNK signaling pathways.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">csa</infon>
          <location offset="941" length="3"/>
          <text>CSA</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">heme</infon>
          <location offset="1004" length="4"/>
          <text>heme</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nad(p)h</infon>
          <location offset="1029" length="7"/>
          <text>NAD(P)H</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quinone</infon>
          <location offset="1037" length="7"/>
          <text>quinone</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="1074" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteine</infon>
          <location offset="1084" length="8"/>
          <text>cysteine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="1135" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="1140" length="3"/>
          <text>AKT</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="1145" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">jnk</infon>
          <location offset="1153" length="3"/>
          <text>JNK</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="953" length="4"/>
          <text>Nrf2</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">are</infon>
          <location offset="968" length="3"/>
          <text>ARE</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">heme oxygenase-1</infon>
          <location offset="1004" length="16"/>
          <text>heme oxygenase-1</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="1022" length="4"/>
          <text>HO-1</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nad(p)h quinone oxidoreductase 1</infon>
          <location offset="1029" length="32"/>
          <text>NAD(P)H quinone oxidoreductase 1</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nqo1</infon>
          <location offset="1063" length="4"/>
          <text>NQO1</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutamate-cysteine ligase</infon>
          <location offset="1074" length="25"/>
          <text>glutamate-cysteine ligase</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1177</offset>
        <text>Inhibition of Nrf2 by siRNA reduced CSA-induced upregulation of these Nrf2-related enzymes.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">csa</infon>
          <location offset="1213" length="3"/>
          <text>CSA</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1191" length="4"/>
          <text>Nrf2</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1247" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1269</offset>
        <text>These results suggest that the Nrf2/ARE pathway plays an important role in the regulation of CSA-mediated antioxidant effects in HepG2 cells.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">csa</infon>
          <location offset="1362" length="3"/>
          <text>CSA</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1300" length="4"/>
          <text>Nrf2</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">are</infon>
          <location offset="1305" length="3"/>
          <text>ARE</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23116643</id>
    <passage>
      <offset>0</offset>
      <text>Rosmarinic acid ameliorates acute liver damage and fibrogenesis in carbon tetrachloride-intoxicated mice.	The aim of this study was to investigate the therapeutic potential of rosmarinic acid (RA), a natural phenolic, in the treatment of acute liver toxicity. RA at 10, 25 and 50mg/kg was administered by gavage once daily for 2 consecutive days, 6h after CCl(4) intoxication. CCl(4) intoxication caused hepatic necrosis and increased serum ALT activity. In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine (3-NT) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in Cu/Zn superoxide dismutase (SOD) activity. CCl(4) administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2). RA improved histological and serum markers of liver damage and significantly ameliorated oxidative/nitrosative stress and inflammatory response in liver tissue. Additionally, RA prevented transforming growth factor-beta1 (TGF-β1) and alpha-smooth muscle actin (α-SMA) expression, suggesting suppression of profibrotic response. Furthermore, RA significantly inhibited the CCl(4)-induced apoptosis, which was evident from decreased cleavage of caspase-3. The hepatoprotective activity of RA coincided with enhanced NF-E2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) expression. The results of this study indicates that RA possesses antioxidant, anti-inflammatory, antiapoptotic and antifibrotic activity against acute liver toxicity.</text>
      <sentence>
        <offset>0</offset>
        <text>Rosmarinic acid ameliorates acute liver damage and fibrogenesis in carbon tetrachloride-intoxicated mice.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosmarinic acid</infon>
          <location offset="0" length="15"/>
          <text>Rosmarinic acid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbon tetrachloride</infon>
          <location offset="67" length="20"/>
          <text>carbon tetrachloride</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>106</offset>
        <text>The aim of this study was to investigate the therapeutic potential of rosmarinic acid (RA), a natural phenolic, in the treatment of acute liver toxicity.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosmarinic acid</infon>
          <location offset="176" length="15"/>
          <text>rosmarinic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>260</offset>
        <text>RA at 10, 25 and 50mg/kg was administered by gavage once daily for 2 consecutive days, 6h after CCl(4) intoxication.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl(4)</infon>
          <location offset="356" length="6"/>
          <text>CCl(4)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>377</offset>
        <text>CCl(4) intoxication caused hepatic necrosis and increased serum ALT activity.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl(4)</infon>
          <location offset="377" length="6"/>
          <text>CCl(4)</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alt</infon>
          <location offset="441" length="3"/>
          <text>ALT</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>455</offset>
        <text>In the livers, oxidative/nitrosative stress was evidenced by increased 3-nitrotyrosine (3-NT) and thiobarbituric acid reactive substances (TBARS) formation and a significant decrease in Cu/Zn superoxide dismutase (SOD) activity.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-nitrotyrosine</infon>
          <location offset="526" length="15"/>
          <text>3-nitrotyrosine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-nt</infon>
          <location offset="543" length="4"/>
          <text>3-NT</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiobarbituric acid</infon>
          <location offset="553" length="19"/>
          <text>thiobarbituric acid</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="641" length="2"/>
          <text>Cu</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zn</infon>
          <location offset="644" length="2"/>
          <text>Zn</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="647" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cu/zn superoxide dismutase</infon>
          <location offset="641" length="26"/>
          <text>Cu/Zn superoxide dismutase</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sod</infon>
          <location offset="669" length="3"/>
          <text>SOD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>684</offset>
        <text>CCl(4) administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2).</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl(4)</infon>
          <location offset="684" length="6"/>
          <text>CCl(4)</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nuclear factor-kappab</infon>
          <location offset="767" length="21"/>
          <text>nuclear factor-kappaB</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="790" length="5"/>
          <text>NF-κB</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor-alpha</infon>
          <location offset="836" length="27"/>
          <text>tumor necrosis factor-alpha</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="865" length="5"/>
          <text>TNF-α</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclooxygenase-2</infon>
          <location offset="876" length="16"/>
          <text>cyclooxygenase-2</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="894" length="5"/>
          <text>COX-2</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>902</offset>
        <text>RA improved histological and serum markers of liver damage and significantly ameliorated oxidative/nitrosative stress and inflammatory response in liver tissue.</text>
      </sentence>
      <sentence>
        <offset>1063</offset>
        <text>Additionally, RA prevented transforming growth factor-beta1 (TGF-β1) and alpha-smooth muscle actin (α-SMA) expression, suggesting suppression of profibrotic response.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β1</infon>
          <location offset="1124" length="6"/>
          <text>TGF-β1</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha-smooth muscle actin</infon>
          <location offset="1136" length="25"/>
          <text>alpha-smooth muscle actin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">α-sma</infon>
          <location offset="1163" length="5"/>
          <text>α-SMA</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">transforming growth factor-beta1</infon>
          <location offset="1090" length="32"/>
          <text>transforming growth factor-beta1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1230</offset>
        <text>Furthermore, RA significantly inhibited the CCl(4)-induced apoptosis, which was evident from decreased cleavage of caspase-3.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl(4)</infon>
          <location offset="1274" length="6"/>
          <text>CCl(4)</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="1345" length="9"/>
          <text>caspase-3</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1356</offset>
        <text>The hepatoprotective activity of RA coincided with enhanced NF-E2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) expression.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nf-e2-related factor 2</infon>
          <location offset="1416" length="22"/>
          <text>NF-E2-related factor 2</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="1440" length="4"/>
          <text>Nrf2</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">heme oxygenase-1</infon>
          <location offset="1450" length="16"/>
          <text>heme oxygenase-1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="1468" length="4"/>
          <text>HO-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1486</offset>
        <text>The results of this study indicates that RA possesses antioxidant, anti-inflammatory, antiapoptotic and antifibrotic activity against acute liver toxicity.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23295228</id>
    <passage>
      <offset>0</offset>
      <text>Potential monovalent cation-binding sites in aldehyde dehydrogenases.	Potassium ions are non-essential activators of several aldehyde dehydrogenases (ALDHs), whereas a few others require the cation for activity. Two kinds of cation-binding sites, which we named intra-subunit and inter-subunit, have been observed in crystal structures of ALDHs, and based on reported crystallographic data, we here propose the existence of a third kind located in the central cavity of some tetrameric ALDHs. Given the high structural similarity between these enzymes, cation-binding sites may be present in many other members of this superfamily. To explore the prevalence of these sites, we compared 37 known crystal structures from 13 different ALDH families and evaluated the possible existence of a cation on the basis of the number, distance and geometry of its potential interactions, as well as of B-factor values of modeled cations obtained in new refinements of some reported crystal structures. Also, by performing multiple alignments of 855 non-redundant amino acid sequences, we assessed the degree of conservation in their respective families of the amino acid residues putatively relevant for cation binding. Among the ALDH enzymes studied, and according to our analyses, potential intra-subunit cation-binding sites seem to be present in most members of ALDH2, ALDH1L, ALDH4, ALDH5, ALDH7, ALDH10, and ALDH25 families, as well as in the bacterial and fungal members of the ALDH9 family and in a few ALDH1, ALDH6, ALDH11 and ALDH26 enzymes; potential inter-subunit sites in members of ALDH1L, ALDH3, ALDH4 from bacillales, ALDH5, ALDH7, ALDH9, ALDH10, ALDH11 and ALDH25 families; and potential central-cavity sites only in some bacterial and animal ALDH9s and in most members of the ALDH1L family. Because potassium is the most abundant intracellular cation, we propose that these are potassium-binding sites, but the specific structural and/or functional roles of the cation bound to these different sites remain to be investigated.</text>
      <sentence>
        <offset>0</offset>
        <text>Potential monovalent cation-binding sites in aldehyde dehydrogenases.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldehyde</infon>
          <location offset="45" length="8"/>
          <text>aldehyde</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldehyde dehydrogenases</infon>
          <location offset="45" length="23"/>
          <text>aldehyde dehydrogenases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>70</offset>
        <text>Potassium ions are non-essential activators of several aldehyde dehydrogenases (ALDHs), whereas a few others require the cation for activity.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">potassium</infon>
          <location offset="70" length="9"/>
          <text>Potassium</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldehyde</infon>
          <location offset="125" length="8"/>
          <text>aldehyde</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldehyde dehydrogenases</infon>
          <location offset="125" length="23"/>
          <text>aldehyde dehydrogenases</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldhs</infon>
          <location offset="150" length="5"/>
          <text>ALDHs</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>212</offset>
        <text>Two kinds of cation-binding sites, which we named intra-subunit and inter-subunit, have been observed in crystal structures of ALDHs, and based on reported crystallographic data, we here propose the existence of a third kind located in the central cavity of some tetrameric ALDHs.</text>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldhs</infon>
          <location offset="339" length="5"/>
          <text>ALDHs</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldhs</infon>
          <location offset="486" length="5"/>
          <text>ALDHs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>493</offset>
        <text>Given the high structural similarity between these enzymes, cation-binding sites may be present in many other members of this superfamily.</text>
      </sentence>
      <sentence>
        <offset>632</offset>
        <text>To explore the prevalence of these sites, we compared 37 known crystal structures from 13 different ALDH families and evaluated the possible existence of a cation on the basis of the number, distance and geometry of its potential interactions, as well as of B-factor values of modeled cations obtained in new refinements of some reported crystal structures.</text>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh</infon>
          <location offset="732" length="4"/>
          <text>ALDH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>990</offset>
        <text>Also, by performing multiple alignments of 855 non-redundant amino acid sequences, we assessed the degree of conservation in their respective families of the amino acid residues putatively relevant for cation binding.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="1148" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="1051" length="10"/>
          <text>amino acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1208</offset>
        <text>Among the ALDH enzymes studied, and according to our analyses, potential intra-subunit cation-binding sites seem to be present in most members of ALDH2, ALDH1L, ALDH4, ALDH5, ALDH7, ALDH10, and ALDH25 families, as well as in the bacterial and fungal members of the ALDH9 family and in a few ALDH1, ALDH6, ALDH11 and ALDH26 enzymes; potential inter-subunit sites in members of ALDH1L, ALDH3, ALDH4 from bacillales, ALDH5, ALDH7, ALDH9, ALDH10, ALDH11 and ALDH25 families; and potential central-cavity sites only in some bacterial and animal ALDH9s and in most members of the ALDH1L family.</text>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh</infon>
          <location offset="1218" length="4"/>
          <text>ALDH</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh2</infon>
          <location offset="1354" length="5"/>
          <text>ALDH2</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh1l</infon>
          <location offset="1361" length="6"/>
          <text>ALDH1L</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh4</infon>
          <location offset="1369" length="5"/>
          <text>ALDH4</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh5</infon>
          <location offset="1376" length="5"/>
          <text>ALDH5</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh7</infon>
          <location offset="1383" length="5"/>
          <text>ALDH7</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh10</infon>
          <location offset="1390" length="6"/>
          <text>ALDH10</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh25</infon>
          <location offset="1402" length="6"/>
          <text>ALDH25</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh9</infon>
          <location offset="1473" length="5"/>
          <text>ALDH9</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh1</infon>
          <location offset="1499" length="5"/>
          <text>ALDH1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh6</infon>
          <location offset="1506" length="5"/>
          <text>ALDH6</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh11</infon>
          <location offset="1513" length="6"/>
          <text>ALDH11</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh26</infon>
          <location offset="1524" length="6"/>
          <text>ALDH26</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh1l</infon>
          <location offset="1584" length="6"/>
          <text>ALDH1L</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh3</infon>
          <location offset="1592" length="5"/>
          <text>ALDH3</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh4</infon>
          <location offset="1599" length="5"/>
          <text>ALDH4</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh5</infon>
          <location offset="1622" length="5"/>
          <text>ALDH5</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh7</infon>
          <location offset="1629" length="5"/>
          <text>ALDH7</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh9</infon>
          <location offset="1636" length="5"/>
          <text>ALDH9</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh10</infon>
          <location offset="1643" length="6"/>
          <text>ALDH10</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh11</infon>
          <location offset="1651" length="6"/>
          <text>ALDH11</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh25</infon>
          <location offset="1662" length="6"/>
          <text>ALDH25</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh9s</infon>
          <location offset="1748" length="6"/>
          <text>ALDH9s</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldh1l</infon>
          <location offset="1782" length="6"/>
          <text>ALDH1L</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1797</offset>
        <text>Because potassium is the most abundant intracellular cation, we propose that these are potassium-binding sites, but the specific structural and/or functional roles of the cation bound to these different sites remain to be investigated.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">potassium</infon>
          <location offset="1805" length="9"/>
          <text>potassium</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">potassium</infon>
          <location offset="1884" length="9"/>
          <text>potassium</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>8102973</id>
    <passage>
      <offset>0</offset>
      <text>Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications.	The dopamine D4 receptor, which is considered a close variant of the dopamine D2 receptor, has recently been cloned. Receptor binding studies demonstrated that clozapine, which is an effective antipsychotic agent but atypical in that it lacks the usual side effects of other antipsychotic agents, has high selectivity for the dopamine D4 receptor versus the dopamine D2 receptor. Comparative binding affinity studies have been carried out for a number of interesting dopaminergic agents using membranes prepared from cloned dopamine D2 and D4 receptor containing cells. It was found that clozapine is selective for the dopamine D4 vs. the D2 receptor by a factor of 2.8. Other compounds with dopamine D4 receptor selectivity were (+)-apomorphine (8.7), (+)-N-propyl-norapomorphine (NPA) (2.4) and melperone (1.3). Compounds with considerable selectivity for the dopamine D2 receptor were haloperidol (0.31), chlorpromazine (0.084), trifluoperazine (0.034) and raclopride (0.001). Overall, the results with the antipsychotic agents tested, support the concept that dopamine D4 receptor selectivity may confer clozapine-like antipsychotic efficacy and furthermore that dopamine D2 receptor selectivity may confer side effect liability (extrapyramidal side effects and tardive dyskinesia).</text>
      <sentence>
        <offset>0</offset>
        <text>Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="0" length="8"/>
          <text>Dopamine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="46" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d4</infon>
          <location offset="0" length="11"/>
          <text>Dopamine D4</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d2 receptor</infon>
          <location offset="19" length="11"/>
          <text>D2 receptor</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine receptor</infon>
          <location offset="46" length="17"/>
          <text>dopamine receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>112</offset>
        <text>The dopamine D4 receptor, which is considered a close variant of the dopamine D2 receptor, has recently been cloned.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="116" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="181" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d4 receptor</infon>
          <location offset="116" length="20"/>
          <text>dopamine D4 receptor</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2 receptor</infon>
          <location offset="181" length="20"/>
          <text>dopamine D2 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>229</offset>
        <text>Receptor binding studies demonstrated that clozapine, which is an effective antipsychotic agent but atypical in that it lacks the usual side effects of other antipsychotic agents, has high selectivity for the dopamine D4 receptor versus the dopamine D2 receptor.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="272" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="438" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="470" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d4 receptor</infon>
          <location offset="438" length="20"/>
          <text>dopamine D4 receptor</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2 receptor</infon>
          <location offset="470" length="20"/>
          <text>dopamine D2 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>492</offset>
        <text>Comparative binding affinity studies have been carried out for a number of interesting dopaminergic agents using membranes prepared from cloned dopamine D2 and D4 receptor containing cells.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="636" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2</infon>
          <location offset="636" length="11"/>
          <text>dopamine D2</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d4 receptor</infon>
          <location offset="652" length="11"/>
          <text>D4 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>682</offset>
        <text>It was found that clozapine is selective for the dopamine D4 vs. the D2 receptor by a factor of 2.8.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="700" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="731" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d4</infon>
          <location offset="731" length="11"/>
          <text>dopamine D4</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d2 receptor</infon>
          <location offset="751" length="11"/>
          <text>D2 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>783</offset>
        <text>Other compounds with dopamine D4 receptor selectivity were (+)-apomorphine (8.7), (+)-N-propyl-norapomorphine (NPA) (2.4) and melperone (1.3).</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="804" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(+)-apomorphine</infon>
          <location offset="842" length="15"/>
          <text>(+)-apomorphine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(+)-n-propyl-norapomorphine</infon>
          <location offset="865" length="27"/>
          <text>(+)-N-propyl-norapomorphine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melperone</infon>
          <location offset="909" length="9"/>
          <text>melperone</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d4 receptor</infon>
          <location offset="804" length="20"/>
          <text>dopamine D4 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T15" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T14" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T13" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>926</offset>
        <text>Compounds with considerable selectivity for the dopamine D2 receptor were haloperidol (0.31), chlorpromazine (0.084), trifluoperazine (0.034) and raclopride (0.001).</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="974" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">haloperidol</infon>
          <location offset="1000" length="11"/>
          <text>haloperidol</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpromazine</infon>
          <location offset="1020" length="14"/>
          <text>chlorpromazine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trifluoperazine</infon>
          <location offset="1044" length="15"/>
          <text>trifluoperazine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">raclopride</infon>
          <location offset="1072" length="10"/>
          <text>raclopride</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2 receptor</infon>
          <location offset="974" length="20"/>
          <text>dopamine D2 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T20" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T19" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T17" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1092</offset>
        <text>Overall, the results with the antipsychotic agents tested, support the concept that dopamine D4 receptor selectivity may confer clozapine-like antipsychotic efficacy and furthermore that dopamine D2 receptor selectivity may confer side effect liability (extrapyramidal side effects and tardive dyskinesia).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1176" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="1220" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1279" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d4 receptor</infon>
          <location offset="1176" length="20"/>
          <text>dopamine D4 receptor</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2 receptor</infon>
          <location offset="1279" length="20"/>
          <text>dopamine D2 receptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23205514</id>
    <passage>
      <offset>0</offset>
      <text>Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats.	1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction. When risperidone (6 mg/kg) was co-administered with silymarin (40 mg/kg) to rats orally, the C(max) of 9-hydroxyrisperidone was significantly increased to1.3-fold (p &lt; 0.05), while the other pharmacokinetic parameters did not show any significant differences. Expanding the experiment where rats were repeatedly administered with silymarin for 5 days prior to giving risperidone, the C(max) of risperidone and 9-hydroxyrisperidone were significantly increased to 2.4-fold (p &lt; 0.001) and 1.7-fold (p &lt; 0.001), respectively, and the AUC(0-t), as well to 1.7-fold (p &lt; 0.05) and 2.1-fold (p &lt; 0.01), respectively. 4. The repeated exposures of silymarin, compared to single administration of silymarin, increased oral bioavailability and affected the pharmacokinetics of risperidone and 9-hydroxyrisperidone, by inhibiting P-gp.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">9-hydroxyrisperidone</infon>
          <location offset="116" length="20"/>
          <text>9-hydroxyrisperidone</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="78" length="11"/>
          <text>risperidone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>146</offset>
        <text>1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="262" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="278" length="4"/>
          <text>P-gp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>359</offset>
        <text>2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="511" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">9-hydroxyrisperidone</infon>
          <location offset="550" length="20"/>
          <text>9-hydroxyrisperidone</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="495" length="4"/>
          <text>P-gp</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>581</offset>
        <text>3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="618" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">9-hydroxyrisperidone</infon>
          <location offset="634" length="20"/>
          <text>9-hydroxyrisperidone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>736</offset>
        <text>When risperidone (6 mg/kg) was co-administered with silymarin (40 mg/kg) to rats orally, the C(max) of 9-hydroxyrisperidone was significantly increased to1.3-fold (p &lt; 0.05), while the other pharmacokinetic parameters did not show any significant differences.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="741" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">9-hydroxyrisperidone</infon>
          <location offset="839" length="20"/>
          <text>9-hydroxyrisperidone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>996</offset>
        <text>Expanding the experiment where rats were repeatedly administered with silymarin for 5 days prior to giving risperidone, the C(max) of risperidone and 9-hydroxyrisperidone were significantly increased to 2.4-fold (p &lt; 0.001) and 1.7-fold (p &lt; 0.001), respectively, and the AUC(0-t), as well to 1.7-fold (p &lt; 0.05) and 2.1-fold (p &lt; 0.01), respectively.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">9-hydroxyrisperidone</infon>
          <location offset="1146" length="20"/>
          <text>9-hydroxyrisperidone</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="1103" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="1130" length="11"/>
          <text>risperidone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1348</offset>
        <text>4. The repeated exposures of silymarin, compared to single administration of silymarin, increased oral bioavailability and affected the pharmacokinetics of risperidone and 9-hydroxyrisperidone, by inhibiting P-gp.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="1504" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">9-hydroxyrisperidone</infon>
          <location offset="1520" length="20"/>
          <text>9-hydroxyrisperidone</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="1556" length="4"/>
          <text>P-gp</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15694653</id>
    <passage>
      <offset>0</offset>
      <text>Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor.	A model of the dopamine D2 receptor was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics clozapine and melperone. The atypical antipsychotics interacted with the halogen atom of the ring system in the direction of the transmembrane helices (TMHs) 2, 3 and 7, while the typical had the corresponding halogen atom in the direction of TMH5. Molecular dynamics simulations indicated that the average helical displacement upon binding increased in the order: typical &lt; atypical &lt; dopamine. Upon binding, the atypical induced larger displacements into TMH5 than did the typical. The typical had stronger non-bonded interactions with the receptor than had the atypical, which is in agreement with the experimental observation that the atypical antipsychotic drugs dissociate faster from the receptor than the typical antipsychotic drugs.</text>
      <sentence>
        <offset>0</offset>
        <text>Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="62" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2 receptor</infon>
          <location offset="62" length="20"/>
          <text>dopamine D2 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>84</offset>
        <text>A model of the dopamine D2 receptor was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics clozapine and melperone.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">haloperidol</infon>
          <location offset="204" length="11"/>
          <text>haloperidol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">loxapine</infon>
          <location offset="220" length="8"/>
          <text>loxapine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="99" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="262" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melperone</infon>
          <location offset="276" length="9"/>
          <text>melperone</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="167" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2 receptor</infon>
          <location offset="99" length="20"/>
          <text>dopamine D2 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>287</offset>
        <text>The atypical antipsychotics interacted with the halogen atom of the ring system in the direction of the transmembrane helices (TMHs) 2, 3 and 7, while the typical had the corresponding halogen atom in the direction of TMH5.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">halogen</infon>
          <location offset="335" length="7"/>
          <text>halogen</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">halogen</infon>
          <location offset="472" length="7"/>
          <text>halogen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>511</offset>
        <text>Molecular dynamics simulations indicated that the average helical displacement upon binding increased in the order: typical &lt; atypical &lt; dopamine.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="648" length="8"/>
          <text>dopamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>658</offset>
        <text>Upon binding, the atypical induced larger displacements into TMH5 than did the typical.</text>
      </sentence>
      <sentence>
        <offset>746</offset>
        <text>The typical had stronger non-bonded interactions with the receptor than had the atypical, which is in agreement with the experimental observation that the atypical antipsychotic drugs dissociate faster from the receptor than the typical antipsychotic drugs.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23194525</id>
    <passage>
      <offset>0</offset>
      <text>The nutritional supplement Active Hexose Correlated Compound (AHCC) has direct immunomodulatory actions on intestinal epithelial cells and macrophages involving TLR/MyD88 and NF-κB/MAPK activation.	Active Hexose Correlated Compound (AHCC) is an immunostimulatory nutritional supplement. AHCC effects and mechanism of action on intestinal epithelial cells or monocytes are poorly described. AHCC was added to the culture medium of intestinal epithelial cells (IEC18 and HT29 cells) and monocytes (THP-1 cells) and assessed the secretion of proinflammatory cytokines by ELISA. Inhibitors of NFκB and MAPKs were used to study signal transduction pathways while TLR4 and MyD88 were silenced in IEC18 cells using shRNA. It was found that AHCC induced GROα and MCP1 secretion in IEC18 and IL-8 in HT29 cells. These effects depended on NFκB activation, and partly on MAPKs activation and on the presence of MyD88 and TLR4. In THP-1 cells AHCC evoked IL-8, IL-1β and TNF-α secretion. The induction of IL-8 depended on JNK and NFκB activation. Therefore, AHCC exerts immunostimulatory effects on intestinal epithelial cells and monocytes involving TLR4/MyD88 and NFκB/MAPK signal transduction pathways.</text>
      <sentence>
        <offset>0</offset>
        <text>The nutritional supplement Active Hexose Correlated Compound (AHCC) has direct immunomodulatory actions on intestinal epithelial cells and macrophages involving TLR/MyD88 and NF-κB/MAPK activation.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hexose</infon>
          <location offset="34" length="6"/>
          <text>Hexose</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tlr</infon>
          <location offset="161" length="3"/>
          <text>TLR</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">myd88</infon>
          <location offset="165" length="5"/>
          <text>MyD88</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="175" length="5"/>
          <text>NF-κB</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="181" length="4"/>
          <text>MAPK</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>198</offset>
        <text>Active Hexose Correlated Compound (AHCC) is an immunostimulatory nutritional supplement.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hexose</infon>
          <location offset="205" length="6"/>
          <text>Hexose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>287</offset>
        <text>AHCC effects and mechanism of action on intestinal epithelial cells or monocytes are poorly described.</text>
      </sentence>
      <sentence>
        <offset>390</offset>
        <text>AHCC was added to the culture medium of intestinal epithelial cells (IEC18 and HT29 cells) and monocytes (THP-1 cells) and assessed the secretion of proinflammatory cytokines by ELISA.</text>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="555" length="9"/>
          <text>cytokines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>575</offset>
        <text>Inhibitors of NFκB and MAPKs were used to study signal transduction pathways while TLR4 and MyD88 were silenced in IEC18 cells using shRNA.</text>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nfκb</infon>
          <location offset="589" length="4"/>
          <text>NFκB</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapks</infon>
          <location offset="598" length="5"/>
          <text>MAPKs</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tlr4</infon>
          <location offset="658" length="4"/>
          <text>TLR4</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">myd88</infon>
          <location offset="667" length="5"/>
          <text>MyD88</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>715</offset>
        <text>It was found that AHCC induced GROα and MCP1 secretion in IEC18 and IL-8 in HT29 cells.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">groα</infon>
          <location offset="746" length="4"/>
          <text>GROα</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp1</infon>
          <location offset="755" length="4"/>
          <text>MCP1</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-8</infon>
          <location offset="783" length="4"/>
          <text>IL-8</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>803</offset>
        <text>These effects depended on NFκB activation, and partly on MAPKs activation and on the presence of MyD88 and TLR4.</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nfκb</infon>
          <location offset="829" length="4"/>
          <text>NFκB</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapks</infon>
          <location offset="860" length="5"/>
          <text>MAPKs</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">myd88</infon>
          <location offset="900" length="5"/>
          <text>MyD88</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tlr4</infon>
          <location offset="910" length="4"/>
          <text>TLR4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>916</offset>
        <text>In THP-1 cells AHCC evoked IL-8, IL-1β and TNF-α secretion.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-8</infon>
          <location offset="943" length="4"/>
          <text>IL-8</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-1β</infon>
          <location offset="949" length="5"/>
          <text>IL-1β</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="959" length="5"/>
          <text>TNF-α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>976</offset>
        <text>The induction of IL-8 depended on JNK and NFκB activation.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-8</infon>
          <location offset="993" length="4"/>
          <text>IL-8</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">jnk</infon>
          <location offset="1010" length="3"/>
          <text>JNK</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nfκb</infon>
          <location offset="1018" length="4"/>
          <text>NFκB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1035</offset>
        <text>Therefore, AHCC exerts immunostimulatory effects on intestinal epithelial cells and monocytes involving TLR4/MyD88 and NFκB/MAPK signal transduction pathways.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tlr4</infon>
          <location offset="1139" length="4"/>
          <text>TLR4</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">myd88</infon>
          <location offset="1144" length="5"/>
          <text>MyD88</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nfκb</infon>
          <location offset="1154" length="4"/>
          <text>NFκB</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="1159" length="4"/>
          <text>MAPK</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23527529</id>
    <passage>
      <offset>0</offset>
      <text>The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway.	Abstract 1. IPI-926 is a novel semisynthetic cyclopamine derivative that is a potent and selective Smoothened inhibitor that blocks the hedgehog signal transduction pathway. 2. The in vivo clearance of IPI-926 is low in mouse and dog and moderate in monkey. The volume of distribution is high across species. Oral bioavailability ranges from moderate in monkey to high in mouse and dog. Predicted human clearance using simple allometry is low (24 L h(-1)), predicted volume of distribution is high (469 L) and predicted half-life is long (20 h). 3. IPI-926 is highly bound to plasma proteins and has minimal interaction with human α-1-acid glycoprotein. 4. In vitro metabolic stability ranges from stable to moderately stable. Twelve oxidative metabolites were detected in mouse, rat, dog, monkey and human liver microsome incubations and none were unique to human. 5. IPI-926 is not a potent reversible inhibitor of CYP1A2, 2C8, 2C9 or 3A4 (testosterone). IPI-926 is a moderate inhibitor of CYP2C19, 2D6 and 3A4 (midazolam) with KI values of 19, 16 and 4.5 µM, respectively. IPI-926 is both a substrate and inhibitor (IC50 = 1.9 µM) of P-glycoprotein. 6. In summary, IPI-926 has desirable pre-clinical absorption, distribution, metabolism and excretion properties.</text>
      <sentence>
        <offset>0</offset>
        <text>The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ipi-926</infon>
          <location offset="82" length="7"/>
          <text>IPI-926</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>170</offset>
        <text>Abstract 1.</text>
      </sentence>
      <sentence>
        <offset>182</offset>
        <text>IPI-926 is a novel semisynthetic cyclopamine derivative that is a potent and selective Smoothened inhibitor that blocks the hedgehog signal transduction pathway.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ipi-926</infon>
          <location offset="182" length="7"/>
          <text>IPI-926</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclopamine</infon>
          <location offset="215" length="11"/>
          <text>cyclopamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>344</offset>
        <text>2. The in vivo clearance of IPI-926 is low in mouse and dog and moderate in monkey.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ipi-926</infon>
          <location offset="372" length="7"/>
          <text>IPI-926</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>428</offset>
        <text>The volume of distribution is high across species.</text>
      </sentence>
      <sentence>
        <offset>479</offset>
        <text>Oral bioavailability ranges from moderate in monkey to high in mouse and dog.</text>
      </sentence>
      <sentence>
        <offset>557</offset>
        <text>Predicted human clearance using simple allometry is low (24 L h(-1)), predicted volume of distribution is high (469 L) and predicted half-life is long (20 h).</text>
      </sentence>
      <sentence>
        <offset>716</offset>
        <text>3. IPI-926 is highly bound to plasma proteins and has minimal interaction with human α-1-acid glycoprotein.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ipi-926</infon>
          <location offset="719" length="7"/>
          <text>IPI-926</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human α-1-acid glycoprotein</infon>
          <location offset="795" length="27"/>
          <text>human α-1-acid glycoprotein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>824</offset>
        <text>4. In vitro metabolic stability ranges from stable to moderately stable.</text>
      </sentence>
      <sentence>
        <offset>897</offset>
        <text>Twelve oxidative metabolites were detected in mouse, rat, dog, monkey and human liver microsome incubations and none were unique to human.</text>
      </sentence>
      <sentence>
        <offset>1036</offset>
        <text>5. IPI-926 is not a potent reversible inhibitor of CYP1A2, 2C8, 2C9 or 3A4 (testosterone).</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ipi-926</infon>
          <location offset="1039" length="7"/>
          <text>IPI-926</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">testosterone</infon>
          <location offset="1112" length="12"/>
          <text>testosterone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp1a2, 2c8, 2c9 or 3a4</infon>
          <location offset="1087" length="23"/>
          <text>CYP1A2, 2C8, 2C9 or 3A4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1127</offset>
        <text>IPI-926 is a moderate inhibitor of CYP2C19, 2D6 and 3A4 (midazolam) with KI values of 19, 16 and 4.5 µM, respectively.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="1184" length="9"/>
          <text>midazolam</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ipi-926</infon>
          <location offset="1127" length="7"/>
          <text>IPI-926</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp2c19, 2d6 and 3a4</infon>
          <location offset="1162" length="20"/>
          <text>CYP2C19, 2D6 and 3A4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1246</offset>
        <text>IPI-926 is both a substrate and inhibitor (IC50 = 1.9 µM) of P-glycoprotein.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ipi-926</infon>
          <location offset="1246" length="7"/>
          <text>IPI-926</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="1307" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1323</offset>
        <text>6. In summary, IPI-926 has desirable pre-clinical absorption, distribution, metabolism and excretion properties.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ipi-926</infon>
          <location offset="1338" length="7"/>
          <text>IPI-926</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>2886642</id>
    <passage>
      <offset>0</offset>
      <text>Effects of ORF 17583, other histamine H2-receptor antagonists and omeprazole on gastric acid secretory states in rats and dogs.	ORF 17583, a histamine H2-receptor antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.). The nonspecific inhibition of gastric acid by ORF 17583 supports the existence of interdependence between histamine and the gastrin and cholinergic receptors on the parietal cell surface. Antisecretory potency of ORF 17583 after intraduodenal administration in pylorus-ligated rats was 6.4 times greater than cimetidine, 1.8 times greater than ranitidine, equal to that of omeprazole and 8 times less than that of famotidine. Oral antisecretory potency of ORF 17583 in gastric fistula dogs was 31 times greater than cimetidine, 3.7 times greater than ranitidine and equal to that of omeprazole and famotidine. Studies using equieffective antisecretory doses of ORF 17583 and ranitidine in dogs suggested that ORF 17583 has a short duration of antisecretory activity similar to that of ranitidine.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of ORF 17583, other histamine H2-receptor antagonists and omeprazole on gastric acid secretory states in rats and dogs.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orf 17583</infon>
          <location offset="11" length="9"/>
          <text>ORF 17583</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="28" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omeprazole</infon>
          <location offset="66" length="10"/>
          <text>omeprazole</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">histamine h2-receptor</infon>
          <location offset="28" length="21"/>
          <text>histamine H2-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T24" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>128</offset>
        <text>ORF 17583, a histamine H2-receptor antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orf 17583</infon>
          <location offset="128" length="9"/>
          <text>ORF 17583</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="141" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">betazole</infon>
          <location offset="370" length="8"/>
          <text>betazole</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="425" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetragastrin</infon>
          <location offset="436" length="12"/>
          <text>tetragastrin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bethanechol</infon>
          <location offset="450" length="11"/>
          <text>bethanechol</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-deoxy-d-glucose</infon>
          <location offset="463" length="17"/>
          <text>2-deoxy-D-glucose</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">histamine h2-receptor</infon>
          <location offset="141" length="21"/>
          <text>histamine H2-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>539</offset>
        <text>The nonspecific inhibition of gastric acid by ORF 17583 supports the existence of interdependence between histamine and the gastrin and cholinergic receptors on the parietal cell surface.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orf 17583</infon>
          <location offset="585" length="9"/>
          <text>ORF 17583</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="645" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">histamine and the gastrin and cholinergic receptors</infon>
          <location offset="645" length="51"/>
          <text>histamine and the gastrin and cholinergic receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>727</offset>
        <text>Antisecretory potency of ORF 17583 after intraduodenal administration in pylorus-ligated rats was 6.4 times greater than cimetidine, 1.8 times greater than ranitidine, equal to that of omeprazole and 8 times less than that of famotidine.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orf 17583</infon>
          <location offset="752" length="9"/>
          <text>ORF 17583</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cimetidine</infon>
          <location offset="848" length="10"/>
          <text>cimetidine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ranitidine</infon>
          <location offset="883" length="10"/>
          <text>ranitidine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omeprazole</infon>
          <location offset="912" length="10"/>
          <text>omeprazole</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">famotidine</infon>
          <location offset="953" length="10"/>
          <text>famotidine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>965</offset>
        <text>Oral antisecretory potency of ORF 17583 in gastric fistula dogs was 31 times greater than cimetidine, 3.7 times greater than ranitidine and equal to that of omeprazole and famotidine.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">famotidine</infon>
          <location offset="1137" length="10"/>
          <text>famotidine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orf 17583</infon>
          <location offset="995" length="9"/>
          <text>ORF 17583</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cimetidine</infon>
          <location offset="1055" length="10"/>
          <text>cimetidine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ranitidine</infon>
          <location offset="1090" length="10"/>
          <text>ranitidine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omeprazole</infon>
          <location offset="1122" length="10"/>
          <text>omeprazole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1149</offset>
        <text>Studies using equieffective antisecretory doses of ORF 17583 and ranitidine in dogs suggested that ORF 17583 has a short duration of antisecretory activity similar to that of ranitidine.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orf 17583</infon>
          <location offset="1200" length="9"/>
          <text>ORF 17583</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ranitidine</infon>
          <location offset="1214" length="10"/>
          <text>ranitidine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orf 17583</infon>
          <location offset="1248" length="9"/>
          <text>ORF 17583</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ranitidine</infon>
          <location offset="1324" length="10"/>
          <text>ranitidine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17617661</id>
    <passage>
      <offset>0</offset>
      <text>Glutathione S-transferase polymorphisms, cruciferous vegetable intake and cancer risk in the Central and Eastern European Kidney Cancer Study.	High consumption of cruciferous vegetables has been associated with reduced kidney cancer risk in many studies. Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by glutathione S-transferases (GSTs) before urinary excretion. Modification of this relationship by host genetic factors is unknown. We investigated cruciferous vegetable intake in 1097 cases and 1555 controls enrolled in a multicentric case-control study from the Czech Republic, Poland, Romania and Russia. To assess possible gene-diet interactions, genotyped cases (N = 925) and controls (N = 1247) for selected functional or non-synonymous polymorphisms including the GSTM1 deletion, GSTM3 3 bp deletion (IVS6 + 22-AGG) and V224I G&gt;A substitution, GSTT1 deletion and the GSTP1 I105V A&gt;G substitution. The odds ratio (OR) for low (less than once per month) versus high (at least once per week) intake of cruciferous vegetables was 1.29 [95% confidence interval (CI): 1.02-1.62; P-trend = 0.03]. When low intake of cruciferous vegetables (less than once per month) was stratified by GST genotype, higher kidney cancer risks were observed among individuals with the GSTT1 null (OR = 1.86; 95% CI: 1.07-3.23; P-interaction = 0.05) or with both GSTM1/T1 null genotypes (OR = 2.49; 95% CI: 1.08-5.77; P-interaction = 0.05). These data provide additional evidence for the role of cruciferous vegetables in cancer prevention among individuals with common, functional genetic polymorphisms.</text>
      <sentence>
        <offset>0</offset>
        <text>Glutathione S-transferase polymorphisms, cruciferous vegetable intake and cancer risk in the Central and Eastern European Kidney Cancer Study.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="0" length="11"/>
          <text>Glutathione</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s</infon>
          <location offset="12" length="1"/>
          <text>S</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathione s-transferase</infon>
          <location offset="0" length="25"/>
          <text>Glutathione S-transferase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>143</offset>
        <text>High consumption of cruciferous vegetables has been associated with reduced kidney cancer risk in many studies.</text>
      </sentence>
      <sentence>
        <offset>255</offset>
        <text>Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by glutathione S-transferases (GSTs) before urinary excretion.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isothiocyanates</infon>
          <location offset="255" length="15"/>
          <text>Isothiocyanates</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="371" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="386" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s</infon>
          <location offset="398" length="1"/>
          <text>S</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathione s-transferases</infon>
          <location offset="386" length="26"/>
          <text>glutathione S-transferases</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gsts</infon>
          <location offset="414" length="4"/>
          <text>GSTs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>446</offset>
        <text>Modification of this relationship by host genetic factors is unknown.</text>
      </sentence>
      <sentence>
        <offset>516</offset>
        <text>We investigated cruciferous vegetable intake in 1097 cases and 1555 controls enrolled in a multicentric case-control study from the Czech Republic, Poland, Romania and Russia.</text>
      </sentence>
      <sentence>
        <offset>692</offset>
        <text>To assess possible gene-diet interactions, genotyped cases (N = 925) and controls (N = 1247) for selected functional or non-synonymous polymorphisms including the GSTM1 deletion, GSTM3 3 bp deletion (IVS6 + 22-AGG) and V224I G&gt;A substitution, GSTT1 deletion and the GSTP1 I105V A&gt;G substitution.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gstm1</infon>
          <location offset="855" length="5"/>
          <text>GSTM1</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gstm3</infon>
          <location offset="871" length="5"/>
          <text>GSTM3</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">v224i</infon>
          <location offset="911" length="5"/>
          <text>V224I</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g&gt;a</infon>
          <location offset="917" length="3"/>
          <text>G&gt;A</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gstt1</infon>
          <location offset="935" length="5"/>
          <text>GSTT1</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gstp1</infon>
          <location offset="958" length="5"/>
          <text>GSTP1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">i105v</infon>
          <location offset="964" length="5"/>
          <text>I105V</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">a&gt;g</infon>
          <location offset="970" length="3"/>
          <text>A&gt;G</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>988</offset>
        <text>The odds ratio (OR) for low (less than once per month) versus high (at least once per week) intake of cruciferous vegetables was 1.29 [95% confidence interval (CI): 1.02-1.62; P-trend = 0.03].</text>
      </sentence>
      <sentence>
        <offset>1181</offset>
        <text>When low intake of cruciferous vegetables (less than once per month) was stratified by GST genotype, higher kidney cancer risks were observed among individuals with the GSTT1 null (OR = 1.86; 95% CI: 1.07-3.23; P-interaction = 0.05) or with both GSTM1/T1 null genotypes (OR = 2.49; 95% CI: 1.08-5.77; P-interaction = 0.05).</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gst</infon>
          <location offset="1268" length="3"/>
          <text>GST</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gstt1</infon>
          <location offset="1350" length="5"/>
          <text>GSTT1</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gstm1/t1</infon>
          <location offset="1427" length="8"/>
          <text>GSTM1/T1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1505</offset>
        <text>These data provide additional evidence for the role of cruciferous vegetables in cancer prevention among individuals with common, functional genetic polymorphisms.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17059881</id>
    <passage>
      <offset>0</offset>
      <text>Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.	The objective of the study is to investigate whether dopamine D2 receptor occupancy by risperidone and plasma levels over time can account for therapeutic efficacy and the latency period to response. Thirty-eight examinations with (123)I-IBZM single photon emission computed tomography were performed on 22 patients with schizophrenia, at diagnosis, 48 h after starting risperidone treatment and at a stable dose. Risperidone plasma levels were determined and psychopathologic evaluations (Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale) were carried out. No differences in the striatal/occipital (S/O) ratio or plasma levels were found between examinations at the 48-h time point and when a stable dose level had been established, so these parameters could not account for the latency period required for clinical response. D2 receptor occupancy at 48 h correlated positively with clinical improvement after 2 weeks of treatment. Therefore, if these results are confirmed, D2 receptor occupancy at the beginning of treatment with risperidone may be a predictor of subsequent clinical response.</text>
      <sentence>
        <offset>0</offset>
        <text>Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="0" length="8"/>
          <text>Dopamine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="34" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2 receptor</infon>
          <location offset="0" length="20"/>
          <text>Dopamine D2 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>111</offset>
        <text>The objective of the study is to investigate whether dopamine D2 receptor occupancy by risperidone and plasma levels over time can account for therapeutic efficacy and the latency period to response.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="164" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="198" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2 receptor</infon>
          <location offset="164" length="20"/>
          <text>dopamine D2 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>311</offset>
        <text>Thirty-eight examinations with (123)I-IBZM single photon emission computed tomography were performed on 22 patients with schizophrenia, at diagnosis, 48 h after starting risperidone treatment and at a stable dose.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(123)i-ibzm</infon>
          <location offset="342" length="11"/>
          <text>(123)I-IBZM</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="481" length="11"/>
          <text>risperidone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>525</offset>
        <text>Risperidone plasma levels were determined and psychopathologic evaluations (Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale) were carried out.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="525" length="11"/>
          <text>Risperidone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>689</offset>
        <text>No differences in the striatal/occipital (S/O) ratio or plasma levels were found between examinations at the 48-h time point and when a stable dose level had been established, so these parameters could not account for the latency period required for clinical response.</text>
      </sentence>
      <sentence>
        <offset>958</offset>
        <text>D2 receptor occupancy at 48 h correlated positively with clinical improvement after 2 weeks of treatment.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d2 receptor</infon>
          <location offset="958" length="11"/>
          <text>D2 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1064</offset>
        <text>Therefore, if these results are confirmed, D2 receptor occupancy at the beginning of treatment with risperidone may be a predictor of subsequent clinical response.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="1164" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d2 receptor</infon>
          <location offset="1107" length="11"/>
          <text>D2 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16973729</id>
    <passage>
      <offset>0</offset>
      <text>Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B receptor genes and plasma des-acyl ghrelin levels in Ay mice.	The central melanocortin (MC) pathway is suggested to mediate satiety signaling downstream of serotonin (5-HT)2C receptors. 5-HT2C receptor mutant mice consume more food, which leads to late-onset obesity and impaired glucose tolerance. Ay mice with ectopic expression of the agouti peptide, which leads to a perturbation of the central MC pathway, develop obesity and diabetes, associated with low levels of plasma total ghrelin. Here, we report that 5-wk-old Ay mice consumed more food in association with decreases in levels of plasma des-acyl ghrelin, but not active ghrelin, and increases in hypothalamic 5-HT2C and 5-HT1B receptor gene expression compared with wild-type mice matched for age and body weight. These alterations were also observed in 8-wk-old obese Ay mice. Restricted feeding significantly decreased hypothalamic 5-HT2C and 5-HT1B receptor gene expression in association with a reversal of the decreases in plasma des-acyl ghrelin levels in 5-wk-old Ay mice. Moreover, restricted feeding reduced body weight, hyperinsulinemia, and hyperglycemia in association with increases in plasma des-acyl ghrelin levels in 8-wk-old obese Ay mice. Administration of m-chlorophenylpiperazine and fenfluramine, both of which induce anorexic effects via 5-HT2C receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice. These findings suggest that the agouti peptide down-regulates hypothalamic 5-HT2C and 5-HT1B receptor gene expression under restricted feeding conditions, whereas chronic hyperphagia increases the expression of these genes and decreases plasma des-acyl ghrelin levels in Ay mice.</text>
      <sentence>
        <offset>0</offset>
        <text>Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B receptor genes and plasma des-acyl ghrelin levels in Ay mice.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="46" length="6"/>
          <text>5-HT2C</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1b</infon>
          <location offset="57" length="6"/>
          <text>5-HT1B</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">des-acyl ghrelin</infon>
          <location offset="90" length="16"/>
          <text>des-acyl ghrelin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>126</offset>
        <text>The central melanocortin (MC) pathway is suggested to mediate satiety signaling downstream of serotonin (5-HT)2C receptors.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">melanocortin</infon>
          <location offset="138" length="12"/>
          <text>melanocortin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mc</infon>
          <location offset="152" length="2"/>
          <text>MC</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serotonin (5-ht)2c receptors</infon>
          <location offset="220" length="28"/>
          <text>serotonin (5-HT)2C receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>250</offset>
        <text>5-HT2C receptor mutant mice consume more food, which leads to late-onset obesity and impaired glucose tolerance.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="344" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="250" length="6"/>
          <text>5-HT2C</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>363</offset>
        <text>Ay mice with ectopic expression of the agouti peptide, which leads to a perturbation of the central MC pathway, develop obesity and diabetes, associated with low levels of plasma total ghrelin.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">agouti peptide</infon>
          <location offset="402" length="14"/>
          <text>agouti peptide</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mc</infon>
          <location offset="463" length="2"/>
          <text>MC</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ghrelin</infon>
          <location offset="548" length="7"/>
          <text>ghrelin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>557</offset>
        <text>Here, we report that 5-wk-old Ay mice consumed more food in association with decreases in levels of plasma des-acyl ghrelin, but not active ghrelin, and increases in hypothalamic 5-HT2C and 5-HT1B receptor gene expression compared with wild-type mice matched for age and body weight.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">des-acyl ghrelin</infon>
          <location offset="664" length="16"/>
          <text>des-acyl ghrelin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ghrelin</infon>
          <location offset="697" length="7"/>
          <text>ghrelin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="736" length="6"/>
          <text>5-HT2C</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1b</infon>
          <location offset="747" length="6"/>
          <text>5-HT1B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>841</offset>
        <text>These alterations were also observed in 8-wk-old obese Ay mice.</text>
      </sentence>
      <sentence>
        <offset>905</offset>
        <text>Restricted feeding significantly decreased hypothalamic 5-HT2C and 5-HT1B receptor gene expression in association with a reversal of the decreases in plasma des-acyl ghrelin levels in 5-wk-old Ay mice.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="961" length="6"/>
          <text>5-HT2C</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1b</infon>
          <location offset="972" length="6"/>
          <text>5-HT1B</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">des-acyl ghrelin</infon>
          <location offset="1062" length="16"/>
          <text>des-acyl ghrelin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1107</offset>
        <text>Moreover, restricted feeding reduced body weight, hyperinsulinemia, and hyperglycemia in association with increases in plasma des-acyl ghrelin levels in 8-wk-old obese Ay mice.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">des-acyl ghrelin</infon>
          <location offset="1233" length="16"/>
          <text>des-acyl ghrelin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1284</offset>
        <text>Administration of m-chlorophenylpiperazine and fenfluramine, both of which induce anorexic effects via 5-HT2C receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">m-chlorophenylpiperazine</infon>
          <location offset="1302" length="24"/>
          <text>m-chlorophenylpiperazine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fenfluramine</infon>
          <location offset="1331" length="12"/>
          <text>fenfluramine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="1387" length="6"/>
          <text>5-HT2C</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1b</infon>
          <location offset="1411" length="6"/>
          <text>5-HT1B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1553</offset>
        <text>These findings suggest that the agouti peptide down-regulates hypothalamic 5-HT2C and 5-HT1B receptor gene expression under restricted feeding conditions, whereas chronic hyperphagia increases the expression of these genes and decreases plasma des-acyl ghrelin levels in Ay mice.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">agouti peptide</infon>
          <location offset="1585" length="14"/>
          <text>agouti peptide</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2c</infon>
          <location offset="1628" length="6"/>
          <text>5-HT2C</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1b</infon>
          <location offset="1639" length="6"/>
          <text>5-HT1B</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">des-acyl ghrelin</infon>
          <location offset="1797" length="16"/>
          <text>des-acyl ghrelin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23628509</id>
    <passage>
      <offset>0</offset>
      <text>Cyclopenta[c]phenanthrenes - Chemistry and biological activity.	Despite cyclopenta-fused polycyclic aromatic hydrocarbons (CP-PAHs) having been detected in the environment, the ability of these compounds to induce cellular and tissue responses remains poorly characterized. In this review, we look at the chemistry and biological activity of the cyclopenta[c]phenanthrenes (CP[c]Ph) as potential chemicals of concern in the process of risk assessment. The first part of the review deals with the environmental occurrence and chemistry of CP-PAHs, focusing on available methods of CP[c]Ph chemical synthesis. The most interesting structural feature of the CP[c]Ph is the presence of a pseudo fjord-region constructed by the cyclopentane ring. This compound can be treated either as a structurally similar one to B[c]Ph, or as a phenanthrene skeleton with an electrodonating alkyl substituent in the bay-region of the molecule. The second thread, providing available data on the adverse effects of CP[c]Ph compounds on cells and tissues of living organisms, mainly fish, improves our understanding of these possible environmental hazards. The data show that CP[c]Ph is less potent at inducing CYP1A gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist. Interestingly, the CP[c]Ph dependent up-regulation of CYP1A mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes. CP[c]Ph has, comparably to B[a]P, a potential to repress expression of tumor suppressor p53, in the head kidney of rainbow trout. Furthermore, estrogen responsive genes in fish liver, ERα and VTG, are not induced by CP[c]Ph, suggesting that the compound has no endocrine disrupting potential. However, some CP[c]Phs show mutagenic activity when investigated in the Ames test, and exhibit genotoxic properties in in vitro micronucleus assay. The above characteristics suggest that CP-PAHs are chemicals of concern for which potential pathways of exposure should be further identified.</text>
      <sentence>
        <offset>0</offset>
        <text>Cyclopenta[c]phenanthrenes - Chemistry and biological activity.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclopenta[c]phenanthrenes</infon>
          <location offset="0" length="26"/>
          <text>Cyclopenta[c]phenanthrenes</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>64</offset>
        <text>Despite cyclopenta-fused polycyclic aromatic hydrocarbons (CP-PAHs) having been detected in the environment, the ability of these compounds to induce cellular and tissue responses remains poorly characterized.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp-pahs</infon>
          <location offset="123" length="7"/>
          <text>CP-PAHs</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclopenta-fused polycyclic aromatic hydrocarbons</infon>
          <location offset="72" length="49"/>
          <text>cyclopenta-fused polycyclic aromatic hydrocarbons</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>274</offset>
        <text>In this review, we look at the chemistry and biological activity of the cyclopenta[c]phenanthrenes (CP[c]Ph) as potential chemicals of concern in the process of risk assessment.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclopenta[c]phenanthrenes</infon>
          <location offset="346" length="26"/>
          <text>cyclopenta[c]phenanthrenes</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp[c]ph</infon>
          <location offset="374" length="7"/>
          <text>CP[c]Ph</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>452</offset>
        <text>The first part of the review deals with the environmental occurrence and chemistry of CP-PAHs, focusing on available methods of CP[c]Ph chemical synthesis.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp-pahs</infon>
          <location offset="538" length="7"/>
          <text>CP-PAHs</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp[c]ph</infon>
          <location offset="580" length="7"/>
          <text>CP[c]Ph</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>608</offset>
        <text>The most interesting structural feature of the CP[c]Ph is the presence of a pseudo fjord-region constructed by the cyclopentane ring.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp[c]ph</infon>
          <location offset="655" length="7"/>
          <text>CP[c]Ph</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclopentane</infon>
          <location offset="723" length="12"/>
          <text>cyclopentane</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>742</offset>
        <text>This compound can be treated either as a structurally similar one to B[c]Ph, or as a phenanthrene skeleton with an electrodonating alkyl substituent in the bay-region of the molecule.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">b[c]ph</infon>
          <location offset="811" length="6"/>
          <text>B[c]Ph</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenanthrene</infon>
          <location offset="827" length="12"/>
          <text>phenanthrene</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alkyl</infon>
          <location offset="873" length="5"/>
          <text>alkyl</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>926</offset>
        <text>The second thread, providing available data on the adverse effects of CP[c]Ph compounds on cells and tissues of living organisms, mainly fish, improves our understanding of these possible environmental hazards.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp[c]ph</infon>
          <location offset="996" length="7"/>
          <text>CP[c]Ph</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1137</offset>
        <text>The data show that CP[c]Ph is less potent at inducing CYP1A gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp[c]ph</infon>
          <location offset="1156" length="7"/>
          <text>CP[c]Ph</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzo[a]pyrene</infon>
          <location offset="1235" length="14"/>
          <text>benzo[a]pyrene</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">b[a]p</infon>
          <location offset="1251" length="5"/>
          <text>B[a]P</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp1a</infon>
          <location offset="1191" length="5"/>
          <text>CYP1A</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1293</offset>
        <text>Interestingly, the CP[c]Ph dependent up-regulation of CYP1A mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp[c]ph</infon>
          <location offset="1312" length="7"/>
          <text>CP[c]Ph</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp1a</infon>
          <location offset="1347" length="5"/>
          <text>CYP1A</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1457</offset>
        <text>CP[c]Ph has, comparably to B[a]P, a potential to repress expression of tumor suppressor p53, in the head kidney of rainbow trout.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp[c]ph</infon>
          <location offset="1457" length="7"/>
          <text>CP[c]Ph</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">b[a]p</infon>
          <location offset="1484" length="5"/>
          <text>B[a]P</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor suppressor p53</infon>
          <location offset="1528" length="20"/>
          <text>tumor suppressor p53</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1587</offset>
        <text>Furthermore, estrogen responsive genes in fish liver, ERα and VTG, are not induced by CP[c]Ph, suggesting that the compound has no endocrine disrupting potential.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="1600" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp[c]ph</infon>
          <location offset="1673" length="7"/>
          <text>CP[c]Ph</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erα</infon>
          <location offset="1641" length="3"/>
          <text>ERα</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vtg</infon>
          <location offset="1649" length="3"/>
          <text>VTG</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1750</offset>
        <text>However, some CP[c]Phs show mutagenic activity when investigated in the Ames test, and exhibit genotoxic properties in in vitro micronucleus assay.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp[c]phs</infon>
          <location offset="1764" length="8"/>
          <text>CP[c]Phs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1898</offset>
        <text>The above characteristics suggest that CP-PAHs are chemicals of concern for which potential pathways of exposure should be further identified.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cp-pahs</infon>
          <location offset="1937" length="7"/>
          <text>CP-PAHs</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23643744</id>
    <passage>
      <offset>0</offset>
      <text>Repeated potentiation of the metabotropic glutamate receptor 5 and the alpha 7 nicotinic acetylcholine receptor modulates behavioural and GABAergic deficits induced by early postnatal phencyclidine (PCP) treatment.	The underlying mechanism of the GABAergic deficits observed in schizophrenia has been proposed to involve NMDA receptor hypofunction. An emerging treatment strategy therefore aims at enhancing GABAergic signalling by increasing the excitatory transmission onto interneurons. We wanted to determine whether behavioural and GABAergic functional deficits induced by the NMDA receptor channel blocker, phencyclidine (PCP), could be reversed by repeated administration of two drugs known to enhance GABAergic transmission: the positive allosteric modulator (PAM) of the metabotropic glutamate receptor 5 (mGluR5), ADX47273, and the partial agonist of the α7 nicotinic acetylcholine receptor (α7 nAChR), SSR180711. Adolescent rats (4-5 weeks) subjected to PCP treatment during the second postnatal week displayed a consistent deficit in prepulse inhibition (PPI), which was reversed by a one week treatment with ADX47273 or SSR180711. We examined GABAergic transmission by whole cell patch-clamp recordings of miniature inhibitory postsynaptic currents (mIPSC) in pyramidal neurons in layer II/III of prefrontal cortex (PFC) and by activation of extrasynaptic δ-containing GABAA receptors by THIP. Following PCP treatment, pyramidal neurons displayed a reduced mIPSC frequency and up-regulation of extrasynaptic THIP-induced current. ADX47273 treatment restored this up-regulation of THIP-induced current. Finally, we showed that repeated treatment with ADX47273 and SSR180711 decreased the induction of spontaneous inhibitory current caused by acute and direct agonism of mGluR5s and α7 nAChRs in slices. These results show that repeated administration of ADX47273 or SSR180711 reverses certain behavioural and functional deficits induced by PCP, likely through down-regulation or desensitisation of mGluR5s and α7 nAChRs, respectively.</text>
      <sentence>
        <offset>0</offset>
        <text>Repeated potentiation of the metabotropic glutamate receptor 5 and the alpha 7 nicotinic acetylcholine receptor modulates behavioural and GABAergic deficits induced by early postnatal phencyclidine (PCP) treatment.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phencyclidine</infon>
          <location offset="184" length="13"/>
          <text>phencyclidine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcp</infon>
          <location offset="199" length="3"/>
          <text>PCP</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="42" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="89" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">metabotropic glutamate receptor 5</infon>
          <location offset="29" length="33"/>
          <text>metabotropic glutamate receptor 5</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha 7 nicotinic acetylcholine receptor</infon>
          <location offset="71" length="40"/>
          <text>alpha 7 nicotinic acetylcholine receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T22" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T22" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>215</offset>
        <text>The underlying mechanism of the GABAergic deficits observed in schizophrenia has been proposed to involve NMDA receptor hypofunction.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="321" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptor</infon>
          <location offset="321" length="13"/>
          <text>NMDA receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>349</offset>
        <text>An emerging treatment strategy therefore aims at enhancing GABAergic signalling by increasing the excitatory transmission onto interneurons.</text>
      </sentence>
      <sentence>
        <offset>490</offset>
        <text>We wanted to determine whether behavioural and GABAergic functional deficits induced by the NMDA receptor channel blocker, phencyclidine (PCP), could be reversed by repeated administration of two drugs known to enhance GABAergic transmission: the positive allosteric modulator (PAM) of the metabotropic glutamate receptor 5 (mGluR5), ADX47273, and the partial agonist of the α7 nicotinic acetylcholine receptor (α7 nAChR), SSR180711.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="582" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phencyclidine</infon>
          <location offset="613" length="13"/>
          <text>phencyclidine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcp</infon>
          <location offset="628" length="3"/>
          <text>PCP</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="793" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="878" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ssr180711</infon>
          <location offset="913" length="9"/>
          <text>SSR180711</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptor</infon>
          <location offset="582" length="13"/>
          <text>NMDA receptor</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">metabotropic glutamate receptor 5</infon>
          <location offset="780" length="33"/>
          <text>metabotropic glutamate receptor 5</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglur5</infon>
          <location offset="815" length="6"/>
          <text>mGluR5</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">α7 nicotinic acetylcholine receptor</infon>
          <location offset="865" length="35"/>
          <text>α7 nicotinic acetylcholine receptor</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">α7 nachr</infon>
          <location offset="902" length="8"/>
          <text>α7 nAChR</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T17" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T17" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>924</offset>
        <text>Adolescent rats (4-5 weeks) subjected to PCP treatment during the second postnatal week displayed a consistent deficit in prepulse inhibition (PPI), which was reversed by a one week treatment with ADX47273 or SSR180711.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcp</infon>
          <location offset="965" length="3"/>
          <text>PCP</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adx47273</infon>
          <location offset="1121" length="8"/>
          <text>ADX47273</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ssr180711</infon>
          <location offset="1133" length="9"/>
          <text>SSR180711</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1144</offset>
        <text>We examined GABAergic transmission by whole cell patch-clamp recordings of miniature inhibitory postsynaptic currents (mIPSC) in pyramidal neurons in layer II/III of prefrontal cortex (PFC) and by activation of extrasynaptic δ-containing GABAA receptors by THIP.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thip</infon>
          <location offset="1401" length="4"/>
          <text>THIP</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gabaa receptors</infon>
          <location offset="1382" length="15"/>
          <text>GABAA receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1407</offset>
        <text>Following PCP treatment, pyramidal neurons displayed a reduced mIPSC frequency and up-regulation of extrasynaptic THIP-induced current.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcp</infon>
          <location offset="1417" length="3"/>
          <text>PCP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thip</infon>
          <location offset="1521" length="4"/>
          <text>THIP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1543</offset>
        <text>ADX47273 treatment restored this up-regulation of THIP-induced current.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adx47273</infon>
          <location offset="1543" length="8"/>
          <text>ADX47273</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thip</infon>
          <location offset="1593" length="4"/>
          <text>THIP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1615</offset>
        <text>Finally, we showed that repeated treatment with ADX47273 and SSR180711 decreased the induction of spontaneous inhibitory current caused by acute and direct agonism of mGluR5s and α7 nAChRs in slices.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adx47273</infon>
          <location offset="1663" length="8"/>
          <text>ADX47273</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ssr180711</infon>
          <location offset="1676" length="9"/>
          <text>SSR180711</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglur5s</infon>
          <location offset="1782" length="7"/>
          <text>mGluR5s</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">α7 nachrs</infon>
          <location offset="1794" length="9"/>
          <text>α7 nAChRs</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1815</offset>
        <text>These results show that repeated administration of ADX47273 or SSR180711 reverses certain behavioural and functional deficits induced by PCP, likely through down-regulation or desensitisation of mGluR5s and α7 nAChRs, respectively.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adx47273</infon>
          <location offset="1866" length="8"/>
          <text>ADX47273</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ssr180711</infon>
          <location offset="1878" length="9"/>
          <text>SSR180711</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcp</infon>
          <location offset="1952" length="3"/>
          <text>PCP</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglur5s</infon>
          <location offset="2010" length="7"/>
          <text>mGluR5s</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">α7 nachrs</infon>
          <location offset="2022" length="9"/>
          <text>α7 nAChRs</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16319075</id>
    <passage>
      <offset>0</offset>
      <text>Calcium-permeable acid-sensing ion channel is a molecular target of the neurotoxic metal ion lead.	Acid-sensing ion channels (ASICs) are emerging as fundamental players in the regulation of neural plasticity and in pathological conditions. Here we showed that lead (Pb2+), a well known neurotoxic metal ion, reversibly and concentration-dependently inhibited ASIC currents in the acutely dissociated spinal dorsal horn and hippocampal CA1 neurons of rats. In vitro expression of ASIC subunits in combination demonstrated that both ASIC1 and -3 subunits were sensitive to Pb2+. Mechanistically, Pb2+ reduced the pH sensitivity of ASICs independent of membrane voltage change. Moreover, Pb2+ inhibited the ASIC-mediated membrane depolarization and the elevation of intracellular Ca2+ concentration. In addition, we compared the effect of Pb2+ with that of Ca2+ or amiloride to explore the possible interactions of Pb2+ and Ca2+ in regulating ASICs, and we found that Pb2+ inhibited ASIC currents independent of the amiloride/Ca2+ blockade. Because ASIC1b and -3 subunits are mainly expressed in peripheral neurons, our data identified ASIC1a-containing Ca2+-permeable ASIC as a novel central target of Pb2+ action, which may contribute to Pb2+ neurotoxicity.</text>
      <sentence>
        <offset>0</offset>
        <text>Calcium-permeable acid-sensing ion channel is a molecular target of the neurotoxic metal ion lead.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="0" length="7"/>
          <text>Calcium</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">acid-sensing ion channel</infon>
          <location offset="18" length="24"/>
          <text>acid-sensing ion channel</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T17" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>99</offset>
        <text>Acid-sensing ion channels (ASICs) are emerging as fundamental players in the regulation of neural plasticity and in pathological conditions.</text>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">acid-sensing ion channels</infon>
          <location offset="99" length="25"/>
          <text>Acid-sensing ion channels</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asics</infon>
          <location offset="126" length="5"/>
          <text>ASICs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>240</offset>
        <text>Here we showed that lead (Pb2+), a well known neurotoxic metal ion, reversibly and concentration-dependently inhibited ASIC currents in the acutely dissociated spinal dorsal horn and hippocampal CA1 neurons of rats.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb2+</infon>
          <location offset="266" length="4"/>
          <text>Pb2+</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asic</infon>
          <location offset="359" length="4"/>
          <text>ASIC</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>456</offset>
        <text>In vitro expression of ASIC subunits in combination demonstrated that both ASIC1 and -3 subunits were sensitive to Pb2+.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb2+</infon>
          <location offset="571" length="4"/>
          <text>Pb2+</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asic</infon>
          <location offset="479" length="4"/>
          <text>ASIC</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asic1 and -3</infon>
          <location offset="531" length="12"/>
          <text>ASIC1 and -3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>577</offset>
        <text>Mechanistically, Pb2+ reduced the pH sensitivity of ASICs independent of membrane voltage change.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb2+</infon>
          <location offset="594" length="4"/>
          <text>Pb2+</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asics</infon>
          <location offset="629" length="5"/>
          <text>ASICs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>675</offset>
        <text>Moreover, Pb2+ inhibited the ASIC-mediated membrane depolarization and the elevation of intracellular Ca2+ concentration.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb2+</infon>
          <location offset="685" length="4"/>
          <text>Pb2+</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca2+</infon>
          <location offset="777" length="4"/>
          <text>Ca2+</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asic</infon>
          <location offset="704" length="4"/>
          <text>ASIC</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T8" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>797</offset>
        <text>In addition, we compared the effect of Pb2+ with that of Ca2+ or amiloride to explore the possible interactions of Pb2+ and Ca2+ in regulating ASICs, and we found that Pb2+ inhibited ASIC currents independent of the amiloride/Ca2+ blockade.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb2+</infon>
          <location offset="836" length="4"/>
          <text>Pb2+</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca2+</infon>
          <location offset="854" length="4"/>
          <text>Ca2+</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amiloride</infon>
          <location offset="862" length="9"/>
          <text>amiloride</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb2+</infon>
          <location offset="912" length="4"/>
          <text>Pb2+</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca2+</infon>
          <location offset="921" length="4"/>
          <text>Ca2+</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb2+</infon>
          <location offset="965" length="4"/>
          <text>Pb2+</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amiloride</infon>
          <location offset="1013" length="9"/>
          <text>amiloride</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca2+</infon>
          <location offset="1023" length="4"/>
          <text>Ca2+</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asics</infon>
          <location offset="940" length="5"/>
          <text>ASICs</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asic</infon>
          <location offset="980" length="4"/>
          <text>ASIC</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1038</offset>
        <text>Because ASIC1b and -3 subunits are mainly expressed in peripheral neurons, our data identified ASIC1a-containing Ca2+-permeable ASIC as a novel central target of Pb2+ action, which may contribute to Pb2+ neurotoxicity.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca2+</infon>
          <location offset="1151" length="4"/>
          <text>Ca2+</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb2+</infon>
          <location offset="1200" length="4"/>
          <text>Pb2+</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb2+</infon>
          <location offset="1237" length="4"/>
          <text>Pb2+</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">asic1a</infon>
          <location offset="1133" length="6"/>
          <text>ASIC1a</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asic</infon>
          <location offset="1166" length="4"/>
          <text>ASIC</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asic1b and -3</infon>
          <location offset="1046" length="13"/>
          <text>ASIC1b and -3</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17125913</id>
    <passage>
      <offset>0</offset>
      <text>Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism.	Breast cancer (BC) is linked to estrogen exposure. Estradiol (E2) stimulates BC cells proliferation by binding the estrogen receptor (ER). Hormone-related cancers have been linked to estrogenic environmental contaminants. Cadmium (Cd) a toxic pollutant, acts as estrogens in BC cells. Purpose of our study was to evaluate whether Cd regulates MCF-7 cell proliferation by activating ERK1/2, Akt and PDGFRalpha kinases. Cd increased cell proliferation and the ER-antagonist ICI 182,780 blunted it. To characterize an ER-dependent mechanism, ERalpha/beta expression was evaluated. Cd decreased ERalpha expression, but not ERbeta. Cd also increased ERK1/2, Akt and PDGFRalpha phosphorylation while ICI blocked it. Since stimulation of phosphorylation was slower than expected, c-fos and c-jun proto-oncogenes, and PDGFA were analyzed. Cd rapidly increased c-jun, c-fos and PDGFA expression. Cells were also co-incubated with the Cd and specific kinases inhibitors, which blocked the Cd-stimulated proliferation. In conclusion, our results indicate that Cd increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.</text>
      <sentence>
        <offset>0</offset>
        <text>Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="0" length="7"/>
          <text>Cadmium</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">eralpha</infon>
          <location offset="64" length="7"/>
          <text>ERalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>93</offset>
        <text>Breast cancer (BC) is linked to estrogen exposure.</text>
      </sentence>
      <sentence>
        <offset>144</offset>
        <text>Estradiol (E2) stimulates BC cells proliferation by binding the estrogen receptor (ER).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estradiol</infon>
          <location offset="144" length="9"/>
          <text>Estradiol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">e2</infon>
          <location offset="155" length="2"/>
          <text>E2</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">estrogen receptor</infon>
          <location offset="208" length="17"/>
          <text>estrogen receptor</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="227" length="2"/>
          <text>ER</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>232</offset>
        <text>Hormone-related cancers have been linked to estrogenic environmental contaminants.</text>
      </sentence>
      <sentence>
        <offset>315</offset>
        <text>Cadmium (Cd) a toxic pollutant, acts as estrogens in BC cells.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="315" length="7"/>
          <text>Cadmium</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cd</infon>
          <location offset="324" length="2"/>
          <text>Cd</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>378</offset>
        <text>Purpose of our study was to evaluate whether Cd regulates MCF-7 cell proliferation by activating ERK1/2, Akt and PDGFRalpha kinases.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cd</infon>
          <location offset="423" length="2"/>
          <text>Cd</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="475" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="483" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgfralpha</infon>
          <location offset="491" length="10"/>
          <text>PDGFRalpha</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinases</infon>
          <location offset="502" length="7"/>
          <text>kinases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>511</offset>
        <text>Cd increased cell proliferation and the ER-antagonist ICI 182,780 blunted it.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cd</infon>
          <location offset="511" length="2"/>
          <text>Cd</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="551" length="2"/>
          <text>ER</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>589</offset>
        <text>To characterize an ER-dependent mechanism, ERalpha/beta expression was evaluated.</text>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="608" length="2"/>
          <text>ER</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">eralpha/beta</infon>
          <location offset="632" length="12"/>
          <text>ERalpha/beta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>671</offset>
        <text>Cd decreased ERalpha expression, but not ERbeta.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cd</infon>
          <location offset="671" length="2"/>
          <text>Cd</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">eralpha</infon>
          <location offset="684" length="7"/>
          <text>ERalpha</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbeta</infon>
          <location offset="712" length="6"/>
          <text>ERbeta</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>720</offset>
        <text>Cd also increased ERK1/2, Akt and PDGFRalpha phosphorylation while ICI blocked it.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cd</infon>
          <location offset="720" length="2"/>
          <text>Cd</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="738" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="746" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgfralpha</infon>
          <location offset="754" length="10"/>
          <text>PDGFRalpha</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>803</offset>
        <text>Since stimulation of phosphorylation was slower than expected, c-fos and c-jun proto-oncogenes, and PDGFA were analyzed.</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-fos</infon>
          <location offset="866" length="5"/>
          <text>c-fos</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-jun</infon>
          <location offset="876" length="5"/>
          <text>c-jun</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgfa</infon>
          <location offset="903" length="5"/>
          <text>PDGFA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>924</offset>
        <text>Cd rapidly increased c-jun, c-fos and PDGFA expression.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cd</infon>
          <location offset="924" length="2"/>
          <text>Cd</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c-jun</infon>
          <location offset="945" length="5"/>
          <text>c-jun</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c-fos</infon>
          <location offset="952" length="5"/>
          <text>c-fos</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgfa</infon>
          <location offset="962" length="5"/>
          <text>PDGFA</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>980</offset>
        <text>Cells were also co-incubated with the Cd and specific kinases inhibitors, which blocked the Cd-stimulated proliferation.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cd</infon>
          <location offset="1018" length="2"/>
          <text>Cd</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cd</infon>
          <location offset="1072" length="2"/>
          <text>Cd</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinases</infon>
          <location offset="1034" length="7"/>
          <text>kinases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1101</offset>
        <text>In conclusion, our results indicate that Cd increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cd</infon>
          <location offset="1142" length="2"/>
          <text>Cd</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="1201" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="1206" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgfralpha</infon>
          <location offset="1217" length="10"/>
          <text>PDGFRalpha</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinases</infon>
          <location offset="1228" length="7"/>
          <text>kinases</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-fos</infon>
          <location offset="1266" length="5"/>
          <text>c-fos</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-jun</infon>
          <location offset="1273" length="5"/>
          <text>c-jun</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgfa</infon>
          <location offset="1283" length="5"/>
          <text>PDGFA</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">eralpha</infon>
          <location offset="1295" length="7"/>
          <text>ERalpha</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11455568</id>
    <passage>
      <offset>0</offset>
      <text>Effects of 1alpha,25-(OH)(2)D(3) on rat growth zone chondrocytes are mediated via cyclooxygenase-1 and phospholipase A(2).	1alpha,25-(OH)(2)D(3) mediates its effects on growth zone chondrocytes via rapid membrane-associated events as well as through traditional nuclear receptor mechanisms. The membrane-associated signaling pathways include rapid production of diacylglycerol and activation of protein kinase C (PKC), as well as activation of phospholipase A(2) (PLA(2)), increased production of arachidonic acid, and increased production of prostaglandins. This study examined the roles of PLA(2) and cyclooxygenase (Cox) in the mechanism of action of 1alpha,25-(OH)(2)D(3) in these cells to determine whether one or both enzymes catalyze the rate limiting step and whether constitutive or inducible Cox is involved. Cultures were incubated with 1alpha,25-(OH)(2)D(3) for 9 min to measure PKC or for 24 h to measure physiological responses ([(3)H]-thymidine incorporation, alkaline phosphatase specific activity, [(35)S]-sulfate incorporation). Based on RT-PCR and Northern blot analysis, growth zone chondrocytes expressed mRNAs for both Cox-1 and Cox-2 and neither Cox was modulated by 1alpha,25-(OH)(2)D(3). To examine the role of Cox, the cultures were also treated with resveratrol (a specific inhibitor of Cox-1), NS-398 (a specific inhibitor of Cox-2), or indomethacin (a general Cox inhibitor). The results showed that Cox-1 inhibition reduced the 1alpha,25-(OH)(2)D(3)-dependent effects on proliferation, differentiation, and matrix production, whereas inhibition of Cox-2 only had an effect on proliferation. The effects of Cox inhibition were not rate limiting, based on experiments in which PLA(2) was activated with melittin or inhibited with quinacrine. However, at least part of the action of 1alpha,25-(OH)(2)D(3) was regulated by metabolism of arachidonic acid to prostaglandins. This supports the hypothesis that 1alpha,25-(OH)(2)D(3) exerts its effects via more than one signaling pathway and that these pathways are interrelated via the modulation of PLA(2) as a rate-limiting step. PKC regulation may occur at multiple stages in the signal transduction cascade. J. Cell. Biochem. Suppl. 36: 32-45, 2001.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of 1alpha,25-(OH)(2)D(3) on rat growth zone chondrocytes are mediated via cyclooxygenase-1 and phospholipase A(2).</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1alpha,25-(oh)(2)d(3)</infon>
          <location offset="11" length="21"/>
          <text>1alpha,25-(OH)(2)D(3)</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phospholipase a(2)</infon>
          <location offset="103" length="18"/>
          <text>phospholipase A(2)</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclooxygenase-1</infon>
          <location offset="82" length="16"/>
          <text>cyclooxygenase-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>123</offset>
        <text>1alpha,25-(OH)(2)D(3) mediates its effects on growth zone chondrocytes via rapid membrane-associated events as well as through traditional nuclear receptor mechanisms.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1alpha,25-(oh)(2)d(3)</infon>
          <location offset="123" length="21"/>
          <text>1alpha,25-(OH)(2)D(3)</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nuclear receptor</infon>
          <location offset="262" length="16"/>
          <text>nuclear receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>291</offset>
        <text>The membrane-associated signaling pathways include rapid production of diacylglycerol and activation of protein kinase C (PKC), as well as activation of phospholipase A(2) (PLA(2)), increased production of arachidonic acid, and increased production of prostaglandins.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diacylglycerol</infon>
          <location offset="362" length="14"/>
          <text>diacylglycerol</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arachidonic acid</infon>
          <location offset="497" length="16"/>
          <text>arachidonic acid</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prostaglandins</infon>
          <location offset="543" length="14"/>
          <text>prostaglandins</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein kinase c</infon>
          <location offset="395" length="16"/>
          <text>protein kinase C</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pkc</infon>
          <location offset="413" length="3"/>
          <text>PKC</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phospholipase a(2)</infon>
          <location offset="444" length="18"/>
          <text>phospholipase A(2)</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pla(2)</infon>
          <location offset="464" length="6"/>
          <text>PLA(2)</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T13" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T13" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T14" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T14" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>559</offset>
        <text>This study examined the roles of PLA(2) and cyclooxygenase (Cox) in the mechanism of action of 1alpha,25-(OH)(2)D(3) in these cells to determine whether one or both enzymes catalyze the rate limiting step and whether constitutive or inducible Cox is involved.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1alpha,25-(oh)(2)d(3)</infon>
          <location offset="654" length="21"/>
          <text>1alpha,25-(OH)(2)D(3)</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pla(2)</infon>
          <location offset="592" length="6"/>
          <text>PLA(2)</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyclooxygenase</infon>
          <location offset="603" length="14"/>
          <text>cyclooxygenase</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="619" length="3"/>
          <text>Cox</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="802" length="3"/>
          <text>Cox</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>819</offset>
        <text>Cultures were incubated with 1alpha,25-(OH)(2)D(3) for 9 min to measure PKC or for 24 h to measure physiological responses ([(3)H]-thymidine incorporation, alkaline phosphatase specific activity, [(35)S]-sulfate incorporation).</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1alpha,25-(oh)(2)d(3)</infon>
          <location offset="848" length="21"/>
          <text>1alpha,25-(OH)(2)D(3)</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">([(3)h]-thymidine</infon>
          <location offset="942" length="17"/>
          <text>([(3)H]-thymidine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(35)s]-sulfate</infon>
          <location offset="1015" length="15"/>
          <text>[(35)S]-sulfate</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pkc</infon>
          <location offset="891" length="3"/>
          <text>PKC</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alkaline phosphatase</infon>
          <location offset="975" length="20"/>
          <text>alkaline phosphatase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1047</offset>
        <text>Based on RT-PCR and Northern blot analysis, growth zone chondrocytes expressed mRNAs for both Cox-1 and Cox-2 and neither Cox was modulated by 1alpha,25-(OH)(2)D(3).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1alpha,25-(oh)(2)d(3)</infon>
          <location offset="1190" length="21"/>
          <text>1alpha,25-(OH)(2)D(3)</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-1</infon>
          <location offset="1141" length="5"/>
          <text>Cox-1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="1151" length="5"/>
          <text>Cox-2</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="1169" length="3"/>
          <text>Cox</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1213</offset>
        <text>To examine the role of Cox, the cultures were also treated with resveratrol (a specific inhibitor of Cox-1), NS-398 (a specific inhibitor of Cox-2), or indomethacin (a general Cox inhibitor).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">resveratrol</infon>
          <location offset="1277" length="11"/>
          <text>resveratrol</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ns-398</infon>
          <location offset="1322" length="6"/>
          <text>NS-398</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="1365" length="12"/>
          <text>indomethacin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="1236" length="3"/>
          <text>Cox</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-1</infon>
          <location offset="1314" length="5"/>
          <text>Cox-1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="1354" length="5"/>
          <text>Cox-2</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="1389" length="3"/>
          <text>Cox</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1405</offset>
        <text>The results showed that Cox-1 inhibition reduced the 1alpha,25-(OH)(2)D(3)-dependent effects on proliferation, differentiation, and matrix production, whereas inhibition of Cox-2 only had an effect on proliferation.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1alpha,25-(oh)(2)d(3)</infon>
          <location offset="1458" length="21"/>
          <text>1alpha,25-(OH)(2)D(3)</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-1</infon>
          <location offset="1429" length="5"/>
          <text>Cox-1</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="1578" length="5"/>
          <text>Cox-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1621</offset>
        <text>The effects of Cox inhibition were not rate limiting, based on experiments in which PLA(2) was activated with melittin or inhibited with quinacrine.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quinacrine</infon>
          <location offset="1758" length="10"/>
          <text>quinacrine</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="1636" length="3"/>
          <text>Cox</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pla(2)</infon>
          <location offset="1705" length="6"/>
          <text>PLA(2)</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1770</offset>
        <text>However, at least part of the action of 1alpha,25-(OH)(2)D(3) was regulated by metabolism of arachidonic acid to prostaglandins.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1alpha,25-(oh)(2)d(3)</infon>
          <location offset="1810" length="21"/>
          <text>1alpha,25-(OH)(2)D(3)</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arachidonic acid</infon>
          <location offset="1863" length="16"/>
          <text>arachidonic acid</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prostaglandins</infon>
          <location offset="1883" length="14"/>
          <text>prostaglandins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1899</offset>
        <text>This supports the hypothesis that 1alpha,25-(OH)(2)D(3) exerts its effects via more than one signaling pathway and that these pathways are interrelated via the modulation of PLA(2) as a rate-limiting step.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1alpha,25-(oh)(2)d(3)</infon>
          <location offset="1933" length="21"/>
          <text>1alpha,25-(OH)(2)D(3)</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pla(2)</infon>
          <location offset="2073" length="6"/>
          <text>PLA(2)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2105</offset>
        <text>PKC regulation may occur at multiple stages in the signal transduction cascade.</text>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pkc</infon>
          <location offset="2105" length="3"/>
          <text>PKC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2185</offset>
        <text>J. Cell.</text>
      </sentence>
      <sentence>
        <offset>2194</offset>
        <text>Biochem.</text>
      </sentence>
      <sentence>
        <offset>2203</offset>
        <text>Suppl.</text>
      </sentence>
      <sentence>
        <offset>2210</offset>
        <text>36: 32-45, 2001.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15554912</id>
    <passage>
      <offset>0</offset>
      <text>Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.	The importance of mineralocorticoid receptor (MR) antagonists in the treatment of cardiovascular disease has been emphasised by two recent clinical trials, one using spironolactone and the other using a new selective MR antagonist, namely eplerenone. Eplerenone has a very low affinity for the glucocorticoid receptor (GR). Determinants of binding specificity of eplerenone to the MR were investigated using chimeras created between the ligand-binding domains (LBD) of the MR and the GR. These chimeras had been used previously to investigate aldosterone and spironolactone binding specificity to the MR. Eplerenone competed strongly for [(3)H]-dexamethasone binding to a MR/GR chimera containing amino acids 804-874 of the MR and weakly to a chimera containing amino acids 672-803 of the MR. Within the 804-874 region, eplerenone competed for [(3)H]-dexamethasone binding to a chimera containing amino acids 820-844 of the MR, although the calculated affinity was approximately 10-fold lower than for binding to the full-length MR LBD. Similar results were obtained using another MR antagonist, namely spironolactone. Modelling of eplerenone binding to the MR LBD, based on the GR LBD crystal structure, suggests that amino acids 820-844 affect the overall shape of the ligand-binding pocket and that eplerenone acts as an MR antagonist because it fails to stabilize the active conformation of the receptor. In contrast with results with the MR antagonists eplerenone and spironolactone, amino acids 820-844 are sufficient in themselves to confer high-affinity aldosterone binding to the MR, suggesting that the binding determinants of the two antagonists are similar to each other but differ from those of aldosterone.</text>
      <sentence>
        <offset>0</offset>
        <text>Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eplerenone</infon>
          <location offset="35" length="10"/>
          <text>eplerenone</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spironolactone</infon>
          <location offset="47" length="14"/>
          <text>spironolactone</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="66" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mineralocorticoid receptor</infon>
          <location offset="93" length="26"/>
          <text>mineralocorticoid receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T22" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T24" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>121</offset>
        <text>The importance of mineralocorticoid receptor (MR) antagonists in the treatment of cardiovascular disease has been emphasised by two recent clinical trials, one using spironolactone and the other using a new selective MR antagonist, namely eplerenone.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spironolactone</infon>
          <location offset="287" length="14"/>
          <text>spironolactone</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eplerenone</infon>
          <location offset="360" length="10"/>
          <text>eplerenone</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mineralocorticoid receptor</infon>
          <location offset="139" length="26"/>
          <text>mineralocorticoid receptor</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="338" length="2"/>
          <text>MR</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="167" length="2"/>
          <text>MR</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T10" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>372</offset>
        <text>Eplerenone has a very low affinity for the glucocorticoid receptor (GR).</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eplerenone</infon>
          <location offset="372" length="10"/>
          <text>Eplerenone</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="415" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="440" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>445</offset>
        <text>Determinants of binding specificity of eplerenone to the MR were investigated using chimeras created between the ligand-binding domains (LBD) of the MR and the GR.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eplerenone</infon>
          <location offset="484" length="10"/>
          <text>eplerenone</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="502" length="2"/>
          <text>MR</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="594" length="2"/>
          <text>MR</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="605" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>609</offset>
        <text>These chimeras had been used previously to investigate aldosterone and spironolactone binding specificity to the MR.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="664" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spironolactone</infon>
          <location offset="680" length="14"/>
          <text>spironolactone</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="722" length="2"/>
          <text>MR</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>726</offset>
        <text>Eplerenone competed strongly for [(3)H]-dexamethasone binding to a MR/GR chimera containing amino acids 804-874 of the MR and weakly to a chimera containing amino acids 672-803 of the MR.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eplerenone</infon>
          <location offset="726" length="10"/>
          <text>Eplerenone</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(3)h]-dexamethasone</infon>
          <location offset="759" length="20"/>
          <text>[(3)H]-dexamethasone</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="818" length="11"/>
          <text>amino acids</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="883" length="11"/>
          <text>amino acids</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="793" length="2"/>
          <text>MR</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="796" length="2"/>
          <text>GR</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="845" length="2"/>
          <text>MR</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="910" length="2"/>
          <text>MR</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T18" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T17" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>914</offset>
        <text>Within the 804-874 region, eplerenone competed for [(3)H]-dexamethasone binding to a chimera containing amino acids 820-844 of the MR, although the calculated affinity was approximately 10-fold lower than for binding to the full-length MR LBD.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eplerenone</infon>
          <location offset="941" length="10"/>
          <text>eplerenone</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(3)h]-dexamethasone</infon>
          <location offset="965" length="20"/>
          <text>[(3)H]-dexamethasone</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="1018" length="11"/>
          <text>amino acids</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mr lbd</infon>
          <location offset="1150" length="6"/>
          <text>MR LBD</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="1045" length="2"/>
          <text>MR</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T21" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1158</offset>
        <text>Similar results were obtained using another MR antagonist, namely spironolactone.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spironolactone</infon>
          <location offset="1224" length="14"/>
          <text>spironolactone</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="1202" length="2"/>
          <text>MR</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1240</offset>
        <text>Modelling of eplerenone binding to the MR LBD, based on the GR LBD crystal structure, suggests that amino acids 820-844 affect the overall shape of the ligand-binding pocket and that eplerenone acts as an MR antagonist because it fails to stabilize the active conformation of the receptor.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eplerenone</infon>
          <location offset="1253" length="10"/>
          <text>eplerenone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eplerenone</infon>
          <location offset="1423" length="10"/>
          <text>eplerenone</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mr lbd</infon>
          <location offset="1279" length="6"/>
          <text>MR LBD</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gr lbd</infon>
          <location offset="1300" length="6"/>
          <text>GR LBD</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="1445" length="2"/>
          <text>MR</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1530</offset>
        <text>In contrast with results with the MR antagonists eplerenone and spironolactone, amino acids 820-844 are sufficient in themselves to confer high-affinity aldosterone binding to the MR, suggesting that the binding determinants of the two antagonists are similar to each other but differ from those of aldosterone.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eplerenone</infon>
          <location offset="1579" length="10"/>
          <text>eplerenone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">spironolactone</infon>
          <location offset="1594" length="14"/>
          <text>spironolactone</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="1610" length="11"/>
          <text>amino acids</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="1683" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="1829" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="1564" length="2"/>
          <text>MR</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mr</infon>
          <location offset="1710" length="2"/>
          <text>MR</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1868500</id>
    <passage>
      <offset>0</offset>
      <text>Mechanisms of lipid-lowering agents.	Lipid-lowering agents are used with the purpose of ameliorating hyperlipoproteinemias, in order to prevent arterial disease. Lipid-lowering drugs can be classified into absorbable agents and into nonabsorbable compounds, acting within the gastrointestinal lumen. Absorbable drugs (fibric acids, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms. Fibric acids, in particular, act by stimulating the catabolism of VLDL and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake. Nicotinic acid and acipimox interfere with the biosynthesis of LDL and can also improve the clearance of VLDL/LDL. Probucol acts by a newly described mechanism, i.e. accelerating reverse transport of cholesteryl esters from high-density lipoproteins to lower-density lipoproteins. Finally, HMG-CoA reductase inhibitors, interfering with the biosynthesis of cholesterol, can induce an increased expression of liver high-affinity lipoprotein receptors. Nonabsorbable agents (anion-exchange resins, neomycin, beta-sitosterol) interrupt the recirculation of bile acids and/or reduce the absorption of cholesterol with the gut. They display a selective activity on hypercholesterolemia, again by increasing LDL receptor expression. The choice of one or more lipid-lowering agents will depend upon the patient's phenotype, determining responsiveness to the pharmacological treatment.</text>
      <sentence>
        <offset>0</offset>
        <text>Mechanisms of lipid-lowering agents.</text>
      </sentence>
      <sentence>
        <offset>37</offset>
        <text>Lipid-lowering agents are used with the purpose of ameliorating hyperlipoproteinemias, in order to prevent arterial disease.</text>
      </sentence>
      <sentence>
        <offset>162</offset>
        <text>Lipid-lowering drugs can be classified into absorbable agents and into nonabsorbable compounds, acting within the gastrointestinal lumen.</text>
      </sentence>
      <sentence>
        <offset>300</offset>
        <text>Absorbable drugs (fibric acids, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fibric acids</infon>
          <location offset="318" length="12"/>
          <text>fibric acids</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nicotinic acid</infon>
          <location offset="332" length="14"/>
          <text>nicotinic acid</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">probucol</infon>
          <location offset="348" length="8"/>
          <text>probucol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hmg-coa</infon>
          <location offset="358" length="7"/>
          <text>HMG-CoA</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hmg-coa reductase</infon>
          <location offset="358" length="17"/>
          <text>HMG-CoA reductase</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">plasma very-low-density lipoproteins</infon>
          <location offset="395" length="36"/>
          <text>plasma very-low-density lipoproteins</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vldl</infon>
          <location offset="433" length="4"/>
          <text>VLDL</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">low-density lipoproteins</infon>
          <location offset="446" length="24"/>
          <text>low-density lipoproteins</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldl</infon>
          <location offset="472" length="3"/>
          <text>LDL</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>505</offset>
        <text>Fibric acids, in particular, act by stimulating the catabolism of VLDL and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fibric acids</infon>
          <location offset="505" length="12"/>
          <text>Fibric acids</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vldl</infon>
          <location offset="571" length="4"/>
          <text>VLDL</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldl</infon>
          <location offset="614" length="3"/>
          <text>LDL</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>663</offset>
        <text>Nicotinic acid and acipimox interfere with the biosynthesis of LDL and can also improve the clearance of VLDL/LDL.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nicotinic acid</infon>
          <location offset="663" length="14"/>
          <text>Nicotinic acid</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldl</infon>
          <location offset="726" length="3"/>
          <text>LDL</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vldl</infon>
          <location offset="768" length="4"/>
          <text>VLDL</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldl</infon>
          <location offset="773" length="3"/>
          <text>LDL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>778</offset>
        <text>Probucol acts by a newly described mechanism, i.e. accelerating reverse transport of cholesteryl esters from high-density lipoproteins to lower-density lipoproteins.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">probucol</infon>
          <location offset="778" length="8"/>
          <text>Probucol</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesteryl esters</infon>
          <location offset="863" length="18"/>
          <text>cholesteryl esters</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">high-density lipoproteins</infon>
          <location offset="887" length="25"/>
          <text>high-density lipoproteins</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lower-density lipoproteins</infon>
          <location offset="916" length="26"/>
          <text>lower-density lipoproteins</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>944</offset>
        <text>Finally, HMG-CoA reductase inhibitors, interfering with the biosynthesis of cholesterol, can induce an increased expression of liver high-affinity lipoprotein receptors.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hmg-coa</infon>
          <location offset="953" length="7"/>
          <text>HMG-CoA</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="1020" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lipoprotein receptors</infon>
          <location offset="1091" length="21"/>
          <text>lipoprotein receptors</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hmg-coa reductase</infon>
          <location offset="953" length="17"/>
          <text>HMG-CoA reductase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1114</offset>
        <text>Nonabsorbable agents (anion-exchange resins, neomycin, beta-sitosterol) interrupt the recirculation of bile acids and/or reduce the absorption of cholesterol with the gut.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">neomycin</infon>
          <location offset="1159" length="8"/>
          <text>neomycin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">beta-sitosterol</infon>
          <location offset="1169" length="15"/>
          <text>beta-sitosterol</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bile acids</infon>
          <location offset="1217" length="10"/>
          <text>bile acids</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="1260" length="11"/>
          <text>cholesterol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1286</offset>
        <text>They display a selective activity on hypercholesterolemia, again by increasing LDL receptor expression.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldl receptor</infon>
          <location offset="1365" length="12"/>
          <text>LDL receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1390</offset>
        <text>The choice of one or more lipid-lowering agents will depend upon the patient's phenotype, determining responsiveness to the pharmacological treatment.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23532375</id>
    <passage>
      <offset>0</offset>
      <text>ERP evidence suggests executive dysfunction in ecstasy polydrug users.	BACKGROUND: Deficits in executive functions such as access to semantic/long-term memory have been shown in ecstasy users in previous research. Equally, there have been many reports of equivocal findings in this area. The current study sought to further investigate behavioural and electro-physiological measures of this executive function in ecstasy users. METHOD: Twenty ecstasy-polydrug users, 20 non-ecstasy-polydrug users and 20 drug-naïve controls were recruited. Participants completed background questionnaires about their drug use, sleep quality, fluid intelligence and mood state. Each individual also completed a semantic retrieval task whilst 64 channel Electroencephalography (EEG) measures were recorded. RESULTS: Analysis of Variance (ANOVA) revealed no between-group differences in behavioural performance on the task. Mixed ANOVA on event-related potential (ERP) components P2, N2 and P3 revealed significant between-group differences in the N2 component. Subsequent exploratory univariate ANOVAs on the N2 component revealed marginally significant between-group differences, generally showing greater negativity at occipito-parietal electrodes in ecstasy users compared to drug-naïve controls. Despite absence of behavioural differences, differences in N2 magnitude are evidence of abnormal executive functioning in ecstasy-polydrug users.</text>
      <sentence>
        <offset>0</offset>
        <text>ERP evidence suggests executive dysfunction in ecstasy polydrug users.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ecstasy</infon>
          <location offset="47" length="7"/>
          <text>ecstasy</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>71</offset>
        <text>BACKGROUND: Deficits in executive functions such as access to semantic/long-term memory have been shown in ecstasy users in previous research.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ecstasy</infon>
          <location offset="178" length="7"/>
          <text>ecstasy</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>214</offset>
        <text>Equally, there have been many reports of equivocal findings in this area.</text>
      </sentence>
      <sentence>
        <offset>288</offset>
        <text>The current study sought to further investigate behavioural and electro-physiological measures of this executive function in ecstasy users.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ecstasy</infon>
          <location offset="413" length="7"/>
          <text>ecstasy</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>428</offset>
        <text>METHOD: Twenty ecstasy-polydrug users, 20 non-ecstasy-polydrug users and 20 drug-naïve controls were recruited.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ecstasy</infon>
          <location offset="443" length="7"/>
          <text>ecstasy</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ecstasy</infon>
          <location offset="474" length="7"/>
          <text>ecstasy</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>540</offset>
        <text>Participants completed background questionnaires about their drug use, sleep quality, fluid intelligence and mood state.</text>
      </sentence>
      <sentence>
        <offset>661</offset>
        <text>Each individual also completed a semantic retrieval task whilst 64 channel Electroencephalography (EEG) measures were recorded.</text>
      </sentence>
      <sentence>
        <offset>789</offset>
        <text>RESULTS: Analysis of Variance (ANOVA) revealed no between-group differences in behavioural performance on the task.</text>
      </sentence>
      <sentence>
        <offset>905</offset>
        <text>Mixed ANOVA on event-related potential (ERP) components P2, N2 and P3 revealed significant between-group differences in the N2 component.</text>
      </sentence>
      <sentence>
        <offset>1043</offset>
        <text>Subsequent exploratory univariate ANOVAs on the N2 component revealed marginally significant between-group differences, generally showing greater negativity at occipito-parietal electrodes in ecstasy users compared to drug-naïve controls.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ecstasy</infon>
          <location offset="1235" length="7"/>
          <text>ecstasy</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1282</offset>
        <text>Despite absence of behavioural differences, differences in N2 magnitude are evidence of abnormal executive functioning in ecstasy-polydrug users.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ecstasy</infon>
          <location offset="1404" length="7"/>
          <text>ecstasy</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17016511</id>
    <passage>
      <offset>0</offset>
      <text>Inhibition of cardiac voltage-gated sodium channels by grape polyphenols.	BACKGROUND AND PURPOSE: The cardiovascular benefits of red wine consumption are often attributed to the antioxidant effects of its polyphenolic constituents, including quercetin, catechin and resveratrol. Inhibition of cardiac voltage-gated sodium channels (VGSCs) is antiarrhythmic and cardioprotective. As polyphenols may also modulate ion channels, and possess structural similarities to several antiarrhythmic VGSC inhibitors, we hypothesised that VGSC inhibition may contribute to cardioprotection by these polyphenols. EXPERIMENTAL APPROACH: The whole-cell voltage-clamp technique was used to record peak and late VGSC currents (INa) from recombinant human heart NaV1.5 channels expressed in tsA201 cells. Right ventricular myocytes from rat heart were isolated and single myocytes were field-stimulated. Either calcium transients or contractility were measured using the calcium-sensitive dye Calcium-Green 1AM or video edge detection, respectively. KEY RESULTS: The red grape polyphenols quercetin, catechin and resveratrol blocked peak INa with IC50s of 19.4 microM, 76.8 microM and 77.3 microM, respectively. In contrast to lidocaine, resveratrol did not exhibit any frequency-dependence of peak INa block. Late INa induced by the VGSC long QT mutant R1623Q was reduced by resveratrol and quercetin. Resveratrol and quercetin also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 microM and 24.9 microM, respectively. In field-stimulated myocytes, ATXII-induced increases in diastolic calcium were prevented and reversed by resveratrol. ATXII-induced contractile dysfunction was delayed and reduced by resveratrol. CONCLUSIONS AND IMPLICATIONS: Our results indicate that several red grape polyphenols inhibit cardiac VGSCs and that this effect may contribute to the documented cardioprotective efficacy of red grape products.</text>
      <sentence>
        <offset>0</offset>
        <text>Inhibition of cardiac voltage-gated sodium channels by grape polyphenols.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="36" length="6"/>
          <text>sodium</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">voltage-gated sodium channels</infon>
          <location offset="22" length="29"/>
          <text>voltage-gated sodium channels</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>74</offset>
        <text>BACKGROUND AND PURPOSE: The cardiovascular benefits of red wine consumption are often attributed to the antioxidant effects of its polyphenolic constituents, including quercetin, catechin and resveratrol.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="242" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">catechin</infon>
          <location offset="253" length="8"/>
          <text>catechin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">resveratrol</infon>
          <location offset="266" length="11"/>
          <text>resveratrol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>279</offset>
        <text>Inhibition of cardiac voltage-gated sodium channels (VGSCs) is antiarrhythmic and cardioprotective.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="315" length="6"/>
          <text>sodium</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">voltage-gated sodium channels</infon>
          <location offset="301" length="29"/>
          <text>voltage-gated sodium channels</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vgscs</infon>
          <location offset="332" length="5"/>
          <text>VGSCs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>379</offset>
        <text>As polyphenols may also modulate ion channels, and possess structural similarities to several antiarrhythmic VGSC inhibitors, we hypothesised that VGSC inhibition may contribute to cardioprotection by these polyphenols.</text>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vgsc</infon>
          <location offset="488" length="4"/>
          <text>VGSC</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vgsc</infon>
          <location offset="526" length="4"/>
          <text>VGSC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>599</offset>
        <text>EXPERIMENTAL APPROACH: The whole-cell voltage-clamp technique was used to record peak and late VGSC currents (INa) from recombinant human heart NaV1.5 channels expressed in tsA201 cells.</text>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vgsc</infon>
          <location offset="694" length="4"/>
          <text>VGSC</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human heart nav1.5</infon>
          <location offset="731" length="18"/>
          <text>human heart NaV1.5</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>786</offset>
        <text>Right ventricular myocytes from rat heart were isolated and single myocytes were field-stimulated.</text>
      </sentence>
      <sentence>
        <offset>885</offset>
        <text>Either calcium transients or contractility were measured using the calcium-sensitive dye Calcium-Green 1AM or video edge detection, respectively.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="892" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="952" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="974" length="7"/>
          <text>Calcium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1031</offset>
        <text>KEY RESULTS: The red grape polyphenols quercetin, catechin and resveratrol blocked peak INa with IC50s of 19.4 microM, 76.8 microM and 77.3 microM, respectively.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">catechin</infon>
          <location offset="1081" length="8"/>
          <text>catechin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">resveratrol</infon>
          <location offset="1094" length="11"/>
          <text>resveratrol</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="1070" length="9"/>
          <text>quercetin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1193</offset>
        <text>In contrast to lidocaine, resveratrol did not exhibit any frequency-dependence of peak INa block.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lidocaine</infon>
          <location offset="1208" length="9"/>
          <text>lidocaine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">resveratrol</infon>
          <location offset="1219" length="11"/>
          <text>resveratrol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1291</offset>
        <text>Late INa induced by the VGSC long QT mutant R1623Q was reduced by resveratrol and quercetin.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">resveratrol</infon>
          <location offset="1357" length="11"/>
          <text>resveratrol</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="1373" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vgsc</infon>
          <location offset="1315" length="4"/>
          <text>VGSC</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">r1623q</infon>
          <location offset="1335" length="6"/>
          <text>R1623Q</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1384</offset>
        <text>Resveratrol and quercetin also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 microM and 24.9 microM, respectively.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">resveratrol</infon>
          <location offset="1384" length="11"/>
          <text>Resveratrol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="1400" length="9"/>
          <text>quercetin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1519</offset>
        <text>In field-stimulated myocytes, ATXII-induced increases in diastolic calcium were prevented and reversed by resveratrol.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="1586" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">resveratrol</infon>
          <location offset="1625" length="11"/>
          <text>resveratrol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1638</offset>
        <text>ATXII-induced contractile dysfunction was delayed and reduced by resveratrol.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">resveratrol</infon>
          <location offset="1703" length="11"/>
          <text>resveratrol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1716</offset>
        <text>CONCLUSIONS AND IMPLICATIONS: Our results indicate that several red grape polyphenols inhibit cardiac VGSCs and that this effect may contribute to the documented cardioprotective efficacy of red grape products.</text>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vgscs</infon>
          <location offset="1818" length="5"/>
          <text>VGSCs</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23364619</id>
    <passage>
      <offset>0</offset>
      <text>Investigation of the toxicokinetics of petroleum hydrocarbon distillates with the earthworm Eisenia andrei.	The Canada-wide standards for petroleum hydrocarbons in soils regulate petroleum hydrocarbons based on four distillate ranges: F1 (C6-C10), F2 (&gt;C10-C16), F3 (&gt;C16-C34), and F4 (&gt;C34). Previous toxicity tests with earthworms and F2, as well as two subfractions of F3, F3a (&gt;C16-C23) and F3a (&gt;C23-C34), indicate that test durations might not be sufficiently long to reach threshold effect concentrations, likely because of the differing toxicokinetics for each distillate. A study was conducted to determine the toxicokinetics of both aliphatic and aromatic fractions of F2, F3a, and F3b with the earthworm Eisenia andrei. Peak accumulation curves were observed for F2 aliphatics and aromatics and F3a aromatics, likely as a result of changes in exposure concentration over the test duration via loss or a decrease in the bioavailable fraction. Biota-soil accumulation factors were &gt;1 for total F2 aliphatics and aromatics and F3a aromatics as well as for several individual polyaromatic hydrocarbons for each distillate. Aromatics were disproportionately accumulated over aliphatics and were the main contributors to toxicity; therefore, aromatics and aliphatics should be regulated separately. The toxicokinetics were used to interpret previous toxicity data. Higher molecular weight distillates need longer-than-standard test durations to determine toxicity, so toxicity test results from fixed, standard-duration tests are not strictly comparable for these petroleum distillates. Environ. Toxicol. Chem. 2013;32:1006-1015. © 2013 SETAC.</text>
      <sentence>
        <offset>0</offset>
        <text>Investigation of the toxicokinetics of petroleum hydrocarbon distillates with the earthworm Eisenia andrei.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">petroleum hydrocarbon</infon>
          <location offset="39" length="21"/>
          <text>petroleum hydrocarbon</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>108</offset>
        <text>The Canada-wide standards for petroleum hydrocarbons in soils regulate petroleum hydrocarbons based on four distillate ranges: F1 (C6-C10), F2 (&gt;C10-C16), F3 (&gt;C16-C34), and F4 (&gt;C34).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">petroleum hydrocarbons</infon>
          <location offset="138" length="22"/>
          <text>petroleum hydrocarbons</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">petroleum hydrocarbons</infon>
          <location offset="179" length="22"/>
          <text>petroleum hydrocarbons</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>293</offset>
        <text>Previous toxicity tests with earthworms and F2, as well as two subfractions of F3, F3a (&gt;C16-C23) and F3a (&gt;C23-C34), indicate that test durations might not be sufficiently long to reach threshold effect concentrations, likely because of the differing toxicokinetics for each distillate.</text>
      </sentence>
      <sentence>
        <offset>581</offset>
        <text>A study was conducted to determine the toxicokinetics of both aliphatic and aromatic fractions of F2, F3a, and F3b with the earthworm Eisenia andrei.</text>
      </sentence>
      <sentence>
        <offset>731</offset>
        <text>Peak accumulation curves were observed for F2 aliphatics and aromatics and F3a aromatics, likely as a result of changes in exposure concentration over the test duration via loss or a decrease in the bioavailable fraction.</text>
      </sentence>
      <sentence>
        <offset>953</offset>
        <text>Biota-soil accumulation factors were &gt;1 for total F2 aliphatics and aromatics and F3a aromatics as well as for several individual polyaromatic hydrocarbons for each distillate.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyaromatic hydrocarbons</infon>
          <location offset="1083" length="25"/>
          <text>polyaromatic hydrocarbons</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1130</offset>
        <text>Aromatics were disproportionately accumulated over aliphatics and were the main contributors to toxicity; therefore, aromatics and aliphatics should be regulated separately.</text>
      </sentence>
      <sentence>
        <offset>1304</offset>
        <text>The toxicokinetics were used to interpret previous toxicity data.</text>
      </sentence>
      <sentence>
        <offset>1370</offset>
        <text>Higher molecular weight distillates need longer-than-standard test durations to determine toxicity, so toxicity test results from fixed, standard-duration tests are not strictly comparable for these petroleum distillates.</text>
      </sentence>
      <sentence>
        <offset>1592</offset>
        <text>Environ.</text>
      </sentence>
      <sentence>
        <offset>1601</offset>
        <text>Toxicol.</text>
      </sentence>
      <sentence>
        <offset>1610</offset>
        <text>Chem.</text>
      </sentence>
      <sentence>
        <offset>1616</offset>
        <text>2013;32:1006-1015.</text>
      </sentence>
      <sentence>
        <offset>1635</offset>
        <text>© 2013 SETAC.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23587021</id>
    <passage>
      <offset>0</offset>
      <text>The tail wagging the dog - regulation of lipid metabolism by protein kinase C.	Upon their discovery almost 40 years ago, isoforms of the lipid-activated protein kinase C (PKC) family were initially regarded only as downstream effectors of the second messengers calcium and diacylglycerol, undergoing activation upon phospholipid hydrolysis in response to acute stimuli. Subsequently, several isoforms were found to be associated with the inhibitory effects of lipid over-supply on glucose homeostasis, especially the negative cross-talk with insulin signal transduction, observed upon accumulation of diacylglycerol in insulin target tissues. The PKC family has therefore attracted much attention in diabetes and obesity research, because intracellular lipid accumulation is strongly correlated with defective insulin action and the development of type 2 diabetes. Causal roles for various isoforms in the generation of insulin resistance have more recently been confirmed using PKC-deficient mice. However, during characterization of these animals, it became increasingly evident that the enzymes play key roles in the modulation of lipid metabolism itself, and may control the supply of lipids between tissues such as adipose and liver. Molecular studies have also demonstrated roles for PKC isoforms in several aspects of lipid metabolism, such as adipocyte differentiation and hepatic lipogenesis. While the precise mechanisms involved, especially the identities of protein substrates, are still unclear, the emerging picture suggests that the currently held view of the contribution of PKC isoforms to metabolism is an over-simplification. Although PKCs may inhibit insulin signal transduction, these enzymes are not merely downstream effectors of lipid accumulation, but in fact control the fate of fatty acids, thus the tail wags the dog.</text>
      <sentence>
        <offset>0</offset>
        <text>The tail wagging the dog - regulation of lipid metabolism by protein kinase C.</text>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein kinase c</infon>
          <location offset="61" length="16"/>
          <text>protein kinase C</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>79</offset>
        <text>Upon their discovery almost 40 years ago, isoforms of the lipid-activated protein kinase C (PKC) family were initially regarded only as downstream effectors of the second messengers calcium and diacylglycerol, undergoing activation upon phospholipid hydrolysis in response to acute stimuli.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="261" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diacylglycerol</infon>
          <location offset="273" length="14"/>
          <text>diacylglycerol</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein kinase c</infon>
          <location offset="153" length="16"/>
          <text>protein kinase C</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pkc</infon>
          <location offset="171" length="3"/>
          <text>PKC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>370</offset>
        <text>Subsequently, several isoforms were found to be associated with the inhibitory effects of lipid over-supply on glucose homeostasis, especially the negative cross-talk with insulin signal transduction, observed upon accumulation of diacylglycerol in insulin target tissues.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="481" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diacylglycerol</infon>
          <location offset="601" length="14"/>
          <text>diacylglycerol</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="542" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="619" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>643</offset>
        <text>The PKC family has therefore attracted much attention in diabetes and obesity research, because intracellular lipid accumulation is strongly correlated with defective insulin action and the development of type 2 diabetes.</text>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pkc</infon>
          <location offset="647" length="3"/>
          <text>PKC</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="810" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>865</offset>
        <text>Causal roles for various isoforms in the generation of insulin resistance have more recently been confirmed using PKC-deficient mice.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="920" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pkc</infon>
          <location offset="979" length="3"/>
          <text>PKC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>999</offset>
        <text>However, during characterization of these animals, it became increasingly evident that the enzymes play key roles in the modulation of lipid metabolism itself, and may control the supply of lipids between tissues such as adipose and liver.</text>
      </sentence>
      <sentence>
        <offset>1239</offset>
        <text>Molecular studies have also demonstrated roles for PKC isoforms in several aspects of lipid metabolism, such as adipocyte differentiation and hepatic lipogenesis.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pkc</infon>
          <location offset="1290" length="3"/>
          <text>PKC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1402</offset>
        <text>While the precise mechanisms involved, especially the identities of protein substrates, are still unclear, the emerging picture suggests that the currently held view of the contribution of PKC isoforms to metabolism is an over-simplification.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pkc</infon>
          <location offset="1591" length="3"/>
          <text>PKC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1645</offset>
        <text>Although PKCs may inhibit insulin signal transduction, these enzymes are not merely downstream effectors of lipid accumulation, but in fact control the fate of fatty acids, thus the tail wags the dog.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acids</infon>
          <location offset="1805" length="11"/>
          <text>fatty acids</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pkcs</infon>
          <location offset="1654" length="4"/>
          <text>PKCs</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1671" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23408434</id>
    <passage>
      <offset>0</offset>
      <text>Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.	Lafora disease (LD) is a teenage-onset inherited progressive myoclonus epilepsy characterized by the accumulations of intracellular inclusions called Lafora bodies and caused by mutations in protein phosphatase laforin or ubiquitin ligase malin. But how the loss of function of either laforin or malin causes disease pathogenesis is poorly understood. Recently, neuronatin was identified as a novel substrate of malin that regulates glycogen synthesis. Here we demonstrate that the level of neuronatin is significantly up-regulated in the skin biopsy sample of LD patients having mutations in both malin and laforin. Neuronatin is highly expressed in human fetal brain with gradual decrease in expression in developing and adult brain. However, in adult brain, neuronatin is predominantly expressed in parvalbumin-positive GABAergic interneurons and localized in their processes. The level of neuronatin is increased and accumulated as insoluble aggregates in the cortical area of LD brain biopsy samples, and there is also a dramatic loss of parvalbumin-positive GABAergic interneurons. Ectopic expression of neuronatin in cultured neuronal cells results in increased intracellular Ca(2+), endoplasmic reticulum stress, proteasomal dysfunction, and cell death that can be partially rescued by malin. These findings suggest that the neuronatin-induced aberrant Ca(2+) signaling and endoplasmic reticulum stress might underlie LD pathogenesis.</text>
      <sentence>
        <offset>0</offset>
        <text>Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="29" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuronatin</infon>
          <location offset="0" length="10"/>
          <text>Neuronatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>123</offset>
        <text>Lafora disease (LD) is a teenage-onset inherited progressive myoclonus epilepsy characterized by the accumulations of intracellular inclusions called Lafora bodies and caused by mutations in protein phosphatase laforin or ubiquitin ligase malin.</text>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein phosphatase</infon>
          <location offset="314" length="19"/>
          <text>protein phosphatase</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">laforin</infon>
          <location offset="334" length="7"/>
          <text>laforin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ubiquitin ligase</infon>
          <location offset="345" length="16"/>
          <text>ubiquitin ligase</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">malin</infon>
          <location offset="362" length="5"/>
          <text>malin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>369</offset>
        <text>But how the loss of function of either laforin or malin causes disease pathogenesis is poorly understood.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">laforin</infon>
          <location offset="408" length="7"/>
          <text>laforin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">malin</infon>
          <location offset="419" length="5"/>
          <text>malin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>475</offset>
        <text>Recently, neuronatin was identified as a novel substrate of malin that regulates glycogen synthesis.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuronatin</infon>
          <location offset="485" length="10"/>
          <text>neuronatin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">malin</infon>
          <location offset="535" length="5"/>
          <text>malin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>576</offset>
        <text>Here we demonstrate that the level of neuronatin is significantly up-regulated in the skin biopsy sample of LD patients having mutations in both malin and laforin.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuronatin</infon>
          <location offset="614" length="10"/>
          <text>neuronatin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">malin</infon>
          <location offset="721" length="5"/>
          <text>malin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">laforin</infon>
          <location offset="731" length="7"/>
          <text>laforin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>740</offset>
        <text>Neuronatin is highly expressed in human fetal brain with gradual decrease in expression in developing and adult brain.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuronatin</infon>
          <location offset="740" length="10"/>
          <text>Neuronatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>859</offset>
        <text>However, in adult brain, neuronatin is predominantly expressed in parvalbumin-positive GABAergic interneurons and localized in their processes.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuronatin</infon>
          <location offset="884" length="10"/>
          <text>neuronatin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">parvalbumin</infon>
          <location offset="925" length="11"/>
          <text>parvalbumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1003</offset>
        <text>The level of neuronatin is increased and accumulated as insoluble aggregates in the cortical area of LD brain biopsy samples, and there is also a dramatic loss of parvalbumin-positive GABAergic interneurons.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">parvalbumin</infon>
          <location offset="1166" length="11"/>
          <text>parvalbumin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuronatin</infon>
          <location offset="1016" length="10"/>
          <text>neuronatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1211</offset>
        <text>Ectopic expression of neuronatin in cultured neuronal cells results in increased intracellular Ca(2+), endoplasmic reticulum stress, proteasomal dysfunction, and cell death that can be partially rescued by malin.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca(2+)</infon>
          <location offset="1306" length="6"/>
          <text>Ca(2+)</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuronatin</infon>
          <location offset="1233" length="10"/>
          <text>neuronatin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">malin</infon>
          <location offset="1417" length="5"/>
          <text>malin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1424</offset>
        <text>These findings suggest that the neuronatin-induced aberrant Ca(2+) signaling and endoplasmic reticulum stress might underlie LD pathogenesis.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca(2+)</infon>
          <location offset="1484" length="6"/>
          <text>Ca(2+)</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neuronatin</infon>
          <location offset="1456" length="10"/>
          <text>neuronatin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23542147</id>
    <passage>
      <offset>0</offset>
      <text>Ethanol extract of Adiantum capillus-veneris L. suppresses the production of inflammatory mediators by inhibiting NF-κB activation.	ETHNOPHARMACOLOGICAL RELEVANCE: Adiantum capillus-veneris L. is a wildly distributed plant species and has been extensively used in south of China as traditional folk medicine for the treatment of inflammatory diseases. AIM OF THE STUDY: To investigate the anti-inflammatory effect of ethanolic extracts of Adiantum capillus-veneris L. and the involvement of NF-κB signaling in the regulation of inflammation. MATERIALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS)-induced prostaglandin E2 (PGE2) production in RAW264.7 mouse macrophages, and interleukin 6 (IL-6) and tumor necrosis factor (TNF) production in human U937 monocytes. The effect of the plant extracts on the transcription factor nuclear factor kappa B (NF-κB) pathway was evaluated in TNF-α stimulated HepG2 cells by luciferase gene reporter assay and Western blotting at the transcriptional and translational levels. Subsequently, the inhibition of NF-κB downstream gene expression (IL-8 and ICAM-1) by the plant extracts was assessed via quantitative real time polymerase chain reaction (qPCR). Lastly, the anti-inflammatory activities of the plant extracts in vivo were evaluated by testing spleen index and NF-κB related protein expression in LPS-stimulated CD1 mice. RESULTS: The plant ethanolic extracts effectively suppressed PGE2, IL-6 and TNF release with an IC50 less than 50μg/ml. Moreover, luciferase expression could be specifically blocked in HepG2 cells, not in HEK293 cells, showing that the plant extracts displayed a cell-specific pattern on NF-κB gene transcription. The assayed biological activity also depended on the order of adding TNF-α and the plant extracts because the plant extracts could only block the NF-κB activation if added earlier but were unable to stop the signal when added after TNF-α. However, the plant extracts did not exert any effect on ubiquitination which regulates several steps in the NF-κB pathway. Additionally, the plant extracts down-regulated phosphorylation of IKKα/β at S176/180, p38 at T180/Y182 and p65 at S536, but not p65 at S276. This was confirmed by their ability to selectively abrogate the induction of IL-8 transcription, whereas the ICAM-1 gene, which is not transcribed selectively by an NF-κB complex containing a form of p65 phosphorylated on Ser536, did not change. Finally, the plant extracts at 200μg/mg could normalize the LPS-induced elevation of spleen index as well as NF-κB and p38 activations in CD1 mice. CONCLUSION: The present studies presents the potential utilization of this plant extracts, as a natural resources for the development of an anti-inflammatory medicine.</text>
      <sentence>
        <offset>0</offset>
        <text>Ethanol extract of Adiantum capillus-veneris L. suppresses the production of inflammatory mediators by inhibiting NF-κB activation.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="0" length="7"/>
          <text>Ethanol</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="114" length="5"/>
          <text>NF-κB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>132</offset>
        <text>ETHNOPHARMACOLOGICAL RELEVANCE: Adiantum capillus-veneris L. is a wildly distributed plant species and has been extensively used in south of China as traditional folk medicine for the treatment of inflammatory diseases.</text>
      </sentence>
      <sentence>
        <offset>352</offset>
        <text>AIM OF THE STUDY: To investigate the anti-inflammatory effect of ethanolic extracts of Adiantum capillus-veneris L. and the involvement of NF-κB signaling in the regulation of inflammation.</text>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="491" length="5"/>
          <text>NF-κB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>542</offset>
        <text>MATERIALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS)-induced prostaglandin E2 (PGE2) production in RAW264.7 mouse macrophages, and interleukin 6 (IL-6) and tumor necrosis factor (TNF) production in human U937 monocytes.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prostaglandin e2</infon>
          <location offset="657" length="16"/>
          <text>prostaglandin E2</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pge2</infon>
          <location offset="675" length="4"/>
          <text>PGE2</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin 6</infon>
          <location offset="727" length="13"/>
          <text>interleukin 6</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-6</infon>
          <location offset="742" length="4"/>
          <text>IL-6</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor</infon>
          <location offset="752" length="21"/>
          <text>tumor necrosis factor</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf</infon>
          <location offset="775" length="3"/>
          <text>TNF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>816</offset>
        <text>The effect of the plant extracts on the transcription factor nuclear factor kappa B (NF-κB) pathway was evaluated in TNF-α stimulated HepG2 cells by luciferase gene reporter assay and Western blotting at the transcriptional and translational levels.</text>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nuclear factor kappa b</infon>
          <location offset="877" length="22"/>
          <text>nuclear factor kappa B</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">(nf-κb</infon>
          <location offset="900" length="6"/>
          <text>(NF-κB</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="933" length="5"/>
          <text>TNF-α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1066</offset>
        <text>Subsequently, the inhibition of NF-κB downstream gene expression (IL-8 and ICAM-1) by the plant extracts was assessed via quantitative real time polymerase chain reaction (qPCR).</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-8</infon>
          <location offset="1132" length="4"/>
          <text>IL-8</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">icam-1</infon>
          <location offset="1141" length="6"/>
          <text>ICAM-1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="1098" length="5"/>
          <text>NF-κB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1245</offset>
        <text>Lastly, the anti-inflammatory activities of the plant extracts in vivo were evaluated by testing spleen index and NF-κB related protein expression in LPS-stimulated CD1 mice.</text>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="1359" length="5"/>
          <text>NF-κB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1420</offset>
        <text>RESULTS: The plant ethanolic extracts effectively suppressed PGE2, IL-6 and TNF release with an IC50 less than 50μg/ml.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pge2</infon>
          <location offset="1481" length="4"/>
          <text>PGE2</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-6</infon>
          <location offset="1487" length="4"/>
          <text>IL-6</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf</infon>
          <location offset="1496" length="3"/>
          <text>TNF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1540</offset>
        <text>Moreover, luciferase expression could be specifically blocked in HepG2 cells, not in HEK293 cells, showing that the plant extracts displayed a cell-specific pattern on NF-κB gene transcription.</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="1708" length="5"/>
          <text>NF-κB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1734</offset>
        <text>The assayed biological activity also depended on the order of adding TNF-α and the plant extracts because the plant extracts could only block the NF-κB activation if added earlier but were unable to stop the signal when added after TNF-α.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="1803" length="5"/>
          <text>TNF-α</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="1880" length="5"/>
          <text>NF-κB</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="1966" length="5"/>
          <text>TNF-α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1973</offset>
        <text>However, the plant extracts did not exert any effect on ubiquitination which regulates several steps in the NF-κB pathway.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="2081" length="5"/>
          <text>NF-κB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2096</offset>
        <text>Additionally, the plant extracts down-regulated phosphorylation of IKKα/β at S176/180, p38 at T180/Y182 and p65 at S536, but not p65 at S276.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikkα/β</infon>
          <location offset="2163" length="6"/>
          <text>IKKα/β</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p38</infon>
          <location offset="2183" length="3"/>
          <text>p38</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="2204" length="3"/>
          <text>p65</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="2225" length="3"/>
          <text>p65</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2238</offset>
        <text>This was confirmed by their ability to selectively abrogate the induction of IL-8 transcription, whereas the ICAM-1 gene, which is not transcribed selectively by an NF-κB complex containing a form of p65 phosphorylated on Ser536, did not change.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="2460" length="3"/>
          <text>Ser</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-8</infon>
          <location offset="2315" length="4"/>
          <text>IL-8</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">icam-1</infon>
          <location offset="2347" length="6"/>
          <text>ICAM-1</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="2403" length="5"/>
          <text>NF-κB</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p65</infon>
          <location offset="2438" length="3"/>
          <text>p65</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2484</offset>
        <text>Finally, the plant extracts at 200μg/mg could normalize the LPS-induced elevation of spleen index as well as NF-κB and p38 activations in CD1 mice.</text>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="2593" length="5"/>
          <text>NF-κB</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p38</infon>
          <location offset="2603" length="3"/>
          <text>p38</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2632</offset>
        <text>CONCLUSION: The present studies presents the potential utilization of this plant extracts, as a natural resources for the development of an anti-inflammatory medicine.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10485486</id>
    <passage>
      <offset>0</offset>
      <text>Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine.	Caffeine exposure sensitizes tumor cells to ionizing radiation and other genotoxic agents. The radiosensitizing effects of caffeine are associated with the disruption of multiple DNA damage-responsive cell cycle checkpoints. The similarity of these checkpoint defects to those seen in ataxia-telangiectasia (A-T) suggested that caffeine might inhibit one or more components in an A-T mutated (ATM)-dependent checkpoint pathway in DNA-damaged cells. We now show that caffeine inhibits the catalytic activity of both ATM and the related kinase, ATM and Rad3-related (ATR), at drug concentrations similar to those that induce radiosensitization. Moreover, like ATM-deficient cells, caffeine-treated A549 lung carcinoma cells irradiated in G2 fail to arrest progression into mitosis, and S-phase-irradiated cells exhibit radioresistant DNA synthesis. Similar concentrations of caffeine also inhibit gamma- and UV radiation-induced phosphorylation of p53 on Ser15, a modification that may be directly mediated by the ATM and ATR kinases. DNA-dependent protein kinase, another ATM-related protein involved in DNA damage repair, was resistant to the inhibitory effects of caffeine. Likewise, the catalytic activity of the G2 checkpoint kinase, hChk1, was only marginally suppressed by caffeine but was inhibited potently by the structurally distinct radiosensitizer, UCN-01. These data suggest that the radiosensitizing effects of caffeine are related to inhibition of the protein kinase activities of ATM and ATR and that both proteins are relevant targets for the development of novel anticancer agents.</text>
      <sentence>
        <offset>0</offset>
        <text>Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="75" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atm</infon>
          <location offset="14" length="3"/>
          <text>ATM</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atr</infon>
          <location offset="22" length="3"/>
          <text>ATR</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="26" length="6"/>
          <text>kinase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>85</offset>
        <text>Caffeine exposure sensitizes tumor cells to ionizing radiation and other genotoxic agents.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="85" length="8"/>
          <text>Caffeine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>176</offset>
        <text>The radiosensitizing effects of caffeine are associated with the disruption of multiple DNA damage-responsive cell cycle checkpoints.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="208" length="8"/>
          <text>caffeine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>310</offset>
        <text>The similarity of these checkpoint defects to those seen in ataxia-telangiectasia (A-T) suggested that caffeine might inhibit one or more components in an A-T mutated (ATM)-dependent checkpoint pathway in DNA-damaged cells.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="413" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">a-t mutated</infon>
          <location offset="465" length="11"/>
          <text>A-T mutated</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atm</infon>
          <location offset="478" length="3"/>
          <text>ATM</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>534</offset>
        <text>We now show that caffeine inhibits the catalytic activity of both ATM and the related kinase, ATM and Rad3-related (ATR), at drug concentrations similar to those that induce radiosensitization.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="551" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atm</infon>
          <location offset="600" length="3"/>
          <text>ATM</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="620" length="6"/>
          <text>kinase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atm and rad3-related</infon>
          <location offset="628" length="20"/>
          <text>ATM and Rad3-related</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atr</infon>
          <location offset="650" length="3"/>
          <text>ATR</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>728</offset>
        <text>Moreover, like ATM-deficient cells, caffeine-treated A549 lung carcinoma cells irradiated in G2 fail to arrest progression into mitosis, and S-phase-irradiated cells exhibit radioresistant DNA synthesis.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="764" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atm</infon>
          <location offset="743" length="3"/>
          <text>ATM</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>932</offset>
        <text>Similar concentrations of caffeine also inhibit gamma- and UV radiation-induced phosphorylation of p53 on Ser15, a modification that may be directly mediated by the ATM and ATR kinases.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="958" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atm</infon>
          <location offset="1097" length="3"/>
          <text>ATM</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atr</infon>
          <location offset="1105" length="3"/>
          <text>ATR</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinases</infon>
          <location offset="1109" length="7"/>
          <text>kinases</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p53</infon>
          <location offset="1031" length="3"/>
          <text>p53</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1118</offset>
        <text>DNA-dependent protein kinase, another ATM-related protein involved in DNA damage repair, was resistant to the inhibitory effects of caffeine.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="1250" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="1140" length="6"/>
          <text>kinase</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atm-related protein</infon>
          <location offset="1156" length="19"/>
          <text>ATM-related protein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1260</offset>
        <text>Likewise, the catalytic activity of the G2 checkpoint kinase, hChk1, was only marginally suppressed by caffeine but was inhibited potently by the structurally distinct radiosensitizer, UCN-01.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="1363" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ucn-01</infon>
          <location offset="1445" length="6"/>
          <text>UCN-01</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">checkpoint kinase</infon>
          <location offset="1303" length="17"/>
          <text>checkpoint kinase</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hchk1</infon>
          <location offset="1322" length="5"/>
          <text>hChk1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1453</offset>
        <text>These data suggest that the radiosensitizing effects of caffeine are related to inhibition of the protein kinase activities of ATM and ATR and that both proteins are relevant targets for the development of novel anticancer agents.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeine</infon>
          <location offset="1509" length="8"/>
          <text>caffeine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein kinase</infon>
          <location offset="1551" length="14"/>
          <text>protein kinase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atm</infon>
          <location offset="1580" length="3"/>
          <text>ATM</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atr</infon>
          <location offset="1588" length="3"/>
          <text>ATR</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>8001268</id>
    <passage>
      <offset>0</offset>
      <text>Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine.	We compared the cardiac electrophysiological actions of two types of H1-receptor antagonists--the piperidines, astemizole and terfenadine, and the nonpiperidines, chlorpheniramine and pyrilamine-in vitro in guinea pig ventricular myocytes and in vivo in chloralose-anesthetized dogs. Astemizole and terfenadine significantly increased action potential duration of guinea pig myocytes. This concentration-dependent prolongation of action potential duration was reverse frequency dependent and led to development of early afterdepolarizations, which occurred more frequently at higher concentrations and slower pacing frequencies. Astemizole and terfenadine potently blocked the rapidly activating component of the delayed rectifier, IKr, with IC50 values of 1.5 and 50 nmol/L, respectively. At 10 mumol/L, terfenadine but not astemizole blocked the slowly activating component of the delayed rectifier, IKs (58.4 +/- 3.1%), and the inward rectifier, IK1 (20.5 +/- 3.4%). Chlorpheniramine and pyrilamine blocked IKr relatively weakly (IC50 = 1.6 and 1.1 mumol/L, respectively) and IKs and IK1 less than 20% at 10 mumol/L. Astemizole and terfenadine (1.0 to 3.0 mg/kg IV) significantly prolonged the QTc interval and ventricular effective refractory period in vivo. Chlorpheniramine and pyrilamine (&lt; or = 3.0 mg/kg) did not significantly affect these parameters. Block of repolarizing K+ currents, particularly IK1, by astemizole and terfenadine produces reverse rate-dependent prolongation of action potential duration and development of early afterdepolarizations, delays ventricular repolarization, and may underlie the development of torsade de pointes ventricular arrhythmias observed with the use and abuse of these agents.</text>
      <sentence>
        <offset>0</offset>
        <text>Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpheniramine</infon>
          <location offset="119" length="16"/>
          <text>chlorpheniramine</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrilamine</infon>
          <location offset="140" length="10"/>
          <text>pyrilamine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="44" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="78" length="10"/>
          <text>astemizole</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terfenadine</infon>
          <location offset="93" length="11"/>
          <text>terfenadine</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h1-receptor</infon>
          <location offset="44" length="21"/>
          <text>histamine H1-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T27" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T23" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T24" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T26" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>152</offset>
        <text>We compared the cardiac electrophysiological actions of two types of H1-receptor antagonists--the piperidines, astemizole and terfenadine, and the nonpiperidines, chlorpheniramine and pyrilamine-in vitro in guinea pig ventricular myocytes and in vivo in chloralose-anesthetized dogs.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="263" length="10"/>
          <text>astemizole</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terfenadine</infon>
          <location offset="278" length="11"/>
          <text>terfenadine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nonpiperidines</infon>
          <location offset="299" length="14"/>
          <text>nonpiperidines</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpheniramine</infon>
          <location offset="315" length="16"/>
          <text>chlorpheniramine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrilamine</infon>
          <location offset="336" length="10"/>
          <text>pyrilamine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloralose</infon>
          <location offset="406" length="10"/>
          <text>chloralose</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">piperidines</infon>
          <location offset="250" length="11"/>
          <text>piperidines</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h1-receptor</infon>
          <location offset="221" length="11"/>
          <text>H1-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T11" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T12" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T10" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T21" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>436</offset>
        <text>Astemizole and terfenadine significantly increased action potential duration of guinea pig myocytes.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="436" length="10"/>
          <text>Astemizole</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terfenadine</infon>
          <location offset="451" length="11"/>
          <text>terfenadine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>537</offset>
        <text>This concentration-dependent prolongation of action potential duration was reverse frequency dependent and led to development of early afterdepolarizations, which occurred more frequently at higher concentrations and slower pacing frequencies.</text>
      </sentence>
      <sentence>
        <offset>781</offset>
        <text>Astemizole and terfenadine potently blocked the rapidly activating component of the delayed rectifier, IKr, with IC50 values of 1.5 and 50 nmol/L, respectively.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="781" length="10"/>
          <text>Astemizole</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terfenadine</infon>
          <location offset="796" length="11"/>
          <text>terfenadine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>942</offset>
        <text>At 10 mumol/L, terfenadine but not astemizole blocked the slowly activating component of the delayed rectifier, IKs (58.4 +/- 3.1%), and the inward rectifier, IK1 (20.5 +/- 3.4%).</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terfenadine</infon>
          <location offset="957" length="11"/>
          <text>terfenadine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="977" length="10"/>
          <text>astemizole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1122</offset>
        <text>Chlorpheniramine and pyrilamine blocked IKr relatively weakly (IC50 = 1.6 and 1.1 mumol/L, respectively) and IKs and IK1 less than 20% at 10 mumol/L.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpheniramine</infon>
          <location offset="1122" length="16"/>
          <text>Chlorpheniramine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrilamine</infon>
          <location offset="1143" length="10"/>
          <text>pyrilamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1272</offset>
        <text>Astemizole and terfenadine (1.0 to 3.0 mg/kg IV) significantly prolonged the QTc interval and ventricular effective refractory period in vivo.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="1272" length="10"/>
          <text>Astemizole</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terfenadine</infon>
          <location offset="1287" length="11"/>
          <text>terfenadine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1415</offset>
        <text>Chlorpheniramine and pyrilamine (&lt; or = 3.0 mg/kg) did not significantly affect these parameters.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpheniramine</infon>
          <location offset="1415" length="16"/>
          <text>Chlorpheniramine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrilamine</infon>
          <location offset="1436" length="10"/>
          <text>pyrilamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1513</offset>
        <text>Block of repolarizing K+ currents, particularly IK1, by astemizole and terfenadine produces reverse rate-dependent prolongation of action potential duration and development of early afterdepolarizations, delays ventricular repolarization, and may underlie the development of torsade de pointes ventricular arrhythmias observed with the use and abuse of these agents.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k+</infon>
          <location offset="1535" length="2"/>
          <text>K+</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="1569" length="10"/>
          <text>astemizole</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terfenadine</infon>
          <location offset="1584" length="11"/>
          <text>terfenadine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11179439</id>
    <passage>
      <offset>0</offset>
      <text>The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.	The bisdioxopiperazines ICRF-187 (dexrazoxane), ICRF-193, and ICRF-154 are catalytic noncleavable complex-forming inhibitors of DNA topoisomerase II that do not produce protein-linked DNA strand breaks. In this study, we showed that bisdioxopiperazines induced erythroid differentiation, inhibited human leukemia K562 cell growth, and caused a slow induction of apoptosis. Dexrazoxane treatment caused DNA endoreduplication resulting in large highly polyploid cells. This result suggested the lack of a DNA topoisomerase II activity-based cell cycle checkpoint. The percentage of K562 cells that became apoptotic was much larger than the percentage of cells that stained for hemoglobin, suggesting that prior differentiation was not required for induction of apoptosis. Use of the Bcr-Abl tyrosine kinase inhibitor STI-571 resulted in a reduction in Bcl-xL levels and potentiation of dexrazoxane-induced apoptosis related to an earlier onset and more extensive cleavage of caspase-3. These results indicated that dexrazoxane-induced apoptosis is associated with a caspase-3 activation/cleavage pathway. In addition, these results were consistent with the antiapoptotic signaling function of Bcr-Abl to regulate expression of Bcl-xL. The ability of dexrazoxane to induce differentiation and apoptosis suggests that bisdioxopiperazines may be useful in treating some types of leukemia.</text>
      <sentence>
        <offset>0</offset>
        <text>The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="45" length="11"/>
          <text>dexrazoxane</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">icrf-187</infon>
          <location offset="58" length="8"/>
          <text>ICRF-187</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dna topoisomerase ii</infon>
          <location offset="14" length="20"/>
          <text>DNA topoisomerase II</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>136</offset>
        <text>The bisdioxopiperazines ICRF-187 (dexrazoxane), ICRF-193, and ICRF-154 are catalytic noncleavable complex-forming inhibitors of DNA topoisomerase II that do not produce protein-linked DNA strand breaks.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">icrf-187</infon>
          <location offset="160" length="8"/>
          <text>ICRF-187</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="170" length="11"/>
          <text>dexrazoxane</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bisdioxopiperazines</infon>
          <location offset="140" length="19"/>
          <text>bisdioxopiperazines</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">icrf-193</infon>
          <location offset="184" length="8"/>
          <text>ICRF-193</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">icrf-154</infon>
          <location offset="198" length="8"/>
          <text>ICRF-154</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dna topoisomerase ii</infon>
          <location offset="264" length="20"/>
          <text>DNA topoisomerase II</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>339</offset>
        <text>In this study, we showed that bisdioxopiperazines induced erythroid differentiation, inhibited human leukemia K562 cell growth, and caused a slow induction of apoptosis.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bisdioxopiperazines</infon>
          <location offset="369" length="19"/>
          <text>bisdioxopiperazines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>509</offset>
        <text>Dexrazoxane treatment caused DNA endoreduplication resulting in large highly polyploid cells.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="509" length="11"/>
          <text>Dexrazoxane</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>603</offset>
        <text>This result suggested the lack of a DNA topoisomerase II activity-based cell cycle checkpoint.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dna topoisomerase ii</infon>
          <location offset="639" length="20"/>
          <text>DNA topoisomerase II</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>698</offset>
        <text>The percentage of K562 cells that became apoptotic was much larger than the percentage of cells that stained for hemoglobin, suggesting that prior differentiation was not required for induction of apoptosis.</text>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemoglobin</infon>
          <location offset="811" length="10"/>
          <text>hemoglobin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>906</offset>
        <text>Use of the Bcr-Abl tyrosine kinase inhibitor STI-571 resulted in a reduction in Bcl-xL levels and potentiation of dexrazoxane-induced apoptosis related to an earlier onset and more extensive cleavage of caspase-3.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="925" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sti-571</infon>
          <location offset="951" length="7"/>
          <text>STI-571</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="1020" length="11"/>
          <text>dexrazoxane</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr</infon>
          <location offset="917" length="3"/>
          <text>Bcr</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abl</infon>
          <location offset="921" length="3"/>
          <text>Abl</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tyrosine kinase</infon>
          <location offset="925" length="15"/>
          <text>tyrosine kinase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-xl</infon>
          <location offset="986" length="6"/>
          <text>Bcl-xL</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="1109" length="9"/>
          <text>caspase-3</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1120</offset>
        <text>These results indicated that dexrazoxane-induced apoptosis is associated with a caspase-3 activation/cleavage pathway.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="1149" length="11"/>
          <text>dexrazoxane</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="1200" length="9"/>
          <text>caspase-3</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1239</offset>
        <text>In addition, these results were consistent with the antiapoptotic signaling function of Bcr-Abl to regulate expression of Bcl-xL.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr</infon>
          <location offset="1327" length="3"/>
          <text>Bcr</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abl</infon>
          <location offset="1331" length="3"/>
          <text>Abl</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-xl</infon>
          <location offset="1361" length="6"/>
          <text>Bcl-xL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1369</offset>
        <text>The ability of dexrazoxane to induce differentiation and apoptosis suggests that bisdioxopiperazines may be useful in treating some types of leukemia.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexrazoxane</infon>
          <location offset="1384" length="11"/>
          <text>dexrazoxane</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bisdioxopiperazines</infon>
          <location offset="1450" length="19"/>
          <text>bisdioxopiperazines</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23537890</id>
    <passage>
      <offset>0</offset>
      <text>The involvement of heme oxygenase 1 but not nitric oxide synthase 2 in a hepatoprotective action of quercetin in lipopolysaccharide-induced hepatotoxicity of d-galactosamine sensitized rats.	The objective of this study was to evaluate potential hepatoprotective capabilities of quercetin in relation to its modulation of the HO-1 and NOS-2 activities in an experimental model of fulminant liver failure. Liver insult was induced by in vivo administration of d-galactosamine (d-GalN, 400mg/kg, i.p.) and lipopolysaccharide (LPS, 10μg/kg, i.p.). The effects of quercetin (50mg/kg, i.p) on d-GalN toxicity was evaluated by standard biochemical, RT-PCR and Western blot methods. Administration of d-GalN/LPS combination resulted in significantly higher plasma levels of aminotransferases, as well as increased mRNA and protein expressions of both HO-1 and NOS-2 enzymes. Quercetin exhibited cytoprotective effects on the liver, as evidenced by decreased aminotransferase plasma levels. Additionally, quercetin treatment in d-GalN/LPS treated rats significantly increased HO-1 mRNA and its protein expressions. On the contrary, quercetin did not exhibit any significant effects on the levels of nitrites, and NOS-2 mRNA and protein expressions in d-GalN/LPS treated rats. Quercetin when given alone did not have any significant changes on liver enzymes nor HO-1 and NOS-2 mRNA and protein expressions. It can be concluded that the quercetin's induction of HO-1 and its byproducts, without concomitant NOS-2 activity reduction, is among mechanisms contributing to the hepatoprotective effect in d-GalN/LPS hepatotoxicity.</text>
      <sentence>
        <offset>0</offset>
        <text>The involvement of heme oxygenase 1 but not nitric oxide synthase 2 in a hepatoprotective action of quercetin in lipopolysaccharide-induced hepatotoxicity of d-galactosamine sensitized rats.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="100" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-galactosamine</infon>
          <location offset="158" length="15"/>
          <text>d-galactosamine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">heme</infon>
          <location offset="19" length="4"/>
          <text>heme</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="44" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">heme oxygenase 1</infon>
          <location offset="19" length="16"/>
          <text>heme oxygenase 1</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nitric oxide synthase 2</infon>
          <location offset="44" length="23"/>
          <text>nitric oxide synthase 2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>191</offset>
        <text>The objective of this study was to evaluate potential hepatoprotective capabilities of quercetin in relation to its modulation of the HO-1 and NOS-2 activities in an experimental model of fulminant liver failure.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="278" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="325" length="4"/>
          <text>HO-1</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nos-2</infon>
          <location offset="334" length="5"/>
          <text>NOS-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>404</offset>
        <text>Liver insult was induced by in vivo administration of d-galactosamine (d-GalN, 400mg/kg, i.p.) and lipopolysaccharide (LPS, 10μg/kg, i.p.).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-galactosamine</infon>
          <location offset="458" length="15"/>
          <text>d-galactosamine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-galn</infon>
          <location offset="475" length="6"/>
          <text>d-GalN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>544</offset>
        <text>The effects of quercetin (50mg/kg, i.p) on d-GalN toxicity was evaluated by standard biochemical, RT-PCR and Western blot methods.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="559" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-galn</infon>
          <location offset="587" length="6"/>
          <text>d-GalN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>675</offset>
        <text>Administration of d-GalN/LPS combination resulted in significantly higher plasma levels of aminotransferases, as well as increased mRNA and protein expressions of both HO-1 and NOS-2 enzymes.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-galn</infon>
          <location offset="693" length="6"/>
          <text>d-GalN</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aminotransferases</infon>
          <location offset="766" length="17"/>
          <text>aminotransferases</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="843" length="4"/>
          <text>HO-1</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nos-2</infon>
          <location offset="852" length="5"/>
          <text>NOS-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>867</offset>
        <text>Quercetin exhibited cytoprotective effects on the liver, as evidenced by decreased aminotransferase plasma levels.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="867" length="9"/>
          <text>Quercetin</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aminotransferase</infon>
          <location offset="950" length="16"/>
          <text>aminotransferase</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>982</offset>
        <text>Additionally, quercetin treatment in d-GalN/LPS treated rats significantly increased HO-1 mRNA and its protein expressions.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="996" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-galn</infon>
          <location offset="1019" length="6"/>
          <text>d-GalN</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="1067" length="4"/>
          <text>HO-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1106</offset>
        <text>On the contrary, quercetin did not exhibit any significant effects on the levels of nitrites, and NOS-2 mRNA and protein expressions in d-GalN/LPS treated rats.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-galn</infon>
          <location offset="1242" length="6"/>
          <text>d-GalN</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="1123" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitrites</infon>
          <location offset="1190" length="8"/>
          <text>nitrites</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nos-2</infon>
          <location offset="1204" length="5"/>
          <text>NOS-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1267</offset>
        <text>Quercetin when given alone did not have any significant changes on liver enzymes nor HO-1 and NOS-2 mRNA and protein expressions.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="1267" length="9"/>
          <text>Quercetin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="1352" length="4"/>
          <text>HO-1</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nos-2</infon>
          <location offset="1361" length="5"/>
          <text>NOS-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1397</offset>
        <text>It can be concluded that the quercetin's induction of HO-1 and its byproducts, without concomitant NOS-2 activity reduction, is among mechanisms contributing to the hepatoprotective effect in d-GalN/LPS hepatotoxicity.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="1426" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-galn</infon>
          <location offset="1589" length="6"/>
          <text>d-GalN</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ho-1</infon>
          <location offset="1451" length="4"/>
          <text>HO-1</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nos-2</infon>
          <location offset="1496" length="5"/>
          <text>NOS-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23500491</id>
    <passage>
      <offset>0</offset>
      <text>Structural Basis for the ATP-Induced Isomerization of Kinesin.	Kinesin superfamily proteins (KIFs) are microtubule-based molecular motors driven by the energy derived from the hydrolysis of ATP. Previous studies have revealed that the ATP binding step is crucial both for the power stroke to produce motility and for the inter-domain regulation of ATPase activity to guarantee the processive movement of dimeric KIFs. Here, we report the first crystal structure of KIF4 complexed with the non-hydrolyzable ATP analog, AMPPNP (adenylyl imidodiphosphate), at 1.7Å resolution. By combining our structure with previously solved KIF1A structures complexed with two ATP analogs, molecular snapshots during ATP binding reveal that the closure of the nucleotide-binding pocket during ATP binding is achieved by closure of the backdoor. Closure of the backdoor stabilizes two mobile regions, switch I and switch II, to generate the phosphate tube from which hydrolyzed phosphate is released. Through the stabilization of switch II, the local conformational change at the catalytic center is further relayed to the neck-linker element that fully docks to the catalytic core to produce the power stroke. Because the neck linker is a sole element that connects the partner heads in dimeric KIFs, this tight structural coordination between the catalytic center and neck linker enables inter-domain communication between the partner heads. This study also revealed the putative microtubule-binding site of KIF4, thus providing structural insights that describe the specific binding of KIF4 to the microtubule.</text>
      <sentence>
        <offset>0</offset>
        <text>Structural Basis for the ATP-Induced Isomerization of Kinesin.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="25" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinesin</infon>
          <location offset="54" length="7"/>
          <text>Kinesin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>63</offset>
        <text>Kinesin superfamily proteins (KIFs) are microtubule-based molecular motors driven by the energy derived from the hydrolysis of ATP.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="190" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinesin superfamily proteins</infon>
          <location offset="63" length="28"/>
          <text>Kinesin superfamily proteins</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kifs</infon>
          <location offset="93" length="4"/>
          <text>KIFs</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">microtubule-based molecular motors</infon>
          <location offset="103" length="34"/>
          <text>microtubule-based molecular motors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>195</offset>
        <text>Previous studies have revealed that the ATP binding step is crucial both for the power stroke to produce motility and for the inter-domain regulation of ATPase activity to guarantee the processive movement of dimeric KIFs.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="235" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atpase</infon>
          <location offset="348" length="6"/>
          <text>ATPase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kifs</infon>
          <location offset="412" length="4"/>
          <text>KIFs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>418</offset>
        <text>Here, we report the first crystal structure of KIF4 complexed with the non-hydrolyzable ATP analog, AMPPNP (adenylyl imidodiphosphate), at 1.7Å resolution.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="506" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amppnp</infon>
          <location offset="518" length="6"/>
          <text>AMPPNP</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenylyl imidodiphosphate</infon>
          <location offset="526" length="25"/>
          <text>adenylyl imidodiphosphate</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kif4</infon>
          <location offset="465" length="4"/>
          <text>KIF4</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>574</offset>
        <text>By combining our structure with previously solved KIF1A structures complexed with two ATP analogs, molecular snapshots during ATP binding reveal that the closure of the nucleotide-binding pocket during ATP binding is achieved by closure of the backdoor.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="660" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="700" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleotide</infon>
          <location offset="743" length="10"/>
          <text>nucleotide</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="776" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kif1a</infon>
          <location offset="624" length="5"/>
          <text>KIF1A</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>828</offset>
        <text>Closure of the backdoor stabilizes two mobile regions, switch I and switch II, to generate the phosphate tube from which hydrolyzed phosphate is released.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phosphate</infon>
          <location offset="923" length="9"/>
          <text>phosphate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phosphate</infon>
          <location offset="960" length="9"/>
          <text>phosphate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>983</offset>
        <text>Through the stabilization of switch II, the local conformational change at the catalytic center is further relayed to the neck-linker element that fully docks to the catalytic core to produce the power stroke.</text>
      </sentence>
      <sentence>
        <offset>1193</offset>
        <text>Because the neck linker is a sole element that connects the partner heads in dimeric KIFs, this tight structural coordination between the catalytic center and neck linker enables inter-domain communication between the partner heads.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kifs</infon>
          <location offset="1278" length="4"/>
          <text>KIFs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1426</offset>
        <text>This study also revealed the putative microtubule-binding site of KIF4, thus providing structural insights that describe the specific binding of KIF4 to the microtubule.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">microtubule-binding site</infon>
          <location offset="1464" length="24"/>
          <text>microtubule-binding site</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kif4</infon>
          <location offset="1492" length="4"/>
          <text>KIF4</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kif4</infon>
          <location offset="1571" length="4"/>
          <text>KIF4</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15878185</id>
    <passage>
      <offset>0</offset>
      <text>Fatty acid metabolism as a target for obesity treatment.	Although metabolites and energy balance have long been known to play roles in the regulation of food intake, the potential role of fatty acid metabolism in this process has been considered only recently. Fatty acid synthase (FAS) catalyzes the condensation of acetyl-CoA and malonyl-CoA to generate long-chain fatty acids in the cytoplasm, while the breakdown of fatty acids (beta-oxidation) occurs in mitochondria and is regulated by carnitine palmitoyltransferase-1 (CPT-1), the rate-limiting step for the entry of fatty acids into the mitochondria. Inhibition of FAS using cerulenin or synthetic FAS inhibitors such as C75 reduces food intake and induces profound reversible weight loss. Subsequent studies reveal that C75 also stimulates CPT-1 and increases beta-oxidation. Hypotheses as to the mechanisms by which C75 and cerulenin mediate their effects have been proposed. Centrally, these compounds alter the expression profiles of feeding-related neuropeptides, often inhibiting the expression of orexigenic peptides. Whether through centrally mediated or peripheral mechanisms, C75 also increases energy consumption, which contributes to weight loss. In vitro and in vivo studies demonstrate that at least part of C75's effects is mediated by modulation of AMP-activated protein kinase (AMPK), a known peripheral energy-sensing kinase. Collectively, these data suggest a role for fatty acid metabolism in the perception and regulation of energy balance.</text>
      <sentence>
        <offset>0</offset>
        <text>Fatty acid metabolism as a target for obesity treatment.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="0" length="10"/>
          <text>Fatty acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>57</offset>
        <text>Although metabolites and energy balance have long been known to play roles in the regulation of food intake, the potential role of fatty acid metabolism in this process has been considered only recently.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="188" length="10"/>
          <text>fatty acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>261</offset>
        <text>Fatty acid synthase (FAS) catalyzes the condensation of acetyl-CoA and malonyl-CoA to generate long-chain fatty acids in the cytoplasm, while the breakdown of fatty acids (beta-oxidation) occurs in mitochondria and is regulated by carnitine palmitoyltransferase-1 (CPT-1), the rate-limiting step for the entry of fatty acids into the mitochondria.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="261" length="10"/>
          <text>Fatty acid</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetyl-coa</infon>
          <location offset="317" length="10"/>
          <text>acetyl-CoA</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malonyl-coa</infon>
          <location offset="332" length="11"/>
          <text>malonyl-CoA</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">long-chain fatty acids</infon>
          <location offset="356" length="22"/>
          <text>long-chain fatty acids</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acids</infon>
          <location offset="420" length="11"/>
          <text>fatty acids</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carnitine</infon>
          <location offset="492" length="9"/>
          <text>carnitine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acids</infon>
          <location offset="574" length="11"/>
          <text>fatty acids</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fatty acid synthase</infon>
          <location offset="261" length="19"/>
          <text>Fatty acid synthase</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="282" length="3"/>
          <text>FAS</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">carnitine palmitoyltransferase-1</infon>
          <location offset="492" length="32"/>
          <text>carnitine palmitoyltransferase-1</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cpt-1</infon>
          <location offset="526" length="5"/>
          <text>CPT-1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T9" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T9" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>609</offset>
        <text>Inhibition of FAS using cerulenin or synthetic FAS inhibitors such as C75 reduces food intake and induces profound reversible weight loss.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cerulenin</infon>
          <location offset="633" length="9"/>
          <text>cerulenin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c75</infon>
          <location offset="679" length="3"/>
          <text>C75</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="623" length="3"/>
          <text>FAS</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="656" length="3"/>
          <text>FAS</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>748</offset>
        <text>Subsequent studies reveal that C75 also stimulates CPT-1 and increases beta-oxidation.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c75</infon>
          <location offset="779" length="3"/>
          <text>C75</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cpt-1</infon>
          <location offset="799" length="5"/>
          <text>CPT-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>835</offset>
        <text>Hypotheses as to the mechanisms by which C75 and cerulenin mediate their effects have been proposed.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c75</infon>
          <location offset="876" length="3"/>
          <text>C75</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cerulenin</infon>
          <location offset="884" length="9"/>
          <text>cerulenin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>936</offset>
        <text>Centrally, these compounds alter the expression profiles of feeding-related neuropeptides, often inhibiting the expression of orexigenic peptides.</text>
      </sentence>
      <sentence>
        <offset>1083</offset>
        <text>Whether through centrally mediated or peripheral mechanisms, C75 also increases energy consumption, which contributes to weight loss.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c75</infon>
          <location offset="1144" length="3"/>
          <text>C75</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1217</offset>
        <text>In vitro and in vivo studies demonstrate that at least part of C75's effects is mediated by modulation of AMP-activated protein kinase (AMPK), a known peripheral energy-sensing kinase.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amp</infon>
          <location offset="1323" length="3"/>
          <text>AMP</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">amp-activated protein kinase</infon>
          <location offset="1323" length="28"/>
          <text>AMP-activated protein kinase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ampk</infon>
          <location offset="1353" length="4"/>
          <text>AMPK</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">energy-sensing kinase</infon>
          <location offset="1379" length="21"/>
          <text>energy-sensing kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1402</offset>
        <text>Collectively, these data suggest a role for fatty acid metabolism in the perception and regulation of energy balance.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="1446" length="10"/>
          <text>fatty acid</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23434506</id>
    <passage>
      <offset>0</offset>
      <text>Coenzyme Q10 protects Pc12 cells from cisplatin-induced DNA damage and neurotoxicity.	The purpose of this study was to investigate the neuroprotective effect of a water-soluble formulation of coenzyme Q10 (WS-CoQ10) in PC12 cells exposed to cisplatin, a chemotherapeutic agent with a dose-limiting factor due to neurotoxicity. In the cytokinesis-block micronucleus cytome assay (CBMN Cyt), WS-CoQ10 (at concentrations of 0.1, 0.5 and 1.0μgmL(-1)) protected PC12 cells from cisplatin-induced DNA damage (0.1μgmL(-1)), reducing the frequency of micronuclei (MNi) and nuclear buds (NBUDs). WS-CoQ10 did not alter the mRNA expression levels of Tp53 (at a concentration of 1.0μgmL(-1)) and exhibited neuroprotective activity by stimulating cisplatin-inhibited neurite outgrowth in nerve growth factor (NGF)-differentiated PC12 cells (at a concentration of 0.1μgmL(-1)). In conclusion, WS-CoQ10 protected the PC12 cells from cisplatin-induced DNA damage and neurotoxicity. Moreover, the neuroprotective effects of WS-CoQ10 suggest a possible application in chemotherapeutic protocols.</text>
      <sentence>
        <offset>0</offset>
        <text>Coenzyme Q10 protects Pc12 cells from cisplatin-induced DNA damage and neurotoxicity.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">coenzyme q10</infon>
          <location offset="0" length="12"/>
          <text>Coenzyme Q10</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="38" length="9"/>
          <text>cisplatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>86</offset>
        <text>The purpose of this study was to investigate the neuroprotective effect of a water-soluble formulation of coenzyme Q10 (WS-CoQ10) in PC12 cells exposed to cisplatin, a chemotherapeutic agent with a dose-limiting factor due to neurotoxicity.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">coenzyme q10</infon>
          <location offset="192" length="12"/>
          <text>coenzyme Q10</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">coq10</infon>
          <location offset="209" length="5"/>
          <text>CoQ10</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="241" length="9"/>
          <text>cisplatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>327</offset>
        <text>In the cytokinesis-block micronucleus cytome assay (CBMN Cyt), WS-CoQ10 (at concentrations of 0.1, 0.5 and 1.0μgmL(-1)) protected PC12 cells from cisplatin-induced DNA damage (0.1μgmL(-1)), reducing the frequency of micronuclei (MNi) and nuclear buds (NBUDs).</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">coq10</infon>
          <location offset="393" length="5"/>
          <text>CoQ10</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="473" length="9"/>
          <text>cisplatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>587</offset>
        <text>WS-CoQ10 did not alter the mRNA expression levels of Tp53 (at a concentration of 1.0μgmL(-1)) and exhibited neuroprotective activity by stimulating cisplatin-inhibited neurite outgrowth in nerve growth factor (NGF)-differentiated PC12 cells (at a concentration of 0.1μgmL(-1)).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">coq10</infon>
          <location offset="590" length="5"/>
          <text>CoQ10</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="735" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tp53</infon>
          <location offset="640" length="4"/>
          <text>Tp53</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nerve growth factor</infon>
          <location offset="776" length="19"/>
          <text>nerve growth factor</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ngf</infon>
          <location offset="797" length="3"/>
          <text>NGF</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>865</offset>
        <text>In conclusion, WS-CoQ10 protected the PC12 cells from cisplatin-induced DNA damage and neurotoxicity.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">coq10</infon>
          <location offset="883" length="5"/>
          <text>CoQ10</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="919" length="9"/>
          <text>cisplatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>967</offset>
        <text>Moreover, the neuroprotective effects of WS-CoQ10 suggest a possible application in chemotherapeutic protocols.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">coq10</infon>
          <location offset="1011" length="5"/>
          <text>CoQ10</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10882160</id>
    <passage>
      <offset>0</offset>
      <text>Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.	When peripheral decarboxylation is blocked by carbidopa or benserazide, the main metabolic pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT). Entacapone and tolcapone are new potent, selective and reversible nitrocatechol-type COMT inhibitors. Animal studies have demonstrated that entacapone mainly has a peripheral effect whereas tolcapone also inhibits O-methylation in the brain. In human volunteers, both entacapone and tolcapone dose-dependently inhibit the COMT activity in erythrocytes, improve the bioavailability and decrease the elimination of levodopa, and inhibit the formation of 3-O-methyldopa (3-OMD). Entacapone is administered with every scheduled dose of levodopa whereas tolcapone is administered 3 times daily. The different administration regimens for these agents are based on their different pharmacokinetic and pharmacodynamic profiles. Both entacapone and tolcapone enhance and extend the therapeutic effect of levodopa in patients with advanced and fluctuating Parkinson's disease. They prolong the duration of levodopa effect. Clinical studies show that they increase the daily ON time by an average 1 to 3 hours, improve the activities of daily living and allow daily levodopa dosage to be decreased. Correspondingly, they significantly reduce the daily OFF time. No comparative studies between entacapone and tolcapone have been performed. Tolcapone also appears to have a beneficial effect in patients with nonfluctuating Parkinson's disease. The main adverse effects of the COMT inhibitors are related to their dopaminergic and gastrointestinal effects. Enhancement of dopaminergic activity may cause an initial worsening of levodopa-induced adverse effects, such as dyskinesia, nausea, vomiting, orthostatic hypotension, sleep disorders and hallucinations. Levodopa dose adjustment is recommended to avoid these events. Tolcapone is associated with diarrhoea in about 16 to 18% of patients and entacapone in less than 10% of patients. Diarrhoea has led to discontinuation in 5 to 6% of patients treated with tolcapone and in 2.5% of those treated with entacapone. Urine discoloration to dark yellow or orange is related to the colour of COMT inhibitors and their metabolites. Elevated liver transaminase levels are reported in 1 to 3% of patients treated with tolcapone but very rarely, if at all, in patients treated with entacapone. The descriptions of acute, fatal fulminant hepatitis and potentially fatal neurological reactions, such as neuroleptic malignant syndrome and rhabdomyolysis, in association with tolcapone led to the suspension of its marketing authorisation in the European Community and Canada. In many other countries, the use of tolcapone is restricted to patients who are not responding satisfactorily to other therapies. Regular monitoring of liver enzymes is required if tolcapone is used. No such adverse reactions have so far been described for entacapone and no laboratory monitoring has been proposed. COMT inhibitors added to levodopa therapy are beneficial, particularly in patients with fluctuating disease. They may be combined with other antiparkinsonian drugs, such as dopamine agonists, selegiline and anticholinergics without adverse interactions. They provide a new treatment possibility in patients with Parkinson's disease who have problems with their present levodopa therapy.</text>
      <sentence>
        <offset>0</offset>
        <text>Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.</text>
        <annotation id="T52">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">comt</infon>
          <location offset="56" length="4"/>
          <text>COMT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>96</offset>
        <text>When peripheral decarboxylation is blocked by carbidopa or benserazide, the main metabolic pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="198" length="8"/>
          <text>levodopa</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="210" length="1"/>
          <text>O</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">catechol</infon>
          <location offset="227" length="8"/>
          <text>catechol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="236" length="1"/>
          <text>O</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbidopa</infon>
          <location offset="142" length="9"/>
          <text>carbidopa</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benserazide</infon>
          <location offset="155" length="11"/>
          <text>benserazide</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catechol-o-methyltransferase</infon>
          <location offset="227" length="28"/>
          <text>catechol-O-methyltransferase</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">comt</infon>
          <location offset="257" length="4"/>
          <text>COMT</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>264</offset>
        <text>Entacapone and tolcapone are new potent, selective and reversible nitrocatechol-type COMT inhibitors.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">entacapone</infon>
          <location offset="264" length="10"/>
          <text>Entacapone</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="279" length="9"/>
          <text>tolcapone</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitrocatechol</infon>
          <location offset="330" length="13"/>
          <text>nitrocatechol</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">comt</infon>
          <location offset="349" length="4"/>
          <text>COMT</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T49" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T49" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T49" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>366</offset>
        <text>Animal studies have demonstrated that entacapone mainly has a peripheral effect whereas tolcapone also inhibits O-methylation in the brain.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">entacapone</infon>
          <location offset="404" length="10"/>
          <text>entacapone</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="454" length="9"/>
          <text>tolcapone</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="478" length="1"/>
          <text>O</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>506</offset>
        <text>In human volunteers, both entacapone and tolcapone dose-dependently inhibit the COMT activity in erythrocytes, improve the bioavailability and decrease the elimination of levodopa, and inhibit the formation of 3-O-methyldopa (3-OMD).</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">entacapone</infon>
          <location offset="532" length="10"/>
          <text>entacapone</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="547" length="9"/>
          <text>tolcapone</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="677" length="8"/>
          <text>levodopa</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-o-methyldopa</infon>
          <location offset="716" length="14"/>
          <text>3-O-methyldopa</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-omd</infon>
          <location offset="732" length="5"/>
          <text>3-OMD</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">comt</infon>
          <location offset="586" length="4"/>
          <text>COMT</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T31" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T37" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T32" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T36" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T34" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>740</offset>
        <text>Entacapone is administered with every scheduled dose of levodopa whereas tolcapone is administered 3 times daily.</text>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">entacapone</infon>
          <location offset="740" length="10"/>
          <text>Entacapone</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="796" length="8"/>
          <text>levodopa</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="813" length="9"/>
          <text>tolcapone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>854</offset>
        <text>The different administration regimens for these agents are based on their different pharmacokinetic and pharmacodynamic profiles.</text>
      </sentence>
      <sentence>
        <offset>984</offset>
        <text>Both entacapone and tolcapone enhance and extend the therapeutic effect of levodopa in patients with advanced and fluctuating Parkinson's disease.</text>
        <annotation id="T41">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">entacapone</infon>
          <location offset="989" length="10"/>
          <text>entacapone</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="1004" length="9"/>
          <text>tolcapone</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="1059" length="8"/>
          <text>levodopa</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1131</offset>
        <text>They prolong the duration of levodopa effect.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="1160" length="8"/>
          <text>levodopa</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1177</offset>
        <text>Clinical studies show that they increase the daily ON time by an average 1 to 3 hours, improve the activities of daily living and allow daily levodopa dosage to be decreased.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="1319" length="8"/>
          <text>levodopa</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1352</offset>
        <text>Correspondingly, they significantly reduce the daily OFF time.</text>
      </sentence>
      <sentence>
        <offset>1415</offset>
        <text>No comparative studies between entacapone and tolcapone have been performed.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">entacapone</infon>
          <location offset="1446" length="10"/>
          <text>entacapone</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="1461" length="9"/>
          <text>tolcapone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1492</offset>
        <text>Tolcapone also appears to have a beneficial effect in patients with nonfluctuating Parkinson's disease.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="1492" length="9"/>
          <text>Tolcapone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1596</offset>
        <text>The main adverse effects of the COMT inhibitors are related to their dopaminergic and gastrointestinal effects.</text>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">comt</infon>
          <location offset="1628" length="4"/>
          <text>COMT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1708</offset>
        <text>Enhancement of dopaminergic activity may cause an initial worsening of levodopa-induced adverse effects, such as dyskinesia, nausea, vomiting, orthostatic hypotension, sleep disorders and hallucinations.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="1779" length="8"/>
          <text>levodopa</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1912</offset>
        <text>Levodopa dose adjustment is recommended to avoid these events.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="1912" length="8"/>
          <text>Levodopa</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1975</offset>
        <text>Tolcapone is associated with diarrhoea in about 16 to 18% of patients and entacapone in less than 10% of patients.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="1975" length="9"/>
          <text>Tolcapone</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">entacapone</infon>
          <location offset="2049" length="10"/>
          <text>entacapone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2090</offset>
        <text>Diarrhoea has led to discontinuation in 5 to 6% of patients treated with tolcapone and in 2.5% of those treated with entacapone.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="2163" length="9"/>
          <text>tolcapone</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">entacapone</infon>
          <location offset="2207" length="10"/>
          <text>entacapone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2219</offset>
        <text>Urine discoloration to dark yellow or orange is related to the colour of COMT inhibitors and their metabolites.</text>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">comt</infon>
          <location offset="2292" length="4"/>
          <text>COMT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2331</offset>
        <text>Elevated liver transaminase levels are reported in 1 to 3% of patients treated with tolcapone but very rarely, if at all, in patients treated with entacapone.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="2415" length="9"/>
          <text>tolcapone</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">entacapone</infon>
          <location offset="2478" length="10"/>
          <text>entacapone</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">liver transaminase</infon>
          <location offset="2340" length="18"/>
          <text>liver transaminase</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2490</offset>
        <text>The descriptions of acute, fatal fulminant hepatitis and potentially fatal neurological reactions, such as neuroleptic malignant syndrome and rhabdomyolysis, in association with tolcapone led to the suspension of its marketing authorisation in the European Community and Canada.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="2668" length="9"/>
          <text>tolcapone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2769</offset>
        <text>In many other countries, the use of tolcapone is restricted to patients who are not responding satisfactorily to other therapies.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="2805" length="9"/>
          <text>tolcapone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2899</offset>
        <text>Regular monitoring of liver enzymes is required if tolcapone is used.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolcapone</infon>
          <location offset="2950" length="9"/>
          <text>tolcapone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2969</offset>
        <text>No such adverse reactions have so far been described for entacapone and no laboratory monitoring has been proposed.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">entacapone</infon>
          <location offset="3026" length="10"/>
          <text>entacapone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>3085</offset>
        <text>COMT inhibitors added to levodopa therapy are beneficial, particularly in patients with fluctuating disease.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="3110" length="8"/>
          <text>levodopa</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">comt</infon>
          <location offset="3085" length="4"/>
          <text>COMT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>3194</offset>
        <text>They may be combined with other antiparkinsonian drugs, such as dopamine agonists, selegiline and anticholinergics without adverse interactions.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="3258" length="8"/>
          <text>dopamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>3339</offset>
        <text>They provide a new treatment possibility in patients with Parkinson's disease who have problems with their present levodopa therapy.</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="3454" length="8"/>
          <text>levodopa</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23474389</id>
    <passage>
      <offset>0</offset>
      <text>Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents.	A series of substituted 3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines has been synthesised and tested in vitro as potential pro-apoptotic Bcl-2-inhibitory anticancer agents. Synthesis of the target compounds was readily accomplished in good yields through a cyclisation reaction between indole-3-carboxylic acid hydrazide and carbon disulfide under basic conditions, followed by S-benzylation. Active compounds, such as the nitrobenzyl analogue 6c, were found to exhibit sub-micromolar IC50 values in Bcl-2 expressing human cancer cell lines. Molecular modelling and ELISA studies further implicated anti-apoptotic Bcl-2 as a candidate molecular target underpinning anticancer activity.</text>
      <sentence>
        <offset>0</offset>
        <text>Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-(benzylthio)-5-(1h-indol-3-yl)-1,2,4-triazol-4-amines</infon>
          <location offset="28" length="55"/>
          <text>3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="87" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>123</offset>
        <text>A series of substituted 3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines has been synthesised and tested in vitro as potential pro-apoptotic Bcl-2-inhibitory anticancer agents.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-(benzylthio)-5-(1h-indol-3-yl)-4h-1,2,4-triazol-4-amines</infon>
          <location offset="147" length="58"/>
          <text>3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="274" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>310</offset>
        <text>Synthesis of the target compounds was readily accomplished in good yields through a cyclisation reaction between indole-3-carboxylic acid hydrazide and carbon disulfide under basic conditions, followed by S-benzylation.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indole-3-carboxylic acid hydrazide</infon>
          <location offset="423" length="34"/>
          <text>indole-3-carboxylic acid hydrazide</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbon disulfide</infon>
          <location offset="462" length="16"/>
          <text>carbon disulfide</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s</infon>
          <location offset="515" length="1"/>
          <text>S</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>530</offset>
        <text>Active compounds, such as the nitrobenzyl analogue 6c, were found to exhibit sub-micromolar IC50 values in Bcl-2 expressing human cancer cell lines.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitrobenzyl</infon>
          <location offset="560" length="11"/>
          <text>nitrobenzyl</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="637" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>679</offset>
        <text>Molecular modelling and ELISA studies further implicated anti-apoptotic Bcl-2 as a candidate molecular target underpinning anticancer activity.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="751" length="5"/>
          <text>Bcl-2</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16855093</id>
    <passage>
      <offset>0</offset>
      <text>The glutamate-aspartate transporter GLAST mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea.	Ribbon synapses formed between inner hair cells (IHCs) and afferent dendrites in the mammalian cochlea can sustain high rates of release, placing strong demands on glutamate clearance mechanisms. To investigate the role of transporters in glutamate removal at these synapses, we made whole-cell recordings from IHCs, afferent dendrites, and glial cells adjacent to IHCs [inner phalangeal cells (IPCs)] in whole-mount preparations of rat organ of Corti. Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated anion channel and blocked by the transporter antagonist D,L-threo-beta-benzyloxyaspartate. These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas. Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of GLAST, and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs. Saturation of transporters by photolysis of caged D-aspartate failed to elicit transporter currents in IHCs, as did local application of D-aspartate to afferent terminals, indicating that neither presynaptic nor postsynaptic membranes are major sites for glutamate removal. These data indicate that GLAST in supporting cells is responsible for transmitter uptake at IHC afferent synapses.</text>
      <sentence>
        <offset>0</offset>
        <text>The glutamate-aspartate transporter GLAST mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="51" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glast</infon>
          <location offset="36" length="5"/>
          <text>GLAST</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutamate-aspartate transporter</infon>
          <location offset="4" length="31"/>
          <text>glutamate-aspartate transporter</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T16" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T16" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>131</offset>
        <text>Ribbon synapses formed between inner hair cells (IHCs) and afferent dendrites in the mammalian cochlea can sustain high rates of release, placing strong demands on glutamate clearance mechanisms.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="295" length="9"/>
          <text>glutamate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>327</offset>
        <text>To investigate the role of transporters in glutamate removal at these synapses, we made whole-cell recordings from IHCs, afferent dendrites, and glial cells adjacent to IHCs [inner phalangeal cells (IPCs)] in whole-mount preparations of rat organ of Corti.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="370" length="9"/>
          <text>glutamate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>584</offset>
        <text>Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated anion channel and blocked by the transporter antagonist D,L-threo-beta-benzyloxyaspartate.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-aspartate</infon>
          <location offset="631" length="11"/>
          <text>D-aspartate</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d,l-threo-beta-benzyloxyaspartate</infon>
          <location offset="818" length="33"/>
          <text>D,L-threo-beta-benzyloxyaspartate</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">anion channel</infon>
          <location offset="762" length="13"/>
          <text>anion channel</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>853</offset>
        <text>These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="885" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspartate</infon>
          <location offset="895" length="9"/>
          <text>aspartate</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="938" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydrokainate</infon>
          <location offset="1002" length="14"/>
          <text>dihydrokainate</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="1035" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="1071" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glutamate-aspartate transporters</infon>
          <location offset="885" length="32"/>
          <text>glutamate-aspartate transporters</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glast</infon>
          <location offset="919" length="5"/>
          <text>GLAST</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">excitatory amino acid transporter 1</infon>
          <location offset="927" length="35"/>
          <text>excitatory amino acid transporter 1</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glutamate transporter-1</infon>
          <location offset="1035" length="23"/>
          <text>glutamate transporter-1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">excitatory amino acid transporter 2</infon>
          <location offset="1060" length="35"/>
          <text>excitatory amino acid transporter 2</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glast</infon>
          <location offset="1126" length="5"/>
          <text>GLAST</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T13" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T13" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1145</offset>
        <text>Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of GLAST, and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-aspartate</infon>
          <location offset="1158" length="11"/>
          <text>D-aspartate</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-glutamate</infon>
          <location offset="1286" length="11"/>
          <text>L-glutamate</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glast</infon>
          <location offset="1322" length="5"/>
          <text>GLAST</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glast</infon>
          <location offset="1361" length="5"/>
          <text>GLAST</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1511</offset>
        <text>Saturation of transporters by photolysis of caged D-aspartate failed to elicit transporter currents in IHCs, as did local application of D-aspartate to afferent terminals, indicating that neither presynaptic nor postsynaptic membranes are major sites for glutamate removal.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-aspartate</infon>
          <location offset="1561" length="11"/>
          <text>D-aspartate</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-aspartate</infon>
          <location offset="1648" length="11"/>
          <text>D-aspartate</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="1766" length="9"/>
          <text>glutamate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1785</offset>
        <text>These data indicate that GLAST in supporting cells is responsible for transmitter uptake at IHC afferent synapses.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glast</infon>
          <location offset="1810" length="5"/>
          <text>GLAST</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16772434</id>
    <passage>
      <offset>0</offset>
      <text>Epigenetic regulation of chromatin structure and gene function by biotin.	Covalent modifications of histones are a crucial component of epigenetic events that regulate chromatin structures and gene function. Evidence exists that distinct lysine residues in histones are modified by covalent attachment of the vitamin biotin, catalyzed by biotinidase and holocarboxylase synthetase. Biotinylation of histones appears to be conserved across species. The following biotinylation sites were identified using both MS and enzymatic biotinylation of synthetic peptides: K9, K13, K125, K127, and K129 in histone H2A; K4, K9, and K18 in histone H3; and K8 and K12 in histone H4. Evidence was provided that biotinylated histone H4 is enriched in pericentromeric heterochromatin, and that biotinylation of histone H4 participates in gene silencing, mitotic condensation of chromatin, and the cellular response to DNA damage. Biotinylation of histones is a reversible process and depends on the exogenous biotin supply, but the identities of histone debiotinylases remain uncertain. We propose that some effects of biotin deficiency can be attributed to abnormal chromatin structures.</text>
      <sentence>
        <offset>0</offset>
        <text>Epigenetic regulation of chromatin structure and gene function by biotin.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="66" length="6"/>
          <text>biotin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>74</offset>
        <text>Covalent modifications of histones are a crucial component of epigenetic events that regulate chromatin structures and gene function.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">histones</infon>
          <location offset="100" length="8"/>
          <text>histones</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>208</offset>
        <text>Evidence exists that distinct lysine residues in histones are modified by covalent attachment of the vitamin biotin, catalyzed by biotinidase and holocarboxylase synthetase.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lysine</infon>
          <location offset="238" length="6"/>
          <text>lysine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin biotin</infon>
          <location offset="309" length="14"/>
          <text>vitamin biotin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">biotinidase</infon>
          <location offset="338" length="11"/>
          <text>biotinidase</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">holocarboxylase synthetase</infon>
          <location offset="354" length="26"/>
          <text>holocarboxylase synthetase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>382</offset>
        <text>Biotinylation of histones appears to be conserved across species.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">histones</infon>
          <location offset="399" length="8"/>
          <text>histones</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>448</offset>
        <text>The following biotinylation sites were identified using both MS and enzymatic biotinylation of synthetic peptides: K9, K13, K125, K127, and K129 in histone H2A; K4, K9, and K18 in histone H3; and K8 and K12 in histone H4.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">histone h2a</infon>
          <location offset="596" length="11"/>
          <text>histone H2A</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">histone h3</infon>
          <location offset="628" length="10"/>
          <text>histone H3</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histone h4</infon>
          <location offset="658" length="10"/>
          <text>histone H4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>670</offset>
        <text>Evidence was provided that biotinylated histone H4 is enriched in pericentromeric heterochromatin, and that biotinylation of histone H4 participates in gene silencing, mitotic condensation of chromatin, and the cellular response to DNA damage.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histone h4</infon>
          <location offset="710" length="10"/>
          <text>histone H4</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histone h4</infon>
          <location offset="795" length="10"/>
          <text>histone H4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>914</offset>
        <text>Biotinylation of histones is a reversible process and depends on the exogenous biotin supply, but the identities of histone debiotinylases remain uncertain.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="993" length="6"/>
          <text>biotin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">histones</infon>
          <location offset="931" length="8"/>
          <text>histones</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">histone debiotinylases</infon>
          <location offset="1030" length="22"/>
          <text>histone debiotinylases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1071</offset>
        <text>We propose that some effects of biotin deficiency can be attributed to abnormal chromatin structures.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biotin</infon>
          <location offset="1103" length="6"/>
          <text>biotin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11535580</id>
    <passage>
      <offset>0</offset>
      <text>Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.	BACKGROUND: Mutations in the cardiac sodium (Na) channel gene (SCN5A) give rise to the congenital long-QT syndrome (LQT3) and the Brugada syndrome. Na channel blockade by antiarrhythmic drugs improves the QT interval prolongation in LQT3 but worsens the Brugada syndrome ST-segment elevation. Although Na channel blockade has been proposed as a treatment for LQT3, flecainide also evokes "Brugada-like" ST-segment elevation in LQT3 patients. Here, we examine how Na channel inactivation gating defects in LQT3 and Brugada syndrome elicit proarrhythmic sensitivity to flecainide. METHODS AND RESULTS: We measured whole-cell Na current (I(Na)) from tsA-201 cells transfected with DeltaKPQ, a LQT3 mutation, and 1795insD, a mutation that provokes both the LQT3 and Brugada syndromes. The 1795insD and DeltaKPQ channels both exhibited modified inactivation gating (from the closed state), thus potentiating tonic I(Na) block. Flecainide (1 micromol/L) tonic block was only 16.8+/-3.0% for wild type but was 58.0+/-6.0% for 1795insD (P&lt;0.01) and 39.4+/-8.0% (P&lt;0.05) for DeltaKPQ. In addition, the 1795insD mutation delayed recovery from inactivation by enhancing intermediate inactivation, with a 4-fold delay in recovery from use-dependent flecainide block. CONCLUSIONS: We have linked 2 inactivation gating defects ("closed-state" fast inactivation and intermediate inactivation) to flecainide sensitivity in patients carrying LQT3 and Brugada syndrome mutations. These results provide a mechanistic rationale for predicting proarrhythmic sensitivity to flecainide based on the identification of specific SCN5A inactivation gating defects.</text>
      <sentence>
        <offset>0</offset>
        <text>Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flecainide</infon>
          <location offset="32" length="10"/>
          <text>flecainide</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">scn5a</infon>
          <location offset="53" length="5"/>
          <text>SCN5A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>88</offset>
        <text>BACKGROUND: Mutations in the cardiac sodium (Na) channel gene (SCN5A) give rise to the congenital long-QT syndrome (LQT3) and the Brugada syndrome.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="125" length="6"/>
          <text>sodium</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="133" length="2"/>
          <text>Na</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sodium (na) channel</infon>
          <location offset="125" length="19"/>
          <text>sodium (Na) channel</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">scn5a</infon>
          <location offset="151" length="5"/>
          <text>SCN5A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>236</offset>
        <text>Na channel blockade by antiarrhythmic drugs improves the QT interval prolongation in LQT3 but worsens the Brugada syndrome ST-segment elevation.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="236" length="2"/>
          <text>Na</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na channel</infon>
          <location offset="236" length="10"/>
          <text>Na channel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>381</offset>
        <text>Although Na channel blockade has been proposed as a treatment for LQT3, flecainide also evokes "Brugada-like" ST-segment elevation in LQT3 patients.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="390" length="2"/>
          <text>Na</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na channel</infon>
          <location offset="390" length="10"/>
          <text>Na channel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>530</offset>
        <text>Here, we examine how Na channel inactivation gating defects in LQT3 and Brugada syndrome elicit proarrhythmic sensitivity to flecainide.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="551" length="2"/>
          <text>Na</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flecainide</infon>
          <location offset="655" length="10"/>
          <text>flecainide</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na channel</infon>
          <location offset="551" length="10"/>
          <text>Na channel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>667</offset>
        <text>METHODS AND RESULTS: We measured whole-cell Na current (I(Na)) from tsA-201 cells transfected with DeltaKPQ, a LQT3 mutation, and 1795insD, a mutation that provokes both the LQT3 and Brugada syndromes.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="711" length="2"/>
          <text>Na</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="725" length="2"/>
          <text>Na</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>869</offset>
        <text>The 1795insD and DeltaKPQ channels both exhibited modified inactivation gating (from the closed state), thus potentiating tonic I(Na) block.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="999" length="2"/>
          <text>Na</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">1795insd and deltakpq channels</infon>
          <location offset="873" length="30"/>
          <text>1795insD and DeltaKPQ channels</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1010</offset>
        <text>Flecainide (1 micromol/L) tonic block was only 16.8+/-3.0% for wild type but was 58.0+/-6.0% for 1795insD (P&lt;0.01) and 39.4+/-8.0% (P&lt;0.05) for DeltaKPQ.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flecainide</infon>
          <location offset="1010" length="10"/>
          <text>Flecainide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1164</offset>
        <text>In addition, the 1795insD mutation delayed recovery from inactivation by enhancing intermediate inactivation, with a 4-fold delay in recovery from use-dependent flecainide block.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flecainide</infon>
          <location offset="1325" length="10"/>
          <text>flecainide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1343</offset>
        <text>CONCLUSIONS: We have linked 2 inactivation gating defects ("closed-state" fast inactivation and intermediate inactivation) to flecainide sensitivity in patients carrying LQT3 and Brugada syndrome mutations.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flecainide</infon>
          <location offset="1469" length="10"/>
          <text>flecainide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1550</offset>
        <text>These results provide a mechanistic rationale for predicting proarrhythmic sensitivity to flecainide based on the identification of specific SCN5A inactivation gating defects.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flecainide</infon>
          <location offset="1640" length="10"/>
          <text>flecainide</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">scn5a</infon>
          <location offset="1691" length="5"/>
          <text>SCN5A</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11018726</id>
    <passage>
      <offset>0</offset>
      <text>The active-site residue tyr-175 in human glyoxalase II contributes to binding of glutathione derivatives.	Tyrosine-175 located in the active site of human glyoxalase II was replaced by phenylalanine in order to study the contribution of this residue to catalysis. The mutation had a marginal effect on the k(cat) value determined using S-D-lactoylglutathione as substrate. However, the Y175F mutant had an 8-fold higher K(m) value than the wild-type enzyme. The competitive inhibitor S-(N-hydroxy-N-bromophenylcarbamoyl)glutathione had a 30-fold higher K(i) value towards the mutant, than that of the wild-type. Pre-equilibrium fluorescence studies with the inhibitor showed that this was due to a significantly increased off-rate for the mutant enzyme. The phenolic hydroxyl group of tyrosine-175 is within hydrogen bonding distance of the amide nitrogen of the glycine in the glutathione moiety and the present study shows that this interaction makes a significant contribution to the binding of the active-site ligand.</text>
      <sentence>
        <offset>0</offset>
        <text>The active-site residue tyr-175 in human glyoxalase II contributes to binding of glutathione derivatives.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyr</infon>
          <location offset="24" length="3"/>
          <text>tyr</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="81" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human glyoxalase ii</infon>
          <location offset="35" length="19"/>
          <text>human glyoxalase II</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T11" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>106</offset>
        <text>Tyrosine-175 located in the active site of human glyoxalase II was replaced by phenylalanine in order to study the contribution of this residue to catalysis.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="106" length="8"/>
          <text>Tyrosine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenylalanine</infon>
          <location offset="185" length="13"/>
          <text>phenylalanine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human glyoxalase ii</infon>
          <location offset="149" length="19"/>
          <text>human glyoxalase II</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>264</offset>
        <text>The mutation had a marginal effect on the k(cat) value determined using S-D-lactoylglutathione as substrate.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s-d-lactoylglutathione</infon>
          <location offset="336" length="22"/>
          <text>S-D-lactoylglutathione</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>373</offset>
        <text>However, the Y175F mutant had an 8-fold higher K(m) value than the wild-type enzyme.</text>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">y175f</infon>
          <location offset="386" length="5"/>
          <text>Y175F</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>458</offset>
        <text>The competitive inhibitor S-(N-hydroxy-N-bromophenylcarbamoyl)glutathione had a 30-fold higher K(i) value towards the mutant, than that of the wild-type.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s-(n-hydroxy-n-bromophenylcarbamoyl)glutathione</infon>
          <location offset="484" length="47"/>
          <text>S-(N-hydroxy-N-bromophenylcarbamoyl)glutathione</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>612</offset>
        <text>Pre-equilibrium fluorescence studies with the inhibitor showed that this was due to a significantly increased off-rate for the mutant enzyme.</text>
      </sentence>
      <sentence>
        <offset>754</offset>
        <text>The phenolic hydroxyl group of tyrosine-175 is within hydrogen bonding distance of the amide nitrogen of the glycine in the glutathione moiety and the present study shows that this interaction makes a significant contribution to the binding of the active-site ligand.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenolic hydroxyl</infon>
          <location offset="758" length="17"/>
          <text>phenolic hydroxyl</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="785" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrogen</infon>
          <location offset="808" length="8"/>
          <text>hydrogen</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amide nitrogen</infon>
          <location offset="841" length="14"/>
          <text>amide nitrogen</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="863" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="878" length="11"/>
          <text>glutathione</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15120421</id>
    <passage>
      <offset>0</offset>
      <text>In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.	In determining the biological profiles of various antiprogestins, it is important to assess the hormonal and antihormonal activity, selectivity, and potency of their proximal metabolites. The early metabolism of mifepristone is characterized by rapid demethylation and hydroxylation. Similar initial metabolic pathways have been proposed for CDB-2914 (CDB: Contraceptive Development Branch of NICHD) and CDB-4124, and their putative metabolites have been synthesized. We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124. The binding affinities of the monodemethylated metabolites for rabbit uterine PR and human PR-A and PR-B were similar to those of the parent compounds. Monodemethylated mifepristone bound to rabbit thymic GR with higher affinity than monodemethylated CDB-2914 or CDB-4124. T47D-CO cells were used to assess inhibition of R5020-stimulated endogenous alkaline phosphatase activity and transactivation of the PRE(2)-thymidine kinase (tk)-luciferase (LUC) reporter plasmid in transient transfections. The antiprogestational potency was as follows: mifepristone/CDB-2914/CDB-4124/monodemethylated metabolites (IC(50)'s approximately 10(-9)M) &gt; aromatic A-ring derivatives (IC(50)'s approximately 10(-8)M) &gt; didemethylated/17alpha-hydroxy derivatives (IC(50)'s approximately 10(-7)M). Antiglucocorticoid activity was determined by inhibition of dexamethasone-stimulated transcriptional activity in HepG2 cells. The mono- and didemethylated metabolites of CDB-2914 and CDB-4124 had less antiglucocorticoid activity (IC(50)'s approximately 10(-6)M) than monodemethylated mifepristone (IC(50) approximately 10(-8)M) or the other test compounds. At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas mifepristone and its monodemethylated metabolite manifested slight glucocorticoid agonist activity. The reduced antiglucocorticoid activity of monodemethylated CDB-2914 and CDB-4124 was confirmed in vivo by the thymus involution assay in adrenalectomized male rats. The aromatic A-ring derivatives-stimulated transcription of an estrogen-responsive reporter plasmid in MCF-7 and T47D-CO human breast cancer cells but were much less potent than estradiol. Taken together, these data suggest that the proximal metabolites of mifepristone, CDB-2914, and CDB-4124 contribute significantly to the antiprogestational activity of the parent compounds in vivo. Furthermore, the reduced antiglucocorticoid activity of CDB-2914 and CDB-4124 compared to mifepristone in vivo may be due in part to decreased activity of their putative proximal metabolites.</text>
      <sentence>
        <offset>0</offset>
        <text>In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.</text>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-2914</infon>
          <location offset="163" length="8"/>
          <text>CDB-2914</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-4124</infon>
          <location offset="173" length="8"/>
          <text>CDB-4124</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="187" length="12"/>
          <text>mifepristone</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestin</infon>
          <location offset="60" length="9"/>
          <text>progestin</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">progestin</infon>
          <location offset="60" length="9"/>
          <text>progestin</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="74" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T35" role="head"/>
          <node refid="T54" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T37" role="head"/>
          <node refid="T54" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T36" role="head"/>
          <node refid="T54" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>201</offset>
        <text>In determining the biological profiles of various antiprogestins, it is important to assess the hormonal and antihormonal activity, selectivity, and potency of their proximal metabolites.</text>
      </sentence>
      <sentence>
        <offset>389</offset>
        <text>The early metabolism of mifepristone is characterized by rapid demethylation and hydroxylation.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="413" length="12"/>
          <text>mifepristone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>485</offset>
        <text>Similar initial metabolic pathways have been proposed for CDB-2914 (CDB: Contraceptive Development Branch of NICHD) and CDB-4124, and their putative metabolites have been synthesized.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-2914</infon>
          <location offset="543" length="8"/>
          <text>CDB-2914</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-4124</infon>
          <location offset="605" length="8"/>
          <text>CDB-4124</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>669</offset>
        <text>We have examined the functional activities and potencies, in various cell-based assays, and relative binding affinities (RBAs) for progesterone receptors (PR) and glucocorticoid receptors (GR) of the putative mono- and didemethylated metabolites of CDB-2914, CDB-4124, and mifepristone and of the 17alpha-hydroxy and aromatic A-ring derivatives of CDB-2914 and CDB-4124.</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="800" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-2914</infon>
          <location offset="918" length="8"/>
          <text>CDB-2914</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-4124</infon>
          <location offset="928" length="8"/>
          <text>CDB-4124</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="942" length="12"/>
          <text>mifepristone</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">17alpha-hydroxy</infon>
          <location offset="966" length="15"/>
          <text>17alpha-hydroxy</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-2914</infon>
          <location offset="1017" length="8"/>
          <text>CDB-2914</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-4124</infon>
          <location offset="1030" length="8"/>
          <text>CDB-4124</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">progesterone receptors</infon>
          <location offset="800" length="22"/>
          <text>progesterone receptors</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pr</infon>
          <location offset="824" length="2"/>
          <text>PR</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptors</infon>
          <location offset="832" length="24"/>
          <text>glucocorticoid receptors</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="858" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1040</offset>
        <text>The binding affinities of the monodemethylated metabolites for rabbit uterine PR and human PR-A and PR-B were similar to those of the parent compounds.</text>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rabbit uterine pr</infon>
          <location offset="1103" length="17"/>
          <text>rabbit uterine PR</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human pr-a</infon>
          <location offset="1125" length="10"/>
          <text>human PR-A</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr-b</infon>
          <location offset="1140" length="4"/>
          <text>PR-B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1192</offset>
        <text>Monodemethylated mifepristone bound to rabbit thymic GR with higher affinity than monodemethylated CDB-2914 or CDB-4124.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="1209" length="12"/>
          <text>mifepristone</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-2914</infon>
          <location offset="1291" length="8"/>
          <text>CDB-2914</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-4124</infon>
          <location offset="1303" length="8"/>
          <text>CDB-4124</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rabbit thymic gr</infon>
          <location offset="1231" length="16"/>
          <text>rabbit thymic GR</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1313</offset>
        <text>T47D-CO cells were used to assess inhibition of R5020-stimulated endogenous alkaline phosphatase activity and transactivation of the PRE(2)-thymidine kinase (tk)-luciferase (LUC) reporter plasmid in transient transfections.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thymidine</infon>
          <location offset="1453" length="9"/>
          <text>thymidine</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alkaline phosphatase</infon>
          <location offset="1389" length="20"/>
          <text>alkaline phosphatase</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pre(2)</infon>
          <location offset="1446" length="6"/>
          <text>PRE(2)</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">thymidine kinase</infon>
          <location offset="1453" length="16"/>
          <text>thymidine kinase</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tk</infon>
          <location offset="1471" length="2"/>
          <text>tk</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1537</offset>
        <text>The antiprogestational potency was as follows: mifepristone/CDB-2914/CDB-4124/monodemethylated metabolites (IC(50)'s approximately 10(-9)M) &gt; aromatic A-ring derivatives (IC(50)'s approximately 10(-8)M) &gt; didemethylated/17alpha-hydroxy derivatives (IC(50)'s approximately 10(-7)M).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="1584" length="12"/>
          <text>mifepristone</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-2914</infon>
          <location offset="1597" length="8"/>
          <text>CDB-2914</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-4124</infon>
          <location offset="1606" length="8"/>
          <text>CDB-4124</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">17alpha-hydroxy</infon>
          <location offset="1757" length="15"/>
          <text>17alpha-hydroxy</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1819</offset>
        <text>Antiglucocorticoid activity was determined by inhibition of dexamethasone-stimulated transcriptional activity in HepG2 cells.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexamethasone</infon>
          <location offset="1879" length="13"/>
          <text>dexamethasone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1945</offset>
        <text>The mono- and didemethylated metabolites of CDB-2914 and CDB-4124 had less antiglucocorticoid activity (IC(50)'s approximately 10(-6)M) than monodemethylated mifepristone (IC(50) approximately 10(-8)M) or the other test compounds.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-2914</infon>
          <location offset="1989" length="8"/>
          <text>CDB-2914</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-4124</infon>
          <location offset="2002" length="8"/>
          <text>CDB-4124</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="2103" length="12"/>
          <text>mifepristone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2176</offset>
        <text>At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas mifepristone and its monodemethylated metabolite manifested slight glucocorticoid agonist activity.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestin</infon>
          <location offset="2243" length="9"/>
          <text>progestin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="2279" length="12"/>
          <text>mifepristone</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">progestin</infon>
          <location offset="2243" length="9"/>
          <text>progestin</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid</infon>
          <location offset="2346" length="14"/>
          <text>glucocorticoid</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T14" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2379</offset>
        <text>The reduced antiglucocorticoid activity of monodemethylated CDB-2914 and CDB-4124 was confirmed in vivo by the thymus involution assay in adrenalectomized male rats.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-2914</infon>
          <location offset="2439" length="8"/>
          <text>CDB-2914</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-4124</infon>
          <location offset="2452" length="8"/>
          <text>CDB-4124</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2545</offset>
        <text>The aromatic A-ring derivatives-stimulated transcription of an estrogen-responsive reporter plasmid in MCF-7 and T47D-CO human breast cancer cells but were much less potent than estradiol.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="2608" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estradiol</infon>
          <location offset="2723" length="9"/>
          <text>estradiol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2734</offset>
        <text>Taken together, these data suggest that the proximal metabolites of mifepristone, CDB-2914, and CDB-4124 contribute significantly to the antiprogestational activity of the parent compounds in vivo.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="2802" length="12"/>
          <text>mifepristone</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-2914</infon>
          <location offset="2816" length="8"/>
          <text>CDB-2914</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-4124</infon>
          <location offset="2830" length="8"/>
          <text>CDB-4124</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2932</offset>
        <text>Furthermore, the reduced antiglucocorticoid activity of CDB-2914 and CDB-4124 compared to mifepristone in vivo may be due in part to decreased activity of their putative proximal metabolites.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-2914</infon>
          <location offset="2988" length="8"/>
          <text>CDB-2914</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb-4124</infon>
          <location offset="3001" length="8"/>
          <text>CDB-4124</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="3022" length="12"/>
          <text>mifepristone</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22796428</id>
    <passage>
      <offset>0</offset>
      <text>A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder.	Drugs used to treat attention deficit hyperactivity disorder (ADHD) improve prefrontal cortex (PFC)-dependent cognitive function. The majority of ADHD-related treatments act either as dual norepinephrine (NE) and dopamine (DA) reuptake inhibitors (psychostimulants) or selective NE reuptake inhibitors (SNRIs). Certain benztropine analogs act as highly selective DA reuptake inhibitors while lacking the reinforcing actions, and thus abuse potential, of psychostimulants. To assess the potential use of these compounds in the treatment of ADHD, we examined the effects of a well-characterized benztropine analog, AHN 2-005, on performance of rats in a PFC-dependent delayed-alternation task of spatial working memory. Similar to that seen with all drugs currently approved for ADHD, AHN 2-005 dose-dependently improved performance in this task. Clinically-relevant doses of psychostimulants and SNRIs elevate NE and DA preferentially in the PFC. Despite the selectivity of this compound for the DA transporter, additional microdialysis studies demonstrated that a cognition-enhancing dose of AHN 2-005 that lacked locomotor activating effects increased extracellular levels of both DA and NE in the PFC. AHN 2-005 produced a larger increase in extracellular DA in the nucleus accumbens, although the magnitude of this was well below that seen with motor activating doses of psychostimulants. Collectively, these observations suggest that benztropine analogs may be efficacious in the treatment of ADHD or other disorders associated with PFC dysfunction. These studies provide a strong rationale for future research focused on the neural mechanisms contributing to the cognition-enhancing actions and the potential clinical utility of AHN 2-005 and related compounds. This article is part of a Special Issue entitled 'Cognitive Enhancers'.</text>
      <sentence>
        <offset>0</offset>
        <text>A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="12" length="8"/>
          <text>dopamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>162</offset>
        <text>Drugs used to treat attention deficit hyperactivity disorder (ADHD) improve prefrontal cortex (PFC)-dependent cognitive function.</text>
      </sentence>
      <sentence>
        <offset>292</offset>
        <text>The majority of ADHD-related treatments act either as dual norepinephrine (NE) and dopamine (DA) reuptake inhibitors (psychostimulants) or selective NE reuptake inhibitors (SNRIs).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">norepinephrine</infon>
          <location offset="351" length="14"/>
          <text>norepinephrine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="375" length="8"/>
          <text>dopamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>473</offset>
        <text>Certain benztropine analogs act as highly selective DA reuptake inhibitors while lacking the reinforcing actions, and thus abuse potential, of psychostimulants.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benztropine</infon>
          <location offset="481" length="11"/>
          <text>benztropine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>634</offset>
        <text>To assess the potential use of these compounds in the treatment of ADHD, we examined the effects of a well-characterized benztropine analog, AHN 2-005, on performance of rats in a PFC-dependent delayed-alternation task of spatial working memory.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benztropine</infon>
          <location offset="755" length="11"/>
          <text>benztropine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahn 2-005</infon>
          <location offset="775" length="9"/>
          <text>AHN 2-005</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>880</offset>
        <text>Similar to that seen with all drugs currently approved for ADHD, AHN 2-005 dose-dependently improved performance in this task.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahn 2-005</infon>
          <location offset="945" length="9"/>
          <text>AHN 2-005</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1007</offset>
        <text>Clinically-relevant doses of psychostimulants and SNRIs elevate NE and DA preferentially in the PFC.</text>
      </sentence>
      <sentence>
        <offset>1108</offset>
        <text>Despite the selectivity of this compound for the DA transporter, additional microdialysis studies demonstrated that a cognition-enhancing dose of AHN 2-005 that lacked locomotor activating effects increased extracellular levels of both DA and NE in the PFC.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahn 2-005</infon>
          <location offset="1254" length="9"/>
          <text>AHN 2-005</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">da transporter</infon>
          <location offset="1157" length="14"/>
          <text>DA transporter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1366</offset>
        <text>AHN 2-005 produced a larger increase in extracellular DA in the nucleus accumbens, although the magnitude of this was well below that seen with motor activating doses of psychostimulants.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahn 2-005</infon>
          <location offset="1366" length="9"/>
          <text>AHN 2-005</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1554</offset>
        <text>Collectively, these observations suggest that benztropine analogs may be efficacious in the treatment of ADHD or other disorders associated with PFC dysfunction.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benztropine</infon>
          <location offset="1600" length="11"/>
          <text>benztropine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1716</offset>
        <text>These studies provide a strong rationale for future research focused on the neural mechanisms contributing to the cognition-enhancing actions and the potential clinical utility of AHN 2-005 and related compounds.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahn 2-005</infon>
          <location offset="1896" length="9"/>
          <text>AHN 2-005</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1929</offset>
        <text>This article is part of a Special Issue entitled 'Cognitive Enhancers'.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23547810</id>
    <passage>
      <offset>0</offset>
      <text>Serotonin (5-HT) in the Regulation of Depression-Related Emotionality: Insight from 5-HT Transporter and Tryptophan Hydroxylase-2 Knockout Mouse Models.	Disorders of emotion regulation such as anxiety disorders and depression are common and yet debilitating. Accumulating evidence suggests involvement of serotonin (5-HT) in the regulation of emotion. Mice with targeted deletion of genes encoding mediators of the serotonergic transmission have proven to be a powerful tool for understanding contributions of such mediators of emotion regulation. Over the last decade, research on mice with a targeted inactivation of the 5-HT transporter (5-Htt, Sert, Slc6a4) has considerably advanced our knowledge about functions that the 5-HTT plays in the context of emotion related to depression. Moreover, the recent advent of knockout (KO) mice for tryptophan hydroxylase 2 (Tph2 KO), which lacks the rate-limiting enzyme for 5-HT synthesis in the brain, has further provided insight to the brain serotonergic system and its role in emotion dysregulation. Here, we first highlight basic characteristics of the serotonergic system including the biosynthesis of 5-HT as well as the anatomy and firing activity of serotonergic neurons. Furthermore, characteristics of 5-Htt and Tph2 KO mice are covered together with association studies on human variants of 5-HTT and TPH2 in emotional regulation. Among various targets of serotonergic projections, which originate from the raphe nuclei in the brain stem, particular focus is placed on the hippocampus due to its unique dual role in memory and emotion. Finally, effects of therapeutic drugs and psychoactive drugs on KO mouse models as well as on synaptic plasticity will be discussed.</text>
      <sentence>
        <offset>0</offset>
        <text>Serotonin (5-HT) in the Regulation of Depression-Related Emotionality: Insight from 5-HT Transporter and Tryptophan Hydroxylase-2 Knockout Mouse Models.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="0" length="9"/>
          <text>Serotonin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptophan</infon>
          <location offset="105" length="10"/>
          <text>Tryptophan</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="11" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="84" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tryptophan hydroxylase-2</infon>
          <location offset="105" length="24"/>
          <text>Tryptophan Hydroxylase-2</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht transporter</infon>
          <location offset="84" length="16"/>
          <text>5-HT Transporter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>153</offset>
        <text>Disorders of emotion regulation such as anxiety disorders and depression are common and yet debilitating.</text>
      </sentence>
      <sentence>
        <offset>259</offset>
        <text>Accumulating evidence suggests involvement of serotonin (5-HT) in the regulation of emotion.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="305" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="316" length="4"/>
          <text>5-HT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>352</offset>
        <text>Mice with targeted deletion of genes encoding mediators of the serotonergic transmission have proven to be a powerful tool for understanding contributions of such mediators of emotion regulation.</text>
      </sentence>
      <sentence>
        <offset>548</offset>
        <text>Over the last decade, research on mice with a targeted inactivation of the 5-HT transporter (5-Htt, Sert, Slc6a4) has considerably advanced our knowledge about functions that the 5-HTT plays in the context of emotion related to depression.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="623" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht transporter</infon>
          <location offset="623" length="16"/>
          <text>5-HT transporter</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-htt</infon>
          <location offset="641" length="5"/>
          <text>5-Htt</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="648" length="4"/>
          <text>Sert</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">slc6a4</infon>
          <location offset="654" length="6"/>
          <text>Slc6a4</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-htt</infon>
          <location offset="727" length="5"/>
          <text>5-HTT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>788</offset>
        <text>Moreover, the recent advent of knockout (KO) mice for tryptophan hydroxylase 2 (Tph2 KO), which lacks the rate-limiting enzyme for 5-HT synthesis in the brain, has further provided insight to the brain serotonergic system and its role in emotion dysregulation.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptophan</infon>
          <location offset="842" length="10"/>
          <text>tryptophan</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="919" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tryptophan hydroxylase 2</infon>
          <location offset="842" length="24"/>
          <text>tryptophan hydroxylase 2</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tph2</infon>
          <location offset="868" length="4"/>
          <text>Tph2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1049</offset>
        <text>Here, we first highlight basic characteristics of the serotonergic system including the biosynthesis of 5-HT as well as the anatomy and firing activity of serotonergic neurons.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="1153" length="4"/>
          <text>5-HT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1226</offset>
        <text>Furthermore, characteristics of 5-Htt and Tph2 KO mice are covered together with association studies on human variants of 5-HTT and TPH2 in emotional regulation.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-htt</infon>
          <location offset="1258" length="5"/>
          <text>5-Htt</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tph2</infon>
          <location offset="1268" length="4"/>
          <text>Tph2</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-htt</infon>
          <location offset="1348" length="5"/>
          <text>5-HTT</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tph2</infon>
          <location offset="1358" length="4"/>
          <text>TPH2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1388</offset>
        <text>Among various targets of serotonergic projections, which originate from the raphe nuclei in the brain stem, particular focus is placed on the hippocampus due to its unique dual role in memory and emotion.</text>
      </sentence>
      <sentence>
        <offset>1593</offset>
        <text>Finally, effects of therapeutic drugs and psychoactive drugs on KO mouse models as well as on synaptic plasticity will be discussed.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23556448</id>
    <passage>
      <offset>0</offset>
      <text>Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population.	Aim: FAAH is a membrane enzyme that terminates the activity of a large class of endogenous signaling lipids. Recent studies suggest that the FAAH Pro129Thr polymorphism is a common mutation in the FAAH gene that is significantly associated with drug-addictive traits. This study investigated the association of the Pro129Thr polymorphism of the FAAH gene with methamphetamine dependence, methamphetamine-induced psychosis, manic episodes and panic disorder in a Malaysian population. Materials &amp; methods: This polymorphism was genotyped in 232 male methamphetamine-dependent subjects and in 241 male controls of four different ethnicities: Malay, Chinese, Kadazan-Dusun and Bajau. Intergroup statistical analyses were performed by using the χ(2)-square test and Fisher's exact test, where necessary. In cases of multiple comparisons, the Bonferroni correction was performed. Results: Our results indicated that the FAAH Pro129Thr polymorphism showed a significant association with risk of methamphetamine dependence in the pooled subjects (odds ratio [OR]: 2.017; p &lt; 0.001) and in the Malay (OR: 2.829; p &lt; 0.001) and Chinese (OR: 3.685; p &lt; 0.001) groups. We also found an association of this polymorphism with episodes of methamphetamine-induced mania in the Malay group (OR: 2.836; p = 0.035). However, there was no association between this polymorphism and age of onset of drug use or the occurrence of methamphetamine-induced psychosis or of panic disorder. Conclusion: Our findings suggest that the FAAH Pro129Thr polymorphism may contribute to methamphetamine dependence in the Malay and Chinese ethnic groups. Original submitted 4 October 2012; Revision submitted 1 February 2013.</text>
      <sentence>
        <offset>0</offset>
        <text>Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methamphetamine</infon>
          <location offset="51" length="15"/>
          <text>methamphetamine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">faah</infon>
          <location offset="28" length="4"/>
          <text>FAAH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>126</offset>
        <text>Aim: FAAH is a membrane enzyme that terminates the activity of a large class of endogenous signaling lipids.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">faah</infon>
          <location offset="131" length="4"/>
          <text>FAAH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>235</offset>
        <text>Recent studies suggest that the FAAH Pro129Thr polymorphism is a common mutation in the FAAH gene that is significantly associated with drug-addictive traits.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">faah</infon>
          <location offset="267" length="4"/>
          <text>FAAH</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pro129thr</infon>
          <location offset="272" length="9"/>
          <text>Pro129Thr</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">faah</infon>
          <location offset="323" length="4"/>
          <text>FAAH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>394</offset>
        <text>This study investigated the association of the Pro129Thr polymorphism of the FAAH gene with methamphetamine dependence, methamphetamine-induced psychosis, manic episodes and panic disorder in a Malaysian population.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methamphetamine</infon>
          <location offset="486" length="15"/>
          <text>methamphetamine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methamphetamine</infon>
          <location offset="514" length="15"/>
          <text>methamphetamine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pro129thr</infon>
          <location offset="441" length="9"/>
          <text>Pro129Thr</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">faah</infon>
          <location offset="471" length="4"/>
          <text>FAAH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>610</offset>
        <text>Materials &amp; methods: This polymorphism was genotyped in 232 male methamphetamine-dependent subjects and in 241 male controls of four different ethnicities: Malay, Chinese, Kadazan-Dusun and Bajau.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methamphetamine</infon>
          <location offset="675" length="15"/>
          <text>methamphetamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>807</offset>
        <text>Intergroup statistical analyses were performed by using the χ(2)-square test and Fisher's exact test, where necessary.</text>
      </sentence>
      <sentence>
        <offset>926</offset>
        <text>In cases of multiple comparisons, the Bonferroni correction was performed.</text>
      </sentence>
      <sentence>
        <offset>1001</offset>
        <text>Results: Our results indicated that the FAAH Pro129Thr polymorphism showed a significant association with risk of methamphetamine dependence in the pooled subjects (odds ratio [OR]: 2.017; p &lt; 0.001) and in the Malay (OR: 2.829; p &lt; 0.001) and Chinese (OR: 3.685; p &lt; 0.001) groups.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methamphetamine</infon>
          <location offset="1115" length="15"/>
          <text>methamphetamine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">faah</infon>
          <location offset="1041" length="4"/>
          <text>FAAH</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pro129thr</infon>
          <location offset="1046" length="9"/>
          <text>Pro129Thr</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1284</offset>
        <text>We also found an association of this polymorphism with episodes of methamphetamine-induced mania in the Malay group (OR: 2.836; p = 0.035).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methamphetamine</infon>
          <location offset="1351" length="15"/>
          <text>methamphetamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1424</offset>
        <text>However, there was no association between this polymorphism and age of onset of drug use or the occurrence of methamphetamine-induced psychosis or of panic disorder.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methamphetamine</infon>
          <location offset="1534" length="15"/>
          <text>methamphetamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1590</offset>
        <text>Conclusion: Our findings suggest that the FAAH Pro129Thr polymorphism may contribute to methamphetamine dependence in the Malay and Chinese ethnic groups.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methamphetamine</infon>
          <location offset="1678" length="15"/>
          <text>methamphetamine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">faah</infon>
          <location offset="1632" length="4"/>
          <text>FAAH</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pro129thr</infon>
          <location offset="1637" length="9"/>
          <text>Pro129Thr</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1745</offset>
        <text>Original submitted 4 October 2012; Revision submitted 1 February 2013.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23223345</id>
    <passage>
      <offset>0</offset>
      <text>The Effects of Carbohydrate, Unsaturated Fat, and Protein Intake on Measures of Insulin Sensitivity: Results from the OmniHeart Trial.	OBJECTIVE Impaired insulin sensitivity increases the risk of cardiovascular disease. Although calorie restriction and weight loss increase insulin sensitivity, the effects of modifying macronutrient composition on insulin sensitivity are uncertain. The purpose of this study is to determine the effects on insulin sensitivity of a carbohydrate-rich diet (CARB; similar to the Dietary Approaches to Stop Hypertension [DASH] diet), a protein-rich diet (PROT; protein predominantly from plant sources), and an unsaturated fat-rich diet (UNSAT; predominantly monounsaturated). RESEARCH DESIGN AND METHODS This study was a randomized, controlled, three-period, crossover feeding study. The study participants were 164 individuals with prehypertension or stage 1 hypertension without diabetes. Diets were administered for 6 weeks each, with a washout period between diets of 2-4 weeks. Weight was held constant throughout the study. For our primary outcome, we calculated the quantitative insulin sensitivity check index (QUICKI) using the end-of-period fasting serum glucose and insulin. QUICKI is a validated measure of insulin sensitivity. The primary analyses used generalized estimating equations. RESULTS At baseline, mean (SD) BMI was 30.2 (6.1) kg/m(2), and mean (SD) QUICKI was 0.35 (0.04). The UNSAT diet increased QUICKI by 0.005, more than the CARB diet (P = 0.04). PROT had no significant effect compared with CARB. CONCLUSIONS A diet that partially replaces carbohydrate with unsaturated fat may improve insulin sensitivity in a population at risk for cardiovascular disease. Given the well-recognized challenges of sustaining weight loss, our results suggest an alternative approach for improving insulin sensitivity.</text>
      <sentence>
        <offset>0</offset>
        <text>The Effects of Carbohydrate, Unsaturated Fat, and Protein Intake on Measures of Insulin Sensitivity: Results from the OmniHeart Trial.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbohydrate</infon>
          <location offset="15" length="12"/>
          <text>Carbohydrate</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="80" length="7"/>
          <text>Insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>135</offset>
        <text>OBJECTIVE Impaired insulin sensitivity increases the risk of cardiovascular disease.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="154" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>220</offset>
        <text>Although calorie restriction and weight loss increase insulin sensitivity, the effects of modifying macronutrient composition on insulin sensitivity are uncertain.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="274" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="349" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>384</offset>
        <text>The purpose of this study is to determine the effects on insulin sensitivity of a carbohydrate-rich diet (CARB; similar to the Dietary Approaches to Stop Hypertension [DASH] diet), a protein-rich diet (PROT; protein predominantly from plant sources), and an unsaturated fat-rich diet (UNSAT; predominantly monounsaturated).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbohydrate</infon>
          <location offset="466" length="12"/>
          <text>carbohydrate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carb</infon>
          <location offset="490" length="4"/>
          <text>CARB</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="441" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>708</offset>
        <text>RESEARCH DESIGN AND METHODS This study was a randomized, controlled, three-period, crossover feeding study.</text>
      </sentence>
      <sentence>
        <offset>816</offset>
        <text>The study participants were 164 individuals with prehypertension or stage 1 hypertension without diabetes.</text>
      </sentence>
      <sentence>
        <offset>923</offset>
        <text>Diets were administered for 6 weeks each, with a washout period between diets of 2-4 weeks.</text>
      </sentence>
      <sentence>
        <offset>1015</offset>
        <text>Weight was held constant throughout the study.</text>
      </sentence>
      <sentence>
        <offset>1062</offset>
        <text>For our primary outcome, we calculated the quantitative insulin sensitivity check index (QUICKI) using the end-of-period fasting serum glucose and insulin.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1197" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1209" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1118" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1218</offset>
        <text>QUICKI is a validated measure of insulin sensitivity.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1251" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1272</offset>
        <text>The primary analyses used generalized estimating equations.</text>
      </sentence>
      <sentence>
        <offset>1332</offset>
        <text>RESULTS At baseline, mean (SD) BMI was 30.2 (6.1) kg/m(2), and mean (SD) QUICKI was 0.35 (0.04).</text>
      </sentence>
      <sentence>
        <offset>1429</offset>
        <text>The UNSAT diet increased QUICKI by 0.005, more than the CARB diet (P = 0.04).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carb</infon>
          <location offset="1485" length="4"/>
          <text>CARB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1507</offset>
        <text>PROT had no significant effect compared with CARB.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carb</infon>
          <location offset="1552" length="4"/>
          <text>CARB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1558</offset>
        <text>CONCLUSIONS A diet that partially replaces carbohydrate with unsaturated fat may improve insulin sensitivity in a population at risk for cardiovascular disease.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbohydrate</infon>
          <location offset="1601" length="12"/>
          <text>carbohydrate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1647" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1719</offset>
        <text>Given the well-recognized challenges of sustaining weight loss, our results suggest an alternative approach for improving insulin sensitivity.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1841" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>9557255</id>
    <passage>
      <offset>0</offset>
      <text>A new concept of drug delivery for acne.	Adapalene is a stable naphthoic acid derivative that displays a strong retinoid agonist pharmacology. This drug controls cell proliferation and differentiation, and possesses significant anti-inflammatory action. The retinoid action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors RAR beta and RAR gamma. We describe here how an aqueous gel containing adapalene was selected for the topical treatment of acne.</text>
      <sentence>
        <offset>0</offset>
        <text>A new concept of drug delivery for acne.</text>
      </sentence>
      <sentence>
        <offset>41</offset>
        <text>Adapalene is a stable naphthoic acid derivative that displays a strong retinoid agonist pharmacology.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adapalene</infon>
          <location offset="41" length="9"/>
          <text>Adapalene</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">naphthoic acid</infon>
          <location offset="63" length="14"/>
          <text>naphthoic acid</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoid</infon>
          <location offset="112" length="8"/>
          <text>retinoid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>143</offset>
        <text>This drug controls cell proliferation and differentiation, and possesses significant anti-inflammatory action.</text>
      </sentence>
      <sentence>
        <offset>254</offset>
        <text>The retinoid action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors RAR beta and RAR gamma.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoid</infon>
          <location offset="258" length="8"/>
          <text>retinoid</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adapalene</infon>
          <location offset="277" length="9"/>
          <text>adapalene</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoic acid</infon>
          <location offset="351" length="13"/>
          <text>retinoic acid</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ligand-activated gene transcription factors</infon>
          <location offset="307" length="43"/>
          <text>ligand-activated gene transcription factors</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">retinoic acid receptors</infon>
          <location offset="351" length="23"/>
          <text>retinoic acid receptors</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rar beta</infon>
          <location offset="375" length="8"/>
          <text>RAR beta</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rar gamma</infon>
          <location offset="388" length="9"/>
          <text>RAR gamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>399</offset>
        <text>We describe here how an aqueous gel containing adapalene was selected for the topical treatment of acne.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adapalene</infon>
          <location offset="446" length="9"/>
          <text>adapalene</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23194532</id>
    <passage>
      <offset>0</offset>
      <text>The in vivo antioxidant and antifibrotic properties of green tea (Camellia sinensis, Theaceae).	The in vivo antioxidant and antifibrotic properties of green tea (Camellia sinensis, Theaceae) were investigated with a study of carbon tetrachloride (CCl(4))-induced oxidative stress and hepatic fibrosis in male ICR mice. Oral administration of green tea extract at doses of 125, 625 and 1250 mg/kg for 8 weeks significantly reduced (p&lt;0.05) the levels of thiobarbituric acid-reactive substances (TBARS) and protein carbonyls in the liver by at least 28% compared with that was induced by CCl(4) (1 mL/kg) in mice. Moreover, green tea extract administration significantly increased (p&lt;0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and glutathione reductase (GSH-Rd) in the liver. Our study found that oral administration of green tea extract prevented CCl(4)-induced hepatic fibrosis, as evidenced by a decreased hydroxyproline level in the liver and a reduced incidence of hepatic fibrosis by histological observations. These results indicate that green tea exhibits potent protective effects against CCl(4)-induced oxidative stress and hepatic fibrosis in mice by inhibiting oxidative damage and increasing antioxidant enzyme activities.</text>
      <sentence>
        <offset>0</offset>
        <text>The in vivo antioxidant and antifibrotic properties of green tea (Camellia sinensis, Theaceae).</text>
      </sentence>
      <sentence>
        <offset>96</offset>
        <text>The in vivo antioxidant and antifibrotic properties of green tea (Camellia sinensis, Theaceae) were investigated with a study of carbon tetrachloride (CCl(4))-induced oxidative stress and hepatic fibrosis in male ICR mice.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbon tetrachloride</infon>
          <location offset="225" length="20"/>
          <text>carbon tetrachloride</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl(4)</infon>
          <location offset="247" length="6"/>
          <text>CCl(4)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>319</offset>
        <text>Oral administration of green tea extract at doses of 125, 625 and 1250 mg/kg for 8 weeks significantly reduced (p&lt;0.05) the levels of thiobarbituric acid-reactive substances (TBARS) and protein carbonyls in the liver by at least 28% compared with that was induced by CCl(4) (1 mL/kg) in mice.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiobarbituric acid</infon>
          <location offset="453" length="19"/>
          <text>thiobarbituric acid</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbonyls</infon>
          <location offset="513" length="9"/>
          <text>carbonyls</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl(4)</infon>
          <location offset="586" length="6"/>
          <text>CCl(4)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>612</offset>
        <text>Moreover, green tea extract administration significantly increased (p&lt;0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and glutathione reductase (GSH-Rd) in the liver.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="716" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="740" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="752" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="775" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catalase</infon>
          <location offset="706" length="8"/>
          <text>catalase</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathione peroxidase</infon>
          <location offset="716" length="22"/>
          <text>glutathione peroxidase</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gsh-px</infon>
          <location offset="740" length="6"/>
          <text>GSH-Px</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glutathione reductase</infon>
          <location offset="752" length="21"/>
          <text>glutathione reductase</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gsh-rd</infon>
          <location offset="775" length="6"/>
          <text>GSH-Rd</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>797</offset>
        <text>Our study found that oral administration of green tea extract prevented CCl(4)-induced hepatic fibrosis, as evidenced by a decreased hydroxyproline level in the liver and a reduced incidence of hepatic fibrosis by histological observations.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl(4)</infon>
          <location offset="869" length="6"/>
          <text>CCl(4)</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydroxyproline</infon>
          <location offset="930" length="14"/>
          <text>hydroxyproline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1038</offset>
        <text>These results indicate that green tea exhibits potent protective effects against CCl(4)-induced oxidative stress and hepatic fibrosis in mice by inhibiting oxidative damage and increasing antioxidant enzyme activities.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ccl(4)</infon>
          <location offset="1119" length="6"/>
          <text>CCl(4)</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11972287</id>
    <passage>
      <offset>0</offset>
      <text>Central 5-HT3 receptor stimulation by m-CPBG increases blood glucose in rats.	The aim of the present study was to investigate the role of central 5-HT3 receptors on the control of blood glucose in stressed and non-stressed rats in both fasted and fed states. Adult Wistar male rats had each their third ventricle cannulated 7 days before the experiments. Injections of m-CPBG, a selective 5-HT3 receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states. The same procedure was unable to modify stress-induced hyperglycemia. The hyperglycemic effect of m-CPBG central administration was blocked by pretreatment with ondansetron, a specific 5-HT3 receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors. Third ventricle injections of ondansetron alone were not able to modify blood glucose in non-stressed animals and did not change the hyperglycemic responses observed after immobilization stress. We conclude that pharmacological activation of the central 5-HT3 receptor induces a hyperglycemic effect in non-stressed animals.</text>
      <sentence>
        <offset>0</offset>
        <text>Central 5-HT3 receptor stimulation by m-CPBG increases blood glucose in rats.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">m-cpbg</infon>
          <location offset="38" length="6"/>
          <text>m-CPBG</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="61" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht3</infon>
          <location offset="8" length="5"/>
          <text>5-HT3</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>78</offset>
        <text>The aim of the present study was to investigate the role of central 5-HT3 receptors on the control of blood glucose in stressed and non-stressed rats in both fasted and fed states.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="186" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht3</infon>
          <location offset="146" length="5"/>
          <text>5-HT3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>259</offset>
        <text>Adult Wistar male rats had each their third ventricle cannulated 7 days before the experiments.</text>
      </sentence>
      <sentence>
        <offset>355</offset>
        <text>Injections of m-CPBG, a selective 5-HT3 receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">m-cpbg</infon>
          <location offset="369" length="6"/>
          <text>m-CPBG</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="453" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht3</infon>
          <location offset="389" length="5"/>
          <text>5-HT3</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>516</offset>
        <text>The same procedure was unable to modify stress-induced hyperglycemia.</text>
      </sentence>
      <sentence>
        <offset>586</offset>
        <text>The hyperglycemic effect of m-CPBG central administration was blocked by pretreatment with ondansetron, a specific 5-HT3 receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">m-cpbg</infon>
          <location offset="614" length="6"/>
          <text>m-CPBG</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">m-cpbg</infon>
          <location offset="775" length="6"/>
          <text>m-CPBG</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht3</infon>
          <location offset="701" length="5"/>
          <text>5-HT3</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht3</infon>
          <location offset="820" length="5"/>
          <text>5-HT3</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>837</offset>
        <text>Third ventricle injections of ondansetron alone were not able to modify blood glucose in non-stressed animals and did not change the hyperglycemic responses observed after immobilization stress.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ondansetron</infon>
          <location offset="867" length="11"/>
          <text>ondansetron</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="915" length="7"/>
          <text>glucose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1032</offset>
        <text>We conclude that pharmacological activation of the central 5-HT3 receptor induces a hyperglycemic effect in non-stressed animals.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht3</infon>
          <location offset="1091" length="5"/>
          <text>5-HT3</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23624423</id>
    <passage>
      <offset>0</offset>
      <text>4-Hydroxytamoxifen-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.	Over-expression of cleaved cyclin E in breast tumors is closely associated with tumor progression and resistance to antiestrogens. 17β-Estradiol (E2) has been recently shown to induce cyclin E processing in breast cancer cells. Tamoxifen has been used in patients with estrogen-sensitive breast cancer, yet resistance to antiestrogens and recurrence will appear in some of the patients after its continued use. We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration. OHT-induced cyclin E truncation also occurred in SK-BR-3 cells that express GPR30 and lack ERα, but not in MDA-MB-231 cells that express neither GPR30 nor ERα. G1, a specific GPR 30 agonist, caused dramatic proteolysis of cyclin E and enhanced migration. Furthermore, OHT-stimulated cleavage of cyclin E and migration were tremendously attenuated by G15, a GPR30 antagonist, or siRNA against GPR30. In addition, inhibitors for EGFR or ERK1/2 remarkably suppressed OHT-induced truncation of cyclin E, suggesting involvement of EGFR signaling. Collectively, our data indicate that OHT contributes to the production of proteolyzed cyclin E via GPR30 with augmented migration in MCF-7 cells.</text>
      <sentence>
        <offset>0</offset>
        <text>4-Hydroxytamoxifen-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-hydroxytamoxifen</infon>
          <location offset="0" length="18"/>
          <text>4-Hydroxytamoxifen</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr30)</infon>
          <location offset="100" length="6"/>
          <text>GPR30)</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin e</infon>
          <location offset="44" length="8"/>
          <text>cyclin E</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">g protein-coupled receptor 30</infon>
          <location offset="69" length="29"/>
          <text>G protein-coupled receptor 30</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>175</offset>
        <text>Over-expression of cleaved cyclin E in breast tumors is closely associated with tumor progression and resistance to antiestrogens.</text>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin e</infon>
          <location offset="202" length="8"/>
          <text>cyclin E</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>306</offset>
        <text>17β-Estradiol (E2) has been recently shown to induce cyclin E processing in breast cancer cells.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">17β-estradiol</infon>
          <location offset="306" length="13"/>
          <text>17β-Estradiol</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin e</infon>
          <location offset="359" length="8"/>
          <text>cyclin E</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>403</offset>
        <text>Tamoxifen has been used in patients with estrogen-sensitive breast cancer, yet resistance to antiestrogens and recurrence will appear in some of the patients after its continued use.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="403" length="9"/>
          <text>Tamoxifen</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="444" length="8"/>
          <text>estrogen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>586</offset>
        <text>We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα).</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="629" length="9"/>
          <text>tamoxifen</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="708" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="811" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin e</infon>
          <location offset="668" length="8"/>
          <text>cyclin E</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">g protein-coupled protein (gpr) 30</infon>
          <location offset="772" length="34"/>
          <text>G protein-coupled protein (GPR) 30</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">estrogen receptor α</infon>
          <location offset="811" length="19"/>
          <text>estrogen receptor α</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erα</infon>
          <location offset="832" length="3"/>
          <text>ERα</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>838</offset>
        <text>4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-hydroxytamoxifen</infon>
          <location offset="838" length="18"/>
          <text>4-Hydroxytamoxifen</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oht</infon>
          <location offset="858" length="3"/>
          <text>OHT</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="863" length="9"/>
          <text>tamoxifen</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin e</infon>
          <location offset="932" length="8"/>
          <text>cyclin E</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin e</infon>
          <location offset="977" length="8"/>
          <text>cyclin E</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1032</offset>
        <text>OHT-induced cyclin E truncation also occurred in SK-BR-3 cells that express GPR30 and lack ERα, but not in MDA-MB-231 cells that express neither GPR30 nor ERα.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oht</infon>
          <location offset="1032" length="3"/>
          <text>OHT</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr30</infon>
          <location offset="1177" length="5"/>
          <text>GPR30</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erα</infon>
          <location offset="1187" length="3"/>
          <text>ERα</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin e</infon>
          <location offset="1044" length="8"/>
          <text>cyclin E</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr30</infon>
          <location offset="1108" length="5"/>
          <text>GPR30</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erα</infon>
          <location offset="1123" length="3"/>
          <text>ERα</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1192</offset>
        <text>G1, a specific GPR 30 agonist, caused dramatic proteolysis of cyclin E and enhanced migration.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr 30</infon>
          <location offset="1207" length="6"/>
          <text>GPR 30</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin e</infon>
          <location offset="1254" length="8"/>
          <text>cyclin E</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1287</offset>
        <text>Furthermore, OHT-stimulated cleavage of cyclin E and migration were tremendously attenuated by G15, a GPR30 antagonist, or siRNA against GPR30.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oht</infon>
          <location offset="1300" length="3"/>
          <text>OHT</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin e</infon>
          <location offset="1327" length="8"/>
          <text>cyclin E</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr30</infon>
          <location offset="1389" length="5"/>
          <text>GPR30</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr30</infon>
          <location offset="1424" length="5"/>
          <text>GPR30</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1431</offset>
        <text>In addition, inhibitors for EGFR or ERK1/2 remarkably suppressed OHT-induced truncation of cyclin E, suggesting involvement of EGFR signaling.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oht</infon>
          <location offset="1496" length="3"/>
          <text>OHT</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1459" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="1467" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin e</infon>
          <location offset="1522" length="8"/>
          <text>cyclin E</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1558" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1574</offset>
        <text>Collectively, our data indicate that OHT contributes to the production of proteolyzed cyclin E via GPR30 with augmented migration in MCF-7 cells.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oht</infon>
          <location offset="1611" length="3"/>
          <text>OHT</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin e</infon>
          <location offset="1660" length="8"/>
          <text>cyclin E</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr30</infon>
          <location offset="1673" length="5"/>
          <text>GPR30</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11106255</id>
    <passage>
      <offset>0</offset>
      <text>The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells.	The carcinoid tumor is an uncommon neuroendocrine neoplasm the hallmark of which is excessive serotonin production. In studying kinetics of tryptophan hydroxylase and aromatic-L-amino acid decarboxylase (AAAD) in human carcinoid hepatic metastases and adjacent normal liver (J. A. Gilbert et al, Biochem. Pharmacol., 50: 845-850, 1995), we identified one significant difference: the Vmax of carcinoid AAAD was 50-fold higher than that in normal liver. Here, we report Western and Northern analyses detecting large quantities of AAAD polypeptide and mRNA in human carcinoid primary as well as metastatic tumors compared with normal surrounding tissues. To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells. Carbidopa and MFMD were lethal (IC50 = 29 +/- 2 microM and 56 +/- 6 microM, respectively); NSD-1015 had no effect on proliferation. On exposure to other human tumor lines, carbidopa was lethal only to NCI-H146 and NCI-H209 small cell lung carcinoma (SCLC) lines (IC50 = 12 +/- 1 microM and 22 +/- 5 microM, respectively). Carbidopa (100 microM) decreased growth of (but did not kill) SK-N-SH neuroblastoma and A204 rhabdomyosarcoma cells and did not affect proliferation of DU 145 prostate, MCF7 breast, or NCI-H460 large cell lung carcinoma lines. The rank order of lines by AAAD activity was NCI-H146 &gt; NCI-H209 &gt; SK-N-SH &gt; NCI-H727, whereas A204, DU 145, MCF7, and NCI-H460 had no measurable activity. For lung tumor lines (carcinoid, two SCLC, and one large cell lung carcinoma), AAAD activity was correlated with the potency of carbidopa-induced cytotoxicity. However, carcinoid cell death was not solely attributable to complete inhibition of either AAAD activity or the serotonin synthetic pathway. In further evaluating potential applications of these findings with carbidopa, we determined that sublethal doses of carbidopa produced additive cytotoxic effects in carcinoid cells in combination with etoposide and cytotoxic synergy in SCLC cells when coincubated with topotecan.</text>
      <sentence>
        <offset>0</offset>
        <text>The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aromatic-l-amino acid</infon>
          <location offset="4" length="21"/>
          <text>aromatic-L-amino acid</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatic-l-amino acid decarboxylase</infon>
          <location offset="4" length="35"/>
          <text>aromatic-L-amino acid decarboxylase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>151</offset>
        <text>The carcinoid tumor is an uncommon neuroendocrine neoplasm the hallmark of which is excessive serotonin production.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="245" length="9"/>
          <text>serotonin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>267</offset>
        <text>In studying kinetics of tryptophan hydroxylase and aromatic-L-amino acid decarboxylase (AAAD) in human carcinoid hepatic metastases and adjacent normal liver (J. A. Gilbert et al, Biochem.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tryptophan</infon>
          <location offset="291" length="10"/>
          <text>tryptophan</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aromatic-l-amino acid</infon>
          <location offset="318" length="21"/>
          <text>aromatic-L-amino acid</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tryptophan hydroxylase</infon>
          <location offset="291" length="22"/>
          <text>tryptophan hydroxylase</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatic-l-amino acid decarboxylase</infon>
          <location offset="318" length="35"/>
          <text>aromatic-L-amino acid decarboxylase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aaad</infon>
          <location offset="355" length="4"/>
          <text>AAAD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>456</offset>
        <text>Pharmacol., 50: 845-850, 1995), we identified one significant difference: the Vmax of carcinoid AAAD was 50-fold higher than that in normal liver.</text>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aaad</infon>
          <location offset="552" length="4"/>
          <text>AAAD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>603</offset>
        <text>Here, we report Western and Northern analyses detecting large quantities of AAAD polypeptide and mRNA in human carcinoid primary as well as metastatic tumors compared with normal surrounding tissues.</text>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aaad</infon>
          <location offset="679" length="4"/>
          <text>AAAD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>803</offset>
        <text>To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbidopa</infon>
          <location offset="899" length="9"/>
          <text>carbidopa</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alpha-methyl-dopahydrazine</infon>
          <location offset="910" length="26"/>
          <text>alpha-methyl-dopahydrazine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alpha-monofluoromethyldopa</infon>
          <location offset="939" length="26"/>
          <text>alpha-monofluoromethyldopa</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mfmd</infon>
          <location offset="967" length="4"/>
          <text>MFMD</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-hydroxybenzylhydrazine</infon>
          <location offset="978" length="24"/>
          <text>3-hydroxybenzylhydrazine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nsd-1015</infon>
          <location offset="1004" length="8"/>
          <text>NSD-1015</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aaad</infon>
          <location offset="853" length="4"/>
          <text>AAAD</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aaad</infon>
          <location offset="883" length="4"/>
          <text>AAAD</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1078</offset>
        <text>Carbidopa and MFMD were lethal (IC50 = 29 +/- 2 microM and 56 +/- 6 microM, respectively); NSD-1015 had no effect on proliferation.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nsd-1015</infon>
          <location offset="1169" length="8"/>
          <text>NSD-1015</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbidopa</infon>
          <location offset="1078" length="9"/>
          <text>Carbidopa</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mfmd</infon>
          <location offset="1092" length="4"/>
          <text>MFMD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1210</offset>
        <text>On exposure to other human tumor lines, carbidopa was lethal only to NCI-H146 and NCI-H209 small cell lung carcinoma (SCLC) lines (IC50 = 12 +/- 1 microM and 22 +/- 5 microM, respectively).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbidopa</infon>
          <location offset="1250" length="9"/>
          <text>carbidopa</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1400</offset>
        <text>Carbidopa (100 microM) decreased growth of (but did not kill) SK-N-SH neuroblastoma and A204 rhabdomyosarcoma cells and did not affect proliferation of DU 145 prostate, MCF7 breast, or NCI-H460 large cell lung carcinoma lines.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbidopa</infon>
          <location offset="1400" length="9"/>
          <text>Carbidopa</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1627</offset>
        <text>The rank order of lines by AAAD activity was NCI-H146 &gt; NCI-H209 &gt; SK-N-SH &gt; NCI-H727, whereas A204, DU 145, MCF7, and NCI-H460 had no measurable activity.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aaad</infon>
          <location offset="1654" length="4"/>
          <text>AAAD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1783</offset>
        <text>For lung tumor lines (carcinoid, two SCLC, and one large cell lung carcinoma), AAAD activity was correlated with the potency of carbidopa-induced cytotoxicity.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbidopa</infon>
          <location offset="1911" length="9"/>
          <text>carbidopa</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aaad</infon>
          <location offset="1862" length="4"/>
          <text>AAAD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1943</offset>
        <text>However, carcinoid cell death was not solely attributable to complete inhibition of either AAAD activity or the serotonin synthetic pathway.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="2055" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aaad</infon>
          <location offset="2034" length="4"/>
          <text>AAAD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2084</offset>
        <text>In further evaluating potential applications of these findings with carbidopa, we determined that sublethal doses of carbidopa produced additive cytotoxic effects in carcinoid cells in combination with etoposide and cytotoxic synergy in SCLC cells when coincubated with topotecan.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbidopa</infon>
          <location offset="2152" length="9"/>
          <text>carbidopa</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbidopa</infon>
          <location offset="2201" length="9"/>
          <text>carbidopa</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">topotecan</infon>
          <location offset="2354" length="9"/>
          <text>topotecan</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23179349</id>
    <passage>
      <offset>0</offset>
      <text>Iron excess disturbs metabolic status and relative gonad mass in rats on high fat, fructose, and salt diets.	The aim of this study was to assess the metabolic and physiological changes in rats fed a diet high in fat, fructose, and salt, and with excess iron level. Mineral status was also estimated. Wistar rats were assigned to groups fed either a standard control diet (C) or a diet high in fat, fructose, and salt. The noncontrol diets contained either normal (M) or high level (MFe) of iron. After 6 weeks, the length and weight of the rats were measured, and the animals were euthanized. The kidneys and gonads were collected, and blood samples were taken. Serum levels of insulin, nitric oxide, and iron were measured. The iron, zinc, copper, and calcium concentrations of tissues were determined. It was found that the M diet led to a significant increase in the relative kidney mass of the rats compared with the control group. Among the rats fed the M diet, markedly higher serum level of iron and lower levels of zinc and copper were observed in tissues, while significantly higher calcium levels were found in the gonads. The MFe diet resulted in decreased obesity index, insulin level, and nitric oxide serum concentration in the rats, when compared with both the M and C diets. The high iron level in the modified diet increased the relative mass of the gonads. The excess iron level in the diet disturbed the zinc, copper, and calcium status of tissues. The decrease in insulin and nitric oxide in rats fed the diet high in iron, fat, fructose, and salt was associated with disorders of zinc, copper, and calcium status, as well as with an increase in the relative mass of the gonads.</text>
      <sentence>
        <offset>0</offset>
        <text>Iron excess disturbs metabolic status and relative gonad mass in rats on high fat, fructose, and salt diets.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="0" length="4"/>
          <text>Iron</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fructose</infon>
          <location offset="83" length="8"/>
          <text>fructose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>109</offset>
        <text>The aim of this study was to assess the metabolic and physiological changes in rats fed a diet high in fat, fructose, and salt, and with excess iron level.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fructose</infon>
          <location offset="217" length="8"/>
          <text>fructose</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="253" length="4"/>
          <text>iron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>265</offset>
        <text>Mineral status was also estimated.</text>
      </sentence>
      <sentence>
        <offset>300</offset>
        <text>Wistar rats were assigned to groups fed either a standard control diet (C) or a diet high in fat, fructose, and salt.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fructose</infon>
          <location offset="398" length="8"/>
          <text>fructose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>418</offset>
        <text>The noncontrol diets contained either normal (M) or high level (MFe) of iron.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="490" length="4"/>
          <text>iron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>496</offset>
        <text>After 6 weeks, the length and weight of the rats were measured, and the animals were euthanized.</text>
      </sentence>
      <sentence>
        <offset>593</offset>
        <text>The kidneys and gonads were collected, and blood samples were taken.</text>
      </sentence>
      <sentence>
        <offset>662</offset>
        <text>Serum levels of insulin, nitric oxide, and iron were measured.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="687" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="705" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="678" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>725</offset>
        <text>The iron, zinc, copper, and calcium concentrations of tissues were determined.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="729" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc</infon>
          <location offset="735" length="4"/>
          <text>zinc</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="741" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="753" length="7"/>
          <text>calcium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>804</offset>
        <text>It was found that the M diet led to a significant increase in the relative kidney mass of the rats compared with the control group.</text>
      </sentence>
      <sentence>
        <offset>936</offset>
        <text>Among the rats fed the M diet, markedly higher serum level of iron and lower levels of zinc and copper were observed in tissues, while significantly higher calcium levels were found in the gonads.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="998" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc</infon>
          <location offset="1023" length="4"/>
          <text>zinc</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="1032" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="1092" length="7"/>
          <text>calcium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1133</offset>
        <text>The MFe diet resulted in decreased obesity index, insulin level, and nitric oxide serum concentration in the rats, when compared with both the M and C diets.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="1202" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1183" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1291</offset>
        <text>The high iron level in the modified diet increased the relative mass of the gonads.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="1300" length="4"/>
          <text>iron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1375</offset>
        <text>The excess iron level in the diet disturbed the zinc, copper, and calcium status of tissues.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="1386" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc</infon>
          <location offset="1423" length="4"/>
          <text>zinc</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="1429" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="1441" length="7"/>
          <text>calcium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1468</offset>
        <text>The decrease in insulin and nitric oxide in rats fed the diet high in iron, fat, fructose, and salt was associated with disorders of zinc, copper, and calcium status, as well as with an increase in the relative mass of the gonads.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="1496" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="1538" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fructose</infon>
          <location offset="1549" length="8"/>
          <text>fructose</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc</infon>
          <location offset="1601" length="4"/>
          <text>zinc</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="1607" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="1619" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1484" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>9625809</id>
    <passage>
      <offset>0</offset>
      <text>Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells.	Gonadotropin-releasing hormone (GnRH) receptor-bearing tumors undergo apoptosis in vivo and in vitro with GnRH analogs. We recently showed that GnRH stimulation induces intratumoral expression of the apoptosis-inducing Fas ligand in human reproductive tract tumors. To provide a potential association of Fas/Fas ligand system with the antiproliferative signaling process of GnRH receptor, we evaluated a correlation between the Fas ligand expression and the number of viable cells in two types of GnRH receptor-bearing endometrial carcinomas that differ in Fas content. Surgically removed uterine endometrial carcinomas had been screened for the presence of GnRH receptor and Fas before analyses. Fas ligand protein was characterized by immunoblotting of membrane proteins with the specific antibody. After a lag time of 2 days, incubation with a GnRH analog leuprolide (10 microM) induced significant growth inhibition of the Fas- and GnRH receptor-bearing cells (p&lt;0.01). Time course analysis showed that Fas ligand production, which was already observed at day 2 (p&lt;0.01), precedes the onset of reduction in viable cell number. The stimulatory effect of GnRH on Fas ligand expression and reduction of viable cells revealed dose-dependency. The analog at concentration of 10 microM induced up to 90% reduction in cell number. In contrast, the growth of Fas-negative cells was not affected by the analog, although Fas ligand appeared in response to the GnRH analog (p&lt;0.01). These data demonstrate that the co-presence of Fas could be essential for GnRH to promote antiproliferative action in endometrial cancer cells carrying GnRH receptor. The hormone may act through intratumor Fas and Fas ligand system to induced growth inhibition in GnRH-sensitive tumors.</text>
      <sentence>
        <offset>0</offset>
        <text>Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="0" length="3"/>
          <text>Fas</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gonadotropin-releasing hormone receptor</infon>
          <location offset="68" length="39"/>
          <text>gonadotropin-releasing hormone receptor</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas ligand</infon>
          <location offset="8" length="10"/>
          <text>Fas ligand</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>137</offset>
        <text>Gonadotropin-releasing hormone (GnRH) receptor-bearing tumors undergo apoptosis in vivo and in vitro with GnRH analogs.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gonadotropin-releasing hormone (gnrh) receptor</infon>
          <location offset="137" length="46"/>
          <text>Gonadotropin-releasing hormone (GnRH) receptor</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh</infon>
          <location offset="243" length="4"/>
          <text>GnRH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>257</offset>
        <text>We recently showed that GnRH stimulation induces intratumoral expression of the apoptosis-inducing Fas ligand in human reproductive tract tumors.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh</infon>
          <location offset="281" length="4"/>
          <text>GnRH</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas ligand</infon>
          <location offset="356" length="10"/>
          <text>Fas ligand</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>403</offset>
        <text>To provide a potential association of Fas/Fas ligand system with the antiproliferative signaling process of GnRH receptor, we evaluated a correlation between the Fas ligand expression and the number of viable cells in two types of GnRH receptor-bearing endometrial carcinomas that differ in Fas content.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="441" length="3"/>
          <text>Fas</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas ligand</infon>
          <location offset="445" length="10"/>
          <text>Fas ligand</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh receptor</infon>
          <location offset="511" length="13"/>
          <text>GnRH receptor</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas ligand</infon>
          <location offset="565" length="10"/>
          <text>Fas ligand</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh receptor</infon>
          <location offset="634" length="13"/>
          <text>GnRH receptor</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="694" length="3"/>
          <text>Fas</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>707</offset>
        <text>Surgically removed uterine endometrial carcinomas had been screened for the presence of GnRH receptor and Fas before analyses.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh receptor</infon>
          <location offset="795" length="13"/>
          <text>GnRH receptor</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="813" length="3"/>
          <text>Fas</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>834</offset>
        <text>Fas ligand protein was characterized by immunoblotting of membrane proteins with the specific antibody.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas ligand</infon>
          <location offset="834" length="10"/>
          <text>Fas ligand</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>938</offset>
        <text>After a lag time of 2 days, incubation with a GnRH analog leuprolide (10 microM) induced significant growth inhibition of the Fas- and GnRH receptor-bearing cells (p&lt;0.01).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">leuprolide</infon>
          <location offset="996" length="10"/>
          <text>leuprolide</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh</infon>
          <location offset="984" length="4"/>
          <text>GnRH</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="1064" length="3"/>
          <text>Fas</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh receptor</infon>
          <location offset="1073" length="13"/>
          <text>GnRH receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1111</offset>
        <text>Time course analysis showed that Fas ligand production, which was already observed at day 2 (p&lt;0.01), precedes the onset of reduction in viable cell number.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas ligand</infon>
          <location offset="1144" length="10"/>
          <text>Fas ligand</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1268</offset>
        <text>The stimulatory effect of GnRH on Fas ligand expression and reduction of viable cells revealed dose-dependency.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh</infon>
          <location offset="1294" length="4"/>
          <text>GnRH</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas ligand</infon>
          <location offset="1302" length="10"/>
          <text>Fas ligand</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1380</offset>
        <text>The analog at concentration of 10 microM induced up to 90% reduction in cell number.</text>
      </sentence>
      <sentence>
        <offset>1465</offset>
        <text>In contrast, the growth of Fas-negative cells was not affected by the analog, although Fas ligand appeared in response to the GnRH analog (p&lt;0.01).</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="1492" length="3"/>
          <text>Fas</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas ligand</infon>
          <location offset="1552" length="10"/>
          <text>Fas ligand</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh</infon>
          <location offset="1591" length="4"/>
          <text>GnRH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1613</offset>
        <text>These data demonstrate that the co-presence of Fas could be essential for GnRH to promote antiproliferative action in endometrial cancer cells carrying GnRH receptor.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="1660" length="3"/>
          <text>Fas</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh</infon>
          <location offset="1687" length="4"/>
          <text>GnRH</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh receptor</infon>
          <location offset="1765" length="13"/>
          <text>GnRH receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1780</offset>
        <text>The hormone may act through intratumor Fas and Fas ligand system to induced growth inhibition in GnRH-sensitive tumors.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="1819" length="3"/>
          <text>Fas</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas ligand</infon>
          <location offset="1827" length="10"/>
          <text>Fas ligand</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnrh</infon>
          <location offset="1877" length="4"/>
          <text>GnRH</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23485651</id>
    <passage>
      <offset>0</offset>
      <text>Cadmium telluride quantum dots cause oxidative stress leading to extrinsic and intrinsic apoptosis in hepatocellular carcinoma HepG2 cells.	The mechanisms of toxicity related to human hepatocellular carcinoma HepG2 cell exposures to cadmium telluride quantum dots (CdTe-QDs) were investigated. CdTe-QDs caused cytotoxicity in HepG2 cells in a dose- and time-dependent manner. Treated cells showed an increase in reactive oxygen species (ROS). Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) and an increased NF-E2-related Factor 2 (Nrf2) activation. Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (GST) activities were depressed. Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, poly ADP-ribose polymerase (PARP) cleavage and phosphatidylserine externalization. Extrinsic apoptotic pathway markers such as Fas levels and caspase-8 activity increased as a result of CdTe-QD exposure. Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun N-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated. Our findings reveal that CdTe-QDs cause oxidative stress, interfere with antioxidant defenses and activate protein kinases, leading to apoptosis via both extrinsic and intrinsic pathways. Since the effects of CdTe-QDs on selected biomarkers were similar or greater compared to those of CdCl2 at equivalent concentrations of cadmium, the study suggests that the toxicity of CdTe-QDs arises from a combination of the effects of cadmium and ROS generated from the NPs.</text>
      <sentence>
        <offset>0</offset>
        <text>Cadmium telluride quantum dots cause oxidative stress leading to extrinsic and intrinsic apoptosis in hepatocellular carcinoma HepG2 cells.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium telluride</infon>
          <location offset="0" length="17"/>
          <text>Cadmium telluride</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>140</offset>
        <text>The mechanisms of toxicity related to human hepatocellular carcinoma HepG2 cell exposures to cadmium telluride quantum dots (CdTe-QDs) were investigated.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdte</infon>
          <location offset="265" length="4"/>
          <text>CdTe</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium telluride</infon>
          <location offset="233" length="17"/>
          <text>cadmium telluride</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>294</offset>
        <text>CdTe-QDs caused cytotoxicity in HepG2 cells in a dose- and time-dependent manner.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdte</infon>
          <location offset="294" length="4"/>
          <text>CdTe</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>376</offset>
        <text>Treated cells showed an increase in reactive oxygen species (ROS).</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="421" length="6"/>
          <text>oxygen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>443</offset>
        <text>Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) and an increased NF-E2-related Factor 2 (Nrf2) activation.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">reduced glutathione</infon>
          <location offset="504" length="19"/>
          <text>reduced glutathione</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="525" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="560" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxidized glutathione</infon>
          <location offset="575" length="20"/>
          <text>oxidized glutathione</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="597" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gssg</infon>
          <location offset="601" length="4"/>
          <text>GSSG</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nf-e2-related factor 2</infon>
          <location offset="624" length="22"/>
          <text>NF-E2-related Factor 2</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nrf2</infon>
          <location offset="648" length="4"/>
          <text>Nrf2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>666</offset>
        <text>Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (GST) activities were depressed.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="692" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="768" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s</infon>
          <location offset="780" length="1"/>
          <text>S</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">superoxide dismutase</infon>
          <location offset="692" length="20"/>
          <text>superoxide dismutase</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sod</infon>
          <location offset="714" length="3"/>
          <text>SOD</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catalase</infon>
          <location offset="749" length="8"/>
          <text>catalase</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cat</infon>
          <location offset="759" length="3"/>
          <text>CAT</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathione-s-transferase</infon>
          <location offset="768" length="25"/>
          <text>glutathione-S-transferase</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gst</infon>
          <location offset="795" length="3"/>
          <text>GST</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>827</offset>
        <text>Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, poly ADP-ribose polymerase (PARP) cleavage and phosphatidylserine externalization.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdte</infon>
          <location offset="858" length="4"/>
          <text>CdTe</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">poly adp-ribose</infon>
          <location offset="952" length="15"/>
          <text>poly ADP-ribose</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phosphatidylserine</infon>
          <location offset="999" length="18"/>
          <text>phosphatidylserine</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="932" length="9"/>
          <text>caspase-3</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">poly adp-ribose polymerase</infon>
          <location offset="952" length="26"/>
          <text>poly ADP-ribose polymerase</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">parp</infon>
          <location offset="980" length="4"/>
          <text>PARP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1035</offset>
        <text>Extrinsic apoptotic pathway markers such as Fas levels and caspase-8 activity increased as a result of CdTe-QD exposure.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdte</infon>
          <location offset="1138" length="4"/>
          <text>CdTe</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="1079" length="3"/>
          <text>Fas</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-8</infon>
          <location offset="1094" length="9"/>
          <text>caspase-8</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T50" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1156</offset>
        <text>Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">b-cell lymphoma 2</infon>
          <location offset="1254" length="17"/>
          <text>B-cell lymphoma 2</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2</infon>
          <location offset="1273" length="4"/>
          <text>Bcl2</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome c</infon>
          <location offset="1305" length="12"/>
          <text>cytochrome c</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2-associated x protein</infon>
          <location offset="1360" length="26"/>
          <text>Bcl-2-associated X protein</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="1388" length="3"/>
          <text>Bax</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome c</infon>
          <location offset="1407" length="12"/>
          <text>cytochrome c</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1421</offset>
        <text>Further, mitogen-activated protein kinases (MAPKs) such as c-Jun N-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="1486" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mitogen-activated protein kinases</infon>
          <location offset="1430" length="33"/>
          <text>mitogen-activated protein kinases</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapks</infon>
          <location offset="1465" length="5"/>
          <text>MAPKs</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c-jun n-terminal kinases</infon>
          <location offset="1480" length="24"/>
          <text>c-Jun N-terminal kinases</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">jnk</infon>
          <location offset="1506" length="3"/>
          <text>JNK</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">extracellular signal-regulated kinases</infon>
          <location offset="1512" length="38"/>
          <text>extracellular signal-regulated kinases</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="1552" length="6"/>
          <text>Erk1/2</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p38</infon>
          <location offset="1565" length="3"/>
          <text>p38</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1589</offset>
        <text>Our findings reveal that CdTe-QDs cause oxidative stress, interfere with antioxidant defenses and activate protein kinases, leading to apoptosis via both extrinsic and intrinsic pathways.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdte</infon>
          <location offset="1614" length="4"/>
          <text>CdTe</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinases</infon>
          <location offset="1704" length="7"/>
          <text>kinases</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1777</offset>
        <text>Since the effects of CdTe-QDs on selected biomarkers were similar or greater compared to those of CdCl2 at equivalent concentrations of cadmium, the study suggests that the toxicity of CdTe-QDs arises from a combination of the effects of cadmium and ROS generated from the NPs.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdte</infon>
          <location offset="1798" length="4"/>
          <text>CdTe</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdcl2</infon>
          <location offset="1875" length="5"/>
          <text>CdCl2</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="1913" length="7"/>
          <text>cadmium</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdte</infon>
          <location offset="1962" length="4"/>
          <text>CdTe</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23164615</id>
    <passage>
      <offset>0</offset>
      <text>Differential modulation of retinal ganglion cell light responses by orthosteric and allosteric metabotropic glutamate receptor 8 compounds.	To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG). These agents were applied to whole-cell voltage-clamped ganglion cells from an isolated, superfused mouse retina preparation. DCPG reduced OFF-ganglion cell excitatory currents, whereas AZ enhanced the peak excitatory currents in ON-, OFF-, and ON-OFF-ganglion cells. The effects on ganglion cell inhibitory currents were more varied. The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous glutamate being stronger during bright light stimulation and with mGluR8 receptors mainly being localized away from glutamate release sites, immuno-labeled with VGLUT1. The differential sensitivity of ganglion cell light responses to DCPG and AZ supports multiple sites where mGluR8 modulates the light responses of ganglion cells.</text>
      <sentence>
        <offset>0</offset>
        <text>Differential modulation of retinal ganglion cell light responses by orthosteric and allosteric metabotropic glutamate receptor 8 compounds.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="108" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">metabotropic glutamate receptor 8</infon>
          <location offset="95" length="33"/>
          <text>metabotropic glutamate receptor 8</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>140</offset>
        <text>To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">az12216052</infon>
          <location offset="309" length="10"/>
          <text>AZ12216052</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(s)-3,4-dicarboxyphenylglycine</infon>
          <location offset="369" length="30"/>
          <text>(S)-3,4-dicarboxyphenylglycine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dcpg</infon>
          <location offset="401" length="4"/>
          <text>DCPG</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglur8</infon>
          <location offset="301" length="6"/>
          <text>mGluR8</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglur8</infon>
          <location offset="333" length="6"/>
          <text>mGluR8</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglur8</infon>
          <location offset="167" length="6"/>
          <text>mGluR8</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>408</offset>
        <text>These agents were applied to whole-cell voltage-clamped ganglion cells from an isolated, superfused mouse retina preparation.</text>
      </sentence>
      <sentence>
        <offset>534</offset>
        <text>DCPG reduced OFF-ganglion cell excitatory currents, whereas AZ enhanced the peak excitatory currents in ON-, OFF-, and ON-OFF-ganglion cells.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dcpg</infon>
          <location offset="534" length="4"/>
          <text>DCPG</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>676</offset>
        <text>The effects on ganglion cell inhibitory currents were more varied.</text>
      </sentence>
      <sentence>
        <offset>743</offset>
        <text>The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous glutamate being stronger during bright light stimulation and with mGluR8 receptors mainly being localized away from glutamate release sites, immuno-labeled with VGLUT1.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="889" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="1005" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglur8</infon>
          <location offset="955" length="6"/>
          <text>mGluR8</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vglut1</infon>
          <location offset="1050" length="6"/>
          <text>VGLUT1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1058</offset>
        <text>The differential sensitivity of ganglion cell light responses to DCPG and AZ supports multiple sites where mGluR8 modulates the light responses of ganglion cells.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dcpg</infon>
          <location offset="1123" length="4"/>
          <text>DCPG</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglur8</infon>
          <location offset="1165" length="6"/>
          <text>mGluR8</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17484506</id>
    <passage>
      <offset>0</offset>
      <text>Endometriosis: the way forward.	Endometriosis, a common cause of morbidity, affects 10% of women of reproductive age. In this review we focus on the new developments in pathogenesis, diagnosis and treatment options, reviewing the literature published about this enigmatic disorder over the past three years. More specifically, new theories of the pathogenesis of the syndrome of Sampson and Cullen are discussed. The new era of genomics may characterize endometriosis and transform clinical management of the disease. Literature suggesting that endometriosis may have an environmental origin is reviewed. New approaches to medical therapy of endometriosis have been developed, including the levonorgestrel-releasing intrauterine device, aromatase inhibitors, immunomodulatory drugs, angiogenesis inhibitors, selective estrogen and progesterone receptor modulators, and statins. Subfertility is another well-known result of endometriosis and often complex decisions must be made regarding management of the endometriosis patient who wishes to conceive. Laparoscopic surgery and assisted reproduction--with or without gonadotropin-releasing hormone-agonist treatment--are reviewed. Finally we speculate about new developments in the field of endometriosis in the coming three years.</text>
      <sentence>
        <offset>0</offset>
        <text>Endometriosis: the way forward.</text>
      </sentence>
      <sentence>
        <offset>32</offset>
        <text>Endometriosis, a common cause of morbidity, affects 10% of women of reproductive age.</text>
      </sentence>
      <sentence>
        <offset>118</offset>
        <text>In this review we focus on the new developments in pathogenesis, diagnosis and treatment options, reviewing the literature published about this enigmatic disorder over the past three years.</text>
      </sentence>
      <sentence>
        <offset>308</offset>
        <text>More specifically, new theories of the pathogenesis of the syndrome of Sampson and Cullen are discussed.</text>
      </sentence>
      <sentence>
        <offset>413</offset>
        <text>The new era of genomics may characterize endometriosis and transform clinical management of the disease.</text>
      </sentence>
      <sentence>
        <offset>518</offset>
        <text>Literature suggesting that endometriosis may have an environmental origin is reviewed.</text>
      </sentence>
      <sentence>
        <offset>605</offset>
        <text>New approaches to medical therapy of endometriosis have been developed, including the levonorgestrel-releasing intrauterine device, aromatase inhibitors, immunomodulatory drugs, angiogenesis inhibitors, selective estrogen and progesterone receptor modulators, and statins.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levonorgestrel</infon>
          <location offset="691" length="14"/>
          <text>levonorgestrel</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="818" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="831" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="737" length="9"/>
          <text>aromatase</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">estrogen and progesterone receptor</infon>
          <location offset="818" length="34"/>
          <text>estrogen and progesterone receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>878</offset>
        <text>Subfertility is another well-known result of endometriosis and often complex decisions must be made regarding management of the endometriosis patient who wishes to conceive.</text>
      </sentence>
      <sentence>
        <offset>1052</offset>
        <text>Laparoscopic surgery and assisted reproduction--with or without gonadotropin-releasing hormone-agonist treatment--are reviewed.</text>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gonadotropin-releasing hormone</infon>
          <location offset="1116" length="30"/>
          <text>gonadotropin-releasing hormone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1180</offset>
        <text>Finally we speculate about new developments in the field of endometriosis in the coming three years.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>3124610</id>
    <passage>
      <offset>0</offset>
      <text>Interleukin 2 toxin: a step toward selective immunomodulation.	We have used protein engineering and recombinant DNA methodologies to genetically replace the eukaryotic cell receptor binding domain of diphtheria toxin with interleukin 2 (IL-2). The toxin-related T cell growth factor fusion gene has been cloned in Escherichia coli K12. Recombinant strains of E coli produce a 68,086 K hybrid toxin, IL-2 toxin that retains immunologic properties intrinsic to both its diphtheria toxin and IL-2 components. IL-2 toxin has been found to selectively inhibit protein synthesis in both human and murine T cell lines that bear high affinity IL-2 receptors, whereas the hybrid toxin is not active against cells that do not bear this receptor. The cytotoxic action of IL-2 toxin is specifically blocked by free IL-2 and monoclonal antibodies that bind to the p55 (Tac antigen) subunit of the high affinity IL-2 receptor. In addition, IL-2 toxin, like diphtheria toxin itself, must pass through an acidic compartment in order to deliver its adenosine diphosphate ribosyl transferase activity to the cytosol of target T cells. In a murine delayed type hypersensitivity (DTH) model system, we have shown that IL-2 toxin treatment induces a marked immunosuppression.</text>
      <sentence>
        <offset>0</offset>
        <text>Interleukin 2 toxin: a step toward selective immunomodulation.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin 2</infon>
          <location offset="0" length="13"/>
          <text>Interleukin 2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>63</offset>
        <text>We have used protein engineering and recombinant DNA methodologies to genetically replace the eukaryotic cell receptor binding domain of diphtheria toxin with interleukin 2 (IL-2).</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin 2</infon>
          <location offset="222" length="13"/>
          <text>interleukin 2</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="237" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">eukaryotic cell receptor binding domain</infon>
          <location offset="157" length="39"/>
          <text>eukaryotic cell receptor binding domain</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>244</offset>
        <text>The toxin-related T cell growth factor fusion gene has been cloned in Escherichia coli K12.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">t cell growth factor</infon>
          <location offset="262" length="20"/>
          <text>T cell growth factor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>336</offset>
        <text>Recombinant strains of E coli produce a 68,086 K hybrid toxin, IL-2 toxin that retains immunologic properties intrinsic to both its diphtheria toxin and IL-2 components.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="399" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="489" length="4"/>
          <text>IL-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>506</offset>
        <text>IL-2 toxin has been found to selectively inhibit protein synthesis in both human and murine T cell lines that bear high affinity IL-2 receptors, whereas the hybrid toxin is not active against cells that do not bear this receptor.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">il-2</infon>
          <location offset="506" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">il-2 receptors</infon>
          <location offset="635" length="14"/>
          <text>IL-2 receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>736</offset>
        <text>The cytotoxic action of IL-2 toxin is specifically blocked by free IL-2 and monoclonal antibodies that bind to the p55 (Tac antigen) subunit of the high affinity IL-2 receptor.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="760" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="803" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p55</infon>
          <location offset="851" length="3"/>
          <text>p55</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tac</infon>
          <location offset="856" length="3"/>
          <text>Tac</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">il-2 receptor</infon>
          <location offset="898" length="13"/>
          <text>IL-2 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>913</offset>
        <text>In addition, IL-2 toxin, like diphtheria toxin itself, must pass through an acidic compartment in order to deliver its adenosine diphosphate ribosyl transferase activity to the cytosol of target T cells.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine diphosphate</infon>
          <location offset="1032" length="21"/>
          <text>adenosine diphosphate</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ribosyl</infon>
          <location offset="1054" length="7"/>
          <text>ribosyl</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="926" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adenosine diphosphate ribosyl transferase</infon>
          <location offset="1032" length="41"/>
          <text>adenosine diphosphate ribosyl transferase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1117</offset>
        <text>In a murine delayed type hypersensitivity (DTH) model system, we have shown that IL-2 toxin treatment induces a marked immunosuppression.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="1198" length="4"/>
          <text>IL-2</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23619386</id>
    <passage>
      <offset>0</offset>
      <text>Rapamycin allosterically inhibits the proteasome.	Rapamycin is a canonical allosteric inhibitor of the mTOR kinase with immunosuppressive and pro-apoptotic activities. We found that in vitro rapamycin also regulates the proteasome, an essential intracellular protease of the ubiquitin-proteasome pathway. Rapamycin inhibits proteinase and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations. Moreover, the drug interferes with binding of the 19S cap essential for processing of polyubiquitinylated substrates, and the PA200 activator to the 20S catalytic core proteasome. These protein complexes are known to bind to specific grooves on the α face region of the 20S core. A treatment with rapamycin affects conformational dynamics of the proteasomal gate, a centrally positioned within the α face and allosterically regulated element responsible for the intake of substrates. Interestingly, we showed that rapamycin shares all the proteasome targeting properties not only with other two-domain, closed-ring analogs (rapalogs), but also with its single domain mimics, and with seco-rapamycin. The latter is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR. We hypothesize that the rapamycin and related compounds bind to the α face and allosterically impact the proteasome function. The implications of our finding for mechanism of in vivo actions of rapamycin and for design of novel allosteric drugs targeting the proteasome are discussed.</text>
      <sentence>
        <offset>0</offset>
        <text>Rapamycin allosterically inhibits the proteasome.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="0" length="9"/>
          <text>Rapamycin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">proteasome</infon>
          <location offset="38" length="10"/>
          <text>proteasome</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>50</offset>
        <text>Rapamycin is a canonical allosteric inhibitor of the mTOR kinase with immunosuppressive and pro-apoptotic activities.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="50" length="9"/>
          <text>Rapamycin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="103" length="4"/>
          <text>mTOR</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="108" length="6"/>
          <text>kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>168</offset>
        <text>We found that in vitro rapamycin also regulates the proteasome, an essential intracellular protease of the ubiquitin-proteasome pathway.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="191" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">proteasome</infon>
          <location offset="220" length="10"/>
          <text>proteasome</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ubiquitin</infon>
          <location offset="275" length="9"/>
          <text>ubiquitin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">proteasome</infon>
          <location offset="285" length="10"/>
          <text>proteasome</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>305</offset>
        <text>Rapamycin inhibits proteinase and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="305" length="9"/>
          <text>Rapamycin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">proteinase</infon>
          <location offset="324" length="10"/>
          <text>proteinase</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">peptidase</infon>
          <location offset="348" length="9"/>
          <text>peptidase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">proteasome</infon>
          <location offset="391" length="10"/>
          <text>proteasome</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>436</offset>
        <text>Moreover, the drug interferes with binding of the 19S cap essential for processing of polyubiquitinylated substrates, and the PA200 activator to the 20S catalytic core proteasome.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pa200</infon>
          <location offset="562" length="5"/>
          <text>PA200</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">20s catalytic core proteasome</infon>
          <location offset="585" length="29"/>
          <text>20S catalytic core proteasome</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>616</offset>
        <text>These protein complexes are known to bind to specific grooves on the α face region of the 20S core.</text>
      </sentence>
      <sentence>
        <offset>716</offset>
        <text>A treatment with rapamycin affects conformational dynamics of the proteasomal gate, a centrally positioned within the α face and allosterically regulated element responsible for the intake of substrates.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="733" length="9"/>
          <text>rapamycin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>920</offset>
        <text>Interestingly, we showed that rapamycin shares all the proteasome targeting properties not only with other two-domain, closed-ring analogs (rapalogs), but also with its single domain mimics, and with seco-rapamycin.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">seco-rapamycin</infon>
          <location offset="1120" length="14"/>
          <text>seco-rapamycin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="950" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">proteasome</infon>
          <location offset="975" length="10"/>
          <text>proteasome</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1136</offset>
        <text>The latter is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="1192" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="1223" length="4"/>
          <text>mTOR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1229</offset>
        <text>We hypothesize that the rapamycin and related compounds bind to the α face and allosterically impact the proteasome function.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="1253" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">proteasome</infon>
          <location offset="1334" length="10"/>
          <text>proteasome</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1355</offset>
        <text>The implications of our finding for mechanism of in vivo actions of rapamycin and for design of novel allosteric drugs targeting the proteasome are discussed.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="1423" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">proteasome</infon>
          <location offset="1488" length="10"/>
          <text>proteasome</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23256819</id>
    <passage>
      <offset>0</offset>
      <text>HR-MAS NMR Spectroscopy of Reconstructed Human Epidermis: Potential for the in Situ Investigation of the Chemical Interactions between Skin Allergens and Nucleophilic Amino Acids.	High-resolution magic angle spinning (HR-MAS) is a nuclear magnetic resonance (NMR) technique that enables the characterization of metabolic phenotypes/metabolite profiles of cells, tissues, and organs, under both normal and pathological conditions, without resorting to time-consuming extraction techniques. In this article, we explore a new domain of application of HR-MAS, namely, reconstructed human epidermis (RHE) and the in situ observation of chemical interactions between skin sensitizers and nucleophilic amino acids. First, the preparation, storage, and analysis of RHE were optimized, and this work demonstrated that HR-MAS NMR was well adapted for investigating RHE with spectra of good quality allowing qualitative as well as quantitative studies of metabolites. Second, in order to study the response of RHE to chemical sensitizers, the ((13)C)methyldodecanesulfonate was chosen as an NMR probe, and we compared adducts formed on human serum albumin (HSA) in solution and adducts formed in RHE. Thus, while the modification of proteins or peptides in solution takes several days to lead to a significant amount of modification, in RHE the modifications of nucleophilic amino acids were observable already at 24 h. The chemioselectivity also appeared to be different with major modifications taking place on histidine, methionine, and cysteine residues in RHE, while on HSA, significant modifications were observed on lysine residues with the formation of methylated and dimethylated amino groups. We thus demonstrated that RHE could be used to investigate in situ chemical interactions taking place between skin sensitizers and nucleophilic amino acids. This opens perspectives for the molecular understanding of the skin immune system activation by sensitizing chemicals.</text>
      <sentence>
        <offset>0</offset>
        <text>HR-MAS NMR Spectroscopy of Reconstructed Human Epidermis: Potential for the in Situ Investigation of the Chemical Interactions between Skin Allergens and Nucleophilic Amino Acids.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="167" length="11"/>
          <text>Amino Acids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>180</offset>
        <text>High-resolution magic angle spinning (HR-MAS) is a nuclear magnetic resonance (NMR) technique that enables the characterization of metabolic phenotypes/metabolite profiles of cells, tissues, and organs, under both normal and pathological conditions, without resorting to time-consuming extraction techniques.</text>
      </sentence>
      <sentence>
        <offset>489</offset>
        <text>In this article, we explore a new domain of application of HR-MAS, namely, reconstructed human epidermis (RHE) and the in situ observation of chemical interactions between skin sensitizers and nucleophilic amino acids.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="695" length="11"/>
          <text>amino acids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>708</offset>
        <text>First, the preparation, storage, and analysis of RHE were optimized, and this work demonstrated that HR-MAS NMR was well adapted for investigating RHE with spectra of good quality allowing qualitative as well as quantitative studies of metabolites.</text>
      </sentence>
      <sentence>
        <offset>957</offset>
        <text>Second, in order to study the response of RHE to chemical sensitizers, the ((13)C)methyldodecanesulfonate was chosen as an NMR probe, and we compared adducts formed on human serum albumin (HSA) in solution and adducts formed in RHE.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">((13)c)methyldodecanesulfonate</infon>
          <location offset="1032" length="30"/>
          <text>((13)C)methyldodecanesulfonate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human serum albumin</infon>
          <location offset="1125" length="19"/>
          <text>human serum albumin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsa</infon>
          <location offset="1146" length="3"/>
          <text>HSA</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1190</offset>
        <text>Thus, while the modification of proteins or peptides in solution takes several days to lead to a significant amount of modification, in RHE the modifications of nucleophilic amino acids were observable already at 24 h.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="1364" length="11"/>
          <text>amino acids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1409</offset>
        <text>The chemioselectivity also appeared to be different with major modifications taking place on histidine, methionine, and cysteine residues in RHE, while on HSA, significant modifications were observed on lysine residues with the formation of methylated and dimethylated amino groups.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histidine</infon>
          <location offset="1502" length="9"/>
          <text>histidine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methionine</infon>
          <location offset="1513" length="10"/>
          <text>methionine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteine</infon>
          <location offset="1529" length="8"/>
          <text>cysteine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lysine</infon>
          <location offset="1612" length="6"/>
          <text>lysine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino</infon>
          <location offset="1678" length="5"/>
          <text>amino</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1692</offset>
        <text>We thus demonstrated that RHE could be used to investigate in situ chemical interactions taking place between skin sensitizers and nucleophilic amino acids.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="1836" length="11"/>
          <text>amino acids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1849</offset>
        <text>This opens perspectives for the molecular understanding of the skin immune system activation by sensitizing chemicals.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23220641</id>
    <passage>
      <offset>0</offset>
      <text>Sirtuins as emerging anti-parasitic targets.	Silent information regulator 2 (Sir2) enzymes or sirtuins are a family of NAD(+)-dependent protein N(ε)-acetyl-lysine (AcK) deacetylases. Sirtuins are also evolutionarily conserved proteins that are present in all kingdoms of life ranging from bacteria to humans. Interestingly, it was recently found that the sirtuins found in various human parasites (especially the Plasmodium, Trypanosoma, and Leishmania species) were pro-survival for the parasites under various conditions. Therefore, these parasitic sirtuins have emerged as novel anti-parasitic therapeutic targets. This article reviews the currently available structural, biochemical, pharmacological, and medicinal chemistry studies on these enzymes, and discusses the perspectives of selectively targeting the parasitic sirtuins as a novel therapeutic strategy for the human parasitic diseases.</text>
      <sentence>
        <offset>0</offset>
        <text>Sirtuins as emerging anti-parasitic targets.</text>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sirtuins</infon>
          <location offset="0" length="8"/>
          <text>Sirtuins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>45</offset>
        <text>Silent information regulator 2 (Sir2) enzymes or sirtuins are a family of NAD(+)-dependent protein N(ε)-acetyl-lysine (AcK) deacetylases.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ack</infon>
          <location offset="164" length="3"/>
          <text>AcK</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nad(+)</infon>
          <location offset="119" length="6"/>
          <text>NAD(+)</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n(ε)-acetyl-lysine</infon>
          <location offset="144" length="18"/>
          <text>N(ε)-acetyl-lysine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">silent information regulator 2</infon>
          <location offset="45" length="30"/>
          <text>Silent information regulator 2</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sir2</infon>
          <location offset="77" length="4"/>
          <text>Sir2</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sirtuins</infon>
          <location offset="94" length="8"/>
          <text>sirtuins</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nad(+)-dependent protein n(ε)-acetyl-lysine (ack) deacetylases</infon>
          <location offset="119" length="62"/>
          <text>NAD(+)-dependent protein N(ε)-acetyl-lysine (AcK) deacetylases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>183</offset>
        <text>Sirtuins are also evolutionarily conserved proteins that are present in all kingdoms of life ranging from bacteria to humans.</text>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sirtuins</infon>
          <location offset="183" length="8"/>
          <text>Sirtuins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>309</offset>
        <text>Interestingly, it was recently found that the sirtuins found in various human parasites (especially the Plasmodium, Trypanosoma, and Leishmania species) were pro-survival for the parasites under various conditions.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sirtuins</infon>
          <location offset="355" length="8"/>
          <text>sirtuins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>524</offset>
        <text>Therefore, these parasitic sirtuins have emerged as novel anti-parasitic therapeutic targets.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">parasitic sirtuins</infon>
          <location offset="541" length="18"/>
          <text>parasitic sirtuins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>618</offset>
        <text>This article reviews the currently available structural, biochemical, pharmacological, and medicinal chemistry studies on these enzymes, and discusses the perspectives of selectively targeting the parasitic sirtuins as a novel therapeutic strategy for the human parasitic diseases.</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">parasitic sirtuins</infon>
          <location offset="815" length="18"/>
          <text>parasitic sirtuins</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23515291</id>
    <passage>
      <offset>0</offset>
      <text>Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) Promotes Growth and Survival of Breast Epithelial Cells: Novel Regulation of the Estrogen Receptor.	In breast tumors IGF binding protein-2 (IGFBP-2) is elevated, and the presence of IGFBP-2 has been shown to correlate with malignancy. However, how IGFBP-2 contributes to the malignant state is still unclear. Silencing IGFBP-2 blocked cell proliferation and in MCF-7 cells increased cell death, indicating that IGFBP-2 was acting in both a mitogenic and a survival capacity. Exogenous IGFBP-2 acting via integrin receptors to reduce phosphatase and tensin homolog deleted from chromosome 10 (PTEN) levels protected these cells against death induced by various chemotherapeutic agents. This was dependent on a functional estrogen receptor (ER)-α because silencing ER-α blocked the ability of IGFBP-2 to confer cell survival. Loss of IGFBP-2 increased levels of PTEN and improved chemosensitivity of the cells, confirming its role as a survival factor. Silencing IGFBP-2 had no effect on the response to IGF-II, but responses to estrogen and tamoxifen were no longer observed due to loss of ER-α, which could be prevented by the inhibition of PTEN. Conversely, exogenous IGFBP-2 increased ER-α mRNA and protein in both normal and cancer cells via its interaction with integrin receptors. These actions of IGFBP-2 on ER-α involved the IGF-I receptor and activation of phosphatidylinositol 3-kinase in the cancer cells but were independent of this in normal breast cells. The production of IGFBP-2 by breast cancer cells enhances their proliferative potential, increases their survival, and protects them against chemotherapy-induced death. IGFBP-2 not only modulates IGFs and directly regulates PTEN but also has a role in maintaining ER-α expression.</text>
      <sentence>
        <offset>0</offset>
        <text>Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) Promotes Growth and Survival of Breast Epithelial Cells: Novel Regulation of the Estrogen Receptor.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="136" length="8"/>
          <text>Estrogen</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin-like growth factor binding protein 2</infon>
          <location offset="0" length="44"/>
          <text>Insulin-Like Growth Factor Binding Protein 2</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">estrogen receptor</infon>
          <location offset="136" length="17"/>
          <text>Estrogen Receptor</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="46" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>155</offset>
        <text>In breast tumors IGF binding protein-2 (IGFBP-2) is elevated, and the presence of IGFBP-2 has been shown to correlate with malignancy.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf binding protein-2</infon>
          <location offset="172" length="21"/>
          <text>IGF binding protein-2</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="195" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="237" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>290</offset>
        <text>However, how IGFBP-2 contributes to the malignant state is still unclear.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="303" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>364</offset>
        <text>Silencing IGFBP-2 blocked cell proliferation and in MCF-7 cells increased cell death, indicating that IGFBP-2 was acting in both a mitogenic and a survival capacity.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="374" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="466" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>530</offset>
        <text>Exogenous IGFBP-2 acting via integrin receptors to reduce phosphatase and tensin homolog deleted from chromosome 10 (PTEN) levels protected these cells against death induced by various chemotherapeutic agents.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="540" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">integrin receptors</infon>
          <location offset="559" length="18"/>
          <text>integrin receptors</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phosphatase and tensin homolog deleted from chromosome 10</infon>
          <location offset="588" length="57"/>
          <text>phosphatase and tensin homolog deleted from chromosome 10</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pten</infon>
          <location offset="647" length="4"/>
          <text>PTEN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>740</offset>
        <text>This was dependent on a functional estrogen receptor (ER)-α because silencing ER-α blocked the ability of IGFBP-2 to confer cell survival.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="775" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">estrogen receptor (er)-α</infon>
          <location offset="775" length="24"/>
          <text>estrogen receptor (ER)-α</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er-α</infon>
          <location offset="818" length="4"/>
          <text>ER-α</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="846" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>879</offset>
        <text>Loss of IGFBP-2 increased levels of PTEN and improved chemosensitivity of the cells, confirming its role as a survival factor.</text>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="887" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pten</infon>
          <location offset="915" length="4"/>
          <text>PTEN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1006</offset>
        <text>Silencing IGFBP-2 had no effect on the response to IGF-II, but responses to estrogen and tamoxifen were no longer observed due to loss of ER-α, which could be prevented by the inhibition of PTEN.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="1082" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="1095" length="9"/>
          <text>tamoxifen</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pten</infon>
          <location offset="1196" length="4"/>
          <text>PTEN</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="1016" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">igf-ii</infon>
          <location offset="1057" length="6"/>
          <text>IGF-II</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er-α</infon>
          <location offset="1144" length="4"/>
          <text>ER-α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1202</offset>
        <text>Conversely, exogenous IGFBP-2 increased ER-α mRNA and protein in both normal and cancer cells via its interaction with integrin receptors.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="1224" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er-α</infon>
          <location offset="1242" length="4"/>
          <text>ER-α</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">integrin receptors</infon>
          <location offset="1321" length="18"/>
          <text>integrin receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1341</offset>
        <text>These actions of IGFBP-2 on ER-α involved the IGF-I receptor and activation of phosphatidylinositol 3-kinase in the cancer cells but were independent of this in normal breast cells.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phosphatidylinositol</infon>
          <location offset="1420" length="20"/>
          <text>phosphatidylinositol</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="1358" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er-α</infon>
          <location offset="1369" length="4"/>
          <text>ER-α</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-i receptor</infon>
          <location offset="1387" length="14"/>
          <text>IGF-I receptor</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphatidylinositol 3-kinase</infon>
          <location offset="1420" length="29"/>
          <text>phosphatidylinositol 3-kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1523</offset>
        <text>The production of IGFBP-2 by breast cancer cells enhances their proliferative potential, increases their survival, and protects them against chemotherapy-induced death.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="1541" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1692</offset>
        <text>IGFBP-2 not only modulates IGFs and directly regulates PTEN but also has a role in maintaining ER-α expression.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igfbp-2</infon>
          <location offset="1692" length="7"/>
          <text>IGFBP-2</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">igfs</infon>
          <location offset="1719" length="4"/>
          <text>IGFs</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pten</infon>
          <location offset="1747" length="4"/>
          <text>PTEN</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er-α</infon>
          <location offset="1787" length="4"/>
          <text>ER-α</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23201927</id>
    <passage>
      <offset>0</offset>
      <text>Cardioprotective effect of salvianolic acid B against arsenic trioxide-induced injury in cardiac H9c2 cells via the PI3K/Akt signal pathway.	The clinical use of arsenic trioxide (ATO), a potent anti-neoplastic agent, is often limited because of its severe cardiotoxicity. Salviae miltiorrhiza is widely used for the treatment of cardiovascular diseases. One of the most abundant ingredients of S. miltiorrhiza is salvianolic acid B (Sal B). The present study was designed to evaluate whether Sal B protects against ATO-induced cardiac cell injury in vitro. With MTT cell viability assay, LDH release, ROS generation, caspase-3 activity assay and Hoechst 33342/PI staining, we found that Sal B pretreatment provided significantly protection against ATO-induced cell death. The effect was correlated with the activation of the PI3K/Akt signal pathway. Conversely, blocking Akt activation with the PI3K inhibitor LY294002 effectively suppressed the protective effect of Sal B against ATO-induced cell apoptosis. In addition, the PI3K inhibitor partially blocked the effects of Sal B on the upregulation of Bcl-2 and Bcl-xl protein expression, and downregulation of Bax protein expression. Collectively, the results showed that Sal B decreased the apoptosis and necrosis of H9c2 cardiomyocytes caused by ATO treatment, and PI3K played a crucial role in enhancing cell survival during this process. These observations indicate that Sal B has the potential to exert cardioprotective effects against ATO toxicity.</text>
      <sentence>
        <offset>0</offset>
        <text>Cardioprotective effect of salvianolic acid B against arsenic trioxide-induced injury in cardiac H9c2 cells via the PI3K/Akt signal pathway.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salvianolic acid b</infon>
          <location offset="27" length="18"/>
          <text>salvianolic acid B</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arsenic trioxide</infon>
          <location offset="54" length="16"/>
          <text>arsenic trioxide</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="116" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="121" length="3"/>
          <text>Akt</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>141</offset>
        <text>The clinical use of arsenic trioxide (ATO), a potent anti-neoplastic agent, is often limited because of its severe cardiotoxicity.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arsenic trioxide</infon>
          <location offset="161" length="16"/>
          <text>arsenic trioxide</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="179" length="3"/>
          <text>ATO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>272</offset>
        <text>Salviae miltiorrhiza is widely used for the treatment of cardiovascular diseases.</text>
      </sentence>
      <sentence>
        <offset>354</offset>
        <text>One of the most abundant ingredients of S. miltiorrhiza is salvianolic acid B (Sal B).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salvianolic acid b</infon>
          <location offset="413" length="18"/>
          <text>salvianolic acid B</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sal b</infon>
          <location offset="433" length="5"/>
          <text>Sal B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>441</offset>
        <text>The present study was designed to evaluate whether Sal B protects against ATO-induced cardiac cell injury in vitro.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sal b</infon>
          <location offset="492" length="5"/>
          <text>Sal B</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="515" length="3"/>
          <text>ATO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>557</offset>
        <text>With MTT cell viability assay, LDH release, ROS generation, caspase-3 activity assay and Hoechst 33342/PI staining, we found that Sal B pretreatment provided significantly protection against ATO-induced cell death.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mtt</infon>
          <location offset="562" length="3"/>
          <text>MTT</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hoechst 33342</infon>
          <location offset="646" length="13"/>
          <text>Hoechst 33342</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sal b</infon>
          <location offset="687" length="5"/>
          <text>Sal B</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="748" length="3"/>
          <text>ATO</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldh</infon>
          <location offset="588" length="3"/>
          <text>LDH</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="617" length="9"/>
          <text>caspase-3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>772</offset>
        <text>The effect was correlated with the activation of the PI3K/Akt signal pathway.</text>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="825" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="830" length="3"/>
          <text>Akt</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>850</offset>
        <text>Conversely, blocking Akt activation with the PI3K inhibitor LY294002 effectively suppressed the protective effect of Sal B against ATO-induced cell apoptosis.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ly294002</infon>
          <location offset="910" length="8"/>
          <text>LY294002</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sal b</infon>
          <location offset="967" length="5"/>
          <text>Sal B</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="981" length="3"/>
          <text>ATO</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="871" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="895" length="4"/>
          <text>PI3K</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1009</offset>
        <text>In addition, the PI3K inhibitor partially blocked the effects of Sal B on the upregulation of Bcl-2 and Bcl-xl protein expression, and downregulation of Bax protein expression.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sal b</infon>
          <location offset="1074" length="5"/>
          <text>Sal B</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="1162" length="3"/>
          <text>Bax</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="1026" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="1103" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-xl</infon>
          <location offset="1113" length="6"/>
          <text>Bcl-xl</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1186</offset>
        <text>Collectively, the results showed that Sal B decreased the apoptosis and necrosis of H9c2 cardiomyocytes caused by ATO treatment, and PI3K played a crucial role in enhancing cell survival during this process.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sal b</infon>
          <location offset="1224" length="5"/>
          <text>Sal B</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="1300" length="3"/>
          <text>ATO</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="1319" length="4"/>
          <text>PI3K</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1394</offset>
        <text>These observations indicate that Sal B has the potential to exert cardioprotective effects against ATO toxicity.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sal b</infon>
          <location offset="1427" length="5"/>
          <text>Sal B</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="1493" length="3"/>
          <text>ATO</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15639300</id>
    <passage>
      <offset>0</offset>
      <text>Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.	Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrations of cyclic AMP, which has a broad range of anti-inflammatory effects on various key effector cells involved in asthma and chronic obstructive pulmonary disease (COPD). The therapeutic ratio for PDE4 inhibitors is thought to be determined by selectivity on receptor subtypes for relative effects on PDE4B (anti-inflammatory) and PDE4D (emesis). The two main orally active PDE4 inhibitors in the late phase III of clinical development are cilomilast and roflumilast; the latter (and its active metabolite N-oxide) is more selective and potent with a superior therapeutic ratio. Studies on cilomilast in COPD based on bronchial biopsy material have shown a broad range of anti-inflammatory activity, and the available evidence on clinical outcomes for up to 6 months with cilomilast 15 mg twice daily and roflumilast 500 mug once daily have shown variable but significant effects on exacerbations and quality of life, with small improvements in measures of pulmonary function. Roflumilast has a better safety and tolerability profile than cilomilast, with the main adverse effects being nausea, diarrhoea, and abdominal pain. Roflumilast also has activity in asthma as assessed by its attenuation of allergen and exercise challenges, and it shows clinical efficacy equivalent to that of beclomethasone dipropionate 400 mug daily. The emerging results of clinical trials on PDE4 inhibitors in asthma and COPD should be interpreted with cautious optimism since much of the evidence has been published only in abstract form to date. The next few years should resolve important issues about the potential role of these drugs as oral non-steroidal anti-inflammatory therapy for asthma and COPD and their place in management guidelines. Ultimately, clinicians will want to know whether PDE4 inhibitors are anything more than expensive "designer" theophylline, the archetypal non-selective phosphodiesterase inhibitor.</text>
      <sentence>
        <offset>0</offset>
        <text>Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.</text>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphodiesterase-4</infon>
          <location offset="0" length="19"/>
          <text>Phosphodiesterase-4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>85</offset>
        <text>Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrations of cyclic AMP, which has a broad range of anti-inflammatory effects on various key effector cells involved in asthma and chronic obstructive pulmonary disease (COPD).</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclic amp</infon>
          <location offset="181" length="10"/>
          <text>cyclic AMP</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphodiesterase type 4</infon>
          <location offset="99" length="24"/>
          <text>phosphodiesterase type 4</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pde4</infon>
          <location offset="125" length="4"/>
          <text>PDE4</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>345</offset>
        <text>The therapeutic ratio for PDE4 inhibitors is thought to be determined by selectivity on receptor subtypes for relative effects on PDE4B (anti-inflammatory) and PDE4D (emesis).</text>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pde4</infon>
          <location offset="371" length="4"/>
          <text>PDE4</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde4b</infon>
          <location offset="475" length="5"/>
          <text>PDE4B</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde4d</infon>
          <location offset="505" length="5"/>
          <text>PDE4D</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>521</offset>
        <text>The two main orally active PDE4 inhibitors in the late phase III of clinical development are cilomilast and roflumilast; the latter (and its active metabolite N-oxide) is more selective and potent with a superior therapeutic ratio.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cilomilast</infon>
          <location offset="614" length="10"/>
          <text>cilomilast</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">roflumilast</infon>
          <location offset="629" length="11"/>
          <text>roflumilast</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-oxide</infon>
          <location offset="680" length="7"/>
          <text>N-oxide</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pde4</infon>
          <location offset="548" length="4"/>
          <text>PDE4</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>753</offset>
        <text>Studies on cilomilast in COPD based on bronchial biopsy material have shown a broad range of anti-inflammatory activity, and the available evidence on clinical outcomes for up to 6 months with cilomilast 15 mg twice daily and roflumilast 500 mug once daily have shown variable but significant effects on exacerbations and quality of life, with small improvements in measures of pulmonary function.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cilomilast</infon>
          <location offset="764" length="10"/>
          <text>cilomilast</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cilomilast</infon>
          <location offset="946" length="10"/>
          <text>cilomilast</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">roflumilast</infon>
          <location offset="979" length="11"/>
          <text>roflumilast</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1151</offset>
        <text>Roflumilast has a better safety and tolerability profile than cilomilast, with the main adverse effects being nausea, diarrhoea, and abdominal pain.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">roflumilast</infon>
          <location offset="1151" length="11"/>
          <text>Roflumilast</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cilomilast</infon>
          <location offset="1213" length="10"/>
          <text>cilomilast</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1300</offset>
        <text>Roflumilast also has activity in asthma as assessed by its attenuation of allergen and exercise challenges, and it shows clinical efficacy equivalent to that of beclomethasone dipropionate 400 mug daily.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">roflumilast</infon>
          <location offset="1300" length="11"/>
          <text>Roflumilast</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">beclomethasone dipropionate</infon>
          <location offset="1461" length="27"/>
          <text>beclomethasone dipropionate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1504</offset>
        <text>The emerging results of clinical trials on PDE4 inhibitors in asthma and COPD should be interpreted with cautious optimism since much of the evidence has been published only in abstract form to date.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pde4</infon>
          <location offset="1547" length="4"/>
          <text>PDE4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1704</offset>
        <text>The next few years should resolve important issues about the potential role of these drugs as oral non-steroidal anti-inflammatory therapy for asthma and COPD and their place in management guidelines.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroidal</infon>
          <location offset="1807" length="9"/>
          <text>steroidal</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1905</offset>
        <text>Ultimately, clinicians will want to know whether PDE4 inhibitors are anything more than expensive "designer" theophylline, the archetypal non-selective phosphodiesterase inhibitor.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">theophylline</infon>
          <location offset="2014" length="12"/>
          <text>theophylline</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pde4</infon>
          <location offset="1954" length="4"/>
          <text>PDE4</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphodiesterase</infon>
          <location offset="2057" length="17"/>
          <text>phosphodiesterase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17275903</id>
    <passage>
      <offset>0</offset>
      <text>Hypoxia and lactate production in trophoblast cells.	The etiology of preeclampsia is unknown but is thought to be related to hypoxia in the placenta. We previously reported that the enzyme lactate dehydrogenase (LDH) has increased activity and gene expression in placentas from preeclamptic pregnancies [Tsoi SCM, Zheng J, Xu F, Kay HH. Differential expression of lactate dehydrogenase isozymes (LDH) in human placenta with high expression of LDH-A(4) isozyme in the endothelial cells of pre-eclampsia villi. Placenta 2001;22:317-22]. LDH is responsible for pyruvate conversion to lactate through glycolysis. In this study, we further investigated the role of hypoxia in primary trophoblast cells and a cultured cell line, JEG3 cells, to obtain a better understanding of how it affects the activities of lactate dehydrogenase, lactate production and regulatory genes, as a possible model for preeclampsia. Primary trophoblast cells and JEG3 cells were cultured under 1% oxygen. At 6, 12 and 24h, cells were analyzed for LDHA and LDHB isozyme activities, mRNA and protein expression compared to standard culture conditions. Lactate was measured from cell medium. The hypoxia inducible transcription factor (HIF-1alpha) protein expression was confirmed by western blot. Two lactate transporters (MCT1 and MCT4) mRNA and protein expression were also studied under hypoxia. Finally, lactate was measured in plasma obtained from patients with severe preeclampsia. Under hypoxic conditions, LDHA mRNA is increased in primary trophoblast cells and JEG3 cells. The HIF-1alpha protein expression is higher in hypoxia-treated JEG3 cells than control. LDHA isozyme activity and its protein expression are increased most significantly at 24h of culture under hypoxia. However, LDHB protein is unchanged while its mRNA is decreased. Lactate secretion from JEG3 cells under hypoxia is increased, as is the lactate levels in the plasma from preeclampsia patients. Of the two lactate transporters studied, MCT4 mRNA and protein level are increased under hypoxia. Our findings support the role of hypoxia in inducing HIF-1alpha activity in trophoblasts and increasing LDH transcription as well as its activity. Higher levels of lactate are produced and secreted which may contribute to the higher lactate levels in plasma of preeclamptic patients. These mechanisms may be important in the pathophysiology of preeclampsia.</text>
      <sentence>
        <offset>0</offset>
        <text>Hypoxia and lactate production in trophoblast cells.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="12" length="7"/>
          <text>lactate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>53</offset>
        <text>The etiology of preeclampsia is unknown but is thought to be related to hypoxia in the placenta.</text>
      </sentence>
      <sentence>
        <offset>150</offset>
        <text>We previously reported that the enzyme lactate dehydrogenase (LDH) has increased activity and gene expression in placentas from preeclamptic pregnancies [Tsoi SCM, Zheng J, Xu F, Kay HH.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="189" length="7"/>
          <text>lactate</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lactate dehydrogenase</infon>
          <location offset="189" length="21"/>
          <text>lactate dehydrogenase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldh</infon>
          <location offset="212" length="3"/>
          <text>LDH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>337</offset>
        <text>Differential expression of lactate dehydrogenase isozymes (LDH) in human placenta with high expression of LDH-A(4) isozyme in the endothelial cells of pre-eclampsia villi.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="364" length="7"/>
          <text>lactate</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lactate dehydrogenase</infon>
          <location offset="364" length="21"/>
          <text>lactate dehydrogenase</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldh</infon>
          <location offset="396" length="3"/>
          <text>LDH</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldh-a(4)</infon>
          <location offset="443" length="8"/>
          <text>LDH-A(4)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>509</offset>
        <text>Placenta 2001;22:317-22].</text>
      </sentence>
      <sentence>
        <offset>535</offset>
        <text>LDH is responsible for pyruvate conversion to lactate through glycolysis.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyruvate</infon>
          <location offset="558" length="8"/>
          <text>pyruvate</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="581" length="7"/>
          <text>lactate</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldh</infon>
          <location offset="535" length="3"/>
          <text>LDH</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T12" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>609</offset>
        <text>In this study, we further investigated the role of hypoxia in primary trophoblast cells and a cultured cell line, JEG3 cells, to obtain a better understanding of how it affects the activities of lactate dehydrogenase, lactate production and regulatory genes, as a possible model for preeclampsia.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="804" length="7"/>
          <text>lactate</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="827" length="7"/>
          <text>lactate</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lactate dehydrogenase</infon>
          <location offset="804" length="21"/>
          <text>lactate dehydrogenase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>906</offset>
        <text>Primary trophoblast cells and JEG3 cells were cultured under 1% oxygen.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="970" length="6"/>
          <text>oxygen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>978</offset>
        <text>At 6, 12 and 24h, cells were analyzed for LDHA and LDHB isozyme activities, mRNA and protein expression compared to standard culture conditions.</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldha</infon>
          <location offset="1020" length="4"/>
          <text>LDHA</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldhb</infon>
          <location offset="1029" length="4"/>
          <text>LDHB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1123</offset>
        <text>Lactate was measured from cell medium.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="1123" length="7"/>
          <text>Lactate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1162</offset>
        <text>The hypoxia inducible transcription factor (HIF-1alpha) protein expression was confirmed by western blot.</text>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hypoxia inducible transcription factor</infon>
          <location offset="1166" length="38"/>
          <text>hypoxia inducible transcription factor</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif-1alpha</infon>
          <location offset="1206" length="10"/>
          <text>HIF-1alpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1268</offset>
        <text>Two lactate transporters (MCT1 and MCT4) mRNA and protein expression were also studied under hypoxia.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="1272" length="7"/>
          <text>lactate</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lactate transporters</infon>
          <location offset="1272" length="20"/>
          <text>lactate transporters</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mct1</infon>
          <location offset="1294" length="4"/>
          <text>MCT1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mct4</infon>
          <location offset="1303" length="4"/>
          <text>MCT4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1370</offset>
        <text>Finally, lactate was measured in plasma obtained from patients with severe preeclampsia.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="1379" length="7"/>
          <text>lactate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1459</offset>
        <text>Under hypoxic conditions, LDHA mRNA is increased in primary trophoblast cells and JEG3 cells.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldha</infon>
          <location offset="1485" length="4"/>
          <text>LDHA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1553</offset>
        <text>The HIF-1alpha protein expression is higher in hypoxia-treated JEG3 cells than control.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif-1alpha</infon>
          <location offset="1557" length="10"/>
          <text>HIF-1alpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1641</offset>
        <text>LDHA isozyme activity and its protein expression are increased most significantly at 24h of culture under hypoxia.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldha</infon>
          <location offset="1641" length="4"/>
          <text>LDHA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1756</offset>
        <text>However, LDHB protein is unchanged while its mRNA is decreased.</text>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldhb</infon>
          <location offset="1765" length="4"/>
          <text>LDHB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1820</offset>
        <text>Lactate secretion from JEG3 cells under hypoxia is increased, as is the lactate levels in the plasma from preeclampsia patients.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="1820" length="7"/>
          <text>Lactate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="1892" length="7"/>
          <text>lactate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1949</offset>
        <text>Of the two lactate transporters studied, MCT4 mRNA and protein level are increased under hypoxia.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="1960" length="7"/>
          <text>lactate</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mct4</infon>
          <location offset="1990" length="4"/>
          <text>MCT4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2047</offset>
        <text>Our findings support the role of hypoxia in inducing HIF-1alpha activity in trophoblasts and increasing LDH transcription as well as its activity.</text>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif-1alpha</infon>
          <location offset="2100" length="10"/>
          <text>HIF-1alpha</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldh</infon>
          <location offset="2151" length="3"/>
          <text>LDH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2194</offset>
        <text>Higher levels of lactate are produced and secreted which may contribute to the higher lactate levels in plasma of preeclamptic patients.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="2211" length="7"/>
          <text>lactate</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="2280" length="7"/>
          <text>lactate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2331</offset>
        <text>These mechanisms may be important in the pathophysiology of preeclampsia.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23220560</id>
    <passage>
      <offset>0</offset>
      <text>Low level prenatal exposure to methylmercury disrupts neuronal migration in the developing rat cerebral cortex.	We determined the effects of low-level prenatal MeHg exposure on neuronal migration in the developing rat cerebral cortex using in utero electroporation. We used offspring rats born to dams that had been exposed to saline or various doses of MeHg (0.01 mg/kg/day, 0.1 mg/kg/day, and 1 mg/kg/day) from gestational day (GD) 11-21. Immunohistochemical examination of the brains of the offspring was conducted on postnatal day (PND) 0, PND3, and PND7. Our results showed that prenatal exposure to low levels of MeHg (0.1 mg/kg/day or 1 mg/kg/day) during the critical stage in neuronal migration resulted in migration defects of the cerebrocortical neurons in offspring rats. Importantly, our data revealed that the abnormal neuronal distribution induced by MeHg was not caused by altered proliferation of neural progenitor cells (NPCs), induction of apoptosis of NPCs and/or newborn neurons, abnormal differentiation of NPCs, and the morphological changes of radial glial scaffold, indicating that the defective neuronal positioning triggered by exposure to low-dose of MeHg is due to the impacts of MeHg on the process of neuronal migration itself. Moreover, we demonstrated that in utero exposure to low-level MeHg suppresses the expression of Rac1, Cdc42, and RhoA, which play key roles in the migration of cerebrocortical neurons during the early stage of brain development, suggesting that the MeHg-induced migratory disturbance of cerebrocortical neurons is likely associated with the Rho GTPases signal pathway. In conclusion, our results provide a novel perspective on clarifying the mechanisms underlying the impairment of neuronal migration induced by MeHg.</text>
      <sentence>
        <offset>0</offset>
        <text>Low level prenatal exposure to methylmercury disrupts neuronal migration in the developing rat cerebral cortex.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methylmercury</infon>
          <location offset="31" length="13"/>
          <text>methylmercury</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>112</offset>
        <text>We determined the effects of low-level prenatal MeHg exposure on neuronal migration in the developing rat cerebral cortex using in utero electroporation.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mehg</infon>
          <location offset="160" length="4"/>
          <text>MeHg</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>266</offset>
        <text>We used offspring rats born to dams that had been exposed to saline or various doses of MeHg (0.01 mg/kg/day, 0.1 mg/kg/day, and 1 mg/kg/day) from gestational day (GD) 11-21.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mehg</infon>
          <location offset="354" length="4"/>
          <text>MeHg</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>441</offset>
        <text>Immunohistochemical examination of the brains of the offspring was conducted on postnatal day (PND) 0, PND3, and PND7.</text>
      </sentence>
      <sentence>
        <offset>560</offset>
        <text>Our results showed that prenatal exposure to low levels of MeHg (0.1 mg/kg/day or 1 mg/kg/day) during the critical stage in neuronal migration resulted in migration defects of the cerebrocortical neurons in offspring rats.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mehg</infon>
          <location offset="619" length="4"/>
          <text>MeHg</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>783</offset>
        <text>Importantly, our data revealed that the abnormal neuronal distribution induced by MeHg was not caused by altered proliferation of neural progenitor cells (NPCs), induction of apoptosis of NPCs and/or newborn neurons, abnormal differentiation of NPCs, and the morphological changes of radial glial scaffold, indicating that the defective neuronal positioning triggered by exposure to low-dose of MeHg is due to the impacts of MeHg on the process of neuronal migration itself.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mehg</infon>
          <location offset="1178" length="4"/>
          <text>MeHg</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mehg</infon>
          <location offset="1208" length="4"/>
          <text>MeHg</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mehg</infon>
          <location offset="865" length="4"/>
          <text>MeHg</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1258</offset>
        <text>Moreover, we demonstrated that in utero exposure to low-level MeHg suppresses the expression of Rac1, Cdc42, and RhoA, which play key roles in the migration of cerebrocortical neurons during the early stage of brain development, suggesting that the MeHg-induced migratory disturbance of cerebrocortical neurons is likely associated with the Rho GTPases signal pathway.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mehg</infon>
          <location offset="1320" length="4"/>
          <text>MeHg</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mehg</infon>
          <location offset="1507" length="4"/>
          <text>MeHg</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rac1</infon>
          <location offset="1354" length="4"/>
          <text>Rac1</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cdc42</infon>
          <location offset="1360" length="5"/>
          <text>Cdc42</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="1371" length="4"/>
          <text>RhoA</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rho</infon>
          <location offset="1599" length="3"/>
          <text>Rho</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gtpases</infon>
          <location offset="1603" length="7"/>
          <text>GTPases</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1627</offset>
        <text>In conclusion, our results provide a novel perspective on clarifying the mechanisms underlying the impairment of neuronal migration induced by MeHg.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mehg</infon>
          <location offset="1770" length="4"/>
          <text>MeHg</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>9141486</id>
    <passage>
      <offset>0</offset>
      <text>Identification of a vitamin K-dependent carboxylase in the venom duct of a Conus snail.	Peptides from the venom ducts of cone snails (genus Conus) contain gamma-carboxyglutamate residues. The gamma-glutamyl carboxylase responsible for this post-translational modification is localized in the microsomal fraction, strictly dependent on vitamin K, activated by ammonium sulfate, and is associated with endogenous substrate. The K(m) of the enzyme for vitamin K is comparable to that for the bovine carboxylase. However, a propeptide containing substrate related to the blood coagulation protein factor IX, a highly efficient substrate for the bovine enzyme, was poorly carboxylated by the Conus enzyme, suggesting differences in gamma-carboxylase recognition signal sequences and/or structural requirements at the carboxylation site.</text>
      <sentence>
        <offset>0</offset>
        <text>Identification of a vitamin K-dependent carboxylase in the venom duct of a Conus snail.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin k</infon>
          <location offset="20" length="9"/>
          <text>vitamin K</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vitamin k-dependent carboxylase</infon>
          <location offset="20" length="31"/>
          <text>vitamin K-dependent carboxylase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>88</offset>
        <text>Peptides from the venom ducts of cone snails (genus Conus) contain gamma-carboxyglutamate residues.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gamma-carboxyglutamate</infon>
          <location offset="155" length="22"/>
          <text>gamma-carboxyglutamate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>188</offset>
        <text>The gamma-glutamyl carboxylase responsible for this post-translational modification is localized in the microsomal fraction, strictly dependent on vitamin K, activated by ammonium sulfate, and is associated with endogenous substrate.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gamma-glutamyl</infon>
          <location offset="192" length="14"/>
          <text>gamma-glutamyl</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin k</infon>
          <location offset="335" length="9"/>
          <text>vitamin K</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ammonium sulfate</infon>
          <location offset="359" length="16"/>
          <text>ammonium sulfate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gamma-glutamyl carboxylase</infon>
          <location offset="192" length="26"/>
          <text>gamma-glutamyl carboxylase</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>422</offset>
        <text>The K(m) of the enzyme for vitamin K is comparable to that for the bovine carboxylase.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin k</infon>
          <location offset="449" length="9"/>
          <text>vitamin K</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">bovine carboxylase</infon>
          <location offset="489" length="18"/>
          <text>bovine carboxylase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>509</offset>
        <text>However, a propeptide containing substrate related to the blood coagulation protein factor IX, a highly efficient substrate for the bovine enzyme, was poorly carboxylated by the Conus enzyme, suggesting differences in gamma-carboxylase recognition signal sequences and/or structural requirements at the carboxylation site.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="593" length="9"/>
          <text>factor IX</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gamma-carboxylase</infon>
          <location offset="727" length="17"/>
          <text>gamma-carboxylase</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23248200</id>
    <passage>
      <offset>0</offset>
      <text>Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1.	Organic anion-transporting polypeptide 1B1 (OATP1B1) is an important hepatic uptake transporter, of which the polymorphic variant OATP1B1*15 (Asn130Asp and Val174Ala) has been associated with decreased transport activity. Rosuvastatin is an OATP1B1 substrate and often concomitantly prescribed with oral antidiabetics in the clinic. The aim of this study was to investigate possible drug-drug interactions between these drugs at the level of OATP1B1 and OATP1B1*15. We generated human embryonic kidney (HEK)293 cells stably overexpressing OATP1B1 or OATP1B1*15 that showed similar protein expression levels of OATP1B1 and OATP1B1*15 at the cell membrane as measured by liquid chromatography-tandem mass spectrometry. In HEK-OATP1B1*15 cells, the V(max) for OATP1B1-mediated transport of E(2)17β-G (estradiol 17β-d-glucuronide) was decreased &gt;60%, whereas K(m) values (Michaelis constant) were comparable. Uptake of rosuvastatin in HEK-OATP1B1 cells (K(m) 13.1 ± 0.43 μM) was nearly absent in HEK-OATP1B1*15 cells. Interestingly, several oral antidiabetics (glyburide, glimepiride, troglitazone, pioglitazone, glipizide, gliclazide, and tolbutamide), but not metformin, were identified as significant inhibitors of the OATP1B1-mediated transport of rosuvastatin. The IC(50) values for inhibition of E(2)17β-G uptake were similar between OATP1B1 and OATP1B1*15. In conclusion, these studies indicate that several oral antidiabetic drugs affect the OATP1B1-mediated uptake of rosuvastatin in vitro. The next step will be to translate these data to the clinical situation, as it remains to be established whether the studied oral antidiabetics indeed affect the clinical pharmacokinetic profile of rosuvastatin in patients.</text>
      <sentence>
        <offset>0</offset>
        <text>Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="31" length="12"/>
          <text>rosuvastatin</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="98" length="7"/>
          <text>OATP1B1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>107</offset>
        <text>Organic anion-transporting polypeptide 1B1 (OATP1B1) is an important hepatic uptake transporter, of which the polymorphic variant OATP1B1*15 (Asn130Asp and Val174Ala) has been associated with decreased transport activity.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">organic anion-transporting polypeptide 1b1</infon>
          <location offset="107" length="42"/>
          <text>Organic anion-transporting polypeptide 1B1</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="237" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asn130asp</infon>
          <location offset="249" length="9"/>
          <text>Asn130Asp</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">val174ala</infon>
          <location offset="263" length="9"/>
          <text>Val174Ala</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="151" length="7"/>
          <text>OATP1B1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>329</offset>
        <text>Rosuvastatin is an OATP1B1 substrate and often concomitantly prescribed with oral antidiabetics in the clinic.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="329" length="12"/>
          <text>Rosuvastatin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="348" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>440</offset>
        <text>The aim of this study was to investigate possible drug-drug interactions between these drugs at the level of OATP1B1 and OATP1B1*15.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="549" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="561" length="7"/>
          <text>OATP1B1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>573</offset>
        <text>We generated human embryonic kidney (HEK)293 cells stably overexpressing OATP1B1 or OATP1B1*15 that showed similar protein expression levels of OATP1B1 and OATP1B1*15 at the cell membrane as measured by liquid chromatography-tandem mass spectrometry.</text>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="646" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="657" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="717" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="729" length="7"/>
          <text>OATP1B1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>824</offset>
        <text>In HEK-OATP1B1*15 cells, the V(max) for OATP1B1-mediated transport of E(2)17β-G (estradiol 17β-d-glucuronide) was decreased &gt;60%, whereas K(m) values (Michaelis constant) were comparable.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estradiol 17β-d-glucuronide</infon>
          <location offset="905" length="27"/>
          <text>estradiol 17β-d-glucuronide</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="831" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="864" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T14" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1012</offset>
        <text>Uptake of rosuvastatin in HEK-OATP1B1 cells (K(m) 13.1 ± 0.43 μM) was nearly absent in HEK-OATP1B1*15 cells.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="1022" length="12"/>
          <text>rosuvastatin</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="1042" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="1103" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T15" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1121</offset>
        <text>Interestingly, several oral antidiabetics (glyburide, glimepiride, troglitazone, pioglitazone, glipizide, gliclazide, and tolbutamide), but not metformin, were identified as significant inhibitors of the OATP1B1-mediated transport of rosuvastatin.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glyburide</infon>
          <location offset="1164" length="9"/>
          <text>glyburide</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glimepiride</infon>
          <location offset="1175" length="11"/>
          <text>glimepiride</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1188" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pioglitazone</infon>
          <location offset="1202" length="12"/>
          <text>pioglitazone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glipizide</infon>
          <location offset="1216" length="9"/>
          <text>glipizide</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gliclazide</infon>
          <location offset="1227" length="10"/>
          <text>gliclazide</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tolbutamide</infon>
          <location offset="1243" length="11"/>
          <text>tolbutamide</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="1265" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="1355" length="12"/>
          <text>rosuvastatin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="1325" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T9" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1369</offset>
        <text>The IC(50) values for inhibition of E(2)17β-G uptake were similar between OATP1B1 and OATP1B1*15.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">e(2)17β-g</infon>
          <location offset="1405" length="9"/>
          <text>E(2)17β-G</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="1443" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="1455" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1467</offset>
        <text>In conclusion, these studies indicate that several oral antidiabetic drugs affect the OATP1B1-mediated uptake of rosuvastatin in vitro.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="1580" length="12"/>
          <text>rosuvastatin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="1553" length="7"/>
          <text>OATP1B1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1603</offset>
        <text>The next step will be to translate these data to the clinical situation, as it remains to be established whether the studied oral antidiabetics indeed affect the clinical pharmacokinetic profile of rosuvastatin in patients.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="1801" length="12"/>
          <text>rosuvastatin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23570561</id>
    <passage>
      <offset>0</offset>
      <text>Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors.	RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (∼7 mmHg). (22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.</text>
      <sentence>
        <offset>0</offset>
        <text>Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">urea</infon>
          <location offset="39" length="4"/>
          <text>Urea</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rho kinase</infon>
          <location offset="87" length="10"/>
          <text>Rho Kinase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>110</offset>
        <text>RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC).</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="110" length="4"/>
          <text>RhoA</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">myosin light chain</infon>
          <location offset="248" length="18"/>
          <text>myosin light chain</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mlc</infon>
          <location offset="268" length="3"/>
          <text>MLC</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rock</infon>
          <location offset="143" length="4"/>
          <text>ROCK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>274</offset>
        <text>Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rhoa</infon>
          <location offset="292" length="4"/>
          <text>RhoA</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rock</infon>
          <location offset="297" length="4"/>
          <text>ROCK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>440</offset>
        <text>In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">urea</infon>
          <location offset="468" length="4"/>
          <text>urea</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rock</infon>
          <location offset="479" length="4"/>
          <text>ROCK</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>529</offset>
        <text>These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (∼7 mmHg).</text>
      </sentence>
      <sentence>
        <offset>685</offset>
        <text>(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">urea</infon>
          <location offset="901" length="4"/>
          <text>urea</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rock</infon>
          <location offset="715" length="4"/>
          <text>ROCK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>934</offset>
        <text>The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed.</text>
      </sentence>
      <sentence>
        <offset>1041</offset>
        <text>Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.</text>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rock</infon>
          <location offset="1062" length="4"/>
          <text>ROCK</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1472079</id>
    <passage>
      <offset>0</offset>
      <text>Mechanism of cadmium-decreased glucuronidation in the rat.	In isolated rat hepatocytes, cadmium (0-200 microM) decreased the overall glucuronidation of both isopropyl N-(3-chloro-4 hydroxyphenyl)carbamate (4-hydroxychlorpropham, 4-OHCIPC) and 4-nitrophenol in a concentration-dependent manner. In contrast, in native rat liver microsomes, glucuronidation of 4-OHCIPC was increased by cadmium through activation of microsomal 4-OHCIPC glucuronosyl transferase. In addition, in rat microsome incubations, the net amount of 4-OHCIPC glucuronide was also indirectly increased by cadmium through a reduction in the activity of beta-glucuronidase. As the effect of cadmium on the activity of 4-OHCIPC glucuronosyl transferase could not account for the decrease in glucuronide formation in intact hepatocytes, the influence of cadmium on the availability of UDP-glucuronic acid (UDPGA) was investigated further. In isolated rat hepatocytes, cadmium depleted the UDPGA content in a dose-dependent manner without a change in the UDP glucose (UDPG) content. Cadmium did not increase the breakdown of UDPGA by microsomal UDPGA pyrophosphatase but strongly decreased (30-66%) the synthesis of the cofactor in the cytosol by inhibiting UDP-glucose dehydrogenase (UDPGDH). Cadmium (10-50 microM) was found to inhibit the purified enzyme from bovine liver (EC 1.1.1.22) non-competitively. In vivo in the absence of a substrate undergoing glucuronidation, cadmium administration, 1.5 and 2.5 mg Cd/kg i.v., to normally fed rats resulted in a 15 and 30% decrease of hepatic UDPGA, respectively. However, in the liver, neither the NAD+/NADH ratio nor the UDPG content was significantly changed following cadmium treatment. Both in vitro and in vivo results support the conclusion that in intact cells the reduction in overall 4-OHCIPC glucuronidation caused by cadmium was due to a decrease in UDPGA availability which results from the inhibiting effect of cadmium on UDPGDH.</text>
      <sentence>
        <offset>0</offset>
        <text>Mechanism of cadmium-decreased glucuronidation in the rat.</text>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="13" length="7"/>
          <text>cadmium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>59</offset>
        <text>In isolated rat hepatocytes, cadmium (0-200 microM) decreased the overall glucuronidation of both isopropyl N-(3-chloro-4 hydroxyphenyl)carbamate (4-hydroxychlorpropham, 4-OHCIPC) and 4-nitrophenol in a concentration-dependent manner.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-hydroxychlorpropham</infon>
          <location offset="206" length="21"/>
          <text>4-hydroxychlorpropham</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-ohcipc</infon>
          <location offset="229" length="8"/>
          <text>4-OHCIPC</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-nitrophenol</infon>
          <location offset="243" length="13"/>
          <text>4-nitrophenol</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="88" length="7"/>
          <text>cadmium</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isopropyl n-(3-chloro-4 hydroxyphenyl)carbamate</infon>
          <location offset="157" length="47"/>
          <text>isopropyl N-(3-chloro-4 hydroxyphenyl)carbamate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>294</offset>
        <text>In contrast, in native rat liver microsomes, glucuronidation of 4-OHCIPC was increased by cadmium through activation of microsomal 4-OHCIPC glucuronosyl transferase.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-ohcipc</infon>
          <location offset="358" length="8"/>
          <text>4-OHCIPC</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="384" length="7"/>
          <text>cadmium</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-ohcipc glucuronosyl</infon>
          <location offset="425" length="21"/>
          <text>4-OHCIPC glucuronosyl</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glucuronosyl transferase</infon>
          <location offset="434" length="24"/>
          <text>glucuronosyl transferase</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T19" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>460</offset>
        <text>In addition, in rat microsome incubations, the net amount of 4-OHCIPC glucuronide was also indirectly increased by cadmium through a reduction in the activity of beta-glucuronidase.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-ohcipc glucuronide</infon>
          <location offset="521" length="20"/>
          <text>4-OHCIPC glucuronide</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="575" length="7"/>
          <text>cadmium</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta-glucuronidase</infon>
          <location offset="622" length="18"/>
          <text>beta-glucuronidase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T22" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>642</offset>
        <text>As the effect of cadmium on the activity of 4-OHCIPC glucuronosyl transferase could not account for the decrease in glucuronide formation in intact hepatocytes, the influence of cadmium on the availability of UDP-glucuronic acid (UDPGA) was investigated further.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="659" length="7"/>
          <text>cadmium</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-ohcipc glucuronosyl</infon>
          <location offset="686" length="21"/>
          <text>4-OHCIPC glucuronosyl</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucuronide</infon>
          <location offset="758" length="11"/>
          <text>glucuronide</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="820" length="7"/>
          <text>cadmium</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp-glucuronic acid</infon>
          <location offset="851" length="19"/>
          <text>UDP-glucuronic acid</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udpga</infon>
          <location offset="872" length="5"/>
          <text>UDPGA</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glucuronosyl transferase</infon>
          <location offset="695" length="24"/>
          <text>glucuronosyl transferase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>905</offset>
        <text>In isolated rat hepatocytes, cadmium depleted the UDPGA content in a dose-dependent manner without a change in the UDP glucose (UDPG) content.</text>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="934" length="7"/>
          <text>cadmium</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udpga</infon>
          <location offset="955" length="5"/>
          <text>UDPGA</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp glucose</infon>
          <location offset="1020" length="11"/>
          <text>UDP glucose</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udpg</infon>
          <location offset="1033" length="4"/>
          <text>UDPG</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1048</offset>
        <text>Cadmium did not increase the breakdown of UDPGA by microsomal UDPGA pyrophosphatase but strongly decreased (30-66%) the synthesis of the cofactor in the cytosol by inhibiting UDP-glucose dehydrogenase (UDPGDH).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udpga</infon>
          <location offset="1090" length="5"/>
          <text>UDPGA</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udpga</infon>
          <location offset="1110" length="5"/>
          <text>UDPGA</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp-glucose</infon>
          <location offset="1223" length="11"/>
          <text>UDP-glucose</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="1048" length="7"/>
          <text>Cadmium</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pyrophosphatase</infon>
          <location offset="1116" length="15"/>
          <text>pyrophosphatase</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">udp-glucose dehydrogenase</infon>
          <location offset="1223" length="25"/>
          <text>UDP-glucose dehydrogenase</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">udpgdh</infon>
          <location offset="1250" length="6"/>
          <text>UDPGDH</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T35" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T35" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1259</offset>
        <text>Cadmium (10-50 microM) was found to inhibit the purified enzyme from bovine liver (EC 1.1.1.22) non-competitively.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="1259" length="7"/>
          <text>Cadmium</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ec 1.1.1.22</infon>
          <location offset="1342" length="11"/>
          <text>EC 1.1.1.22</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1374</offset>
        <text>In vivo in the absence of a substrate undergoing glucuronidation, cadmium administration, 1.5 and 2.5 mg Cd/kg i.v., to normally fed rats resulted in a 15 and 30% decrease of hepatic UDPGA, respectively.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="1440" length="7"/>
          <text>cadmium</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udpga</infon>
          <location offset="1557" length="5"/>
          <text>UDPGA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1578</offset>
        <text>However, in the liver, neither the NAD+/NADH ratio nor the UDPG content was significantly changed following cadmium treatment.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nad+</infon>
          <location offset="1613" length="4"/>
          <text>NAD+</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadh</infon>
          <location offset="1618" length="4"/>
          <text>NADH</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udpg</infon>
          <location offset="1637" length="4"/>
          <text>UDPG</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="1686" length="7"/>
          <text>cadmium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1705</offset>
        <text>Both in vitro and in vivo results support the conclusion that in intact cells the reduction in overall 4-OHCIPC glucuronidation caused by cadmium was due to a decrease in UDPGA availability which results from the inhibiting effect of cadmium on UDPGDH.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-ohcipc</infon>
          <location offset="1808" length="8"/>
          <text>4-OHCIPC</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="1843" length="7"/>
          <text>cadmium</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udpga</infon>
          <location offset="1876" length="5"/>
          <text>UDPGA</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="1939" length="7"/>
          <text>cadmium</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">udpgdh</infon>
          <location offset="1950" length="6"/>
          <text>UDPGDH</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23489976</id>
    <passage>
      <offset>0</offset>
      <text>Light at Night Alters Daily Patterns of Cortisol and Clock Proteins in Female Siberian Hamsters.	Humans and other organisms have adapted to a 24-h solar cycle in response to life on Earth. The rotation of the planet on its axis and its revolution around the sun cause predictable daily and seasonal patterns in day length. In order to successfully anticipate and adapt to these patterns in the environment, a variety of biological processes oscillate with a daily rhythm approximately 24 h in length. These rhythms arise from hierarchally-coupled cellular clocks generated by positive and negative transcription factors of core circadian clock gene expression. From these endogenous cellular clocks, overt rhythms in activity and patterns in hormone secretion and other homeostatic processes emerge. These circadian rhythms in physiology and behavior can be organized by a variety of cues, but they are most potently entrained by light. In recent history, there has been a major change from naturally occurring light cycles set by the sun, to artificial and sometimes erratic light cycles determined by the use of electric lighting. Virtually every individual living in an industrialized country experiences light at night (LAN), but despite its prevalence, the biological effects of such unnatural lighting have not been fully considered. Using female Siberian hamsters (Phodopus sungorus), we investigated the effects of chronic nightly exposure to dim light on daily rhythms in locomotor activity, serum cortisol concentrations, and brain expression of circadian clock proteins (i.e., PER1, PER2, BMAL1). Although locomotor activity remained entrained to the light cycle, the diurnal fluctuation of cortisol concentrations was blunted and the expression patterns of clock proteins in the SCN and hippocampus were altered. These results demonstrate that chronic exposure to dim LAN can dramatically affect fundamental cellular function and emergent physiology. © 2013 British Society for Neuroendocrinology.</text>
      <sentence>
        <offset>0</offset>
        <text>Light at Night Alters Daily Patterns of Cortisol and Clock Proteins in Female Siberian Hamsters.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cortisol</infon>
          <location offset="40" length="8"/>
          <text>Cortisol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">clock proteins</infon>
          <location offset="53" length="14"/>
          <text>Clock Proteins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>97</offset>
        <text>Humans and other organisms have adapted to a 24-h solar cycle in response to life on Earth.</text>
      </sentence>
      <sentence>
        <offset>189</offset>
        <text>The rotation of the planet on its axis and its revolution around the sun cause predictable daily and seasonal patterns in day length.</text>
      </sentence>
      <sentence>
        <offset>323</offset>
        <text>In order to successfully anticipate and adapt to these patterns in the environment, a variety of biological processes oscillate with a daily rhythm approximately 24 h in length.</text>
      </sentence>
      <sentence>
        <offset>501</offset>
        <text>These rhythms arise from hierarchally-coupled cellular clocks generated by positive and negative transcription factors of core circadian clock gene expression.</text>
      </sentence>
      <sentence>
        <offset>661</offset>
        <text>From these endogenous cellular clocks, overt rhythms in activity and patterns in hormone secretion and other homeostatic processes emerge.</text>
      </sentence>
      <sentence>
        <offset>800</offset>
        <text>These circadian rhythms in physiology and behavior can be organized by a variety of cues, but they are most potently entrained by light.</text>
      </sentence>
      <sentence>
        <offset>937</offset>
        <text>In recent history, there has been a major change from naturally occurring light cycles set by the sun, to artificial and sometimes erratic light cycles determined by the use of electric lighting.</text>
      </sentence>
      <sentence>
        <offset>1133</offset>
        <text>Virtually every individual living in an industrialized country experiences light at night (LAN), but despite its prevalence, the biological effects of such unnatural lighting have not been fully considered.</text>
      </sentence>
      <sentence>
        <offset>1340</offset>
        <text>Using female Siberian hamsters (Phodopus sungorus), we investigated the effects of chronic nightly exposure to dim light on daily rhythms in locomotor activity, serum cortisol concentrations, and brain expression of circadian clock proteins (i.e., PER1, PER2, BMAL1).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cortisol</infon>
          <location offset="1507" length="8"/>
          <text>cortisol</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">circadian clock proteins</infon>
          <location offset="1556" length="24"/>
          <text>circadian clock proteins</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">per1</infon>
          <location offset="1588" length="4"/>
          <text>PER1</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">per2</infon>
          <location offset="1594" length="4"/>
          <text>PER2</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bmal1</infon>
          <location offset="1600" length="5"/>
          <text>BMAL1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1608</offset>
        <text>Although locomotor activity remained entrained to the light cycle, the diurnal fluctuation of cortisol concentrations was blunted and the expression patterns of clock proteins in the SCN and hippocampus were altered.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cortisol</infon>
          <location offset="1702" length="8"/>
          <text>cortisol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">clock proteins</infon>
          <location offset="1769" length="14"/>
          <text>clock proteins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1825</offset>
        <text>These results demonstrate that chronic exposure to dim LAN can dramatically affect fundamental cellular function and emergent physiology.</text>
      </sentence>
      <sentence>
        <offset>1963</offset>
        <text>© 2013 British Society for Neuroendocrinology.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11936838</id>
    <passage>
      <offset>0</offset>
      <text>Inhibition of MCP-1 and MIP-2 transcription and translation by mimosine in muscle tissue infected with the parasite Trichinella spiralis.	Mimosine is a non-toxic plant aminoacid which is an effective inhibitor of DNA replication by acting at the S-phase. In this study we infected mice with T. spiralis, a nematode parasite, and studied the inflammatory response through the determination of MIP-2, a C-X-C chemokine and MCP-1, a C-C chemokine in the inflamed area around the parasitic cyst. The animals were infected and their diaphragms were tested for inflammatory response. MCP-1 and MIP-2 was tested after 1, 10, 20, 30, and 40 days post inoculation, before and after mimosine treatment. The inflammatory index was calculated by counting the white blood cells around the nematode cysts, while expression of MIP-2 and MCP-1 was calculated by ELISA method and transcription by Northern blot and RT-PCR. Here we found that mimosine strongly inhibited the inflammatory index in the diaphragmatic tissue at 10, 20, 30 and 40 days post-treatment. In these experiments, mimosine had no effect on the number of cysts produced. In addition, we found that MCP-1 transcription and translation was completely inhibited by mimosine, while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T. spiralis. Our studies suggest that mimosine has an inhibitory effect through the inhibition of cytoplasmatic serine hydroxymethyltransferase altering the cell cycle of white blood cells. This study suggests for the first time the premise that mimosine acts as an anti-inflammatory compound.</text>
      <sentence>
        <offset>0</offset>
        <text>Inhibition of MCP-1 and MIP-2 transcription and translation by mimosine in muscle tissue infected with the parasite Trichinella spiralis.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mimosine</infon>
          <location offset="63" length="8"/>
          <text>mimosine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="14" length="5"/>
          <text>MCP-1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mip-2</infon>
          <location offset="24" length="5"/>
          <text>MIP-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>138</offset>
        <text>Mimosine is a non-toxic plant aminoacid which is an effective inhibitor of DNA replication by acting at the S-phase.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mimosine</infon>
          <location offset="138" length="8"/>
          <text>Mimosine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aminoacid</infon>
          <location offset="168" length="9"/>
          <text>aminoacid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>255</offset>
        <text>In this study we infected mice with T. spiralis, a nematode parasite, and studied the inflammatory response through the determination of MIP-2, a C-X-C chemokine and MCP-1, a C-C chemokine in the inflamed area around the parasitic cyst.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mip-2</infon>
          <location offset="392" length="5"/>
          <text>MIP-2</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c-x-c chemokine</infon>
          <location offset="401" length="15"/>
          <text>C-X-C chemokine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="421" length="5"/>
          <text>MCP-1</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c-c chemokine</infon>
          <location offset="430" length="13"/>
          <text>C-C chemokine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>492</offset>
        <text>The animals were infected and their diaphragms were tested for inflammatory response.</text>
      </sentence>
      <sentence>
        <offset>578</offset>
        <text>MCP-1 and MIP-2 was tested after 1, 10, 20, 30, and 40 days post inoculation, before and after mimosine treatment.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mimosine</infon>
          <location offset="673" length="8"/>
          <text>mimosine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="578" length="5"/>
          <text>MCP-1</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mip-2</infon>
          <location offset="588" length="5"/>
          <text>MIP-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>693</offset>
        <text>The inflammatory index was calculated by counting the white blood cells around the nematode cysts, while expression of MIP-2 and MCP-1 was calculated by ELISA method and transcription by Northern blot and RT-PCR.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mip-2</infon>
          <location offset="812" length="5"/>
          <text>MIP-2</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="822" length="5"/>
          <text>MCP-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>906</offset>
        <text>Here we found that mimosine strongly inhibited the inflammatory index in the diaphragmatic tissue at 10, 20, 30 and 40 days post-treatment.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mimosine</infon>
          <location offset="925" length="8"/>
          <text>mimosine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1046</offset>
        <text>In these experiments, mimosine had no effect on the number of cysts produced.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mimosine</infon>
          <location offset="1068" length="8"/>
          <text>mimosine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1124</offset>
        <text>In addition, we found that MCP-1 transcription and translation was completely inhibited by mimosine, while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T. spiralis.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mimosine</infon>
          <location offset="1215" length="8"/>
          <text>mimosine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcp-1</infon>
          <location offset="1151" length="5"/>
          <text>MCP-1</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mip-2</infon>
          <location offset="1231" length="5"/>
          <text>MIP-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1414</offset>
        <text>Our studies suggest that mimosine has an inhibitory effect through the inhibition of cytoplasmatic serine hydroxymethyltransferase altering the cell cycle of white blood cells.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mimosine</infon>
          <location offset="1439" length="8"/>
          <text>mimosine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1591</offset>
        <text>This study suggests for the first time the premise that mimosine acts as an anti-inflammatory compound.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mimosine</infon>
          <location offset="1647" length="8"/>
          <text>mimosine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23629516</id>
    <passage>
      <offset>0</offset>
      <text>In ovo effects of two organophosphate flame retardants, TCPP and TDCPP, on pipping success, development, mRNA expression and thyroid hormone levels in chicken embryos.	Tris(1-chloro-2-propyl) phosphate (TCPP) and tris(1,3-dichloro-2-propyl) phosphate (TDCPP) are organic flame retardants detected in the environment and biota for which toxicological data for avian species are limited. In this study, domestic chicken eggs were injected with TCPP or TDCPP (maximum dose = 51600 and 45000 ng/g egg, respectively) to determine dose-dependent effects on pipping success, development, hepatic messenger RNA (mRNA) expression levels of genes associated with xenobiotic metabolism and the thyroid hormone (TH) pathway, and TH levels following 20-22 days of incubation. Neither compound reduced pipping success; however, TCPP significantly delayed pipping at 9240 and 51600 ng/g and reduced tarsus length at 51600 ng/g. TDCPP exposure resulted in significant decreases in head plus bill length, embryo mass and gallbladder size at 45000 ng/g and reduced plasma free T4 levels at 7640 ng/g. Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while TDCPP induced CYP3A37 and CYP2H1. Chemical analysis of egg contents at incubation days 0, 5, 11, 18, and 19 revealed that &gt;92% of the injected TCPP or TDCPP concentration was detectable up to day 5; however, &lt;1% was detected by day 19. The observed phenotypic responses to TCPP and TDCPP exposure may be associated with disruption of the TH-axis, which is critical for normal growth and development in birds. The effects of TDCPP on the gallbladder indicate that the disturbance of lipid metabolism is a likely target in its mechanism of toxicity.</text>
      <sentence>
        <offset>0</offset>
        <text>In ovo effects of two organophosphate flame retardants, TCPP and TDCPP, on pipping success, development, mRNA expression and thyroid hormone levels in chicken embryos.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">organophosphate</infon>
          <location offset="22" length="15"/>
          <text>organophosphate</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcpp</infon>
          <location offset="56" length="4"/>
          <text>TCPP</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tdcpp</infon>
          <location offset="65" length="5"/>
          <text>TDCPP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>168</offset>
        <text>Tris(1-chloro-2-propyl) phosphate (TCPP) and tris(1,3-dichloro-2-propyl) phosphate (TDCPP) are organic flame retardants detected in the environment and biota for which toxicological data for avian species are limited.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tris(1-chloro-2-propyl) phosphate</infon>
          <location offset="168" length="33"/>
          <text>Tris(1-chloro-2-propyl) phosphate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcpp</infon>
          <location offset="203" length="4"/>
          <text>TCPP</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tris(1,3-dichloro-2-propyl) phosphate</infon>
          <location offset="213" length="37"/>
          <text>tris(1,3-dichloro-2-propyl) phosphate</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tdcpp</infon>
          <location offset="252" length="5"/>
          <text>TDCPP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>386</offset>
        <text>In this study, domestic chicken eggs were injected with TCPP or TDCPP (maximum dose = 51600 and 45000 ng/g egg, respectively) to determine dose-dependent effects on pipping success, development, hepatic messenger RNA (mRNA) expression levels of genes associated with xenobiotic metabolism and the thyroid hormone (TH) pathway, and TH levels following 20-22 days of incubation.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcpp</infon>
          <location offset="442" length="4"/>
          <text>TCPP</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tdcpp</infon>
          <location offset="450" length="5"/>
          <text>TDCPP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>763</offset>
        <text>Neither compound reduced pipping success; however, TCPP significantly delayed pipping at 9240 and 51600 ng/g and reduced tarsus length at 51600 ng/g.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcpp</infon>
          <location offset="814" length="4"/>
          <text>TCPP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>913</offset>
        <text>TDCPP exposure resulted in significant decreases in head plus bill length, embryo mass and gallbladder size at 45000 ng/g and reduced plasma free T4 levels at 7640 ng/g.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tdcpp</infon>
          <location offset="913" length="5"/>
          <text>TDCPP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1083</offset>
        <text>Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while TDCPP induced CYP3A37 and CYP2H1.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcpp</infon>
          <location offset="1208" length="4"/>
          <text>TCPP</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tdcpp</infon>
          <location offset="1220" length="5"/>
          <text>TDCPP</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a37</infon>
          <location offset="1234" length="7"/>
          <text>CYP3A37</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2h1</infon>
          <location offset="1246" length="6"/>
          <text>CYP2H1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">type i deiodinase</infon>
          <location offset="1083" length="17"/>
          <text>Type I deiodinase</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">liver fatty-acid binding protein</infon>
          <location offset="1102" length="32"/>
          <text>liver fatty-acid binding protein</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome p450 (cyp) 3a37</infon>
          <location offset="1139" length="26"/>
          <text>cytochrome P450 (CYP) 3A37</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1254</offset>
        <text>Chemical analysis of egg contents at incubation days 0, 5, 11, 18, and 19 revealed that &gt;92% of the injected TCPP or TDCPP concentration was detectable up to day 5; however, &lt;1% was detected by day 19.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcpp</infon>
          <location offset="1363" length="4"/>
          <text>TCPP</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tdcpp</infon>
          <location offset="1371" length="5"/>
          <text>TDCPP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1456</offset>
        <text>The observed phenotypic responses to TCPP and TDCPP exposure may be associated with disruption of the TH-axis, which is critical for normal growth and development in birds.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcpp</infon>
          <location offset="1493" length="4"/>
          <text>TCPP</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tdcpp</infon>
          <location offset="1502" length="5"/>
          <text>TDCPP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1629</offset>
        <text>The effects of TDCPP on the gallbladder indicate that the disturbance of lipid metabolism is a likely target in its mechanism of toxicity.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tdcpp</infon>
          <location offset="1644" length="5"/>
          <text>TDCPP</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15072849</id>
    <passage>
      <offset>0</offset>
      <text>Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro.	Imiquimod (IMQ), an activator of Toll-like receptor-7 (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo. Physiologically, the immune system is using perforin-containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose. This functional synergism prompted our current experiments addressing the question whether IMQ may influence perforin-release and/or induce perforin in CTLs in vitro. In peripheral lymphocytes of healthy and diseased subjects, IMQ induced a significant increase of perforin(+) CTLs within 12h in all experiments performed. This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of perforin(+) CTLs were induced by 2.5 microg/ml [corrected] IMQ. Perforin release from peripheral blood CTLs after PMA/ionomycin-stimulation was not influenced significantly by IMQ. Thus, the biological activity of IMQ appears to exceed its previously known functions, inasmuch as it boosts up significantly the perforin-granule system.</text>
      <sentence>
        <offset>0</offset>
        <text>Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imiquimod</infon>
          <location offset="0" length="9"/>
          <text>Imiquimod</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">toll-like receptor-7</infon>
          <location offset="13" length="20"/>
          <text>Toll-like receptor-7</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">perforin</infon>
          <location offset="51" length="8"/>
          <text>perforin</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T8" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>97</offset>
        <text>Imiquimod (IMQ), an activator of Toll-like receptor-7 (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imiquimod</infon>
          <location offset="97" length="9"/>
          <text>Imiquimod</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imq</infon>
          <location offset="108" length="3"/>
          <text>IMQ</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">toll-like receptor-7</infon>
          <location offset="130" length="20"/>
          <text>Toll-like receptor-7</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tlr-7</infon>
          <location offset="152" length="5"/>
          <text>TLR-7</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>239</offset>
        <text>Physiologically, the immune system is using perforin-containing granules of cytotoxic T lymphocytes (CTL) towards the same biological purpose.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">perforin</infon>
          <location offset="283" length="8"/>
          <text>perforin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>382</offset>
        <text>This functional synergism prompted our current experiments addressing the question whether IMQ may influence perforin-release and/or induce perforin in CTLs in vitro.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imq</infon>
          <location offset="473" length="3"/>
          <text>IMQ</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">perforin</infon>
          <location offset="491" length="8"/>
          <text>perforin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">perforin</infon>
          <location offset="522" length="8"/>
          <text>perforin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>549</offset>
        <text>In peripheral lymphocytes of healthy and diseased subjects, IMQ induced a significant increase of perforin(+) CTLs within 12h in all experiments performed.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imq</infon>
          <location offset="609" length="3"/>
          <text>IMQ</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">perforin</infon>
          <location offset="647" length="8"/>
          <text>perforin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>705</offset>
        <text>This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of perforin(+) CTLs were induced by 2.5 microg/ml [corrected] IMQ.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imq</infon>
          <location offset="984" length="3"/>
          <text>IMQ</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">perforin</infon>
          <location offset="822" length="8"/>
          <text>perforin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">perforin</infon>
          <location offset="858" length="8"/>
          <text>perforin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">perforin</infon>
          <location offset="925" length="8"/>
          <text>perforin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>989</offset>
        <text>Perforin release from peripheral blood CTLs after PMA/ionomycin-stimulation was not influenced significantly by IMQ.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imq</infon>
          <location offset="1101" length="3"/>
          <text>IMQ</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">perforin</infon>
          <location offset="989" length="8"/>
          <text>Perforin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1106</offset>
        <text>Thus, the biological activity of IMQ appears to exceed its previously known functions, inasmuch as it boosts up significantly the perforin-granule system.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imq</infon>
          <location offset="1139" length="3"/>
          <text>IMQ</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">perforin</infon>
          <location offset="1236" length="8"/>
          <text>perforin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23501490</id>
    <passage>
      <offset>0</offset>
      <text>The protective role of l-carnitine against cylindrospermopsin-induced oxidative stress in tilapia (Oreochromis niloticus).	Cylindrospermopsin (CYN) is one of the most important cyanotoxins in terms of both human health and environmental quality and is produced by several different species of cyanobacteria, including Aphanizomenon ovalisporum. The principal mechanisms of action of CYN involve inhibition of protein and glutathione synthesis. In addition, CYN-mediated genotoxicity results from DNA fragmentation. The results of both in vivo and in vitro studies suggest that oxidative stress also plays a significant role in CYN pathogenesis in fish. We investigated the protective effects of l-carnitine (LC) pre-treatment on A. ovalisporum-induced oxidative stress in cells containing CYN and deoxy-CYN, or pure standard CYN, in tilapia (Oreochromis niloticus) that had been acutely exposed via oral administration. Various oxidative stress markers, including lipid peroxidation (LPO), protein oxidation, DNA oxidation, and the ratio of reduced glutathione to oxidised glutathione (GSH/GSSG), and the activities of NADPH oxidase, superoxide dismutase (SOD), catalase (CAT), and gamma-glutamyl-cysteine synthetase (γ-GCS), were evaluated in the livers and kidneys of fish in the absence and presence of 400 or 880mgLC/kgfish/day during a 21 day period prior to CYN-intoxication. The results of our study demonstrated for the first time the beneficial antioxidant effects of LC dietary supplementation on oxidative stress status in fish. No pro-oxidant effects were detected at any of the LC doses assayed, suggesting that LC is a chemoprotectant that reduces hepatic and renal oxidative stress and may be effective when used for the prophylaxis and treatment of CYN-related intoxication in fish.</text>
      <sentence>
        <offset>0</offset>
        <text>The protective role of l-carnitine against cylindrospermopsin-induced oxidative stress in tilapia (Oreochromis niloticus).</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-carnitine</infon>
          <location offset="23" length="11"/>
          <text>l-carnitine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cylindrospermopsin</infon>
          <location offset="43" length="18"/>
          <text>cylindrospermopsin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>123</offset>
        <text>Cylindrospermopsin (CYN) is one of the most important cyanotoxins in terms of both human health and environmental quality and is produced by several different species of cyanobacteria, including Aphanizomenon ovalisporum.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cylindrospermopsin</infon>
          <location offset="123" length="18"/>
          <text>Cylindrospermopsin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyn</infon>
          <location offset="143" length="3"/>
          <text>CYN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>345</offset>
        <text>The principal mechanisms of action of CYN involve inhibition of protein and glutathione synthesis.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyn</infon>
          <location offset="383" length="3"/>
          <text>CYN</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="421" length="11"/>
          <text>glutathione</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>444</offset>
        <text>In addition, CYN-mediated genotoxicity results from DNA fragmentation.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyn</infon>
          <location offset="457" length="3"/>
          <text>CYN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>515</offset>
        <text>The results of both in vivo and in vitro studies suggest that oxidative stress also plays a significant role in CYN pathogenesis in fish.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyn</infon>
          <location offset="627" length="3"/>
          <text>CYN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>653</offset>
        <text>We investigated the protective effects of l-carnitine (LC) pre-treatment on A. ovalisporum-induced oxidative stress in cells containing CYN and deoxy-CYN, or pure standard CYN, in tilapia (Oreochromis niloticus) that had been acutely exposed via oral administration.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-carnitine</infon>
          <location offset="695" length="11"/>
          <text>l-carnitine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyn</infon>
          <location offset="789" length="3"/>
          <text>CYN</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deoxy-cyn</infon>
          <location offset="797" length="9"/>
          <text>deoxy-CYN</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyn</infon>
          <location offset="825" length="3"/>
          <text>CYN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>920</offset>
        <text>Various oxidative stress markers, including lipid peroxidation (LPO), protein oxidation, DNA oxidation, and the ratio of reduced glutathione to oxidised glutathione (GSH/GSSG), and the activities of NADPH oxidase, superoxide dismutase (SOD), catalase (CAT), and gamma-glutamyl-cysteine synthetase (γ-GCS), were evaluated in the livers and kidneys of fish in the absence and presence of 400 or 880mgLC/kgfish/day during a 21 day period prior to CYN-intoxication.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="1134" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gamma-glutamyl-cysteine</infon>
          <location offset="1182" length="23"/>
          <text>gamma-glutamyl-cysteine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyn</infon>
          <location offset="1364" length="3"/>
          <text>CYN</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">reduced glutathione</infon>
          <location offset="1041" length="19"/>
          <text>reduced glutathione</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxidised glutathione</infon>
          <location offset="1064" length="20"/>
          <text>oxidised glutathione</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="1086" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gssg</infon>
          <location offset="1090" length="4"/>
          <text>GSSG</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadph</infon>
          <location offset="1119" length="5"/>
          <text>NADPH</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">superoxide dismutase</infon>
          <location offset="1134" length="20"/>
          <text>superoxide dismutase</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sod</infon>
          <location offset="1156" length="3"/>
          <text>SOD</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catalase</infon>
          <location offset="1162" length="8"/>
          <text>catalase</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cat</infon>
          <location offset="1172" length="3"/>
          <text>CAT</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gamma-glutamyl-cysteine synthetase</infon>
          <location offset="1182" length="34"/>
          <text>gamma-glutamyl-cysteine synthetase</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">γ-gcs</infon>
          <location offset="1218" length="5"/>
          <text>γ-GCS</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nadph oxidase</infon>
          <location offset="1119" length="13"/>
          <text>NADPH oxidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1382</offset>
        <text>The results of our study demonstrated for the first time the beneficial antioxidant effects of LC dietary supplementation on oxidative stress status in fish.</text>
      </sentence>
      <sentence>
        <offset>1540</offset>
        <text>No pro-oxidant effects were detected at any of the LC doses assayed, suggesting that LC is a chemoprotectant that reduces hepatic and renal oxidative stress and may be effective when used for the prophylaxis and treatment of CYN-related intoxication in fish.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyn</infon>
          <location offset="1765" length="3"/>
          <text>CYN</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>14766200</id>
    <passage>
      <offset>0</offset>
      <text>Expression of DDAH1 in chick and rat embryos.	Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is an enzyme that metabolizes methylated arginine to citrulline and methylamine, thus working to produce nitric oxide (NO). We isolated a gene encoding chick DDAH1. In situ hybridization analysis revealed characteristic DDAH1 mRNA expression in the embryonic spinal cord, which was especially strong in the ventral horn and dorsal root ganglion (DRG). DDAH1 was also detected in the brain, kidney, digestive tract, and in other tissues. We examined the expression pattern of DDAH1 in developing rats and compared this with the expression pattern in chicks. The expression pattern in the rats was very similar to that in the chicks, but there were some differences between the chicks and rats in the amount of DDAH1 detected in the heart, liver, lung, and DRG. We also investigated neural nitric oxide synthase (nNOS) mRNA expression patterns in rat embryos. The DDAH1 expression patterns were completely different from nNOS expression patterns. Our study suggests that DDAH1 plays an important role in development.</text>
      <sentence>
        <offset>0</offset>
        <text>Expression of DDAH1 in chick and rat embryos.</text>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ddah1</infon>
          <location offset="14" length="5"/>
          <text>DDAH1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>46</offset>
        <text>Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is an enzyme that metabolizes methylated arginine to citrulline and methylamine, thus working to produce nitric oxide (NO).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dimethylarginine</infon>
          <location offset="46" length="16"/>
          <text>Dimethylarginine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">citrulline</infon>
          <location offset="149" length="10"/>
          <text>citrulline</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methylamine</infon>
          <location offset="164" length="11"/>
          <text>methylamine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="201" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">no</infon>
          <location offset="215" length="2"/>
          <text>NO</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dimethylarginine dimethylaminohydrolase 1</infon>
          <location offset="46" length="41"/>
          <text>Dimethylarginine dimethylaminohydrolase 1</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ddah1</infon>
          <location offset="89" length="5"/>
          <text>DDAH1</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>220</offset>
        <text>We isolated a gene encoding chick DDAH1.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">chick ddah1</infon>
          <location offset="248" length="11"/>
          <text>chick DDAH1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>261</offset>
        <text>In situ hybridization analysis revealed characteristic DDAH1 mRNA expression in the embryonic spinal cord, which was especially strong in the ventral horn and dorsal root ganglion (DRG).</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ddah1</infon>
          <location offset="316" length="5"/>
          <text>DDAH1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>448</offset>
        <text>DDAH1 was also detected in the brain, kidney, digestive tract, and in other tissues.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ddah1</infon>
          <location offset="448" length="5"/>
          <text>DDAH1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>533</offset>
        <text>We examined the expression pattern of DDAH1 in developing rats and compared this with the expression pattern in chicks.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ddah1</infon>
          <location offset="571" length="5"/>
          <text>DDAH1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>653</offset>
        <text>The expression pattern in the rats was very similar to that in the chicks, but there were some differences between the chicks and rats in the amount of DDAH1 detected in the heart, liver, lung, and DRG.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ddah1</infon>
          <location offset="805" length="5"/>
          <text>DDAH1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>856</offset>
        <text>We also investigated neural nitric oxide synthase (nNOS) mRNA expression patterns in rat embryos.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="884" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neural nitric oxide synthase</infon>
          <location offset="877" length="28"/>
          <text>neural nitric oxide synthase</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nnos</infon>
          <location offset="907" length="4"/>
          <text>nNOS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>954</offset>
        <text>The DDAH1 expression patterns were completely different from nNOS expression patterns.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ddah1</infon>
          <location offset="958" length="5"/>
          <text>DDAH1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nnos</infon>
          <location offset="1015" length="4"/>
          <text>nNOS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1041</offset>
        <text>Our study suggests that DDAH1 plays an important role in development.</text>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ddah1</infon>
          <location offset="1065" length="5"/>
          <text>DDAH1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15381832</id>
    <passage>
      <offset>0</offset>
      <text>Secretion of gastric mucus phospholipids in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation.	Recent advances in understanding the nature of cellular responses mediated by G protein-coupled receptor (GPCR) activation indicate that integration of the converging regulatory signals into functional cellular pathways requires epidermal growth factor receptor (EGFR) transactivation. In this study, we report that G protein-coupled beta-adrenergic receptor activation leading to stimulation in gastric mucus phospholipid secretion occurs with the involvement of EGFR. Using [14C]choline-labeled gastric mucosal cells in culture, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on phospholipid release was subject to a dose-dependent suppression by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K. Both inhibitors, moreover, caused the reduction in the gastric mucosal cell phospholipid secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenyl cyclase activator, forskolin. The gastric mucosal phospholipid secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR phosphorylation, but not by ERK inhibitor, PD98059. The inhibition of ERK, moreover, did not cause attenuation in phospholipid secretory responses to cAMP and forskolin. The findings underline the central role of EGFR in mediation of gastric mucosal secretory processes, and demonstrate the requirement for Src kinase-dependent EGFR transactivation in regulation of gastric mucosal phospholipid secretion in response to beta-adrenergic GPCR activation.</text>
      <sentence>
        <offset>0</offset>
        <text>Secretion of gastric mucus phospholipids in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation.</text>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">src</infon>
          <location offset="125" length="3"/>
          <text>SRC</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="129" length="6"/>
          <text>kinase</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epidermal growth factor receptor</infon>
          <location offset="146" length="32"/>
          <text>epidermal growth factor receptor</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenergic g protein-coupled receptor</infon>
          <location offset="56" length="42"/>
          <text>beta-adrenergic G protein-coupled receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>196</offset>
        <text>Recent advances in understanding the nature of cellular responses mediated by G protein-coupled receptor (GPCR) activation indicate that integration of the converging regulatory signals into functional cellular pathways requires epidermal growth factor receptor (EGFR) transactivation.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epidermal growth factor receptor</infon>
          <location offset="425" length="32"/>
          <text>epidermal growth factor receptor</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="459" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g protein-coupled receptor</infon>
          <location offset="274" length="26"/>
          <text>G protein-coupled receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>482</offset>
        <text>In this study, we report that G protein-coupled beta-adrenergic receptor activation leading to stimulation in gastric mucus phospholipid secretion occurs with the involvement of EGFR.</text>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g protein-coupled beta-adrenergic receptor</infon>
          <location offset="512" length="42"/>
          <text>G protein-coupled beta-adrenergic receptor</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="660" length="4"/>
          <text>EGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>666</offset>
        <text>Using [14C]choline-labeled gastric mucosal cells in culture, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on phospholipid release was subject to a dose-dependent suppression by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[14c]choline</infon>
          <location offset="672" length="12"/>
          <text>[14C]choline</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoproterenol</infon>
          <location offset="787" length="13"/>
          <text>isoproterenol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pd153035</infon>
          <location offset="896" length="8"/>
          <text>PD153035</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wortmannin</infon>
          <location offset="917" length="10"/>
          <text>wortmannin</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="873" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="878" length="6"/>
          <text>kinase</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="953" length="4"/>
          <text>PI3K</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>959</offset>
        <text>Both inhibitors, moreover, caused the reduction in the gastric mucosal cell phospholipid secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenyl cyclase activator, forskolin.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="1123" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">forskolin</infon>
          <location offset="1165" length="9"/>
          <text>forskolin</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adenyl cyclase</infon>
          <location offset="1139" length="14"/>
          <text>adenyl cyclase</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1176</offset>
        <text>The gastric mucosal phospholipid secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR phosphorylation, but not by ERK inhibitor, PD98059.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoproterenol</infon>
          <location offset="1232" length="13"/>
          <text>isoproterenol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="1308" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pd98059</infon>
          <location offset="1411" length="7"/>
          <text>PD98059</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tyrosine kinase</infon>
          <location offset="1308" length="15"/>
          <text>tyrosine kinase</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">src</infon>
          <location offset="1324" length="3"/>
          <text>Src</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1363" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="1396" length="3"/>
          <text>ERK</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1420</offset>
        <text>The inhibition of ERK, moreover, did not cause attenuation in phospholipid secretory responses to cAMP and forskolin.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="1518" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">forskolin</infon>
          <location offset="1527" length="9"/>
          <text>forskolin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="1438" length="3"/>
          <text>ERK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1538</offset>
        <text>The findings underline the central role of EGFR in mediation of gastric mucosal secretory processes, and demonstrate the requirement for Src kinase-dependent EGFR transactivation in regulation of gastric mucosal phospholipid secretion in response to beta-adrenergic GPCR activation.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1581" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">src</infon>
          <location offset="1675" length="3"/>
          <text>Src</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="1679" length="6"/>
          <text>kinase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">egfr</infon>
          <location offset="1696" length="4"/>
          <text>EGFR</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenergic gpcr</infon>
          <location offset="1788" length="20"/>
          <text>beta-adrenergic GPCR</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10433694</id>
    <passage>
      <offset>0</offset>
      <text>Crystal structure of human quinone reductase type 2, a metalloflavoprotein.	In mammals, two separate but homologous cytosolic quinone reductases have been identified: NAD(P)H:quinone oxidoreductase type 1 (QR1) (EC 1.6.99.2) and quinone reductase type 2 (QR2). Although QR1 and QR2 are nearly 50% identical in protein sequence, they display markedly different catalytic properties and substrate specificities. We report here two crystal structures of QR2: in its native form and bound to menadione (vitamin K(3)), a physiological substrate. Phases were obtained by molecular replacement, using our previously determined rat QR1 structure as the search model. QR2 shares the overall fold of the major catalytic domain of QR1, but lacks the smaller C-terminal domain. The FAD binding sites of QR1 and QR2 are very similar, but their hydride donor binding sites are considerably different. Unexpectedly, we found that QR2 contains a specific metal binding site, which is not present in QR1. Two histidine nitrogens, one cysteine thiol, and a main chain carbonyl group are involved in metal coordination. The metal binding site is solvent-accessible, and is separated from the FAD cofactor by a distance of about 13 A.</text>
      <sentence>
        <offset>0</offset>
        <text>Crystal structure of human quinone reductase type 2, a metalloflavoprotein.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quinone</infon>
          <location offset="27" length="7"/>
          <text>quinone</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human quinone reductase type 2</infon>
          <location offset="21" length="30"/>
          <text>human quinone reductase type 2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>76</offset>
        <text>In mammals, two separate but homologous cytosolic quinone reductases have been identified: NAD(P)H:quinone oxidoreductase type 1 (QR1) (EC 1.6.99.2) and quinone reductase type 2 (QR2).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quinone</infon>
          <location offset="229" length="7"/>
          <text>quinone</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quinone</infon>
          <location offset="126" length="7"/>
          <text>quinone</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nad(p)h</infon>
          <location offset="167" length="7"/>
          <text>NAD(P)H</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quinone</infon>
          <location offset="175" length="7"/>
          <text>quinone</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">qr1</infon>
          <location offset="206" length="3"/>
          <text>QR1</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ec 1.6.99.2</infon>
          <location offset="212" length="11"/>
          <text>EC 1.6.99.2</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">quinone reductase type 2</infon>
          <location offset="229" length="24"/>
          <text>quinone reductase type 2</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">qr2</infon>
          <location offset="255" length="3"/>
          <text>QR2</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">quinone reductases</infon>
          <location offset="126" length="18"/>
          <text>quinone reductases</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nad(p)h:quinone oxidoreductase type 1</infon>
          <location offset="167" length="37"/>
          <text>NAD(P)H:quinone oxidoreductase type 1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>261</offset>
        <text>Although QR1 and QR2 are nearly 50% identical in protein sequence, they display markedly different catalytic properties and substrate specificities.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">qr1</infon>
          <location offset="270" length="3"/>
          <text>QR1</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">qr2</infon>
          <location offset="278" length="3"/>
          <text>QR2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>410</offset>
        <text>We report here two crystal structures of QR2: in its native form and bound to menadione (vitamin K(3)), a physiological substrate.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">menadione</infon>
          <location offset="488" length="9"/>
          <text>menadione</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin k(3)</infon>
          <location offset="499" length="12"/>
          <text>vitamin K(3)</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">qr2</infon>
          <location offset="451" length="3"/>
          <text>QR2</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>541</offset>
        <text>Phases were obtained by molecular replacement, using our previously determined rat QR1 structure as the search model.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rat qr1</infon>
          <location offset="620" length="7"/>
          <text>rat QR1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>659</offset>
        <text>QR2 shares the overall fold of the major catalytic domain of QR1, but lacks the smaller C-terminal domain.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c</infon>
          <location offset="747" length="1"/>
          <text>C</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">qr2</infon>
          <location offset="659" length="3"/>
          <text>QR2</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">qr1</infon>
          <location offset="720" length="3"/>
          <text>QR1</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>766</offset>
        <text>The FAD binding sites of QR1 and QR2 are very similar, but their hydride donor binding sites are considerably different.</text>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fad binding sites</infon>
          <location offset="770" length="17"/>
          <text>FAD binding sites</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">qr1</infon>
          <location offset="791" length="3"/>
          <text>QR1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">qr2</infon>
          <location offset="799" length="3"/>
          <text>QR2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>887</offset>
        <text>Unexpectedly, we found that QR2 contains a specific metal binding site, which is not present in QR1.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">qr2</infon>
          <location offset="915" length="3"/>
          <text>QR2</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">qr1</infon>
          <location offset="983" length="3"/>
          <text>QR1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>988</offset>
        <text>Two histidine nitrogens, one cysteine thiol, and a main chain carbonyl group are involved in metal coordination.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histidine nitrogens</infon>
          <location offset="992" length="19"/>
          <text>histidine nitrogens</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteine thiol</infon>
          <location offset="1017" length="14"/>
          <text>cysteine thiol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbonyl</infon>
          <location offset="1050" length="8"/>
          <text>carbonyl</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1101</offset>
        <text>The metal binding site is solvent-accessible, and is separated from the FAD cofactor by a distance of about 13 A.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>14744615</id>
    <passage>
      <offset>0</offset>
      <text>5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine.	Dihydroergotamine produces external carotid vasoconstriction in vagosympathectomized dogs by 5-HT(1B/1D) receptors and alpha(2)-adrenoceptors. This study identified the specific subtypes involved in this response. One-minute intracarotid infusions of dihydroergotamine (5.6-10 microg/min) dose-dependently decreased external carotid blood flow without affecting blood pressure or heart rate. This response was: (1) partly blocked in dogs pretreated intravenously with the antagonists SB224289 (5-HT(1B); 2,3,6,7-tetrahydro-1'-methyl-5-[2'-methyl-4' (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carbonyl]furo[2,3-f]indole-3-spiro-4'-p iperidine hydrochloride), rauwolscine (alpha(2)), BRL44408 (alpha(2A); 2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole) or MK912 (alpha(2C); (2S,12bS)-1'3'-dimethylspiro(1,3,4,5',6,6',7,12b-octahydro-2Hbenzo[b]furo[2,3-a]q uinazoline)-2,4'-pyrimidin-2'-one); (2) markedly blocked after SB224289 plus rauwolscine; and (3) unaffected after BRL15572 (5-HT(1D); 1-(3-chlorophenyl)-4-[3,3-diphenyl (2-(S,R) hydroxypropanyl) piperazine] hydrochloride) or imiloxan (alpha(2B)). Therefore, the above response involves 5-HT(1B) receptors and alpha(2A/2C)-adrenoceptors.</text>
      <sentence>
        <offset>0</offset>
        <text>5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydroergotamine</infon>
          <location offset="92" length="17"/>
          <text>dihydroergotamine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1b</infon>
          <location offset="0" length="6"/>
          <text>5-HT1B</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 2a/2c-adrenoceptors</infon>
          <location offset="21" length="25"/>
          <text>alpha 2A/2C-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>111</offset>
        <text>Dihydroergotamine produces external carotid vasoconstriction in vagosympathectomized dogs by 5-HT(1B/1D) receptors and alpha(2)-adrenoceptors.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydroergotamine</infon>
          <location offset="111" length="17"/>
          <text>Dihydroergotamine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(2)-adrenoceptors</infon>
          <location offset="230" length="22"/>
          <text>alpha(2)-adrenoceptors</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht(1b/1d) receptors</infon>
          <location offset="204" length="21"/>
          <text>5-HT(1B/1D) receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>254</offset>
        <text>This study identified the specific subtypes involved in this response.</text>
      </sentence>
      <sentence>
        <offset>325</offset>
        <text>One-minute intracarotid infusions of dihydroergotamine (5.6-10 microg/min) dose-dependently decreased external carotid blood flow without affecting blood pressure or heart rate.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydroergotamine</infon>
          <location offset="362" length="17"/>
          <text>dihydroergotamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>503</offset>
        <text>This response was: (1) partly blocked in dogs pretreated intravenously with the antagonists SB224289 (5-HT(1B); 2,3,6,7-tetrahydro-1'-methyl-5-[2'-methyl-4' (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carbonyl]furo[2,3-f]indole-3-spiro-4'-p iperidine hydrochloride), rauwolscine (alpha(2)), BRL44408 (alpha(2A); 2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole) or MK912 (alpha(2C); (2S,12bS)-1'3'-dimethylspiro(1,3,4,5',6,6',7,12b-octahydro-2Hbenzo[b]furo[2,3-a]q uinazoline)-2,4'-pyrimidin-2'-one); (2) markedly blocked after SB224289 plus rauwolscine; and (3) unaffected after BRL15572 (5-HT(1D); 1-(3-chlorophenyl)-4-[3,3-diphenyl (2-(S,R) hydroxypropanyl) piperazine] hydrochloride) or imiloxan (alpha(2B)).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1-(3-chlorophenyl)-4-[3,3-diphenyl (2-(s,r) hydroxypropanyl) piperazine] hydrochloride</infon>
          <location offset="1118" length="86"/>
          <text>1-(3-chlorophenyl)-4-[3,3-diphenyl (2-(S,R) hydroxypropanyl) piperazine] hydrochloride</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imiloxan</infon>
          <location offset="1209" length="8"/>
          <text>imiloxan</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sb224289</infon>
          <location offset="595" length="8"/>
          <text>SB224289</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2,3,6,7-tetrahydro-1'-methyl-5-[2'-methyl-4' (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carbonyl]furo[2,3-f]indole-3-spiro-4'-p iperidine hydrochloride</infon>
          <location offset="615" length="150"/>
          <text>2,3,6,7-tetrahydro-1'-methyl-5-[2'-methyl-4' (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carbonyl]furo[2,3-f]indole-3-spiro-4'-p iperidine hydrochloride</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rauwolscine</infon>
          <location offset="768" length="11"/>
          <text>rauwolscine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">brl44408</infon>
          <location offset="792" length="8"/>
          <text>BRL44408</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-[2h-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole</infon>
          <location offset="813" length="65"/>
          <text>2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mk912</infon>
          <location offset="883" length="5"/>
          <text>MK912</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(2s,12bs)-1'3'-dimethylspiro(1,3,4,5',6,6',7,12b-octahydro-2hbenzo[b]furo[2,3-a]q uinazoline)-2,4'-pyrimidin-2'-one</infon>
          <location offset="901" length="115"/>
          <text>(2S,12bS)-1'3'-dimethylspiro(1,3,4,5',6,6',7,12b-octahydro-2Hbenzo[b]furo[2,3-a]q uinazoline)-2,4'-pyrimidin-2'-one</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sb224289</infon>
          <location offset="1046" length="8"/>
          <text>SB224289</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rauwolscine</infon>
          <location offset="1060" length="11"/>
          <text>rauwolscine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">brl15572</infon>
          <location offset="1098" length="8"/>
          <text>BRL15572</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha(2b)</infon>
          <location offset="1219" length="9"/>
          <text>alpha(2B)</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht(1b)</infon>
          <location offset="605" length="8"/>
          <text>5-HT(1B)</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(2)</infon>
          <location offset="781" length="8"/>
          <text>alpha(2)</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha(2a)</infon>
          <location offset="802" length="9"/>
          <text>alpha(2A)</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(2c)</infon>
          <location offset="890" length="9"/>
          <text>alpha(2C)</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T8" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T6" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T10" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1231</offset>
        <text>Therefore, the above response involves 5-HT(1B) receptors and alpha(2A/2C)-adrenoceptors.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht(1b)</infon>
          <location offset="1270" length="8"/>
          <text>5-HT(1B)</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(2a/2c)-adrenoceptors</infon>
          <location offset="1293" length="26"/>
          <text>alpha(2A/2C)-adrenoceptors</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10735801</id>
    <passage>
      <offset>0</offset>
      <text>N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH.	UNLABELLED: Large concentrations of meperidine inhibit N-methyl-D-aspartate-(NMDA) receptor channels by channel block mechanisms. Extracellular pH regulates the activity and drug sensitivity of NMDA-receptor channels. We examined the influence of extracellular pH on sensitivity to meperidine of epsilon/zeta heteromeric NMDA-receptor channels expressed in Xenopus oocytes. Inhibition of epsilon1/zeta1, epsilon2/zeta1, epsilon3/zeta1, and epsilon4/zeta1 channels by meperidine was dependent on pH, with more inhibition at acidic pH and less inhibition at alkaline pH. The degree of voltage-dependence of meperidine block was only slightly affected by changes in pH, whereas affinity for meperidine was greatly reduced at alkaline pH. Furthermore, interaction of meperidine with Mg(2+) block was reduced at alkaline pH. Because the percentage of the protonated form of meperidine is only slightly affected by pH, changes in properties of the meperidine binding site may be involved in mechanisms of alteration of meperidine potency by pH. IMPLICATIONS: At acidic pH the potency of meperidine for N-methyl-D-aspartate-receptor channels was increased. Any antinociceptive and neuroprotective benefit from the N-methyl-D-aspartate-receptor antagonist property of meperidine may be pH dependent.</text>
      <sentence>
        <offset>0</offset>
        <text>N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-methyl-d-aspartate</infon>
          <location offset="0" length="20"/>
          <text>N-methyl-D-aspartate</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="47" length="10"/>
          <text>meperidine</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">n-methyl-d-aspartate receptor</infon>
          <location offset="0" length="29"/>
          <text>N-methyl-D-aspartate receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>92</offset>
        <text>UNLABELLED: Large concentrations of meperidine inhibit N-methyl-D-aspartate-(NMDA) receptor channels by channel block mechanisms.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="128" length="10"/>
          <text>meperidine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-methyl-d-aspartate</infon>
          <location offset="147" length="20"/>
          <text>N-methyl-D-aspartate</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="169" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">n-methyl-d-aspartate-(nmda) receptor</infon>
          <location offset="147" length="36"/>
          <text>N-methyl-D-aspartate-(NMDA) receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>222</offset>
        <text>Extracellular pH regulates the activity and drug sensitivity of NMDA-receptor channels.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="286" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda-receptor</infon>
          <location offset="286" length="13"/>
          <text>NMDA-receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>310</offset>
        <text>We examined the influence of extracellular pH on sensitivity to meperidine of epsilon/zeta heteromeric NMDA-receptor channels expressed in Xenopus oocytes.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="374" length="10"/>
          <text>meperidine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="413" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda-receptor</infon>
          <location offset="413" length="13"/>
          <text>NMDA-receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>466</offset>
        <text>Inhibition of epsilon1/zeta1, epsilon2/zeta1, epsilon3/zeta1, and epsilon4/zeta1 channels by meperidine was dependent on pH, with more inhibition at acidic pH and less inhibition at alkaline pH.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="559" length="10"/>
          <text>meperidine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epsilon1/zeta1</infon>
          <location offset="480" length="14"/>
          <text>epsilon1/zeta1</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epsilon2/zeta1</infon>
          <location offset="496" length="14"/>
          <text>epsilon2/zeta1</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epsilon3/zeta1</infon>
          <location offset="512" length="14"/>
          <text>epsilon3/zeta1</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epsilon4/zeta1 channels</infon>
          <location offset="532" length="23"/>
          <text>epsilon4/zeta1 channels</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>661</offset>
        <text>The degree of voltage-dependence of meperidine block was only slightly affected by changes in pH, whereas affinity for meperidine was greatly reduced at alkaline pH.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="697" length="10"/>
          <text>meperidine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="780" length="10"/>
          <text>meperidine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>827</offset>
        <text>Furthermore, interaction of meperidine with Mg(2+) block was reduced at alkaline pH.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="855" length="10"/>
          <text>meperidine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mg(2+)</infon>
          <location offset="871" length="6"/>
          <text>Mg(2+)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>912</offset>
        <text>Because the percentage of the protonated form of meperidine is only slightly affected by pH, changes in properties of the meperidine binding site may be involved in mechanisms of alteration of meperidine potency by pH.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="1105" length="10"/>
          <text>meperidine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="961" length="10"/>
          <text>meperidine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="1034" length="10"/>
          <text>meperidine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1131</offset>
        <text>IMPLICATIONS: At acidic pH the potency of meperidine for N-methyl-D-aspartate-receptor channels was increased.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="1173" length="10"/>
          <text>meperidine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-methyl-d-aspartate</infon>
          <location offset="1188" length="20"/>
          <text>N-methyl-D-aspartate</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">n-methyl-d-aspartate-receptor</infon>
          <location offset="1188" length="29"/>
          <text>N-methyl-D-aspartate-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1242</offset>
        <text>Any antinociceptive and neuroprotective benefit from the N-methyl-D-aspartate-receptor antagonist property of meperidine may be pH dependent.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-methyl-d-aspartate</infon>
          <location offset="1299" length="20"/>
          <text>N-methyl-D-aspartate</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="1352" length="10"/>
          <text>meperidine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">n-methyl-d-aspartate-receptor</infon>
          <location offset="1299" length="29"/>
          <text>N-methyl-D-aspartate-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23564645</id>
    <passage>
      <offset>0</offset>
      <text>Detection of Statin Cytotoxicity Is Increased in Cells Expressing the OATP1B1 Transporter.	Cytotoxicity of a compound is determined by the intracellular concentration mediated both by passive permeability and active uptake through drug transporters. However, the major liver uptake transporters were either absent or expressed at significantly lower levels in human liver cell lines than in human liver. When comparing cytotoxicity of five statins, the organic anion transporting polypeptide 1B1 (OATP1B1) expressing HEK cells showed a significantly higher sensitivity than the wild-type HEK cells. The IC50 shifts ranged from 9- to &gt;100-fold, and the potency shifts collapsed in the presence of rifampicin, the inhibitor for OATPs. The extent of the IC50 shift correlated with the permeability of the statins with high permeable compounds having smaller shifts and low permeable compounds having larger shifts. The changes in statin potency in transporter transfected cells reflect the active uptake of statins into the cells and the increased intracellular drug concentration lead to increased toxicity. The data suggested that uptake transporters have a significant impact on the outcomes of a cell-based assay and should be considered during the early stages of compound toxicity screening in drug discovery. For compounds with low permeability which are likely to undergo transporter-mediated uptake, it is important to test them in transporter-competent cell models.</text>
      <sentence>
        <offset>0</offset>
        <text>Detection of Statin Cytotoxicity Is Increased in Cells Expressing the OATP1B1 Transporter.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="70" length="7"/>
          <text>OATP1B1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>91</offset>
        <text>Cytotoxicity of a compound is determined by the intracellular concentration mediated both by passive permeability and active uptake through drug transporters.</text>
      </sentence>
      <sentence>
        <offset>250</offset>
        <text>However, the major liver uptake transporters were either absent or expressed at significantly lower levels in human liver cell lines than in human liver.</text>
        <annotation id="T2">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">liver uptake transporters</infon>
          <location offset="269" length="25"/>
          <text>liver uptake transporters</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>404</offset>
        <text>When comparing cytotoxicity of five statins, the organic anion transporting polypeptide 1B1 (OATP1B1) expressing HEK cells showed a significantly higher sensitivity than the wild-type HEK cells.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">organic anion transporting polypeptide 1b1</infon>
          <location offset="453" length="42"/>
          <text>organic anion transporting polypeptide 1B1</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1b1</infon>
          <location offset="497" length="7"/>
          <text>OATP1B1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>599</offset>
        <text>The IC50 shifts ranged from 9- to &gt;100-fold, and the potency shifts collapsed in the presence of rifampicin, the inhibitor for OATPs.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="696" length="10"/>
          <text>rifampicin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">oatps</infon>
          <location offset="726" length="5"/>
          <text>OATPs</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T5" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>733</offset>
        <text>The extent of the IC50 shift correlated with the permeability of the statins with high permeable compounds having smaller shifts and low permeable compounds having larger shifts.</text>
      </sentence>
      <sentence>
        <offset>912</offset>
        <text>The changes in statin potency in transporter transfected cells reflect the active uptake of statins into the cells and the increased intracellular drug concentration lead to increased toxicity.</text>
      </sentence>
      <sentence>
        <offset>1106</offset>
        <text>The data suggested that uptake transporters have a significant impact on the outcomes of a cell-based assay and should be considered during the early stages of compound toxicity screening in drug discovery.</text>
      </sentence>
      <sentence>
        <offset>1313</offset>
        <text>For compounds with low permeability which are likely to undergo transporter-mediated uptake, it is important to test them in transporter-competent cell models.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23576175</id>
    <passage>
      <offset>0</offset>
      <text>Attenuation of Gouty Arthritis by Emodinol in Monosodium Urate Crystal-Treated Mice.	A series of studies have recently demonstrated that the release of interleukin 1β induced by monosodium urate crystals is central to the experimental gouty arthritis. Elaeagnus pungens has been traditionally used for the treatment of gouty arthritis in China for more than thousands years. However, there is still little known about the active ingredients and mechanisms of E. pungens against gouty arthritis. Emodinol, as a major triterpene compound in E. pungens, has been seldom reported to have an effect on gouty arthritis. Therefore, the potential beneficial effects and mechanisms of emodinol on gouty arthritis were investigated in this study. Results showed that it significantly ameliorated the hyperalgesia, inflammation, and levels of multiple proinflammatory cytokines in monosodium urate crystals-treated mice. These findings elucidate that emodinol exhibits a prominent effect on improving symptoms of acute gouty arthritis induced by monosodium urate crystals through inhibiting the generation of proinflammatory cytokines.</text>
      <sentence>
        <offset>0</offset>
        <text>Attenuation of Gouty Arthritis by Emodinol in Monosodium Urate Crystal-Treated Mice.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">emodinol</infon>
          <location offset="34" length="8"/>
          <text>Emodinol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monosodium urate</infon>
          <location offset="46" length="16"/>
          <text>Monosodium Urate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>85</offset>
        <text>A series of studies have recently demonstrated that the release of interleukin 1β induced by monosodium urate crystals is central to the experimental gouty arthritis.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monosodium urate</infon>
          <location offset="178" length="16"/>
          <text>monosodium urate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin 1β</infon>
          <location offset="152" length="14"/>
          <text>interleukin 1β</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>252</offset>
        <text>Elaeagnus pungens has been traditionally used for the treatment of gouty arthritis in China for more than thousands years.</text>
      </sentence>
      <sentence>
        <offset>375</offset>
        <text>However, there is still little known about the active ingredients and mechanisms of E. pungens against gouty arthritis.</text>
      </sentence>
      <sentence>
        <offset>495</offset>
        <text>Emodinol, as a major triterpene compound in E. pungens, has been seldom reported to have an effect on gouty arthritis.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">emodinol</infon>
          <location offset="495" length="8"/>
          <text>Emodinol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triterpene</infon>
          <location offset="516" length="10"/>
          <text>triterpene</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>614</offset>
        <text>Therefore, the potential beneficial effects and mechanisms of emodinol on gouty arthritis were investigated in this study.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">emodinol</infon>
          <location offset="676" length="8"/>
          <text>emodinol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>737</offset>
        <text>Results showed that it significantly ameliorated the hyperalgesia, inflammation, and levels of multiple proinflammatory cytokines in monosodium urate crystals-treated mice.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monosodium urate</infon>
          <location offset="870" length="16"/>
          <text>monosodium urate</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="857" length="9"/>
          <text>cytokines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>910</offset>
        <text>These findings elucidate that emodinol exhibits a prominent effect on improving symptoms of acute gouty arthritis induced by monosodium urate crystals through inhibiting the generation of proinflammatory cytokines.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">emodinol</infon>
          <location offset="940" length="8"/>
          <text>emodinol</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monosodium urate</infon>
          <location offset="1035" length="16"/>
          <text>monosodium urate</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="1114" length="9"/>
          <text>cytokines</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23345168</id>
    <passage>
      <offset>0</offset>
      <text>Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds.	In cancer tumors, growth, invasion, and formation of metastasis at a secondary site play a pivotal role, participating in diverse processes in the development of the pathology, such as degradation of extracellular matrix. Bauhinia seeds contain relatively large quantities of peptidase inhibitors, and two Bauhinia inhibitors were obtained in a recombinant form from the Bauhinia bauhinioides species, B. bauhinoides cruzipain inhibitor, which is a cysteine and serine peptidase inhibitor, and B. bauhinioides kallikrein inhibitor, which is a serine peptidase inhibitor. While recombinant B. bauhinoides cruzipain inhibitor inhibits human neutrophil elastase cathepsin G and the cysteine proteinase cathepsin L, recombinant B. bauhinioides kallikrein inhibitor inhibits plasma kallikrein and plasmin. The effects of recombinant B. bauhinoides cruzipain inhibitor and recombinant B. bauhinioides kallikrein inhibitor on the viability of tumor cell lines with a distinct potential of growth from the same tissue were compared to those of the clinical cytotoxic drug 5-fluorouracil. At 12.5 µM concentration, recombinant B. bauhinoides cruzipain inhibitor and recombinant B. bauhinioides kallikrein inhibitor were more efficient than 5-fluorouracil in inhibiting MKN-28 and Hs746T (gastric), HCT116 and HT29 (colorectal), SkBr-3 and MCF-7 (breast), and THP-1 and K562 (leukemia) cell lines. Additionally, recombinant B. bauhinoides cruzipain inhibitor inhibited 40 % of the migration of Hs746T, the most invasive gastric cell line, while recombinant B. bauhinioides kallikrein inhibitor did not affect cell migration. Recombinant B. bauhinioides kallikrein inhibitor and recombinant B. bauhinoides cruzipain inhibitor, even at high doses, did not affect hMSC proliferation while 5-fluorouracil greatly reduced the proliferation rates of hMSCs. Therefore, both recombinant B. bauhinoides cruzipain inhibitor and recombinant B. bauhinioides kallikrein inhibitor might be considered for further studies to block peptidase activities in order to target specific peptidase-mediated growth and invasion characteristics of individual tumors, mainly in patients resistant to 5-fluorouracil chemotherapy.</text>
      <sentence>
        <offset>0</offset>
        <text>Blocking the proliferation of human tumor cell lines by peptidase inhibitors from Bauhinia seeds.</text>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">peptidase</infon>
          <location offset="56" length="9"/>
          <text>peptidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>98</offset>
        <text>In cancer tumors, growth, invasion, and formation of metastasis at a secondary site play a pivotal role, participating in diverse processes in the development of the pathology, such as degradation of extracellular matrix.</text>
      </sentence>
      <sentence>
        <offset>320</offset>
        <text>Bauhinia seeds contain relatively large quantities of peptidase inhibitors, and two Bauhinia inhibitors were obtained in a recombinant form from the Bauhinia bauhinioides species, B. bauhinoides cruzipain inhibitor, which is a cysteine and serine peptidase inhibitor, and B. bauhinioides kallikrein inhibitor, which is a serine peptidase inhibitor.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteine</infon>
          <location offset="547" length="8"/>
          <text>cysteine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="560" length="6"/>
          <text>serine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="641" length="6"/>
          <text>serine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">peptidase</infon>
          <location offset="374" length="9"/>
          <text>peptidase</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cysteine and serine peptidase</infon>
          <location offset="547" length="29"/>
          <text>cysteine and serine peptidase</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">b. bauhinioides kallikrein</infon>
          <location offset="592" length="26"/>
          <text>B. bauhinioides kallikrein</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serine peptidase</infon>
          <location offset="641" length="16"/>
          <text>serine peptidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>669</offset>
        <text>While recombinant B. bauhinoides cruzipain inhibitor inhibits human neutrophil elastase cathepsin G and the cysteine proteinase cathepsin L, recombinant B. bauhinioides kallikrein inhibitor inhibits plasma kallikrein and plasmin.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteine</infon>
          <location offset="777" length="8"/>
          <text>cysteine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human neutrophil elastase</infon>
          <location offset="731" length="25"/>
          <text>human neutrophil elastase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cathepsin g</infon>
          <location offset="757" length="11"/>
          <text>cathepsin G</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cysteine proteinase</infon>
          <location offset="777" length="19"/>
          <text>cysteine proteinase</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cathepsin l</infon>
          <location offset="797" length="11"/>
          <text>cathepsin L</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">b. bauhinioides kallikrein</infon>
          <location offset="822" length="26"/>
          <text>B. bauhinioides kallikrein</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">plasma kallikrein</infon>
          <location offset="868" length="17"/>
          <text>plasma kallikrein</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasmin</infon>
          <location offset="890" length="7"/>
          <text>plasmin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>899</offset>
        <text>The effects of recombinant B. bauhinoides cruzipain inhibitor and recombinant B. bauhinioides kallikrein inhibitor on the viability of tumor cell lines with a distinct potential of growth from the same tissue were compared to those of the clinical cytotoxic drug 5-fluorouracil.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fluorouracil</infon>
          <location offset="1162" length="14"/>
          <text>5-fluorouracil</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">b. bauhinioides kallikrein</infon>
          <location offset="977" length="26"/>
          <text>B. bauhinioides kallikrein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1178</offset>
        <text>At 12.5 µM concentration, recombinant B. bauhinoides cruzipain inhibitor and recombinant B. bauhinioides kallikrein inhibitor were more efficient than 5-fluorouracil in inhibiting MKN-28 and Hs746T (gastric), HCT116 and HT29 (colorectal), SkBr-3 and MCF-7 (breast), and THP-1 and K562 (leukemia) cell lines.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fluorouracil</infon>
          <location offset="1329" length="14"/>
          <text>5-fluorouracil</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">b. bauhinioides kallikrein</infon>
          <location offset="1267" length="26"/>
          <text>B. bauhinioides kallikrein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1486</offset>
        <text>Additionally, recombinant B. bauhinoides cruzipain inhibitor inhibited 40 % of the migration of Hs746T, the most invasive gastric cell line, while recombinant B. bauhinioides kallikrein inhibitor did not affect cell migration.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">b. bauhinioides kallikrein</infon>
          <location offset="1645" length="26"/>
          <text>B. bauhinioides kallikrein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1713</offset>
        <text>Recombinant B. bauhinioides kallikrein inhibitor and recombinant B. bauhinoides cruzipain inhibitor, even at high doses, did not affect hMSC proliferation while 5-fluorouracil greatly reduced the proliferation rates of hMSCs.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fluorouracil</infon>
          <location offset="1874" length="14"/>
          <text>5-fluorouracil</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">b. bauhinioides kallikrein</infon>
          <location offset="1725" length="26"/>
          <text>B. bauhinioides kallikrein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1939</offset>
        <text>Therefore, both recombinant B. bauhinoides cruzipain inhibitor and recombinant B. bauhinioides kallikrein inhibitor might be considered for further studies to block peptidase activities in order to target specific peptidase-mediated growth and invasion characteristics of individual tumors, mainly in patients resistant to 5-fluorouracil chemotherapy.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fluorouracil</infon>
          <location offset="2262" length="14"/>
          <text>5-fluorouracil</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">b. bauhinioides kallikrein</infon>
          <location offset="2018" length="26"/>
          <text>B. bauhinioides kallikrein</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">peptidase</infon>
          <location offset="2104" length="9"/>
          <text>peptidase</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">peptidase</infon>
          <location offset="2153" length="9"/>
          <text>peptidase</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17629760</id>
    <passage>
      <offset>0</offset>
      <text>Muscular dystrophy associated mutations in caveolin-1 induce neurotransmission and locomotion defects in Caenorhabditis elegans.	Mutations in human caveolin-3 are known to underlie a range of myopathies. The cav-1 gene of Caenorhabditis elegans is a homologue of human caveolin-3 and is expressed in both neurons and body wall muscles. Within the body wall muscle CAV-1 localises adjacent to neurons, most likely at the neuromuscular junction (NMJ). Using fluorescently tagged CAV-1 and pre- and post-synaptic markers we demonstrate that CAV-1 co-localises with UNC-63, a post-synaptic marker, but not with several pre-synaptic markers. To establish a model for human muscular dystrophies caused by dominant-negative mutations in caveolin-3 we created transgenic animals carrying versions of cav-1 with homologous mutations. These animals had increased sensitivity to levamisole, suggesting a role for cav-1 at the NMJ. Animals carrying a deletion in cav-1 show a similar sensitivity. Sensitivity to levamisole and locomotion were also perturbed in animals carrying a dominant-negative cav-1 and a mutation in dynamin, which is a protein known to interact with caveolins. Thus, indicating an interaction between CAV-1 and dynamin at the NMJ and/or in neurons.</text>
      <sentence>
        <offset>0</offset>
        <text>Muscular dystrophy associated mutations in caveolin-1 induce neurotransmission and locomotion defects in Caenorhabditis elegans.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caveolin-1</infon>
          <location offset="43" length="10"/>
          <text>caveolin-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>129</offset>
        <text>Mutations in human caveolin-3 are known to underlie a range of myopathies.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human caveolin-3</infon>
          <location offset="142" length="16"/>
          <text>human caveolin-3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>204</offset>
        <text>The cav-1 gene of Caenorhabditis elegans is a homologue of human caveolin-3 and is expressed in both neurons and body wall muscles.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human caveolin-3</infon>
          <location offset="263" length="16"/>
          <text>human caveolin-3</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cav-1</infon>
          <location offset="208" length="5"/>
          <text>cav-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>336</offset>
        <text>Within the body wall muscle CAV-1 localises adjacent to neurons, most likely at the neuromuscular junction (NMJ).</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cav-1</infon>
          <location offset="364" length="5"/>
          <text>CAV-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>450</offset>
        <text>Using fluorescently tagged CAV-1 and pre- and post-synaptic markers we demonstrate that CAV-1 co-localises with UNC-63, a post-synaptic marker, but not with several pre-synaptic markers.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cav-1</infon>
          <location offset="477" length="5"/>
          <text>CAV-1</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cav-1</infon>
          <location offset="538" length="5"/>
          <text>CAV-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>637</offset>
        <text>To establish a model for human muscular dystrophies caused by dominant-negative mutations in caveolin-3 we created transgenic animals carrying versions of cav-1 with homologous mutations.</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">caveolin-3</infon>
          <location offset="730" length="10"/>
          <text>caveolin-3</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cav-1</infon>
          <location offset="792" length="5"/>
          <text>cav-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>825</offset>
        <text>These animals had increased sensitivity to levamisole, suggesting a role for cav-1 at the NMJ.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levamisole</infon>
          <location offset="868" length="10"/>
          <text>levamisole</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cav-1</infon>
          <location offset="902" length="5"/>
          <text>cav-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>920</offset>
        <text>Animals carrying a deletion in cav-1 show a similar sensitivity.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cav-1</infon>
          <location offset="951" length="5"/>
          <text>cav-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>985</offset>
        <text>Sensitivity to levamisole and locomotion were also perturbed in animals carrying a dominant-negative cav-1 and a mutation in dynamin, which is a protein known to interact with caveolins.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levamisole</infon>
          <location offset="1000" length="10"/>
          <text>levamisole</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">caveolins</infon>
          <location offset="1161" length="9"/>
          <text>caveolins</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cav-1</infon>
          <location offset="1086" length="5"/>
          <text>cav-1</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dynamin</infon>
          <location offset="1110" length="7"/>
          <text>dynamin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1172</offset>
        <text>Thus, indicating an interaction between CAV-1 and dynamin at the NMJ and/or in neurons.</text>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cav-1</infon>
          <location offset="1212" length="5"/>
          <text>CAV-1</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dynamin</infon>
          <location offset="1222" length="7"/>
          <text>dynamin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>8836655</id>
    <passage>
      <offset>0</offset>
      <text>Epinastine (WAL 801CL) modulates the noncholinergic contraction in guinea-pig airways in vitro by a prejunctional 5-HT1-like receptor.	Electrical field stimulation (EFS) of guinea-pig airways, in vitro, evokes an excitatory nonadrenergic noncholinergic (eNANC) contraction mediated by release of tachykinins from sensory nerve endings. Epinastine (WAL 801CL) is an antihistaminic drug with binding affinity at certain other receptors, including alpha-adrenergic receptors and various serotonin (5-HT) receptor subtypes. It is used in asthma treatment; however, its mechanism of action remains to be fully defined. We have investigated whether epinastine could modulate the eNANC contraction in guinea-pig airways in vitro, and have tried to elucidate its receptor mechanism. Epinastine (0.1-100 microM) produced a concentration-dependent inhibition of the noncholinergic contraction, with a maximum inhibition of 91 +/- 7% at 100 microM. Pretreatment of the tissues with combined 5-HT1/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction. Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect. Chlorpheniramine (10 microM), another histamine H1 receptor antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction. Epinastine (100 microM) did not displace the dose-response curve to exogenously applied substance P (0.01-10 microM). These results suggest that epinastine, although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves.</text>
      <sentence>
        <offset>0</offset>
        <text>Epinastine (WAL 801CL) modulates the noncholinergic contraction in guinea-pig airways in vitro by a prejunctional 5-HT1-like receptor.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">epinastine</infon>
          <location offset="0" length="10"/>
          <text>Epinastine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wal 801cl</infon>
          <location offset="12" length="9"/>
          <text>WAL 801CL</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1-like receptor</infon>
          <location offset="114" length="19"/>
          <text>5-HT1-like receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>135</offset>
        <text>Electrical field stimulation (EFS) of guinea-pig airways, in vitro, evokes an excitatory nonadrenergic noncholinergic (eNANC) contraction mediated by release of tachykinins from sensory nerve endings.</text>
      </sentence>
      <sentence>
        <offset>336</offset>
        <text>Epinastine (WAL 801CL) is an antihistaminic drug with binding affinity at certain other receptors, including alpha-adrenergic receptors and various serotonin (5-HT) receptor subtypes.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">epinastine</infon>
          <location offset="336" length="10"/>
          <text>Epinastine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wal 801cl</infon>
          <location offset="348" length="9"/>
          <text>WAL 801CL</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="484" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="495" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha-adrenergic receptors</infon>
          <location offset="445" length="26"/>
          <text>alpha-adrenergic receptors</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serotonin (5-ht) receptor</infon>
          <location offset="484" length="25"/>
          <text>serotonin (5-HT) receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>520</offset>
        <text>It is used in asthma treatment; however, its mechanism of action remains to be fully defined.</text>
      </sentence>
      <sentence>
        <offset>614</offset>
        <text>We have investigated whether epinastine could modulate the eNANC contraction in guinea-pig airways in vitro, and have tried to elucidate its receptor mechanism.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">epinastine</infon>
          <location offset="643" length="10"/>
          <text>epinastine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>775</offset>
        <text>Epinastine (0.1-100 microM) produced a concentration-dependent inhibition of the noncholinergic contraction, with a maximum inhibition of 91 +/- 7% at 100 microM.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">epinastine</infon>
          <location offset="775" length="10"/>
          <text>Epinastine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>938</offset>
        <text>Pretreatment of the tissues with combined 5-HT1/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methysergide</infon>
          <location offset="1005" length="12"/>
          <text>methysergide</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methiothepin</infon>
          <location offset="1032" length="12"/>
          <text>methiothepin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">epinastine</infon>
          <location offset="1109" length="10"/>
          <text>epinastine</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1</infon>
          <location offset="980" length="5"/>
          <text>5-HT1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht2</infon>
          <location offset="986" length="5"/>
          <text>5-HT2</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T19" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T18" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T19" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T18" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1155</offset>
        <text>Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tropisetron</infon>
          <location offset="1173" length="11"/>
          <text>tropisetron</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketanserin</infon>
          <location offset="1217" length="10"/>
          <text>ketanserin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thioperamide</infon>
          <location offset="1261" length="12"/>
          <text>thioperamide</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="1289" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phentolamine</infon>
          <location offset="1317" length="12"/>
          <text>phentolamine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht3</infon>
          <location offset="1199" length="5"/>
          <text>5-HT3</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht2</infon>
          <location offset="1243" length="5"/>
          <text>5-HT2</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h3</infon>
          <location offset="1289" length="12"/>
          <text>histamine H3</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1399</offset>
        <text>Chlorpheniramine (10 microM), another histamine H1 receptor antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpheniramine</infon>
          <location offset="1399" length="16"/>
          <text>Chlorpheniramine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="1437" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="1490" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h1 receptor</infon>
          <location offset="1437" length="21"/>
          <text>histamine H1 receptor</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht receptor</infon>
          <location offset="1490" length="13"/>
          <text>5-HT receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T6" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1579</offset>
        <text>Epinastine (100 microM) did not displace the dose-response curve to exogenously applied substance P (0.01-10 microM).</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">epinastine</infon>
          <location offset="1579" length="10"/>
          <text>Epinastine</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">substance p</infon>
          <location offset="1667" length="11"/>
          <text>substance P</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1697</offset>
        <text>These results suggest that epinastine, although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">epinastine</infon>
          <location offset="1724" length="10"/>
          <text>epinastine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="1761" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1</infon>
          <location offset="1788" length="5"/>
          <text>5-HT1</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1-like receptor</infon>
          <location offset="1915" length="19"/>
          <text>5-HT1-like receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T10" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22917842</id>
    <passage>
      <offset>0</offset>
      <text>High multivitamin intakes during pregnancy and postweaning obesogenic diets interact to affect the relationship between expression of PPAR genes and glucose regulation in the offspring.	High multivitamin intake (HV) during pregnancy increases body fat and weight and alters glucose and fatty acid metabolism in Wistar rat offspring. This study investigated the expression of peroxisome-proliferator activated receptors (PPARs) genes involved in regulation of glucose and fatty acid metabolism in their tissues. Dams received the AIN-93G diet with either the regular (RV) or 10-fold multivitamins (HV) during pregnancy. Male offspring were weaned to either the RV diet (RV-RV and HV-RV) or an obesogenic diet (RV-Ob and HV-Ob). Gene expression of PPARs in tissues was analyzed by real-time reverse transcriptase polymerase chain reaction. Gestational diet (GD) did not affect PPARs gene expression in offspring at either birth or weaning. In liver, at 14 weeks postweaning, PPAR-γ was 30% lower in the HV-RV and 30% higher in HV-Ob than in the RV-RV group [GD P=.76, postweaning diet (PD) P=.19, interaction P=.02, by two-way analysis of variance]. In muscle, PPAR-α expression was affected by GD and PD (GD P=.05, PD P&lt;.01, interaction P=.07). In adipose tissue, PPAR-α expression was higher in all groups compared to RV-RV (GD P=.25, PD P=.85, interaction P=.03). PPAR-γ mRNA levels correlated with abdominal fat (r=0.45, P&lt;.05) and insulin resistance index (r=0.39, P&lt;.05). In liver, PPAR-γ expression correlated with insulin resistance index in offspring from RV (r=-0.62, P&lt;.05), but not in those from HV dams (r=0.13, P&gt;.05). In conclusion, the HV diet during pregnancy interacts with postweaning diets in determining the expression of PPARs genes in a tissue- and age-dependent manner and uncouples the relationship between these genes and glucose regulation and fat mass in the rat offspring.</text>
      <sentence>
        <offset>0</offset>
        <text>High multivitamin intakes during pregnancy and postweaning obesogenic diets interact to affect the relationship between expression of PPAR genes and glucose regulation in the offspring.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="149" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ppar</infon>
          <location offset="134" length="4"/>
          <text>PPAR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>186</offset>
        <text>High multivitamin intake (HV) during pregnancy increases body fat and weight and alters glucose and fatty acid metabolism in Wistar rat offspring.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="286" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="274" length="7"/>
          <text>glucose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>333</offset>
        <text>This study investigated the expression of peroxisome-proliferator activated receptors (PPARs) genes involved in regulation of glucose and fatty acid metabolism in their tissues.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="459" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="471" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">peroxisome-proliferator activated receptors</infon>
          <location offset="375" length="43"/>
          <text>peroxisome-proliferator activated receptors</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ppars</infon>
          <location offset="420" length="5"/>
          <text>PPARs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>511</offset>
        <text>Dams received the AIN-93G diet with either the regular (RV) or 10-fold multivitamins (HV) during pregnancy.</text>
      </sentence>
      <sentence>
        <offset>619</offset>
        <text>Male offspring were weaned to either the RV diet (RV-RV and HV-RV) or an obesogenic diet (RV-Ob and HV-Ob).</text>
      </sentence>
      <sentence>
        <offset>727</offset>
        <text>Gene expression of PPARs in tissues was analyzed by real-time reverse transcriptase polymerase chain reaction.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ppars</infon>
          <location offset="746" length="5"/>
          <text>PPARs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>838</offset>
        <text>Gestational diet (GD) did not affect PPARs gene expression in offspring at either birth or weaning.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ppars</infon>
          <location offset="875" length="5"/>
          <text>PPARs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>938</offset>
        <text>In liver, at 14 weeks postweaning, PPAR-γ was 30% lower in the HV-RV and 30% higher in HV-Ob than in the RV-RV group [GD P=.76, postweaning diet (PD) P=.19, interaction P=.02, by two-way analysis of variance].</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar-γ</infon>
          <location offset="973" length="6"/>
          <text>PPAR-γ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1148</offset>
        <text>In muscle, PPAR-α expression was affected by GD and PD (GD P=.05, PD P&lt;.01, interaction P=.07).</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar-α</infon>
          <location offset="1159" length="6"/>
          <text>PPAR-α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1244</offset>
        <text>In adipose tissue, PPAR-α expression was higher in all groups compared to RV-RV (GD P=.25, PD P=.85, interaction P=.03).</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar-α</infon>
          <location offset="1263" length="6"/>
          <text>PPAR-α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1365</offset>
        <text>PPAR-γ mRNA levels correlated with abdominal fat (r=0.45, P&lt;.05) and insulin resistance index (r=0.39, P&lt;.05).</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar-γ</infon>
          <location offset="1365" length="6"/>
          <text>PPAR-γ</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1434" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1476</offset>
        <text>In liver, PPAR-γ expression correlated with insulin resistance index in offspring from RV (r=-0.62, P&lt;.05), but not in those from HV dams (r=0.13, P&gt;.05).</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar-γ</infon>
          <location offset="1486" length="6"/>
          <text>PPAR-γ</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1520" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1631</offset>
        <text>In conclusion, the HV diet during pregnancy interacts with postweaning diets in determining the expression of PPARs genes in a tissue- and age-dependent manner and uncouples the relationship between these genes and glucose regulation and fat mass in the rat offspring.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1846" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ppars</infon>
          <location offset="1741" length="5"/>
          <text>PPARs</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12538485</id>
    <passage>
      <offset>0</offset>
      <text>In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.	One challenging aspect in the clinical development of molecularly targeted therapies, which represent a new and promising approach to treating cancers, has been the identification of a biologically active dose rather than a maximum tolerated dose. The goal of the present study was to identify a pharmacokinetic/pharmacodynamic relationship in preclinical models that could be used to help guide selection of a clinical dose. SU11248, a novel small molecule receptor tyrosine kinase inhibitor with direct antitumor as well as antiangiogenic activity via targeting the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), KIT, and FLT3 receptor tyrosine kinases, was used as the pharmacological agent in these studies. In mouse xenograft models, SU11248 exhibited broad and potent antitumor activity causing regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines. To predict the target SU11248 exposure required to achieve antitumor activity in mouse xenograft models, we directly measured target phosphorylation in tumor xenografts before and after SU11248 treatment and correlated this with plasma inhibitor levels. In target modulation studies in vivo, SU11248 selectively inhibited Flk-1/KDR (VEGF receptor 2) and PDGF receptor beta phosphorylation (in a time- and dose-dependent manner) when plasma concentrations of inhibitor reached or exceeded 50-100 ng/ml. Similar results were obtained in a functional assay of VEGF-induced vascular permeability in vivo. Constant inhibition of VEGFR2 and PDGF receptor beta phosphorylation was not required for efficacy; at highly efficacious doses, inhibition was sustained for 12 h of a 24-h dosing interval. The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.</text>
      <sentence>
        <offset>0</offset>
        <text>In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">su11248</infon>
          <location offset="30" length="7"/>
          <text>SU11248</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="47" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">platelet-derived growth factor receptors</infon>
          <location offset="122" length="40"/>
          <text>platelet-derived growth factor receptors</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tyrosine kinase</infon>
          <location offset="47" length="15"/>
          <text>tyrosine kinase</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vascular endothelial growth factor</infon>
          <location offset="83" length="34"/>
          <text>vascular endothelial growth factor</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>229</offset>
        <text>One challenging aspect in the clinical development of molecularly targeted therapies, which represent a new and promising approach to treating cancers, has been the identification of a biologically active dose rather than a maximum tolerated dose.</text>
      </sentence>
      <sentence>
        <offset>477</offset>
        <text>The goal of the present study was to identify a pharmacokinetic/pharmacodynamic relationship in preclinical models that could be used to help guide selection of a clinical dose.</text>
      </sentence>
      <sentence>
        <offset>655</offset>
        <text>SU11248, a novel small molecule receptor tyrosine kinase inhibitor with direct antitumor as well as antiangiogenic activity via targeting the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), KIT, and FLT3 receptor tyrosine kinases, was used as the pharmacological agent in these studies.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">su11248</infon>
          <location offset="655" length="7"/>
          <text>SU11248</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="696" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="902" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">receptor tyrosine kinase</infon>
          <location offset="687" length="24"/>
          <text>receptor tyrosine kinase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vascular endothelial growth factor</infon>
          <location offset="797" length="34"/>
          <text>vascular endothelial growth factor</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="833" length="4"/>
          <text>VEGF</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">platelet-derived growth factor</infon>
          <location offset="840" length="30"/>
          <text>platelet-derived growth factor</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pdgf</infon>
          <location offset="872" length="4"/>
          <text>PDGF</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kit</infon>
          <location offset="879" length="3"/>
          <text>KIT</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flt3</infon>
          <location offset="888" length="4"/>
          <text>FLT3</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">receptor tyrosine kinases</infon>
          <location offset="893" length="25"/>
          <text>receptor tyrosine kinases</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>976</offset>
        <text>In mouse xenograft models, SU11248 exhibited broad and potent antitumor activity causing regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">su11248</infon>
          <location offset="1003" length="7"/>
          <text>SU11248</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1202</offset>
        <text>To predict the target SU11248 exposure required to achieve antitumor activity in mouse xenograft models, we directly measured target phosphorylation in tumor xenografts before and after SU11248 treatment and correlated this with plasma inhibitor levels.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">su11248</infon>
          <location offset="1388" length="7"/>
          <text>SU11248</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">su11248</infon>
          <location offset="1224" length="7"/>
          <text>SU11248</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1456</offset>
        <text>In target modulation studies in vivo, SU11248 selectively inhibited Flk-1/KDR (VEGF receptor 2) and PDGF receptor beta phosphorylation (in a time- and dose-dependent manner) when plasma concentrations of inhibitor reached or exceeded 50-100 ng/ml.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">su11248</infon>
          <location offset="1494" length="7"/>
          <text>SU11248</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flk-1</infon>
          <location offset="1524" length="5"/>
          <text>Flk-1</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kdr</infon>
          <location offset="1530" length="3"/>
          <text>KDR</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf receptor 2</infon>
          <location offset="1535" length="15"/>
          <text>VEGF receptor 2</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgf receptor beta</infon>
          <location offset="1556" length="18"/>
          <text>PDGF receptor beta</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1704</offset>
        <text>Similar results were obtained in a functional assay of VEGF-induced vascular permeability in vivo.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="1759" length="4"/>
          <text>VEGF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1803</offset>
        <text>Constant inhibition of VEGFR2 and PDGF receptor beta phosphorylation was not required for efficacy; at highly efficacious doses, inhibition was sustained for 12 h of a 24-h dosing interval.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vegfr2</infon>
          <location offset="1826" length="6"/>
          <text>VEGFR2</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pdgf receptor beta</infon>
          <location offset="1837" length="18"/>
          <text>PDGF receptor beta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1993</offset>
        <text>The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">su11248</infon>
          <location offset="2058" length="7"/>
          <text>SU11248</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18073378</id>
    <passage>
      <offset>0</offset>
      <text>Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.	BACKGROUND: Clinical trial data have shown that among breast cancer patients who were disease free after 5 years of adjuvant treatment with tamoxifen, further extended treatment with the nonsteroidal aromatase inhibitor letrozole reduces breast cancer recurrence. We examined the efficacy and tolerability of extended adjuvant therapy with another aromatase inhibitor, anastrozole, for 3 years among women who had completed 5 years of adjuvant therapy. METHODS: Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 6a is an extension of ABCSG Trial 6, in which hormone receptor-positive postmenopausal patients received 5 years of adjuvant tamoxifen, with or without the aromatase inhibitor aminoglutethimide, for the first 2 years of therapy. For ABCSG Trial 6a, patients who were disease free at the end of Trial 6 were randomly assigned to receive either 3 years of anastrozole or no further treatment. Efficacy data were analyzed with the use of a Cox proportional hazards regression model with two-sided P values and Kaplan-Meier curves, and tolerability data were estimated using logistic regression analysis with odds ratios and 95% confidence intervals (CIs). RESULTS: ABCSG Trial 6a included 856 patients. At a median follow-up of 62.3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0.62; 95% CI = 0.40 to 0.96, P = .031). Anastrozole was well tolerated, and no unexpected adverse events were reported. CONCLUSIONS: These data confirm the benefit of extending adjuvant tamoxifen therapy beyond 5 years with anastrozole compared with no further treatment. Further research is required to define the optimum length of extended adjuvant therapy and to investigate the possibility of tailoring this period to suit different disease types.</text>
      <sentence>
        <offset>0</offset>
        <text>Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anastrozole</infon>
          <location offset="31" length="11"/>
          <text>anastrozole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>176</offset>
        <text>BACKGROUND: Clinical trial data have shown that among breast cancer patients who were disease free after 5 years of adjuvant treatment with tamoxifen, further extended treatment with the nonsteroidal aromatase inhibitor letrozole reduces breast cancer recurrence.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="316" length="9"/>
          <text>tamoxifen</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">letrozole</infon>
          <location offset="396" length="9"/>
          <text>letrozole</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="376" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>440</offset>
        <text>We examined the efficacy and tolerability of extended adjuvant therapy with another aromatase inhibitor, anastrozole, for 3 years among women who had completed 5 years of adjuvant therapy.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anastrozole</infon>
          <location offset="545" length="11"/>
          <text>anastrozole</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="524" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>629</offset>
        <text>METHODS: Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 6a is an extension of ABCSG Trial 6, in which hormone receptor-positive postmenopausal patients received 5 years of adjuvant tamoxifen, with or without the aromatase inhibitor aminoglutethimide, for the first 2 years of therapy.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="827" length="9"/>
          <text>tamoxifen</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aminoglutethimide</infon>
          <location offset="878" length="17"/>
          <text>aminoglutethimide</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hormone receptor</infon>
          <location offset="748" length="16"/>
          <text>hormone receptor</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="858" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>931</offset>
        <text>For ABCSG Trial 6a, patients who were disease free at the end of Trial 6 were randomly assigned to receive either 3 years of anastrozole or no further treatment.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anastrozole</infon>
          <location offset="1056" length="11"/>
          <text>anastrozole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1093</offset>
        <text>Efficacy data were analyzed with the use of a Cox proportional hazards regression model with two-sided P values and Kaplan-Meier curves, and tolerability data were estimated using logistic regression analysis with odds ratios and 95% confidence intervals (CIs).</text>
      </sentence>
      <sentence>
        <offset>1355</offset>
        <text>RESULTS: ABCSG Trial 6a included 856 patients.</text>
      </sentence>
      <sentence>
        <offset>1402</offset>
        <text>At a median follow-up of 62.3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0.62; 95% CI = 0.40 to 0.96, P = .031).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anastrozole</infon>
          <location offset="1459" length="11"/>
          <text>anastrozole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1739</offset>
        <text>Anastrozole was well tolerated, and no unexpected adverse events were reported.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anastrozole</infon>
          <location offset="1739" length="11"/>
          <text>Anastrozole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1819</offset>
        <text>CONCLUSIONS: These data confirm the benefit of extending adjuvant tamoxifen therapy beyond 5 years with anastrozole compared with no further treatment.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tamoxifen</infon>
          <location offset="1885" length="9"/>
          <text>tamoxifen</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anastrozole</infon>
          <location offset="1923" length="11"/>
          <text>anastrozole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1971</offset>
        <text>Further research is required to define the optimum length of extended adjuvant therapy and to investigate the possibility of tailoring this period to suit different disease types.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>7832763</id>
    <passage>
      <offset>0</offset>
      <text>Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase.	The enzyme cyclo-oxygenase catalyses the oxygenation of arachidonic acid, leading to the formation of prostaglandins. Recently two forms of cyclo-oxygenase have been described: a constitutive (COX-1) enzyme present in most cells and tissues, and an inducible (COX-2) isoenzyme observed in many cells in response to pro-inflammatory cytokines. Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme. Indomethacin inhibited both hCOX-1 and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2. Both NS-398 and Dup-697 exhibited time-dependent inactivation of hCOX-2, as did indomethacin on both enzymes. The competitive inhibitor of hCOX-1, mefenamic acid, also displayed competitive inhibition of hCOX-2. These results demonstrate the ability to generate selective non-steroidal anti-inflammatory drugs (NSAIDs), which could provide useful improvement therapeutically in the treatment of chronic inflammatory disease.</text>
      <sentence>
        <offset>0</offset>
        <text>Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase.</text>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">constitutive and inducible forms of human cyclo-oxygenase</infon>
          <location offset="43" length="57"/>
          <text>constitutive and inducible forms of human cyclo-oxygenase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>102</offset>
        <text>The enzyme cyclo-oxygenase catalyses the oxygenation of arachidonic acid, leading to the formation of prostaglandins.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prostaglandins</infon>
          <location offset="204" length="14"/>
          <text>prostaglandins</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arachidonic acid</infon>
          <location offset="158" length="16"/>
          <text>arachidonic acid</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyclo-oxygenase</infon>
          <location offset="113" length="15"/>
          <text>cyclo-oxygenase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>220</offset>
        <text>Recently two forms of cyclo-oxygenase have been described: a constitutive (COX-1) enzyme present in most cells and tissues, and an inducible (COX-2) isoenzyme observed in many cells in response to pro-inflammatory cytokines.</text>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyclo-oxygenase</infon>
          <location offset="242" length="15"/>
          <text>cyclo-oxygenase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-1</infon>
          <location offset="295" length="5"/>
          <text>COX-1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="362" length="5"/>
          <text>COX-2</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="434" length="9"/>
          <text>cytokines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>445</offset>
        <text>Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system.</text>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">constitutive and inducible forms of human cyclo-oxygenase</infon>
          <location offset="445" length="57"/>
          <text>Constitutive and inducible forms of human cyclo-oxygenase</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hcox-1</infon>
          <location offset="504" length="6"/>
          <text>hCOX-1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hcox-2</infon>
          <location offset="515" length="6"/>
          <text>hCOX-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>609</offset>
        <text>hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o2</infon>
          <location offset="657" length="2"/>
          <text>O2</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arachidonate</infon>
          <location offset="692" length="12"/>
          <text>arachidonate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o2</infon>
          <location offset="806" length="2"/>
          <text>O2</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arachidonate</infon>
          <location offset="840" length="12"/>
          <text>arachidonate</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o2</infon>
          <location offset="881" length="2"/>
          <text>O2</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hcox-1</infon>
          <location offset="609" length="6"/>
          <text>hCOX-1</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hcox-2</infon>
          <location offset="758" length="6"/>
          <text>hCOX-2</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T8" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>900</offset>
        <text>Indomethacin inhibited both hCOX-1 and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="900" length="12"/>
          <text>Indomethacin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ns-398</infon>
          <location offset="955" length="6"/>
          <text>NS-398</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dup-697</infon>
          <location offset="966" length="7"/>
          <text>Dup-697</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hcox-1</infon>
          <location offset="928" length="6"/>
          <text>hCOX-1</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hcox-2</infon>
          <location offset="939" length="6"/>
          <text>hCOX-2</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hcox-2</infon>
          <location offset="996" length="6"/>
          <text>hCOX-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1004</offset>
        <text>Both NS-398 and Dup-697 exhibited time-dependent inactivation of hCOX-2, as did indomethacin on both enzymes.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ns-398</infon>
          <location offset="1009" length="6"/>
          <text>NS-398</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dup-697</infon>
          <location offset="1020" length="7"/>
          <text>Dup-697</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="1084" length="12"/>
          <text>indomethacin</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hcox-2</infon>
          <location offset="1069" length="6"/>
          <text>hCOX-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1114</offset>
        <text>The competitive inhibitor of hCOX-1, mefenamic acid, also displayed competitive inhibition of hCOX-2.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mefenamic acid</infon>
          <location offset="1151" length="14"/>
          <text>mefenamic acid</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hcox-1</infon>
          <location offset="1143" length="6"/>
          <text>hCOX-1</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hcox-2</infon>
          <location offset="1208" length="6"/>
          <text>hCOX-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1216</offset>
        <text>These results demonstrate the ability to generate selective non-steroidal anti-inflammatory drugs (NSAIDs), which could provide useful improvement therapeutically in the treatment of chronic inflammatory disease.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroidal</infon>
          <location offset="1280" length="9"/>
          <text>steroidal</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23542815</id>
    <passage>
      <offset>0</offset>
      <text>Arsenic trioxide induces cardiac fibroblast apoptosis in vitro and in vivo by up-regulating TGF-β1 expression.	Arsenic trioxide (As2O3; ATO) is clinically effective in treating acute promyelocytic leukemia (APL); however, it frequently causes cardiotoxic effects. This study was designed to investigate whether ATO could induce apoptosis of cardiac fibroblasts (CFs) that play very important roles in maintaining the structure integrity and function of the heart. Cardiac fibroblasts from guinea pigs administered with ATO (1mg/kgbw) were used to test the pro-apoptotic role of ATO in vivo. The current study demonstrated that ATO induced morphological characteristics of apoptosis and Caspase-3 activation in CFs of guinea pigs along with a significant up-regulation in TGF-β1 protein expression, Bax/Bcl-2 ratio and ERK1/2 phosphorylation. In vitro MTT assay showed that ATO remarkably reduced the viability of cultured cardiac fibroblasts (NRCFs) from neonatal rat in a concentration- and time-dependent manner. Consistent with the notions in vivo, ATO significantly induced the apoptosis in NRCFs, dramatically up-regulated TGF-β1 protein level and Bax/Bcl-2 ratio in a time-dependent fashion and activated Caspase-3 and ERK1/2. Finally, pretreatment with LY364947, an inhibitor of TGF-β signaling could apparently reverse these changes. We therefore conclude that TGF-β is functionally linked to ERK1/2 and that TGF-β signaling is responsible for ATO-induced CFs apoptosis, which provides a novel mechanism of ATO related cardiac toxicology.</text>
      <sentence>
        <offset>0</offset>
        <text>Arsenic trioxide induces cardiac fibroblast apoptosis in vitro and in vivo by up-regulating TGF-β1 expression.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arsenic trioxide</infon>
          <location offset="0" length="16"/>
          <text>Arsenic trioxide</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tgf-β1</infon>
          <location offset="92" length="6"/>
          <text>TGF-β1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>111</offset>
        <text>Arsenic trioxide (As2O3; ATO) is clinically effective in treating acute promyelocytic leukemia (APL); however, it frequently causes cardiotoxic effects.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arsenic trioxide</infon>
          <location offset="111" length="16"/>
          <text>Arsenic trioxide</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">as2o3</infon>
          <location offset="129" length="5"/>
          <text>As2O3</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="136" length="3"/>
          <text>ATO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>264</offset>
        <text>This study was designed to investigate whether ATO could induce apoptosis of cardiac fibroblasts (CFs) that play very important roles in maintaining the structure integrity and function of the heart.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="311" length="3"/>
          <text>ATO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>464</offset>
        <text>Cardiac fibroblasts from guinea pigs administered with ATO (1mg/kgbw) were used to test the pro-apoptotic role of ATO in vivo.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="519" length="3"/>
          <text>ATO</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="578" length="3"/>
          <text>ATO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>591</offset>
        <text>The current study demonstrated that ATO induced morphological characteristics of apoptosis and Caspase-3 activation in CFs of guinea pigs along with a significant up-regulation in TGF-β1 protein expression, Bax/Bcl-2 ratio and ERK1/2 phosphorylation.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="627" length="3"/>
          <text>ATO</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="686" length="9"/>
          <text>Caspase-3</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β1</infon>
          <location offset="771" length="6"/>
          <text>TGF-β1</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="798" length="3"/>
          <text>Bax</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="802" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="818" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>842</offset>
        <text>In vitro MTT assay showed that ATO remarkably reduced the viability of cultured cardiac fibroblasts (NRCFs) from neonatal rat in a concentration- and time-dependent manner.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mtt</infon>
          <location offset="851" length="3"/>
          <text>MTT</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="873" length="3"/>
          <text>ATO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1015</offset>
        <text>Consistent with the notions in vivo, ATO significantly induced the apoptosis in NRCFs, dramatically up-regulated TGF-β1 protein level and Bax/Bcl-2 ratio in a time-dependent fashion and activated Caspase-3 and ERK1/2.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="1052" length="3"/>
          <text>ATO</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β1</infon>
          <location offset="1128" length="6"/>
          <text>TGF-β1</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="1153" length="3"/>
          <text>Bax</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="1157" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="1211" length="9"/>
          <text>Caspase-3</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="1225" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1233</offset>
        <text>Finally, pretreatment with LY364947, an inhibitor of TGF-β signaling could apparently reverse these changes.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ly364947</infon>
          <location offset="1260" length="8"/>
          <text>LY364947</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tgf-β</infon>
          <location offset="1286" length="5"/>
          <text>TGF-β</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1342</offset>
        <text>We therefore conclude that TGF-β is functionally linked to ERK1/2 and that TGF-β signaling is responsible for ATO-induced CFs apoptosis, which provides a novel mechanism of ATO related cardiac toxicology.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="1452" length="3"/>
          <text>ATO</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ato</infon>
          <location offset="1515" length="3"/>
          <text>ATO</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tgf-β</infon>
          <location offset="1369" length="5"/>
          <text>TGF-β</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="1401" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tgf-β</infon>
          <location offset="1417" length="5"/>
          <text>TGF-β</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1326878</id>
    <passage>
      <offset>0</offset>
      <text>Effects of nedocromil sodium on the binding of N-formyl-methionyl-leucyl-phenylalanine in human neutrophils.	In the present study the inhibition by nedocromil sodium of the specific receptor binding of FMLP was evaluated in human neutrophils (PMNs) using a FMLP-(3H) binding assay. The time course of the binding was markedly influenced by nedocromil sodium used at a concentration of 300 microM. No significant inhibition was obtained when the cells were treated with nedocromil sodium 3 microM or with sodium cromoglycate 300 microM. FMLP binding is essentially eliminated by the highest dose of nedocromil sodium. The biologic meaning of this effect in asthmatic patients should be further evaluated.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of nedocromil sodium on the binding of N-formyl-methionyl-leucyl-phenylalanine in human neutrophils.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nedocromil sodium</infon>
          <location offset="11" length="17"/>
          <text>nedocromil sodium</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-formyl-methionyl-leucyl-phenylalanine</infon>
          <location offset="47" length="39"/>
          <text>N-formyl-methionyl-leucyl-phenylalanine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>109</offset>
        <text>In the present study the inhibition by nedocromil sodium of the specific receptor binding of FMLP was evaluated in human neutrophils (PMNs) using a FMLP-(3H) binding assay.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nedocromil sodium</infon>
          <location offset="148" length="17"/>
          <text>nedocromil sodium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>282</offset>
        <text>The time course of the binding was markedly influenced by nedocromil sodium used at a concentration of 300 microM.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nedocromil sodium</infon>
          <location offset="340" length="17"/>
          <text>nedocromil sodium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>397</offset>
        <text>No significant inhibition was obtained when the cells were treated with nedocromil sodium 3 microM or with sodium cromoglycate 300 microM.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nedocromil sodium</infon>
          <location offset="469" length="17"/>
          <text>nedocromil sodium</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="504" length="6"/>
          <text>sodium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>536</offset>
        <text>FMLP binding is essentially eliminated by the highest dose of nedocromil sodium.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nedocromil sodium</infon>
          <location offset="598" length="17"/>
          <text>nedocromil sodium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>617</offset>
        <text>The biologic meaning of this effect in asthmatic patients should be further evaluated.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12416991</id>
    <passage>
      <offset>0</offset>
      <text>Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2).	Allopregnanolone is a neurosteroid which exhibits anxiolytic and anticonvulsant activities through potentiation of the GABA(A) receptor. The reduction of 5alpha-dihydroprogesterone (5alpha-DHP), the last step in allopregnanolone biosynthesis, is catalyzed by 3alpha-hydroxysteroid dehydrogenases (3alpha-HSDs). While the mechanism of action of allopregnanolone and the physiological and pharmacological modulation of allopregnanolone concentrations in vivo have been extensively studied, there has been little characterization of the kinetics of human 3alpha-HSD catalyzed allopregnanolone formation. We report here determination of the kinetic mechanism for 5alpha-DHP reduction catalyzed by human 3alpha-HSD type III by using steady-state kinetics studies and assessment of the ability of fluoxetine and various other small molecules to activate 3alpha-HSD type III catalyzed allopregnanolone formation. Enzyme-catalyzed 5alpha-DHP reduction yielded two products, allopregnanolone and 5alpha,20alpha-tetrahydroprogesterone, as measured by using a radiometric thin-layer chromatography assay, while 5beta-DHP reduction yielded the neurosteroid pregnanolone as the only product. 5Beta-DHP reduction proceeded with a catalytic efficiency 10 times higher than that of 5alpha-DHP reduction. Two-substrate kinetic analysis and dead-end inhibition studies for 5alpha-DHP reduction and allopregnanolone oxidation indicated that 3alpha-HSD type III utilized a ternary complex (sequential) kinetic mechanism, with nicotinamide adenine dinucleotide cofactor binding before steroid substrate and leaving after steroid product. Since previous reports suggested that fluoxetine and certain other small molecules increased allopregnanolone concentrations in vivo by activating 3alpha-HSD type III, we investigated whether these small molecules were able to activate human 3alpha-HSD type III. Our results showed that, at concentrations up to 50 microM, fluoxetine, paroxetine, sertraline, norfluoxetine, carbamazepine, clozapine, flurbiprofen, and sulfobromophthalein did not activate the enzyme. These results characterize the role of 3alpha-HSD type III in allopregnanolone formation and suggest that activation of this enzyme by fluoxetine is likely not the mechanism by which fluoxetine increases allopregnanolone concentrations.</text>
      <sentence>
        <offset>0</offset>
        <text>Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2).</text>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="12" length="16"/>
          <text>allopregnanolone</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3 alpha-hydroxysteroid</infon>
          <location offset="58" length="22"/>
          <text>3 alpha-hydroxysteroid</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c2</infon>
          <location offset="105" length="6"/>
          <text>AKR1C2</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human 3 alpha-hydroxysteroid dehydrogenase type iii</infon>
          <location offset="52" length="51"/>
          <text>human 3 alpha-hydroxysteroid dehydrogenase type III</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T38" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T38" role="head"/>
          <node refid="T50" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>114</offset>
        <text>Allopregnanolone is a neurosteroid which exhibits anxiolytic and anticonvulsant activities through potentiation of the GABA(A) receptor.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="114" length="16"/>
          <text>Allopregnanolone</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gaba(a) receptor</infon>
          <location offset="233" length="16"/>
          <text>GABA(A) receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>251</offset>
        <text>The reduction of 5alpha-dihydroprogesterone (5alpha-DHP), the last step in allopregnanolone biosynthesis, is catalyzed by 3alpha-hydroxysteroid dehydrogenases (3alpha-HSDs).</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5alpha-dihydroprogesterone</infon>
          <location offset="268" length="26"/>
          <text>5alpha-dihydroprogesterone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5alpha-dhp</infon>
          <location offset="296" length="10"/>
          <text>5alpha-DHP</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="326" length="16"/>
          <text>allopregnanolone</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3alpha-hydroxysteroid</infon>
          <location offset="373" length="21"/>
          <text>3alpha-hydroxysteroid</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">3alpha-hydroxysteroid dehydrogenases</infon>
          <location offset="373" length="36"/>
          <text>3alpha-hydroxysteroid dehydrogenases</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">3alpha-hsds</infon>
          <location offset="411" length="11"/>
          <text>3alpha-HSDs</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T23" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T23" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T14" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T14" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T9" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T9" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>425</offset>
        <text>While the mechanism of action of allopregnanolone and the physiological and pharmacological modulation of allopregnanolone concentrations in vivo have been extensively studied, there has been little characterization of the kinetics of human 3alpha-HSD catalyzed allopregnanolone formation.</text>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="458" length="16"/>
          <text>allopregnanolone</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="531" length="16"/>
          <text>allopregnanolone</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="687" length="16"/>
          <text>allopregnanolone</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human 3alpha-hsd</infon>
          <location offset="660" length="16"/>
          <text>human 3alpha-HSD</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T31" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>715</offset>
        <text>We report here determination of the kinetic mechanism for 5alpha-DHP reduction catalyzed by human 3alpha-HSD type III by using steady-state kinetics studies and assessment of the ability of fluoxetine and various other small molecules to activate 3alpha-HSD type III catalyzed allopregnanolone formation.</text>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5alpha-dhp</infon>
          <location offset="773" length="10"/>
          <text>5alpha-DHP</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="905" length="10"/>
          <text>fluoxetine</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="992" length="16"/>
          <text>allopregnanolone</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human 3alpha-hsd type iii</infon>
          <location offset="807" length="25"/>
          <text>human 3alpha-HSD type III</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">3alpha-hsd type iii</infon>
          <location offset="962" length="19"/>
          <text>3alpha-HSD type III</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T34" role="head"/>
          <node refid="T49" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T33" role="head"/>
          <node refid="T49" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T32" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1020</offset>
        <text>Enzyme-catalyzed 5alpha-DHP reduction yielded two products, allopregnanolone and 5alpha,20alpha-tetrahydroprogesterone, as measured by using a radiometric thin-layer chromatography assay, while 5beta-DHP reduction yielded the neurosteroid pregnanolone as the only product.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5beta-dhp</infon>
          <location offset="1214" length="9"/>
          <text>5beta-DHP</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pregnanolone</infon>
          <location offset="1259" length="12"/>
          <text>pregnanolone</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5alpha-dhp</infon>
          <location offset="1037" length="10"/>
          <text>5alpha-DHP</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="1080" length="16"/>
          <text>allopregnanolone</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5alpha,20alpha-tetrahydroprogesterone</infon>
          <location offset="1101" length="37"/>
          <text>5alpha,20alpha-tetrahydroprogesterone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1293</offset>
        <text>5Beta-DHP reduction proceeded with a catalytic efficiency 10 times higher than that of 5alpha-DHP reduction.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5beta-dhp</infon>
          <location offset="1293" length="9"/>
          <text>5Beta-DHP</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5alpha-dhp</infon>
          <location offset="1380" length="10"/>
          <text>5alpha-DHP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1402</offset>
        <text>Two-substrate kinetic analysis and dead-end inhibition studies for 5alpha-DHP reduction and allopregnanolone oxidation indicated that 3alpha-HSD type III utilized a ternary complex (sequential) kinetic mechanism, with nicotinamide adenine dinucleotide cofactor binding before steroid substrate and leaving after steroid product.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5alpha-dhp</infon>
          <location offset="1469" length="10"/>
          <text>5alpha-DHP</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="1494" length="16"/>
          <text>allopregnanolone</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nicotinamide adenine dinucleotide</infon>
          <location offset="1620" length="33"/>
          <text>nicotinamide adenine dinucleotide</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="1678" length="7"/>
          <text>steroid</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="1714" length="7"/>
          <text>steroid</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">3alpha-hsd type iii</infon>
          <location offset="1536" length="19"/>
          <text>3alpha-HSD type III</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T7" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T11" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1731</offset>
        <text>Since previous reports suggested that fluoxetine and certain other small molecules increased allopregnanolone concentrations in vivo by activating 3alpha-HSD type III, we investigated whether these small molecules were able to activate human 3alpha-HSD type III.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="1769" length="10"/>
          <text>fluoxetine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="1824" length="16"/>
          <text>allopregnanolone</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">3alpha-hsd type iii</infon>
          <location offset="1878" length="19"/>
          <text>3alpha-HSD type III</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human 3alpha-hsd type iii</infon>
          <location offset="1967" length="25"/>
          <text>human 3alpha-HSD type III</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T13" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1994</offset>
        <text>Our results showed that, at concentrations up to 50 microM, fluoxetine, paroxetine, sertraline, norfluoxetine, carbamazepine, clozapine, flurbiprofen, and sulfobromophthalein did not activate the enzyme.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="2054" length="10"/>
          <text>fluoxetine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="2066" length="10"/>
          <text>paroxetine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sertraline</infon>
          <location offset="2078" length="10"/>
          <text>sertraline</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">norfluoxetine</infon>
          <location offset="2090" length="13"/>
          <text>norfluoxetine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbamazepine</infon>
          <location offset="2105" length="13"/>
          <text>carbamazepine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="2120" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flurbiprofen</infon>
          <location offset="2131" length="12"/>
          <text>flurbiprofen</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfobromophthalein</infon>
          <location offset="2149" length="19"/>
          <text>sulfobromophthalein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2198</offset>
        <text>These results characterize the role of 3alpha-HSD type III in allopregnanolone formation and suggest that activation of this enzyme by fluoxetine is likely not the mechanism by which fluoxetine increases allopregnanolone concentrations.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="2260" length="16"/>
          <text>allopregnanolone</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="2333" length="10"/>
          <text>fluoxetine</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="2381" length="10"/>
          <text>fluoxetine</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">allopregnanolone</infon>
          <location offset="2402" length="16"/>
          <text>allopregnanolone</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">3alpha-hsd type iii</infon>
          <location offset="2237" length="19"/>
          <text>3alpha-HSD type III</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T25" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T24" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23022069</id>
    <passage>
      <offset>0</offset>
      <text>Performance of urinary and gene expression biomarkers in detecting the nephrotoxic effects of melamine and cyanuric acid following diverse scenarios of co-exposure.	Although standard nephrotoxicity assessments primarily detect impaired renal function, KIM-1, clusterin, NGAL, osteopontin and TIMP-1 were recently identified biomarkers proposed to indicate earlier perturbations in renal integrity. The recent adulteration of infant and pet food with melamine (MEL) and structurally-related compounds revealed that co-ingestion of MEL and cyanuric acid (CYA) could form melamine-cyanurate crystals which obstruct renal tubules and induce acute renal failure. This study concurrently evaluated the ability of multiplexed urinary biomarker immunoassays and biomarker gene expression analysis to detect nephrotoxicity in F344 rats co-administered 60ppm each of MEL and CYA in feed or via gavage for 28days. The biomarkers were also evaluated for the ability to differentiate the effects of the compounds when co-administered using diverse dosing schedules (i.e., consecutive vs. staggered gavage) and dosing matrixes (i.e., feed vs. gavage). Our results illustrate the ability of both methods to detect and differentiate the severity of adverse effects in the staggered and consecutive gavage groups at much lower doses than previously observed in animals co-exposed to the compounds in feed. We also demonstrate that these urinary biomarkers outperform traditional diagnostic methods and represent a powerful, non-invasive indicator of chemical-induced nephrotoxicity prior to the onset of renal dysfunction.</text>
      <sentence>
        <offset>0</offset>
        <text>Performance of urinary and gene expression biomarkers in detecting the nephrotoxic effects of melamine and cyanuric acid following diverse scenarios of co-exposure.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyanuric acid</infon>
          <location offset="107" length="13"/>
          <text>cyanuric acid</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melamine</infon>
          <location offset="94" length="8"/>
          <text>melamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>165</offset>
        <text>Although standard nephrotoxicity assessments primarily detect impaired renal function, KIM-1, clusterin, NGAL, osteopontin and TIMP-1 were recently identified biomarkers proposed to indicate earlier perturbations in renal integrity.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ngal</infon>
          <location offset="270" length="4"/>
          <text>NGAL</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">osteopontin</infon>
          <location offset="276" length="11"/>
          <text>osteopontin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">timp-1</infon>
          <location offset="292" length="6"/>
          <text>TIMP-1</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kim-1</infon>
          <location offset="252" length="5"/>
          <text>KIM-1</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">clusterin</infon>
          <location offset="259" length="9"/>
          <text>clusterin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>398</offset>
        <text>The recent adulteration of infant and pet food with melamine (MEL) and structurally-related compounds revealed that co-ingestion of MEL and cyanuric acid (CYA) could form melamine-cyanurate crystals which obstruct renal tubules and induce acute renal failure.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melamine</infon>
          <location offset="450" length="8"/>
          <text>melamine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mel</infon>
          <location offset="460" length="3"/>
          <text>MEL</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mel</infon>
          <location offset="530" length="3"/>
          <text>MEL</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyanuric acid</infon>
          <location offset="538" length="13"/>
          <text>cyanuric acid</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cya</infon>
          <location offset="553" length="3"/>
          <text>CYA</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">melamine</infon>
          <location offset="569" length="8"/>
          <text>melamine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyanurate</infon>
          <location offset="578" length="9"/>
          <text>cyanurate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>658</offset>
        <text>This study concurrently evaluated the ability of multiplexed urinary biomarker immunoassays and biomarker gene expression analysis to detect nephrotoxicity in F344 rats co-administered 60ppm each of MEL and CYA in feed or via gavage for 28days.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mel</infon>
          <location offset="857" length="3"/>
          <text>MEL</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cya</infon>
          <location offset="865" length="3"/>
          <text>CYA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>903</offset>
        <text>The biomarkers were also evaluated for the ability to differentiate the effects of the compounds when co-administered using diverse dosing schedules (i.e., consecutive vs. staggered gavage) and dosing matrixes (i.e., feed vs. gavage).</text>
      </sentence>
      <sentence>
        <offset>1138</offset>
        <text>Our results illustrate the ability of both methods to detect and differentiate the severity of adverse effects in the staggered and consecutive gavage groups at much lower doses than previously observed in animals co-exposed to the compounds in feed.</text>
      </sentence>
      <sentence>
        <offset>1389</offset>
        <text>We also demonstrate that these urinary biomarkers outperform traditional diagnostic methods and represent a powerful, non-invasive indicator of chemical-induced nephrotoxicity prior to the onset of renal dysfunction.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23142425</id>
    <passage>
      <offset>0</offset>
      <text>4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism-related enzymes gene polymorphisms, NNK metabolites levels and urothelial carcinoma.	Gene polymorphisms of the 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism-related enzymes-cytochrome P450 (CYP) monooxygenase 2A13 (CYP2A13) and UDP-glucuronosyltransferases (UGT)-2B7 could contribute to the levels of NNK-related metabolites in urine, thereby increasing the susceptibility to urothelial carcinoma (UC). Therefore, our study aimed to evaluate the roles of two gene polymorphisms (CYP2A13 and UGT2B7) of NNK metabolism-related enzymes in the carcinogenesis of UC in Taiwan. A hospital-based pilot case-control study was conducted. There were 121 UC cases and 121 age- and sex-matched healthy participants recruited from March 2007 to April 2009. Urine samples were analyzed for NNK-related metabolites using the liquid chromatography-tandem mass spectrometry method. Genotyping was conducted using a polymerase chain reaction-restriction fragment length polymorphism technique. ANCOVA and multivariate logistic regression were applied for data analyses. In healthy controls, former smokers had significantly higher total NNAL and higher NNAL-Gluc than never smokers or current smokers. Subjects carrying the UGT2B7 268 His/Tyr or Tyr/Tyr genotype had significantly lower total NNAL than those carrying His/His genotype. However, no association was seen between gene polymorphisms of CYP2A13 and UGT2B7 and UC risk after adjustment for age and sex. Significant dose -response associations between total NNAL, free NNAL, the ratios of free NNAL/total NNAL and NNAL-Gluc/total NNAL and UC risk were observed. In the future, large-scale studies will be required to verify the association between the single nucleotide polymorphisms of NNK metabolism-related enzymes and UC risk.</text>
      <sentence>
        <offset>0</offset>
        <text>4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism-related enzymes gene polymorphisms, NNK metabolites levels and urothelial carcinoma.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone</infon>
          <location offset="0" length="46"/>
          <text>4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnk</infon>
          <location offset="100" length="3"/>
          <text>NNK</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnk</infon>
          <location offset="48" length="3"/>
          <text>NNK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>149</offset>
        <text>Gene polymorphisms of the 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism-related enzymes-cytochrome P450 (CYP) monooxygenase 2A13 (CYP2A13) and UDP-glucuronosyltransferases (UGT)-2B7 could contribute to the levels of NNK-related metabolites in urine, thereby increasing the susceptibility to urothelial carcinoma (UC).</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="310" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnk</infon>
          <location offset="383" length="3"/>
          <text>NNK</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone</infon>
          <location offset="175" length="46"/>
          <text>4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnk</infon>
          <location offset="223" length="3"/>
          <text>NNK</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome p450 (cyp) monooxygenase 2a13</infon>
          <location offset="255" length="40"/>
          <text>cytochrome P450 (CYP) monooxygenase 2A13</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2a13</infon>
          <location offset="297" length="7"/>
          <text>CYP2A13</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">udp-glucuronosyltransferases (ugt)-2b7</infon>
          <location offset="310" length="38"/>
          <text>UDP-glucuronosyltransferases (UGT)-2B7</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T19" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T19" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T23" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T23" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T20" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T19" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T23" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T20" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T20" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>485</offset>
        <text>Therefore, our study aimed to evaluate the roles of two gene polymorphisms (CYP2A13 and UGT2B7) of NNK metabolism-related enzymes in the carcinogenesis of UC in Taiwan.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnk</infon>
          <location offset="584" length="3"/>
          <text>NNK</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2a13</infon>
          <location offset="561" length="7"/>
          <text>CYP2A13</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ugt2b7</infon>
          <location offset="573" length="6"/>
          <text>UGT2B7</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T21" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T21" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>654</offset>
        <text>A hospital-based pilot case-control study was conducted.</text>
      </sentence>
      <sentence>
        <offset>711</offset>
        <text>There were 121 UC cases and 121 age- and sex-matched healthy participants recruited from March 2007 to April 2009.</text>
      </sentence>
      <sentence>
        <offset>826</offset>
        <text>Urine samples were analyzed for NNK-related metabolites using the liquid chromatography-tandem mass spectrometry method.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnk</infon>
          <location offset="858" length="3"/>
          <text>NNK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>947</offset>
        <text>Genotyping was conducted using a polymerase chain reaction-restriction fragment length polymorphism technique.</text>
      </sentence>
      <sentence>
        <offset>1058</offset>
        <text>ANCOVA and multivariate logistic regression were applied for data analyses.</text>
      </sentence>
      <sentence>
        <offset>1134</offset>
        <text>In healthy controls, former smokers had significantly higher total NNAL and higher NNAL-Gluc than never smokers or current smokers.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnal</infon>
          <location offset="1201" length="4"/>
          <text>NNAL</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnal-gluc</infon>
          <location offset="1217" length="9"/>
          <text>NNAL-Gluc</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1266</offset>
        <text>Subjects carrying the UGT2B7 268 His/Tyr or Tyr/Tyr genotype had significantly lower total NNAL than those carrying His/His genotype.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">his</infon>
          <location offset="1299" length="3"/>
          <text>His</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyr</infon>
          <location offset="1303" length="3"/>
          <text>Tyr</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyr</infon>
          <location offset="1310" length="3"/>
          <text>Tyr</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyr</infon>
          <location offset="1314" length="3"/>
          <text>Tyr</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnal</infon>
          <location offset="1357" length="4"/>
          <text>NNAL</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">his</infon>
          <location offset="1382" length="3"/>
          <text>His</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">his</infon>
          <location offset="1386" length="3"/>
          <text>His</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ugt2b7</infon>
          <location offset="1288" length="6"/>
          <text>UGT2B7</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">268 his/tyr</infon>
          <location offset="1295" length="11"/>
          <text>268 His/Tyr</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T9" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1400</offset>
        <text>However, no association was seen between gene polymorphisms of CYP2A13 and UGT2B7 and UC risk after adjustment for age and sex.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2a13</infon>
          <location offset="1463" length="7"/>
          <text>CYP2A13</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ugt2b7</infon>
          <location offset="1475" length="6"/>
          <text>UGT2B7</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1528</offset>
        <text>Significant dose -response associations between total NNAL, free NNAL, the ratios of free NNAL/total NNAL and NNAL-Gluc/total NNAL and UC risk were observed.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnal</infon>
          <location offset="1582" length="4"/>
          <text>NNAL</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnal</infon>
          <location offset="1593" length="4"/>
          <text>NNAL</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnal</infon>
          <location offset="1618" length="4"/>
          <text>NNAL</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnal</infon>
          <location offset="1629" length="4"/>
          <text>NNAL</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnal-gluc</infon>
          <location offset="1638" length="9"/>
          <text>NNAL-Gluc</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnal</infon>
          <location offset="1654" length="4"/>
          <text>NNAL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1686</offset>
        <text>In the future, large-scale studies will be required to verify the association between the single nucleotide polymorphisms of NNK metabolism-related enzymes and UC risk.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleotide</infon>
          <location offset="1783" length="10"/>
          <text>nucleotide</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nnk</infon>
          <location offset="1811" length="3"/>
          <text>NNK</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15794712</id>
    <passage>
      <offset>0</offset>
      <text>The development and application of imatinib.	The hallmark characteristics of cancer include an unrestrained proliferation involving activation of growth signals, loss of negative regulation and dysfunctional apoptotic pathways. Targeting abnormal cell signalling pathways should provide a more selective approach to cancer treatment than conventional cytotoxic chemotherapy. Tyrosine kinases play an essential role in the signalling pathways involved in the control of cellular proliferation and growth. Imatinib is a small-molecule tyrosine kinase inhibitor of the ABL fusion gene, platelet derived growth factor receptors (PDGFR) and KIT. This agent has demonstrated considerable activity in chronic myeloid leukaemia (CML) by inhibiting the BCR-ABL fusion protein and gastrointestinal stromal tumours (GISTs), which are predominantly driven by activating mutations in KIT. A number of other rare conditions are also responsive, for example, dermatofibrosarcoma protuberans, which is driven by a chromosomal translocation involving PDGF-B and Col1A1, resulting in overexpression of PDGF-B, and hypereosinophillic syndrome, which can be caused by activating PDGFR mutations. The pivotal registration study for newly diagnosed CML was a large randomised trial comparing 400 mg/day of imatinib to a combination of IFN-alpha and cytarabine, which demonstrated a significantly higher complete haematological and cytogenetic response rate in the imatinib arm. In the case of GIST a randomised study in patients with inoperable or metastatic disease explored doses of 400 - 600mg and reported a response rate of &gt; 50% in each arm plus disease stabilisation and an improvement in performance status. Large randomised trials have subsequently been performed, comparing 400 with 800mg/day. The first to report indicates that the larger dose is associated with improved progression-free survival, although it is not yet known whether or not this will translate into a difference in overall survival. The most common KIT mutation involves exon 11 and is associated with a statistically significant better response and prognosis compared with other mutations or no detectable mutations. Mutational analysis is likely to become increasingly important in the selection of patients for neoadjuvant and adjuvant treatment and in helping to understand the nature of acquired resistance.</text>
      <sentence>
        <offset>0</offset>
        <text>The development and application of imatinib.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="35" length="8"/>
          <text>imatinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>45</offset>
        <text>The hallmark characteristics of cancer include an unrestrained proliferation involving activation of growth signals, loss of negative regulation and dysfunctional apoptotic pathways.</text>
      </sentence>
      <sentence>
        <offset>228</offset>
        <text>Targeting abnormal cell signalling pathways should provide a more selective approach to cancer treatment than conventional cytotoxic chemotherapy.</text>
      </sentence>
      <sentence>
        <offset>375</offset>
        <text>Tyrosine kinases play an essential role in the signalling pathways involved in the control of cellular proliferation and growth.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="375" length="8"/>
          <text>Tyrosine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tyrosine kinases</infon>
          <location offset="375" length="16"/>
          <text>Tyrosine kinases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>504</offset>
        <text>Imatinib is a small-molecule tyrosine kinase inhibitor of the ABL fusion gene, platelet derived growth factor receptors (PDGFR) and KIT.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="504" length="8"/>
          <text>Imatinib</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="533" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tyrosine kinase</infon>
          <location offset="533" length="15"/>
          <text>tyrosine kinase</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abl</infon>
          <location offset="566" length="3"/>
          <text>ABL</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">platelet derived growth factor receptors</infon>
          <location offset="583" length="40"/>
          <text>platelet derived growth factor receptors</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pdgfr</infon>
          <location offset="625" length="5"/>
          <text>PDGFR</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kit</infon>
          <location offset="636" length="3"/>
          <text>KIT</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>641</offset>
        <text>This agent has demonstrated considerable activity in chronic myeloid leukaemia (CML) by inhibiting the BCR-ABL fusion protein and gastrointestinal stromal tumours (GISTs), which are predominantly driven by activating mutations in KIT.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcr</infon>
          <location offset="744" length="3"/>
          <text>BCR</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abl</infon>
          <location offset="748" length="3"/>
          <text>ABL</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kit</infon>
          <location offset="871" length="3"/>
          <text>KIT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>876</offset>
        <text>A number of other rare conditions are also responsive, for example, dermatofibrosarcoma protuberans, which is driven by a chromosomal translocation involving PDGF-B and Col1A1, resulting in overexpression of PDGF-B, and hypereosinophillic syndrome, which can be caused by activating PDGFR mutations.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">col1a1</infon>
          <location offset="1045" length="6"/>
          <text>Col1A1</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgf-b</infon>
          <location offset="1084" length="6"/>
          <text>PDGF-B</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pdgfr</infon>
          <location offset="1159" length="5"/>
          <text>PDGFR</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgf-b</infon>
          <location offset="1034" length="6"/>
          <text>PDGF-B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1176</offset>
        <text>The pivotal registration study for newly diagnosed CML was a large randomised trial comparing 400 mg/day of imatinib to a combination of IFN-alpha and cytarabine, which demonstrated a significantly higher complete haematological and cytogenetic response rate in the imatinib arm.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1284" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cytarabine</infon>
          <location offset="1327" length="10"/>
          <text>cytarabine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1442" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ifn-alpha</infon>
          <location offset="1313" length="9"/>
          <text>IFN-alpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1456</offset>
        <text>In the case of GIST a randomised study in patients with inoperable or metastatic disease explored doses of 400 - 600mg and reported a response rate of &gt; 50% in each arm plus disease stabilisation and an improvement in performance status.</text>
      </sentence>
      <sentence>
        <offset>1694</offset>
        <text>Large randomised trials have subsequently been performed, comparing 400 with 800mg/day.</text>
      </sentence>
      <sentence>
        <offset>1782</offset>
        <text>The first to report indicates that the larger dose is associated with improved progression-free survival, although it is not yet known whether or not this will translate into a difference in overall survival.</text>
      </sentence>
      <sentence>
        <offset>1991</offset>
        <text>The most common KIT mutation involves exon 11 and is associated with a statistically significant better response and prognosis compared with other mutations or no detectable mutations.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kit</infon>
          <location offset="2007" length="3"/>
          <text>KIT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2176</offset>
        <text>Mutational analysis is likely to become increasingly important in the selection of patients for neoadjuvant and adjuvant treatment and in helping to understand the nature of acquired resistance.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22902307</id>
    <passage>
      <offset>0</offset>
      <text>A human hemi-cornea model for eye irritation testing: quality control of production, reliability and predictive capacity.	We have developed a 3-dimensional human hemi-cornea which comprises an immortalized epithelial cell line and keratocytes embedded in a collagen stroma. In the present study, we have used MTT reduction of the whole tissue to clarify whether the production of this complex 3-D-model is transferable into other laboratories and whether these tissues can be constructed reproducibly. Our results demonstrate the reproducible production of the hemi-cornea model according to standard operation procedures using 15 independent batches of reconstructed hemi-cornea models in two independent laboratories each. Furthermore, the hemi-cornea tissues have been treated with 20 chemicals of different eye-irritating potential under blind conditions to assess the performance and limitations of our test system comparing three different prediction models. The most suitable prediction model revealed an overall in vitro-in vivo concordance of 80% and 70% in the participating laboratories, respectively, and an inter-laboratory concordance of 80%. Sensitivity of the test was 77% and specificity was between 57% and 86% to discriminate classified from non-classified chemicals. We conclude that additional physiologically relevant endpoints in both epithelium and stroma have to be developed for the reliable prediction of all GHS classes of eye irritation in one stand alone test system.</text>
      <sentence>
        <offset>0</offset>
        <text>A human hemi-cornea model for eye irritation testing: quality control of production, reliability and predictive capacity.</text>
      </sentence>
      <sentence>
        <offset>122</offset>
        <text>We have developed a 3-dimensional human hemi-cornea which comprises an immortalized epithelial cell line and keratocytes embedded in a collagen stroma.</text>
        <annotation id="T2">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">collagen</infon>
          <location offset="257" length="8"/>
          <text>collagen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>274</offset>
        <text>In the present study, we have used MTT reduction of the whole tissue to clarify whether the production of this complex 3-D-model is transferable into other laboratories and whether these tissues can be constructed reproducibly.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mtt</infon>
          <location offset="309" length="3"/>
          <text>MTT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>502</offset>
        <text>Our results demonstrate the reproducible production of the hemi-cornea model according to standard operation procedures using 15 independent batches of reconstructed hemi-cornea models in two independent laboratories each.</text>
      </sentence>
      <sentence>
        <offset>725</offset>
        <text>Furthermore, the hemi-cornea tissues have been treated with 20 chemicals of different eye-irritating potential under blind conditions to assess the performance and limitations of our test system comparing three different prediction models.</text>
      </sentence>
      <sentence>
        <offset>965</offset>
        <text>The most suitable prediction model revealed an overall in vitro-in vivo concordance of 80% and 70% in the participating laboratories, respectively, and an inter-laboratory concordance of 80%.</text>
      </sentence>
      <sentence>
        <offset>1157</offset>
        <text>Sensitivity of the test was 77% and specificity was between 57% and 86% to discriminate classified from non-classified chemicals.</text>
      </sentence>
      <sentence>
        <offset>1287</offset>
        <text>We conclude that additional physiologically relevant endpoints in both epithelium and stroma have to be developed for the reliable prediction of all GHS classes of eye irritation in one stand alone test system.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17603545</id>
    <passage>
      <offset>0</offset>
      <text>Alpha1-adrenoceptors are required for normal male sexual function.	BACKGROUND AND PURPOSE: Alpha(1)-adrenoceptor antagonists are extensively used in the treatment of hypertension and lower urinary tract symptoms associated with benign prostatic hyperplasia. Among the side effects, ejaculatory dysfunction occurs more frequently with drugs that are relatively selective for alpha(1A)-adrenoceptors compared with other drugs of this class. This suggests that alpha(1A)-adrenoceptors may contribute to ejaculation. However, this has not been studied at the molecular level. EXPERIMENTAL APPROACH: The physiological contribution of each alpha(1)-adrenoceptor subtype was characterized using alpha(1)-adrenoceptor subtype-selective knockout (KO) mice (alpha(1A)-, alpha(1B)- and alpha(1D)-AR KO mice) since the subtype-specific drugs available are only moderately selective. We analysed the role of alpha(1)-adrenoceptors in the blood pressure and vascular response as well as ejaculation by determining these variables in alpha(1)-adrenoceptor subtype-selective KO mice and in mice with all their alpha(1)-adrenoceptor subtypes deleted (alpha(1)-AR triple-KO mice). KEY RESULTS: The pregnancy rate was reduced by 50% in alpha(1A)-adrenoceptor KO mice, and this reduction was dramatically enhanced in alpha(1)-adrenoceptor triple-KO mice. Contractile tension of the vas deferens in response to noradrenaline was markedly decreased in alpha(1A)-adrenoceptor KO mice, and this contraction was completely abolished in alpha(1)-adrenoceptor triple-KO mice. This attenuation of contractility was also observed in the electrically stimulated vas deferens. CONCLUSIONS AND IMPLICATIONS: These results demonstrate that alpha(1)-adrenoceptors, particularly alpha(1A)-adrenoceptors, are required for normal contractility of the vas deferens and consequent sperm ejaculation as well as having a function in fertility.</text>
      <sentence>
        <offset>0</offset>
        <text>Alpha1-adrenoceptors are required for normal male sexual function.</text>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha1-adrenoceptors</infon>
          <location offset="0" length="20"/>
          <text>Alpha1-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>67</offset>
        <text>BACKGROUND AND PURPOSE: Alpha(1)-adrenoceptor antagonists are extensively used in the treatment of hypertension and lower urinary tract symptoms associated with benign prostatic hyperplasia.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)-adrenoceptor</infon>
          <location offset="91" length="21"/>
          <text>Alpha(1)-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>258</offset>
        <text>Among the side effects, ejaculatory dysfunction occurs more frequently with drugs that are relatively selective for alpha(1A)-adrenoceptors compared with other drugs of this class.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha(1a)-adrenoceptors</infon>
          <location offset="374" length="23"/>
          <text>alpha(1A)-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>439</offset>
        <text>This suggests that alpha(1A)-adrenoceptors may contribute to ejaculation.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha(1a)-adrenoceptors</infon>
          <location offset="458" length="23"/>
          <text>alpha(1A)-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>513</offset>
        <text>However, this has not been studied at the molecular level.</text>
      </sentence>
      <sentence>
        <offset>572</offset>
        <text>EXPERIMENTAL APPROACH: The physiological contribution of each alpha(1)-adrenoceptor subtype was characterized using alpha(1)-adrenoceptor subtype-selective knockout (KO) mice (alpha(1A)-, alpha(1B)- and alpha(1D)-AR KO mice) since the subtype-specific drugs available are only moderately selective.</text>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)-adrenoceptor</infon>
          <location offset="634" length="21"/>
          <text>alpha(1)-adrenoceptor</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)-adrenoceptor</infon>
          <location offset="688" length="21"/>
          <text>alpha(1)-adrenoceptor</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1a)-, alpha(1b)- and alpha(1d)-ar</infon>
          <location offset="748" length="39"/>
          <text>alpha(1A)-, alpha(1B)- and alpha(1D)-AR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>871</offset>
        <text>We analysed the role of alpha(1)-adrenoceptors in the blood pressure and vascular response as well as ejaculation by determining these variables in alpha(1)-adrenoceptor subtype-selective KO mice and in mice with all their alpha(1)-adrenoceptor subtypes deleted (alpha(1)-AR triple-KO mice).</text>
        <annotation id="T2">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)-adrenoceptor</infon>
          <location offset="1094" length="21"/>
          <text>alpha(1)-adrenoceptor</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)-ar</infon>
          <location offset="1134" length="11"/>
          <text>alpha(1)-AR</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)-adrenoceptors</infon>
          <location offset="895" length="22"/>
          <text>alpha(1)-adrenoceptors</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)-adrenoceptor</infon>
          <location offset="1019" length="21"/>
          <text>alpha(1)-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1163</offset>
        <text>KEY RESULTS: The pregnancy rate was reduced by 50% in alpha(1A)-adrenoceptor KO mice, and this reduction was dramatically enhanced in alpha(1)-adrenoceptor triple-KO mice.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha(1a)-adrenoceptor</infon>
          <location offset="1217" length="22"/>
          <text>alpha(1A)-adrenoceptor</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)-adrenoceptor</infon>
          <location offset="1297" length="21"/>
          <text>alpha(1)-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1335</offset>
        <text>Contractile tension of the vas deferens in response to noradrenaline was markedly decreased in alpha(1A)-adrenoceptor KO mice, and this contraction was completely abolished in alpha(1)-adrenoceptor triple-KO mice.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">noradrenaline</infon>
          <location offset="1390" length="13"/>
          <text>noradrenaline</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha(1a)-adrenoceptor</infon>
          <location offset="1430" length="22"/>
          <text>alpha(1A)-adrenoceptor</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)-adrenoceptor</infon>
          <location offset="1511" length="21"/>
          <text>alpha(1)-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1549</offset>
        <text>This attenuation of contractility was also observed in the electrically stimulated vas deferens.</text>
      </sentence>
      <sentence>
        <offset>1646</offset>
        <text>CONCLUSIONS AND IMPLICATIONS: These results demonstrate that alpha(1)-adrenoceptors, particularly alpha(1A)-adrenoceptors, are required for normal contractility of the vas deferens and consequent sperm ejaculation as well as having a function in fertility.</text>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)-adrenoceptors</infon>
          <location offset="1707" length="22"/>
          <text>alpha(1)-adrenoceptors</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha(1a)-adrenoceptors</infon>
          <location offset="1744" length="23"/>
          <text>alpha(1A)-adrenoceptors</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23230132</id>
    <passage>
      <offset>0</offset>
      <text>Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse.	Ethyl glucuronide (EtG) determination is increasingly used in clinical and forensic toxicology to document ethanol consumption. The enzymes involved in EtG production, as well as potential interactions with common drugs of abuse, have not been extensively studied. Activities of human liver (HLM), kidney (HKM), and intestinal (HIM) microsomes, as well as of 12 major human recombinant UDP-glucuronosyltransferases (UGTs), toward ethanol (50 and 500 mM) were evaluated in vitro using liquid chromatography-tandem mass spectrometry. Enzyme kinetic parameters were determined for pooled microsomes and recombinant UGTs with significant activity. Individual contributions of UGTs were estimated using the relative activity factor approach, proposed for scaling activities obtained with cDNA-expressed enzymes to HLM. Interaction of morphine, codeine, lorazepam, oxazepam, nicotine, cotinine, cannabinol, and cannabidiol (5, 10, 15 mg/l) with ethanol (1.15, 4.6, 11.5 g/l; i.e., 25, 100, 250 mM) glucuronidation was assessed using pooled HLM. Ethanol glucuronidation intrinsic clearance (Cl(int)) was 4 and 12.7 times higher for HLM than for HKM and HIM, respectively. All recombinant UGTs, except UGT1A1, 1A6, and 1A10, produced EtG in detectable amounts. UGT1A9 and 2B7 were the most active enzymes, each accounting for 17 and 33% of HLM Cl(int), respectively. Only cannabinol and cannabidiol significantly affected ethanol glucuronidation. Cannabinol increased ethanol glucuronidation in a concentration-dependent manner, whereas cannabidiol significantly inhibited EtG formation in a noncompetitive manner (IC(50) = 1.17 mg/l; inhibition constant (K(i)) = 3.1 mg/l). UGT1A9 and 2B7 are the main enzymes involved in ethanol glucuronidation. In addition, our results suggest that cannabinol and cannabidiol could significantly alter ethanol glucuronidation.</text>
      <sentence>
        <offset>0</offset>
        <text>Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse.</text>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="15" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="65" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">udp-glucuronosyltransferases</infon>
          <location offset="15" length="28"/>
          <text>UDP-glucuronosyltransferases</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ugt1a9</infon>
          <location offset="44" length="6"/>
          <text>UGT1A9</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ugt2b7</infon>
          <location offset="55" length="6"/>
          <text>UGT2B7</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T30" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T30" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T30" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>135</offset>
        <text>Ethyl glucuronide (EtG) determination is increasingly used in clinical and forensic toxicology to document ethanol consumption.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethyl glucuronide</infon>
          <location offset="135" length="17"/>
          <text>Ethyl glucuronide</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="242" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etg</infon>
          <location offset="154" length="3"/>
          <text>EtG</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>263</offset>
        <text>The enzymes involved in EtG production, as well as potential interactions with common drugs of abuse, have not been extensively studied.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etg</infon>
          <location offset="287" length="3"/>
          <text>EtG</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>400</offset>
        <text>Activities of human liver (HLM), kidney (HKM), and intestinal (HIM) microsomes, as well as of 12 major human recombinant UDP-glucuronosyltransferases (UGTs), toward ethanol (50 and 500 mM) were evaluated in vitro using liquid chromatography-tandem mass spectrometry.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">udp</infon>
          <location offset="521" length="3"/>
          <text>UDP</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="565" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human recombinant udp-glucuronosyltransferases</infon>
          <location offset="503" length="46"/>
          <text>human recombinant UDP-glucuronosyltransferases</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ugts</infon>
          <location offset="551" length="4"/>
          <text>UGTs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>667</offset>
        <text>Enzyme kinetic parameters were determined for pooled microsomes and recombinant UGTs with significant activity.</text>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ugts</infon>
          <location offset="747" length="4"/>
          <text>UGTs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>779</offset>
        <text>Individual contributions of UGTs were estimated using the relative activity factor approach, proposed for scaling activities obtained with cDNA-expressed enzymes to HLM.</text>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ugts</infon>
          <location offset="807" length="4"/>
          <text>UGTs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>949</offset>
        <text>Interaction of morphine, codeine, lorazepam, oxazepam, nicotine, cotinine, cannabinol, and cannabidiol (5, 10, 15 mg/l) with ethanol (1.15, 4.6, 11.5 g/l; i.e., 25, 100, 250 mM) glucuronidation was assessed using pooled HLM.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morphine</infon>
          <location offset="964" length="8"/>
          <text>morphine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">codeine</infon>
          <location offset="974" length="7"/>
          <text>codeine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lorazepam</infon>
          <location offset="983" length="9"/>
          <text>lorazepam</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxazepam</infon>
          <location offset="994" length="8"/>
          <text>oxazepam</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nicotine</infon>
          <location offset="1004" length="8"/>
          <text>nicotine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cotinine</infon>
          <location offset="1014" length="8"/>
          <text>cotinine</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cannabinol</infon>
          <location offset="1024" length="10"/>
          <text>cannabinol</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cannabidiol</infon>
          <location offset="1040" length="11"/>
          <text>cannabidiol</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1074" length="7"/>
          <text>ethanol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1174</offset>
        <text>Ethanol glucuronidation intrinsic clearance (Cl(int)) was 4 and 12.7 times higher for HLM than for HKM and HIM, respectively.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1174" length="7"/>
          <text>Ethanol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1300</offset>
        <text>All recombinant UGTs, except UGT1A1, 1A6, and 1A10, produced EtG in detectable amounts.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etg</infon>
          <location offset="1361" length="3"/>
          <text>EtG</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ugts</infon>
          <location offset="1316" length="4"/>
          <text>UGTs</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ugt1a1, 1a6, and 1a10</infon>
          <location offset="1329" length="21"/>
          <text>UGT1A1, 1A6, and 1A10</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1388</offset>
        <text>UGT1A9 and 2B7 were the most active enzymes, each accounting for 17 and 33% of HLM Cl(int), respectively.</text>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ugt1a9 and 2b7</infon>
          <location offset="1388" length="14"/>
          <text>UGT1A9 and 2B7</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1494</offset>
        <text>Only cannabinol and cannabidiol significantly affected ethanol glucuronidation.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cannabinol</infon>
          <location offset="1499" length="10"/>
          <text>cannabinol</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cannabidiol</infon>
          <location offset="1514" length="11"/>
          <text>cannabidiol</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1549" length="7"/>
          <text>ethanol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1574</offset>
        <text>Cannabinol increased ethanol glucuronidation in a concentration-dependent manner, whereas cannabidiol significantly inhibited EtG formation in a noncompetitive manner (IC(50) = 1.17 mg/l; inhibition constant (K(i)) = 3.1 mg/l).</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cannabinol</infon>
          <location offset="1574" length="10"/>
          <text>Cannabinol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1595" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cannabidiol</infon>
          <location offset="1664" length="11"/>
          <text>cannabidiol</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">etg</infon>
          <location offset="1700" length="3"/>
          <text>EtG</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1802</offset>
        <text>UGT1A9 and 2B7 are the main enzymes involved in ethanol glucuronidation.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1850" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ugt1a9 and 2b7</infon>
          <location offset="1802" length="14"/>
          <text>UGT1A9 and 2B7</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1875</offset>
        <text>In addition, our results suggest that cannabinol and cannabidiol could significantly alter ethanol glucuronidation.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cannabinol</infon>
          <location offset="1913" length="10"/>
          <text>cannabinol</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cannabidiol</infon>
          <location offset="1928" length="11"/>
          <text>cannabidiol</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="1966" length="7"/>
          <text>ethanol</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10226872</id>
    <passage>
      <offset>0</offset>
      <text>Disodium cromoglycate does not prevent terbutaline-induced desensitization of beta 2-adrenoceptor-mediated cardiovascular in vivo functions in human volunteers.	In humans, prolonged administration of the beta 2-adrenoceptor agonist terbutaline leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen. This study investigated the effect of disodium cromoglycate, another antiallergic drug, on terbutaline-induced desensitization of beta-adrenoceptor-mediated cardiovascular and noncardiovascular responses. In a double-blind, placebo-controlled, randomized design, nine healthy male volunteers received disodium cromoglycate (4 x 200 mg/day, p.o.) or placebo for 3 weeks with terbutaline (3 x 5 mg/day, p.o.) administered concomitantly during the last 2 weeks. beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist isoprenaline; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia. Tremulousness was monitored as a beta 2-adrenoceptor-mediated noncardiovascular effect. After 2 weeks' administration of terbutaline, there was a marked and significant (p &lt; 0.001) attenuation of isoprenaline-induced tachycardia (mean percentage attenuation, 53.3%) and of the isoprenaline-induced decrease in diastolic blood pressure (mean percentage attenuation, 55.6%). Exercise-induced tachycardia also was significantly (p &lt; 0.001) blunted, but the magnitude of this attenuation was only very small (mean attenuation, 5.6%). Disodium cromoglycate affected neither the rightward shift of beta 2-adrenoceptor-mediated responses nor the small rightward shift in beta 1-adrenoceptor-mediated exercise tachycardia after 2 weeks' administration of terbutaline. Tremulousness observed during the first few days of terbutaline administration disappeared after 4 to 8 days, indicating development of desensitization of beta 2-adrenoceptor-mediated noncardiovascular responses. This was not prevented by disodium cromoglycate. These results confirm that long-term beta 2-adrenoceptor agonist therapy leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular and noncardiovascular effects in humans in vivo. However, unlike ketotifen, cromolyn sodium is not able to attenuate this desensitization.</text>
      <sentence>
        <offset>0</offset>
        <text>Disodium cromoglycate does not prevent terbutaline-induced desensitization of beta 2-adrenoceptor-mediated cardiovascular in vivo functions in human volunteers.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">disodium cromoglycate</infon>
          <location offset="0" length="21"/>
          <text>Disodium cromoglycate</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terbutaline</infon>
          <location offset="39" length="11"/>
          <text>terbutaline</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="78" length="19"/>
          <text>beta 2-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>161</offset>
        <text>In humans, prolonged administration of the beta 2-adrenoceptor agonist terbutaline leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketotifen</infon>
          <location offset="409" length="9"/>
          <text>ketotifen</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terbutaline</infon>
          <location offset="232" length="11"/>
          <text>terbutaline</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="274" length="19"/>
          <text>beta 2-adrenoceptor</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="204" length="19"/>
          <text>beta 2-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T15" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>420</offset>
        <text>This study investigated the effect of disodium cromoglycate, another antiallergic drug, on terbutaline-induced desensitization of beta-adrenoceptor-mediated cardiovascular and noncardiovascular responses.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">disodium cromoglycate</infon>
          <location offset="458" length="21"/>
          <text>disodium cromoglycate</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terbutaline</infon>
          <location offset="511" length="11"/>
          <text>terbutaline</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenoceptor</infon>
          <location offset="550" length="17"/>
          <text>beta-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>625</offset>
        <text>In a double-blind, placebo-controlled, randomized design, nine healthy male volunteers received disodium cromoglycate (4 x 200 mg/day, p.o.) or placebo for 3 weeks with terbutaline (3 x 5 mg/day, p.o.) administered concomitantly during the last 2 weeks.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">disodium cromoglycate</infon>
          <location offset="721" length="21"/>
          <text>disodium cromoglycate</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terbutaline</infon>
          <location offset="794" length="11"/>
          <text>terbutaline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>879</offset>
        <text>beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist isoprenaline; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoprenaline</infon>
          <location offset="1100" length="12"/>
          <text>isoprenaline</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="879" length="19"/>
          <text>beta 2-Adrenoceptor</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenoceptor</infon>
          <location offset="1074" length="17"/>
          <text>beta-adrenoceptor</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 1-adrenoceptor</infon>
          <location offset="1114" length="19"/>
          <text>beta 1-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T16" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1204</offset>
        <text>Tremulousness was monitored as a beta 2-adrenoceptor-mediated noncardiovascular effect.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="1237" length="19"/>
          <text>beta 2-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1292</offset>
        <text>After 2 weeks' administration of terbutaline, there was a marked and significant (p &lt; 0.001) attenuation of isoprenaline-induced tachycardia (mean percentage attenuation, 53.3%) and of the isoprenaline-induced decrease in diastolic blood pressure (mean percentage attenuation, 55.6%).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terbutaline</infon>
          <location offset="1325" length="11"/>
          <text>terbutaline</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoprenaline</infon>
          <location offset="1400" length="12"/>
          <text>isoprenaline</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoprenaline</infon>
          <location offset="1481" length="12"/>
          <text>isoprenaline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1577</offset>
        <text>Exercise-induced tachycardia also was significantly (p &lt; 0.001) blunted, but the magnitude of this attenuation was only very small (mean attenuation, 5.6%).</text>
      </sentence>
      <sentence>
        <offset>1734</offset>
        <text>Disodium cromoglycate affected neither the rightward shift of beta 2-adrenoceptor-mediated responses nor the small rightward shift in beta 1-adrenoceptor-mediated exercise tachycardia after 2 weeks' administration of terbutaline.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">disodium cromoglycate</infon>
          <location offset="1734" length="21"/>
          <text>Disodium cromoglycate</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terbutaline</infon>
          <location offset="1951" length="11"/>
          <text>terbutaline</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="1796" length="19"/>
          <text>beta 2-adrenoceptor</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 1-adrenoceptor</infon>
          <location offset="1868" length="19"/>
          <text>beta 1-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1964</offset>
        <text>Tremulousness observed during the first few days of terbutaline administration disappeared after 4 to 8 days, indicating development of desensitization of beta 2-adrenoceptor-mediated noncardiovascular responses.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">terbutaline</infon>
          <location offset="2016" length="11"/>
          <text>terbutaline</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="2119" length="19"/>
          <text>beta 2-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2177</offset>
        <text>This was not prevented by disodium cromoglycate.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">disodium cromoglycate</infon>
          <location offset="2203" length="21"/>
          <text>disodium cromoglycate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2226</offset>
        <text>These results confirm that long-term beta 2-adrenoceptor agonist therapy leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular and noncardiovascular effects in humans in vivo.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="2263" length="19"/>
          <text>beta 2-adrenoceptor</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="2329" length="19"/>
          <text>beta 2-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2422</offset>
        <text>However, unlike ketotifen, cromolyn sodium is not able to attenuate this desensitization.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketotifen</infon>
          <location offset="2438" length="9"/>
          <text>ketotifen</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cromolyn sodium</infon>
          <location offset="2449" length="15"/>
          <text>cromolyn sodium</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23567490</id>
    <passage>
      <offset>0</offset>
      <text>The cyclin D1 (CCND1) rs9344 G&gt;A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.	Recent evidence indicates a potential prognostic and predictive value for germline polymorphisms in genes involved in cell cycle control. We investigated the effect of cyclin D1 (CCND1) rs9344 G&gt;A in stage II/III colon cancer patients and validated the findings in an independent study cohort. For evaluation and validation set, a total of 264 and 234 patients were included. Patients treated with 5-fluorouracil-based chemotherapy, carrying the CCND1 rs9344 A/A genotype had significantly decreased time-to-tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16-5.29; P=0.019). There was no significant association between CCND1 rs9344 G&gt;A and TTR in patients with curative surgery alone. In the validation set, the A allele of CCND1 rs9344 G&gt;A remained significantly associated with decreased TTR in univariate and multivariate analyses (HR 1.94; 95% CI 1.05-3.58; P=0.035). CCND1 rs9344 G&gt;A may be a predictive and/or prognostic biomarker in stage II/III colon cancer patients, however, prospective trials are warranted to confirm our findings.The Pharmacogenomics Journal advance online publication, 9 April 2013; doi:10.1038/tpj.2013.15.</text>
      <sentence>
        <offset>0</offset>
        <text>The cyclin D1 (CCND1) rs9344 G&gt;A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fu</infon>
          <location offset="119" length="4"/>
          <text>5-FU</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ccnd1</infon>
          <location offset="15" length="5"/>
          <text>CCND1</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rs9344 g&gt;a</infon>
          <location offset="22" length="10"/>
          <text>rs9344 G&gt;A</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin d1</infon>
          <location offset="4" length="9"/>
          <text>cyclin D1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>144</offset>
        <text>Recent evidence indicates a potential prognostic and predictive value for germline polymorphisms in genes involved in cell cycle control.</text>
      </sentence>
      <sentence>
        <offset>282</offset>
        <text>We investigated the effect of cyclin D1 (CCND1) rs9344 G&gt;A in stage II/III colon cancer patients and validated the findings in an independent study cohort.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin d1</infon>
          <location offset="312" length="9"/>
          <text>cyclin D1</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ccnd1</infon>
          <location offset="323" length="5"/>
          <text>CCND1</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rs9344 g&gt;a</infon>
          <location offset="330" length="10"/>
          <text>rs9344 G&gt;A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>438</offset>
        <text>For evaluation and validation set, a total of 264 and 234 patients were included.</text>
      </sentence>
      <sentence>
        <offset>520</offset>
        <text>Patients treated with 5-fluorouracil-based chemotherapy, carrying the CCND1 rs9344 A/A genotype had significantly decreased time-to-tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16-5.29; P=0.019).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fluorouracil</infon>
          <location offset="542" length="14"/>
          <text>5-fluorouracil</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ccnd1</infon>
          <location offset="590" length="5"/>
          <text>CCND1</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rs9344 a/a</infon>
          <location offset="596" length="10"/>
          <text>rs9344 A/A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>799</offset>
        <text>There was no significant association between CCND1 rs9344 G&gt;A and TTR in patients with curative surgery alone.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ccnd1</infon>
          <location offset="844" length="5"/>
          <text>CCND1</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rs9344 g&gt;a</infon>
          <location offset="850" length="10"/>
          <text>rs9344 G&gt;A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>910</offset>
        <text>In the validation set, the A allele of CCND1 rs9344 G&gt;A remained significantly associated with decreased TTR in univariate and multivariate analyses (HR 1.94; 95% CI 1.05-3.58; P=0.035).</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ccnd1</infon>
          <location offset="949" length="5"/>
          <text>CCND1</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rs9344 g&gt;a</infon>
          <location offset="955" length="10"/>
          <text>rs9344 G&gt;A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1097</offset>
        <text>CCND1 rs9344 G&gt;A may be a predictive and/or prognostic biomarker in stage II/III colon cancer patients, however, prospective trials are warranted to confirm our findings.The Pharmacogenomics Journal advance online publication, 9 April 2013; doi:10.1038/tpj.2013.15.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ccnd1</infon>
          <location offset="1097" length="5"/>
          <text>CCND1</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rs9344 g&gt;a</infon>
          <location offset="1103" length="10"/>
          <text>rs9344 G&gt;A</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>7948825</id>
    <passage>
      <offset>0</offset>
      <text>Sucralfate: the Bangkok review.	Sucralfate is a site-protective ulcer healing drug with a remarkable range of mechanisms of action. Recent studies highlight the capacity of sucralfate to bind basic fibroblast growth factor (bFGF) and deliver it in high concentration to the ulcer. Basic fibroblast growth factor stimulates the production of granulation tissue, angiogenesis and re-epithelization, thus improving the quality of ulcer healing. The effect of sucralfate in reducing parietal cell sensitivity may be another factor important in the lower relapse rate demonstrated after duodenal ulcer healing. Sucralfate has been demonstrated to be efficacious in healing both duodenal and gastric ulcers together with mild oesophagitis, and it is safe for both short-term use and maintenance. In stress ulcer prophylaxis it is as effective as acid suppression or neutralization and has the advantage of lesser rates of nosocomial pneumonia than are demonstrated with antacids or H2 antagonists. The potential advantages of sucralfate lie in the better quality of ulcer healing associated with longer duration of remission.</text>
      <sentence>
        <offset>0</offset>
        <text>Sucralfate: the Bangkok review.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sucralfate</infon>
          <location offset="0" length="10"/>
          <text>Sucralfate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>32</offset>
        <text>Sucralfate is a site-protective ulcer healing drug with a remarkable range of mechanisms of action.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sucralfate</infon>
          <location offset="32" length="10"/>
          <text>Sucralfate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>132</offset>
        <text>Recent studies highlight the capacity of sucralfate to bind basic fibroblast growth factor (bFGF) and deliver it in high concentration to the ulcer.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sucralfate</infon>
          <location offset="173" length="10"/>
          <text>sucralfate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">basic fibroblast growth factor</infon>
          <location offset="192" length="30"/>
          <text>basic fibroblast growth factor</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bfgf</infon>
          <location offset="224" length="4"/>
          <text>bFGF</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>281</offset>
        <text>Basic fibroblast growth factor stimulates the production of granulation tissue, angiogenesis and re-epithelization, thus improving the quality of ulcer healing.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">basic fibroblast growth factor</infon>
          <location offset="281" length="30"/>
          <text>Basic fibroblast growth factor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>442</offset>
        <text>The effect of sucralfate in reducing parietal cell sensitivity may be another factor important in the lower relapse rate demonstrated after duodenal ulcer healing.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sucralfate</infon>
          <location offset="456" length="10"/>
          <text>sucralfate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>606</offset>
        <text>Sucralfate has been demonstrated to be efficacious in healing both duodenal and gastric ulcers together with mild oesophagitis, and it is safe for both short-term use and maintenance.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sucralfate</infon>
          <location offset="606" length="10"/>
          <text>Sucralfate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>790</offset>
        <text>In stress ulcer prophylaxis it is as effective as acid suppression or neutralization and has the advantage of lesser rates of nosocomial pneumonia than are demonstrated with antacids or H2 antagonists.</text>
      </sentence>
      <sentence>
        <offset>992</offset>
        <text>The potential advantages of sucralfate lie in the better quality of ulcer healing associated with longer duration of remission.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sucralfate</infon>
          <location offset="1020" length="10"/>
          <text>sucralfate</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>2083404</id>
    <passage>
      <offset>0</offset>
      <text>Salicylate pre-treatment attenuates intensity of bronchial and nasal symptoms precipitated by aspirin in aspirin-intolerant patients.	Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients. However, salicylate moiety appears to interfere with aspirin inhibitory action on platelets and vascular COX. Such interaction, if present at the level of respiratory tract, may be of interest to pathogenesis of ASA-induced asthma. We performed a double-blind, placebo-controlled, randomized cross-over study on the effect of choline magnesium trisalicylate (CMT, trilisate) pre-treatment on ASA-induced adverse reactions in nine patients. Pulmonary function tests, nasal symptoms score, PNIF and serum salicylate levels were monitored following challenges with threshold doses of ASA. Trilisate administered at a dose of 3000 mg daily for 3 days, offered a moderate protection against ASA-induced symptoms; it diminished the severity and/or delayed the appearance of FEV1 fall. Maximal decreases in FEV1 as well as reaction intensity indexes were significantly lower (P less than 0.02 and P less than 0.002, respectively) after trilisate pre-treatment as compared to placebo. Trilisate also attenuated nasal symptoms in three out of five patients. Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between salicylate and ASA on cyclo-oxygenase locus in the respiratory tract in ASA-intolerant patients.</text>
      <sentence>
        <offset>0</offset>
        <text>Salicylate pre-treatment attenuates intensity of bronchial and nasal symptoms precipitated by aspirin in aspirin-intolerant patients.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salicylate</infon>
          <location offset="0" length="10"/>
          <text>Salicylate</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspirin</infon>
          <location offset="105" length="7"/>
          <text>aspirin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspirin</infon>
          <location offset="94" length="7"/>
          <text>aspirin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>134</offset>
        <text>Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspirin</infon>
          <location offset="134" length="7"/>
          <text>Aspirin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asa</infon>
          <location offset="273" length="3"/>
          <text>ASA</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium salicylate</infon>
          <location offset="304" length="17"/>
          <text>sodium salicylate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroidal</infon>
          <location offset="162" length="9"/>
          <text>steroidal</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asa</infon>
          <location offset="143" length="3"/>
          <text>ASA</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="340" length="3"/>
          <text>COX</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyclooxygenase</infon>
          <location offset="207" length="14"/>
          <text>cyclooxygenase</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="223" length="3"/>
          <text>COX</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>392</offset>
        <text>However, salicylate moiety appears to interfere with aspirin inhibitory action on platelets and vascular COX.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salicylate</infon>
          <location offset="401" length="10"/>
          <text>salicylate</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspirin</infon>
          <location offset="445" length="7"/>
          <text>aspirin</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="497" length="3"/>
          <text>COX</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>502</offset>
        <text>Such interaction, if present at the level of respiratory tract, may be of interest to pathogenesis of ASA-induced asthma.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asa</infon>
          <location offset="604" length="3"/>
          <text>ASA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>624</offset>
        <text>We performed a double-blind, placebo-controlled, randomized cross-over study on the effect of choline magnesium trisalicylate (CMT, trilisate) pre-treatment on ASA-induced adverse reactions in nine patients.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline magnesium trisalicylate</infon>
          <location offset="718" length="31"/>
          <text>choline magnesium trisalicylate</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cmt</infon>
          <location offset="751" length="3"/>
          <text>CMT</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trilisate</infon>
          <location offset="756" length="9"/>
          <text>trilisate</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asa</infon>
          <location offset="784" length="3"/>
          <text>ASA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>832</offset>
        <text>Pulmonary function tests, nasal symptoms score, PNIF and serum salicylate levels were monitored following challenges with threshold doses of ASA.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salicylate</infon>
          <location offset="895" length="10"/>
          <text>salicylate</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asa</infon>
          <location offset="973" length="3"/>
          <text>ASA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>978</offset>
        <text>Trilisate administered at a dose of 3000 mg daily for 3 days, offered a moderate protection against ASA-induced symptoms; it diminished the severity and/or delayed the appearance of FEV1 fall.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trilisate</infon>
          <location offset="978" length="9"/>
          <text>Trilisate</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asa</infon>
          <location offset="1078" length="3"/>
          <text>ASA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1171</offset>
        <text>Maximal decreases in FEV1 as well as reaction intensity indexes were significantly lower (P less than 0.02 and P less than 0.002, respectively) after trilisate pre-treatment as compared to placebo.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trilisate</infon>
          <location offset="1321" length="9"/>
          <text>trilisate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1369</offset>
        <text>Trilisate also attenuated nasal symptoms in three out of five patients.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trilisate</infon>
          <location offset="1369" length="9"/>
          <text>Trilisate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1441</offset>
        <text>Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between salicylate and ASA on cyclo-oxygenase locus in the respiratory tract in ASA-intolerant patients.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trilisate</infon>
          <location offset="1500" length="9"/>
          <text>trilisate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salicylate</infon>
          <location offset="1578" length="10"/>
          <text>salicylate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asa</infon>
          <location offset="1593" length="3"/>
          <text>ASA</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">asa</infon>
          <location offset="1650" length="3"/>
          <text>ASA</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyclo-oxygenase</infon>
          <location offset="1600" length="15"/>
          <text>cyclo-oxygenase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23588312</id>
    <passage>
      <offset>0</offset>
      <text>A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity.	5-Fluorouracil (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck. The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene). In this study, the genetic associations between DPYD variations and circulating mononuclear-cell DPD enzyme activity were evaluated in 94 African-American and 81 European-American volunteers. The DPYD-Y186C variant was unique to individuals of African ancestry, and DPD activity was 46% lower in carriers as compared with noncarriers (279 ± 35 vs. 514 ± 168 pmol 5-FU min(-1) mg(-1); P = 0.00029). In this study, 26% of the African Americans with reduced DPD activity were carriers of Y186C. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609 ± 152 and 480 ± 152 pmol 5-FU min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology &amp; Therapeutics (2013); advance online publication 1 May 2013. doi:10.1038/clpt.2013.69.</text>
      <sentence>
        <offset>0</offset>
        <text>A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity.</text>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">y186c</infon>
          <location offset="16" length="5"/>
          <text>Y186C</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dpyd</infon>
          <location offset="2" length="4"/>
          <text>DPYD</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dpd</infon>
          <location offset="85" length="3"/>
          <text>DPD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>106</offset>
        <text>5-Fluorouracil (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fluorouracil</infon>
          <location offset="106" length="14"/>
          <text>5-Fluorouracil</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fu</infon>
          <location offset="122" length="4"/>
          <text>5-FU</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>225</offset>
        <text>The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fu</infon>
          <location offset="242" length="4"/>
          <text>5-FU</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydropyrimidine</infon>
          <location offset="390" length="17"/>
          <text>dihydropyrimidine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dihydropyrimidine dehydrogenase</infon>
          <location offset="390" length="31"/>
          <text>dihydropyrimidine dehydrogenase</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dpd</infon>
          <location offset="423" length="3"/>
          <text>DPD</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dpyd</infon>
          <location offset="443" length="4"/>
          <text>DPYD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>455</offset>
        <text>In this study, the genetic associations between DPYD variations and circulating mononuclear-cell DPD enzyme activity were evaluated in 94 African-American and 81 European-American volunteers.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dpyd</infon>
          <location offset="503" length="4"/>
          <text>DPYD</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dpd</infon>
          <location offset="552" length="3"/>
          <text>DPD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>647</offset>
        <text>The DPYD-Y186C variant was unique to individuals of African ancestry, and DPD activity was 46% lower in carriers as compared with noncarriers (279 ± 35 vs. 514 ± 168 pmol 5-FU min(-1) mg(-1); P = 0.00029).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fu</infon>
          <location offset="818" length="4"/>
          <text>5-FU</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dpyd</infon>
          <location offset="651" length="4"/>
          <text>DPYD</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">y186c</infon>
          <location offset="656" length="5"/>
          <text>Y186C</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dpd</infon>
          <location offset="721" length="3"/>
          <text>DPD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>853</offset>
        <text>In this study, 26% of the African Americans with reduced DPD activity were carriers of Y186C.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dpd</infon>
          <location offset="910" length="3"/>
          <text>DPD</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">y186c</infon>
          <location offset="940" length="5"/>
          <text>Y186C</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>947</offset>
        <text>In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609 ± 152 and 480 ± 152 pmol 5-FU min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology &amp; Therapeutics (2013); advance online publication 1 May 2013.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fu</infon>
          <location offset="1129" length="4"/>
          <text>5-FU</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">y186c</infon>
          <location offset="995" length="5"/>
          <text>Y186C</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">c29r</infon>
          <location offset="1034" length="4"/>
          <text>C29R</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dpd</infon>
          <location offset="1057" length="3"/>
          <text>DPD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1259</offset>
        <text>doi:10.1038/clpt.2013.69.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23624419</id>
    <passage>
      <offset>0</offset>
      <text>Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.	We evaluated the positive effects of vildagliptin in addition to metformin on glycemic control and β-cell function in type 2 diabetic patients. One hundred and seventy-one type 2 diabetic patients were instructed to add vildaglipin 50mg twice a day or placebo to metformin for 12 months. Body mass index (BMI), glycemic control, fasting plasma insulin (FPI), HOMA-IR, HOMA-β, fasting plasma proinsulin (FPPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, vaspin, visfatin, and omentin-1 were evaluated. Before, and after 12 months since the addition of vildagliptin, patients underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation. Vildagliptin+metformin were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and insulin resistance measurements. Vildagliptin+metformin gave also a better increase of HOMA-β, and of all β-cell parameters after the clamp. We also recorded a significant correlation between M value increase and the decrease of vaspin, visfatin, and omentin-1 obtained with vildagliptin+metformin. Vildagliptin, in addition to metformin, proved to be effective in improving β-cell function and in reducing insulin resistance measurements.</text>
      <sentence>
        <offset>0</offset>
        <text>Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="112" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vildagliptin</infon>
          <location offset="84" length="12"/>
          <text>vildagliptin</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="38" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>151</offset>
        <text>We evaluated the positive effects of vildagliptin in addition to metformin on glycemic control and β-cell function in type 2 diabetic patients.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vildagliptin</infon>
          <location offset="188" length="12"/>
          <text>vildagliptin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="216" length="9"/>
          <text>metformin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>295</offset>
        <text>One hundred and seventy-one type 2 diabetic patients were instructed to add vildaglipin 50mg twice a day or placebo to metformin for 12 months.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vildaglipin</infon>
          <location offset="371" length="11"/>
          <text>vildaglipin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="414" length="9"/>
          <text>metformin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>439</offset>
        <text>Body mass index (BMI), glycemic control, fasting plasma insulin (FPI), HOMA-IR, HOMA-β, fasting plasma proinsulin (FPPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, vaspin, visfatin, and omentin-1 were evaluated.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="495" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">proinsulin</infon>
          <location offset="542" length="10"/>
          <text>proinsulin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">proinsulin</infon>
          <location offset="561" length="10"/>
          <text>proinsulin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="587" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-peptide</infon>
          <location offset="617" length="9"/>
          <text>C-peptide</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucagon</infon>
          <location offset="628" length="8"/>
          <text>glucagon</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vaspin</infon>
          <location offset="638" length="6"/>
          <text>vaspin</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">visfatin</infon>
          <location offset="646" length="8"/>
          <text>visfatin</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">omentin-1</infon>
          <location offset="660" length="9"/>
          <text>omentin-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>686</offset>
        <text>Before, and after 12 months since the addition of vildagliptin, patients underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vildagliptin</infon>
          <location offset="736" length="12"/>
          <text>vildagliptin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arginine</infon>
          <location offset="849" length="8"/>
          <text>arginine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>871</offset>
        <text>Vildagliptin+metformin were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and insulin resistance measurements.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vildagliptin</infon>
          <location offset="871" length="12"/>
          <text>Vildagliptin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="884" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="927" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucagon</infon>
          <location offset="997" length="8"/>
          <text>glucagon</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1010" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1043</offset>
        <text>Vildagliptin+metformin gave also a better increase of HOMA-β, and of all β-cell parameters after the clamp.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vildagliptin</infon>
          <location offset="1043" length="12"/>
          <text>Vildagliptin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="1056" length="9"/>
          <text>metformin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1151</offset>
        <text>We also recorded a significant correlation between M value increase and the decrease of vaspin, visfatin, and omentin-1 obtained with vildagliptin+metformin.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vildagliptin</infon>
          <location offset="1285" length="12"/>
          <text>vildagliptin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="1298" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vaspin</infon>
          <location offset="1239" length="6"/>
          <text>vaspin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">visfatin</infon>
          <location offset="1247" length="8"/>
          <text>visfatin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">omentin-1</infon>
          <location offset="1261" length="9"/>
          <text>omentin-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1309</offset>
        <text>Vildagliptin, in addition to metformin, proved to be effective in improving β-cell function and in reducing insulin resistance measurements.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vildagliptin</infon>
          <location offset="1309" length="12"/>
          <text>Vildagliptin</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="1338" length="9"/>
          <text>metformin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1417" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10866053</id>
    <passage>
      <offset>0</offset>
      <text>Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.	In recent years, analogs of human insulin have been engineered with the aim of improving therapy for people with diabetes. To ensure that the safety profile of the human hormone is not compromised by the molecular modifications, the toxico-pharmacological properties of insulin analogs should be carefully monitored. In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(epsilon-tetradecanoyl), desB30 human insulin], and reference insulin analogs. Receptor affinities were measured using purified human receptors, insulin receptor dissociation rates were determined using Chinese hamster ovary cells overexpressing the human insulin receptor, metabolic potencies were evaluated using primary mouse adipocytes, and mitogenic potencies were determined in human osteosarcoma cells. Metabolic potencies correlated well with insulin receptor affinities. Mitogenic potencies in general correlated better with IGF-I receptor affinities than with insulin receptor off-rates. The 2 rapid-acting insulin analogs aspart and lispro resembled human insulin on all parameters, except for a slightly elevated IGF-I receptor affinity of lispro. In contrast, the 2 long-acting insulin analogs, glargine and detemir, differed significantly from human insulin. The combination of the B31B32diArg and A21Gly substitutions provided insulin glargine with a 6- to 8-fold increased IGF-I receptor affinity and mitogenic potency compared with human insulin. The attachment of a fatty acid chain to LysB29 provided insulin detemir with reduced receptor affinities and metabolic and mitogenic potencies but did not change the balance between mitogenic and metabolic potencies. The safety implications of the increased growth-stimulating potential of insulin glargine are unclear. The reduced in vitro potency of insulin detemir might explain why this analog is not as effective on a molar basis as human insulin in humans.</text>
      <sentence>
        <offset>0</offset>
        <text>Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.</text>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="74" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>117</offset>
        <text>In recent years, analogs of human insulin have been engineered with the aim of improving therapy for people with diabetes.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human insulin</infon>
          <location offset="145" length="13"/>
          <text>human insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>240</offset>
        <text>To ensure that the safety profile of the human hormone is not compromised by the molecular modifications, the toxico-pharmacological properties of insulin analogs should be carefully monitored.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="387" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>434</offset>
        <text>In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(epsilon-tetradecanoyl), desB30 human insulin], and reference insulin analogs.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">epsilon-tetradecanoyl</infon>
          <location offset="724" length="21"/>
          <text>epsilon-tetradecanoyl</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="465" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-i receptor</infon>
          <location offset="477" length="14"/>
          <text>IGF-I receptor</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="552" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human insulin</infon>
          <location offset="575" length="13"/>
          <text>human insulin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="591" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human insulin</infon>
          <location offset="621" length="13"/>
          <text>human insulin</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="637" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human insulin</infon>
          <location offset="676" length="13"/>
          <text>human insulin</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="692" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="761" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="785" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>802</offset>
        <text>Receptor affinities were measured using purified human receptors, insulin receptor dissociation rates were determined using Chinese hamster ovary cells overexpressing the human insulin receptor, metabolic potencies were evaluated using primary mouse adipocytes, and mitogenic potencies were determined in human osteosarcoma cells.</text>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin receptor</infon>
          <location offset="868" length="16"/>
          <text>insulin receptor</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human insulin receptor</infon>
          <location offset="973" length="22"/>
          <text>human insulin receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1133</offset>
        <text>Metabolic potencies correlated well with insulin receptor affinities.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin receptor</infon>
          <location offset="1174" length="16"/>
          <text>insulin receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1203</offset>
        <text>Mitogenic potencies in general correlated better with IGF-I receptor affinities than with insulin receptor off-rates.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-i receptor</infon>
          <location offset="1257" length="14"/>
          <text>IGF-I receptor</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin receptor</infon>
          <location offset="1293" length="16"/>
          <text>insulin receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1321</offset>
        <text>The 2 rapid-acting insulin analogs aspart and lispro resembled human insulin on all parameters, except for a slightly elevated IGF-I receptor affinity of lispro.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1340" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human insulin</infon>
          <location offset="1384" length="13"/>
          <text>human insulin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-i receptor</infon>
          <location offset="1448" length="14"/>
          <text>IGF-I receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1483</offset>
        <text>In contrast, the 2 long-acting insulin analogs, glargine and detemir, differed significantly from human insulin.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1514" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human insulin</infon>
          <location offset="1581" length="13"/>
          <text>human insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1596</offset>
        <text>The combination of the B31B32diArg and A21Gly substitutions provided insulin glargine with a 6- to 8-fold increased IGF-I receptor affinity and mitogenic potency compared with human insulin.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1665" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-i receptor</infon>
          <location offset="1712" length="14"/>
          <text>IGF-I receptor</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human insulin</infon>
          <location offset="1772" length="13"/>
          <text>human insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1787</offset>
        <text>The attachment of a fatty acid chain to LysB29 provided insulin detemir with reduced receptor affinities and metabolic and mitogenic potencies but did not change the balance between mitogenic and metabolic potencies.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="1807" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1843" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2004</offset>
        <text>The safety implications of the increased growth-stimulating potential of insulin glargine are unclear.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="2077" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2107</offset>
        <text>The reduced in vitro potency of insulin detemir might explain why this analog is not as effective on a molar basis as human insulin in humans.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="2139" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human insulin</infon>
          <location offset="2225" length="13"/>
          <text>human insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16554356</id>
    <passage>
      <offset>0</offset>
      <text>Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain.	Drug delivery to the brain is becoming more and more important but is severely restricted by the blood-brain barrier. Nanoparticles coated with polysorbates have previously been shown to enable the transport of several drugs across the blood-brain barrier, which under normal circumstances is impermeable to these compounds. Apolipoprotein E was suggested to mediate this drug transport across the blood-brain barrier. In the present study, apolipoprotein E was coupled by chemical methods to nanoparticles made of human serum albumin (HSA-NP). Loperamide, which does not cross the blood-brain barrier but exerts antinociceptive effects after direct injection into the brain, was used as model drug. Apolipoprotein E was chemically bound via linkers to loperamide-loaded HSA-NP. This preparation induced antinociceptive effects in the tail-flick test in ICR mice after i.v. injection. In contrast, nanoparticles linked to apolipoprotein E variants that do not recognize lipoprotein receptors failed to induce these effects. These results indicate that apolipoprotein E attached to the surface of nanoparticles facilitates transport of drugs across the blood-brain barrier, probably after interaction with lipoprotein receptors on the brain capillary endothelial cell membranes.</text>
      <sentence>
        <offset>0</offset>
        <text>Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apolipoprotein e</infon>
          <location offset="20" length="16"/>
          <text>apolipoprotein e</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">albumin</infon>
          <location offset="40" length="7"/>
          <text>albumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>111</offset>
        <text>Drug delivery to the brain is becoming more and more important but is severely restricted by the blood-brain barrier.</text>
      </sentence>
      <sentence>
        <offset>229</offset>
        <text>Nanoparticles coated with polysorbates have previously been shown to enable the transport of several drugs across the blood-brain barrier, which under normal circumstances is impermeable to these compounds.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polysorbates</infon>
          <location offset="255" length="12"/>
          <text>polysorbates</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>436</offset>
        <text>Apolipoprotein E was suggested to mediate this drug transport across the blood-brain barrier.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apolipoprotein e</infon>
          <location offset="436" length="16"/>
          <text>Apolipoprotein E</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>530</offset>
        <text>In the present study, apolipoprotein E was coupled by chemical methods to nanoparticles made of human serum albumin (HSA-NP).</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apolipoprotein e</infon>
          <location offset="552" length="16"/>
          <text>apolipoprotein E</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human serum albumin</infon>
          <location offset="626" length="19"/>
          <text>human serum albumin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsa</infon>
          <location offset="647" length="3"/>
          <text>HSA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>656</offset>
        <text>Loperamide, which does not cross the blood-brain barrier but exerts antinociceptive effects after direct injection into the brain, was used as model drug.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">loperamide</infon>
          <location offset="656" length="10"/>
          <text>Loperamide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>811</offset>
        <text>Apolipoprotein E was chemically bound via linkers to loperamide-loaded HSA-NP.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">loperamide</infon>
          <location offset="864" length="10"/>
          <text>loperamide</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apolipoprotein e</infon>
          <location offset="811" length="16"/>
          <text>Apolipoprotein E</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsa</infon>
          <location offset="882" length="3"/>
          <text>HSA</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>890</offset>
        <text>This preparation induced antinociceptive effects in the tail-flick test in ICR mice after i.v. injection.</text>
      </sentence>
      <sentence>
        <offset>996</offset>
        <text>In contrast, nanoparticles linked to apolipoprotein E variants that do not recognize lipoprotein receptors failed to induce these effects.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apolipoprotein e</infon>
          <location offset="1033" length="16"/>
          <text>apolipoprotein E</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lipoprotein receptors</infon>
          <location offset="1081" length="21"/>
          <text>lipoprotein receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1135</offset>
        <text>These results indicate that apolipoprotein E attached to the surface of nanoparticles facilitates transport of drugs across the blood-brain barrier, probably after interaction with lipoprotein receptors on the brain capillary endothelial cell membranes.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apolipoprotein e</infon>
          <location offset="1163" length="16"/>
          <text>apolipoprotein E</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lipoprotein receptors</infon>
          <location offset="1316" length="21"/>
          <text>lipoprotein receptors</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16851960</id>
    <passage>
      <offset>0</offset>
      <text>Methyl transfer in glycine N-methyltransferase. A theoretical study.	Density functional theory calculations using the hybrid functional B3LYP have been performed to study the methyl transfer step in glycine N-methyltransferase (GNMT). This enzyme catalyzes the S-adenosyl-L-methionine (SAM)-dependent methylation of glycine to form sarcosine. The starting point for the calculations is the recent X-ray crystal structure of GNMT complexed with SAM and acetate. Several quantum chemical models with different sizes, employing up to 98 atoms, were used. The calculations demonstrate that the suggested mechanism, where the methyl group is transferred in a single S(N)2 step, is thermodynamically plausible. By adding or eliminating various groups at the active site, it was furthermore demonstrated that hydrogen bonds to the amino group of the glycine substrate lower the reaction barrier, while hydrogen bonds to the carboxylate group raise the barrier.</text>
      <sentence>
        <offset>0</offset>
        <text>Methyl transfer in glycine N-methyltransferase.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methyl</infon>
          <location offset="0" length="6"/>
          <text>Methyl</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="19" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="27" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glycine n-methyltransferase</infon>
          <location offset="19" length="27"/>
          <text>glycine N-methyltransferase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>48</offset>
        <text>A theoretical study.</text>
      </sentence>
      <sentence>
        <offset>69</offset>
        <text>Density functional theory calculations using the hybrid functional B3LYP have been performed to study the methyl transfer step in glycine N-methyltransferase (GNMT).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methyl</infon>
          <location offset="175" length="6"/>
          <text>methyl</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="199" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="207" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glycine n-methyltransferase</infon>
          <location offset="199" length="27"/>
          <text>glycine N-methyltransferase</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnmt</infon>
          <location offset="228" length="4"/>
          <text>GNMT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>235</offset>
        <text>This enzyme catalyzes the S-adenosyl-L-methionine (SAM)-dependent methylation of glycine to form sarcosine.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s-adenosyl-l-methionine</infon>
          <location offset="261" length="23"/>
          <text>S-adenosyl-L-methionine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sam</infon>
          <location offset="286" length="3"/>
          <text>SAM</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="316" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sarcosine</infon>
          <location offset="332" length="9"/>
          <text>sarcosine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>343</offset>
        <text>The starting point for the calculations is the recent X-ray crystal structure of GNMT complexed with SAM and acetate.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sam</infon>
          <location offset="444" length="3"/>
          <text>SAM</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gnmt</infon>
          <location offset="424" length="4"/>
          <text>GNMT</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T8" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>461</offset>
        <text>Several quantum chemical models with different sizes, employing up to 98 atoms, were used.</text>
      </sentence>
      <sentence>
        <offset>552</offset>
        <text>The calculations demonstrate that the suggested mechanism, where the methyl group is transferred in a single S(N)2 step, is thermodynamically plausible.</text>
      </sentence>
      <sentence>
        <offset>705</offset>
        <text>By adding or eliminating various groups at the active site, it was furthermore demonstrated that hydrogen bonds to the amino group of the glycine substrate lower the reaction barrier, while hydrogen bonds to the carboxylate group raise the barrier.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrogen</infon>
          <location offset="802" length="8"/>
          <text>hydrogen</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino</infon>
          <location offset="824" length="5"/>
          <text>amino</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="843" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrogen</infon>
          <location offset="895" length="8"/>
          <text>hydrogen</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carboxylate</infon>
          <location offset="917" length="11"/>
          <text>carboxylate</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23086035</id>
    <passage>
      <offset>0</offset>
      <text>PGC-1α improves glucose homeostasis in skeletal muscle in an activity-dependent manner.	Metabolic disorders are a major burden for public health systems globally. Regular exercise improves metabolic health. Pharmacological targeting of exercise mediators might facilitate physical activity or amplify the effects of exercise. The peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) largely mediates musculoskeletal adaptations to exercise, including lipid refueling, and thus constitutes such a putative target. Paradoxically, forced expression of PGC-1α in muscle promotes diet-induced insulin resistance in sedentary animals. We show that elevated PGC-1α in combination with exercise preferentially improves glucose homeostasis, increases Krebs cycle activity, and reduces the levels of acylcarnitines and sphingosine. Moreover, patterns of lipid partitioning are altered in favor of enhanced insulin sensitivity in response to combined PGC-1α and exercise. Our findings reveal how physical activity improves glucose homeostasis. Furthermore, our data suggest that the combination of elevated muscle PGC-1α and exercise constitutes a promising approach for the treatment of metabolic disorders.</text>
      <sentence>
        <offset>0</offset>
        <text>PGC-1α improves glucose homeostasis in skeletal muscle in an activity-dependent manner.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="16" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgc-1α</infon>
          <location offset="0" length="6"/>
          <text>PGC-1α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>88</offset>
        <text>Metabolic disorders are a major burden for public health systems globally.</text>
      </sentence>
      <sentence>
        <offset>163</offset>
        <text>Regular exercise improves metabolic health.</text>
      </sentence>
      <sentence>
        <offset>207</offset>
        <text>Pharmacological targeting of exercise mediators might facilitate physical activity or amplify the effects of exercise.</text>
      </sentence>
      <sentence>
        <offset>326</offset>
        <text>The peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) largely mediates musculoskeletal adaptations to exercise, including lipid refueling, and thus constitutes such a putative target.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor γ coactivator 1α</infon>
          <location offset="330" length="59"/>
          <text>peroxisome proliferator-activated receptor γ coactivator 1α</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgc-1α</infon>
          <location offset="391" length="6"/>
          <text>PGC-1α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>529</offset>
        <text>Paradoxically, forced expression of PGC-1α in muscle promotes diet-induced insulin resistance in sedentary animals.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgc-1α</infon>
          <location offset="565" length="6"/>
          <text>PGC-1α</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="604" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>645</offset>
        <text>We show that elevated PGC-1α in combination with exercise preferentially improves glucose homeostasis, increases Krebs cycle activity, and reduces the levels of acylcarnitines and sphingosine.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="727" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acylcarnitines</infon>
          <location offset="806" length="14"/>
          <text>acylcarnitines</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sphingosine</infon>
          <location offset="825" length="11"/>
          <text>sphingosine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgc-1α</infon>
          <location offset="667" length="6"/>
          <text>PGC-1α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>838</offset>
        <text>Moreover, patterns of lipid partitioning are altered in favor of enhanced insulin sensitivity in response to combined PGC-1α and exercise.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="912" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgc-1α</infon>
          <location offset="956" length="6"/>
          <text>PGC-1α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>977</offset>
        <text>Our findings reveal how physical activity improves glucose homeostasis.</text>
      </sentence>
      <sentence>
        <offset>1049</offset>
        <text>Furthermore, our data suggest that the combination of elevated muscle PGC-1α and exercise constitutes a promising approach for the treatment of metabolic disorders.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgc-1α</infon>
          <location offset="1119" length="6"/>
          <text>PGC-1α</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>7905294</id>
    <passage>
      <offset>0</offset>
      <text>Ethanol inhibits glutamate-induced currents in heteromeric NMDA receptor subtypes.	Maximal L-glutamate/glycine-evoked currents were inhibited by ethanol in Xenopus laevis oocytes expressing recombinant heteromeric NMDA receptors consisting of NR1-NR2A, NR1-NR2B, and NR1-NR2C subunit combinations. Concentration-dependent inhibition was observed at ethanol concentrations of &gt; or = 50 mM both in Ca(2+)-containing and Ca(2+)-deficient, Ba(2+)-containing Mg(2+)-free media. The NR1-NR2C channels were slightly less sensitive to ethanol inhibition than the other heteromeric channels in Ca(2+)-deficient, Ba(2+)-containing medium. The inhibition was unaffected by the clamping-voltage and by a mutation [NR1-NR2A(N595Q)] that prevents the Mg(2+)-blockade of the channels, indicating that the mechanism of action of ethanol differs from that of Mg2+. The results are consistent with the hypothesis that the NMDA receptor subtypes can mediate many behavioural actions of ethanol.</text>
      <sentence>
        <offset>0</offset>
        <text>Ethanol inhibits glutamate-induced currents in heteromeric NMDA receptor subtypes.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="0" length="7"/>
          <text>Ethanol</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="17" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="59" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptor</infon>
          <location offset="59" length="13"/>
          <text>NMDA receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>83</offset>
        <text>Maximal L-glutamate/glycine-evoked currents were inhibited by ethanol in Xenopus laevis oocytes expressing recombinant heteromeric NMDA receptors consisting of NR1-NR2A, NR1-NR2B, and NR1-NR2C subunit combinations.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="214" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="103" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="145" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-glutamate</infon>
          <location offset="91" length="11"/>
          <text>L-glutamate</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptors</infon>
          <location offset="214" length="14"/>
          <text>NMDA receptors</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr1</infon>
          <location offset="243" length="3"/>
          <text>NR1</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr2a</infon>
          <location offset="247" length="4"/>
          <text>NR2A</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr1</infon>
          <location offset="253" length="3"/>
          <text>NR1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr2b</infon>
          <location offset="257" length="4"/>
          <text>NR2B</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr1</infon>
          <location offset="267" length="3"/>
          <text>NR1</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr2c</infon>
          <location offset="271" length="4"/>
          <text>NR2C</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>298</offset>
        <text>Concentration-dependent inhibition was observed at ethanol concentrations of &gt; or = 50 mM both in Ca(2+)-containing and Ca(2+)-deficient, Ba(2+)-containing Mg(2+)-free media.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="349" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca(2+)</infon>
          <location offset="396" length="6"/>
          <text>Ca(2+)</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca(2+)</infon>
          <location offset="418" length="6"/>
          <text>Ca(2+)</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ba(2+)</infon>
          <location offset="436" length="6"/>
          <text>Ba(2+)</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mg(2+)</infon>
          <location offset="454" length="6"/>
          <text>Mg(2+)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>473</offset>
        <text>The NR1-NR2C channels were slightly less sensitive to ethanol inhibition than the other heteromeric channels in Ca(2+)-deficient, Ba(2+)-containing medium.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="527" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca(2+)</infon>
          <location offset="585" length="6"/>
          <text>Ca(2+)</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ba(2+)</infon>
          <location offset="603" length="6"/>
          <text>Ba(2+)</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr1</infon>
          <location offset="477" length="3"/>
          <text>NR1</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr2c</infon>
          <location offset="481" length="4"/>
          <text>NR2C</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>629</offset>
        <text>The inhibition was unaffected by the clamping-voltage and by a mutation [NR1-NR2A(N595Q)] that prevents the Mg(2+)-blockade of the channels, indicating that the mechanism of action of ethanol differs from that of Mg2+.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mg(2+)</infon>
          <location offset="737" length="6"/>
          <text>Mg(2+)</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="813" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mg2+</infon>
          <location offset="842" length="4"/>
          <text>Mg2+</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr1</infon>
          <location offset="702" length="3"/>
          <text>NR1</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr2a</infon>
          <location offset="706" length="4"/>
          <text>NR2A</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">n595q</infon>
          <location offset="711" length="5"/>
          <text>N595Q</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>848</offset>
        <text>The results are consistent with the hypothesis that the NMDA receptor subtypes can mediate many behavioural actions of ethanol.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="904" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethanol</infon>
          <location offset="967" length="7"/>
          <text>ethanol</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptor</infon>
          <location offset="904" length="13"/>
          <text>NMDA receptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16622728</id>
    <passage>
      <offset>0</offset>
      <text>Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody.	We report that a-63-year-old woman developed Pneumocystis jiroveci pneumonia (PCP) as a complication from treatment with infliximab for rheumatoid arthritis. Although there was neither symptoms of dyspnea nor typical observations on a chest X-ray examination, low levels of oxygen saturation and findings of high-resolution chest computed tomographic scanning suggested a possibility of interstitial pneumonia. A polymerase chain reaction-based detection of Pneumocystis jiroveci in induced sputum allowed an early diagnosis of PCP and subsequent effective treatment.</text>
      <sentence>
        <offset>0</offset>
        <text>Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor alpha</infon>
          <location offset="124" length="27"/>
          <text>tumor necrosis factor alpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>175</offset>
        <text>We report that a-63-year-old woman developed Pneumocystis jiroveci pneumonia (PCP) as a complication from treatment with infliximab for rheumatoid arthritis.</text>
      </sentence>
      <sentence>
        <offset>333</offset>
        <text>Although there was neither symptoms of dyspnea nor typical observations on a chest X-ray examination, low levels of oxygen saturation and findings of high-resolution chest computed tomographic scanning suggested a possibility of interstitial pneumonia.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="449" length="6"/>
          <text>oxygen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>586</offset>
        <text>A polymerase chain reaction-based detection of Pneumocystis jiroveci in induced sputum allowed an early diagnosis of PCP and subsequent effective treatment.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23204443</id>
    <passage>
      <offset>0</offset>
      <text>Sphingosine 1-phosphate receptor 1 (S1P(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist.	Sphingosine 1-phosphate receptor 1 (S1P(1)) is a G protein-coupled receptor that is critical for proper lymphocyte development and recirculation. Agonists to S1P(1) are currently in use clinically for the treatment of multiple sclerosis, and these drugs may act on both S1P(1) expressed on lymphocytes and S1P(1) expressed within the central nervous system. Agonists to S1P(1) and deficiency in S1P(1) both cause lymphocyte sequestration in the lymph nodes. In the present study, we show that S1P(1) antagonism induces lymphocyte sequestration in the lymph nodes similar to that observed with S1P(1) agonists while upregulating S1P(1) on lymphocytes and endothelial cells. Additionally, we show that S1P(1) antagonism reverses experimental autoimmune encephalomyelitis in mice without acting on S1P(1) expressed within the central nervous system, demonstrating that lymphocyte sequestration via S1P(1) antagonism is sufficient to alleviate autoimmune pathology.</text>
      <sentence>
        <offset>0</offset>
        <text>Sphingosine 1-phosphate receptor 1 (S1P(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sphingosine 1-phosphate</infon>
          <location offset="0" length="23"/>
          <text>Sphingosine 1-phosphate</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sphingosine 1-phosphate receptor 1</infon>
          <location offset="0" length="34"/>
          <text>Sphingosine 1-phosphate receptor 1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="125" length="6"/>
          <text>S1P(1)</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="36" length="6"/>
          <text>S1P(1)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>144</offset>
        <text>Sphingosine 1-phosphate receptor 1 (S1P(1)) is a G protein-coupled receptor that is critical for proper lymphocyte development and recirculation.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sphingosine 1-phosphate</infon>
          <location offset="144" length="23"/>
          <text>Sphingosine 1-phosphate</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sphingosine 1-phosphate receptor 1</infon>
          <location offset="144" length="34"/>
          <text>Sphingosine 1-phosphate receptor 1</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="180" length="6"/>
          <text>S1P(1)</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g protein-coupled receptor</infon>
          <location offset="193" length="26"/>
          <text>G protein-coupled receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>290</offset>
        <text>Agonists to S1P(1) are currently in use clinically for the treatment of multiple sclerosis, and these drugs may act on both S1P(1) expressed on lymphocytes and S1P(1) expressed within the central nervous system.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="302" length="6"/>
          <text>S1P(1)</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="414" length="6"/>
          <text>S1P(1)</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="450" length="6"/>
          <text>S1P(1)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>502</offset>
        <text>Agonists to S1P(1) and deficiency in S1P(1) both cause lymphocyte sequestration in the lymph nodes.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="514" length="6"/>
          <text>S1P(1)</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="539" length="6"/>
          <text>S1P(1)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>602</offset>
        <text>In the present study, we show that S1P(1) antagonism induces lymphocyte sequestration in the lymph nodes similar to that observed with S1P(1) agonists while upregulating S1P(1) on lymphocytes and endothelial cells.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="637" length="6"/>
          <text>S1P(1)</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="737" length="6"/>
          <text>S1P(1)</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="772" length="6"/>
          <text>S1P(1)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>817</offset>
        <text>Additionally, we show that S1P(1) antagonism reverses experimental autoimmune encephalomyelitis in mice without acting on S1P(1) expressed within the central nervous system, demonstrating that lymphocyte sequestration via S1P(1) antagonism is sufficient to alleviate autoimmune pathology.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="844" length="6"/>
          <text>S1P(1)</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="939" length="6"/>
          <text>S1P(1)</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">s1p(1)</infon>
          <location offset="1039" length="6"/>
          <text>S1P(1)</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23452205</id>
    <passage>
      <offset>0</offset>
      <text>mGluR2 positive allosteric modulators: a patent review (2009 - present).	Introduction: The mGlu2 receptor, which belongs to the group II subfamily of metabotropic glutamate receptors (mGlu) along with the mGlu3 receptor, has proven to be of particular importance in neuropharmacology. Preferentially expressed on presynaptic nerve terminals, the mGlu2 receptor negatively modulates glutamate and GABA release and is widely distributed in the brain. High levels of mGlu2 receptors are seen in brain areas such as prefrontal cortex, hippocampus and amygdala where glutamate hyperfunction may be implicated in disorders and diseases such as anxiety and schizophrenia. Given the promise offered by mGlu2/3 receptor activation, there is increased interest in identifying small molecules which activate the receptor. A preferred approach is via positive allosteric modulators (PAMs) which bind at an alternative site to agonists. Areas covered: This review covers the patent applications which were published between April 2009 and December 2012 on PAMs of the mGlu2, and it is a continuation of an earlier review published in this journal. Expert opinion: Advances in medicinal chemistry and pharmacology have set the stage in the field of mGlu2 receptor PAMs. Compounds currently advancing in clinical trials will soon establish the therapeutic potential of this allosteric approach.</text>
      <sentence>
        <offset>0</offset>
        <text>mGluR2 positive allosteric modulators: a patent review (2009 - present).</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglur2</infon>
          <location offset="0" length="6"/>
          <text>mGluR2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>73</offset>
        <text>Introduction: The mGlu2 receptor, which belongs to the group II subfamily of metabotropic glutamate receptors (mGlu) along with the mGlu3 receptor, has proven to be of particular importance in neuropharmacology.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="163" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglu3 receptor</infon>
          <location offset="205" length="14"/>
          <text>mGlu3 receptor</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglu2 receptor</infon>
          <location offset="91" length="14"/>
          <text>mGlu2 receptor</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">group ii subfamily of metabotropic glutamate receptors</infon>
          <location offset="128" length="54"/>
          <text>group II subfamily of metabotropic glutamate receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>285</offset>
        <text>Preferentially expressed on presynaptic nerve terminals, the mGlu2 receptor negatively modulates glutamate and GABA release and is widely distributed in the brain.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="382" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaba</infon>
          <location offset="396" length="4"/>
          <text>GABA</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglu2 receptor</infon>
          <location offset="346" length="14"/>
          <text>mGlu2 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>449</offset>
        <text>High levels of mGlu2 receptors are seen in brain areas such as prefrontal cortex, hippocampus and amygdala where glutamate hyperfunction may be implicated in disorders and diseases such as anxiety and schizophrenia.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="562" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglu2 receptors</infon>
          <location offset="464" length="15"/>
          <text>mGlu2 receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>665</offset>
        <text>Given the promise offered by mGlu2/3 receptor activation, there is increased interest in identifying small molecules which activate the receptor.</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mglu2/3 receptor</infon>
          <location offset="694" length="16"/>
          <text>mGlu2/3 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>811</offset>
        <text>A preferred approach is via positive allosteric modulators (PAMs) which bind at an alternative site to agonists.</text>
      </sentence>
      <sentence>
        <offset>924</offset>
        <text>Areas covered: This review covers the patent applications which were published between April 2009 and December 2012 on PAMs of the mGlu2, and it is a continuation of an earlier review published in this journal.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglu2</infon>
          <location offset="1055" length="5"/>
          <text>mGlu2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1135</offset>
        <text>Expert opinion: Advances in medicinal chemistry and pharmacology have set the stage in the field of mGlu2 receptor PAMs.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mglu2 receptor</infon>
          <location offset="1235" length="14"/>
          <text>mGlu2 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1256</offset>
        <text>Compounds currently advancing in clinical trials will soon establish the therapeutic potential of this allosteric approach.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23511711</id>
    <passage>
      <offset>0</offset>
      <text>A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions.	The objective of the study was to establish an in vivo method for assessing cytochrome P450 3A (CYP3A) activity using therapeutically inert nanogram doses of midazolam. We administered four escalating single doses of oral midazolam (0.0001-3 mg) to 12 healthy participants, stratified according to CYP3A5 carrier status, to assess pharmacokinetics linearity. We then evaluated the interactions with the CYP3A inhibitor ketoconazole (400 mg q.d.) after nanogram and regular doses of midazolam. Area under the plasma concentration-time curve (AUC) and peak plasma concentration (Cmax) were linear over the entire range of doses. Ketoconazole reduced midazolam oral clearance by 92.8%. AUC and Cmax increased by 1,540 and 363%, respectively. CYP3A5 carrier status had no influence on midazolam oral clearance or its inhibition by ketoconazole. This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong CYP3A inhibitors.Clinical Pharmacology &amp; Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.</text>
      <sentence>
        <offset>0</offset>
        <text>A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="45" length="9"/>
          <text>Midazolam</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="23" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>86</offset>
        <text>The objective of the study was to establish an in vivo method for assessing cytochrome P450 3A (CYP3A) activity using therapeutically inert nanogram doses of midazolam.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="244" length="9"/>
          <text>midazolam</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450 3a</infon>
          <location offset="162" length="18"/>
          <text>cytochrome P450 3A</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="182" length="5"/>
          <text>CYP3A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>255</offset>
        <text>We administered four escalating single doses of oral midazolam (0.0001-3 mg) to 12 healthy participants, stratified according to CYP3A5 carrier status, to assess pharmacokinetics linearity.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="308" length="9"/>
          <text>midazolam</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a5</infon>
          <location offset="384" length="6"/>
          <text>CYP3A5</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>445</offset>
        <text>We then evaluated the interactions with the CYP3A inhibitor ketoconazole (400 mg q.d.) after nanogram and regular doses of midazolam.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketoconazole</infon>
          <location offset="505" length="12"/>
          <text>ketoconazole</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="568" length="9"/>
          <text>midazolam</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="489" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>579</offset>
        <text>Area under the plasma concentration-time curve (AUC) and peak plasma concentration (Cmax) were linear over the entire range of doses.</text>
      </sentence>
      <sentence>
        <offset>713</offset>
        <text>Ketoconazole reduced midazolam oral clearance by 92.8%.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketoconazole</infon>
          <location offset="713" length="12"/>
          <text>Ketoconazole</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="734" length="9"/>
          <text>midazolam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>769</offset>
        <text>AUC and Cmax increased by 1,540 and 363%, respectively.</text>
      </sentence>
      <sentence>
        <offset>825</offset>
        <text>CYP3A5 carrier status had no influence on midazolam oral clearance or its inhibition by ketoconazole.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="867" length="9"/>
          <text>midazolam</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketoconazole</infon>
          <location offset="913" length="12"/>
          <text>ketoconazole</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a5</infon>
          <location offset="825" length="6"/>
          <text>CYP3A5</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>927</offset>
        <text>This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong CYP3A inhibitors.Clinical Pharmacology &amp; Therapeutics (2013); advance online publication 20 March 2013.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="1087" length="9"/>
          <text>midazolam</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="1142" length="9"/>
          <text>midazolam</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">midazolam</infon>
          <location offset="964" length="9"/>
          <text>midazolam</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="1199" length="5"/>
          <text>CYP3A</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a</infon>
          <location offset="1245" length="5"/>
          <text>CYP3A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1349</offset>
        <text>doi:10.1038/clpt.2013.27.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23224291</id>
    <passage>
      <offset>0</offset>
      <text>Proteomic and metabolomic responses to connexin43 silencing in primary hepatocyte cultures.	Freshly established cultures of primary hepatocytes progressively adopt a foetal-like phenotype and display increased production of connexin43. The latter is a multifaceted cellular entity with variable subcellular locations, including the mitochondrial compartment. Cx43 forms hemichannels and gap junctions that are involved in a plethora of physiological and pathological processes, such as apoptosis. The present study was conducted with the goal of shedding more light onto the role of connexin43 in primary hepatocyte cultures. Connexin43 expression was suppressed by means of RNA interference technology, and the overall outcome of this treatment on the hepatocellular proteome and metabolome was investigated using tandem mass tag-based differential protein profiling and (1)H NMR spectroscopy, respectively. Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70). At the metabolomic level, connexin43 silencing caused no overt changes, though there was some evidence for a subtle increase in intracellular glycine quantities. Collectively, these data could further substantiate the established existence of a mitochondrial connexin pool and could be reconciled with the previously reported involvement of connexin43 signalling in spontaneously occurring apoptosis in primary hepatocyte cultures.</text>
      <sentence>
        <offset>0</offset>
        <text>Proteomic and metabolomic responses to connexin43 silencing in primary hepatocyte cultures.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">connexin43</infon>
          <location offset="39" length="10"/>
          <text>connexin43</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>92</offset>
        <text>Freshly established cultures of primary hepatocytes progressively adopt a foetal-like phenotype and display increased production of connexin43.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">connexin43</infon>
          <location offset="224" length="10"/>
          <text>connexin43</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>236</offset>
        <text>The latter is a multifaceted cellular entity with variable subcellular locations, including the mitochondrial compartment.</text>
      </sentence>
      <sentence>
        <offset>359</offset>
        <text>Cx43 forms hemichannels and gap junctions that are involved in a plethora of physiological and pathological processes, such as apoptosis.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cx43</infon>
          <location offset="359" length="4"/>
          <text>Cx43</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemichannels</infon>
          <location offset="370" length="12"/>
          <text>hemichannels</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>497</offset>
        <text>The present study was conducted with the goal of shedding more light onto the role of connexin43 in primary hepatocyte cultures.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">connexin43</infon>
          <location offset="583" length="10"/>
          <text>connexin43</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>626</offset>
        <text>Connexin43 expression was suppressed by means of RNA interference technology, and the overall outcome of this treatment on the hepatocellular proteome and metabolome was investigated using tandem mass tag-based differential protein profiling and (1)H NMR spectroscopy, respectively.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(1)h</infon>
          <location offset="872" length="4"/>
          <text>(1)H</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">connexin43</infon>
          <location offset="626" length="10"/>
          <text>Connexin43</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>909</offset>
        <text>Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine triphosphate</infon>
          <location offset="1126" length="22"/>
          <text>adenosine triphosphate</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="1184" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s</infon>
          <location offset="1196" length="1"/>
          <text>S</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1060" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiosulphate</infon>
          <location offset="1090" length="12"/>
          <text>thiosulphate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adenosine triphosphate synthase</infon>
          <location offset="1126" length="31"/>
          <text>adenosine triphosphate synthase</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glutathione s-transferase μ 2</infon>
          <location offset="1184" length="29"/>
          <text>glutathione S-transferase μ 2</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450 2c70</infon>
          <location offset="1218" length="20"/>
          <text>cytochrome P450 2C70</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">connexin43</infon>
          <location offset="970" length="10"/>
          <text>connexin43</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">heat shock protein 60</infon>
          <location offset="1037" length="21"/>
          <text>heat shock protein 60</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucose-regulated protein 75</infon>
          <location offset="1060" length="28"/>
          <text>glucose-regulated protein 75</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thiosulphate sulphurtransferase</infon>
          <location offset="1090" length="31"/>
          <text>thiosulphate sulphurtransferase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1241</offset>
        <text>At the metabolomic level, connexin43 silencing caused no overt changes, though there was some evidence for a subtle increase in intracellular glycine quantities.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="1383" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">connexin43</infon>
          <location offset="1267" length="10"/>
          <text>connexin43</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1403</offset>
        <text>Collectively, these data could further substantiate the established existence of a mitochondrial connexin pool and could be reconciled with the previously reported involvement of connexin43 signalling in spontaneously occurring apoptosis in primary hepatocyte cultures.</text>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">connexin</infon>
          <location offset="1500" length="8"/>
          <text>connexin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">connexin43</infon>
          <location offset="1582" length="10"/>
          <text>connexin43</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10370904</id>
    <passage>
      <offset>0</offset>
      <text>Multiple mechanisms of action: the pharmacological profile of budipine.	Four major components of the mechanism of action have been identified for the antiparkinsonian drug budipine up to now. 1) The primary action of budipine is an indirect dopaminergic effect as shown by facilitation of dopamine (DA) release, inhibition of monoamine oxidase type B (MAO-B) and of DA (re) up-take and stimulation of aromatic L-amino acid decarboxylase (AADC), which in sum might be responsible for enhancing the endogenous dopaminergic activity. 2) Radioligand and functional studies at the N-methyl-D-aspartate (NMDA) type glutamate receptor characterize budipine as a low-affinity, uncompetitive antagonist with fast kinetics and moderate voltage-dependency at the phencyclidine (PCP) binding site, comparable to that observed with amantadine, thereby counteracting an increased excitatory glutamatergic activity. 3) The antimuscarinic action of budipine, verified by functional and binding studies at native muscarinic M1-M3 and human recombinant m1-m5 receptor subtypes in vitro, is up to 125-fold weaker than that of biperiden and corresponds to its approximately 100-fold lower potency to cause experimentally-induced peripheral antimuscarinic effects and explains only part of its high potency, which equals biperiden, to suppress cholinergically evoked tremor. 4) An additional inhibition of striatal gamma-aminobutyric acid (GABA) release by budipine may be beneficial to suppress an increased striatal GABAergic output activity. The contribution of other observed effects to the therapeutic action of budipine, i.e. weak stimulation of noradrenaline and serotonin release, binding to brain sigma1 receptors and blockade of histamine H1 receptors, is not yet clear. By means of these multiple mechanisms, budipine might correct the imbalance of striatal output pathways by restoring DA levels in the striatum, and positively influence the secondary changes in other transmitter systems (glutamate, acetylcholine, GABA) observed in Parkinson's disease.</text>
      <sentence>
        <offset>0</offset>
        <text>Multiple mechanisms of action: the pharmacological profile of budipine.</text>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">budipine</infon>
          <location offset="62" length="8"/>
          <text>budipine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>72</offset>
        <text>Four major components of the mechanism of action have been identified for the antiparkinsonian drug budipine up to now.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">budipine</infon>
          <location offset="172" length="8"/>
          <text>budipine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>192</offset>
        <text>1) The primary action of budipine is an indirect dopaminergic effect as shown by facilitation of dopamine (DA) release, inhibition of monoamine oxidase type B (MAO-B) and of DA (re) up-take and stimulation of aromatic L-amino acid decarboxylase (AADC), which in sum might be responsible for enhancing the endogenous dopaminergic activity.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">budipine</infon>
          <location offset="217" length="8"/>
          <text>budipine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="289" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">da</infon>
          <location offset="299" length="2"/>
          <text>DA</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoamine</infon>
          <location offset="326" length="9"/>
          <text>monoamine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">da</infon>
          <location offset="366" length="2"/>
          <text>DA</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aromatic l-amino acid</infon>
          <location offset="401" length="21"/>
          <text>aromatic L-amino acid</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monoamine oxidase type b</infon>
          <location offset="326" length="24"/>
          <text>monoamine oxidase type B</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-b</infon>
          <location offset="352" length="5"/>
          <text>MAO-B</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatic l-amino acid decarboxylase</infon>
          <location offset="401" length="35"/>
          <text>aromatic L-amino acid decarboxylase</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aadc</infon>
          <location offset="438" length="4"/>
          <text>AADC</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>531</offset>
        <text>2) Radioligand and functional studies at the N-methyl-D-aspartate (NMDA) type glutamate receptor characterize budipine as a low-affinity, uncompetitive antagonist with fast kinetics and moderate voltage-dependency at the phencyclidine (PCP) binding site, comparable to that observed with amantadine, thereby counteracting an increased excitatory glutamatergic activity.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-methyl-d-aspartate</infon>
          <location offset="576" length="20"/>
          <text>N-methyl-D-aspartate</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="598" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="609" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">budipine</infon>
          <location offset="641" length="8"/>
          <text>budipine</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phencyclidine</infon>
          <location offset="752" length="13"/>
          <text>phencyclidine</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcp</infon>
          <location offset="767" length="3"/>
          <text>PCP</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amantadine</infon>
          <location offset="819" length="10"/>
          <text>amantadine</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">n-methyl-d-aspartate (nmda) type glutamate receptor</infon>
          <location offset="576" length="51"/>
          <text>N-methyl-D-aspartate (NMDA) type glutamate receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T25" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T27" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T28" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T26" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>901</offset>
        <text>3) The antimuscarinic action of budipine, verified by functional and binding studies at native muscarinic M1-M3 and human recombinant m1-m5 receptor subtypes in vitro, is up to 125-fold weaker than that of biperiden and corresponds to its approximately 100-fold lower potency to cause experimentally-induced peripheral antimuscarinic effects and explains only part of its high potency, which equals biperiden, to suppress cholinergically evoked tremor.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biperiden</infon>
          <location offset="1107" length="9"/>
          <text>biperiden</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biperiden</infon>
          <location offset="1300" length="9"/>
          <text>biperiden</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">budipine</infon>
          <location offset="933" length="8"/>
          <text>budipine</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">muscarinic m1-m3</infon>
          <location offset="996" length="16"/>
          <text>muscarinic M1-M3</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human recombinant m1-m5 receptor</infon>
          <location offset="1017" length="32"/>
          <text>human recombinant m1-m5 receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1354</offset>
        <text>4) An additional inhibition of striatal gamma-aminobutyric acid (GABA) release by budipine may be beneficial to suppress an increased striatal GABAergic output activity.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gamma-aminobutyric acid</infon>
          <location offset="1394" length="23"/>
          <text>gamma-aminobutyric acid</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaba</infon>
          <location offset="1419" length="4"/>
          <text>GABA</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">budipine</infon>
          <location offset="1436" length="8"/>
          <text>budipine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1524</offset>
        <text>The contribution of other observed effects to the therapeutic action of budipine, i.e. weak stimulation of noradrenaline and serotonin release, binding to brain sigma1 receptors and blockade of histamine H1 receptors, is not yet clear.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">budipine</infon>
          <location offset="1596" length="8"/>
          <text>budipine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">noradrenaline</infon>
          <location offset="1631" length="13"/>
          <text>noradrenaline</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="1649" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="1718" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">brain sigma1 receptors</infon>
          <location offset="1679" length="22"/>
          <text>brain sigma1 receptors</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h1 receptors</infon>
          <location offset="1718" length="22"/>
          <text>histamine H1 receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1760</offset>
        <text>By means of these multiple mechanisms, budipine might correct the imbalance of striatal output pathways by restoring DA levels in the striatum, and positively influence the secondary changes in other transmitter systems (glutamate, acetylcholine, GABA) observed in Parkinson's disease.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">budipine</infon>
          <location offset="1799" length="8"/>
          <text>budipine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">da</infon>
          <location offset="1877" length="2"/>
          <text>DA</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="1981" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="1992" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaba</infon>
          <location offset="2007" length="4"/>
          <text>GABA</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23632310</id>
    <passage>
      <offset>0</offset>
      <text>Immunoregulatory effects of Glycyrrhizic acid exerts anti-asthmatic effects via modulation of Th1/Th2 cytokines and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in ovalbumin-sensitized mice.	ETHNOPHARMACOLOGICAL RELEVANCE: Glycyrrhizic acid (GA) is the main bioactive ingredient of licorice (Glycyrrhiza glabra), and has been found to be associated with multiple therapeutic properties. AIM OF THE STUDY: In this study, we investigated immunoregulatory effects of glycyrrhizic acid on anti-asthmatic effects and underlying mechanisms. MATERIALS AND METHODS: Asthma model was established by ovalbumin-induced. A total of 60 mice were randomly assigned to six experimental groups: control, model, dexamethasone (2mg/kg) and GA (10mg/kg, 20mg/kg, 40mg/kg). Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The hematoxylin and eosin (HE) staining, Th1/Th2 and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the forkhead/winged helix transcription factor (Foxp3) was evaluated by western blotting. RESULTS: Our study demonstrated that, compared with model group, GA inhibited OVA-induced increases in Raw and eosinophil count; interleukin (IL)-4, IL-5, IL-13 levels were recovered in bronchoalveolar lavage fluid compared; increased IFN-γlevel in bronchoalveolar lavage fluid; histological studies demonstrated that GA substantially inhibited OVA-induced eosinophilia in lung tissue and airway tissue compared with model group. Flow cytometry studies demonstrated that GA substantially enhanced Tregs compared with model group. CONCLUSION: These findings suggest that GA may effectively ameliorate the progression of asthma and could be used as a therapy for patients with allergic asthma.</text>
      <sentence>
        <offset>0</offset>
        <text>Immunoregulatory effects of Glycyrrhizic acid exerts anti-asthmatic effects via modulation of Th1/Th2 cytokines and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in ovalbumin-sensitized mice.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycyrrhizic acid</infon>
          <location offset="28" length="17"/>
          <text>Glycyrrhizic acid</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="102" length="9"/>
          <text>cytokines</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ovalbumin</infon>
          <location offset="175" length="9"/>
          <text>ovalbumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>202</offset>
        <text>ETHNOPHARMACOLOGICAL RELEVANCE: Glycyrrhizic acid (GA) is the main bioactive ingredient of licorice (Glycyrrhiza glabra), and has been found to be associated with multiple therapeutic properties.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycyrrhizic acid</infon>
          <location offset="234" length="17"/>
          <text>Glycyrrhizic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>398</offset>
        <text>AIM OF THE STUDY: In this study, we investigated immunoregulatory effects of glycyrrhizic acid on anti-asthmatic effects and underlying mechanisms.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycyrrhizic acid</infon>
          <location offset="475" length="17"/>
          <text>glycyrrhizic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>546</offset>
        <text>MATERIALS AND METHODS: Asthma model was established by ovalbumin-induced.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ovalbumin</infon>
          <location offset="601" length="9"/>
          <text>ovalbumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>620</offset>
        <text>A total of 60 mice were randomly assigned to six experimental groups: control, model, dexamethasone (2mg/kg) and GA (10mg/kg, 20mg/kg, 40mg/kg).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexamethasone</infon>
          <location offset="706" length="13"/>
          <text>dexamethasone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>765</offset>
        <text>Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The hematoxylin and eosin (HE) staining, Th1/Th2 and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the forkhead/winged helix transcription factor (Foxp3) was evaluated by western blotting.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hematoxylin</infon>
          <location offset="883" length="11"/>
          <text>hematoxylin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eosin</infon>
          <location offset="899" length="5"/>
          <text>eosin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="937" length="9"/>
          <text>cytokines</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">forkhead/winged helix transcription factor</infon>
          <location offset="1104" length="42"/>
          <text>forkhead/winged helix transcription factor</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">foxp3</infon>
          <location offset="1148" length="5"/>
          <text>Foxp3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1190</offset>
        <text>RESULTS: Our study demonstrated that, compared with model group, GA inhibited OVA-induced increases in Raw and eosinophil count; interleukin (IL)-4, IL-5, IL-13 levels were recovered in bronchoalveolar lavage fluid compared; increased IFN-γlevel in bronchoalveolar lavage fluid; histological studies demonstrated that GA substantially inhibited OVA-induced eosinophilia in lung tissue and airway tissue compared with model group.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ova</infon>
          <location offset="1268" length="3"/>
          <text>OVA</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin (il)-4</infon>
          <location offset="1319" length="18"/>
          <text>interleukin (IL)-4</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-5</infon>
          <location offset="1339" length="4"/>
          <text>IL-5</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-13</infon>
          <location offset="1345" length="5"/>
          <text>IL-13</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ifn-γ</infon>
          <location offset="1425" length="5"/>
          <text>IFN-γ</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ova</infon>
          <location offset="1535" length="3"/>
          <text>OVA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1620</offset>
        <text>Flow cytometry studies demonstrated that GA substantially enhanced Tregs compared with model group.</text>
      </sentence>
      <sentence>
        <offset>1720</offset>
        <text>CONCLUSION: These findings suggest that GA may effectively ameliorate the progression of asthma and could be used as a therapy for patients with allergic asthma.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23537005</id>
    <passage>
      <offset>0</offset>
      <text>Biotransformation of 2,2',4,4'-Tetrabromodiphenyl Ether (BDE-47) by Human Liver Microsomes: Identification of Cytochrome P450 2B6 as the Major Enzyme Involved.	Polybrominated diphenyl ethers (PBDEs) were widely used flame retardants that have become persistent environmental pollutants. In the present study, we investigated the in vitro oxidative metabolism of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47), a major PBDE detected in human tissue and environmental samples. Biotransformation of BDE-47 by pooled and individual human liver microsomes and by human recombinant cytochrome P450 (P450) enzymes was assessed using a liquid chromatography/tandem mass spectrometry-based method. Of the nine hydroxylated metabolites of BDE-47 produced by human liver microsomes, seven metabolites were identified using authentic standards. A monohydroxy-tetrabrominated and a dihydroxy-tetrabrominated metabolite remain unidentified. Kinetic analysis of the rates of metabolite formation revealed that the major metabolites were 5-hydroxy-2,2',4,4'-tetrabromodiphenyl ether (5-OH-BDE-47), 6-hydroxy-2,2',4,4'-tetrabromodiphenyl ether (6-OH-BDE-47), and possibly the unidentified monohydroxy-tetrabrominated metabolite. Among the human recombinant P450 enzymes tested, P450 2B6 was the most active enzyme in the formation of the hydroxylated metabolites of BDE-47. Moreover, the formation of all metabolites of BDE-47 by pooled human liver microsomes was inhibited by a P450 2B6-specific antibody and was highly correlated with P450 2B6-mediated activity in single donor liver microsomes indicating that P450 2B6 was the major P450 responsible for the biotransformation of BDE-47. Additional experiments involving the incubation of liver microsomes with individual monohydroxy-tetrabrominated metabolites in place of BDE-47 demonstrated that 2,4-dibromophenol was a product of BDE-47 and several primary metabolites, but the dihydroxy-tetrabrominated metabolite was not formed by sequential hydroxylation of any of the monohydroxy-tetrabrominated metabolites tested. The present study provides a comprehensive characterization of the oxidative metabolism of BDE-47 by human liver microsomes and P450 2B6.</text>
      <sentence>
        <offset>0</offset>
        <text>Biotransformation of 2,2',4,4'-Tetrabromodiphenyl Ether (BDE-47) by Human Liver Microsomes: Identification of Cytochrome P450 2B6 as the Major Enzyme Involved.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2,2',4,4'-tetrabromodiphenyl ether</infon>
          <location offset="21" length="34"/>
          <text>2,2',4,4'-Tetrabromodiphenyl Ether</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bde-47</infon>
          <location offset="57" length="6"/>
          <text>BDE-47</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome p450 2b6</infon>
          <location offset="110" length="19"/>
          <text>Cytochrome P450 2B6</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T25" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T26" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>160</offset>
        <text>Polybrominated diphenyl ethers (PBDEs) were widely used flame retardants that have become persistent environmental pollutants.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polybrominated diphenyl ethers</infon>
          <location offset="160" length="30"/>
          <text>Polybrominated diphenyl ethers</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pbdes</infon>
          <location offset="192" length="5"/>
          <text>PBDEs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>287</offset>
        <text>In the present study, we investigated the in vitro oxidative metabolism of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47), a major PBDE detected in human tissue and environmental samples.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2,2',4,4'-tetrabromodiphenyl ether</infon>
          <location offset="362" length="34"/>
          <text>2,2',4,4'-tetrabromodiphenyl ether</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bde-47</infon>
          <location offset="398" length="6"/>
          <text>BDE-47</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pbde</infon>
          <location offset="415" length="4"/>
          <text>PBDE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>472</offset>
        <text>Biotransformation of BDE-47 by pooled and individual human liver microsomes and by human recombinant cytochrome P450 (P450) enzymes was assessed using a liquid chromatography/tandem mass spectrometry-based method.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bde-47</infon>
          <location offset="493" length="6"/>
          <text>BDE-47</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human recombinant cytochrome p450</infon>
          <location offset="555" length="33"/>
          <text>human recombinant cytochrome P450</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p450</infon>
          <location offset="590" length="4"/>
          <text>P450</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T17" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T17" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>686</offset>
        <text>Of the nine hydroxylated metabolites of BDE-47 produced by human liver microsomes, seven metabolites were identified using authentic standards.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bde-47</infon>
          <location offset="726" length="6"/>
          <text>BDE-47</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>830</offset>
        <text>A monohydroxy-tetrabrominated and a dihydroxy-tetrabrominated metabolite remain unidentified.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monohydroxy</infon>
          <location offset="832" length="11"/>
          <text>monohydroxy</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydroxy</infon>
          <location offset="866" length="9"/>
          <text>dihydroxy</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>924</offset>
        <text>Kinetic analysis of the rates of metabolite formation revealed that the major metabolites were 5-hydroxy-2,2',4,4'-tetrabromodiphenyl ether (5-OH-BDE-47), 6-hydroxy-2,2',4,4'-tetrabromodiphenyl ether (6-OH-BDE-47), and possibly the unidentified monohydroxy-tetrabrominated metabolite.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monohydroxy</infon>
          <location offset="1169" length="11"/>
          <text>monohydroxy</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-hydroxy-2,2',4,4'-tetrabromodiphenyl ether</infon>
          <location offset="1019" length="44"/>
          <text>5-hydroxy-2,2',4,4'-tetrabromodiphenyl ether</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-oh-bde-47</infon>
          <location offset="1065" length="11"/>
          <text>5-OH-BDE-47</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-hydroxy-2,2',4,4'-tetrabromodiphenyl ether</infon>
          <location offset="1079" length="44"/>
          <text>6-hydroxy-2,2',4,4'-tetrabromodiphenyl ether</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-oh-bde-47</infon>
          <location offset="1125" length="11"/>
          <text>6-OH-BDE-47</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1209</offset>
        <text>Among the human recombinant P450 enzymes tested, P450 2B6 was the most active enzyme in the formation of the hydroxylated metabolites of BDE-47.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bde-47</infon>
          <location offset="1346" length="6"/>
          <text>BDE-47</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human recombinant p450</infon>
          <location offset="1219" length="22"/>
          <text>human recombinant P450</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p450 2b6</infon>
          <location offset="1258" length="8"/>
          <text>P450 2B6</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1354</offset>
        <text>Moreover, the formation of all metabolites of BDE-47 by pooled human liver microsomes was inhibited by a P450 2B6-specific antibody and was highly correlated with P450 2B6-mediated activity in single donor liver microsomes indicating that P450 2B6 was the major P450 responsible for the biotransformation of BDE-47.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bde-47</infon>
          <location offset="1400" length="6"/>
          <text>BDE-47</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bde-47</infon>
          <location offset="1662" length="6"/>
          <text>BDE-47</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p450 2b6</infon>
          <location offset="1459" length="8"/>
          <text>P450 2B6</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p450 2b6</infon>
          <location offset="1517" length="8"/>
          <text>P450 2B6</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p450 2b6</infon>
          <location offset="1593" length="8"/>
          <text>P450 2B6</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p450</infon>
          <location offset="1616" length="4"/>
          <text>P450</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1670</offset>
        <text>Additional experiments involving the incubation of liver microsomes with individual monohydroxy-tetrabrominated metabolites in place of BDE-47 demonstrated that 2,4-dibromophenol was a product of BDE-47 and several primary metabolites, but the dihydroxy-tetrabrominated metabolite was not formed by sequential hydroxylation of any of the monohydroxy-tetrabrominated metabolites tested.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monohydroxy</infon>
          <location offset="1754" length="11"/>
          <text>monohydroxy</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bde-47</infon>
          <location offset="1806" length="6"/>
          <text>BDE-47</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2,4-dibromophenol</infon>
          <location offset="1831" length="17"/>
          <text>2,4-dibromophenol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bde-47</infon>
          <location offset="1866" length="6"/>
          <text>BDE-47</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dihydroxy</infon>
          <location offset="1914" length="9"/>
          <text>dihydroxy</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monohydroxy</infon>
          <location offset="2008" length="11"/>
          <text>monohydroxy</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2056</offset>
        <text>The present study provides a comprehensive characterization of the oxidative metabolism of BDE-47 by human liver microsomes and P450 2B6.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bde-47</infon>
          <location offset="2147" length="6"/>
          <text>BDE-47</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p450 2b6</infon>
          <location offset="2184" length="8"/>
          <text>P450 2B6</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23624148</id>
    <passage>
      <offset>0</offset>
      <text>Sciadopitysin protects osteoblast function via its antioxidant activity in MC3T3-E1 cells.	Age-related osteoblast dysfunction is the main cause of age-related bone loss in both men and women. In the present study, the effect of sciadopitysin, a type of biflavonoids, on osteoblast function was investigated in osteoblastic MC3T3-E1 cells. Sciadopitysin caused a significant elevation of alkaline phosphatase activity, collagen synthesis, osteocalcin production, mineralization, and glutathione content in the cells (P&lt;0.05). Sciadopitysin also decreased the production of tumor necrosis factor-a (TNF-α) induced by antimycin A, a mitochondrial electron transport inhibitor. We investigated the protective effects of sciadopitysin on antimycin A-induced toxicity in osteoblastic MC3T3-E1 cells. Exposure of MC3T3-E1 cells to antimycin A caused a significant reduction in osteoblast dysfunction. However, pretreatment with sciadopitysin prior to antimycin A exposure significantly reduced antimycin A-induced cell damage by preventing mitochondrial membrane potential dissipation, adenosine triphosphate (ATP) loss, reactive oxygen species (ROS) release, and nitrotyrosine increase, suggesting that sciadopitysin may be useful for protecting mitochondria against a burst of oxidative stress. Moreover, sciadopitysin increased phosphorylation of cAMP-response element-binding protein (CREB) inhibited by antimycin A. Our results demonstrate that sciadopitysin may reduce or prevent osteoblasts degeneration.</text>
      <sentence>
        <offset>0</offset>
        <text>Sciadopitysin protects osteoblast function via its antioxidant activity in MC3T3-E1 cells.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sciadopitysin</infon>
          <location offset="0" length="13"/>
          <text>Sciadopitysin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>91</offset>
        <text>Age-related osteoblast dysfunction is the main cause of age-related bone loss in both men and women.</text>
      </sentence>
      <sentence>
        <offset>192</offset>
        <text>In the present study, the effect of sciadopitysin, a type of biflavonoids, on osteoblast function was investigated in osteoblastic MC3T3-E1 cells.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sciadopitysin</infon>
          <location offset="228" length="13"/>
          <text>sciadopitysin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biflavonoids</infon>
          <location offset="253" length="12"/>
          <text>biflavonoids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>339</offset>
        <text>Sciadopitysin caused a significant elevation of alkaline phosphatase activity, collagen synthesis, osteocalcin production, mineralization, and glutathione content in the cells (P&lt;0.05).</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sciadopitysin</infon>
          <location offset="339" length="13"/>
          <text>Sciadopitysin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="482" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alkaline phosphatase</infon>
          <location offset="387" length="20"/>
          <text>alkaline phosphatase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">collagen</infon>
          <location offset="418" length="8"/>
          <text>collagen</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">osteocalcin</infon>
          <location offset="438" length="11"/>
          <text>osteocalcin</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>525</offset>
        <text>Sciadopitysin also decreased the production of tumor necrosis factor-a (TNF-α) induced by antimycin A, a mitochondrial electron transport inhibitor.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sciadopitysin</infon>
          <location offset="525" length="13"/>
          <text>Sciadopitysin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">antimycin a</infon>
          <location offset="615" length="11"/>
          <text>antimycin A</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor-a</infon>
          <location offset="572" length="23"/>
          <text>tumor necrosis factor-a</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="597" length="5"/>
          <text>TNF-α</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>674</offset>
        <text>We investigated the protective effects of sciadopitysin on antimycin A-induced toxicity in osteoblastic MC3T3-E1 cells.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sciadopitysin</infon>
          <location offset="716" length="13"/>
          <text>sciadopitysin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">antimycin a</infon>
          <location offset="733" length="11"/>
          <text>antimycin A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>794</offset>
        <text>Exposure of MC3T3-E1 cells to antimycin A caused a significant reduction in osteoblast dysfunction.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">antimycin a</infon>
          <location offset="824" length="11"/>
          <text>antimycin A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>894</offset>
        <text>However, pretreatment with sciadopitysin prior to antimycin A exposure significantly reduced antimycin A-induced cell damage by preventing mitochondrial membrane potential dissipation, adenosine triphosphate (ATP) loss, reactive oxygen species (ROS) release, and nitrotyrosine increase, suggesting that sciadopitysin may be useful for protecting mitochondria against a burst of oxidative stress.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="1103" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="1123" length="6"/>
          <text>oxygen</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitrotyrosine</infon>
          <location offset="1157" length="13"/>
          <text>nitrotyrosine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sciadopitysin</infon>
          <location offset="1197" length="13"/>
          <text>sciadopitysin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sciadopitysin</infon>
          <location offset="921" length="13"/>
          <text>sciadopitysin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">antimycin a</infon>
          <location offset="944" length="11"/>
          <text>antimycin A</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">antimycin a</infon>
          <location offset="987" length="11"/>
          <text>antimycin A</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine triphosphate</infon>
          <location offset="1079" length="22"/>
          <text>adenosine triphosphate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1290</offset>
        <text>Moreover, sciadopitysin increased phosphorylation of cAMP-response element-binding protein (CREB) inhibited by antimycin A.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sciadopitysin</infon>
          <location offset="1300" length="13"/>
          <text>sciadopitysin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="1343" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">antimycin a</infon>
          <location offset="1401" length="11"/>
          <text>antimycin A</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">camp-response element-binding protein</infon>
          <location offset="1343" length="37"/>
          <text>cAMP-response element-binding protein</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">creb</infon>
          <location offset="1382" length="4"/>
          <text>CREB</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1414</offset>
        <text>Our results demonstrate that sciadopitysin may reduce or prevent osteoblasts degeneration.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sciadopitysin</infon>
          <location offset="1443" length="13"/>
          <text>sciadopitysin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1647395</id>
    <passage>
      <offset>0</offset>
      <text>Evidence that estramustine binds MAP-1A to inhibit type IV collagenase secretion.	Estramustine is a novel anti-microtubule drug shown to bind MAP-1 and MAP-2 (microtubule-associated proteins) in vitro. In this paper we have shown that estramustine specifically binds MAP-1A in Du 145a cells, resulting in disruption of MAP-1A microtubules and inhibition of type IV collagenase secretion. Immunofluorescence studies revealed that at 30 microM levels estramustine blocked type IV collagenase secretion by partial disruption of the MAP-1A microtubule networks. Immunoprecipitation studies with polyclonal antibodies provided quantitative evidence that 30-60 microM estramustine blocked secretion of a 105 x 10(3) Mr type IV collagenase. Pulse-labeling experiments confirmed that the effect was not a result of inhibition of either protein synthesis or altered rates of type IV collagenase turnover. Finally, drug uptake studies with [3H]estramustine, scintillation counting and fluorography demonstrated that the principal target of the drug was MAP-1A. For the first time we have shown that the drug blocks secretion by binding MAP-1A and causing incomplete disruption of the microtubule networks.</text>
      <sentence>
        <offset>0</offset>
        <text>Evidence that estramustine binds MAP-1A to inhibit type IV collagenase secretion.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="14" length="12"/>
          <text>estramustine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">map-1a</infon>
          <location offset="33" length="6"/>
          <text>MAP-1A</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">type iv collagenase</infon>
          <location offset="51" length="19"/>
          <text>type IV collagenase</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>82</offset>
        <text>Estramustine is a novel anti-microtubule drug shown to bind MAP-1 and MAP-2 (microtubule-associated proteins) in vitro.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="82" length="12"/>
          <text>Estramustine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">microtubule</infon>
          <location offset="111" length="11"/>
          <text>microtubule</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">map-1</infon>
          <location offset="142" length="5"/>
          <text>MAP-1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">map-2</infon>
          <location offset="152" length="5"/>
          <text>MAP-2</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">microtubule-associated proteins</infon>
          <location offset="159" length="31"/>
          <text>microtubule-associated proteins</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>202</offset>
        <text>In this paper we have shown that estramustine specifically binds MAP-1A in Du 145a cells, resulting in disruption of MAP-1A microtubules and inhibition of type IV collagenase secretion.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="235" length="12"/>
          <text>estramustine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">map-1a</infon>
          <location offset="267" length="6"/>
          <text>MAP-1A</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">map-1a</infon>
          <location offset="319" length="6"/>
          <text>MAP-1A</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">type iv collagenase</infon>
          <location offset="357" length="19"/>
          <text>type IV collagenase</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>388</offset>
        <text>Immunofluorescence studies revealed that at 30 microM levels estramustine blocked type IV collagenase secretion by partial disruption of the MAP-1A microtubule networks.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="449" length="12"/>
          <text>estramustine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">type iv collagenase</infon>
          <location offset="470" length="19"/>
          <text>type IV collagenase</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">map-1a</infon>
          <location offset="529" length="6"/>
          <text>MAP-1A</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">microtubule</infon>
          <location offset="536" length="11"/>
          <text>microtubule</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>558</offset>
        <text>Immunoprecipitation studies with polyclonal antibodies provided quantitative evidence that 30-60 microM estramustine blocked secretion of a 105 x 10(3) Mr type IV collagenase.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="662" length="12"/>
          <text>estramustine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">type iv collagenase</infon>
          <location offset="713" length="19"/>
          <text>type IV collagenase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>734</offset>
        <text>Pulse-labeling experiments confirmed that the effect was not a result of inhibition of either protein synthesis or altered rates of type IV collagenase turnover.</text>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">type iv collagenase</infon>
          <location offset="866" length="19"/>
          <text>type IV collagenase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>896</offset>
        <text>Finally, drug uptake studies with [3H]estramustine, scintillation counting and fluorography demonstrated that the principal target of the drug was MAP-1A.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]estramustine</infon>
          <location offset="930" length="16"/>
          <text>[3H]estramustine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">map-1a</infon>
          <location offset="1043" length="6"/>
          <text>MAP-1A</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1051</offset>
        <text>For the first time we have shown that the drug blocks secretion by binding MAP-1A and causing incomplete disruption of the microtubule networks.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">map-1a</infon>
          <location offset="1126" length="6"/>
          <text>MAP-1A</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">microtubule</infon>
          <location offset="1174" length="11"/>
          <text>microtubule</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23372018</id>
    <passage>
      <offset>0</offset>
      <text>Manganese supplementation protects against diet-induced diabetes in wild type mice by enhancing insulin secretion.	Mitochondrial dysfunction is both a contributing mechanism and complication of diabetes, and oxidative stress contributes to that dysfunction. Mitochondrial manganese-superoxide dismutase (MnSOD) is a metalloenzyme that provides antioxidant protection. We have previously shown in a mouse model of hereditary iron overload that cytosolic iron levels affected mitochondrial manganese availability, MnSOD activity, and insulin secretion. We therefore sought to determine the metallation status of MnSOD in wild-type mice and whether altering that status affected β-cell function. 129/SvEVTac mice given supplemental manganese exhibited a 73% increase in hepatic MnSOD activity and increased metallation of MnSOD. To determine whether manganese supplementation offered glucose homeostasis under a situation of β-cell stress, we challenged C57BL/6J mice, which are more susceptible to diet-induced diabetes, with a high-fat diet for 12 weeks. Manganese was supplemented or not for the final 8 weeks on that diet, after which we examined glucose tolerance and the function of isolated islets. Liver mitochondria from manganese-injected C57BL/6J mice had similar increases in MnSOD activity (81%) and metallation as were seen in 129/SvEVTac mice. The manganese-treated group fed high fat had improved glucose tolerance (24% decrease in fasting glucose and 41% decrease in area under the glucose curve), comparable with mice on normal chow and increased serum insulin levels. Isolated islets from the manganese-treated group exhibited improved insulin secretion, decreased lipid peroxidation, and improved mitochondrial function. In conclusion, MnSOD metallation and activity can be augmented with manganese supplementation in normal mice on normal chow, and manganese treatment can increase insulin secretion to improve glucose tolerance under conditions of dietary stress.</text>
      <sentence>
        <offset>0</offset>
        <text>Manganese supplementation protects against diet-induced diabetes in wild type mice by enhancing insulin secretion.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="0" length="9"/>
          <text>Manganese</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="96" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>115</offset>
        <text>Mitochondrial dysfunction is both a contributing mechanism and complication of diabetes, and oxidative stress contributes to that dysfunction.</text>
      </sentence>
      <sentence>
        <offset>258</offset>
        <text>Mitochondrial manganese-superoxide dismutase (MnSOD) is a metalloenzyme that provides antioxidant protection.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="272" length="9"/>
          <text>manganese</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="282" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">manganese-superoxide dismutase</infon>
          <location offset="272" length="30"/>
          <text>manganese-superoxide dismutase</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mnsod</infon>
          <location offset="304" length="5"/>
          <text>MnSOD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>368</offset>
        <text>We have previously shown in a mouse model of hereditary iron overload that cytosolic iron levels affected mitochondrial manganese availability, MnSOD activity, and insulin secretion.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="453" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="488" length="9"/>
          <text>manganese</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mn</infon>
          <location offset="512" length="2"/>
          <text>Mn</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mnsod</infon>
          <location offset="512" length="5"/>
          <text>MnSOD</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="532" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>551</offset>
        <text>We therefore sought to determine the metallation status of MnSOD in wild-type mice and whether altering that status affected β-cell function.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mn</infon>
          <location offset="610" length="2"/>
          <text>Mn</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mnsod</infon>
          <location offset="610" length="5"/>
          <text>MnSOD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>693</offset>
        <text>129/SvEVTac mice given supplemental manganese exhibited a 73% increase in hepatic MnSOD activity and increased metallation of MnSOD.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mn</infon>
          <location offset="775" length="2"/>
          <text>Mn</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mn</infon>
          <location offset="819" length="2"/>
          <text>Mn</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mnsod</infon>
          <location offset="775" length="5"/>
          <text>MnSOD</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mnsod</infon>
          <location offset="819" length="5"/>
          <text>MnSOD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>826</offset>
        <text>To determine whether manganese supplementation offered glucose homeostasis under a situation of β-cell stress, we challenged C57BL/6J mice, which are more susceptible to diet-induced diabetes, with a high-fat diet for 12 weeks.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="881" length="7"/>
          <text>glucose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1054</offset>
        <text>Manganese was supplemented or not for the final 8 weeks on that diet, after which we examined glucose tolerance and the function of isolated islets.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1148" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="1054" length="9"/>
          <text>Manganese</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1203</offset>
        <text>Liver mitochondria from manganese-injected C57BL/6J mice had similar increases in MnSOD activity (81%) and metallation as were seen in 129/SvEVTac mice.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="1227" length="9"/>
          <text>manganese</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mn</infon>
          <location offset="1285" length="2"/>
          <text>Mn</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mnsod</infon>
          <location offset="1285" length="5"/>
          <text>MnSOD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1356</offset>
        <text>The manganese-treated group fed high fat had improved glucose tolerance (24% decrease in fasting glucose and 41% decrease in area under the glucose curve), comparable with mice on normal chow and increased serum insulin levels.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="1360" length="9"/>
          <text>manganese</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1410" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1453" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1496" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serum insulin</infon>
          <location offset="1562" length="13"/>
          <text>serum insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1584</offset>
        <text>Isolated islets from the manganese-treated group exhibited improved insulin secretion, decreased lipid peroxidation, and improved mitochondrial function.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="1609" length="9"/>
          <text>manganese</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1652" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1738</offset>
        <text>In conclusion, MnSOD metallation and activity can be augmented with manganese supplementation in normal mice on normal chow, and manganese treatment can increase insulin secretion to improve glucose tolerance under conditions of dietary stress.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mn</infon>
          <location offset="1753" length="2"/>
          <text>Mn</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="1806" length="9"/>
          <text>manganese</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">manganese</infon>
          <location offset="1867" length="9"/>
          <text>manganese</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1929" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mnsod</infon>
          <location offset="1753" length="5"/>
          <text>MnSOD</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1900" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10215901</id>
    <passage>
      <offset>0</offset>
      <text>Pre- or post-training injection of buspirone impaired retention in the inhibitory avoidance task: involvement of amygdala 5-HT1A receptors.	The present study investigated the effect of buspirone on memory formation in an aversive learning task. Male Wistar rats were trained on the inhibitory avoidance task and tested for retention 1 day after training. They received peripheral or intra-amygdala administration of buspirone or other 5-HT1A drugs either before or after training. Results indicated that pretraining systemic injections of buspirone caused a dose-dependent retention deficit; 5. 0 mg/kg had a marked effect and 1.0 mg/kg had no effect. Post-training injections of the drug caused a time-dependent retention deficit, which was not due to a state-dependent effect on retrieval. When training in the inhibitory avoidance task was divided into a context-training phase and a shock-training phase, buspirone impaired retention only when administered in the shock-training phase, suggesting that the drug influenced memory processing of affective events. Further results indicated that post-training intra-amygdala infusion of buspirone or the 5-HT1A agonist 8-hydroxy-di-n-propylaminotetralin (8-OH-DPAT) caused a time-dependent and dose-dependent retention deficit. Post-training intra-amygdala infusion of the 5-HT1A antagonist WAY100635 (N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)-N-(2-pyridyl) cyclohexane carboxamine maleate) attenuated the memory-impairing effects of buspirone. These findings suggest that buspirone may modulate memory storage processes in the inhibitory avoidance task through an action on amygdaloid 5-HT1A receptors.</text>
      <sentence>
        <offset>0</offset>
        <text>Pre- or post-training injection of buspirone impaired retention in the inhibitory avoidance task: involvement of amygdala 5-HT1A receptors.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">buspirone</infon>
          <location offset="35" length="9"/>
          <text>buspirone</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="122" length="6"/>
          <text>5-HT1A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>140</offset>
        <text>The present study investigated the effect of buspirone on memory formation in an aversive learning task.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">buspirone</infon>
          <location offset="185" length="9"/>
          <text>buspirone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>245</offset>
        <text>Male Wistar rats were trained on the inhibitory avoidance task and tested for retention 1 day after training.</text>
      </sentence>
      <sentence>
        <offset>355</offset>
        <text>They received peripheral or intra-amygdala administration of buspirone or other 5-HT1A drugs either before or after training.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">buspirone</infon>
          <location offset="416" length="9"/>
          <text>buspirone</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="435" length="6"/>
          <text>5-HT1A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>481</offset>
        <text>Results indicated that pretraining systemic injections of buspirone caused a dose-dependent retention deficit; 5.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">buspirone</infon>
          <location offset="539" length="9"/>
          <text>buspirone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>595</offset>
        <text>0 mg/kg had a marked effect and 1.0 mg/kg had no effect.</text>
      </sentence>
      <sentence>
        <offset>652</offset>
        <text>Post-training injections of the drug caused a time-dependent retention deficit, which was not due to a state-dependent effect on retrieval.</text>
      </sentence>
      <sentence>
        <offset>792</offset>
        <text>When training in the inhibitory avoidance task was divided into a context-training phase and a shock-training phase, buspirone impaired retention only when administered in the shock-training phase, suggesting that the drug influenced memory processing of affective events.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">buspirone</infon>
          <location offset="909" length="9"/>
          <text>buspirone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1065</offset>
        <text>Further results indicated that post-training intra-amygdala infusion of buspirone or the 5-HT1A agonist 8-hydroxy-di-n-propylaminotetralin (8-OH-DPAT) caused a time-dependent and dose-dependent retention deficit.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8-hydroxy-di-n-propylaminotetralin</infon>
          <location offset="1169" length="34"/>
          <text>8-hydroxy-di-n-propylaminotetralin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">8-oh-dpat</infon>
          <location offset="1205" length="9"/>
          <text>8-OH-DPAT</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">buspirone</infon>
          <location offset="1137" length="9"/>
          <text>buspirone</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="1154" length="6"/>
          <text>5-HT1A</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1278</offset>
        <text>Post-training intra-amygdala infusion of the 5-HT1A antagonist WAY100635 (N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)-N-(2-pyridyl) cyclohexane carboxamine maleate) attenuated the memory-impairing effects of buspirone.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">way100635</infon>
          <location offset="1341" length="9"/>
          <text>WAY100635</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-(2-(4-(2-methoxyphenyl)-1-piperazinyl)-n-(2-pyridyl) cyclohexane carboxamine maleate</infon>
          <location offset="1352" length="86"/>
          <text>N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)-N-(2-pyridyl) cyclohexane carboxamine maleate</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">buspirone</infon>
          <location offset="1483" length="9"/>
          <text>buspirone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="1323" length="6"/>
          <text>5-HT1A</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1494</offset>
        <text>These findings suggest that buspirone may modulate memory storage processes in the inhibitory avoidance task through an action on amygdaloid 5-HT1A receptors.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">buspirone</infon>
          <location offset="1522" length="9"/>
          <text>buspirone</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="1635" length="6"/>
          <text>5-HT1A</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11031122</id>
    <passage>
      <offset>0</offset>
      <text>Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach.	Fumarate reductase (FRD) is the key enzyme in fumarate respiration induced by anaerobic growth of bacteria. In Helicobacter pylori, this enzyme appears to be constitutively expressed under microaerobic conditions and is not essential for its survival in vitro. In this study, the role of FRD in the colonization of H. pylori was investigated using a mouse model. The frdA gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes. The isogenic mutants of H. pylori strain AH244 were obtained by natural transformation. Seventy-five ICR mice (15 mice/group) were orogastrically dosed with either the wild type H. pylori strain AH244, its isogenic mutants, or Brucella broth (negative control). Five mice from each group were killed at 2, 4 and 8 weeks post-inoculation (WPI), respectively. H. pylori colonization was not detected in mouse gastric mucosa infected with the frdA mutant at any time point in the study by both quantitative culture and PCR. In contrast, the mice inoculated with either wild type AH244, copA or copPH. pylori mutants became readily infected. These data indicate that FRD plays a crucial role in H. pylori survival in the gastric mucosa of mice. Given that FRD, present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics (morantel, oxantel and thiabendazole), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.</text>
      <sentence>
        <offset>0</offset>
        <text>Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fumarate</infon>
          <location offset="0" length="8"/>
          <text>Fumarate</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fumarate reductase</infon>
          <location offset="0" length="18"/>
          <text>Fumarate reductase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>91</offset>
        <text>Fumarate reductase (FRD) is the key enzyme in fumarate respiration induced by anaerobic growth of bacteria.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fumarate</infon>
          <location offset="91" length="8"/>
          <text>Fumarate</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fumarate</infon>
          <location offset="137" length="8"/>
          <text>fumarate</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fumarate reductase</infon>
          <location offset="91" length="18"/>
          <text>Fumarate reductase</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">frd</infon>
          <location offset="111" length="3"/>
          <text>FRD</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>199</offset>
        <text>In Helicobacter pylori, this enzyme appears to be constitutively expressed under microaerobic conditions and is not essential for its survival in vitro.</text>
      </sentence>
      <sentence>
        <offset>352</offset>
        <text>In this study, the role of FRD in the colonization of H. pylori was investigated using a mouse model.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">frd</infon>
          <location offset="379" length="3"/>
          <text>FRD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>454</offset>
        <text>The frdA gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of copper out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="564" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloramphenicol</infon>
          <location offset="626" length="15"/>
          <text>chloramphenicol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">frda</infon>
          <location offset="458" length="4"/>
          <text>frdA</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">subunit a of frd</infon>
          <location offset="479" length="16"/>
          <text>subunit A of FRD</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">copa</infon>
          <location offset="520" length="4"/>
          <text>copA</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">copp</infon>
          <location offset="529" length="4"/>
          <text>copP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>698</offset>
        <text>The isogenic mutants of H. pylori strain AH244 were obtained by natural transformation.</text>
      </sentence>
      <sentence>
        <offset>786</offset>
        <text>Seventy-five ICR mice (15 mice/group) were orogastrically dosed with either the wild type H. pylori strain AH244, its isogenic mutants, or Brucella broth (negative control).</text>
      </sentence>
      <sentence>
        <offset>960</offset>
        <text>Five mice from each group were killed at 2, 4 and 8 weeks post-inoculation (WPI), respectively.</text>
      </sentence>
      <sentence>
        <offset>1056</offset>
        <text>H. pylori colonization was not detected in mouse gastric mucosa infected with the frdA mutant at any time point in the study by both quantitative culture and PCR.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">frda</infon>
          <location offset="1138" length="4"/>
          <text>frdA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1219</offset>
        <text>In contrast, the mice inoculated with either wild type AH244, copA or copPH.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">copa</infon>
          <location offset="1281" length="4"/>
          <text>copA</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">copp</infon>
          <location offset="1289" length="4"/>
          <text>copP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1296</offset>
        <text>pylori mutants became readily infected.</text>
      </sentence>
      <sentence>
        <offset>1336</offset>
        <text>These data indicate that FRD plays a crucial role in H. pylori survival in the gastric mucosa of mice.</text>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">frd</infon>
          <location offset="1361" length="3"/>
          <text>FRD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1439</offset>
        <text>Given that FRD, present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics (morantel, oxantel and thiabendazole), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morantel</infon>
          <location offset="1607" length="8"/>
          <text>morantel</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxantel</infon>
          <location offset="1617" length="7"/>
          <text>oxantel</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiabendazole</infon>
          <location offset="1629" length="13"/>
          <text>thiabendazole</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">frd</infon>
          <location offset="1450" length="3"/>
          <text>FRD</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>8700871</id>
    <passage>
      <offset>0</offset>
      <text>A general two-process model describes the hydrogen exchange behavior of RNase A in unfolding conditions.	When NMR hydrogen exchange was used previously to monitor the kinetics of RNase A unfolding, some peptide NH protons were found to show EX2 exchange (detected by base catalysis) in addition to the expected EX1 exchange, whose rate is limited by the kinetic unfolding process. In earlier work, two groups showed independently that a restricted two-process model successfully fits published hydrogen exchange rates of native RNase A in the range 0-0.7 M guanidinium chloride. We find that this model predicts properties that are very different from the observed properties of the EX2 exchange reactions of RNase A in conditions where guanidine-induced unfolding takes place. The model predicts that EX2 exchange should be too fast to measure by the technique used, whereas it is readily measurable. Possible explanations for the contradiction are considered here, and we show that removing the restriction from the earlier two-process model is sufficient to resolve the contradiction; instead of specifying that exchange caused by global unfolding occurs by the EX2 mechanism, we allow it to occur by the general mechanism, which includes both the EX1 and EX2 cases. It is logical to remove this restriction because global unfolding of RNase A is known to give rise to EX1 exchange in these unfolding conditions. Resolving the contradiction makes it possible to determine whether populated unfolding intermediates contribute to the EX2 exchange, and this question is considered elsewhere. The results and simulations indicate that moderate or high denaturant concentrations readily give rise to EX1 exchange in native proteins. Earlier studies showed that hydrogen exchange in native proteins typically occurs by the EX2 mechanism but that high temperatures or pH values above 7 may give rise to EX1 exchange. High denaturant concentrations should be added to the list of variables likely to cause EX1 exchange.</text>
      <sentence>
        <offset>0</offset>
        <text>A general two-process model describes the hydrogen exchange behavior of RNase A in unfolding conditions.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrogen</infon>
          <location offset="42" length="8"/>
          <text>hydrogen</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rnase a</infon>
          <location offset="72" length="7"/>
          <text>RNase A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>105</offset>
        <text>When NMR hydrogen exchange was used previously to monitor the kinetics of RNase A unfolding, some peptide NH protons were found to show EX2 exchange (detected by base catalysis) in addition to the expected EX1 exchange, whose rate is limited by the kinetic unfolding process.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrogen</infon>
          <location offset="114" length="8"/>
          <text>hydrogen</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rnase a</infon>
          <location offset="179" length="7"/>
          <text>RNase A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>381</offset>
        <text>In earlier work, two groups showed independently that a restricted two-process model successfully fits published hydrogen exchange rates of native RNase A in the range 0-0.7 M guanidinium chloride.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrogen</infon>
          <location offset="494" length="8"/>
          <text>hydrogen</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">guanidinium chloride</infon>
          <location offset="557" length="20"/>
          <text>guanidinium chloride</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rnase a</infon>
          <location offset="528" length="7"/>
          <text>RNase A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>579</offset>
        <text>We find that this model predicts properties that are very different from the observed properties of the EX2 exchange reactions of RNase A in conditions where guanidine-induced unfolding takes place.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">guanidine</infon>
          <location offset="737" length="9"/>
          <text>guanidine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rnase a</infon>
          <location offset="709" length="7"/>
          <text>RNase A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>778</offset>
        <text>The model predicts that EX2 exchange should be too fast to measure by the technique used, whereas it is readily measurable.</text>
      </sentence>
      <sentence>
        <offset>902</offset>
        <text>Possible explanations for the contradiction are considered here, and we show that removing the restriction from the earlier two-process model is sufficient to resolve the contradiction; instead of specifying that exchange caused by global unfolding occurs by the EX2 mechanism, we allow it to occur by the general mechanism, which includes both the EX1 and EX2 cases.</text>
      </sentence>
      <sentence>
        <offset>1270</offset>
        <text>It is logical to remove this restriction because global unfolding of RNase A is known to give rise to EX1 exchange in these unfolding conditions.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rnase a</infon>
          <location offset="1339" length="7"/>
          <text>RNase A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1416</offset>
        <text>Resolving the contradiction makes it possible to determine whether populated unfolding intermediates contribute to the EX2 exchange, and this question is considered elsewhere.</text>
      </sentence>
      <sentence>
        <offset>1592</offset>
        <text>The results and simulations indicate that moderate or high denaturant concentrations readily give rise to EX1 exchange in native proteins.</text>
      </sentence>
      <sentence>
        <offset>1731</offset>
        <text>Earlier studies showed that hydrogen exchange in native proteins typically occurs by the EX2 mechanism but that high temperatures or pH values above 7 may give rise to EX1 exchange.</text>
      </sentence>
      <sentence>
        <offset>1913</offset>
        <text>High denaturant concentrations should be added to the list of variables likely to cause EX1 exchange.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22708686</id>
    <passage>
      <offset>0</offset>
      <text>The atypical antidepressant mianserin exhibits agonist activity at kappa-opioid receptors.	BACKGROUND AND PURPOSE: Antidepressants are known to interact with the opioid system through mechanisms not completely understood. We previously reported that tricyclic antidepressants act as agonists at distinct opioid receptors. Here, we investigated the effect of the atypical antidepressant mianserin at cloned and native opioid receptors. EXPERIMENTAL APPROACH: Effects of mianserin were examined in CHO cells transfected with human opioid receptors, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of [(35)S]GTPgammaS binding and MAPK phosphorylation. KEY RESULTS: Mianserin displayed 12- and 18-fold higher affinity for kappa- than micro- and delta-opioid receptors respectively. In [(35)S]GTPgammaS assays, mianserin selectively activated kappa-opioid receptors. The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI). The mianserin analogue mirtazapine also displayed kappa-opioid agonist activity. Mianserin and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing kappa-opioid receptors and C6 cells, and these effects were antagonized by nor-BNI. In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and dynorphin A. When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A. CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors. Thus, this property appears to be a common feature of different classes of antidepressants.</text>
      <sentence>
        <offset>0</offset>
        <text>The atypical antidepressant mianserin exhibits agonist activity at kappa-opioid receptors.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mianserin</infon>
          <location offset="28" length="9"/>
          <text>mianserin</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kappa-opioid receptors</infon>
          <location offset="67" length="22"/>
          <text>kappa-opioid receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T24" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>91</offset>
        <text>BACKGROUND AND PURPOSE: Antidepressants are known to interact with the opioid system through mechanisms not completely understood.</text>
      </sentence>
      <sentence>
        <offset>222</offset>
        <text>We previously reported that tricyclic antidepressants act as agonists at distinct opioid receptors.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tricyclic</infon>
          <location offset="250" length="9"/>
          <text>tricyclic</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">opioid receptors</infon>
          <location offset="304" length="16"/>
          <text>opioid receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T11" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>322</offset>
        <text>Here, we investigated the effect of the atypical antidepressant mianserin at cloned and native opioid receptors.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mianserin</infon>
          <location offset="386" length="9"/>
          <text>mianserin</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">opioid receptors</infon>
          <location offset="417" length="16"/>
          <text>opioid receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>435</offset>
        <text>EXPERIMENTAL APPROACH: Effects of mianserin were examined in CHO cells transfected with human opioid receptors, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of [(35)S]GTPgammaS binding and MAPK phosphorylation.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mianserin</infon>
          <location offset="469" length="9"/>
          <text>mianserin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(35)s]gtpgammas</infon>
          <location offset="672" length="16"/>
          <text>[(35)S]GTPgammaS</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human opioid receptors</infon>
          <location offset="523" length="22"/>
          <text>human opioid receptors</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="701" length="4"/>
          <text>MAPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>723</offset>
        <text>KEY RESULTS: Mianserin displayed 12- and 18-fold higher affinity for kappa- than micro- and delta-opioid receptors respectively.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mianserin</infon>
          <location offset="736" length="9"/>
          <text>Mianserin</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kappa- than micro- and delta-opioid receptors</infon>
          <location offset="792" length="45"/>
          <text>kappa- than micro- and delta-opioid receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>852</offset>
        <text>In [(35)S]GTPgammaS assays, mianserin selectively activated kappa-opioid receptors.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(35)s]gtpgammas</infon>
          <location offset="855" length="16"/>
          <text>[(35)S]GTPgammaS</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mianserin</infon>
          <location offset="880" length="9"/>
          <text>mianserin</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kappa-opioid receptors</infon>
          <location offset="912" length="22"/>
          <text>kappa-opioid receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>936</offset>
        <text>The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI).</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nor-binaltorphimine</infon>
          <location offset="1011" length="19"/>
          <text>nor-binaltorphimine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nor-bni</infon>
          <location offset="1032" length="7"/>
          <text>nor-BNI</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kappa-opioid</infon>
          <location offset="990" length="12"/>
          <text>kappa-opioid</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T20" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T21" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1042</offset>
        <text>The mianserin analogue mirtazapine also displayed kappa-opioid agonist activity.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mianserin</infon>
          <location offset="1046" length="9"/>
          <text>mianserin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mirtazapine</infon>
          <location offset="1065" length="11"/>
          <text>mirtazapine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kappa-opioid</infon>
          <location offset="1092" length="12"/>
          <text>kappa-opioid</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T22" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T23" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1123</offset>
        <text>Mianserin and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing kappa-opioid receptors and C6 cells, and these effects were antagonized by nor-BNI.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mianserin</infon>
          <location offset="1123" length="9"/>
          <text>Mianserin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mirtazapine</infon>
          <location offset="1137" length="11"/>
          <text>mirtazapine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nor-bni</infon>
          <location offset="1281" length="7"/>
          <text>nor-BNI</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="1159" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kappa-opioid receptors</infon>
          <location offset="1206" length="22"/>
          <text>kappa-opioid receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1290</offset>
        <text>In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and dynorphin A.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mianserin</infon>
          <location offset="1329" length="9"/>
          <text>mianserin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[35s]gtpgammas</infon>
          <location offset="1350" length="14"/>
          <text>[35S]GTPgammaS</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nor-bni</infon>
          <location offset="1378" length="7"/>
          <text>nor-BNI</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(-)-u50,488</infon>
          <location offset="1475" length="11"/>
          <text>(-)-U50,488</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dynorphin a</infon>
          <location offset="1491" length="11"/>
          <text>dynorphin A</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kappa-opioid</infon>
          <location offset="1453" length="12"/>
          <text>kappa-opioid</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dynorphin a</infon>
          <location offset="1491" length="11"/>
          <text>dynorphin A</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T8" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1504</offset>
        <text>When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mianserin</infon>
          <location offset="1519" length="9"/>
          <text>mianserin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(35)s]gtpgammas</infon>
          <location offset="1599" length="16"/>
          <text>[(35)S]GTPgammaS</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dynorphin a</infon>
          <location offset="1693" length="11"/>
          <text>dynorphin A</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kappa-opioid receptor</infon>
          <location offset="1565" length="21"/>
          <text>kappa-opioid receptor</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p38</infon>
          <location offset="1654" length="3"/>
          <text>p38</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="1658" length="4"/>
          <text>MAPK</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="1667" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dynorphin a</infon>
          <location offset="1693" length="11"/>
          <text>dynorphin A</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1706</offset>
        <text>CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mianserin</infon>
          <location offset="1763" length="9"/>
          <text>mianserin</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kappa-opioid receptors</infon>
          <location offset="1792" length="22"/>
          <text>kappa-opioid receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T13" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1872</offset>
        <text>Thus, this property appears to be a common feature of different classes of antidepressants.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23587648</id>
    <passage>
      <offset>0</offset>
      <text>Regulation of connexin hemichannel activity by membrane potential and the extracellular calcium in health and disease.	Connexins are thought to solely mediate cell-to-cell communication by forming gap junction channels composed of two membrane-spanning hemichannels positioned end-to-end. However, many if not all connexin isoforms also form functional hemichannels (i.e., the precursors of complete channels) that mediate the rapid exchange of ions, second messengers and metabolites between the cell interior and the interstitial space. Electrical and molecular signaling via connexin hemichannels is now widely recognized to be important in many physiological scenarios and pathological conditions. Indeed, mutations in connexins that alter hemichannel function have been implicated in several diseases. Here, we present a comprehensive overview of how hemichannel activity is tightly regulated by membrane potential and the external calcium concentration. In addition, we discuss the genetic mutations known to alter hemichannel function and their deleterious effects, of which a better understanding is necessary to develop novel therapeutic approaches for diseases caused by hemichannel dysfunction. This article is part of a Special Issue entitled 'Connexin based channels'.</text>
      <sentence>
        <offset>0</offset>
        <text>Regulation of connexin hemichannel activity by membrane potential and the extracellular calcium in health and disease.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="88" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">connexin hemichannel</infon>
          <location offset="14" length="20"/>
          <text>connexin hemichannel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>119</offset>
        <text>Connexins are thought to solely mediate cell-to-cell communication by forming gap junction channels composed of two membrane-spanning hemichannels positioned end-to-end.</text>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">connexins</infon>
          <location offset="119" length="9"/>
          <text>Connexins</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemichannels</infon>
          <location offset="253" length="12"/>
          <text>hemichannels</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gap junction channels</infon>
          <location offset="197" length="21"/>
          <text>gap junction channels</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>289</offset>
        <text>However, many if not all connexin isoforms also form functional hemichannels (i.e., the precursors of complete channels) that mediate the rapid exchange of ions, second messengers and metabolites between the cell interior and the interstitial space.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">connexin</infon>
          <location offset="314" length="8"/>
          <text>connexin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>539</offset>
        <text>Electrical and molecular signaling via connexin hemichannels is now widely recognized to be important in many physiological scenarios and pathological conditions.</text>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">connexin hemichannels</infon>
          <location offset="578" length="21"/>
          <text>connexin hemichannels</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>702</offset>
        <text>Indeed, mutations in connexins that alter hemichannel function have been implicated in several diseases.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">connexins</infon>
          <location offset="723" length="9"/>
          <text>connexins</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemichannel</infon>
          <location offset="744" length="11"/>
          <text>hemichannel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>807</offset>
        <text>Here, we present a comprehensive overview of how hemichannel activity is tightly regulated by membrane potential and the external calcium concentration.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="937" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemichannel</infon>
          <location offset="856" length="11"/>
          <text>hemichannel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>960</offset>
        <text>In addition, we discuss the genetic mutations known to alter hemichannel function and their deleterious effects, of which a better understanding is necessary to develop novel therapeutic approaches for diseases caused by hemichannel dysfunction.</text>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemichannel</infon>
          <location offset="1181" length="11"/>
          <text>hemichannel</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemichannel</infon>
          <location offset="1021" length="11"/>
          <text>hemichannel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1206</offset>
        <text>This article is part of a Special Issue entitled 'Connexin based channels'.</text>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">connexin based channels</infon>
          <location offset="1256" length="23"/>
          <text>Connexin based channels</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23345579</id>
    <passage>
      <offset>0</offset>
      <text>Mass spectrometry method to identify aging pathways of Sp- and Rp-tabun adducts on human butyrylcholinesterase based on the acid labile P-N bond.	The phosphoramidate nerve agent tabun inhibits butyrylcholinesterase (BChE) and acetylcholinesterase by making a covalent bond on the active site serine. The adduct loses an alkyl group in a process called aging. The mechanism of aging of the tabun adduct is controversial. Some studies claim that aging proceeds through deamination, whereas crystal structure studies show aging by O-dealkylation. Our goal was to develop a method that clearly distinguishes between deamination and O-dealkylation. We began by studying the tetraisopropyl pyrophosphoramide adduct of BChE because this adduct has two P-N bonds. Mass spectra showed that the P-N bonds were stable during trypsin digestion at pH 8 but were cleaved during pepsin digestion at pH 2. The P-N bond in tabun was also acid labile, whereas the P-O bond was stable. A scheme to distinguish aging by deamination from aging by O-dealkylation was based on the acid labile P-N bond. BChE was inhibited with Sp- and Rp-tabun thiocholine nerve agent model compounds to make adducts identical to those of tabun with known stereochemistry. After aging and digestion with pepsin at pH 2, peptide FGES198AGAAS from Sp-tabun thiocholine had a mass of 902.2 m/z in negative mode, indicating that it had aged by deamination, whereas peptide FGES198AGAAS from Rp-tabun thiocholine had a mass of 874.2 m/z in negative mode, indicating that it had aged by O-dealkylation. BChE inhibited by authentic, racemic tabun yielded both 902.2 and 874.2 m/z peptides, indicating that both stereoisomers reacted with BChE and aged either by deamination or dealkylation.</text>
      <sentence>
        <offset>0</offset>
        <text>Mass spectrometry method to identify aging pathways of Sp- and Rp-tabun adducts on human butyrylcholinesterase based on the acid labile P-N bond.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-n</infon>
          <location offset="136" length="3"/>
          <text>P-N</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sp- and rp-tabun</infon>
          <location offset="55" length="16"/>
          <text>Sp- and Rp-tabun</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human butyrylcholinesterase</infon>
          <location offset="83" length="27"/>
          <text>human butyrylcholinesterase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>146</offset>
        <text>The phosphoramidate nerve agent tabun inhibits butyrylcholinesterase (BChE) and acetylcholinesterase by making a covalent bond on the active site serine.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="292" length="6"/>
          <text>serine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tabun</infon>
          <location offset="178" length="5"/>
          <text>tabun</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phosphoramidate</infon>
          <location offset="150" length="15"/>
          <text>phosphoramidate</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">butyrylcholinesterase</infon>
          <location offset="193" length="21"/>
          <text>butyrylcholinesterase</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bche</infon>
          <location offset="216" length="4"/>
          <text>BChE</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="226" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>300</offset>
        <text>The adduct loses an alkyl group in a process called aging.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alkyl</infon>
          <location offset="320" length="5"/>
          <text>alkyl</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>359</offset>
        <text>The mechanism of aging of the tabun adduct is controversial.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tabun</infon>
          <location offset="389" length="5"/>
          <text>tabun</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>420</offset>
        <text>Some studies claim that aging proceeds through deamination, whereas crystal structure studies show aging by O-dealkylation.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="528" length="1"/>
          <text>O</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>544</offset>
        <text>Our goal was to develop a method that clearly distinguishes between deamination and O-dealkylation.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="628" length="1"/>
          <text>O</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>644</offset>
        <text>We began by studying the tetraisopropyl pyrophosphoramide adduct of BChE because this adduct has two P-N bonds.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetraisopropyl pyrophosphoramide</infon>
          <location offset="669" length="32"/>
          <text>tetraisopropyl pyrophosphoramide</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-n</infon>
          <location offset="745" length="3"/>
          <text>P-N</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bche</infon>
          <location offset="712" length="4"/>
          <text>BChE</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>756</offset>
        <text>Mass spectra showed that the P-N bonds were stable during trypsin digestion at pH 8 but were cleaved during pepsin digestion at pH 2.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-n</infon>
          <location offset="785" length="3"/>
          <text>P-N</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">trypsin</infon>
          <location offset="814" length="7"/>
          <text>trypsin</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pepsin</infon>
          <location offset="864" length="6"/>
          <text>pepsin</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T15" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>890</offset>
        <text>The P-N bond in tabun was also acid labile, whereas the P-O bond was stable.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-n</infon>
          <location offset="894" length="3"/>
          <text>P-N</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tabun</infon>
          <location offset="906" length="5"/>
          <text>tabun</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-o</infon>
          <location offset="946" length="3"/>
          <text>P-O</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>967</offset>
        <text>A scheme to distinguish aging by deamination from aging by O-dealkylation was based on the acid labile P-N bond.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="1026" length="1"/>
          <text>O</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-n</infon>
          <location offset="1070" length="3"/>
          <text>P-N</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1080</offset>
        <text>BChE was inhibited with Sp- and Rp-tabun thiocholine nerve agent model compounds to make adducts identical to those of tabun with known stereochemistry.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tabun</infon>
          <location offset="1199" length="5"/>
          <text>tabun</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sp- and rp-tabun thiocholine</infon>
          <location offset="1104" length="28"/>
          <text>Sp- and Rp-tabun thiocholine</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bche</infon>
          <location offset="1080" length="4"/>
          <text>BChE</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1233</offset>
        <text>After aging and digestion with pepsin at pH 2, peptide FGES198AGAAS from Sp-tabun thiocholine had a mass of 902.2 m/z in negative mode, indicating that it had aged by deamination, whereas peptide FGES198AGAAS from Rp-tabun thiocholine had a mass of 874.2 m/z in negative mode, indicating that it had aged by O-dealkylation.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sp-tabun thiocholine</infon>
          <location offset="1306" length="20"/>
          <text>Sp-tabun thiocholine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp-tabun thiocholine</infon>
          <location offset="1447" length="20"/>
          <text>Rp-tabun thiocholine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="1541" length="1"/>
          <text>O</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pepsin</infon>
          <location offset="1264" length="6"/>
          <text>pepsin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fges198agaas</infon>
          <location offset="1288" length="12"/>
          <text>FGES198AGAAS</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fges198agaas</infon>
          <location offset="1429" length="12"/>
          <text>FGES198AGAAS</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1557</offset>
        <text>BChE inhibited by authentic, racemic tabun yielded both 902.2 and 874.2 m/z peptides, indicating that both stereoisomers reacted with BChE and aged either by deamination or dealkylation.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">racemic tabun</infon>
          <location offset="1586" length="13"/>
          <text>racemic tabun</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bche</infon>
          <location offset="1557" length="4"/>
          <text>BChE</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bche</infon>
          <location offset="1691" length="4"/>
          <text>BChE</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23567959</id>
    <passage>
      <offset>0</offset>
      <text>Design, synthesis and antiproliferative properties of some new 5-substituted-2-iminobenzimidazole derivatives.	Some new 1,3,5-substituted-2,3-dihydro-2-imino-benzimidazoles were synthesized under solid-liquid phase transfer catalysis conditions using 5-substituted-2-aminobenzimidazoles as precursors in order to assess their cytotoxicity respectively proliferative activity. The structures of the compounds were confirmed by IR, (1)H NMR, (13)C NMR and elemental analysis. Compounds 9-10, 12 and 16-17 were evaluated for their cytotoxical effect on four cancer cell lines: HT-29, breast cancer cells MDA-MB-231, HeLa, HepG2 and as well as human diploid cell line Lep-3. Significant cytotoxicity of hydrazone 16 against MDA-MB-231 was established by biologically study, the IC50 was 6.2 nM while the EC50 value to Lep 3 is 0.21 nM. Relative high antiproliferative effects of the acetate 12 and compound 16 against HT-29 were ascertained and the calculated IC50 values were IC50 - 0.85 nM and IC50 - 2.83 nM respectively. Cytotoxic activity against HeLa and HepG2 cells was demonstrated by hydrazone 17, IC50 was 7.2 nM and 117 nM respectively. All tested compounds revealed proliferative activities to human diploid cell line Lep-3. The EC50 values were in the range from 0.05 to 16.91 nM. The obtained results prove the selective cytotoxicity of the tested compounds and are promising for further evaluation of the investigated compounds in vivo experiments using experimentally induced tumors in laboratory animals.</text>
      <sentence>
        <offset>0</offset>
        <text>Design, synthesis and antiproliferative properties of some new 5-substituted-2-iminobenzimidazole derivatives.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-substituted-2-iminobenzimidazole</infon>
          <location offset="63" length="34"/>
          <text>5-substituted-2-iminobenzimidazole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>111</offset>
        <text>Some new 1,3,5-substituted-2,3-dihydro-2-imino-benzimidazoles were synthesized under solid-liquid phase transfer catalysis conditions using 5-substituted-2-aminobenzimidazoles as precursors in order to assess their cytotoxicity respectively proliferative activity.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-substituted-2-aminobenzimidazoles</infon>
          <location offset="251" length="35"/>
          <text>5-substituted-2-aminobenzimidazoles</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1,3,5-substituted-2,3-dihydro-2-imino-benzimidazoles</infon>
          <location offset="120" length="52"/>
          <text>1,3,5-substituted-2,3-dihydro-2-imino-benzimidazoles</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>376</offset>
        <text>The structures of the compounds were confirmed by IR, (1)H NMR, (13)C NMR and elemental analysis.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(1)h</infon>
          <location offset="430" length="4"/>
          <text>(1)H</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(13)c</infon>
          <location offset="440" length="5"/>
          <text>(13)C</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>474</offset>
        <text>Compounds 9-10, 12 and 16-17 were evaluated for their cytotoxical effect on four cancer cell lines: HT-29, breast cancer cells MDA-MB-231, HeLa, HepG2 and as well as human diploid cell line Lep-3.</text>
      </sentence>
      <sentence>
        <offset>671</offset>
        <text>Significant cytotoxicity of hydrazone 16 against MDA-MB-231 was established by biologically study, the IC50 was 6.2 nM while the EC50 value to Lep 3 is 0.21 nM.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrazone</infon>
          <location offset="699" length="9"/>
          <text>hydrazone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>832</offset>
        <text>Relative high antiproliferative effects of the acetate 12 and compound 16 against HT-29 were ascertained and the calculated IC50 values were IC50 - 0.85 nM and IC50 - 2.83 nM respectively.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetate</infon>
          <location offset="879" length="7"/>
          <text>acetate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1021</offset>
        <text>Cytotoxic activity against HeLa and HepG2 cells was demonstrated by hydrazone 17, IC50 was 7.2 nM and 117 nM respectively.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrazone</infon>
          <location offset="1089" length="9"/>
          <text>hydrazone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1144</offset>
        <text>All tested compounds revealed proliferative activities to human diploid cell line Lep-3.</text>
      </sentence>
      <sentence>
        <offset>1233</offset>
        <text>The EC50 values were in the range from 0.05 to 16.91 nM.</text>
      </sentence>
      <sentence>
        <offset>1290</offset>
        <text>The obtained results prove the selective cytotoxicity of the tested compounds and are promising for further evaluation of the investigated compounds in vivo experiments using experimentally induced tumors in laboratory animals.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18045203</id>
    <passage>
      <offset>0</offset>
      <text>The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers.	Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence. The major metabolite of oxybutynin in humans is desethyloxybutynin (2). We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace N-CT(3)-scopolamine chloride ((3)H-NMS) binding on human cloned muscarinic m1-5 receptors. Compounds 1 and 2 potently displaced (3)H-NMS binding at m1, m3 and m4 receptors, but were less potent at the m2 and m5 subtypes. However, metabolite 2 was more potent than the parent compound 1 in the binding assay. In general the R enantiomers were more potent than their respective S enantiomers. Therefore, we suggest that the cholinergic side effects associated with 2 may be due to its greater apparent potency with m1 and m3 receptors, especially of its R-enantiomer, when compared with parent drug 1.</text>
      <sentence>
        <offset>0</offset>
        <text>The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxybutynin</infon>
          <location offset="59" length="10"/>
          <text>oxybutynin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-desethyloxybutynin</infon>
          <location offset="74" length="20"/>
          <text>N-desethyloxybutynin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human muscarinic receptor</infon>
          <location offset="20" length="25"/>
          <text>human muscarinic receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>108</offset>
        <text>Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxybutynin</infon>
          <location offset="108" length="10"/>
          <text>Oxybutynin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">muscarinic receptor</infon>
          <location offset="142" length="19"/>
          <text>muscarinic receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>240</offset>
        <text>The major metabolite of oxybutynin in humans is desethyloxybutynin (2).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxybutynin</infon>
          <location offset="264" length="10"/>
          <text>oxybutynin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">desethyloxybutynin</infon>
          <location offset="288" length="18"/>
          <text>desethyloxybutynin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>312</offset>
        <text>We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace N-CT(3)-scopolamine chloride ((3)H-NMS) binding on human cloned muscarinic m1-5 receptors.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-ct(3)-scopolamine chloride</infon>
          <location offset="396" length="28"/>
          <text>N-CT(3)-scopolamine chloride</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(3)h-nms</infon>
          <location offset="426" length="8"/>
          <text>(3)H-NMS</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human cloned muscarinic m1-5 receptors</infon>
          <location offset="447" length="38"/>
          <text>human cloned muscarinic m1-5 receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>487</offset>
        <text>Compounds 1 and 2 potently displaced (3)H-NMS binding at m1, m3 and m4 receptors, but were less potent at the m2 and m5 subtypes.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(3)h-nms</infon>
          <location offset="524" length="8"/>
          <text>(3)H-NMS</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">m1, m3 and m4 receptors</infon>
          <location offset="544" length="23"/>
          <text>m1, m3 and m4 receptors</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">m2</infon>
          <location offset="597" length="2"/>
          <text>m2</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">m5</infon>
          <location offset="604" length="2"/>
          <text>m5</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>617</offset>
        <text>However, metabolite 2 was more potent than the parent compound 1 in the binding assay.</text>
      </sentence>
      <sentence>
        <offset>704</offset>
        <text>In general the R enantiomers were more potent than their respective S enantiomers.</text>
      </sentence>
      <sentence>
        <offset>787</offset>
        <text>Therefore, we suggest that the cholinergic side effects associated with 2 may be due to its greater apparent potency with m1 and m3 receptors, especially of its R-enantiomer, when compared with parent drug 1.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">m1 and m3 receptors</infon>
          <location offset="909" length="19"/>
          <text>m1 and m3 receptors</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23354070</id>
    <passage>
      <offset>0</offset>
      <text>Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin.	Glycogen synthase kinase 3β (GSK-3β) is widely recognised as a relevant player in the pathogenesis of several highly prevalent disorders such as Alzheimer's disease, mood disorders, diabetes and cancer. Therefore, this enzyme constitutes a highly attractive therapeutic target for the development of selective inhibitors as new promising drugs for the treatment of these pathologies. We describe here the isolation and biochemical characterization of the marine natural sesquiterpene palinurin as a GSK-3β inhibitor. Experimental studies performed for characterizing the inhibitory mechanism indicate that GSK-3β inhibition by palinurin cannot be competed out by ATP nor peptide substrate. Molecular modelling techniques have enabled us to propose an unconventional binding mode to GSK-3β. Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of palinurin leads to GSK-3β inhibition. The inhibitory activities determined for a series of structurally related analogues support the proposed binding mode of palinurin, which is the first compound described to target this allosteric site. The results offer new opportunities for designing and developing selective inhibitors with novel mechanisms of action.</text>
      <sentence>
        <offset>0</offset>
        <text>Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">palinurin</infon>
          <location offset="87" length="9"/>
          <text>palinurin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gsk-3</infon>
          <location offset="35" length="5"/>
          <text>GSK-3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>98</offset>
        <text>Glycogen synthase kinase 3β (GSK-3β) is widely recognised as a relevant player in the pathogenesis of several highly prevalent disorders such as Alzheimer's disease, mood disorders, diabetes and cancer.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glycogen synthase kinase 3β</infon>
          <location offset="98" length="27"/>
          <text>Glycogen synthase kinase 3β</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gsk-3β</infon>
          <location offset="127" length="6"/>
          <text>GSK-3β</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>301</offset>
        <text>Therefore, this enzyme constitutes a highly attractive therapeutic target for the development of selective inhibitors as new promising drugs for the treatment of these pathologies.</text>
      </sentence>
      <sentence>
        <offset>482</offset>
        <text>We describe here the isolation and biochemical characterization of the marine natural sesquiterpene palinurin as a GSK-3β inhibitor.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sesquiterpene</infon>
          <location offset="568" length="13"/>
          <text>sesquiterpene</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">palinurin</infon>
          <location offset="582" length="9"/>
          <text>palinurin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gsk-3β</infon>
          <location offset="597" length="6"/>
          <text>GSK-3β</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>615</offset>
        <text>Experimental studies performed for characterizing the inhibitory mechanism indicate that GSK-3β inhibition by palinurin cannot be competed out by ATP nor peptide substrate.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">palinurin</infon>
          <location offset="725" length="9"/>
          <text>palinurin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="761" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gsk-3β</infon>
          <location offset="704" length="6"/>
          <text>GSK-3β</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>788</offset>
        <text>Molecular modelling techniques have enabled us to propose an unconventional binding mode to GSK-3β.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gsk-3β</infon>
          <location offset="880" length="6"/>
          <text>GSK-3β</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>888</offset>
        <text>Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of palinurin leads to GSK-3β inhibition.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">palinurin</infon>
          <location offset="989" length="9"/>
          <text>palinurin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gsk-3β</infon>
          <location offset="1008" length="6"/>
          <text>GSK-3β</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1027</offset>
        <text>The inhibitory activities determined for a series of structurally related analogues support the proposed binding mode of palinurin, which is the first compound described to target this allosteric site.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">palinurin</infon>
          <location offset="1148" length="9"/>
          <text>palinurin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1229</offset>
        <text>The results offer new opportunities for designing and developing selective inhibitors with novel mechanisms of action.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23327532</id>
    <passage>
      <offset>0</offset>
      <text>Cooperative effects for CYP2E1 differ between styrene and its metabolites.	Abstract 1. Cooperative interactions are frequently observed in the metabolism of drugs and pollutants by cytochrome P450s; nevertheless, the molecular determinants for cooperativity remain elusive. Previously, we demonstrated that steady-state styrene metabolism by CYP2E1 exhibits positive cooperativity. 2. We hypothesized that styrene metabolites have lower affinity than styrene toward CYP2E1 and limited ability to induce cooperative effects during metabolism. To test the hypothesis, we determined the potency and mechanism of inhibition for styrene and its metabolites toward oxidation of 4-nitrophenol using CYP2E1 Supersomes® and human liver microsomes. 3. Styrene inhibited the reaction through a mixed cooperative mechanism with high affinity for the catalytic site (67 µM) and lower affinity for the cooperative site (1100 µM), while increasing substrate turnover at high concentrations. Styrene oxide and 4-vinylphenol possessed similar affinity for CYP2E1. Styrene oxide behaved cooperatively like styrene, but 4-vinylphenol decreased turnover at high concentrations. Styrene glycol was a very poor competitive inhibitor. Among all compounds, there was a positive correlation with binding and hydrophobicity. 4. Taken together, these findings for CYP2E1 further validate contributions of cooperative mechanisms to metabolic processes, demonstrate the role of molecular structure on those mechanisms and underscore the potential for heterotropic cooperative effects between different compounds.</text>
      <sentence>
        <offset>0</offset>
        <text>Cooperative effects for CYP2E1 differ between styrene and its metabolites.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">styrene</infon>
          <location offset="46" length="7"/>
          <text>styrene</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="24" length="6"/>
          <text>CYP2E1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>75</offset>
        <text>Abstract 1.</text>
      </sentence>
      <sentence>
        <offset>87</offset>
        <text>Cooperative interactions are frequently observed in the metabolism of drugs and pollutants by cytochrome P450s; nevertheless, the molecular determinants for cooperativity remain elusive.</text>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450s</infon>
          <location offset="181" length="16"/>
          <text>cytochrome P450s</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>274</offset>
        <text>Previously, we demonstrated that steady-state styrene metabolism by CYP2E1 exhibits positive cooperativity.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="342" length="6"/>
          <text>CYP2E1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>382</offset>
        <text>2. We hypothesized that styrene metabolites have lower affinity than styrene toward CYP2E1 and limited ability to induce cooperative effects during metabolism.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">styrene</infon>
          <location offset="406" length="7"/>
          <text>styrene</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">styrene</infon>
          <location offset="451" length="7"/>
          <text>styrene</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="466" length="6"/>
          <text>CYP2E1</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>542</offset>
        <text>To test the hypothesis, we determined the potency and mechanism of inhibition for styrene and its metabolites toward oxidation of 4-nitrophenol using CYP2E1 Supersomes® and human liver microsomes.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">styrene</infon>
          <location offset="624" length="7"/>
          <text>styrene</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-nitrophenol</infon>
          <location offset="672" length="13"/>
          <text>4-nitrophenol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="692" length="6"/>
          <text>CYP2E1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>739</offset>
        <text>3. Styrene inhibited the reaction through a mixed cooperative mechanism with high affinity for the catalytic site (67 µM) and lower affinity for the cooperative site (1100 µM), while increasing substrate turnover at high concentrations.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">styrene</infon>
          <location offset="742" length="7"/>
          <text>Styrene</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>976</offset>
        <text>Styrene oxide and 4-vinylphenol possessed similar affinity for CYP2E1.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">styrene oxide</infon>
          <location offset="976" length="13"/>
          <text>Styrene oxide</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-vinylphenol</infon>
          <location offset="994" length="13"/>
          <text>4-vinylphenol</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="1039" length="6"/>
          <text>CYP2E1</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1047</offset>
        <text>Styrene oxide behaved cooperatively like styrene, but 4-vinylphenol decreased turnover at high concentrations.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">styrene</infon>
          <location offset="1088" length="7"/>
          <text>styrene</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-vinylphenol</infon>
          <location offset="1101" length="13"/>
          <text>4-vinylphenol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">styrene oxide</infon>
          <location offset="1047" length="13"/>
          <text>Styrene oxide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1158</offset>
        <text>Styrene glycol was a very poor competitive inhibitor.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">styrene glycol</infon>
          <location offset="1158" length="14"/>
          <text>Styrene glycol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1212</offset>
        <text>Among all compounds, there was a positive correlation with binding and hydrophobicity.</text>
      </sentence>
      <sentence>
        <offset>1299</offset>
        <text>4. Taken together, these findings for CYP2E1 further validate contributions of cooperative mechanisms to metabolic processes, demonstrate the role of molecular structure on those mechanisms and underscore the potential for heterotropic cooperative effects between different compounds.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2e1</infon>
          <location offset="1337" length="6"/>
          <text>CYP2E1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>14871882</id>
    <passage>
      <offset>0</offset>
      <text>Ornithine metabolism in male and female rat kidney: mitochondrial expression of ornithine aminotransferase and arginase II.	In the kidney, L-ornithine is reabsorbed along the proximal convoluted tubule (PCT), transported by basolateral carriers, and produced by arginase II (AII). Here, the renal metabolic fate of L-ornithine was analyzed in male and female rats. Kidneys and renal zones were dissected and used for Western blot analysis, immunofluorescence, and electron microscopic studies. Ornithine aminotransferase (OAT) and AII were localized using specific antibodies. Ornithine oxidation was determined by incubating microdissected tubules with L-[1-14C] or L-[U-14C]ornithine in the presence or absence of energy-providing substrates. Ornithine decarboxylase (ODC) mRNAs were localized by in situ hybridization. The 48-kDa OAT protein was detected in male and female kidneys, but its level was fourfold higher in the latter. OAT relative distribution increased from the superficial cortex toward the outer medulla to reach its highest level. Almost all OAT protein was localized in cortical and medullary proximal straight tubules (CPST and OSPST, respectively). In proximal straight tubule (PST), AII protein distribution overlapped that of OAT. No gender difference in AII protein level was found. OAT and AII were colocalized within PST mitochondria. L-[1-14C]ornithine decarboxylation occurred in all tubules, but predominantly in proximal tubules. L-[1-14C]ornithine decarboxylation was enhanced when L-[1-14C]ornithine was given to tubules as the sole substrate. The use of L-[U-14C]ornithine demonstrated the complete oxidation of ornithine. In conclusion, the OAT gene was expressed more in female rat proximal tubules than in male. Because OAT and AII proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by ornithine oxidation. However, the coexpression of ODC, glutamate decarboxylase, and glutamine synthetase in PST suggests that L-ornithine can also be metabolized to putrescine, GABA, and L-glutamine. The fate of L-ornithine may depend on the cellular context.</text>
      <sentence>
        <offset>0</offset>
        <text>Ornithine metabolism in male and female rat kidney: mitochondrial expression of ornithine aminotransferase and arginase II.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ornithine</infon>
          <location offset="0" length="9"/>
          <text>Ornithine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ornithine</infon>
          <location offset="80" length="9"/>
          <text>ornithine</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">arginase ii</infon>
          <location offset="111" length="11"/>
          <text>arginase II</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ornithine aminotransferase</infon>
          <location offset="80" length="26"/>
          <text>ornithine aminotransferase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>124</offset>
        <text>In the kidney, L-ornithine is reabsorbed along the proximal convoluted tubule (PCT), transported by basolateral carriers, and produced by arginase II (AII).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-ornithine</infon>
          <location offset="139" length="11"/>
          <text>L-ornithine</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">arginase ii</infon>
          <location offset="262" length="11"/>
          <text>arginase II</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aii</infon>
          <location offset="275" length="3"/>
          <text>AII</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>281</offset>
        <text>Here, the renal metabolic fate of L-ornithine was analyzed in male and female rats.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-ornithine</infon>
          <location offset="315" length="11"/>
          <text>L-ornithine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>365</offset>
        <text>Kidneys and renal zones were dissected and used for Western blot analysis, immunofluorescence, and electron microscopic studies.</text>
      </sentence>
      <sentence>
        <offset>494</offset>
        <text>Ornithine aminotransferase (OAT) and AII were localized using specific antibodies.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ornithine</infon>
          <location offset="494" length="9"/>
          <text>Ornithine</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ornithine aminotransferase</infon>
          <location offset="494" length="26"/>
          <text>Ornithine aminotransferase</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oat</infon>
          <location offset="522" length="3"/>
          <text>OAT</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aii</infon>
          <location offset="531" length="3"/>
          <text>AII</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>577</offset>
        <text>Ornithine oxidation was determined by incubating microdissected tubules with L-[1-14C] or L-[U-14C]ornithine in the presence or absence of energy-providing substrates.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ornithine</infon>
          <location offset="577" length="9"/>
          <text>Ornithine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-[1-14c]</infon>
          <location offset="654" length="9"/>
          <text>L-[1-14C]</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-[u-14c]ornithine</infon>
          <location offset="667" length="18"/>
          <text>L-[U-14C]ornithine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>745</offset>
        <text>Ornithine decarboxylase (ODC) mRNAs were localized by in situ hybridization.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ornithine</infon>
          <location offset="745" length="9"/>
          <text>Ornithine</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ornithine decarboxylase</infon>
          <location offset="745" length="23"/>
          <text>Ornithine decarboxylase</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">odc</infon>
          <location offset="770" length="3"/>
          <text>ODC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>822</offset>
        <text>The 48-kDa OAT protein was detected in male and female kidneys, but its level was fourfold higher in the latter.</text>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oat</infon>
          <location offset="833" length="3"/>
          <text>OAT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>935</offset>
        <text>OAT relative distribution increased from the superficial cortex toward the outer medulla to reach its highest level.</text>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oat</infon>
          <location offset="935" length="3"/>
          <text>OAT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1052</offset>
        <text>Almost all OAT protein was localized in cortical and medullary proximal straight tubules (CPST and OSPST, respectively).</text>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oat</infon>
          <location offset="1063" length="3"/>
          <text>OAT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1173</offset>
        <text>In proximal straight tubule (PST), AII protein distribution overlapped that of OAT.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aii</infon>
          <location offset="1208" length="3"/>
          <text>AII</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oat</infon>
          <location offset="1252" length="3"/>
          <text>OAT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1257</offset>
        <text>No gender difference in AII protein level was found.</text>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aii</infon>
          <location offset="1281" length="3"/>
          <text>AII</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1310</offset>
        <text>OAT and AII were colocalized within PST mitochondria.</text>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oat</infon>
          <location offset="1310" length="3"/>
          <text>OAT</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aii</infon>
          <location offset="1318" length="3"/>
          <text>AII</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1364</offset>
        <text>L-[1-14C]ornithine decarboxylation occurred in all tubules, but predominantly in proximal tubules.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-[1-14c]ornithine</infon>
          <location offset="1364" length="18"/>
          <text>L-[1-14C]ornithine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1463</offset>
        <text>L-[1-14C]ornithine decarboxylation was enhanced when L-[1-14C]ornithine was given to tubules as the sole substrate.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-[1-14c]ornithine</infon>
          <location offset="1463" length="18"/>
          <text>L-[1-14C]ornithine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-[1-14c]ornithine</infon>
          <location offset="1516" length="18"/>
          <text>L-[1-14C]ornithine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1579</offset>
        <text>The use of L-[U-14C]ornithine demonstrated the complete oxidation of ornithine.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-[u-14c]ornithine</infon>
          <location offset="1590" length="18"/>
          <text>L-[U-14C]ornithine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ornithine</infon>
          <location offset="1648" length="9"/>
          <text>ornithine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1659</offset>
        <text>In conclusion, the OAT gene was expressed more in female rat proximal tubules than in male.</text>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oat</infon>
          <location offset="1678" length="3"/>
          <text>OAT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1751</offset>
        <text>Because OAT and AII proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by ornithine oxidation.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-arginine</infon>
          <location offset="1812" length="10"/>
          <text>L-arginine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ornithine</infon>
          <location offset="1831" length="9"/>
          <text>ornithine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-glutamate</infon>
          <location offset="1876" length="11"/>
          <text>L-glutamate</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ornithine</infon>
          <location offset="1902" length="9"/>
          <text>ornithine</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oat</infon>
          <location offset="1759" length="3"/>
          <text>OAT</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aii</infon>
          <location offset="1767" length="3"/>
          <text>AII</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1923</offset>
        <text>However, the coexpression of ODC, glutamate decarboxylase, and glutamine synthetase in PST suggests that L-ornithine can also be metabolized to putrescine, GABA, and L-glutamine.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="1957" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamine</infon>
          <location offset="1986" length="9"/>
          <text>glutamine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-ornithine</infon>
          <location offset="2028" length="11"/>
          <text>L-ornithine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">putrescine</infon>
          <location offset="2067" length="10"/>
          <text>putrescine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gaba</infon>
          <location offset="2079" length="4"/>
          <text>GABA</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-glutamine</infon>
          <location offset="2089" length="11"/>
          <text>L-glutamine</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">odc</infon>
          <location offset="1952" length="3"/>
          <text>ODC</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutamate decarboxylase</infon>
          <location offset="1957" length="23"/>
          <text>glutamate decarboxylase</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glutamine synthetase</infon>
          <location offset="1986" length="20"/>
          <text>glutamine synthetase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2102</offset>
        <text>The fate of L-ornithine may depend on the cellular context.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-ornithine</infon>
          <location offset="2114" length="11"/>
          <text>L-ornithine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23556446</id>
    <passage>
      <offset>0</offset>
      <text>Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease.	Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials &amp; methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G&gt;T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C&gt;T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013.</text>
      <sentence>
        <offset>0</offset>
        <text>Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="15" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atp-binding cassette transporter</infon>
          <location offset="15" length="32"/>
          <text>ATP-binding cassette transporter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>95</offset>
        <text>Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcb1</infon>
          <location offset="143" length="5"/>
          <text>ABCB1</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcrp</infon>
          <location offset="153" length="4"/>
          <text>BCRP</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="159" length="5"/>
          <text>ABCG2</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aβ</infon>
          <location offset="185" length="2"/>
          <text>Aβ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>189</offset>
        <text>We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls.</text>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">multidrug transporters</infon>
          <location offset="261" length="22"/>
          <text>multidrug transporters</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>370</offset>
        <text>Materials &amp; methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abca1</infon>
          <location offset="584" length="5"/>
          <text>ABCA1</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abca7</infon>
          <location offset="591" length="5"/>
          <text>ABCA7</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcb1</infon>
          <location offset="598" length="5"/>
          <text>ABCB1</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcc2</infon>
          <location offset="605" length="5"/>
          <text>ABCC2</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcg2</infon>
          <location offset="615" length="5"/>
          <text>ABCG2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>622</offset>
        <text>In addition, the APOE4 status was analyzed.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apoe4</infon>
          <location offset="639" length="5"/>
          <text>APOE4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>666</offset>
        <text>Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abca7</infon>
          <location offset="685" length="5"/>
          <text>ABCA7</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>753</offset>
        <text>Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcb1</infon>
          <location offset="765" length="5"/>
          <text>ABCB1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>862</offset>
        <text>This association of ABCB1 2677G&gt;T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005).</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcb1</infon>
          <location offset="882" length="5"/>
          <text>ABCB1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">2677g&gt;t</infon>
          <location offset="888" length="7"/>
          <text>2677G&gt;T</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">apoe4</infon>
          <location offset="931" length="5"/>
          <text>APOE4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>965</offset>
        <text>However, only ABCC2 3972C&gt;T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcc2</infon>
          <location offset="979" length="5"/>
          <text>ABCC2</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">3972c&gt;t</infon>
          <location offset="985" length="7"/>
          <text>3972C&gt;T</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1106</offset>
        <text>Other transporters showed a lack of association.</text>
      </sentence>
      <sentence>
        <offset>1155</offset>
        <text>Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcb1</infon>
          <location offset="1207" length="5"/>
          <text>ABCB1</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">abc-transporters</infon>
          <location offset="1232" length="16"/>
          <text>ABC-transporters</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aβ</infon>
          <location offset="1280" length="2"/>
          <text>Aβ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1452</offset>
        <text>Original submitted 8 October 2012; Revision submitted 22 January 2013.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10826417</id>
    <passage>
      <offset>0</offset>
      <text>Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction.	BACKGROUND: Ogilvie's syndrome, or acute colonic pseudo-obstruction, is a common and relatively dangerous condition. If left untreated, it may cause ischemic necrosis and colonic perforation, with a mortality rate as high as 50 percent. Neostigmine enhances excitatory parasympathetic activity by competing with acetylcholine for attachment to acetylcholinesterase at sites of cholinergic transmission and enhancing cholinergic action. We hypothesized that neostigmine would restore peristalsis in patients with acute colonic pseudo-obstruction. METHODS: Twenty-eight patients at Fletcher Allen Health Care and The Cleveland Clinic Foundation were treated for acute colonic pseudo-obstruction with neostigmine 2.5 mg IV over 3 minutes while being monitored with telemetry. Mechanical obstruction had been excluded. RESULTS: Complete clinical resolution of large bowel distention occurred in 26 of the 28 patients. Time to pass flatus varied from 30 seconds to 10 minutes after administration of neostigmine. No adverse effects or complications were noted. Of the two patients who did not resolve, one had a sigmoid cancer that required resection and one patient died from multiorgan failure. CONCLUSION: This study supports the theory that acute colonic pseudo-obstruction is the result of excessive parasympathetic suppression rather than sympathetic overactivity. We have shown that neostigmine is a safe and effective treatment for acute colonic pseudo-obstruction.</text>
      <sentence>
        <offset>0</offset>
        <text>Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">neostigmine</infon>
          <location offset="0" length="11"/>
          <text>Neostigmine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>80</offset>
        <text>BACKGROUND: Ogilvie's syndrome, or acute colonic pseudo-obstruction, is a common and relatively dangerous condition.</text>
      </sentence>
      <sentence>
        <offset>197</offset>
        <text>If left untreated, it may cause ischemic necrosis and colonic perforation, with a mortality rate as high as 50 percent.</text>
      </sentence>
      <sentence>
        <offset>317</offset>
        <text>Neostigmine enhances excitatory parasympathetic activity by competing with acetylcholine for attachment to acetylcholinesterase at sites of cholinergic transmission and enhancing cholinergic action.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">neostigmine</infon>
          <location offset="317" length="11"/>
          <text>Neostigmine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="392" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="424" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>516</offset>
        <text>We hypothesized that neostigmine would restore peristalsis in patients with acute colonic pseudo-obstruction.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">neostigmine</infon>
          <location offset="537" length="11"/>
          <text>neostigmine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>626</offset>
        <text>METHODS: Twenty-eight patients at Fletcher Allen Health Care and The Cleveland Clinic Foundation were treated for acute colonic pseudo-obstruction with neostigmine 2.5 mg IV over 3 minutes while being monitored with telemetry.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">neostigmine</infon>
          <location offset="778" length="11"/>
          <text>neostigmine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>853</offset>
        <text>Mechanical obstruction had been excluded.</text>
      </sentence>
      <sentence>
        <offset>895</offset>
        <text>RESULTS: Complete clinical resolution of large bowel distention occurred in 26 of the 28 patients.</text>
      </sentence>
      <sentence>
        <offset>994</offset>
        <text>Time to pass flatus varied from 30 seconds to 10 minutes after administration of neostigmine.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">neostigmine</infon>
          <location offset="1075" length="11"/>
          <text>neostigmine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1088</offset>
        <text>No adverse effects or complications were noted.</text>
      </sentence>
      <sentence>
        <offset>1136</offset>
        <text>Of the two patients who did not resolve, one had a sigmoid cancer that required resection and one patient died from multiorgan failure.</text>
      </sentence>
      <sentence>
        <offset>1272</offset>
        <text>CONCLUSION: This study supports the theory that acute colonic pseudo-obstruction is the result of excessive parasympathetic suppression rather than sympathetic overactivity.</text>
      </sentence>
      <sentence>
        <offset>1446</offset>
        <text>We have shown that neostigmine is a safe and effective treatment for acute colonic pseudo-obstruction.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">neostigmine</infon>
          <location offset="1465" length="11"/>
          <text>neostigmine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23103613</id>
    <passage>
      <offset>0</offset>
      <text>Chloroacetic acid induced neuronal cells death through oxidative stress-mediated p38-MAPK activation pathway regulated mitochondria-dependent apoptotic signals.	Chloroacetic acid (CA), a toxic chlorinated analog of acetic acid, is widely used in chemical industries as an herbicide, detergent, and disinfectant, and chemical intermediates that are formed during the synthesis of various products. In addition, CA has been found as a by-product of chlorination disinfection of drinking water. However, there is little known about neurotoxic injuries of CA on the mammalian, the toxic effects and molecular mechanisms of CA-induced neuronal cell injury are mostly unknown. In this study, we examined the cytotoxicity of CA on cultured Neuro-2a cells and investigated the possible mechanisms of CA-induced neurotoxicity. Treatment of Neuro-2a cells with CA significantly reduced the number of viable cells (in a dose-dependent manner with a range from 0.1 to 3mM), increased the generation of ROS, and reduced the intracellular levels of glutathione depletion. CA also increased the number of sub-G1 hypodiploid cells; increased mitochondrial dysfunction (loss of MMP, cytochrome c release, and accompanied by Bcl-2 and Mcl-1 down-regulation and Bax up-regulation), and activated the caspase cascades activations, which displayed features of mitochondria-dependent apoptosis pathway. These CA-induced apoptosis-related signals were markedly prevented by the antioxidant N-acetylcysteine (NAC). Moreover, CA activated the JNK and p38-MAPK pathways, but did not that ERK1/2 pathway, in treated Neuro-2a cells. Pretreatment with NAC and specific p38-MAPK inhibitor (SB203580), but not JNK inhibitor (SP600125) effectively abrogated the phosphorylation of p38-MAPK and attenuated the apoptotic signals (including: decrease in cytotoxicity, caspase-3/-7 activation, the cytosolic cytochrome c release, and the reversed alteration of Bcl-2 and Bax mRNA) in CA-treated Neuro-2a cells. Taken together, these data suggest that oxidative stress-induced p38-MAPK activated pathway-regulated mitochondria-dependent apoptosis plays an important role in CA-caused neuronal cell death.</text>
      <sentence>
        <offset>0</offset>
        <text>Chloroacetic acid induced neuronal cells death through oxidative stress-mediated p38-MAPK activation pathway regulated mitochondria-dependent apoptotic signals.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloroacetic acid</infon>
          <location offset="0" length="17"/>
          <text>Chloroacetic acid</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p38</infon>
          <location offset="81" length="3"/>
          <text>p38</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="85" length="4"/>
          <text>MAPK</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>161</offset>
        <text>Chloroacetic acid (CA), a toxic chlorinated analog of acetic acid, is widely used in chemical industries as an herbicide, detergent, and disinfectant, and chemical intermediates that are formed during the synthesis of various products.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloroacetic acid</infon>
          <location offset="161" length="17"/>
          <text>Chloroacetic acid</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetic acid</infon>
          <location offset="215" length="11"/>
          <text>acetic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>397</offset>
        <text>In addition, CA has been found as a by-product of chlorination disinfection of drinking water.</text>
      </sentence>
      <sentence>
        <offset>492</offset>
        <text>However, there is little known about neurotoxic injuries of CA on the mammalian, the toxic effects and molecular mechanisms of CA-induced neuronal cell injury are mostly unknown.</text>
      </sentence>
      <sentence>
        <offset>671</offset>
        <text>In this study, we examined the cytotoxicity of CA on cultured Neuro-2a cells and investigated the possible mechanisms of CA-induced neurotoxicity.</text>
      </sentence>
      <sentence>
        <offset>818</offset>
        <text>Treatment of Neuro-2a cells with CA significantly reduced the number of viable cells (in a dose-dependent manner with a range from 0.1 to 3mM), increased the generation of ROS, and reduced the intracellular levels of glutathione depletion.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="1035" length="11"/>
          <text>glutathione</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1058</offset>
        <text>CA also increased the number of sub-G1 hypodiploid cells; increased mitochondrial dysfunction (loss of MMP, cytochrome c release, and accompanied by Bcl-2 and Mcl-1 down-regulation and Bax up-regulation), and activated the caspase cascades activations, which displayed features of mitochondria-dependent apoptosis pathway.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome c</infon>
          <location offset="1166" length="12"/>
          <text>cytochrome c</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="1207" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcl-1</infon>
          <location offset="1217" length="5"/>
          <text>Mcl-1</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="1243" length="3"/>
          <text>Bax</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">caspase</infon>
          <location offset="1281" length="7"/>
          <text>caspase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1381</offset>
        <text>These CA-induced apoptosis-related signals were markedly prevented by the antioxidant N-acetylcysteine (NAC).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-acetylcysteine</infon>
          <location offset="1467" length="16"/>
          <text>N-acetylcysteine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nac</infon>
          <location offset="1485" length="3"/>
          <text>NAC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1491</offset>
        <text>Moreover, CA activated the JNK and p38-MAPK pathways, but did not that ERK1/2 pathway, in treated Neuro-2a cells.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">jnk</infon>
          <location offset="1518" length="3"/>
          <text>JNK</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p38</infon>
          <location offset="1526" length="3"/>
          <text>p38</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="1530" length="4"/>
          <text>MAPK</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="1562" length="6"/>
          <text>ERK1/2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1605</offset>
        <text>Pretreatment with NAC and specific p38-MAPK inhibitor (SB203580), but not JNK inhibitor (SP600125) effectively abrogated the phosphorylation of p38-MAPK and attenuated the apoptotic signals (including: decrease in cytotoxicity, caspase-3/-7 activation, the cytosolic cytochrome c release, and the reversed alteration of Bcl-2 and Bax mRNA) in CA-treated Neuro-2a cells.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nac</infon>
          <location offset="1623" length="3"/>
          <text>NAC</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sb203580</infon>
          <location offset="1660" length="8"/>
          <text>SB203580</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sp600125</infon>
          <location offset="1694" length="8"/>
          <text>SP600125</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p38</infon>
          <location offset="1640" length="3"/>
          <text>p38</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="1644" length="4"/>
          <text>MAPK</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">jnk</infon>
          <location offset="1679" length="3"/>
          <text>JNK</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p38</infon>
          <location offset="1749" length="3"/>
          <text>p38</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="1753" length="4"/>
          <text>MAPK</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">caspase-3/-7</infon>
          <location offset="1833" length="12"/>
          <text>caspase-3/-7</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome c</infon>
          <location offset="1872" length="12"/>
          <text>cytochrome c</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="1925" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="1935" length="3"/>
          <text>Bax</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1975</offset>
        <text>Taken together, these data suggest that oxidative stress-induced p38-MAPK activated pathway-regulated mitochondria-dependent apoptosis plays an important role in CA-caused neuronal cell death.</text>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p38</infon>
          <location offset="2040" length="3"/>
          <text>p38</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="2044" length="4"/>
          <text>MAPK</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23541928</id>
    <passage>
      <offset>0</offset>
      <text>Osteochondral tissue regeneration using a bilayered composite hydrogel with modulating dual growth factor release kinetics in a rabbit model.	Biodegradable oligo(poly(ethylene glycol) fumarate) (OPF) composite hydrogels have been investigated for the delivery of growth factors (GFs) with the aid of gelatin microparticles (GMPs) and stem cell populations for osteochondral tissue regeneration. In this study, a bilayered OPF composite hydrogel that mimics the distinctive hierarchical structure of native osteochondral tissue was utilized to investigate the effect of transforming growth factor-β3 (TGF-β3) with varying release kinetics and/or insulin-like growth factor-1 (IGF-1) on osteochondral tissue regeneration in a rabbit full-thickness osteochondral defect model. The four groups investigated included (i) a blank control (no GFs), (ii) GMP-loaded IGF-1 alone, (iii) GMP-loaded IGF-1 and gel-loaded TGF-β3, and (iv) GMP-loaded IGF-1 and GMP-loaded TGF-β3 in OPF composite hydrogels. The results of an in vitro release study demonstrated that TGF-β3 release kinetics could be modulated by the GF incorporation method. At 12weeks post-implantation, the quality of tissue repair in both chondral and subchondral layers was analyzed based on quantitative histological scoring. All groups incorporating GFs resulted in a significant improvement in cartilage morphology compared to the control. Single delivery of IGF-1 showed higher scores in subchondral bone morphology as well as chondrocyte and glycosaminoglycan amount in adjacent cartilage tissue when compared to a dual delivery of IGF-1 and TGF-β3, independent of the TGF-β3 release kinetics. The results suggest that although the dual delivery of TGF-β3 and IGF-1 may not synergistically enhance the quality of engineered tissue, the delivery of IGF-1 alone from bilayered composite hydrogels positively affects osteochondral tissue repair and holds promise for osteochondral tissue engineering applications.</text>
      <sentence>
        <offset>0</offset>
        <text>Osteochondral tissue regeneration using a bilayered composite hydrogel with modulating dual growth factor release kinetics in a rabbit model.</text>
      </sentence>
      <sentence>
        <offset>142</offset>
        <text>Biodegradable oligo(poly(ethylene glycol) fumarate) (OPF) composite hydrogels have been investigated for the delivery of growth factors (GFs) with the aid of gelatin microparticles (GMPs) and stem cell populations for osteochondral tissue regeneration.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oligo(poly(ethylene glycol) fumarate)</infon>
          <location offset="156" length="37"/>
          <text>oligo(poly(ethylene glycol) fumarate)</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">opf</infon>
          <location offset="195" length="3"/>
          <text>OPF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>395</offset>
        <text>In this study, a bilayered OPF composite hydrogel that mimics the distinctive hierarchical structure of native osteochondral tissue was utilized to investigate the effect of transforming growth factor-β3 (TGF-β3) with varying release kinetics and/or insulin-like growth factor-1 (IGF-1) on osteochondral tissue regeneration in a rabbit full-thickness osteochondral defect model.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">opf</infon>
          <location offset="422" length="3"/>
          <text>OPF</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">transforming growth factor-β3</infon>
          <location offset="569" length="29"/>
          <text>transforming growth factor-β3</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β3</infon>
          <location offset="600" length="6"/>
          <text>TGF-β3</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin-like growth factor-1</infon>
          <location offset="645" length="28"/>
          <text>insulin-like growth factor-1</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-1</infon>
          <location offset="675" length="5"/>
          <text>IGF-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>774</offset>
        <text>The four groups investigated included (i) a blank control (no GFs), (ii) GMP-loaded IGF-1 alone, (iii) GMP-loaded IGF-1 and gel-loaded TGF-β3, and (iv) GMP-loaded IGF-1 and GMP-loaded TGF-β3 in OPF composite hydrogels.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">opf</infon>
          <location offset="968" length="3"/>
          <text>OPF</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-1</infon>
          <location offset="858" length="5"/>
          <text>IGF-1</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-1</infon>
          <location offset="888" length="5"/>
          <text>IGF-1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β3</infon>
          <location offset="909" length="6"/>
          <text>TGF-β3</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-1</infon>
          <location offset="937" length="5"/>
          <text>IGF-1</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β3</infon>
          <location offset="958" length="6"/>
          <text>TGF-β3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>993</offset>
        <text>The results of an in vitro release study demonstrated that TGF-β3 release kinetics could be modulated by the GF incorporation method.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β3</infon>
          <location offset="1052" length="6"/>
          <text>TGF-β3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1127</offset>
        <text>At 12weeks post-implantation, the quality of tissue repair in both chondral and subchondral layers was analyzed based on quantitative histological scoring.</text>
      </sentence>
      <sentence>
        <offset>1283</offset>
        <text>All groups incorporating GFs resulted in a significant improvement in cartilage morphology compared to the control.</text>
      </sentence>
      <sentence>
        <offset>1399</offset>
        <text>Single delivery of IGF-1 showed higher scores in subchondral bone morphology as well as chondrocyte and glycosaminoglycan amount in adjacent cartilage tissue when compared to a dual delivery of IGF-1 and TGF-β3, independent of the TGF-β3 release kinetics.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-1</infon>
          <location offset="1418" length="5"/>
          <text>IGF-1</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-1</infon>
          <location offset="1593" length="5"/>
          <text>IGF-1</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β3</infon>
          <location offset="1603" length="6"/>
          <text>TGF-β3</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β3</infon>
          <location offset="1630" length="6"/>
          <text>TGF-β3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1655</offset>
        <text>The results suggest that although the dual delivery of TGF-β3 and IGF-1 may not synergistically enhance the quality of engineered tissue, the delivery of IGF-1 alone from bilayered composite hydrogels positively affects osteochondral tissue repair and holds promise for osteochondral tissue engineering applications.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-β3</infon>
          <location offset="1710" length="6"/>
          <text>TGF-β3</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-1</infon>
          <location offset="1721" length="5"/>
          <text>IGF-1</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-1</infon>
          <location offset="1809" length="5"/>
          <text>IGF-1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23601412</id>
    <passage>
      <offset>0</offset>
      <text>Biogenic amines content as a measure of the quality of wines of Abruzzo (Italy).	Aim of this research was to study the effect of some agronomic and oenological factors on the content of biogenic amines as quality index of sixty-five Abruzzo wines. Sum of amines was found to be decreasing in the order: red (19.3±12.8mgL(-1)), rosé (9.20±6.34mgL(-1)), white (7.67±3.84mgL(-1)) wine. Significant differences in relationship among amines levels and chemical and chemico-physical characteristics of red, white and rosé wine are due to their different biotechnological process and winemaking. Besides the aging treatment, influential seems to be the effect of the winery, regardless of the area in which it is situated. The single amines significantly correlated with their sum were putrescine, histamine and tyramine, even if reached levels were below toxicity threshold, demonstrating a good quality of the wines of Abruzzo whose consumption is no risk to the health of the consumer following the rules of proper nutrition.</text>
      <sentence>
        <offset>0</offset>
        <text>Biogenic amines content as a measure of the quality of wines of Abruzzo (Italy).</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amines</infon>
          <location offset="9" length="6"/>
          <text>amines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>81</offset>
        <text>Aim of this research was to study the effect of some agronomic and oenological factors on the content of biogenic amines as quality index of sixty-five Abruzzo wines.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amines</infon>
          <location offset="195" length="6"/>
          <text>amines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>248</offset>
        <text>Sum of amines was found to be decreasing in the order: red (19.3±12.8mgL(-1)), rosé (9.20±6.34mgL(-1)), white (7.67±3.84mgL(-1)) wine.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amines</infon>
          <location offset="255" length="6"/>
          <text>amines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>383</offset>
        <text>Significant differences in relationship among amines levels and chemical and chemico-physical characteristics of red, white and rosé wine are due to their different biotechnological process and winemaking.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amines</infon>
          <location offset="429" length="6"/>
          <text>amines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>589</offset>
        <text>Besides the aging treatment, influential seems to be the effect of the winery, regardless of the area in which it is situated.</text>
      </sentence>
      <sentence>
        <offset>716</offset>
        <text>The single amines significantly correlated with their sum were putrescine, histamine and tyramine, even if reached levels were below toxicity threshold, demonstrating a good quality of the wines of Abruzzo whose consumption is no risk to the health of the consumer following the rules of proper nutrition.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amines</infon>
          <location offset="727" length="6"/>
          <text>amines</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">putrescine</infon>
          <location offset="779" length="10"/>
          <text>putrescine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="791" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyramine</infon>
          <location offset="805" length="8"/>
          <text>tyramine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17896959</id>
    <passage>
      <offset>0</offset>
      <text>Na+/Ca2+ exchange inhibitors: a new class of calcium regulators.	The Na(+)/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization. There are three mammalian NCX isoforms: NCX1 is widely expressed in the heart, kidney, brain, blood vessels, and so on; whereas the expression of NCX2 and NCX3 is limited mainly to the brain and skeletal muscle. The pharmacology of NCX inhibitors has been studied extensively since the development of KB-R7943, a prototype benzyloxyphenyl NCX inhibitor, in 1996. Currently, experiments are actively progressing with more selective inhibitors: SEA0400, SN-6, and YM-244769. Intriguingly, the inhibitory potency of benzyloxyphenyl NCX inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation. Therefore, the benzyloxyphenyl inhibitors are apparently dormant during the forward mode under normal conditions (low Na(+)(i)), but become effective during the reverse mode under pathological conditions (high Na(+)(i)). This should be an ideal profile for calcium regulators against Na(+)(i)-related diseases, such as ischemia/reperfusion injuries, salt-dependent hypertension, and digitalis arrhythmia. Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action. It is possible that this property is partly responsible for their antiarrhythmic and cardioprotective effects. This article presents the characteristics of selective and non-selective NCX inhibitors and their therapeutic potential as a new calcium regulator.</text>
      <sentence>
        <offset>0</offset>
        <text>Na+/Ca2+ exchange inhibitors: a new class of calcium regulators.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na+</infon>
          <location offset="0" length="3"/>
          <text>Na+</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="45" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca2+</infon>
          <location offset="4" length="4"/>
          <text>Ca2+</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>65</offset>
        <text>The Na(+)/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca(2+)</infon>
          <location offset="75" length="6"/>
          <text>Ca(2+)</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca(2+)</infon>
          <location offset="205" length="6"/>
          <text>Ca(2+)</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="288" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="295" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="69" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca(2+)</infon>
          <location offset="152" length="6"/>
          <text>Ca(2+)</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ncx</infon>
          <location offset="93" length="3"/>
          <text>NCX</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na(+)/ca(2+) exchanger</infon>
          <location offset="69" length="22"/>
          <text>Na(+)/Ca(2+) exchanger</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T23" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>346</offset>
        <text>There are three mammalian NCX isoforms: NCX1 is widely expressed in the heart, kidney, brain, blood vessels, and so on; whereas the expression of NCX2 and NCX3 is limited mainly to the brain and skeletal muscle.</text>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mammalian ncx</infon>
          <location offset="362" length="13"/>
          <text>mammalian NCX</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ncx1</infon>
          <location offset="386" length="4"/>
          <text>NCX1</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ncx2</infon>
          <location offset="492" length="4"/>
          <text>NCX2</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ncx3</infon>
          <location offset="501" length="4"/>
          <text>NCX3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>558</offset>
        <text>The pharmacology of NCX inhibitors has been studied extensively since the development of KB-R7943, a prototype benzyloxyphenyl NCX inhibitor, in 1996.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">kb-r7943</infon>
          <location offset="647" length="8"/>
          <text>KB-R7943</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzyloxyphenyl</infon>
          <location offset="669" length="15"/>
          <text>benzyloxyphenyl</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ncx</infon>
          <location offset="578" length="3"/>
          <text>NCX</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ncx</infon>
          <location offset="685" length="3"/>
          <text>NCX</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>709</offset>
        <text>Currently, experiments are actively progressing with more selective inhibitors: SEA0400, SN-6, and YM-244769.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sea0400</infon>
          <location offset="789" length="7"/>
          <text>SEA0400</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sn-6</infon>
          <location offset="798" length="4"/>
          <text>SN-6</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ym-244769</infon>
          <location offset="808" length="9"/>
          <text>YM-244769</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>819</offset>
        <text>Intriguingly, the inhibitory potency of benzyloxyphenyl NCX inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzyloxyphenyl</infon>
          <location offset="859" length="15"/>
          <text>benzyloxyphenyl</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="925" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ncx</infon>
          <location offset="875" length="3"/>
          <text>NCX</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>958</offset>
        <text>Therefore, the benzyloxyphenyl inhibitors are apparently dormant during the forward mode under normal conditions (low Na(+)(i)), but become effective during the reverse mode under pathological conditions (high Na(+)(i)).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1076" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1168" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzyloxyphenyl</infon>
          <location offset="973" length="15"/>
          <text>benzyloxyphenyl</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1179</offset>
        <text>This should be an ideal profile for calcium regulators against Na(+)(i)-related diseases, such as ischemia/reperfusion injuries, salt-dependent hypertension, and digitalis arrhythmia.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="1215" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1242" length="5"/>
          <text>Na(+)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1363</offset>
        <text>Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amiodarone</infon>
          <location offset="1402" length="10"/>
          <text>amiodarone</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dronedarone</infon>
          <location offset="1414" length="11"/>
          <text>dronedarone</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bepridil</infon>
          <location offset="1427" length="8"/>
          <text>bepridil</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aprindine</infon>
          <location offset="1437" length="9"/>
          <text>aprindine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cibenzoline</infon>
          <location offset="1452" length="11"/>
          <text>cibenzoline</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ion channel</infon>
          <location offset="1372" length="11"/>
          <text>ion channel</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ncx</infon>
          <location offset="1492" length="3"/>
          <text>NCX</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1515</offset>
        <text>It is possible that this property is partly responsible for their antiarrhythmic and cardioprotective effects.</text>
      </sentence>
      <sentence>
        <offset>1626</offset>
        <text>This article presents the characteristics of selective and non-selective NCX inhibitors and their therapeutic potential as a new calcium regulator.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="1755" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ncx</infon>
          <location offset="1699" length="3"/>
          <text>NCX</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10907719</id>
    <passage>
      <offset>0</offset>
      <text>Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain.	UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB). Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors. 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was 3H-QNB. A similar discrepancy in sensitivity to competitors between 3H-NMPB and 3H-QNB was also observed when biperiden was used as a competitor, indicating that binding to different subtypes of the mAch receptor could not account for the observed differences in sensitivity to competition. An in vivo saturation study suggested that the apparent association rate constant (k on) of 3H-QNB binding might be changed by ligand concentration. The heterogeneity of the free ligand concentration in intact brain was assessed in relation to the ligand concentration dependency of the apparent association rate constant (k on) of 3H-QNB binding. This finding, together with the more favorable accumulation of 3H-NMPB in cerebral cortex, hippocampus, and striatum, leads us to conclude that 3H-NMPB, or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of mAch receptor occupancy by cholinergic drugs in the brain. KEYWORDS: mAch receptor, QNB, NMPB, in vivo, mouse.</text>
      <sentence>
        <offset>0</offset>
        <text>Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-nmpb</infon>
          <location offset="44" length="7"/>
          <text>3H-NMPB</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-qnb</infon>
          <location offset="56" length="6"/>
          <text>3H-QNB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>79</offset>
        <text>UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">scopolamine</infon>
          <location offset="206" length="11"/>
          <text>scopolamine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biperiden</infon>
          <location offset="238" length="9"/>
          <text>biperiden</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-n-methyl piperidyl benzilate</infon>
          <location offset="368" length="31"/>
          <text>3H-N-methyl piperidyl benzilate</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-nmpb</infon>
          <location offset="401" length="7"/>
          <text>3H-NMPB</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="111" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-quinuclidinyl benzilate</infon>
          <location offset="414" length="26"/>
          <text>3H-quinuclidinyl benzilate</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-qnb</infon>
          <location offset="442" length="6"/>
          <text>3H-QNB</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">m1</infon>
          <location offset="272" length="2"/>
          <text>M1</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">muscarinic acetylcholine (mach) receptor</infon>
          <location offset="100" length="40"/>
          <text>muscarinic acetylcholine (mAch) receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T6" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>451</offset>
        <text>Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-nmpb</infon>
          <location offset="583" length="7"/>
          <text>3H-NMPB</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mach receptors</infon>
          <location offset="477" length="14"/>
          <text>mAch receptors</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mach receptors</infon>
          <location offset="630" length="14"/>
          <text>mAch receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>646</offset>
        <text>3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was 3H-QNB.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-nmpb</infon>
          <location offset="646" length="7"/>
          <text>3H-NMPB</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">scopolamine</infon>
          <location offset="730" length="11"/>
          <text>scopolamine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-qnb</infon>
          <location offset="751" length="6"/>
          <text>3H-QNB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>759</offset>
        <text>A similar discrepancy in sensitivity to competitors between 3H-NMPB and 3H-QNB was also observed when biperiden was used as a competitor, indicating that binding to different subtypes of the mAch receptor could not account for the observed differences in sensitivity to competition.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-nmpb</infon>
          <location offset="819" length="7"/>
          <text>3H-NMPB</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-qnb</infon>
          <location offset="831" length="6"/>
          <text>3H-QNB</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">biperiden</infon>
          <location offset="861" length="9"/>
          <text>biperiden</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mach receptor</infon>
          <location offset="950" length="13"/>
          <text>mAch receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1042</offset>
        <text>An in vivo saturation study suggested that the apparent association rate constant (k on) of 3H-QNB binding might be changed by ligand concentration.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-qnb</infon>
          <location offset="1134" length="6"/>
          <text>3H-QNB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1191</offset>
        <text>The heterogeneity of the free ligand concentration in intact brain was assessed in relation to the ligand concentration dependency of the apparent association rate constant (k on) of 3H-QNB binding.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-qnb</infon>
          <location offset="1374" length="6"/>
          <text>3H-QNB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1390</offset>
        <text>This finding, together with the more favorable accumulation of 3H-NMPB in cerebral cortex, hippocampus, and striatum, leads us to conclude that 3H-NMPB, or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of mAch receptor occupancy by cholinergic drugs in the brain.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-nmpb</infon>
          <location offset="1453" length="7"/>
          <text>3H-NMPB</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3h-nmpb</infon>
          <location offset="1534" length="7"/>
          <text>3H-NMPB</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mach receptor</infon>
          <location offset="1644" length="13"/>
          <text>mAch receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1703</offset>
        <text>KEYWORDS: mAch receptor, QNB, NMPB, in vivo, mouse.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">qnb</infon>
          <location offset="1728" length="3"/>
          <text>QNB</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmpb</infon>
          <location offset="1733" length="4"/>
          <text>NMPB</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mach receptor</infon>
          <location offset="1713" length="13"/>
          <text>mAch receptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>7513381</id>
    <passage>
      <offset>0</offset>
      <text>Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain.	To compare in vivo effects of eleven compounds of different classes of histamine H1-receptor antagonists (alcoholamines: diphenhydramine, carbinoxamine, and clemastine; ethylenediamines: mepyramine, tripelennamine, and clemizole; alkylamines: triprolidine and chlorpheniramine; piperazines: meclizine and homochlorcyclizine; phenothiazines: promethazine) on neuronal uptake of dopamine (DA), noradrenaline (NA), and 5-hydroxytryptamine (5-HT), the effects on the turnover of these monoamines were examined in the mouse brain, based on the alpha-methyl-p-tyrosine-induced depletion of DA and NA or probenecid-induced accumulation of 5-hydroxyindoleacetic acid. The DA turnover was reduced remarkably by diphenhydramine, tripelennamine, and promethazine, and also significantly by chlorpheniramine, mepyramine, clemizole, and homochlorcyclizine, at doses used in the ordinary animal experiments. The 5-HT turnover was reduced markedly by mepyramine, tripelennamine, and chlorpheniramine. In contrast, the NA turnover was increased by promethazine and homochlorcyclizine, possibly due to their antagonistic effects on alpha-adrenoceptors. These results suggest that (1) the degree of inhibition of the uptake of DA and 5-HT by histamine H1-receptor antagonists is considerably different, (2) most H1-antagonists have little influence on NA uptake and some compounds enhance NA release, and that (3) carbinoxamine, clemastine, triprolidine, and meclizine have comparatively weak influences on monoamine metabolism. These effects on brain monoamine systems may be related to some central actions of histamine H1-receptor antagonists, such as an addiction to these compounds combined with opioids.</text>
      <sentence>
        <offset>0</offset>
        <text>Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain.</text>
        <annotation id="T51">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="36" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoamine</infon>
          <location offset="73" length="9"/>
          <text>monoamine</text>
        </annotation>
        <annotation id="T58">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h1-receptor</infon>
          <location offset="36" length="21"/>
          <text>histamine H1-receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>112</offset>
        <text>To compare in vivo effects of eleven compounds of different classes of histamine H1-receptor antagonists (alcoholamines: diphenhydramine, carbinoxamine, and clemastine; ethylenediamines: mepyramine, tripelennamine, and clemizole; alkylamines: triprolidine and chlorpheniramine; piperazines: meclizine and homochlorcyclizine; phenothiazines: promethazine) on neuronal uptake of dopamine (DA), noradrenaline (NA), and 5-hydroxytryptamine (5-HT), the effects on the turnover of these monoamines were examined in the mouse brain, based on the alpha-methyl-p-tyrosine-induced depletion of DA and NA or probenecid-induced accumulation of 5-hydroxyindoleacetic acid.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alcoholamines</infon>
          <location offset="218" length="13"/>
          <text>alcoholamines</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diphenhydramine</infon>
          <location offset="233" length="15"/>
          <text>diphenhydramine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbinoxamine</infon>
          <location offset="250" length="13"/>
          <text>carbinoxamine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clemastine</infon>
          <location offset="269" length="10"/>
          <text>clemastine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethylenediamines</infon>
          <location offset="281" length="16"/>
          <text>ethylenediamines</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mepyramine</infon>
          <location offset="299" length="10"/>
          <text>mepyramine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tripelennamine</infon>
          <location offset="311" length="14"/>
          <text>tripelennamine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clemizole</infon>
          <location offset="331" length="9"/>
          <text>clemizole</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alkylamines</infon>
          <location offset="342" length="11"/>
          <text>alkylamines</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triprolidine</infon>
          <location offset="355" length="12"/>
          <text>triprolidine</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpheniramine</infon>
          <location offset="372" length="16"/>
          <text>chlorpheniramine</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">piperazines</infon>
          <location offset="390" length="11"/>
          <text>piperazines</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meclizine</infon>
          <location offset="403" length="9"/>
          <text>meclizine</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homochlorcyclizine</infon>
          <location offset="417" length="18"/>
          <text>homochlorcyclizine</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenothiazines</infon>
          <location offset="437" length="14"/>
          <text>phenothiazines</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">promethazine</infon>
          <location offset="453" length="12"/>
          <text>promethazine</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="489" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">da</infon>
          <location offset="499" length="2"/>
          <text>DA</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">noradrenaline</infon>
          <location offset="504" length="13"/>
          <text>noradrenaline</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="519" length="2"/>
          <text>NA</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-hydroxytryptamine</infon>
          <location offset="528" length="19"/>
          <text>5-hydroxytryptamine</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="549" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoamines</infon>
          <location offset="593" length="10"/>
          <text>monoamines</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="183" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T57">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h1-receptor</infon>
          <location offset="183" length="21"/>
          <text>histamine H1-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T28" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T29" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T11" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T18" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T23" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T30" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T20" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T27" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T22" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T25" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T31" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T21" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T24" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T6" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T26" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>772</offset>
        <text>The DA turnover was reduced remarkably by diphenhydramine, tripelennamine, and promethazine, and also significantly by chlorpheniramine, mepyramine, clemizole, and homochlorcyclizine, at doses used in the ordinary animal experiments.</text>
        <annotation id="T39">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diphenhydramine</infon>
          <location offset="814" length="15"/>
          <text>diphenhydramine</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tripelennamine</infon>
          <location offset="831" length="14"/>
          <text>tripelennamine</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">promethazine</infon>
          <location offset="851" length="12"/>
          <text>promethazine</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpheniramine</infon>
          <location offset="891" length="16"/>
          <text>chlorpheniramine</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mepyramine</infon>
          <location offset="909" length="10"/>
          <text>mepyramine</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clemizole</infon>
          <location offset="921" length="9"/>
          <text>clemizole</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homochlorcyclizine</infon>
          <location offset="936" length="18"/>
          <text>homochlorcyclizine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1006</offset>
        <text>The 5-HT turnover was reduced markedly by mepyramine, tripelennamine, and chlorpheniramine.</text>
        <annotation id="T47">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="1010" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mepyramine</infon>
          <location offset="1048" length="10"/>
          <text>mepyramine</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tripelennamine</infon>
          <location offset="1060" length="14"/>
          <text>tripelennamine</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpheniramine</infon>
          <location offset="1080" length="16"/>
          <text>chlorpheniramine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1098</offset>
        <text>In contrast, the NA turnover was increased by promethazine and homochlorcyclizine, possibly due to their antagonistic effects on alpha-adrenoceptors.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="1115" length="2"/>
          <text>NA</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">promethazine</infon>
          <location offset="1144" length="12"/>
          <text>promethazine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homochlorcyclizine</infon>
          <location offset="1161" length="18"/>
          <text>homochlorcyclizine</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha-adrenoceptors</infon>
          <location offset="1227" length="19"/>
          <text>alpha-adrenoceptors</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T3" role="head"/>
          <node refid="T53" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T53" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1248</offset>
        <text>These results suggest that (1) the degree of inhibition of the uptake of DA and 5-HT by histamine H1-receptor antagonists is considerably different, (2) most H1-antagonists have little influence on NA uptake and some compounds enhance NA release, and that (3) carbinoxamine, clemastine, triprolidine, and meclizine have comparatively weak influences on monoamine metabolism.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">da</infon>
          <location offset="1321" length="2"/>
          <text>DA</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="1328" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="1336" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="1446" length="2"/>
          <text>NA</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na</infon>
          <location offset="1483" length="2"/>
          <text>NA</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbinoxamine</infon>
          <location offset="1508" length="13"/>
          <text>carbinoxamine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clemastine</infon>
          <location offset="1523" length="10"/>
          <text>clemastine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triprolidine</infon>
          <location offset="1535" length="12"/>
          <text>triprolidine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meclizine</infon>
          <location offset="1553" length="9"/>
          <text>meclizine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoamine</infon>
          <location offset="1601" length="9"/>
          <text>monoamine</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h1-receptor</infon>
          <location offset="1336" length="21"/>
          <text>histamine H1-receptor</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h1</infon>
          <location offset="1406" length="2"/>
          <text>H1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1623</offset>
        <text>These effects on brain monoamine systems may be related to some central actions of histamine H1-receptor antagonists, such as an addiction to these compounds combined with opioids.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoamine</infon>
          <location offset="1646" length="9"/>
          <text>monoamine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="1706" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T56">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h1-receptor</infon>
          <location offset="1706" length="21"/>
          <text>histamine H1-receptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23194529</id>
    <passage>
      <offset>0</offset>
      <text>The presence of D-fagomine in the human diet from buckwheat-based foodstuffs.	Buckwheat (Fagopyrum esculentum Moench) groats contain the iminosugar D-fagomine as a minor component that might contribute to the alleged health benefits of this pseudo-cereal. This study presents analysis of D-fagomine in buckwheat-based foodstuffs by liquid chromatography coupled to mass spectrometry and an estimation of its presence in the human diet based on a published population-based cross-sectional nutrition survey. D-fagomine is present in common buckwheat-based foodstuffs in amounts ranging from 1 to 25 mg/kg or mg/L, it is stable during boiling, baking, frying and fermentation, and it is biosynthesised upon sprouting. The estimated total intake of D-fagomine resulting from a diet that includes such foodstuffs would be between 3 and 17 mg per day (mean for both genders; range from P5 to P95). A diet rich in buckwheat products would provide a daily amount of D-fagomine that may in part explain the beneficial properties traditionally attributed to buckwheat consumption.</text>
      <sentence>
        <offset>0</offset>
        <text>The presence of D-fagomine in the human diet from buckwheat-based foodstuffs.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-fagomine</infon>
          <location offset="16" length="10"/>
          <text>D-fagomine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>78</offset>
        <text>Buckwheat (Fagopyrum esculentum Moench) groats contain the iminosugar D-fagomine as a minor component that might contribute to the alleged health benefits of this pseudo-cereal.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-fagomine</infon>
          <location offset="148" length="10"/>
          <text>D-fagomine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>256</offset>
        <text>This study presents analysis of D-fagomine in buckwheat-based foodstuffs by liquid chromatography coupled to mass spectrometry and an estimation of its presence in the human diet based on a published population-based cross-sectional nutrition survey.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-fagomine</infon>
          <location offset="288" length="10"/>
          <text>D-fagomine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>507</offset>
        <text>D-fagomine is present in common buckwheat-based foodstuffs in amounts ranging from 1 to 25 mg/kg or mg/L, it is stable during boiling, baking, frying and fermentation, and it is biosynthesised upon sprouting.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-fagomine</infon>
          <location offset="507" length="10"/>
          <text>D-fagomine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>716</offset>
        <text>The estimated total intake of D-fagomine resulting from a diet that includes such foodstuffs would be between 3 and 17 mg per day (mean for both genders; range from P5 to P95).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-fagomine</infon>
          <location offset="746" length="10"/>
          <text>D-fagomine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>893</offset>
        <text>A diet rich in buckwheat products would provide a daily amount of D-fagomine that may in part explain the beneficial properties traditionally attributed to buckwheat consumption.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-fagomine</infon>
          <location offset="959" length="10"/>
          <text>D-fagomine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17409318</id>
    <passage>
      <offset>0</offset>
      <text>Competition between 24:5n-3 and ALA for Delta 6 desaturase may limit the accumulation of DHA in HepG2 cell membranes.	The use of Delta 6 desaturase (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids. The accumulation of ALA, eicosapentaenoic acid (20:5n-3), docosapentaenoic acid (22:5n-3), and 24:5n-3 in cell phospholipids was linearly related to the concentration of supplemented ALA over the range tested (1.8-72 microM). The accumulation of the post-D6D products of 22:5n-3, 24:6n-3 and DHA, in cell phospholipids was saturated at concentrations of &gt;18 microM ALA. Supplementation of HepG2 cells with preformed DHA revealed that, although the accumulation of DHA in cell phospholipids approached saturation, the level of DHA in cell phospholipids was significantly greater compared with the accumulation of DHA from ALA, indicating that the accumulation of DHA from ALA was not limited by incorporation. The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for D6D may contribute to the limited accumulation of DHA in cell membranes.</text>
      <sentence>
        <offset>0</offset>
        <text>Competition between 24:5n-3 and ALA for Delta 6 desaturase may limit the accumulation of DHA in HepG2 cell membranes.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">delta 6 desaturase</infon>
          <location offset="40" length="18"/>
          <text>Delta 6 desaturase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>118</offset>
        <text>The use of Delta 6 desaturase (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">docosahexaenoic acid</infon>
          <location offset="220" length="20"/>
          <text>docosahexaenoic acid</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dha</infon>
          <location offset="242" length="3"/>
          <text>DHA</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dha</infon>
          <location offset="350" length="3"/>
          <text>DHA</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="359" length="3"/>
          <text>ALA</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alpha-linolenic acid</infon>
          <location offset="181" length="20"/>
          <text>alpha-linolenic acid</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="203" length="3"/>
          <text>ALA</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">delta 6 desaturase</infon>
          <location offset="129" length="18"/>
          <text>Delta 6 desaturase</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d6d</infon>
          <location offset="149" length="3"/>
          <text>D6D</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T11" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T12" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T12" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T23" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T19" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T23" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T19" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>364</offset>
        <text>We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="408" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="491" length="3"/>
          <text>ALA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>524</offset>
        <text>The accumulation of ALA, eicosapentaenoic acid (20:5n-3), docosapentaenoic acid (22:5n-3), and 24:5n-3 in cell phospholipids was linearly related to the concentration of supplemented ALA over the range tested (1.8-72 microM).</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="544" length="3"/>
          <text>ALA</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eicosapentaenoic acid</infon>
          <location offset="549" length="21"/>
          <text>eicosapentaenoic acid</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">docosapentaenoic acid</infon>
          <location offset="582" length="21"/>
          <text>docosapentaenoic acid</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="707" length="3"/>
          <text>ALA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>750</offset>
        <text>The accumulation of the post-D6D products of 22:5n-3, 24:6n-3 and DHA, in cell phospholipids was saturated at concentrations of &gt;18 microM ALA.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dha</infon>
          <location offset="816" length="3"/>
          <text>DHA</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="889" length="3"/>
          <text>ALA</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d6d</infon>
          <location offset="779" length="3"/>
          <text>D6D</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T20" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>894</offset>
        <text>Supplementation of HepG2 cells with preformed DHA revealed that, although the accumulation of DHA in cell phospholipids approached saturation, the level of DHA in cell phospholipids was significantly greater compared with the accumulation of DHA from ALA, indicating that the accumulation of DHA from ALA was not limited by incorporation.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dha</infon>
          <location offset="1136" length="3"/>
          <text>DHA</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="1145" length="3"/>
          <text>ALA</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dha</infon>
          <location offset="1186" length="3"/>
          <text>DHA</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="1195" length="3"/>
          <text>ALA</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dha</infon>
          <location offset="940" length="3"/>
          <text>DHA</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dha</infon>
          <location offset="988" length="3"/>
          <text>DHA</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dha</infon>
          <location offset="1050" length="3"/>
          <text>DHA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1233</offset>
        <text>The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for D6D may contribute to the limited accumulation of DHA in cell membranes.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dha</infon>
          <location offset="1285" length="3"/>
          <text>DHA</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="1333" length="3"/>
          <text>ALA</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ala</infon>
          <location offset="1387" length="3"/>
          <text>ALA</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dha</infon>
          <location offset="1445" length="3"/>
          <text>DHA</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d6d</infon>
          <location offset="1395" length="3"/>
          <text>D6D</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T9" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16874462</id>
    <passage>
      <offset>0</offset>
      <text>Overexpression of proline oxidase induces proline-dependent and mitochondria-mediated apoptosis.	Proline oxidase (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C). Previously we showed that overexpression of POX is associated with generation of reactive oxygen species (ROS) and apoptosis in POX-inducible colorectal cancer cells, DLD-1.POX. We also showed expression of mitochondrial MnSOD partially blunts POX-induced ROS generation and apoptosis. To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing POX exhibit an L-proline-dependent apoptotic response. The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of L-proline to cells with maximally induced POX. The apoptotic response is mitochondria-mediated with release of cytochrome c, activation of caspase-9, chromatin condensation/DNA fragmentation, and cell shrinkage. We conclude that in the presence of proline, high POX activity is sufficient to induce mitochondria-mediated apoptosis.</text>
      <sentence>
        <offset>0</offset>
        <text>Overexpression of proline oxidase induces proline-dependent and mitochondria-mediated apoptosis.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">proline</infon>
          <location offset="18" length="7"/>
          <text>proline</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">proline</infon>
          <location offset="42" length="7"/>
          <text>proline</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">proline oxidase</infon>
          <location offset="18" length="15"/>
          <text>proline oxidase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T11" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>97</offset>
        <text>Proline oxidase (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">proline</infon>
          <location offset="97" length="7"/>
          <text>Proline</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">proline</infon>
          <location offset="201" length="7"/>
          <text>proline</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrroline- 5-carboxylate</infon>
          <location offset="212" length="24"/>
          <text>pyrroline- 5-carboxylate</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p5c</infon>
          <location offset="238" length="3"/>
          <text>P5C</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">proline oxidase</infon>
          <location offset="97" length="15"/>
          <text>Proline oxidase</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="114" length="3"/>
          <text>POX</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>244</offset>
        <text>Previously we showed that overexpression of POX is associated with generation of reactive oxygen species (ROS) and apoptosis in POX-inducible colorectal cancer cells, DLD-1.POX.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="334" length="6"/>
          <text>oxygen</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="288" length="3"/>
          <text>POX</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="372" length="3"/>
          <text>POX</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="417" length="3"/>
          <text>POX</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>422</offset>
        <text>We also showed expression of mitochondrial MnSOD partially blunts POX-induced ROS generation and apoptosis.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mnsod</infon>
          <location offset="465" length="5"/>
          <text>MnSOD</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="488" length="3"/>
          <text>POX</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>530</offset>
        <text>To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing POX exhibit an L-proline-dependent apoptotic response.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-proline</infon>
          <location offset="679" length="9"/>
          <text>L-proline</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="576" length="3"/>
          <text>POX</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="621" length="3"/>
          <text>POX</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="664" length="3"/>
          <text>POX</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>719</offset>
        <text>The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of L-proline to cells with maximally induced POX.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-proline</infon>
          <location offset="756" length="9"/>
          <text>L-proline</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-proline</infon>
          <location offset="858" length="9"/>
          <text>L-proline</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="900" length="3"/>
          <text>POX</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T9" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>905</offset>
        <text>The apoptotic response is mitochondria-mediated with release of cytochrome c, activation of caspase-9, chromatin condensation/DNA fragmentation, and cell shrinkage.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome c</infon>
          <location offset="969" length="12"/>
          <text>cytochrome c</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-9</infon>
          <location offset="997" length="9"/>
          <text>caspase-9</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1070</offset>
        <text>We conclude that in the presence of proline, high POX activity is sufficient to induce mitochondria-mediated apoptosis.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">proline</infon>
          <location offset="1106" length="7"/>
          <text>proline</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pox</infon>
          <location offset="1120" length="3"/>
          <text>POX</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>2889803</id>
    <passage>
      <offset>0</offset>
      <text>Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam.	Triazolobenzodiazepines are in clinical use as hypnotics and anxiolytics. We analyzed in vivo receptor binding and brain concentrations of alprazolam, triazolam, and estazolam. Drug concentrations measured in the cerebral cortex 1 h after administration were directly proportional to dose for all three compounds. In vivo receptor binding, as defined by the specific uptake of [3H]Ro15-1788, decreased with increasing doses of estazolam and triazolam, a finding indicating dose-related increases in receptor occupancy due to these compounds. Triazolam was substantially more potent, with an IC50 value of 16 ng/g, compared with 117 ng/g for estazolam. At higher doses of alprazolam (greater than 0.2 mg/kg), receptor binding by [3H]Ro15-1788, likewise decreased with increasing dose of the former drug. However, at lower doses of alprazolam (0.02-0.05 mg/kg), which resulted in cortex concentrations of 2-7 ng/g, receptor binding was increased above control values in cortex, hypothalamus, and hippocampus but not in several other brain regions. Binding returned to control values at doses of greater than or equal to 0.01 mg/kg. Similar results were obtained in time course studies. At 8 and 10 h after a dose of 1 mg/kg i.p., corresponding to cortex concentrations of 2.7-7 ng/g, receptor binding was increased compared with controls. Similarly, at 1, 2, and 3 h after a single dose of 0.05 mg/kg, corresponding to cortex concentrations of 3.7-5.8 ng/g, receptor binding was also increased. The apparent affinity of benzodiazepine receptors for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)</text>
      <sentence>
        <offset>0</offset>
        <text>Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzodiazepine</infon>
          <location offset="0" length="14"/>
          <text>Benzodiazepine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alprazolam</infon>
          <location offset="108" length="10"/>
          <text>alprazolam</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triazolobenzodiazepines</infon>
          <location offset="35" length="23"/>
          <text>triazolobenzodiazepines</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">benzodiazepine receptor</infon>
          <location offset="0" length="23"/>
          <text>Benzodiazepine receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>120</offset>
        <text>Triazolobenzodiazepines are in clinical use as hypnotics and anxiolytics.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triazolobenzodiazepines</infon>
          <location offset="120" length="23"/>
          <text>Triazolobenzodiazepines</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>194</offset>
        <text>We analyzed in vivo receptor binding and brain concentrations of alprazolam, triazolam, and estazolam.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alprazolam</infon>
          <location offset="259" length="10"/>
          <text>alprazolam</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triazolam</infon>
          <location offset="271" length="9"/>
          <text>triazolam</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estazolam</infon>
          <location offset="286" length="9"/>
          <text>estazolam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>297</offset>
        <text>Drug concentrations measured in the cerebral cortex 1 h after administration were directly proportional to dose for all three compounds.</text>
      </sentence>
      <sentence>
        <offset>434</offset>
        <text>In vivo receptor binding, as defined by the specific uptake of [3H]Ro15-1788, decreased with increasing doses of estazolam and triazolam, a finding indicating dose-related increases in receptor occupancy due to these compounds.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]ro15-1788</infon>
          <location offset="497" length="13"/>
          <text>[3H]Ro15-1788</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estazolam</infon>
          <location offset="547" length="9"/>
          <text>estazolam</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triazolam</infon>
          <location offset="561" length="9"/>
          <text>triazolam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>662</offset>
        <text>Triazolam was substantially more potent, with an IC50 value of 16 ng/g, compared with 117 ng/g for estazolam.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triazolam</infon>
          <location offset="662" length="9"/>
          <text>Triazolam</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estazolam</infon>
          <location offset="761" length="9"/>
          <text>estazolam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>772</offset>
        <text>At higher doses of alprazolam (greater than 0.2 mg/kg), receptor binding by [3H]Ro15-1788, likewise decreased with increasing dose of the former drug.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alprazolam</infon>
          <location offset="791" length="10"/>
          <text>alprazolam</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]ro15-1788</infon>
          <location offset="848" length="13"/>
          <text>[3H]Ro15-1788</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>923</offset>
        <text>However, at lower doses of alprazolam (0.02-0.05 mg/kg), which resulted in cortex concentrations of 2-7 ng/g, receptor binding was increased above control values in cortex, hypothalamus, and hippocampus but not in several other brain regions.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alprazolam</infon>
          <location offset="950" length="10"/>
          <text>alprazolam</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1166</offset>
        <text>Binding returned to control values at doses of greater than or equal to 0.01 mg/kg.</text>
      </sentence>
      <sentence>
        <offset>1250</offset>
        <text>Similar results were obtained in time course studies.</text>
      </sentence>
      <sentence>
        <offset>1304</offset>
        <text>At 8 and 10 h after a dose of 1 mg/kg i.p., corresponding to cortex concentrations of 2.7-7 ng/g, receptor binding was increased compared with controls.</text>
      </sentence>
      <sentence>
        <offset>1457</offset>
        <text>Similarly, at 1, 2, and 3 h after a single dose of 0.05 mg/kg, corresponding to cortex concentrations of 3.7-5.8 ng/g, receptor binding was also increased.</text>
      </sentence>
      <sentence>
        <offset>1613</offset>
        <text>The apparent affinity of benzodiazepine receptors for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzodiazepine</infon>
          <location offset="1638" length="14"/>
          <text>benzodiazepine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clonazepam</infon>
          <location offset="1667" length="10"/>
          <text>clonazepam</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alprazolam</infon>
          <location offset="1696" length="10"/>
          <text>alprazolam</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alprazolam</infon>
          <location offset="1815" length="10"/>
          <text>alprazolam</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">benzodiazepine receptors</infon>
          <location offset="1638" length="24"/>
          <text>benzodiazepine receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23605050</id>
    <passage>
      <offset>0</offset>
      <text>Effects of High Iron and Glucose Concentrations over the Relative Expression of Bcl2, Bax, and Mfn2 in MIN6 Cells.	Type 2 diabetes is characterized by hyperglycemia and oxidative stress. Hyperglycemia is linked to mitochondrial dysfunction and reduced β-cell mass due to the reduced expression of genes such as Mfn2 as well as the participation of the Bcl2 gene family, responsible for increased apoptosis. The purpose of this study was to describe the effect of different iron and/or glucose concentrations over Mfn2, Bax, and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells). MIN6 cells were pre-incubated with different iron and/or glucose concentrations, and the relative mRNA abundance of the Bcl2/Bax ratio and of Mfn2 genes was measured by qRT-PCR. Heme oxygenase (HO) activity, iron uptake, superoxide dismutase activity, and glutathione content were also determined. The Bcl2/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after glucose stimulation. These effects were higher when glucose and iron were incubated together. Additionally, treatment with glucose/iron showed a higher HO activity. Our study revealed that high glucose/Fe concentrations in MIN6 cells induced an increase of the Bcl2/Bax ratio, an indicator of increased cell apoptosis.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of High Iron and Glucose Concentrations over the Relative Expression of Bcl2, Bax, and Mfn2 in MIN6 Cells.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="16" length="4"/>
          <text>Iron</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="25" length="7"/>
          <text>Glucose</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2</infon>
          <location offset="80" length="4"/>
          <text>Bcl2</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="86" length="3"/>
          <text>Bax</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mfn2</infon>
          <location offset="95" length="4"/>
          <text>Mfn2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>115</offset>
        <text>Type 2 diabetes is characterized by hyperglycemia and oxidative stress.</text>
      </sentence>
      <sentence>
        <offset>187</offset>
        <text>Hyperglycemia is linked to mitochondrial dysfunction and reduced β-cell mass due to the reduced expression of genes such as Mfn2 as well as the participation of the Bcl2 gene family, responsible for increased apoptosis.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mfn2</infon>
          <location offset="311" length="4"/>
          <text>Mfn2</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2</infon>
          <location offset="352" length="4"/>
          <text>Bcl2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>407</offset>
        <text>The purpose of this study was to describe the effect of different iron and/or glucose concentrations over Mfn2, Bax, and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="473" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="485" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mfn2</infon>
          <location offset="513" length="4"/>
          <text>Mfn2</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="519" length="3"/>
          <text>Bax</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2</infon>
          <location offset="528" length="4"/>
          <text>Bcl2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>587</offset>
        <text>MIN6 cells were pre-incubated with different iron and/or glucose concentrations, and the relative mRNA abundance of the Bcl2/Bax ratio and of Mfn2 genes was measured by qRT-PCR.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="632" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="644" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2</infon>
          <location offset="707" length="4"/>
          <text>Bcl2</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="712" length="3"/>
          <text>Bax</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mfn2</infon>
          <location offset="729" length="4"/>
          <text>Mfn2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>765</offset>
        <text>Heme oxygenase (HO) activity, iron uptake, superoxide dismutase activity, and glutathione content were also determined.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="795" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="808" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="843" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">heme oxygenase</infon>
          <location offset="765" length="14"/>
          <text>Heme oxygenase</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ho</infon>
          <location offset="781" length="2"/>
          <text>HO</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">superoxide dismutase</infon>
          <location offset="808" length="20"/>
          <text>superoxide dismutase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>885</offset>
        <text>The Bcl2/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after glucose stimulation.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="964" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2</infon>
          <location offset="889" length="4"/>
          <text>Bcl2</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="894" length="3"/>
          <text>Bax</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mfn2</infon>
          <location offset="918" length="4"/>
          <text>Mfn2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>985</offset>
        <text>These effects were higher when glucose and iron were incubated together.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1016" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="1028" length="4"/>
          <text>iron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1058</offset>
        <text>Additionally, treatment with glucose/iron showed a higher HO activity.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1087" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="1095" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ho</infon>
          <location offset="1116" length="2"/>
          <text>HO</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1129</offset>
        <text>Our study revealed that high glucose/Fe concentrations in MIN6 cells induced an increase of the Bcl2/Bax ratio, an indicator of increased cell apoptosis.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1158" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fe</infon>
          <location offset="1166" length="2"/>
          <text>Fe</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2</infon>
          <location offset="1225" length="4"/>
          <text>Bcl2</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="1230" length="3"/>
          <text>Bax</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23427190</id>
    <passage>
      <offset>0</offset>
      <text>The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral- electroencephalography study.	Phosphodiesterase type 5 inhibitors (PDE5-Is) improve cognitive performance of rodents, but the few human studies investigating their effects did not systematically investigate cognitive effects and the results have been quite contradictory. Therefore, we examined whether the PDE5-I vardenafil improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults. Participants were selected out of a group of volunteers, based on their performance on a memory screening and they were orally treated with vardenafil (10-20 mg or placebo). Memory and executive functioning were tested while EEG activity was recorded. Additionally, a simple reaction time task and questionnaires addressing various complaints were presented. No prominent effects of vardenafil on cognition were found: participants only made more mistakes on a reaction time task after 20 mg vardenafil. During encoding of words, the P300 was generally smaller after vardenafil treatment. Furthermore, the N400 was larger after vardenafil 10 mg than placebo treatment in a spatial memory task at Fz. Finally, headache and feeling weak were reported more after vardenafil treatment. Vardenafil did not affect cognitive performance of healthy adults and showed only some incidental effects on ERPs. These findings in humans do not corroborate the cognition-enhancing effects of PDE5-Is in healthy animals.</text>
      <sentence>
        <offset>0</offset>
        <text>The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral- electroencephalography study.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vardenafil</infon>
          <location offset="54" length="10"/>
          <text>vardenafil</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phosphodiesterase type 5</infon>
          <location offset="19" length="24"/>
          <text>phosphodiesterase type 5</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>153</offset>
        <text>Phosphodiesterase type 5 inhibitors (PDE5-Is) improve cognitive performance of rodents, but the few human studies investigating their effects did not systematically investigate cognitive effects and the results have been quite contradictory.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phosphodiesterase type 5</infon>
          <location offset="153" length="24"/>
          <text>Phosphodiesterase type 5</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde5</infon>
          <location offset="190" length="4"/>
          <text>PDE5</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>395</offset>
        <text>Therefore, we examined whether the PDE5-I vardenafil improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vardenafil</infon>
          <location offset="437" length="10"/>
          <text>vardenafil</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde5</infon>
          <location offset="430" length="4"/>
          <text>PDE5</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>555</offset>
        <text>Participants were selected out of a group of volunteers, based on their performance on a memory screening and they were orally treated with vardenafil (10-20 mg or placebo).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vardenafil</infon>
          <location offset="695" length="10"/>
          <text>vardenafil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>729</offset>
        <text>Memory and executive functioning were tested while EEG activity was recorded.</text>
      </sentence>
      <sentence>
        <offset>807</offset>
        <text>Additionally, a simple reaction time task and questionnaires addressing various complaints were presented.</text>
      </sentence>
      <sentence>
        <offset>914</offset>
        <text>No prominent effects of vardenafil on cognition were found: participants only made more mistakes on a reaction time task after 20 mg vardenafil.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vardenafil</infon>
          <location offset="938" length="10"/>
          <text>vardenafil</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vardenafil</infon>
          <location offset="1047" length="10"/>
          <text>vardenafil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1059</offset>
        <text>During encoding of words, the P300 was generally smaller after vardenafil treatment.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vardenafil</infon>
          <location offset="1122" length="10"/>
          <text>vardenafil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1144</offset>
        <text>Furthermore, the N400 was larger after vardenafil 10 mg than placebo treatment in a spatial memory task at Fz.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vardenafil</infon>
          <location offset="1183" length="10"/>
          <text>vardenafil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1255</offset>
        <text>Finally, headache and feeling weak were reported more after vardenafil treatment.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vardenafil</infon>
          <location offset="1315" length="10"/>
          <text>vardenafil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1337</offset>
        <text>Vardenafil did not affect cognitive performance of healthy adults and showed only some incidental effects on ERPs.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vardenafil</infon>
          <location offset="1337" length="10"/>
          <text>Vardenafil</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1452</offset>
        <text>These findings in humans do not corroborate the cognition-enhancing effects of PDE5-Is in healthy animals.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pde5</infon>
          <location offset="1531" length="4"/>
          <text>PDE5</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16477002</id>
    <passage>
      <offset>0</offset>
      <text>Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor.	IL-2 is a cytokine that functions as a growth factor and central regulator in the immune system and mediates its effects through ligand-induced hetero-trimerization of the receptor subunits IL-2R alpha, IL-2R beta, and gamma(c). Here, we describe the crystal structure of the trimeric assembly of the human IL-2 receptor ectodomains in complex with IL-2 at 3.0 A resolution. The quaternary structure is consistent with a stepwise assembly from IL-2/IL-2R alpha to IL-2/IL-2R alpha/IL-2R beta to IL-2/IL-2R alpha/IL-2R beta/gamma(c). The IL-2R alpha subunit forms the largest of the three IL-2/IL-2R interfaces, which, together with the high abundance of charge-charge interactions, correlates well with the rapid association rate and high-affinity interaction of IL-2R alpha with IL-2 at the cell surface. Surprisingly, IL-2R alpha makes no contacts with IL-2R beta or gamma(c), and only minor changes are observed in the IL-2 structure in response to receptor binding. These findings support the principal role of IL-2R alpha to deliver IL-2 to the signaling complex and act as regulator of signal transduction. Cooperativity in assembly of the final quaternary complex is easily explained by the extraordinarily extensive set of interfaces found within the fully assembled IL-2 signaling complex, which nearly span the entire length of the IL-2R beta and gamma(c) subunits. Helix A of IL-2 wedges tightly between IL-2R beta and gamma(c) to form a three-way junction that coalesces into a composite binding site for the final gamma(c) recruitment. The IL-2/gamma(c) interface itself exhibits the smallest buried surface and the fewest hydrogen bonds in the complex, which is consistent with its promiscuous use in other cytokine receptor complexes.</text>
      <sentence>
        <offset>0</offset>
        <text>Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor.</text>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="25" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine receptor</infon>
          <location offset="79" length="17"/>
          <text>cytokine receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>98</offset>
        <text>IL-2 is a cytokine that functions as a growth factor and central regulator in the immune system and mediates its effects through ligand-induced hetero-trimerization of the receptor subunits IL-2R alpha, IL-2R beta, and gamma(c).</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="98" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine</infon>
          <location offset="108" length="8"/>
          <text>cytokine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2r alpha</infon>
          <location offset="288" length="11"/>
          <text>IL-2R alpha</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">il-2r beta, and gamma(c)</infon>
          <location offset="301" length="24"/>
          <text>IL-2R beta, and gamma(c)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>327</offset>
        <text>Here, we describe the crystal structure of the trimeric assembly of the human IL-2 receptor ectodomains in complex with IL-2 at 3.0 A resolution.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human il-2 receptor</infon>
          <location offset="399" length="19"/>
          <text>human IL-2 receptor</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="447" length="4"/>
          <text>IL-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>473</offset>
        <text>The quaternary structure is consistent with a stepwise assembly from IL-2/IL-2R alpha to IL-2/IL-2R alpha/IL-2R beta to IL-2/IL-2R alpha/IL-2R beta/gamma(c).</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="542" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2r alpha</infon>
          <location offset="547" length="11"/>
          <text>IL-2R alpha</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="562" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2r alpha</infon>
          <location offset="567" length="11"/>
          <text>IL-2R alpha</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2r beta</infon>
          <location offset="579" length="10"/>
          <text>IL-2R beta</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="593" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2r alpha</infon>
          <location offset="598" length="11"/>
          <text>IL-2R alpha</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">il-2r beta/gamma(c)</infon>
          <location offset="610" length="19"/>
          <text>IL-2R beta/gamma(c)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>631</offset>
        <text>The IL-2R alpha subunit forms the largest of the three IL-2/IL-2R interfaces, which, together with the high abundance of charge-charge interactions, correlates well with the rapid association rate and high-affinity interaction of IL-2R alpha with IL-2 at the cell surface.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2r alpha</infon>
          <location offset="635" length="11"/>
          <text>IL-2R alpha</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="686" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">il-2r</infon>
          <location offset="691" length="5"/>
          <text>IL-2R</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2r alpha</infon>
          <location offset="861" length="11"/>
          <text>IL-2R alpha</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="878" length="4"/>
          <text>IL-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>904</offset>
        <text>Surprisingly, IL-2R alpha makes no contacts with IL-2R beta or gamma(c), and only minor changes are observed in the IL-2 structure in response to receptor binding.</text>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2r alpha</infon>
          <location offset="918" length="11"/>
          <text>IL-2R alpha</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">il-2r beta or gamma(c)</infon>
          <location offset="953" length="22"/>
          <text>IL-2R beta or gamma(c)</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="1020" length="4"/>
          <text>IL-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1068</offset>
        <text>These findings support the principal role of IL-2R alpha to deliver IL-2 to the signaling complex and act as regulator of signal transduction.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2r alpha</infon>
          <location offset="1113" length="11"/>
          <text>IL-2R alpha</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="1136" length="4"/>
          <text>IL-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1211</offset>
        <text>Cooperativity in assembly of the final quaternary complex is easily explained by the extraordinarily extensive set of interfaces found within the fully assembled IL-2 signaling complex, which nearly span the entire length of the IL-2R beta and gamma(c) subunits.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="1373" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">il-2r beta and gamma(c)</infon>
          <location offset="1440" length="23"/>
          <text>IL-2R beta and gamma(c)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1474</offset>
        <text>Helix A of IL-2 wedges tightly between IL-2R beta and gamma(c) to form a three-way junction that coalesces into a composite binding site for the final gamma(c) recruitment.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="1485" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">il-2r beta and gamma(c)</infon>
          <location offset="1513" length="23"/>
          <text>IL-2R beta and gamma(c)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1647</offset>
        <text>The IL-2/gamma(c) interface itself exhibits the smallest buried surface and the fewest hydrogen bonds in the complex, which is consistent with its promiscuous use in other cytokine receptor complexes.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrogen</infon>
          <location offset="1734" length="8"/>
          <text>hydrogen</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-2</infon>
          <location offset="1651" length="4"/>
          <text>IL-2</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine receptor</infon>
          <location offset="1819" length="17"/>
          <text>cytokine receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1346768</id>
    <passage>
      <offset>0</offset>
      <text>Subtypes of alpha 1- and alpha 2-adrenergic receptors.	The adrenergic receptors are members of the superfamily of G protein-coupled receptors. There are three major types of adrenergic receptors: alpha 1, alpha 2, and beta. Each of these three major types can be divided into three subtypes. Within the alpha 1-adrenergic receptors, alpha 1A and alpha 1B subtypes have been defined pharmacologically on the basis of reversible antagonists, such as WB4101 and phentolamine, and the irreversible antagonist chloroethylclonidine. In at least some tissues the mechanism of action of the alpha 1A subtype is related to activation of a calcium channel, whereas the alpha 1B receptor exerts its effect through the second messenger inositol trisphosphate. Both of these receptor subtypes as well as a third, the alpha 1C, have been identified by molecular cloning. Three pharmacological subtypes of the alpha 2-adrenergic receptor have also been identified. Prototypic tissues and cell lines in continuous culture have been developed for each of these subtypes, which facilitated their study. The definition of the alpha 2 subtypes has been based on radioligand binding data and more limited functional data. All three subtypes have been shown to inhibit the activation of adenylate cyclase and thus reduce the levels of cAMP. Three alpha 2-adrenergic receptor subtypes have been identified by molecular cloning in both the human and rat species. There is reasonable agreement between the pharmacological identified subtypes and those identified by molecular cloning.</text>
      <sentence>
        <offset>0</offset>
        <text>Subtypes of alpha 1- and alpha 2-adrenergic receptors.</text>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 1- and alpha 2-adrenergic receptors</infon>
          <location offset="12" length="41"/>
          <text>alpha 1- and alpha 2-adrenergic receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>55</offset>
        <text>The adrenergic receptors are members of the superfamily of G protein-coupled receptors.</text>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adrenergic receptors</infon>
          <location offset="59" length="20"/>
          <text>adrenergic receptors</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g protein-coupled receptors</infon>
          <location offset="114" length="27"/>
          <text>G protein-coupled receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>143</offset>
        <text>There are three major types of adrenergic receptors: alpha 1, alpha 2, and beta.</text>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adrenergic receptors: alpha 1, alpha 2, and beta</infon>
          <location offset="174" length="48"/>
          <text>adrenergic receptors: alpha 1, alpha 2, and beta</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>224</offset>
        <text>Each of these three major types can be divided into three subtypes.</text>
      </sentence>
      <sentence>
        <offset>292</offset>
        <text>Within the alpha 1-adrenergic receptors, alpha 1A and alpha 1B subtypes have been defined pharmacologically on the basis of reversible antagonists, such as WB4101 and phentolamine, and the irreversible antagonist chloroethylclonidine.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wb4101</infon>
          <location offset="448" length="6"/>
          <text>WB4101</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phentolamine</infon>
          <location offset="459" length="12"/>
          <text>phentolamine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloroethylclonidine</infon>
          <location offset="505" length="20"/>
          <text>chloroethylclonidine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 1-adrenergic receptors, alpha 1a and alpha 1b</infon>
          <location offset="303" length="51"/>
          <text>alpha 1-adrenergic receptors, alpha 1A and alpha 1B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>527</offset>
        <text>In at least some tissues the mechanism of action of the alpha 1A subtype is related to activation of a calcium channel, whereas the alpha 1B receptor exerts its effect through the second messenger inositol trisphosphate.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="630" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">inositol trisphosphate</infon>
          <location offset="724" length="22"/>
          <text>inositol trisphosphate</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">calcium channel</infon>
          <location offset="630" length="15"/>
          <text>calcium channel</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha 1b receptor</infon>
          <location offset="659" length="17"/>
          <text>alpha 1B receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>748</offset>
        <text>Both of these receptor subtypes as well as a third, the alpha 1C, have been identified by molecular cloning.</text>
      </sentence>
      <sentence>
        <offset>857</offset>
        <text>Three pharmacological subtypes of the alpha 2-adrenergic receptor have also been identified.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 2-adrenergic receptor</infon>
          <location offset="895" length="27"/>
          <text>alpha 2-adrenergic receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>950</offset>
        <text>Prototypic tissues and cell lines in continuous culture have been developed for each of these subtypes, which facilitated their study.</text>
      </sentence>
      <sentence>
        <offset>1085</offset>
        <text>The definition of the alpha 2 subtypes has been based on radioligand binding data and more limited functional data.</text>
      </sentence>
      <sentence>
        <offset>1201</offset>
        <text>All three subtypes have been shown to inhibit the activation of adenylate cyclase and thus reduce the levels of cAMP.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenylate</infon>
          <location offset="1265" length="9"/>
          <text>adenylate</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="1313" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adenylate cyclase</infon>
          <location offset="1265" length="17"/>
          <text>adenylate cyclase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1319</offset>
        <text>Three alpha 2-adrenergic receptor subtypes have been identified by molecular cloning in both the human and rat species.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 2-adrenergic receptor</infon>
          <location offset="1325" length="27"/>
          <text>alpha 2-adrenergic receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1439</offset>
        <text>There is reasonable agreement between the pharmacological identified subtypes and those identified by molecular cloning.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>20600573</id>
    <passage>
      <offset>0</offset>
      <text>Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.	Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD). Its S-isomer, TVP1022 is thousand times less potent as an MAO-B inhibitor. However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins. Novel findings demonstrated that the major metabolite of rasagiline, 1-(R)-aminoindan has antioxidant and neuroprotective capabilities and thus, may contribute to the overt activity of its parent compound, rasagiline. This paper will review the earlier and present studies in the development of rasagiline for treatment of PD and discuss its pharmacology and applicable mechanism of action.</text>
      <sentence>
        <offset>0</offset>
        <text>Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rasagiline</infon>
          <location offset="0" length="10"/>
          <text>Rasagiline</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoamine</infon>
          <location offset="38" length="9"/>
          <text>monoamine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monoamine oxidase-b</infon>
          <location offset="38" length="19"/>
          <text>monoamine oxidase-B</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>99</offset>
        <text>Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rasagiline</infon>
          <location offset="99" length="10"/>
          <text>Rasagiline</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-propargyl-1-(r)-aminoindan</infon>
          <location offset="111" length="28"/>
          <text>N-propargyl-1-(R)-aminoindan</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoamine</infon>
          <location offset="180" length="9"/>
          <text>monoamine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monoamine oxidase (mao)-b</infon>
          <location offset="180" length="25"/>
          <text>monoamine oxidase (MAO)-B</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>241</offset>
        <text>Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD).</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rasagiline</infon>
          <location offset="241" length="10"/>
          <text>Rasagiline</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-dopa</infon>
          <location offset="294" length="6"/>
          <text>L-Dopa</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>360</offset>
        <text>Its S-isomer, TVP1022 is thousand times less potent as an MAO-B inhibitor.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tvp1022</infon>
          <location offset="374" length="7"/>
          <text>TVP1022</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-b</infon>
          <location offset="418" length="5"/>
          <text>MAO-B</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>435</offset>
        <text>However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rasagiline</infon>
          <location offset="621" length="10"/>
          <text>rasagiline</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-propargyl</infon>
          <location offset="706" length="11"/>
          <text>N-propargyl</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-b</infon>
          <location offset="665" length="5"/>
          <text>MAO-B</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="818" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>841</offset>
        <text>Novel findings demonstrated that the major metabolite of rasagiline, 1-(R)-aminoindan has antioxidant and neuroprotective capabilities and thus, may contribute to the overt activity of its parent compound, rasagiline.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rasagiline</infon>
          <location offset="898" length="10"/>
          <text>rasagiline</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1-(r)-aminoindan</infon>
          <location offset="910" length="16"/>
          <text>1-(R)-aminoindan</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rasagiline</infon>
          <location offset="1047" length="10"/>
          <text>rasagiline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1059</offset>
        <text>This paper will review the earlier and present studies in the development of rasagiline for treatment of PD and discuss its pharmacology and applicable mechanism of action.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rasagiline</infon>
          <location offset="1136" length="10"/>
          <text>rasagiline</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23598363</id>
    <passage>
      <offset>0</offset>
      <text>Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network.	Non-proliferating oocytes within avascular regions of the ovary are exquisitely susceptible to chemotherapy. Early menopause and sterility are unintended consequences of chemotherapy, and efforts to understand the oocyte apoptotic pathway may provide new targets for mitigating this outcome. Recently, the c-Abl kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin. However, the mechanism by which imatinib protects oocytes is not fully understood, and reports of the drug's efficacy have been contradictory. Using in vitro culture and subrenal grafting of mouse ovaries, we demonstrated that imatinib inhibits the cisplatin-induced apoptosis of oocytes within primordial follicles. We found that, before apoptosis, cisplatin induces c-Abl and TAp73 expression in the oocyte. Oocytes undergoing apoptosis showed downregulation of TAp63 and upregulation of Bax. While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death. Surprisingly, the conditional deletion of Trp63, but not ΔNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin. These data suggest that TAp63 is the master regulator of cisplatin-induced oocyte death. The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression. Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX-mediated apoptosis. Thus, imatinib and other c-Abl kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.</text>
      <sentence>
        <offset>0</offset>
        <text>Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">platinum</infon>
          <location offset="10" length="8"/>
          <text>platinum</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="90" length="3"/>
          <text>p53</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>120</offset>
        <text>Non-proliferating oocytes within avascular regions of the ovary are exquisitely susceptible to chemotherapy.</text>
      </sentence>
      <sentence>
        <offset>229</offset>
        <text>Early menopause and sterility are unintended consequences of chemotherapy, and efforts to understand the oocyte apoptotic pathway may provide new targets for mitigating this outcome.</text>
      </sentence>
      <sentence>
        <offset>412</offset>
        <text>Recently, the c-Abl kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib mesylate</infon>
          <location offset="449" length="17"/>
          <text>imatinib mesylate</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="468" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="545" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-abl</infon>
          <location offset="426" length="5"/>
          <text>c-Abl</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="432" length="6"/>
          <text>kinase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>556</offset>
        <text>However, the mechanism by which imatinib protects oocytes is not fully understood, and reports of the drug's efficacy have been contradictory.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="588" length="8"/>
          <text>imatinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>699</offset>
        <text>Using in vitro culture and subrenal grafting of mouse ovaries, we demonstrated that imatinib inhibits the cisplatin-induced apoptosis of oocytes within primordial follicles.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="783" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="805" length="9"/>
          <text>cisplatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>873</offset>
        <text>We found that, before apoptosis, cisplatin induces c-Abl and TAp73 expression in the oocyte.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="906" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-abl</infon>
          <location offset="924" length="5"/>
          <text>c-Abl</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap73</infon>
          <location offset="934" length="5"/>
          <text>TAp73</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T49" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>966</offset>
        <text>Oocytes undergoing apoptosis showed downregulation of TAp63 and upregulation of Bax.</text>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap63</infon>
          <location offset="1020" length="5"/>
          <text>TAp63</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="1046" length="3"/>
          <text>Bax</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1051</offset>
        <text>While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1169" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="1192" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1057" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="1086" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="1164" length="3"/>
          <text>p53</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-abl</infon>
          <location offset="1234" length="5"/>
          <text>c-Abl</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap73</infon>
          <location offset="1240" length="5"/>
          <text>TAp73</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap63</infon>
          <location offset="1283" length="5"/>
          <text>TAp63</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="1309" length="3"/>
          <text>Bax</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1352</offset>
        <text>Surprisingly, the conditional deletion of Trp63, but not ΔNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trp</infon>
          <location offset="1394" length="3"/>
          <text>Trp</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="1505" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">trp63</infon>
          <location offset="1394" length="5"/>
          <text>Trp63</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">δnp63</infon>
          <location offset="1409" length="5"/>
          <text>ΔNp63</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-abl</infon>
          <location offset="1479" length="5"/>
          <text>c-Abl</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap73</infon>
          <location offset="1489" length="5"/>
          <text>TAp73</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1516</offset>
        <text>These data suggest that TAp63 is the master regulator of cisplatin-induced oocyte death.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="1573" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap63</infon>
          <location offset="1540" length="5"/>
          <text>TAp63</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1605</offset>
        <text>The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="1668" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap63</infon>
          <location offset="1632" length="5"/>
          <text>TAp63</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-abl</infon>
          <location offset="1639" length="5"/>
          <text>c-Abl</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap73</infon>
          <location offset="1649" length="5"/>
          <text>TAp73</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap63</infon>
          <location offset="1688" length="5"/>
          <text>TAp63</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-abl</infon>
          <location offset="1718" length="5"/>
          <text>c-Abl</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap73</infon>
          <location offset="1728" length="5"/>
          <text>TAp73</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap73</infon>
          <location offset="1766" length="5"/>
          <text>TAp73</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-abl</infon>
          <location offset="1775" length="5"/>
          <text>c-Abl</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="1789" length="3"/>
          <text>BAX</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1805</offset>
        <text>Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1832" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="1863" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-abl</infon>
          <location offset="1906" length="5"/>
          <text>c-Abl</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="1912" length="6"/>
          <text>kinase</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tap73</infon>
          <location offset="1951" length="5"/>
          <text>TAp73</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bax</infon>
          <location offset="1957" length="3"/>
          <text>BAX</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1981</offset>
        <text>Thus, imatinib and other c-Abl kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1987" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="2068" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-abl</infon>
          <location offset="2006" length="5"/>
          <text>c-Abl</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="2012" length="6"/>
          <text>kinase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12085361</id>
    <passage>
      <offset>0</offset>
      <text>Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.	The antibiotics rifamycin SV and rifampicin substantially reduce sulfobromophthalein (BSP) elimination in humans. In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2. Therefore, we investigated the effects of rifamycin SV and rifampicin on the OATPs of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers. In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes. In the presence of 100 micromol/L rifamycin SV, BSP uptake was almost completely abolished. Approximate K(i) values were 2 micromol/L for OATP-C, 3 micromol/L for OATP8, 3 micromol/L for OATP-B and 11 micromol/L for OATP-A. Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively. The corresponding K(i) values were 17 micromol/L for OATP-C, 5 micromol/L for OATP8, and 51 micromol/L for OATP-A. Direct transport of rifampicin could be shown for OATP-C (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L). In conclusion, these results show that rifamycin SV and rifampicin interact with OATP-mediated substrate transport to different extents. Inhibition of human liver OATPs can explain the previously observed effects of rifamycin SV and rifampicin on hepatic organic anion elimination.</text>
      <sentence>
        <offset>0</offset>
        <text>Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifamycin sv</infon>
          <location offset="16" length="12"/>
          <text>rifamycin SV</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="33" length="10"/>
          <text>rifampicin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>94</offset>
        <text>The antibiotics rifamycin SV and rifampicin substantially reduce sulfobromophthalein (BSP) elimination in humans.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifamycin sv</infon>
          <location offset="110" length="12"/>
          <text>rifamycin SV</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="127" length="10"/>
          <text>rifampicin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfobromophthalein</infon>
          <location offset="159" length="19"/>
          <text>sulfobromophthalein</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bsp</infon>
          <location offset="180" length="3"/>
          <text>BSP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>208</offset>
        <text>In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifamycin sv</infon>
          <location offset="217" length="12"/>
          <text>rifamycin SV</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="234" length="10"/>
          <text>rifampicin</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">organic anion transporting polypeptides</infon>
          <location offset="324" length="39"/>
          <text>organic anion transporting polypeptides</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp1</infon>
          <location offset="364" length="5"/>
          <text>Oatp1</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp2</infon>
          <location offset="374" length="5"/>
          <text>Oatp2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>381</offset>
        <text>Therefore, we investigated the effects of rifamycin SV and rifampicin on the OATPs of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifamycin sv</infon>
          <location offset="423" length="12"/>
          <text>rifamycin SV</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="440" length="10"/>
          <text>rifampicin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="502" length="10"/>
          <text>rifampicin</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">oatps</infon>
          <location offset="458" length="5"/>
          <text>OATPs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>563</offset>
        <text>In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifamycin sv</infon>
          <location offset="624" length="12"/>
          <text>rifamycin SV</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human organic anion transporting polypeptide c</infon>
          <location offset="667" length="46"/>
          <text>human organic anion transporting polypeptide C</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">slc21a6</infon>
          <location offset="715" length="7"/>
          <text>SLC21A6</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-c</infon>
          <location offset="725" length="6"/>
          <text>OATP-C</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human organic anion transporting polypeptide 8</infon>
          <location offset="734" length="46"/>
          <text>human organic anion transporting polypeptide 8</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">slc21a8</infon>
          <location offset="782" length="7"/>
          <text>SLC21A8</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp8</infon>
          <location offset="792" length="5"/>
          <text>OATP8</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human organic anion transporting polypeptide b</infon>
          <location offset="800" length="46"/>
          <text>human organic anion transporting polypeptide B</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">slc21a9</infon>
          <location offset="848" length="7"/>
          <text>SLC21A9</text>
        </annotation>
        <annotation id="T56">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-b</infon>
          <location offset="858" length="6"/>
          <text>OATP-B</text>
        </annotation>
        <annotation id="T57">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human organic anion transporting polypeptide a</infon>
          <location offset="871" length="46"/>
          <text>human organic anion transporting polypeptide A</text>
        </annotation>
        <annotation id="T58">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">slc21a3</infon>
          <location offset="919" length="7"/>
          <text>SLC21A3</text>
        </annotation>
        <annotation id="T59">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-a</infon>
          <location offset="929" length="6"/>
          <text>OATP-A</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T54" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T49" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T58" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T52" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T53" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T55" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T51" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T50" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T59" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T56" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1044</offset>
        <text>In the presence of 100 micromol/L rifamycin SV, BSP uptake was almost completely abolished.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifamycin sv</infon>
          <location offset="1078" length="12"/>
          <text>rifamycin SV</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bsp</infon>
          <location offset="1092" length="3"/>
          <text>BSP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1136</offset>
        <text>Approximate K(i) values were 2 micromol/L for OATP-C, 3 micromol/L for OATP8, 3 micromol/L for OATP-B and 11 micromol/L for OATP-A.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-c</infon>
          <location offset="1182" length="6"/>
          <text>OATP-C</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp8</infon>
          <location offset="1207" length="5"/>
          <text>OATP8</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-b</infon>
          <location offset="1231" length="6"/>
          <text>OATP-B</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-a</infon>
          <location offset="1260" length="6"/>
          <text>OATP-A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1268</offset>
        <text>Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="1268" length="10"/>
          <text>Rifampicin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bsp</infon>
          <location offset="1320" length="3"/>
          <text>BSP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bsp</infon>
          <location offset="1399" length="3"/>
          <text>BSP</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp8</infon>
          <location offset="1305" length="5"/>
          <text>OATP8</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-c</infon>
          <location offset="1361" length="6"/>
          <text>OATP-C</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-b</infon>
          <location offset="1370" length="6"/>
          <text>OATP-B</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-a</infon>
          <location offset="1383" length="6"/>
          <text>OATP-A</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1428</offset>
        <text>100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="1443" length="10"/>
          <text>rifampicin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bsp</infon>
          <location offset="1512" length="3"/>
          <text>BSP</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-c</infon>
          <location offset="1464" length="6"/>
          <text>OATP-C</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp8</infon>
          <location offset="1476" length="5"/>
          <text>OATP8</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-b</infon>
          <location offset="1484" length="6"/>
          <text>OATP-B</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-a</infon>
          <location offset="1496" length="6"/>
          <text>OATP-A</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1564</offset>
        <text>The corresponding K(i) values were 17 micromol/L for OATP-C, 5 micromol/L for OATP8, and 51 micromol/L for OATP-A.</text>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-c</infon>
          <location offset="1617" length="6"/>
          <text>OATP-C</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp8</infon>
          <location offset="1642" length="5"/>
          <text>OATP8</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-a</infon>
          <location offset="1671" length="6"/>
          <text>OATP-A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1679</offset>
        <text>Direct transport of rifampicin could be shown for OATP-C (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="1699" length="10"/>
          <text>rifampicin</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp-c</infon>
          <location offset="1729" length="6"/>
          <text>OATP-C</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oatp8</infon>
          <location offset="1776" length="5"/>
          <text>OATP8</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T8" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T8" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1800</offset>
        <text>In conclusion, these results show that rifamycin SV and rifampicin interact with OATP-mediated substrate transport to different extents.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifamycin sv</infon>
          <location offset="1839" length="12"/>
          <text>rifamycin SV</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="1856" length="10"/>
          <text>rifampicin</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">oatp</infon>
          <location offset="1881" length="4"/>
          <text>OATP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1937</offset>
        <text>Inhibition of human liver OATPs can explain the previously observed effects of rifamycin SV and rifampicin on hepatic organic anion elimination.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifamycin sv</infon>
          <location offset="2016" length="12"/>
          <text>rifamycin SV</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rifampicin</infon>
          <location offset="2033" length="10"/>
          <text>rifampicin</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human liver oatps</infon>
          <location offset="1951" length="17"/>
          <text>human liver OATPs</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>8937933</id>
    <passage>
      <offset>0</offset>
      <text>Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus.	We studied the effects of the new rapid acting human insulin analogue (Lys(B28), Pro(B29) insulin), insulin Lispro (Lispro) on metabolic control and insulin receptor binding in type II diabetes mellitus. We investigated 2 patients: Patient 1 was obese, clearly insulin-resistant, injected high doses of insulin (3-4 IU/kg body weight), and had insufficient diabetes control. Patient 2 was of normal body weight, injected normal insulin doses (0.7-0.8 IU/kg body weight), and had good diabetes control. Patient 1 showed a considerable improvement of insulin binding after receiving Lispro (26,700 vs. 5,600 receptors/monocyte; Kd 560 vs. 1,500 pM). Concommitantly, a decrease of serum glucose and insulin dose was observed, reflecting a higher insulin sensitivity during Lispro treatment. In patient 2 injected with Lispro the time course of serum glucose, serum insulin, and insulin binding after an oral meal was comparable to values obtained in healthy controls. We conclude that the quick and pulsatile pharmacokinetic profile of the insulin analogue Lispro may improve glycemia, insulin receptor binding, and insulin resistance in type II diabetes.</text>
      <sentence>
        <offset>0</offset>
        <text>Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="20" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>81</offset>
        <text>We studied the effects of the new rapid acting human insulin analogue (Lys(B28), Pro(B29) insulin), insulin Lispro (Lispro) on metabolic control and insulin receptor binding in type II diabetes mellitus.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="181" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin receptor</infon>
          <location offset="230" length="16"/>
          <text>insulin receptor</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human insulin</infon>
          <location offset="128" length="13"/>
          <text>human insulin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="171" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>285</offset>
        <text>We investigated 2 patients: Patient 1 was obese, clearly insulin-resistant, injected high doses of insulin (3-4 IU/kg body weight), and had insufficient diabetes control.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="342" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="384" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>456</offset>
        <text>Patient 2 was of normal body weight, injected normal insulin doses (0.7-0.8 IU/kg body weight), and had good diabetes control.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="509" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>583</offset>
        <text>Patient 1 showed a considerable improvement of insulin binding after receiving Lispro (26,700 vs. 5,600 receptors/monocyte; Kd 560 vs. 1,500 pM).</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="630" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>729</offset>
        <text>Concommitantly, a decrease of serum glucose and insulin dose was observed, reflecting a higher insulin sensitivity during Lispro treatment.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="765" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="777" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="824" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>869</offset>
        <text>In patient 2 injected with Lispro the time course of serum glucose, serum insulin, and insulin binding after an oral meal was comparable to values obtained in healthy controls.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="928" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="943" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="956" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1046</offset>
        <text>We conclude that the quick and pulsatile pharmacokinetic profile of the insulin analogue Lispro may improve glycemia, insulin receptor binding, and insulin resistance in type II diabetes.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1118" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin receptor</infon>
          <location offset="1164" length="16"/>
          <text>insulin receptor</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1194" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17353509</id>
    <passage>
      <offset>0</offset>
      <text>Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.	Progressive cardiac remodeling is characterized by subsequent chamber hypertrophy, enlargement, and pump dysfunction. It is also associated with increased cardiac fibrosis and matrix turnover. Interestingly, peroxisome proliferator-activated receptor (PPAR) alpha activators reduce cardiac hypertrophy, inflammation, and fibrosis. Little is known about the role of fenofibrates in mediating PPARalpha-independent effects in response to chronic pressure overload (PO). Wild-type and PPARalpha-deficient mice were subjected to chronic PO caused by ascending aortic constriction to test the role of fenofibrates in chronic, progressive cardiac remodeling by a PPARalpha-independent mechanism. Mice were randomized to regular chow or chow-containing fenofibrate (100 mg/kg of body weight per day) for 1 week before and 8 weeks after ascending aortic constriction. In the presence of PPARalpha, wild-type chronic PO mice, treated with fenofibrate, had improved cardiac remodeling. However, PO PPARalpha-deficient mice treated with fenofibrate had increased mortality, significantly adverse left ventricular end diastolic (3.4+/-0.1 versus 4.2+/-0.1 mm) and end systolic (1.5+/-0.2 versus 2.5+/-0.2 mm) dimensions, and fractional shortening (57+/-3% versus 40+/-3%). Fenofibrate also increased myocardial hypertrophy, cardiac fibrosis, and the ratio of matrix metalloproteinase-2/tissue inhibitor of matrix metalloproteinase-2 in PO PPARalpha-deficient mice. Fenofibrate inhibited matrix metalloproteinase activity in vitro and aldosterone-induced increases in extracellular signal-regulated kinase phosphorylation. Thus, fenofibrate improved cardiac remodeling in chronic PO mice. However, in PPARalpha-deficient mice, this chronic PO was exacerbated and associated with increased myocardial fibrosis and altered matrix remodeling. In the absence of PPARalpha, fenofibrates exerts deleterious, pleiotropic myocardial actions. This is an important observation, because PPARalpha agonists are considered possible inhibitory regulators of cardiac remodeling in the remodeled heart.</text>
      <sentence>
        <offset>0</offset>
        <text>Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fenofibrate</infon>
          <location offset="72" length="11"/>
          <text>fenofibrate</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor alpha</infon>
          <location offset="0" length="48"/>
          <text>Peroxisome proliferator-activated receptor alpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>165</offset>
        <text>Progressive cardiac remodeling is characterized by subsequent chamber hypertrophy, enlargement, and pump dysfunction.</text>
      </sentence>
      <sentence>
        <offset>283</offset>
        <text>It is also associated with increased cardiac fibrosis and matrix turnover.</text>
      </sentence>
      <sentence>
        <offset>358</offset>
        <text>Interestingly, peroxisome proliferator-activated receptor (PPAR) alpha activators reduce cardiac hypertrophy, inflammation, and fibrosis.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor (ppar) alpha</infon>
          <location offset="373" length="55"/>
          <text>peroxisome proliferator-activated receptor (PPAR) alpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>496</offset>
        <text>Little is known about the role of fenofibrates in mediating PPARalpha-independent effects in response to chronic pressure overload (PO).</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fenofibrates</infon>
          <location offset="530" length="12"/>
          <text>fenofibrates</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="556" length="9"/>
          <text>PPARalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>633</offset>
        <text>Wild-type and PPARalpha-deficient mice were subjected to chronic PO caused by ascending aortic constriction to test the role of fenofibrates in chronic, progressive cardiac remodeling by a PPARalpha-independent mechanism.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fenofibrates</infon>
          <location offset="761" length="12"/>
          <text>fenofibrates</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="647" length="9"/>
          <text>PPARalpha</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="822" length="9"/>
          <text>PPARalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>855</offset>
        <text>Mice were randomized to regular chow or chow-containing fenofibrate (100 mg/kg of body weight per day) for 1 week before and 8 weeks after ascending aortic constriction.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fenofibrate</infon>
          <location offset="911" length="11"/>
          <text>fenofibrate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1025</offset>
        <text>In the presence of PPARalpha, wild-type chronic PO mice, treated with fenofibrate, had improved cardiac remodeling.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fenofibrate</infon>
          <location offset="1095" length="11"/>
          <text>fenofibrate</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="1044" length="9"/>
          <text>PPARalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1141</offset>
        <text>However, PO PPARalpha-deficient mice treated with fenofibrate had increased mortality, significantly adverse left ventricular end diastolic (3.4+/-0.1 versus 4.2+/-0.1 mm) and end systolic (1.5+/-0.2 versus 2.5+/-0.2 mm) dimensions, and fractional shortening (57+/-3% versus 40+/-3%).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fenofibrate</infon>
          <location offset="1191" length="11"/>
          <text>fenofibrate</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="1153" length="9"/>
          <text>PPARalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1426</offset>
        <text>Fenofibrate also increased myocardial hypertrophy, cardiac fibrosis, and the ratio of matrix metalloproteinase-2/tissue inhibitor of matrix metalloproteinase-2 in PO PPARalpha-deficient mice.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fenofibrate</infon>
          <location offset="1426" length="11"/>
          <text>Fenofibrate</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">matrix metalloproteinase-2</infon>
          <location offset="1512" length="26"/>
          <text>matrix metalloproteinase-2</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tissue inhibitor of matrix metalloproteinase-2</infon>
          <location offset="1539" length="46"/>
          <text>tissue inhibitor of matrix metalloproteinase-2</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="1592" length="9"/>
          <text>PPARalpha</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1618</offset>
        <text>Fenofibrate inhibited matrix metalloproteinase activity in vitro and aldosterone-induced increases in extracellular signal-regulated kinase phosphorylation.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fenofibrate</infon>
          <location offset="1618" length="11"/>
          <text>Fenofibrate</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldosterone</infon>
          <location offset="1687" length="11"/>
          <text>aldosterone</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">matrix metalloproteinase</infon>
          <location offset="1640" length="24"/>
          <text>matrix metalloproteinase</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="1751" length="6"/>
          <text>kinase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1775</offset>
        <text>Thus, fenofibrate improved cardiac remodeling in chronic PO mice.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fenofibrate</infon>
          <location offset="1781" length="11"/>
          <text>fenofibrate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1841</offset>
        <text>However, in PPARalpha-deficient mice, this chronic PO was exacerbated and associated with increased myocardial fibrosis and altered matrix remodeling.</text>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="1853" length="9"/>
          <text>PPARalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1992</offset>
        <text>In the absence of PPARalpha, fenofibrates exerts deleterious, pleiotropic myocardial actions.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fenofibrates</infon>
          <location offset="2021" length="12"/>
          <text>fenofibrates</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="2010" length="9"/>
          <text>PPARalpha</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2086</offset>
        <text>This is an important observation, because PPARalpha agonists are considered possible inhibitory regulators of cardiac remodeling in the remodeled heart.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="2128" length="9"/>
          <text>PPARalpha</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23000445</id>
    <passage>
      <offset>0</offset>
      <text>Wogonoside induces autophagy in MDA-MB-231 cells by regulating MAPK-mTOR pathway.	Previous studies have demonstrated that wogonoside, a bioactive flavonoid extracted from the root of Scutellaria baicalensis Gerogi, has anti-inflammatory and anti-angiogenic activities. In this study, we evaluated wogonoside-induced autophagy on human breast MDA-MB-231 cells. We report that wogonoside triggered the formation of microtubule-associated protein-light chain 3 (MAP-LC3) positive autophagosomes and the accumulation of acidic vesicular and autolysosomes in MDA-MB-231 cells. In addition, cells treated by wogonoside developed autophagosome-like characteristics, including single and double membrane vacuoles containing intact and degraded cellular debris. The results showed that wogonoside promotes the expression of LC3-II and Beclin-1. Furthermore, wogonoside inhibited cell growth of MDA-MB-231 cells in a concentration- and time-dependent manner, which was associated with wogonoside-induced autophagy. Wogonoside also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway. Taken together, these results suggest that wogonoside partially inhibits MDA-MB-231 cell growth by inducing autophagy through the MAPK-mTOR pathway and may be a promising anti-tumor agent.</text>
      <sentence>
        <offset>0</offset>
        <text>Wogonoside induces autophagy in MDA-MB-231 cells by regulating MAPK-mTOR pathway.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wogonoside</infon>
          <location offset="0" length="10"/>
          <text>Wogonoside</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="63" length="4"/>
          <text>MAPK</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="68" length="4"/>
          <text>mTOR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>82</offset>
        <text>Previous studies have demonstrated that wogonoside, a bioactive flavonoid extracted from the root of Scutellaria baicalensis Gerogi, has anti-inflammatory and anti-angiogenic activities.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wogonoside</infon>
          <location offset="122" length="10"/>
          <text>wogonoside</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flavonoid</infon>
          <location offset="146" length="9"/>
          <text>flavonoid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>269</offset>
        <text>In this study, we evaluated wogonoside-induced autophagy on human breast MDA-MB-231 cells.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wogonoside</infon>
          <location offset="297" length="10"/>
          <text>wogonoside</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>360</offset>
        <text>We report that wogonoside triggered the formation of microtubule-associated protein-light chain 3 (MAP-LC3) positive autophagosomes and the accumulation of acidic vesicular and autolysosomes in MDA-MB-231 cells.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wogonoside</infon>
          <location offset="375" length="10"/>
          <text>wogonoside</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">microtubule-associated protein-light chain 3</infon>
          <location offset="413" length="44"/>
          <text>microtubule-associated protein-light chain 3</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">map-lc3</infon>
          <location offset="459" length="7"/>
          <text>MAP-LC3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>572</offset>
        <text>In addition, cells treated by wogonoside developed autophagosome-like characteristics, including single and double membrane vacuoles containing intact and degraded cellular debris.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wogonoside</infon>
          <location offset="602" length="10"/>
          <text>wogonoside</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>753</offset>
        <text>The results showed that wogonoside promotes the expression of LC3-II and Beclin-1.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wogonoside</infon>
          <location offset="777" length="10"/>
          <text>wogonoside</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lc3-ii</infon>
          <location offset="815" length="6"/>
          <text>LC3-II</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beclin-1</infon>
          <location offset="826" length="8"/>
          <text>Beclin-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>836</offset>
        <text>Furthermore, wogonoside inhibited cell growth of MDA-MB-231 cells in a concentration- and time-dependent manner, which was associated with wogonoside-induced autophagy.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wogonoside</infon>
          <location offset="849" length="10"/>
          <text>wogonoside</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wogonoside</infon>
          <location offset="975" length="10"/>
          <text>wogonoside</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1005</offset>
        <text>Wogonoside also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wogonoside</infon>
          <location offset="1005" length="10"/>
          <text>Wogonoside</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="1070" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p70-s6 kinase</infon>
          <location offset="1091" length="13"/>
          <text>p70-S6 kinase</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p70s6k)</infon>
          <location offset="1106" length="7"/>
          <text>p70S6K)</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">extracellular signal-regulated kinase</infon>
          <location offset="1150" length="37"/>
          <text>extracellular signal-regulated kinase</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk1/2</infon>
          <location offset="1189" length="6"/>
          <text>ERK1/2</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p38</infon>
          <location offset="1201" length="3"/>
          <text>p38</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mitogen-activated protein kinase</infon>
          <location offset="1214" length="32"/>
          <text>mitogen-activated protein kinase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="1248" length="4"/>
          <text>MAPK</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mammalian target of rapamycin</infon>
          <location offset="1050" length="29"/>
          <text>mammalian target of rapamycin</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="1081" length="4"/>
          <text>mTOR</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1273</offset>
        <text>Taken together, these results suggest that wogonoside partially inhibits MDA-MB-231 cell growth by inducing autophagy through the MAPK-mTOR pathway and may be a promising anti-tumor agent.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wogonoside</infon>
          <location offset="1316" length="10"/>
          <text>wogonoside</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="1403" length="4"/>
          <text>MAPK</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mtor</infon>
          <location offset="1408" length="4"/>
          <text>mTOR</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>19019313</id>
    <passage>
      <offset>0</offset>
      <text>Treatment of neuromuscular channelopathies: current concepts and future prospects.	Our understanding of the molecular pathogenesis of the neuromuscular ion channelopathies has increased rapidly over the past two decades due to the identification of many of the genes whose mutation causes these diseases. These molecular discoveries have facilitated identification and classification of the hereditary periodic paralyses and the myotonias, and are likely to shed light on acquired ion channelopathies as well. Despite our better understanding of the pathogenesis of these disorders, current treatments are largely empirical and the evidence in favor of specific therapy largely anecdotal. For periodic paralysis, dichlorphenamide--a carbonic anhydrase inhibitor--has been shown in a controlled trial to prevent attacks for many patients with both hypokalemic and hypokalemic periodic paralysis. A second trial, comparing dichlorphenamide with acetazolamide versus placebo, is currently in progress. For myotonia, there is only anecdotal evidence for treatment, but a controlled trial of mexiletine versus placebo is currently being funded by a Food and Drug Administration-orphan products grant and is scheduled to begin in late 2008. In the future, mechanism-based approaches are likely to be developed. For example, exciting advances have already been made in one disorder, myotonic dystrophy-1 (DM-1). In a mouse model of DM-1, a morpholino antisense oligonucleuotide targeting the 3' splice site of CLCN1 exon 7a repaired the RNA splicing defect by promoting the production of full-length chloride channel transcripts. Abnormal chloride conductance was restored, and myotonia was abolished. Similar strategies hold potential for DM-2. The era of molecularly-based treatments is about to begin.</text>
      <sentence>
        <offset>0</offset>
        <text>Treatment of neuromuscular channelopathies: current concepts and future prospects.</text>
      </sentence>
      <sentence>
        <offset>83</offset>
        <text>Our understanding of the molecular pathogenesis of the neuromuscular ion channelopathies has increased rapidly over the past two decades due to the identification of many of the genes whose mutation causes these diseases.</text>
      </sentence>
      <sentence>
        <offset>305</offset>
        <text>These molecular discoveries have facilitated identification and classification of the hereditary periodic paralyses and the myotonias, and are likely to shed light on acquired ion channelopathies as well.</text>
      </sentence>
      <sentence>
        <offset>510</offset>
        <text>Despite our better understanding of the pathogenesis of these disorders, current treatments are largely empirical and the evidence in favor of specific therapy largely anecdotal.</text>
      </sentence>
      <sentence>
        <offset>689</offset>
        <text>For periodic paralysis, dichlorphenamide--a carbonic anhydrase inhibitor--has been shown in a controlled trial to prevent attacks for many patients with both hypokalemic and hypokalemic periodic paralysis.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dichlorphenamide</infon>
          <location offset="713" length="16"/>
          <text>dichlorphenamide</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbonic</infon>
          <location offset="733" length="8"/>
          <text>carbonic</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">carbonic anhydrase</infon>
          <location offset="733" length="18"/>
          <text>carbonic anhydrase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>895</offset>
        <text>A second trial, comparing dichlorphenamide with acetazolamide versus placebo, is currently in progress.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dichlorphenamide</infon>
          <location offset="921" length="16"/>
          <text>dichlorphenamide</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetazolamide</infon>
          <location offset="943" length="13"/>
          <text>acetazolamide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>999</offset>
        <text>For myotonia, there is only anecdotal evidence for treatment, but a controlled trial of mexiletine versus placebo is currently being funded by a Food and Drug Administration-orphan products grant and is scheduled to begin in late 2008.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mexiletine</infon>
          <location offset="1087" length="10"/>
          <text>mexiletine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1235</offset>
        <text>In the future, mechanism-based approaches are likely to be developed.</text>
      </sentence>
      <sentence>
        <offset>1305</offset>
        <text>For example, exciting advances have already been made in one disorder, myotonic dystrophy-1 (DM-1).</text>
      </sentence>
      <sentence>
        <offset>1405</offset>
        <text>In a mouse model of DM-1, a morpholino antisense oligonucleuotide targeting the 3' splice site of CLCN1 exon 7a repaired the RNA splicing defect by promoting the production of full-length chloride channel transcripts.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">morpholino</infon>
          <location offset="1433" length="10"/>
          <text>morpholino</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloride</infon>
          <location offset="1593" length="8"/>
          <text>chloride</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">clcn1</infon>
          <location offset="1503" length="5"/>
          <text>CLCN1</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">chloride channel transcripts</infon>
          <location offset="1593" length="28"/>
          <text>chloride channel transcripts</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1623</offset>
        <text>Abnormal chloride conductance was restored, and myotonia was abolished.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloride</infon>
          <location offset="1632" length="8"/>
          <text>chloride</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1695</offset>
        <text>Similar strategies hold potential for DM-2.</text>
      </sentence>
      <sentence>
        <offset>1739</offset>
        <text>The era of molecularly-based treatments is about to begin.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17389249</id>
    <passage>
      <offset>0</offset>
      <text>Cooperation of the conserved aspartate 439 and bound amino acid substrate is important for high-affinity Na+ binding to the glutamate transporter EAAC1.	The neuronal glutamate transporter EAAC1 contains several conserved acidic amino acids in its transmembrane domain, which are possibly important in catalyzing transport and/or binding of co/countertransported cations. Here, we have studied the effects of neutralization by site-directed mutagenesis of three of these amino acid side chains, glutamate 373, aspartate 439, and aspartate 454, on the functional properties of the transporter. Transport was analyzed by whole-cell current recording from EAAC1-expressing mammalian cells after applying jumps in voltage, substrate, or cation concentration. Neutralization mutations in positions 373 and 454, although eliminating steady-state glutamate transport, have little effect on the kinetics and thermodynamics of Na(+) and glutamate binding, suggesting that these two positions do not constitute the sites of Na(+) and glutamate association with EAAC1. In contrast, the D439N mutation resulted in an approximately 10-fold decrease of apparent affinity of the glutamate-bound transporter form for Na(+), and an approximately 2,000-fold reduction in the rate of Na(+) binding, whereas the kinetics and thermodynamics of Na(+) binding to the glutamate-free transporter were almost unchanged compared to EAAC1(WT). Furthermore, the D439N mutation converted l-glutamate, THA, and PDC, which are activating substrates for the wild-type anion conductance, but not l-aspartate, into transient inhibitors of the EAAC1(D439) anion conductance. Activation of the anion conductance by l-glutamate was biphasic, allowing us to directly analyze binding of two of the three cotransported Na(+) ions as a function of time and [Na(+)]. The data can be explained with a model in which the D439N mutation results in a dramatic slowing of Na(+) binding and a reduced affinity of the substrate-bound EAAC1 for Na(+). We propose that the bound substrate controls the rate and the extent of Na(+) interaction with the transporter, depending on the amino acid side chain in position 439.</text>
      <sentence>
        <offset>0</offset>
        <text>Cooperation of the conserved aspartate 439 and bound amino acid substrate is important for high-affinity Na+ binding to the glutamate transporter EAAC1.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na+</infon>
          <location offset="105" length="3"/>
          <text>Na+</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="124" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspartate</infon>
          <location offset="29" length="9"/>
          <text>aspartate</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="53" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutamate transporter</infon>
          <location offset="124" length="21"/>
          <text>glutamate transporter</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">eaac1</infon>
          <location offset="146" length="5"/>
          <text>EAAC1</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T25" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T25" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T26" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T26" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>153</offset>
        <text>The neuronal glutamate transporter EAAC1 contains several conserved acidic amino acids in its transmembrane domain, which are possibly important in catalyzing transport and/or binding of co/countertransported cations.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="166" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acids</infon>
          <location offset="228" length="11"/>
          <text>amino acids</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutamate transporter</infon>
          <location offset="166" length="21"/>
          <text>glutamate transporter</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">eaac1</infon>
          <location offset="188" length="5"/>
          <text>EAAC1</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T18" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T18" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>371</offset>
        <text>Here, we have studied the effects of neutralization by site-directed mutagenesis of three of these amino acid side chains, glutamate 373, aspartate 439, and aspartate 454, on the functional properties of the transporter.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="470" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="494" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspartate</infon>
          <location offset="509" length="9"/>
          <text>aspartate</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspartate</infon>
          <location offset="528" length="9"/>
          <text>aspartate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>592</offset>
        <text>Transport was analyzed by whole-cell current recording from EAAC1-expressing mammalian cells after applying jumps in voltage, substrate, or cation concentration.</text>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">eaac1</infon>
          <location offset="652" length="5"/>
          <text>EAAC1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>754</offset>
        <text>Neutralization mutations in positions 373 and 454, although eliminating steady-state glutamate transport, have little effect on the kinetics and thermodynamics of Na(+) and glutamate binding, suggesting that these two positions do not constitute the sites of Na(+) and glutamate association with EAAC1.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="917" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="927" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1013" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="1023" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">eaac1</infon>
          <location offset="1050" length="5"/>
          <text>EAAC1</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T22" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1057</offset>
        <text>In contrast, the D439N mutation resulted in an approximately 10-fold decrease of apparent affinity of the glutamate-bound transporter form for Na(+), and an approximately 2,000-fold reduction in the rate of Na(+) binding, whereas the kinetics and thermodynamics of Na(+) binding to the glutamate-free transporter were almost unchanged compared to EAAC1(WT).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1200" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1264" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1322" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="1343" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">eaac1</infon>
          <location offset="1404" length="5"/>
          <text>EAAC1</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d439n</infon>
          <location offset="1074" length="5"/>
          <text>D439N</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1415</offset>
        <text>Furthermore, the D439N mutation converted l-glutamate, THA, and PDC, which are activating substrates for the wild-type anion conductance, but not l-aspartate, into transient inhibitors of the EAAC1(D439) anion conductance.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-glutamate</infon>
          <location offset="1457" length="11"/>
          <text>l-glutamate</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d439n</infon>
          <location offset="1432" length="5"/>
          <text>D439N</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">eaac1</infon>
          <location offset="1607" length="5"/>
          <text>EAAC1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1638</offset>
        <text>Activation of the anion conductance by l-glutamate was biphasic, allowing us to directly analyze binding of two of the three cotransported Na(+) ions as a function of time and [Na(+)].</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-glutamate</infon>
          <location offset="1677" length="11"/>
          <text>l-glutamate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1777" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1815" length="5"/>
          <text>Na(+)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1823</offset>
        <text>The data can be explained with a model in which the D439N mutation results in a dramatic slowing of Na(+) binding and a reduced affinity of the substrate-bound EAAC1 for Na(+).</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1923" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1993" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d439n</infon>
          <location offset="1875" length="5"/>
          <text>D439N</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">eaac1</infon>
          <location offset="1983" length="5"/>
          <text>EAAC1</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2000</offset>
        <text>We propose that the bound substrate controls the rate and the extent of Na(+) interaction with the transporter, depending on the amino acid side chain in position 439.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="2072" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="2129" length="10"/>
          <text>amino acid</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23529671</id>
    <passage>
      <offset>0</offset>
      <text>Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia.	The effects of hyperprolactinemia on metabolic parameters are not clear and a few data evaluating adiponectin levels in prolactinoma and idiopathic hyperprolactinemia exist. The aim of this study was to evaluate the effects of hyperprolactinemia on body weight, insulin resistance, beta cell function, and leptin and adiponectin levels in premenopausal women with hyperprolactinemia. Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age-matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma glucose, insulin levels, insulin resistance measured by homeostasis model assessment (HOMA)-insulin resistance index, beta cell function measured by HOMA-β index, leptin and adiponectin levels. Plasma insulin levels and HOMA indexes (both insulin resistance and beta indexes) were significantly higher in hyperprolactinemic women. The other parameters were similar between both groups. There was a positive correlation between prolactin levels and fasting plasma glucose in hyperprolactinemic women. The results of this study showed that high prolactin levels may be associated with hyperinsulinemia and insulin resistance in premenopausal women. This effect seems to be independent of body weight, leptin and adiponectin levels. High prolactin levels may directly stimulate insulin secretion from pancreas and directly cause hepatic and whole-body insulin resistance.</text>
      <sentence>
        <offset>0</offset>
        <text>Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="27" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">leptin</infon>
          <location offset="47" length="6"/>
          <text>leptin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adiponectin</infon>
          <location offset="58" length="11"/>
          <text>adiponectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>125</offset>
        <text>The effects of hyperprolactinemia on metabolic parameters are not clear and a few data evaluating adiponectin levels in prolactinoma and idiopathic hyperprolactinemia exist.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adiponectin</infon>
          <location offset="223" length="11"/>
          <text>adiponectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>299</offset>
        <text>The aim of this study was to evaluate the effects of hyperprolactinemia on body weight, insulin resistance, beta cell function, and leptin and adiponectin levels in premenopausal women with hyperprolactinemia.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">leptin</infon>
          <location offset="431" length="6"/>
          <text>leptin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adiponectin</infon>
          <location offset="442" length="11"/>
          <text>adiponectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>509</offset>
        <text>Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age-matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma glucose, insulin levels, insulin resistance measured by homeostasis model assessment (HOMA)-insulin resistance index, beta cell function measured by HOMA-β index, leptin and adiponectin levels.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="756" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="765" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="781" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="848" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">leptin</infon>
          <location offset="919" length="6"/>
          <text>leptin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adiponectin</infon>
          <location offset="930" length="11"/>
          <text>adiponectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>950</offset>
        <text>Plasma insulin levels and HOMA indexes (both insulin resistance and beta indexes) were significantly higher in hyperprolactinemic women.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="957" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="995" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1087</offset>
        <text>The other parameters were similar between both groups.</text>
      </sentence>
      <sentence>
        <offset>1142</offset>
        <text>There was a positive correlation between prolactin levels and fasting plasma glucose in hyperprolactinemic women.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1219" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">prolactin</infon>
          <location offset="1183" length="9"/>
          <text>prolactin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1256</offset>
        <text>The results of this study showed that high prolactin levels may be associated with hyperinsulinemia and insulin resistance in premenopausal women.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">prolactin</infon>
          <location offset="1299" length="9"/>
          <text>prolactin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1360" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1403</offset>
        <text>This effect seems to be independent of body weight, leptin and adiponectin levels.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">leptin</infon>
          <location offset="1455" length="6"/>
          <text>leptin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adiponectin</infon>
          <location offset="1466" length="11"/>
          <text>adiponectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1486</offset>
        <text>High prolactin levels may directly stimulate insulin secretion from pancreas and directly cause hepatic and whole-body insulin resistance.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">prolactin</infon>
          <location offset="1491" length="9"/>
          <text>prolactin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1531" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1605" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23183084</id>
    <passage>
      <offset>0</offset>
      <text>Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line.	Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity. This disease is associated with diminished protective effects of progesterone, which are usually explained by inadequate activation of progesterone receptors and also enhanced pre-receptor metabolism of progesterone. Endometriosis is often treated with progestins, which act as progesterone receptor agonists, although their exact mechanisms of action are not completely understood. The aim of the present study was to investigate how the progestins medroxyprogesterone acetate, dydrogesterone and dienogest, as well as progesterone, impact on the expression of genes of pre-receptor progesterone metabolism in Z-12 epithelial cell line, a model system of peritoneal endometriosis. Our data demonstrate that these progestins affect local pre-receptor metabolism to a different extent. The most favorable effects were seen for dydrogesterone and dienogest, where the first, dydrogesterone, significantly reduced SRD5A1, AKR1C2 and AKR1C3 expression, and additionally had a nonsignificant impact on progesterone receptor B (PR-B) protein levels. This might slow down the first step of pre-receptor metabolism, the conversion of progesterone to 5α-dihydroprogestrone by SRD5A1, and it might also affect further reduction of 3-keto and 20-keto groups catalyzed by AKR1C2 and AKR1C3. Similarly favorable effects were seen for dienogest, which promoted significant reduction of AKR1C1 and AKR1C2 expression and also showed no effect on PR-B protein levels. Different effects were seen for progesterone, which significantly decreased SRD5A1, PR-B and HSD17B2 protein levels. In contrast, treatment with medroxyprogesterone acetate resulted in increased AKR1C1 expression and decreased levels of PR-B, which might lead to enhanced progesterone metabolism and reduced signaling through progesterone receptors. Altogether, our data in this Z-12 cell model suggest that the beneficial effects of treatment with progestin observed in endometriosis patients might arise from decreased pre-receptor metabolism of the protective progesterone by the SRD5A1 and AKR1C enzymes.</text>
      <sentence>
        <offset>0</offset>
        <text>Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line.</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestin</infon>
          <location offset="0" length="9"/>
          <text>Progestin</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="35" length="6"/>
          <text>AKR1C1</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c3</infon>
          <location offset="42" length="6"/>
          <text>AKR1C3</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">srd5a1</infon>
          <location offset="50" length="6"/>
          <text>SRD5A1</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pgr</infon>
          <location offset="61" length="3"/>
          <text>PGR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>113</offset>
        <text>Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity.</text>
      </sentence>
      <sentence>
        <offset>215</offset>
        <text>This disease is associated with diminished protective effects of progesterone, which are usually explained by inadequate activation of progesterone receptors and also enhanced pre-receptor metabolism of progesterone.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="280" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="350" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="418" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">progesterone receptors</infon>
          <location offset="350" length="22"/>
          <text>progesterone receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>432</offset>
        <text>Endometriosis is often treated with progestins, which act as progesterone receptor agonists, although their exact mechanisms of action are not completely understood.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestins</infon>
          <location offset="468" length="10"/>
          <text>progestins</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="493" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">progesterone receptor</infon>
          <location offset="493" length="21"/>
          <text>progesterone receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T16" role="head"/>
          <node refid="T49" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>598</offset>
        <text>The aim of the present study was to investigate how the progestins medroxyprogesterone acetate, dydrogesterone and dienogest, as well as progesterone, impact on the expression of genes of pre-receptor progesterone metabolism in Z-12 epithelial cell line, a model system of peritoneal endometriosis.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestins</infon>
          <location offset="654" length="10"/>
          <text>progestins</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">medroxyprogesterone acetate</infon>
          <location offset="665" length="27"/>
          <text>medroxyprogesterone acetate</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dydrogesterone</infon>
          <location offset="694" length="14"/>
          <text>dydrogesterone</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dienogest</infon>
          <location offset="713" length="9"/>
          <text>dienogest</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="735" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="799" length="12"/>
          <text>progesterone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>897</offset>
        <text>Our data demonstrate that these progestins affect local pre-receptor metabolism to a different extent.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestins</infon>
          <location offset="929" length="10"/>
          <text>progestins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1000</offset>
        <text>The most favorable effects were seen for dydrogesterone and dienogest, where the first, dydrogesterone, significantly reduced SRD5A1, AKR1C2 and AKR1C3 expression, and additionally had a nonsignificant impact on progesterone receptor B (PR-B) protein levels.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="1212" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dydrogesterone</infon>
          <location offset="1041" length="14"/>
          <text>dydrogesterone</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dienogest</infon>
          <location offset="1060" length="9"/>
          <text>dienogest</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dydrogesterone</infon>
          <location offset="1088" length="14"/>
          <text>dydrogesterone</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">srd5a1</infon>
          <location offset="1126" length="6"/>
          <text>SRD5A1</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c2</infon>
          <location offset="1134" length="6"/>
          <text>AKR1C2</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c3</infon>
          <location offset="1145" length="6"/>
          <text>AKR1C3</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">progesterone receptor b</infon>
          <location offset="1212" length="23"/>
          <text>progesterone receptor B</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr-b</infon>
          <location offset="1237" length="4"/>
          <text>PR-B</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T27" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T27" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T27" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1259</offset>
        <text>This might slow down the first step of pre-receptor metabolism, the conversion of progesterone to 5α-dihydroprogestrone by SRD5A1, and it might also affect further reduction of 3-keto and 20-keto groups catalyzed by AKR1C2 and AKR1C3.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="1341" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5α-dihydroprogestrone</infon>
          <location offset="1357" length="21"/>
          <text>5α-dihydroprogestrone</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-keto</infon>
          <location offset="1436" length="6"/>
          <text>3-keto</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">20-keto</infon>
          <location offset="1447" length="7"/>
          <text>20-keto</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">srd5a1</infon>
          <location offset="1382" length="6"/>
          <text>SRD5A1</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c2</infon>
          <location offset="1475" length="6"/>
          <text>AKR1C2</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c3</infon>
          <location offset="1486" length="6"/>
          <text>AKR1C3</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T3" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1494</offset>
        <text>Similarly favorable effects were seen for dienogest, which promoted significant reduction of AKR1C1 and AKR1C2 expression and also showed no effect on PR-B protein levels.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dienogest</infon>
          <location offset="1536" length="9"/>
          <text>dienogest</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="1587" length="6"/>
          <text>AKR1C1</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c2</infon>
          <location offset="1598" length="6"/>
          <text>AKR1C2</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr-b</infon>
          <location offset="1645" length="4"/>
          <text>PR-B</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1666</offset>
        <text>Different effects were seen for progesterone, which significantly decreased SRD5A1, PR-B and HSD17B2 protein levels.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="1698" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">srd5a1</infon>
          <location offset="1742" length="6"/>
          <text>SRD5A1</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr-b</infon>
          <location offset="1750" length="4"/>
          <text>PR-B</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hsd17b2</infon>
          <location offset="1759" length="7"/>
          <text>HSD17B2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1783</offset>
        <text>In contrast, treatment with medroxyprogesterone acetate resulted in increased AKR1C1 expression and decreased levels of PR-B, which might lead to enhanced progesterone metabolism and reduced signaling through progesterone receptors.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">medroxyprogesterone acetate</infon>
          <location offset="1811" length="27"/>
          <text>medroxyprogesterone acetate</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="1938" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="1992" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="1861" length="6"/>
          <text>AKR1C1</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr-b</infon>
          <location offset="1903" length="4"/>
          <text>PR-B</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">progesterone receptors</infon>
          <location offset="1992" length="22"/>
          <text>progesterone receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2016</offset>
        <text>Altogether, our data in this Z-12 cell model suggest that the beneficial effects of treatment with progestin observed in endometriosis patients might arise from decreased pre-receptor metabolism of the protective progesterone by the SRD5A1 and AKR1C enzymes.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progestin</infon>
          <location offset="2115" length="9"/>
          <text>progestin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="2229" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">srd5a1</infon>
          <location offset="2249" length="6"/>
          <text>SRD5A1</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akr1c</infon>
          <location offset="2260" length="5"/>
          <text>AKR1C</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12907443</id>
    <passage>
      <offset>0</offset>
      <text>Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.	Fetal hemoglobin (HbF) decreases polymerization of sickle hemoglobin (HbS) and improves outcomes in sickle cell disease (SSD). Therefore, a therapeutic goal in SSD is pharmacologic reactivation of HbF. Silencing of the gamma-globin (HbF) gene is associated with DNA methylation. The cytosine analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting DNA methyltransferase. We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity. Eight symptomatic SSD patients resistant or intolerant of standard treatment with hydroxyurea received decitabine 0.2 mg/kg subcutaneously 1 to 3 times per week in 2 cycles of 6-week duration. Treatment decreased neutrophils and increased mean HbF (6.5% to 20.4%, P &lt;.0001) and mean total hemoglobin (76 to 96 g/L [7.6 to 9.6 g/dL], P &lt;.001). Features of vaso-occlusive crisis pathophysiology such as red cell adhesion, endothelial damage, and coagulation pathway activity significantly improved. gamma-Globin gene promoter methylation decreased, and platelets and the proportion of megakaryocytes and erythroid cells in the marrow increased without a decrease in marrow cellularity, consistent with a DNA hypomethylating, noncytotoxic mechanism of action. Weekly subcutaneous decitabine produces cumulative increases in HbF and total hemoglobin through a noncytotoxic mechanism of action. Chronic dosing and sustained increases in hemoglobin F and total hemoglobin levels may be possible. Further studies in SSD and thalassemia are indicated.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-aza-2'-deoxycytidine</infon>
          <location offset="11" length="22"/>
          <text>5-aza-2'-deoxycytidine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fetal hemoglobin</infon>
          <location offset="37" length="16"/>
          <text>fetal hemoglobin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>153</offset>
        <text>Fetal hemoglobin (HbF) decreases polymerization of sickle hemoglobin (HbS) and improves outcomes in sickle cell disease (SSD).</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fetal hemoglobin</infon>
          <location offset="153" length="16"/>
          <text>Fetal hemoglobin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hbf</infon>
          <location offset="171" length="3"/>
          <text>HbF</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">sickle hemoglobin</infon>
          <location offset="204" length="17"/>
          <text>sickle hemoglobin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hbs</infon>
          <location offset="223" length="3"/>
          <text>HbS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>280</offset>
        <text>Therefore, a therapeutic goal in SSD is pharmacologic reactivation of HbF.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hbf</infon>
          <location offset="350" length="3"/>
          <text>HbF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>355</offset>
        <text>Silencing of the gamma-globin (HbF) gene is associated with DNA methylation.</text>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gamma-globin</infon>
          <location offset="372" length="12"/>
          <text>gamma-globin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hbf</infon>
          <location offset="386" length="3"/>
          <text>HbF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>432</offset>
        <text>The cytosine analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting DNA methyltransferase.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cytosine</infon>
          <location offset="436" length="8"/>
          <text>cytosine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-aza-2'-deoxycytidine</infon>
          <location offset="452" length="22"/>
          <text>5-aza-2'-deoxycytidine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">decitabine</infon>
          <location offset="476" length="10"/>
          <text>decitabine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dna methyltransferase</infon>
          <location offset="521" length="21"/>
          <text>DNA methyltransferase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>544</offset>
        <text>We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">decitabine</infon>
          <location offset="572" length="10"/>
          <text>decitabine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hbf</infon>
          <location offset="598" length="3"/>
          <text>HbF</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>663</offset>
        <text>Eight symptomatic SSD patients resistant or intolerant of standard treatment with hydroxyurea received decitabine 0.2 mg/kg subcutaneously 1 to 3 times per week in 2 cycles of 6-week duration.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydroxyurea</infon>
          <location offset="745" length="11"/>
          <text>hydroxyurea</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">decitabine</infon>
          <location offset="766" length="10"/>
          <text>decitabine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>856</offset>
        <text>Treatment decreased neutrophils and increased mean HbF (6.5% to 20.4%, P &lt;.0001) and mean total hemoglobin (76 to 96 g/L [7.6 to 9.6 g/dL], P &lt;.001).</text>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hbf</infon>
          <location offset="907" length="3"/>
          <text>HbF</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemoglobin</infon>
          <location offset="952" length="10"/>
          <text>hemoglobin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1006</offset>
        <text>Features of vaso-occlusive crisis pathophysiology such as red cell adhesion, endothelial damage, and coagulation pathway activity significantly improved.</text>
      </sentence>
      <sentence>
        <offset>1160</offset>
        <text>gamma-Globin gene promoter methylation decreased, and platelets and the proportion of megakaryocytes and erythroid cells in the marrow increased without a decrease in marrow cellularity, consistent with a DNA hypomethylating, noncytotoxic mechanism of action.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gamma-globin gene promoter</infon>
          <location offset="1160" length="26"/>
          <text>gamma-Globin gene promoter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1420</offset>
        <text>Weekly subcutaneous decitabine produces cumulative increases in HbF and total hemoglobin through a noncytotoxic mechanism of action.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">decitabine</infon>
          <location offset="1440" length="10"/>
          <text>decitabine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hbf</infon>
          <location offset="1484" length="3"/>
          <text>HbF</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemoglobin</infon>
          <location offset="1498" length="10"/>
          <text>hemoglobin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1553</offset>
        <text>Chronic dosing and sustained increases in hemoglobin F and total hemoglobin levels may be possible.</text>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemoglobin f</infon>
          <location offset="1595" length="12"/>
          <text>hemoglobin F</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemoglobin</infon>
          <location offset="1618" length="10"/>
          <text>hemoglobin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1653</offset>
        <text>Further studies in SSD and thalassemia are indicated.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23259841</id>
    <passage>
      <offset>0</offset>
      <text>Visualization and virtual screening of the chemical universe database GDB-17.	The chemical universe database GDB-17 contains 166.4 billion molecules of up to 17 atoms of C, N, O, S, and halogens obeying rules for chemical stability, synthetic feasibility, and medicinal chemistry. GDB-17 was analyzed using 42 integer value descriptors of molecular structure which we term "Molecular Quantum Numbers" (MQN). Principal component analysis and representation of the (PC1, PC2)-plane provided a graphical overview of the GDB-17 chemical space. Rapid ligand-based virtual screening (LBVS) of GDB-17 using the city-block distance CBD(MQN) as a similarity search measure was enabled by a hashed MQN-fingerprint. LBVS of the entire GDB-17 and of selected subsets identified shape similar, scaffold hopping analogs (ROCS &gt; 1.6 and T(SF) &lt; 0.5) of 15 drugs. Over 97% of these analogs occurred within CBD(MQN) ≤ 12 from each drug, a constraint which might help focus advanced virtual screening. An MQN-searchable 50 million subset of GDB-17 is publicly available at www.gdb.unibe.ch .</text>
      <sentence>
        <offset>0</offset>
        <text>Visualization and virtual screening of the chemical universe database GDB-17.</text>
      </sentence>
      <sentence>
        <offset>78</offset>
        <text>The chemical universe database GDB-17 contains 166.4 billion molecules of up to 17 atoms of C, N, O, S, and halogens obeying rules for chemical stability, synthetic feasibility, and medicinal chemistry.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s</infon>
          <location offset="179" length="1"/>
          <text>S</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">halogens</infon>
          <location offset="186" length="8"/>
          <text>halogens</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c</infon>
          <location offset="170" length="1"/>
          <text>C</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="173" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="176" length="1"/>
          <text>O</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>281</offset>
        <text>GDB-17 was analyzed using 42 integer value descriptors of molecular structure which we term "Molecular Quantum Numbers" (MQN).</text>
      </sentence>
      <sentence>
        <offset>408</offset>
        <text>Principal component analysis and representation of the (PC1, PC2)-plane provided a graphical overview of the GDB-17 chemical space.</text>
      </sentence>
      <sentence>
        <offset>540</offset>
        <text>Rapid ligand-based virtual screening (LBVS) of GDB-17 using the city-block distance CBD(MQN) as a similarity search measure was enabled by a hashed MQN-fingerprint.</text>
      </sentence>
      <sentence>
        <offset>705</offset>
        <text>LBVS of the entire GDB-17 and of selected subsets identified shape similar, scaffold hopping analogs (ROCS &gt; 1.6 and T(SF) &lt; 0.5) of 15 drugs.</text>
      </sentence>
      <sentence>
        <offset>848</offset>
        <text>Over 97% of these analogs occurred within CBD(MQN) ≤ 12 from each drug, a constraint which might help focus advanced virtual screening.</text>
      </sentence>
      <sentence>
        <offset>984</offset>
        <text>An MQN-searchable 50 million subset of GDB-17 is publicly available at www.gdb.unibe.ch .</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17513393</id>
    <passage>
      <offset>0</offset>
      <text>Copper deficiency decreases plasma homocysteine in rats.	The purpose of this study was to determine the effects of copper deficiency on key aspects of homocysteine metabolism that involve methionine recycling and transsulfuration. Male weanling Sprague-Dawley rats were fed AIN-93G-based diets containing &lt;1 or approximately 6 mg Cu/kg. After 6 wk (Expt. 1) and 4 wk (Expt. 2) we found that plasma homocysteine was significantly decreased, and plasma glutathione significantly increased, in rats fed the low-Cu diet. Real-time RT-PCR was used to determine the expression of the subunits of glutamate-cysteine ligase (Gcl) in liver that catalyzes the rate-limiting step in glutathione biosynthesis. The expression of Gclc, the catalytic subunit of Gcl, was upregulated by Cu deficiency; Gclm, the modifier subunit, was not affected. Hepatic betaine-homocysteine methyltransferase (Bhmt), which catalyzes one of the two ways that homocysteine can be remethylated to methionine, was downregulated by Cu deficiency. Because Cu deficiency results in upregulation of Gclc and an increase in the biosynthesis of glutathione, it is plausible that the net flux of homocysteine through the transsulfuration pathway is increased. Furthermore, if Bhmt is downregulated, less homocysteine is available for remethylation (methionine recycling) and more is then available to irreversibly enter the transsulfuration pathway where it is lost. The net effect of increased Gclc and decreased Bhmt would be a decrease in homocysteine as a result of Cu deficiency.</text>
      <sentence>
        <offset>0</offset>
        <text>Copper deficiency decreases plasma homocysteine in rats.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="0" length="6"/>
          <text>Copper</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="35" length="12"/>
          <text>homocysteine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>57</offset>
        <text>The purpose of this study was to determine the effects of copper deficiency on key aspects of homocysteine metabolism that involve methionine recycling and transsulfuration.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methionine</infon>
          <location offset="188" length="10"/>
          <text>methionine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="115" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="151" length="12"/>
          <text>homocysteine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>231</offset>
        <text>Male weanling Sprague-Dawley rats were fed AIN-93G-based diets containing &lt;1 or approximately 6 mg Cu/kg.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="330" length="2"/>
          <text>Cu</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>337</offset>
        <text>After 6 wk (Expt. 1) and 4 wk (Expt. 2) we found that plasma homocysteine was significantly decreased, and plasma glutathione significantly increased, in rats fed the low-Cu diet.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="398" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="451" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="508" length="2"/>
          <text>Cu</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>517</offset>
        <text>Real-time RT-PCR was used to determine the expression of the subunits of glutamate-cysteine ligase (Gcl) in liver that catalyzes the rate-limiting step in glutathione biosynthesis.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="590" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteine</infon>
          <location offset="600" length="8"/>
          <text>cysteine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="672" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutamate-cysteine ligase</infon>
          <location offset="590" length="25"/>
          <text>glutamate-cysteine ligase</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gcl</infon>
          <location offset="617" length="3"/>
          <text>Gcl</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>698</offset>
        <text>The expression of Gclc, the catalytic subunit of Gcl, was upregulated by Cu deficiency; Gclm, the modifier subunit, was not affected.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="771" length="2"/>
          <text>Cu</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gclc</infon>
          <location offset="716" length="4"/>
          <text>Gclc</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gcl</infon>
          <location offset="747" length="3"/>
          <text>Gcl</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gclm</infon>
          <location offset="786" length="4"/>
          <text>Gclm</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>832</offset>
        <text>Hepatic betaine-homocysteine methyltransferase (Bhmt), which catalyzes one of the two ways that homocysteine can be remethylated to methionine, was downregulated by Cu deficiency.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">betaine</infon>
          <location offset="840" length="7"/>
          <text>betaine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="848" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="928" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methionine</infon>
          <location offset="964" length="10"/>
          <text>methionine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="997" length="2"/>
          <text>Cu</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">betaine-homocysteine methyltransferase</infon>
          <location offset="840" length="38"/>
          <text>betaine-homocysteine methyltransferase</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bhmt</infon>
          <location offset="880" length="4"/>
          <text>Bhmt</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T19" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T20" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T19" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T20" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1012</offset>
        <text>Because Cu deficiency results in upregulation of Gclc and an increase in the biosynthesis of glutathione, it is plausible that the net flux of homocysteine through the transsulfuration pathway is increased.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="1105" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="1155" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="1020" length="2"/>
          <text>Cu</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gclc</infon>
          <location offset="1061" length="4"/>
          <text>Gclc</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1219</offset>
        <text>Furthermore, if Bhmt is downregulated, less homocysteine is available for remethylation (methionine recycling) and more is then available to irreversibly enter the transsulfuration pathway where it is lost.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="1263" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methionine</infon>
          <location offset="1308" length="10"/>
          <text>methionine</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bhmt</infon>
          <location offset="1235" length="4"/>
          <text>Bhmt</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1426</offset>
        <text>The net effect of increased Gclc and decreased Bhmt would be a decrease in homocysteine as a result of Cu deficiency.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="1501" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="1529" length="2"/>
          <text>Cu</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gclc</infon>
          <location offset="1454" length="4"/>
          <text>Gclc</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bhmt</infon>
          <location offset="1473" length="4"/>
          <text>Bhmt</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23041113</id>
    <passage>
      <offset>0</offset>
      <text>Phlorotannin-rich Ecklonia cava reduces the production of beta-amyloid by modulating alpha- and gamma-secretase expression and activity.	Beta-amyloid (Aβ) is a major pathogenic peptide in Alzheimer's disease (AD) and is generated by the processing of amyloid precursor protein (APP). We have previously reported that the brown algae Ecklonia cava, which has anti-oxidant and anti-inflammatory functions, decreased Aβ production and further aggregation in HEK293 cells expressing the APP Swedish mutation. Here, we show the reduction mechanism of Aβ production using the butanol extract of Ecklonia cava through the examination of expression and activity of alpha-, beta-, and gamma-secretase. Treatment with the extract resulted in the activation of alpha-secretase with a contrasting decrease in its mRNA and protein expression. This activation was consistent with the translocation of the extract into the plasma membrane of the secretase. Gamma-secretase activity was lowered by E. cava, and this effect may be due to the decreased expression of PSEN1 mRNA and protein. In addition, the basal nuclear location of PSEN1, which may affect chromosome missegregation in neurodegenerative disease, was reduced by the extract, despite the significance of this finding remains unclear. Taken together, these results led us to conclude that E. cava regulated the expression and activity of gamma-secretase and alpha-secretase, leading to a reduction in Aβ production by the stable cells. Our data indicate that E. cava is a novel natural-product candidate for AD treatment, although further in vivo studies are needed.</text>
      <sentence>
        <offset>0</offset>
        <text>Phlorotannin-rich Ecklonia cava reduces the production of beta-amyloid by modulating alpha- and gamma-secretase expression and activity.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phlorotannin</infon>
          <location offset="0" length="12"/>
          <text>Phlorotannin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta-amyloid</infon>
          <location offset="58" length="12"/>
          <text>beta-amyloid</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha- and gamma-secretase</infon>
          <location offset="85" length="26"/>
          <text>alpha- and gamma-secretase</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>137</offset>
        <text>Beta-amyloid (Aβ) is a major pathogenic peptide in Alzheimer's disease (AD) and is generated by the processing of amyloid precursor protein (APP).</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta-amyloid</infon>
          <location offset="137" length="12"/>
          <text>Beta-amyloid</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">amyloid precursor protein</infon>
          <location offset="251" length="25"/>
          <text>amyloid precursor protein</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">app</infon>
          <location offset="278" length="3"/>
          <text>APP</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aβ</infon>
          <location offset="151" length="2"/>
          <text>Aβ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>284</offset>
        <text>We have previously reported that the brown algae Ecklonia cava, which has anti-oxidant and anti-inflammatory functions, decreased Aβ production and further aggregation in HEK293 cells expressing the APP Swedish mutation.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aβ</infon>
          <location offset="414" length="2"/>
          <text>Aβ</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">app</infon>
          <location offset="483" length="3"/>
          <text>APP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>505</offset>
        <text>Here, we show the reduction mechanism of Aβ production using the butanol extract of Ecklonia cava through the examination of expression and activity of alpha-, beta-, and gamma-secretase.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">butanol</infon>
          <location offset="570" length="7"/>
          <text>butanol</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aβ</infon>
          <location offset="546" length="2"/>
          <text>Aβ</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha-, beta-, and gamma-secretase</infon>
          <location offset="657" length="34"/>
          <text>alpha-, beta-, and gamma-secretase</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>693</offset>
        <text>Treatment with the extract resulted in the activation of alpha-secretase with a contrasting decrease in its mRNA and protein expression.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha-secretase</infon>
          <location offset="750" length="15"/>
          <text>alpha-secretase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>830</offset>
        <text>This activation was consistent with the translocation of the extract into the plasma membrane of the secretase.</text>
      </sentence>
      <sentence>
        <offset>942</offset>
        <text>Gamma-secretase activity was lowered by E. cava, and this effect may be due to the decreased expression of PSEN1 mRNA and protein.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gamma-secretase</infon>
          <location offset="942" length="15"/>
          <text>Gamma-secretase</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">psen1</infon>
          <location offset="1049" length="5"/>
          <text>PSEN1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1073</offset>
        <text>In addition, the basal nuclear location of PSEN1, which may affect chromosome missegregation in neurodegenerative disease, was reduced by the extract, despite the significance of this finding remains unclear.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">psen1</infon>
          <location offset="1116" length="5"/>
          <text>PSEN1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1282</offset>
        <text>Taken together, these results led us to conclude that E. cava regulated the expression and activity of gamma-secretase and alpha-secretase, leading to a reduction in Aβ production by the stable cells.</text>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gamma-secretase</infon>
          <location offset="1385" length="15"/>
          <text>gamma-secretase</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha-secretase</infon>
          <location offset="1405" length="15"/>
          <text>alpha-secretase</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aβ</infon>
          <location offset="1448" length="2"/>
          <text>Aβ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1483</offset>
        <text>Our data indicate that E. cava is a novel natural-product candidate for AD treatment, although further in vivo studies are needed.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23567961</id>
    <passage>
      <offset>0</offset>
      <text>Identification of novel FLT3 kinase inhibitors.	FLT3 and PDGFR tyrosine kinases are important targets for therapy of different types of leukemia. Several FLT3/PDGFR inhibitors are currently under clinical investigation for combination with standard therapy for treatment of acute myeloid leukemia (AML), however these agents only induce partial remission and development of resistance has been reported. In this work we describe the identification of potent and novel dual FLT3/PDGFR inhibitors that resulted from our efforts to screen a library of 25,607 small molecules against the FLT3 dependent cell line MOLM-13 and the PDGFR dependent cell line EOL-1. This effort led to the identification of five compounds that were confirmed to be active on additional FLT3 dependent cell lines (cellular EC50 values between 35 and 700 nM), while having no significant effect on 24 other tyrosine kinases.</text>
      <sentence>
        <offset>0</offset>
        <text>Identification of novel FLT3 kinase inhibitors.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flt3</infon>
          <location offset="24" length="4"/>
          <text>FLT3</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="29" length="6"/>
          <text>kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>48</offset>
        <text>FLT3 and PDGFR tyrosine kinases are important targets for therapy of different types of leukemia.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="63" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flt3</infon>
          <location offset="48" length="4"/>
          <text>FLT3</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tyrosine kinases</infon>
          <location offset="63" length="16"/>
          <text>tyrosine kinases</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pdgfr</infon>
          <location offset="57" length="5"/>
          <text>PDGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>146</offset>
        <text>Several FLT3/PDGFR inhibitors are currently under clinical investigation for combination with standard therapy for treatment of acute myeloid leukemia (AML), however these agents only induce partial remission and development of resistance has been reported.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flt3</infon>
          <location offset="154" length="4"/>
          <text>FLT3</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pdgfr</infon>
          <location offset="159" length="5"/>
          <text>PDGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>404</offset>
        <text>In this work we describe the identification of potent and novel dual FLT3/PDGFR inhibitors that resulted from our efforts to screen a library of 25,607 small molecules against the FLT3 dependent cell line MOLM-13 and the PDGFR dependent cell line EOL-1.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flt3</infon>
          <location offset="473" length="4"/>
          <text>FLT3</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pdgfr</infon>
          <location offset="478" length="5"/>
          <text>PDGFR</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flt3</infon>
          <location offset="584" length="4"/>
          <text>FLT3</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pdgfr</infon>
          <location offset="625" length="5"/>
          <text>PDGFR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>658</offset>
        <text>This effort led to the identification of five compounds that were confirmed to be active on additional FLT3 dependent cell lines (cellular EC50 values between 35 and 700 nM), while having no significant effect on 24 other tyrosine kinases.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="880" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">flt3</infon>
          <location offset="761" length="4"/>
          <text>FLT3</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tyrosine kinases</infon>
          <location offset="880" length="16"/>
          <text>tyrosine kinases</text>
        </annotation>
      </sentence>
    </passage>
  </document>
</collection>
